<SEC-DOCUMENT>0001140361-25-011169.txt : 20250331
<SEC-HEADER>0001140361-25-011169.hdr.sgml : 20250331
<ACCEPTANCE-DATETIME>20250331075037
ACCESSION NUMBER:		0001140361-25-011169
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		92
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250331
DATE AS OF CHANGE:		20250331

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GALECTIN THERAPEUTICS INC
		CENTRAL INDEX KEY:			0001133416
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				043562325
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31791
		FILM NUMBER:		25788957

	BUSINESS ADDRESS:	
		STREET 1:		4960 PEACHTREE INDUSTRIAL BOULEVARD
		STREET 2:		SUITE 240
		CITY:			NORCROSS
		STATE:			GA
		ZIP:			30071
		BUSINESS PHONE:		678-620-3186

	MAIL ADDRESS:	
		STREET 1:		4960 PEACHTREE INDUSTRIAL BOULEVARD
		STREET 2:		SUITE 240
		CITY:			NORCROSS
		STATE:			GA
		ZIP:			30071

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PRO PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20010612
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>ef20039001_10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2024" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:cef="http://xbrl.sec.gov/cef/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:galt="http://galectintherapeutics.com/20241231" xmlns="http://www.w3.org/1999/xhtml">
<head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc
         Document created using Broadridge PROfile 25.3.1.5296
         Copyright 1995 - 2025 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html"/>
</head>

<body style="background-color: #ffffff; color: #000000;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_8d49a8eb31cb48aeb750f62f1c79329e" contextRef="c20240101to20241231" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric name="dei:CurrentFiscalYearEndDate" id="Fact_5c46843e57324b84ba22d20b5c7120f2" contextRef="c20240101to20241231" format="ixt:date-month-day">12-31</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalYearFocus" id="Fact_e9ef3d473ff54310a354df04f49ab23d" contextRef="c20240101to20241231">2024</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" id="Fact_2ee2ac31eca347aabd9c7dba5f9cd928" contextRef="c20240101to20241231">FY</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_d3a041f1810748ec875770cb1cd2eb88" contextRef="c20240101to20241231">0001133416</ix:nonNumeric><ix:nonNumeric name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="Fact_3bef161157d441a4b194359a2b8c08a3" contextRef="c20231231">http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="Fact_a8602fa8d1ea4021ae045ee98e73f8f6" contextRef="c20231231">http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="Fact_4b297d7d29a9481e88136db097de88dd" contextRef="c20241231">http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="Fact_5c08786f5dcb4bc5a62f72d8c0d8264d" contextRef="c20241231">http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric name="galt:FreeRentPeriod" id="Fact_5e16282e65184d8eabf15666ce8cae25" contextRef="c20240101to20241231">P6M15D</ix:nonNumeric><ix:nonNumeric name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="Fact_2a011c7177224f80b904fcc70e46eb35" contextRef="c20231231">http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="Fact_c96ca38e0f664780917ece0461c411fe" contextRef="c20241231">http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="Fact_47d32f393cdc43fc8f131674cf3a7b9b" contextRef="c20231231">http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonFraction name="us-gaap:NumberOfOperatingSegments" id="Fact_600409bbedd14e1db752c48e58053e6c" contextRef="c20240101to20241231" unitRef="U011" decimals="INF">1</ix:nonFraction><ix:nonNumeric name="dei:AuditorFirmId" id="Fact_8aa86162ab1a4132867b6ccb28da17b8" contextRef="c20240101to20241231">677</ix:nonNumeric><ix:nonNumeric name="galt:NumberOfConsecutiveTradingDays" id="Fact_9d42133c6fda4902871913ae7391078b" contextRef="c20240101to20241231_StatementClassOfStockAxis_SeriesCPreferredStockMember">P10D</ix:nonNumeric><ix:nonNumeric name="galt:OperatingLossCarryforwardsExpirationYear" id="Fact_f036db385a5043f9b416f31ccdd089ed" contextRef="c20240101to20241231">2037</ix:nonNumeric><ix:nonNumeric name="galt:FederalAndStateResearchAndDevelopmentCreditsExpirationYear" id="Fact_64f60f3069914649af3fc7ac5db90c6c" contextRef="c20240101to20241231">2042</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="galt-20241231.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="c20240101to20241231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20250303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20231231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_LongtermDebtTypeAxis_LoansPayableMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_LongtermDebtTypeAxis_LineOfCreditMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20241001to20241231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20241231_CreditFacilityAxis_LineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20250331_CreditFacilityAxis_SupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_SubsequentEventTypeAxis_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">galt:SupplementalLineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_PropertyPlantAndEquipmentByTypeAxis_ComputerAndOfficeEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">galt:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_PropertyPlantAndEquipmentByTypeAxis_ComputerAndOfficeEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">galt:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210416_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:AprilConvertiblePromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210917_DebtInstrumentAxis_FirstClosingMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:FirstClosingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211220_DebtInstrumentAxis_SecondClosingMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:SecondClosingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210917_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:SeptemberConvertiblePromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210416to20210416_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:AprilConvertiblePromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-16</xbrli:startDate><xbrli:endDate>2021-04-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20211220to20211220_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:DecemberConvertiblePromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-20</xbrli:startDate><xbrli:endDate>2021-12-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:SeptemberConvertiblePromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240514to20240514_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:AprilConvertiblePromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-14</xbrli:startDate><xbrli:endDate>2024-05-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:AprilConvertiblePromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210917to20210917_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:SeptemberConvertiblePromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-17</xbrli:startDate><xbrli:endDate>2021-09-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240514_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:AprilConvertiblePromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:AprilConvertiblePromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211220_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:DecemberConvertiblePromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:SeptemberConvertiblePromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:DecemberConvertiblePromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:SeptemberConvertiblePromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:DecemberConvertiblePromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:AprilConvertiblePromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20231231_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:SeptemberConvertiblePromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:DecemberConvertiblePromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:AprilConvertiblePromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:DecemberConvertiblePromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:SeptemberConvertiblePromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:AprilConvertiblePromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:AprilConvertiblePromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:SeptemberConvertiblePromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250917to20250917_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_StatementScenarioAxis_ScenarioForecastMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:SeptemberConvertiblePromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-09-17</xbrli:startDate><xbrli:endDate>2025-09-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20251230to20251230_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember_StatementScenarioAxis_ScenarioForecastMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:DecemberConvertiblePromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-12-30</xbrli:startDate><xbrli:endDate>2025-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputSharePriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputDiscountRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputConversionPriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputConversionPriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedDividendRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputConversionPriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputConversionPriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputDiscountRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedDividendRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedDividendRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputSharePriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedDividendRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputSharePriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputSharePriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedDividendRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputDiscountRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputConversionPriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputConversionPriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputConversionPriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputConversionPriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputDiscountRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputDiscountRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputDiscountRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputSharePriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputConversionPriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputConversionPriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedDividendRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputConversionPriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputConversionPriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputSharePriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedTermMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedTermMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedTermMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedTermMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedTermMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedTermMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_StatementClassOfStockAxis_SeriesBOneConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">galt:SeriesBOneConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_StatementClassOfStockAxis_SeriesBTwoConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">galt:SeriesBTwoConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_StatementClassOfStockAxis_SeriesBThreeConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">galt:SeriesBThreeConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_StatementClassOfStockAxis_SeriesAPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_StatementClassOfStockAxis_SeriesCPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_TypeOfArrangementAxis_TwoThousandTwentyMarketAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">galt:TwoThousandTwentyMarketAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_TypeOfArrangementAxis_TwoThousandTwentyMarketAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">galt:TwoThousandTwentyMarketAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20080204to20080204_StatementClassOfStockAxis_SeriesAPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2008-02-04</xbrli:startDate><xbrli:endDate>2008-02-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20080204_StatementClassOfStockAxis_SeriesAPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2008-02-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20080204_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementScenarioAxis_DividendPaymentScenarioOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">galt:DividendPaymentScenarioOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2008-02-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20080204_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementScenarioAxis_DividendPaymentScenarioTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">galt:DividendPaymentScenarioTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2008-02-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20080204to20080204_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementScenarioAxis_DividendPaymentScenarioOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">galt:DividendPaymentScenarioOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2008-02-04</xbrli:startDate><xbrli:endDate>2008-02-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20080204to20080204_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementScenarioAxis_DividendPaymentScenarioTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">galt:DividendPaymentScenarioTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2008-02-04</xbrli:startDate><xbrli:endDate>2008-02-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20080204_RangeAxis_MinimumMember_StatementClassOfStockAxis_SeriesAPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2008-02-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_StatementClassOfStockAxis_SeriesAPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20200101to20201231_StatementClassOfStockAxis_SeriesAPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20110101to20110131_StatementClassOfStockAxis_SeriesCPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2011-01-01</xbrli:startDate><xbrli:endDate>2011-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20101230to20101230_StatementClassOfStockAxis_SeriesCPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2010-12-30</xbrli:startDate><xbrli:endDate>2010-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20101229to20101229_RangeAxis_MaximumMember_StatementClassOfStockAxis_SeriesCPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2010-12-29</xbrli:startDate><xbrli:endDate>2010-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20101229_StatementClassOfStockAxis_SeriesCPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2010-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20101230_StatementClassOfStockAxis_SeriesCPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2010-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20110131_StatementClassOfStockAxis_SeriesCPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2011-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20101229_RangeAxis_MaximumMember_StatementClassOfStockAxis_SeriesCPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2010-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_StatementClassOfStockAxis_SeriesCPreferredStockMember_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_StatementClassOfStockAxis_SeriesCPreferredStockMember_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20131231to20131231_StatementClassOfStockAxis_SeriesCPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-12-31</xbrli:startDate><xbrli:endDate>2013-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20110731to20110731_StatementClassOfStockAxis_SeriesCPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2011-07-31</xbrli:startDate><xbrli:endDate>2011-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_StatementClassOfStockAxis_SeriesCPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20141231to20141231_StatementClassOfStockAxis_SeriesCPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-12-31</xbrli:startDate><xbrli:endDate>2014-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_StatementClassOfStockAxis_SeriesCPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20101230_StatementClassOfStockAxis_SeriesCPreferredStockMember_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2010-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20101230to20101230_StatementClassOfStockAxis_SeriesCPreferredStockMember_StatementScenarioAxis_DividendPaymentScenarioOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">galt:DividendPaymentScenarioOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2010-12-30</xbrli:startDate><xbrli:endDate>2010-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20101230to20101230_StatementClassOfStockAxis_SeriesCPreferredStockMember_StatementScenarioAxis_DividendPaymentScenarioTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">galt:DividendPaymentScenarioTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2010-12-30</xbrli:startDate><xbrli:endDate>2010-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20101230to20101230_RangeAxis_MaximumMember_StatementClassOfStockAxis_SeriesCPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2010-12-30</xbrli:startDate><xbrli:endDate>2010-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20221231_FinancialInstrumentAxis_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_FinancialInstrumentAxis_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_FinancialInstrumentAxis_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20241231_FinancialInstrumentAxis_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_FinancialInstrumentAxis_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230930_RelatedPartyTransactionsByRelatedPartyAxis_One0XFundLPAnd10XCapitalManagementLLCMember_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">galt:One0XFundLPAnd10XCapitalManagementLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230922_RelatedPartyTransactionsByRelatedPartyAxis_One0XFundLPAnd10XCapitalManagementLLCMember_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">galt:One0XFundLPAnd10XCapitalManagementLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_RelatedPartyTransactionsByRelatedPartyAxis_One0XFundLPAnd10XCapitalManagementLLCMember_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">galt:One0XFundLPAnd10XCapitalManagementLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20241231_RangeAxis_MinimumMember_RelatedPartyTransactionsByRelatedPartyAxis_One0XFundLPAnd10XCapitalManagementLLCMember_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">galt:One0XFundLPAnd10XCapitalManagementLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_RangeAxis_MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20241231_RelatedPartyTransactionsByRelatedPartyAxis_One0XFundLPMember_StatementEquityComponentsAxis_SeriesBWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">galt:SeriesBWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">galt:One0XFundLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_RelatedPartyTransactionsByRelatedPartyAxis_One0XFundLPMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">galt:One0XFundLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230901to20230930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_ClassOfWarrantOrRightAxis_AfterModificationMember_FinancialInstrumentAxis_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:AfterModificationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_ClassOfWarrantOrRightAxis_BeforeModificationMember_FinancialInstrumentAxis_WarrantMember_RangeAxis_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:BeforeModificationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_ClassOfWarrantOrRightAxis_BeforeModificationMember_FinancialInstrumentAxis_WarrantMember_RangeAxis_MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:BeforeModificationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_ClassOfWarrantOrRightAxis_BeforeModificationMember_FinancialInstrumentAxis_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:BeforeModificationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20241231_ClassOfWarrantOrRightAxis_DecemberTwentyThreeTwentySixteenSeriesBThreeTransactionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:DecemberTwentyThreeTwentySixteenSeriesBThreeTransactionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_ClassOfWarrantOrRightAxis_AprilThirtyTwentyTenSeriesBTwoTransactionTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:AprilThirtyTwentyTenSeriesBTwoTransactionTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_ClassOfWarrantOrRightAxis_SeptemberThirtyTwentyZeroNineSeriesBTwoTransactionOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:SeptemberThirtyTwentyZeroNineSeriesBTwoTransactionOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_ClassOfWarrantOrRightAxis_MarchEightTwentyTenSeriesBTwoTransactionTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:MarchEightTwentyTenSeriesBTwoTransactionTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_ClassOfWarrantOrRightAxis_December292023WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:December292023WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_ClassOfWarrantOrRightAxis_AugustTwelveTwentyZeroNineSeriesBTwoTransactionOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:AugustTwelveTwentyZeroNineSeriesBTwoTransactionOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_ClassOfWarrantOrRightAxis_SeptemberTwentyTwoTwentySixteenSeriesBThreeTransactionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:SeptemberTwentyTwoTwentySixteenSeriesBThreeTransactionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_ClassOfWarrantOrRightAxis_DecemberEightTwentyZeroNineSeriesBTwoTransactionOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:DecemberEightTwentyZeroNineSeriesBTwoTransactionOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_ClassOfWarrantOrRightAxis_AprilThirtyTwentyTenSeriesBTwoTransactionOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:AprilThirtyTwentyTenSeriesBTwoTransactionOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_ClassOfWarrantOrRightAxis_September302024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:September302024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_ClassOfWarrantOrRightAxis_MayTenTwentyTenSeriesBTwoTransactionOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:MayTenTwentyTenSeriesBTwoTransactionOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_ClassOfWarrantOrRightAxis_SeptemberTwentyNineTwentySixteenSeriesBThreeTransactionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:SeptemberTwentyNineTwentySixteenSeriesBThreeTransactionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_ClassOfWarrantOrRightAxis_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:JanuaryTwentyNineTwentyTenSeriesBTwoTransactionOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_ClassOfWarrantOrRightAxis_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:JanuaryTwentyNineTwentyTenSeriesBTwoTransactionTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_ClassOfWarrantOrRightAxis_June282024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:June282024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_ClassOfWarrantOrRightAxis_TwentyEighteenAndTwentySeventeenWarrantsIssuedForServicesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:TwentyEighteenAndTwentySeventeenWarrantsIssuedForServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_ClassOfWarrantOrRightAxis_MayTenTwentyTenSeriesBTwoTransactionTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:MayTenTwentyTenSeriesBTwoTransactionTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_ClassOfWarrantOrRightAxis_NovemberFourTwentyZeroNineSeriesBTwoTransactionOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:NovemberFourTwentyZeroNineSeriesBTwoTransactionOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_ClassOfWarrantOrRightAxis_July222022WarrantsIssuedInConnectionWithRelatedPartyLineOfCreditMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:July222022WarrantsIssuedInConnectionWithRelatedPartyLineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_ClassOfWarrantOrRightAxis_March292024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:March292024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_ClassOfWarrantOrRightAxis_MarchEightTwentyTenSeriesBTwoTransactionOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:MarchEightTwentyTenSeriesBTwoTransactionOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_ClassOfWarrantOrRightAxis_MayTwentyThreeTwentyNinteenRightsOfferingWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:MayTwentyThreeTwentyNinteenRightsOfferingWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_ClassOfWarrantOrRightAxis_FebruaryTwelveTwentyZeroNineSeriesBOneTransactionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:FebruaryTwelveTwentyZeroNineSeriesBOneTransactionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_ClassOfWarrantOrRightAxis_JuneThirtyTwentyZeroNineSeriesBTwoTransactionOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:JuneThirtyTwentyZeroNineSeriesBTwoTransactionOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_ClassOfWarrantOrRightAxis_MayThirteenTwentyZeroNineSeriesBTwoTransactionOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:MayThirteenTwentyZeroNineSeriesBTwoTransactionOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_ClassOfWarrantOrRightAxis_SeptemberTwentyTwoTwentySixteenSeriesBThreeTransactionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:SeptemberTwentyTwoTwentySixteenSeriesBThreeTransactionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_ClassOfWarrantOrRightAxis_MayTenTwentyTenSeriesBTwoTransactionTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:MayTenTwentyTenSeriesBTwoTransactionTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_ClassOfWarrantOrRightAxis_NovemberFourTwentyZeroNineSeriesBTwoTransactionOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:NovemberFourTwentyZeroNineSeriesBTwoTransactionOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_ClassOfWarrantOrRightAxis_July222022WarrantsIssuedInConnectionWithRelatedPartyLineOfCreditMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:July222022WarrantsIssuedInConnectionWithRelatedPartyLineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_ClassOfWarrantOrRightAxis_MayTwentyThreeTwentyNinteenRightsOfferingWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:MayTwentyThreeTwentyNinteenRightsOfferingWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_ClassOfWarrantOrRightAxis_December292023WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:December292023WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_ClassOfWarrantOrRightAxis_MayTenTwentyTenSeriesBTwoTransactionOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:MayTenTwentyTenSeriesBTwoTransactionOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_ClassOfWarrantOrRightAxis_SeptemberThirtyTwentyZeroNineSeriesBTwoTransactionOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:SeptemberThirtyTwentyZeroNineSeriesBTwoTransactionOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_ClassOfWarrantOrRightAxis_MarchEightTwentyTenSeriesBTwoTransactionTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:MarchEightTwentyTenSeriesBTwoTransactionTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_ClassOfWarrantOrRightAxis_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:JanuaryTwentyNineTwentyTenSeriesBTwoTransactionOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_ClassOfWarrantOrRightAxis_September302024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:September302024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_ClassOfWarrantOrRightAxis_March292024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:March292024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_ClassOfWarrantOrRightAxis_AprilThirtyTwentyTenSeriesBTwoTransactionOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:AprilThirtyTwentyTenSeriesBTwoTransactionOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_ClassOfWarrantOrRightAxis_MayThirteenTwentyZeroNineSeriesBTwoTransactionOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:MayThirteenTwentyZeroNineSeriesBTwoTransactionOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_ClassOfWarrantOrRightAxis_SeptemberTwentyNineTwentySixteenSeriesBThreeTransactionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:SeptemberTwentyNineTwentySixteenSeriesBThreeTransactionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_ClassOfWarrantOrRightAxis_DecemberEightTwentyZeroNineSeriesBTwoTransactionOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:DecemberEightTwentyZeroNineSeriesBTwoTransactionOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_ClassOfWarrantOrRightAxis_June282024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:June282024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_ClassOfWarrantOrRightAxis_MarchEightTwentyTenSeriesBTwoTransactionOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:MarchEightTwentyTenSeriesBTwoTransactionOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_ClassOfWarrantOrRightAxis_DecemberTwentyThreeTwentySixteenSeriesBThreeTransactionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:DecemberTwentyThreeTwentySixteenSeriesBThreeTransactionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_ClassOfWarrantOrRightAxis_AugustTwelveTwentyZeroNineSeriesBTwoTransactionOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:AugustTwelveTwentyZeroNineSeriesBTwoTransactionOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_ClassOfWarrantOrRightAxis_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:JanuaryTwentyNineTwentyTenSeriesBTwoTransactionTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_ClassOfWarrantOrRightAxis_JuneThirtyTwentyZeroNineSeriesBTwoTransactionOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:JuneThirtyTwentyZeroNineSeriesBTwoTransactionOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_ClassOfWarrantOrRightAxis_AprilThirtyTwentyTenSeriesBTwoTransactionTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:AprilThirtyTwentyTenSeriesBTwoTransactionTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_ClassOfWarrantOrRightAxis_FebruaryTwelveTwentyZeroNineSeriesBOneTransactionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:FebruaryTwelveTwentyZeroNineSeriesBOneTransactionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20231231_PlanNameAxis_EquityIncentivePlan2019Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">galt:EquityIncentivePlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211231_PlanNameAxis_EquityIncentivePlan2019Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">galt:EquityIncentivePlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_PlanNameAxis_EquityIncentivePlan2019Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">galt:EquityIncentivePlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_PlanNameAxis_IncentiveCompensationPlanTwoThousandNineMemberMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">galt:IncentiveCompensationPlanTwoThousandNineMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_PlanNameAxis_EquityIncentivePlan2019Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">galt:EquityIncentivePlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_RangeAxis_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_RangeAxis_MinimumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">galt:ExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_RangeAxis_MinimumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">galt:ExercisePriceRangeTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_RangeAxis_MinimumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeThreeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">galt:ExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_RangeAxis_MinimumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeFourMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">galt:ExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_RangeAxis_MaximumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeThreeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">galt:ExercisePriceRangeThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_RangeAxis_MaximumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">galt:ExercisePriceRangeTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_RangeAxis_MaximumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeFourMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">galt:ExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_RangeAxis_MaximumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">galt:ExercisePriceRangeOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeThreeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">galt:ExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">galt:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">galt:ExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeFourMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">galt:ExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">galt:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeThreeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">galt:ExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">galt:ExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeFourMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">galt:ExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20241231_AwardTypeAxis_RestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_AwardTypeAxis_RestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_AwardTypeAxis_RestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20240131_AwardTypeAxis_RestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_AwardTypeAxis_RestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis">us-gaap:DeferredBonusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis">us-gaap:DeferredBonusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20221231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis">us-gaap:DeferredBonusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis">us-gaap:DeferredBonusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis">us-gaap:DeferredBonusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis">us-gaap:DeferredBonusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20211231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_BonusSharesMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis">galt:BonusSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_BonusSharesMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis">galt:BonusSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_BonusSharesMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis">galt:BonusSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20241231_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220725_CreditFacilityAxis_LineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240329_CreditFacilityAxis_SupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">galt:SupplementalLineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241114_CreditFacilityAxis_AdditionalSupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">galt:AdditionalSupplementalLineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231229to20231229_CreditFacilityAxis_LineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-29</xbrli:startDate><xbrli:endDate>2023-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20241113to20241114_CreditFacilityAxis_AdditionalSupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">galt:AdditionalSupplementalLineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-13</xbrli:startDate><xbrli:endDate>2024-11-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240329to20240329_CreditFacilityAxis_LineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-29</xbrli:startDate><xbrli:endDate>2024-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240628to20240628_CreditFacilityAxis_LineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-28</xbrli:startDate><xbrli:endDate>2024-06-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240401to20240630_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_June2023PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">galt:June2023PromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240329to20240329_CreditFacilityAxis_SupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">galt:SupplementalLineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-29</xbrli:startDate><xbrli:endDate>2024-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20240331_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_March2023PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">galt:March2023PromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220725to20220725_CreditFacilityAxis_LineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-25</xbrli:startDate><xbrli:endDate>2022-07-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240328to20240930_CreditFacilityAxis_SupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">galt:SupplementalLineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-28</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20221219to20221219_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_December2022PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">galt:December2022PromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-19</xbrli:startDate><xbrli:endDate>2022-12-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_CreditFacilityAxis_SupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">galt:SupplementalLineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240630_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_June2023PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">galt:June2023PromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_CreditFacilityAxis_SupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">galt:SupplementalLineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_CreditFacilityAxis_SupplementalLineOfCreditMember_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">galt:SupplementalLineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241114_CreditFacilityAxis_AdditionalSupplementalLineOfCreditMember_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">galt:AdditionalSupplementalLineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231229_CreditFacilityAxis_LineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241114_CreditFacilityAxis_AdditionalSupplementalLineOfCreditMember_RangeAxis_MinimumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">galt:AdditionalSupplementalLineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220725_CreditFacilityAxis_LineOfCreditMember_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_CreditFacilityAxis_SupplementalLineOfCreditMember_RangeAxis_MinimumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">galt:SupplementalLineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240329_CreditFacilityAxis_LineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240628_CreditFacilityAxis_LineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220725_CreditFacilityAxis_LineOfCreditMember_RangeAxis_MinimumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_December2022PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">galt:December2022PromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240331_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_March2023PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">galt:March2023PromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220725_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220725_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221219_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240628_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240329_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240630_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231229_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240930_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240331_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220725_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231229_FinancialInstrumentAxis_WarrantOneMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">galt:WarrantOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240331_FinancialInstrumentAxis_WarrantOneMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">galt:WarrantOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240329_FinancialInstrumentAxis_WarrantOneMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">galt:WarrantOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221219_FinancialInstrumentAxis_WarrantOneMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">galt:WarrantOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240930_CreditFacilityAxis_SupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">galt:SupplementalLineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240630_FinancialInstrumentAxis_WarrantOneMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">galt:WarrantOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240628_FinancialInstrumentAxis_WarrantOneMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">galt:WarrantOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220725_FinancialInstrumentAxis_WarrantMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221219_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_December2022PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">galt:December2022PromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_September2024PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">galt:September2024PromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_March24PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">galt:March24PromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_June2023PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">galt:June2023PromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_March2023PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">galt:March2023PromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_March2023PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">galt:March2023PromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_December2022PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">galt:December2022PromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_June2023PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">galt:June2023PromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_December2023PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">galt:December2023PromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_June2024PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">galt:June2024PromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220725to20220725_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-25</xbrli:startDate><xbrli:endDate>2022-07-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20241231_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_FinancialInstrumentAxis_WarrantTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">galt:WarrantTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20221219to20221219_FinancialInstrumentAxis_WarrantOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">galt:WarrantOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-19</xbrli:startDate><xbrli:endDate>2022-12-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20240331_FinancialInstrumentAxis_WarrantTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">galt:WarrantTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240329to20240329_FinancialInstrumentAxis_WarrantTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">galt:WarrantTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-29</xbrli:startDate><xbrli:endDate>2024-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240401to20240630_FinancialInstrumentAxis_WarrantTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">galt:WarrantTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240628to20240628_FinancialInstrumentAxis_WarrantTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">galt:WarrantTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-28</xbrli:startDate><xbrli:endDate>2024-06-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220725to20220725_FinancialInstrumentAxis_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-25</xbrli:startDate><xbrli:endDate>2022-07-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240328to20240930_FinancialInstrumentAxis_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-28</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_FinancialInstrumentAxis_WarrantOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">galt:WarrantOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_FinancialInstrumentAxis_WarrantThreeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">galt:WarrantThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_FinancialInstrumentAxis_WarrantTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">galt:WarrantTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_FinancialInstrumentAxis_WarrantOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">galt:WarrantOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_FinancialInstrumentAxis_WarrantThreeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">galt:WarrantThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_FinancialInstrumentAxis_WarrantSevenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">galt:WarrantSevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_FinancialInstrumentAxis_WarrantFiveMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">galt:WarrantFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_FinancialInstrumentAxis_WarrantSixMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">galt:WarrantSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_FinancialInstrumentAxis_WarrantFourMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">galt:WarrantFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertibleNotesPayableMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertibleNotesPayableMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_LineOfCreditMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_LineOfCreditMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20140101to20140131_OwnershipAxis_GalectinSciencesLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">galt:GalectinSciencesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-01-01</xbrli:startDate><xbrli:endDate>2014-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20140131_CounterpartyNameAxis_SBHSciencesIncMember_FiniteLivedIntangibleAssetsByMajorClassAxis_InProcessResearchAndDevelopmentMember_OwnershipAxis_GalectinSciencesLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">galt:GalectinSciencesLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">galt:SBHSciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_OwnershipAxis_GalectinSciencesLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">galt:GalectinSciencesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20140131_CounterpartyNameAxis_SBHSciencesIncMember_OwnershipAxis_GalectinSciencesLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">galt:GalectinSciencesLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">galt:SBHSciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20141001to20141231_OwnershipAxis_GalectinSciencesLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">galt:GalectinSciencesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-10-01</xbrli:startDate><xbrli:endDate>2014-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_OwnershipAxis_GalectinSciencesLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">galt:GalectinSciencesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20150101to20211231_OwnershipAxis_GalectinSciencesLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">galt:GalectinSciencesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_OwnershipAxis_GalectinSciencesLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">galt:GalectinSciencesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20140101to20231231_CounterpartyNameAxis_SBHSciencesIncMember_OwnershipAxis_GalectinSciencesLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">galt:GalectinSciencesLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">galt:SBHSciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20140101to20141231_OwnershipAxis_GalectinSciencesLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">galt:GalectinSciencesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-01-01</xbrli:startDate><xbrli:endDate>2014-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20241231_IncomeTaxAuthorityAxis_DomesticCountryMember_TaxPeriodAxis_ExpiringAsAResultOf2017TaxActMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">galt:ExpiringAsAResultOf2017TaxActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_IncomeTaxAuthorityAxis_DomesticCountryMember_TaxPeriodAxis_ExpiringThrough2037Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">galt:ExpiringThrough2037Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_IncomeTaxAuthorityAxis_StateAndLocalJurisdictionMember_TaxPeriodAxis_ExpiringAsAResultOf2017TaxActMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">galt:ExpiringAsAResultOf2017TaxActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_IncomeTaxAuthorityAxis_StateAndLocalJurisdictionMember_TaxPeriodAxis_ExpiringThrough2037Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">galt:ExpiringThrough2037Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_IncomeTaxAuthorityAxis_StateAndLocalJurisdictionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_IncomeTaxAuthorityAxis_DomesticCountryMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_StatementBusinessSegmentsAxis_BusinessOperatingSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">galt:BusinessOperatingSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_StatementBusinessSegmentsAxis_BusinessOperatingSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">galt:BusinessOperatingSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20231231_StatementBusinessSegmentsAxis_BusinessOperatingSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">galt:BusinessOperatingSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_StatementBusinessSegmentsAxis_BusinessOperatingSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">galt:BusinessOperatingSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20250331to20250331_CreditFacilityAxis_SupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">galt:SupplementalLineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-03-31</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250331_CreditFacilityAxis_SupplementalLineOfCreditMember_RangeAxis_MinimumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">galt:SupplementalLineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20250331_CreditFacilityAxis_SupplementalLineOfCreditMember_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">galt:SupplementalLineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20250331_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20250331_CreditFacilityAxis_SupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">galt:SupplementalLineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="U001"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="U002"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U003"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U004"><xbrli:measure>galt:LineofCredit</xbrli:measure></xbrli:unit><xbrli:unit id="U005"><xbrli:measure>galt:loan</xbrli:measure></xbrli:unit><xbrli:unit id="U006"><xbrli:measure>galt:PromissoryNote</xbrli:measure></xbrli:unit><xbrli:unit id="U007"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U008"><xbrli:measure>galt:Rights</xbrli:measure></xbrli:unit><xbrli:unit id="U009"><xbrli:measure>galt:Director</xbrli:measure></xbrli:unit><xbrli:unit id="U010"><xbrli:measure>galt:Lease</xbrli:measure></xbrli:unit><xbrli:unit id="U011"><xbrli:measure>galt:Segment</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
<div style="line-height: initial;">
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">

    <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"/>
    <div>
      <div style="text-align: center; font-size: 14pt; font-weight: bold; font-family: 'Times New Roman';">UNITED STATES<br/>
      </div>

      <div style="text-align: center; font-size: 14pt; font-weight: bold; font-family: 'Times New Roman';">SECURITIES AND EXCHANGE COMMISSION</div>

      <div style="text-align: center; font-size: 12pt; font-weight: bold; font-family: 'Times New Roman';">Washington, D.C. 20549</div>

      <div>
        <div style="text-align: center; margin-right: 216pt; margin-left: 216pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

        <hr style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 20%; color: #000000; text-align: center; margin-left: auto; margin-right: auto;"/></div>

      <div><br/></div>

      <div style="text-align: center; font-size: 18pt; font-weight: bold; font-family: 'Times New Roman';">FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_1d39da308fee4509978fb7b40ff088db" contextRef="c20240101to20241231">10-K</ix:nonNumeric></div>

      <div>
<div><br/></div>

        <hr style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 20%; color: #000000; text-align: center; margin-left: auto; margin-right: auto;"/></div>

      <div><br/></div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 24.5pt; vertical-align: top;"><ix:nonNumeric name="dei:DocumentAnnualReport" id="Fact_fddfb87ae304439aa691840231dd694e" contextRef="c20240101to20241231" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric><br/>
            </td>

    <td style="width: auto; vertical-align: top;">
              <div style="font-weight: bold;">Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</div>
            </td>

  </tr>


</table>
      <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">For the fiscal year ended <ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_c5c2f5a79dfb4096a2f424028c306a06" contextRef="c20240101to20241231" format="ixt:date-monthname-day-year-en">December 31, 2024</ix:nonNumeric></div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 24.5pt; vertical-align: top;"><ix:nonNumeric name="dei:DocumentTransitionReport" id="Fact_18e8f5f4b4bf470eb157dbdda1d79885" contextRef="c20240101to20241231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
            </td>

    <td style="width: auto; vertical-align: top;">
              <div style="font-weight: bold;">Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</div>
            </td>

  </tr>


</table>
      <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">For the transition period from <span style="text-decoration: underline;">&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; </span> to <span style="text-decoration: underline;">&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; </span></div>

      <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Commission File No. <ix:nonNumeric name="dei:EntityFileNumber" id="Fact_21754fde14a747e1bc18ab04ee5e8ed7" contextRef="c20240101to20241231">001-31791</ix:nonNumeric></div>

      <div>
<div><br/></div>

        <hr style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 20%; color: #000000; text-align: center; margin-left: auto; margin-right: auto;"/></div>

      <div><br/></div>

      <div style="text-align: center; font-size: 24pt; font-weight: bold; font-family: 'Times New Roman';"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_953eabfdf9874804aff1aa19f6b0881e" contextRef="c20240101to20241231">GALECTIN THERAPEUTICS INC.</ix:nonNumeric><br/>
      </div>

      <div>
        <div style="text-align: center; margin-right: 216pt; margin-left: 216pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

      </div>

      <div>
        <hr style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 20%; color: #000000; text-align: center; margin-left: auto; margin-right: auto;"/></div>

      <div><br/></div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 49%; vertical-align: top;">
              <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_4f057a264fa44629bc712c8aaeb63d51" contextRef="c20240101to20241231" format="ixt-sec:stateprovnameen">Nevada</ix:nonNumeric><br/>
              </div>
            </td>

    <td style="width: 2%; vertical-align: top;" colspan="1">&#160;</td>

    <td style="width: 49%; vertical-align: top;">
              <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_a442f07f6924441883c9389d925957cf" contextRef="c20240101to20241231">04-3562325</ix:nonNumeric><br/>
              </div>
            </td>

  </tr>

  <tr>

    <td style="width: 49%; vertical-align: top;">
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 8pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(State or other jurisdiction</span><span style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;<span style="font-weight: bold;">of incorporation)</span></span></div>
            </td>

    <td style="width: 2%; vertical-align: top;" colspan="1">&#160;</td>

    <td style="width: 49%; vertical-align: top;">
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 8pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(I.R.S. Employer</span><span style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;<span style="font-weight: bold;">Identification No.)</span></span></div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 49%; vertical-align: top;">
              <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_9b1b374e479a45eeb77ceeb840774e47" contextRef="c20240101to20241231">4960 Peachtree Industrial Blvd</ix:nonNumeric>., <ix:nonNumeric name="dei:EntityAddressAddressLine2" id="Fact_beabffa1284d4dc2b257ff74043b19a9" contextRef="c20240101to20241231">Suite 240</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_b6a5751053ab4b6e8455e9314eedd6ec" contextRef="c20240101to20241231">Norcross</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="Fact_71fa7d70e9d84d95a135b27a805d60f1" contextRef="c20240101to20241231">GA</ix:nonNumeric></div>
            </td>

    <td style="width: 2%; vertical-align: top;" colspan="1">&#160;</td>

    <td style="width: 49%; vertical-align: top;">
              <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_0262fd809588421c8d8ffa119dbcbf89" contextRef="c20240101to20241231">30071</ix:nonNumeric><br/>
              </div>
            </td>

  </tr>

  <tr>

    <td style="width: 49%; vertical-align: top;">
              <div style="text-align: center; font-weight: bold;">(Address of Principal Executive Offices)</div>
            </td>

    <td style="width: 2%; vertical-align: top;" colspan="1">&#160;</td>

    <td style="width: 49%; vertical-align: top;">
              <div style="text-align: center; font-weight: bold;">(Zip Code)</div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

      <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonNumeric name="dei:CityAreaCode" id="Fact_955ba63ee38743d286f46c8419e7f2e9" contextRef="c20240101to20241231">678</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_582e971dca4d431d9d5556d352f9f3a3" contextRef="c20240101to20241231">620-3186</ix:nonNumeric></div>

      <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">(Registrant&#8217;s Telephone Number, Including Area Code)</div>

      <div>
        <div style="text-align: center; margin-right: 216pt; margin-left: 216pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

      </div>

      <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Securities registered pursuant to Section 12(b) of the Act:</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 32%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
              <div style="text-align: center; font-weight: bold;">Title of each class</div>
            </td>

    <td style="width: 1%; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td style="width: 34%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
              <div style="text-align: center; font-weight: bold;">Trading </div>
              <div style="text-align: center; font-weight: bold;">Symbol <br/>
              </div>
            </td>

    <td style="width: 1%; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td style="width: 32%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
              <div style="text-align: center; font-weight: bold;">Name of each exchange</div>
              <div style="text-align: center; font-weight: bold;">on which registered <br/>
              </div>
            </td>

  </tr>

  <tr>

    <td style="width: 32%; vertical-align: top;">
              <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_d2ee777d449841ffad449d4a32fd62d3" contextRef="c20240101to20241231">Common Stock, $0.001 Par Value Per Share</ix:nonNumeric><br/>
              </div>
            </td>

    <td style="width: 1%; vertical-align: top;" colspan="1">&#160;</td>

    <td style="width: 34%; vertical-align: top;">
              <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_c0855df1a74b4623ae0742076a8ea271" contextRef="c20240101to20241231">GALT</ix:nonNumeric><br/>
              </div>
            </td>

    <td style="width: 1%; vertical-align: top;" colspan="1">&#160;</td>

    <td style="width: 32%; vertical-align: top;">
              <div style="text-align: center; font-weight: bold;">The <ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_07ceb375ec1a49848e09aac01b59ce8e" contextRef="c20240101to20241231">NASDAQ</ix:nonNumeric> Stock Market<br/>
              </div>
            </td>

  </tr>


</table>
      <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

      <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Securities registered pursuant to Section 12(g) of the Act:</div>

      <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">None</div>

      <div>
        <div style="text-align: center; margin-right: 216pt; margin-left: 216pt; font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

        <div>
          <hr style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 20%; color: #000000; text-align: center; margin-left: auto; margin-right: auto;"/></div>

        <div style="text-align: center; margin-right: 216pt; margin-left: 216pt; font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

      </div>

      <div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160; &#160; Yes&#160; &#9744;&#160; &#160; <ix:nonNumeric name="dei:EntityWellKnownSeasonedIssuer" id="Fact_a04a1a5f92fd410f9d24b8ef4ad816f5" contextRef="c20240101to20241231">No</ix:nonNumeric>&#160; &#9746;</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

      <div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.&#160; &#160; Yes &#9744;&#160; &#160; <ix:nonNumeric name="dei:EntityVoluntaryFilers" id="Fact_08a13c58f71942ca9915f7e6f545f138" contextRef="c20240101to20241231">No</ix:nonNumeric> &#9746;</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

      <div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the
        preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160; &#160; <ix:nonNumeric name="dei:EntityCurrentReportingStatus" id="Fact_b5f0b75412224e21a57d9cf92b0c50cc" contextRef="c20240101to20241231">Yes</ix:nonNumeric>&#160; &#9746;&#160; &#160; No&#160; &#9744;</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

      <div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T
        (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160; &#160; <ix:nonNumeric name="dei:EntityInteractiveDataCurrent" id="Fact_5e82b61e4c584356b6c36644bdc3f734" contextRef="c20240101to20241231">Yes</ix:nonNumeric>&#160;
        &#9746;&#160; &#160; No&#160; &#9744;</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

      <div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging
        growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 45%; vertical-align: bottom;">
              <div>Large accelerated filer</div>
            </td>

    <td style="width: 5%; vertical-align: bottom;">
              <div>&#9744;</div>
            </td>

    <td style="width: 45%; vertical-align: bottom;">
              <div>Accelerated filer</div>
            </td>

    <td style="width: 5%; vertical-align: bottom;">
              <div>&#9744;</div>
            </td>

  </tr>

  <tr>

    <td style="width: 45%; vertical-align: bottom;">
              <div><ix:nonNumeric name="dei:EntityFilerCategory" id="Fact_90e8a6e744cd4a68b69b96e8f06ee0de" contextRef="c20240101to20241231" format="ixt-sec:entityfilercategoryen">Non-accelerated filer</ix:nonNumeric><br/>
              </div>
            </td>

    <td style="width: 5%; vertical-align: bottom;">
              <div>&#9746;</div>
            </td>

    <td style="width: 45%; vertical-align: bottom;">
              <div>Smaller reporting company</div>
            </td>

    <td style="width: 5%; vertical-align: bottom;">
              <div><ix:nonNumeric name="dei:EntitySmallBusiness" id="Fact_854f2798404642e586e7572f74f65334" contextRef="c20240101to20241231" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric><br/>
              </div>
            </td>

  </tr>

  <tr>

    <td style="width: 45%; vertical-align: bottom;">&#160;</td>

    <td style="width: 5%; vertical-align: bottom;">&#160;</td>

    <td style="width: 45%; vertical-align: bottom;">
              <div>Emerging growth company</div>
            </td>

    <td style="width: 5%; vertical-align: bottom;">
              <div><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_bda773c3412c4710ac19396fa4a115d5" contextRef="c20240101to20241231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
              </div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

      <div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
        financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

      <div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over
        financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.&#160; &#160; Yes&#160; <ix:nonNumeric name="dei:IcfrAuditorAttestationFlag" id="Fact_bb55b33498bc4a509bfed4d47ced5f6b" contextRef="c20240101to20241231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric>&#160; &#160; No&#160; &#9746;</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <div style="background-color: #FFFFFF; letter-spacing: normal; white-space: normal; word-spacing: 0px; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: left; text-indent: 24.5pt; text-transform: none;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to
          previously issued financial statements. <ix:nonNumeric name="dei:DocumentFinStmtErrorCorrectionFlag" id="Fact_36b3ac4ee47645f9b1bee69e6d59d745" contextRef="c20240101to20241231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></div>

        <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman', Times, serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"><br/>
        </div>

        <div style="background-color: #FFFFFF; letter-spacing: normal; white-space: normal; word-spacing: 0px; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: left; text-indent: 24.5pt; text-transform: none;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive o&#64259;cers
          during the relevant recovery period pursuant to &#167;240.10D-1(b).&#160;<span style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</span></div>

      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

      <div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160; &#160; Yes&#160; <ix:nonNumeric name="dei:EntityShellCompany" id="Fact_fcbad44f818c474781665b0b63606aeb" contextRef="c20240101to20241231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric>&#160; &#160; No&#160; &#9746;</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

      <div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was sold, or
        the average bid and asked price of such common equity, as of June 30, 2024 was<span style="font-family: 'Times New Roman'; font-size: 10pt;"> approximately </span>$<ix:nonFraction name="dei:EntityPublicFloat" id="Fact_7d3fc79be079490ab4b65a286b372783" contextRef="c20240630" unitRef="U001" decimals="-6" scale="6" format="ixt:num-dot-decimal">112</ix:nonFraction> million.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

      <div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">The number of shares outstanding of the registrant&#8217;s common stock as of <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0);">March 3, 2025 was <ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" id="Fact_9146d9ca18fb4c9eaadd1077bdf89fc1" contextRef="c20250303" unitRef="U002" decimals="INF" scale="0" format="ixt:num-dot-decimal">63,180,491</ix:nonFraction></span>.</div>

      <div>
        <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

      </div>

      <div style="padding-top: 1pt;">
        <div>
          <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"/></div>

      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

      </div>

    </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">

    <div>
      <div style="text-align: center; color: #000000; font-weight: bold;"><a id="INDEX"><!--Anchor--></a>INDEX TO FORM 10-K</div>

      <div style="text-align: center; color: #000000; font-weight: bold;">FOR THE YEAR ENDED DECEMBER 31, 2022</div>

      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td style="width: 5%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; font-weight: bold;">PAGE</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: bottom;">
              <div style="font-weight: bold;"><span style="text-decoration: underline;">PART 1</span></div>
            </td>

    <td style="width: 85%; vertical-align: bottom;">&#160;</td>

    <td style="width: 5%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div>ITEM 1.</div>
            </td>

    <td style="width: 85%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div><a href="#Item1.">Business</a></div>
            </td>

    <td style="width: 5%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">1</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: bottom;">
              <div>ITEM 1A.</div>
            </td>

    <td style="width: 85%; vertical-align: bottom;">
              <div><a href="#Item1A.">Risk Factors</a></div>
            </td>

    <td style="width: 5%; vertical-align: bottom;">
              <div style="text-align: right;">9</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div>ITEM 1B.</div>
            </td>

    <td style="width: 85%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div><a href="#Item1B.">Unresolved Staff Comments</a></div>
            </td>

    <td style="width: 5%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">20</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: bottom;">
              <div>ITEM IC</div>
            </td>

    <td style="width: 85%; vertical-align: bottom;">
              <div><a href="#Item1C.">Cybersecurity</a></div>
            </td>

    <td style="width: 5%; vertical-align: bottom;">
              <div style="text-align: right;">20</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 85%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 5%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: bottom;">
              <div>ITEM 2.</div>
            </td>

    <td style="width: 85%; vertical-align: bottom;">
              <div><a href="#Item2.">Properties</a></div>
            </td>

    <td style="width: 5%; vertical-align: bottom;">
              <div style="text-align: right;">20</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div>ITEM 3.</div>
            </td>

    <td style="width: 85%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div><a href="#Item3.">Legal Proceedings</a></div>
            </td>

    <td style="width: 5%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">20</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: bottom;">
              <div>ITEM 4.</div>
            </td>

    <td style="width: 85%; vertical-align: bottom;">
              <div><a href="#Item4.">Mine Safety Disclosure</a></div>
            </td>

    <td style="width: 5%; vertical-align: bottom;">
              <div style="text-align: right;">20</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 85%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 5%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: bottom;">
              <div style="font-weight: bold;"><span style="text-decoration: underline;">PART II</span></div>
            </td>

    <td style="width: 85%; vertical-align: bottom;">&#160;</td>

    <td style="width: 5%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div>ITEM 5.</div>
            </td>

    <td style="width: 85%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div><a href="#Item5.">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></div>
            </td>

    <td style="width: 5%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">21</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: bottom;">
              <div>ITEM 6.</div>
            </td>

    <td style="width: 85%; vertical-align: bottom;">
              <div><a href="#Item6.">[Reserved]</a></div>
            </td>

    <td style="width: 5%; vertical-align: bottom;">
              <div style="text-align: right;">21</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div>ITEM 7.</div>
            </td>

    <td style="width: 85%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div><a href="#Item7.">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></div>
            </td>

    <td style="width: 5%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">21</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: bottom;">
              <div>ITEM 7A.</div>
            </td>

    <td style="width: 85%; vertical-align: bottom;">
              <div><a href="#Item7A.">Quantitative and Qualitative Discussions About Market Risk</a></div>
            </td>

    <td style="width: 5%; vertical-align: bottom;">
              <div style="text-align: right;">25</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div>ITEM 8.</div>
            </td>

    <td style="width: 85%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div><a href="#Item8.">Financial Statements and Supplementary Data</a></div>
            </td>

    <td style="width: 5%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">26</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: bottom;">
              <div>ITEM 9.</div>
            </td>

    <td style="width: 85%; vertical-align: bottom;">
              <div><a href="#Item9.">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></div>
            </td>

    <td style="width: 5%; vertical-align: bottom;">
              <div style="text-align: right;">26</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div>ITEM 9A.</div>
            </td>

    <td style="width: 85%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div><a href="#Item9A.">Controls and Procedures</a></div>
            </td>

    <td style="width: 5%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">26</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: bottom;">
              <div>ITEM 9B.</div>
            </td>

    <td style="width: 85%; vertical-align: bottom;">
              <div><a href="#Item9B.">Other Information</a></div>
            </td>

    <td style="width: 5%; vertical-align: bottom;">
              <div style="text-align: right;">27</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div>ITEM 9C</div>
            </td>

    <td style="width: 85%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div><a href="#Item9C.">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></div>
            </td>

    <td style="width: 5%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">27</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: bottom;">&#160;</td>

    <td style="width: 85%; vertical-align: bottom;">&#160;</td>

    <td style="width: 5%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="font-weight: bold;"><span style="text-decoration: underline;">PART III</span></div>
            </td>

    <td style="width: 85%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 5%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: bottom;">
              <div>ITEM 10.</div>
            </td>

    <td style="width: 85%; vertical-align: bottom;">
              <div><a href="#Item10.">Directors, Executive Officers and Corporate Governance</a></div>
            </td>

    <td style="width: 5%; vertical-align: bottom;">
              <div style="text-align: right;">28</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div>ITEM 11.</div>
            </td>

    <td style="width: 85%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div><a href="#Item11.">Executive Compensation</a></div>
            </td>

    <td style="width: 5%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">31</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: bottom;">
              <div>ITEM 12.</div>
            </td>

    <td style="width: 85%; vertical-align: bottom;">
              <div><a href="#Item12.">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></div>
            </td>

    <td style="width: 5%; vertical-align: bottom;">
              <div style="text-align: right;">39</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div>ITEM 13.</div>
            </td>

    <td style="width: 85%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div><a href="#Item13.">Certain Relationships, Related Transactions and Director Independence</a></div>
            </td>

    <td style="width: 5%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">41</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 10%; vertical-align: bottom;">
              <div>ITEM 14.</div>
            </td>

    <td style="width: 85%; vertical-align: bottom;">
              <div><a href="#Item14.">Principal Accountant Fees and Services</a></div>
            </td>

    <td style="width: 5%; vertical-align: bottom;">
              <div style="text-align: right;">42</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 85%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 5%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: bottom;">
              <div style="font-weight: bold;"><span style="text-decoration: underline;">PART IV</span></div>
            </td>

    <td style="width: 85%; vertical-align: bottom;">&#160;</td>

    <td style="width: 5%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div>ITEM 15.</div>
            </td>

    <td style="width: 85%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div><a href="#Item15.">Exhibits and Financial Statement Schedules</a></div>
            </td>

    <td style="width: 5%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">43</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: bottom;">
              <div>ITEM 16</div>
            </td>

    <td style="width: 85%; vertical-align: bottom;">
              <div><a href="#Item16.">Form 10-K Summary</a></div>
            </td>

    <td style="width: 5%; vertical-align: bottom;">
              <div style="text-align: right;">46</div>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="2">
              <div><a href="#SIGNATURES">SIGNATURES</a></div>
            </td>

    <td style="width: 5%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">47</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div style="width: 100%;" class="BRPFPageHeader">
          <div>
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

            </div>

          </div>

        </div>

      </div>

      <!--PROfilePageNumberReset%Num%1%%%-->
      <div style="text-align: center; color: #000000; font-weight: bold;">PART I</div>

      <div><br/>
      </div>

      <div>
        <div>
          <a id="Item1."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="text-align: right; vertical-align: top; width: 54pt;">
                  <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">Item 1.</div>
                </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                  <div style="color: rgb(0, 0, 0); font-weight: bold; font-style: italic;">Business</div>
                </td>

  </tr>


</table>
        </div>

        <div style="color: #000000; font-weight: bold;"> <br/>
        </div>

      </div>

      <div style="color: rgb(0, 0, 0); font-weight: bold;">Overview</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt; color: #000000;">We are a clinical stage biopharmaceutical company engaged in drug research and development to create new therapies for fibrotic disease, cancer and selected other diseases. Our drug candidates are based
        on our method of targeting galectin proteins, which are key mediators of biologic and pathologic functions. We use naturally occurring, readily-available plant products as starting material in manufacturing processes to create proprietary, patented
        complex carbohydrates with specific molecular weights and other pharmaceutical properties. These complex carbohydrate molecules are appropriately formulated into acceptable pharmaceutical formulations. Using these unique carbohydrate-based
        candidate compounds that largely bind and inhibit galectin proteins, particularly galectin-3, we are undertaking the focused pursuit of therapies for indications where galectin proteins have a demonstrated role in the pathogenesis of a given
        disease. We focus on diseases with serious, life-threatening consequences and those where current treatment options are limited specifically in NASH (non-alcoholic steatohepatitis) with cirrhosis and certain cancer indications. Our strategy is to
        establish and implement clinical development programs that add value to our business in the shortest period of time possible and to seek strategic partners when one of our programs becomes advanced and requires significant additional resources.</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt; color: #000000;">Our lead galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis and in clinical studies to decrease portal hypertension
        and prevent its complication: the development of esophageal varices. Belapectin has the potential to treat many diseases due to galectin-3&#8217;s involvement in multiple key biological pathways such as fibrosis, immune cell function and immunity, cell
        differentiation, cell growth, and apoptosis (cell death). The importance of galectin-3 in the fibrotic process is supported by experimental evidence. Animals with the galectin-3 gene &#8220;knocked-out&#8221; can no longer develop fibrosis in response to
        experimental stimuli compared to animals with an intact galectin-3 gene. We are using our galectin-3 inhibitor to treat advanced liver fibrosis and liver cirrhosis in NASH patients. We have completed two Phase 1 clinical studies, a Phase 2 clinical
        study in NASH patients with advanced fibrosis (NASH-FX) and a second Phase 2b clinical trial in NASH patients with compensated cirrhosis and portal hypertension (NASH-CX).</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt; color: #000000;">In February 2023, we completed randomizations totaling 357 patients in a large, global Phase 2b/3 clinical trial, the NAVIGATE trial. Our study protocol was filed with the FDA on April 30, 2020, for a
        seamless adaptively-designed Phase 2b/3 clinical study evaluating the safety and efficacy of our galectin-3 inhibitor, belapectin, for the prevention of esophageal varices in patients with non-alcoholic steatohepatitis (NASH) cirrhosis Further
        details are available at <span style="text-decoration: underline;">www.clinicaltrials.gov</span> under study NCT04365868. The information contained therein is not incorporated herein by reference.&#160; &#160; In September 2020, the Company received a letter from the FDA providing comments, asking
        questions and providing guidance on various aspects of the ongoing NAVIGATE trial. These comments were addressed, and the study proceeded accordingly.</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt; color: #000000;">
        <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Based on feedback from the U.S. Food and Drug Administration (FDA), the Company decided to analyze stage 1 of the NAVIGATE clinical trial results as a
          stand-alone trial.&#160;&#160; Therefore, the decision was made to present full top-line efficacy and safety results, following last patient last visit and database lock which occurred in fall 2024.&#160;&#160; In December 2024, we presented top-line results of the
          NAVIGATE clinical trial.&#160; In the intent-to-treat (ITT) population (N=355), while the incidence of varices was 43.2% reduced in the belapectin 2 mg/kg dose group vs placebo, the composite endpoint did not reach statistical significance. The
          per-protocol population (PPP) was pre-defined as subjects who completed 18 months of therapy with upper endoscopy performed at both baseline and 18 months. In the PPP (n=287), the incidence of varices was reduced by 49.3% (compared to the
          targeted 52.5% reduction) in the belapectin 2 mg/kg dose group (p-value &lt; 0.05). The Company further analyzed the two thirds of the completer patients in the NAVIGATE trial enrolled in the U.S. (n=186). The incidence of varices in this
          population was significantly reduced by 68.1% (p=0.02) in patients treated with belapectin 2 mg (4 out of 60) vs placebo (13 out of 62) in the U.S. While all three cohorts of patients in the U.S. had a higher percentage use of GLP-1 and statins
          than the rest of the world, the belapectin cohorts performed much better than placebo in the U.S.&#160; The Company continues to analyze trial data and expects to report additional information on specific biomarkers in the second quarter of 2025.</div>

      </div>

      <div><br/></div>

      <!--PROfilePageNumberReset%Num%1%%%-->
      <div style="text-indent: 36pt; color: #000000;">As in prior trials, the safety profile of belapectin remains highly encouraging with incidence of adverse events and serious adverse events comparable across the three cohorts. Rates of discontinuation,
        adverse events (AEs), and serious adverse events (SAEs) were comparable to placebo, with no drug-related SAEs reported in the NAVIGATE trial.</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt; color: #000000;">The Company continues to analyze data from approximately 55 patients that completed 36 months of treatment prior to the ending of the trial in February 2025. While data from this group would not change
        the results of the NAVIGATE clinical trial for patients completing 18 months of treatment, the Company believes that any encouraging results from this group of patients may draw interest from potential strategic partners.</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt; color: #000000;">Additionally, a study protocol entitled &#8220;A Single-dose, Open-label, Pharmacokinetic Study of Belapectin (GR-MD-02) in Subjects With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic
        Impairment&#8221; has been filed with the FDA to examine the effects of the drug in subjects with normal hepatic function and subjects with varying degrees of hepatic impairment (study details are listed under study NCT04332432 on <span style="text-decoration: underline;">www.clinicaltrials.gov</span>);

























        this study became fully enrolled in February 2022 and favorable results were reported in 2023. The information contained therein is not incorporated herein by reference.</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt; color: #000000;">We endeavor to leverage our scientific and product development expertise as well as established relationships with outside sources to achieve cost-effective and efficient drug development. These outside
        sources, amongst others, provide us with expertise in preclinical models, pharmaceutical development, toxicology, clinical trial operations, pharmaceutical manufacturing, including physical and chemical drug characterization, and commercial
        development. We also have established through our majority-owned joint venture subsidiary, Galectin Sciences LLC, a discovery program developing small molecules that inhibit galectin-3 and may afford alternative drug delivery (e.g., oral) and as a
        result expand the potential uses of galectin-3 inhibitor beyond belapectin. Three chemical series of composition of matter patents have been filed.</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt; color: #000000;">We are also pursuing a development pathway to clinical enhancement and commercialization for our lead compounds in immuno-oncology following our previous successful collaboration with Providence
        Portland Cancer Center. In 2022, we filed a new IND with FDA for advanced or metastatic head and neck cancer using belapectin in combination with a checkpoint (PD-1) inhibitor and received a Study May Proceed letter. The proposed phase 2 trial
        commencement is dependent on timing of financing.</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt; color: #000000;">All of our proposed products are presently in development, including pre-clinical and clinical trials.</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt; color: #000000;">We were founded in July 2000 as Pro-Pharmaceuticals, Inc., a Massachusetts corporation. On April 25, 2001, DTR-Med Pharma Corp. (&#8220;DTR&#8221;), which was incorporated in Nevada on January 26, 2001, entered
        into a stock exchange agreement with Pro-Pharmaceuticals, Inc., whereby DTR acquired all of the outstanding shares of common stock of Pro-Pharmaceuticals, Inc. On May 10, 2001, DTR changed its name to &#8220;Pro-Pharmaceuticals, Inc.&#8221; and on June 7,
        2001, the Massachusetts corporation was merged into the Nevada corporation. On May 26, 2011, Pro-Pharmaceuticals, Inc. changed its name to &#8220;Galectin Therapeutics Inc.&#8221; In October 2012, we moved our headquarters to a suburb of Atlanta, GA to be
        closer to a center of discovery collaboration while maintaining a laboratory operation in the Boston area.</div>

      <div><br/>
      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">1</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div style="width: 100%;" class="BRPFPageHeader">
          <div>
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

            </div>

          </div>

        </div>

      </div>

      <div style="color: #000000; font-weight: bold;">Our Drug Development Programs</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt; color: #000000;">Galectins are a class of proteins that are made by many cells in the body, but predominantly in cells of the immune system. As a group, these proteins are able to bind to sugar molecules that are
        attached to other proteins, called glycoproteins that are responsible for various functions within the body, most notably inflammation and fibrosis. Galectins, in particular galectin-3, act as a molecular glue, bringing together molecules that have
        sugars on them. Galectin-3, is known to be markedly increased in a number of significant diseases including inflammatory diseases leading to organs scarring (e.g. liver, lung, kidney, and heart) and cancers. The increase in galectin-3, by creating
        the so-called galectin-3 fibrosome, promotes the progression of multiple diseases. Published data substantiating the importance of galectin-3 in the fibrotic process arises from gene knockout experiments in animal studies. For instance, mice
        genetically altered to eliminate the galectin-3 gene, and thus unable to produce galectin-3, do not develop liver fibrosis in response to toxic insult to the liver.</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt; color: #000000;">We have one new proprietary chemical entity (NCE) in development, belapectin, which has shown promise in preclinical and clinical studies for the treatment of liver fibrosis, severe skin disease, and
        cancer (melanoma and head and neck squamous cell carcinoma). Currently, we are focusing on development of belapectin for the treatment of NASH cirrhosis and head and neck cancer. Belapectin is a proprietary, patented compound derived from natural,
        plant-based, starting materials, which following chemical processing, exhibits the properties of binding to and inhibiting galectin-3.</div>

      <div><br/>
      </div>

      <div style="color: #000000;">Our product pipeline is shown below:</div>

      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 28%; vertical-align: bottom;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Indication</div>
            </td>

    <td style="width: 14%; vertical-align: bottom;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Drug</div>
            </td>

    <td style="width: 58%; vertical-align: bottom;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Status</div>
            </td>

  </tr>

  <tr>

    <td style="width: 28%; vertical-align: bottom;">
              <div style="color: #000000; font-weight: bold;">Prevention of esophageal </div>
              <div style="color: #000000; font-weight: bold;">varices in</div>
              <div style="color: #000000; font-weight: bold;">NASH cirrhosis</div>
            </td>

    <td style="width: 14%; vertical-align: bottom;">&#160;</td>

    <td style="width: 58%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 28%; vertical-align: bottom;">&#160;</td>

    <td style="width: 14%; vertical-align: bottom;">&#160;</td>

    <td style="width: 58%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 28%; vertical-align: top;">
              <div style="color: #000000;">Phase 1 interaction trial:</div>
              <div style="color: #000000;">NASH-CX trial and</div>
              <div style="color: #000000;">NASH-FX trial</div>
            </td>

    <td style="width: 14%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">belapectin</div>
            </td>

    <td style="width: 58%; vertical-align: top;">
              <div style="color: #000000;">IND submitted January 2013. Results from the Phase 1 interaction trial were reported in 2014, with final results reported in January 2015.</div>
              <div>&#160;</div>
              <div style="color: #000000;">The Phase 2 NASH FX trial was conducted in patients with advanced fibrosis but not cirrhosis. Its principal purpose was to evaluate various imaging modalities. The NASH FX trial top line data was reported in
                September 2016 and published in Alimentary Pharmacology and Therapeutics in 2016.</div>
              <div>&#160;</div>
              <div style="color: #000000;">The Phase 2 NASH CX trial was conducted in patients with compensated cirrhosis and portal hypertension. The NASH CX trial top line data was reported in December 2017 and was published in <span style="font-style: italic;">Gastroenterology</span> in 2020.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 28%; vertical-align: bottom;">&#160;</td>

    <td style="width: 14%; vertical-align: bottom;">&#160;</td>

    <td style="width: 58%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 28%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">NASH NAVIGATE</div>
            </td>

    <td style="width: 14%; vertical-align: top;">&#160;</td>

    <td style="width: 58%; vertical-align: top;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Following FDA feedback, the NAVIGATE trial was for the prevention of esophageal varices in NASH patients with compensated cirrhosis and clinical
                signs of portal hypertension.. The final patient was randomized in February 2023 and top-line results were presented in December 2024</div>
            </td>

  </tr>

  <tr>

    <td style="width: 28%; vertical-align: top;">&#160;</td>

    <td style="width: 14%; vertical-align: top;">&#160;</td>

    <td style="width: 58%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 28%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Phase 1 study: hepatic insufficiency</div>
            </td>

    <td style="width: 14%; vertical-align: top;">&#160;</td>

    <td style="width: 58%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">A hepatic impairment study is being conducted in subjects with normal hepatic function and subjects with varying degrees of hepatic impairment (www.clinicaltrials.gov NCT04332432) and began enrolling patients
                in the second quarter of 2020. The study completed enrollment in February 2022 and favorable results were presented in 2023.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 28%; vertical-align: bottom;">&#160;</td>

    <td style="width: 14%; vertical-align: bottom;">&#160;</td>

    <td style="width: 58%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 28%; vertical-align: bottom;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Cancer Immunotherapy</div>
            </td>

    <td style="width: 14%; vertical-align: bottom;">&#160;</td>

    <td style="width: 58%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 28%; vertical-align: bottom;">&#160;</td>

    <td style="width: 14%; vertical-align: bottom;">&#160;</td>

    <td style="width: 58%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 28%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Melanoma, Head, Neck Squamous Cell belapectin Carcinoma (HNSCC)</div>
            </td>

    <td style="width: 14%; vertical-align: bottom;">&#160;</td>

    <td style="width: 58%; vertical-align: bottom;">
              <div style="color: rgb(0, 0, 0);">Investigator IND study was completed. A Phase 1B study began in Q-1 2016. Early data was reported in February 2017 and additional data were reported in September 2018. Data from an extension trial was
                reported in July 2021 for additional melanoma and HNSCC patients which provided a rational basis for additional trials which the Company is exploring. In the third quarter of 2022, the Company announced its IND application for belapectin in
                combination with a checkpoint inhibitor for the treatment of HNSCC was filed and a Study May Proceed letter was received from FDA. The Company is reviewing options for financing this trial which will determine when such trial could
                commence.</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">2</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div style="width: 100%;" class="BRPFPageHeader">
          <div>
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

            </div>

          </div>

        </div>

      </div>

      <div style="text-indent: 27pt; color: #000000;"><span style="font-style: italic;">Liver cirrhosis. </span>Belapectin is our lead product candidate for treatment of compensated NASH cirrhosis in patients with portal hypertension. Our preclinical data
        show that belapectin has a significant therapeutic effect on liver fibrosis as shown in several relevant animal models. In addition, in NASH animal models, belapectin has been shown to reduce liver fat, inflammation, portal pressure, and ballooning
        degeneration (death of liver cells). Therefore, we chose belapectin as the lead candidate in a development program targeted initially at fibrotic liver disease associated with non-alcoholic steatohepatitis (NASH). In January 2013, an
        Investigational New Drug (&#8220;IND&#8221;) was submitted to the FDA with the goal of initiating a Phase 1 study in patients with NASH and advanced liver fibrosis to evaluate the safety of belapectin and pharmacodynamics biomarkers of disease. On March 1,
        2013, the FDA indicated we could proceed with a US Phase 1 clinical trial for belapectin with a development program aimed at obtaining support for a proposed indication of belapectin for treatment of NASH with advanced fibrosis. The Phase 1 trial
        was completed and demonstrated that belapectin up to 8 mg/kg Lean Body Mass (LBM), i.v. was safe and well tolerated.</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt; color: #000000;">Additionally, an open label drug-drug phase 1 interaction study was completed in healthy volunteers during the second quarter of 2015 with belapectin and it showed that with 8 mg/kg LBM dose of
        belapectin and 2 mg/kg LBM dose of midazolam there was no drug-drug interaction, and no serious adverse events or drug-related adverse events were observed. The secondary objective was to assess the safety and tolerability of belapectin when
        administered concomitantly with midazolam.</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt; color: #000000;">Our Phase 2 program in fibrotic disease consisted of two separate human clinical trials. The main clinical trial was the Phase 2b NASH-CX study for one year for patients with NASH with compensated
        cirrhosis and portal hypertension, which began enrolling patients in June 2015. This study was a randomized, placebo-controlled, double-blind, parallel-group Phase 2b trial to evaluate the safety and efficacy of belapectin for treatment of liver
        fibrosis and resultant portal hypertension in NASH patients with compensated cirrhosis. A smaller, exploratory NASH-FX trial was conducted to explore potential use of various non-invasive imaging techniques in NASH patients with advanced fibrosis
        but not cirrhosis.</div>

      <div><br/>
      </div>

      <div style="text-indent: 24.3pt; color: #000000;"><span style="font-weight: bold;">NASH-FX Trial: </span>The NASH-FX trial was a Phase 2a pilot trial for patients with NASH and advanced fibrosis that explored use of three non-invasive imaging
        technologies. It was a short, single site, four-month trial in 30 NASH patients with advanced fibrosis (F3) randomized 1:1 to either 9 bi-weekly doses of 8 mg/kg LBM of belapectin or placebo. The trial did not meet its primary endpoint as measured
        using multi-parametric magnetic resonance imaging (LiverMultiScan<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(R)</sup>, Perspectum Diagnostics). The trial also did not meet secondary endpoints that measure liver
        stiffness as a surrogate for fibrosis using, magnetic resonance-elastography and FibroScan<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> score. With a four-month treatment period and a small number of patients
        per arm the study was not powered to demonstrate efficacy results in established advanced liver fibrosis. In the trial however, belapectin was found to be safe and well tolerated with no serious adverse events and showing evidence of a
        pharmacodynamic effect. These results provided support for further development in NASH.</div>

      <div><br/>
      </div>

      <div style="text-indent: 27pt; color: #000000;"><span style="font-weight: bold;">NASH-CX Trial: </span>The NASH-CX trial was a larger multi-center clinical trial that explored the use of belapectin for the treatment of patients with well-compensated
        NASH cirrhosis and portal hypertension. Enrollment was completed in September 2016, and a total of 162 patients at 36 sites in the United States were randomized to receive either 2 mg/kg LBM of belapectin, 8 mg/kg LBM of belapectin or placebo.
        Approximately 50% of patients at baseline had esophageal varices (a complication of portal hypertension). The primary endpoint was a reduction in hepatic venous pressure gradient (HVPG), a hemodynamic measure that estimates portal hypertension.
        Patients received an infusion of belapectin or placebo every other week for one year and were evaluated to determine the change in HVPG as compared with placebo. Secondary or exploratory endpoints included evaluation of fibrosis on liver biopsy,
        measurement of liver stiffness (FibroScan) and assessment of liver metabolism (<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">13</sup>C-methacetin breath test). Top line data readout was reported in December 2017. The
        study demonstrated a favorable safety profile and clinically meaningful efficacy results in patients without esophageal varices at baseline as demonstrated by a decrease in portal pressure associated with the prevention of development of varices
        when compared to placebo.</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt; color: #000000;">In the total patient population, the primary endpoint HVPG showed a trend toward benefit with belapectin treatment, but the difference from placebo was not statistically significant. The mean change in
        HVPG of placebo from baseline to week 54 was 0.3 mm Hg. The mean change in HVPG from baseline was -0.37 and -0.42 for the 2 mg/kg LBM dose and 8 mg/kg LBM dose of belapectin, respectively.</div>

      <div><br/></div>

      <div style="text-indent: 36pt; color: #000000;">In those NASH cirrhosis patients with portal hypertension who have not yet developed esophageal varices at baseline (about 50% of the total population), there was a statistically significant effect of
        the 2 mg/kg LBM dose of belapectin on the absolute change in HVPG (-1.08 mm Hg, p&lt;0.01). The effect of the 8 mg/Kg LBM dose of belapectin on absolute or percent change in HVPG from baseline to week 54 was not significant.</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt; color: #000000;">Also because of the clinical relevance of this population, a responder analysis was performed on those patients without esophageal varices at baseline. Analysis was performed looking at two groups:
        those with an equal to or greater than 2 mm Hg decrease in HVPG from baseline or those with an equal to or greater than 2 mm Hg and a greater than or equal to 20% decrease in HVPG from baseline. In both cases, the change observed in the belapectin
        2 mg/kg LBM group was statistically significant (p&lt;0.01) while that of the 8 mg/kg LBM group was not.</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt; color: #000000;">Over the 54-week treatment period, in patients without varices at baseline there were also a statistically significantly fewer new varices that developed in the belapectin treatment groups (0% and 4% in
        the 2 mg/kg LBM and the 8 mg/kg LBM, respectively) vs placebo (18%). This meant that the decrease seen in portal pressure was associated with a decreased incidence of esophageal varices. The results were noticeable in the belapectin 2 mg/Kg LBM
        group as statistical significance against placebo was achieved for both parameters. As esophageal varices can lead to hemorrhagic complication, which can be fatal, and are a severe complication of liver cirrhosis, we believe the prevention of
        esophageal varices may represent a clinically relevant measure of clinical efficacy in patients with NASH cirrhosis.</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt; color: #000000;">The major conclusions from the NASH-CX trial results were that: (i) belapectin had a statistically significant and clinically meaningful effect in improving HVPG vs placebo in patients with NASH
        cirrhosis who did not have esophageal varices at baseline, (ii) Belapectin in the total patient population was associated with a statistically significant improvement in hepatocyte ballooning (i.e. cell death), (iii) There was a statistically
        significant reduction (p=0.02) in the development of new esophageal varices in drug-treated patients compared to placebo. We believe that the prevention of esophageal varices is a clinically relevant endpoint related to patient outcomes, (iv) While
        there was a drug effect in both the 2 mg/kg LBM and 8 mg/kg LBM groups on the development of varices and liver biopsy there was a consistently greater and statistically significant effect of the 2 mg/kg LBM dose of belapectin, (v) belapectin
        appears to be safe and well tolerated in this one year clinical trial, a feature that is of prime importance for a cirrhotic population and (vi) This is the first large, randomized clinical trial to demonstrate a clinically meaningful improvement
        in portal hypertension in patients with compensated NASH cirrhosis who have not yet developed esophageal varices.</div>

      <div><br/>
      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">3</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div style="width: 100%;" class="BRPFPageHeader">
          <div>
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

            </div>

          </div>

        </div>

      </div>

      <div style="text-indent: 36pt; color: #000000;">Further information and details on the NASH-CX results is available in public presentations posted to our website and filed with the SEC and in a peer reviewed publication in <span style="font-style: italic;">Gastroenterology</span> 2020;158:1334&#8211;1345.</div>

      <div><br/>
      </div>

      <div style="text-indent: 24.3pt; color: #000000;"><span style="font-weight: bold;">NASH NAVIGATE Trial: </span>Building on the experience of the NASH-CX trial, the NAVIGATE Trial was designed as a seamless adaptively-designed Phase<span style="font-weight: bold;">&#160;</span>2b/3 clinical study evaluating the safety and efficacy of our galectin-3 inhibitor, belapectin, for the prevention of esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis. The major
        features of this innovative Phase 2b/3 study design are: i) In patients with NASH cirrhosis and clinical signs of portal hypertension but without esophageal varices at baseline, evaluated by an esophago-gastro-duodeno endoscopy, this trial will
        assess the effect of belapectin on the incidence of new varices&#160; (the primary endpoint) &#8211; as well as assessing the effect of belapectin on the incidence of additional clinically significant cirrhosis-related outcomes (a key secondary efficacy
        endpoint), (ii) The study targets NASH patients with a clearly identified unmet medical need: patients with compensated cirrhosis who have clinical signs of portal hypertension and, thus, are at risk of developing esophageal varices, a potentially
        life-threatening complication of cirrhosis (bleeding varices are a cause of death in about one-third of cirrhotic patients). There is currently no approved treatment for preventing varices in these patients. In addition, the development of
        esophageal varices reflects the progression of hepatic cirrhosis and thus portends the development of other cirrhosis complications such as ascites, hepatic encephalopathy, and liver failure, and (iii) During the first 18 months, two belapectin
        dose levels (2 mg/kg LBM and 4 mg/kg LBM) will be compared to placebo (phase 2b).</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt; color: #000000;">
        <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Based on feedback from the U.S. Food and Drug Administration (FDA), the Company has decided to analyze stage 1 of the NAVIGATE
          clinical trial results as a stand-alone trial.&#160;&#160; Therefore, a decision was made to present full top-line efficacy and safety results, following last patient last visit and database lock which occurred in fall 2024.&#160;&#160; In December 2024, we
          presented top-line results of the NAVIGATE clinical trial.&#160; In the intent-to-treat (ITT) population (N=355), while the incidence of varices was 43.2% reduced in the belapectin 2 mg/kg dose group vs placebo, the composite endpoint did not reach
          statistical significance. The per-protocol population (PPP) was pre-defined as subjects who completed 18 months of therapy with upper endoscopy performed at both baseline and 18 months. In the PPP (n=287), the incidence of varices was reduced by
          49.3% (compared to the targeted 52.5% reduction) in the belapectin 2 mg/kg dose group (p-value &lt; 0.05). The Company further analyzed the two thirds of the completer patients in the NAVIGATE trial enrolled in the U.S. (n=186). The incidence of
          varices in this population was significantly reduced by 68.1% (p=0.02) in patients treated with belapectin 2 mg (4 out of 60) vs placebo (13 out of 62) in the U.S. While all three cohorts of patients in the U.S. had a higher percentage use of
          GLP-1 and statins than the rest of the world, the belapectin cohorts performed much better than placebo in the U.S.&#160; The Company continues to analyze trial data and expects to report additional information on specific biomarkers in the second
          quarter of 2025.</div>

      </div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt; color: #000000;">As in prior trials, the safety profile of belapectin remains highly encouraging with incidence of adverse events and serious adverse events comparable across the three cohorts. Rates of discontinuation,
        adverse events (AEs), and serious adverse events (SAEs) were comparable to placebo, with no drug-related SAEs reported in the NAVIGATE trial.</div>

      <div><br/>
      </div>

      <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">The Company continues to analyze data from the 57 patients that completed 36 months of treatment prior to the ending of the trial in
        February 2025. While data from this group would not change the results of the NAVIGATE clinical trial for patients completing 18 months of treatment, the Company believes that any encouraging data from this group of patients may draw interest from
        potential strategic partners.</div>

      <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

      <div style="text-indent: 36pt; color: #000000;">In the NAVIGATE trial, as proposed in the protocol, secondary endpoints include a composite clinical outcomes endpoint, including varices requiring treatment (development of large varices or varices
        with a red wale), decompensating events, all-cause mortality, MELD score increase, liver transplant. Also, NASH non-invasive biomarkers will be evaluated. To target a population at risk of developing esophageal varices, patient selection was based
        on clinical signs of portal hypertension, including, but not limited to, a low platelet count, an increased spleen size, an increased liver stiffness, and/or evidence of abdominal collaterals circulation.</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt; color: #000000;">The focus and goal of the therapeutic program is to stop the progression of and/or reverse portal hypertension and thereby prevent the development of varices, potentially one of the most
        life-threatening complications of cirrhosis. Based on the results of the NASH-CX trial and subject to confirmation in later stage clinical trials, we believe that this goal is achievable in a significant portion of the NASH cirrhosis patient
        population i.e. those NASH cirrhosis patients with clinical signs of portal hypertension for whom, currently, apart from a liver transplantation, no specific liver targeted, treatments are available.</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt; color: #000000;">We activated more than 150 clinical trial sites in 14 countries for the NAVIGATE trial.</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt; color: #000000;">The COVID-19 pandemic delayed our regulatory and ethics approvals, recruitment of sites, and enrollment of patients for our NAVIGATE trial. For several reasons, the pandemic made enrolling patients for
        the NAVIGATE trial more challenging, notably because patients eligible for the NAVIGATE trial have liver cirrhosis and, as such, were at a greater health risk of complications from COVID-19 and needed to be vaccinated before taking the risk of
        infection associated with a visit to a healthcare facility. As we emerged from the COVID-19 pandemic, site recruitment and patient enrollment accelerated and we experienced increases in the speed of enrollment, particularly in the United States.
        However, we did not see the enrollment in Europe that we anticipated. Consequently, we activated multiple sites in Latin America.</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt; color: #000000;">Further details on the NAVIGATE trial can be found on <span style="text-decoration: underline;">www.clinicaltrials.gov</span> under study NCT04365868 and on our NAVIGATE website (navigatenash.com).&#160; The information contained therein is not
        incorporated herein by reference.</div>

      <div><br/>
      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">4</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div style="width: 100%;" class="BRPFPageHeader">
          <div>
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

            </div>

          </div>

        </div>

      </div>

      <div style="text-indent: 36pt;"><span style="color: #000000;">The Company also has completed a Hepatic Impairment Study, which ran in parallel with the phase 2b/3 trial as part of the development program. The Hepatic Impairment Study was conducted at
          three sites and involved approximately 40 patients (divided amongst normal healthy volunteers, and patients with hepatic impairment categorized as Child-Turcotte-Pugh (CTP) classes A (mild), B (moderate), and C (severe). Each subject received a
          single infusion of belapectin (4 mg/kg LBM) and their serum belapectin levels were monitored for up to approximately two weeks to define the effects of various stages of cirrhosis on serum belapectin levels. The tolerance and safety of belapectin
          was evaluated. Enrollment in this study was completed in February 2022, and the final results were presented the T</span><span style="color: #333333;">he Liver Meeting&#8482; 2023, hosted by the American Association for the Study of Liver Diseases. The
          data indicated that belapectin exposure did not increase with the degree of hepatic insufficiency, a property that is consistent with the observed distribution of the drug into activated macrophages. </span><span style="color: #000000;">Further
          details on this hepatic impairment study can be found on <span style="text-decoration: underline;">www.clinicaltrials.gov</span> study NCT04332432. The information contained therein is not incorporated herein by reference.</span></div>

      <div><br/>
      </div>

      <div style="text-indent: 24.3pt; color: #000000;"><span style="font-style: italic;">Cancer Immunotherapy. </span>We believe there is potential for galectin inhibition to play a key role in the innovative area of cancer immunotherapy.<span style="font-style: italic;">&#160;</span>For example, there have been several recent approvals of drugs that enhance a patient&#8217;s immune system to fight cancer. It is our goal to use ourgalectin-3 inhibitor to further enhance the immune system function
        to help the body to fight cancer in a way that complements other approaches to this type of therapy. This hypothesis is supported by the fact that galectin-3 is expressed at high levels in multiple types of tumors and their micro-environment, where
        it fosters the malignant nature of the tumors, and protects the tumors from immune attack by the patient&#8217;s own defense mechanism. Our drug candidates provide a promising new therapeutic approach to enhance the activity of the immune system against
        cancer cells. Preclinical studies have indicated that belapectin enhances the immune response to cancer cells, increased tumor shrinkage and enhanced survival in immune competent mice with prostate, breast, melanoma and sarcoma cancers when
        combined with one of the immune checkpoint inhibitors, anti-CTLA-4 or anti-PD-1, or with the immune cell activator anti-OX40. These preclinical data led to the filing of two Investigator-sponsored INDs and the initiation of Phase 1B studies of
        belapectin in combination with Yervoy<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> (ipilimumab) in metastatic melanoma and another phase 1B study in combination with KEYTRUDA (pembrolizumab) in patients with
        metastatic melanoma and head and neck squamous cell carcinoma. These studies were conducted under the sponsorship of Providence Portland Medical Center&#8217;s Earle A. Chiles Research Institute (EACRI).</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt; color: #000000;">The phase IB study in combination with Yervoy was rapidly discontinued after the first patients were recruited because of the availability of new treatment in the selected population.</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt; color: #000000;">Promising results were reported in the Phase 1b trial combining belapectin with pembrolizumab (KEYTRUDA<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>). When
        aggregated cohorts are combined, in advanced melanoma, a 50% objective response rate with belapectin in combination with KEYTRUDA, was documented. In addition, a 33% response rate was documented in patients with head and neck cancer. The results
        have been published in 2021 in a highly rated peer reviewed journal (Curti et al. Journal of Immunotherapy of cancer 2021;9:e002371). There was also a suggestion that the combination of belapectin with pembrolizumab could decrease the auto-immune
        side-effect induced by pembrolizumab. These side-effects, which are directly linked to the mechanism of action of pembrolizumab, can be poorly tolerated and even severe enough to lead to treatment interruption, even if the effect on the cancer was
        encouraging. This is, a very frustrating situation for patients who have to discontinue an active treatment but have no other options available to them. We believe these data, taken together with the observed favorable safety and tolerability of
        the combination, provide a rationale to move the belapectin program in oncology forward.</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt; color: #000000;">Late in 2021, we engaged three noted physicians &#8211; Dr. Chetan Bettegowda, from Johns Hopkins, and Dr. Nishant Agrawal and Dr. Ari Rosenberg, both from University of Chicago Medical Center &#8211; as
        consultants to help define the path forward in oncology. In consultation with our oncology experts, we have now selected the treatment of recurrent or metastatic head and neck cancer as the lead indication to pursue for belapectin in combination
        with an immune checkpoint inhibitor. The decision is notably based on the lack of available treatments for these patients, the limited number of therapies in development, and the resulting very high medical need. We filed an IND with FDA and are
        planning a phase 2 trial to be filed with the FDA oncology division, dependent in part on finding a suitable partner or obtaining financing for the trial.</div>

      <div><br/>
      </div>

      <div style="color: #000000; font-weight: bold;">Patents and Proprietary Rights</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt; color: #000000;">Our development and commercial viability, and ultimately our competitiveness, depend on our ability to develop and maintain the proprietary aspects of our technology and operate without infringing on
        the proprietary rights of others. We rely on a combination of patent, trademark, trade secret and copyright law and contract restrictions to protect the proprietary aspects of our technologies. We seek to protect our intellectual property by
        requiring employees, consultants, and any third parties with access to our proprietary information to execute confidentiality agreements and by restricting access to that information.</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt; color: #000000;">In August 2015, we received a notice of allowance from the U.S. Patent and Trademark Office for patent application number 13/726,900, titled &#8220;Galactose-pronged polysaccharides in a formulation for
        antifibrotic therapies.&#8221; This patent extends coverage of the Company&#8217;s pectin-derived compounds (including broad molecular weight ranges and other sources of pectin) to include treatment of chronic kidney disease associated with the development of
        fibrosis, established kidney fibrosis, chronic lung disease associated with the development of fibrosis and established lung fibrosis. Claims in this patent include administering pectin-derived compound parenterally to a patient having at least one
        of the four aforementioned diseases where the established fibrosis or progression of the fibrosis or cirrhosis is inhibited or slowed down. Additional specific claims encompass deriving the compound from citrus pectin, apple pectin, soybean hull
        pectin or sugar beet pectin with a molecular weight between 2 kDa and 400kDa. Also covered is the step of administering the modified galacto-rhamnogalacturonan compound in an admixture with a therapeutic agent, where the agent is an antifibrotic
        compound.</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt; color: #000000;">In August 2014, we received a notice of allowance from the U.S. Patent and Trademark Office for patent application number 13/573,442 titled &#8220;Composition of Novel Carbohydrate Drug for Treatment of Human
        Diseases.&#8221; The patent covers composition and chemical structural claims for compounds that includes the Company&#8217;s lead galectin inhibitor compound belapectin and will expire in December 2031. Claims include multiple routes of administration,
        including intravenous, subcutaneous and oral. The application also covers therapeutic formulations for use in the treatment of NASH (fatty liver disease), cancer and fibrotic, inflammatory and autoimmune disorders in which galectin proteins are
        involved, at least in part, in the pathogenesis. Additional specific claims encompass liver fibrosis, kidney fibrosis, lung fibrosis or heart fibrosis. The patent, assigned U.S. Patent No. 8,871,925, was issued October 28, 2014.</div>

      <div><br/>
      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">5</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div style="width: 100%;" class="BRPFPageHeader">
          <div>
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

            </div>

          </div>

        </div>

      </div>

      <div style="text-indent: 36pt; color: #000000;">In May 2014, we received notice of allowance from the U.S. Patent and Trademark Office for patent application number 13/998,197 titled &#8220;Galactose-Pronged Carbohydrate Compounds for the Treatment of
        Diabetic Nephropathy and Associated Disorders.&#8221; The patent covers both composition claim for and uses of the Company&#8217;s carbohydrate-based galectin inhibitor compound belapectin in patients with diabetic nephropathy, a type of progressive kidney
        disease that occurs in individuals with diabetes. Diabetic nephropathy is the major cause for chronic renal failure in the United States. The patent, assigned U.S. Patent No. 8,828,971, was issued September 9, 2014.</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt; color: #000000;">In February 2014, we received notice of issuance that the U.S. Patent and Trademark Office issued patent number 8,658,787 to the Company for its application titled &#8220;Galacto-rhamnogalacturonate
        compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease.&#8221; The patent covers the Company&#8217;s carbohydrate-based galectin inhibitor compound belapectin for use in patients with fatty liver disease with or
        without fibrosis or cirrhosis, providing patent protection through 2031. The major claims are for methods of obtaining galectin inhibitor compounds, obtaining a composition for parenteral or enteral administration in an acceptable pharmaceutical
        carrier and administering to a subject having at least one of the following: fatty liver, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, non-alcoholic hepatitis with liver fibrosis, non-alcoholic steatohepatitis with cirrhosis,
        or non-alcoholic steatohepatitis with cirrhosis and hepatocellular carcinoma. The use covers reversing or slowing the progression of disease activity or medical consequences of the disease. Applications are pending in multiple countries to extend
        patent protection globally.</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt; color: #000000;">In January 2014, we received a notice of allowance from the U.S. Patent and Trademark Office for Patent Application Number 13/550,962 titled &#8220;Galactose-Pronged Polysaccharides in a Formulation for
        Anti-fibrotic Therapies.&#8221; The patent covers both composition claim for and uses of the Company&#8217;s carbohydrate-based galectin inhibitor compound belapectin for use in patients with liver fibrosis in combination with other potential therapeutic
        agents. The patent covers use of belapectin with agents directed at multiple targets, some of which are currently in clinical development for fibrotic disorders including monoclonal antibodies to connective tissue growth factor, integrins, and
        TGF-&#223;1. The patent, assigned U.S. Patent No. 8,722,645, was issued May 13, 2014.</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt; color: #000000;">In July 2012, we received a notice of issuance from the U.S. Patent and Trademark Office for the U.S. Patent number 8,236,780 issued on August 7, 2013 titled &#8220;Galactose-prolonged polysaccharides in a
        formulation for antifibrotic therapies&#8221;. This methods patent covers key methods of derivation and use for our carbohydrate-based galectin inhibitor compound for use in patients with chronic liver disease associated with the development of fibrosis,
        established liver fibrosis or end-stage scarring, or cirrhosis. The major claim is for a method of obtaining a galacto-rhamnogalacturan compound from an apple pectin, obtaining a composition for parenteral administration the
        galacto-rhamnogalacturonan compound in an acceptable pharmaceutical carrier and administering to a subject having at least one of the following: chronic liver disease associated with the development of fibrosis, established liver fibrosis or
        cirrhosis. The use covers inhibiting or slowing the progression of fibrosis. belapectin is covered by this patent and it provides opportunities for development of additional compounds in the class.</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt; color: #000000;">As of December 31, 2024, Galectin Therapeutics Inc. held 19 granted U.S. patents, 86 foreign granted, and 1 U.S. patent applications pending. Many of our patents and patent applications cover
        composition of matter for complex carbohydrate drugs and/or methods of use for reducing toxicity and enhancing chemotherapeutic drugs by co-administering a polysaccharide with a chemotherapeutic agent or for use in treatment of fibrosis. The
        scheduled expiration dates of our many of our United States patents span out to 2034 before considering any potential extensions. We have corresponding patent applications pending in various territories where we see potential for commercial
        interest. Additionally, we have patent applications in other areas to utilize our carbohydrate-based compounds to treat disease other than cancer. See &#8220;Risk Factors &#8212; Risks Related to Our Intellectual Property&#8221;. Our competitive position, in part,
        is contingent upon protection of our intellectual property. Galectin Sciences LLC has 2 granted U.S. patents, 24 granted international patents, 2 US patent application pending, and 5 foreign applications pending.</div>

      <div><br/>
      </div>

      <div style="color: #000000; font-weight: bold;">Research</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt; color: #000000;">Our primary focus is on the design and testing of agents that target galectins in various <span style="font-style: italic;">in vitro</span> and <span style="font-style: italic;">in vivo</span> systems
        and that demonstrate efficacy in treatment of experimentally induced fibrosis or enhance immune system responsiveness in various tissues and in live animal models. We contract with independent laboratories and other facilities to conduct our
        research, which is designed, evaluated and managed by our scientists. We do not anticipate building additional in-house research or development facilities or hiring significantly additional staff other than for purposes of designing and managing
        our out-sourced research and development activities.</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt; color: #000000;">As we develop products eligible for clinical trials, we contract with independent parties to assist in the design of the clinical trial protocols, arrange for and monitor the clinical trials, collect
        data and analyze data. In addition, certain clinical trials for our products may be conducted by government-sponsored agencies and will be dependent on governmental participation and funding. Our dependence on independent parties and clinical sites
        involves risks including reduced control over the timing and other aspects of our clinical trials.</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt; color: #000000;">During the years ended December 31, 2024 and 2023, our expenditures for research and development were $36.1 million and $32.1 million, respectively. We expense all research and development costs as they
        are incurred.</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt; color: #000000;">In January 2014 we created, with SBH Sciences, Inc. (Natick, Ma), Galectin Sciences, LLC, a collaborative joint venture to research and develop small organic molecule inhibitors of galectin-3 for oral
        administration.</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt; color: #000000;">Using computer molecular modeling techniques coupled with <span style="font-style: italic;">in vitro</span> screening of a variety of compound libraries, SBH Sciences had identified several small
        organic molecules with promising galectin-3 inhibitory activity <span style="font-style: italic;">in vitro</span>. Galectin Sciences LLC will further develop these unique organic molecule inhibitors of galectin-3 as drug candidates as well as
        develop additional candidates. Subject to availability of funding, Galectin Sciences LLC will build on the scientific body of knowledge amassed by SBH Sciences, coupled with Galectin Therapeutics&#8217; knowledge and expertise of galectins&#8217; pathological
        role and mechanism of action in inflammation, fibrosis and many cancers. The long-term goal of this effort is to identify and develop drug candidates that are highly specific galectin inhibitors which may be formulated for oral administration. The
        intermediate term goal is the development of small molecule inhibitors of galectin-3 which exhibit activity in <span style="font-style: italic;">in vivo</span> preclinical disease models of fibrosis and cancer in which galectins play a key role.
        Several patent applications have been filed to protect the various series of compounds discovered by these efforts.</div>

      <div><br/>
      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">6</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div style="width: 100%;" class="BRPFPageHeader">
          <div>
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

            </div>

          </div>

        </div>

      </div>

      <div style="text-indent: 36pt; color: #000000;">Because increased levels of galectin proteins have been implicated in a very large number of inflammatory, fibrotic and neoplastic diseases; the discovery and development of orally active galectin
        inhibitors would be a major step towards expanded treatment approaches for these disorders. This early drug discovery effort may lead to drugs that would expand our pipeline as follow-on compounds to our first in class galectin inhibitors,
        belapectin and GM-CT-01. These efforts have identified several potential compounds which are continuing to be explored to identify lead molecules that may be identified for clinical development.</div>

      <div><br/>
      </div>

      <div style="color: #000000; font-weight: bold;">Manufacturing and Marketing</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt; color: #000000;">We are a development stage Company at this time and do not intend to establish internal facilities for the manufacture of our products for clinical or commercial production. To have our products
        manufactured, we have developed and will continue to develop relationships with third-parties that have established pharmaceutical manufacturing capabilities and expertise. We are not a party to any long-term agreement with any of our suppliers
        and, accordingly, we have our products manufactured on a purchase-order basis from one of two primary well-known and established pharmaceutical suppliers that meet FDA requirements. Additionally, belapectin is manufactured as a sterile liquid
        formulation. We have experienced, and may experience in the future, certain delays related to global supply chain issues with certain components necessary to manufacture belapectin.</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt; color: #000000;">Because our products are in the development stage, we have not created a sales and marketing staff to commercialize pharmaceutical products. If we develop products eligible for commercial sale, we will
        need to develop a sales and marketing capability or rely on third parties such as licensees, collaborators, joint venture partners or independent distributors to market and sell those products. Our dependence on third-party manufacturers,
        analytical testing and other laboratories and marketers will involve risks relating to our reduced control, and other risks including those discussed in &#8220;Risk Factors &#8212; Risks Related to our Company &#8212; There are risks associated with reliance on our
        third parties for manufacturing, marketing, sales, managed care and distribution infrastructure channels.&#8221;</div>

      <div><br/>
      </div>

      <div style="color: #000000; font-weight: bold;">Competition</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt; color: #000000;">Many biotechnology and pharmaceutical companies are developing new technologies for the treatment of cancer, fibrotic diseases and other diseases. Technologies such as monoclonal antibodies could be
        competitive with our galectin therapeutic platforms. Other companies are trying to improve the therapeutic profile of widely used protein-based drugs. While these companies may broaden the market for our products they may also provide competitive
        alternatives to our products. We expect increased competition in the area of galectins will be fueled by a nearly exponential increase in the publication rate of research papers on galectins.</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt; color: #000000;">See &#8220;Risk Factors &#8212; Risks Related to Our Company &#8212; We face intense competition in the biotechnology and pharmaceutical industries&#8221; for additional discussion related to our current and potential
        competition.</div>

      <div><br/>
      </div>

      <div style="color: #000000; font-weight: bold;">Government Regulation</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt; color: #000000;">The research, development, testing, manufacture, labeling, promotion, advertising, distribution, and marketing, among other things, of our products are extensively regulated by governmental authorities
        in the United States and other countries. The FDA regulates drugs under the federal Food, Drug, and Cosmetic Act and its implementing regulations. Failure to comply with the applicable U.S. requirements may subject us to administrative or judicial
        sanctions, such as FDA refusal to approve pending New Drug Applications (&#8220;NDAs&#8221;), warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, and/or criminal prosecution.</div>

      <div><br/>
      </div>

      <div style="color: #000000; font-style: italic; font-weight: bold;">Drug Approval Process</div>

      <div><br/>
      </div>

      <div style="color: #000000;">Drugs may not be marketed in the U.S. until the FDA has approved them. The steps required before a drug may be marketed in the U.S. include:</div>

      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0);">1.</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">Pre-clinical laboratory tests, animal studies, and formulation studies,</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">2.</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">Submission to the FDA of an IND for human clinical testing, which must become effective before human clinical trials may begin,</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">3.</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">Adequate and well-controlled human clinical trials to establish the safety and efficacy of the drug for each indication,</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">4.</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">Submission to the FDA of a NDA,</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">5.</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">Satisfactory completion of an FDA inspection of the manufacturing facility or facilities, at which the drug is produced to assess compliance with current good manufacturing procedures (&#8220;cGMP&#8221;) established by
                the FDA,</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">6.</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">FDA review and approval of the NDA, and</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">7.</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">FDA review and approval of a trademark used in connection with a pharmaceutical.</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <div style="text-indent: 36pt; color: #000000;">Pre-clinical tests include laboratory evaluation of product chemistry, toxicity, and formulation, as well as numerous in vitro and in vivo animal studies. The results of the pre-clinical tests, together
        with manufacturing information and analytical data, are submitted to the FDA as part of an IND, which must become effective before human clinical trials may begin and the Company must resolve any outstanding FDA concerns or questions before
        clinical trials can proceed. There is no certainty that submission of an IND will result in the FDA allowing clinical trials to begin.</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt; color: #000000;">Clinical trials involve the administration of the investigational drug to human subjects under the supervision of qualified investigators and constant oversight by the FDA or foreign regulatory
        authorities. Clinical trials are conducted under protocols detailing the objectives of the study, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. Each protocol must be submitted to the FDA as part of
        the IND.</div>

      <div><br/>
      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">7</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div style="width: 100%;" class="BRPFPageHeader">
          <div>
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

            </div>

          </div>

        </div>

      </div>

      <div style="text-indent: 36pt; color: #000000;">Clinical trials typically are conducted in three sequential phases, but the phases may overlap or be combined. Each trial must be reviewed and approved by an independent Institutional Review Board
        (&#8220;IRB&#8221;), before it can begin. Study subjects must sign an informed consent form before participating in a clinical trial. Phase 1 usually involves the initial introduction of the investigational drug into patients to evaluate its safety, dosage
        tolerance, pharmacodynamics, and, if possible, to gain an early indication of its effectiveness. Phase 2 usually involves trials in a limited patient population to (i) evaluate dosage tolerance and appropriate dosage; (ii) identify possible adverse
        effects and safety risks; and (iii) evaluate preliminarily the efficacy of the drug for specific indications. Phase 3 trials usually further evaluate clinical efficacy and test further for safety by using the drug in its final form in an expanded
        patient population. There is no assurance that these trials will be completed within a specified period of time, if at all.</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt; color: #000000;">Assuming successful completion of the required clinical testing, the results of the pre-clinical studies and of the clinical studies, together with other detailed information, including information on
        the manufacture and composition of the drug, are submitted to the FDA in an NDA requesting approval to market the product for one or more indications. Before approving an NDA, the FDA usually will inspect the facilities at which the drug is
        manufactured and will not approve the product unless compliance with cGMP is satisfactory. If the FDA evaluates the NDA and the manufacturing facilities as acceptable, the FDA will generally issue an approval letter. If the FDA evaluates the NDA
        submission or the manufacturing facilities as not acceptable, the FDA will generally outline the deficiencies in the submission and often will request additional testing or information. Even if an applicant submits the requested additional
        information, the FDA ultimately may decide that the NDA does not satisfy the regulatory criteria for approval. The testing and approval process require substantial time, effort, and financial resources, and there is no assurance that any approval
        will be granted on a timely basis, if at all. After approval, certain changes to the approved product, such as adding new indications, manufacturing changes, or additional labeling claims are subject to further FDA review and approval.</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt; color: #000000;">See &#8220;Risk Factors &#8212; Risks Related to the Regulation of Our Products &#8212; We will need regulatory approvals to commercialize our products&#8221; for additional discussion of regulatory risks related to our drug
        development program.</div>

      <div><br/>
      </div>

      <div style="color: #000000; font-style: italic; font-weight: bold;">FDA Priority Review</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt; color: #000000;">FDA procedures provide for priority review of an NDA submitted for drugs that, compared to currently marketed products, offer a significant improvement in the treatment, diagnosis, or prevention of a
        disease. NDAs that are granted priority review are acted upon more quickly than NDAs given standard review. If we were to seek priority review, there can be no guarantee that the FDA will grant priority review status, that priority review status
        will affect the time of review, or that the FDA will approve the NDA submitted for any of our product candidates, whether or not priority review status is granted.</div>

      <div><br/>
      </div>

      <div style="color: #000000; font-style: italic; font-weight: bold;">Post-Approval Requirements</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt; color: #000000;">If FDA approval of one or more of our products is obtained, we will be required to comply with a number of post-approval requirements. For example, holders of an approved NDA are required to report
        certain adverse reactions to the FDA and to comply with certain requirements concerning advertising and promotional labeling for their products. Also, quality control and manufacturing procedures must continue to conform to current Good
        Manufacturing Practices (&#8220;cGMP&#8221;) after approval, and the FDA periodically inspects manufacturing facilities to assess compliance with cGMP. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and
        quality control to maintain cGMP compliance. In addition, discovery of problems with a product after approval may result in restrictions on a product, manufacturer, or holder of an approved NDA, including withdrawal of the product from the market.
        Also, new government requirements may be established that could delay or prevent regulatory approval of our products under development.</div>

      <div><br/>
      </div>

      <div style="color: #000000; font-style: italic; font-weight: bold;">Regulation Outside the United States</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt; color: #000000;">Before our products can be marketed outside of the United States, they are subject to regulatory approval similar to that required in the United States, although the requirements governing the conduct
        of clinical trials, product licensing, pricing and reimbursement vary widely from country to country. No action can be taken to market any product in a country until an appropriate application has been approved by the regulatory authorities in that
        country. The current approval process varies from country to country, and the time spent in gaining approval varies from that required for FDA approval. In certain countries, the sales price of a product must also be approved. The pricing review
        period often begins after market approval is granted. No assurance can be given that even if a product is approved by a regulatory authority, satisfactory prices will be approved for such product.</div>

      <div><br/>
      </div>

      <div style="color: #000000; font-style: italic; font-weight: bold;">Environmental Regulation</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt; color: #000000;">Pharmaceutical research and development involves the controlled use of hazardous materials. Biotechnology and pharmaceutical companies must comply with laws and regulations governing the use,
        generation, manufacture, storage, air emission, effluent discharge, handling and disposal of certain materials, biological specimens and wastes. We do not anticipate building in-house research, development or manufacturing facilities, and,
        accordingly, do not expect to have to comply directly with environmental regulation. However, our contractors and others conducting research, development or manufacturing activities for us may be required to incur significant compliance cost, and
        this could in turn could increase our expense or delay our completion of research or manufacturing programs.</div>

      <div><br/>
      </div>

      <div style="color: #000000; font-weight: bold;">Human Capital Resources</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt; color: #000000;">As of February 28, 2025, we had fifteen full-time employees, twelve of whom are involved primarily in management of our pre-clinical research and development and clinical trials and three who were
        involved primarily in management and administration of our Company. We also utilize several contractors and consultants who provide product development, manufacture, analytical testing, clinical trial expertise, and clinical trial support.</div>

      <div><br/>
      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">8</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div style="width: 100%;" class="BRPFPageHeader">
          <div>
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

            </div>

          </div>

        </div>

      </div>

      <div style="color: #000000; font-weight: bold;">Available Information</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt; color: #000000;">The Company is required to file annual, quarterly and current reports, proxy statements and other information with the Securities and Exchange Commission (&#8220;SEC&#8221;), including Annual Reports on Form 10-K,
        Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to reports filed pursuant to Sections 13(a) and 15(d) of the Securities Exchange Act of 1934. The SEC maintains an Internet site that contains reports, proxy and information
        statements, and other information regarding issuers that file electronically with the SEC at http://www.sec.gov. The Company&#8217;s website is www.galectintherapeutics.com. The information contained on, or hyperlinked from, our website or any other
        websites is not a part of, nor is it incorporated by reference into, this Annual Report on Form 10-K.</div>

      <div><br/>
      </div>

      <div>
        <div>
          <a id="Item1A."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="text-align: right; vertical-align: top; width: 54pt;">
                  <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">Item 1A.</div>
                </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                  <div style="color: rgb(0, 0, 0); font-weight: bold; font-style: italic;">Risk Factors</div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div><br/>
      </div>

      <div style="color: #000000;">An investment in our common stock involves a high degree of risk. You should carefully consider the risks described below and the other information before deciding to invest in our common stock. The risks described below
        are not the only ones facing our Company. Additional risks not presently known to us or that we currently consider immaterial may also adversely affect our business. We have attempted to identify below the major factors that could cause differences
        between actual and planned or expected results, but we cannot assure you that we have identified all of those factors.</div>

      <div><br/>
      </div>

      <div style="color: #000000;">If any of the following risks actually happen, our business, financial condition and operating results could be materially adversely affected. In this case, the trading price of our common stock could decline, and you
        could lose all or part of your investment.</div>

      <div><br/>
      </div>

      <div style="color: #000000; font-weight: bold;">Risks Related to Our Company</div>

      <div><br/>
      </div>

      <div style="color: #000000; font-style: italic; font-weight: bold;">We have incurred net losses to date and must raise additional capital in order to continue to operate.</div>

      <div><br/>
      </div>

      <div style="text-align: left; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt;">
        <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">We have incurred net losses in each year of operation since our inception in July 2000 and have no revenues. Our accumulated deficit as of December 31,
          2023 was $354 million. We had $15.1 million of unrestricted cash as of December 31, 2024 and $6 million of available borrowings under a line of credit provided by our chairman. Additionally, in March 2025, we signed a new supplemental line of
          credit agreement with our chairman for an additional $5 million of available borrowings.&#160; The Company believes there is sufficient cash, including the $11 million under the two lines of credit, to fund currently planned operations through August
          2025. We will require more cash to fund our operations after August 2025. There can be no assurance that we will be successful in obtaining such new financing or, if available, that such financing will be on terms favorable to us.</div>

      </div>

      <div><br/>
      </div>

      <div style="color: #000000;">We may raise capital through public or private equity financings, partnerships, debt financings, bank borrowings, or other sources. Additional funding may not be available on favorable terms or at all. Though his
        investments in the Company, Mr. Uihlein has been a critical source of funding via equity and debt financings. There is no assurance as to the level of future investments to be made in the Company by Mr. Uihlein.&#160; If adequate funds are not otherwise
        available, we may need to significantly curtail operations. To obtain additional funding, we may need to enter into arrangements that require us to relinquish rights to certain technologies, products and/or potential markets. To the extent that
        additional capital is raised through the sale of equity, or securities convertible into equity, our equity holders may experience dilution of their proportionate ownership of the Company.</div>

      <div><br/>
      </div>

      <div style="text-align: justify; color: #000000; font-style: italic; font-weight: bold;">Our NAVIGATE trial was our only active clinical trial, and we currently do not have plans or funding to undertake another clinical trial.</div>

      <div>&#160;</div>

      <div style="color: #000000;">
        <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">In December 2024, we presented top-line results of the NAVIGATE clinical trial.&#160; The composite endpoint did not reach statistical significance. Because
          the data from NAVIGATE clinical trial did not reach statistical significance, we may determine not to conduct an additional clinical trial to test the efficacy of our drug candidate, belapectin. Furthermore, it will be difficult for us to raise
          the capital necessary for another clinical trial. The Company continues to analyze data from the 57 patients that completed 36 months of treatment prior to the ending of the trial in February 2025. While data from this group patient would not
          change the results of results of the NAVIGATE clinical trial, the Company believes that encouraging results from this group of patients may draw interest from potential strategic partners.</div>

      </div>

      <div><br/>
      </div>

      <div style="color: #000000; font-style: italic; font-weight: bold;">There is substantial doubt about our ability to continue as a going concern.</div>

      <div>&#160;</div>

      <div style="color: #000000;">In 2024, we experienced net losses of $47.2 million, had no revenue from operations, and used $41.8 million in cash to fund our operations. Due to the current level of liquidity at December 31, 2024 and the projected
        shortfall to cover operating expenses requiring cash for a period of 12 months from the report date of the annual report, management has expressed substantial doubt as to our ability to continue as a going concern.</div>

      <div>&#160;</div>

      <div style="color: #000000; font-style: italic; font-weight: bold;">We are a development stage company and have not yet generated any revenue.</div>

      <div><br/>
      </div>

      <div style="color: #000000;">We are a development stage company and have not generated any revenues to date. There is no assurance that we will obtain FDA approval of belapectin or other products that we may develop, and, even if we do so, that we
        will generate revenue sufficient to become profitable. Our failure to generate revenue and profit would likely lead to loss of your investment.</div>

      <div><br/>
      </div>

      <div style="color: #000000;">Our ability to generate revenue from product sales and achieve profitability will depend upon our ability to successfully commercialize products, including our lead product candidate, or other product candidates that we
        may in-license or acquire in the future. Even if we are able to successfully achieve regulatory approval for these product candidates, we do not know when any of these products will generate revenue from product sales for us, if at all. Our ability
        to generate revenue from product sales from our current or future product candidates also depends on a number of additional factors, including our ability to:</div>

      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">successfully complete development activities, including the necessary clinical trials;</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">complete and submit new drug applications, or NDAs, to the U.S. Food and Drug Administration, or FDA, and obtain regulatory approval for indications for which there is a commercial market;</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">complete and submit applications to, and obtain regulatory approval from, foreign regulatory authorities;</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">successfully complete all required regulatory agency inspections;</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">set a commercially viable price for our products;</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">obtain commercial quantities of our products at acceptable cost levels;</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">find suitable distribution partners to help us market, sell and distribute our approved products in other markets; and</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">obtain coverage and adequate reimbursement from third parties, including government and private payers.</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">9</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div style="width: 100%;" class="BRPFPageHeader">
          <div>
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

            </div>

          </div>

        </div>

      </div>

      <div style="color: #000000;">In addition, because of the numerous risks and uncertainties associated with product development, including that our product candidates may not advance through development or achieve the endpoints of applicable clinical
        trials, we are unable to predict the timing or amount of increased expenses, or when or if we will be able to achieve or maintain profitability. Even if we are able to complete the development and regulatory process for any product candidates, we
        anticipate incurring significant costs associated with commercializing these products.</div>

      <div><br/>
      </div>

      <div style="color: #000000;">If we are unable to generate revenues from the sale of our products, we may not become profitable and may need to obtain additional funding to continue operations. If we fail to become profitable or are unable to sustain
        profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce our operations.</div>

      <div><br/>
      </div>

      <div style="color: #000000; font-style: italic; font-weight: bold;">We are dependent on the success of our lead product candidate, belapectin, and we cannot be certain that our product candidates will receive regulatory approval or be successfully
        commercialized.</div>

      <div><br/>
      </div>

      <div style="color: #000000;">We currently have no products for sale, and we cannot guarantee that we will ever have any drug products approved for sale. We and our product candidates are subject to extensive regulation by the FDA and comparable
        regulatory authorities in other countries governing, among other things, research, testing, clinical trials, manufacturing, labeling, promotion, selling, adverse event reporting and recordkeeping. We are not permitted to market any of our product
        candidates in or outside the United States until we receive approval of a new drug application for a product candidate from the FDA or the equivalent approval from a foreign regulatory authority. Obtaining FDA approval is a lengthy, expensive and
        uncertain process.</div>

      <div><br/>
      </div>

      <div style="color: #000000;">Before obtaining regulatory approval for the sale of any drug candidate, we must conduct extensive pre-clinical studies and clinical trials to demonstrate the safety and efficacy of our product candidates in humans.</div>

      <div><br/>
      </div>

      <div style="color: #000000;">To obtain FDA approval, we will need to conduct one or more Phase 3 clinical trial for belapectin; however, we cannot assure you that we will be able to finance Phase 3 trials. Additionally, we cannot assure you that our
        future trials will yield successful results, that they will lead to the generation of revenue, or that we will obtain regulatory approval in other countries.</div>

      <div><br/>
      </div>

      <div style="color: #000000;">Pre-clinical studies and clinical trials are expensive, time-consuming and ultimately may not be successful. The results of pre-clinical and initial clinical testing of these products may not necessarily indicate the
        results that will be obtained from later or more extensive testing. Also, it is possible to suffer significant setbacks in advanced clinical trials, even after obtaining promising results in earlier trials. For example, although there was positive
        data from our NASH-CX Phase 2 trial for belapectin, it did not meet its primary endpoint. Similarly, our Phase 2a pilot trial NASH-FX for patients with advanced fibrosis, which explored three non-invasive imaging technologies, did not meet its
        primary endpoint. Top-line results from the NAVIGATE trial were presented in the December 2024.&#160; Again, while there was positive data, especially in the 2 mg cohort, the composite endpoint did not reach statistical significance. We may engage
        others to conduct our clinical trials, including clinical research organizations and, possibly, government-sponsored agencies. Additional clinical trials may not start or be completed as we forecast and may not achieve the desired results. The time
        required to obtain FDA and other approvals is unpredictable but often can take years following the commencement of clinical trials, depending upon the complexity of the drug candidate.</div>

      <div><br/>
      </div>

      <div style="color: #000000; font-style: italic; font-weight: bold;">Even if we receive regulatory approval, we may be unable to commercialize our product candidates.</div>

      <div><br/>
      </div>

      <div style="color: #000000;">Even if belapectin and other future product candidates achieve positive results in clinical trials, we may be unable to commercialize them. The availability of government and third-party payer reimbursement, and pricing,
        especially compared to competitor products, could affect our ability to commercialize our product candidates. Our general inability to obtain necessary regulatory approvals and, if obtained, to commercialize our products would substantially impair
        our viability.</div>

      <div><br/>
      </div>

      <div style="color: #000000; font-style: italic; font-weight: bold;">There are risks associated with our reliance on third parties to design trial protocols, arrange for and monitor the clinical trials, and collect and analyze data.</div>

      <div><br/>
      </div>

      <div style="color: #000000;">As we develop products eligible for clinical trials, we will contract with independent parties to assist us in the design of the trial protocols, arrange for and monitor the clinical trials, provide lab kits, collect data
        and analyze data and samples. In addition, certain clinical trials for our products may be conducted by government-sponsored agencies and will be dependent on governmental participation and funding. We have contracted with a third party, Covance
        (now known as Fortrea), for assistance with the design and conduct of our NAVIGATE trial.</div>

      <div><br/>
      </div>

      <div style="color: #000000;">Our dependence on independent parties and clinical sites involves risks including reduced control over the timing and other aspects of our clinical trials.</div>

      <div><br/>
      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">10</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div style="width: 100%;" class="BRPFPageHeader">
          <div>
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

            </div>

          </div>

        </div>

      </div>

      <div style="color: #000000; font-style: italic; font-weight: bold;">There are risks associated with our reliance on third parties for manufacturing belapectin.</div>

      <div><br/>
      </div>

      <div style="color: #000000;">We do not have, and do not now intend to develop, facilities for the manufacture of any of our products, including belapectin, for clinical or commercial production. At this time, we are not a party to any long-term
        agreement with any of our suppliers, and accordingly, we have our products manufactured on a purchase-order basis from one of two primary suppliers. We are developing relationships with manufacturers and will enter into collaborative arrangements
        with licensees or have others manufacture our products on a contract basis. We expect to depend on such collaborators to supply us with products manufactured in compliance with standards imposed by the FDA and foreign regulators.</div>

      <div><br/>
      </div>

      <div style="color: #000000; font-style: italic; font-weight: bold;">We are exposed to pre-clinical and clinical liability risks which could place a financial burden upon us, should we be sued, because we do not currently have product liability
        insurance beyond our general insurance coverage.</div>

      <div><br/>
      </div>

      <div style="color: #000000;">Our business exposes us to potential pre-clinical, clinical liability and other liability risks that are inherent in the testing pharmaceutical formulations and products; accordingly, claims may be asserted against us. In
        addition, the use in our clinical trials of pharmaceutical formulations and products that our potential collaborators may develop and the subsequent sale of such formulations or products by us or our potential collaborators may cause us to assume a
        portion of or all of the product liability risks. A successful liability claim or series of claims brought against us could have a material adverse effect on our business, financial condition and results of operations. Because we do not currently
        have any FDA-approved products or formulations, we do not currently have any product liability insurance covering commercialized products. Our current and potential partners with whom we have collaborative agreements or our future licensees may not
        be willing to indemnify us against these types of liabilities and may not, themselves, be sufficiently insured or have sufficient liquidity to satisfy any product liability claims. Claims or losses in excess of any insurance coverage that may be
        obtained by us could have a material adverse effect on our business, financial condition and results of operations.</div>

      <div><br/>
      </div>

      <div style="color: #000000; font-style: italic; font-weight: bold;">We face intense competition in the biotechnology and pharmaceutical industries.</div>

      <div><br/>
      </div>

      <div style="color: #000000;">The biotechnology and pharmaceutical industries are intensely competitive. We face direct competition from U.S. and foreign companies focusing on pharmaceutical products, which are rapidly evolving. Our competitors
        include major multinational pharmaceutical and chemical companies, specialized biotechnology firms and universities and other research institutions. Many of these competitors possess greater financial and other resources, larger research and
        development staffs and more effective marketing and manufacturing organizations than we possess. In addition, academic and government institutions are increasingly likely to enter into exclusive licensing agreements with commercial enterprises,
        including our competitors, to market commercial products based on technology developed at such institutions. Our competitors may succeed in developing or licensing technologies and products that are more effective or succeed in obtaining FDA or
        other regulatory approvals for product candidates before we do. Acquisitions of, or investments in, competing pharmaceutical or biotechnology companies by large corporations could increase such competitors&#8217; financial, marketing, manufacturing and
        other resources.</div>

      <div><br/>
      </div>

      <div style="color: #000000; font-style: italic; font-weight: bold;">The market for our proposed products is rapidly changing and competitive, and new drugs and new treatments that may be developed by others could impair our ability to maintain and
        grow our business and remain competitive.</div>

      <div><br/>
      </div>

      <div style="color: #000000;">The pharmaceutical and biotechnology industries are subject to rapid and substantial technological change. Developments by others may render our proposed products noncompetitive or obsolete, or we may be unable to keep
        pace with technological developments or other market factors. Technological competition from pharmaceutical and biotechnology companies, universities, governmental entities and others diversifying into the field is intense and is expected to
        increase. Our resources are limited and we may experience technical challenges inherent in such technologies. Our competitors may develop drugs that are safer, more effective and less costly than our proposed products and, therefore, present a
        serious competitive threat to us.</div>

      <div><br/>
      </div>

      <div style="color: #000000;">The potential widespread acceptance of therapies that are alternatives to ours may limit market acceptance of our proposed products, even if commercialized. Some of our targeted diseases and conditions may also be treated
        by other medications. These treatments may be widely accepted in medical communities and have a longer history of use. The established use of these competitive drugs may limit the potential for our technologies, formulations and products to receive
        widespread acceptance even if commercialized.</div>

      <div><br/>
      </div>

      <div style="color: #000000; font-style: italic; font-weight: bold;">Our lack of operating experience may cause us difficulty in managing our growth.</div>

      <div><br/>
      </div>

      <div style="color: #000000;">We have limited experience in manufacturing or procuring products in commercial quantities, conducting other later-stage phases of the regulatory approval process, selling pharmaceutical products, and negotiating,
        establishing and maintaining strategic relationships. Although we may engage consultants to assist us, any additional growth may require us to expand our management, operational and financial systems and controls. If we are unable to do so, our
        business and financial condition would be materially harmed. If rapid growth occurs, it may strain our managerial, operational and financial resources.</div>

      <div><br/>
      </div>

      <div style="color: #000000; font-style: italic; font-weight: bold;">We depend on key individuals to develop our products and core technologies and pursue collaborative relationships.</div>

      <div><br/>
      </div>

      <div style="color: #000000;">We are highly dependent on our current base of a few employees and external consultants. These individuals, among other things, design and lead our pre-clinical and clinical studies, as well as our U.S. and European
        regulatory processes. With little or no redundancy in our personnel, the loss of any personnel or failure to attract or retain other key personnel and consultants could result in a loss of experience and accumulated knowledge and prevent us from
        developing our products and core technologies and pursuing collaborative relationships.</div>

      <div><br/>
      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">11</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div style="width: 100%;" class="BRPFPageHeader">
          <div>
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

            </div>

          </div>

        </div>

      </div>

      <div style="color: #000000; font-style: italic; font-weight: bold;">We may fail to comply with our reporting and other requirements under federal securities laws.</div>

      <div><br/>
      </div>

      <div style="color: #000000;">As a publicly traded company, we are subject to the reporting requirements of the Exchange Act. The Exchange Act requires that we file annual, quarterly and current reports. Our failure to prepare and disclose this
        information in a timely manner could subject us to penalties under federal securities laws, expose us to lawsuits and restrict our ability to access financing. We may be required to implement additional and expensive finance and accounting systems,
        procedures and controls as we grow our business and organization to satisfy new reporting requirements, which will increase our costs and require additional management resources.</div>

      <div><br/>
      </div>

      <div style="color: #000000; font-style: italic; font-weight: bold;">Our long-term success is dependent not only upon the success of our trials but also upon us being able to capitalize upon potential positive results of our trials, which is not
        assured.</div>

      <div><br/>
      </div>

      <div style="color: #000000;">To conduct Phase 3 clinical trials or other clinical trials we will need sufficient cash resources to conduct those undertakings. We will also need to obtain sufficient dosages of belapectin for such trials. Manufacturing
        of belapectin is performed by third parties on a contract basis and production is ongoing to generate what we believe are sufficient quantities of belapectin for our NAVIGATE or other clinical trials. Manufacturing could become delayed due to
        circumstances beyond our control which could delay any clinical trials. Further because of limited resources, we have curtailed most of our expenditures in research focused on the development of an oral galectin inhibitor to replace our current
        drug candidate that is delivered via infusion.</div>

      <div><br/>
      </div>

      <div style="color: #000000; font-style: italic; font-weight: bold;">We have previously been a defendant in a shareholder derivative action, and any possible future such lawsuits may adversely affect our business, financial condition, results of
        operations and cash flows.</div>

      <div><br/>
      </div>

      <div style="color: #000000;">We and certain of our officers and directors have previously been defendants in a state court shareholder derivative action that concluded in our favor. In addition, there is the potential for other future shareholder
        litigation and for governmental investigations and/or enforcement actions. Similar lawsuits in the future may divert our attention from our ordinary business operations, and we may incur significant expenses associated with their defense
        (including, without limitation, substantial attorneys&#8217; fees and other fees of professional advisors and potential obligations to indemnify current and former officers and directors who are or may become parties to such actions). If similar lawsuits
        do arise in the future, we may be required to pay material damages and fines, consent to injunctions on future conduct and/or suffer other penalties, remedies or sanctions. Accordingly, the ultimate resolution of these matters could have a material
        adverse effect on our business, results of operations, financial condition, liquidity and ability to meet any debt obligations and, consequently, could negatively impact the trading price of our common stock. Any existing or future shareholder
        lawsuits and any future governmental investigations and/or enforcement actions could adversely impact our reputation, our relationships with our customers and our ability to generate revenue.</div>

      <div><br/>
      </div>

      <div style="color: #000000; font-weight: bold;">Risks Related to the Regulation of our Products</div>

      <div><br/>
      </div>

      <div style="color: #000000; font-style: italic; font-weight: bold;">We will need regulatory approvals to commercialize our products.</div>

      <div><br/>
      </div>

      <div style="color: #000000;">We are required to obtain approval (i) from the FDA in order to sell our products in the U.S. and (ii) from foreign regulatory authorities in order to sell our products in other countries. The FDA&#8217;s review and approval
        process is lengthy, expensive and uncertain. Extensive pre-clinical and clinical data and supporting information must be submitted to the FDA for each indication for each product candidate in order to secure FDA approval. Before receiving FDA
        clearance to market our proposed products, we will have to demonstrate that our products are safe on the patient population and effective for the diseases that are to be treated. Clinical trials, manufacturing and marketing of drugs are subject to
        the rigorous testing and approval process of the FDA and equivalent foreign regulatory authorities. FDA may change, at any time, its requirements for approval of new drugs based on information and data received from others and ourselves potentially
        resulting in product approval delays or non-approvals. The Federal Food, Drug and Cosmetic Act and other federal, state and foreign statutes and regulations govern and influence the testing, manufacture, labeling, advertising, distribution and
        promotion of drugs and medical devices. As a result, regulatory approvals can take several years to acquire and may further require the expenditure of substantial financial, managerial and other resources. The FDA could reject an application or, in
        the alternative, require us to conduct additional clinical or other studies as part of the regulatory review process. Delays in obtaining or failure to obtain FDA approvals would delay or prevent the commercialization of our product candidates,
        which would prevent, defer or decrease our receipt of revenues. In addition, should we receive initial regulatory approval, our product candidates will be subject to extensive and rigorous ongoing domestic and foreign government regulation.</div>

      <div><br/>
      </div>

      <div style="color: #000000; font-style: italic; font-weight: bold;">Even if we obtain regulatory approvals, our marketed drugs will be subject to ongoing regulatory review. If we fail to comply with ongoing regulatory requirements, we could lose our
        approvals to market drugs, in which case our business would be materially adversely affected.</div>

      <div><br/>
      </div>

      <div style="color: #000000;">Following regulatory approval in the United States of any drugs we may develop, we will remain subject to continuing regulatory review, including the review of adverse drug experiences and clinical results that are
        reported after our drug products are made available to patients. This would include results from any post marketing tests or vigilance required as a condition of approval. The manufacturer and manufacturing facilities we use to make any of our drug
        products will also be subject to periodic review and inspection by the FDA. The discovery of any new or previously unknown problems with the product, manufacturer or facility may result in restrictions on the drug, manufacturer or facility,
        including withdrawal of the drug from the market. We would continue to be subject to the FDA requirements governing the labeling, packaging, storage, advertising, promotion, recordkeeping, and submission of safety and other post-market information
        for all of our product candidates, even those that the FDA had approved. If we fail to comply with applicable continuing regulatory requirements, we may be subject to fines, suspension or withdrawal of regulatory approval, product recalls and
        seizures, operating restrictions and other adverse consequences.</div>

      <div><br/>
      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">12</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div style="width: 100%;" class="BRPFPageHeader">
          <div>
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

            </div>

          </div>

        </div>

      </div>

      <div style="color: #000000; font-style: italic; font-weight: bold;">The drug development process to obtain FDA approval is very costly and time consuming, and if we cannot complete our clinical trials in a cost-effective manner, our results of
        operations may be adversely affected.</div>

      <div><br/>
      </div>

      <div style="color: #000000;">Costs and timing of clinical trials may vary significantly over the life of a project owing to the following non-exclusive reasons:</div>

      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">the duration of the clinical trials;</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">the number of sites included in the trials;</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">the countries in which the trial is conducted;</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">the length of time required and ability to enroll eligible patients;</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">the number of patients that participate in the trials;</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">the number of doses that patients receive;</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">the drop-out or discontinuation rates of patients;</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">per patient trial costs;</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">third party contractors failing to comply with regulatory requirements or meet their contractual obligations to us in a timely manner;</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">our drug product candidates having different chemical and pharmacological properties in humans than in lab testing;</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">the need to suspend or terminate our clinical trials;</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">insufficient or inadequate supply or quality of drug product candidates or other necessary materials to conduct our trials;</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">potential additional safety monitoring, or other conditions required by FDA or comparable foreign regulatory authorities regarding the scope or design of our clinical trials, or other studies requested by
                regulatory agencies;</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">problems engaging IRBs to oversee trials or in obtaining and maintaining IRB approval of studies;</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">the duration of patient follow-up;</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">the efficacy and safety profile of the product candidate;</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">the costs and timing of obtaining regulatory approvals; and</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">the costs involved in enforcing or defending patent claims or other intellectual property rights.</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <div style="color: #000000;">Each of the above factors and other unanticipated factors beyond our control could prevent us from gaining approval for our drugs in a cost-effective and timely manner, which could have a material adverse impact on our
        business.</div>

      <div><br/>
      </div>

      <div style="color: #000000; font-style: italic; font-weight: bold;">Data obtained from clinical trials are not necessarily predictive of future results, may be negative or inconclusive, and are susceptible to varying interpretations, which could
        delay, limit or prevent regulatory clearances.</div>

      <div><br/>
      </div>

      <div style="color: #000000;">Data already obtained, or in the future obtained, from pre-clinical studies and clinical trials do not necessarily predict the results that will be obtained from later pre-clinical studies and clinical trials. Moreover,
        pre-clinical and clinical data may be negative or inconclusive. In addition, data is susceptible to varying interpretations. Negative or inconclusive data, or data interpreted in various ways, could delay, limit or prevent regulatory approval. A
        number of companies in the pharmaceutical industry have suffered significant setbacks in advanced clinical trials, even after they obtained promising results in earlier trials. Despite the results reported in some of our earlier clinical trials for
        belapectin, our clinical trials may not demonstrate sufficient levels of safety and efficacy necessary to obtain the requisite regulatory approvals for our drugs, and thus, our proposed drugs may not be approved for marketing. If later-stage
        clinical trials do not produce favorable results, our ability to achieve regulatory approval for any of our product candidates may be adversely impacted. The failure to adequately demonstrate the safety and effectiveness of a proposed formulation
        or product under development could delay or prevent regulatory clearance of the potential drug. The resulting delays in commercialization could materially harm our business.</div>

      <div><br/>
      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">13</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div style="width: 100%;" class="BRPFPageHeader">
          <div>
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

            </div>

          </div>

        </div>

      </div>

      <div style="color: #000000; font-style: italic; font-weight: bold;">Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved
        label, or result in significant negative consequences following any marketing approval.</div>

      <div><br/>
      </div>

      <div style="color: #000000;">Undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of
        regulatory approval by the FDA or other comparable foreign regulatory authority. Although we are not currently aware of any undesirable side effects caused by our product candidates, it is possible that they may be identified in the clinical trial
        process.</div>

      <div><br/>
      </div>

      <div style="color: #000000;">As a result of undesirable side effects or safety or toxicity issues that we may experience in our clinical trials, we may not receive approval to market any product candidates, which could prevent us from ever generating
        revenues or achieving profitability. Results of our trials could reveal an unacceptably high severity and prevalence of side effects. In such an event, our trials could be suspended or terminated, and the FDA or comparable foreign regulatory
        authorities could order us to cease further development or deny approval of our product candidates for any or all targeted indications. These side effects could affect patient recruitment or the ability of enrolled subjects to complete the trial or
        result in potential product liability claims.</div>

      <div><br/>
      </div>

      <div style="color: #000000;">Additionally, if any of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by such product, a number of potentially significant negative consequences could
        result, including:</div>

      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">we may be forced to suspend marketing of such product;</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">regulatory authorities may withdraw their approvals of such product;</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">regulatory authorities may require additional warnings on the label that could diminish the usage or otherwise limit the commercial success of such products;</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">we may be required to conduct post-market studies;</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">we could be sued and held liable for harm caused to subjects or patients; and</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">our reputation may suffer.</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <div style="color: #000000;">Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved.</div>

      <div><br/>
      </div>

      <div style="color: #000000; font-style: italic; font-weight: bold;">Failure to obtain regulatory approval in international jurisdictions would prevent our product candidates from being marketed abroad.</div>

      <div><br/>
      </div>

      <div style="color: #000000;">In order to market and sell our products in the European Union and many other jurisdictions, we must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure
        varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The regulatory approval process outside the United States generally includes all of
        the risks associated with obtaining FDA approval. In addition, in many countries outside the United States, it is required that the product be approved for reimbursement before the product can be approved for sale in that country. We may not obtain
        approvals from regulatory authorities outside the United States on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority
        outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. We may not be able to file for marketing approvals and may not receive necessary approvals to commercialize our products
        in any market. If we are unable to obtain approval of any of our product candidates by regulatory authorities in the European Union or other countries, the commercial prospects of that product candidate may be significantly diminished, and our
        business prospects could decline.</div>

      <div><br/>
      </div>

      <div style="color: #000000; font-weight: bold;">Risks Related to Our Intellectual Property</div>

      <div><br/>
      </div>

      <div style="color: #000000; font-style: italic; font-weight: bold;">Our competitive position is contingent upon the protection of our intellectual property.</div>

      <div><br/>
      </div>

      <div style="color: #000000;">Development and protection of our intellectual property are critical to our business. All of our intellectual property, patented or otherwise, has been invented and/or developed by employees or former employees of the
        Company. Our success depends, in part, on our ability to obtain patent protection for our products or processes in the U.S. and other countries, protect trade secrets and prevent others from infringing on our proprietary rights. We will only be
        able to protect our product candidates from unauthorized making, using, selling, offering to sell or importation by third parties to the extent that we have rights under valid and enforceable patents or trade secrets that cover these activities. If
        we do not adequately protect our intellectual property, competitors may be able to practice our technologies.</div>

      <div><br/>
      </div>

      <div style="color: #000000;">The patent positions of pharmaceutical and biotechnology companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. No consistent policy
        regarding the breadth of claims allowed in biotechnology patents has emerged to date in the United States. The biotechnology patent situation outside the United States is even more uncertain. Changes in either the patent laws or in interpretations
        of patent laws in the United States and other countries may diminish the value of our intellectual property. Accordingly, we cannot predict the breadth of claims that may be allowed in our pending patent applications or enforced in our issued
        patents or in third-party patents.</div>

      <div><br/>
      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">14</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div style="width: 100%;" class="BRPFPageHeader">
          <div>
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

            </div>

          </div>

        </div>

      </div>

      <div style="color: #000000;">The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage.
        For example:</div>

      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">others may be able to make compounds that are competitive with our product candidates but are not covered by the claims of our patents;</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">we might not have been the first to make the inventions covered by our pending patent applications;</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">we might not have been the first to file patent applications for these inventions;</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">it is possible that our pending patent applications will not result in issued patents;</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">we may not develop additional proprietary technologies that are patentable; or</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">the patents of others may have an adverse effect on our business.</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <div style="color: #000000;">We also may rely on trade secrets to protect our technology, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. Although we require our
        scientific and technical employees and consultants to enter into broad assignment of inventions agreements, and all of our employees, consultants and corporate partners with access to proprietary information to enter into confidentiality
        agreements, these agreements may not be honored. Enforcing a claim that a third party illegally obtained, and is using, our trade secrets is expensive and time consuming, and the outcome is unpredictable. In addition, courts outside the United
        States are sometimes less willing to protect trade secrets. Moreover, our competitors may independently develop equivalent knowledge, methods and know-how.</div>

      <div><br/>
      </div>

      <div style="color: #000000; font-style: italic; font-weight: bold;">We may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights, and we may be unable to protect our rights
        to, or use of, our technology.</div>

      <div><br/>
      </div>

      <div style="color: #000000;">Some or all of our patent applications may not issue as patents, or the claims of any issued patents may not afford meaningful protection for our technologies or products. In addition, patents issued to us or our
        licensors, if any, may be challenged and subsequently narrowed, invalidated or circumvented. Patent litigation is widespread in the biotechnology industry and could harm our business. Litigation might be necessary to protect our patent position or
        to determine the scope and validity of third-party proprietary rights.</div>

      <div><br/>
      </div>

      <div style="color: #000000;">If we choose to go to court to stop someone else from using the inventions claimed in our patents, that individual or company would have the right to ask the court to rule that such patents are invalid and/or should not
        be enforced against that third party. These lawsuits are expensive, and we may not have the required resources to pursue such litigation or to protect our patent rights. In addition, there is a risk that the court will decide that these patents are
        not valid and that we do not have the right to stop the other party from using the inventions. There is also the risk that, even if the validity of these patents is upheld, the court will refuse to stop the other party on the ground that such other
        party&#8217;s activities do not infringe our rights in these patents.</div>

      <div><br/>
      </div>

      <div style="color: #000000;">Furthermore, a third party may claim that we are using inventions covered by the third party&#8217;s patent rights and may go to court to stop us from engaging in our normal operations and activities, including making or
        selling our product candidates. These lawsuits are costly and could affect our results of operations and divert the attention of managerial and technical personnel. There is a risk that a court would decide that we are infringing the third party&#8217;s
        patents and would order us to stop the activities covered by the patents. In addition, there is a risk that a court will order us to pay the other party treble damages for having violated the other party&#8217;s patents. The biotechnology industry has
        produced a proliferation of patents, and it is not always clear to industry participants, including us, which patents cover various types of products or methods of use. The coverage of patents is subject to interpretation by the courts, and the
        interpretation is not always uniform. If we are sued for patent infringement, we would need to demonstrate that our products or methods of use either do not infringe the claims of the relevant patent and/or that the patent claims are invalid, and
        we may not be able to do this. Proving invalidity in the U.S., in particular, is difficult since it requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents.</div>

      <div><br/>
      </div>

      <div style="color: #000000;">Because some patent applications in the United States may be maintained in secrecy until the patents are issued, patent applications in the United States and many foreign jurisdictions are typically not published until
        eighteen months after filing, and publications in the scientific literature often lag behind actual discoveries, we cannot be certain that others have not filed patent applications for technology covered by our issued patents or our pending
        applications or that we were the first to invent the technology. Our competitors may have filed, and may in the future file, patent applications covering technology similar to ours. Any such patent application may have priority over our patent
        applications and could further require us to obtain rights to issued patents covering such technologies. If another party has filed a United States patent application on inventions similar to ours, we may have to participate in an interference or
        other proceeding in the PTO or a court to determine priority of invention in the United States. The costs of these proceedings could be substantial, and it is possible that such efforts would be unsuccessful, resulting in a loss of our United
        States patent position with respect to such inventions.</div>

      <div><br/>
      </div>

      <div style="text-align: justify; color: #000000;">Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties
        resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations.</div>

      <div><br/>
      </div>

      <div style="color: #000000; font-style: italic; font-weight: bold;">Obtaining and maintaining our patent protection depends upon compliance with various procedural, document submission, fee payment and other requirements imposed by governmental
        patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</div>

      <div><br/>
      </div>

      <div style="color: #000000;">The PTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process. There are situations in which noncompliance
        can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise
        have been the case.</div>

      <div><br/>
      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">15</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div style="width: 100%;" class="BRPFPageHeader">
          <div>
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

            </div>

          </div>

        </div>

      </div>

      <div style="color: #000000; font-style: italic; font-weight: bold;">Our failure to secure trademark registration could adversely affect our ability to market our product candidates and our business.</div>

      <div><br/>
      </div>

      <div style="color: #000000;">Our trademark applications in the United States, when filed, and any other jurisdictions where we may file may not be allowed for registration, and our registered trademarks may not be maintained or enforced. During
        trademark registration proceedings, we may receive rejections. Although we are given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the PTO and in comparable agencies in many foreign
        jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our applications and/or registrations, and our
        applications and/or registrations may not survive such proceedings. Failure to secure such trademark registrations in the United States and in foreign jurisdictions could adversely affect our ability to market our product candidates and our
        business.</div>

      <div><br/>
      </div>

      <div style="color: #000000; font-style: italic; font-weight: bold;">Confidentiality agreements with employees and others may not adequately prevent disclosure of our trade secrets and other proprietary information and may not adequately protect our
        intellectual property, which could impede our ability to compete.</div>

      <div><br/>
      </div>

      <div style="color: #000000;">Because we operate in the highly technical field of biotechnology and pharmaceutical development, we rely in part on trade secret protection in order to protect our proprietary trade secrets and unpatented know-how.
        However, trade secrets are difficult to protect, and we cannot be certain that others will not develop the same or similar technologies on their own. We have taken steps, including entering into confidentiality agreements with all of our employees,
        consultants and corporate partners to protect our trade secrets and unpatented know-how. These agreements generally require that the other party keep confidential and not disclose to third parties all confidential information developed by the party
        or made known to the party by us during the course of the party&#8217;s relationship with us. We also typically obtain agreements from these parties that provide that inventions conceived by the party in the course of rendering services to us will be our
        exclusive property. However, these agreements may not be honored and may not effectively assign intellectual property rights to us. Enforcing a claim that a party illegally obtained and is using our trade secrets or know-how is difficult, expensive
        and time consuming, and the outcome is unpredictable. In addition, courts outside the United States may be less willing to protect trade secrets or know-how. The failure to obtain or maintain trade secret protection could adversely affect our
        competitive position.</div>

      <div><br/>
      </div>

      <div style="color: #000000; font-style: italic; font-weight: bold;">We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</div>

      <div><br/>
      </div>

      <div style="color: #000000;">As is common in the biotechnology and pharmaceutical industry, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies, including our competitors or potential competitors.
        Although no claims against us are currently pending, we may be subject to claims that these employees or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. Litigation may
        be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management.</div>

      <div><br/>
      </div>

      <div style="color: #000000; font-weight: bold;">Risks Related to Information Technology and Cybersecurity</div>

      <div><br/>
      </div>

      <div style="color: #000000; font-style: italic; font-weight: bold;">We are dependent on information technology and our systems and infrastructure face certain risks, including from cybersecurity breaches and data leakage.</div>

      <div><br/>
      </div>

      <div style="color: #000000;">We rely extensively on information technology systems, networks and services that are managed and hosted provided by third-parties or their vendors, to assist in conducting our business. A significant breakdown, invasion,
        corruption, destruction or interruption of critical information technology systems or infrastructure, by our personnel or others with authorized access to our systems or unauthorized persons could negatively impact our operations. The
        ever-increasing use and evolution of technology, including cloud-based computing, creates opportunities for the unintentional dissemination or intentional destruction or modification of confidential information stored in our, or our third-party
        providers&#8217; systems, portable media or storage devices. We could also experience a business interruption, theft of confidential information or reputational damage from malicious cyber-attacks, which may compromise our system infrastructure or lead
        to data leakage, either internally or at our third-party providers.&#160; We have observed an increase in cybersecurity incidents across the industry, predominantly ransomware and social engineering attacks. As the cyber-threat landscape evolves, these
        attacks are growing in frequency, sophistication and intensity, and due to the nature of some of these attacks, there is also a risk that they may remain undetected for a period of time. There can be no assurance that we will be able to prevent
        breakdowns or breaches to our or our third-party providers&#8217; databases or systems that could adversely affect our business.</div>

      <div><br/>
      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">16</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div style="width: 100%;" class="BRPFPageHeader">
          <div>
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

            </div>

          </div>

        </div>

      </div>

      <div style="color: #000000; font-weight: bold;">Risks Related to Our Common Stock</div>

      <div><br/>
      </div>

      <div style="color: #000000; font-style: italic; font-weight: bold;">The market price of our common stock may be volatile and adversely affected by several factors. This could subject us to securities class action litigation, and our stockholders
        could incur substantial losses.</div>

      <div><br/>
      </div>

      <div style="color: #000000;">The market price of our common stock could fluctuate significantly in response to various factors and events, including but not limited to:</div>

      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">the results of our pre-clinical studies and clinical trials, including interim results, as well as those of our competitors;</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">regulatory actions with respect to our products or our competitors&#8217; products;</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">our ability to integrate operations, technology, products and services;</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">our ability to execute our business plan;</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">operating results below expectations;</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">our issuance of additional securities, including debt or equity or a combination thereof, which may be necessary to fund our operating expenses and the cost of our clinical trials;</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">announcements of technological innovations or new products by us or our competitors;</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">the success of competitive products;</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">loss of any strategic relationship;</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">industry developments, including, without limitation, changes in healthcare policies or practices or third-party reimbursement policies;</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">regulatory or legal developments in the United States and other countries;</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">the level of expenses related to any of our product candidates or clinical development programs;</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">disputes or other developments related to proprietary rights, including patents, litigation matters, and our ability to obtain patent protection for our technologies;</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">economic and other external factors;</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">period-to-period fluctuations in our financial results;</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">sales of our common stock by us, our insiders or our other stockholders;</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">whether an active trading market in our common stock develops and is maintained;</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">engagement and retention of senior management needed for our clinical trials; and</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">novel and unforeseen market forces and trading strategies, such as the massive short squeeze rally caused by retail investors on companies such as Gamestop.</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">17</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div style="width: 100%;" class="BRPFPageHeader">
          <div>
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

            </div>

          </div>

        </div>

      </div>

      <div style="color: #000000;">In addition, the market price for securities of pharmaceutical and biotechnology companies historically has been highly volatile, and the securities markets have from time-to-time experienced significant price and volume
        fluctuations that are unrelated to the operating performance of particular companies. These broad market fluctuations may cause the market price of our common stock to decline substantially.</div>

      <div><br/>
      </div>

      <div style="color: #000000;">In the past, securities class action litigation has often been brought against a company, including us, following a decline in the market price of its securities. This risk is especially relevant for us because
        biotechnology and biopharmaceutical companies have experienced significant stock price volatility in recent years. As described above, we have recently defended a consolidated federal securities class action lawsuit and a consolidated shareholder
        derivative actions, and we may become involved in additional instances of this type of litigation in the future. Litigation often is expensive and diverts management&#8217;s attention and resources, which could materially and adversely affect our
        business.</div>

      <div><br/>
      </div>

      <div style="color: #000000;">Additionally, fluctuations in the trading price or liquidity of our common stock may materially and adversely affect, among other things, the interest of investors to purchase our common stock on the open market and,
        generally, our ability to raise capital.</div>

      <div><br/>
      </div>

      <div style="color: #000000; font-style: italic; font-weight: bold;">Our board of directors has the power to designate, without stockholder approval, additional series of preferred capital, the shares of which could be senior to our common stock and
        be entitled to conversion or voting rights that adversely affect the holders of our common stock.</div>

      <div><br/>
      </div>

      <div style="color: #000000;">Our articles of incorporation authorize the issuance of capital stock including 20,000,000 authorized undesignated shares (all have been designated as of December 31, 2022), and empowers our board of directors to
        prescribe, by resolution and without stockholder approval, a class or series of undesignated shares, including the number of shares in the class or series and the voting powers, designations, rights, preferences, restrictions and the relative
        rights in each such class or series. Accordingly, in the event that additional undesignated shares are authorized under our charter documents, our board of directors may designate and issue additional shares or series of preferred stock that would
        rank senior to the shares of common stock as to dividend rights or rights upon our liquidation, winding-up, or dissolution</div>

      <div><br/>
      </div>

      <div style="color: #000000; font-style: italic; font-weight: bold;">Nevada law and our charter documents could make it more difficult for a third party to acquire us and discourage a takeover, which could depress the trading price of our common
        stock.</div>

      <div><br/>
      </div>

      <div style="color: #000000;">Nevada corporate law and our articles of incorporation and bylaws contain provisions that could discourage, delay, or prevent a change in control of our Company or changes in our management that our stockholders may deem
        advantageous. For example, holders of our common stock do not have cumulative voting rights in the election of directors, meaning that stockholders owning a majority of our outstanding shares of common stock will be able to elect all of our
        directors. In addition, because if and when we have 200 or more stockholders of record, we are subject to the &#8220;business combinations&#8221; provisions of the Nevada Revised Statutes, or NRS. These provisions could prohibit or delay a merger or other
        takeover or change in control attempt and, accordingly, may discourage attempts to acquire our Company even though such a transaction may be in our stockholders&#8217; best interest and offer our stockholders the opportunity to sell their stock at a
        price above the prevailing market price.</div>

      <div><br/>
      </div>

      <div style="color: #000000; font-style: italic; font-weight: bold;">We may issue additional common stock, which might dilute the net tangible book value per share of our common stock.</div>

      <div><br/>
      </div>

      <div style="color: #000000;">Our board of directors has the authority, without action or vote of our stockholders, to issue all or a part of our authorized but unissued shares. Such stock issuances could be made at a price that reflects a discount
        to, or a premium from, the then-current market price of our common stock. In addition, in order to raise capital, we may need to issue securities that are convertible into or exchangeable for a significant amount of our common stock. We may engage
        in additional capital raising transactions within the next twelve months, which would likely result in issuances of additional shares which would be dilutive to current shareholders. These issuances would dilute the percentage ownership interest,
        which would have the effect of reducing your influence on matters on which our stockholders vote, and might dilute the net tangible book value per share of our common stock. You may incur additional dilution if holders of stock options, whether
        currently outstanding or subsequently granted, exercise their options, or if the holders of warrants, whether currently outstanding or subsequently granted, exercise their warrants to purchase shares of our common stock.</div>

      <div><br/>
      </div>

      <div style="color: #000000; font-style: italic; font-weight: bold;">A sale of a substantial number of shares of the common stock may cause the price of our common stock to decline.</div>

      <div><br/>
      </div>

      <div style="color: #000000;">Finance transactions resulting in a large amount of newly issued shares that become readily tradable, or other events that cause current stockholders to sell shares, could place downward pressure on the trading price of
        our stock. Some of our shareholders have registration rights to facilitate sales of large blocks of our common stock. We have filed a shelf registration statement to allow registered sales by us of up to $100 million, which includes the offer and
        sell shares of our common stock having an aggregate offering price of up to $35,967,000 from time to time pursuant to our At The Market Issuance Sales Agreement with H.C. Wainwright &amp; Co., LLC. We may consider additional or other capital
        raising transactions within the next twelve months, which would likely result in issuances of additional shares that would be dilutive to current shareholders. In addition, the lack of a robust resale market may require a stockholder who desires to
        sell a large number of shares of common stock to sell the shares in increments over time to mitigate any adverse impact of the sales on the market price of our stock.</div>

      <div><br/>
      </div>

      <div style="color: #000000;">If our stockholders sell, or the market perceives that our stockholders intend to sell for various reasons substantial amounts of our common stock in the public market, including shares issued upon the exercise of
        outstanding options or warrants, the market price of our common stock could fall. Sales of a substantial number of shares of our common stock may make it more difficult for us to sell equity or equity-related securities in the future at a time and
        price that we deem reasonable or appropriate. We may become involved in securities class action litigation that could divert management&#8217;s attention and harm our business.</div>

      <div><br/>
      </div>

      <div style="color: #000000; font-style: italic; font-weight: bold;">We have not paid cash dividends on our common stock in the past and do not expect to pay cash dividends in the foreseeable future.</div>

      <div><br/>
      </div>

      <div style="color: #000000;">We have never paid cash dividends on our common stock and do not anticipate paying cash dividends on our common stock in the foreseeable future. The payment of dividends on our common stock will depend on our earnings,
        financial condition and other business and economic factors affecting us at such time as the board of directors may consider relevant. If we do not pay dividends, our common stock may be less valuable because a return on your investment will only
        occur if the market price of our common stock price appreciates.</div>

      <div><br/>
      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">18</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div style="width: 100%;" class="BRPFPageHeader">
          <div>
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

            </div>

          </div>

        </div>

      </div>

      <div style="color: #000000; font-style: italic; font-weight: bold;">Our shares of common stock have been thinly traded, so you may be unable to sell at or near ask prices or even at all if you need to sell your shares to raise money or otherwise
        desire to liquidate your shares.</div>

      <div><br/>
      </div>

      <div style="color: #000000;">We cannot predict the extent to which an active public market for our common stock will develop or be sustained. Our common stock is currently traded on The NASDAQ Capital Market and experiences periods when it is
        considered &#8220;thinly-traded.&#8221; This situation may be attributable to several factors, including the fact that we are a small company that is relatively unknown to stock analysts, stockbrokers, institutional investors and others in the investment
        community that generate or influence sales volume. Furthermore, even if our stock came to the attention of such persons, they may be reluctant to follow us or purchase or recommend the purchase of our shares. Therefore, there may be periods of
        several days, weeks or months when trading activity in our shares is minimal, as compared to a seasoned issuer that has a large and steady volume of trading activity that will generally support continuous sales without an adverse effect on share
        price. We cannot give you any assurance that a broader or more active public trading market for our common stock will be sustained, or that current trading levels will be sustained or not diminish.</div>

      <div><br/>
      </div>

      <div style="color: #000000; font-style: italic; font-weight: bold;">Concentration of ownership by our principal stockholders may limit your ability to influence the outcome of director elections and other transactions requiring stockholder approval.</div>

      <div><br/>
      </div>

      <div style="color: #000000;">A significant percentage of our outstanding stock is held by a limited number of investors, including Richard E. Uihlein. Mr. Uihlein, the chairman of our board of directors, who beneficially owns approximately 16.4% of
        our outstanding common stock as of February 28, 2025 (which does not include any shares issuable upon exercise of options and warrants nor shares issuable upon conversion of convertible notes and lines of credit) and the 10X Fund, LP , which now
        owns 9.4% of the issued and outstanding shares of common stock of the Company as of February 28, 2025 (which does not include any shares issuable upon exercise of options and warrants). Mr. Uihlein is also an investor in the 10X Fund as a limited
        partner but is not deemed to be a beneficial owner of, or have a reportable interest in, any shares owned by 10X Fund. As a result of their ownership of shares of common stock, Mr. Uihlein and 10X Fund have and will have significant influence over
        corporate actions requiring stockholder approval, including the following actions:</div>

      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">to elect or defeat the election of our directors;</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">to amend or prevent amendment of our certificate of incorporation or bylaws;</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">to effect or prevent a merger, sale of assets or other corporate transaction; and</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">to control the outcome of any other matter submitted to our stockholders for vote.</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <div style="text-align: justify; color: #000000;">Such persons&#8217; stock ownership may discourage a potential acquirer from making a tender offer or otherwise attempting to obtain control of our company, which in turn could reduce our stock price or
        prevent our stockholders from realizing a premium over our stock price.</div>

      <div><br/>
      </div>

      <div style="color: #000000; font-style: italic; font-weight: bold;">Richard E. Uihlein&#8217;s and 10X Fund&#8217;s significant ownership positions may deter or prevent efforts by other companies to acquire us, which could prevent our stockholders from realizing
        a control premium.</div>

      <div><br/>
      </div>

      <div style="text-align: justify; color: #000000;">As a result of Mr. Uihlein&#8217;s and 10X Fund&#8217;s significant ownership and Mr. Uihlein&#8217;s position as chairman of the board of directors, other companies may be less inclined to pursue an acquisition of us
        or we may not have the opportunity to be acquired in a transaction that stockholders might otherwise deem favorable, including transactions in which our stockholders might realize a substantial premium for their shares.</div>

      <div><br/>
      </div>

      <div style="color: #000000; font-style: italic; font-weight: bold;">Richard E. Uilhlein and/or 10X Fund could sell or transfer a substantial number of shares of our common stock, which could depress the price of our securities or result in a change
        in control of our company.</div>

      <div><br/>
      </div>

      <div style="color: #000000;">Although Mr. Uihlein has held common stock of the Company since 2012 and has not sold any of the shares of common stock that he has acquired during this time period, and although 10X Fund has been a long-time investor in
        the Company, neither Mr. Uihlein nor 10X Fund are subject to any contractual restrictions with us on their ability to sell or transfer our common stock on the open market, in privately negotiated transactions or otherwise, and these sales or
        transfers could create substantial declines in the price of our securities or, if these sales or transfers were made to a single buyer or group of buyers, could contribute to a transfer of control of our company to a third party. Sales by Mr.
        Uihlein or 10X Fund of a substantial number of shares, or the expectation of such sales, could cause a significant reduction in the market price of our common stock.</div>

      <div><br/>
      </div>

      <div style="color: #000000; font-weight: bold;">A pandemic similar to the COVID-19 pandemic, or the reemergence of the COVID-19 pandemic could adversely impact our business, including our preclinical studies and clinical trials.</div>

      <div><br/>
      </div>

      <div style="color: #000000;">The occurrence of a pandemic similar to the COVID-19 pandemic, or the reemergence of the COVID-19 pandemic could cause disruptions that could severely impact our business and our clinical trials including:</div>

      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">delays or difficulties in enrolling patients in our clinical trials;</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">delays or disruptions in non-clinical experiments due to unforeseen circumstances at contract research organizations and vendors along their supply chain;</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">increased rates of patients withdrawing from our clinical trials following enrollment as a result of contracting a contagious illness, being forced to quarantine, or not accepting in office or home health
                visits;</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as sites for our NAVIGATE trial and hospital staff supporting the conduct of such
                trials;</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">19</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div style="width: 100%;" class="BRPFPageHeader">
          <div>
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

            </div>

          </div>

        </div>

      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">interruption of key clinical trial activities, such as clinical trial site data monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others or
                interruption of clinical trial subject visits and study procedures (particularly any procedures that may be deemed non-essential), which may impact the integrity of subject data and clinical study endpoints;</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">interruption or delays in the operations of the FDA and comparable foreign regulatory agencies, which may impact review and approval timelines;</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">interruption of, or delays in receiving, supplies of our product candidates from our contract manufacturing organizations due to staffing shortages, production slowdowns or stoppages and disruptions in
                delivery systems; and</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">limitations on employee resources that would otherwise be focused on the conduct of our preclinical studies and clinical trials, including because of sickness of employees or their families, the desire of
                employees to avoid contact with large groups of people, an increased reliance on working from home or mass transit disruptions.</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <div style="color: #000000;">In addition, the trading prices for our common stock and other biopharmaceutical companies could experience extreme volatility during a pandemic.&#160; The extent to which a pandemic may impact our business, preclinical
        studies and clinical trials will depend factors that we cannot predict or control, such as the ultimate geographic spread of the disease, the duration of the outbreak, travel restrictions and actions to contain the outbreak or treat its impact,
        such as social distancing and quarantines or lock-downs in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the
        disease.</div>

      <div><br/>
      </div>

      <div>
        <div>
          <a id="Item1B."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="text-align: right; vertical-align: top; width: 54pt;">
                  <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">Item 1B.</div>
                </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                  <div style="color: rgb(0, 0, 0); font-weight: bold; font-style: italic;">Unresolved Staff Comments</div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div><br/>
      </div>

      <div style="color: #000000;">None.</div>

      <div><br/>
      </div>

    </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">

    <div>
      <div>
        <div>
          <div>
            <a id="Item1C."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 54pt; vertical-align: top; font-weight: bold;"><!--Anchor-->Item 1C.</td>

    <td style="width: auto; vertical-align: top;">
                    <div style="font-weight: bold;"><!--Anchor-->Cybersecurity</div>
                  </td>

  </tr>


</table>
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
            </div>


            <ix:nonNumeric name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" id="Text_3b8ad099d87f4e5cb733d4babc97962b" contextRef="c20240101to20241231" escape="true" continuedAt="Text_567dbde2bb2a49a2ac92bcf9e26b90851">
<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Risk management and strategy</div>
</ix:nonNumeric>
            <ix:continuation id="Text_567dbde2bb2a49a2ac92bcf9e26b90851" continuedAt="Text_567dbde2bb2a49a2ac92bcf9e26b90852">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
            </div>
</ix:continuation>
            <ix:continuation id="Text_567dbde2bb2a49a2ac92bcf9e26b90852" continuedAt="Text_567dbde2bb2a49a2ac92bcf9e26b90853"><ix:nonNumeric name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" id="Text_5d70e5104c8f434294818c951b222848" contextRef="c20240101to20241231" escape="true">
<div style="display:none;"><br/></div>
<div style="text-indent: 24.3pt; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" id="Fact_33ee45c031f84a49b187379990f32ab0" contextRef="c20240101to20241231" format="ixt:fixed-true">We have policies and processes designed to protect our information technology systems</ix:nonNumeric>, which are managed by outside consultants.&#160; Our cybersecurity consultants resolve issues in a timely manner in the event of a cybersecurity threat or
              incident.</div>
</ix:nonNumeric></ix:continuation>

            <ix:continuation id="Text_567dbde2bb2a49a2ac92bcf9e26b90853" continuedAt="Text_567dbde2bb2a49a2ac92bcf9e26b90854">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
            </div>
</ix:continuation>
            <ix:continuation id="Text_567dbde2bb2a49a2ac92bcf9e26b90854" continuedAt="Text_567dbde2bb2a49a2ac92bcf9e26b90855">
<div style="display:none;"><br/></div>
<div style="text-indent: 24.3pt; font-family: 'Times New Roman'; font-size: 10pt;">As part of our broader risk management framework, from time to time, we seek to identify potential cybersecurity risks to our business and improve our policies
              and processes to address such risks. We have designed our business applications to minimize the impact that cybersecurity incidents could have on our business and have identified back-up systems where appropriate. We seek to further mitigate
              cybersecurity risks through a combination of monitoring and detection activities, use of anti-malware applications, employee training, quality reviews and communication and reporting structures, among other processes. We have an incident
              response plan in place that outlines containment, eradication and recovery plans in the event of a cybersecurity threat or incident.</div>
</ix:continuation>
            <ix:continuation id="Text_567dbde2bb2a49a2ac92bcf9e26b90855" continuedAt="Text_567dbde2bb2a49a2ac92bcf9e26b90856">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
            </div>
</ix:continuation>
            <ix:continuation id="Text_567dbde2bb2a49a2ac92bcf9e26b90856" continuedAt="Text_567dbde2bb2a49a2ac92bcf9e26b90857">
<div style="display:none;"><br/></div>
<div style="text-indent: 24.3pt; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" id="Fact_e496bc4be127456d8e33d49401e5cfe3" contextRef="c20240101to20241231" format="ixt:fixed-true">We engage a third-party consultant to assist us with designing controls and our cybersecurity risk management framework.</ix:nonNumeric> We are also engaging with a third party to perform penetration testing. We also retain third parties to assist with the monitoring and detection of cybersecurity
              threats and responding to any cybersecurity threats or incidents.</div>
</ix:continuation>
            <ix:continuation id="Text_567dbde2bb2a49a2ac92bcf9e26b90857" continuedAt="Text_567dbde2bb2a49a2ac92bcf9e26b90858">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
            </div>
</ix:continuation>
            <ix:continuation id="Text_567dbde2bb2a49a2ac92bcf9e26b90858" continuedAt="Text_567dbde2bb2a49a2ac92bcf9e26b90859">
<div style="display:none;"><br/></div>
<div style="text-indent: 24.3pt; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" id="Fact_f325eaa8b5894dcba9d3d35eb2547d59" contextRef="c20240101to20241231" format="ixt:fixed-true">With respect to third parties that manage or use our information technology or data, we obtain reports to assess the security of their systems and processes. We engage in ongoing monitoring of third-party providers to ensure compliance with our cybersecurity standards.</ix:nonNumeric><br/>
            </div>
</ix:continuation>
            <ix:continuation id="Text_567dbde2bb2a49a2ac92bcf9e26b90859" continuedAt="Text_567dbde2bb2a49a2ac92bcf9e26b908510">
<div><br/></div>
</ix:continuation>
            <ix:continuation id="Text_567dbde2bb2a49a2ac92bcf9e26b908510"><ix:nonNumeric name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" id="Text_ef625999d8304a4fa97dca43ce0e8714" contextRef="c20240101to20241231" escape="true">
<div style="display:none;"><br/></div>
<div style="text-indent: 24.3pt; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" id="Fact_541575825c4e4cce88420c9e71066a92" contextRef="c20240101to20241231" format="ixt:fixed-false">We have not encountered cybersecurity threats or incidents that have had a material impact on our business.</ix:nonNumeric><br/>
            </div>
</ix:nonNumeric></ix:continuation>

            <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
            </div>


            <ix:nonNumeric name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" id="Text_4c79b204119d48098ed2777c5a1222c4" contextRef="c20240101to20241231" escape="true" continuedAt="Text_cc90bbd675464554b8618c353fba25e11">
<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Cybersecurity Governance</div>
</ix:nonNumeric>
            <ix:continuation id="Text_cc90bbd675464554b8618c353fba25e11" continuedAt="Text_cc90bbd675464554b8618c353fba25e12">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
            </div>
</ix:continuation>

            <ix:nonNumeric name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="Text_3c237d91d5214797a307ee045d99e83d" contextRef="c20240101to20241231" escape="true"><ix:continuation id="Text_cc90bbd675464554b8618c353fba25e12" continuedAt="Text_cc90bbd675464554b8618c353fba25e13">
<div style="display:none;"><br/></div>
<div style="text-indent: 24.3pt; font-family: 'Times New Roman'; font-size: 10pt;">Our Nomination and Corporate Governance Committee has specific oversight responsibility for cybersecurity The Nomination and Corporate Governance Committee
              reviews and discusses with management our policies, practices and risks related to information security and cybersecurity.</div>
</ix:continuation></ix:nonNumeric>

            <ix:continuation id="Text_cc90bbd675464554b8618c353fba25e13" continuedAt="Text_cc90bbd675464554b8618c353fba25e14">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
            </div>
</ix:continuation>
            <ix:continuation id="Text_cc90bbd675464554b8618c353fba25e14" continuedAt="Text_cc90bbd675464554b8618c353fba25e15"><ix:nonNumeric name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" id="Text_86e7cc5936864b40be4f2bbbcd19eacc" contextRef="c20240101to20241231" escape="true"><ix:nonNumeric name="cyd:CybersecurityRiskRoleOfManagementTextBlock" id="Text_6d34d35cd2ac4f249b3b3c15bf2d98d8" contextRef="c20240101to20241231" escape="true">
<div style="display:none;"><br/></div>
<div style="text-indent: 24.3pt; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" id="Fact_61e6c7aae9134630a2630c17aba697ec" contextRef="c20240101to20241231" format="ixt:fixed-true">Our chief financial officer has primary responsibility for assessing, monitoring and managing cybersecurity risks.</ix:nonNumeric> We utilize cybersecurity consultants to monitor and
              report cybersecurity threats or incidents to our chief financial officer and to resolve issues arising from such threats or incidents.</div>
</ix:nonNumeric></ix:nonNumeric></ix:continuation>

            <ix:continuation id="Text_cc90bbd675464554b8618c353fba25e15" continuedAt="Text_cc90bbd675464554b8618c353fba25e16">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
            </div>
</ix:continuation>
            <ix:continuation id="Text_cc90bbd675464554b8618c353fba25e16"><ix:nonNumeric name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="Text_d3cbcebe11d74b7f9430dbc1a6471221" contextRef="c20240101to20241231" escape="true"><ix:nonNumeric name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" id="Text_815c0823911d4a2fbf14e7ef0aa9d580" contextRef="c20240101to20241231" escape="true">
<div style="display:none;"><br/></div>
<div style="text-indent: 24.3pt; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" id="Fact_5c80d41dfe4f4b08908f5c9373143a8e" contextRef="c20240101to20241231" format="ixt:fixed-true">Our chief financial officer updates the Nomination and Corporate Governance Committee on any risks related to cybersecurity as needed.</ix:nonNumeric><br/>
            </div>
</ix:nonNumeric></ix:nonNumeric></ix:continuation>
            <div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
            </div>

            <!--Anchor--> </div>

        </div>

      </div>

    </div>


  </div>
<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div>
      <div>
        <a id="Item2."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="text-align: right; vertical-align: top; width: 54pt;">
                <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">Item 2.</div>
              </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                <div style="color: rgb(0, 0, 0); font-weight: bold; font-style: italic;">Properties</div>
              </td>

  </tr>


</table>
      </div>

    </div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">We lease 3,610 square feet for our executive offices located at 4960 Peachtree Industrial Blvd., Norcross, GA. We also lease on a month-to-month basis approximately 300 square feet in Natick, MA, for use
      by research and development employees and which is collocated with one of our research and development service vendors. We believe these spaces are suitable for our present operations.</div>

    <div><br/>
    </div>

    <div>
      <div>
        <a id="Item3."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="text-align: right; vertical-align: top; width: 54pt;">
                <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">Item 3.</div>
              </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                <div style="color: rgb(0, 0, 0); font-weight: bold; font-style: italic;">Legal Proceedings</div>
              </td>

  </tr>


</table>
      </div>

    </div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">From time to time, the Company is exposed to litigation relating to its operations. The Company is not currently engaged in any legal proceedings that are expected, individually or in the aggregate, to
      have a material, adverse effect on its financial condition or results of operations.</div>

    <div><br/>
    </div>

    <div>
      <div>
        <a id="Item4."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="text-align: right; vertical-align: top; width: 54pt;">
                <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">Item 4.</div>
              </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                <div style="color: rgb(0, 0, 0); font-weight: bold; font-style: italic;">Mine Safety Disclosures</div>
              </td>

  </tr>


</table>
      </div>

    </div>

    <div><br/>
    </div>

    <div style="color: #000000;">Not applicable.</div>

    <div><br/>
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">20</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div>
          <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

          </div>

        </div>

      </div>

    </div>

    <div style="text-align: center; color: #000000; font-weight: bold;"><a id="PARTII"><!--Anchor--></a>PART II</div>

    <div><br/>
    </div>

    <div>
      <div>
        <a id="Item5."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="text-align: right; vertical-align: top; width: 54pt;">
                <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">Item 5.</div>
              </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                <div style="color: rgb(0, 0, 0); font-weight: bold; font-style: italic;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</div>
              </td>

  </tr>


</table>
      </div>

    </div>

    <div><br/>
    </div>

    <div style="color: #000000;">Our common stock began trading on The NASDAQ Capital Market under the symbol GALT effective March 23, 2012.</div>

    <div><br/>
    </div>

    <div style="color: #000000; font-style: italic; font-weight: bold;">Holders of Common Stock</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">As of February 28, 2025, there were 136 shareholders of record of our common stock. Because shares of our common stock are held by depositaries, brokers and other nominees, the number of beneficial
      holders of our shares is substantially larger than the number of record holders.</div>

    <div><br/>
    </div>

    <div style="color: #000000; font-style: italic; font-weight: bold;">Dividends</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">We have never paid cash dividends on our common stock and do not anticipate paying cash dividends on our common stock in the foreseeable future. The payment of dividends on our common stock will depend on
      our earnings, financial condition and other business and economic factors affecting us at such time as the board of directors may consider relevant.</div>

    <div><br/>
    </div>

    <div>
      <div>
        <a id="Item6."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="text-align: right; vertical-align: top; width: 54pt;">
                <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">Item 6.</div>
              </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                <div style="color: rgb(0, 0, 0); font-weight: bold; font-style: italic;">[Reserved]</div>
              </td>

  </tr>


</table>
      </div>

    </div>

    <div><br/>
    </div>

    <div>
      <div>
        <a id="Item7."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="text-align: right; vertical-align: top; width: 54pt;">
                <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">Item 7.</div>
              </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                <div style="color: rgb(0, 0, 0); font-weight: bold; font-style: italic;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</div>
              </td>

  </tr>


</table>
      </div>

    </div>

    <div><br/>
    </div>

    <div style="color: #000000; font-weight: bold;">Forward-Looking Statements</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: rgb(0, 0, 0);">In addition to historical information, the following Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations contains forward-looking statements as defined under Section
      21E of the Securities Exchange Act of 1934, as amended, and is subject to the safe harbor created therein for forward-looking statements. Such statements include, but are not limited to, statements concerning our anticipated operating results,
      research and development, clinical trials, regulatory proceedings, and financial resources, and can be identified by use of words such as, for example, &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;project,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe&#8221; and &#8220;would,&#8221; &#8220;should,&#8221;
      &#8220;could&#8221; or &#8220;may.&#8221; All statements, other than statements of historical facts, included herein that address activities, events, or developments that the Company expects or anticipates will or may occur in the future, are forward-looking statements,
      including statements regarding: plans and expectations regarding clinical trials; plans and expectations regarding regulatory approvals; our strategy and expectations for clinical development and commercialization of our products; potential strategic
      partnerships; expectations regarding the effectiveness of our products; plans for research and development and related costs; statements about accounting assumptions and estimates; expectations regarding liquidity and the sufficiency of cash to fund
      currently planned operations through at least December 31, 2024; our commitments and contingencies; and our market risk exposure. Forward-looking statements are based on current expectations, estimates and projections about the industry and markets
      in which Galectin Therapeutics operates, and management&#8217;s beliefs and assumptions. These statements are not guarantees of future performance and involve certain known and unknown risks and uncertainties that could cause actual results to differ
      materially from those expressed or implied by such statements. Such risks and uncertainties are related to and include, without limitation,</div>

    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
          </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">our early stage of development,</div>
          </td>

  </tr>


</table>
    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
          </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">our NAVIGATE trial was our only active clinical trial, and we currently do not have plans or funding to undertake another clinical trial;</div>
          </td>

  </tr>


</table>
    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
          </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">there is substantial doubt about our ability to continue as a going concern;</div>
          </td>

  </tr>


</table>
    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
          </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">we have incurred significant operating losses since our inception and cannot assure you that we will generate revenue or profit,</div>
          </td>

  </tr>


</table>
    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
          </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">our dependence on additional outside capital,</div>
          </td>

  </tr>


</table>
    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
          </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">we may be unable to enter into strategic partnerships for the development, commercialization, manufacturing and distribution of our proposed product candidates,</div>
          </td>

  </tr>


</table>
    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
          </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">uncertainties related to any litigation,</div>
          </td>

  </tr>


</table>
    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
          </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">uncertainties related to our technology and clinical trials, including expected dates of availability of clinical data,</div>
          </td>

  </tr>


</table>
    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
          </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">we may be unable to demonstrate the efficacy and safety of our developmental product candidates in human trials,</div>
          </td>

  </tr>


</table>
    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
          </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">we may be unable to improve upon, protect and/or enforce our intellectual property,</div>
          </td>

  </tr>


</table>
    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
          </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">we are subject to extensive and costly regulation by the U.S. Food and Drug Administration (FDA) and by foreign regulatory authorities, which must approve our product candidates in development and could
              restrict the sales and marketing and pricing of such products,</div>
          </td>

  </tr>


</table>
    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
          </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">competition and stock price volatility in the biotechnology industry,</div>
          </td>

  </tr>


</table>
    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
          </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">limited trading volume for our stock, concentration of ownership of our stock, and other risks detailed herein and from time to time in our SEC reports, and</div>
          </td>

  </tr>


</table>
    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
          </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">the impact resulting from a pandemic or the reemergence of COVID-19, which delayed our clinical trial and development efforts, as well as the impact that such a pandemic has on the volatility of the capital
              market and our ability to access the capital market.</div>
          </td>

  </tr>


</table>
    <div><br/>
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">21</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div>
          <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

          </div>

        </div>

      </div>

    </div>

    <div style="text-indent: 36pt; color: #000000;">We caution investors that actual results or business conditions may differ materially from those projected or suggested in forward-looking statements as a result of various factors including, but not
      limited to, those described above and in the Risk Factors section of this annual report on Form 10-K. We cannot assure you that we have identified all the factors that create uncertainties. Moreover, new risks emerge from time to time and it is not
      possible for our management to predict all risks, nor can we assess the impact of all risks on our business or the extent to which any risk, or combination of risks, may cause actual results to differ from those contained in any forward-looking
      statements. Readers should not place undue reliance on forward-looking statements. We undertake no obligation to publicly release the result of any revision of these forward-looking statements to reflect events or circumstances after the date they
      are made or to reflect the occurrence of unanticipated events.</div>

    <div><br/>
    </div>

    <div style="color: #000000; font-weight: bold;">Overview</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">We are a clinical stage biopharmaceutical company engaged in drug research and development to create new therapies for fibrotic disease, cancer and selected other diseases. Our drug candidates are based
      on our method of targeting galectin proteins, which are key mediators of biologic and pathologic functions. We use naturally occurring, readily-available plant products as starting material in manufacturing processes to create proprietary, patented
      complex carbohydrates with specific molecular weights and other pharmaceutical properties. These complex carbohydrate molecules are appropriately formulated into acceptable pharmaceutical formulations. Using these unique carbohydrate-based candidate
      compounds that largely bind and inhibit galectin proteins, particularly galectin-3, we are undertaking the focused pursuit of therapies for indications where galectin proteins have a demonstrated role in the pathogenesis of a given disease. We focus
      on diseases with serious, life-threatening consequences and those where current treatment options are limited specifically in NASH (non-alcoholic steatohepatitis) with cirrhosis and certain cancer indications. Our strategy is to establish and
      implement clinical development programs that add value to our business in the shortest period of time possible and to seek strategic partners when one of our programs becomes advanced and requires significant additional resources.</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">Our lead galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis and in clinical studies to decrease portal hypertension
      and prevent its complication: the development of esophageal varices. Belapectin has the potential to treat many diseases due to galectin-3&#8217;s involvement in multiple key biological pathways such as fibrosis, immune cell function and immunity, cell
      differentiation, cell growth, and apoptosis (cell death). The importance of galectin-3 in the fibrotic process is supported by experimental evidence. Animals with the galectin-3 gene &#8220;knocked-out&#8221; can no longer develop fibrosis in response to
      experimental stimuli compared to animals with an intact galectin-3 gene. We are using our galectin-3 inhibitor to treat advanced liver fibrosis and liver cirrhosis in NASH patients. We have completed two Phase 1 clinical studies, a Phase 2 clinical
      study in NASH patients with advanced fibrosis (NASH-FX) and a second Phase 2b clinical trial in NASH patients with compensated cirrhosis and portal hypertension (NASH-CX).</div>

    <div><br/>
    </div>

    <div style="color: #000000; font-weight: bold;">Results of Operations from the Years Ended December 31, 2024 and 2023</div>

    <div><br/>
    </div>

    <div style="text-indent: 27pt; color: #000000; font-style: italic; font-weight: bold;">Research and Development Expense</div>

    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 47%;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="6">
            <div style="text-align: center; color: #000000; font-weight: bold;">Year ended</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">December 31,</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="6">
            <div style="text-align: center; color: #000000; font-weight: bold;">2024 as Compared to</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">2023</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 2%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 47%;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> 2024</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2023</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">$ Change</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">% </div>
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Change</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 2%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 47%;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="6">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">(in thousands, except %)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 2%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 47%; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">Research and development</div>
          </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="color: rgb(0, 0, 0);">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 10.15%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="color: rgb(0, 0, 0);">36,571</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="color: rgb(0, 0, 0);">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 10.15%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="color: rgb(0, 0, 0);">32,130</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="color: rgb(0, 0, 0);">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 10.15%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="color: rgb(0, 0, 0);">4,441<br/>
            </div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 10.15%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="color: rgb(0, 0, 0);">
              <div style="color: rgb(0, 0, 0);">13.8</div>
            </div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 2%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">% <br/>
          </td>

  </tr>


</table>
    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">We generally categorize research and development expenses as either direct external expenses, comprised of amounts paid to third party vendors for services, or all other research and development expenses,
      comprised of employee payroll and general overhead allocable to research and development. We consider a clinical program to have begun upon acceptance by the FDA, or similar agency outside of the United States, to commence a clinical trial in humans,
      at which time we begin tracking expenditures by the product candidate. Clinical program expenses comprise payments to vendors related to preparation for, and conduct of, all phases of the clinical trial, including costs for drug manufacture, patient
      dosing and monitoring, data collection and management, oversight of the trials and reports of results. Pre-clinical expenses comprise all research and development amounts incurred before human trials begin and for additional toxicology studies to
      support advanced development, including payments to vendors for services related to product experiments and discovery, toxicology, pharmacology, metabolism and efficacy studies, as well as manufacturing process development for a drug candidate. We
      have two product candidates, belapectin and GM-CT-01; however only belapectin is in active development.</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">Our research and development expenses were as follows:</div>

    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="6">
            <div style="text-align: center; color: #000000; font-weight: bold;">Year Ended</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">December 31,</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> 2024</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2023</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom;" rowspan="2">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Direct external expenses:</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="6">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">(in thousands)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Clinical programs</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">29,079</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">23,942</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Pre-clinical activities</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">1,084</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">3,021</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Other research and development expenses:</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Payroll and other including stock-based compensation</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
            <div style="color: rgb(0, 0, 0);">6,408</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
            <div style="color: rgb(0, 0, 0);">5,167</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">36,571</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">32,130</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
    <div><br/>
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">22</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div>
          <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

          </div>

        </div>

      </div>

    </div>

    <div style="text-indent: 36pt; color: #000000;">Clinical programs expenses increased in the year ended December 31, 2024 over the year ended December 31, 2023 primarily due to costs related to our the NAVIGATE clinical trial activities and an increase
      in costs related to contract manufacturing of belapectin.&#160; Pre-clinical activities decreased due to activities incurred in support of the clinical program such as development and reproductive toxicity studies, clinical supplies and other supportive
      activities. Payroll and other costs increased primarily due to additional employees being hired in research and development.</div>

    <div><br/>
    </div>

    <div style="color: #000000; font-style: italic; font-weight: bold;">General and Administrative Expense</div>

    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="6">
            <div style="text-align: center; color: #000000; font-weight: bold;">Year ended</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">December 31,</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="6">
            <div style="text-align: center; color: #000000; font-weight: bold;">2024 as Compared to</div>
            <div style="text-align: center; color: #000000; font-weight: bold;"> 2023</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> 2024</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2023</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">$ Change</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">% </div>
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Change</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="6">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">(in thousands, except %)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;">
            <div style="color: rgb(0, 0, 0);">General and administrative</div>
          </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">5,862</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">5,942</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">(80</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);">)</div>
          </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">(1.3</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);">%)</div>
          </td>

  </tr>


</table>
    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">General and administrative expenses consist primarily of salaries including stock-based compensation, legal and accounting fees, insurance, investor relations, business development and other office
      related expenses. The primary reasons for the decrease for the year ended December 31, 2024, as compared to the same period for 2023 are due to a decrease in non-cash stock-based compensation of $206,000 offset by other administrative costs.</div>

    <div><br/>
    </div>

    <div style="color: #000000; font-style: italic; font-weight: bold;">Other Income and Expense</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">During the year ended December 31, 2024, other income and expense consisted of $336,000 of interest income offset by interest expense and amortization of debt discounts on convertible notes payable and
      convertible line of credit of $5,540,000 and change in fair value of derivatives of $(590,000).</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">During the year ended December 31, 2023, other income and expense consisted of $230,000 of interest income offset by interest expense and amortization of debt discounts on convertible notes payable and
      convertible line of credit of $2,792,000 and change in fair value of derivatives of $432,000.</div>

    <div><br/>
    </div>

    <div style="color: #000000; font-weight: bold;">Results of Operations from the Years Ended December 31, 2023 and 2022</div>

    <div><br/>
    </div>

    <div style="text-indent: 27pt; color: #000000; font-style: italic; font-weight: bold;">Research and Development Expense</div>

    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="6">
            <div style="text-align: center; color: #000000; font-weight: bold;">Year ended</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">December 31,</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="6">
            <div>&#160;</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">2023 as Compared to </div>
            <div style="text-align: center; color: #000000; font-weight: bold;">2022</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> 2023</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2022</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">$Change</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">% Change</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="6">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">(in thousands, except %)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;">
            <div style="color: rgb(0, 0, 0);">Research and development</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">32,130</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">31,737</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">393</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">1</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);">%</div>
          </td>

  </tr>


</table>
    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">We generally categorize research and development expenses as either direct external expenses, comprised of amounts paid to third party vendors for services, or all other research and development expenses,
      comprised of employee payroll and general overhead allocable to research and development. We consider a clinical program to have begun upon acceptance by the FDA, or similar agency outside of the United States, to commence a clinical trial in humans,
      at which time we begin tracking expenditures by the product candidate. Clinical program expenses comprise payments to vendors related to preparation for, and conduct of, all phases of the clinical trial, including costs for drug manufacture, patient
      dosing and monitoring, data collection and management, oversight of the trials and reports of results. Pre-clinical expenses comprise all research and development amounts incurred before human trials begin and for additional toxicology studies to
      support advanced development, including payments to vendors for services related to product experiments and discovery, toxicology, pharmacology, metabolism and efficacy studies, as well as manufacturing process development for a drug candidate. We
      have two product candidates, belapectin and GM-CT-01; however only belapectin is in active development.</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">Our research and development expenses were as follows:</div>

    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="6">
            <div style="text-align: center; color: #000000; font-weight: bold;">Year Ended</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">December 31,</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> 2023</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2022</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom;" rowspan="2">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Direct external expenses:</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="6">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">(in thousands)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Clinical programs</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">23,942</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">26,746</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Pre-clinical activities</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">3,021</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">1,262</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Other research and development expenses:</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Payroll and other including stock-based compensation</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
            <div style="color: rgb(0, 0, 0);">5,167</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
            <div style="color: rgb(0, 0, 0);">3,727</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">32,130</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">31,737</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
    <div><br/>
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">23</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div>
          <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

          </div>

        </div>

      </div>

    </div>

    <div style="text-indent: 36pt; color: #000000;">Clinical programs expenses decreased in the year ended December 31, 2023 over the year ended December 31, 2022 primarily due to costs related to our the NAVIGATE clinical trial activities and a decrease
      in costs related to contract manufacturing of belapectin.&#160; Pre-clinical activities increased due to activities incurred in support of the clinical program such as development and reproductive toxicity studies, clinical supplies and other supportive
      activities. Payroll and other costs increased primarily due to additional employees being hired in research and development.</div>

    <div><br/>
    </div>

    <div style="color: #000000; font-style: italic; font-weight: bold;">General and Administrative Expense</div>

    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="6">
            <div style="text-align: center; color: #000000; font-weight: bold;">Year ended</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">December 31,</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="6">
            <div>&#160;</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">2023 as Compared to </div>
            <div style="text-align: center; color: #000000; font-weight: bold;">2022</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> 2023</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2022</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">$ Change</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">% </div>
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Change</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="6">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">(in thousands, except <br/>
              %)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;">
            <div style="color: rgb(0, 0, 0);">General and administrative</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">5,942</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">6,615</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">(673</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);">)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">(10</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);">%)</div>
          </td>

  </tr>


</table>
    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">General and administrative expenses consist primarily of salaries including stock-based compensation, legal and accounting fees, insurance, investor relations, business development and other office
      related expenses. The primary reasons for the decrease for the year ended December 31, 2023, as compared to the same period for 2022 are due to a decrease in non-cash stock-based compensation of $624,000.</div>

    <div><br/>
    </div>

    <div style="color: #000000; font-style: italic; font-weight: bold;">Other Income and Expense</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">During the year ended December 31, 2023, other income and expense consisted of $230,000 of interest income offset by interest expense and amortization of debt discounts on convertible notes payable and
      convertible line of credit of $2,792,000 and change in fair value of derivatives of $432,000.</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">During the year ended December 31, 2022, other income and expense consisted of $52,000 of interest income and change in fair value of derivatives of $557,000 offset by interest expense and amortization of
      debt discounts on convertible notes payable and convertible line of credit of $1,033,000.</div>

    <div><br/>
    </div>

    <div style="color: #000000; font-weight: bold;">Liquidity and Capital Resources</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">
      <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt;">
        <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">As described above in the Overview and elsewhere in this Annual Report on Form 10-K, we are in the development stage and have not
          generated any revenues to date. Since our inception on July 10, 2000, we have financed our operations from proceeds of public and private offerings of debt and equity. As of December 31, 2024, we raised a net total of $314.5 million from these
          offerings. At December 31, 2024, the Company had $15.1 million of unrestricted cash and cash equivalents in addition to $6 million available under a line of credit provided by our chairman available to fund future operations. Additionally, in
          March 2025, we signed a new supplemental line of credit agreement with our chairman for an additional $5 million of available borrowings.&#160; The Company believes there is sufficient cash, including $11 million under the two lines of credit, to fund
          currently planned operations through August 2025. We will require more cash to fund our operations after August 2025. There can be no assurance that we will be successful in obtaining such new financing or, if available, that such financing will
          be on terms favorable to us.</div>

      </div>

    </div>

    <div><br/>
    </div>

    <div style="color: #000000; font-style: italic;">2024 compared to 2023</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">Net cash used in operations increased by $8,802,000 to $41,767,000 for 2024, as compared to $32,965,000 for 2023. Cash operating expenses increased principally due to increased research and development
      activities primarily related to our NAVIGATE clinical trial and associated activities.</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">There were no equipment purchases or other investing activities in 2024 or 2023.</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">Net cash provided by financing activities was $31,227,000 during 2024 as compared to $40,033,000 during 2023, due primarily to the transactions described below.</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">In 2024, we received $30,000,000 in proceeds under a convertible line of credit provided by our chairman in addition to $1.2 million in proceeds from exercises of stock options and purchase warrants. In
      2023, we received $30,000,000 in proceeds under a convertible line of credit provided by our chairman in addition to $10 million in proceeds from stock purchase warrants exercised by our chairman.</div>

    <div><br/>
    </div>

    <div style="color: #000000; font-style: italic;">2023 compared to 2022</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">Net cash used in operations increased by $1,909,000 to $32,965,000 for 2023, as compared to $31,056,000 for 2022. Cash operating expenses increased principally due to increased research and development
      activities primarily related to our NAVIGATE clinical trial and associated activities.</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">There were no equipment purchases or other investing activities in 2023 or 2022.</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">Net cash provided by financing activities was $40,033,000 during 2023 as compared to $10,000,000 during 2022, due primarily to the transactions described below.</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">In 2023, we received $30,000,000 in proceeds under a convertible line of credit provided by our chairman in addition to $10 million in proceeds from stock purchase warrants exercised by our chairman. In
      2022, we received proceeds of $10,000,000 under a convertible line of credit provided by our chairman.</div>

    <div><br/>
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">24</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div>
          <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

          </div>

        </div>

      </div>

    </div>

    <div style="color: #000000; font-style: italic; font-weight: bold;">Operating leases</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: rgb(0, 0, 0);">Effective February 28, 2022, the Company entered into an amendment to its operating lease for office space in Norcross, GA for a term of thirty-eight months, beginning on March 1, 2022 and ending
      April 30, 2025 at an average rate of approximately $4,250 per month. The amended lease provided for free rent for the first six months of the lease and continues the security deposit of $6,000. In addition to base rental payments included in the
      contractual obligations table above, the Company is responsible for our pro-rata share of the operating expenses for the building.</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">In October 2012, the Company entered into an operating lease for office and lab space for research and development activities in Natick, MA. The lease is for a period of one year, beginning on October 1,
      2012, for a rate of $15,000 for the term, payable in equal monthly increments. This lease was continued on a month-to-month basis from October 1, 2013.</div>

    <div><br/>
    </div>

    <div style="text-indent: 24.3pt; color: #000000;"><span style="font-weight: bold; font-style: italic;">Other</span><span style="font-weight: bold;">.</span><span style="font-weight: bold; font-style: italic;">&#160;</span>We have engaged outside vendors for
      certain services associated with our clinical trials. These services are generally available from<span style="font-weight: bold; font-style: italic;">&#160;</span>several providers and, accordingly, our arrangements are typically cancellable on 30 days
      notice.</div>

    <div><br/>
    </div>

    <div style="color: #000000; font-style: italic; font-weight: bold;">Off-Balance Sheet Arrangements</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">We have not created, and are not a party to, any special-purpose or off-balance sheet entities for the purpose of raising capital, incurring debt or operating parts of our business that are not
      consolidated into our financial statements. We do not have any arrangements or relationships with entities that are not consolidated into our financial statements that are reasonably likely to materially affect our liquidity or the availability of
      capital resources.</div>

    <div><br/>
    </div>

    <div style="color: #000000; font-weight: bold;">Critical Accounting Policies and Estimates</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">Our significant accounting policies are more fully described in Note 2 to our consolidated financial statements included elsewhere in this annual report on Form 10-K. Certain of our accounting policies,
      however, are critical to the portrayal of our financial position and results of operations and require the application of significant judgment by our management, which subjects them to an inherent degree of uncertainty. In applying our accounting
      policies, our management uses its best judgment to determine the appropriate assumptions to be used in the determination of certain estimates. Our more significant estimates include stock option valuations and performance vesting features of certain
      of these instruments, accrued liabilities, deferred income taxes and cash flows. These estimates are based on our historical experience, terms of existing contracts, our observance of trends in the industry, information available from other outside
      sources, and on various other factors that we believe to be appropriate under the circumstances. We believe that the critical accounting policies discussed below involve more complex management judgment due to the sensitivity of the methods,
      assumptions and estimates necessary in determining the related asset, liability, revenue and expense amounts.</div>

    <div><br/>
    </div>

    <div style="text-indent: 24.3pt; color: #000000;"><span style="font-style: italic;">Accrued Expenses</span>. As part of the process of preparing our consolidated financial statements, we are required to estimate accrued expenses. This process involves
      identifying services that third parties have performed on our behalf and estimating the level of service performed and the associated cost incurred on these services as of each balance sheet date in our consolidated financial statements. Examples of
      estimated accrued expenses include professional service fees, such as those arising from the services of attorneys and accountants and accrued payroll expenses. In connection with these service fees, our estimates are most affected by our
      understanding of the status and timing of services provided relative to the actual services incurred by the service providers. In the event that we do not identify certain costs that have been incurred or we under- or over-estimate the level of
      services or costs of such services, our reported expenses for a reporting period could be understated or overstated. The date on which certain services commence, the level of services performed on or before a given date, and the cost of services are
      often subject to our judgment. We make these judgments based upon the facts and circumstances known to us in accordance with accounting principles generally accepted in the U.S.</div>

    <div><br/>
    </div>

    <div style="text-indent: 24.3pt; color: #000000;"><span style="font-style: italic;">Research and Development Expenses. </span>Research and development expenses, including personnel costs, allocated facility costs, lab supplies,<span style="font-style: italic;">&#160;</span>outside services, contract laboratory costs related to manufacturing drug product, clinical trials and preclinical studies are charged to research and development expense as incurred. The Company accounts for nonrefundable advance
      payments for goods and services that will be used in future research and development activities as expense when the service has been performed or when the goods have been received. Our current NAVIGATE clinical trial is being supported by third-party
      contract research organizations, or CROs, and other vendors. We accrue expenses for clinical trial activities performed by CROs based upon the estimated amount of work completed on each trial. For clinical trial expenses and related expenses
      associated with the conduct of clinical trials, the significant factors used in estimating accruals include the number of patients enrolled, the number of active clinical sites, and the duration for which the patients have been enrolled in the trial.
      We monitor patient enrollment levels and related activities to the extent possible through internal reviews, review of contractual terms and correspondence with CROs. We base our estimates on the best information available at the time. We monitor
      patient enrollment levels and related activities to the extent possible through discussions with CRO personnel and based our estimates of clinical trial costs on the best information available at the time. However, additional information may become
      available to us which will allow us to make a more accurate estimate in future periods. In that event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more
      certain.</div>

    <div><br/>
    </div>

    <div style="text-indent: 24.3pt; color: #000000;"><span style="font-style: italic;">Stock-Based Compensation</span>. Stock-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense over the
      service period, which generally represents the vesting period. For awards that have performance-based vesting conditions the Company recognizes the expense over the estimated period that the awards are expected to be earned. The Company generally
      uses the Black-Scholes option-pricing model to calculate the grant date fair value of stock options. The expense recognized over the service period is required to include an estimate of the awards that will be forfeited.</div>

    <div><br/>
    </div>

    <div>
      <div>
        <a id="Item7A."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="text-align: right; vertical-align: top; width: 54pt;">
                <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">Item 7A.</div>
              </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                <div style="color: rgb(0, 0, 0); font-weight: bold; font-style: italic;">Quantitative and Qualitative Disclosures About Market Risk</div>
              </td>

  </tr>


</table>
      </div>

    </div>

    <div><br/>
    </div>

    <div style="color: #000000;">Due to the nature of our operations, assets and debt, we are not exposed to any significant market risks at December 31, 2024 and 2023.</div>

    <div><br/>
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">25</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div>
          <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

          </div>

        </div>

      </div>

    </div>

    <div>
      <div>
        <a id="Item8."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="text-align: right; vertical-align: top; width: 54pt;">
                <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">Item 8.</div>
              </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                <div style="color: rgb(0, 0, 0); font-weight: bold; font-style: italic;">Financial Statements and Supplementary Data</div>
              </td>

  </tr>


</table>
      </div>

    </div>

    <div style="font-style: italic;"><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">The financial statements required by this item are attached to this Annual Report on Form 10-K beginning on Page F-1.</div>

    <div><br/>
    </div>

    <div>
      <div>
        <a id="Item9."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="text-align: right; vertical-align: top; width: 54pt;">
                <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">Item 9.</div>
              </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                <div style="color: rgb(0, 0, 0); font-weight: bold; font-style: italic;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</div>
              </td>

  </tr>


</table>
      </div>

    </div>

    <div><br/>
    </div>

    <div style="color: #000000;">None.</div>

    <div><br/>
    </div>

    <div>
      <div>
        <a id="Item9A."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="text-align: right; vertical-align: top; width: 54pt;">
                <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">Item 9A.</div>
              </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                <div style="color: rgb(0, 0, 0); font-weight: bold; font-style: italic;">Controls and Procedures</div>
              </td>

  </tr>


</table>
      </div>

    </div>

    <div><br/>
    </div>

    <div style="text-indent: 24.3pt; color: #000000; font-style: italic;">(a) Evaluation of Disclosure Controls and Procedures</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">As required by Rule 13a-15 under the Securities Exchange Act of 1934, (the &#8220;Exchange Act&#8221;) as of the end of the period covered by this Annual Report, we carried out an evaluation, under the supervision
      and with the participation of our Chief Executive Officer and our Chief Financial Officer, of the effectiveness of our disclosure controls and procedures as of December 31, 2024. Our management has concluded, based on their evaluation, that our
      disclosure controls and procedures were effective as of December 31, 2024 to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the
      time periods specified in the Securities and Exchange Commission&#8217;s rules and forms.</div>

    <div><br/>
    </div>

    <div style="text-indent: 24.3pt; color: #000000; font-style: italic;">(b) Management&#8217;s Annual Report on Internal Control Over Financial Reporting</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">Management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting. As defined in Rule 13a-15(f) under the Exchange Act, internal control over
      financial reporting is a process designed by, or under the supervision of, a company&#8217;s principal executive and principal financial officers and effected by a company&#8217;s board of directors, management and other personnel, to provide reasonable
      assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. It includes those policies and procedures that:</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">a)&#160; &#160; &#160; &#160; Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the Company;</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">b)&#160; &#160; &#160; &#160; Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that
      receipts and expenditures of a company are being made only in accordance with authorizations of management and the board of directors of the Company; and</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">c)&#160; &#160; &#160; &#160; Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company&#8217;s assets that could have a material effect on its financial
      statements.</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">Because of the inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject
      to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">The Company&#8217;s management has used the criteria established in &#8220;Internal Control-Integrated Framework&#8221; issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), or
      COSO, to evaluate the effectiveness of the Company&#8217;s internal control over financial reporting. Management has selected the COSO 2013 framework for its evaluation as it is a control framework recognized by the SEC and the Public Company Accounting
      Oversight Board, that is free from bias, permits reasonably consistent qualitative and quantitative measurement of the Company&#8217;s internal controls, is sufficiently complete so that relevant controls are not omitted, and is relevant to an evaluation
      of internal controls over financial reporting. Management conducted an evaluation of internal controls based on the COSO 2013 framework. The evaluation included a full scale, documented risk assessment, based on the principles described in the
      framework, and included identification of key controls. Management completed documentation of its testing to verify the effectiveness of the key controls. Based on the evaluation, management concluded that our internal control over financial
      reporting was effective as of December 31, 2024.</div>

    <div><br/>
    </div>

    <div style="text-indent: 24.3pt; color: #000000; font-style: italic;">(c) Changes in Internal Control Over Financial Reporting</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">There was no change in our internal control over financial reporting that occurred during the fourth quarter of 2024 that has materially affected, or is reasonably likely to materially affect, our
      internal control over financial reporting.</div>

    <div><br/>
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">26</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div>
          <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

          </div>

        </div>

      </div>

    </div>

    <div>
      <div>
        <a id="Item9B."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="text-align: right; vertical-align: top; width: 54pt;">
                <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">Item 9B.</div>
              </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                <div style="color: rgb(0, 0, 0); font-weight: bold; font-style: italic;">Other Information</div>
              </td>

  </tr>


</table>
      </div>

    </div>

    <div><br/>
    </div>

    <div style="color: #000000;">
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;"><span style="text-decoration: underline;">March 2025 Supplemental Line of Credit</span></div>

      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">On March 31, 2025, the Company and Richard E. Uihlein (the &#8220;Lender&#8221;) entered into a Supplemental Line of Credit Letter Agreement (the &#8220;March 2025
        Supplemental Credit Agreement&#8221;), pursuant to which the Lender shall provide the Company a line of credit of up to $5.0 million (the &#8220;March 2025 Supplemental Line of Credit&#8221;) to finance the Company&#8217;s working capital needs. The Company may draw upon
        the Supplemental Line of Credit through September 30, 2025.</div>

      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Each advance made pursuant to the Supplemental Credit Agreement shall be evidenced by an unsecured, convertible promissory note (individually, a
        &#8220;Promissory Note,&#8221; and collectively, the &#8220;Promissory Notes&#8221;), and bear interest at the Applicable Federal Rate for short term loans, plus two (2%) percent. Principal and interest on the Promissory Notes are due on or before March 31, 2026.</div>

      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Only with the consent of the Lender, may the Promissory Notes be prepaid, in whole or in part, at any time without premium or penalty, but with interest
        on the amount or amounts prepaid. At the election of Lender, the principal and accrued interest on Promissory Note(s) may be converted into the number of shares of the Company&#8217;s Common Stock equal to the amount of principal and accrued interest on
        such Promissory Note divided by the price equal to the closing price of the Common Stock on the date of such Promissory Note, but in no event less than $3.00 per share.</div>

      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">In connection with the Supplemental Credit Agreement, the Company agreed to issue the Lender warrants to purchase up to an aggregate of 100,000 shares of
        the Company&#8217;s common stock, par value $0.001 per share (collectively, the &#8220;Warrants&#8221;). The Company shall issue to the Lender Warrants ratably, upon borrowings under the Supplemental Line of Credit, with exercise prices equal to 150% of the closing
        price of the Company&#8217;s common Stock on the date of the Promissory Note evidencing such draw, but in no event more than $10.00 per share nor less than $3.00 per share. The Warrants expire on July 31, 2029.</div>

      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">The securities referred to in this Item 9B are being issued by the Company to the Lender in reliance upon the exemption from the registration requirements
        of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), pursuant to Section 4(a)(2) thereof and Regulation D thereunder. The Company relied, in part, upon representations from the Lender that the Lender is an accredited investor as
        defined in Regulation D under the Securities Act.</div>

    </div>

    <div>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;"> <br/>
      </div>

      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;"><span style="text-decoration: underline;">November 2024 Supplemental Line of Credit</span></div>

      <div><br/>
      </div>

      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">In March 2025, the Company and Richard E. Uihlein entered into an amendment to the November 2024 Supplemental Line of Credit to extend the date by which
        the Company could draw on the line of credit from March 31, 2025 to May 31, 2025.</div>

      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">
        <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;"><span style="text-decoration: underline;">April 2021 Convertible Promissory Note</span></div>

        <div><br/>
        </div>

        <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">In connection with entering into the March 2025 Supplemental Line of Credit, the Company agreed to extend the maturity date of the Convertible
          Promissory Note dated April 16, 2021 from April 16, 2025 to September 30, 2025.</div>

      </div>

    </div>

    <div><br/>
    </div>

    <div style="color: #000000; font-style: italic;"><span style="text-decoration: underline;">Securities Trading Plans of Directors and Executive Officers</span></div>

    <div><span style="color: #000000;">&#160;</span><br/>
    </div>

    <div style="color: #000000;">No officers or directors, as defined in Rule 16a-1(f), <ix:nonNumeric name="ecd:Rule10b51ArrAdoptedFlag" id="Fact_95a3b0644e3c49be8f3d8a96abeebfe2" contextRef="c20241001to20241231" format="ixt:fixed-false"><ix:nonNumeric name="ecd:NonRule10b51ArrTrmntdFlag" id="Fact_60a65f9e8aa04f079cf26741c3eebaed" contextRef="c20241001to20241231" format="ixt:fixed-false">adopted</ix:nonNumeric></ix:nonNumeric> or <ix:nonNumeric name="ecd:NonRule10b51ArrAdoptedFlag" id="Fact_82bcbca26a994112b0f83d21a601a927" contextRef="c20241001to20241231" format="ixt:fixed-false"><ix:nonNumeric name="ecd:Rule10b51ArrTrmntdFlag" id="Fact_77b30304038a4d8eabd7f4fc1c91f703" contextRef="c20241001to20241231" format="ixt:fixed-false">terminated</ix:nonNumeric></ix:nonNumeric> a &#8220;Rule 10b5-1 trading arrangement&#8221; or a &#8220;non-Rule 10b5-1 trading arrangement,&#8221; as defined in Regulation S-K Item 408, during the fiscal quarter ended December 31,
      2024.</div>

    <div><span style="color: #000000;">&#160;</span><br/>
    </div>

    <div>
      <a id="Item9C."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="text-align: right; vertical-align: top; width: 54pt;">
              <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">Item 9C.</div>
            </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</div>
            </td>

  </tr>


</table>
    </div>

    <div><br/>
    </div>

    <div style="color: #000000;">Not applicable.</div>

    <div><br/>
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">27</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div>
          <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

          </div>

        </div>

      </div>

    </div>

    <div style="text-align: center; color: #000000; font-weight: bold;"><a id="PARTIII"><!--Anchor--></a>PART III</div>

    <div>
      <div style="color: rgb(0, 0, 0); font-weight: bold;"> <br/>
      </div>

      <div>
        <a id="Item10."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="text-align: right; vertical-align: top; width: 54pt;">
                <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">Item 10.</div>
              </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                <div style="color: rgb(0, 0, 0); font-weight: bold; font-style: italic;">Directors, Executive Officers and Corporate Governance</div>
              </td>

  </tr>


</table>
      </div>

    </div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">Each of our directors is elected annually and holds office until his or her successor has been elected and qualified or until the earlier of his or her death, resignation or removal. Our board of
      directors currently consists of eleven members, all of whom were elected at our 2024 Annual Meeting of Stockholders.</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">The following table sets forth certain biographical information about our directors as of February 28, 2025, and the qualifications, experiences and skills considered in determining that each such person
      should serve as a director.</div>

    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 76.37%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="color: rgb(0, 0, 0); font-weight: bold;">Name</div>
          </td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 9.37%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Age</div>
          </td>

    <td style="width: 1%; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td style="width: 12%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
            <div style="text-align: right; color: rgb(0, 0, 0); font-weight: bold;">Director Since</div>
          </td>

    <td style="width: 1%; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 76.37%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">Gilbert F. Amelio, Ph.D. (2)(3)</div>
          </td>

    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 9.37%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; color: rgb(0, 0, 0);">81</div>
          </td>

    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td style="width: 12%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: right; color: rgb(0, 0, 0);">2009</div>
          </td>

    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 76.37%; vertical-align: bottom;">
            <div style="color: rgb(0, 0, 0);">Benjamin S. Carson, Sr., M.D.</div>
          </td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 9.37%; vertical-align: bottom;">
            <div style="text-align: center; color: rgb(0, 0, 0);">73</div>
          </td>

    <td style="width: 1%; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td style="width: 12%; vertical-align: bottom;">
            <div style="text-align: right; color: rgb(0, 0, 0);">2023</div>
          </td>

    <td style="width: 1%; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 76.37%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">Kary Eldred (1)</div>
          </td>

    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 9.37%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; color: rgb(0, 0, 0);">51</div>
          </td>

    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td style="width: 12%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: right; color: rgb(0, 0, 0);">2018</div>
          </td>

    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 76.37%; vertical-align: bottom;">
            <div style="color: rgb(0, 0, 0);">Kevin D. Freeman (1)(2)(3)</div>
          </td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 9.37%; vertical-align: bottom;">
            <div style="text-align: center; color: rgb(0, 0, 0);">63</div>
          </td>

    <td style="width: 1%; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td style="width: 12%; vertical-align: bottom;">
            <div style="text-align: right; color: rgb(0, 0, 0);">2011</div>
          </td>

    <td style="width: 1%; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 76.37%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">Joel Lewis</div>
          </td>

    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 9.37%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; color: rgb(0, 0, 0);">55</div>
          </td>

    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td style="width: 12%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: right; color: rgb(0, 0, 0);">2017</div>
          </td>

    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 76.37%; vertical-align: bottom;">
            <div style="color: rgb(0, 0, 0);">Gilbert S. Omenn, M.D., Ph.D. (2)</div>
          </td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 9.37%; vertical-align: bottom;">
            <div style="text-align: center; color: rgb(0, 0, 0);">83</div>
          </td>

    <td style="width: 1%; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td style="width: 12%; vertical-align: bottom;">
            <div style="text-align: right; color: rgb(0, 0, 0);">2014</div>
          </td>

    <td style="width: 1%; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 76.37%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">Marc Rubin, M.D. (3)</div>
          </td>

    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 9.37%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; color: rgb(0, 0, 0);">70</div>
          </td>

    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td style="width: 12%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: right; color: rgb(0, 0, 0);">2011</div>
          </td>

    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 76.37%; vertical-align: bottom;">
            <div style="color: rgb(0, 0, 0);">Elissa J. Schwartz, Ph.D. (3)</div>
          </td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 9.37%; vertical-align: bottom;">
            <div style="text-align: center; color: rgb(0, 0, 0);">54</div>
          </td>

    <td style="width: 1%; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td style="width: 12%; vertical-align: bottom;">
            <div style="text-align: right; color: rgb(0, 0, 0);">2020</div>
          </td>

    <td style="width: 1%; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 76.37%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">Harold H. Shlevin, Ph.D.</div>
          </td>

    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 9.37%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; color: rgb(0, 0, 0);">75</div>
          </td>

    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td style="width: 12%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: right; color: rgb(0, 0, 0);">2019</div>
          </td>

    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 76.37%; vertical-align: bottom;">
            <div style="color: rgb(0, 0, 0);">Richard E. Uihlein, Chairman</div>
          </td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 9.37%; vertical-align: bottom;">
            <div style="text-align: center; color: rgb(0, 0, 0);">79</div>
          </td>

    <td style="width: 1%; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td style="width: 12%; vertical-align: bottom;">
            <div style="text-align: right; color: rgb(0, 0, 0);">2017</div>
          </td>

    <td style="width: 1%; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 76.37%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">Richard A. Zordani (1)</div>
          </td>

    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 9.37%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; color: rgb(0, 0, 0);">52</div>
          </td>

    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td style="width: 12%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: right; color: rgb(0, 0, 0);">2020</div>
          </td>

    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>


</table>
    <div><br/>
    </div>

    <div>
      <hr style="height: 2px; width: 10%; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/></div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 27pt; vertical-align: top; color: #000000;">(1)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">Member of audit committee</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 27pt; vertical-align: top; color: #000000;">(2)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">Member of compensation committee</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 27pt; vertical-align: top; color: #000000;">(3)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">Member of nominating and governance committee</div>
          </td>

  </tr>


</table>
    <div><br/>
    </div>

    <div style="text-indent: 24.5pt; color: #000000;"><span style="font-style: italic;">Gilbert F. Amelio, Ph.D</span>., a director since February 2009, began his career at Bell Labs in Murray Hill, New Jersey. Since January 1, 2012, Dr. Amelio has
      provided consulting and advisory services through GFA, LLC, a California limited liability company. He was a Senior Partner of Sienna Ventures (a privately held venture capital firm in Sausalito, California) from April 2001 until the fund closed per
      plan on December 31, 2011. Dr. Amelio was Chairman and Chief Executive Officer of Jazz Technologies, Inc. (now a wholly owned subsidiary of Tower Semiconductor Ltd., an independent specialty wafer foundry) from August 2005 until his retirement in
      September 2008 (when he was named Chairman Emeritus). Dr. Amelio was Chairman and Chief Executive Officer of Beneventure Capital, LLC (a full-service venture capital firm in San Francisco, California) from 1999 to 2005 and was Principal of Aircraft
      Ventures, LLC (a consulting firm in Newport Beach, California) from April 1997 to December 2004. Dr. Amelio was elected a Director of AT&amp;T in February 2001 and had previously served as an Advisory Director of AT&amp;T (then known as SBC
      Communications Inc.) from April 1997 to February 2001. He served as a Director of Pacific Telesis Group from 1995 until the company was acquired by AT&amp;T in 1997. Prior to 1997, he served as Chairman, President and CEO of National Semiconductor
      (1991-1996) and Apple Computer (1996-1997). We believe Dr. Amelio&#8217;s qualifications to sit on our Board of Directors include his executive leadership and management experience, as well as his extensive experience with global companies, his financial
      expertise and his years of experience providing strategic advisory services to organizations.</div>

    <div><br/>
    </div>

    <div style="text-indent: 24.5pt; color: #000000;"><span style="font-style: italic;">Dr. Benjamin S. Carson, Sr., </span>a director since 2023, served as the 17th Secretary of the U.S. Department of Housing and Urban Development (&#8220;HUD&#8221;) from 2017 to
      2021. Dr. Carson is a world-renowned neurosurgeon who prior to serving as HUD Secretary was involved with more than 15,000 surgical procedures and was the recipient of numerous awards, including the Presidential Medal of Freedom, more than 70
      honorary doctorate degrees and the Spingarn Medal, the NAACP&#8217;s highest honor. Dr. Carson serves on the Board of Directors for D.R. Horton, Inc. (NYSE: DHI), Covenant Logistics Group, Inc. (NASDAQ: CVLG), and Sinclair Broadcast Group, Inc. (NASDAQ:
      SBGI). In addition, Dr. Carson previously served on the Board of Directors of both The Kellogg Company (NYSE: K) and Costco Wholesale Corporation (NASDAQ: COST). Dr. Carson is the founder and current Chairman of the American Cornerstone Institute.
      Dr. Carson is on the Board of Directors of the Carson Scholars Fund, an organization he and his wife, Mrs. Candy Carson, founded in 1994. Throughout his distinguished career, Dr. Carson contributed to the field of medicine through the thousands of
      surgeries he performed and the many leadership positions he held, including serving as Director of the Division of Pediatric Neurosurgery at The Johns Hopkins Medical Institutions from 1984 to 2013 as well a Professor of Neurological Surgery,
      Oncology, Plastic Surgery, and Pediatrics at The Johns Hopkins Medical Institutions from 1999 to 2013. The Board believes that Dr. Carson&#8217;s extensive medical, management, director, leadership, financial, and information security experience make him
      highly qualified to serve as a member of our Board.</div>

    <div><br/>
    </div>

    <div style="text-indent: 24.5pt; color: #000000;"><span style="font-style: italic;">Kary Eldred, </span>is a director since 2018 and Chief Investment Officer for the Living Stones Foundation since July 2015 and has been an active<span style="font-style: italic;">&#160;</span>private equity investor for many years. In these capacities, he serves and has served on a number of corporate boards of companies with potential for and driving toward initial public offerings and is currently
      serving as a board member in Buy It Installed (since 2017), Babywise and Wise King Media (since 2015). Kary Eldred also served on the board and audit committee of GCT Semiconductor. From January 2011 through October 2014, Mr. Eldred was CEO &amp;
      Chairman of Altadona, S.A. a software integration company based in Europe and prior to that was a principal in Parakletos Ventures, an institutional venture capital firm with several investments in companies that went on to be acquired or become
      publicly listed on different exchanges around the world including the NASDAQ, KOSDAQ and the GEM market. Mr. Eldred has an Executive MBA from IE Business School and a BA in Foreign Service from Baylor University. We believe that Mr. Eldred&#8217;s
      qualifications to sit on our board include his experience serving on boards of several companies and experience in venture capital and private equity investing.</div>

    <div><br/>
    </div>

    <div style="text-indent: 24.5pt; color: #000000;"><span style="font-style: italic;">Kevin D. Freeman, </span>a director since May 2011, holds the Chartered Financial Analyst designation and is Chief Executive Officer of Cross<span style="font-style: italic;">&#160;</span>Consulting and Services, LLC, an investment advisory and consulting firm founded in 2004. He is also author of a New York Times best-selling book about the stock market and economy and the host of a television program (Economic War
      Room with Kevin Freeman) that airs on BlazeTV. Formerly he was Chairman of Separate Account Solutions, Inc. and held several offices at Franklin Templeton Investment Services from 1991 to 2000. He holds a B.S. in business administration from
      University of Tulsa, Tulsa, Oklahoma. We believe Mr. Freeman&#8217;s qualifications to sit on our Board of Directors includes his extensive financial expertise and his years of experience providing financial advisory services.</div>

    <div><br/>
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">28</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div>
          <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

          </div>

        </div>

      </div>

    </div>

    <div style="text-indent: 24.5pt; color: #000000;"><span style="font-style: italic;">Joel Lewis</span>, a director since 2017, became our President and Chief Executive Officer on September 2, 2020. Previously, he was the<span style="font-style: italic;">&#160;</span>Managing
      Director of Shareholder Services at Uline, Inc. (a distributor of shipping, packaging and industrial supplies), a position he held from 2007 through 2019. Mr. Lewis is a financial executive with over 26 years of experience started his career in
      public accounting in 1992. Prior to his employment with Uline Inc., Mr. Lewis served as a Tax and Accounting Manager for Century America LLC from 2001 to 2006 and a Tax Manager for Deloitte &amp; Touche from 1998 to 2001. After spending a decade in
      public accounting where he specialized in both financial reporting and taxation, Mr. Lewis migrated to privately held companies focusing on high-net-worth family businesses. Mr. Lewis has a wide range of expertise including working in a variety of
      industries and disciplines including taxation, restructuring, acquisition and private equity ventures. Mr. Lewis is a registered CPA in the state of Illinois. He holds a B.S. in Accountancy from the University of Illinois and a Masters in Taxation
      from DePaul University. We believe that Mr. Lewis&#8217; qualifications to sit on our Board include his business and financial expertise and his service as a board observer on our Board during 2017.</div>

    <div><br/>
    </div>

    <div style="text-indent: 24.5pt; color: #000000;"><span style="font-style: italic;">Gilbert S. Omenn, M.D., Ph.D.</span>, a director since September 2014, served on the board of directors of Amgen Inc. for 27 years and of Rohm &amp;<span style="font-style: italic;">&#160;</span>Haas Company for 22 years. He currently serves on the boards of Oncofusion Therapeutics and MedsynBio LLC of Ann Arbor, MI. Dr. Omenn is the Harold T. Shapiro Distinguished University Professor of Computational
      Medicine &amp; Bioinformatics, Internal Medicine, Human Genetics, and Public Health and Director of the university-wide Center for Computational Medicine and Bioinformatics at the University of Michigan. Dr. Omenn served as executive vice president
      for medical affairs and as chief executive officer of the University of Michigan Health System from 1997 to 2002. Prior, he was dean of the School of Public Health and Community Medicine and professor of medicine and a Howard Hughes Medical Institute
      investigator at the University of Washington and Member of the Fred Hutchinson Cancer Research Center. Earlier he was Associate Director of the White House Office of Science and Technology Policy and of the Office of Management and Budget. He is the
      author of 600 research papers and scientific reviews and author/editor of 18 books. Dr. Omenn received his B.A. summa cum laude from Princeton University, M.D. magna cum laude from Harvard Medical School, and Ph.D. in genetics from the University of
      Washington. We believe Dr. Omenn&#8217;s qualifications to sit on our Board of Directors include his extensive executive leadership and management experience in the medical industry and his continuing cutting-edge research.</div>

    <div><br/>
    </div>

    <div style="text-indent: 24.5pt; color: #000000;"><span style="font-style: italic;">Marc Rubin, M.D, </span>a director since October 2011 and Chairman of the Board from January 2016 through May 2018, is Executive Chairman of<span style="font-style: italic;">&#160;</span>the Board of Directors of Titan Pharmaceuticals, Inc. (TTNP: OTC BB) and served as its President and Chief Executive Officer from October 2007 to January 2009. Until February 2007, Dr. Rubin served as Head of Global Research and
      Development for Bayer Schering Pharma, as well as a member of the Executive Committee of Bayer Healthcare and the Board of Management of Bayer Schering Pharma. Prior to the merger of Bayer Pharmaceuticals and Schering AG in June 2006, Dr. Rubin was a
      member of the Executive Board of Schering AG since joining the company in October 2003, as well as Chairman of Schering Berlin Inc. and President of Berlex Pharmaceuticals, a division of Schering AG. From 1990 until August 2003, Dr. Rubin was
      employed by GlaxoSmithKline where he held positions of responsibility in global clinical and commercial development overseeing programs in the United States, Europe, Asia and Latin America. From 2001 through 2003 at GlaxoSmithKline, he was Senior
      Vice President of Global Clinical Pharmacology &amp; Discovery Medicine. Dr. Rubin holds an M.D. from Cornell University Medical College and is board certified in internal medicine with subspecialties in medical oncology and infectious diseases. Dr.
      Rubin is a member of the Board of Directors of Curis Inc. (Nasdaq: CRIS) and formerly served on the Board of Directors of Medarex, Inc., now a subsidiary of Bristol-Myers Squibb Company. We believe Dr. Rubin&#8217;s qualifications to sit on our Board of
      Directors include his extensive executive leadership and management experience in the pharmaceutical industry.</div>

    <div><br/>
    </div>

    <div style="text-indent: 24.5pt; color: #000000;"><span style="font-style: italic;">Elissa J. Schwartz, Ph.D., </span>a director appointed by the board in September 2020, is a disease modeler who is currently a professor of biological sciences and
      mathematics at Washington State University (WSU). She received a PhD in Biomedical Sciences from Mount Sinai&#8211;NYU, a BA in Mathematics from UC Berkeley, and interdisciplinary postdoctoral training in Biomathematics and Biostatistics from UCLA. She is
      also affiliated with the WSU College of Veterinary Medicine in microbiology and pathology, and she is currently on the WSU COVID-19 modeling task force. Dr. Schwartz is the author of over 30 scientific publications on infectious disease, the immune
      response, and biological modeling. She serves on the Board of Directors for the Society for Mathematical Biology, and she previously served as a consultant for Pharmerit International, LP, a pharmaceutical economics company. Dr. Schwartz has held
      fellowships with the Mathematical Biosciences Institute (Ohio State University) and the African Institute for Mathematical Sciences (Cape Town, South Africa), and she served on the teaching faculty for courses in British Columbia, India, and Nepal.
      We believe Dr. Schwartz&#8217; qualifications to sit on our Board of Directors include her extensive expertise in biomathematics and biostatistics in the pharmaceutical industry.</div>

    <div><br/>
    </div>

    <div style="text-indent: 24.5pt; color: #000000;"><span style="font-style: italic;">Harold Shlevin, Ph.D.</span>, retired from being our President and Chief Executive Officer on September 2, 2020, a position he had held since June 14, 2018; however,
      Dr. Shlevin has entered into a consulting agreement with the Company which ran through December 31, 2021. Dr. Shlevin previously served as our Chief Operating Officer and Secretary from October 1, 2012. Dr. Shlevin previously had been employed at the
      Georgia Institute of Technology&#8217;s Advanced Technology Development Center as Principle and Manager of bioscience commercialization efforts since November 2009, where he has assisted faculty in identifying technology worthy of commercialization,
      catalyzed formation of new start-up bioscience companies, and mentored new company management. From October 2008 to November 2009, he served as Head of Operations and Commercial Development for Altea Therapeutics Corporation, an advanced drug
      delivery company focused on the delivery of therapeutic levels of water-soluble biotherapeutics and small drugs through the skin. At Altea, he was responsible for pharmaceutical research and development, clinical research, regulatory affairs,
      engineering, clinical and commercial manufacturing, quality assurance, information technology, facility operations and finance. From July 2006 to September 2008, Dr. Shlevin served as the President and Chief Executive Officer of Tikvah Therapeutics,
      Inc., a start-up pharmaceutical enterprise focused on later-stage development of neuroscience therapeutics. From May 2000 to January 2006, he served as President and CEO of Solvay Pharmaceuticals, Inc. (US). In January 2006, he was promoted to a
      global senior Vice President role within Solvay Pharmaceuticals, SA and member of the Board of Solvay Pharmaceuticals, SA. Previously, Dr. Shlevin served on the Board of Directors of Cardiome Pharma Corporation (NASDAQ: CRME), now known as Correvio
      Pharma Corp. (NASDAQ: CORV) from 2004 to June 2016. He was Chair of the Compensation Committee and member of the Corporate Governance Committee and Audit Committees. Dr. Shlevin currently serves on the Board of Directors of Moonlight Therapeutics. We
      believe Dr. Shlevin&#8217;s qualifications to sit on our Board of Directors include his extensive executive leadership and management experience in the pharmaceutical industry.</div>

    <div><br/>
    </div>

    <div style="text-indent: 24.5pt; color: #000000;"><span style="font-style: italic;">Richard E. Uihlein</span>, a director since 2017 and Chairman since May 2018, co-founded Uline, Inc. (a leading distributor of shipping, packaging<span style="font-style: italic;">&#160;</span>and industrial supplies) in 1980, and has served as its Chief Executive Officer and Chairman since its founding. Prior to founding Uline Inc., Mr. Uihlein was employed at General Bindings Corp., Northbrook, IL
      from 1967 to 1980. Mr. Uihlein graduated from Stanford University, Palo Alto, CA. with a BA degree in history in 1967. We believe Mr. Uihlein&#8217;s qualifications to sit on our Board includes his extensive executive leadership and management experience.</div>

    <div><br/>
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">29</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div>
          <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

          </div>

        </div>

      </div>

    </div>

    <div style="text-indent: 24.5pt; color: #000000;"><span style="font-style: italic;">Richard A. Zordani, </span>a director appointed by the board in September 2020, has been the Director of Shareholder Services at Uline, Inc. (a<span style="font-style: italic;">&#160;</span>distributor of shipping, packaging and industrial supplies) since 2013. Prior to joining Uline, Mr. Zordani served as a Director and Vice President for Diversified Financial Management Corp. (Pritzker family office) where he
      advised on complex legal and tax structures for domestic and foreign entities and trusts from 2003 through 2013 and an Audit Manager for Altschuler, Melvoin &amp; Glasser LLP (now RSM McGladrey) from 1996 through 2003. Mr. Zordani received his
      undergraduate degree from the University of Illinois at Urbana/Champaign and is a Registered CPA in the state of Illinois. We believe that Mr. Zordani&#8217;s qualifications to sit on our Board include his business and financial expertise.</div>

    <div><br/>
    </div>

    <div style="color: #000000; font-weight: bold;">Code of Ethics</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">We have adopted a Code of Ethics that applies to all our directors, officers and employees. The Code of Ethics is publicly available on our website at www.galectintherapeutics.com. Amendments to the Code
      of Ethics and any grant of a waiver from a provision of the Code of Ethics requiring disclosure under applicable SEC rules will be disclosed on our website.</div>

    <div><br/>
    </div>

    <div style="color: #000000; font-weight: bold;">Hedging Policy</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">At this time, the Company has not adopted a policy regarding the ability of officers, directors and employees to purchase financial instruments (including prepaid variable forward contracts, equity swaps,
      collars, and exchange funds) or otherwise engage in transactions, that hedge or offset, or are designed to hedge or offset, any decrease in the market value of the Company&#8217;s equity securities.</div>

    <div><br/>
    </div>

    <div style="color: #000000; font-weight: bold;">Clawback Policy</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">The SEC adopted final rules implementing the incentive-based compensation recovery provisions of the Dodd-Frank Act, and Nasdaq has adopted listing standards consistent with the SEC rules. In compliance
      with those standards, we have adopted an incentive compensation recoupment policy, or &#8220;clawback&#8221; policy, which applies to our executive officers, within the meaning of Section 10D of the Exchange Act and Rule 10D-1 promulgated thereunder, who were
      employed by the Company during the applicable recovery period. Under the policy, in the event that the financial results upon which a cash or equity-based incentive award was predicated become the subject of a financial restatement that is required
      because of material non-compliance with financial reporting requirements, the Compensation Committee will conduct a review of awards covered by the policy and recoup any erroneously awarded incentive-based compensation to ensure that the ultimate
      payout gives retroactive effect to the financial results as restated. The Company may not indemnify any such covered officer against the loss of such recovered compensation.</div>

    <div><br/>
    </div>

    <div style="font-weight: bold;">Insider Trading Policy</div>

    <div>&#160;</div>

    <div style="text-indent: 18pt;">The Company <ix:nonNumeric name="ecd:InsiderTrdPoliciesProcAdoptedFlag" id="Fact_c1d19b1eecaa418ba1f794f7525c7d7b" contextRef="c20241001to20241231" format="ixt:fixed-true">has an</ix:nonNumeric> Insider Trading Policy is applicable to the Company&#8217;s directors, officers, and all
      employees of the Company.&#160; The Insider Trading Policy governs the purchase, sale, and/or other dispositions of the Company&#8217;s securities and prohibits purchasing or selling any securities of the Company while a person covered by the Insider Trading
      Policy is aware of material, non-public information concerning the Company. The Company believes that its Insider Trading Policy is reasonably designed to promote compliance with insider trading laws, rules and regulations, and the exchange listing
      standards of the Nasdaq Stock Market. A copy of the Company&#8217;s Insider Trading Policy is filed with the SEC as an exhibit to this Annual Report on Form 10-K.</div>

    <div>&#160;</div>

    <div style="font-weight: bold;">Equity Grant Policy and Procedures</div>

    <div>&#160;</div>

    <div style="text-indent: 18pt;">The Company&#8217;s policy is to grant stock options and other similar awards in the ordinary course of business in connection with our annual compensation program, hiring new employees, and in recognition of the retention or
      promotion of employees from time to time. The Company does not grant stock options or similar awards in anticipation of the release of material nonpublic information, such as a significant positive or negative earnings announcement, and does not time
      the public release of such information based on stock option grant dates. In addition, it is the Company&#8217;s policy to not grant stock options or similar awards during at any time during the four business days prior to or the one business day following
      the filing of the Company&#8217;s periodic reports or the filing or furnishing of a Form 8-K that discloses material nonpublic information (each, a &#8220;Filing Window&#8221;).</div>

    <div>&#160;</div>

    <div style="text-indent: 18pt;">Under the Company&#8217;s current practices, executive officers do not choose or have influence over the grant date for their individual stock option grants. Stock option grants to the Company&#8217;s executive officers are
      generally approved annually at a meeting of the Company&#8217;s Compensation Committee that is held during the first quarter of each year, and the grants are generally effective immediately after the meeting on which the grants are eligible to be made
      under our grant policies discussed above.</div>

    <div>&#160;</div>

    <div style="color: #000000; font-weight: bold;">Director Nominations</div>

    <div><br/>
    </div>

    <div style="color: #000000;">No material changes have been made to the procedures by which security holders may recommend nominees to our board of directors.</div>

    <div><br/>
    </div>

    <div style="color: #000000; font-weight: bold;">Audit Committee</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">The members of this committee are Richard A. Zordani (chair), Kary Eldred and Kevin D. Freeman. The Audit Committee is responsible for oversight of the quality and integrity of the accounting, auditing
      and reporting practices of Galectin Therapeutics. More specifically, it assists the Board of Directors in fulfilling its oversight responsibilities relating to (i) the quality and integrity of our financial statements, reports and related information
      provided to stockholders, regulators and others, (ii) our compliance with legal and regulatory requirements, (iii) the qualifications, independence and performance of our independent registered public accounting firm, (iv) the internal control over
      financial reporting that management and the Board have established, and (v) the audit, accounting and financial reporting processes generally. The Committee is also responsible for review and approval of related-party transactions. The Board has
      determined that Mr. Zordani is an &#8220;audit committee financial expert&#8221; within the meaning of SEC rules. The Audit Committee has the authority to obtain advice and assistance from, and receive appropriate funding from the Company for, outside legal,
      accounting or other advisors as it deems necessary to carry out its duties.</div>

    <div><br/>
    </div>

    <div style="color: #000000; font-weight: bold;">Risk Management</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">The Board has an active role, as a whole and also at the committee level, in overseeing management of our risks. The Board regularly reviews information regarding our credit, liquidity and operations, as
      well as the risks associated with each. The Compensation Committee of our Board is responsible for overseeing the management of risks relating to our executive compensation plans and arrangements. The Audit Committee of our Board oversees management
      of financial risks. The Nominating and Corporate Governance Committee of our Board manages risks associated with the independence of the Board members and potential conflicts of interest. While each committee is responsible for evaluating certain
      risks and overseeing the management of such risks, the entire Board of Directors is regularly informed through committee reports about such risks.</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">We believe that any risks arising from our policies and programs are not reasonably likely to have a material adverse effect on the Company. Our programs reflect sound risk management practices including:</div>

    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
          </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">Use of multiple compensation vehicles that provide a balance of long- and short-term incentives with fixed and variable components; and</div>
          </td>

  </tr>


</table>
    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
          </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">Equity incentive awards that generally vest over several years, so while the potential compensation payable for equity incentive awards is tied directly to appreciation of our stock price, taking excessive risk
              for a short term gain is discouraged because it would not maximize the value of equity incentive awards over the long-term.</div>
          </td>

  </tr>


</table>
    <div><br/>
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">30</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div>
          <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

          </div>

        </div>

      </div>

    </div>

    <div style="color: #000000; font-weight: bold;">EXECUTIVE OFFICERS</div>

    <div><br/>
    </div>

    <div style="text-indent: 24.5pt; color: #000000;"><span style="font-style: italic;">Joel Lewis</span>, see above under directors.</div>

    <div><br/>
    </div>

    <div style="text-indent: 20pt; color: #000000;"><span style="font-style: italic;">Khurram Jamil, M.D</span>. age 49, become the Company&#8217;s Chief Medical Officer on August 1, 2024 after joining the Company as vice president of clinical development in
      March 2024. Prior to joining the Company, Dr. Jamil was employed at Mallinckrodt Pharmaceuticals from July 2015 to February 2024, where he was Vice President Hepatology and led the development teams that achieved approval of two compounds in the U.S.
      and Japan, conducted trials in liver cirrhosis and its complications, and designed and executed the largest trial in Hepatorenal Syndrome. Earlier in his career he held positions in medical affairs in Ikaria Inc and Organon Pharmaceuticals USA where
      he led successful launches of first-in-class therapies and developed strategies to assess disease burden, cost-effectiveness, and value proposition of approved drugs in new therapeutic areas. He holds 7 patents, has given over 95 poster and oral
      presentations and published over 40 manuscripts, including in the prestigious New England Journal of Medicine. Dr. Jamil is board certified in General Surgery. He completed his residency in Seaton Hall University, NJ, and earned his M.B.B.S. from
      King Edward Medical University at Lahore, Pakistan.</div>

    <div><br/>
    </div>

    <div style="text-indent: 24.5pt; color: #000000;"><span style="font-style: italic;">Jack W. Callicutt</span>, age 57, became our Chief Financial Officer on July 1, 2013. From August 2011 through June 2012, Mr. Callicutt was the<span style="font-style: italic;">&#160;</span>Chief Financial Officer of REACH Health, Inc., a telemedicine technology company headquartered in Alpharetta, GA. From April 2010 through August 2012, Mr. Callicutt was the Chief Financial Officer of Vystar Corporation, a publicly
      traded company that holds proprietary technology to remove antigenic proteins from natural rubber latex. Prior to that Mr. Callicutt was Chief Financial Officer of IVOX, Inc., Tikvah Therapeutics and Corautus Genetics, a publicly traded biotechnology
      company which was developing gene therapy for treatment of cardiovascular disease. Mr. Callicutt previously spent more than fourteen years in public accounting, most recently as a senior manager at Deloitte, where he specialized in technology
      companies from 1989 to 2003. Mr. Callicutt is a Certified Public Accountant and graduated with honors from Delta State University with a B.B.A. in accounting and computer information systems.</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">None of the directors, executive officers and significant employees share any familial relationship.</div>

    <div><br/>
    </div>

    <div style="color: #000000; font-weight: bold;">Section 16(a) Beneficial Ownership Reporting Compliance</div>

    <div><br/>
    </div>

    <div style="color: #000000;">Section 16(a) of the Exchange Act requires our officers and directors, and persons who beneficially own more than ten percent of our common stock, to file reports of ownership and changes of ownership of such securities
      with the SEC. All reports were filed timely during the fiscal year ended December 31, 2024.</div>

    <div><br/>
    </div>

    <div>
      <div>
        <a id="Item11."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="text-align: right; vertical-align: top; width: 54pt;">
                <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">Item 11.</div>
              </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                <div style="color: rgb(0, 0, 0); font-weight: bold; font-style: italic;">Executive Compensation</div>
              </td>

  </tr>


</table>
      </div>

    </div>

    <div><br/>
    </div>

    <div style="color: #000000; font-weight: bold;">COMPENSATION PHILOSOPHY DISCUSSION</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">The Compensation Committee is responsible for creating and reviewing the compensation of the Company&#8217;s executive officers, as well as overseeing the Company&#8217;s compensation and benefit plans and policies
      and administering the Company&#8217;s equity incentive plans. The following Compensation Philosophy Discussion (&#8220;Compensation Discussion&#8221;) describes our 2024 executive compensation program and explains the Company&#8217;s compensation philosophy, policies, and
      practices, focusing primarily on the compensation of our named executive officers, or NEOs. This Compensation Discussion is intended to be read in conjunction with the tables that follow, which provide detailed historical compensation information for
      our following NEOs:</div>

    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 49.11%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="color: rgb(0, 0, 0); font-weight: bold;">Name</div>
          </td>

    <td style="width: 5%; vertical-align: bottom;"><br/>
          </td>

    <td style="width: 49%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Title</div>
          </td>

  </tr>

  <tr>

    <td style="width: 49.11%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">Joel Lewis</div>
          </td>

    <td style="width: 5%; vertical-align: bottom; background-color: rgb(204, 238, 255);"><br/>
          </td>

    <td style="width: 49%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">Chief Executive Officer and President</div>
          </td>

  </tr>

  <tr>

    <td style="width: 49.11%; vertical-align: bottom;">
            <div style="color: rgb(0, 0, 0);">Khurram Jamil, M.D.</div>
          </td>

    <td style="width: 5%; vertical-align: bottom;"><br/>
          </td>

    <td style="width: 49%; vertical-align: bottom;">
            <div style="color: rgb(0, 0, 0);">Chief Medical Officer</div>
          </td>

  </tr>

  <tr>

    <td style="width: 49.11%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">Jack W. Callicutt</div>
          </td>

    <td style="width: 5%; vertical-align: bottom; background-color: rgb(204, 238, 255);"><br/>
          </td>

    <td style="width: 49%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">Chief Financial Officer</div>
          </td>

  </tr>


</table>
    <div><br/>
    </div>

    <div style="color: #000000; font-weight: bold;">Compensation Philosophy</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">The Company believes in providing a competitive total compensation package to its executives through a combination of base salary, annual performance bonuses, and long-term equity awards. The executive
      compensation program is designed to achieve the following objectives:</div>

    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
          </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">provide competitive compensation that will help attract, retain and reward qualified executives;</div>
          </td>

  </tr>


</table>
    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
          </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">align executives&#8217; interests with our success by making a portion of the executive&#8217;s compensation dependent upon corporate performance; and</div>
          </td>

  </tr>


</table>
    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
          </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">align executives&#8217; interests with the interests of stockholders by including long-term equity incentives.</div>
          </td>

  </tr>


</table>
    <div><br/>
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">31</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div>
          <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

          </div>

        </div>

      </div>

    </div>

    <div style="text-indent: 36pt; color: #000000;">The Compensation Committee believes that the Company&#8217;s executive compensation program should include annual and long-term components, including cash and equity-based compensation, and should reward
      consistent performance that meets or exceeds expectations. The Compensation Committee evaluates both performance and compensation to make sure that the compensation provided to executives remains competitive relative to compensation paid by companies
      of similar size and stage of development operating in the life sciences industry and taking into account the Company&#8217;s relative performance and its own strategic objectives.</div>

    <div><br/>
    </div>

    <div style="color: #000000; font-weight: bold;">Executive Compensation Review and Design</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">The Company has historically conducted a review of the a level of its executive compensation, as well as the mix of elements used to compensate its NEOs. The Company has based this review primarily on the
      experience of the members of the Compensation Committee and our Board, many of whom sit on the boards of directors of, or have previously advised, numerous companies, including companies in the life sciences industry.</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">At our last &#8220;Say-on-Pay vote&#8221; held at our 2022 annual meeting of stockholders approximately 90% of votes cast were in favor of the compensation of our NEOs, as disclosed in the proxy materials for the
      2022 annual meeting. At our 2019 annual meeting, the holders of approximately 78% of our outstanding common stock voting on the matter voted in favor of holding the stockholder advisory vote every three years. As a result of such vote, our Board
      decided to hold the &#8220;Say-on-Pay&#8221; advisory vote every three years. Accordingly, the Company&#8217;s next &#8220;Say-on-Pay&#8221; advisory vote on the compensation of our NEOs will be held at our 2025 annual meeting of stockholders.</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">Several years ago, the Compensation Committee undertook a review of our compensation policies and practices and retained the compensation consulting firm of Barney &amp; Barney LLC to provide compensation
      information and analysis with respect to the life science and healthcare industry and with respect to our peer companies within the industry. Barney &amp; Barney LLC reviewed information from industry and other sources, surveys and databases,
      including publicly-available compensation information of other companies with which we compete, to gauge the competitiveness of our compensation programs. Barney &amp; Barney LLC then reported its findings to the Compensation Committee, with
      recommendations to bring the Company&#8217;s executive compensation closer to the 50<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> percentile of the total compensation of our competitor companies. These findings
      continued to inform the Compensation Committee&#8217;s decisions on compensation in subsequent years, including 2024.</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">The Compensation Committee may use a compensation consultant in the future and will take into account publicly-available data relating to the compensation practices and policies of other companies within
      and outside our industry. The Compensation Committee intends to benchmark its executive compensation program to target at least the 50<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> percentile of the total
      compensation programs of our competitor companies; however, adjusted as deemed to be in the best interest of the Company to assure retention of key employees during the NAVIGATE trial.</div>

    <div><br/>
    </div>

    <div style="color: #000000; font-weight: bold;">Elements of Executive Compensation</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">The compensation program for the Company&#8217;s NEOs consists principally of three components:</div>

    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
          </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">base salary;</div>
          </td>

  </tr>


</table>
    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
          </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">performance and retention bonuses;</div>
          </td>

  </tr>


</table>
    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
          </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">long-term compensation in the form of equity-based awards.</div>
          </td>

  </tr>


</table>
    <div><br/>
    </div>

    <div style="color: #000000; font-style: italic; font-weight: bold;">Base Salary</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">Base salary is the only fixed-pay component in our executive compensation program. Base salaries for the NEOs are initially established through arm&#8217;s-length negotiation at the time the NEO is hired,
      taking into account such NEO&#8217;s qualifications, experience, prior salary, the scope of his or her responsibilities, and known competitive market compensation paid by other companies for similar positions within the industry. Base salaries are reviewed
      annually and adjusted from time to time to realign salaries with market levels after taking into account individual responsibilities, performance, and experience. In making decisions regarding salary increases, the Company may also draw upon the
      experience of members of the Compensation Committee and the Board of Directors, many of whom sit on the boards of directors of, or have previously advised, numerous companies, including companies in the life sciences industry. The Compensation
      Committee has not previously applied specific formulas to determine increases. This strategy is consistent with the Company&#8217;s intent of offering base salaries that are cost-effective while remaining competitive.</div>

    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 66%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="color: rgb(0, 0, 0); font-weight: bold;">Name</div>
          </td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="2">
            <div style="color: rgb(0, 0, 0); font-weight: bold;">2024 Base Salary</div>
          </td>

    <td style="width: 1%; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="2">
            <div style="color: rgb(0, 0, 0); font-weight: bold;">2023 Base Salary</div>
          </td>

    <td style="width: 1%; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 66%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">Joel Lewis</div>
          </td>

    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">$</div>
          </td>

    <td style="width: 14%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: right; color: rgb(0, 0, 0);">624,000</div>
          </td>

    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">$</div>
          </td>

    <td style="width: 14%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: right; color: rgb(0, 0, 0);">578,000</div>
          </td>

    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
            <div style="color: rgb(0, 0, 0);">(1)</div>
          </td>

  </tr>

  <tr>

    <td style="width: 66%; vertical-align: bottom;">
            <div style="color: rgb(0, 0, 0);">Khurram Jamil, M.D. (2)</div>
          </td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 1%; vertical-align: bottom;">
            <div style="color: rgb(0, 0, 0);">$</div>
          </td>

    <td style="width: 14%; vertical-align: bottom;">
            <div style="text-align: right; color: rgb(0, 0, 0);">500,000</div>
          </td>

    <td style="width: 1%; vertical-align: bottom; white-space: nowrap;">
            <div style="color: rgb(0, 0, 0);">(2)</div>
          </td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 1%; vertical-align: bottom;">
            <div style="color: rgb(0, 0, 0);">$</div>
          </td>

    <td style="width: 14%; vertical-align: bottom;">
            <div style="text-align: right; color: rgb(0, 0, 0);">-</div>
          </td>

    <td style="width: 1%; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 66%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">Jack W. Callicutt</div>
          </td>

    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">$</div>
          </td>

    <td style="width: 14%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: right; color: rgb(0, 0, 0);">400,000</div>
          </td>

    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">$</div>
          </td>

    <td style="width: 14%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: right; color: rgb(0, 0, 0);">368,000</div>
          </td>

    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>


</table>
    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
          </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">(1)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">Pursuant to Mr. Lewis&#8217;s Employment Agreement and Deferred Stock Unit Agreement, 20% of Mr. Lewis&#8217; base salary will be paid in cash and 80% will be paid in the form of deferred-stock units in accordance with the
              terms and subject to the provisions of the DSU Agreement through December 2023.</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 20.25pt;"><br/>
          </td>

    <td style="width: 27pt; vertical-align: top; color: #000000;">(2)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">Dr. Jamil joined the Company in March 2024 and was promoted to Chief Medical Officer effective August 1, 2024 and his base salary was adjusted to $500,000.</div>
          </td>

  </tr>


</table>
    <div><br/>
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">32</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div>
          <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

          </div>

        </div>

      </div>

    </div>

    <div style="color: #000000; font-style: italic; font-weight: bold;">Performance Bonuses</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">In addition to the payment of base salaries, the Company believes that annual performance bonuses can play an important role in providing appropriate incentives to its NEOs to achieve the Company&#8217;s
      strategic objectives.</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">In prior years, performance bonuses were awarded based on the Company&#8217;s Employee Short-Term and Long-Term Incentive Program (the &#8220;Program&#8221;), which was adopted for executives and employees of the Company.
      The Program is a performance-based program and was adopted in recognition of the importance of aligning executive and employee interests with that of our stockholders. Our Program is designed to reward the efforts of our executives and employees and
      to be competitive in attracting and retaining them. There are two elements of the Program: (1) a short-term incentive in the form of cash bonuses and (2) a long-term incentive in the form of stock option grants. The cash bonus incentive is targeted
      to be up to 30% to 50% of the NEO&#8217;s base salary as of the end of the applicable year. Half of each NEO&#8217;s annual performance bonus is based upon achievement of the Company&#8217;s documented performance objectives for the year and the other half is based
      upon achievement of individual performance objectives set for the year. The 2024 performance bonuses payments were split with half paid in February 2025 and half to be paid in April 2025, if the employee had not voluntarily resigned by that date.</div>

    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); width: 72%;">
            <div style="color: rgb(0, 0, 0); font-weight: bold;">Name</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
            <div style="text-align: center; color: #000000; font-weight: bold;">Performance</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Bonus</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Amount</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="2">
            <div style="text-align: center; color: #000000; font-weight: bold;">Awarded Amount</div>
            <div style="text-align: right; color: #000000; font-weight: bold;">As % of Base Salary</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 72%;">
            <div style="color: rgb(0, 0, 0);">Joel Lewis</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); width: 10%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">312,000</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); width: 13%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">50</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);">%</div>
          </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 72%;">
            <div style="color: rgb(0, 0, 0);">Khurram Jamil, M.D.</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 10%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">120,625</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">(1)<br/>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 13%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">30</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);">%</div>
          </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 72%; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">Jack W. Callicutt</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="color: rgb(0, 0, 0);">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 10%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="color: rgb(0, 0, 0);">120,000</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 13%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="color: rgb(0, 0, 0);">30</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);">%</div>
          </td>

  </tr>


</table>
    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">(1)</td>

    <td style="vertical-align: top;">
            <div style="color: rgb(0, 0, 0);">Dr. Jamil&#8217;s 2024 bonus was prorated for his employment during 2024.</div>
          </td>

  </tr>


</table>
    <div><br/>
    </div>

    <div style="color: #000000; font-style: italic; font-weight: bold;">Long-Term Incentive Compensation</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">The Company believes that by providing its NEOs the opportunity to increase their ownership of Company stock, the interests of its NEOs will be more closely-aligned with the best interests of the
      Company&#8217;s stockholders and it will encourage long-term performance. The stock awards enable the NEOs to participate in the appreciation in the value of the Company&#8217;s stock, while personally participating in the risks of business setbacks.</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">Under the long-term incentive portion of the Program, the NEOs are granted options based upon achievement of the Company performance and individual performance objectives and rank in the Company. All
      option grants under the Program through December 2019 were made under the 2009 Incentive Compensation Plan. Grants made after January 1, 2020, were made pursuant to the 2019 Omnibus Equity Incentive Plan.</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">On January 24, 2024, Mr. Lewis and Mr. Callicutt were awarded the options noted below based on 2023 performance. For the performance options, 25% vest on each of June 30, 2024, December 31, 2024, June 30,
      2025, and December 31, 2025. The exercise price of the options is set at the closing price of our stock as of the grant date.</div>

    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 33%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div><span style="color: #000000;">&#160;</span>&#160;</div>
            <div style="color: #000000; font-weight: bold;">Name</div>
          </td>

    <td style="width: 0.53%; vertical-align: bottom;">&#160;</td>

    <td style="width: 31.32%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div><span style="color: #000000;">&#160;</span>&#160;</div>
            <div style="color: #000000; font-weight: bold;">Grant Date</div>
          </td>

    <td style="width: 0.53%; vertical-align: bottom;">&#160;</td>

    <td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="2">
            <div style="text-align: right; color: #000000; font-weight: bold;">Number of Securities</div>
            <div style="text-align: right; color: #000000; font-weight: bold;">Underlying Options</div>
          </td>

    <td style="width: 0.54%; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td style="width: 0.54%; vertical-align: bottom;">&#160;</td>

    <td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="2">
            <div style="color: rgb(0, 0, 0); font-weight: bold;">Exercise Price</div>
          </td>

    <td style="width: 0.54%; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 33%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">Joel Lewis</div>
          </td>

    <td style="width: 0.53%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 31.32%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: right; color: rgb(0, 0, 0);">1/24/2024</div>
          </td>

    <td style="width: 0.53%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 17.4%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: right; color: rgb(0, 0, 0);">91,000</div>
          </td>

    <td style="width: 0.54%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td style="width: 0.54%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">$</div>
          </td>

    <td style="width: 11.69%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: right; color: rgb(0, 0, 0);">1.72</div>
          </td>

    <td style="width: 0.54%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 33%; vertical-align: bottom;">
            <div style="color: rgb(0, 0, 0);">Jack W. Callicutt</div>
          </td>

    <td style="width: 0.53%; vertical-align: bottom;">&#160;</td>

    <td style="width: 31.32%; vertical-align: bottom;">
            <div style="text-align: right; color: rgb(0, 0, 0);">1/24/2024</div>
          </td>

    <td style="width: 0.53%; vertical-align: bottom;">&#160;</td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 17.4%; vertical-align: bottom;">
            <div style="text-align: right; color: rgb(0, 0, 0);">65,000</div>
          </td>

    <td style="width: 0.54%; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td style="width: 0.54%; vertical-align: bottom;">&#160;</td>

    <td style="width: 1%; vertical-align: bottom;">
            <div style="color: rgb(0, 0, 0);">$</div>
          </td>

    <td style="width: 11.69%; vertical-align: bottom;">
            <div style="text-align: right; color: rgb(0, 0, 0);">1.72</div>
          </td>

    <td style="width: 0.54%; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>


</table>
    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">Also, on January 24, 2024, Mr. Lewis and Mr. Callicutt were granted restricted stock units of 56,000 shares and 40,000 shares, respectively.&#160;&#160; These restricted stock units vesting only would occur if the
      Company presented top-line results from its NAVIGATE clinical trial by the end of 2024.&#160;&#160; The restricted stock units vested on December 20, 2024.</div>

    <div><br/>
    </div>

    <div style="color: #000000; font-style: italic; font-weight: bold;">Material Terms of Employment Contracts of Named Executive Officers</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: rgb(0, 0, 0);">Set forth below are descriptions of the principal terms of the employment agreements for each of our NEOs. Each employment agreement provides for post-termination restrictive covenants and payments
      due upon termination of employment or change in control of the Company, which is provided in further detail under the section entitled &#8220;Potential Payments Upon Termination or Change in Control.&#8221;</div>

    <div><br/>
    </div>

    <div style="color: rgb(0, 0, 0); font-style: italic;">Joel Lewis, Chief Executive Officer</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">In connection with the appointment of Mr. Lewis, the Company and Mr. Lewis entered into an employment agreement, dated August 31, 2020 (the &#8220;<span style="text-decoration: underline;">Employment Agreement</span>&#8221;), and a Deferred Stock Unit
      Agreement, dated August 31, 2020 (the &#8220;<span style="text-decoration: underline;">DSU Agreement</span>&#8221;). The Employment Agreement has an initial term of two years and automatically renews for additional one-year terms thereafter, unless either Mr. Lewis or the Company elects not to renew.
      Mr. Lewis will serve as Chief Executive Officer of the Company effective as of September 2, 2020 (the &#8220;<span style="text-decoration: underline;">Start Date</span>&#8221;), and will be paid an annual base salary of $500,000. Under the terms of the Employment Agreement, 20% of his base salary will
      be paid in cash, and 80% will be paid in the form of deferred-stock-units (&#8220;<span style="text-decoration: underline;">DSUs</span>&#8221;) in accordance with the terms and subject to the provisions set forth in the DSU Agreement. In addition, Mr. Lewis is entitled to participate in the Company&#8217;s
      performance bonus plan with a potential of up to 50% of his annual base salary, which will also be paid 20% in cash and 80% in DSU&#8217;s. Further, Mr. Lewis received on the date of the agreement an initial grant of options to purchase 250,000 shares of
      the Company&#8217;s common stock, par value $0.001 per share, which options shall vest one-twelfth on a quarterly basis for twelve consecutive quarters, such that the options shall be fully vested twelve quarters following the date of grant (the &#8220;<span style="text-decoration: underline;">Award</span>&#8221;).





























      The options under the Award shall be issued pursuant to the Company&#8217;s 2019 Omnibus Equity Incentive Plan (the &#8220;<span style="text-decoration: underline;">Plan</span>&#8221;). Pursuant to the Employment Agreement, Mr. Lewis is also eligible to receive healthcare benefits as may be provided from time
      to time by the Company to its employees generally, to participate in the Company&#8217;s 401(k) plan and to receive paid time off annually in accordance with the Company&#8217;s policies in effect from time to time. Finally, pursuant to the Employment Agreement,
      the Company will be required to furnish a lump sum cash payment to Mr. Lewis upon a termination of Mr. Lewis without &#8220;Cause&#8221; or upon Mr. Lewis&#8217; resignation for &#8220;Good Reason&#8221; as such terms are defined in the Employment Agreement or in the event the
      Company gives notice of non-renewal on or before September 30, 2023. The Employment Agreement includes customary intellectual property, assignment, and other representations by Mr. Lewis.</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">On July 25, 2022, we entered into amendments to the Employment Agreement and DSU Agreement with Mr. Lewis. Pursuant to the amendments, Mr. Lewis&#8217; base salary earned in 2023 will be paid 20% in cash and
      80% in DSUs. Additionally, the term of the Employment Agreement was extended until December 31, 2024. Unless either party gives written notice of non-renewal at least 60 days prior to December 31, 2024, the amended employment agreement will
      automatically renew for an additional twelve months. Also, if either Mr. Lewis terminates his employment for Good Reason (ii) the Company terminates Mr. Lewis&#8217;s employment without Cause, or if this Employment Agreement expires as a result of the
      Company giving written notice of non-renewal, then the Company shall pay to Mr. Lewis (1) any accrued benefits, (2) a lump sum amount equal to twelve (12) months of Mr. Lewis&#8217;s base salary payable within thirty (30) days after the date of such
      termination, and (3) the performance bonus, if any, for the year in which termination occurs, based on actual individual and Company performance results and multiplied by a fraction, (A) the numerator of which shall be the number of days elapsed from
      the beginning of the fiscal year in which such termination occurs and (B) the denominator of which shall be 365; provided, however, that the portion of the performance bonus payable in the form of DSUs, will be paid in accordance with the terms of
      the DSU Award Agreements. Notwithstanding the foregoing, the payments described in clauses above are expressly conditioned upon Mr. Lewis executing returning a full release of the Company and its affiliates and from all obligations and any usual and
      customary indemnification obligations of the Company to Mr. Lewis as an officer thereof.</div>

    <div><br/>
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">33</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div>
          <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

          </div>

        </div>

      </div>

    </div>

    <div style="text-indent: 36pt; color: #000000;">The Deferred Stock Unit Agreement with Mr. Lewis specifies that 20% of his base salary and performance bonuses will be paid in cash, and 80% will be paid in the form of deferred stock units (&#8220;DSUs&#8221;)
      through December 31, 2022 in accordance with the terms and subject to the provisions set forth in the DSU Agreement. DSUs credited to Mr. Lewis as of any date shall be fully vested and nonforfeitable at all times. Pursuant to an amendment to the DSU
      Agreement in July 2022, the Company shall issue the shares earned through December 31, 2022 underlying the outstanding whole number of DSUs credited to Mr. Lewis as follows: twenty five percent shall be issued on March 1, 2023, fifty percent shall be
      issued on March 1, 2024 and twenty five percent shall be issued on September 1, 2028. On March 1, 2023, twenty five percent of the DSU&#8217;s were issued to Mr. Lewis in accordance with the DSU Agreement. A total of 183,900 shares were due to be issued&#894;
      however, 75,529 shares were withheld to cover income tax withholding of $156,345 resulting in 108,371 shares actually issued. Additionally, a 2023 DSU Agreement was executed in July 2022, whereby Mr. Lewis would continue to receive 20% of salary in
      cash and 80% in DSUs for 2023. The shares under the 2023 DSU Agreement are to be issued fifty percent on March 1, 2025 and fifty percent on January 5, 2026.</div>

    <div><br/>
    </div>

    <div style="color: #000000; font-style: italic;">Khurram Jamil, M.D., Chief Medical Officer</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">On August 1, 2024, the Company entered into an Employment Agreement with Dr. Jamil (the &#8220;Jamil Employment Agreement&#8221;), which governs the terms of Dr. Jamil&#8217;s employment in his position as the Company&#8217;s
      Chief Medical Officer. Dr. Jamil will serve as the Chief Medical Officer of the Company during an initial term that commences on August 1, 2024 (the &#8220;<span style="text-decoration: underline;">Commencement Date</span>&#8221;) and expires on August 1, 2025 (the &#8220;<span style="text-decoration: underline;">Initial Term</span>&#8221;). Following the
      Initial Term, the term of the Agreement automatically renews for successive twelve (12) month terms unless either party provides the other party with notice of non-renewal at least sixty (60) days prior to the expiration of the then-current term.
      Under the Agreement, the Company has agreed to pay Dr. Jamil a base salary of $500,000 per year (the &#8220;<span style="text-decoration: underline;">Base Salary</span>&#8221;). Provided that certain performance objectives are met, Dr. Jamil will also be entitled to receive an annual performance bonus
      equal to thirty percent (30%) of the Base Salary (the &#8220;<span style="text-decoration: underline;">Performance Bonus</span>&#8221;). Subject to certain restrictions described in the Agreement, Dr. Jamil was granted options to purchase 100,000 shares (the &#8220;<span style="text-decoration: underline;">Options</span>&#8221;) of the Company&#8217;s common
      stock and restricted stock units for 10,000 shares of the Company&#8217;s common stock pursuant to the Company&#8217;s 2019 Omnibus Equity Incentive Plan. The Options vest as follows: twenty-five percent (25%) of the Options shall vest upon each of October 31,
      2024; January 31, 2025; April 30, 2025; and July 31, 2025.&#160;&#160; The restricted stock units vesting only would occur if the Company presented top-line results from its NAVIGATE clinical trial by the end of 2024.&#160;&#160; The restricted stock units vested on
      December 20, 2024.</div>

    <div style="text-indent: 36pt; color: #000000;">Prior to his appointment as Chief Medical Officer, on March 11, 2024, Dr. Jamil joined the Company as vice president of clinical development and medical director.&#160;&#160; His annual salary was $400,000.&#160;&#160; He
      also was granted options to purchase 150,000 shares of the Company&#8217;s common stock which vest one-third at each of the first three anniversaries of his employment date.&#160;&#160; Additionally, he was granted restricted stock units for 10,000 shares of the
      Company&#8217;s common stock.&#160;&#160; The restricted stock units vesting only would occur if the Company presented top-line results from its NAVIGATE clinical trial by the end of 2024.&#160;&#160; The restricted stock units vested on December 20, 2024.</div>

    <div><br/>
    </div>

    <div style="color: #000000; font-style: italic;">Jack W. Callicutt, Chief Financial Officer</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">We entered into an employment agreement with Mr. Callicutt dated July 1, 2013 (the &#8220;Callicutt Employment Agreement&#8221;), in conjunction with Mr. Callicutt&#8217;s appointment as our Chief Financial Officer.
      Pursuant to the terms of the Callicutt Employment Agreement, Mr. Callicutt received an initial base salary of $175,000 and was eligible to receive a performance bonus equal to 20% of his base salary. Effective March 31, 2015, Mr. Callicutt&#8217;s annual
      base salary was increased to $240,000, and his annual base salary was increased again to $260,000 in February 2016. In June 2018, Mr. Callicutt&#8217;s annual base salary increased to $285,000. He also received a signing bonus of $10,000. In addition to
      his cash compensation, the Company awarded Mr. Callicutt a grant of options to purchase 200,000 shares of the Company&#8217;s Common Stock at an exercise price equal to the closing price of the Company&#8217;s Common Stock on July 1, 2013, with 25,000 shares
      vesting on December 31, 2013, 50,000 shares vesting on December 31, 2014, 50,000 shares vesting on December 31, 2015 and 75,000 shares vesting on December 31, 2016. The options were granted pursuant to the 2009 Incentive Compensation Plan and expire
      ten years after the date of grant.</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">On August 11, 2017, we entered into an amendment to the Callicutt Employment Agreement with Mr. Callicutt (the &#8220;Amendment&#8221;). Pursuant to the Amendment, (i) Mr. Callicutt&#8217;s target bonus opportunity was
      increased to 30% of his base salary and (ii) an error in the severance provision of the Callicutt Employment Agreement was corrected. Prior to the Amendment, the Callicutt Employment Agreement did not provide for any severance if Mr. Callicutt&#8217;s
      employment was terminated by the Company &#8220;without cause,&#8221; or by Mr. Callicutt for &#8220;good reason&#8221; after the date that was 24 months after the Commencement Date.</div>

    <div><br/>
    </div>

    <div style="color: #000000; font-style: italic; font-weight: bold;">Employee Benefits &amp; Perquisites</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">From time to time, the Company has provided the NEOs with employee benefits and perquisites that our Board believes are reasonable. Our NEOs are eligible to participate in the same broad-based employee
      benefit plans that are offered to our other employees, such as health insurance, disability insurance, life insurance and a 401(k) plan. These benefits are provided as part of the basic conditions of employment for all of our employees, and therefore
      providing them to our NEOs does not represent a significant incremental cost to us. The Company does not view employee benefits and perquisites as a significant element of its comprehensive compensation structure, but does believe they can be useful
      in attracting, motivating, and retaining the executive talent for which the Company competes. The Company believes that these additional benefits may assist the NEOs in performing their duties and provide time efficiencies for the NEOs in appropriate
      circumstances, and the Company may consider providing additional employee benefits and perquisites in the future. All future practices regarding employee benefits and perquisites will be approved and subject to periodic review by the Compensation
      Committee.</div>

    <div><br/>
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">34</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div>
          <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

          </div>

        </div>

      </div>

    </div>

    <div style="color: #000000; font-weight: bold;">SUMMARY COMPENSATION TABLE</div>

    <div><br/>
    </div>

    <div style="color: #000000;">The following table summarizes the compensation paid to our NEOs for the fiscal years ended December 31, 2024 and 2023.</div>

    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); width: 22%; white-space: nowrap;">
            <div style="color: rgb(0, 0, 0); font-weight: bold;">Name and Principal Position</div>
          </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); width: 19%;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Year</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
            <div style="text-align: center; color: #000000; font-weight: bold;">Salary</div>
            <div style="text-align: center; color: #000000;">($)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
            <div style="text-align: center; color: #000000; font-weight: bold;">Bonus</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">($)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
            <div style="text-align: center; color: #000000; font-weight: bold;">Stock Compensation</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Awards</div>
            <div style="text-align: center; color: #000000;">($) (1)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" colspan="1"><br/>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;" colspan="1"><br/>
          </td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
            <div style="text-align: center; color: #000000; font-weight: bold;">All Other</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Compensation</div>
            <div style="text-align: center; color: #000000;">($)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;"><br/>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;" colspan="1"><br/>
          </td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
            <div style="text-align: center; color: #000000; font-weight: bold;">Total</div>
            <div style="text-align: center; color: #000000;">($)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 22%; background-color: rgb(204, 238, 255);" rowspan="2">
            <div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 9pt; background-color: rgb(204, 238, 255);">Joel Lewis, Chief Executive Officer &amp; President</div>
          </td>

    <td valign="bottom" colspan="1" style="vertical-align: top; width: 1%; background-color: rgb(204, 238, 255);" rowspan="2">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 19%; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; color: rgb(0, 0, 0); background-color: rgb(204, 238, 255);">2024(2)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7.92%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="color: rgb(0, 0, 0); background-color: rgb(204, 238, 255);">620,167</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7.92%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="color: rgb(0, 0, 0); background-color: rgb(204, 238, 255);">312,000</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9.65%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="color: rgb(0, 0, 0); background-color: rgb(204, 238, 255);">202,635</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9.78%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="color: rgb(0, 0, 0); background-color: rgb(204, 238, 255);">54,872(3</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0); background-color: rgb(204, 238, 255); text-align: left;">)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1"><br/>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6.93%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="color: rgb(0, 0, 0); background-color: rgb(204, 238, 255);">1,189,674</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 19%;">
            <div style="text-align: center; color: rgb(0, 0, 0); background-color: rgb(204, 238, 255);">2023(2)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7.92%;" colspan="1">
            <div style="color: rgb(0, 0, 0); background-color: rgb(204, 238, 255);">573,583</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7.92%;" colspan="1">
            <div style="color: rgb(0, 0, 0); background-color: rgb(204, 238, 255);">289,000</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9.65%;" colspan="1">
            <div style="color: rgb(0, 0, 0); background-color: rgb(204, 238, 255);">55,924</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9.78%;" colspan="1">
            <div style="color: rgb(0, 0, 0); background-color: rgb(204, 238, 255);">45,140(4</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 1%; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0); background-color: rgb(204, 238, 255); text-align: left;">)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6.93%;" colspan="1">
            <div style="color: rgb(0, 0, 0); background-color: rgb(204, 238, 255);">963,647</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 22%;" rowspan="2">
            <div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 9pt; background-color: rgb(255, 255, 255);">Khurram Jamil, M.D., Chief Medical Officer (5)</div>
          </td>

    <td valign="bottom" colspan="1" style="vertical-align: top; width: 1%;" rowspan="2">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 19%;">
            <div style="text-align: center; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255);">2024(6)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7.92%;" colspan="1">
            <div style="color: rgb(0, 0, 0); background-color: rgb(255, 255, 255);">365,909</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7.92%;" colspan="1">
            <div style="color: rgb(0, 0, 0); background-color: rgb(255, 255, 255);">120,625</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9.65%;" colspan="1">
            <div style="color: rgb(0, 0, 0); background-color: rgb(255, 255, 255);">398,500</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9.78%;" colspan="1">
            <div style="color: rgb(0, 0, 0); background-color: rgb(255, 255, 255);">60,813(7</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 1%; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); text-align: left;">)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6.93%;" colspan="1">
            <div style="color: rgb(0, 0, 0); background-color: rgb(255, 255, 255);">945,847</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 19%;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7.92%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7.92%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9.65%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9.78%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6.93%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 22%; background-color: rgb(204, 238, 255);" rowspan="2">
            <div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 9pt;">Jack W. Callicutt, Chief Financial Officer</div>
          </td>

    <td valign="bottom" colspan="1" style="vertical-align: top; width: 1%; background-color: rgb(204, 238, 255);" rowspan="2">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 19%; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; color: rgb(0, 0, 0);">2024(8)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7.92%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="color: rgb(0, 0, 0);">397,333</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7.92%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="color: rgb(0, 0, 0);">120,000</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9.65%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="color: rgb(0, 0, 0);">144,740</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9.78%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="color: rgb(0, 0, 0);">54,872(9</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0); text-align: left;">)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6.93%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="color: rgb(0, 0, 0);">716,945</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 19%; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; color: rgb(0, 0, 0);">2023(8)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7.92%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="color: rgb(0, 0, 0);">364,000</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7.92%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="color: rgb(0, 0, 0);">110,400</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9.65%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="color: rgb(0, 0, 0);">39,946</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9.78%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="color: rgb(0, 0, 0);">47,073(10</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0); text-align: left;">)<br/>
            </div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6.93%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="color: rgb(0, 0, 0);">561,419</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
    <div><br/>
    </div>

    <div>
      <hr style="height: 2px; width: 15%; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/></div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 27pt; vertical-align: top; color: #000000;">(1)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">Represents the aggregate grant date fair value of restricted stock units and option awards made during 2024 and 2023 computed in accordance with the Stock Compensation Topic of the FASB ASC, as modified of
              supplemented. Option awards fair values were calculated using the Black-Scholes options pricing model. For a description of the assumptions used to determine these amounts, see Note 9 of the Notes to the Consolidated Financial Statements in
              our Annual Reports on Form 10-K for the fiscal years ended December 31, 2024 and 2023.</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 27pt; vertical-align: top; color: #000000;">(2)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">Mr. Lewis&#8217;s performance bonuses for 2024 and 2023 were approved in January 2025 and January 2024, respectively. Pursuant to his employment agreement 20% of his salary and bonus were paid in cash and 80% were
              awarded in deferred stock units through December 31, 2023.</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 27pt; vertical-align: top; color: #000000;">(3)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">Includes $41,072 for health and other insurance and $13,800 for 401(k) plan contributions.</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 27pt; vertical-align: top; color: #000000;">(4)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">Includes $33,244 for health and other insurance and $11,896 for 401(k) plan contributions.</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 27pt; vertical-align: top; color: #000000;">(5)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">Dr. Jamil joined the Company in March 2024 as vice president of clinical development and was promoted to Chief Medical Officer effective August 1, 2024.</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 27pt; vertical-align: top; color: #000000;">(6)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">Dr. Jamil&#8217;s performance bonus for 2024 was approved in January 2025.</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 27pt; vertical-align: top; color: #000000;">(7)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">Includes $47,146 for health and other insurance and $13,667 for 401(k) plan contributions.</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 27pt; vertical-align: top; color: #000000;">(8)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">Mr. Callicutt&#8217;s performance bonuses for 2024 and 2023 were approved in January 2025 and January 2024, respectively.</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 27pt; vertical-align: top; color: #000000;">(9)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">Includes $41,072 for health and other insurance and $13,800 for 401(k) plan contributions.</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0);">(10)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">Includes $33,873 for health and other insurance and $12,200 for 401(k) plan contributions.</div>
          </td>

  </tr>


</table>
    <div><br/>
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">35</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div>
          <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

          </div>

        </div>

      </div>

    </div>

    <div style="text-align: center; color: #000000; font-weight: bold;">OUTSTANDING EQUITY AWARDS AT FISCAL YEAR-END 2024</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">The following table sets forth information regarding all outstanding equity awards held by the NEOs at December 31, 2024. The exercise price of the options is set at the closing price of our stock at the
      date prior to or as of the date of grant. Outstanding options have been approved by our Compensation Committee and our Board.</div>

    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 16%;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); width: 0.99%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); width: 11.01%; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0); font-weight: bold;">Option Awards</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); width: 8.04%;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="6">
            <div style="text-indent: 23pt; color: rgb(0, 0, 0); font-weight: bold;">Stock Awards</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); width: 16%;">
            <div style="color: rgb(0, 0, 0); font-weight: bold;">Name</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
            <div>&#160;</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Number of</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Securities</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Underlying</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Unexercised</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Options</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">(#)</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Exercisable</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
            <div>&#160;</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Number of</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Securities</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Underlying</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Unexercised</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Options</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">(#)</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Unexercisable</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); width: 11.01%;" colspan="1">
            <div>&#160;</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Equity</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Incentive</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Plan</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Awards:</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Number of</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Securities</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Underlying</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Unexercised</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Unearned</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Options</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">(#)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
            <div>&#160;</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Option</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Exercise</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Price</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">($)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); width: 8.04%;">
            <div>&#160;</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Option</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Expiration</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Date</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
            <div>&#160;</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Number</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">of Shares</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">or Units</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">of Stock</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">That</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Have Not</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Vested</div>
            <div style="text-align: center; color: #000000;">(#)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
            <div>&#160;</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Market</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Value of</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Shares</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">or </div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Units</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">of </div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Stock</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">That</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Have Not</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Vested</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">($)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
            <div>&#160;</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Equity</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Incentive</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Plan</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Awards:</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Number of</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Unearned</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Shares,</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Units or</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Other</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Rights</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">That</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Have</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Not</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Vested</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">(#)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
            <div style="text-align: center; color: #000000; font-weight: bold;">Equity</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Incentive</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Plan</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Awards:</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Market</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">or Payout</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Value of</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Unearned</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Shares,</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Units or</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Other</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Rights</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">That</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Have Not</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Vested</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">($)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 16%; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">Joel Lewis</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 8.04%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="color: rgb(0, 0, 0);">54,250(1</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0); text-align: left;">)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9.28%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 11.01%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 4.7%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="color: rgb(0, 0, 0);">2.39</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 8.04%; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">12/14/2027</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5.45%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5.07%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6.19%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6.19%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 16%;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 8.04%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">35,000(2</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 0.99%; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0); text-align: left;">)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9.28%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 11.01%;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 4.7%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">4.72</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 8.04%;">
            <div style="color: rgb(0, 0, 0);">01/16/2029</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5.45%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5.07%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6.19%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6.19%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 16%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 8.04%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="color: rgb(0, 0, 0);">40,000(3</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0); text-align: left;">)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9.28%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 11.01%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 4.7%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="color: rgb(0, 0, 0);">2.86</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 8.04%; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">01/09/2030</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5.45%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5.07%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6.19%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6.19%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 16%;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 8.04%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">250,000(4</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 0.99%; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0); text-align: left;">)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9.28%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 11.01%;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 4.7%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">2.65</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 8.04%;">
            <div style="color: rgb(0, 0, 0);">08/31/2030</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5.45%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5.07%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6.19%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6.19%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 16%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 8.04%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="color: rgb(0, 0, 0);">70,000(5</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0); text-align: left;">)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9.28%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 11.01%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 4.7%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="color: rgb(0, 0, 0);">2.11</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 8.04%; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">03/25/2031</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5.45%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5.07%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6.19%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6.19%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 16%;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 8.04%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">140,000(6</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 0.99%; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0); text-align: left;">)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9.28%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 11.01%;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 4.7%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">2.11</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 8.04%;">
            <div style="color: rgb(0, 0, 0);">03/25/2031</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5.45%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5.07%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6.19%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6.19%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 16%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 8.04%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="color: rgb(0, 0, 0);">70,000(7</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0); text-align: left;">)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9.28%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 11.01%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 4.7%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="color: rgb(0, 0, 0);">1.98</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 8.04%; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">01/24/2032</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5.45%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5.07%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6.19%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6.19%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 16%;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 8.04%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">70,000(8</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 0.99%; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0); text-align: left;">)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9.28%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 11.01%;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 4.7%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">1.11</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 8.04%;">
            <div style="color: rgb(0, 0, 0);">01/26/2033</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5.45%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5.07%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6.19%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6.19%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 16%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 8.04%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="color: rgb(0, 0, 0);">45,500(9&#160; <br/>
            </div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0); text-align: left;">)<br/>
            </div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9.28%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="color: rgb(0, 0, 0);">45,000(9</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);">)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 11.01%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 4.7%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="color: rgb(0, 0, 0);">1.72</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 8.04%; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">01/24/2034</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5.45%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5.07%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6.19%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6.19%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 16%; white-space: nowrap;">
            <div style="color: rgb(0, 0, 0);">Khurram Jamil, M.D.</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 8.04%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9.28%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">150,000(10</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);">)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 11.01%;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 4.7%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">2.20</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 8.04%;">
            <div style="color: rgb(0, 0, 0);">03/20/2034</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5.45%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5.07%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6.19%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6.19%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 16%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 8.04%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="color: rgb(0, 0, 0);">25,000(</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0); text-align: left;">)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9.28%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="color: rgb(0, 0, 0);">75,000(11</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);">)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 11.01%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 4.7%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="color: rgb(0, 0, 0);">2.50</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 8.04%; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">08/01/2034</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5.45%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5.07%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6.19%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6.19%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 16%;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 8.04%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9.28%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 11.01%;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 4.7%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 8.04%;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5.45%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5.07%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6.19%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6.19%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 16%; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">Jack W. Callicutt</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 8.04%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="color: rgb(0, 0, 0);">26,000(12</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0); text-align: left;">)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9.28%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 11.01%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 4.7%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="color: rgb(0, 0, 0);">13.38</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 8.04%; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">01/21/2024</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5.45%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5.07%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6.19%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6.19%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 16%;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 8.04%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">8,706(13</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 0.99%; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0); text-align: left;">)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9.28%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 11.01%;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 4.7%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">1.37</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 8.04%;">
            <div style="color: rgb(0, 0, 0);">01/20/2026</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5.45%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5.07%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6.19%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6.19%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 16%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 8.04%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="color: rgb(0, 0, 0);">90,000(14</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0); text-align: left;">)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9.28%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 11.01%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 4.7%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="color: rgb(0, 0, 0);">5.87</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 8.04%; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">01/15/2028</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5.45%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5.07%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6.19%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6.19%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 16%;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 8.04%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">90,000(15</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 0.99%; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0); text-align: left;">)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9.28%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 11.01%;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 4.7%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">4.16</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 8.04%;">
            <div style="color: rgb(0, 0, 0);">05/22/2028</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5.45%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5.07%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6.19%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6.19%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 16%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 8.04%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="color: rgb(0, 0, 0);">50,000(16</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0); text-align: left;">)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9.28%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 11.01%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 4.7%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="color: rgb(0, 0, 0);">4.72</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 8.04%; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">01/16/2029</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5.45%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5.07%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6.19%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6.19%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 16%;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 8.04%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">50,000(17</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 0.99%; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0); text-align: left;">)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9.28%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 11.01%;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 4.7%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">2.86</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 8.04%;">
            <div style="color: rgb(0, 0, 0);">01/09/2030</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5.45%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5.07%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6.19%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6.19%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 16%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 8.04%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="color: rgb(0, 0, 0);">50,500(5</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0); text-align: left;">)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9.28%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 11.01%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 4.7%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="color: rgb(0, 0, 0);">2.11</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 8.04%; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">03/25/2031</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5.45%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5.07%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6.19%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6.19%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 16%;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 8.04%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">100,000(6</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 0.99%; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0); text-align: left;">)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9.28%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 11.01%;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 4.7%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">2.11</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 8.04%;">
            <div style="color: rgb(0, 0, 0);">03/25/2031</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5.45%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5.07%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6.19%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6.19%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 16%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 8.04%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="color: rgb(0, 0, 0);">50,000(7</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0); text-align: left;">)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9.28%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 11.01%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 4.7%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="color: rgb(0, 0, 0);">1.98</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 8.04%; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">01/24/2032</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5.45%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5.07%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6.19%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6.19%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 16%;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 8.04%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">50,000(8</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 0.99%; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0); text-align: left;">)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9.28%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 11.01%;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 4.7%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">1.11</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 8.04%;">
            <div style="color: rgb(0, 0, 0);">01/26/2033</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5.45%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5.07%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6.19%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6.19%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 16%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 8.04%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="color: rgb(0, 0, 0);">32,500(9</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">)</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9.28%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="color: rgb(0, 0, 0);">32,500(9</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);">)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 11.01%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 4.7%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="color: rgb(0, 0, 0);">1.72</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 8.04%; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">01/24/2034</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5.45%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5.07%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6.19%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6.19%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 0.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
    <div><br/>
    </div>

    <div>
      <hr style="height: 2px; width: 15%; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/></div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 27pt; vertical-align: top; color: #000000;">(1)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">100% of the options vested in full on December 14, 2018.</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 27pt; vertical-align: top; color: #000000;">(2)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">100% of the options vested in full on January 16, 2020.</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 27pt; vertical-align: top; color: #000000;">(3)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">100% of the options vested in full on December 31, 2020.</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 27pt; vertical-align: top; color: #000000;">(4)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">One-twelfth of the total options vested quarterly from August 31, 2020, which was the grant date.</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 27pt; vertical-align: top; color: #000000;">(5)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">25% of the options vested on September 30, 2021, 25% vested on March 31, 2022, 25% vested on September 30, 2022, 25% vest on March 31, 2023.</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 27pt; vertical-align: top; color: #000000;">(6)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">100% of the options vested on December 20, 2024 when the Company received the top-line results of the NAVIGATE clinical trial and made a public announcement of such results.</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 27pt; vertical-align: top; color: #000000;">(7)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">25% of the options vested on June 30, 2022, 25% vested on December 31, 2022, 25% vested on June 30, 2023, 25% vested on December 31, 2023.</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 27pt; vertical-align: top; color: #000000;">(8)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">25% of the options vested on June 30, 2023, 25% vested on December 31, 2023, 25% vested on June 30, 2024, 25% vested on December 31, 2024.</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 27pt; vertical-align: top; color: #000000;">(9)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">25% of the options vested on June 30, 2024, 25% vested on December 31, 2024, 25% vest on June 30, 2025, 25% vest on December 31, 2025.</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0);">(10)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">One third of the options vest on each of March 11, 2025, March 11, 2026, and March 11, 2027.</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0);">(11)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">25% of the options vest on each of October 31, 2024, January 31, 2025, April 30, 2025, and July 31, 2025.</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0);">(12)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">25% of the options vested on January 21, 2014, the grant date with the remainder vested ratably on a monthly basis over a three-year period.</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0);">(13)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">25% of the options vested on January 29, 2015, the grant date with the remainder vested ratably on a monthly basis over a three-year period.</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0);">(14)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">25% of the options vested on January 15, 2018 (grant date), 25% vested on June 30, 2018, and 50% vested on December 31, 2018.</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0);">(15)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">25% of the options vested on June 30, 2018, 25% vested on September 30, 2018, and 50% vested on December 31, 2018.</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0);">(16)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">25% of the options vested on June 30, 2019, 25% vested on December 31, 2019, 25% vested on June 30, 2020, and 25% vested on December 31, 2020.</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0);">(17)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">25% of the options vested on June 30, 2020, 25% vested on December 31, 2020, 25% vested on June 30, 2021, and 25% vested on December 31, 2021.</div>
          </td>

  </tr>


</table>
    <div><br/>
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">36</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div>
          <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

          </div>

        </div>

      </div>

    </div>

    <div style="color: #000000; font-style: italic; font-weight: bold;">2019 Omnibus Equity Incentive Plan</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">Under the 2019 Omnibus Equity Incentive Plan, if there is a merger or consolidation of the Company with or into another corporation or a sale of substantially all of the Company&#8217;s stock (a &#8220;Corporate
      Transaction&#8221;), and the outstanding awards are not assumed by surviving company (or its parent company) or replaced with economically equivalent awards granted by the surviving company (or its parent company), the Company will cancel any outstanding
      awards that are not vested and nonforfeitable as of the consummation of such Corporate Transaction (unless the Company accelerates the vesting of any such awards) and with respect to any vested and nonforfeitable awards, the Company may either (i)
      allow all grantees to exercise options and SARs within a reasonable period prior to the consummation of the Corporate Transaction and cancel any outstanding options or SARs that remain unexercised upon consummation of the Corporate Transaction, or
      (ii) cancel any or all of such outstanding awards (including options and SARs) in exchange for a payment (in cash, or in securities or other property) in an amount equal to the amount that the grantee would have received (net of the exercise price
      with respect to any options or SARs) if the vested awards were settled or distributed or such vested options and SARs were exercised immediately prior to the consummation of the Corporate Transaction. If an exercise price of the option or SAR exceeds
      the fair market value of our Common Stock and the option or SAR is not assumed or replaced by the surviving company (or its parent company), such options and SARs will be cancelled without any payment to the grantee.</div>

    <div><br/>
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">37</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div>
          <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

          </div>

        </div>

      </div>

    </div>

    <div style="color: #000000; font-style: italic; font-weight: bold;">Potential Payments Upon Termination or Change-in-Control</div>

    <div><br/>
    </div>

    <div style="color: #000000; font-style: italic;">Joel Lewis:</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">If either Mr. Lewis terminates his employment for Good Reason (ii) the Company terminates Mr. Lewis&#8217;s employment without Cause, or if this Employment Agreement expires as a result of the Company giving
      written notice of non-renewal, then the Company shall pay to Mr. Lewis (1) any accrued benefits, (2) a lump sum amount equal to twelve (12) months of Mr. Lewis&#8217;s base salary payable within thirty (30) days after the date of such termination, and (3)
      the performance bonus, if any, for the year in which termination occurs, based on actual individual and Company performance results and multiplied by a fraction, (A) the numerator of which shall be the number of days elapsed from the beginning of the
      fiscal year in which such termination occurs and (B) the denominator of which shall be 365; provided, however, that the portion of the performance bonus payable in the form of DSUs, will be paid in accordance with the terms of the DSU Award
      Agreements. Notwithstanding the foregoing, the payments described in clauses above are expressly conditioned upon Mr. Lewis executing returning a full release of the Company and its affiliates and from all obligations and any usual and customary
      indemnification obligations of the Company to Mr. Lewis as an officer thereof.</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">Under the Deferred Stock Unit Agreement, if a Change in Control of the Company occurs prior to the date on which Mr. Lewis is scheduled to receive shares and cash in an installment payment or in a lump
      sum (a &#8220;Settlement Date&#8221;), Mr. Lewis&#8217; account will be credited with the consideration payable in such Change in Control with respect to the shares subject to the DSUs then credited to Mr. Lewis&#8217; Account immediately prior to such Change in Control. If
      Mr. Lewis&#8217; employment with the Company continues after a Change in Control, Mr. Lewis&#8217; account will be credited with the cash value of the portion of his base salary and annual performance bonus that would have been credited in the form of DSUs but
      for the Change in Control. The portion of Mr. Lewis&#8217; Account denominated in cash pursuant to the preceding sentence (i.e., the amount attributable to base salary and annual performance bonuses credited to Mr. Lewis&#8217; Account after the Change in
      Control) shall be credited with interest at three (3%) percent compounded annually. For avoidance of doubt, a Change in Control shall not result in acceleration of the settlement of Mr. Lewis&#8217; Account and the payment of all amounts or other property
      credited to Mr. Lewis&#8217; Account in connection with the Change in Control shall be paid or delivered to Mr. Lewis on as soon as reasonably practicable after the Settlement Date.</div>

    <div><br/>
    </div>

    <div style="color: #000000; font-style: italic;">Khurram Jamil, M.D.:</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">Under the Employment Agreement with Dr. Jamil, if (i) Dr. Jamil terminates the Agreement for Good Reason (as defined in the Agreement) or (ii) the Company terminates the Agreement without Cause (as
      defined in the Agreement), then the Company shall pay to Dr. Jamil: (1) the Base Salary accrued through the date of termination, (2)(A) if termination occurs within twelve (12) months of the Commencement Date, an amount equal to three (3) months of
      the Base Salary, or (B) if such termination occurs after the twelve-month anniversary of the Commencement Date, but prior to the eighteen-month anniversary of the Commencement Date, an amount equal to six (6) months of the Base Salary or (C) if
      termination occurs after the eighteen-month anniversary of the Commencement Date, but prior to the twenty four-month anniversary of the Commencement Date, an amount equal to nine (9) months of Base Salary or (D) if termination occurs after the twenty
      four-month anniversary of the Commencement Date, an amount equal to twelve (12) months of the Base Salary, (3) reimbursement of unreimbursed expenses and (4) payment of a portion of the Performance Bonus.</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">If, within the period ending twelve (12) months after the date of a Change of Control, Dr. Jamil&#8217;s employment with the Company is (i) terminated without Cause or (ii) terminated for Good Reason by Dr.
      Jamil, the Company shall pay to Dr. Boudes (A) the Base Salary accrued through the date of termination, to the extent not theretofore paid, (B) Jamil of any unreimbursed expenses, (C) a pro-rated amount of the Performance Bonus assuming payout at
      maximum performance and (D) an amount equal to twelve (12) months of Base Salary, payable in a lump sum no later than thirty (30) days following such termination. Upon any such Change of Control, Dr. Jamil&#8217;s unvested Options shall be one hundred
      percent (100%) vested, but shall otherwise continue to be governed by the terms and conditions of the Plan and the applicable stock option agreement.</div>

    <div><br/>
    </div>

    <div style="color: #000000; font-style: italic;">Jack Callicutt:</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">Mr. Callicutt&#8217;s Employment Agreement provides that if, within the period ending twelve (12) months after the date of a Change of Control, Mr. Callicutt&#8217;s employment with the Company is (i) without Cause
      by the Company (or by the acquiring or successor business entity following a Change of Control), or (ii) terminated for Good Reason by Mr. Callicutt, the Company shall pay to Mr. Callicutt (A) the Base Salary accrued through the date of termination,
      to the extent not theretofore paid, (B) reimbursement of any unreimbursed expenses, (C) a portion of the amount of the Performance Bonus (as defined in the Employment Agreement) equal to the maximum amount of the Performance Bonus multiplied by a
      fraction, (X) the numerator of which shall be the number of days elapsed from the beginning of the calendar year in which such termination occurs and (Y) the denominator of which shall be the total number of days in the calendar year in which such
      termination occurs (being 365 in a full year and 184 in 2013) and (D) an amount equal to twelve (12) months of Mr. Callicutt&#8217;s Base Salary, payable in a lump sum no later than thirty (30) days following such termination. Upon any such Change of
      Control, Mr. Callicutt&#8217;s unvested options to purchase shares of the Company&#8217;s common stock shall be one hundred percent (100%) vested, but shall otherwise continue to be governed by the terms and conditions of the Stock Option Agreement. However, if,
      in connection with a transaction that technically meets, or may meet, the definition of Change of Control (as defined in the Employment Agreement), Mr. Callicutt&#8217;s employment by the Company or a successor to the Company is terminated, but Mr.
      Callicutt is immediately re-hired as an employee of a successor to the Company or surviving company in such a transaction in a comparable position, with the same or greater total annual cash compensation, including bonus potential, and with an
      employment agreement containing substantially equivalent provisions as this Agreement with respect to termination of the Mr. Callicutt and severance, no benefits shall be payable under the Change of Control provision of the Employment Agreement.</div>

    <div><br/>
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">38</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div>
          <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

          </div>

        </div>

      </div>

    </div>

    <div style="color: #000000; font-weight: bold;">DIRECTOR COMPENSATION</div>

    <div><br/>
    </div>

    <div style="color: #000000;">The following table details the total compensation earned by our non-employee directors during the year ended December 31, 2024.</div>

    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div>&#160;</div>
            <div style="color: #000000; font-weight: bold;">Name</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
            <div style="text-align: center; color: #000000; font-weight: bold;">Fees </div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Earned</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">or Paid in</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Cash ($)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
            <div style="text-align: center; color: #000000; font-weight: bold;">Restricted</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Stock</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Awards</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">($) (1)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
            <div style="text-align: center; color: #000000; font-weight: bold;">Option</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Awards</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">($) (2)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
            <div style="text-align: center; color: #000000; font-weight: bold;">Non-Equity</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Incentive Plan</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Compensation</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">($)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
            <div style="text-align: center; color: #000000; font-weight: bold;">All Other</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Compensation</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">($) (3)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
            <div style="text-align: center;"><span style="color: #000000;">&#160;</span> </div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Total</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">($)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;">
            <div style="color: rgb(0, 0, 0);">Gilbert F. Amelio, Ph.D.</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">55,500</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">58,000</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">113,500</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 28%;">
            <div style="color: rgb(0, 0, 0);">Benjamin S. Carson, Sr., M.D.</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">40,000</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">58,000</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">98,000</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;">
            <div style="color: rgb(0, 0, 0);">Kary Eldred</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">47,500</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">58,000</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">105,500</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 28%;">
            <div style="color: rgb(0, 0, 0);">Kevin D. Freeman</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">56,000</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">58,000</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">114,000</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;">
            <div style="color: rgb(0, 0, 0);">Gilbert S. Omenn, M.D., Ph.D.</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">50,000</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">58,000</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">98,000</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 28%;">
            <div style="color: rgb(0, 0, 0);">Marc Rubin, M.D.</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">43,500</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">58,000</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">101,500</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;">
            <div style="color: rgb(0, 0, 0);">Elissa J. Schwartz, Ph.D.</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">43,500</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">58,000</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">101,500</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 28%;">
            <div style="color: rgb(0, 0, 0);">Harold H. Shlevin, Ph.D.</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">40,000</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">58,000</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">98,000</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;">
            <div style="color: rgb(0, 0, 0);">Richard Uihlein</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">40,000</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">58,000</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">98,000</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 28%;">
            <div style="color: rgb(0, 0, 0);">Richard A. Zordani</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">55,000</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">58,000</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">113,000</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
    <div><br/>
    </div>

    <div>
      <hr style="height: 2px; width: 15%; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/></div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 27pt; vertical-align: top; color: #000000;">(1)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">Mr. Uihlein elected to receive restricted stock in lieu of cash retainer for their service. The restricted shares vested in full on December 31, 2024.</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 27pt; vertical-align: top; color: #000000;">(2)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">Represents the grant date fair value of option awards based upon the Black Scholes valuation model made in 2024. The option grants were made on January 24, 2024. Each non-employee director received one grant of
              50,000 options which will vest in full on December 31, 2024. For a description of the assumptions used to determine these amounts, see Note 9 to the Notes to the Consolidated Financial Statements herein our Annual Report on Form 10-K for the
              fiscal year ended December 31, 2024.</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 27pt; vertical-align: top; color: #000000;">(3)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">Excludes travel expense reimbursements.</div>
          </td>

  </tr>


</table>
    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div>&#160;</div>
            <div style="color: #000000; font-weight: bold;">Name</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
            <div style="text-align: center; color: #000000; font-weight: bold;">Number of</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Shares</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Subject</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">to Option</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Awards </div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Held</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">as of</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">December </div>
            <div style="text-align: center; color: #000000; font-weight: bold;">31,</div>
            <div style="text-align: center; text-indent: 1pt; color: #000000; font-weight: bold;">2024</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;">
            <div style="color: rgb(0, 0, 0);">Gilbert F. Amelio, Ph.D.</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">315,000</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%;">
            <div style="color: rgb(0, 0, 0);">Benjamin S. Carson, Sr., M.D.</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">150,000</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;">
            <div style="color: rgb(0, 0, 0);">Kary Eldred</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">341,875</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%;">
            <div style="color: rgb(0, 0, 0);">Kevin D. Freeman</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">403,125</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;">
            <div style="color: rgb(0, 0, 0);">Gilbert S. Omenn, M.D., Ph.D.</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">418,750</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%;">
            <div style="color: rgb(0, 0, 0);">Marc Rubin, M.D.</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">344,565</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;">
            <div style="color: rgb(0, 0, 0);">Elissa J. Schwartz, Ph.D.</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">240,000</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%;">
            <div style="color: rgb(0, 0, 0);">Harold H. Shlevin, Ph.D.</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">595,000</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;">
            <div style="color: rgb(0, 0, 0);">Richard Uihlein</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">306,362</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; padding-bottom: 2px;">
            <div style="color: rgb(0, 0, 0);">Richard A. Zordani</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
            <div style="color: rgb(0, 0, 0);">240,000</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;">
            <div style="color: rgb(0, 0, 0);">TOTAL</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">3,354,677</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">For a more detailed description of the assumptions used for purposes of determining grant date fair value, see Note 9 to the Consolidated Financial Statements and &#8220;Management&#8217;s Discussion and Analysis of
      Financial Condition and Results of Operations &#8212; Critical Accounting Policies and Estimates &#8212; Stock-Based Compensation&#8221; included herein the Form 10-K for the 2024 fiscal year.</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">We also reimburse our directors for reasonable travel and other related expenses.</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">Pursuant to the Company&#8217;s cash compensation program for directors, non-employee directors of the Company will receive an annual cash retainer of $40,000. Each Nominating and Corporate Governance Committee
      member will receive an additional cash retainer of $3,500; each Compensation Committee member will receive an additional cash retainer of $5,000; and each Audit Committee member will receive an additional cash retainer of $7,500. In addition to the
      annual fee and committee membership retainers, the Nominating and Corporate Governance Committee Chairman will receive an annual cash retainer of $3,500; the Compensation Committee Chairman will receive an annual cash retainer of $5,000; and the
      Audit Committee Chairman will receive an annual cash retainer of $7,500.</div>

    <div><br/>
    </div>

    <div>
      <div>
        <a id="Item12."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="text-align: right; vertical-align: top; width: 54pt;">
                <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">Item 12.</div>
              </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                <div style="color: rgb(0, 0, 0); font-weight: bold; font-style: italic;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</div>
              </td>

  </tr>


</table>
      </div>

    </div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">The following table sets forth, as of February 28, 2025, certain information concerning the beneficial ownership of our common stock and Series A Preferred Stock by (i) each person known by us to own
      beneficially five percent (5%) or more of the outstanding shares of each class, (ii) each of our directors and named executive officers, and (iii) all of our executive officers and directors as a group. The table also sets forth, in its final column,
      the combined voting power of the voting securities on all matters presented to the stockholders for their approval at the Annual Meeting, except for such separate class votes as are required by law.</div>

    <div><br/>
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">39</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div>
          <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

          </div>

        </div>

      </div>

    </div>

    <div style="text-indent: 36pt; color: #000000;">The number of shares beneficially owned by each 5% stockholder, director or executive officer is determined under the rules of the Securities and Exchange Commission, or SEC, and the information is not
      necessarily indicative of beneficial ownership for any other purpose. Under those rules, beneficial ownership includes any shares as to which the individual or entity has sole or shared voting power or investment power and also any shares that the
      individual or entity has the right to acquire within 60 days after February 28, 2025 through the exercise of any stock option, warrant or other right, or the conversion of any security. Unless otherwise indicated, each person or entity has sole
      voting and investment power (or shares such power with his or her spouse) with respect to the shares set forth in the following table. The inclusion in the table below of any shares deemed beneficially owned does not constitute an admission of
      beneficial ownership of those shares.</div>

    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div>&#160;</div>
            <div style="color: #000000; font-weight: bold;">Name and Address (1)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
            <div style="text-align: center; color: #000000; font-weight: bold;">Shares of</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Common</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Stock</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Beneficially</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Owned (2)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
            <div>&#160;</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Percent </div>
            <div style="text-align: center; color: #000000; font-weight: bold;">of</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Common</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Stock (3)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
            <div style="text-align: center; color: #000000; font-weight: bold;">Shares of</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Series A</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Preferred</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Stock</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Beneficially</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Owned</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
            <div style="text-align: center; color: #000000; font-weight: bold;">Percent </div>
            <div style="text-align: center; color: #000000; font-weight: bold;">of</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Series A</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Preferred</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Stock (4)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom;">
            <div style="color: rgb(0, 0, 0); font-weight: bold;">5% Stockholders</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;">
            <div style="color: rgb(0, 0, 0);">James C. Czirr</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">12,758,868(5</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);">)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">18.4</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);">%</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">100,000</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">7.9</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);">%</div>
          </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%;">
            <div style="color: rgb(0, 0, 0);">10X Fund, L.P. (8)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">11,654,460(6</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);">)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">16.9</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);">%</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;">
            <div style="color: rgb(0, 0, 0);">David Smith (9)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">175,000</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">13.9</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);">%</div>
          </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%;">
            <div style="color: rgb(0, 0, 0);">Early Equities LLC (9)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">100,000(7</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);">)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">7.9</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);">%</div>
          </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;">
            <div style="color: rgb(0, 0, 0);">Richard E. Uihlein (11)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">45,523,946(12</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);">)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">46.3</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);">%</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%;">
            <div style="color: rgb(0, 0, 0); font-weight: bold;">Directors and Named Executive Officers</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;">
            <div style="color: rgb(0, 0, 0);">Benjamin S. Carson, Sr., M.D.</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">150,000</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">*</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%;">
            <div style="color: rgb(0, 0, 0);">Gilbert F. Amelio, Ph.D.</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">375,614</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">*</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;">
            <div style="color: rgb(0, 0, 0);">Kevin Freeman</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">865,134(10</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);">)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">1.4</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);">%</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%;">
            <div style="color: rgb(0, 0, 0);">Joel Lewis</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">1,760,974</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">2.7</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);">%</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;">
            <div style="color: rgb(0, 0, 0);">Gilbert S. Omenn, M.D., Ph.D.</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">500,990</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">*</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">50,000</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">3.8</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);">%</div>
          </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%;">
            <div style="color: rgb(0, 0, 0);">Marc Rubin, M.D.</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">358,146</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">*</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;">
            <div style="color: rgb(0, 0, 0);">Richard E. Uihlein</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">45,523,946(12</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);">)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">46,.3</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);">%</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%;">
            <div style="color: rgb(0, 0, 0);">Richard A. Zordani</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">284,853</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">*</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;">
            <div style="color: rgb(0, 0, 0);">Elissa J. Schwartz, Ph.D.</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">241,000</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">*</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%;">
            <div style="color: rgb(0, 0, 0);">Kary Eldred</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">847,608(13</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);">)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">1.3</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);">%</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;">
            <div style="color: rgb(0, 0, 0);">Harold H. Shlevin, Ph.D.</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">610,206</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">1.0</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);">%</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%;">
            <div style="color: rgb(0, 0, 0);">Khurram Jamil, M.D.</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">185,000</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">*</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;">
            <div style="color: rgb(0, 0, 0);">Jack W. Callicutt</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">639,405</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">1.0</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);">%</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%;">
            <div style="color: rgb(0, 0, 0); font-weight: bold;">All executive officers and directors as a group (13 persons)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">52,342,876(14</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);">)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">50.8</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);">%</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">50,000</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">3.8</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);">%</div>
          </td>

  </tr>


</table>
    <div><br/>
    </div>

    <div>
      <hr style="height: 2px; width: 15%; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/></div>

    <div style="color: #000000;">* Less than 1%.</div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 27pt; vertical-align: top; color: #000000;">(1)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">Except as otherwise indicated, the address for each named person is c/o Galectin Therapeutics Inc., 4960 Peachtree Industrial Blvd., Suite 240, Norcross, GA 30071.</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 27pt; vertical-align: top; color: #000000;">(2)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">Includes the following number of shares of our common stock issuable upon exercise of outstanding stock options granted to our named executive officers and directors that are exercisable within 60 days after
              February 28, 2025.</div>
          </td>

  </tr>


</table>
    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="color: rgb(0, 0, 0); font-weight: bold;">Directors, Nominees and Named Executive Officers</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
            <div style="text-align: center; color: #000000; font-weight: bold;">Options Exercisable</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Within 60 Days</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;">
            <div style="color: rgb(0, 0, 0);">Benjamin S. Carson, Sr., M.D.</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">150,000</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%;">
            <div style="color: rgb(0, 0, 0);">Gilbert F. Amelio, Ph.D.</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">315,000</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;">
            <div style="color: rgb(0, 0, 0);">Marc Rubin, M.D.</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">344,565</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%;">
            <div style="color: rgb(0, 0, 0);">Gilbert S. Omenn, M.D., Ph.D</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">418,750</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;">
            <div style="color: rgb(0, 0, 0);">Kevin Freeman</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">403,125</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%;">
            <div style="color: rgb(0, 0, 0);">Kary Eldred</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">341,875</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;">
            <div style="color: rgb(0, 0, 0);">Joel Lewis</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">774,250</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%;">
            <div style="color: rgb(0, 0, 0);">Richard E. Uihlein.</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">306,362</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;">
            <div style="color: rgb(0, 0, 0);">Harold Shlevin, Ph.D.</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">595,000</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%;">
            <div style="color: rgb(0, 0, 0);">Richard A. Zordani</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">240,000</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;">
            <div style="color: rgb(0, 0, 0);">Elissa J. Schwartz, Ph.D.</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">240,000</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%;">
            <div style="color: rgb(0, 0, 0);">Khurram Jamil, M.D.</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">125,000</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;">
            <div style="color: rgb(0, 0, 0);">Jack Callicutt</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">571,706</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; padding-bottom: 2px;">
            <div style="color: rgb(0, 0, 0);">All executive officers and directors as a group</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
            <div style="color: rgb(0, 0, 0);">4,825,633</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 27pt; vertical-align: top; color: #000000;">(3)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">For each named person and group included in this table, percentage ownership of our common stock is calculated by dividing the number of shares of our common stock beneficially owned by such person or group by
              the sum of (i) 63,168,196 shares of our common stock outstanding as of February 28, 2025 and (ii) the number of shares of our common stock that such person has the right to acquire within 60 days after February 28, 2025.</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 27pt; vertical-align: top; color: #000000;">(4)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">Based on 1,235,000 shares of Series A preferred stock outstanding as of February 28, 2025.</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 27pt; vertical-align: top; color: #000000;">(5)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">Includes (i) 5,922,207 shares of common shares, and (ii) 5,732,253 common shares issuable upon exercise of warrants as to which Mr. Czirr, in his capacity as a managing member of 10X Capital Management Fund,
              LLC, a Florida limited liability company and general partner of 10X Fund (referred to herein as 10X Management) has shared voting and investment power, and disclaims beneficial ownership, also includes 764,616 shares of common stock owned
              directly by Mr. Czirr, 323,125 shares issuable upon the exercise of vested stock options owned by Mr. Czirr, and 16,667 shares of our common stock issuable upon conversion of Series A preferred stock owned by Mr. Czirr.</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 27pt; vertical-align: top; color: #000000;">(6)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">Includes (i) 5,922,207 shares of common shares, and (ii) 5,732,253 common shares issuable upon exercise of warrants.</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 27pt; vertical-align: top; color: #000000;">(7)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">Mr. Smith is the manager of Early Equities LLC, a Connecticut limited liability company, and may be deemed to have voting and investment control over, but disclaims beneficial ownership of, the shares of Series
              A preferred stock.</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 27pt; vertical-align: top; color: #000000;">(8)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">Contact: c/o 10X Capital Management, LLC at Investment Law Group attn: Bob Mottern 545 Dutch Valley Road NE, Suite A, Atlanta, GA 30324.</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 27pt; vertical-align: top; color: #000000;">(9)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">Contact: c/o David Smith 34 Shorehaven Road E., Norwalk, CT 06855.</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0);">(10)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">Includes 243,745 shares of the Company&#8217;s common stock managed by Cross Consulting and Services, LLC, a Texas limited liability company, d/b/a Freeman Global Investment Counsel. Mr. Freeman, in his capacity as
              CEO of Freeman Global Investment Counsel, has voting and investment control over, but disclaims beneficial ownership of, these shares.</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0);">(11)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">Contact: c/o Uline Corporation, 12575 Uline Drive, Pleasant Prairie, WI 53158</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0);">(12)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">Includes (i) 10,338,981 shares of common stock, (ii) 2,300,180 common shares issuable upon the exercise of common stock purchase warrants, (iii) 306,362 common shares issuable upon the exercise of common stock
              options, (iv) 83,334 common shares issuable upon conversion of Series C preferred non-voting stock, (iv) 7,125,228 common shares issuable upon conversion of convertible notes payable and (v) 25,369,861 common shares issuable upon conversion
              of convertible line of credit.</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0);">(13)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">Includes 63,682 shares of common stock, 6,599 common stock purchase warrants, and 311,875 common stock options personally owned by Mr. Eldred and 431,527 shares of Common Stock and 311,964 Common Stock purchase
              warrants owned by two private foundations over which Mr. Eldred shares management control, and 4,425 shares of Common Stock held in a trust for a minor child; however, Mr. Eldred disclaims beneficial ownership of the shares and warrants owned
              by such private foundations and trust.</div>
          </td>

  </tr>


</table>
    <div><br/>
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">40</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div>
          <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

          </div>

        </div>

      </div>

    </div>

    <div style="color: #000000; font-weight: bold;">EQUITY COMPENSATION PLAN INFORMATION</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">The following table provides information as of December 31, 2024, about the securities issued, or authorized for future issuance, under our equity compensation plans, consisting of our 2009 Incentive
      Compensation Plan and our 2019 Omnibus Equity Incentive Plan at December 31, 2024.</div>

    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div>&#160;</div>
            <div style="color: #000000; font-weight: bold;">Plan Category</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
            <div style="text-align: center; color: #000000; font-weight: bold;">Number of Securities</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">to be issued upon</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">exercise of</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">outstanding options</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
            <div style="text-align: center; color: #000000; font-weight: bold;">Weighted-</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">average</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">exercise</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">price of</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">outstanding</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">options</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
            <div style="text-align: center; color: #000000; font-weight: bold;">Number of</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">securities</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">remaining</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">available for</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">future</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">issuance</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">under</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">equity</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">compensation</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">plans</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">(excluding</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">securities</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">reflected in</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">column (a))</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;">
            <div style="color: rgb(0, 0, 0);">Equity compensation plans approved by security holders</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">6,854,758</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">2.45</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">4,135,213</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
    <div><br/>
    </div>

    <div>
      <div>
        <a id="Item13."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="text-align: right; vertical-align: top; width: 54pt;">
                <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">Item 13.</div>
              </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                <div style="color: rgb(0, 0, 0); font-weight: bold; font-style: italic;">Certain Relationships, Related Transactions and Director Independence</div>
              </td>

  </tr>


</table>
      </div>

    </div>

    <div><br/>
    </div>

    <div style="color: #000000; font-weight: bold;">Certain Relationships and Related Transactions</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">Except as set forth below, since the beginning of fiscal year 2024, we did not participate in any transactions in which any of the Company&#8217;s executive officers, any beneficial owner of more than 5% of our
      common stock, nor any of their immediate family members, had a direct or indirect material interest.</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">Our Audit Committee Charter requires that members of the Audit Committee, all of whom are independent directors, conduct an appropriate review of, and be responsible for the oversight of, all related
      party transactions on an ongoing basis. Except as set forth below, there were no related party transactions during the fiscal year ended December 31, 2023.</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">On March 29, 2024, the Company and Richard E. Uihlein (the &#8220;Lender&#8221;) entered into a Supplemental Line of Credit Letter Agreement (the &#8220;Supplemental Credit Agreement&#8221;), pursuant to which the Lender shall
      provide the Company a line of credit of up to $10.0 million (the &#8220;Supplemental Line of Credit&#8221;) to finance the Company&#8217;s working capital needs. The Company may draw upon the Supplemental Line of Credit through March 31, 2025.</div>

    <div style="text-indent: 36pt;"><span style="color: #000000;">&#160;</span><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">Each advance made pursuant to the Supplemental Credit Agreement shall be evidenced by an unsecured, convertible promissory note (individually, a &#8220;Promissory Note,&#8221; and collectively, the &#8220;Promissory
      Notes&#8221;), and bear interest at the Applicable Federal Rate for short term loans, plus two (2%) percent. Principal and interest on the Promissory Notes are due on or before March 31, 2026.</div>

    <div style="text-indent: 36pt;"><span style="color: #000000;">&#160;</span><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">Only with the consent of the Lender, may the Promissory Notes be prepaid, in whole or in part, at any time without premium or penalty, but with interest on the amount or amounts prepaid. At the election
      of Lender, the principal and accrued interest on Promissory Note(s) may be converted into the number of shares of the Company&#8217;s Common Stock equal to the amount of principal and accrued interest on such Promissory Note divided by the price equal to
      the closing price of the Common Stock on the date of such Promissory Note, but in no event less than $3.00 per share.</div>

    <div style="text-indent: 36pt;"><span style="color: #000000;">&#160;</span><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">In connection with the Supplemental Credit Agreement, the Company agreed to issue the Lender warrants to purchase up to an aggregate of 200,000 shares of the Company&#8217;s common stock, par value $0.001 per
      share (collectively, the &#8220;Warrants&#8221;). The Company shall issue to the Lender Warrants ratably, upon borrowings under the Supplemental Line of Credit, with exercise prices equal to 150% of the closing price of the Company&#8217;s common Stock on the date of
      the Promissory Note evidencing such draw, but in no event more than $10.00 per share nor less than $3.00 per share. The Warrants expire on July 31, 2029.</div>

    <div style="text-indent: 36pt;"><span style="color: #000000;">&#160;</span><br/>
    </div>

    <div>
      <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">On November 14, 2024, the Company and Richard E. Uihlein (the &#8220;Lender&#8221;) entered into an additional Supplemental Line of Credit Letter
        Agreement (the &#8220;November 2024 Supplemental Credit Agreement&#8221;), pursuant to which the Lender shall provide the Company a line of credit of up to $6.0 million (the &#8220;November 2024 Supplemental Line of Credit&#8221;) to finance the Company&#8217;s working capital
        needs. The Company may draw upon the November 2024 Supplemental Line of Credit through March 31, 2025.</div>

      <div><br/>
      </div>

      <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Each advance made pursuant to the November 2024 Supplemental Credit Agreement shall be evidenced by an unsecured, convertible
        promissory note (individually, a &#8220;Promissory Note,&#8221; and collectively, the &#8220;Promissory Notes&#8221;), and bear interest at the Applicable Federal Rate for short term loans, plus two (2%) percent. Principal and interest on the Promissory Notes are due on
        or before March 31, 2026. Only with the consent of the Lender, may the Promissory Notes be prepaid, in whole or in part, at any time without premium or penalty, but with interest on the amount or amounts prepaid.</div>

      <div><br/>
      </div>

      <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">At the election of Lender, the principal and accrued interest on Promissory Note(s) may be converted into the number of shares of the
        Company&#8217;s Common Stock equal to the amount of principal and accrued interest on such Promissory Note divided by the price equal to the closing price of the Common Stock on the date of such Promissory Note, but in no event less than $3.00 per share.</div>

      <div><br/>
      </div>

      <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">In connection with the November 2024 Supplemental Credit Agreement, the Company agreed to issue the Lender warrants to purchase up to
        an aggregate of 120,000 shares of the Company&#8217;s common stock, par value $0.001 per share (collectively, the &#8220;Warrants&#8221;). The Company shall issue to the Lender Warrants ratably, upon borrowings under the November 2024 Supplemental Line of Credit,
        with exercise prices equal to 150% of the closing price of the Company&#8217;s common Stock on the date of the Promissory Note evidencing such draw, but in no event more than $10.00 per share nor less than $3.00 per share. The Warrants expire on July 31,
        2029.</div>

    </div>

    <div><br/>
    </div>

    <div style="color: #000000; font-weight: bold;">Compensation Committee Interlocks and Insider Participation</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">None of our executive officers or directors serves as a member of the board of directors or compensation committee of any entity that has one or more of its executive officers serving as a member of our
      Board of Directors or Compensation Committee.</div>

    <div><br/>
    </div>

    <div style="color: #000000; font-weight: bold;">Board Determination of Director Independence</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">Our board of directors has reviewed the materiality of any relationship that each of our directors has with the Company, either directly or indirectly. Based upon this review, our board has determined
      that all of our directors other than Mr. Lewis are &#8220;independent directors&#8221; as defined by The NASDAQ Stock Market. Our board of directors also determined that Drs. Amelio, Rubin, and Mr. Freeman, who comprise our nominating and governance committee,
      all satisfy the independence standards for such committees established by the SEC and the NASDAQ Marketplace Rules, as applicable. With respect to our audit committee, our board of directors has determined that Messrs. Zordani, Freeman and Eldred
      satisfy the independence standards for such committee established by Rule 10A-3 under the Exchange Act, the SEC and the NASDAQ Marketplace Rules, as applicable. Furthermore, the Nominating and Corporate Governance Committee, with concurrence by the
      Board, has determined that Mr. Zordani is an &#8220;audit committee financial expert&#8221; within the meaning of SEC rules. With respect to our compensation committee, our board of directors has determined that Drs. Omenn, Amelio and Mr. Freeman satisfy the
      independence standards for such committee established by Rule 10C-1 under the Exchange Act, the SEC and the NASDAQ Marketplace Rules, as applicable.</div>

    <div><br/>
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">41</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div>
          <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

          </div>

        </div>

      </div>

    </div>

    <div style="text-indent: 36pt; color: #000000;">In making such determinations, the board of directors considered the relationships that each such non-employee director or director nominee has with our company and all other facts and circumstances the
      board of directors deemed relevant in determining their independence, including the beneficial ownership of our capital stock by each non-employee director. In considering the independence of our directors, our board of directors considered the
      association of each such non-employee director has with us and all other facts and circumstances our board of directors deemed relevant in determining independence.</div>

    <div><br/>
    </div>

    <div>
      <div>
        <a id="Item14."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="text-align: right; vertical-align: top; width: 54pt;">
                <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">Item 14.</div>
              </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                <div style="color: rgb(0, 0, 0); font-weight: bold; font-style: italic;">Principal Accountant Fees and Services</div>
              </td>

  </tr>


</table>
      </div>

    </div>

    <div><br/>
    </div>

    <div style="color: #000000;">The Board of Directors has appointed Cherry Bekaert LLP as our independent auditors for the fiscal year ending December 31, 2024.</div>

    <div><br/>
    </div>

    <div style="text-align: center; color: #000000; font-weight: bold;">FEES PAID TO CHERRY BEKAERT LLP</div>

    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
            <div style="text-align: center; color: #000000; font-weight: bold;">Fiscal </div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Year</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">2024</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
            <div style="text-align: center; color: #000000; font-weight: bold;">Fiscal </div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Year</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">2023</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
            <div style="color: rgb(0, 0, 0);">Audit Fees (1)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">182,000</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">177,000</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
            <div style="color: rgb(0, 0, 0);">Audit-Related Fees (2)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">17,237</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="color: rgb(0, 0, 0);">8,000</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
            <div style="color: rgb(0, 0, 0);">Tax Fees</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">40,194</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">48,812</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
            <div style="color: rgb(0, 0, 0);">All Other Fees</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
            <div style="color: rgb(0, 0, 0);">&#8212;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
            <div style="color: rgb(0, 0, 0);">Total Fees</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">239,431</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
            <div style="color: rgb(0, 0, 0);">233,812</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 27pt; vertical-align: top; color: #000000;">(1)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: #000000;"><span style="font-style: italic;">Audit Fees. </span>These are fees for professional services for the audit of our annual financial statements dated December 31, 2024 and 2023 included in our<span style="font-style: italic;">&#160;</span>Annual Reports on Form 10-K for fiscal years then ended, and review of financial statements included in our Quarterly Reports on Form 10-Q for each fiscal quarter during the 2024 and 2023 fiscal years.</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 27pt; vertical-align: top; color: #000000;">(2)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: #000000;"><span style="font-style: italic;">Audit-Related Fees</span>. These are fees for assurance and related services that are reasonably related to the performance of the audit or review of our financial statements,
              including financial disclosures made in our equity finance documentation and registration statements filed with the SEC that incorporate financial statements and the auditors&#8217; report thereon and reviewed with our Audit Committee on financial
              accounting/reporting standards.</div>
          </td>

  </tr>


</table>
    <div><br/>
    </div>

    <div style="color: #000000;">The Audit Committee has considered whether the provision of non-core audit services to Galectin Therapeutics by Cherry Bekaert LLP is compatible with maintaining independence.</div>

    <div><br/>
    </div>

    <div style="color: #000000; font-style: italic;">Pre-Approval Policy and Procedures</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">The Audit Committee of our Board of Directors has adopted policies and procedures which set forth the manner in which the Committee will review and approve all services to be provided by the independent
      auditor before the auditor is retained to provide such services. The policy requires Audit Committee pre-approval of the terms and fees of the annual audit services engagement, as well as any changes in terms and fees resulting from changes in audit
      scope or other items. The Audit Committee also pre-approves, on an annual basis, other audit services, and audit-related and tax services set forth in the policy, subject to estimated fee levels, on a project basis and aggregate annual basis, which
      have been pre-approved by the Committee.</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">All other services performed by the auditor that are not prohibited non-audit services under SEC or other regulatory authority rules must be separately pre-approved by the Audit Committee. Amounts in
      excess of pre-approved limits for audit services, audit-related services and tax services require separate pre-approval of the Audit Committee.</div>

    <div><br/>
    </div>

    <div style="text-indent: 36pt; color: #000000;">Our Chief Financial Officer reports quarterly to the Audit Committee on the status of pre-approved services, including projected fees. All of the services reflected in the above table were approved by the
      Audit Committee.</div>

    <div><br/>
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">42</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div>
          <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

          </div>

        </div>

      </div>

    </div>

    <div style="text-align: center; color: #000000; font-weight: bold;"><a id="PARTIV"><!--Anchor--></a>PART IV</div>

    <div><br/>
    </div>

    <div>
      <div>
        <a id="Item15."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="text-align: right; vertical-align: top; width: 54pt;">
                <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">Item 15.</div>
              </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                <div style="color: rgb(0, 0, 0); font-weight: bold; font-style: italic;">Exhibits and Financial Statement Schedules</div>
              </td>

  </tr>


</table>
      </div>

    </div>

    <div><br/>
    </div>

    <div style="color: #000000;">(a) 1.&#160; Consolidated Financial Statement Schedules</div>

    <div><br/>
    </div>

    <div style="color: #000000;">The Consolidated Financial Statements are filed as part of this report.</div>

    <div><br/>
    </div>

    <div style="color: #000000;">2. Consolidated Financial Statement Schedules</div>

    <div><br/>
    </div>

    <div style="color: #000000;">All schedules are omitted because of the absence of conditions under which they are required or because the required information is included in the Consolidated Financial Statements or notes thereto.</div>

    <div><br/>
    </div>

    <div style="color: #000000;">3. Exhibits</div>

    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 10%; vertical-align: bottom;">
            <div style="text-align: center; color: #000000; font-weight: bold;">Exhibit</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Number</div>
          </td>

    <td style="width: 90%; vertical-align: bottom;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Description of Document</div>
          </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: bottom;">&#160;</td>

    <td style="width: 90%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">3.1</div>
          </td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="https://www.sec.gov/Archives/edgar/data/1133416/000119312512252748/d359382dex32.htm">Amended and Restated Articles of Incorporation of Galectin Therapeutics Inc., as amended (Incorporated by reference to the Company&#8217;s Current
                Report on Form 8-K filed with the Commission on May 30, 2012.)</a></div>
          </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">&#160;</td>

    <td style="width: 90%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">3.2</div>
          </td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="https://www.sec.gov/Archives/edgar/data/1133416/000119312516721558/d269553dex53.htm">Amended and Restated Bylaws of Galectin Therapeutics Inc., as amended (Incorporated by reference to the Company&#8217;s Current Report on Form 8-K
                filed with the Commission on September 27, 2016.)</a></div>
          </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">&#160;</td>

    <td style="width: 90%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">3.3</div>
          </td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="https://www.sec.gov/Archives/edgar/data/1133416/000119312507214815/dex32.htm">Certificate of Designation of Preferences, Rights and Limitations of Series A 12% Convertible Preferred Stock of Pro Pharmaceuticals, Inc., as filed
                with the Secretary of State of the State of Nevada on October 5, 2007. (Incorporated by reference to the Company&#8217;s Current Report on Form 8-K filed with the Commission on October 9, 2007.)</a></div>
          </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">&#160;</td>

    <td style="width: 90%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">3.4</div>
          </td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="https://www.sec.gov/Archives/edgar/data/1133416/000119312517176606/d590602dex31.htm">First Amendment to Certificate of Designation of Preferences, Rights and Limitations of Series A 12% Convertible Preferred Stock of Galectin
                Therapeutics, Inc., as filed with the Secretary of State of the State of Nevada on May 15, 2017. (Incorporated by reference to the Company&#8217;s Current Report on Form 8-K filed with the Commission on May 19, 2017.)</a></div>
          </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">&#160;</td>

    <td style="width: 90%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">3.5</div>
          </td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="https://www.sec.gov/Archives/edgar/data/1133416/000119312511002455/dex31.htm">Certificate of Designation of Preferences, Rights and Limitation of Series C Super Dividend Convertible Preferred Stock of Pro- Pharmaceuticals, Inc.,
                as filed with the Secretary of State of Nevada on December 30, 2010. (Incorporated by reference to the Company&#8217;s Current Report on Form 8-K as filed with the Commission on January 6, 2011.)</a></div>
          </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">&#160;</td>

    <td style="width: 90%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">3.6</div>
          </td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="https://www.sec.gov/Archives/edgar/data/1133416/000119312512129902/d322145dex31.htm">Certificate of Change as filed with the Nevada Secretary of State on March 1, 2012. (Incorporated by reference to the Company&#8217;s Current Report on
                Form 8-K as filed with the Commission on March 23, 2012.)</a></div>
          </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">&#160;</td>

    <td style="width: 90%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">3.7</div>
          </td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="https://www.sec.gov/Archives/edgar/data/1133416/000114036123014658/brhc10049486_ex3-7.htm">Amendment to the Articles of Incorporation of Galectin Therapeutics Inc. (Incorporated by reference to the Company&#8217;s Annual Report on Form
                10-K as filed with the Commission on March 30, 2023)</a></div>
          </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">&#160;</td>

    <td style="width: 90%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">4.1</div>
          </td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="https://www.sec.gov/Archives/edgar/data/1133416/000119312516806268/d314862dex41.htm">Form of Common Stock Purchase Warrant (Incorporated by reference to the Company&#8217;s Current Report on Form 8-K as filed with the Commission on
                December 29, 2016.)</a></div>
          </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">&#160;</td>

    <td style="width: 90%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">4.2</div>
          </td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="https://www.sec.gov/Archives/edgar/data/1133416/000119312517373610/d466346dex41.htm">Form of Common Stock Purchase Warrant issued to Richard E. Uihlein (Incorporated by reference to the Company&#8217;s Current Report on Form 8-K as
                filed with the Commission on December 19, 2017.)</a></div>
          </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">&#160;</td>

    <td style="width: 90%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">4.3</div>
          </td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="https://www.sec.gov/Archives/edgar/data/1133416/000119312519001150/d685114dex41.htm">First Amendment to Common Stock Purchase Warrant, dated December 20, 2018, by and between Richard E. Uihlein and the Company (Incorporated by
                reference to the Company&#8217;s Current Report on Form 8-K as filed with the Commission on January 3, 2019.)</a></div>
          </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">&#160;</td>

    <td style="width: 90%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">4.4</div>
          </td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="https://www.sec.gov/Archives/edgar/data/1133416/000119312519009410/d684051dex41.htm">Second Amendment to Common Stock Purchase Warrant, dated January 11, 2019, by and between Richard E. Uihlein and the Company (Incorporated by
                reference to the Company&#8217;s Current Report on Form 8-K as filed with the Commission on January 15, 2019.)</a></div>
          </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">&#160;</td>

    <td style="width: 90%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">4.5</div>
          </td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="https://www.sec.gov/Archives/edgar/data/1133416/000119312519009410/d684051dex42.htm">Form of Amended and Restated Class B Common Stock Purchase Warrant (Incorporated by reference to the Company&#8217;s Current Report on Form 8-K as
                filed with the Commission on January 15, 2019.)</a></div>
          </td>

  </tr>


</table>
    <div><br/>
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">43</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div>
          <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

          </div>

        </div>

      </div>

    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 10%; vertical-align: bottom;">
            <div style="text-align: center; color: #000000; font-weight: bold;">Exhibit</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Number</div>
          </td>

    <td style="width: 90%; vertical-align: bottom;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Description of Document</div>
          </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: bottom;">&#160;</td>

    <td style="width: 90%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">4.6</div>
          </td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="https://www.sec.gov/Archives/edgar/data/1133416/000119312519009410/d684051dex43.htm">Form of Amended and Restated 10X Fund Class B Common Stock Purchase Warrant (Incorporated by reference to the Company&#8217;s Current Report on Form
                8-K as filed with the Commission on January 15, 2019.)</a></div>
          </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">&#160;</td>

    <td style="width: 90%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">4.7</div>
          </td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="https://www.sec.gov/Archives/edgar/data/1133416/000119312519064707/d626180dex417.htm">Form of Common Stock Purchase Warrant (Incorporated by reference to the Company&#8217;s Registration Statement on Form S-3 as filed with the
                Commission on March 6, 2019.)</a></div>
          </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">&#160;</td>

    <td style="width: 90%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">4.8</div>
          </td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="https://www.sec.gov/Archives/edgar/data/1133416/000119312519064707/d626180dex418.htm">Form of Warrant Agency Agreement (Incorporated by reference to the Company&#8217;s Registration Statement on Form S-3 as filed with the Commission on
                March 6, 2019.)</a></div>
          </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">&#160;</td>

    <td style="width: 90%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">4.09</div>
          </td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="https://www.sec.gov/Archives/edgar/data/1133416/000114036122026910/brhc10039901_ex4-1.htm">Form of Common Stock Purchase Warrant (Incorporated by reference to exhibit 4.1 the Company&#8217;s Current Report on Form 8-K as filed with the
                Commission on July 26, 2022.)</a></div>
          </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">&#160;</td>

    <td style="width: 90%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">4.10</div>
          </td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="https://www.sec.gov/Archives/edgar/data/1133416/000119312521101402/d30125dex420.htm">Description of Registrant&#8217;s securities (Incorporated by reference to exhibit 4.20 the Company&#8217;s Annual Report on Form 10-K for the year ended
                December 31, 2020, as filed on March 31, 2021.)</a></div>
          </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">&#160;</td>

    <td style="width: 90%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">4.11</div>
          </td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="https://www.sec.gov/Archives/edgar/data/1133416/000114036124016452/ef20015363_ex4-11.htm">Warrant Extension Agreement between the Company and 10X Fund L.P.&#160;(incorporated by reference to Exhibit 4.11 to the Company&#8217;s Annual Report
                on form 10-K for the year ended December 31, 2023, as filed on March 29, 2024)</a></div>
          </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">&#160;</td>

    <td style="width: 90%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">4.12</div>
          </td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="https://www.sec.gov/Archives/edgar/data/1133416/000114036124016452/ef20015363_ex4-12.htm">Form of Common Stock Purchase Warrant&#160;(incorporated by reference to Exhibit 4.11 to the Company&#8217;s Annual Report on form 10-K for the year
                ended December 31, 2023, as filed on March 29, 2024)</a></div>
          </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">&#160;</td>

    <td style="width: 90%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">10.1&#8224;</div>
          </td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="https://www.sec.gov/Archives/edgar/data/1133416/000119312519268920/d814474ddef14a.htm#toc814474_22">Galectin Therapeutics 2019 Omnibus Equity Incentive Plan (Incorporated by reference to Appendix A to the Company&#8217;s definitive
                proxy statement filed with the Commission on October 17, 2019.)</a></div>
          </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">&#160;</td>

    <td style="width: 90%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">10.2</div>
          </td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="https://www.sec.gov/Archives/edgar/data/1133416/000114036124016452/ef20015363_ex10-2.htm">Form of Stock Option Award Agreement under Galectin Therapeutics 2019 Omnibus Equity Incentive Plan (incorporated by reference to Exhibit
                10.2 to the Company&#8217;s Annual Report on form 10-K for the year ended December 31, 2023, as filed on March 29, 2024)</a></div>
          </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">&#160;</td>

    <td style="width: 90%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">10.3</div>
          </td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="https://www.sec.gov/Archives/edgar/data/1133416/000114036124016452/ef20015363_ex10-3.htm">Form of Restricted Stock Unit Award Agreement under Galectin Therapeutics 2019 Omnibus Equity Incentive Plan (incorporated by reference to
                Exhibit 10.3 to the Company&#8217;s Annual Report on form 10-K for the year ended December 31, 2023, as filed on March 29, 2024)</a></div>
          </td>

  </tr>


</table>
    <div><br/>
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">44</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div>
          <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

          </div>

        </div>

      </div>

    </div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 10%; vertical-align: bottom;">
            <div style="text-align: center; color: #000000; font-weight: bold;">Exhibit</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Number</div>
          </td>

    <td style="width: 90%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Description of Document</div>
          </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: bottom;">&#160;</td>

    <td style="width: 90%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">10.4&#8224;</div>
          </td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="https://www.sec.gov/Archives/edgar/data/1133416/000119312513334603/d551206dex103.htm">Employment Agreement dated June 20, 2013 between Jack W. Callicutt and Galectin Therapeutics Inc. (Incorporated by reference to the Company&#8217;s
                Quarterly Report on Form 10-Q as filed with the Commission on August 14, 2013.)</a></div>
          </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">&#160;</td>

    <td style="width: 90%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">10.5&#8224;</div>
          </td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="https://www.sec.gov/Archives/edgar/data/1133416/000119312517256668/d595775dex101.htm">Amendment to Employment Agreement dated August 11, 2017 between Jack W. Callicutt and Galectin Therapeutics Inc. (Incorporated by reference to
                the Company&#8217;s Quarterly Report on Form 10-Q as filed with the Commission on August 14, 2017.)</a></div>
          </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">&#160;</td>

    <td style="width: 90%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">10.6</div>
          </td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="https://www.sec.gov/Archives/edgar/data/1133416/000114036124035212/ef20033332_ex10-1.htm">Employment Agreement, dated August 1, 2024, by and between Galectin Therapeutics Inc. and Khurram Jamil, M.D. (Incorporated by reference to
                the Company&#8217;s Current Report on Form 8-K as filed with the Commission on August 1, 2024.)</a></div>
          </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">&#160;</td>

    <td style="width: 90%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">10.7***</div>
          </td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="https://www.sec.gov/Archives/edgar/data/1133416/000119312520075484/d883597dex101.htm">Master Services Agreement, effective as of March 12, 2020, by and between Galectin Therapeutics, Inc. and Covance Inc. (Incorporated by
                reference to the Company&#8217;s Current Report on Form 8-K as filed with the Commission on March 17, 2020.)</a></div>
          </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">&#160;</td>

    <td style="width: 90%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">10.8***</div>
          </td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="https://www.sec.gov/Archives/edgar/data/1133416/000119312520075484/d883597dex102.htm">Work Order, dated as of March 12, 2020, by and between Galectin Therapeutics, Inc. and Covance Clinical Research Unit Inc. (Incorporated by
                reference to the Company&#8217;s Current Report on Form 8-K as filed with the Commission on March 17, 2020.)</a></div>
          </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">&#160;</td>

    <td style="width: 90%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">10.9***</div>
          </td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="https://www.sec.gov/Archives/edgar/data/1133416/000119312520181006/d944255dex101.htm">Work Order, dated as of June 22, 2020, by and between Galectin Therapeutics Inc. and Covance Inc. (Incorporated by reference to the Company&#8217;s
                Current Report on Form 8-K as filed with the Commission on June 26, 2020.)</a></div>
          </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">&#160;</td>

    <td style="width: 90%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">10.10</div>
          </td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="https://www.sec.gov/Archives/edgar/data/1133416/000119312521120391/d135127dex101.htm">Convertible Promissory Note, dated April 16, 2021 (Incorporated by reference to the Company&#8217;s Current Report on Form 8-K as filed with the
                Commission on April 19, 2021.)</a></div>
          </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">&#160;</td>

    <td style="width: 90%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">10.11</div>
          </td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="https://www.sec.gov/Archives/edgar/data/1133416/000119312521277824/d213954dex101.htm">Loan Agreement, dated September 17, 2021 (Incorporated by reference to the Company&#8217;s Current Report on Form 8-K as filed with the Commission on
                September 21, 2021.)</a></div>
          </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">&#160;</td>

    <td style="width: 90%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">10.12</div>
          </td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="https://www.sec.gov/Archives/edgar/data/1133416/000119312521277824/d213954dex102.htm">Unsecured Convertible Promissory Note, dated September 17, 2021 (Incorporated by reference to the Company&#8217;s Current Report on Form 8-K as filed
                with the Commission on September 21, 2021.)</a></div>
          </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">&#160;</td>

    <td style="width: 90%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">10.13</div>
          </td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="https://www.sec.gov/Archives/edgar/data/1133416/000114036121042519/brhc10032081_ex10-1.htm">Unsecured Convertible Promissory Note, dated December 20, 2021 (Incorporated by reference to the Company&#8217;s Current Report on Form 8-K as
                filed with the Commission on December 21, 2021.)</a></div>
          </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">&#160;</td>

    <td style="width: 90%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">10.14</div>
          </td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="https://www.sec.gov/Archives/edgar/data/1133416/000114036122026910/brhc10039901_ex10-1.htm">Line of Credit Letter Agreement, dated as of July 25, 2022, by and between Richard E. Uihlein and the Company. (Incorporated by reference
                to exhibit 10.1 the Company&#8217;s Current Report on Form 8-K as filed with the Commission on July 26, 2022.)</a></div>
          </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">&#160;</td>

    <td style="width: 90%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">10.15</div>
          </td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="https://www.sec.gov/Archives/edgar/data/1133416/000114036122026910/brhc10039901_ex10-2.htm">Form of Convertible Promissory Note issued to Richard E. Uihlein. (Incorporated by reference to exhibit 10.2 the Company&#8217;s Current Report
                on Form 8-K as filed with the Commission on July 26, 2022.)</a></div>
          </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">&#160;</td>

    <td style="width: 90%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">10.16</div>
          </td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="https://www.sec.gov/Archives/edgar/data/1133416/000114036122026910/brhc10039901_ex10-3.htm">Employment Agreement Amendment of Joel Lewis. (Incorporated by reference to exhibit 10.3 the Company&#8217;s Current Report on Form 8-K as filed
                with the Commission on July 26, 2022.)</a></div>
          </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">&#160;</td>

    <td style="width: 90%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">10.17</div>
          </td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="https://www.sec.gov/Archives/edgar/data/1133416/000114036122026910/brhc10039901_ex10-4.htm">2023 Deferred Stock Unit Agreement. (Incorporated by reference to exhibit 10.4 the Company&#8217;s Current Report on Form 8-K as filed with the
                Commission on July 26, 2022.)</a></div>
          </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">&#160;</td>

    <td style="width: 90%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">10.18</div>
          </td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="https://www.sec.gov/Archives/edgar/data/1133416/000114036122026910/brhc10039901_ex10-5.htm">2020 Deferred Stock Unit Amendment. (Incorporated by reference to exhibit 10.5 the Company&#8217;s Current Report on Form 8-K as filed with the
                Commission on July 26, 2022.)</a></div>
          </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">&#160;</td>

    <td style="width: 90%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">10.19</div>
          </td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="https://www.sec.gov/Archives/edgar/data/1133416/000114036124016452/ef20015363_ex10-19.htm">Supplemental Line of Credit Agreement, dated as of March 29, 2024, by and between Richard E. Uihlein and the Company.&#160;(incorporated by
                reference to Exhibit 10.19 to the Company&#8217;s Annual Report on form 10-K for the year ended December 31, 2023, as filed on March 29, 2024)</a></div>
          </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">&#160;</td>

    <td style="width: 90%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">10.20</div>
          </td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="https://www.sec.gov/Archives/edgar/data/1133416/000114036124016452/ef20015363_ex10-20.htm">Form of Convertible Promissory Note issued to Richard E. Uihlein&#160;(incorporated by reference to Exhibit 10.20 to the Company&#8217;s Annual Report
                on form 10-K for the year ended December 31, 2023, as filed on March 29, 2024)</a></div>
          </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 90%; vertical-align: top;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);" rowspan="1">10.20</td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);" rowspan="1"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001133416/000114036124016452/ef20015363_10k.htm">Supplemental Line of Credit Agreement, dated
              as of March 29, 2024, by and between Richard E. Uihlein and the Company.&#160;(incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on form 10-Q for the nine months ended September 30, 2024, as filed on November 14, 2024)</a></td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 90%; vertical-align: top;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);" rowspan="1">
            <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">10.21*</div>
          </td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);" rowspan="1">
            <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><a href="ef20039001_ex10-21.htm">Supplemental Line of
                Credit Agreement, dated as of March 31, 2025, by and between Richard E. Uihlein and the Company.&#160;(incorporated by reference to Exhibit 10.21 to the Company&#8217;s Annual Report on form 10-K for the year ended December 31, 2024, as filed on March
                31, 2025)</a></div>
          </td>

  </tr>


</table>
    <div><br/>
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">45</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div>
          <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

          </div>

        </div>

      </div>

    </div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 10%; vertical-align: bottom;">
            <div style="text-align: center; color: #000000; font-weight: bold;">Exhibit</div>
            <div style="text-align: center; color: #000000; font-weight: bold;">Number</div>
          </td>

    <td style="width: 90%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Description of Document</div>
          </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: bottom;">&#160;</td>

    <td style="width: 90%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">19*</div>
          </td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="ef20039001_ex19.htm">Insider Trading Policy</a></div>
          </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: bottom;">&#160;</td>

    <td style="width: 90%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">21.1</div>
          </td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="ef20039001_ex21-1.htm">Subsidiaries of Galectin Therapeutics Inc.</a></div>
          </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">&#160;</td>

    <td style="width: 90%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">23.1*</div>
          </td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="ef20039001_ex23-1.htm">Consent of Cherry Bekaert LLP, an independent registered public accounting firm.</a></div>
          </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">&#160;</td>

    <td style="width: 90%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">31.1*</div>
          </td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="ef20039001_ex31-1.htm">Certification Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934.</a></div>
          </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">&#160;</td>

    <td style="width: 90%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">31.2*</div>
          </td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="ef20039001_ex31-2.htm">Certification Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934.</a></div>
          </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">&#160;</td>

    <td style="width: 90%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">32.1#</div>
          </td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="ef20039001_ex32-1.htm">Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of
                2002.</a></div>
          </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">&#160;</td>

    <td style="width: 90%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">32.2#</div>
          </td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="ef20039001_ex32-2.htm">Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of
                2002.</a></div>
          </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">&#160;</td>

    <td style="width: 90%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">97*</div>
          </td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Executive Compensation Clawback Policy</div>
          </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">&#160;</td>

    <td style="width: 90%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">101.INS</div>
          </td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</div>
          </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">&#160;</td>

    <td style="width: 90%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">101.SCH</div>
          </td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">Inline XBRL Taxonomy Extension Schema Document</div>
          </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">&#160;</td>

    <td style="width: 90%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">101.CAL</div>
          </td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">Inline XBRL Taxonomy Extension Calculation Linkbase Document</div>
          </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">&#160;</td>

    <td style="width: 90%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">101.DEF</div>
          </td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">Inline XBRL Taxonomy Extension Definition Linkbase Document</div>
          </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">&#160;</td>

    <td style="width: 90%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">101.LAB</div>
          </td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">Inline XBRL Taxonomy Extension Label Linkbase Document</div>
          </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">&#160;</td>

    <td style="width: 90%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">101.PRE</div>
          </td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">Inline XBRL Taxonomy Extension Presentation Linkbase Document</div>
          </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">&#160;</td>

    <td style="width: 90%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">104</div>
          </td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">The cover page for the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, has been formatted in Inline XBRL and contained in Exhibit 101</div>
          </td>

  </tr>


</table>
    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 27pt; vertical-align: top; color: #000000;">*</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">Filed herewith.</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 27pt; vertical-align: top; color: #000000;">#</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">Furnished herewith and not &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0);">***</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">Galectin Therapeutics, Inc. has requested confidential treatment with respect to portions of this exhibit. Those portions have been omitted from the exhibit and filed separately with the U.S. Securities and
              Exchange Commission.</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 27pt; vertical-align: top; color: #000000;">&#8224;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">Executive Compensation Arrangement pursuant to 601(b)(10)(iii)(A) of Regulation S-K</div>
          </td>

  </tr>


</table>
    <div><br/>
    </div>

    <div>
      <div>
        <a id="Item16."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="text-align: right; vertical-align: top; width: 54pt;">
                <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">Item 16.</div>
              </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                <div style="color: rgb(0, 0, 0); font-weight: bold;">Form 10&#8211;K Summary</div>
              </td>

  </tr>


</table>
      </div>

    </div>

    <div><br/>
    </div>

    <div style="color: #000000;">None</div>

    <div><br/>
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">46</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div>
          <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

          </div>

        </div>

      </div>

    </div>

    <div style="text-align: center; color: #000000; font-weight: bold;"><a id="SIGNATURES"><!--Anchor--></a>SIGNATURES</div>

    <div><br/>
    </div>

    <div style="color: #000000;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on March 31,
      2025.</div>

    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 49.96%; vertical-align: middle;">&#160;</td>

    <td style="width: 50.04%; vertical-align: middle;" colspan="2">
            <div style="color: rgb(0, 0, 0);">GALECTIN THERAPEUTICS INC.</div>
          </td>

  </tr>

  <tr>

    <td style="width: 49.96%; vertical-align: middle;">&#160;</td>

    <td style="width: 3.09%; vertical-align: middle;">
            <div style="color: rgb(0, 0, 0);">By:</div>
          </td>

    <td style="width: 46.96%; vertical-align: middle; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="color: rgb(0, 0, 0);">/S/ JOEL LEWIS</div>
          </td>

  </tr>

  <tr>

    <td style="width: 49.96%; vertical-align: middle;">&#160;</td>

    <td style="width: 3.09%; vertical-align: middle;">&#160;</td>

    <td style="width: 46.96%; vertical-align: middle;">
            <div style="color: rgb(0, 0, 0);">Name: JOEL LEWIS.</div>
          </td>

  </tr>

  <tr>

    <td style="width: 49.96%; vertical-align: middle;">&#160;</td>

    <td style="width: 3.09%; vertical-align: middle;">&#160;</td>

    <td style="width: 46.96%; vertical-align: middle;">
            <div style="color: rgb(0, 0, 0);">Title: Chief Executive Officer and President</div>
          </td>

  </tr>


</table>
    <div><br/>
    </div>

    <div style="color: #000000;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</div>

    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 40.99%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Signature</div>
          </td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 41%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="color: rgb(0, 0, 0); font-weight: bold;">Title</div>
          </td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 16%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="color: rgb(0, 0, 0); font-weight: bold;">Date</div>
          </td>

  </tr>

  <tr>

    <td style="width: 40.99%; vertical-align: top;">&#160;</td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 41%; vertical-align: bottom;">&#160;</td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 16%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 40.99%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="color: rgb(0, 0, 0);">/S/ JOEL LEWIS</div>
          </td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 41%; vertical-align: bottom;">
            <div style="color: rgb(0, 0, 0);">Chief Executive Officer, President and Director</div>
          </td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 16%; vertical-align: bottom;">
            <div style="color: rgb(0, 0, 0);">March 31, 2025</div>
          </td>

  </tr>

  <tr>

    <td style="width: 40.99%; vertical-align: top;">
            <div style="color: rgb(0, 0, 0);">Joel Lewis</div>
          </td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 41%; vertical-align: bottom;">
            <div style="color: rgb(0, 0, 0);">(principal executive officer)</div>
          </td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 16%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 40.99%; vertical-align: top;">&#160;</td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 41%; vertical-align: bottom;">&#160;</td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 16%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 40.99%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="color: rgb(0, 0, 0);">/S/ JACK W. CALLICUTT</div>
          </td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 41%; vertical-align: bottom;">
            <div style="color: rgb(0, 0, 0);">Chief Financial Officer</div>
          </td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 16%; vertical-align: bottom;">
            <div style="color: rgb(0, 0, 0);">March 31, 2025</div>
          </td>

  </tr>

  <tr>

    <td style="width: 40.99%; vertical-align: top;">
            <div style="color: rgb(0, 0, 0);">Jack W. Callicutt</div>
          </td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 41%; vertical-align: bottom;">
            <div style="color: rgb(0, 0, 0);">(principal financial and accounting officer)</div>
          </td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 16%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 40.99%; vertical-align: top;">&#160;</td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 41%; vertical-align: bottom;">&#160;</td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 16%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 40.99%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="color: rgb(0, 0, 0);">/S/ RICHARD E. UIHLEIN</div>
          </td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 41%; vertical-align: bottom;">
            <div style="color: rgb(0, 0, 0);">Director and Chairman of the Board</div>
          </td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 16%; vertical-align: bottom;">
            <div style="color: rgb(0, 0, 0);">March 31, 2025</div>
          </td>

  </tr>

  <tr>

    <td style="width: 40.99%; vertical-align: top;">
            <div style="color: rgb(0, 0, 0);">Richard E. Uihlein</div>
          </td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 41%; vertical-align: bottom;">&#160;</td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 16%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 40.99%; vertical-align: top;">&#160;</td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 41%; vertical-align: bottom;">&#160;</td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 16%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 40.99%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="color: rgb(0, 0, 0);">/S/ GILBERT F. AMELIO, Ph.D.</div>
          </td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 41%; vertical-align: bottom;">
            <div style="color: rgb(0, 0, 0);">Director</div>
          </td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 16%; vertical-align: bottom;">
            <div style="color: rgb(0, 0, 0);">March 31, 2025</div>
          </td>

  </tr>

  <tr>

    <td style="width: 40.99%; vertical-align: top;">
            <div style="color: rgb(0, 0, 0);">Gilbert F. Amelio, Ph.D.</div>
          </td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 41%; vertical-align: bottom;">&#160;</td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 16%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 40.99%; vertical-align: top;">&#160;</td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 41%; vertical-align: bottom;">&#160;</td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 16%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 40.99%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="color: rgb(0, 0, 0);">/S/ BENJAMIN S. CARSON, SR., M.D.</div>
          </td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 41%; vertical-align: bottom;">
            <div style="color: rgb(0, 0, 0);">Director</div>
          </td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 16%; vertical-align: bottom;">
            <div style="color: rgb(0, 0, 0);">March 31, 2025</div>
          </td>

  </tr>

  <tr>

    <td style="width: 40.99%; vertical-align: top;">
            <div style="color: rgb(0, 0, 0);">Benjamin S. Carson, Sr., M.D.</div>
          </td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 41%; vertical-align: bottom;">&#160;</td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 16%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 40.99%; vertical-align: top;">&#160;</td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 41%; vertical-align: bottom;">&#160;</td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 16%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 40.99%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="color: rgb(0, 0, 0);">/S/ KARY ELDRED</div>
          </td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 41%; vertical-align: bottom;">
            <div style="color: rgb(0, 0, 0);">Director</div>
          </td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 16%; vertical-align: bottom;">
            <div style="color: rgb(0, 0, 0);">March 31, 2025</div>
          </td>

  </tr>

  <tr>

    <td style="width: 40.99%; vertical-align: top;">
            <div style="color: rgb(0, 0, 0);">Kary Eldred</div>
          </td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 41%; vertical-align: bottom;">&#160;</td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 16%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 40.99%; vertical-align: top;">&#160;</td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 41%; vertical-align: bottom;">&#160;</td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 16%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 40.99%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="color: rgb(0, 0, 0);">/S/ KEVIN D. FREEMAN</div>
          </td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 41%; vertical-align: bottom;">
            <div style="color: rgb(0, 0, 0);">Director</div>
          </td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 16%; vertical-align: bottom;">
            <div style="color: rgb(0, 0, 0);">March 31, 2025</div>
          </td>

  </tr>

  <tr>

    <td style="width: 40.99%; vertical-align: top;">
            <div style="color: rgb(0, 0, 0);">Kevin D. Freeman</div>
          </td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 41%; vertical-align: bottom;">&#160;</td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 16%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 40.99%; vertical-align: top;">&#160;</td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 41%; vertical-align: bottom;">&#160;</td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 16%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 40.99%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="color: rgb(0, 0, 0);">/S/ GILBERT S. OMENN, M.D., Ph.D.</div>
          </td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 41%; vertical-align: bottom;">
            <div style="color: rgb(0, 0, 0);">Director</div>
          </td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 16%; vertical-align: bottom;">
            <div style="color: rgb(0, 0, 0);">March 31, 2025</div>
          </td>

  </tr>

  <tr>

    <td style="width: 40.99%; vertical-align: top;">
            <div style="color: rgb(0, 0, 0);">Gilbert S. Omenn, M.D., Ph.D.</div>
          </td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 41%; vertical-align: bottom;">&#160;</td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 16%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 40.99%; vertical-align: top;">&#160;</td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 41%; vertical-align: bottom;">&#160;</td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 16%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 40.99%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="color: rgb(0, 0, 0);">/S/ MARC RUBIN, M.D.</div>
          </td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 41%; vertical-align: bottom;">
            <div style="color: rgb(0, 0, 0);">Director</div>
          </td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 16%; vertical-align: bottom;">
            <div style="color: rgb(0, 0, 0);">March 31, 2025</div>
          </td>

  </tr>

  <tr>

    <td style="width: 40.99%; vertical-align: top;">
            <div style="color: rgb(0, 0, 0);">Marc Rubin, M.D.</div>
          </td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 41%; vertical-align: bottom;">&#160;</td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 16%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 40.99%; vertical-align: top;">&#160;</td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 41%; vertical-align: bottom;">&#160;</td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 16%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 40.99%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="color: rgb(0, 0, 0);">/S/ ELISSA J. SCHWARTZ, Ph.D.</div>
          </td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 41%; vertical-align: bottom;">
            <div style="color: rgb(0, 0, 0);">Director</div>
          </td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 16%; vertical-align: bottom;">
            <div style="color: rgb(0, 0, 0);">March 31, 2025</div>
          </td>

  </tr>

  <tr>

    <td style="width: 40.99%; vertical-align: top;">
            <div style="color: rgb(0, 0, 0);">Elissa J. Schwartz, Ph.D.</div>
          </td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 41%; vertical-align: bottom;">&#160;</td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 16%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 40.99%; vertical-align: top;">&#160;</td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 41%; vertical-align: bottom;">&#160;</td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 16%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 40.99%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="color: rgb(0, 0, 0);">/S/ HAROLD H. SHLEVIN, Ph.D.</div>
          </td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 41%; vertical-align: bottom;">
            <div style="color: rgb(0, 0, 0);">Director</div>
          </td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 16%; vertical-align: bottom;">
            <div style="color: rgb(0, 0, 0);">March 31, 2025</div>
          </td>

  </tr>

  <tr>

    <td style="width: 40.99%; vertical-align: top;">
            <div style="color: rgb(0, 0, 0);">Harold H. Shlevin, Ph.D.</div>
          </td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 41%; vertical-align: bottom;">&#160;</td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 16%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 40.99%; vertical-align: top;">&#160;</td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 41%; vertical-align: bottom;">&#160;</td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 16%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 40.99%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="color: rgb(0, 0, 0);">/S/ RICHARD A. ZORDANI</div>
          </td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 41%; vertical-align: bottom;">
            <div style="color: rgb(0, 0, 0);">Director</div>
          </td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 16%; vertical-align: bottom;">
            <div style="color: rgb(0, 0, 0);">March 31, 2025</div>
          </td>

  </tr>

  <tr>

    <td style="width: 40.99%; vertical-align: top;">
            <div style="color: rgb(0, 0, 0);">Richard A. Zordani</div>
          </td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 41%; vertical-align: bottom;">&#160;</td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 16%; vertical-align: bottom;">&#160;</td>

  </tr>


</table>
    <div><br/>
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">47</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div>
          <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

          </div>

        </div>

      </div>

    </div>

    <!--PROfilePageNumberReset%Num%48%%%--> </div>

</div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">

    <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Galectin Therapeutics Inc. and subsidiaries</div>

    <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Table of Contents</div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 5%; vertical-align: middle;" colspan="1">&#160;</td>

    <td style="width: 90%; vertical-align: middle;">&#160;</td>

    <td style="width: 5%; vertical-align: middle;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);" colspan="1">1.</td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-indent: -12pt; margin-left: 12pt; color: rgb(0, 0, 0);"><a href="#Report">Reports of Independent Registered Public Accounting Firm</a> (PCAOB ID <span style="text-indent: 0pt;"><span style="-sec-ix-hidden:Fact_8aa86162ab1a4132867b6ccb28da17b8">677</span></span>)<br/>
            </div>
          </td>

    <td style="width: 5%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
            <div style="text-align: right;">F-1</div>
          </td>

  </tr>

  <tr>

    <td style="width: 5%; vertical-align: top;" colspan="1">2.</td>

    <td style="width: 90%; vertical-align: top;">
            <div style="text-indent: -12pt; margin-left: 12pt; color: rgb(0, 0, 0);"><a href="#BALANCESHEETS">Consolidated Balance Sheets as of December 31, 2024 and 2023</a><br/>
            </div>
          </td>

    <td style="width: 5%; vertical-align: bottom; white-space: nowrap;">
            <div style="text-align: right;">F-3</div>
          </td>

  </tr>

  <tr>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);" colspan="1">3.</td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-indent: -12pt; margin-left: 12pt; color: rgb(0, 0, 0);"><a href="#OPERATIONS">Consolidated Statements of Operations for the years ended December 31, 2024 and 2023</a><br/>
            </div>
          </td>

    <td style="width: 5%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
            <div style="text-align: right;">F-4</div>
          </td>

  </tr>

  <tr>

    <td style="width: 5%; vertical-align: top;" colspan="1">4.</td>

    <td style="width: 90%; vertical-align: top; white-space: nowrap;">
            <div style="text-indent: -12pt; margin-left: 12pt; color: rgb(0, 0, 0);"><a href="#A2024and202">Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit) for the years ended December 31,
                2024 and 2023</a><br/>
            </div>
          </td>

    <td style="width: 5%; vertical-align: bottom; white-space: nowrap;">
            <div style="text-align: right;">F-5</div>
          </td>

  </tr>

  <tr>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);" colspan="1">5.</td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-indent: -12pt; margin-left: 12pt; color: rgb(0, 0, 0);"><a href="#CASHFLOWS">Consolidated Statements of Cash Flows for the years ended December 31, 2024 and 2023</a><br/>
            </div>
          </td>

    <td style="width: 5%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
            <div style="text-align: right;">F-7</div>
          </td>

  </tr>

  <tr>

    <td style="width: 5%; vertical-align: top;" colspan="1">6.</td>

    <td style="width: 90%; vertical-align: top;">
            <div style="text-indent: -12pt; margin-left: 12pt; color: rgb(0, 0, 0);"><a href="#NOTES">Notes to Consolidated Financial Statements</a></div>
          </td>

    <td style="width: 5%; vertical-align: bottom; white-space: nowrap;">
            <div style="text-align: right;">F-8</div>
          </td>

  </tr>


</table>
    <div><br/></div>

    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">48</span></div>

      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

      <div class="BRPFPageHeader" style="width: 100%;">
        <div>
          <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

          </div>

        </div>

      </div>

    </div>

    <!--PROfilePageNumberReset%Num%1%F-%%-->
  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
   <div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><!--Anchor--><a id="Report"><!--Anchor--></a>Report of Independent Registered Public Accounting Firm</div>

      <div><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </span></div>

      <div style="text-align: justify;">
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">To the Board of Directors and Stockholders</div>

        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Galectin Therapeutics Inc. and Subsidiaries</div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;">
          <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Opinion on the Consolidated Financial Statements</div>

          <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">We have audited the accompanying consolidated balance sheets of Galectin Therapeutics Inc. and Subsidiaries (the &#8220;Company&#8221;) as of December 31, 2024 and 2023, and
            the related consolidated statements of operations, changes in redeemable convertible preferred stock and stockholders&#8217; equity (deficit), and cash flows for each of the years then ended, and the related notes (collectively referred to as the
            &#8220;consolidated financial statements&#8221;).</div>

          <div><br/>
          </div>

          <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of
            December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the years then ended, in conformity with accounting principles generally accepted in the United States of America.</div>

          <div><br/>
          </div>

          <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Going Concern Uncertainty</div>

          <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the
            consolidated financial statements, the Company has suffered recurring losses from operations and negative cash flows from operations. These conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern.
            Management&#8217;s plans concerning these matters are described in Note 1 to the consolidated financial statements. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</div>

          <div><br/>
          </div>

          <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Basis for Opinion</div>

          <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s
            consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in
            accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</div>

          <div><br/>
          </div>

          <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance
            about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial
            reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial
            reporting. Accordingly, we express no such opinion.</div>

          <div><br/>
          </div>

          <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial
            statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our
            audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe our audits provide a reasonable
            basis for our opinions.</div>

          <div><br/>
          </div>

          <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Critical Audit Matters</div>

          <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that
            was communicated or required to be communicated to the audit committee and that: (1)&#160;relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or
            complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing
            separate opinions on the critical audit matter or on the accounts or disclosures to which it relates.</div>

        </div>

        <div><br/></div>

      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">F-1</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div>
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

            </div>

          </div>

        </div>

      </div>

      <div style="text-align: justify;">
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 16%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" rowspan="3">
                <div style="text-align: left; font-style: italic;">Description of Matter</div>
              </td>

    <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
                <div style="text-align: left;">&#160;</div>
              </td>

    <td style="width: 82%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" colspan="2">
                <div style="text-align: justify; font-style: italic; font-weight: bold;">
                  <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Accrued and Prepaid Clinical Trial Expenses</div>
                </div>
              </td>

  </tr>

  <tr>

    <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
                <div style="text-align: left;">&#160;</div>
              </td>

    <td style="width: 82%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" colspan="2">
                <div style="text-align: left;">&#160;</div>
              </td>

  </tr>

  <tr>

    <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
                <div style="text-align: left;">&#160;</div>
              </td>

    <td style="width: 82%; vertical-align: top;" colspan="2">
                <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">
                  <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The Company&#8217;s accrued expenses total approximately $8.2 million at December 31, 2024, which included the estimated obligation for clinical trial expenses
                    incurred as of December&#160;31, 2024, but not paid as of that date in the amount of approximately $6.6 million. In addition, the Company&#8217;s total prepaid expenses and other current assets totaled $2.1&#160;million, which included amounts that
                    were paid in advance of services incurred pursuant to clinical trials in the amount of approximately $1.1&#160;million.</div>
                  <div>&#160;</div>
                  <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">As discussed in Note 2 to the consolidated financial statements, when the third party contract research organization and other vendor billing terms do not
                    coincide with the Company&#8217;s period-end, the Company is required to make estimates of its obligations to those vendors, including personnel costs, allocated facility costs, lab supplies, outside services, contract laboratory costs
                    related to manufacturing drug product, clinical trials, and preclinical studies costs incurred in a given accounting period and record accruals at the end of the period. The Company bases its estimates on its knowledge of the research
                    and development programs, services performed for the period, past history for related activities, and the expected duration of the vendor service contract, where applicable. Payments for these activities are based on the terms of the
                    individual arrangements and may result in payment terms that differ from the pattern of costs incurred. There may be instances in which payments made to vendors will exceed the level of services provided and result in a prepayment of
                    the clinical expense.</div>
                  <div>&#160;</div>
                  <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Auditing the Company&#8217;s accrued and prepaid clinical trial expenses is especially challenging due to the large volume of information
                    received from multiple vendors that perform services on the Company&#8217;s behalf. While the Company&#8217;s estimates of accrued and prepaid clinical trial expenses are primarily based on information received related to each study from its
                    vendors, the Company may need to make an estimate for additional costs incurred. Additionally, due to the long duration of clinical trials and the timing of invoicing received from vendors, the actual amounts incurred are not typically
                    known at the time the financial statements are issued.</div>
                </div>
              </td>

  </tr>

  <tr>

    <td style="width: 16%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
                <div style="text-align: left;">&#160;</div>
              </td>

    <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
                <div style="text-align: left;">&#160;</div>
              </td>

    <td style="width: 82%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" colspan="2">
                <div style="text-align: left;">&#160;</div>
              </td>

  </tr>

  <tr>

    <td style="width: 16%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" rowspan="5">
                <div style="text-align: left; font-style: italic;">How We Addressed the Matter in Our Audit</div>
              </td>

    <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
                <div style="text-align: left;">&#160;</div>
              </td>

    <td style="width: 82%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" colspan="2">
                <div style="text-align: justify;">
                  <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Our audit procedures included, among others, the following:</div>
                </div>
              </td>

  </tr>

  <tr>

    <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
                <div style="text-align: left;">&#160;</div>
              </td>

    <td style="width: 5%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
                <div style="text-align: left;">&#160;</div>
              </td>

    <td style="width: 77%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
                <div style="text-align: left;">&#160;</div>
              </td>

  </tr>

  <tr>

    <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
                <div style="text-align: left;">&#160;</div>
              </td>

    <td style="width: 5%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>

    <td style="width: 77%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
                <div style="text-align: justify;">
                  <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman';">Obtained</span> an understanding of the internal controls and processes
                    in place over the Company&#8217;s<span style="font-size: 10pt; font-family: 'Times New Roman';"> process used in determining the completeness and existence of accrued and prepaid clinical trial expenses.</span></div>
                </div>
              </td>

  </tr>

  <tr>

    <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
                <div style="text-align: left;">&#160;</div>
              </td>

    <td style="width: 5%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
                <div style="text-align: left;">&#160;</div>
              </td>

    <td style="width: 77%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
                <div style="text-align: left;">&#160;</div>
              </td>

  </tr>

  <tr>

    <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
                <div style="text-align: left;">&#160;</div>
              </td>

    <td style="width: 5%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>

    <td style="width: 77%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
                <div style="text-align: justify;">
                  <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Tested the accuracy and completeness of the underlying data used in determining the accrued and prepaid clinical trial expenses and
                    evaluating the assumptions and estimates used by management to adjust the actual information received. We corroborated the schedules of the underlying data used in the accrual calculation with the Company&#8217;s third party contract research
                    organization who oversees the clinical trials. To evaluate the completeness of the accrual, we also tested subsequent invoices received to assess the impact to the accrual.</div>
                </div>
              </td>

  </tr>


</table>
        <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">We have served as the Company&#8217;s auditor since 2015.</div>

        <div style="text-align: justify;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</span><br/>
        </div>

        <div><span style="font-family: 'Times New Roman'; font-size: 10pt;">/s/ <span style="font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"><span style="font-style: normal;"><ix:nonNumeric name="dei:AuditorName" id="Fact_901026108d70446cb6a2d7a5ab388d9a" contextRef="c20240101to20241231">Cherry Bekaert LLP</ix:nonNumeric></span></span><br/>
          <br/>
          <ix:nonNumeric name="dei:AuditorLocation" id="Fact_fc0377fc4feb48dea7e2d988c4739741" contextRef="c20240101to20241231">Atlanta, Georgia</ix:nonNumeric><br/>
          March 31, 2025<br/>
        </span></div>
</div>

    </div>

    <div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </span></div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">F-2</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div>
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

            </div>

          </div>

        </div>

      </div>

    </div>

    <div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>

  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">

    <div>
      <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">GALECTIN THERAPEUTICS INC. AND SUBSIDIARIES</div>

      <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">CONSOLIDATED <a id="BALANCESHEETS"><!--Anchor--></a>BALANCE SHEETS<!--Anchor--></div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="6">
              <div style="text-align: center; font-weight: bold;">December 31,</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; font-weight: bold;">2024<br/>
              </div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; font-weight: bold;">2023<br/>
              </div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="6">
              <div style="text-align: center; font-weight: bold;">(in thousands, except per share </div>
              <div style="text-align: center; font-weight: bold;">amounts)</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">ASSETS</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="6">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Current assets:</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Cash and cash equivalents</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" id="Fact_bbca9e4a9ee94045a1b3d57cc99ac39c" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,120</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" id="Fact_cd78e6af80e44c1c9bc4e9b5517e5f91" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">25,660</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
              <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Prepaid expenses and other current assets</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" id="Fact_4c65d4385b7c4217a3f492cfff23ae3a" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,132</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" id="Fact_77fd02ab7d424de4b34c4096b176aceb" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,050</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Total current assets</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:AssetsCurrent" id="Fact_1576b3cff5fb4d54a475fdce8e724783" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">17,252</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:AssetsCurrent" id="Fact_43ca7f4e57634d5383232c31c02f3848" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">27,710</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Property and equipment, net</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" id="Fact_bffe5b1ce0ab4e5a909b42c22780024f" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" id="Fact_fa6dd7cac03b4114be09ff4d0c38dec3" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Other</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" id="Fact_497c39140ad345fa82f8de407a0c08de" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">243</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" id="Fact_5675bb4cad404edcad20cdd5ddcdb93a" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">490</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px;">
              <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Total assets</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:Assets" id="Fact_88c758354ccf4fef83505a018c2f0ed0" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">17,495</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:Assets" id="Fact_885a1d27eea24105bb05dfac97350eb2" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">28,200</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)<br/>
              </div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Current liabilities:</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Accounts payable</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:AccountsPayableCurrent" id="Fact_ddd9c3d55edb4e6f815a5260cdf498ed" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,656</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:AccountsPayableCurrent" id="Fact_04ca153660d4427e83e4343c04e71791" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,431</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
              <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Accrued expenses</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" id="Fact_7198922d3f0d43708a6967569de22f21" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,204</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" id="Fact_18f3f8f8bd2c4f828adc74491c226d86" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,182</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;" rowspan="1">
              <div style="margin-left: 9pt;">Current portion of convertible notes payable and accrued interest, net of debt discounts &#8211; related party (Note 5)<br/>
              </div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="galt:ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyCurrent" id="Fact_982d13b386654698a996f80b90339db3" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">21,117</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="galt:ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyCurrent" id="Fact_a965e3ea878d43c9879164f6c484afc7" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;" rowspan="1">
              <div style="margin-left: 9pt;">Current portion of derivative liabilities (Note 6)<br/>
              </div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" id="Fact_7933d7fa11d74009b9137b8217447020" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">369</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" id="Fact_5469c02469f4437ab8812e10d59badee" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Accrued dividends payable</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:DividendsPayableCurrent" id="Fact_0b2a760b84364a7a8a490208fe743549" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">63</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:DividendsPayableCurrent" id="Fact_dee0d8e202754f529c69ce08b79abd5b" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">63</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
              <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Total current liabilities</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:LiabilitiesCurrent" id="Fact_aef721c9a6584cddac579602c463f775" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">35,409</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:LiabilitiesCurrent" id="Fact_ff1d4830a1ce490a9bef12e2bd52f090" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,676</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Convertible notes payable and accrued interest, net of debt discounts &#8211; related party (Note 5)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="galt:ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent" id="Fact_3b21ee8e01d14a0c9d84995d050d74e5" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,733</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="galt:ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent" id="Fact_3282f47d80c94d4c91728230f2d2d23c" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">30,902</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
              <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Derivative liabilities (Note 6)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" id="Fact_1b28fec860e94ab69fff62381d387edf" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">47</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" id="Fact_60f5420e19f84873a6d755a8d72b2f99" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,004</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;" rowspan="1">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -18pt; margin-left: 18pt;">&#160;&#160;&#160; Borrowing and accrued interest under convertible line of credit, net of debt discount &#8211; related party (Note 10)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="galt:BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent" id="Fact_02b53b63f3af45edabf1f7a488504fc8" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">74,376</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="galt:BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent" id="Fact_77bd1182e43642b2b5ff1e2e6986a1de" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">40,839</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
              <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Other liabilities</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" id="Fact_cb594bdfa02c46538b17609f6a84d3d8" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" id="Fact_365546d0d7fc47498dbd9618394a14c9" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">20</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Total liabilities</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:Liabilities" id="Fact_f8b2211ecfd44328938316119df04c0f" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">120,565</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:Liabilities" id="Fact_f38a12ebb5734a93a0cc22d830a4fa4c" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">88,441</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Commitments and contingencies (Note 12)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" id="Fact_fff5fbc7fbf24f2dac3658bc72b91145" contextRef="c20241231" unitRef="U001" xsi:nil="true" format="ixt:fixed-empty"></ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" id="Fact_13b532b1af064425868750deae19da4d" contextRef="c20231231" unitRef="U001" xsi:nil="true" format="ixt:fixed-empty"></ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Series C 6% super dividend redeemable convertible preferred stock; <span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:TemporaryEquitySharesAuthorized" id="Fact_a6b80c15a58f48888fa994d92343b0bc" contextRef="c20231231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:TemporaryEquitySharesAuthorized" id="Fact_ae7a40d2cea84c0899acd9d8dee394a3" contextRef="c20241231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,000</ix:nonFraction></ix:nonFraction></span>
                shares authorized, <span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" id="Fact_142b696c418b481585ef3986e174fe72" contextRef="c20231231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" id="Fact_8b7d057252e1455380c977f85d38f644" contextRef="c20241231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" id="Fact_75058e81a86f41c18252dd1e0831d4a0" contextRef="c20231231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" id="Fact_1c5b94f5e7734b64bb9e35d5c28ee441" contextRef="c20241231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">176</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span> issued and outstanding at December 31, 2024 and 2023, redemption value: $<span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:TemporaryEquityAggregateAmountOfRedemptionRequirement" id="Fact_37805c8bc3d64de19446724331e8eb6b" contextRef="c20241231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">8,018,000</ix:nonFraction></span>, liquidation value: $<span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:TemporaryEquityLiquidationPreference" id="Fact_d3ffbdd803ed443292a2a5cbe3c3ad67" contextRef="c20241231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">1,760,000</ix:nonFraction></span>
                at December 31, 2024</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" id="Fact_1ef31a93785748fcbff533e50235f114" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,723</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" id="Fact_2a02a2161fdc4c44b23a7cdd3e96e92e" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,723</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Stockholders&#8217; equity (deficit):</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Undesignated stock, $<span style="text-indent: 0pt;"><ix:nonFraction name="galt:UndesignatedCapitalStockParValue" id="Fact_bd6d6bee829048a0ac65480a4105c591" contextRef="c20231231" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="galt:UndesignatedCapitalStockParValue" id="Fact_4977a342dc974770b077501cdeb4a06f" contextRef="c20241231" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">0.01</ix:nonFraction></ix:nonFraction></span> par value; <span style="text-indent: 0pt;"><ix:nonFraction name="galt:UndesignatedCapitalStockSharesAuthorized" id="Fact_42a7f1152bf94d03a3ca821c2ea48ee8" contextRef="c20231231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="galt:UndesignatedCapitalStockSharesAuthorized" id="Fact_9a6fe323594e4b088638118d810150e1" contextRef="c20241231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">20,000,000</ix:nonFraction></ix:nonFraction></span> shares authorized at December 31, 2024 and 2023, <span style="text-indent: 0pt;"><ix:nonFraction name="galt:UndesignatedCapitalStockSharesDesignated" id="Fact_bb49bd5d0ec64f51ab62e56d06d224da" contextRef="c20231231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="galt:UndesignatedCapitalStockSharesDesignated" id="Fact_ab604681a2b647abb26c38c48f148f87" contextRef="c20241231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">20,000,000</ix:nonFraction></ix:nonFraction></span> shares designated at December 31, 2024 and 2023, respectively</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="galt:UndesignatedCapitalStockValue" id="Fact_4924f7f276b1452184d94ee92b435427" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="galt:UndesignatedCapitalStockValue" id="Fact_98e3289c235d4c33bab0a3e64ce46529" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
              <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Series A 12% convertible preferred stock; <span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" id="Fact_0c8041630b12436dae0237398190c89d" contextRef="c20231231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" id="Fact_6aaf538e1dae41f984a96bdc2804ff4a" contextRef="c20241231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,742,500</ix:nonFraction></ix:nonFraction></span> shares authorized,
                <span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" id="Fact_a65882718f254f6f8618ddce54a58a8c" contextRef="c20241231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" id="Fact_6a9c5078cc494cfbb3daba52fdd9a056" contextRef="c20241231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,235,000</ix:nonFraction></ix:nonFraction></span> and <span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" id="Fact_484dcd99f8ef4c0a8b076da6e8a4287a" contextRef="c20231231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" id="Fact_360a8fda2d0e4b62b8d77c07ec32cfad" contextRef="c20231231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,235,000</ix:nonFraction></ix:nonFraction></span>
                issued and outstanding at December 31, 2024 and 2023, respectively, liquidation value $<span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:PreferredStockLiquidationPreferenceValue" id="Fact_7318283e140343bbb6823dd12ca10091" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,235,000</ix:nonFraction></span> at December 31, 2024</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:PreferredStockValue" id="Fact_62563c5aceb1491d87cc3c3dac37aa26" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">500</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:PreferredStockValue" id="Fact_313563c914b34c118f368ab06eae96c6" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">500</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Common stock, $<span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact_95b7426ec1544df5bb84d192c3ff410d" contextRef="c20231231" unitRef="U003" decimals="3" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact_ec67611e468e4149bf52d270d7c65614" contextRef="c20241231" unitRef="U003" decimals="3" scale="0" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span> par value; <span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" id="Fact_d25b7fc87d0c4bc499950bc8f2899a04" contextRef="c20241231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" id="Fact_6759c49cd8114b11953310e387f6b016" contextRef="c20231231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">150,000,000</ix:nonFraction></ix:nonFraction></span> shares authorized at December 31, 2024 and 2023, <span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" id="Fact_b2090e5612144a4f91754172bfc48860" contextRef="c20241231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" id="Fact_4011c44b62884958b8888c91ec932024" contextRef="c20241231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">63,157,235</ix:nonFraction></ix:nonFraction></span> and <span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" id="Fact_d3d1e3b12e4b4387aba22cf738dc2cd0" contextRef="c20231231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" id="Fact_a9f5c35c00fe4a0cadb7f3c906e31ecd" contextRef="c20231231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">61,852,914</ix:nonFraction></ix:nonFraction></span> issued and outstanding at December 31, 2024 and 2023,
                respectively</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:CommonStockValue" id="Fact_40b2da82d2c846f6baecaa21989eea2a" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">62</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:CommonStockValue" id="Fact_1be985dca9d54962bc927d3ecb4d1dac" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">61</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
              <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Additional paid-in capital</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" id="Fact_1e55a9f7daa94d2eb9face6dedbae45c" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">296,217</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" id="Fact_f5e7d8f294404b0699473fcb238c1747" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">291,847</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Accumulated deficit</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" id="Fact_358920cc6ea84fcda9afd39b3ebdb18f" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">401,572</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" id="Fact_56d738c77d6148668b8bf6f7de93b5be" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">354,372</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
              <div style="text-indent: -7.2pt; margin-left: 34.2pt;">Total stockholders&#8217; deficit<br/>
              </div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_305370a981e34253914babe9eedf1c6e" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">104,793</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_4e41920def004bcd8011d0f39fac11af" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">61,964</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Total liabilities, redeemable convertible preferred stock and stockholders&#8217; deficit<br/>
              </div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" id="Fact_097b0c69ec7e4542bffa879e41974a4e" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">17,495</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" id="Fact_54b1f80104884777b1173d20a4777fe6" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">28,200</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        See notes to consolidated financial statements.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">F-3</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

        <div style="width: 100%;" class="BRPFPageHeader">
          <div>
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

            </div>

          </div>

        </div>

      </div>

    </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">

    <div>
      <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">GALECTIN THERAPEUTICS INC. AND SUBSIDIARIES</div>

      <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">CONSOLIDATED STATEMENTS OF <a id="OPERATIONS"><!--Anchor--></a>OPERATIONS<!--Anchor--></div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="6">
              <div style="text-align: center; font-weight: bold;">Year Ended</div>
              <div style="text-align: center; font-weight: bold;">December 31,</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; font-weight: bold;"> 2024</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; font-weight: bold;">2023</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="6">
              <div style="text-align: center; font-weight: bold;">(in thousands, except</div>
              <div style="text-align: center; font-weight: bold;">per share amounts)</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Operating expenses:</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Research and development</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_c7e8bde7f8544a12a7651d0e8617eef9" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">36,571</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_73d3766bbdfd4ccc94527b4ed056b1cc" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">32,130</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
              <div style="text-indent: -7.2pt; margin-left: 16.2pt;">General and administrative</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" id="Fact_708f1f29ad664bc799b8cd5f369872d8" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,862</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" id="Fact_0103e2e8df6e449e86f0fbacc18c94bb" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,942</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Total operating expenses</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:OperatingExpenses" id="Fact_e84e796fe00c4cd18da7b60ff7439ed1" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">42,433</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:OperatingExpenses" id="Fact_56e43da523ac46329e6f1012b8cb01bf" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">38,072</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
              <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Total operating loss</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_fe7750176f83440fbf05029b10f16685" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">42,433</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_6e78d032a8094674ad40a950be5a6973" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">38,072</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Other income (expense):</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
              <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Interest income</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" id="Fact_319661290cfe4f5a8b25ff7f8fc2b031" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">338</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" id="Fact_ba5b66ff13a84069a4ea924716baf4d5" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">230</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Interest expense</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" id="Fact_119ebc778e4a4c3a8ccb01fbd9de95b8" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,540</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" id="Fact_c6b63b7dbae44a72ba197ad2a339f887" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,792</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
              <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Change in fair value of derivatives</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" id="Fact_334fb373b5d24970a2f6861cb96088d2" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">588</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" id="Fact_df6dec1129f74e7397aed70b100013b1" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">432</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 34.2pt;">Total other expense</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" id="Fact_3ba3ab21b0534fe1b40070455c912f9d" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">4,614</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" id="Fact_0adcbe74280448c9824b47ca74ecacf8" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,994</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Net loss</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_89ff8c69f7fe4a7c9d56dc5fb14e0d89" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">47,047</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_58c1ddfe88c5468fa46d1b79a74cca2c" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">41,066</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Preferred stock dividends</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="us-gaap:PreferredStockDividendsAndOtherAdjustments" id="Fact_ba4ac9d52d7b4d19a9ddb1512788bea6" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">153</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="us-gaap:PreferredStockDividendsAndOtherAdjustments" id="Fact_50a7a24246b34425b3a23afdbfd28c4d" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">120</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;" rowspan="1"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman', Times, serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">Warrant modification</span></td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="galt:FairValueAdjustmentOfWarrant" id="Fact_2c30dad60e854ab3a6b95ce386a94388" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" rowspan="1" colspan="1">(<ix:nonFraction name="galt:FairValueAdjustmentOfWarrant" id="Fact_9bf3db2c0a0d4f97adcf9a6ec7eaa5dd" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,619</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">)</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Net loss applicable to common stockholders</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" id="Fact_2f49fad7c5a849dabfab00fa2ace30c9" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">47,200</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" id="Fact_7c5ca9d4558049c3b2e8a7b142901bda" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">44,805</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Basic and diluted net loss per share</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="Fact_aaf0b80d115441a296d54e7ae8f4e88a" contextRef="c20240101to20241231" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_742dd2241498481da149fbd263314de2" contextRef="c20240101to20241231" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:num-dot-decimal">0.76</ix:nonFraction></ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="Fact_941b465d135a4e348d28242bdf11dc98" contextRef="c20230101to20231231" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_231d72b27d434d0e851bd47e049f1d78" contextRef="c20230101to20231231" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:num-dot-decimal">0.74</ix:nonFraction></ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Weighted average common and potential common shares outstanding basic and diluted</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Fact_dd1d17180cf1486789587fdff9364463" contextRef="c20240101to20241231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_ef8c8ef405014a59934833c645da0812" contextRef="c20240101to20241231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">62,309</ix:nonFraction></ix:nonFraction><br/>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Fact_459fb8f6c3b14ca4a3662af73b76fb53" contextRef="c20230101to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_fdd2c146ea0f4ef6ad779dc61d535609" contextRef="c20230101to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">60,159</ix:nonFraction></ix:nonFraction><br/>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">See notes to consolidated financial statements.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">F-4</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div>
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

            </div>

          </div>

        </div>

      </div>

    </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">

    <div>
      <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">GALECTIN THERAPEUTICS INC. AND SUBSIDIARIES</div>

      <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">CONSOLIDATED
        <!--Anchor-->STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</div>

      <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">For the Years Ended December 31, <a id="A2024and202"><!--Anchor--></a>2024 and 2023</div>

      <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">(amounts in thousands except share data)</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="6">
              <div style="text-align: center; font-weight: bold;">Series C Super</div>
              <div style="text-align: center; font-weight: bold;">Dividend Redeemable</div>
              <div style="text-align: center; font-weight: bold;">Convertible</div>
              <div style="text-align: center; font-weight: bold;">Preferred Stock</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
              <div style="text-align: center; font-weight: bold;">Number of</div>
              <div style="text-align: center; font-weight: bold;">Shares</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
              <div style="text-align: center; font-weight: bold;">Amount</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 2px;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Balance at January 1, 2023</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
              <div><span style="font-weight: bold;"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" id="Fact_57260f8149784c33a75d0826024e9db5" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">176</ix:nonFraction></span></div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
              <div><span style="font-weight: bold;">$</span></div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
              <div><span style="font-weight: bold;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" id="Fact_a65e9609ac4c43e894b8f6c01ac4bec5" contextRef="c20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,723</ix:nonFraction></span></div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Balance at December 31, 2023</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
              <div><span style="font-weight: bold;"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" id="Fact_8dded3da2fb94045890683f7ccced236" contextRef="c20231231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">176</ix:nonFraction></span></div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
              <div><span style="font-weight: bold;">$</span></div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
              <div><span style="font-weight: bold;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" id="Fact_ba2c6c20e0124d95bcc8d53e23824c45" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,723</ix:nonFraction></span></div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 4px;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Balance at December 31, 2024</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" colspan="1">
              <div><span style="font-weight: bold;"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" id="Fact_6702def6d03146c2b4bb37faa54a5cd0" contextRef="c20241231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">176</ix:nonFraction></span></div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" colspan="1">
              <div><span style="font-weight: bold;">$</span></div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" colspan="1">
              <div><span style="font-weight: bold;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" id="Fact_054b2693e9fd4ade867614d3344dd388" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,723</ix:nonFraction></span></div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">See notes to consolidated financial statements.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">F-5</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

        <div style="width: 100%;" class="BRPFPageHeader">
          <div>
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

            </div>

          </div>

        </div>

      </div>

      <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">GALECTIN THERAPEUTICS INC. AND SUBSIDIARIES</div>

      <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">CONSOLIDATED STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; EQUITY (DEFICIT) &#8212;&#160;&#160; (Continued)</div>

      <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">For the Years Ended December 31, 2024 and 2023</div>

      <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">(amounts in thousands except share data)</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="6">
              <div style="text-align: center; font-weight: bold;">Series A 12%</div>
              <div style="text-align: center; font-weight: bold;">Convertible</div>
              <div style="text-align: center; font-weight: bold;">Preferred Stock</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="6">
              <div style="text-align: center; font-weight: bold;">Common Stock</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; font-weight: bold;">Number of</div>
              <div style="text-align: center; font-weight: bold;">Shares</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; font-weight: bold;">Amount</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; font-weight: bold;">Number of</div>
              <div style="text-align: center; font-weight: bold;">Shares</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; font-weight: bold;">Amount</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; font-weight: bold;">Additional</div>
              <div style="text-align: center; font-weight: bold;">Paid-In</div>
              <div style="text-align: center; font-weight: bold;">Capital</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; font-weight: bold;">Retained</div>
              <div style="text-align: center; font-weight: bold;">Deficit</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; font-weight: bold;">Total</div>
              <div style="text-align: center; font-weight: bold;">Stockholders&#8217;</div>
              <div style="text-align: center; font-weight: bold;">Equity </div>
              <div style="text-align: center; font-weight: bold;">(Deficit)</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 16%; background-color: #CCEEFF;">
              <div style="text-indent: -12pt; margin-left: 12pt; font-weight: bold;">Balance at January 1, 2023</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;"><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_3c87f7d102cd49759256d5c94e47fdf1" contextRef="c20221231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,260,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><span style="font-weight: bold;">$</span></div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><span style="font-weight: bold;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_1deaaad821414238b346a03bf7e03626" contextRef="c20221231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">510</ix:nonFraction></span></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;"><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_4db1d1740c2a48f586e5474f1c49c416" contextRef="c20221231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">59,426,005</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">$</td>

    <td valign="bottom" style="font-weight: bold; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_be795687cb3c4136ba53a15d4573400f" contextRef="c20221231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">59</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_ab589d305254411981781407d3297bf4" contextRef="c20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">275,081</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;">(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_c5a85feee317465aacb47a8ceb700d8f" contextRef="c20221231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">309,567</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;">)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><span style="font-weight: bold;">$</span></div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><span style="font-weight: bold;">(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_d49412b136364a33a9c727e49a6475da" contextRef="c20221231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">33,917</ix:nonFraction></span></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><span style="font-weight: bold;">)</span></div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 16%;">
              <div style="text-indent: -12pt; margin-left: 12pt;">Series A 12% convertible preferred stock dividend&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="galt:ConvertiblePreferredStockDividendsShares" id="Fact_49ad3af2bc8c41279fe2587c9b3c61e4" contextRef="c20230101to20231231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">25,200</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="galt:ConvertiblePreferredStockDividends" id="Fact_753ada14bb544a218c4fc6864dd13194" contextRef="c20230101to20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">50</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="galt:ConvertiblePreferredStockDividends" id="Fact_ad9d8c731301437094f15acc4d6e5c61" contextRef="c20230101to20231231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">50</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 16%; background-color: #CCEEFF;">
              <div style="text-indent: -9pt; margin-left: 9pt;">Series C super dividend redeemable convertible preferred stock dividend&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1"><ix:nonFraction name="galt:TemporaryEquityDividendsShares" id="Fact_b6c8e4382d4a498f82534eb1cb13052d" contextRef="c20230101to20231231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">35,200</ix:nonFraction><br/>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="galt:TemporaryEquityDividends" id="Fact_89088549a1e64265baecebdeaee29680" contextRef="c20230101to20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">70</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="galt:TemporaryEquityDividends" id="Fact_7fb5df5d4ac3488aaf8cc17ab8eb7f26" contextRef="c20230101to20231231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">70</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 16%;" rowspan="1">
              <div style="margin-left: 9pt; text-indent: -9pt;">Conversion of Series A Convertible Preferred to common<br/>
              </div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" id="Fact_877f640437c7425a9efbd6be7da2afb5" contextRef="c20230101to20231231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">25,000</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" id="Fact_f827682236cb4dc8aba82a9abf7f3e38" contextRef="c20230101to20231231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">10</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" id="Fact_4e8436011f7947dabbad6d50263ce8c0" contextRef="c20230101to20231231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">4,257</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" id="Fact_0bd6f4f8aeb7402c863b546cf549edee" contextRef="c20230101to20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">10</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 16%; background-color: #CCEEFF;" rowspan="1">
              <div style="margin-left: 9pt; text-indent: -9pt;">Issuance of common stock from exercise of warrants<br/>
              </div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="galt:StockIssuedDuringPeriodSharesWarrantExercise" id="Fact_192f9e5309e1472f900922bccf242a56" contextRef="c20230101to20231231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,236,204</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="galt:StockIssuedDuringPeriodValueWarrantExercise" id="Fact_6bace7c72ee84b29af7ef11afa364503" contextRef="c20230101to20231231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="galt:StockIssuedDuringPeriodValueWarrantExercise" id="Fact_cfd4ab1fc3be416da6cc1f988216598c" contextRef="c20230101to20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,031</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="galt:StockIssuedDuringPeriodValueWarrantExercise" id="Fact_18dbae7aed2e429ca8eda5e38bc8883c" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,033</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 16%;" rowspan="1">
              <div style="margin-left: 9pt; text-indent: -9pt;">Issuance of common stock purchase warrants in connection with related party line of credit<br/>
              </div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" id="Fact_93c178a3da19438381b7af7e15659a2f" contextRef="c20230101to20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">671</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" id="Fact_099b618a1bd841ea9ce2718f23ce0d94" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">671</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 16%; background-color: #CCEEFF;" rowspan="1">Warrant modification<br/>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="galt:WarrantModificationIncreaseDecreaseInEquityAmount" id="Fact_69af7fbd6c56407e8cd5a59fa09d8499" contextRef="c20230101to20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,619</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">(<ix:nonFraction name="galt:WarrantModificationIncreaseDecreaseInEquityAmount" id="Fact_6b93044f4a0c48ff8cd19f14f3afb5a0" contextRef="c20230101to20231231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">3,619</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 16%;">
              <div style="text-indent: -12pt; margin-left: 12pt;">Stock-based compensation expense&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" id="Fact_b08b4ee9eebe416eb52ac8896c08bbae" contextRef="c20230101to20231231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">126,048</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_977262688b8f4253973c1cb301eaae14" contextRef="c20230101to20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,315</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_b365f87a01d14d2c8cb18a764c7af863" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,315</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 16%; background-color: #CCEEFF;">
              <div style="text-indent: -12pt; margin-left: 12pt;">Net loss&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_859aa4d02db34ceeb085bf425ca5793a" contextRef="c20230101to20231231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">41,066</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_6399920251fb422d8510e48e254bff73" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">41,066</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 16%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 16%; padding-bottom: 2px; background-color: #CCEEFF;">
              <div style="text-indent: -12pt; margin-left: 12pt; font-weight: bold;">Balance at December 31, 2023<br/>
              </div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;"><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_86e8156ee26a48879993dc0b64dfa2f6" contextRef="c20231231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,235,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><span style="font-weight: bold;">$</span></div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><span style="font-weight: bold;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_1d8507c954414b219b8fd07e7f7b7f4c" contextRef="c20231231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">500</ix:nonFraction></span></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;"><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_19781b40a526446fbc032408e3d86410" contextRef="c20231231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">61,852,914</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><span style="font-weight: bold;">$</span></div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><span style="font-weight: bold;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_0904471724734e2082930cd8f1d44871" contextRef="c20231231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">61</ix:nonFraction></span></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_56b7d9d9cdd14e69bf6e8f2f35ef32bf" contextRef="c20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">291,847</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;">(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_8d66303f374148f2a0cdb5939ea401d5" contextRef="c20231231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">354,372</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;">)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><span style="font-weight: bold;">$</span></div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><span style="font-weight: bold;">(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_ccc9c93ff99b4c57a5068c330917eebd" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">61,964</ix:nonFraction></span></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><span style="font-weight: bold;">)</span></div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 16%;">
              <div style="text-indent: -12pt; margin-left: 12pt;">Series A 12% convertible preferred stock dividend&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="galt:ConvertiblePreferredStockDividendsShares" id="Fact_586eaf6fa6ea4a27a4dabbf192b4f137" contextRef="c20240101to20241231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">24,700</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="galt:ConvertiblePreferredStockDividends" id="Fact_9551a7435ac24758a70ee6e66524bf93" contextRef="c20240101to20241231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">64</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="galt:ConvertiblePreferredStockDividends" id="Fact_c0cc495c1ee54383b03c43509276a1ca" contextRef="c20240101to20241231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">64</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 16%; background-color: #CCEEFF;">
              <div style="text-indent: -9pt; margin-left: 9pt;">Series C super dividend redeemable convertible preferred stock dividend&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="galt:TemporaryEquityDividendsShares" id="Fact_9d17e78d958a4bddaec7ff43781a2bff" contextRef="c20240101to20241231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">35,200</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="galt:TemporaryEquityDividends" id="Fact_bca485e916c940aa81821e4c35d0800d" contextRef="c20240101to20241231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">89</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="galt:TemporaryEquityDividends" id="Fact_b93dfabd25a64b278210a4fc3a2d5b55" contextRef="c20240101to20241231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">89</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 16%;" rowspan="1">
              <div style="margin-left: 9pt; text-indent: -9pt;">Issuance of common stock from exercise of warrants<br/>
              </div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="galt:StockIssuedDuringPeriodSharesWarrantExercise" id="Fact_b51f6b23474e4ff0878bc976d4dcdf3e" contextRef="c20240101to20241231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">142,370</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="galt:StockIssuedDuringPeriodValueWarrantExercise" id="Fact_470cafbfb09b43919adb4278bd500ef5" contextRef="c20240101to20241231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="galt:StockIssuedDuringPeriodValueWarrantExercise" id="Fact_baf69a505b554a5abb91c81802f22f38" contextRef="c20240101to20241231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">427</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="galt:StockIssuedDuringPeriodValueWarrantExercise" id="Fact_c7f88344ca51425b996b27b60f7ef6e0" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">428</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 16%; background-color: rgb(204, 238, 255);" rowspan="1">
              <div style="text-indent: -9pt; margin-left: 9pt;">Issuance of common stock from exercise of stock options, net of shares withheld<br/>
              </div>
              <div style="margin-left: 9pt; text-indent: 0pt;">for exercise<br/>
              </div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" id="Fact_3393cd8f1c0b4f749b5f62c9b66ae170" contextRef="c20240101to20241231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">473,370</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_366fb6c21c3c42f7ac09d7c997802b4e" contextRef="c20240101to20241231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">799</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_76d41d6ab41b4f78bde36d810a163d48" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">799</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 16%;" rowspan="1">
              <div style="margin-left: 9pt; text-indent: -9pt;">Issuance of common stock from restricted stock units<br/>
              </div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" id="Fact_ad36457bbb6d44af8bd9aa287dcab527" contextRef="c20240101to20241231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">378,000</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 16%; background-color: #CCEEFF;">
              <div style="text-indent: -9pt; margin-left: 9pt;">Issuance of common stock purchase warrants in connection with related party line of credit</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" id="Fact_041090d334e04405b928f98c18d48412" contextRef="c20240101to20241231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">845</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" id="Fact_274005e1208a4e6a8234cd3342ac6dd5" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">845</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 16%;">
              <div style="text-indent: -12pt; margin-left: 12pt;">Stock-based compensation expense&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" id="Fact_ebaf1d4c03c64d03a0422661aca80e72" contextRef="c20240101to20241231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">250,548</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_9ff7a5d6caf442ffb1cc8f9c97cedb77" contextRef="c20240101to20241231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,146</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_72fb30f184e14fbba282310673438801" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,146</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 16%; background-color: #CCEEFF;">
              <div style="text-indent: -12pt; margin-left: 12pt;">Net loss&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_db4ba997d0aa4f54892ec553b5a7a39d" contextRef="c20240101to20241231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">47,047</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_f35bc8d3156a4e4a847e3fa13ee66ee1" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">47,047</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 16%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 16%; padding-bottom: 4px; background-color: #CCEEFF;">
              <div style="text-indent: -12pt; margin-left: 12pt; font-weight: bold;">Balance at December 31, 2024<br/>
              </div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;"><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_94fd06f95bc24fc3b04181f0b802a0d5" contextRef="c20241231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,235,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><span style="font-weight: bold;">$</span></div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><span style="font-weight: bold;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_bf96460a203448b3a55abae46fa419a1" contextRef="c20241231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">500</ix:nonFraction></span></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;"><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_a0a76a1e16284b9a9486fe9024f16dbd" contextRef="c20241231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">63,157,235</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><span style="font-weight: bold;">$</span></div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><span style="font-weight: bold;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_69d09af51ae846ff9f1ef4f3d5b85e92" contextRef="c20241231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">62</ix:nonFraction></span></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_a840f54e14d642048ca195141e6bd53a" contextRef="c20241231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">296,217</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;">(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_02797e623cbf4ecd87d5b0f8b9fb02b7" contextRef="c20241231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">401,572</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-weight: bold;">)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><span style="font-weight: bold;">$</span></div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><span style="font-weight: bold;">(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_ce28eb8bbfe84be28741db7d2e3b500c" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">104,793</ix:nonFraction></span></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><span style="font-weight: bold;">)</span></div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">See notes to consolidated financial statements.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">F-6</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

        <div style="width: 100%;" class="BRPFPageHeader">
          <div>
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

            </div>

          </div>

        </div>

      </div>

    </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">

    <div>
      <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">GALECTIN THERAPEUTICS INC. AND SUBSIDIARIES</div>

      <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">CONSOLIDATED
        <!--Anchor-->STATEMENTS OF <a id="CASHFLOWS"><!--Anchor--></a>CASH FLOWS</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="6">
              <div style="text-align: center; font-weight: bold;">Year Ended</div>
              <div style="text-align: center; font-weight: bold;">December 31,</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; font-weight: bold;">2024<br/>
              </div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; font-weight: bold;">2023<br/>
              </div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="6">
              <div style="text-align: center; font-weight: bold;">(in thousands)</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt;">CASH FLOWS FROM OPERATING ACTIVITIES:</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Net loss</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_4114b34d5fd145bd9fd4fad2e251c860" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">47,047</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_3cebf1671f2a4b96b7bc5ee62610028a" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">41,066</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
              <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Adjustments to reconcile net loss to net cash from operating activities:</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 34.2pt;">Amortization of right to use asset</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" id="Fact_16e1f17e54674154b77472be9df32fa6" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">37</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" id="Fact_ea59af9643a044aaab6d533225c92029" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">33</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
              <div style="text-indent: -7.2pt; margin-left: 34.2pt;">Stock-based compensation expense</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_2cab8b70a6944746a3ed58ebb1b72549" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,447</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_9d54680d04de4f89804adc0aafe60c50" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,261</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 34.2pt;">Non-cash interest expense</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:PaidInKindInterest" id="Fact_0d1d6d6034a04a0686c5a94a0199846b" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,100</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:PaidInKindInterest" id="Fact_e0441861310940fdbae77bd43a3e8c40" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">697</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
              <div style="text-indent: -7.2pt; margin-left: 34.2pt;">Change in fair value of derivatives</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" id="Fact_71bc96a667004de9acd5bf20197c1f17" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">588</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" id="Fact_48e96c38a32748ce8c849dc385459011" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">432</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 34.2pt;">Changes in operating assets and liabilities:</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
              <div style="text-indent: -7.2pt; margin-left: 43.2pt;">Prepaid expenses and other assets</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" id="Fact_33f7059acce44ff3b16af780cda70da9" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">82</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" id="Fact_10d1e62a950843c8b05b9aa42d0ea5f3" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">90</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;" rowspan="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Accrued interest on convertible notes payable and convertible line of credit &#8211; related party</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInterestPayableNet" id="Fact_0f6804f36ac7411494eca796fc06b6e5" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,440</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInterestPayableNet" id="Fact_5660f13310bf452f936dd53d209f4217" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,097</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
              <div style="text-indent: -7.2pt; margin-left: 43.2pt;">Accounts payable, accrued expenses and other liabilities</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" id="Fact_5d7e6b8c01f04e4bbe5547a15422b318" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,074</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" id="Fact_a89913ce81124309ac5f91ec32285ad6" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,671</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 52.2pt;">Net cash from operating activities</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" id="Fact_cc2dee6c27664a4d9c2b0f46f7a76486" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">41,767</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" id="Fact_600ac72197264f7ebda6ccb8f4ac1d82" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">32,965</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt;">CASH FLOWS FROM INVESTING ACTIVITIES:</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 52.2pt;">Net cash from investing activities</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" id="Fact_6d2ff7ece99a4ff19996082b9b252c9d" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" id="Fact_12156c678bfa437e8384f2000906f951" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt;">CASH FLOWS FROM FINANCING ACTIVITIES:</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;" rowspan="1">
              <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160; &#160; Net proceeds from convertible line of credit &#8211; related party</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" id="Fact_d5fa6fafabf84eb3a7bc71224135e1af" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">30,000</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" id="Fact_45c485eee2514c7e987eec45dd4c62d4" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">30,000</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; font-family: 'Times New Roman'; width: 76%; padding-bottom: 2px;" rowspan="1">
              <div style="text-align: left; font-size: 10pt; text-indent: 0pt; margin-left: 18pt;">Net proceeds from exercise of common stock options and warrants</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" id="Fact_361c3c30029e4acf9df442b3f441951a" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,227</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" id="Fact_05f53fe537fd4a2aa771ff5cfaac2860" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,033</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 52.2pt;">Net cash from financing activities</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" id="Fact_4bf27a7c58c44144a7d114478fcb072a" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">31,227</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" id="Fact_7731ff9c232a4eaba47e05651a952bc5" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">40,033</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt;">NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" id="Fact_9626c2c9170c48a3a6689e3b2e70d36f" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">10,540</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" id="Fact_a2e50081d77241a5bb4df251f0648def" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,068</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
              <div></div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt;">CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_fe329329184a4fd08ee89a4d735064a5" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">25,660</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_b1f0380f94194989876c9bdbdb97bb75" contextRef="c20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">18,592</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt;">CASH AND CASH EQUIVALENTS, END OF PERIOD</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_6a1aaeef3516463f9c0ba1dc1d32b032" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,120</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_f65b706c6a804afc88b577fbd24c1ced" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">25,660</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt;">NONCASH FINANCING ACTIVITIES:</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
              <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Payment of preferred stock dividends in common stock</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:StockIssued1" id="Fact_676c593f2cb64b3b99227a5e855bfa39" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">91</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:StockIssued1" id="Fact_ec26df895ed34cb7919610c0c07dcac4" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">120</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;" rowspan="1">
              <div style="margin-left: 9pt;">
                <div style="margin-left: 9pt;">Reclassification of accrued bonus to additional paid in capital</div>
              </div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="galt:ReclassificationOfAccruedBonusToAdditionalPaidInCapital" id="Fact_485ea77e997a4ba89a5e9b6a0e9c6c1b" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="galt:ReclassificationOfAccruedBonusToAdditionalPaidInCapital" id="Fact_ed9cf0a0ee70486d9b95a8b6f06c1d1d" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">210</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;" rowspan="1"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">&#160;&#160;&#160;&#160;&#160;&#160;
                Common stock purchase warrants issued in connection with related party line of credit</span></td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="galt:CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit" id="Fact_f5fae8713af3428fa88b68459d380088" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">845</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="galt:CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit" id="Fact_a1fe9c08f3b449eb8f259d23cbfcb396" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">671</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">See notes to consolidated financial statements.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">F-7</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div>
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

            </div>

          </div>

        </div>

      </div>

    </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">

    <div>
      <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">GALECTIN THERAPEUTICS INC. AND SUBSIDIARIES</div>

      <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"><!--Anchor--><a id="NOTES"><!--Anchor--></a>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>


      <ix:nonNumeric name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="Text_bfab20d001ab4043a7b33c71ade0e2a5" contextRef="c20240101to20241231" escape="true" continuedAt="Text_4b954f15ace542c28fe75faa7594c32c1">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 27.05pt; vertical-align: top; font-weight: bold;">1.</td>

    <td style="width: auto; vertical-align: top;">
              <div style="font-weight: bold;">Nature of Business, Basis of Presentation, Liquidity, and Going Concern<br/>
              </div>
            </td>

  </tr>


</table>
</ix:nonNumeric>
      <ix:continuation id="Text_4b954f15ace542c28fe75faa7594c32c1" continuedAt="Text_4b954f15ace542c28fe75faa7594c32c2">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>
</ix:continuation>
      <ix:continuation id="Text_4b954f15ace542c28fe75faa7594c32c2" continuedAt="Text_4b954f15ace542c28fe75faa7594c32c3">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">Galectin Therapeutics Inc. and subsidiaries (the &#8220;Company&#8221;) is a clinical stage biopharmaceutical company that is applying its leadership in galectin science and drug
        development to create new therapies for fibrotic disease and cancer. These candidates are based on the Company&#8217;s targeting of galectin proteins which are key mediators of biologic and pathologic function. These compounds also may have application
        for drugs to treat other diseases and chronic health conditions.</div>
</ix:continuation>
      <ix:continuation id="Text_4b954f15ace542c28fe75faa7594c32c3" continuedAt="Text_4b954f15ace542c28fe75faa7594c32c4">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>
</ix:continuation>
      <ix:continuation id="Text_4b954f15ace542c28fe75faa7594c32c4" continuedAt="Text_4b954f15ace542c28fe75faa7594c32c5">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">The Company was founded in July 2000, was incorporated in the State of Nevada in January 2001 under the name &#8220;Pro-Pharmaceuticals, Inc.,&#8221; and changed its name to
        &#8220;Galectin Therapeutics Inc.&#8221; on May 26, 2011.</div>
</ix:continuation>
      <ix:continuation id="Text_4b954f15ace542c28fe75faa7594c32c5" continuedAt="Text_4b954f15ace542c28fe75faa7594c32c6">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>
</ix:continuation>
      <ix:continuation id="Text_4b954f15ace542c28fe75faa7594c32c6" continuedAt="Text_4b954f15ace542c28fe75faa7594c32c7">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The Company has operated at a loss since its inception and has had no revenues. The Company anticipates that losses will continue for the foreseeable future. At December 31, 2024, the company had $<ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" id="Fact_ef0c0e4e421c428fb33c56bcc58c97bb" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,120</ix:nonFraction>,000 of unrestricted cash and cash equivalents available to fund future operations. As of December 31, 2024, the Company has available
          borrowings under a line of credit in the amount of $<ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" id="Fact_52fed55ceb584ba59e5cd009da127582" contextRef="c20241231_CreditFacilityAxis_LineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U001" decimals="-6" scale="6" format="ixt:num-dot-decimal">6</ix:nonFraction> million provided by our chairman, Richard Uihlein, (See Notes 10). Additionally,
          in March 2025, we signed a new supplemental line of credit agreement with our chairman for an additional $<ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" id="Fact_dfb8733d4e3640d9a81d2bb8d418cbe9" contextRef="c20250331_CreditFacilityAxis_SupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U001" decimals="-6" scale="6" format="ixt:num-dot-decimal">5</ix:nonFraction> million of available
          borrowings (See Note 16). The Company believes there is sufficient cash, including availability of the <ix:nonFraction name="galt:NumberOfLineOfCredit" id="Fact_6b50c7cf83d2489b8d0a5c096e42405e" contextRef="c20240101to20241231" unitRef="U004" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> lines of credit, to fund
          currently planned operations through August 2025. To meet its future capital needs, the Company intends to raise additional capital through debt or equity financings, collaborations, partnerships or other strategic transactions. However, there
          can be no assurance that the Company will be able to complete any such transactions on acceptable terms or otherwise. The inability of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on
          the Company&#8217;s business, results of operations and financial condition.<br/>
        </span></div>
</ix:continuation>
      <ix:continuation id="Text_4b954f15ace542c28fe75faa7594c32c7" continuedAt="Text_4b954f15ace542c28fe75faa7594c32c8">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>
</ix:continuation>
      <ix:continuation id="Text_4b954f15ace542c28fe75faa7594c32c8">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">The Company is subject to a number of risks similar to those of clinical stage companies, including dependence on key individuals, uncertainty of product development
        and generation of revenues, dependence on outside sources of capital, risks associated with clinical trials of products, dependence on third-party collaborators for research operations, need for regulatory approval of products, risks associated
        with protection of intellectual property, and competition with larger, better-capitalized companies. Successful completion of the Company&#8217;s development program and, ultimately, the attainment of profitable operations is dependent upon future
        events, including obtaining adequate financing to fulfill its development activities and achieving a level of revenues adequate to support the Company&#8217;s cost structure. There are no assurances that the Company will be able to obtain additional
        financing on favorable terms, or at all, or successfully market its products.</div>
</ix:continuation>

    </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">

    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
    </div>


    <ix:nonNumeric name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Text_22755ad67a6841ae90ef10504916f40a" contextRef="c20240101to20241231" escape="true" continuedAt="Text_89b0eb58a4da40e982e8f71316f98bd41">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 27.05pt; vertical-align: top; font-weight: bold;">2.</td>

    <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">Summary of Significant Accounting Policies</div>
          </td>

  </tr>


</table>
</ix:nonNumeric>
    <ix:continuation id="Text_89b0eb58a4da40e982e8f71316f98bd41" continuedAt="Text_89b0eb58a4da40e982e8f71316f98bd42">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
    </div>
</ix:continuation>
    <ix:continuation id="Text_89b0eb58a4da40e982e8f71316f98bd42" continuedAt="Text_89b0eb58a4da40e982e8f71316f98bd43">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;).</div>
</ix:continuation>
    <ix:continuation id="Text_89b0eb58a4da40e982e8f71316f98bd43" continuedAt="Text_89b0eb58a4da40e982e8f71316f98bd44">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
    </div>
</ix:continuation>

    <ix:nonNumeric name="us-gaap:ConsolidationPolicyTextBlock" id="Text_576bbc0ac16e42daa79f042194dc628e" contextRef="c20240101to20241231" escape="true"><ix:continuation id="Text_89b0eb58a4da40e982e8f71316f98bd44" continuedAt="Text_89b0eb58a4da40e982e8f71316f98bd45">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-style: italic;">Basis of Consolidation.</span><span style="font-family: 'Times New Roman';"> The consolidated
        financial statements include the accounts of the Company and Galectin Therapeutics Security Corp., its wholly-owned subsidiary, which was incorporated in Delaware on December 23, 2003 and Galectin Sciences LLC (see Note 13). All intercompany
        transactions have been eliminated.</span></div>
</ix:continuation></ix:nonNumeric>

    <ix:continuation id="Text_89b0eb58a4da40e982e8f71316f98bd45" continuedAt="Text_89b0eb58a4da40e982e8f71316f98bd46">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
    </div>
</ix:continuation>

    <ix:nonNumeric name="us-gaap:UseOfEstimates" id="Text_cfb371ba539d4092ae0bcc20029c66a9" contextRef="c20240101to20241231" escape="true"><ix:continuation id="Text_89b0eb58a4da40e982e8f71316f98bd46" continuedAt="Text_89b0eb58a4da40e982e8f71316f98bd47">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-style: italic;">Use of Estimates.</span><span style="font-family: 'Times New Roman';"> The preparation of financial
        statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and judgments that may affect the reported amounts of assets, liabilities, equity, revenue, expenses and
        related disclosure of contingent assets and liabilities. Management&#8217;s estimates and judgments include assumptions used in stock option valuations, accrued liabilities, derivative valuations, deferred income taxes and various other assumptions that
        are believed to be reasonable under the circumstances. Actual results may differ from those estimates under different assumptions or conditions.</span></div>
</ix:continuation></ix:nonNumeric>

    <ix:continuation id="Text_89b0eb58a4da40e982e8f71316f98bd47" continuedAt="Text_89b0eb58a4da40e982e8f71316f98bd48">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
    </div>
</ix:continuation>

    <ix:continuation id="Text_89b0eb58a4da40e982e8f71316f98bd48" continuedAt="Text_89b0eb58a4da40e982e8f71316f98bd49"><ix:nonNumeric name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="Text_3aa92e6f871d41cab1ee670d224c8288" contextRef="c20240101to20241231" escape="true">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-style: italic;">Fair Value Measurements</span><span style="font-family: 'Times New Roman';">. The Company has certain
        financial assets and liabilities recorded at fair value. Fair values determined by Level 1 inputs utilize observable data such as quoted prices in active markets. Fair values determined by Level 2 inputs utilize data points other than quoted prices
        in active markets that are observable either directly or indirectly. Fair values determined by Level 3 inputs utilize unobservable data points in which there is little or no market data, which require the reporting entity to develop its own
        assumptions. The estimated value of accounts payable and accrued expenses approximates their carrying value due to their short-term nature. See</span> Footnote 6 for Fair Value of Derivatives related to Convertible Notes Payable at December 31,
      2024 and 2023, which are level 3 liabilities. </div>
</ix:nonNumeric></ix:continuation>
    <ix:continuation id="Text_89b0eb58a4da40e982e8f71316f98bd49" continuedAt="Text_89b0eb58a4da40e982e8f71316f98bd410">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
    </div>
</ix:continuation>

    <ix:nonNumeric name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Text_d2f252797760441693f882ab7dac7e3e" contextRef="c20240101to20241231" escape="true"><ix:continuation id="Text_89b0eb58a4da40e982e8f71316f98bd410" continuedAt="Text_89b0eb58a4da40e982e8f71316f98bd411">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-style: italic;">Cash and Cash Equivalents.</span><span style="font-family: 'Times New Roman';"> The Company considers
        all highly-liquid investments with original maturities of 90 days or less at the time of acquisition to be cash equivalents. The Company had <ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" id="Fact_c37dd1d510984e23b52d784125c761b0" contextRef="c20241231" unitRef="U001" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" id="Fact_9290d7cf121341aca9bc9f5b5388e3f7" contextRef="c20231231" unitRef="U001" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction>
        cash equivalents at December 31, 2024 or 2023.</span></div>
</ix:continuation></ix:nonNumeric>

    <ix:continuation id="Text_89b0eb58a4da40e982e8f71316f98bd411" continuedAt="Text_89b0eb58a4da40e982e8f71316f98bd412">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
    </div>
</ix:continuation>

    <ix:nonNumeric name="galt:PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" id="Text_f833225790ea4dd19c619b5b7ecb5f7c" contextRef="c20240101to20241231" escape="true"><ix:continuation id="Text_89b0eb58a4da40e982e8f71316f98bd412" continuedAt="Text_89b0eb58a4da40e982e8f71316f98bd413">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-style: italic;">Prepaid Expenses and Other Current Assets.</span><span style="font-family: 'Times New Roman';">
        Prepaid expenses and other assets consist principally of prepaid insurance, deposits related to the NAVIGATE trial and deferred financing costs (see Note 10).</span></div>
</ix:continuation></ix:nonNumeric>

    <ix:continuation id="Text_89b0eb58a4da40e982e8f71316f98bd413" continuedAt="Text_89b0eb58a4da40e982e8f71316f98bd414">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
    </div>
</ix:continuation>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">F-8</span></div>

      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

      <div class="BRPFPageHeader" style="width: 100%;">
        <div>
          <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

          </div>

        </div>

      </div>

    </div>


    <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="Text_195e6e03ef6741179151f31cfc44129d" contextRef="c20240101to20241231" escape="true"><ix:continuation id="Text_89b0eb58a4da40e982e8f71316f98bd414" continuedAt="Text_89b0eb58a4da40e982e8f71316f98bd415">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-style: italic;">Property and Equipment.</span><span style="font-family: 'Times New Roman';"> Property and equipment,
        including leasehold improvements, are stated at cost, net of accumulated depreciation and amortization, and are depreciated or amortized using the straight-line method over the estimated useful lives of the related assets of generally <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Fact_4e93b09d587e400e8c3466835704ec43" contextRef="c20241231_PropertyPlantAndEquipmentByTypeAxis_ComputerAndOfficeEquipmentMember" format="ixt-sec:durwordsen">three years</ix:nonNumeric> for computers and office equipment, <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Fact_526fdb01eb814eb8ab38e6fb0d161239" contextRef="c20241231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember" format="ixt-sec:durwordsen">five years</ix:nonNumeric>
        for furniture and fixtures and the shorter of the useful life or life of the lease for leasehold improvements.</span></div>
</ix:continuation></ix:nonNumeric>

    <ix:continuation id="Text_89b0eb58a4da40e982e8f71316f98bd415" continuedAt="Text_89b0eb58a4da40e982e8f71316f98bd416">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
    </div>
</ix:continuation>

    <ix:nonNumeric name="galt:SecurityDepositPolicyTextBlock" id="Text_28429d51bba34e3f93adcc2f7dc95852" contextRef="c20240101to20241231" escape="true"><ix:continuation id="Text_89b0eb58a4da40e982e8f71316f98bd416" continuedAt="Text_89b0eb58a4da40e982e8f71316f98bd417">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-style: italic;">Security Deposit.</span><span style="font-family: 'Times New Roman';"> At December 31, 2024 and 2023,
        the Company had a security deposit of $<ix:nonFraction name="us-gaap:SecurityDeposit" id="Fact_ddee787e704e4c2dab4d39796316f491" contextRef="c20231231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:SecurityDeposit" id="Fact_bea6144633b4466aa7e963b4538d7a39" contextRef="c20241231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">6,000</ix:nonFraction></ix:nonFraction> for leased office space included in Prepaid Expenses and Other Current Assets.</span></div>
</ix:continuation></ix:nonNumeric>

    <ix:continuation id="Text_89b0eb58a4da40e982e8f71316f98bd417" continuedAt="Text_89b0eb58a4da40e982e8f71316f98bd418">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
    </div>
</ix:continuation>

    <ix:nonNumeric name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="Text_4783b54031154a91852e7a053d95ee4c" contextRef="c20240101to20241231" escape="true"><ix:continuation id="Text_89b0eb58a4da40e982e8f71316f98bd418" continuedAt="Text_89b0eb58a4da40e982e8f71316f98bd419">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-style: italic;">Long-Lived Assets.</span><span style="font-family: 'Times New Roman';"> The Company reviews all
        long-lived assets for impairment whenever events or circumstances indicate the carrying amount of such assets may not be recoverable. Recoverability of assets to be held or used is measured by comparison of the carrying value of the asset to the
        future undiscounted net cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment recognized is measured by the amount by which the carrying value of the asset exceeds the discounted future cash
        flows expected to be generated by the asset. There were <ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" id="Fact_e091e92fc8bb4622882d646dfeb7e9c7" contextRef="c20240101to20241231" unitRef="U001" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" id="Fact_9d0e587d39b44e9d9aa9bfa6c40819d5" contextRef="c20230101to20231231" unitRef="U001" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> impairments of long-lived assets at December 31, 2024 or 2023.</span></div>
</ix:continuation></ix:nonNumeric>

    <ix:continuation id="Text_89b0eb58a4da40e982e8f71316f98bd419" continuedAt="Text_89b0eb58a4da40e982e8f71316f98bd420">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
    </div>
</ix:continuation>

    <ix:nonNumeric name="galt:AccruedExpensePolicyTextBlock" id="Text_6dfd834fe4014bc0bf99ea2720f622c1" contextRef="c20240101to20241231" escape="true"><ix:continuation id="Text_89b0eb58a4da40e982e8f71316f98bd420" continuedAt="Text_89b0eb58a4da40e982e8f71316f98bd421">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-style: italic;">Accrued Expenses</span><span style="font-family: 'Times New Roman';">. As part of the process of
        preparing our consolidated financial statements, we are required to estimate accrued expenses. This process involves identifying services that third parties have performed on our behalf and estimating the level of service performed and the
        associated cost incurred on these services as of each balance sheet date in our consolidated financial statements. Examples of estimated accrued expenses include professional service fees, such as those arising from the services of attorneys and
        accountants and accrued payroll expenses. In connection with these service fees, our estimates are most affected by our understanding of the status and timing of services provided relative to the actual services incurred by the service providers.
        In the event that we do not identify certain costs that have been incurred or we under- or over-estimate the level of services or costs of such services, our reported expenses for a reporting period could be understated or overstated. The date on
        which certain services commence, the level of services performed on or before a given date, and the cost of services are often subject to our judgment. We make these judgments based upon the facts and circumstances known to us in accordance with
        accounting principles generally accepted in the U.S.</span></div>
</ix:continuation></ix:nonNumeric>

    <ix:continuation id="Text_89b0eb58a4da40e982e8f71316f98bd421" continuedAt="Text_89b0eb58a4da40e982e8f71316f98bd422">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
    </div>
</ix:continuation>

    <ix:nonNumeric name="us-gaap:DerivativesPolicyTextBlock" id="Text_2fb4857d7bc445efa390b93a8c20252f" contextRef="c20240101to20241231" escape="true"><ix:continuation id="Text_89b0eb58a4da40e982e8f71316f98bd422" continuedAt="Text_89b0eb58a4da40e982e8f71316f98bd423">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-style: italic;">Warrants.</span><span style="font-family: 'Times New Roman';"> The Company has issued common stock
        warrants in connection with the execution of certain equity and debt financings. The fair value of warrants is determined using the Black-Scholes option-pricing model using assumptions regarding volatility of our common share price, remaining life
        of the warrant, and risk-free interest rates at each period end. There were <ix:nonFraction name="us-gaap:DerivativeLiabilities" id="Fact_4b0b15bc84f04e9a9374c583c24b60b8" contextRef="c20231231" unitRef="U001" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:DerivativeLiabilities" id="Fact_40c4de5eb08e41888bfb8b9804fbe42b" contextRef="c20241231" unitRef="U001" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> warrant liabilities as of December 31, 2024 or 2023.</span></div>
</ix:continuation></ix:nonNumeric>

    <ix:continuation id="Text_89b0eb58a4da40e982e8f71316f98bd423" continuedAt="Text_89b0eb58a4da40e982e8f71316f98bd424">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
    </div>
</ix:continuation>

    <ix:nonNumeric name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Text_59560cc295c64b9baed774eb1eee90ee" contextRef="c20240101to20241231" escape="true"><ix:continuation id="Text_89b0eb58a4da40e982e8f71316f98bd424" continuedAt="Text_89b0eb58a4da40e982e8f71316f98bd425">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-style: italic;">Research and Development Expenses.</span><span style="font-family: 'Times New Roman';"> Research and
        development expenses, including personnel costs, allocated facility costs, lab supplies, outside services, contract laboratory costs related to manufacturing drug product, clinical trials and preclinical studies are charged to research and
        development expense as incurred. The Company accounts for nonrefundable advance payments for goods and services that will be used in future research and development activities as expense when the service has been performed or when the goods have
        been received. Our current NAVIGATE clinical trial is being supported by third-party contract research organizations, or CROs, and other vendors. We accrue expenses for clinical trial activities performed by CROs based upon the estimated amount of
        work completed on each trial. For clinical trial expenses and related expenses associated with the conduct of clinical trials, the significant factors used in estimating accruals include the number of patients enrolled, the number of active
        clinical sites, and the duration for which the patients have been enrolled in the trial. We monitor patient enrollment levels and related activities to the extent possible through internal reviews, review of contractual terms and correspondence
        with CROs. We base our estimates on the best information available at the time. We monitor patient enrollment levels and related activities to the extent possible through discussions with CRO personnel and based our estimates of clinical trial
        costs on the best information available at the time. However, additional information may become available to us which will allow us to make a more accurate estimate in future periods. In that event, we may be required to record adjustments to
        research and development expenses in future periods when the actual level of activity becomes more certain.</span></div>
</ix:continuation></ix:nonNumeric>

    <ix:continuation id="Text_89b0eb58a4da40e982e8f71316f98bd425" continuedAt="Text_89b0eb58a4da40e982e8f71316f98bd426">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
    </div>
</ix:continuation>

    <ix:nonNumeric name="us-gaap:IncomeTaxPolicyTextBlock" id="Text_1bad36be4bf94cfaa50a5da3feef0171" contextRef="c20240101to20241231" escape="true"><ix:continuation id="Text_89b0eb58a4da40e982e8f71316f98bd426" continuedAt="Text_89b0eb58a4da40e982e8f71316f98bd427">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-style: italic;">Income Taxes.</span><span style="font-family: 'Times New Roman';"> The Company accounts for income
        taxes in accordance with the accounting rules that requires an asset and liability approach to accounting for income taxes based upon the future expected values of the related assets and liabilities. Deferred income tax assets and liabilities are
        determined based on the differences between the financial reporting and tax bases of assets and liabilities and for tax loss and credit carry forwards and are measured using the expected tax rates estimated to be in effect when such basis
        differences reverse. Valuation allowances are established, if necessary, to reduce the deferred tax asset to the amount that will, more likely than not, be realized.</span></div>
</ix:continuation></ix:nonNumeric>

    <ix:continuation id="Text_89b0eb58a4da40e982e8f71316f98bd427" continuedAt="Text_89b0eb58a4da40e982e8f71316f98bd428">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
    </div>
</ix:continuation>

    <ix:nonNumeric name="us-gaap:ConcentrationRiskCreditRisk" id="Text_ca88d8c1d6de4a6c849098a0f00aeac1" contextRef="c20240101to20241231" escape="true"><ix:continuation id="Text_89b0eb58a4da40e982e8f71316f98bd428" continuedAt="Text_89b0eb58a4da40e982e8f71316f98bd429">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-style: italic;">Concentration of Credit Risk.</span><span style="font-family: 'Times New Roman';"> Financial
        instruments that subject the Company to credit risk consist of cash and cash equivalents. The Company maintains cash and cash equivalents and certificates of deposit with well-capitalized financial institutions. At times, those amounts may exceed
        federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant credit risk beyond the normal credit risk associated with commercial banking relationships. The Company has no other
        significant concentrations of credit risk.</span></div>
</ix:continuation></ix:nonNumeric>

    <ix:continuation id="Text_89b0eb58a4da40e982e8f71316f98bd429" continuedAt="Text_89b0eb58a4da40e982e8f71316f98bd430"><ix:nonNumeric name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="Text_5b26e59f6c78407388deb19ff860b827" contextRef="c20240101to20241231" escape="true" continuedAt="Text_4e891c70f68643c88435e093f77d97451">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman';"> <br/>
      </span></div>
</ix:nonNumeric></ix:continuation>
    <ix:continuation id="Text_89b0eb58a4da40e982e8f71316f98bd430" continuedAt="Text_89b0eb58a4da40e982e8f71316f98bd431"><ix:continuation id="Text_4e891c70f68643c88435e093f77d97451">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-style: italic;">Stock-Based Compensation.</span> Stock-based compensation cost is measured at the grant date based on
      the fair value of the award and is recognized as expense over the service period, which generally represents the vesting period. For awards that have performance-based vesting conditions the Company recognizes the expense over the estimated period
      that the awards are expected to be earned. The Company generally uses the Black-Scholes option-pricing model to calculate the grant date fair value of stock options. The expense recognized over the service period is required to include an estimate of
      the awards that will be forfeited.</div>
</ix:continuation></ix:continuation>

    <div style="margin-top: 0px; margin-bottom: 0px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: left;"><ix:continuation id="Text_89b0eb58a4da40e982e8f71316f98bd431" continuedAt="Text_89b0eb58a4da40e982e8f71316f98bd432"><ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Text_f00615456f664e71bd0ca8f0c58efb6b" contextRef="c20240101to20241231" escape="true" continuedAt="Text_0c11326e3516460eb072800c3720ee341">
<div><br/>
      </div>
</ix:nonNumeric></ix:continuation>
      <ix:continuation id="Text_89b0eb58a4da40e982e8f71316f98bd432" continuedAt="Text_89b0eb58a4da40e982e8f71316f98bd433"><ix:continuation id="Text_0c11326e3516460eb072800c3720ee341" continuedAt="Text_0c11326e3516460eb072800c3720ee342">
<div style="margin: 0px 0px 0px 24.45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; text-align: left;">Recently Adopted Accounting Pronouncements</div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_89b0eb58a4da40e982e8f71316f98bd433" continuedAt="Text_89b0eb58a4da40e982e8f71316f98bd434"><ix:continuation id="Text_0c11326e3516460eb072800c3720ee342" continuedAt="Text_0c11326e3516460eb072800c3720ee343">
<div style="margin: 0px 0px 0px 24.45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; text-align: left;"> <br/>
      </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_89b0eb58a4da40e982e8f71316f98bd434" continuedAt="Text_89b0eb58a4da40e982e8f71316f98bd435"><ix:continuation id="Text_0c11326e3516460eb072800c3720ee343" continuedAt="Text_0c11326e3516460eb072800c3720ee344">
<div style="margin: 0px 0px 0px 24.45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">In November 2023, the FASB issued ASU 2023-07,&#160;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span>. This guidance is intended to improve reportable segment disclosure requirements through enhanced disclosures as well as clarify that
        entities with a single reportable segment are subject to new and existing segment reporting requirements. This guidance is effective for annual periods in fiscal years beginning after December 15, 2023, and interim periods within fiscal years
        beginning after December 15, 2024, with early adoption permitted. Entities must apply this guidance on a retrospective basis. Accordingly, the Company adopted this new standard for the fiscal year ended December 31, 2024. See footnote 15 for
        segment disclosures.</div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_89b0eb58a4da40e982e8f71316f98bd435" continuedAt="Text_89b0eb58a4da40e982e8f71316f98bd436"><ix:continuation id="Text_0c11326e3516460eb072800c3720ee344" continuedAt="Text_0c11326e3516460eb072800c3720ee345">
<div style="margin: 0px 0px 0px 24.45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"> <br/>
      </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_89b0eb58a4da40e982e8f71316f98bd436" continuedAt="Text_89b0eb58a4da40e982e8f71316f98bd437"><ix:continuation id="Text_0c11326e3516460eb072800c3720ee345" continuedAt="Text_0c11326e3516460eb072800c3720ee346">
<div style="margin: 0px 0px 0px 24.45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; text-align: left;">Recent Accounting Pronouncements - Yet to be Adopted</div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_89b0eb58a4da40e982e8f71316f98bd437" continuedAt="Text_89b0eb58a4da40e982e8f71316f98bd438"><ix:continuation id="Text_0c11326e3516460eb072800c3720ee346" continuedAt="Text_0c11326e3516460eb072800c3720ee347">
<div style="margin: 0px 0px 0px 24.45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; text-align: left;"> <br/>
      </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_89b0eb58a4da40e982e8f71316f98bd438" continuedAt="Text_89b0eb58a4da40e982e8f71316f98bd439"><ix:continuation id="Text_0c11326e3516460eb072800c3720ee347" continuedAt="Text_0c11326e3516460eb072800c3720ee348">
<div style="margin: 0px 0px 0px 24.45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">In December 2023, the FASB issued ASU 2023-09,&#160;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span>. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate
        reconciliation and income taxes paid both in the United States and in foreign jurisdictions. This guidance is effective for fiscal years beginning after December 15, 2024 on a prospective basis, with the option to apply the standard
        retrospectively, and early adoption is permitted. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements.</div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_89b0eb58a4da40e982e8f71316f98bd439" continuedAt="Text_89b0eb58a4da40e982e8f71316f98bd440"><ix:continuation id="Text_0c11326e3516460eb072800c3720ee348" continuedAt="Text_0c11326e3516460eb072800c3720ee349">
<div style="margin: 0px 0px 0px 24.45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"> <br/>
      </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_89b0eb58a4da40e982e8f71316f98bd440" continuedAt="Text_89b0eb58a4da40e982e8f71316f98bd441"><ix:continuation id="Text_0c11326e3516460eb072800c3720ee349" continuedAt="Text_0c11326e3516460eb072800c3720ee3410">
<div style="margin: 0px 0px 0px 24.45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">In November 2024, the FASB issued ASU 2024-03,&#160;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</span>. The amendments in ASU 2024-03 address investor requests for more
        detailed expense information and require additional disaggregated disclosures in the notes to financial statements for certain categories of expenses that are included on the face of the income statement. This guidance is effective for fiscal years
        beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated
        financial statements.</div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_89b0eb58a4da40e982e8f71316f98bd441" continuedAt="Text_89b0eb58a4da40e982e8f71316f98bd442"><ix:continuation id="Text_0c11326e3516460eb072800c3720ee3410" continuedAt="Text_0c11326e3516460eb072800c3720ee3411">
<div style="margin: 0px 0px 0px 24.45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"> <br/>
      </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_89b0eb58a4da40e982e8f71316f98bd442"><ix:continuation id="Text_0c11326e3516460eb072800c3720ee3411">
<div style="margin: 0px 0px 0px 24.45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">In November 2024, the FASB, issued ASUS 2024-04,&#160;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Debt- Debt with Conversions and Other Option.&#160;</span>ASU 2024-04 is intended to clarify requirements for determining whether certain settlements of convertible debt instruments, including convertible debt instruments with
        cash conversion features or convertible debt instruments that are not currently convertible, should be accounted for as an induced conversion. This ASU is effective for all entities for annual reporting periods beginning after December 15, 2025,
        and interim reporting periods within those annual reporting periods, with early adoption permitted. The Company is currently evaluating the potential impact of this guidance on its disclosures.</div>
</ix:continuation></ix:continuation>
       </div>


    <div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
    </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">

    <div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">F-9</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

        <div style="width: 100%;" class="BRPFPageHeader">
          <div>
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

            </div>

          </div>

        </div>

      </div>


      <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="Text_4d11178decd54050b00dcad6e3799e34" contextRef="c20240101to20241231" escape="true" continuedAt="Text_410e75a158d04f8d83acbb13899edd9b1">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 27.05pt; vertical-align: top; font-weight: bold;">3.</td>

    <td style="width: auto; vertical-align: top;">
              <div style="font-weight: bold;">Property and Equipment</div>
            </td>

  </tr>


</table>
</ix:nonNumeric>
      <ix:continuation id="Text_410e75a158d04f8d83acbb13899edd9b1" continuedAt="Text_410e75a158d04f8d83acbb13899edd9b2">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>
</ix:continuation>

      <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="Text_d3264ff0a1a441338b91ce2800081bf7" contextRef="c20240101to20241231" escape="true" continuedAt="Text_d355659902b04341a64b7798cc2468ae1"><ix:continuation id="Text_410e75a158d04f8d83acbb13899edd9b2" continuedAt="Text_410e75a158d04f8d83acbb13899edd9b3">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">Property and equipment consist of the following at December 31:</div>
</ix:continuation></ix:nonNumeric>
      <ix:continuation id="Text_d355659902b04341a64b7798cc2468ae1" continuedAt="Text_d355659902b04341a64b7798cc2468ae2"><ix:continuation id="Text_410e75a158d04f8d83acbb13899edd9b3" continuedAt="Text_410e75a158d04f8d83acbb13899edd9b4">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_410e75a158d04f8d83acbb13899edd9b4" continuedAt="Text_410e75a158d04f8d83acbb13899edd9b5"><ix:continuation id="Text_d355659902b04341a64b7798cc2468ae2">
<div style="margin-left: 27pt;">
        <table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;"> 2024<br/>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">2023<br/>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">(in thousands)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <div style="text-indent: -16.2pt; margin-left: 16.2pt;">Leasehold improvements</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_d20ba1910ae34b82b67412044e849ec1" contextRef="c20241231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_74fbb1156dd04338a724f72f872035a7" contextRef="c20231231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <div style="text-indent: -16.2pt; margin-left: 16.2pt;">Computer and office equipment</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_aef57c28ddfc4736ab6f50b07d0b0fd7" contextRef="c20241231_PropertyPlantAndEquipmentByTypeAxis_ComputerAndOfficeEquipmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">13</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_bdf382be1a554dae86e82f7a026fe519" contextRef="c20231231_PropertyPlantAndEquipmentByTypeAxis_ComputerAndOfficeEquipmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">13</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
                <div style="text-indent: -16.2pt; margin-left: 16.2pt;">Furniture and fixtures</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_2d21f6bdb2404f418f11d8c282288482" contextRef="c20241231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">59</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_68119940ea94486e898de0a26c8ff8ab" contextRef="c20231231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">59</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <div style="text-indent: -16.2pt; margin-left: 16.2pt;">Total</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_ee2c7f8adebd49fb98db8215676952d4" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">74</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_a39af23592d74e339c12009259e71757" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">74</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
                <div style="text-indent: -16.2pt; margin-left: 16.2pt;">Less accumulated depreciation and amortization</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" id="Fact_afd195cecf5f4c8b944c86e41f1b6fda" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">74</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" id="Fact_7f3c1658dd3e46e2ac7dddd30a02e117" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">74</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px;">
                <div style="text-indent: -16.2pt; margin-left: 25.2pt;">Property and equipment &#8212; net</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" id="Fact_343983fa7c40403885e70e9f88162bf4" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" id="Fact_b0faded862f44bb4a87584a3c513ec83" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

  </tr>


</table>
         </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_410e75a158d04f8d83acbb13899edd9b5" continuedAt="Text_410e75a158d04f8d83acbb13899edd9b6">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>
</ix:continuation>
      <ix:continuation id="Text_410e75a158d04f8d83acbb13899edd9b6">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">Depreciation and amortization expense for the years ended December 31, 2024 and 2023 was $<ix:nonFraction name="us-gaap:DepreciationAndAmortization" id="Fact_ea5f8495285140608206c59f91f923d7" contextRef="c20240101to20241231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">0</ix:nonFraction> and $<ix:nonFraction name="us-gaap:DepreciationAndAmortization" id="Fact_caa8b27fec16458a989b2b85a2aabe1e" contextRef="c20230101to20231231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">0</ix:nonFraction>, respectively.</div>
</ix:continuation>
       </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">

    <div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>


      <ix:nonNumeric name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="Text_a3471463059d45209ce95f6afbac06bf" contextRef="c20240101to20241231" escape="true" continuedAt="Text_86eb43cb4d854fd0b2eb28fa8090fb581">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 27.05pt; vertical-align: top; font-weight: bold;">4.</td>

    <td style="width: auto; vertical-align: top;">
              <div style="font-weight: bold;">Accrued Expenses</div>
            </td>

  </tr>


</table>
</ix:nonNumeric>
      <ix:continuation id="Text_86eb43cb4d854fd0b2eb28fa8090fb581" continuedAt="Text_86eb43cb4d854fd0b2eb28fa8090fb582">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>
</ix:continuation>

      <ix:nonNumeric name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="Text_8d41e3af9d8b460cba4ca7b9516fc85f" contextRef="c20240101to20241231" escape="true" continuedAt="Text_774a5fb332a0490395310f3f81eaa31d1"><ix:continuation id="Text_86eb43cb4d854fd0b2eb28fa8090fb582" continuedAt="Text_86eb43cb4d854fd0b2eb28fa8090fb583">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">Accrued expenses consist of the following at December 31:</div>
</ix:continuation></ix:nonNumeric>
      <ix:continuation id="Text_774a5fb332a0490395310f3f81eaa31d1" continuedAt="Text_774a5fb332a0490395310f3f81eaa31d2"><ix:continuation id="Text_86eb43cb4d854fd0b2eb28fa8090fb583" continuedAt="Text_86eb43cb4d854fd0b2eb28fa8090fb584">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_86eb43cb4d854fd0b2eb28fa8090fb584"><ix:continuation id="Text_774a5fb332a0490395310f3f81eaa31d2">
<div style="margin-left: 27pt;">
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                <div style="text-align: center; font-weight: bold;">2024</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                <div style="text-align: center; font-weight: bold;">2023</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="6">
                <div style="text-align: center; font-weight: bold;">(in thousands)</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Legal and accounting fees</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" id="Fact_fd74099bb3bb427f8882a7f364e3b335" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">74</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" id="Fact_5a0da24b1e934d4ca520827b8e8badd6" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">40</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Accrued compensation</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" id="Fact_3b16079fe16e409da85eac67d670283b" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,523</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" id="Fact_b952b0fe82d94a7cb990f7a88339355a" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,129</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Lease liability </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" id="Fact_0e2bcab54f254f2abe864c9ba8ff20bb" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">19</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" id="Fact_a67e474529a44e92bcf5df378b606468" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">46</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Accrued research and development costs and other</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="galt:AccruedResearchAndDevelopmentCostsAndOtherCurrent" id="Fact_938bd465841046b68ebe233dc6f43985" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,588</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="galt:AccruedResearchAndDevelopmentCostsAndOtherCurrent" id="Fact_3ef68296521b4dbdb19d755dea77b8df" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,967</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;"><span style="text-indent: 0pt;"><span style="-sec-ix-hidden:Fact_a8602fa8d1ea4021ae045ee98e73f8f6"><span style="-sec-ix-hidden:Fact_5c08786f5dcb4bc5a62f72d8c0d8264d">Total</span></span></span></div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" id="Fact_700b3445211f42718bcd1825d69d7aa0" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,204</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" id="Fact_2ae5f3b6afe54089b5edcce6c7aac88e" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,182</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
         </div>
</ix:continuation></ix:continuation>
    </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">

    <div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>


      <ix:nonNumeric name="us-gaap:DebtDisclosureTextBlock" id="Text_30653b6b0e8d44858c5c16baf19a5305" contextRef="c20240101to20241231_LongtermDebtTypeAxis_LoansPayableMember" escape="true" continuedAt="Text_05c9ef758cdd412fbc82eafaea96bee61">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 27pt; vertical-align: top; font-weight: bold;">5.</td>

    <td style="width: auto; vertical-align: top;">
              <div style="font-weight: bold;">Convertible Notes Payable &#8211; Related Party</div>
            </td>

  </tr>


</table>
</ix:nonNumeric>
      <ix:continuation id="Text_05c9ef758cdd412fbc82eafaea96bee61" continuedAt="Text_05c9ef758cdd412fbc82eafaea96bee62">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>
</ix:continuation>
      <ix:continuation id="Text_05c9ef758cdd412fbc82eafaea96bee62" continuedAt="Text_05c9ef758cdd412fbc82eafaea96bee63">
<div style="margin-left: 22.5pt; font-family: 'Times New Roman'; font-size: 10pt;">On April 16, 2021, the Company and Richard E. Uihlein entered into a debt financing arrangement whereby Mr. Uihlein loaned $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" id="Fact_2713fcf124234f9da51a266413ecaf03" contextRef="c20210416_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction> to Company. In consideration for the loan, the Company issued a convertible promissory note (the &#8220;April 2021 Note&#8221;) in the principal amount of <ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentAmount1" id="Fact_d2641f5039644251b44b6b5a9803135a" contextRef="c20210416to20210416_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U001" decimals="0" scale="0" format="ixt-sec:numwordsen">ten million</ix:nonFraction> dollars.</div>
</ix:continuation>
      <ix:continuation id="Text_05c9ef758cdd412fbc82eafaea96bee63" continuedAt="Text_05c9ef758cdd412fbc82eafaea96bee64">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>
</ix:continuation>
      <ix:continuation id="Text_05c9ef758cdd412fbc82eafaea96bee64" continuedAt="Text_05c9ef758cdd412fbc82eafaea96bee65">
<div style="margin-left: 22.5pt; font-family: 'Times New Roman'; font-size: 10pt;">The April 2021 Note has a maturity date of <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" id="Fact_4ce33135ab5c444fa78a945711ee65c2" contextRef="c20240101to20241231_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" format="ixt:date-monthname-day-year-en">April 16, 2025</ix:nonNumeric>,
        is prepayable at the option of the Company in whole or in part at any time and is convertible into the Company&#8217;s common stock at a conversion price equal to $<ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" id="Fact_975609c5e9e3470c8bfe4c4b38be2831" contextRef="c20241231_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">5.00</ix:nonFraction> per share at the option of the noteholder. The April 2021 Note bears interest at the rate of two percent (<ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_499f66d0466944ec9271f8378f4202d6" contextRef="c20241231_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">2</ix:nonFraction>%)
        per annum, compounded annually with an effective interest rate of approximately <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" id="Fact_52d8ad51a64643618477246a2e699a1d" contextRef="c20241231_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">3</ix:nonFraction>%. For the years ended December 31, 2024 and 2023,
        approximately $<ix:nonFraction name="us-gaap:InterestExpenseDebt" id="Fact_11db0d2fd2de45e1a8bd9c138b3180a5" contextRef="c20240101to20241231_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">212,000</ix:nonFraction> and $<ix:nonFraction name="us-gaap:InterestExpenseDebt" id="Fact_e9698cb7514c4dfca3b98d62da3b6857" contextRef="c20230101to20231231_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">207,000</ix:nonFraction>,
        respectively, of interest expense was accrued and included with the principal in the financial statements.</div>
</ix:continuation>
      <ix:continuation id="Text_05c9ef758cdd412fbc82eafaea96bee65" continuedAt="Text_05c9ef758cdd412fbc82eafaea96bee66">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>
</ix:continuation>
      <ix:continuation id="Text_05c9ef758cdd412fbc82eafaea96bee66" continuedAt="Text_05c9ef758cdd412fbc82eafaea96bee67">
<div style="margin-left: 22.5pt; font-family: 'Times New Roman'; font-size: 10pt;">The April 2021 Note also includes a contingent interest component that requires the Company to pay additional interest at a rate of two and one-half percent (<ix:nonFraction name="galt:QuarterlyInterestRate" id="Fact_a9a00d44e7944a8198adb35ca1cb9a1c" contextRef="c20210416_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">2.5</ix:nonFraction>%) per quarter (<ix:nonFraction name="galt:AnnualInterestRate" id="Fact_9069c50caa5f47d6a5157af34914fda2" contextRef="c20210416_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">10</ix:nonFraction>% per annum) (the
        &#8220;Additional Interest&#8221;) beginning on the date of issuance of this Note and ending on the maturity date, provided however, that such payment is only required if and only if the noteholder elects to convert the entire balance of the April 2021 Note
        into the Company&#8217;s common stock on or prior to maturity. As the contingent event is not based on creditworthiness, such feature is not clearly and closely related to the host instrument and accordingly must be bifurcated and recognized as a
        derivative liability and a debt discount on the April 2021 Note at its inception. The fair value of the contingent interest derivative liability was $<ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" id="Fact_94e890658938435484d2e437f9120443" contextRef="c20210416_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">420,000</ix:nonFraction>
        at note inception (April 16, 2021). The fair value of the contingent interest derivative liability was $<ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" id="Fact_404a67450c554ebcb77a7b60b4bf43c1" contextRef="c20241231_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">47,000</ix:nonFraction> and $<ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" id="Fact_00b2ec7b8cb34ce4b78140aec2202c6d" contextRef="c20231231_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">431,000</ix:nonFraction> and December 31, 2024 and 2023, respectively, and is recognized as a derivative liability in the consolidated balance sheet. The change in the
        fair value of the derivative liability for the years ended December 31, 2024 and 2023 of ($<ix:nonFraction name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" id="Fact_d5bfe3449aa545e39aa984cc8c838ed3" contextRef="c20240101to20241231_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">384,000</ix:nonFraction>) and $<ix:nonFraction name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" id="Fact_0552d15706564c5ebfda338497cd2ed4" contextRef="c20230101to20231231_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember" unitRef="U001" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">182,000</ix:nonFraction>, respectively, was charged to other expense/(income) for the years ended December 31, 2024 and 2023. The amortization of the original $<ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" id="Fact_5290c79730ba44cdae71a8122da60122" contextRef="c20240101to20241231_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">420,000</ix:nonFraction> debt discount of $<ix:nonFraction name="us-gaap:InterestExpenseOther" id="Fact_0b7bd7638b3a465ba3787fe4e929506e" contextRef="c20240101to20241231_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">105,000</ix:nonFraction> and $<ix:nonFraction name="us-gaap:InterestExpenseOther" id="Fact_b512e7f9b7184f43812f49fedc2ce60f" contextRef="c20230101to20231231_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">105,000</ix:nonFraction> was recorded as additional interest expense for the years ended December 31, 2024 and 2023, respectively.</div>
</ix:continuation>
      <ix:continuation id="Text_05c9ef758cdd412fbc82eafaea96bee67" continuedAt="Text_05c9ef758cdd412fbc82eafaea96bee68">
<div style="margin-left: 22.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-family: 'Times New Roman';"><br/>
        </span></div>
</ix:continuation>
      <ix:continuation id="Text_05c9ef758cdd412fbc82eafaea96bee68" continuedAt="Text_05c9ef758cdd412fbc82eafaea96bee69">
<div style="margin-left: 22.5pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman';">On May 14, 2024, Mr. Uihlein, as holder of the April 2021 Note irrevocably elected to convert the entire principal amount
          of such note, plus accrued and unpaid interest, into shares of common stock of the Company at a price of $<ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" id="Fact_2a916b2c399c4072b80d0eb6aecd6066" contextRef="c20240514_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">5.00</ix:nonFraction> per share, effective as
          of <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" id="Fact_99dcb49f39b24322ba1e107efd3b8f15" contextRef="c20240514to20240514_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" format="ixt:date-monthname-day-year-en">April 16, 2025</ix:nonNumeric>, which is the maturity date of the April 2021 Note. The April 2021 Note will remain outstanding and accrue interest
          until maturity and <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" id="Fact_8d6040e53d994651b572fa813123df44" contextRef="c20240514to20240514_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U002" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction> shares of common stock will be issued as a result of this election until April 16, 2025. As a result, the
          principal, plus accrued interest and related derivative liability are included in noncurrent liabilities at December 31, 2024.</span> </div>
</ix:continuation>
      <ix:continuation id="Text_05c9ef758cdd412fbc82eafaea96bee69" continuedAt="Text_05c9ef758cdd412fbc82eafaea96bee610">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>
</ix:continuation>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">F-10</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

        <div style="width: 100%;" class="BRPFPageHeader">
          <div>
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

            </div>

          </div>

        </div>

      </div>

      <ix:continuation id="Text_05c9ef758cdd412fbc82eafaea96bee610" continuedAt="Text_05c9ef758cdd412fbc82eafaea96bee611">
<div style="margin-left: 22.5pt; font-family: 'Times New Roman'; font-size: 10pt;">On September 17, 2021, the Company and Mr. Uihlein entered into a loan agreement in the aggregate of $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" id="Fact_0bea27b5ac724fc9857afe964933abd1" contextRef="c20210917_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">20,000,000</ix:nonFraction> (the &#8220;Loan Agreement&#8221;) to be funded in <ix:nonFraction name="galt:NumberOfLoansClosing" id="Fact_45dae238908247ca809d0e8ec098c9c2" contextRef="c20210917to20210917_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U005" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> closings
        and evidenced by <ix:nonFraction name="galt:NumberOfPromissoryNotesEvidencedByLoansAgreement" id="Fact_d4474845663945878b43b01f6460951a" contextRef="c20210917to20210917_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U006" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> separate unsecured convertible promissory notes.&#160; The first of the <ix:nonFraction name="galt:NumberOfPromissoryNotesExecuted" id="Fact_e77c13f4fac5487c93dc0d4b365f8b39" contextRef="c20210917to20210917_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U006" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> promissory notes was also executed and delivered on September 17, 2021, (the &#8220;September 2021 Note&#8221;) to evidence the first loan in the principal amount of $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" id="Fact_1c5ba7c8514a4095b67127ae2aa6ebc5" contextRef="c20210917_DebtInstrumentAxis_FirstClosingMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction>.&#160; The second closing under the Loan Agreement for the remaining $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" id="Fact_61c3864063e248b9bc9aa6133acab22d" contextRef="c20211220_DebtInstrumentAxis_SecondClosingMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction> occurred on December 20, 2021.</div>
</ix:continuation>
      <ix:continuation id="Text_05c9ef758cdd412fbc82eafaea96bee611" continuedAt="Text_05c9ef758cdd412fbc82eafaea96bee612">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>
</ix:continuation>
      <ix:continuation id="Text_05c9ef758cdd412fbc82eafaea96bee612" continuedAt="Text_05c9ef758cdd412fbc82eafaea96bee613">
<div style="margin-left: 22.5pt; font-family: 'Times New Roman'; font-size: 10pt;">The September 2021 Note has a maturity date of <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" id="Fact_cf16a649b11144ceae03f13d7b61be03" contextRef="c20240101to20241231_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" format="ixt:date-monthname-day-year-en">September 17, 2025</ix:nonNumeric>,
        is prepayable at the option of the Company in whole or in part at any time and is convertible into the Company&#8217;s common stock at a conversion price equal to $<ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" id="Fact_7d647f8fdbe34b69a7919ef06b638d66" contextRef="c20241231_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">8.64</ix:nonFraction> per share at the option of the noteholder. The September 2021 Note bears interest at the rate of two percent (<ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_c4c4f6f9e7734c8d9db8f944c64d21cd" contextRef="c20241231_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">2</ix:nonFraction>%)
        per annum, compounded annually with an effective interest rate of approximately <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" id="Fact_1aab4d0b75ee4baaa05ddb92a46240ac" contextRef="c20241231_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">3</ix:nonFraction>%. For the years ended December 31, 2024 and 2023,
        approximately $<ix:nonFraction name="us-gaap:InterestExpenseDebt" id="Fact_82ab2d99d1ea4f8c9d7a01a1e65e7107" contextRef="c20240101to20241231_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">210,000</ix:nonFraction> and $<ix:nonFraction name="us-gaap:InterestExpenseDebt" id="Fact_b2c8bc996e2a42ef9a741c9939f98516" contextRef="c20230101to20231231_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">206,000</ix:nonFraction>,
        respectively, of interest expense was accrued and included with the principal in the financial statements.</div>
</ix:continuation>
      <ix:continuation id="Text_05c9ef758cdd412fbc82eafaea96bee613" continuedAt="Text_05c9ef758cdd412fbc82eafaea96bee614">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>
</ix:continuation>
      <ix:continuation id="Text_05c9ef758cdd412fbc82eafaea96bee614" continuedAt="Text_05c9ef758cdd412fbc82eafaea96bee615">
<div style="margin-left: 22.5pt; font-family: 'Times New Roman'; font-size: 10pt;">The September 2021 Note also includes a contingent interest component that requires the Company to pay additional interest at a rate of two and one-half percent (<ix:nonFraction name="galt:QuarterlyInterestRate" id="Fact_01b06df7f31647e384cf453acd3f741d" contextRef="c20210917_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">2.5</ix:nonFraction>%) per quarter (<ix:nonFraction name="galt:AnnualInterestRate" id="Fact_46df9b7b4f5045d78029306178de71ce" contextRef="c20210917_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">10</ix:nonFraction>% per annum) (the
        &#8220;Additional Interest&#8221;) beginning on the date of issuance of this Note and ending on the maturity date, provided however, that such payment is only required if and only if the noteholder elects to convert the entire balance of the September 2021
        Note into the Company&#8217;s common stock on or prior to maturity. As the contingent event is not based on creditworthiness, such feature is not clearly and closely related to the host instrument and accordingly must be bifurcated and recognized as a
        derivative liability and a debt discount on the September Note at its inception. The fair value of the contingent interest derivative liability was $<ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" id="Fact_7fdd3ffc8ce04c6cbfbf6ff8445af728" contextRef="c20210917_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">433,000</ix:nonFraction>
        at note inception (September 17, 2021). The fair value of the contingent interest derivative liability was $<ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" id="Fact_8ba9cfc1f63e45bab5825a1087d04939" contextRef="c20241231_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">94,000</ix:nonFraction> and $<ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" id="Fact_d843bda2f6ae4cc09f48760e18b0aebf" contextRef="c20231231_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">169,000</ix:nonFraction> and December 31, 2024 and 2023, respectively, and is recognized as a derivative liability in the consolidated balance sheet. The change in the
        fair value of the derivative liability for the years ended December 31, 2024 and 2023 of ($<ix:nonFraction name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" id="Fact_091315b8c19d41f9a0a3c46327aaecae" contextRef="c20240101to20241231_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">75,000</ix:nonFraction>) and $<ix:nonFraction name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" id="Fact_3b216d1f547a46a9813492974cc0f8c9" contextRef="c20230101to20231231_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember" unitRef="U001" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">60,000</ix:nonFraction>, respectively, was recorded to other expense/(income) for the years ended December 31, 2024 and 2023. The amortization of the original $<ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" id="Fact_a0a73beccca4417da21a6312c4e451ff" contextRef="c20240101to20241231_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">433,000</ix:nonFraction> debt discount of $<ix:nonFraction name="us-gaap:InterestExpenseOther" id="Fact_6d9e044813a542e09363279674679efd" contextRef="c20240101to20241231_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">108,000</ix:nonFraction> and $<ix:nonFraction name="us-gaap:InterestExpenseOther" id="Fact_c068a148b1f34ee89fd421416326c81a" contextRef="c20230101to20231231_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">108,000</ix:nonFraction> was recorded as additional interest expense for the years ended December 31, 2024 and 2023, respectively.</div>
</ix:continuation>
      <ix:continuation id="Text_05c9ef758cdd412fbc82eafaea96bee615" continuedAt="Text_05c9ef758cdd412fbc82eafaea96bee616">
<div style="margin-left: 22.5pt; font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>
</ix:continuation>
      <ix:continuation id="Text_05c9ef758cdd412fbc82eafaea96bee616" continuedAt="Text_05c9ef758cdd412fbc82eafaea96bee617">
<div style="margin-left: 22.5pt; font-family: 'Times New Roman'; font-size: 10pt;">On December 20, 2021, the second of the <ix:nonFraction name="galt:NumberOfPromissoryNotesEvidencedByLoansAgreement" id="Fact_b65a953bd97240e49bcf99b447069bf8" contextRef="c20211220to20211220_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember" unitRef="U006" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> promissory
        notes under the Loan Agreement was executed and delivered, (the &#8220;December 2021 Note&#8221;) to evidence the second loan in the principal amount of $<ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentAmount1" id="Fact_55abea4dda984c1998749cbc01e00350" contextRef="c20211220to20211220_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction>.&#160;























































































        The December 2021 Note has a maturity date of <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" id="Fact_ddd323e9960e495a85ca599044de5691" contextRef="c20211220to20211220_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember" format="ixt:date-monthname-day-year-en">December 20, 2025</ix:nonNumeric>, is prepayable at the option of the Company in whole or in part at any
        time and is convertible into the Company&#8217;s common stock at a conversion price equal to $<ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" id="Fact_69f6ac4e7cf64ef0a66587b369620827" contextRef="c20211220_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">5.43</ix:nonFraction> per share at the option of the noteholder.
        The December Note bears interest at the rate of two percent (<ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_c7d8f0469c3f46c5a28ac11c9e869c2c" contextRef="c20211220_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">2</ix:nonFraction>%) per annum, compounded annually with an effective interest rate of
        approximately <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" id="Fact_67439535778c4aecbfe0e88407a22179" contextRef="c20211220_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">3</ix:nonFraction>%. For the years ended December 31, 2024 and 2023, approximately $<ix:nonFraction name="us-gaap:InterestExpenseDebt" id="Fact_f3c67c2b79b14ed8a5d290d6e944a2d9" contextRef="c20240101to20241231_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">209,000</ix:nonFraction> and $<ix:nonFraction name="us-gaap:InterestExpenseDebt" id="Fact_fc1598e58e5a4b068f4e5289c8e2d04d" contextRef="c20230101to20231231_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">204,000</ix:nonFraction>, respectively, of interest expense was accrued and
        included with the principal in the financial statements.</div>
</ix:continuation>
      <ix:continuation id="Text_05c9ef758cdd412fbc82eafaea96bee617" continuedAt="Text_05c9ef758cdd412fbc82eafaea96bee618">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>
</ix:continuation>
      <ix:continuation id="Text_05c9ef758cdd412fbc82eafaea96bee618" continuedAt="Text_05c9ef758cdd412fbc82eafaea96bee619">
<div style="margin-left: 22.5pt; font-family: 'Times New Roman'; font-size: 10pt;">The December 2021 Note also includes a contingent interest component that requires the Company to pay additional interest at a rate of two and one-half percent (<ix:nonFraction name="galt:QuarterlyInterestRate" id="Fact_7daeba3064cf4f5fa6a21ca5a0fbd797" contextRef="c20211220_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">2.5</ix:nonFraction>%) per quarter (<ix:nonFraction name="galt:AnnualInterestRate" id="Fact_6a75ca6e79ce4a88b4d76f920f5eddbb" contextRef="c20211220_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">10</ix:nonFraction>% per annum) (the
        &#8220;Additional Interest&#8221;) beginning on the date of issuance of this Note and ending on the maturity date, provided however, that such payment is only required if and only if the noteholder elects to convert the entire balance of the December 2021 Note
        into the Company&#8217;s common stock on or prior to maturity. As the contingent event is not based on creditworthiness, such feature is not clearly and closely related to the host instrument and accordingly must be bifurcated and recognized as a
        derivative liability and a debt discount on the December Note at its inception. The fair value of the contingent interest derivative liability was $<ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" id="Fact_7418275339384953973bbacd6850cab9" contextRef="c20211220_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">415,000</ix:nonFraction>
        at note inception (December 20, 2021). The fair value of the contingent interest derivative liability was $<ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" id="Fact_5d349e641be340b5aadbf6c28f947eb1" contextRef="c20241231_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">275,000</ix:nonFraction> and $<ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" id="Fact_e65452d95c98400a812f84187fa19a59" contextRef="c20231231_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">404,000</ix:nonFraction> at December 31, 2024 and 2023, respectively, and is recognized as a derivative liability in the consolidated balance sheet. The change in the
        fair value of the derivative liability for the years ended December 31, 2024 and 2023 of ($<ix:nonFraction name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" id="Fact_385137fbb314408893e958a189fcd2f2" contextRef="c20240101to20241231_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">129,000</ix:nonFraction>) and $<ix:nonFraction name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" id="Fact_61d7fee3f4164b13a978a95c7d57c38f" contextRef="c20230101to20231231_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember" unitRef="U001" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">190,000</ix:nonFraction>, respectively was recorded to other expense/(income) for the years ended December 31, 2024 and 2023. The amortization of the original $<ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" id="Fact_4f77f69517b3443592b348dabe390c48" contextRef="c20240101to20241231_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">415,000</ix:nonFraction> debt discount of $<ix:nonFraction name="us-gaap:InterestExpenseOther" id="Fact_6ea03c542dd840698d33869dd64faacb" contextRef="c20240101to20241231_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">104,000</ix:nonFraction> and $<ix:nonFraction name="us-gaap:InterestExpenseOther" id="Fact_27f1dd0ad9c34ac2b98976d419b21ea0" contextRef="c20230101to20231231_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">104,000</ix:nonFraction> was recorded as additional interest expense for the years ended December 31, 2024 and 2023, respectively.</div>
</ix:continuation>
      <ix:continuation id="Text_05c9ef758cdd412fbc82eafaea96bee619" continuedAt="Text_05c9ef758cdd412fbc82eafaea96bee620">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>
</ix:continuation>
      <ix:continuation id="Text_05c9ef758cdd412fbc82eafaea96bee620">
<div style="margin-left: 22.5pt; font-family: 'Times New Roman'; font-size: 10pt;">The Company&#8217;s contractual cash obligations related to the outstanding convertible notes payable is a repayment of the repayment of the September 2021 Note of the $<ix:nonFraction name="us-gaap:RepaymentsOfDebt" id="Fact_f6d1f1e1ff0240b3885f310a6abca69f" contextRef="c20250917to20250917_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_StatementScenarioAxis_ScenarioForecastMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction> plus accrued interest on September 17, 2025 and a repayment of the December 2021 Note of the $<ix:nonFraction name="us-gaap:RepaymentsOfDebt" id="Fact_31bfbcc4c6e544748d33c342d5648514" contextRef="c20251230to20251230_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember_StatementScenarioAxis_ScenarioForecastMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction> plus accrued interest on December 30, 2025, unless converted at the option of the noteholder.</div>
</ix:continuation>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">F-11</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

        <div style="width: 100%;" class="BRPFPageHeader">
          <div>
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

            </div>

          </div>

        </div>

      </div>

    </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">

    <div>
      <ix:nonNumeric name="us-gaap:FairValueDisclosuresTextBlock" id="Text_d4685a0fad0a4c129cfb4ad971b000c4" contextRef="c20240101to20241231" escape="true" continuedAt="Text_e0eae8630e974ecba8a5f5de29ac98c11">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 27pt; vertical-align: top; font-weight: bold;">6.</td>

    <td style="width: auto; vertical-align: top;">
              <div style="font-weight: bold;">Fair Value of Financial Instruments</div>
            </td>

  </tr>


</table>
</ix:nonNumeric>
      <ix:continuation id="Text_e0eae8630e974ecba8a5f5de29ac98c11" continuedAt="Text_e0eae8630e974ecba8a5f5de29ac98c12">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>
</ix:continuation>
      <ix:continuation id="Text_e0eae8630e974ecba8a5f5de29ac98c12" continuedAt="Text_e0eae8630e974ecba8a5f5de29ac98c13">
<div style="margin: 0px 0px 0px 27pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">There were <ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" id="Fact_f0f76a611a61480997d5c072d144fb25" contextRef="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" id="Fact_ef06d1c764e94d2c8305902fe179c236" contextRef="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" id="Fact_d95f177c87104dedabf1859521ef9763" contextRef="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" id="Fact_8f0d12c45ed040d78795ae7762682a30" contextRef="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" id="Fact_851b186510764ae28d3dfa53b675b039" contextRef="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" id="Fact_5c9c3ec85ae14451bcdf8626bc94a878" contextRef="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" id="Fact_4386c7aa9d244786ade7c20f5562dc04" contextRef="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" id="Fact_08329a2d9bce4f07a9c6692817c5fcf4" contextRef="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> level 1 or 2 assets or liabilities at December 31, 2024 or 2023.<br/>
        </span> </div>
</ix:continuation>
      <ix:continuation id="Text_e0eae8630e974ecba8a5f5de29ac98c13" continuedAt="Text_e0eae8630e974ecba8a5f5de29ac98c14">
<div style="margin: 0px 0px 0px 27pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span><br/>
      </div>
</ix:continuation>

      <ix:nonNumeric name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="Text_79e128d45a2c4990bab4a109e52a10b3" contextRef="c20240101to20241231" escape="true" continuedAt="Text_2dd1bcd378bf4adaba01dd6ba4a942361"><ix:continuation id="Text_e0eae8630e974ecba8a5f5de29ac98c14" continuedAt="Text_e0eae8630e974ecba8a5f5de29ac98c15">
<div style="margin-left: 27pt; font-family: 'Times New Roman'; font-size: 10pt;">Level 3 assets and liabilities measured and recorded at fair value on a recurring basis at December 31, 2024 and 2023 were as follows:</div>
</ix:continuation></ix:nonNumeric>
      <ix:continuation id="Text_2dd1bcd378bf4adaba01dd6ba4a942361" continuedAt="Text_2dd1bcd378bf4adaba01dd6ba4a942362"><ix:continuation id="Text_e0eae8630e974ecba8a5f5de29ac98c15" continuedAt="Text_e0eae8630e974ecba8a5f5de29ac98c16">
<div style="margin-left: 27pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_e0eae8630e974ecba8a5f5de29ac98c16" continuedAt="Text_e0eae8630e974ecba8a5f5de29ac98c17"><ix:continuation id="Text_2dd1bcd378bf4adaba01dd6ba4a942362">
<div style="margin-left: 27pt;">
        <table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;">


  <tr>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-left: 17%; padding-bottom: 2px;">
                <div style="text-align: center; margin-left: 27pt;"><br/>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                <div style="text-align: center; font-weight: bold;">December 31, 2024<br/>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                <div style="text-align: center; font-weight: bold;">December 31, 2023<br/>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 68.7%; background-color: rgb(204, 238, 255);">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Derivative Liability &#8211; Contingent Interest April Note</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1.22%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1.22%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 11.94%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" id="Fact_1896f9b4b5ab4076bca544b7d7022870" contextRef="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">47,000</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1.22%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1.22%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1.22%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 11.94%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" id="Fact_0814294ce886446e9090d119fd7befaa" contextRef="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">431,000</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1.22%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 68.7%;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Derivative Liability &#8211; Contingent Interest September Note</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1.22%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1.22%; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 11.94%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" id="Fact_ca51f2581b234435ad9b45dc05d35029" contextRef="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">94,000</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1.22%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1.22%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1.22%; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 11.94%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" id="Fact_d69554ec004b4f0cafb4917a13e68d57" contextRef="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">169,000</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1.22%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 68.7%; background-color: rgb(204, 238, 255);">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Derivative Liability &#8211; Contingent Interest December Note</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1.22%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1.22%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 11.94%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" id="Fact_96a36f0940e748d78009843984146095" contextRef="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">275,000</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1.22%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1.22%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1.22%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 11.94%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" id="Fact_2af58f3e8c8e45b7893daa4b42d284be" contextRef="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">404,000</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1.22%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>


</table>
         </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_e0eae8630e974ecba8a5f5de29ac98c17" continuedAt="Text_e0eae8630e974ecba8a5f5de29ac98c18">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>
</ix:continuation>

      <ix:nonNumeric name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="Text_89a76df31fde4a86969b359d4ee886ca" contextRef="c20240101to20241231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember" escape="true" continuedAt="Text_7dab7ba3937f4f69ac9dfb4f5d6a948f1"><ix:continuation id="Text_e0eae8630e974ecba8a5f5de29ac98c18" continuedAt="Text_e0eae8630e974ecba8a5f5de29ac98c19">
<div style="margin-left: 27pt; font-family: 'Times New Roman'; font-size: 10pt;">The April 2021 Note derivative liability &#8211; contingent interest was valued using a Monte Carlo Geometric Brownian Stock Path Model. The key assumptions used in the model
        at December 31, 2024 and 2023 are as follows:</div>
</ix:continuation></ix:nonNumeric>
      <ix:continuation id="Text_7dab7ba3937f4f69ac9dfb4f5d6a948f1" continuedAt="Text_7dab7ba3937f4f69ac9dfb4f5d6a948f2"><ix:continuation id="Text_e0eae8630e974ecba8a5f5de29ac98c19" continuedAt="Text_e0eae8630e974ecba8a5f5de29ac98c110">
<div style="margin-left: 27pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_e0eae8630e974ecba8a5f5de29ac98c110" continuedAt="Text_e0eae8630e974ecba8a5f5de29ac98c111"><ix:continuation id="Text_7dab7ba3937f4f69ac9dfb4f5d6a948f2">
<div style="margin-left: 27pt;">
        <table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 70%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; font-weight: bold;">December 31, 2024<br/>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">December 31, 2023</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 70%; background-color: rgb(204, 238, 255);">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Stock Price</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_b5058c32a8f04e3e8abf17bb1ed515c2" contextRef="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputSharePriceMember" unitRef="U007" decimals="2" scale="0" format="ixt:num-dot-decimal">1.29</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_7e5411ee80a0487ab8e5e9fc99d9658d" contextRef="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputSharePriceMember" unitRef="U007" decimals="2" scale="0" format="ixt:num-dot-decimal">1.66</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 70%;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Conversion Price of conversion feature</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_e4500300760f4f95bba0950328aa56b0" contextRef="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputConversionPriceMember" unitRef="U007" decimals="2" scale="0" format="ixt:num-dot-decimal">5.00</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_825acf07b6c74146b4d2a5fd7c567fa3" contextRef="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputConversionPriceMember" unitRef="U007" decimals="2" scale="0" format="ixt:num-dot-decimal">5.00</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; background-color: rgb(204, 238, 255); width: 70%;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Term</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="font-family: 'Times New Roman'; text-indent: 25pt; text-align: right;"><span style="font-family: 'Times New Roman'; color: rgb(0, 255, 0);"> <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="text-indent: 0pt;"><ix:nonNumeric name="us-gaap:DebtInstrumentTerm" id="Fact_f10999370c654da3b05b0d3d10e6355f" contextRef="c20240101to20241231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedTermMember" format="ixt-sec:duryear">0.29</ix:nonNumeric></span> years</span><br/>
                  </span></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="text-align: right;"><ix:nonNumeric name="us-gaap:DebtInstrumentTerm" id="Fact_2b929b50c5ca4e1ca92696a2da1c7c3e" contextRef="c20230101to20231231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedTermMember" format="ixt-sec:duryear">1.29</ix:nonNumeric> years<br/>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 70%;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Risk Free Interest Rate</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_4d8ab1c8deac454390f0b93df2c899d7" contextRef="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">4.37</ix:nonFraction></span></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';">%</span></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_99e111e12045424e9bce24d384702c4a" contextRef="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">4.79</ix:nonFraction></span></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';">%</span></div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 70%; background-color: rgb(204, 238, 255);">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Credit Adjusted Discount Rate</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_a6615a2c3f1644209cd6a504ca2a9a90" contextRef="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputDiscountRateMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">12.43</ix:nonFraction></span></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';">%</span></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_aa810dc98df342adb92e31893127302e" contextRef="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputDiscountRateMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">12.86</ix:nonFraction></span></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';">%</span></div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 70%;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Volatility</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_666594034d6146f39588f217fbc67b9b" contextRef="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">152</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div>%</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_d39167aebcaf404eae9d2919b7befcba" contextRef="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">69</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div>%</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 70%; background-color: rgb(204, 238, 255);">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Dividend Rate</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_9f5d08c29eff4648b019c5096b6a7c87" contextRef="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedDividendRateMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">0</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>%</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_5020ac74888a4e6da19a0a22117f4e8d" contextRef="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedDividendRateMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">0</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>%</div>
              </td>

  </tr>


</table>
         </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_e0eae8630e974ecba8a5f5de29ac98c111" continuedAt="Text_e0eae8630e974ecba8a5f5de29ac98c112">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>
</ix:continuation>

      <ix:nonNumeric name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="Text_4a3bfb7e8e0a4e0896b8dc64f4bf4f8b" contextRef="c20240101to20241231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember" escape="true" continuedAt="Text_94d01473086144dfb4b8eb7347fbb3541"><ix:continuation id="Text_e0eae8630e974ecba8a5f5de29ac98c112" continuedAt="Text_e0eae8630e974ecba8a5f5de29ac98c113">
<div style="margin-left: 27pt; font-family: 'Times New Roman'; font-size: 10pt;">The roll forward of the April 2021 Note derivative liability &#8211; contingent interest is as follows:</div>
</ix:continuation></ix:nonNumeric>
      <ix:continuation id="Text_94d01473086144dfb4b8eb7347fbb3541" continuedAt="Text_94d01473086144dfb4b8eb7347fbb3542"><ix:continuation id="Text_e0eae8630e974ecba8a5f5de29ac98c113" continuedAt="Text_e0eae8630e974ecba8a5f5de29ac98c114">
<div style="margin-left: 27pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_e0eae8630e974ecba8a5f5de29ac98c114" continuedAt="Text_e0eae8630e974ecba8a5f5de29ac98c115"><ix:continuation id="Text_94d01473086144dfb4b8eb7347fbb3542">
<div style="margin-left: 27pt;">
        <table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;">


  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%; background-color: #CCEEFF;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Balance &#8211; December 31, <span style="text-indent: 0pt;">2022</span></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" id="Fact_dde33b2e445d47c7811c22b414e9e2a1" contextRef="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">249,000</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%; padding-bottom: 2px;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Fair Value Adjustment</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" id="Fact_d9ce2b0549ff47db8a12f731649711c4" contextRef="c20230101to20231231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">182,000</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%; background-color: #CCEEFF;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Balance &#8211; December 31, <span style="text-indent: 0pt;">2023</span></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" id="Fact_09c1162f2ba044faa607e47d5efae8d8" contextRef="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">431,000</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 2px;">Fair Value Adjustment</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" id="Fact_12c6088ee8cf410db530f702106684a0" contextRef="c20240101to20241231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember" unitRef="U001" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">384,000</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">)</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 4px; background-color: #CCEEFF;">Balance &#8211; December 31, 2024</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">$</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" id="Fact_794a131ee15a43ecb3925c5cc2c89f98" contextRef="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">47,000</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>


</table>

      </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_e0eae8630e974ecba8a5f5de29ac98c115" continuedAt="Text_e0eae8630e974ecba8a5f5de29ac98c116">
<div style="margin-left: 27pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>
</ix:continuation>

      <ix:nonNumeric name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="Text_5b5f5494613745f6a0a2150a8423cdf6" contextRef="c20240101to20241231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember" escape="true" continuedAt="Text_160efe7ee986451a97a462b02a9adf491"><ix:continuation id="Text_e0eae8630e974ecba8a5f5de29ac98c116" continuedAt="Text_e0eae8630e974ecba8a5f5de29ac98c117">
<div style="margin-left: 27pt; font-family: 'Times New Roman'; font-size: 10pt;">The September 2021 Note derivative liability &#8211; contingent interest was valued using a Monte Carlo Geometric Brownian Stock Path Model. The key assumptions used in the
        model at inception, and at December 31, 2024 and 2023 are as follows:</div>
</ix:continuation></ix:nonNumeric>
      <ix:continuation id="Text_160efe7ee986451a97a462b02a9adf491" continuedAt="Text_160efe7ee986451a97a462b02a9adf492"><ix:continuation id="Text_e0eae8630e974ecba8a5f5de29ac98c117" continuedAt="Text_e0eae8630e974ecba8a5f5de29ac98c118">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_e0eae8630e974ecba8a5f5de29ac98c118" continuedAt="Text_e0eae8630e974ecba8a5f5de29ac98c119"><ix:continuation id="Text_160efe7ee986451a97a462b02a9adf492">
<div style="margin-left: 27pt;">
        <table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 70%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="font-weight: bold;">December 31, 2024<br/>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div style="font-weight: bold;">December 31, 2023</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 70%; background-color: rgb(204, 238, 255);">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Stock Price</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_d1d5e7482ecb45deafd872ac8ff7bba8" contextRef="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputSharePriceMember" unitRef="U007" decimals="2" scale="0" format="ixt:num-dot-decimal">1.29</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_54ffee996f6941459c535e9dbae2761a" contextRef="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputSharePriceMember" unitRef="U007" decimals="2" scale="0" format="ixt:num-dot-decimal">1.66</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 70%;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Conversion Price of conversion feature</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_dd7b1724e534432b9c056dfb7f4a830f" contextRef="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputConversionPriceMember" unitRef="U007" decimals="2" scale="0" format="ixt:num-dot-decimal">8.64</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_3175cfc193ae4e9b9ba8ab369b7bf9c5" contextRef="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputConversionPriceMember" unitRef="U007" decimals="2" scale="0" format="ixt:num-dot-decimal">8.64</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; background-color: rgb(204, 238, 255); width: 70%;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Term</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); white-space: nowrap;"><ix:nonNumeric name="us-gaap:DebtInstrumentTerm" id="Fact_651bccb5c228416ab4d1e47d9cad801e" contextRef="c20240101to20241231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedTermMember" format="ixt-sec:duryear">0.72</ix:nonNumeric>
                years<br/>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); white-space: nowrap;"><ix:nonNumeric name="us-gaap:DebtInstrumentTerm" id="Fact_561cf89cb33b48d09039901d29580e5c" contextRef="c20230101to20231231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedTermMember" format="ixt-sec:duryear">1.72</ix:nonNumeric>
                years</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 70%;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Risk Free Interest Rate</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_fd4a286e1b304e12bb815fc6b51b42de" contextRef="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">4.16</ix:nonFraction></span></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';">%</span></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_955bb81e982043028b0b15166fb07688" contextRef="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">4.23</ix:nonFraction></span></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';">%</span></div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 70%; background-color: rgb(204, 238, 255);">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Credit Adjusted Discount Rate</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_dae80d81068c425ba92fd8607465b789" contextRef="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputDiscountRateMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">12.43</ix:nonFraction></span></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';">%</span></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_14b1d9cd4d7e46e19f150b780f578f71" contextRef="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputDiscountRateMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">12.86</ix:nonFraction></span></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';">%</span></div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 70%;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Volatility</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_c6120f4b53804c9ca9c5d62bd7e61e24" contextRef="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">111</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div>%</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_860c6ac12696490a9771474118834e30" contextRef="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">75</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div>%</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 70%; background-color: rgb(204, 238, 255);">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Dividend Rate</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_624963a5f6464541a20ecea607d1fb66" contextRef="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedDividendRateMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">0</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>%</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_c7b78da66c2441eba1ee6b45dedbd88b" contextRef="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedDividendRateMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">0</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>%</div>
              </td>

  </tr>


</table>
         </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_e0eae8630e974ecba8a5f5de29ac98c119" continuedAt="Text_e0eae8630e974ecba8a5f5de29ac98c120">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>
</ix:continuation>

      <ix:nonNumeric name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="Text_fbea72618b0f4b059c7d91e9f4e15583" contextRef="c20240101to20241231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember" escape="true" continuedAt="Text_20d532e066b64f8983256ef01aefdbe11"><ix:continuation id="Text_e0eae8630e974ecba8a5f5de29ac98c120" continuedAt="Text_e0eae8630e974ecba8a5f5de29ac98c121">
<div style="margin-left: 27pt; font-family: 'Times New Roman'; font-size: 10pt;">The roll forward of the September 2021 Note derivative liability &#8211; contingent interest is as follows:</div>
</ix:continuation></ix:nonNumeric>
      <ix:continuation id="Text_20d532e066b64f8983256ef01aefdbe11" continuedAt="Text_20d532e066b64f8983256ef01aefdbe12"><ix:continuation id="Text_e0eae8630e974ecba8a5f5de29ac98c121" continuedAt="Text_e0eae8630e974ecba8a5f5de29ac98c122">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_e0eae8630e974ecba8a5f5de29ac98c122" continuedAt="Text_e0eae8630e974ecba8a5f5de29ac98c123"><ix:continuation id="Text_20d532e066b64f8983256ef01aefdbe12">
<div style="margin-left: 27pt;">
        <table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;">


  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%; background-color: #CCEEFF;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Balance &#8211; December 31, <span style="text-indent: 0pt;">2022</span></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" id="Fact_1961fdda673348ae9fa10ab2fabe7295" contextRef="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">109,000</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%; padding-bottom: 2px;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Fair Value Adjustment</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" id="Fact_7e22ba62158240bab3d97dd4f1f069c0" contextRef="c20230101to20231231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">60,000</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%; background-color: #CCEEFF;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Balance &#8211; December 31, <span style="text-indent: 0pt;">2023</span></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" id="Fact_9a35f91a2a854c62bc60dad6e215031e" contextRef="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">169,000</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 2px;">Fair Value Adjustment</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" id="Fact_d24da70cdeb1463587bb0c9352d5e80a" contextRef="c20240101to20241231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember" unitRef="U001" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">75,000</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">)</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 4px; background-color: #CCEEFF;">Balance &#8211; December 31, 2024</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">$</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" id="Fact_8c8f0f31aa8744318e7201acd1368dd3" contextRef="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">94,000</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>


</table>

      </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_e0eae8630e974ecba8a5f5de29ac98c123" continuedAt="Text_e0eae8630e974ecba8a5f5de29ac98c124">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>
</ix:continuation>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">F-12</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div>
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

            </div>

          </div>

        </div>

      </div>


      <ix:nonNumeric name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="Text_6d4a9a81036e4c01b6e0f4aa11080da1" contextRef="c20240101to20241231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember" escape="true" continuedAt="Text_679397ad05ef4dc9a4973882e70deb121"><ix:continuation id="Text_e0eae8630e974ecba8a5f5de29ac98c124" continuedAt="Text_e0eae8630e974ecba8a5f5de29ac98c125">
<div style="margin-left: 27pt; font-family: 'Times New Roman'; font-size: 10pt;">The December 2021 Note derivative liability &#8211; contingent interest was valued using a Monte Carlo Geometric Brownian Stock Path Model. The key assumptions used in the
        model at inception, and at December 31, 2024 and 2023 are as follows:</div>
</ix:continuation></ix:nonNumeric>
      <ix:continuation id="Text_679397ad05ef4dc9a4973882e70deb121" continuedAt="Text_679397ad05ef4dc9a4973882e70deb122"><ix:continuation id="Text_e0eae8630e974ecba8a5f5de29ac98c125" continuedAt="Text_e0eae8630e974ecba8a5f5de29ac98c126">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_e0eae8630e974ecba8a5f5de29ac98c126" continuedAt="Text_e0eae8630e974ecba8a5f5de29ac98c127"><ix:continuation id="Text_679397ad05ef4dc9a4973882e70deb122">
<div style="margin-left: 27pt;">
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 70%;">&#160;</td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
                <div style="font-weight: bold;">December 31, 2024<br/>
                </div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="2">
                <div style="font-weight: bold;">December 31, 2023</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 70%; background-color: rgb(204, 238, 255);">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Stock Price</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_b193a6757cc9488187040f5ae5a7d142" contextRef="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputSharePriceMember" unitRef="U007" decimals="2" scale="0" format="ixt:num-dot-decimal">1.29</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_a04d29fb9081483fa2126c8a139bd630" contextRef="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputSharePriceMember" unitRef="U007" decimals="2" scale="0" format="ixt:num-dot-decimal">1.66</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 70%;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Conversion Price of conversion feature</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_e9951fb46d2d420fb010d31c1cc96b1d" contextRef="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputConversionPriceMember" unitRef="U007" decimals="2" scale="0" format="ixt:num-dot-decimal">5.43</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_6dbd58e2c4194b5b8986851fe219f6cd" contextRef="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputConversionPriceMember" unitRef="U007" decimals="2" scale="0" format="ixt:num-dot-decimal">5.43</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; background-color: rgb(204, 238, 255); width: 70%;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Term</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="2">
                <div style="font-family: 'Times New Roman'; text-indent: 25pt; text-align: right;"><span style="font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="text-indent: 0pt;"><ix:nonNumeric name="us-gaap:DebtInstrumentTerm" id="Fact_c7a8690bc45f4e6d9f287672b4eb5769" contextRef="c20240101to20241231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedTermMember" format="ixt-sec:duryear">0.97</ix:nonNumeric></span> years</span></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="2">
                <div style="text-indent: 14pt;"><span style="text-indent: 0pt;"><ix:nonNumeric name="us-gaap:DebtInstrumentTerm" id="Fact_03f42706943849489b32d86e5d684a3f" contextRef="c20230101to20231231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedTermMember" format="ixt-sec:duryear">1.97</ix:nonNumeric></span> years</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 70%;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Risk Free Interest Rate</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" colspan="1">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_ee7e83d0ac6345c5a928cc5bb119398b" contextRef="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">4.16</ix:nonFraction></span></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';">%</span></div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" colspan="1">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_2d90420fdfa34bcfa73e18bbca165cb3" contextRef="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">4.23</ix:nonFraction></span></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';">%</span></div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 70%; background-color: rgb(204, 238, 255);">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Credit Adjusted Discount Rate</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_d3634533083b45a3953abe133a83db34" contextRef="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputDiscountRateMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">12.43</ix:nonFraction></span></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';">%</span></div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_a112ebe7dd6f461ead70c88a0c6956bf" contextRef="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputDiscountRateMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">12.86</ix:nonFraction></span></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';">%</span></div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 70%;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Volatility</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_b3ac772c819740f4b80c29f44784a006" contextRef="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">102</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                <div>%</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_97af8995a27a4a0f9d3759e69b6ea66c" contextRef="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">72</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                <div>%</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 70%; background-color: rgb(204, 238, 255);">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Dividend Rate</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_1350523f09e04bf089f805d3e57b5a33" contextRef="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedDividendRateMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">0</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>%</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" id="Fact_9d4aafdbb44e45c38d73a26275972223" contextRef="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedDividendRateMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">0</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>%</div>
              </td>

  </tr>


</table>
         </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_e0eae8630e974ecba8a5f5de29ac98c127" continuedAt="Text_e0eae8630e974ecba8a5f5de29ac98c128">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>
</ix:continuation>

      <ix:nonNumeric name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="Text_a6230b83587249babd93c2994a882880" contextRef="c20240101to20241231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember" escape="true" continuedAt="Text_36f1c8e9b951419d81bc1478276ff81b1"><ix:continuation id="Text_e0eae8630e974ecba8a5f5de29ac98c128" continuedAt="Text_e0eae8630e974ecba8a5f5de29ac98c129">
<div style="margin-left: 27pt; font-family: 'Times New Roman'; font-size: 10pt;">The roll forward of the December 2021 Note derivative liability &#8211; contingent interest is as follows:</div>
</ix:continuation></ix:nonNumeric>
      <ix:continuation id="Text_36f1c8e9b951419d81bc1478276ff81b1" continuedAt="Text_36f1c8e9b951419d81bc1478276ff81b2"><ix:continuation id="Text_e0eae8630e974ecba8a5f5de29ac98c129" continuedAt="Text_e0eae8630e974ecba8a5f5de29ac98c130">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>
</ix:continuation></ix:continuation>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <ix:continuation id="Text_36f1c8e9b951419d81bc1478276ff81b2"><ix:continuation id="Text_e0eae8630e974ecba8a5f5de29ac98c130">
<div style="margin-left: 27pt;">
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Balance &#8211; December 31, <span style="text-indent: 0pt;">2022</span></div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div>$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" id="Fact_77eb91b3e1974d3f93db4a052243e5a0" contextRef="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">214,000</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%; padding-bottom: 2px;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Fair Value Adjustment</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                  <div><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" id="Fact_0fbead46c73d43dd833d6afd596969f1" contextRef="c20230101to20231231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">190,000</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                  <div></div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Balance &#8211; December 31, <span style="text-indent: 0pt;">2023</span></div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" id="Fact_c4ecaea928d24996bd99e69d8f40cca7" contextRef="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">404,000</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%; padding-bottom: 2px;" rowspan="1">Fair Value Adjustment</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" id="Fact_0104ce9e1ada40c98572f70a73c61535" contextRef="c20240101to20241231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember" unitRef="U001" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">129,000</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">)</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%; padding-bottom: 4px; background-color: #CCEEFF;" rowspan="1">Balance &#8211; December 31, 2024</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" id="Fact_6487d94a9e1541768dbe75e4ff68684e" contextRef="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">275,000</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>


</table>
        </div>
</ix:continuation></ix:continuation>
         </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

    </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">

    <div>
      <ix:nonNumeric name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Text_e086e552c31544b38a446bfb96b43ef1" contextRef="c20240101to20241231" escape="true" continuedAt="Text_030d691cd9f44aa4af74f8417b6e78981">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 24.5pt; vertical-align: top; font-weight: bold;">7.</td>

    <td style="width: auto; vertical-align: top;">
              <div style="font-weight: bold;">Stockholders&#8217; Equity</div>
            </td>

  </tr>


</table>
</ix:nonNumeric>
      <ix:continuation id="Text_030d691cd9f44aa4af74f8417b6e78981" continuedAt="Text_030d691cd9f44aa4af74f8417b6e78982">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>
</ix:continuation>
      <ix:continuation id="Text_030d691cd9f44aa4af74f8417b6e78982" continuedAt="Text_030d691cd9f44aa4af74f8417b6e78983">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">At December 31, 2024, the Company had <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" id="Fact_df254785226a49ada338443f8a746383" contextRef="c20241231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">150,000,000</ix:nonFraction>
        shares of common stock and <ix:nonFraction name="galt:UndesignatedCapitalStockSharesAuthorized" id="Fact_bff5e191f3b74e1bbb7c661f36ebd166" contextRef="c20241231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">20,000,000</ix:nonFraction> undesignated shares authorized. As of December 31, 2024, <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" id="Fact_685470cd9ce24de384226e69a5d0e1fe" contextRef="c20241231_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,742,500</ix:nonFraction> shares have been designated for Series A 12% Convertible Preferred Stock, <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" id="Fact_01a7b4051d6f41149064922a8959faa2" contextRef="c20241231_StatementClassOfStockAxis_SeriesBOneConvertiblePreferredStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">900,000</ix:nonFraction> shares have been designated for Series B-1 Convertible Preferred Stock, <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" id="Fact_643e7671f7804f3e9e07eeefe33ed2a3" contextRef="c20241231_StatementClassOfStockAxis_SeriesBTwoConvertiblePreferredStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,100,000</ix:nonFraction>
        shares have been designated for Series B-2 Convertible Preferred Stock, <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" id="Fact_f59905fc9d9c45a3bfa57a8ca1ca45d6" contextRef="c20241231_StatementClassOfStockAxis_SeriesCPreferredStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,000</ix:nonFraction> shares have been designated for Series C Super Dividend
        Convertible Preferred Stock, <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" id="Fact_6aee83ac89b442e5a47cd6861ab4764a" contextRef="c20241231_StatementClassOfStockAxis_SeriesBThreeConvertiblePreferredStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,508,000</ix:nonFraction> shares have been designated for Series B-3 Convertible Preferred Stock, <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" id="Fact_f2e2fc937f294834bf4c4efc82cf5061" contextRef="c20241231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">12,748,500</ix:nonFraction> have been designated as common stock and no shares remain undesignated. All issued and outstanding shares of Series B-1, Series B-2 and
        Series B-3 Preferred Stock were converted into Common Stock on January 19, 2019.</div>
</ix:continuation>
      <ix:continuation id="Text_030d691cd9f44aa4af74f8417b6e78983" continuedAt="Text_030d691cd9f44aa4af74f8417b6e78984">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>
</ix:continuation>
      <ix:continuation id="Text_030d691cd9f44aa4af74f8417b6e78984" continuedAt="Text_030d691cd9f44aa4af74f8417b6e78985">
<div style="margin-left: 24.45pt; font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">2020 At Market Issuance of Common Stock</div>
</ix:continuation>
      <ix:continuation id="Text_030d691cd9f44aa4af74f8417b6e78985" continuedAt="Text_030d691cd9f44aa4af74f8417b6e78986">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>
</ix:continuation>
      <ix:continuation id="Text_030d691cd9f44aa4af74f8417b6e78986" continuedAt="Text_030d691cd9f44aa4af74f8417b6e78987">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">On May 11, 2020, the Company entered into an At Market Issuance Sales Agreement (the &#8220;2020 At Market Agreement&#8221;) with a sales agent under which the Company may issue
        and sell shares of its common stock having an aggregate offering price of up to $<ix:nonFraction name="galt:AggregateOfferingPrice" id="Fact_acca4a3007244adf89bd9c63188e8dbf" contextRef="c20231231_TypeOfArrangementAxis_TwoThousandTwentyMarketAgreementMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">40.0</ix:nonFraction> million from time to time through the sales agent.
        Sales of the Company&#8217;s common stock through the sales agent, if any, will be made by any method that is deemed an &#8220;at the market&#8221; offering as defined by the U.S. Securities and Exchange Commission. The Company will pay to the sales agent a
        commission rate equal to <ix:nonFraction name="galt:CommissionRate" id="Fact_236a85b561bd4e8e961783fdced243e3" contextRef="c20231231_TypeOfArrangementAxis_TwoThousandTwentyMarketAgreementMember" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">3.0</ix:nonFraction>% of the gross proceeds from the sale of any shares of common stock sold through the sales agent under the
        2020 At Market Agreement. There were <ix:nonFraction name="us-gaap:CommonStockSharesIssued" id="Fact_ea699487cda64fd388dd717c0500e46c" contextRef="c20241231_TypeOfArrangementAxis_TwoThousandTwentyMarketAgreementMember" unitRef="U002" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" id="Fact_66dcb95c168547b58cb56dd92079201d" contextRef="c20231231_TypeOfArrangementAxis_TwoThousandTwentyMarketAgreementMember" unitRef="U002" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> issuances of common stock under the 2020 At Market Agreement during the year ended December
        31, 2024 or 2023.<br/>
      </div>
</ix:continuation>
      <ix:continuation id="Text_030d691cd9f44aa4af74f8417b6e78987" continuedAt="Text_030d691cd9f44aa4af74f8417b6e78988">
<div><br/></div>
</ix:continuation>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">F-13</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div>
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

            </div>

          </div>

        </div>

      </div>

      <ix:continuation id="Text_030d691cd9f44aa4af74f8417b6e78988" continuedAt="Text_030d691cd9f44aa4af74f8417b6e78989">
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Series A <ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" id="Fact_57f5cea6b93f44098ee283e9aada0b8f" contextRef="c20080204to20080204_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">12</ix:nonFraction>% Convertible Preferred
        Stock &#8212; February 4, 2008 Private Placement</div>
</ix:continuation>
      <ix:continuation id="Text_030d691cd9f44aa4af74f8417b6e78989" continuedAt="Text_030d691cd9f44aa4af74f8417b6e789810">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>
</ix:continuation>
      <ix:continuation id="Text_030d691cd9f44aa4af74f8417b6e789810" continuedAt="Text_030d691cd9f44aa4af74f8417b6e789811">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">On February 4, 2008, the Company closed a private placement begun in October 2007 of its Series A <ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" id="Fact_640f11e1d132450ab7b83c3997c07407" contextRef="c20080204to20080204_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">12</ix:nonFraction>% Convertible Preferred Stock (&#8220;Series A&#8221;) and related warrants. In this transaction, the Company sold units of securities at $<ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" id="Fact_fa8319fff8a940d191363eb745813294" contextRef="c20080204_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">6.00</ix:nonFraction> per unit, each unit comprised of (i) <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" id="Fact_9f8e8fd750de4334af956ba69838289b" contextRef="c20080204_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="U002" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction> share of Series A Preferred,
        (ii) a warrant to purchase one share of common stock for $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_84fc14076d884b2d91d9d38b8ca46c25" contextRef="c20080204_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementScenarioAxis_DividendPaymentScenarioOneMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">9.00</ix:nonFraction>, and (iii) a warrant to purchase one share of common stock for $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_9baf5742bfa54477898a183e6b077110" contextRef="c20080204_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementScenarioAxis_DividendPaymentScenarioTwoMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">12.00</ix:nonFraction>. Each share of the Series A is entitled to dividends at the rate of <ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" id="Fact_24b7bfaf3c3143f69c75d246502a6404" contextRef="c20080204to20080204_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">12</ix:nonFraction>% per annum payable at the Company&#8217;s option in cash or shares of common stock valued at the higher of $<ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" id="Fact_a5bc08538bbc4f65a9c2861f033fd9e3" contextRef="c20080204_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">6.00</ix:nonFraction> per share or <ix:nonFraction name="galt:PercentageOfWeightedAverageStockPriceForDividendsPriorToPaymentDate" id="Fact_a210a11aeffe473c9ef43d63c8373e6f" contextRef="c20080204to20080204_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction>% of the value weighted average price of the Company&#8217;s
        share price for the <ix:nonNumeric name="galt:NumberOfConsecutiveTradingDays" id="Fact_818f40e79da9490180fc8eb118e5f5a8" contextRef="c20080204to20080204_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementScenarioAxis_DividendPaymentScenarioOneMember" format="ixt-sec:durday">20</ix:nonNumeric> consecutive trading days prior to the applicable dividend payment date. Dividends are payable semi-annually on
        March 30 and September 30. The dividend paid on the initial dividend payment date is calculated from the date the Company deposited each subscription advance.</div>
</ix:continuation>
      <ix:continuation id="Text_030d691cd9f44aa4af74f8417b6e789811" continuedAt="Text_030d691cd9f44aa4af74f8417b6e789812">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>
</ix:continuation>
      <ix:continuation id="Text_030d691cd9f44aa4af74f8417b6e789812" continuedAt="Text_030d691cd9f44aa4af74f8417b6e789813">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">The shares of Series A are entitled to vote as a class with the Company&#8217;s common stock and each share of Series A is convertible at any time to one-sixth of a share
        of common stock, subject to adjustment in the event of a stock dividend, stock split or combination, reclassification or similar event. The Company has the right to require conversion if the closing price of the common stock exceeds $<ix:nonFraction name="us-gaap:SharePrice" id="Fact_a75a68f2092045d188c4fb70aa9887a8" contextRef="c20080204_RangeAxis_MinimumMember_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">18.00</ix:nonFraction> for <ix:nonNumeric name="galt:NumberOfConsecutiveTradingDays" id="Fact_a7d17af460884037a45016a26f12ca76" contextRef="c20080204to20080204_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementScenarioAxis_DividendPaymentScenarioTwoMember" format="ixt-sec:durday">15</ix:nonNumeric> consecutive trading days
        and a registration statement covering the resale of the shares of common stock issuable upon conversion of the Series A is then in effect. Each warrant is exercisable solely for cash beginning August 3, 2008 and expired on February 4, 2012. The
        exercise price of each warrant is adjustable in the event of a stock split or stock combination, capital reorganization, merger or similar event.</div>
</ix:continuation>
      <ix:continuation id="Text_030d691cd9f44aa4af74f8417b6e789813" continuedAt="Text_030d691cd9f44aa4af74f8417b6e789814">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>
</ix:continuation>
      <ix:continuation id="Text_030d691cd9f44aa4af74f8417b6e789814" continuedAt="Text_030d691cd9f44aa4af74f8417b6e789815">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">In 2023, <ix:nonFraction name="us-gaap:ConversionOfStockSharesIssued1" id="Fact_296b420cccdc4c64937ae9697d136573" contextRef="c20230101to20231231_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">25,000</ix:nonFraction> shares of Series A were converted into
        <ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" id="Fact_acfedec74dbc4160893b935c211ffebc" contextRef="c20230101to20231231_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">4,257</ix:nonFraction> shares of common stock. Prior to 2021, a total of <ix:nonFraction name="us-gaap:ConversionOfStockSharesIssued1" id="Fact_12bb80f812104d739134c7904db3e5c9" contextRef="c20200101to20201231_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">507,500</ix:nonFraction> shares of Series A had been converted into <ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" id="Fact_74f716ead72a465d91b6c0b71afe5811" contextRef="c20200101to20201231_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">81,152</ix:nonFraction> shares of common
        stock.</div>
</ix:continuation>
      <ix:continuation id="Text_030d691cd9f44aa4af74f8417b6e789815" continuedAt="Text_030d691cd9f44aa4af74f8417b6e789816">
<div><br/></div>
</ix:continuation>
      <ix:continuation id="Text_030d691cd9f44aa4af74f8417b6e789816" continuedAt="Text_030d691cd9f44aa4af74f8417b6e789817">
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Series C <ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" id="Fact_3424f5ca515f432faefeca03588626f5" contextRef="c20101230to20101230_StatementClassOfStockAxis_SeriesCPreferredStockMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">6</ix:nonFraction>% Super Dividend Redeemable
        Convertible Preferred Stock</div>
</ix:continuation>
      <ix:continuation id="Text_030d691cd9f44aa4af74f8417b6e789817" continuedAt="Text_030d691cd9f44aa4af74f8417b6e789818">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>
</ix:continuation>
      <ix:continuation id="Text_030d691cd9f44aa4af74f8417b6e789818" continuedAt="Text_030d691cd9f44aa4af74f8417b6e789819">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">On December 29, 2010, the Company designated and authorized the sale and issuance of up to <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" id="Fact_302b98ba983e4438961033e524ed7f4c" contextRef="c20101229to20101229_RangeAxis_MaximumMember_StatementClassOfStockAxis_SeriesCPreferredStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,000</ix:nonFraction> shares of Series C Super Dividend Redeemable Convertible Preferred Stock (&#8220;Series C&#8221;) with a par value of $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact_608fe797421745229cc08100807957fa" contextRef="c20101229_StatementClassOfStockAxis_SeriesCPreferredStockMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">0.01</ix:nonFraction> and a stated value equal to $<ix:nonFraction name="us-gaap:PreferredStockLiquidationPreference" id="Fact_9e94c58f51f84647a58fa3b7b1a5bb18" contextRef="c20101229_RangeAxis_MaximumMember_StatementClassOfStockAxis_SeriesCPreferredStockMember" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">10,000</ix:nonFraction> (the &#8220;Stated Value&#8221;).</div>
</ix:continuation>
      <ix:continuation id="Text_030d691cd9f44aa4af74f8417b6e789819" continuedAt="Text_030d691cd9f44aa4af74f8417b6e789820">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>
</ix:continuation>
      <ix:continuation id="Text_030d691cd9f44aa4af74f8417b6e789820" continuedAt="Text_030d691cd9f44aa4af74f8417b6e789821">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">On December 30, 2010, the Company sold and issued <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" id="Fact_dc881ed5354846d6b918b70f38d98499" contextRef="c20101230to20101230_StatementClassOfStockAxis_SeriesCPreferredStockMember" unitRef="U002" decimals="INF" scale="0" format="ixt:num-dot-decimal">212</ix:nonFraction>
        shares of Series C at a price of $<ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" id="Fact_fe850a955c814bf8ad471ad0658a1c94" contextRef="c20101230_StatementClassOfStockAxis_SeriesCPreferredStockMember" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">10,000</ix:nonFraction> per share for gross proceeds of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" id="Fact_5e1c2a4ad86d48d9b6c27301b35d89ce" contextRef="c20101230to20101230_StatementClassOfStockAxis_SeriesCPreferredStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">2,120,000</ix:nonFraction>. The Company incurred $<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" id="Fact_74d94247be3142ce81f254f5a68bbece" contextRef="c20101230to20101230_StatementClassOfStockAxis_SeriesCPreferredStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">47,000</ix:nonFraction> of cash transaction costs resulting in
        net cash proceeds of $<ix:nonFraction name="galt:ProceedsFromIssuanceOfPreferredStockNetOfIssuanceCosts" id="Fact_be713bc4cccc43e99dbaa04d9c089a41" contextRef="c20101230to20101230_StatementClassOfStockAxis_SeriesCPreferredStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">2,073,000</ix:nonFraction>. In addition, the Company issued <ix:nonFraction name="galt:ClassOfWarrantOrRightIssued" id="Fact_45e58d5086a44ddcb194fffc73b5fab3" contextRef="c20101230to20101230_StatementClassOfStockAxis_SeriesCPreferredStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">500</ix:nonFraction> warrants exercisable at $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_f4da2f90abda431aa006830d2c038f09" contextRef="c20101230_StatementClassOfStockAxis_SeriesCPreferredStockMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">7.20</ix:nonFraction> to a placement agent which had a de minimis
        value. Additionally, in January 2011, the Company sold and issued <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" id="Fact_86ca22d6c37c4a75b503bf08c92fbcb8" contextRef="c20110101to20110131_StatementClassOfStockAxis_SeriesCPreferredStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">13</ix:nonFraction> shares of Series C at a price of $<ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" id="Fact_091d670c07194bf5aa1a50cc7b641683" contextRef="c20110131_StatementClassOfStockAxis_SeriesCPreferredStockMember" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">10,000</ix:nonFraction> per share for gross proceeds of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" id="Fact_e268bd8e43d04556a9c3581a55893886" contextRef="c20110101to20110131_StatementClassOfStockAxis_SeriesCPreferredStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">130,000</ix:nonFraction>.</div>
</ix:continuation>
      <ix:continuation id="Text_030d691cd9f44aa4af74f8417b6e789821" continuedAt="Text_030d691cd9f44aa4af74f8417b6e789822">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>
</ix:continuation>
      <ix:continuation id="Text_030d691cd9f44aa4af74f8417b6e789822" continuedAt="Text_030d691cd9f44aa4af74f8417b6e789823">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">The terms of the Series C are as follows:</div>
</ix:continuation>
      <ix:continuation id="Text_030d691cd9f44aa4af74f8417b6e789823" continuedAt="Text_030d691cd9f44aa4af74f8417b6e789824">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>
</ix:continuation>
      <ix:continuation id="Text_030d691cd9f44aa4af74f8417b6e789824" continuedAt="Text_030d691cd9f44aa4af74f8417b6e789825">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-style: italic;">Conversion Rights</span><span style="font-family: 'Times New Roman';">. Each holder of Series C may
          convert all, but not less than all, of his Series C shares plus accrued and unpaid dividends into Common Stock at the price of $<ix:nonFraction name="galt:EquityIssuancePerShareAmount" id="Fact_3a88b4ef92444c2ba490d156b247f031" contextRef="c20101230to20101230_StatementClassOfStockAxis_SeriesCPreferredStockMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">6.00</ix:nonFraction>
          per share of Common Stock (&#8220;Conversion Price&#8221;), such that approximately <ix:nonFraction name="galt:CommonSharesIssuableUponConversionOfConvertibleStock" id="Fact_761a3dfa1bca4e47a7a15eae7b41e59a" contextRef="c20101230_StatementClassOfStockAxis_SeriesCPreferredStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,667</ix:nonFraction> shares of Common Stock will be issued per each converted
          share of Series C (accrued and unpaid dividends will be issued as additional shares). At December 31, 2024 and 2023, the <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" id="Fact_e38121c16d5749e9b2b3819a2d9f4e19" contextRef="c20241231_StatementClassOfStockAxis_SeriesCPreferredStockMember_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" id="Fact_87cdbe2c71e34229a611bc72c62eedd5" contextRef="c20231231_StatementClassOfStockAxis_SeriesCPreferredStockMember_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">176</ix:nonFraction></ix:nonFraction>
          outstanding shares of Series C were convertible into a total of approximately <ix:nonFraction name="us-gaap:ConversionOfStockSharesIssued1" id="Fact_60e5481797ac4f5c85a6890bef1c5e74" contextRef="c20230101to20231231_StatementClassOfStockAxis_SeriesCPreferredStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:ConversionOfStockSharesIssued1" id="Fact_254e1d56fb104ca09d06c99be9a33112" contextRef="c20240101to20241231_StatementClassOfStockAxis_SeriesCPreferredStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">293,340</ix:nonFraction></ix:nonFraction> shares of Common Stock.</span></div>
</ix:continuation>
      <ix:continuation id="Text_030d691cd9f44aa4af74f8417b6e789825" continuedAt="Text_030d691cd9f44aa4af74f8417b6e789826">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>
</ix:continuation>
      <ix:continuation id="Text_030d691cd9f44aa4af74f8417b6e789826" continuedAt="Text_030d691cd9f44aa4af74f8417b6e789827">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">Subject to the continuing obligation to pay post conversion dividends, the Company may convert all, but not less than all, of the Series C (plus all accrued and
        unpaid dividends) into Common Stock, at the Conversion Price, upon such time that the closing price of the Common Stock is no less than $<ix:nonFraction name="us-gaap:SharePrice" id="Fact_6dafb4f88e4e48f1a163317ed795ad99" contextRef="c20101230_StatementClassOfStockAxis_SeriesCPreferredStockMember_StatementEquityComponentsAxis_CommonStockMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">18.00</ix:nonFraction>
        per share for <ix:nonNumeric name="galt:NumberOfConsecutiveTradingDays" id="Fact_f96faa08361c45db8c0437cafeb364c2" contextRef="c20101230to20101230_StatementClassOfStockAxis_SeriesCPreferredStockMember" format="ixt-sec:durday">15</ix:nonNumeric> consecutive trading days.</div>
</ix:continuation>
      <ix:continuation id="Text_030d691cd9f44aa4af74f8417b6e789827" continuedAt="Text_030d691cd9f44aa4af74f8417b6e789828">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>
</ix:continuation>
      <ix:continuation id="Text_030d691cd9f44aa4af74f8417b6e789828" continuedAt="Text_030d691cd9f44aa4af74f8417b6e789829">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-style: italic;">Dividends</span><span style="font-family: 'Times New Roman';">. Holders of Series C shall be
          entitled to receive cumulative non-compounding dividends at the rate per share of Series C equal to the greater of (i) <ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" id="Fact_a390204869d44806b9606f1c1571a2a0" contextRef="c20101230to20101230_StatementClassOfStockAxis_SeriesCPreferredStockMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">6</ix:nonFraction>% per annum of
          the Stated Value (also defined as the &#8220;Floor&#8221;) or (ii) <ix:nonFraction name="galt:DividendAsPercentageOfNetSales" id="Fact_40b87453f88f4b1e9eceb6516bf985ab" contextRef="c20101230to20101230_StatementClassOfStockAxis_SeriesCPreferredStockMember_StatementScenarioAxis_DividendPaymentScenarioOneMember" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">2.5</ix:nonFraction>% of net sales until the total dividends paid is equal to the initial
          investment and <ix:nonFraction name="galt:DividendAsPercentageOfNetSales" id="Fact_3e80a830351c4fafa8b7b0968588819c" contextRef="c20101230to20101230_StatementClassOfStockAxis_SeriesCPreferredStockMember_StatementScenarioAxis_DividendPaymentScenarioTwoMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">1.25</ix:nonFraction>% of net sales thereafter. The maximum amount each Series C shareholder will receive in dividend payments is equal
          to $<ix:nonFraction name="us-gaap:DividendsPreferredStock" id="Fact_492b12f561964f4eb67c3122b532167b" contextRef="c20101230to20101230_RangeAxis_MaximumMember_StatementClassOfStockAxis_SeriesCPreferredStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">100,000</ix:nonFraction> (the &#8220;Maximum Payout&#8221;). For purposes of this dividend calculation, net sales shall mean gross revenues actually received by
          the Company, from the sale or licensing of the product DAVANAT<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> (GM-CT-01), less chargebacks, returns, expenses attributable to product recalls, duties, customs,
          sales tax, freight, insurance, shipping expenses, allowances and other customary deductions.</span></div>
</ix:continuation>
      <ix:continuation id="Text_030d691cd9f44aa4af74f8417b6e789829" continuedAt="Text_030d691cd9f44aa4af74f8417b6e789830">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>
</ix:continuation>
      <ix:continuation id="Text_030d691cd9f44aa4af74f8417b6e789830" continuedAt="Text_030d691cd9f44aa4af74f8417b6e789831">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">The dividend shall be payable in arrears semiannually on March 31 and September 30, beginning with the first such date after the original issue date; provided,
        however, that all dividends and all other distributions shall cease, and no further dividends or other distributions shall be paid, in respect of each share of Series C from and after such time that the Maximum Payout has been paid in respect of
        such share of Series C. Such dividends shall be payable at the Company&#8217;s option either in cash or in duly authorized, fully paid and non-assessable shares of Common Stock valued at the higher of (i) $<ix:nonFraction name="us-gaap:PreferredStockRedemptionPricePerShare" id="Fact_17b43a0ea51c41e98b9183f9a47d077a" contextRef="c20101230_StatementClassOfStockAxis_SeriesCPreferredStockMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.00</ix:nonFraction> per share or (ii) the average of the Common Stock trading price for the ten (<ix:nonNumeric name="galt:NumberOfConsecutiveTradingDays" id="Fact_59722c6840f043febe2211d025cca8aa" contextRef="c20240101to20241231_StatementClassOfStockAxis_SeriesCPreferredStockMember" format="ixt-sec:durday">10</ix:nonNumeric>)
        consecutive trading days ending on the trading day that is immediately prior to the dividend payment date.</div>
</ix:continuation>
      <ix:continuation id="Text_030d691cd9f44aa4af74f8417b6e789831" continuedAt="Text_030d691cd9f44aa4af74f8417b6e789832">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>
</ix:continuation>
      <ix:continuation id="Text_030d691cd9f44aa4af74f8417b6e789832" continuedAt="Text_030d691cd9f44aa4af74f8417b6e789833">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-style: italic;">Series C Post Conversion Dividend Right</span><span style="font-family: 'Times New Roman';">. In the
          event that any share of Series C is converted into Common Stock before the Maximum Payout is paid in respect of such converted share of Series C, then the holder shall have the right to continue to receive dividends in respect of such converted
          share of Series C equal to the remaining payout (the &#8220;Series C Preferred Stock Post Conversion Dividend Right&#8221;) which shall be equal to the Maximum Payout less the cumulative dividends received through the conversion date. One share of Series C
          Preferred Stock Post Conversion Dividend Right shall be issued for each such converted share of Series C. The holder of each Series C Preferred Stock Post Conversion Dividend Right shall receive the remaining payout on an equal basis and in
          conjunction with the then outstanding shares of Series C and all the other then outstanding Series C Post Conversion Dividend Rights, in the same manner and subject to the same terms and conditions as applicable to the payment of dividends on
          each share of Series C, except that for purposes of calculating the dividend the Floor shall not apply. The Series C Preferred Stock Post Conversion Dividend Right shall have no stated value, liquidation preference or right to any dividends or
          distributions other than the remaining payout. The Series C Preferred Stock Post Conversion Right is subject to redemption in the same manner as outstanding Series C shares.</span></div>
</ix:continuation>
      <ix:continuation id="Text_030d691cd9f44aa4af74f8417b6e789833" continuedAt="Text_030d691cd9f44aa4af74f8417b6e789834">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>
</ix:continuation>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">F-14</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div>
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

            </div>

          </div>

        </div>

      </div>

      <ix:continuation id="Text_030d691cd9f44aa4af74f8417b6e789834" continuedAt="Text_030d691cd9f44aa4af74f8417b6e789835">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">At the date of issuance, the Series C have an embedded dividend right to continue to receive dividend payments after conversion to common stock (the Series C Post
        Conversion Dividend Right) which requires bifurcation. The value of this post conversion dividend right on the date of issuance was determined to be de minimis due to the fact that the payment of a dividend stream other than the <ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" id="Fact_dd569a345c7946adb6600b5ff47266a6" contextRef="c20101230to20101230_StatementClassOfStockAxis_SeriesCPreferredStockMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">6</ix:nonFraction>% dividend and conversion of Series C prior to the Company achieving sales of GM-CT-01 was deemed improbable at that time. Upon a conversion of the
        Series C, the Company will be required to record a liability and the related expense during the period of conversion.</div>
</ix:continuation>
      <ix:continuation id="Text_030d691cd9f44aa4af74f8417b6e789835" continuedAt="Text_030d691cd9f44aa4af74f8417b6e789836">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>
</ix:continuation>
      <ix:continuation id="Text_030d691cd9f44aa4af74f8417b6e789836" continuedAt="Text_030d691cd9f44aa4af74f8417b6e789837">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">In July 2011, 5 shares of Series C were converted into <ix:nonFraction name="us-gaap:ConversionOfStockSharesIssued1" id="Fact_1fa47e23b797493593462dc2f9f2175d" contextRef="c20110731to20110731_StatementClassOfStockAxis_SeriesCPreferredStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">8,334</ix:nonFraction>
        shares of common stock and <ix:nonFraction name="galt:PostConversionDividendRightsIssued" id="Fact_aa77337d441e4524991b4fa91a6f03f4" contextRef="c20110731to20110731_StatementClassOfStockAxis_SeriesCPreferredStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">5</ix:nonFraction> Series C Post Conversion Dividend Rights (Dividend Rights) were issued. In 2013, 24 shares of Series C were
        converted into <ix:nonFraction name="us-gaap:ConversionOfStockSharesIssued1" id="Fact_5e100aee54ab4dfc86f320930815d1e3" contextRef="c20131231to20131231_StatementClassOfStockAxis_SeriesCPreferredStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">40,193</ix:nonFraction> shares of common stock and <ix:nonFraction name="galt:PostConversionDividendRightsIssued" id="Fact_6977c303539745afa6f60f7c0ddaf390" contextRef="c20131231to20131231_StatementClassOfStockAxis_SeriesCPreferredStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">24</ix:nonFraction> Dividend Rights were issued. In 2014, 20 shares of Series C were converted into <ix:nonFraction name="us-gaap:ConversionOfStockSharesIssued1" id="Fact_321cd5b345414273be07ee8f9be8998d" contextRef="c20141231to20141231_StatementClassOfStockAxis_SeriesCPreferredStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">33,756</ix:nonFraction>
        shares of common stock and <ix:nonFraction name="galt:PostConversionDividendRightsIssued" id="Fact_6955d89a5c9b486da72bf864a591c77d" contextRef="c20141231to20141231_StatementClassOfStockAxis_SeriesCPreferredStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">20</ix:nonFraction> Dividend Rights were issued. Per the terms of the Series C, these Dividend Rights shall continue to
        participate in dividends, however the Floor shall not apply. At December 31, 2016 and 2015, these Dividend Rights were determined to have a de minimis value, as the payment of a dividend is considered improbable at this time. The Company will
        continue to evaluate and assess the Series C Post Conversion Dividend Right for each reporting period.</div>
</ix:continuation>
      <ix:continuation id="Text_030d691cd9f44aa4af74f8417b6e789837" continuedAt="Text_030d691cd9f44aa4af74f8417b6e789838">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>
</ix:continuation>
      <ix:continuation id="Text_030d691cd9f44aa4af74f8417b6e789838" continuedAt="Text_030d691cd9f44aa4af74f8417b6e789839">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-style: italic;">Liquidation Rights</span><span style="font-family: 'Times New Roman';">. In the event of any
          liquidation, dissolution or winding up of the Company, either voluntarily or involuntarily, the holders of Series C will receive $<ix:nonFraction name="us-gaap:PreferredStockLiquidationPreference" id="Fact_0aba91a0877446368002c778fc3361f8" contextRef="c20101230_StatementClassOfStockAxis_SeriesCPreferredStockMember" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">10,000</ix:nonFraction>
          per share plus accrued and unpaid dividends, payable prior and in preference to any distributions to the holders of Common Stock but after and subordinate to the Series A <ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" id="Fact_d70b322f657c40ef9a471b049040ccf6" contextRef="c20080204to20080204_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">12</ix:nonFraction>% Convertible Preferred Stock (&#8220;Series A&#8221;), Series B-1 and Series B-2, subject to the Maximum Payout.</span></div>
</ix:continuation>
      <ix:continuation id="Text_030d691cd9f44aa4af74f8417b6e789839" continuedAt="Text_030d691cd9f44aa4af74f8417b6e789840">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>
</ix:continuation>
      <ix:continuation id="Text_030d691cd9f44aa4af74f8417b6e789840" continuedAt="Text_030d691cd9f44aa4af74f8417b6e789841">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-style: italic;">Redemption</span><span style="font-family: 'Times New Roman';">. Upon a sale of the Company, the
          Company shall redeem all of the then outstanding shares of Series C and Series C Preferred Stock Post Conversion Rights within thirty (<ix:nonNumeric name="galt:ClosingDaysAfterConversionRights" id="Fact_e3e5fa04183d4d8fb7938b5b2f629a4b" contextRef="c20240101to20241231_StatementClassOfStockAxis_SeriesCPreferredStockMember" format="ixt-sec:durday">30</ix:nonNumeric>)
          days after the transaction constituting the sale of the Company is closed and such closing is fully funded. The price to redeem a share of Series C and each redeemed Series C Preferred Stock Post Conversion Redemption Right shall be equal to (i)
          (A) the applicable return on investment (&#8220;ROI&#8221;) percentage, multiplied by (B) $<ix:nonFraction name="galt:PostConversionRedemptionRightReturnOnInvestmentMultiplierAmount" id="Fact_b457f5030f124fcc8f0f7c1f4d85d1a5" contextRef="c20240101to20241231_StatementClassOfStockAxis_SeriesCPreferredStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">10,000</ix:nonFraction>, minus (ii) the cumulative dividends received
          through the redemption date. The redemption price shall be payable at the Company&#8217;s option either in cash or in shares of common stock valued at the higher of (i) $<ix:nonFraction name="us-gaap:PreferredStockRedemptionPricePerShare" id="Fact_55dd51582d9142aabbaf16c2086e807a" contextRef="c20241231_StatementClassOfStockAxis_SeriesCPreferredStockMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.00</ix:nonFraction> per share or (ii) the average market price for the <span style="-sec-ix-hidden:Fact_9d42133c6fda4902871913ae7391078b">ten</span> consecutive
          trading days ending immediately prior to the date of redemption. The ROI Percentage shall mean the percentage that applies as of the redemption date, as follows:</span></div>
</ix:continuation>
      <ix:continuation id="Text_030d691cd9f44aa4af74f8417b6e789841" continuedAt="Text_030d691cd9f44aa4af74f8417b6e789842">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>
</ix:continuation>
      <ix:continuation id="Text_030d691cd9f44aa4af74f8417b6e789842" continuedAt="Text_030d691cd9f44aa4af74f8417b6e789843">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">ROI Percentage</span></div>
</ix:continuation>
      <ix:continuation id="Text_030d691cd9f44aa4af74f8417b6e789843" continuedAt="Text_030d691cd9f44aa4af74f8417b6e789844">
<div style="margin-left: 27pt;">
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 6%; vertical-align: middle;">&#160;</td>

    <td style="width: 94%; vertical-align: middle;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div><ix:nonFraction name="galt:ReturnOnInvestmentsPercentagePeriodOne" id="Fact_26d52204518c48e593f30f5cbe563927" contextRef="c20240101to20241231" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">200</ix:nonFraction>%</div>
              </td>

    <td style="width: 94%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>before the second anniversary of the date of issuance;</div>
              </td>

  </tr>

  <tr>

    <td style="width: 6%; vertical-align: top;">
                <div><ix:nonFraction name="galt:ReturnOnInvestmentsPercentagePeriodTwo" id="Fact_508448f4977f482cbeefd3a2c0cb99cf" contextRef="c20240101to20241231" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">250</ix:nonFraction>%</div>
              </td>

    <td style="width: 94%; vertical-align: top;">
                <div>on or after the second anniversary of the date of issuance, but before the third anniversary of the date of issuance;</div>
              </td>

  </tr>

  <tr>

    <td style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="text-indent: -12pt; margin-left: 12pt;"><span style="text-indent: 0pt;"><ix:nonFraction name="galt:ReturnOnInvestmentsPercentagePeriodThree" id="Fact_4331ff0b64c64ad3bd49c2b335e7c612" contextRef="c20240101to20241231" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">300</ix:nonFraction></span>%</div>
              </td>

    <td style="width: 94%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-indent: -12pt; margin-left: 12pt;">on or after the third anniversary of the date of issuance, but before the fourth anniversary of the date of issuance;</div>
              </td>

  </tr>

  <tr>

    <td style="width: 6%; vertical-align: bottom;">
                <div style="text-indent: -12pt; margin-left: 12pt;"><span style="text-indent: 0pt;"><ix:nonFraction name="galt:ReturnOnInvestmentsPercentagePeriodFour" id="Fact_0c1f5d790e234afeba594acbc32fbf70" contextRef="c20240101to20241231" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">350</ix:nonFraction></span>%</div>
              </td>

    <td style="width: 94%; vertical-align: top;">
                <div style="text-indent: -12pt; margin-left: 12pt;">on or after the fourth anniversary of the date of issuance, but before the fifth anniversary of the date of issuance;</div>
              </td>

  </tr>

  <tr>

    <td style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="text-indent: -12pt; margin-left: 12pt;"><span style="text-indent: 0pt;"><ix:nonFraction name="galt:ReturnOnInvestmentsPercentagePeriodFive" id="Fact_d3eec8a6db5d4f6b80cd32d279406be8" contextRef="c20240101to20241231" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">400</ix:nonFraction></span>%</div>
              </td>

    <td style="width: 94%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-indent: -12pt; margin-left: 12pt;">on or after the fifth anniversary of the date of issuance, but before the sixth anniversary of the date of issuance;</div>
              </td>

  </tr>

  <tr>

    <td style="width: 6%; vertical-align: bottom;">
                <div style="text-indent: -12pt; margin-left: 12pt;"><span style="text-indent: 0pt;"><ix:nonFraction name="galt:ReturnOnInvestmentsPercentagePeriodSix" id="Fact_4e5e8b97ed6d4ce88f41f238c8c7e0cd" contextRef="c20240101to20241231" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">450</ix:nonFraction></span>%</div>
              </td>

    <td style="width: 94%; vertical-align: top;">
                <div style="text-indent: -12pt; margin-left: 12pt;">on or after the sixth anniversary of the date of issuance, but before the seventh anniversary of the date of issuance;</div>
              </td>

  </tr>

  <tr>

    <td style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="text-indent: -12pt; margin-left: 12pt;"><span style="text-indent: 0pt;"><ix:nonFraction name="galt:ReturnOnInvestmentsPercentagePeriodSeven" id="Fact_353a4276a5594c4393a13ec929814074" contextRef="c20240101to20241231" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">500</ix:nonFraction></span>%</div>
              </td>

    <td style="width: 94%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-indent: -12pt; margin-left: 12pt;">on or after the seventh anniversary of the date of issuance, but before the eighth anniversary of the date of issuance; and</div>
              </td>

  </tr>

  <tr>

    <td style="width: 6%; vertical-align: bottom;">
                <div style="text-indent: -12pt; margin-left: 12pt;"><span style="text-indent: 0pt;"><ix:nonFraction name="galt:ReturnOnInvestmentsPercentagePeriodEight" id="Fact_5fa7246351074f9898097fd8cbb8ccf3" contextRef="c20240101to20241231" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">550</ix:nonFraction></span>%</div>
              </td>

    <td style="width: 94%; vertical-align: top;">
                <div style="text-indent: -12pt; margin-left: 12pt;">on or after the eighth anniversary of the date of issuance, but before the ninth anniversary of the date of issuance.</div>
              </td>

  </tr>


</table>
      </div>
</ix:continuation>
      <ix:continuation id="Text_030d691cd9f44aa4af74f8417b6e789844" continuedAt="Text_030d691cd9f44aa4af74f8417b6e789845">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>
</ix:continuation>
      <ix:continuation id="Text_030d691cd9f44aa4af74f8417b6e789845" continuedAt="Text_030d691cd9f44aa4af74f8417b6e789846">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">Due to the redemption feature, the Company has presented the Series C outside of permanent equity, in the mezzanine of the consolidated balance sheets at December 31,
        2024 and 2023. At December 31, 2024, the Series C redemption value was $<ix:nonFraction name="us-gaap:TemporaryEquityAggregateAmountOfRedemptionRequirement" id="Fact_4080157ea64b48e6862e26ffe3d602fb" contextRef="c20241231_StatementClassOfStockAxis_SeriesCPreferredStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">8,018,000</ix:nonFraction>.</div>
</ix:continuation>
      <ix:continuation id="Text_030d691cd9f44aa4af74f8417b6e789846" continuedAt="Text_030d691cd9f44aa4af74f8417b6e789847">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>
</ix:continuation>
      <ix:continuation id="Text_030d691cd9f44aa4af74f8417b6e789847">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-style: italic;">Voting Rights</span><span style="font-family: 'Times New Roman';">. The Series C shares have <ix:nonFraction name="galt:ConvertiblePreferredStockNumberOfVotingRights" id="Fact_046ac146462147d8a6046cab129f34c3" contextRef="c20240101to20241231_StatementClassOfStockAxis_SeriesCPreferredStockMember" unitRef="U008" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction> voting rights.</span></div>
</ix:continuation>

      <div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman';"> <br/>
        </span></div>

    </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">

    <div>
      <ix:nonNumeric name="galt:CommonStockWarrantsDisclosureTextBlock" id="Text_7f9a4d7e923e48c892d19edaa82eda5b" contextRef="c20240101to20241231" escape="true" continuedAt="Text_13e37f4d960c4dd0aa64d3a4b82f67f61">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 27pt; vertical-align: top; font-weight: bold;">8.</td>

    <td style="width: auto; vertical-align: top;">
              <div style="font-weight: bold;">Warrants</div>
            </td>

  </tr>


</table>
</ix:nonNumeric>
      <ix:continuation id="Text_13e37f4d960c4dd0aa64d3a4b82f67f61" continuedAt="Text_13e37f4d960c4dd0aa64d3a4b82f67f62">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>
</ix:continuation>

      <ix:nonNumeric name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="Text_9e6b387325544389b22e8a1d0a7ec84e" contextRef="c20240101to20241231" escape="true" continuedAt="Text_e4cab196efee4404816147fb05bc5f321"><ix:continuation id="Text_13e37f4d960c4dd0aa64d3a4b82f67f62" continuedAt="Text_13e37f4d960c4dd0aa64d3a4b82f67f63">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">Warrant activity is summarized as follows:</div>
</ix:continuation></ix:nonNumeric>
      <ix:continuation id="Text_e4cab196efee4404816147fb05bc5f321" continuedAt="Text_e4cab196efee4404816147fb05bc5f322"><ix:continuation id="Text_13e37f4d960c4dd0aa64d3a4b82f67f63" continuedAt="Text_13e37f4d960c4dd0aa64d3a4b82f67f64">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_e4cab196efee4404816147fb05bc5f322" continuedAt="Text_e4cab196efee4404816147fb05bc5f323"><ix:continuation id="Text_13e37f4d960c4dd0aa64d3a4b82f67f64" continuedAt="Text_13e37f4d960c4dd0aa64d3a4b82f67f65">
<div style="margin-left: 27pt;">
        <table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;">


  <tr>

    <td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;">
                <div><span style="font-weight: bold;">Warrants</span></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="font-weight: bold;">Weighted average </div>
                <div style="font-weight: bold;">exercise price</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: top;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Outstanding at December 31, <span style="text-indent: 0pt;">2022</span></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" id="Fact_be48e1aa8b1749468a808e2c40cdf447" contextRef="c20221231_FinancialInstrumentAxis_WarrantMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">11,557,964</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                <div><ix:nonFraction name="galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" id="Fact_8e1d0fa7d4c04daf8c92c7d97c202d92" contextRef="c20221231" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">4.37</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Issued</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" id="Fact_0f3af02305664200a3a7bbc281aeb472" contextRef="c20230101to20231231_FinancialInstrumentAxis_WarrantMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">600,000</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice" id="Fact_23448748e7ad4406b22e1fd55a56020c" contextRef="c20230101to20231231" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.09</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Exercised</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" id="Fact_1ee6e49dc194411789db316feee949e5" contextRef="c20230101to20231231_FinancialInstrumentAxis_WarrantMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,236,204</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice" id="Fact_aab36f861f4a4892aa117e819a134af5" contextRef="c20230101to20231231" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">4.49</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Canceled/Expired</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" id="Fact_f91455761992423395ba4be963a2649f" contextRef="c20230101to20231231_FinancialInstrumentAxis_WarrantMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">665,267</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><ix:nonFraction name="galt:ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice" id="Fact_4042b18cdf0c4399823eab102d3c7726" contextRef="c20230101to20231231" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">4.94</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Outstanding at December 31, <span style="text-indent: 0pt;">2023</span></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" id="Fact_de6326986662484b834a233c6bc96c0b" contextRef="c20231231_FinancialInstrumentAxis_WarrantMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">9,256,493</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">
                <div><ix:nonFraction name="galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" id="Fact_10e3473d10cc4f1195f3dfc67eaac152" contextRef="c20231231" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">4.22</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Issued</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" id="Fact_cad509b4e821479db1ce8ce3fe371684" contextRef="c20240101to20241231_FinancialInstrumentAxis_WarrantMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">600,000</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice" id="Fact_865cacdd3db64d5facd39debbf1c1a1f" contextRef="c20240101to20241231" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.70</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Exercised</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" id="Fact_dd528c705c904441af8a3b40b583587a" contextRef="c20240101to20241231_FinancialInstrumentAxis_WarrantMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">142,503</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice" id="Fact_b83cef91bf074edcb8235f3e7ae863a8" contextRef="c20240101to20241231" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.00</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Canceled/Expired</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" id="Fact_15d739cf028c479eb5d0a6b6c793e9bc" contextRef="c20240101to20241231_FinancialInstrumentAxis_WarrantMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">118,050</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><ix:nonFraction name="galt:ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice" id="Fact_e4e117fa49254b3d834daee9683ba92c" contextRef="c20240101to20241231" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">4.33</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Outstanding at December 31, <span style="text-indent: 0pt;">2024</span></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" id="Fact_3c6932a3d4bb47cabcf05d7d2f28d0b6" contextRef="c20241231_FinancialInstrumentAxis_WarrantMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">9,595,940</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
                <div><ix:nonFraction name="galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" id="Fact_40a2c302fd4541169611355ee91ce8cf" contextRef="c20241231" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">4.21</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>


</table>
      </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_e4cab196efee4404816147fb05bc5f323" continuedAt="Text_e4cab196efee4404816147fb05bc5f324"><ix:continuation id="Text_13e37f4d960c4dd0aa64d3a4b82f67f65" continuedAt="Text_13e37f4d960c4dd0aa64d3a4b82f67f66">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;<br/>
      </div>
</ix:continuation></ix:continuation>

      <ix:continuation id="Text_13e37f4d960c4dd0aa64d3a4b82f67f66" continuedAt="Text_13e37f4d960c4dd0aa64d3a4b82f67f67">
<div><br/>
      </div>
</ix:continuation>
      <ix:continuation id="Text_13e37f4d960c4dd0aa64d3a4b82f67f67" continuedAt="Text_13e37f4d960c4dd0aa64d3a4b82f67f68">
<div style="margin-left: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">The weighted average expiration of the warrants outstanding as of December 31, 2024 is <ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Fact_9a767e462202443e81bf15d641dcc8c0" contextRef="c20241231" format="ixt-sec:duryear">2.2</ix:nonNumeric> years.</div>
</ix:continuation>
      <ix:continuation id="Text_13e37f4d960c4dd0aa64d3a4b82f67f68" continuedAt="Text_13e37f4d960c4dd0aa64d3a4b82f67f69">
<div style="margin-left: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>
</ix:continuation>
      <ix:continuation id="Text_13e37f4d960c4dd0aa64d3a4b82f67f69" continuedAt="Text_13e37f4d960c4dd0aa64d3a4b82f67f610">
<div style="margin-left: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">On September 22, 2023, the Company executed an agreement with 10X Fund L.P., and 10X Capital Management LLC (which had been a related party due to having nominated a
        board member) whereby the Company extended the exercise date for a total of <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" id="Fact_7f6b0f3bc1bf4fdc8d3e436aed2fd578" contextRef="c20230922_RelatedPartyTransactionsByRelatedPartyAxis_One0XFundLPAnd10XCapitalManagementLLCMember_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">5,732,253</ix:nonFraction> common stock purchase warrants to the earliest of
        (a) September 30, 2026, (b) <ix:nonNumeric name="galt:ThresholdPeriodForExtensionOfExerciseDateOfPurchaseWarrantsUnderAgreement" id="Fact_c8da83c63fba4cb09d7b7e0d77a7a710" contextRef="c20240101to20241231_RelatedPartyTransactionsByRelatedPartyAxis_One0XFundLPAnd10XCapitalManagementLLCMember_StatementEquityComponentsAxis_CommonStockMember" format="ixt-sec:durwordsen">thirty days</ix:nonNumeric> after 10X fails to vote all of the shares of common stock in the Company then owned by it in the
        manner recommended by the board of directors of the Company in any vote of the stockholders of the Company&#894; or (c) <ix:nonNumeric name="galt:ThresholdPeriodForStockClosingPriceInTenConsecutiveDaysUnderPurchaseWarrantsAgreement" id="Fact_9cd93f71fe684d3895885d03b7790885" contextRef="c20240101to20241231_RelatedPartyTransactionsByRelatedPartyAxis_One0XFundLPAnd10XCapitalManagementLLCMember_StatementEquityComponentsAxis_CommonStockMember" format="ixt-sec:durwordsen">thirty days</ix:nonNumeric> after the
        shares of common stock of the Company have a closing price of $<ix:nonFraction name="us-gaap:SharePrice" id="Fact_dd13348e94cb41a3861e815e9fece375" contextRef="c20241231_RangeAxis_MinimumMember_RelatedPartyTransactionsByRelatedPartyAxis_One0XFundLPAnd10XCapitalManagementLLCMember_StatementEquityComponentsAxis_CommonStockMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">6.00</ix:nonFraction> or greater for <ix:nonNumeric name="galt:NumberOfTradingDaysToBeConsideredStockClosingPriceInPurchaseAgreement" id="Fact_6847d033209a44b3a8f3cb6b03f732bb" contextRef="c20240101to20241231_RangeAxis_MinimumMember" format="ixt-sec:durday">10</ix:nonNumeric> consecutive trading days. Previously, the common stock purchase warrants exercise dates would have expired at various dates from September 22, 2023 through May 10, 2025.</div>
</ix:continuation>
      <ix:continuation id="Text_13e37f4d960c4dd0aa64d3a4b82f67f610" continuedAt="Text_13e37f4d960c4dd0aa64d3a4b82f67f611">
<div style="margin-left: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>
</ix:continuation>
      <ix:continuation id="Text_13e37f4d960c4dd0aa64d3a4b82f67f611" continuedAt="Text_13e37f4d960c4dd0aa64d3a4b82f67f612">
<div style="margin-left: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">Also pursuant to the terms of the agreement, the right of the 10X Fund L.P. to nominate a member of the board of directors was eliminated, and the cashless exercise
        option in certain of the common stock purchase warrants was deleted. Finally, a beneficial ownership limitation provision was added in the Series B Warrants, which would have the effect of decreasing 10X Fund&#8217;s beneficial ownership to <ix:nonFraction name="galt:BeneficialOwnershipPercentage" id="Fact_aee4532df9ed436c8e5b04f5c86a830c" contextRef="c20241231_RelatedPartyTransactionsByRelatedPartyAxis_One0XFundLPMember_StatementEquityComponentsAxis_SeriesBWarrantsMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">9.99</ix:nonFraction>% and would bar the voluntary exercise of any warrants that would result in 10X Fund&#8217;s ownership beyond <ix:nonFraction name="galt:BeneficialOwnershipPercentage" id="Fact_1845133d653f418c9698051e7658b0f1" contextRef="c20241231_RelatedPartyTransactionsByRelatedPartyAxis_One0XFundLPMember_StatementEquityComponentsAxis_SeriesBWarrantsMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">9.99</ix:nonFraction>% without at least <ix:nonNumeric name="galt:PeriodOfPriorNoticeThatWouldBarVoluntaryExerciseOfAnyWarrants" id="Fact_c78ec0998a134114bcda96e40dae0eaf" contextRef="c20240101to20241231_RelatedPartyTransactionsByRelatedPartyAxis_One0XFundLPMember" format="ixt-sec:durday">61</ix:nonNumeric> days&#8217; prior notice from 10X Fund.</div>
</ix:continuation>
      <ix:continuation id="Text_13e37f4d960c4dd0aa64d3a4b82f67f612" continuedAt="Text_13e37f4d960c4dd0aa64d3a4b82f67f613">
<div style="margin-left: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>
</ix:continuation>
      <ix:continuation id="Text_13e37f4d960c4dd0aa64d3a4b82f67f613" continuedAt="Text_13e37f4d960c4dd0aa64d3a4b82f67f614">
<div style="margin-left: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">The Company has accounted for the modified terms of the warrants pursuant to ASC 815, Derivatives and Hedging, whereby the Company has recognized a deemed dividend for
        the change in fair value of the warrants immediately before and immediately after the modification. In September 2023, the Company recognized a non cash deemed dividend of $<ix:nonFraction name="us-gaap:PreferredStockRedemptionPremium" id="Fact_8ccc1c1918a5435ea558f66bafb92093" contextRef="c20230901to20230930" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">3,619,000</ix:nonFraction> related to the extension of the <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" id="Fact_5af42fafd8b646dba151fbc789320883" contextRef="c20230930_RelatedPartyTransactionsByRelatedPartyAxis_One0XFundLPAnd10XCapitalManagementLLCMember_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">5,732,253</ix:nonFraction> warrants. The following
        assumptions were used to value the extension of the warrants immediately before and immediately after the modification: a) immediately before the modification &#8212; an expected life range of <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_d4b7dd462d0149f4a4603b9b5579b8bd" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_BeforeModificationMember_FinancialInstrumentAxis_WarrantMember_RangeAxis_MinimumMember" format="ixt-sec:duryear">0</ix:nonNumeric> to <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_d59ff99e52094f128717de95989f2cb2" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_BeforeModificationMember_FinancialInstrumentAxis_WarrantMember_RangeAxis_MaximumMember" format="ixt-sec:duryear">1.63</ix:nonNumeric> years, volatility range of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact_2490e39dd4a64d8f8e7ca03b56b38f79" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_BeforeModificationMember_FinancialInstrumentAxis_WarrantMember_RangeAxis_MinimumMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">71</ix:nonFraction>% to <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact_17dee1cde14c4f649438d58ba1c6673f" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_BeforeModificationMember_FinancialInstrumentAxis_WarrantMember_RangeAxis_MaximumMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">77</ix:nonFraction>%%, risk free interest rate range of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_0524be557cdd41e0b0c7b15b3e23e668" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_BeforeModificationMember_FinancialInstrumentAxis_WarrantMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">5.37</ix:nonFraction>% and <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="Fact_5076b60aae9f41ca8786f39975257fae" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_BeforeModificationMember_FinancialInstrumentAxis_WarrantMember" unitRef="U007" decimals="0" scale="0" format="ixt-sec:numwordsen">zero</ix:nonFraction> dividends and&#894; b)
        immediately following the modification &#8212; an expected life of <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_587b7bac00dd4f789540ca82c380bf3b" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_AfterModificationMember_FinancialInstrumentAxis_WarrantMember" format="ixt-sec:duryear">3</ix:nonNumeric> years, volatility of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact_1dea0029e6f1486f8e10922e799351af" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_AfterModificationMember_FinancialInstrumentAxis_WarrantMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">79</ix:nonFraction>%, risk free interest rate range of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_a05f4c2f919244eba148f8a99dead20f" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_AfterModificationMember_FinancialInstrumentAxis_WarrantMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">4.59</ix:nonFraction>% and <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="Fact_73726c1615484dd2a79ea4dd382af5df" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_AfterModificationMember_FinancialInstrumentAxis_WarrantMember" unitRef="U007" decimals="0" scale="0" format="ixt-sec:numwordsen">zero</ix:nonFraction> dividends.</div>
</ix:continuation>
      <ix:continuation id="Text_13e37f4d960c4dd0aa64d3a4b82f67f614" continuedAt="Text_13e37f4d960c4dd0aa64d3a4b82f67f615">
<div style="margin-left: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>
</ix:continuation>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">F-15</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div>
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

            </div>

          </div>

        </div>

      </div>


      <ix:continuation id="Text_e4cab196efee4404816147fb05bc5f324" continuedAt="Text_e4cab196efee4404816147fb05bc5f325"><ix:continuation id="Text_13e37f4d960c4dd0aa64d3a4b82f67f615" continuedAt="Text_13e37f4d960c4dd0aa64d3a4b82f67f616">
<div style="margin-left: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">The following table summarizes information with regard to outstanding warrants issued in connection with equity and debt financings and consultants as of December 31,
        2024.</div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_e4cab196efee4404816147fb05bc5f325" continuedAt="Text_e4cab196efee4404816147fb05bc5f326"><ix:continuation id="Text_13e37f4d960c4dd0aa64d3a4b82f67f616" continuedAt="Text_13e37f4d960c4dd0aa64d3a4b82f67f617">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_13e37f4d960c4dd0aa64d3a4b82f67f617"><ix:continuation id="Text_e4cab196efee4404816147fb05bc5f326">
<div style="margin-left: 27pt;">
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-weight: bold; border-bottom: 2px solid rgb(0, 0, 0); text-align: left;" rowspan="1">Issued in Connection With</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="2">
                <div style="text-align: center; font-weight: bold;">Number</div>
                <div style="text-align: center; font-weight: bold;">Outstanding<br/>
                </div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="2">
                <div style="text-align: center; font-weight: bold;">Exercise</div>
                <div style="text-align: center; font-weight: bold;">Price</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1">&#160;Exercisable Date</td>

    <td valign="bottom" style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1">&#160;Expiration Date</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; text-align: left; width: 25.3333%; text-indent: -9pt; margin-left: 9pt; background-color: rgb(204, 238, 255);" rowspan="1">
                <div style="margin-left: 9pt"><span style="text-indent: 0pt;"><ix:nonNumeric name="galt:WarrantIssueDate" id="Fact_1345bf44a71242d1974f0d9f65545565" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_FebruaryTwelveTwentyZeroNineSeriesBOneTransactionMember" format="ixt:date-monthname-day-year-en">February 12, 2009</ix:nonNumeric></span> Series B-1 Transaction $<span style="text-indent: 0pt;"><ix:nonFraction name="galt:WarrantsIssuedPrice" id="Fact_c53425516242433dbb73bc7d861a2c46" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_FebruaryTwelveTwentyZeroNineSeriesBOneTransactionMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.00</ix:nonFraction></span> Investor Warrants &#8211; Class B</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">
                <div><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" id="Fact_3828bbdc4b244bcbbdf6990bfbc71833" contextRef="c20241231_ClassOfWarrantOrRightAxis_FebruaryTwelveTwentyZeroNineSeriesBOneTransactionMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,200,000</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_b59ba3ca7db54a8db7ccb08573476eb1" contextRef="c20241231_ClassOfWarrantOrRightAxis_FebruaryTwelveTwentyZeroNineSeriesBOneTransactionMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.00</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1"><ix:nonNumeric name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" id="Fact_64d71489e332425fb2298d9d0c4bc0e4" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_FebruaryTwelveTwentyZeroNineSeriesBOneTransactionMember" format="ixt:date-monthname-day-year-en">February 12, 2009</ix:nonNumeric></td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1"><ix:nonNumeric name="galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired" id="Fact_4bc2f29c22514466b1bcc1d1ac213a69" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_FebruaryTwelveTwentyZeroNineSeriesBOneTransactionMember" format="ixt:date-monthname-day-year-en">September 30, 2026</ix:nonNumeric></td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; text-align: left; width: 25.3333%; text-indent: -9pt; margin-left: 9pt;" rowspan="1">
                <div style="margin-left: 9pt"><span style="text-indent: 0pt;"><ix:nonNumeric name="galt:WarrantIssueDate" id="Fact_48c69d40478d42ebb19f96f2a5e207e6" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_MayThirteenTwentyZeroNineSeriesBTwoTransactionOneMember" format="ixt:date-monthname-day-year-en">May 13, 2009</ix:nonNumeric></span> Series B-2 Transaction $<span style="text-indent: 0pt;"><ix:nonFraction name="galt:WarrantsIssuedPrice" id="Fact_7d4a4414282c47bc860ac97f05d41a1b" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_MayThirteenTwentyZeroNineSeriesBTwoTransactionOneMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.00</ix:nonFraction></span> Investor Warrants &#8211; Class B</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" id="Fact_b324a055c585463a906b72b3ad4eec84" contextRef="c20241231_ClassOfWarrantOrRightAxis_MayThirteenTwentyZeroNineSeriesBTwoTransactionOneMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">525,119</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">$ <br/>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_2063f28d5d194073be3af592308a757e" contextRef="c20241231_ClassOfWarrantOrRightAxis_MayThirteenTwentyZeroNineSeriesBTwoTransactionOneMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.00</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 25.3333%; white-space: nowrap;" rowspan="1"><ix:nonNumeric name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" id="Fact_57265ad1f3cd4575bd715a7ad5893bda" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_MayThirteenTwentyZeroNineSeriesBTwoTransactionOneMember" format="ixt:date-monthname-day-year-en">May 13, 2009</ix:nonNumeric></td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 25.3333%; white-space: nowrap;" rowspan="1"><ix:nonNumeric name="galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired" id="Fact_22745ee0de194fb382a954ecd45068f2" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_MayThirteenTwentyZeroNineSeriesBTwoTransactionOneMember" format="ixt:date-monthname-day-year-en">September 30, 2026</ix:nonNumeric></td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 25.3333%; text-indent: -9pt; margin-left: 9pt; background-color: rgb(204, 238, 255);" rowspan="1">
                <div style="margin-left: 9pt"><span style="text-indent: 0pt;"><ix:nonNumeric name="galt:WarrantIssueDate" id="Fact_68ec3c35863341f6a82af8ccbd8dfd5a" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_JuneThirtyTwentyZeroNineSeriesBTwoTransactionOneMember" format="ixt:date-monthname-day-year-en">June 30, 2009</ix:nonNumeric></span> Series B-2 Transaction $<span style="text-indent: 0pt;"><ix:nonFraction name="galt:WarrantsIssuedPrice" id="Fact_f2fbf9fdebca46269dcb29d8ba163e2d" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_JuneThirtyTwentyZeroNineSeriesBTwoTransactionOneMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.00</ix:nonFraction></span> Investor Warrants &#8211; Class B</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" id="Fact_059a3f80f7c4445f94987d90a8f7f692" contextRef="c20241231_ClassOfWarrantOrRightAxis_JuneThirtyTwentyZeroNineSeriesBTwoTransactionOneMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">306,547</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">$ <br/>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_0c2a4e2bf4a040e289737eef42fe9fd3" contextRef="c20241231_ClassOfWarrantOrRightAxis_JuneThirtyTwentyZeroNineSeriesBTwoTransactionOneMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.00</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1"><ix:nonNumeric name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" id="Fact_ec50a090565e412f8ab09c99d055e75b" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_JuneThirtyTwentyZeroNineSeriesBTwoTransactionOneMember" format="ixt:date-monthname-day-year-en">June 30, 2009</ix:nonNumeric></td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1"><ix:nonNumeric name="galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired" id="Fact_8841109adcd84c828cfc94160594bbdb" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_JuneThirtyTwentyZeroNineSeriesBTwoTransactionOneMember" format="ixt:date-monthname-day-year-en">September 30, 2026</ix:nonNumeric></td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 25.3333%; text-indent: -9pt; margin-left: 9pt;" rowspan="1">
                <div style="margin-left: 9pt"><span style="text-indent: 0pt;"><ix:nonNumeric name="galt:WarrantIssueDate" id="Fact_cbd50dd60d5e475483ff53113d663193" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_AugustTwelveTwentyZeroNineSeriesBTwoTransactionOneMember" format="ixt:date-monthname-day-year-en">August 12, 2009</ix:nonNumeric></span> Series B-2 Transaction $<span style="text-indent: 0pt;"><ix:nonFraction name="galt:WarrantsIssuedPrice" id="Fact_7db17b2c90cb467789fee351dd97a9ad" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_AugustTwelveTwentyZeroNineSeriesBTwoTransactionOneMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.00</ix:nonFraction></span> Investor Warrants &#8211; Class B</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" id="Fact_a1f5a56301004166b56b48715a4bc06c" contextRef="c20241231_ClassOfWarrantOrRightAxis_AugustTwelveTwentyZeroNineSeriesBTwoTransactionOneMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">183,928</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">$ <br/>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_55d343aa183c4ee68a69391c526f5af3" contextRef="c20241231_ClassOfWarrantOrRightAxis_AugustTwelveTwentyZeroNineSeriesBTwoTransactionOneMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.00</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 25.3333%; white-space: nowrap;" rowspan="1"><ix:nonNumeric name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" id="Fact_f48693e95a5b46a59a5d5e0110fecd8d" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_AugustTwelveTwentyZeroNineSeriesBTwoTransactionOneMember" format="ixt:date-monthname-day-year-en">August 12, 2009</ix:nonNumeric></td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 25.3333%; white-space: nowrap;" rowspan="1"><ix:nonNumeric name="galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired" id="Fact_9a4cae67ce714dc68412fe16c6a0de18" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_AugustTwelveTwentyZeroNineSeriesBTwoTransactionOneMember" format="ixt:date-monthname-day-year-en">September 30, 2026</ix:nonNumeric></td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 25.3333%; background-color: rgb(204, 238, 255);" rowspan="1">
                <div style="text-indent: -9pt; margin-left: 9pt;"><span style="text-indent: 0pt;"><ix:nonNumeric name="galt:WarrantIssueDate" id="Fact_98f70f1170584fd090c30f3992fcbd30" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_SeptemberThirtyTwentyZeroNineSeriesBTwoTransactionOneMember" format="ixt:date-monthname-day-year-en">September 30, 2009</ix:nonNumeric></span> Series B-2 Transaction $<span style="text-indent: 0pt;"><ix:nonFraction name="galt:WarrantsIssuedPrice" id="Fact_f945db2f84d340c988cf4970258a8e45" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_SeptemberThirtyTwentyZeroNineSeriesBTwoTransactionOneMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.00</ix:nonFraction></span> Investor Warrants &#8211; Class B</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" id="Fact_0c9314004a834532939b886c23958440" contextRef="c20241231_ClassOfWarrantOrRightAxis_SeptemberThirtyTwentyZeroNineSeriesBTwoTransactionOneMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">195,922</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">$ <br/>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_ab9ef12bebd747778418ff4cfe973eb6" contextRef="c20241231_ClassOfWarrantOrRightAxis_SeptemberThirtyTwentyZeroNineSeriesBTwoTransactionOneMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.00</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1"><ix:nonNumeric name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" id="Fact_f08312d0dac94fd09aecc27dfbbbd6eb" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_SeptemberThirtyTwentyZeroNineSeriesBTwoTransactionOneMember" format="ixt:date-monthname-day-year-en">September 30, 2009</ix:nonNumeric></td>

    <td valign="bottom" style="vertical-align: bottom; width: 25.3333%; text-align: right; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1"><ix:nonNumeric name="galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired" id="Fact_e24a997b5fd84c3cb3710683c0e3403e" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_SeptemberThirtyTwentyZeroNineSeriesBTwoTransactionOneMember" format="ixt:date-monthname-day-year-en">September 30, 2026</ix:nonNumeric></td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 25.3333%; text-indent: -9pt; margin-left: 9pt;" rowspan="1">
                <div style="margin-left: 9pt"><span style="text-indent: 0pt;"><ix:nonNumeric name="galt:WarrantIssueDate" id="Fact_e04c3f4ef8ff4c51ace11d8a1941a6e1" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_NovemberFourTwentyZeroNineSeriesBTwoTransactionOneMember" format="ixt:date-monthname-day-year-en">November 4, 2009</ix:nonNumeric></span> Series B-2 Transaction $<span style="text-indent: 0pt;"><ix:nonFraction name="galt:WarrantsIssuedPrice" id="Fact_7d7e267d876f4b30832109e97cf59ea8" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_NovemberFourTwentyZeroNineSeriesBTwoTransactionOneMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.00</ix:nonFraction></span> Investor Warrants &#8211; Class B<br/>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" id="Fact_7e45701f95834244a59d219aeafb412b" contextRef="c20241231_ClassOfWarrantOrRightAxis_NovemberFourTwentyZeroNineSeriesBTwoTransactionOneMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">85,463</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">$ <br/>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_71191c9bd350421aa6fa80ddcf3e1d36" contextRef="c20241231_ClassOfWarrantOrRightAxis_NovemberFourTwentyZeroNineSeriesBTwoTransactionOneMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.00</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 25.3333%; text-align: right; white-space: nowrap;" rowspan="1"><ix:nonNumeric name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" id="Fact_596702e694e24ba0aaddada32e3598e6" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_NovemberFourTwentyZeroNineSeriesBTwoTransactionOneMember" format="ixt:date-monthname-day-year-en">November 4, 2009</ix:nonNumeric></td>

    <td valign="bottom" style="vertical-align: bottom; width: 25.3333%; text-align: right; white-space: nowrap;" rowspan="1"><ix:nonNumeric name="galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired" id="Fact_a1077d38aef644c683dd62773612c88c" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_NovemberFourTwentyZeroNineSeriesBTwoTransactionOneMember" format="ixt:date-monthname-day-year-en">September 30, 2026</ix:nonNumeric></td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: top; width: 25.3333%; background-color: rgb(204, 238, 255);">
                <div style="margin-left: 9pt; text-indent: -9pt;"><span style="text-indent: 0pt;"><ix:nonNumeric name="galt:WarrantIssueDate" id="Fact_f7ad14ba33fd481192e9e149ed302966" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_DecemberEightTwentyZeroNineSeriesBTwoTransactionOneMember" format="ixt:date-monthname-day-year-en">December 8, 2009</ix:nonNumeric></span> Series B-2 Transaction $<span style="text-indent: 0pt;"><ix:nonFraction name="galt:WarrantsIssuedPrice" id="Fact_60780d6d44a44ae9bb2fb7f1dc6dd592" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_DecemberEightTwentyZeroNineSeriesBTwoTransactionOneMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.00</ix:nonFraction></span> Investor Warrants &#8211; Class B<br/>
                </div>
              </td>

    <td valign="bottom" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" id="Fact_9bb872e7aa2b4fd287f982d75ecae43b" contextRef="c20241231_ClassOfWarrantOrRightAxis_DecemberEightTwentyZeroNineSeriesBTwoTransactionOneMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">110,919</ix:nonFraction></td>

    <td valign="bottom" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">$ <br/>
              </td>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_3dba74fbd6574c5d9993a0ac7499e0f5" contextRef="c20241231_ClassOfWarrantOrRightAxis_DecemberEightTwentyZeroNineSeriesBTwoTransactionOneMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.00</ix:nonFraction></td>

    <td valign="bottom" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 25.3333%; text-align: right; background-color: rgb(204, 238, 255); white-space: nowrap;"><ix:nonNumeric name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" id="Fact_3310403e448644ba8e7be5e59ea85930" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_DecemberEightTwentyZeroNineSeriesBTwoTransactionOneMember" format="ixt:date-monthname-day-year-en">December 8, 2009</ix:nonNumeric></td>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 25.3333%; text-align: right; background-color: rgb(204, 238, 255); white-space: nowrap;"><ix:nonNumeric name="galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired" id="Fact_e85af4eecce44ad3bbc49e75c3222d9b" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_DecemberEightTwentyZeroNineSeriesBTwoTransactionOneMember" format="ixt:date-monthname-day-year-en">September 30, 2026</ix:nonNumeric></td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: top; width: 25.3333%;">
                <div style="margin-left: 9pt; text-indent: -9pt;"><span style="text-indent: 0pt;"><ix:nonNumeric name="galt:WarrantIssueDate" id="Fact_6c4eb176bf8b4a37b16ddeb2a24cdc9f" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionOneMember" format="ixt:date-monthname-day-year-en">January 29, 2010</ix:nonNumeric></span> Series B-2 Transaction $<span style="text-indent: 0pt;"><ix:nonFraction name="galt:WarrantsIssuedPrice" id="Fact_fd963eab4cb14456a15e8d3ae67f139b" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionOneMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.00</ix:nonFraction></span> Investor Warrants &#8211; Class B<br/>
                </div>
              </td>

    <td valign="bottom" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" id="Fact_aa3b001e9a544ea0ad525716d0f70245" contextRef="c20241231_ClassOfWarrantOrRightAxis_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionOneMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">198,664</ix:nonFraction></td>

    <td valign="bottom" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">$ <br/>
              </td>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_b4ac31eca4ca4d3f93bf014f3fcc9895" contextRef="c20241231_ClassOfWarrantOrRightAxis_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionOneMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.00</ix:nonFraction></td>

    <td valign="bottom" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 25.3333%; text-align: right; white-space: nowrap;"><ix:nonNumeric name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" id="Fact_aabbbcb547754be798b764903bc08172" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionOneMember" format="ixt:date-monthname-day-year-en">January 29, 2010</ix:nonNumeric></td>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 25.3333%; text-align: right; white-space: nowrap;"><ix:nonNumeric name="galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired" id="Fact_8b0ab1624b734407822d612c5e4311bc" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionOneMember" format="ixt:date-monthname-day-year-en">September 30, 2026</ix:nonNumeric></td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 25.3333%; background-color: rgb(204, 238, 255);">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;"><span style="text-indent: 0pt;"><ix:nonNumeric name="galt:WarrantIssueDate" id="Fact_ee2614e58d9542a090b61fe5cb08d191" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionTwoMember" format="ixt:date-monthname-day-year-en">January 29, 2010</ix:nonNumeric></span> Series B-2 Transaction $<span style="text-indent: 0pt;"><ix:nonFraction name="galt:WarrantsIssuedPrice" id="Fact_df675e5565cc4823ac8a88d3e7df6c03" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionTwoMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.00</ix:nonFraction></span> Investor Warrants &#8211; Class B</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" id="Fact_a9fa5355936f461d85363abf52b9c869" contextRef="c20241231_ClassOfWarrantOrRightAxis_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionTwoMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">18,003</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_4608507642b9463b9fb9a5b1fc47ba1a" contextRef="c20241231_ClassOfWarrantOrRightAxis_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionTwoMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.00</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="text-align: right;"><ix:nonNumeric name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" id="Fact_a1e5295f0323445799f66862bedc19c6" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionTwoMember" format="ixt:date-monthname-day-year-en">January 29, 2010</ix:nonNumeric></div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="text-align: right;"><ix:nonNumeric name="galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired" id="Fact_468b5807a856463e81751d8f3c56fe06" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionTwoMember" format="ixt:date-monthname-day-year-en">January 29, 2025</ix:nonNumeric></div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: top; width: 25.3333%;">
                <div style="margin-left: 9pt; text-indent: -9pt;"><span style="text-indent: 0pt;"><ix:nonNumeric name="galt:WarrantIssueDate" id="Fact_2617270096034defb5af37ca398f8e24" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_MarchEightTwentyTenSeriesBTwoTransactionOneMember" format="ixt:date-monthname-day-year-en">March 8, 2010</ix:nonNumeric></span> Series B-2 Transaction $<span style="text-indent: 0pt;"><ix:nonFraction name="galt:WarrantsIssuedPrice" id="Fact_d670c1950ca14d4e960d27e6dd3485ac" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_MarchEightTwentyTenSeriesBTwoTransactionOneMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.00</ix:nonFraction></span> Investor Warrants &#8211; Class B<br/>
                </div>
              </td>

    <td valign="bottom" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" id="Fact_726027d3bfae41ac90c905a6bc2e4bf5" contextRef="c20241231_ClassOfWarrantOrRightAxis_MarchEightTwentyTenSeriesBTwoTransactionOneMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">184,132</ix:nonFraction></td>

    <td valign="bottom" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">$ <br/>
              </td>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_5002062f58c64e69aad6809692d0eee3" contextRef="c20241231_ClassOfWarrantOrRightAxis_MarchEightTwentyTenSeriesBTwoTransactionOneMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.00</ix:nonFraction></td>

    <td valign="bottom" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 25.3333%; text-align: right; white-space: nowrap;"><ix:nonNumeric name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" id="Fact_793e8eb1c39d468da21b735f256f2b34" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_MarchEightTwentyTenSeriesBTwoTransactionOneMember" format="ixt:date-monthname-day-year-en">March 8, 2010</ix:nonNumeric></td>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 25.3333%; text-align: right; white-space: nowrap;"><ix:nonNumeric name="galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired" id="Fact_f52f79963ce9492fbf39b16f847baec3" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_MarchEightTwentyTenSeriesBTwoTransactionOneMember" format="ixt:date-monthname-day-year-en">September 30, 2026</ix:nonNumeric></td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 25.3333%; background-color: rgb(204, 238, 255);">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;"><span style="text-indent: 0pt;"><ix:nonNumeric name="galt:WarrantIssueDate" id="Fact_2864a279ace840808def7f2aee4754ec" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_MarchEightTwentyTenSeriesBTwoTransactionTwoMember" format="ixt:date-monthname-day-year-en">March 8, 2010</ix:nonNumeric></span> Series B-2 Transaction $<span style="text-indent: 0pt;"><ix:nonFraction name="galt:WarrantsIssuedPrice" id="Fact_975e0be06ce6448aace6e8424b931183" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_MarchEightTwentyTenSeriesBTwoTransactionTwoMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.00</ix:nonFraction></span> Investor Warrants &#8211; Class B</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" id="Fact_ff564beaa73042b88838c077285f9f3b" contextRef="c20241231_ClassOfWarrantOrRightAxis_MarchEightTwentyTenSeriesBTwoTransactionTwoMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">39,202</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_c8af4821b14a46d399ef687cc1ca20a2" contextRef="c20241231_ClassOfWarrantOrRightAxis_MarchEightTwentyTenSeriesBTwoTransactionTwoMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.00</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="text-align: right;"><ix:nonNumeric name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" id="Fact_84f61d6e3dfb470a9f95a1b0f477063d" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_MarchEightTwentyTenSeriesBTwoTransactionTwoMember" format="ixt:date-monthname-day-year-en">March 8, 2010</ix:nonNumeric></div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="text-align: right;"><ix:nonNumeric name="galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired" id="Fact_2cfd611890e04c2bb60edf93d867e05c" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_MarchEightTwentyTenSeriesBTwoTransactionTwoMember" format="ixt:date-monthname-day-year-en">March 8, 2025</ix:nonNumeric></div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: top; width: 25.3333%;">
                <div style="margin-left: 9pt; text-indent: -9pt;"><span style="text-indent: 0pt;"><ix:nonNumeric name="galt:WarrantIssueDate" id="Fact_e3b7f7cc2160462e9b65fefaab09790c" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_AprilThirtyTwentyTenSeriesBTwoTransactionOneMember" format="ixt:date-monthname-day-year-en">April 30, 2010</ix:nonNumeric></span> Series B-2 Transaction $<span style="text-indent: 0pt;"><ix:nonFraction name="galt:WarrantsIssuedPrice" id="Fact_4aeed9664160400d80789815eb8bc94c" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_AprilThirtyTwentyTenSeriesBTwoTransactionOneMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.00</ix:nonFraction></span> Investor Warrants &#8211; Class B<br/>
                </div>
              </td>

    <td valign="bottom" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" id="Fact_f7dd3cee2d1640c8b9e0ab2371021608" contextRef="c20241231_ClassOfWarrantOrRightAxis_AprilThirtyTwentyTenSeriesBTwoTransactionOneMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">180,689</ix:nonFraction></td>

    <td valign="bottom" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">$ <br/>
              </td>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_878e248884c44cc0b26b4acf61c41f32" contextRef="c20241231_ClassOfWarrantOrRightAxis_AprilThirtyTwentyTenSeriesBTwoTransactionOneMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.00</ix:nonFraction></td>

    <td valign="bottom" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 25.3333%; text-align: right; white-space: nowrap;"><ix:nonNumeric name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" id="Fact_4edd23c6222544229ff4c4b72d57d1c9" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_AprilThirtyTwentyTenSeriesBTwoTransactionOneMember" format="ixt:date-monthname-day-year-en">April 30, 2010</ix:nonNumeric></td>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 25.3333%; text-align: right; white-space: nowrap;"><ix:nonNumeric name="galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired" id="Fact_664f577e44404813a2cf3cf304595ac8" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_AprilThirtyTwentyTenSeriesBTwoTransactionOneMember" format="ixt:date-monthname-day-year-en">September 30, 2026</ix:nonNumeric></td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 25.3333%; background-color: rgb(204, 238, 255);">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;"><span style="text-indent: 0pt;"><ix:nonNumeric name="galt:WarrantIssueDate" id="Fact_5de23bb05a2b4e1eace29987b68cf3df" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_AprilThirtyTwentyTenSeriesBTwoTransactionTwoMember" format="ixt:date-monthname-day-year-en">April 30, 2010</ix:nonNumeric></span> Series B-2 Transaction $<span style="text-indent: 0pt;"><ix:nonFraction name="galt:WarrantsIssuedPrice" id="Fact_0a379b9f07794d29bc7b6bffb030769a" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_AprilThirtyTwentyTenSeriesBTwoTransactionTwoMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.00</ix:nonFraction></span> Investor Warrants &#8211; Class B</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" id="Fact_cec6575444754ab3947fa68488133767" contextRef="c20241231_ClassOfWarrantOrRightAxis_AprilThirtyTwentyTenSeriesBTwoTransactionTwoMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">23,503</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_8aa20b9e6fcd4b1e97c7112b3fc9bd31" contextRef="c20241231_ClassOfWarrantOrRightAxis_AprilThirtyTwentyTenSeriesBTwoTransactionTwoMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.00</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="text-align: right;"><ix:nonNumeric name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" id="Fact_ad30a2637e4044c39633180337ed59f4" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_AprilThirtyTwentyTenSeriesBTwoTransactionTwoMember" format="ixt:date-monthname-day-year-en">April 30, 2010</ix:nonNumeric></div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="text-align: right;"><ix:nonNumeric name="galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired" id="Fact_520ea5544cb54e70ad60ff6361e55cda" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_AprilThirtyTwentyTenSeriesBTwoTransactionTwoMember" format="ixt:date-monthname-day-year-en">April 30, 2025</ix:nonNumeric></div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: top; width: 25.3333%;">
                <div style="margin-left: 9pt; text-indent: -9pt;"><span style="text-indent: 0pt;"><ix:nonNumeric name="galt:WarrantIssueDate" id="Fact_9b49c6925c6647ebaa8aaf734eefb7fd" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_MayTenTwentyTenSeriesBTwoTransactionOneMember" format="ixt:date-monthname-day-year-en">May 10, 2010</ix:nonNumeric></span> Series B-2 Transaction $<span style="text-indent: 0pt;"><ix:nonFraction name="galt:WarrantsIssuedPrice" id="Fact_7ed9d6c7491c4f4b81bc425dbb5a976a" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_MayTenTwentyTenSeriesBTwoTransactionOneMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.00</ix:nonFraction></span> Investor Warrants &#8211; Class B<br/>
                </div>
              </td>

    <td valign="bottom" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" id="Fact_7d339babd2ca438d80ea62612756651f" contextRef="c20241231_ClassOfWarrantOrRightAxis_MayTenTwentyTenSeriesBTwoTransactionOneMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">112,631</ix:nonFraction></td>

    <td valign="bottom" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">$ <br/>
              </td>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_66ea00a6289a438ebd2edc13290dc7ee" contextRef="c20241231_ClassOfWarrantOrRightAxis_MayTenTwentyTenSeriesBTwoTransactionOneMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.00</ix:nonFraction></td>

    <td valign="bottom" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 25.3333%; text-align: right; white-space: nowrap;"><ix:nonNumeric name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" id="Fact_66b77b3f5c2a4da38c2bfdc07b1ff292" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_MayTenTwentyTenSeriesBTwoTransactionOneMember" format="ixt:date-monthname-day-year-en">May 10, 2010</ix:nonNumeric></td>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 25.3333%; text-align: right; white-space: nowrap;"><ix:nonNumeric name="galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired" id="Fact_03f4c1f6d7de45528dc99e5977f6f602" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_MayTenTwentyTenSeriesBTwoTransactionOneMember" format="ixt:date-monthname-day-year-en">September 30, 2026</ix:nonNumeric></td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 25.3333%; background-color: rgb(204, 238, 255);">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;"><span style="text-indent: 0pt;"><ix:nonNumeric name="galt:WarrantIssueDate" id="Fact_d6cdd4e945404756a6b72fcb34dfb3e4" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_MayTenTwentyTenSeriesBTwoTransactionTwoMember" format="ixt:date-monthname-day-year-en">May 10, 2010</ix:nonNumeric></span> Series B-2 Transaction $<span style="text-indent: 0pt;"><ix:nonFraction name="galt:WarrantsIssuedPrice" id="Fact_ce84956ccd484e9a9f992993f8d53459" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_MayTenTwentyTenSeriesBTwoTransactionTwoMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.00</ix:nonFraction></span> Investor Warrants &#8211; Class B</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" id="Fact_aba5ba053b754a7f913b71db7cff27de" contextRef="c20241231_ClassOfWarrantOrRightAxis_MayTenTwentyTenSeriesBTwoTransactionTwoMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">30,535</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_1b87c58b4560436f8e9f9f69eebe8bc2" contextRef="c20241231_ClassOfWarrantOrRightAxis_MayTenTwentyTenSeriesBTwoTransactionTwoMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.00</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="text-align: right;"><ix:nonNumeric name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" id="Fact_40d73ffe4aec4238b05a767ca0762fd6" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_MayTenTwentyTenSeriesBTwoTransactionTwoMember" format="ixt:date-monthname-day-year-en">May 10, 2010</ix:nonNumeric></div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="text-align: right;"><ix:nonNumeric name="galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired" id="Fact_8fbd078f73034cdfb8a41c559e274524" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_MayTenTwentyTenSeriesBTwoTransactionTwoMember" format="ixt:date-monthname-day-year-en">May 10, 2025</ix:nonNumeric></div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 25.3333%;">
                <div style="text-indent: -9pt; margin-left: 9pt;"><span style="text-indent: 0pt;"><ix:nonNumeric name="galt:WarrantIssueDate" id="Fact_bc3dd487c75a4ce897ac414720b6ae0e" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_SeptemberTwentyTwoTwentySixteenSeriesBThreeTransactionMember" format="ixt:date-monthname-day-year-en">September 22, 2016</ix:nonNumeric></span> Series B-3 Transaction $<span style="text-indent: 0pt;"><ix:nonFraction name="galt:WarrantsIssuedPrice" id="Fact_cc9eb9965da042fc8ef9bc1883149c2c" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_SeptemberTwentyTwoTwentySixteenSeriesBThreeTransactionMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.00</ix:nonFraction></span> Investor Warrants &#8211; Class B </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" id="Fact_5b568945e7734a18a7b4d6a2f565a041" contextRef="c20241231_ClassOfWarrantOrRightAxis_SeptemberTwentyTwoTwentySixteenSeriesBThreeTransactionMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">682,572</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_21665cf314e64457a045ce09a1d479d7" contextRef="c20241231_ClassOfWarrantOrRightAxis_SeptemberTwentyTwoTwentySixteenSeriesBThreeTransactionMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.00</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 25.3333%; white-space: nowrap;">
                <div style="text-align: right;"><ix:nonNumeric name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" id="Fact_a557a6b979d949b2b958deb9f8308c68" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_SeptemberTwentyTwoTwentySixteenSeriesBThreeTransactionMember" format="ixt:date-monthname-day-year-en">September 22, 2016</ix:nonNumeric></div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; width: 25.3333%; white-space: nowrap;">
                <div style="text-align: right;"><ix:nonNumeric name="galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired" id="Fact_c31be64ec7f24099a6b06b9bb77cae74" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_SeptemberTwentyTwoTwentySixteenSeriesBThreeTransactionMember" format="ixt:date-monthname-day-year-en">September 30, 2026</ix:nonNumeric></div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 25.3333%; background-color: rgb(204, 238, 255);">
                <div style="text-indent: -9pt; margin-left: 9pt;"><span style="text-indent: 0pt;"><ix:nonNumeric name="galt:WarrantIssueDate" id="Fact_ed624306ad1c472991d8cd4a344f089e" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_SeptemberTwentyNineTwentySixteenSeriesBThreeTransactionMember" format="ixt:date-monthname-day-year-en">September 29, 2016</ix:nonNumeric></span> Series B-3 Transaction $<span style="text-indent: 0pt;"><ix:nonFraction name="galt:WarrantsIssuedPrice" id="Fact_34fe274dda3b488e923c4561b0acdc7a" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_SeptemberTwentyNineTwentySixteenSeriesBThreeTransactionMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.00</ix:nonFraction></span> Investor Warrants &#8211; Class B </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" id="Fact_ec5376642bdf4248b32b5494195eeeda" contextRef="c20241231_ClassOfWarrantOrRightAxis_SeptemberTwentyNineTwentySixteenSeriesBThreeTransactionMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">843,351</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_130303cecdfc4018a48617406e98343f" contextRef="c20241231_ClassOfWarrantOrRightAxis_SeptemberTwentyNineTwentySixteenSeriesBThreeTransactionMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.00</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="text-align: right;"><ix:nonNumeric name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" id="Fact_172ce59d3faf40278fe565f8f276cb62" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_SeptemberTwentyNineTwentySixteenSeriesBThreeTransactionMember" format="ixt:date-monthname-day-year-en">September 29, 2016</ix:nonNumeric></div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="text-align: right;"><ix:nonNumeric name="galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired" id="Fact_08097e4df55e45d4ba047d1f7b7120b1" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_SeptemberTwentyNineTwentySixteenSeriesBThreeTransactionMember" format="ixt:date-monthname-day-year-en">September 30, 2026</ix:nonNumeric></div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 25.3333%;">
                <div style="text-indent: -9pt; margin-left: 9pt;"><span style="text-indent: 0pt;"><ix:nonNumeric name="galt:WarrantIssueDate" id="Fact_f44cdafcab3f4ff68c3c33fe1d314a10" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_DecemberTwentyThreeTwentySixteenSeriesBThreeTransactionMember" format="ixt:date-monthname-day-year-en">December 23, 2016</ix:nonNumeric></span> Series B-3 Transaction $<span style="text-indent: 0pt;"><ix:nonFraction name="galt:WarrantsIssuedPrice" id="Fact_db8fa5d9f4a84b659b9efd55289f0e45" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_DecemberTwentyThreeTwentySixteenSeriesBThreeTransactionMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.00</ix:nonFraction></span> Investor Warrants &#8211; Class B </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" id="Fact_56d0d42abcef441e84038a6e86916f37" contextRef="c20241231_ClassOfWarrantOrRightAxis_DecemberTwentyThreeTwentySixteenSeriesBThreeTransactionMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">922,316</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_81732f8d15d24b3f81b5d1715f24fae3" contextRef="c20241231_ClassOfWarrantOrRightAxis_DecemberTwentyThreeTwentySixteenSeriesBThreeTransactionMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.00</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 25.3333%; white-space: nowrap;">
                <div style="text-align: right;"><ix:nonNumeric name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" id="Fact_97d3c21f414c42b5a2adea9bed8035d1" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_DecemberTwentyThreeTwentySixteenSeriesBThreeTransactionMember" format="ixt:date-monthname-day-year-en">December 23, 2016</ix:nonNumeric></div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; width: 25.3333%; white-space: nowrap;">
                <div style="text-align: right;"><ix:nonNumeric name="galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired" id="Fact_1548d7ca24504140a4e5af63edda5cad" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_DecemberTwentyThreeTwentySixteenSeriesBThreeTransactionMember" format="ixt:date-monthname-day-year-en">September 30, 2026</ix:nonNumeric></div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 25.3333%; background-color: rgb(204, 238, 255);">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">2018 and 2017 Warrants issued for services</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" id="Fact_252e3a297d63442a8af29cae4a2ea750" contextRef="c20241231_ClassOfWarrantOrRightAxis_TwentyEighteenAndTwentySeventeenWarrantsIssuedForServicesMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">290</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_3e32846d056648298913bd649d613bf0" contextRef="c20241231_ClassOfWarrantOrRightAxis_TwentyEighteenAndTwentySeventeenWarrantsIssuedForServicesMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">5.00</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="text-align: right;">Various dates in 2017</div>
                <div style="text-align: right;">and 2018</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="text-align: right;">Various dates in <br/>
                </div>
                <div style="text-align: right;">2025</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 25.3333%;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;"><span style="text-indent: 0pt;"><ix:nonNumeric name="galt:WarrantIssueDate" id="Fact_7f959e1d245b4149819457d14111b746" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_MayTwentyThreeTwentyNinteenRightsOfferingWarrantsMember" format="ixt:date-monthname-day-year-en">May 23, 2019</ix:nonNumeric></span> Rights Offering warrants</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" id="Fact_4e35b034dd3c465ca6f8cedc5fab871c" contextRef="c20241231_ClassOfWarrantOrRightAxis_MayTwentyThreeTwentyNinteenRightsOfferingWarrantsMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,622,154</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_03525d40fbb249b097c5e4d30ba0c367" contextRef="c20241231_ClassOfWarrantOrRightAxis_MayTwentyThreeTwentyNinteenRightsOfferingWarrantsMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">7.00</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 25.3333%; white-space: nowrap;">
                <div style="text-align: right;"><ix:nonNumeric name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" id="Fact_d019a58f5052456882816c8130eaea37" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_MayTwentyThreeTwentyNinteenRightsOfferingWarrantsMember" format="ixt:date-monthname-day-year-en">May 23, 2019</ix:nonNumeric></div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; width: 25.3333%; white-space: nowrap;">
                <div style="text-align: right;"><ix:nonNumeric name="galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired" id="Fact_c38f2eec20a04b7895f441785860a46d" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_MayTwentyThreeTwentyNinteenRightsOfferingWarrantsMember" format="ixt:date-monthname-day-year-en">May 23, 2026</ix:nonNumeric></div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; text-indent: -9pt; margin-left: 9pt; width: 25.3333%; background-color: rgb(204, 238, 255);" rowspan="1">
                <div style="margin-left: 9pt;"><span style="text-indent: 0pt;"><ix:nonNumeric name="galt:WarrantIssueDate" id="Fact_bb6a0e9b78a54fa4a3e5701c8714d60a" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_July222022WarrantsIssuedInConnectionWithRelatedPartyLineOfCreditMember" format="ixt:date-monthname-day-year-en">July 22, 2022</ix:nonNumeric></span> Warrants issued in connection with related party line of credit</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" id="Fact_6c895356dee9488cb1d0833a52b30749" contextRef="c20241231_ClassOfWarrantOrRightAxis_July222022WarrantsIssuedInConnectionWithRelatedPartyLineOfCreditMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">330,000</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">$ <br/>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_49447cf323db48b4aca1aa66cd06c93b" contextRef="c20241231_ClassOfWarrantOrRightAxis_July222022WarrantsIssuedInConnectionWithRelatedPartyLineOfCreditMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">5.00</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1"><ix:nonNumeric name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" id="Fact_05035e93438040489d2a1daa4596dfb7" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_July222022WarrantsIssuedInConnectionWithRelatedPartyLineOfCreditMember" format="ixt:date-monthname-day-year-en">July 22, 2022</ix:nonNumeric></td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1"><ix:nonNumeric name="galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired" id="Fact_24b80677a3f6496aa9cb44e4c38acf91" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_July222022WarrantsIssuedInConnectionWithRelatedPartyLineOfCreditMember" format="ixt:date-monthname-day-year-en">July 31, 2029</ix:nonNumeric></td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; text-indent: -9pt; margin-left: 9pt; width: 25.3333%;" rowspan="1">
                <div style="margin-left: 9pt;"><span style="text-indent: 0pt;"><ix:nonNumeric name="galt:WarrantIssueDate" id="Fact_3a81d003c3d04a2e9199de7f98e97769" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_December292023WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" format="ixt:date-monthname-day-year-en">December 29, 2023</ix:nonNumeric></span> Warrants issued for draw on related party line of credit</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" id="Fact_81d83403ea1b48c78fc17949b0c840f6" contextRef="c20241231_ClassOfWarrantOrRightAxis_December292023WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">200,000</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">$ <br/>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_8b00dc4bf2414c268cfada442078c093" contextRef="c20241231_ClassOfWarrantOrRightAxis_December292023WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.00</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 25.3333%; white-space: nowrap;" rowspan="1"><ix:nonNumeric name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" id="Fact_d1ff867c16eb43cda4eaf99e32073169" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_December292023WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" format="ixt:date-monthname-day-year-en">December 29, 2023</ix:nonNumeric></td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 25.3333%; white-space: nowrap;" rowspan="1"><ix:nonNumeric name="galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired" id="Fact_ce87301f781448fb9cdcdf923dc64295" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_December292023WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" format="ixt:date-monthname-day-year-en">July 31, 2029</ix:nonNumeric></td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 25.3333%; text-align: left; background-color: rgb(204, 238, 255);" rowspan="1">
                <div style="text-indent: -9pt; margin-left: 9pt;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="text-indent: 0pt;"><ix:nonNumeric name="galt:WarrantIssueDate" id="Fact_6d2fefee97924eb9a9bb4b1e028f95f3" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_March292024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" format="ixt:date-monthname-day-year-en">March 29, 2024</ix:nonNumeric></span> Warrants issued for draw on related party line of credit</span></div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" id="Fact_740f2c9095b946d0b2f1bdd61307dc30" contextRef="c20241231_ClassOfWarrantOrRightAxis_March292024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">200,000</ix:nonFraction><br/>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">$ <br/>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_ad918febb4d64fd0a33293fdddb138c3" contextRef="c20241231_ClassOfWarrantOrRightAxis_March292024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.59</ix:nonFraction><br/>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1">&#160;<ix:nonNumeric name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" id="Fact_9398d522fe094004b58a7d5ba4dcec51" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_March292024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" format="ixt:date-monthname-day-year-en">March 29, 2024</ix:nonNumeric><br/>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1">&#160;<ix:nonNumeric name="galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired" id="Fact_991a79abc6e44ee0b430f889fd3f2772" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_March292024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" format="ixt:date-monthname-day-year-en">July 31, 2029</ix:nonNumeric><br/>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 25.3333%; text-align: left;" rowspan="1">
                <div>
                  <div style="text-indent: -9pt; margin-left: 9pt;"><span style="text-indent: 0pt;"><ix:nonNumeric name="galt:WarrantIssueDate" id="Fact_f33caca15c1a44ddb560cd917633b063" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_June282024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" format="ixt:date-monthname-day-year-en">June 28, 2024</ix:nonNumeric></span> Warrants issued for draw on related&#160; party line of credit</div>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1">&#160;<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" id="Fact_01b0e30286f54b47a67c971560bf5ad6" contextRef="c20241231_ClassOfWarrantOrRightAxis_June282024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">200,000</ix:nonFraction><br/>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">$ <br/>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1">&#160;<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_cec673e718de483ca42c78bc9ce8bd7f" contextRef="c20241231_ClassOfWarrantOrRightAxis_June282024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.39</ix:nonFraction><br/>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 25.3333%; white-space: nowrap;" rowspan="1">&#160;<ix:nonNumeric name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" id="Fact_822c69060b7b4af4a12183493fb6e001" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_June282024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" format="ixt:date-monthname-day-year-en">June 29, 2024</ix:nonNumeric><br/>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 25.3333%; white-space: nowrap;" rowspan="1">&#160;<ix:nonNumeric name="galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired" id="Fact_73b741053afe47daa0611786fb22af91" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_June282024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" format="ixt:date-monthname-day-year-en">July 31, 2029</ix:nonNumeric><br/>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 25.3333%; padding-bottom: 2px; text-align: left; background-color: rgb(204, 238, 255);" rowspan="1">
                <div>
                  <div style="text-indent: -9pt; margin-left: 9pt;"><span style="text-indent: 0pt;"><ix:nonNumeric name="galt:WarrantIssueDate" id="Fact_c26f8c0696834a1c8bb4c7c37b8a25e7" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_September302024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" format="ixt:date-monthname-day-year-en">September 30, 2024</ix:nonNumeric></span> Warrants issued for draw on related party line of credit</div>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" id="Fact_4d1a187320514a698ae5dd47896d6b8e" contextRef="c20241231_ClassOfWarrantOrRightAxis_September302024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">200,000</ix:nonFraction><br/>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">$ <br/>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_9cd18ac7a6f44e9a85da041cb31e061a" contextRef="c20241231_ClassOfWarrantOrRightAxis_September302024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">4.13</ix:nonFraction><br/>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 25.3333%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1">&#160;<ix:nonNumeric name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" id="Fact_42997761c9334e8aa227a68716d11321" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_September302024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" format="ixt:date-monthname-day-year-en">September 30, 2024</ix:nonNumeric><br/>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 25.3333%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1">&#160;<ix:nonNumeric name="galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired" id="Fact_42809897948c45f2982f6bab5928f6fd" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_September302024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" format="ixt:date-monthname-day-year-en">July 31, 2029</ix:nonNumeric><br/>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 25.3333%; padding-bottom: 4px;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Total Outstanding Warrants</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" id="Fact_9e85756ef8114bdab557c729efaffdc6" contextRef="c20241231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">9,595,940</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 25.3333%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 25.3333%; padding-bottom: 4px;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>

  </tr>


</table>
          </div>
</ix:continuation></ix:continuation>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">F-16</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div>
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

            </div>

          </div>

        </div>

      </div>

    </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">

    <div>
      <ix:nonNumeric name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Text_7bc7a5f072db49898e6496e5436a5a7d" contextRef="c20240101to20241231" escape="true" continuedAt="Text_d64f756c0c6e4313921971669add0e331">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 24.5pt; vertical-align: top; font-weight: bold;">9.</td>

    <td style="width: auto; vertical-align: top;">
              <div style="font-weight: bold;">Stock-Based Compensation</div>
            </td>

  </tr>


</table>
</ix:nonNumeric>
      <ix:continuation id="Text_d64f756c0c6e4313921971669add0e331" continuedAt="Text_d64f756c0c6e4313921971669add0e332">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>
</ix:continuation>
      <ix:continuation id="Text_d64f756c0c6e4313921971669add0e332" continuedAt="Text_d64f756c0c6e4313921971669add0e333">
<div style="margin: 0px 0px 0px 12.25pt; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Summary of Stock-Based Compensation Plans</div>
</ix:continuation>
      <ix:continuation id="Text_d64f756c0c6e4313921971669add0e333" continuedAt="Text_d64f756c0c6e4313921971669add0e334">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>
</ix:continuation>
      <ix:continuation id="Text_d64f756c0c6e4313921971669add0e334" continuedAt="Text_d64f756c0c6e4313921971669add0e335">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">At December 31, 2024, the Company has a stock-based compensation plan where the Company&#8217;s common stock has been made available for equity-based incentive grants as
        part of the Company&#8217;s compensation programs. In December 2019, the Company adopted the 2019 Omnibus Equity Incentive Plan (the &#8220;2019 Plan&#8221;) which provided originally for the issuance of up to <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" id="Fact_79229601389f4d9c9c3fb221c179ad58" contextRef="c20191231_PlanNameAxis_EquityIncentivePlan2019Member" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">4,000,000</ix:nonFraction> shares of the Company&#8217;s common stock, subsequently increased to <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" id="Fact_8bd96a2a20944b628d8e3c6ba28b65bb" contextRef="c20211231_PlanNameAxis_EquityIncentivePlan2019Member" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">7,000,000</ix:nonFraction>
        in December 2021, and increased to <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" id="Fact_70a2a7958cfd47bb8cc65224e3c23617" contextRef="c20231231_PlanNameAxis_EquityIncentivePlan2019Member" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction> in December 2023 in the form of options, stock appreciation rights, restricted stock and
        other stock-based awards to employees, officers, directors, consultants and other eligible persons. At December 31, 2024, <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" id="Fact_76ca590d44d94d9fa4f0c0104e3a0257" contextRef="c20241231_PlanNameAxis_EquityIncentivePlan2019Member" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">4,135,213</ix:nonFraction>
        shares were available for future grant under the 2019 Plan. Also, the Company previously had the 2009 Incentive Compensation Plan (the &#8220;2009 Plan&#8221;) which, after amendments, provided for issuance of up to <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" id="Fact_0cb81c5c258344aba1135e4d1657c8c1" contextRef="c20241231_PlanNameAxis_IncentiveCompensationPlanTwoThousandNineMemberMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">6,733,334</ix:nonFraction> shares of the Company&#8217;s common stock in the form of options, stock appreciation rights, restricted stock and other stock-based awards to employees, officers,
        directors, consultants and other eligible persons. Provisions of the 2009 Plan stipulated that no grants could be made after February 2019; however, grants made prior to that date remain outstanding for their legal term.</div>
</ix:continuation>
      <ix:continuation id="Text_d64f756c0c6e4313921971669add0e335" continuedAt="Text_d64f756c0c6e4313921971669add0e336">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>
</ix:continuation>
      <ix:continuation id="Text_d64f756c0c6e4313921971669add0e336" continuedAt="Text_d64f756c0c6e4313921971669add0e337">
<div style="margin: 0px 0px 0px 12.25pt; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Stock-Based Compensation</div>
</ix:continuation>
      <ix:continuation id="Text_d64f756c0c6e4313921971669add0e337" continuedAt="Text_d64f756c0c6e4313921971669add0e338">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>
</ix:continuation>

      <ix:nonNumeric name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Text_e5cee5aa72524054a1c1da57b9f86b09" contextRef="c20240101to20241231" escape="true" continuedAt="Text_73885c2b8fe74d88acd52b6dc1a8d3471"><ix:continuation id="Text_d64f756c0c6e4313921971669add0e338" continuedAt="Text_d64f756c0c6e4313921971669add0e339">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">Following is the stock-based compensation expense related to common stock options, restricted common stock, common stock warrants and deferred stock units:</div>
</ix:continuation></ix:nonNumeric>
      <ix:continuation id="Text_73885c2b8fe74d88acd52b6dc1a8d3471" continuedAt="Text_73885c2b8fe74d88acd52b6dc1a8d3472"><ix:continuation id="Text_d64f756c0c6e4313921971669add0e339" continuedAt="Text_d64f756c0c6e4313921971669add0e3310">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_d64f756c0c6e4313921971669add0e3310" continuedAt="Text_d64f756c0c6e4313921971669add0e3311"><ix:continuation id="Text_73885c2b8fe74d88acd52b6dc1a8d3472">
<div style="margin-left: 27pt;">
        <table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; font-weight: bold;">Year Ended</div>
                <div style="text-align: center; font-weight: bold;">December 31, <br/>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; font-weight: bold;"> 2024</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; font-weight: bold;">2023</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Research and development</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_829ffc5b1818412eaa67bead7c8070da" contextRef="c20240101to20241231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,222</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_08a1860f4f6b48a4b9d1c5f825ead199" contextRef="c20230101to20231231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">829</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">General and administrative</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_b2798822d41a4290af440d9ea1eaae0a" contextRef="c20240101to20241231_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,225</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_267dec81156140f09abca524a8c49cb3" contextRef="c20230101to20231231_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,432</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 4px;">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Total stock-based compensation expense</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_aa5e580ff8ac4dfe9ff3d1cd747b7f48" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,447</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_76c2303d94a842dc958d6c36e6e08e83" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,261</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;">&#160;</td>

  </tr>


</table>
         </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_d64f756c0c6e4313921971669add0e3311" continuedAt="Text_d64f756c0c6e4313921971669add0e3312">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>
</ix:continuation>

      <ix:nonNumeric name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Text_2f7c7162c04041e1891796c04ef0ac88" contextRef="c20240101to20241231" escape="true" continuedAt="Text_aa3c19a688ac440396c23dfef1392f301"><ix:continuation id="Text_d64f756c0c6e4313921971669add0e3312" continuedAt="Text_d64f756c0c6e4313921971669add0e3313">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">The fair value of the options granted is determined using the Black-Scholes option-pricing model. The following weighted average assumptions were used:</div>
</ix:continuation></ix:nonNumeric>
      <ix:continuation id="Text_aa3c19a688ac440396c23dfef1392f301" continuedAt="Text_aa3c19a688ac440396c23dfef1392f302"><ix:continuation id="Text_d64f756c0c6e4313921971669add0e3313" continuedAt="Text_d64f756c0c6e4313921971669add0e3314">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_d64f756c0c6e4313921971669add0e3314" continuedAt="Text_d64f756c0c6e4313921971669add0e3315"><ix:continuation id="Text_aa3c19a688ac440396c23dfef1392f302">
<div style="margin-left: 27pt;">
        <table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; font-weight: bold;"> 2024</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; font-weight: bold;">2023</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Risk-free interest rate</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_9f9bea919ee7485cb31bf95651d1f670" contextRef="c20240101to20241231" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">3.89</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>%</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_0fdb8d75699c431c8c5198a42c73dbb0" contextRef="c20230101to20231231" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">3.84</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>%</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Expected life of the options</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; white-space: nowrap;">
                <div style="text-align: right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_de1687eac25841e892394970b9bcccbf" contextRef="c20240101to20241231" format="ixt-sec:duryear">5.4</ix:nonNumeric> years </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; white-space: nowrap;">
                <div style="text-align: right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_380debffb9504727891b7c0f3028130c" contextRef="c20230101to20231231" format="ixt-sec:duryear">5.7</ix:nonNumeric> years </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Expected volatility of the underlying stock</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact_983ec67cc3f549b18dbff7d77276682f" contextRef="c20240101to20241231" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">75.1</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>%</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact_b027e4b53b094874a0cef2a45348aefc" contextRef="c20230101to20231231" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">85.6</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>%</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Expected dividend rate</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="Fact_c885b0a0d7414fb69a64b66c7286dfcf" contextRef="c20240101to20241231" unitRef="U007" decimals="0" scale="0" format="ixt:num-dot-decimal">0</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div>%</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="Fact_539d792b86874fc4a44d0e6b8a824cdd" contextRef="c20230101to20231231" unitRef="U007" decimals="0" scale="0" format="ixt:num-dot-decimal">0</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div>%</div>
              </td>

  </tr>


</table>

      </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_d64f756c0c6e4313921971669add0e3315" continuedAt="Text_d64f756c0c6e4313921971669add0e3316">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>
</ix:continuation>
      <ix:continuation id="Text_d64f756c0c6e4313921971669add0e3316" continuedAt="Text_d64f756c0c6e4313921971669add0e3317">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">As noted above, the fair value of stock options is determined by using the Black-Scholes option pricing model. For all options granted since January 1, 2006 the
        Company has generally used option terms of between <ix:nonNumeric name="galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfAward" id="Fact_d742011810944ec088fef185da180bf6" contextRef="c20240101to20241231_RangeAxis_MinimumMember" format="ixt-sec:duryear">5</ix:nonNumeric> to <ix:nonNumeric name="galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfAward" id="Fact_691c5d22f93c4cb4ad86d5d6b6c84fe5" contextRef="c20240101to20241231_RangeAxis_MaximumMember" format="ixt-sec:duryear">10</ix:nonNumeric> years, generally with <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_4f8d2c6c72934b5d8e9ac57a246f38f8" contextRef="c20240101to20241231_RangeAxis_MinimumMember" format="ixt-sec:duryear">5</ix:nonNumeric> to <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_204c0c03f1574f02b312622c1d57cf9d" contextRef="c20240101to20241231_RangeAxis_MaximumMember" format="ixt-sec:duryear">6</ix:nonNumeric> years representing the estimated life of options granted to employees. The volatility of the common stock is estimated using historical volatility over a period equal to the
        expected life at the date of grant. The risk-free interest rate used in the Black-Scholes option pricing model is determined by reference to historical U.S. Treasury constant maturity rates with terms equal to the expected terms of the awards. An
        expected dividend yield of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="Fact_8f9c6e864abc4f3f871d9c8b5e1e7c9f" contextRef="c20240101to20241231" unitRef="U007" decimals="0" scale="0" format="ixt-sec:numwordsen">zero</ix:nonFraction> is used in the option valuation model, because the Company does not expect to pay any cash dividends on
        common stock in the foreseeable future. At December 31, 2024, the Company does not anticipate any option awards will be forfeited in the calculation of compensation expense due to the limited number of employees that receive stock option grants and
        the Company&#8217;s historical employee turnover; however, any forfeitures will be accounted for as incurred.</div>
</ix:continuation>
      <ix:continuation id="Text_d64f756c0c6e4313921971669add0e3317" continuedAt="Text_d64f756c0c6e4313921971669add0e3318">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>
</ix:continuation>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">F-17</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"/></div>

        <div style="width: 100%;" class="BRPFPageHeader">
          <div>
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

            </div>

          </div>

        </div>

      </div>


      <ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Text_2c589c2863d14b8aae26e244e8c6f921" contextRef="c20240101to20241231" escape="true" continuedAt="Text_81f5eea988d6465fb76d3024b34b7adf1"><ix:continuation id="Text_d64f756c0c6e4313921971669add0e3318" continuedAt="Text_d64f756c0c6e4313921971669add0e3319">
<div style="margin-left: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">The following table summarizes the stock option activity in the stock-based compensation plans:</div>
</ix:continuation></ix:nonNumeric>
      <ix:continuation id="Text_81f5eea988d6465fb76d3024b34b7adf1" continuedAt="Text_81f5eea988d6465fb76d3024b34b7adf2"><ix:continuation id="Text_d64f756c0c6e4313921971669add0e3319" continuedAt="Text_d64f756c0c6e4313921971669add0e3320">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_d64f756c0c6e4313921971669add0e3320" continuedAt="Text_d64f756c0c6e4313921971669add0e3321"><ix:continuation id="Text_81f5eea988d6465fb76d3024b34b7adf2">
<div style="margin-left: 27pt;">
        <table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 53%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">Number of</div>
                <div style="text-align: center; font-weight: bold;">Shares</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">Weighted</div>
                <div style="text-align: center; font-weight: bold;">Average</div>
                <div style="text-align: center; font-weight: bold;">Exercise</div>
                <div style="text-align: center; font-weight: bold;">Price</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="text-align: left; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1">&#160;
                <div style="text-align: center; font-weight: bold;">Weighted</div>
                <div style="text-align: center; font-weight: bold;">Average</div>
                <div style="text-align: center; font-weight: bold;">Remaining</div>
                <div style="text-align: center; font-weight: bold;">Contractual</div>
                <div style="text-align: center; font-weight: bold;">Life</div>
                <div style="text-align: center; font-weight: bold;">(in years) <br/>
                </div>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;">&#160;</td>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;">&#160;&#160;</td>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="2">&#160;&#160;&#160;
                <div style="text-align: center; font-weight: bold;">Aggregate</div>
                <div style="text-align: center; font-weight: bold;">Intrinsic Value</div>
                <div style="text-align: center; font-weight: bold;">(in thousands) <br/>
                </div>
              </td>

    <td style="width: 1%; padding-bottom: 2px;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 53%; background-color: rgb(204, 238, 255);">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Outstanding, December 31, 2022</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" id="Fact_17f51877b724487d8e2bae2a680acc8e" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">5,745,561</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" id="Fact_a994747107b24a8ba2b5cd76d838bc4a" contextRef="c20221231" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">2.90</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 8.95%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 7.95%; background-color: rgb(204, 238, 255);">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 53%;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Granted</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" id="Fact_aa14a017324a42c9962d371af9c22adf" contextRef="c20230101to20231231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,025,000</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1.01%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" id="Fact_b232be53802d427e995881de54e57d34" contextRef="c20230101to20231231" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">1.18</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 8.95%;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 7.95%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 53%; background-color: rgb(204, 238, 255);">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Forfeited/Cancelled</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" id="Fact_a831211d2d0b4a5aa471f64ff6063221" contextRef="c20230101to20231231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">436,720</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" id="Fact_bd217fd337b749869b77a9dc835821aa" contextRef="c20230101to20231231" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">2.23</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 8.95%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 7.95%; background-color: rgb(204, 238, 255);">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 53%; padding-bottom: 2px;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Exercised</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" id="Fact_f4d6278a66e74ead82c9b9408d3a02e5" contextRef="c20230101to20231231" unitRef="U002" decimals="INF" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1.01%; padding-bottom: 2px; white-space: nowrap;">
                <div></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" id="Fact_5d8e8417fd08420391986d8537195ece" contextRef="c20230101to20231231" unitRef="U003" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 8.95%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 7.95%; padding-bottom: 2px;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 53%; background-color: rgb(204, 238, 255);">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Outstanding, December 31, 2023</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" id="Fact_3e71c803aace4f17af6475d61e0f9f51" contextRef="c20231231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">6,333,841</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" id="Fact_421693bdc3744daf83580a01104549a9" contextRef="c20231231" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">2.66</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 8.95%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 7.95%; background-color: rgb(204, 238, 255);">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 53%;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Granted</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" id="Fact_557d9c8305774f76a4e166faad392564" contextRef="c20240101to20241231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,373,000</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1.01%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" id="Fact_c9c4efd1b1524e8ebe088a19226363da" contextRef="c20240101to20241231" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">1.86</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 8.95%;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 7.95%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 53%; background-color: rgb(204, 238, 255);">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Forfeited/Cancelled</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" id="Fact_e1977b5fc736467191443d5e6067ed4c" contextRef="c20240101to20241231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">348,750</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" id="Fact_2d1f8ca6d2ab4461abb28393f4c81a5a" contextRef="c20240101to20241231" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">6.35</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 8.95%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 7.95%; background-color: rgb(204, 238, 255);">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 53%; padding-bottom: 2px;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Exercised</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" id="Fact_44d8158c34e74348bd1d9cec49c0f905" contextRef="c20240101to20241231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">503,333</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1.01%; padding-bottom: 2px; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" id="Fact_58c77de0defc4c8892cb05cf02952d90" contextRef="c20240101to20241231" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">1.71</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 8.95%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 7.95%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 53%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Outstanding, December 31, 2024</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" id="Fact_5497b22fd2994795b89aed33bd8418ca" contextRef="c20241231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">6,854,758</ix:nonFraction><br/>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1.01%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" id="Fact_2b14c77f00334d47af17a67040d93d09" contextRef="c20241231" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">2.39</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 8.95%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">
                <div style="text-align: right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="Fact_bb9c758b70f54d049964bd4f95894ca3" contextRef="c20240101to20241231" format="ixt-sec:duryear">6.27</ix:nonNumeric> <br/>
                </div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" colspan="1">&#160;$</td>

    <td valign="bottom" style="vertical-align: bottom; width: 7.95%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">
                <div style="text-align: right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" id="Fact_07a15ad342bc4816a4301b6ccce8d57a" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">183</ix:nonFraction><br/>
                </div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 53%;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Exercisable, December 31, 2024</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" id="Fact_f19fc6d1ad9e412396c1bca7e0af8b10" contextRef="c20241231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">6,138,254</ix:nonFraction><br/>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1.01%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">$</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" id="Fact_a6d7e51ff21c4dfc9b5a4b8871129ca2" contextRef="c20241231" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">2.45</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 8.95%; white-space: nowrap;">
                <div style="text-align: right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Fact_e8d27791f7fa4fe592409ee0f8c341c9" contextRef="c20240101to20241231" format="ixt-sec:duryear">6.00</ix:nonNumeric> <br/>
                </div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;$</td>

    <td valign="bottom" style="vertical-align: bottom; width: 7.95%; white-space: nowrap;">
                <div style="text-align: right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" id="Fact_ebbb494781b54b75803ea0680ee957ed" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">176</ix:nonFraction> </div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
         </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_d64f756c0c6e4313921971669add0e3321" continuedAt="Text_d64f756c0c6e4313921971669add0e3322">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>
</ix:continuation>
      <ix:continuation id="Text_d64f756c0c6e4313921971669add0e3322" continuedAt="Text_d64f756c0c6e4313921971669add0e3323">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">The aggregate intrinsic value in the table above represents the total pre-tax amount, net of exercise price, which would have been received by option holders if all
        option holders had exercised all options with an exercise price lower than the market price on December 31, 2024, based on the closing price of the Company&#8217;s common stock of $<ix:nonFraction name="us-gaap:SharePrice" id="Fact_82f8c52d9eaf4fa1ad6482754ae55094" contextRef="c20241231" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">1.29</ix:nonFraction> on that date.</div>
</ix:continuation>
      <ix:continuation id="Text_d64f756c0c6e4313921971669add0e3323" continuedAt="Text_d64f756c0c6e4313921971669add0e3324">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>
</ix:continuation>
      <ix:continuation id="Text_d64f756c0c6e4313921971669add0e3324" continuedAt="Text_d64f756c0c6e4313921971669add0e3325">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">The weighted-average grant-date fair values of options granted during 2024 and 2023 were $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" id="Fact_28ca4ccfda7648369e3994a72bdd9a66" contextRef="c20240101to20241231" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">1.26</ix:nonFraction> and $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" id="Fact_a31e41d3fe31487f8ccc17566fe3228f" contextRef="c20230101to20231231" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">0.85</ix:nonFraction>, respectively. As of December 31, 2024 and 2023,
        there were unvested options to purchase <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" id="Fact_6319f6c64d3d4315bc8b01f568b47248" contextRef="c20241231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">716,504</ix:nonFraction> and <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" id="Fact_876b7057f7e14db3b059aae3c3ac9933" contextRef="c20231231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,792,080</ix:nonFraction> shares of common stock, respectively. Total expected unrecognized compensation cost related to such unvested options is $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" id="Fact_f4255fd7541f4ab3aa61c4124664c82c" contextRef="c20241231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">775,000</ix:nonFraction> at December 31, 2024, which is expected to be recognized over a weighted-average period of <ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Fact_5aa29eb5145643f2b76ca9fb77717580" contextRef="c20240101to20241231" format="ixt-sec:duryear">1.0</ix:nonNumeric>
        years.</div>
</ix:continuation>
      <ix:continuation id="Text_d64f756c0c6e4313921971669add0e3325" continuedAt="Text_d64f756c0c6e4313921971669add0e3326">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>
</ix:continuation>
      <ix:continuation id="Text_d64f756c0c6e4313921971669add0e3326" continuedAt="Text_d64f756c0c6e4313921971669add0e3327">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">During the years ended December 31, 2024 and 2023, <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" id="Fact_7f08c5fcbe8e42f5aa5dc5d7103c9a2a" contextRef="c20240101to20241231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,966,167</ix:nonFraction>
        and <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" id="Fact_63ec93f4d5424ab2a2dbf89fe78f423e" contextRef="c20230101to20231231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,119,168</ix:nonFraction> options became vested, respectively. The total grant date fair value of options vested during the years ended December 31,
        2024 and 2023 was $<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" id="Fact_a8ecc398852d4a0c808519c44222c183" contextRef="c20240101to20241231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">2,772,748</ix:nonFraction> and $<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" id="Fact_7d545a6fb16d416f8b6cd82715ce1ad3" contextRef="c20230101to20231231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">1,384,284</ix:nonFraction>,
        respectively.</div>
</ix:continuation>
      <ix:continuation id="Text_d64f756c0c6e4313921971669add0e3327" continuedAt="Text_d64f756c0c6e4313921971669add0e3328">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>
</ix:continuation>

      <ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" id="Text_9935f85e603949549a8c899d8e1228a5" contextRef="c20240101to20241231" escape="true" continuedAt="Text_07d00bfeeabb4722ac9a0bcca976e4bf1"><ix:continuation id="Text_d64f756c0c6e4313921971669add0e3328" continuedAt="Text_d64f756c0c6e4313921971669add0e3329">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">The following table summarizes additional information regarding outstanding and exercisable options under our stock-based compensation plans at December 31, 2024:</div>
</ix:continuation></ix:nonNumeric>
      <ix:continuation id="Text_07d00bfeeabb4722ac9a0bcca976e4bf1" continuedAt="Text_07d00bfeeabb4722ac9a0bcca976e4bf2"><ix:continuation id="Text_d64f756c0c6e4313921971669add0e3329" continuedAt="Text_d64f756c0c6e4313921971669add0e3330">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_d64f756c0c6e4313921971669add0e3330" continuedAt="Text_d64f756c0c6e4313921971669add0e3331"><ix:continuation id="Text_07d00bfeeabb4722ac9a0bcca976e4bf2">
<div style="margin-left: 27pt;">
        <table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 39%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="10" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; font-weight: bold;">Options Outstanding</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; font-weight: bold;">Options Exercisable</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); width: 39%; white-space: nowrap;">
                <div style="font-weight: bold;">Exercise</div>
                <div style="font-weight: bold;">Price (Range)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">Number of</div>
                <div style="text-align: center; font-weight: bold;">Shares</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">Weighted</div>
                <div style="text-align: center; font-weight: bold;">Average</div>
                <div style="text-align: center; font-weight: bold;">Remaining</div>
                <div style="text-align: center; font-weight: bold;">Contractual</div>
                <div style="text-align: center; font-weight: bold;">Life</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">Weighted</div>
                <div style="text-align: center; font-weight: bold;">Average</div>
                <div style="text-align: center; font-weight: bold;">Exercise</div>
                <div style="text-align: center; font-weight: bold;">Price</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">Number of</div>
                <div style="text-align: center; font-weight: bold;">Shares</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">Weighted</div>
                <div style="text-align: center; font-weight: bold;">Average</div>
                <div style="text-align: center; font-weight: bold;">Exercise</div>
                <div style="text-align: center; font-weight: bold;">Price</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 39%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom;">
                <div style="text-align: center; font-weight: bold;">(in years)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 39%; background-color: rgb(204, 238, 255);" rowspan="1">
                <div>$<ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" id="Fact_db2042862bba4fb194c5791e1b0f73a0" contextRef="c20240101to20241231_RangeAxis_MinimumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeOneMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">0.89</ix:nonFraction> &#8211; <ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" id="Fact_b278ede36ce749348d4000b81240a5d1" contextRef="c20240101to20241231_RangeAxis_MaximumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeOneMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">1.50</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" id="Fact_b43a76e113d94eb4a0c7f007d0db984b" contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeOneMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,134,206</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div><ix:nonNumeric name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="Fact_64f5d9b7797b44998838841fa3d302ba" contextRef="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeOneMember" format="ixt-sec:duryear">7.13</ix:nonNumeric></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" id="Fact_84b2543e46314547925ed82a82f29d4d" contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeOneMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">1.16</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" id="Fact_07f9a88b5ad24d26b2227862a241bf6d" contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeOneMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">934,202</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" id="Fact_0be236027fa04a32baea919bc29e92ff" contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeOneMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">1.12</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 39%;" rowspan="1">
                <div>$<ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" id="Fact_6af57083f3984cabb31dd9e904b874e9" contextRef="c20240101to20241231_RangeAxis_MinimumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeTwoMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">1.51</ix:nonFraction> &#8211; <ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" id="Fact_7488909fcc5145209db2b1bd1a6e9dd5" contextRef="c20240101to20241231_RangeAxis_MaximumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeTwoMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">2.50</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" id="Fact_63ef040b2b01428dada2f2bcafe15cae" contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeTwoMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">3,691,315</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonNumeric name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="Fact_ff4638af858347b2a4b05edf6992f969" contextRef="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeTwoMember" format="ixt-sec:duryear">6.88</ix:nonNumeric></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" id="Fact_da2bd782fff74f1babe02e12e603b862" contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeTwoMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">2.02</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" id="Fact_ea0ebaf467a34ece8e6718f8bf159d96" contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeTwoMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">3,199,815</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" id="Fact_e24dfb86f7824f2fa61cbaea303ebda6" contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeTwoMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">2.02</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 39%; background-color: rgb(204, 238, 255);" rowspan="1">
                <div>$<ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" id="Fact_69e8929091a54a58aa1dc3595cb21e49" contextRef="c20240101to20241231_RangeAxis_MinimumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeThreeMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">2.51</ix:nonFraction> &#8211; <ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" id="Fact_1989391763394792955e92e7f9159910" contextRef="c20240101to20241231_RangeAxis_MaximumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeThreeMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">5.00</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" id="Fact_1bd77882dbda40a19cc5d4f3a0aa5051" contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeThreeMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,809,237</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div><ix:nonNumeric name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="Fact_1ba8d6bb1573440d921d8aa68868a1e2" contextRef="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeThreeMember" format="ixt-sec:duryear">4.88</ix:nonNumeric></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" id="Fact_9c2c5aa9d8824b26a4dd60900e5e0e28" contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeThreeMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.48</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" id="Fact_b093bb1e435546cc985d564464f59cd0" contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeThreeMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,784,237</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" id="Fact_07d4c4df9956404f82243d2e09933213" contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeThreeMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.48</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 39%; padding-bottom: 2px;" rowspan="1">
                <div>$<ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" id="Fact_388aa13c0bf3481e9e59fb8459ee9c27" contextRef="c20240101to20241231_RangeAxis_MinimumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeFourMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">5.01</ix:nonFraction> &#8211; <ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" id="Fact_e6adafb6340e4969bb42aa9f27b7bde2" contextRef="c20240101to20241231_RangeAxis_MaximumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeFourMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">6.71</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" id="Fact_0b77493d37ea43d4bcd6e9e1681a3b8c" contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeFourMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">220,000</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div><ix:nonNumeric name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="Fact_5ab7bc82822f4e2bbab52c163b492952" contextRef="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeFourMember" format="ixt-sec:duryear">3.10</ix:nonNumeric></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" id="Fact_3f4884422dbe44e898d37a51471ca285" contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeFourMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">5.92</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" id="Fact_8b6dc5951d6b4f2795b39f217a111ddf" contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeFourMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">220,000</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" id="Fact_ae5e7254411f429d8f4cd3cb2d61edf4" contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeFourMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">5.92</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 39%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" rowspan="1">&#160;&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" id="Fact_a8fbe935b21a46fbb1870c682ebc9e14" contextRef="c20241231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">6,854,758</ix:nonFraction><br/>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div><ix:nonNumeric name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="Fact_c8f993f54d304af2b95bcc98a7b46eed" contextRef="c20240101to20241231" format="ixt-sec:duryear">6.27</ix:nonNumeric><br/>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" id="Fact_7b0e8c5075704fa2b5b6b13ecf530442" contextRef="c20241231" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">2.39</ix:nonFraction><br/>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" id="Fact_d5bc3f021c0d4dc8aec5ebbb24af2e91" contextRef="c20241231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">6,138,254</ix:nonFraction><br/>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" id="Fact_4547acd868c2427aad66b09ca3e66722" contextRef="c20241231" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">2.45</ix:nonFraction><br/>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>


</table>

      </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_d64f756c0c6e4313921971669add0e3331" continuedAt="Text_d64f756c0c6e4313921971669add0e3332">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>
</ix:continuation>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">F-18</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"/></div>

        <div style="width: 100%;" class="BRPFPageHeader">
          <div>
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

            </div>

          </div>

        </div>

      </div>

      <ix:continuation id="Text_d64f756c0c6e4313921971669add0e3332" continuedAt="Text_d64f756c0c6e4313921971669add0e3333">
<div style="margin: 0px 0px 0px 12.25pt; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Restricted Stock Issuances</div>
</ix:continuation>
      <ix:continuation id="Text_d64f756c0c6e4313921971669add0e3333" continuedAt="Text_d64f756c0c6e4313921971669add0e3334">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman';"><br/>
        </span> </div>
</ix:continuation>
      <ix:continuation id="Text_d64f756c0c6e4313921971669add0e3334" continuedAt="Text_d64f756c0c6e4313921971669add0e3335">
<div style="display:none;"><br/></div>
<div style="margin: 0px 0px 0px 24.45pt; text-indent: 0pt;"><span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In January 2024, the Company issued <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" id="Fact_1ba9f766171248398171864f0391175a" contextRef="c20240101to20240131_AwardTypeAxis_RestrictedStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">408,000</ix:nonFraction> restricted stock units to its employees valued at $<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" id="Fact_25878712710c44f8adcef13a345dbe65" contextRef="c20240101to20240131_AwardTypeAxis_RestrictedStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">734,000</ix:nonFraction> at the date of grant. These restricted stock units would vest <ix:nonFraction name="galt:VestingPercentageOfRestrictedStockUnits" id="Fact_726a8e12a89e459c871fbc8ba0fb5562" contextRef="c20240101to20241231_AwardTypeAxis_RestrictedStockMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction>% if the Company publicly presents the results of the Interim Analysis of its NAVIGATE clinical trial on or before December 31, 2024. The Company believed it was probable that the
          vesting condition will be met and is amortized the restricted stock unit expense ratably in 2024. The vesting condition was met in December 2024. </span></div>
</ix:continuation>
      <ix:continuation id="Text_d64f756c0c6e4313921971669add0e3335" continuedAt="Text_d64f756c0c6e4313921971669add0e3336">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><br/>
      </div>
</ix:continuation>
      <ix:continuation id="Text_d64f756c0c6e4313921971669add0e3336" continuedAt="Text_d64f756c0c6e4313921971669add0e3337">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">In January 2024, <ix:nonFraction name="galt:NumberOfDirectors" id="Fact_db772f2f617e4e428ba893bb43da3007" contextRef="c20231231_AwardTypeAxis_RestrictedStockMember" unitRef="U009" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction> <span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 0px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">director elected to take a restricted stock grant in lieu of cash retainers for 2024.</span> A total of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" id="Fact_84b8f31bb2a44a65a245df6546517aa9" contextRef="c20230101to20231231_AwardTypeAxis_RestrictedStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">23,256</ix:nonFraction> shares of restricted stock valued at approximately $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_3cccc8d0c46f42c3bd0e3103ec36c3ac" contextRef="c20230101to20231231_AwardTypeAxis_RestrictedStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">40,000</ix:nonFraction>
        was amortized to expense on a straight-line basis until December 31, 2024 when the stock vested in full.</div>
</ix:continuation>
      <ix:continuation id="Text_d64f756c0c6e4313921971669add0e3337" continuedAt="Text_d64f756c0c6e4313921971669add0e3338">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>
</ix:continuation>
      <ix:continuation id="Text_d64f756c0c6e4313921971669add0e3338" continuedAt="Text_d64f756c0c6e4313921971669add0e3339">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">In January 2023, <ix:nonFraction name="galt:NumberOfDirectors" id="Fact_40e83dcde60b47ad980e0af5f088df4e" contextRef="c20241231_AwardTypeAxis_RestrictedStockMember" unitRef="U009" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction> <span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 0px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">director elected to take a restricted stock grant in lieu of cash retainers for 202</span>3. A total of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" id="Fact_e82d9a6a5e354ba99fb32ad954a0baab" contextRef="c20240101to20241231_AwardTypeAxis_RestrictedStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">36,036</ix:nonFraction> shares of restricted stock valued at approximately $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_3e172197d217419782168423b22f39ae" contextRef="c20240101to20241231_AwardTypeAxis_RestrictedStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">40,000</ix:nonFraction>
        was amortized to expense on a straight-line basis until December 31, 2023 when the stock vested in full.</div>
</ix:continuation>
      <ix:continuation id="Text_d64f756c0c6e4313921971669add0e3339" continuedAt="Text_d64f756c0c6e4313921971669add0e3340">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>
</ix:continuation>
      <ix:continuation id="Text_d64f756c0c6e4313921971669add0e3340" continuedAt="Text_d64f756c0c6e4313921971669add0e3341">
<div style="margin: 0px 0px 0px 12.25pt; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Deferred Stock Units</div>
</ix:continuation>
      <ix:continuation id="Text_d64f756c0c6e4313921971669add0e3341" continuedAt="Text_d64f756c0c6e4313921971669add0e3342">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>
</ix:continuation>
      <ix:continuation id="Text_d64f756c0c6e4313921971669add0e3342" continuedAt="Text_d64f756c0c6e4313921971669add0e3343">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">In September 2020, the Company entered into an employment agreement with its new Chief Executive Officer whereby <ix:nonFraction name="galt:DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent" id="Fact_2bde12c4a8b74a39ae23720df188ebc9" contextRef="c20220101to20221231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">20</ix:nonFraction>% of his base salary and performance bonuses will be paid in cash, and <ix:nonFraction name="galt:DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent" id="Fact_e0b064951ecb46048dd3e77ffebef504" contextRef="c20220101to20221231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">80</ix:nonFraction>%
        will be paid in the form of deferred stock units (&#8220;<span style="text-decoration: underline;">DSUs</span>&#8221;) through December 31, 2022 in accordance with the terms and subject to the provisions set forth in the DSU Agreement. DSUs credited to Mr. Lewis as of any date shall be fully vested
        and nonforfeitable at all times.<span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> Pursuant to an amendment to the DSU
          Agreement in July 2022, </span><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">the
          Company shall issue the shares earned through December 31, 2022 underlying the outstanding whole number of DSUs credited to Mr. Lewis as follows: <ix:nonFraction name="galt:DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne" id="Fact_5c82d541b1f445ce89cf26d7ef243437" contextRef="c20221231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember" unitRef="U007" decimals="2" scale="-2" format="ixt-sec:numwordsen">twenty five </ix:nonFraction>percent shall be issued on March 1, 2023, <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="galt:DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo" id="Fact_7b0d17317e8b4f8086a67d9e3968bbe2" contextRef="c20221231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember" unitRef="U007" decimals="2" scale="-2" format="ixt-sec:numwordsen">fifty </ix:nonFraction>percent shall be issued on March 1, 2024</span> and&#160;<span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="galt:DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree" id="Fact_c6fb62428063432cad201270b1772ce5" contextRef="c20221231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember" unitRef="U007" decimals="2" scale="-2" format="ixt-sec:numwordsen">twenty five </ix:nonFraction>percent </span></span>shall














            be issued on September 1, 2028. </span></span></div>
</ix:continuation>
      <ix:continuation id="Text_d64f756c0c6e4313921971669add0e3343" continuedAt="Text_d64f756c0c6e4313921971669add0e3344">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
        </span> </div>
</ix:continuation>
      <ix:continuation id="Text_d64f756c0c6e4313921971669add0e3344" continuedAt="Text_d64f756c0c6e4313921971669add0e3345">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
      <ix:continuation id="Text_d64f756c0c6e4313921971669add0e3345" continuedAt="Text_d64f756c0c6e4313921971669add0e3346">
<div style="display:none;"><br/></div>
<div style="margin: 0px 0px 0px 24.45pt; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 0pt;"><span style="background-color: rgb(255, 255, 255); margin-top: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: left; text-transform: none;">On </span><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">March 1, 2024, <ix:nonFraction name="galt:DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFour" id="Fact_4a261d0bbf7349eaa9d192bb30506e88" contextRef="c20241231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember" unitRef="U007" decimals="2" scale="-2" format="ixt-sec:numwordsen">fifty </ix:nonFraction>percent of the
          DSU&#8217;s were issued to Mr. Lewis in accordance with the DSU Agreement. A total of <ix:nonFraction name="us-gaap:CommonStockSharesSubscribedButUnissued" id="Fact_8e5a1371dc9f4c6685fb2b782153cad7" contextRef="c20241231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">367,800</ix:nonFraction> shares were due to be issued&#894; however, <ix:nonFraction name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" id="Fact_8627ac6360184ce596234dcafd7afa06" contextRef="c20240101to20241231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">153,288</ix:nonFraction> shares were withheld to cover income tax withholding of $<ix:nonFraction name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" id="Fact_ad3723eec8a04f88b2b65a2f405b51fa" contextRef="c20240101to20241231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">300,445</ix:nonFraction> resulting in <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" id="Fact_f28ebeb84848492e918124145953fc24" contextRef="c20240101to20241231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">214,512</ix:nonFraction> shares actually issued. On March 1, 2023, <ix:nonFraction name="galt:DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFive" id="Fact_9391461ffcd24d54a7cc3793470db6c1" contextRef="c20231231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember" unitRef="U007" decimals="2" scale="-2" format="ixt-sec:numwordsen">twenty five </ix:nonFraction>percent of the DSU&#8217;s were issued to Mr. Lewis in accordance with the DSU Agreement. A total of <ix:nonFraction name="us-gaap:CommonStockSharesSubscribedButUnissued" id="Fact_788f94492c7540ea998e97e74d73ecb8" contextRef="c20231231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">183,900</ix:nonFraction> shares were due to be issued&#894; however, <ix:nonFraction name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" id="Fact_9e7c956910374265bff6e2266f53b467" contextRef="c20230101to20231231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">75,529</ix:nonFraction> shares
          were withheld to cover income tax withholding of $<ix:nonFraction name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" id="Fact_be33515774684a59bc618779050fef15" contextRef="c20230101to20231231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">156,345</ix:nonFraction> resulting in <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" id="Fact_c270e2dab81f49538c1e89f5e50616d1" contextRef="c20230101to20231231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">108,371</ix:nonFraction> shares actually issued.</span></div>
</ix:continuation>
      <ix:continuation id="Text_d64f756c0c6e4313921971669add0e3346" continuedAt="Text_d64f756c0c6e4313921971669add0e3347">
<div style="display:none;"><br/></div>
<div style="margin: 0px 0px 0px 24.45pt; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -27pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><br/>
        <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Additionally, a 2023 DSU Agreement was
          executed in July 2022, whereby Mr. Lewis would continue to receive <ix:nonFraction name="galt:DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent" id="Fact_638d03f59a304baa832b363ad8be9cd8" contextRef="c20230101to20231231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">20</ix:nonFraction>% of salary in cash and <ix:nonFraction name="galt:DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent" id="Fact_2cb549c8251d4f15b1e1d4347b920f5b" contextRef="c20230101to20231231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">80</ix:nonFraction>% in DSUs for 2023. The shares under the 2023 DSU Agreement are to be issued <ix:nonFraction name="galt:DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSix" id="Fact_b97cbd8e3bbb48f0b05071f609a2de5d" contextRef="c20231231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember" unitRef="U007" decimals="2" scale="-2" format="ixt-sec:numwordsen">fifty </ix:nonFraction>percent on March 1, 2025 and <ix:nonFraction name="galt:DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSeven" id="Fact_31d21ecb8976450d8116e464cf044ee9" contextRef="c20231231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember" unitRef="U007" decimals="2" scale="-2" format="ixt-sec:numwordsen">fifty </ix:nonFraction>percent on January 5, 2026.</span></div>
</ix:continuation>
      <ix:continuation id="Text_d64f756c0c6e4313921971669add0e3347" continuedAt="Text_d64f756c0c6e4313921971669add0e3348">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/>
        </span></div>
</ix:continuation>
      <ix:continuation id="Text_d64f756c0c6e4313921971669add0e3348" continuedAt="Text_d64f756c0c6e4313921971669add0e3349">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">For the year ended December 31, 2023, approximately $<ix:nonFraction name="us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" id="Fact_50af2d0d404848c3b38ef8f94df9c288" contextRef="c20230101to20231231_TitleOfIndividualAxis_ChiefExecutiveOfficerMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">459,000</ix:nonFraction> of his compensation was recorded as stock compensation expense
            representing <ix:nonFraction name="us-gaap:DeferredCompensationArrangementWithIndividualSharesIssued" id="Fact_f6b9d1dce0684dd893ce9802785de16c" contextRef="c20230101to20231231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">275,126</ix:nonFraction> shares of common stock to be issued under the DSU agreement with a weighted average grant date fair value of $<ix:nonFraction name="us-gaap:DeferredCompensationArrangementWithIndividualExercisePrice" id="Fact_ba8ff613e6aa4298a76739acfe4c34d7" contextRef="c20230101to20231231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">1.71</ix:nonFraction> per share. For the year ended December 31, 2022, approximately $<ix:nonFraction name="us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" id="Fact_e15d09f22242412d9c3bc2f98018c1ad" contextRef="c20220101to20221231_TitleOfIndividualAxis_ChiefExecutiveOfficerMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">418,000</ix:nonFraction> of his compensation was recorded as stock compensation expense representing <ix:nonFraction name="us-gaap:DeferredCompensationArrangementWithIndividualSharesIssued" id="Fact_7188004f556742b198e60bb2453149db" contextRef="c20220101to20221231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">268,596</ix:nonFraction>
            shares of common stock to be issued under the DSU agreement with a weighted average grant date fair value of $<ix:nonFraction name="us-gaap:DeferredCompensationArrangementWithIndividualExercisePrice" id="Fact_a9f1d83656f24a3cb15aab32f18c8044" contextRef="c20220101to20221231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">1.56</ix:nonFraction> per share.</span></span></div>
</ix:continuation>
      <ix:continuation id="Text_d64f756c0c6e4313921971669add0e3349" continuedAt="Text_d64f756c0c6e4313921971669add0e3350">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/>
          </span></span></div>
</ix:continuation>
      <ix:continuation id="Text_d64f756c0c6e4313921971669add0e3350" continuedAt="Text_d64f756c0c6e4313921971669add0e3351">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> Also, Mr. Lewis&#8217; bonus for the year ended December 31, 2022 of $<ix:nonFraction name="us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" id="Fact_cbd26f87e73c43638b9bda0910f411e1" contextRef="c20220101to20221231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_BonusSharesMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">210,000</ix:nonFraction> (which was included in accrued compensation at
            December 31, 2022) was approved in January 2023 and represents <ix:nonFraction name="us-gaap:DeferredCompensationArrangementWithIndividualSharesIssued" id="Fact_96f9461b58ae42bf8535da19aa0ca5d7" contextRef="c20220101to20221231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_BonusSharesMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">143,836</ix:nonFraction> shares of common stock to be issued under the DSU agreement
            with a grant date fair value of $<ix:nonFraction name="us-gaap:DeferredCompensationArrangementWithIndividualExercisePrice" id="Fact_2d6d4f8fa0f3404cb60eb60c1289a9cc" contextRef="c20220101to20221231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_BonusSharesMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">1.46</ix:nonFraction> per share. The $<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" id="Fact_6581b4eccb8747739220a7c3d7ed6e4f" contextRef="c20230101to20231231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_BonusSharesMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">210,000</ix:nonFraction> was reclassified from accrued compensation to additional paid in capital in January 2023. Mr. Lewis&#8217; bonus for the year ended December 31, 2021 of $<ix:nonFraction name="us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" id="Fact_2ae57f7eb8b3479b8d25feffea683a35" contextRef="c20210101to20211231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_BonusSharesMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">200,000</ix:nonFraction> (which was included in accrued compensation at December 31, 2021) was approved in January 2022, and represents <ix:nonFraction name="us-gaap:DeferredCompensationArrangementWithIndividualSharesIssued" id="Fact_d95ccb4bbee24fe4a2849cdc4d41ca38" contextRef="c20210101to20211231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_BonusSharesMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">103,627</ix:nonFraction> shares of common stock to be issued under the DSU agreement with a grant date fair value of $<ix:nonFraction name="us-gaap:DeferredCompensationArrangementWithIndividualExercisePrice" id="Fact_db85a0f85d6b4395a7568850c309073e" contextRef="c20210101to20211231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_BonusSharesMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">1.93</ix:nonFraction> per share. The $<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" id="Fact_e76a73a6480c4df68fece06282222579" contextRef="c20220101to20221231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_BonusSharesMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">200,000</ix:nonFraction> was reclassified from accrued
            compensation to additional paid in capital in January 2022.</span></span></div>
</ix:continuation>
      <ix:continuation id="Text_d64f756c0c6e4313921971669add0e3351" continuedAt="Text_d64f756c0c6e4313921971669add0e3352">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/>
          </span></span></div>
</ix:continuation>
      <ix:continuation id="Text_d64f756c0c6e4313921971669add0e3352">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">There is <ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" id="Fact_05f33c1c3e884d36a838f6ab5d94868c" contextRef="c20241231_TitleOfIndividualAxis_ChiefExecutiveOfficerMember" unitRef="U001" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction> unrecognized compensation expense related to the DSUs.</span></span></div>
</ix:continuation>
       </div>

    <div><br/>
    </div>

    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">F-19</span></div>

      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div>
          <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

          </div>

        </div>

      </div>

    </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">

    <div>
      <ix:nonNumeric name="us-gaap:DebtDisclosureTextBlock" id="Text_8692324ab2ad4d2786377a23b752b756" contextRef="c20240101to20241231_LongtermDebtTypeAxis_LineOfCreditMember" escape="true" continuedAt="Text_5de5bc6a7eab46768823bb3eef11a6eb1">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 27.05pt; vertical-align: top; font-weight: bold;">10.</td>

    <td style="width: auto; vertical-align: top;">
              <div style="font-weight: bold;">Convertible Line of Credit &#8211; Related Party and Supplemental Lines of Credit &#8211; Related Party<br/>
              </div>
            </td>

  </tr>


</table>
</ix:nonNumeric>
      <ix:continuation id="Text_5de5bc6a7eab46768823bb3eef11a6eb1" continuedAt="Text_5de5bc6a7eab46768823bb3eef11a6eb2">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>
</ix:continuation>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <ix:continuation id="Text_5de5bc6a7eab46768823bb3eef11a6eb2" continuedAt="Text_5de5bc6a7eab46768823bb3eef11a6eb3">
<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt;">On July 25, 2022, the Company and Richard E. Uihlein (the &#8220;Lender&#8221;) entered into a Line of Credit Letter Agreement (the &#8220;Credit Agreement&#8221;), pursuant
          to which the Lender shall provide the Company a line of credit of up to $<ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" id="Fact_cc679c0619224860929208e53cf67b89" contextRef="c20220725_CreditFacilityAxis_LineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">60.0</ix:nonFraction> million (the &#8220;Line of Credit&#8221;) to finance the Company&#8217;s
          working capital needs. The Company may draw upon the Line of Credit through July 31, 2024.</div>
</ix:continuation>
        <ix:continuation id="Text_5de5bc6a7eab46768823bb3eef11a6eb3" continuedAt="Text_5de5bc6a7eab46768823bb3eef11a6eb4">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_5de5bc6a7eab46768823bb3eef11a6eb4" continuedAt="Text_5de5bc6a7eab46768823bb3eef11a6eb5">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman';"><br/>
          </span> </div>
</ix:continuation>
        <ix:continuation id="Text_5de5bc6a7eab46768823bb3eef11a6eb5" continuedAt="Text_5de5bc6a7eab46768823bb3eef11a6eb6">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_5de5bc6a7eab46768823bb3eef11a6eb6" continuedAt="Text_5de5bc6a7eab46768823bb3eef11a6eb7">
<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt;">Each advance made pursuant to the Credit Agreement shall be evidenced by an unsecured, convertible promissory note (individually, a &#8220;Promissory
          Note,&#8221; and collectively, the &#8220;Promissory Notes&#8221;), and bear interest at the Applicable Federal Rate for short term loans, plus two (<ix:nonFraction name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" id="Fact_105309e78a754ec0bd05e8cbddbfcdbd" contextRef="c20220725to20220725_CreditFacilityAxis_LineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">2</ix:nonFraction>%)
          percent. Principal and interest on the Promissory Notes are due on or before <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" id="Fact_515a98fb5d9a4cfd9e5bc7e88231ce66" contextRef="c20220725to20220725_CreditFacilityAxis_LineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" format="ixt:date-monthname-day-year-en">January 31, 2026</ix:nonNumeric>. Only with the consent of the Lender,
          may the Promissory Notes be prepaid, in whole or in part, at any time without premium or penalty, but with interest on the amount or amounts prepaid.</div>
</ix:continuation>
        <ix:continuation id="Text_5de5bc6a7eab46768823bb3eef11a6eb7" continuedAt="Text_5de5bc6a7eab46768823bb3eef11a6eb8">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_5de5bc6a7eab46768823bb3eef11a6eb8" continuedAt="Text_5de5bc6a7eab46768823bb3eef11a6eb9">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman';"><br/>
          </span> </div>
</ix:continuation>
        <ix:continuation id="Text_5de5bc6a7eab46768823bb3eef11a6eb9" continuedAt="Text_5de5bc6a7eab46768823bb3eef11a6eb10">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_5de5bc6a7eab46768823bb3eef11a6eb10" continuedAt="Text_5de5bc6a7eab46768823bb3eef11a6eb11">
<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt;">At the election of Lender, the principal and accrued interest on Promissory Note(s) may be converted into the number of shares of the Company&#8217;s
          Common Stock equal to the amount of principal and accrued interest on such Promissory Note divided by the price equal to the closing price of the Common Stock on the date of such Promissory Note, but in no event less than $<ix:nonFraction name="us-gaap:SharePrice" id="Fact_5674f5a4bd274d8c9be8ee511d03e6c3" contextRef="c20220725_CreditFacilityAxis_LineOfCreditMember_RangeAxis_MinimumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.00</ix:nonFraction> per share.</div>
</ix:continuation>
        <ix:continuation id="Text_5de5bc6a7eab46768823bb3eef11a6eb11" continuedAt="Text_5de5bc6a7eab46768823bb3eef11a6eb12">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_5de5bc6a7eab46768823bb3eef11a6eb12" continuedAt="Text_5de5bc6a7eab46768823bb3eef11a6eb13">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman';"><br/>
          </span> </div>
</ix:continuation>
        <ix:continuation id="Text_5de5bc6a7eab46768823bb3eef11a6eb13" continuedAt="Text_5de5bc6a7eab46768823bb3eef11a6eb14">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_5de5bc6a7eab46768823bb3eef11a6eb14" continuedAt="Text_5de5bc6a7eab46768823bb3eef11a6eb15">
<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt;">In connection with the Credit Agreement, the Company agreed to issue the Lender warrants to purchase up to an aggregate of <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" id="Fact_0433c06a5f134624bf0dba2517c50f51" contextRef="c20220725_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,700,000</ix:nonFraction> shares of the Company&#8217;s common stock, par value $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact_c082f17af9f04f639eda3a4150c0681e" contextRef="c20220725_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U003" decimals="3" scale="0" format="ixt:num-dot-decimal">0.001</ix:nonFraction> per share (collectively, the &#8220;Warrants&#8221;). Upon execution of the Credit Agreement, the Company issued the Lender a Warrant to purchase up to <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" id="Fact_0d6e4cdb53494b73b155dc16135bfe0f" contextRef="c20220725_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">500,000</ix:nonFraction> shares of Company&#8217;s Common Stock at an exercise price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_acbbc5a67f504b45a93b478aee53a5b9" contextRef="c20220725_FinancialInstrumentAxis_WarrantMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">5.00</ix:nonFraction>
          per share, which Warrant is exercisable upon issuance. Further, pursuant to the Credit Agreement, the Company shall issue to the Lender additional Warrants to purchase up to the remaining <ix:nonFraction name="galt:ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" id="Fact_9c901907c05d456486c612a5c565e01c" contextRef="c20220725to20220725_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,200,000</ix:nonFraction> shares of the Company&#8217;s common stock, ratably, upon borrowings under the Credit Agreement, with exercise prices equal to <ix:nonFraction name="galt:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock" id="Fact_8d4f93f0ebb747aa913c3881f299f7d8" contextRef="c20220725_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">150</ix:nonFraction>% of the closing price of the Company&#8217;s common Stock on the date of the Promissory Note evidencing such draw, but in no event more than $<ix:nonFraction name="us-gaap:SharePrice" id="Fact_ad87526836f24f85a9c929494e641880" contextRef="c20220725_CreditFacilityAxis_LineOfCreditMember_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction> per share nor less than $<ix:nonFraction name="us-gaap:SharePrice" id="Fact_15b2d16b684f4b698a9263e058743d4f" contextRef="c20220725_CreditFacilityAxis_LineOfCreditMember_RangeAxis_MinimumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.00</ix:nonFraction> per share. The Warrants
          expire on <ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" id="Fact_cc09fb2bced041af9551a01bc724faec" contextRef="c20241231_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" format="ixt:date-monthname-day-year-en">July 31, 2029</ix:nonNumeric>.</div>
</ix:continuation>
        <ix:continuation id="Text_5de5bc6a7eab46768823bb3eef11a6eb15" continuedAt="Text_5de5bc6a7eab46768823bb3eef11a6eb16">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_5de5bc6a7eab46768823bb3eef11a6eb16" continuedAt="Text_5de5bc6a7eab46768823bb3eef11a6eb17">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman';"><br/>
          </span> </div>
</ix:continuation>
        <ix:continuation id="Text_5de5bc6a7eab46768823bb3eef11a6eb17" continuedAt="Text_5de5bc6a7eab46768823bb3eef11a6eb18">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_5de5bc6a7eab46768823bb3eef11a6eb18" continuedAt="Text_5de5bc6a7eab46768823bb3eef11a6eb19">
<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt;">The fair value of the <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" id="Fact_29c39ff47cde42e2951903663b2cfb24" contextRef="c20220725_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">500,000</ix:nonFraction>
          warrants vested at closing on July 25, 2022 was $<ix:nonFraction name="galt:IssuanceOfWarrantsValue" id="Fact_43bb8efbb53f48ebbb90f63ea96715f0" contextRef="c20220725to20220725_FinancialInstrumentAxis_WarrantMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">738,000</ix:nonFraction> at the date of issuance based on the following assumptions: an expected life
          of <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_3639be65b72442cab33d950b3cad0939" contextRef="c20240101to20241231_FinancialInstrumentAxis_WarrantMember" format="ixt-sec:duryear">7</ix:nonNumeric> years, volatility of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact_c87237d5879a4e3a8ee527b52422f4ac" contextRef="c20240101to20241231_FinancialInstrumentAxis_WarrantMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">92</ix:nonFraction>%,
          risk free interest rate of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_e91b98af19404d3b8d4105b7c4ae931b" contextRef="c20240101to20241231_FinancialInstrumentAxis_WarrantMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">3.19</ix:nonFraction>% and <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="Fact_80d8c78343114658b04fb8497fbba222" contextRef="c20240101to20241231_FinancialInstrumentAxis_WarrantMember" unitRef="U007" decimals="0" scale="0" format="ixt-sec:numwordsen">zero</ix:nonFraction>
          dividends. The fair value of the vested warrants was recorded in other assets (non-current) as a deferred financing cost and will be amortized on a straight-line basis from July 25, 2022 through January 31, 2026. Amortization for the years ended
          December 31, 2024 and 2023 of $<ix:nonFraction name="us-gaap:InterestExpense" id="Fact_d80b19aa74e54ef9b3dff4a7627a1995" contextRef="c20240101to20241231_FinancialInstrumentAxis_WarrantMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">210,000</ix:nonFraction> and $<ix:nonFraction name="us-gaap:InterestExpense" id="Fact_f6e78f124544485da04766cbde136660" contextRef="c20230101to20231231_FinancialInstrumentAxis_WarrantMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">209,000</ix:nonFraction>, respectively, was recorded as interest expense.</div>
</ix:continuation>
        <ix:continuation id="Text_5de5bc6a7eab46768823bb3eef11a6eb19" continuedAt="Text_5de5bc6a7eab46768823bb3eef11a6eb20">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_5de5bc6a7eab46768823bb3eef11a6eb20" continuedAt="Text_5de5bc6a7eab46768823bb3eef11a6eb21">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman';"><br/>
          </span> </div>
</ix:continuation>
        <ix:continuation id="Text_5de5bc6a7eab46768823bb3eef11a6eb21" continuedAt="Text_5de5bc6a7eab46768823bb3eef11a6eb22">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_5de5bc6a7eab46768823bb3eef11a6eb22" continuedAt="Text_5de5bc6a7eab46768823bb3eef11a6eb23">
<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt;">On December 19, 2022, the Company executed a $<ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" id="Fact_b14e29a4d38848e8b6d6abaf9333c933" contextRef="c20221219to20221219_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_December2022PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U001" decimals="-6" scale="6" format="ixt:num-dot-decimal">10</ix:nonFraction>
          million Promissory Note under the Line of Credit. The interest rate on this draw is <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" id="Fact_caf91ed0091f4437b1d616fff494280c" contextRef="c20221219to20221219_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_December2022PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">6.46</ix:nonFraction>% (Applicable Federal Rate for short term
          loans on date of draw of <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_18eecdce86d84ea5be10e6e79d18f0ed" contextRef="c20221219_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_December2022PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">4.46</ix:nonFraction>% plus <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" id="Fact_37bfa9bc783c4840a4a6035bac478eec" contextRef="c20221219to20221219_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_December2022PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">2</ix:nonFraction>%).





























































          The effective interest rate is approximately <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" id="Fact_235ecaee6b4042dc9fb3665d3aec8f51" contextRef="c20221219_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_December2022PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">7.1</ix:nonFraction>%. Accrued interest on this draw was approximately $<ix:nonFraction name="galt:DebtInstrumentAccruedInterest" id="Fact_2fb9e997d1a8423a9f79fbd5c0a063e5" contextRef="c20241231_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_December2022PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">1,399,000</ix:nonFraction> and $<ix:nonFraction name="galt:DebtInstrumentAccruedInterest" id="Fact_1392d10fc9ce449ba93d8d326525b1b5" contextRef="c20231231_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_December2022PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">688,000</ix:nonFraction> at December 31,
          2024 and 2023, respectively. The principal and accrued interest is convertible at the option of the Lender at $<ix:nonFraction name="us-gaap:SharePrice" id="Fact_9ac9c53006c04474948abdc9608b4d3b" contextRef="c20241231_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_December2022PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.00</ix:nonFraction> per share. In
          accordance with the Credit Agreement, the Company issued the Lender a Warrant to purchase up to <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" id="Fact_56475f877106482092f1e7035815f429" contextRef="c20221219_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">200,000</ix:nonFraction> shares of Company&#8217;s Common
          Stock at an exercise price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_3a4184e29009404197199281b7c6818a" contextRef="c20221219_FinancialInstrumentAxis_WarrantOneMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.00</ix:nonFraction> per share, which Warrant is exercisable upon issuance.</div>
</ix:continuation>
        <ix:continuation id="Text_5de5bc6a7eab46768823bb3eef11a6eb23" continuedAt="Text_5de5bc6a7eab46768823bb3eef11a6eb24">
<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">F-20</span></div>

          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div>
              <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

              </div>

            </div>

          </div>

        </div>

        <ix:continuation id="Text_5de5bc6a7eab46768823bb3eef11a6eb24" continuedAt="Text_5de5bc6a7eab46768823bb3eef11a6eb25">
<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt;">The fair value of the <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" id="Fact_704ab1f3db034807a66583246e0c20eb" contextRef="c20221219_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">200,000</ix:nonFraction>
          warrants vested at closing on December 19, 2022 was $<ix:nonFraction name="galt:IssuanceOfWarrantsValue" id="Fact_fbdf0517070c45cb851d10160ef1a368" contextRef="c20221219to20221219_FinancialInstrumentAxis_WarrantOneMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">160,780</ix:nonFraction> at the date of issuance based on the following assumptions: an expected
          life of <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_9a29b4ed515840339e61175da08639fc" contextRef="c20240101to20241231_FinancialInstrumentAxis_WarrantOneMember" format="ixt-sec:durwordsen">7 years</ix:nonNumeric>, volatility of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact_bc319ac9be244c1b8ea73379a20e73e1" contextRef="c20240101to20241231_FinancialInstrumentAxis_WarrantOneMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">91</ix:nonFraction>%,
          risk free interest rate of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_0ad516faf8ab4a338648f5fa77bd526e" contextRef="c20240101to20241231_FinancialInstrumentAxis_WarrantOneMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">4.06</ix:nonFraction>% and <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="Fact_f764f993608240be89b74262f650cf81" contextRef="c20240101to20241231_FinancialInstrumentAxis_WarrantOneMember" unitRef="U007" decimals="0" scale="0" format="ixt-sec:numwordsen">zero</ix:nonFraction>
          dividends. The proceeds were allocated between the Promissory Note and the warrants issued, and the amount allocated to the warrants was recorded as a debt discount netted against principal to be amortized on a straight-line basis, which is not
          materially different than the effective interest method, from December 19, 2022 through January 31, 2026. Amortization for the years ended December 31, 2024 and 2023 of $<ix:nonFraction name="us-gaap:InterestExpense" id="Fact_471becca59b9466393f87bdf441f939e" contextRef="c20240101to20241231_FinancialInstrumentAxis_WarrantOneMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">52,000</ix:nonFraction> and $<ix:nonFraction name="us-gaap:InterestExpense" id="Fact_9fa3fa25e4f04e4091e9bd1bdfbc6cd5" contextRef="c20230101to20231231_FinancialInstrumentAxis_WarrantOneMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">51,000</ix:nonFraction>, respectively, was recorded as interest
          expense.</div>
</ix:continuation>
        <ix:continuation id="Text_5de5bc6a7eab46768823bb3eef11a6eb25" continuedAt="Text_5de5bc6a7eab46768823bb3eef11a6eb26">
<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt;"> <br/>
        </div>
</ix:continuation>
        <ix:continuation id="Text_5de5bc6a7eab46768823bb3eef11a6eb26" continuedAt="Text_5de5bc6a7eab46768823bb3eef11a6eb27">
<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt;">On March 31, 2023, the Company executed an additional $<ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" id="Fact_15c0524cc1cb43dbbbc345914f4730ae" contextRef="c20240101to20240331_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_March2023PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U001" decimals="-6" scale="6" format="ixt:num-dot-decimal">10</ix:nonFraction>
          million Promissory Note under the Line of Credit. The interest rate on this draw is <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" id="Fact_0e9cfc0c53884d04b0ff66104b8345d3" contextRef="c20240101to20240331_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_March2023PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">6.41</ix:nonFraction>% (Applicable Federal Rate for short term
          loans on date of draw of <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_f8eff09b77f34922beec911833f92947" contextRef="c20240331_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_March2023PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">4.41</ix:nonFraction>% plus <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" id="Fact_cf2e33e51cee41459f6b87b711551248" contextRef="c20240101to20240331_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_March2023PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">2</ix:nonFraction>%).

















































          The effective interest rate is approximately <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" id="Fact_6d5a347a2b154075b9dbd8b05e7d190e" contextRef="c20240331_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_March2023PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">7.1</ix:nonFraction>%.&#160; Accrued interest on this draw was approximately $<ix:nonFraction name="galt:DebtInstrumentAccruedInterest" id="Fact_d8015e6a620a4d1ba9aee9de581beb15" contextRef="c20241231_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_March2023PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">1,184,000</ix:nonFraction> and $<ix:nonFraction name="galt:DebtInstrumentAccruedInterest" id="Fact_f36d54c08fb349a0a6b4306526c683fc" contextRef="c20231231_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_March2023PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">491,000</ix:nonFraction> at December 31,
          2024 and 2023, respectively. The principal and accrued interest is convertible at the option of the Lender at $<ix:nonFraction name="us-gaap:SharePrice" id="Fact_10a7a1655d0f4189b39d9ffc3e20e3d5" contextRef="c20240331_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_March2023PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.00</ix:nonFraction> per share. In
          accordance with the Credit Agreement, the Company issued the Lender a Warrant to purchase up to <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" id="Fact_f211e39768754cefa6c47447ed2ad21c" contextRef="c20240331_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">200,000</ix:nonFraction> shares of Company&#8217;s Common
          Stock at an exercise price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_ffe6c77e69874c94981d6ca7a5fabc18" contextRef="c20240331_FinancialInstrumentAxis_WarrantOneMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U003" decimals="INF" scale="0" format="ixt:num-dot-decimal">3.26</ix:nonFraction> per share, which Warrant is exercisable upon issuance.</div>
</ix:continuation>
        <ix:continuation id="Text_5de5bc6a7eab46768823bb3eef11a6eb27" continuedAt="Text_5de5bc6a7eab46768823bb3eef11a6eb28">
<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt;"> <br/>
        </div>
</ix:continuation>
        <ix:continuation id="Text_5de5bc6a7eab46768823bb3eef11a6eb28" continuedAt="Text_5de5bc6a7eab46768823bb3eef11a6eb29">
<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt;">The fair value of the <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" id="Fact_1349aa03c8b24f1f834c4c76ae613b56" contextRef="c20240331_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">200,000</ix:nonFraction>
          warrants vested at closing on March 31, 2023 was $<ix:nonFraction name="galt:IssuanceOfWarrantsValue" id="Fact_2f83026146bc41949440b89129a6701d" contextRef="c20240101to20240331_FinancialInstrumentAxis_WarrantTwoMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">296,680</ix:nonFraction> at the date of issuance based on the following assumptions: an expected life
          of <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_fb85ebb1b82c47509f86890d6d204188" contextRef="c20240101to20240331_FinancialInstrumentAxis_WarrantTwoMember" format="ixt-sec:duryear">6.33</ix:nonNumeric> years, volatility of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact_ac0c7e70fe4045c88ef41173ea5274a1" contextRef="c20240101to20240331_FinancialInstrumentAxis_WarrantTwoMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">88</ix:nonFraction>%,
          risk free interest rate of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_042c77574b9b4093bde8de332d18896f" contextRef="c20240101to20240331_FinancialInstrumentAxis_WarrantTwoMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">3.94</ix:nonFraction>% and <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="Fact_fd1b733b711b4be180d461cc9d749950" contextRef="c20240101to20240331_FinancialInstrumentAxis_WarrantTwoMember" unitRef="U007" decimals="0" scale="0" format="ixt-sec:numwordsen">zero</ix:nonFraction>
          dividends. The proceeds were allocated between the Promissory Note and the warrants issued, and the amount allocated to the warrants was recorded as a debt discount netted against principal amortized on a straight-line basis, which is not
          materially different than the effective interest method, from March 31, 2023 through January 31, 2026. Amortization for the year ended December 31, 2024 and 2023 of $<ix:nonFraction name="us-gaap:InterestExpense" id="Fact_985cd3355f4a439f8f5eeb2306f8d628" contextRef="c20240101to20241231_FinancialInstrumentAxis_WarrantTwoMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">105,000</ix:nonFraction> and $<ix:nonFraction name="us-gaap:InterestExpense" id="Fact_007455f032e44114b468fe5cb5fb8ef3" contextRef="c20230101to20231231_FinancialInstrumentAxis_WarrantTwoMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">79,000</ix:nonFraction>, respectively, was recorded as interest expense.</div>
</ix:continuation>
        <ix:continuation id="Text_5de5bc6a7eab46768823bb3eef11a6eb29" continuedAt="Text_5de5bc6a7eab46768823bb3eef11a6eb30">
<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt;"> <br/>
        </div>
</ix:continuation>
        <ix:continuation id="Text_5de5bc6a7eab46768823bb3eef11a6eb30" continuedAt="Text_5de5bc6a7eab46768823bb3eef11a6eb31">
<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt;">On June 30, 2023, the Company executed an additional $<ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" id="Fact_4cef56d85a854085a9f7b9c8021c156a" contextRef="c20240401to20240630_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_June2023PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U001" decimals="-6" scale="6" format="ixt:num-dot-decimal">10</ix:nonFraction>
          million Promissory Note under the Line of Credit. The interest rate on this draw is <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" id="Fact_624e0428d85a47bc8606ed0e52135472" contextRef="c20240401to20240630_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_June2023PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">6.34</ix:nonFraction>% (Applicable Federal Rate for short term
          loans on date of draw of <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_9318f1177e7a4a1ea388a11290d55043" contextRef="c20240630_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_June2023PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">4.34</ix:nonFraction>% plus <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" id="Fact_57aa1478842b41f0af6d5d7f19ac5b7b" contextRef="c20240401to20240630_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_June2023PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">2</ix:nonFraction>%).

















































          The effective interest rate is approximately <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" id="Fact_843db755d8d74901b9f38aa2a9eea6c8" contextRef="c20240630_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_June2023PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">7.1</ix:nonFraction>%.&#160; Accrued interest on this draw was approximately $<ix:nonFraction name="galt:DebtInstrumentAccruedInterest" id="Fact_a2766e28f06d42d4b44cbd98187db102" contextRef="c20241231_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_June2023PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">995,000</ix:nonFraction> and $<ix:nonFraction name="galt:DebtInstrumentAccruedInterest" id="Fact_564d96dd946b4fb7a1325da9b98df16b" contextRef="c20231231_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_June2023PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">321,000</ix:nonFraction> at December 31,
          2024 and 2023, respectively. The principal and accrued interest is convertible at the option of the Lender at $<ix:nonFraction name="us-gaap:SharePrice" id="Fact_5364a42b75c3445baba469ba16fe12a1" contextRef="c20240630_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_June2023PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.00</ix:nonFraction> per share. In
          accordance with the Credit Agreement, the Company issued the Lender a Warrant to purchase up to <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" id="Fact_177bcd99ce64480caff658a6c68a227c" contextRef="c20240630_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">200,000</ix:nonFraction> shares of Company&#8217;s Common
          Stock at an exercise price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_2ce41b16367c4f2fb20a7f1db5c6b078" contextRef="c20240630_FinancialInstrumentAxis_WarrantOneMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.00</ix:nonFraction> per share, which Warrant is exercisable upon issuance.</div>
</ix:continuation>
        <ix:continuation id="Text_5de5bc6a7eab46768823bb3eef11a6eb31" continuedAt="Text_5de5bc6a7eab46768823bb3eef11a6eb32">
<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt;"> <br/>
        </div>
</ix:continuation>
        <ix:continuation id="Text_5de5bc6a7eab46768823bb3eef11a6eb32" continuedAt="Text_5de5bc6a7eab46768823bb3eef11a6eb33">
<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt;">The fair value of the <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" id="Fact_ad8d7ad3ff9c4e93ab0ddd9069229fd4" contextRef="c20240630_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">200,000</ix:nonFraction>
          warrants vested at closing on June 30, 2023 was $<ix:nonFraction name="galt:IssuanceOfWarrantsValue" id="Fact_ce29850fde7e4294b812b8fba178395a" contextRef="c20240401to20240630_FinancialInstrumentAxis_WarrantTwoMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">179,920</ix:nonFraction> at the date of issuance based on the following assumptions: an expected life
          of <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_c7fd4d77cf96462f8d11a69098b7ae4b" contextRef="c20240401to20240630_FinancialInstrumentAxis_WarrantTwoMember" format="ixt-sec:duryear">6.08</ix:nonNumeric> years, volatility of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact_3f15bc1fe1624b77b39a0fbd47ce2a1d" contextRef="c20240401to20240630_FinancialInstrumentAxis_WarrantTwoMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">85</ix:nonFraction>%,
          risk free interest rate of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_0bda8c4cbc30420aa11d1c97e4ff8e50" contextRef="c20240401to20240630_FinancialInstrumentAxis_WarrantTwoMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">3.59</ix:nonFraction>% and <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="Fact_5aa88eccb1e64a4a984bcc140129b075" contextRef="c20240401to20240630_FinancialInstrumentAxis_WarrantTwoMember" unitRef="U007" decimals="0" scale="0" format="ixt-sec:numwordsen">zero</ix:nonFraction>
          dividends. The proceeds were allocated between the Promissory Note and the warrants issued, and the amount allocated to the warrants was recorded as a debt discount netted against principal amortized on a straight-line basis, which is not
          materially different than the effective interest method, from June 30, 2023 through January 31, 2026. Amortization for the year ended December 31, 2024 and 2023 of $<ix:nonFraction name="us-gaap:InterestExpense" id="Fact_a8cd74c23d3047be8391b16ce9415686" contextRef="c20240101to20241231_FinancialInstrumentAxis_WarrantThreeMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">69,000</ix:nonFraction> and $<ix:nonFraction name="us-gaap:InterestExpense" id="Fact_9687622b9cc84d488f38a0c7e0b778fd" contextRef="c20230101to20231231_FinancialInstrumentAxis_WarrantThreeMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">35,000</ix:nonFraction>, respectively, was recorded as interest expense.</div>
</ix:continuation>
        <ix:continuation id="Text_5de5bc6a7eab46768823bb3eef11a6eb33" continuedAt="Text_5de5bc6a7eab46768823bb3eef11a6eb34">
<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt;"> <br/>
        </div>
</ix:continuation>
        <ix:continuation id="Text_5de5bc6a7eab46768823bb3eef11a6eb34" continuedAt="Text_5de5bc6a7eab46768823bb3eef11a6eb35">
<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt;">On December 29, 2023, the Company executed an additional $<ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" id="Fact_9357a1c556be49f9878c3a9601b94b96" contextRef="c20231229to20231229_CreditFacilityAxis_LineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U001" decimals="-6" scale="6" format="ixt:num-dot-decimal">10</ix:nonFraction> million Promissory Note under the Line of Credit. The interest rate on this draw is <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" id="Fact_fdcefb3ea87d42de8b98f94ef4f770ca" contextRef="c20231229to20231229_CreditFacilityAxis_LineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">7.13</ix:nonFraction>%
          (Applicable Federal Rate for short term loans on date of draw of <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_f529cff972994f10bc4f5d54fa0ae5aa" contextRef="c20231229_CreditFacilityAxis_LineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">5.13</ix:nonFraction>% plus <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" id="Fact_6cdeebd12c9f4b9f8d91652c13a65125" contextRef="c20231229to20231229_CreditFacilityAxis_LineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">2</ix:nonFraction>%). The effective interest rate is approximately <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" id="Fact_7dae9f0d8bcd4e45ac693d93a701c720" contextRef="c20231229_CreditFacilityAxis_LineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">7.5</ix:nonFraction>%.
          Accrued interest on this draw was approximately $<ix:nonFraction name="galt:DebtInstrumentAccruedInterest" id="Fact_380ca38cc3084f15be9f05dc8add13c0" contextRef="c20241231_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_December2023PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">737,000</ix:nonFraction> at December 31, 2024. The principal and accrued interest is convertible at the
          option of the Lender at $<ix:nonFraction name="us-gaap:SharePrice" id="Fact_f5c907ffd3ae4f198b970673cd180a60" contextRef="c20231229_CreditFacilityAxis_LineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.00</ix:nonFraction> per share. In accordance with the Credit Agreement, the Company issued the Lender a Warrant to purchase
          up to <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" id="Fact_d4f215a00e5a4731a5d3bf8bd8296356" contextRef="c20231229_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">200,000</ix:nonFraction> shares of Company&#8217;s Common Stock at an exercise price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_b78e97ec22ac4b43abe23bb17b85cc33" contextRef="c20231229_FinancialInstrumentAxis_WarrantOneMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.00</ix:nonFraction> per share, which Warrant is exercisable upon issuance.</div>
</ix:continuation>
        <ix:continuation id="Text_5de5bc6a7eab46768823bb3eef11a6eb35" continuedAt="Text_5de5bc6a7eab46768823bb3eef11a6eb36">
<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman', Times, serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"> <br/>
          </span></div>
</ix:continuation>
        <ix:continuation id="Text_5de5bc6a7eab46768823bb3eef11a6eb36" continuedAt="Text_5de5bc6a7eab46768823bb3eef11a6eb37">
<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><span style="letter-spacing: normal; text-align: left; text-indent: 0px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The fair value of the <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" id="Fact_79084d0a115346ce9a85481a65721f3a" contextRef="c20231229_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">200,000</ix:nonFraction> warrants vested at closing on December 31, 2023 was $<ix:nonFraction name="galt:IssuanceOfWarrantsValue" id="Fact_2a53c0f389d540f985c1a0f289a9f7dc" contextRef="c20240101to20241231_FinancialInstrumentAxis_WarrantTwoMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">193,745</ix:nonFraction> at the date of issuance based on the following assumptions: an expected life of <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_dd7fefba05924359a6dabb52a2bf41ba" contextRef="c20240101to20241231_FinancialInstrumentAxis_WarrantTwoMember" format="ixt-sec:duryear">5.7</ix:nonNumeric> years,
            volatility of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact_03b51062ec8145a09fb81a71b9b86372" contextRef="c20240101to20241231_FinancialInstrumentAxis_WarrantTwoMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">79</ix:nonFraction>%, risk free interest rate of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_9fae9aaa15d24209bcbd56193d2792b0" contextRef="c20240101to20241231_FinancialInstrumentAxis_WarrantTwoMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">4.49</ix:nonFraction>% and <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="Fact_7fa18f9d270948aeae04d9ea95630323" contextRef="c20240101to20241231_FinancialInstrumentAxis_WarrantTwoMember" unitRef="U007" decimals="0" scale="0" format="ixt-sec:numwordsen">zero</ix:nonFraction> dividends. The proceeds were allocated between the Promissory Note and the warrants
            issued, and the amount allocated to the warrants was recorded as a debt discount netted against principal amortized on a straight-line basis, which is not materially different than the effective interest method, from December 29, 2023 through
            January 31, 2026. Amortization for the year ended December 31, 2024 of $<ix:nonFraction name="us-gaap:InterestExpense" id="Fact_8d2f05434bd6496da4e9a60c272b6213" contextRef="c20240101to20241231_FinancialInstrumentAxis_WarrantFourMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">93,000</ix:nonFraction> was recorded as interest expense. On March 29, 2024,
            the Company executed an additional $<ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" id="Fact_a20f4ca8985a4c7fb2d48432cdacdd57" contextRef="c20240329to20240329_CreditFacilityAxis_LineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U001" decimals="-6" scale="6" format="ixt:num-dot-decimal">10</ix:nonFraction> million Promissory Note under the Line of Credit. The interest rate on this draw is <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" id="Fact_130f53eeeff049f58ae5f59abd3da1c5" contextRef="c20240329to20240329_CreditFacilityAxis_LineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">6.62</ix:nonFraction>% (Applicable Federal Rate for short term loans on date of draw of <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_08fd1fd96c09404cb2ac4d118d024c88" contextRef="c20240329_CreditFacilityAxis_LineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">4.62</ix:nonFraction>% plus <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" id="Fact_da26bc59051c48cca52a299fae599a10" contextRef="c20240329to20240329_CreditFacilityAxis_LineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">2</ix:nonFraction>%). The effective interest rate is approximately <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" id="Fact_9db845501e6248baa0e7d795be0553db" contextRef="c20240329_CreditFacilityAxis_LineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">7.1</ix:nonFraction>%. Accrued interest on this draw was $<ix:nonFraction name="galt:DebtInstrumentAccruedInterest" id="Fact_b7bf449b11804119ae1b798bf74fd7eb" contextRef="c20241231_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_March24PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">508,000</ix:nonFraction>
            at December 31, 2024. The principal and accrued interest is convertible at the option of the Lender at $<ix:nonFraction name="us-gaap:SharePrice" id="Fact_193532f6e5f048ec9129a4b30d363ec1" contextRef="c20240329_CreditFacilityAxis_LineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.00</ix:nonFraction> per share. In accordance
            with the Credit Agreement, the Company issued the Lender a Warrant to purchase up to <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" id="Fact_e87613f788be4e1082b445c00da6179a" contextRef="c20240329_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">200,000</ix:nonFraction> shares of Company&#8217;s Common Stock at an
            exercise price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_2891974e8668402ab58883ead3ea4e7f" contextRef="c20240329_FinancialInstrumentAxis_WarrantOneMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.59</ix:nonFraction> per share, which Warrant is exercisable upon issuance.</span></div>
</ix:continuation>
        <ix:continuation id="Text_5de5bc6a7eab46768823bb3eef11a6eb37" continuedAt="Text_5de5bc6a7eab46768823bb3eef11a6eb38">
<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><span style="letter-spacing: normal; text-align: left; text-indent: 0px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> <br/>
          </span></div>
</ix:continuation>
        <ix:continuation id="Text_5de5bc6a7eab46768823bb3eef11a6eb38" continuedAt="Text_5de5bc6a7eab46768823bb3eef11a6eb39">
<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><span style="letter-spacing: normal; text-align: left; text-indent: 0px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The fair value of the <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" id="Fact_2fc48bc60f0f4c47ba540cabd7268587" contextRef="c20240329_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">200,000</ix:nonFraction> warrants vested at closing on March 29, 2024, was $<ix:nonFraction name="galt:IssuanceOfWarrantsValue" id="Fact_b628e110ed2f4e1da3da56c72a88544f" contextRef="c20240329to20240329_FinancialInstrumentAxis_WarrantTwoMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">277,389</ix:nonFraction> at the date of issuance based on the following assumptions: an expected life of <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_756d043a6f6f409697a5aa56cd8ee8e1" contextRef="c20240329to20240329_FinancialInstrumentAxis_WarrantTwoMember" format="ixt-sec:duryear">5.33</ix:nonNumeric>
            years, volatility of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact_4a6a84888dbe427aaf8e0e5ed2e2105a" contextRef="c20240329to20240329_FinancialInstrumentAxis_WarrantTwoMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">75</ix:nonFraction>%, risk free interest rate of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_9e956f4a94fe4e83ab2319f9b4541fef" contextRef="c20240329to20240329_FinancialInstrumentAxis_WarrantTwoMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">4.19</ix:nonFraction>% and <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="Fact_e8724436b55240bb95ade043cb5c9045" contextRef="c20240329to20240329_FinancialInstrumentAxis_WarrantTwoMember" unitRef="U007" decimals="0" scale="0" format="ixt-sec:numwordsen">zero</ix:nonFraction> dividends. The proceeds were allocated between the
            Promissory Note and the warrants issued, and the amount allocated to the warrants was recorded as a debt discount netted against principal amortized on a straight-line basis, which is not materially different than the effective interest method,
            from March 29, 2024 through January 31, 2026. Amortization for the year ended December 31, 2024 of $<ix:nonFraction name="us-gaap:InterestExpense" id="Fact_e4a2739536854c339cf623e28976cf59" contextRef="c20240101to20241231_FinancialInstrumentAxis_WarrantFiveMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">114,000</ix:nonFraction> was recorded as interest
            expense.<br/>
            <br/>
            On June 28, 2024, the Company executed an additional $<ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" id="Fact_54f7ec8479224f7daaab976736346c13" contextRef="c20240628to20240628_CreditFacilityAxis_LineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U001" decimals="-6" scale="6" format="ixt:num-dot-decimal">10</ix:nonFraction> million Promissory Note under the Line of Credit. The interest rate on this
            draw is <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" id="Fact_3b5d816fe39f406aa2e079eac9b8e91e" contextRef="c20240628to20240628_CreditFacilityAxis_LineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">7.01</ix:nonFraction>% (Applicable Federal Rate for short term loans on date of draw of <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_815e6e97075f4fb5b5650bd05ab99ed0" contextRef="c20240628_CreditFacilityAxis_LineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">5.01</ix:nonFraction>% plus <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" id="Fact_af695518208243228662239cc8f3d646" contextRef="c20240628to20240628_CreditFacilityAxis_LineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">2</ix:nonFraction>%). The effective interest rate is approximately
            <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" id="Fact_c765b744e64446e7bc71b88094244aee" contextRef="c20240628_CreditFacilityAxis_LineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">7.4</ix:nonFraction>%. Accrued interest on this draw was $<ix:nonFraction name="galt:DebtInstrumentAccruedInterest" id="Fact_aa5f123e799542f294dcc165f172a8d9" contextRef="c20241231_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_June2024PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">336,000</ix:nonFraction>
            at December 31, 2024.&#160; The principal and accrued interest is convertible at the option of the Lender at $<ix:nonFraction name="us-gaap:SharePrice" id="Fact_7bbc2f9896bc4abd993f4d3534ca0404" contextRef="c20240628_CreditFacilityAxis_LineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.00</ix:nonFraction> per share. In
            accordance with the Credit Agreement, the Company issued the Lender a Warrant to purchase up to <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" id="Fact_fa261d98dd364fe7a0ff6dd27af01284" contextRef="c20240628_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">200,000</ix:nonFraction> shares of Company&#8217;s Common
            Stock at an exercise price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_540a8ce843e44611a4dfb0733b52bca3" contextRef="c20240628_FinancialInstrumentAxis_WarrantOneMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.39</ix:nonFraction> per share, which Warrant is exercisable upon issuance.<br/>
            <br/>
            The fair value of the <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" id="Fact_3ad88f9bf22848b1a2dea8d4ffd1c24f" contextRef="c20240628_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">200,000</ix:nonFraction> warrants vested at closing on June 28, 2024, was $<ix:nonFraction name="galt:IssuanceOfWarrantsValue" id="Fact_f179da1a658d49d49032d5502e54fdde" contextRef="c20240628to20240628_FinancialInstrumentAxis_WarrantTwoMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">260,000</ix:nonFraction> at the date of issuance based on the following assumptions: an expected life of <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_103592e463894dccacff65dd40192a9d" contextRef="c20240628to20240628_FinancialInstrumentAxis_WarrantTwoMember" format="ixt-sec:duryear">5.03</ix:nonNumeric> years, volatility of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact_eec407a2d31041f89f1164a1828452df" contextRef="c20240628to20240628_FinancialInstrumentAxis_WarrantTwoMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">77</ix:nonFraction>%, risk free interest rate of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_bfa969dd15914a1bac1b41b0d9ab2e81" contextRef="c20240628to20240628_FinancialInstrumentAxis_WarrantTwoMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">4.29</ix:nonFraction>% and <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="Fact_7ae47251fb0b4c679ebf4c54faa10917" contextRef="c20240628to20240628_FinancialInstrumentAxis_WarrantTwoMember" unitRef="U007" decimals="0" scale="0" format="ixt-sec:numwordsen">zero</ix:nonFraction> dividends. The
            proceeds were allocated between the Promissory Note and the warrants issued, and the amount allocated to the warrants was recorded as a debt discount netted against principal amortized on a straight-line basis, which is not materially different
            than the effective interest method, from June 28, 2024 through January 31, 2026. Amortization for the year ended December 31, 2024 of $<ix:nonFraction name="us-gaap:InterestExpense" id="Fact_ba1fea2732d04e629f0ef9669e1afd00" contextRef="c20240101to20241231_FinancialInstrumentAxis_WarrantSixMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">82,000</ix:nonFraction>
            was recorded as interest expense.<br/>
          </span></div>
</ix:continuation>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">F-21</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div>
              <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

              </div>

            </div>

          </div>

        </div>

        <ix:continuation id="Text_5de5bc6a7eab46768823bb3eef11a6eb39" continuedAt="Text_5de5bc6a7eab46768823bb3eef11a6eb40">
<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><span style="letter-spacing: normal; text-align: left; text-indent: 0px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><br/>
            On March 29, 2024, the Company and Richard E. Uihlein (the &#8220;Lender&#8221;) entered into a Supplemental Line of Credit Letter Agreement (the &#8220;Supplemental Credit Agreement&#8221;), pursuant to which the Lender shall provide the Company a line of credit of
            up to $<ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" id="Fact_f5bebd42cebe460080d9a2fcb28f1da2" contextRef="c20240329_CreditFacilityAxis_SupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">10.0</ix:nonFraction> million (the &#8220;Supplemental Line of Credit&#8221;) to finance the Company&#8217;s working capital needs. The Company may draw upon the
            Supplemental Line of Credit through March 31, 2025.<br/>
            <br/>
            Each advance made pursuant to the Supplemental Credit Agreement shall be evidenced by an unsecured, convertible promissory note (individually, a &#8220;Promissory Note,&#8221; and collectively, the &#8220;Promissory Notes&#8221;), and bear interest at the Applicable
            Federal Rate for short term loans, plus two (<ix:nonFraction name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" id="Fact_259c9047bc634ab19e9c93c82b5f3fd7" contextRef="c20240329to20240329_CreditFacilityAxis_SupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">2</ix:nonFraction>%) percent. Principal and interest on the Promissory Notes are due on or before <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" id="Fact_eedf2a4911b042ea87889cb05c3e4ede" contextRef="c20240101to20241231_CreditFacilityAxis_SupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" format="ixt:date-monthname-day-year-en">January 31, 2026</ix:nonNumeric>. Only with the consent of the Lender, may the Promissory Notes be prepaid, in whole or in part, at any time without premium or
            penalty, but with interest on the amount or amounts prepaid.<br/>
            <br/>
            At the election of Lender, the principal and accrued interest on Promissory Note(s) may be converted into the number of shares of the Company&#8217;s Common Stock equal to the amount of principal and accrued interest on such Promissory Note divided
            by the price equal to the closing price of the Common Stock on the date of such Promissory Note, but in no event less than $<ix:nonFraction name="us-gaap:SharePrice" id="Fact_e42cd08732184d5cb80cb9e3c9ca98e6" contextRef="c20241231_CreditFacilityAxis_SupplementalLineOfCreditMember_RangeAxis_MinimumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.00</ix:nonFraction> per
            share.<br/>
            <br/>
            In connection with the Supplemental Credit Agreement, the Company agreed to issue the Lender warrants to purchase up to an aggregate of <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" id="Fact_0a55fc819c8747fd84f78df0a360ff1f" contextRef="c20240930_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">200,000</ix:nonFraction>
            shares of the Company&#8217;s common stock, par value $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact_e450fc2a6a3146ab9f48820af2db60fb" contextRef="c20241231_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember" unitRef="U003" decimals="3" scale="0" format="ixt:num-dot-decimal">0.001</ix:nonFraction> per share (collectively, the &#8220;Warrants&#8221;). The Company shall issue to the
            Lender Warrants ratably, upon borrowings under the Supplemental Line of Credit, with exercise prices equal to <ix:nonFraction name="galt:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock" id="Fact_6e0674f97fcc49eb802d073570d5a854" contextRef="c20241231_CreditFacilityAxis_SupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">150</ix:nonFraction>% of the closing
            price of the Company&#8217;s common Stock on the date of the Promissory Note evidencing such draw, but in no event more than $<ix:nonFraction name="us-gaap:SharePrice" id="Fact_ede594833f7b477aad6d0e79e4d12b83" contextRef="c20241231_CreditFacilityAxis_SupplementalLineOfCreditMember_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction> per
            share nor less than $<ix:nonFraction name="us-gaap:SharePrice" id="Fact_23b803c794124fd6884b9753780bcbee" contextRef="c20241231_CreditFacilityAxis_SupplementalLineOfCreditMember_RangeAxis_MinimumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.00</ix:nonFraction> per share. The Warrants expire on <ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" id="Fact_f1c8bc115779412baa4ac4369924b2a6" contextRef="c20241231_CreditFacilityAxis_SupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" format="ixt:date-monthname-day-year-en">July 31, 2029</ix:nonNumeric>.<br/>
            <br/>
            On September 30, 2024, the Company executed a $<ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" id="Fact_283453b743764cfd90e1f4dfef44512c" contextRef="c20240328to20240930_CreditFacilityAxis_SupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U001" decimals="-6" scale="6" format="ixt:num-dot-decimal">10</ix:nonFraction> million Promissory Note under the Supplemental Line of Credit. The interest rate on
            this draw is <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" id="Fact_c6a0b92767354cbc95041d28579c1cd2" contextRef="c20240328to20240930_CreditFacilityAxis_SupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">6.13</ix:nonFraction>% (Applicable Federal Rate for short term loans on date of draw of <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_d3c9a7d573ce40c4b26cc558c4dec4f0" contextRef="c20240930_CreditFacilityAxis_SupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">5.01</ix:nonFraction>% plus <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" id="Fact_2bbc331360b04168bf701ef79654e605" contextRef="c20240328to20240930_CreditFacilityAxis_SupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">2</ix:nonFraction>%). The effective interest rate is approximately
            <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" id="Fact_039d3158147341a788fb5e8f1a57bd92" contextRef="c20240930_CreditFacilityAxis_SupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">6.4</ix:nonFraction>%. Accrued interest on this draw was $<ix:nonFraction name="galt:DebtInstrumentAccruedInterest" id="Fact_50bb00cc28c74773981b1e94e59b6863" contextRef="c20241231_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_September2024PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">154,000</ix:nonFraction>
            at December 31, 2024.&#160; The principal and accrued interest is convertible at the option of the Lender at $<ix:nonFraction name="us-gaap:SharePrice" id="Fact_aafca8e464e54c89be5858bfbace1b3d" contextRef="c20241231_CreditFacilityAxis_SupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.00</ix:nonFraction> per share. In
            accordance with the Credit Agreement, the Company issued the Lender a Warrant to purchase up to <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" id="Fact_7df0142939a544d49d44a8f7cb7fc6e6" contextRef="c20240930_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">200,000</ix:nonFraction> shares of Company&#8217;s Common
            Stock at an exercise price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_e04f7d3884044241bf63974da5acfc96" contextRef="c20240930_CreditFacilityAxis_SupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">4.13</ix:nonFraction> per share, which Warrant is exercisable upon issuance. The fair value of the <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" id="Fact_9f7e10d598b141fa967dbffbb4054896" contextRef="c20240930_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">200,000</ix:nonFraction> warrants vested at closing on September 30, 2024, was $<ix:nonFraction name="galt:IssuanceOfWarrantsValue" id="Fact_c84704d05d50419589e0ea7b094fb0db" contextRef="c20240328to20240930_CreditFacilityAxis_SupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">307,780</ix:nonFraction> at the date of issuance based on the following assumptions: an expected life of <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_23b0dbe1354b43cc8cc2795574a1326c" contextRef="c20240328to20240930_FinancialInstrumentAxis_WarrantMember" format="ixt-sec:duryear">4.83</ix:nonNumeric>
            years, volatility of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact_b1fa1b2bd86e4223a72fd80a5a914fe4" contextRef="c20240328to20240930_FinancialInstrumentAxis_WarrantMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">78</ix:nonFraction>%, risk free interest rate of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_3fe314b7ed9e42c4ba2ea76f03be96a2" contextRef="c20240328to20240930_FinancialInstrumentAxis_WarrantMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">3.58</ix:nonFraction>% and <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="Fact_e3e44c5ed695464cae89a8ad91e787f1" contextRef="c20240328to20240930_FinancialInstrumentAxis_WarrantMember" unitRef="U007" decimals="0" scale="0" format="ixt-sec:numwordsen">zero</ix:nonFraction> dividends. The proceeds were allocated between the
            Promissory Note and the warrants issued, and the amount allocated to the warrants was recorded as a debt discount netted against principal amortized on a straight-line basis, which is not materially different than the effective interest method,
            from October 1, 2024 through January 31, 2026. Amortization for the year ended December 31, 2024 of $<ix:nonFraction name="us-gaap:InterestExpense" id="Fact_9bcd6ad6ba454ec1afc7b8e7f8460b1f" contextRef="c20240101to20241231_FinancialInstrumentAxis_WarrantSevenMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">58,000</ix:nonFraction> was recorded as interest
            expense.<br/>
          </span></div>
</ix:continuation>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">F-22</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div>
              <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

              </div>

            </div>

          </div>

        </div>

        <ix:continuation id="Text_5de5bc6a7eab46768823bb3eef11a6eb40" continuedAt="Text_5de5bc6a7eab46768823bb3eef11a6eb41">
<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><span style="letter-spacing: normal; text-align: left; text-indent: 0px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><br/>
            On November 14, 2024, the Company and Richard E. Uihlein (the &#8220;Lender&#8221;) entered into an additional Supplemental Line of Credit Letter Agreement (the &#8220;November 2024 Supplemental Credit Agreement&#8221;), pursuant to which the Lender shall provide the
            Company a line of credit of up to $<ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" id="Fact_bf7e4ae665dc47c2a99b70ad28ba9e23" contextRef="c20241114_CreditFacilityAxis_AdditionalSupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">6.0</ix:nonFraction> million (the &#8220;November 2024 Supplemental Line of Credit&#8221;) to finance the Company&#8217;s working
            capital needs. The Company may draw upon the November 2024 Supplemental Line of Credit through March 31, 2025.<br/>
            <br/>
            Each advance made pursuant to the November 2024 Supplemental Credit Agreement shall be evidenced by an unsecured, convertible promissory note (individually, a &#8220;Promissory Note,&#8221; and collectively, the &#8220;Promissory Notes&#8221;), and bear interest at
            the Applicable Federal Rate for short term loans, plus two (<ix:nonFraction name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" id="Fact_90ecfb0e34bc4528b60dad070f27ef90" contextRef="c20241113to20241114_CreditFacilityAxis_AdditionalSupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">2</ix:nonFraction>%) percent. Principal and interest on the Promissory Notes are due on or
            before <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" id="Fact_418538ee6d074b93b450da7897f9e893" contextRef="c20241113to20241114_CreditFacilityAxis_AdditionalSupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" format="ixt:date-monthname-day-year-en">March 31, 2026</ix:nonNumeric>. Only with the consent of the Lender, may the Promissory Notes be prepaid, in whole or in part, at any time
            without premium or penalty, but with interest on the amount or amounts prepaid.<br/>
            <br/>
            At the election of Lender, the principal and accrued interest on Promissory Note(s) may be converted into the number of shares of the Company&#8217;s Common Stock equal to the amount of principal and accrued interest on such Promissory Note divided
            by the price equal to the closing price of the Common Stock on the date of such Promissory Note, but in no event less than $<ix:nonFraction name="us-gaap:SharePrice" id="Fact_047132e3c7644d23aef1a5ff395b79de" contextRef="c20241114_CreditFacilityAxis_AdditionalSupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.00</ix:nonFraction> per
            share.<br/>
            <br/>
            In connection with the November 2024 Supplemental Credit Agreement, the Company agreed to issue the Lender warrants to purchase up to an aggregate of <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" id="Fact_60651c293b444296b2c8a3de5301fa28" contextRef="c20241114_CreditFacilityAxis_AdditionalSupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">120,000</ix:nonFraction>
            shares of the Company&#8217;s common stock, par value $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact_e83352653ae745c08f525a1403317f69" contextRef="c20241114_CreditFacilityAxis_AdditionalSupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U003" decimals="3" scale="0" format="ixt:num-dot-decimal">0.001</ix:nonFraction> per share (collectively, the &#8220;Warrants&#8221;). The Company shall issue to the
            Lender Warrants ratably, upon borrowings under the November 2024 Supplemental Line of Credit, with exercise prices equal to <ix:nonFraction name="galt:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock" id="Fact_efe631f0c9324fb3aca46e8845d42761" contextRef="c20241114_CreditFacilityAxis_AdditionalSupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">150</ix:nonFraction>% of
            the closing price of the Company&#8217;s common Stock on the date of the Promissory Note evidencing such draw, but in no event more than $<ix:nonFraction name="us-gaap:SharePrice" id="Fact_c5eeaa72191c4b35a2ff175d00fa6e3b" contextRef="c20241114_CreditFacilityAxis_AdditionalSupplementalLineOfCreditMember_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction>
            per share nor less than $<ix:nonFraction name="us-gaap:SharePrice" id="Fact_ab68cab89a6d43df86f3f79fff7748a8" contextRef="c20241114_CreditFacilityAxis_AdditionalSupplementalLineOfCreditMember_RangeAxis_MinimumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.00</ix:nonFraction> per share. The Warrants expire on <ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" id="Fact_f13a8ea23728438f982ce0f37762c27b" contextRef="c20241114_CreditFacilityAxis_AdditionalSupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" format="ixt:date-monthname-day-year-en">July 31, 2029</ix:nonNumeric>.<br/>
            <br/>
          </span></div>
</ix:continuation>
        <ix:continuation id="Text_5de5bc6a7eab46768823bb3eef11a6eb41">
<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The fair value
            of warrants that vest in the future based on borrowings will be computed when those borrowings occur and amortized over the remaining period through March 31, 2026</span><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">.</span> </div>
</ix:continuation>

        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

      </div>

    </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">

    <div>
      <ix:nonNumeric name="us-gaap:EarningsPerShareTextBlock" id="Text_0a4dcc0fc2a448d9a1c9226b0d4f33ea" contextRef="c20240101to20241231" escape="true" continuedAt="Text_f6e0ddd3792440149c8a4017eee1222d1">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 27.05pt; vertical-align: top; font-weight: bold;">11.</td>

    <td style="width: auto; vertical-align: top;">
              <div style="font-weight: bold;">Loss Per Share</div>
            </td>

  </tr>


</table>
</ix:nonNumeric>
      <ix:continuation id="Text_f6e0ddd3792440149c8a4017eee1222d1" continuedAt="Text_f6e0ddd3792440149c8a4017eee1222d2">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>
</ix:continuation>
      <ix:continuation id="Text_f6e0ddd3792440149c8a4017eee1222d2" continuedAt="Text_f6e0ddd3792440149c8a4017eee1222d3">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">Basic net loss per common share is computed by dividing the net loss available to common stockholders by the weighted average number of common shares outstanding
        during the period. For the years ended December 31, 2024 and 2023, as the Company was in a net loss position, the diluted loss per share computations for such periods did not assume the exercise of warrants and stock options or the conversion of
        Convertible Notes, or the conversion of convertible preferred stock as they would have had an anti-dilutive effect on loss per share.</div>
</ix:continuation>
      <ix:continuation id="Text_f6e0ddd3792440149c8a4017eee1222d3" continuedAt="Text_f6e0ddd3792440149c8a4017eee1222d4">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>
</ix:continuation>

      <ix:nonNumeric name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Text_eba6844b00424b8993ec13233ebf31fb" contextRef="c20240101to20241231" escape="true" continuedAt="Text_241c709e201448f788e9f6fdbeed9ca11"><ix:continuation id="Text_f6e0ddd3792440149c8a4017eee1222d4" continuedAt="Text_f6e0ddd3792440149c8a4017eee1222d5">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">The following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as of December 31, 2024 and 2023
        as the inclusion thereof would have been anti-dilutive:</div>
</ix:continuation></ix:nonNumeric>
      <ix:continuation id="Text_241c709e201448f788e9f6fdbeed9ca11" continuedAt="Text_241c709e201448f788e9f6fdbeed9ca12"><ix:continuation id="Text_f6e0ddd3792440149c8a4017eee1222d5" continuedAt="Text_f6e0ddd3792440149c8a4017eee1222d6">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_f6e0ddd3792440149c8a4017eee1222d6"><ix:continuation id="Text_241c709e201448f788e9f6fdbeed9ca12">
<div style="margin-left: 27pt;">
        <table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="6" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                <div style="text-align: center; font-weight: bold;">Year Ended</div>
                <div style="text-align: center; font-weight: bold;">December 31,</div>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                <div style="text-align: center; font-weight: bold;">2024</div>
                <div style="text-align: center; font-weight: bold;">(Shares)</div>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                <div style="text-align: center; font-weight: bold;">2023</div>
                <div style="text-align: center; font-weight: bold;">(Shares)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Warrants to purchase shares of common stock</div>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_559a2289b9854e3db5fd0ade080bbae1" contextRef="c20240101to20241231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">9,595,940</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_68cdc9c4fd1443dcb710acf1c5e993fb" contextRef="c20230101to20231231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">9,256,493</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Options to purchase shares of common stock</div>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_c31ab18c70664f64810cc99208e17d39" contextRef="c20240101to20241231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">6,854,758</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_c1ff56679789410e933e8d8e20085f18" contextRef="c20230101to20231231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">6,333,841</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Shares of common stock issuable upon conversion of convertible notes payable &#8211; related party</div>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_4c35a707e5ce4a0dbef6c550988ed219" contextRef="c20240101to20241231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertibleNotesPayableMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">7,024,053</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_39645a82ac344c708a29211ce786489f" contextRef="c20230101to20231231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertibleNotesPayableMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">6,418,913</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: top; text-indent: -9pt; margin-left: 9pt; width: 76%;">
                <div style="margin-left: 9pt;">Shares of common stock issuable upon conversion of convertible line of credit &#8211; related party<br/>
                </div>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_5787b9113e9c4cd68d3c7d60ef7d7bd1" contextRef="c20240101to20241231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_LineOfCreditMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">25,103,873</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_89a0759842e049f490358efbad4670bb" contextRef="c20230101to20231231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_LineOfCreditMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">13,833,356</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Shares of common stock issuable upon conversion preferred stock</div>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_7f2a3a1851374078b3c0e7cff52fc23c" contextRef="c20240101to20241231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertiblePreferredStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">499,174</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_49a6b43274454e60b11c6cc12b7d5fa7" contextRef="c20230101to20231231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertiblePreferredStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">499,174</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;">
                <div style="font-weight: bold;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_164b09d545cd482eb697102e12e33171" contextRef="c20240101to20241231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">49,077,798</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-weight: bold; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-weight: bold; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_6df2efca967040b584e7838464f50549" contextRef="c20230101to20231231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">36,341,777</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

  </tr>


</table>
         </div>
</ix:continuation></ix:continuation>
    </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
   <div><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span></div>

    <div>
      <div><br/>
      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">F-23</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

        <div style="width: 100%;" class="BRPFPageHeader">
          <div>
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

            </div>

          </div>

        </div>

      </div>


      <ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Text_4e7485949ee24fa49fbc883acf1a4cb9" contextRef="c20240101to20241231" escape="true" continuedAt="Text_37388cf92eb84937ac64f8d14867a7471">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 24.5pt; vertical-align: top; font-weight: bold; font-size: 10pt; font-family: 'Times New Roman';">12.</td>

    <td style="width: auto; vertical-align: top;">
              <div style="font-weight: bold; font-size: 10pt; font-family: 'Times New Roman';">Commitments and Contingencies</div>
            </td>

  </tr>


</table>
</ix:nonNumeric>
      <ix:continuation id="Text_37388cf92eb84937ac64f8d14867a7471" continuedAt="Text_37388cf92eb84937ac64f8d14867a7472">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman';"><br/>
        </span> </div>
</ix:continuation>
      <ix:continuation id="Text_37388cf92eb84937ac64f8d14867a7472" continuedAt="Text_37388cf92eb84937ac64f8d14867a7473">
<div style="margin: 0px 0px 0px 12.25pt; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Lease Commitments</div>
</ix:continuation>
      <ix:continuation id="Text_37388cf92eb84937ac64f8d14867a7473" continuedAt="Text_37388cf92eb84937ac64f8d14867a7474">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman';"><br/>
        </span> </div>
</ix:continuation>
      <ix:continuation id="Text_37388cf92eb84937ac64f8d14867a7474" continuedAt="Text_37388cf92eb84937ac64f8d14867a7475">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">The Company has <ix:nonFraction name="galt:NumberOfOperatingLeases" id="Fact_ee1cd955049140f191290f3906215d26" contextRef="c20240101to20241231" unitRef="U010" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction> operating lease for its office
        space which was amended effective March 1, 2022 for a term of <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseTermOfContract" id="Fact_bc8e5121386c449cb42c96fb0006aeed" contextRef="c20241231" format="ixt-sec:durmonth">38</ix:nonNumeric> months with no residual value guarantees or material restrictive
        covenants. The amended lease provided for free rent for the first <span style="-sec-ix-hidden:Fact_5e16282e65184d8eabf15666ce8cae25">six and one-half months</span> of the lease and continues the security
        deposit of $<ix:nonFraction name="us-gaap:SecurityDeposit" id="Fact_4feb5d9c5ba14a68ab7a2f38eeab835e" contextRef="c20241231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">6,000</ix:nonFraction>. In addition to base rental payments included in the contractual obligations table below, the Company is responsible
        for our pro-rata share of the operating expenses for the building. Our lease cost for the years ended December 31, 2024 and 2023 was $<ix:nonFraction name="us-gaap:OperatingLeaseCost" id="Fact_93e890deb7b5498299ad550b493e8984" contextRef="c20240101to20241231_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">44,000</ix:nonFraction>
        and $<ix:nonFraction name="us-gaap:OperatingLeaseCost" id="Fact_a545e36dd95d498d9bcee651fcd253db" contextRef="c20230101to20231231_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">44,000</ix:nonFraction>, respectively, and is included in general and administrative expenses. As of December 31, 2024, the right to use lease asset
        consisted of $<ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" id="Fact_a0d815a9f3ab4a57a0d2e4d7e588a6d1" contextRef="c20241231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">16,000</ix:nonFraction> and is included in <span style="-sec-ix-hidden:Fact_c96ca38e0f664780917ece0461c411fe">other assets</span>. Also, at December 31, 2024, current lease liability of $<ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" id="Fact_ef124626ace84ca9965aea16c95800a1" contextRef="c20241231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">19,000</ix:nonFraction> is included in <span style="-sec-ix-hidden:Fact_4b297d7d29a9481e88136db097de88dd">accrued expenses</span>.<span style="font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160; <span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">As of December 31, 2023, the right to use lease asset consisted of $<ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" id="Fact_ae28b17e68634613bdfcd4153a910a8d" contextRef="c20231231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">46,000</ix:nonFraction> and is included in <span style="-sec-ix-hidden:Fact_2a011c7177224f80b904fcc70e46eb35">other assets</span>.
            Also, at December 31, 2023, current lease liability of $<ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" id="Fact_a0ec72fc9e2e4e90970f532543d9e93a" contextRef="c20231231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">46,000</ix:nonFraction> is included in <span style="-sec-ix-hidden:Fact_3bef161157d441a4b194359a2b8c08a3">accrued expenses</span> and the noncurrent lease liability of $<ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" id="Fact_a1ed0ae7a4514c2d9deed1609ac1032c" contextRef="c20231231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">20,000</ix:nonFraction> is included
            in <span style="-sec-ix-hidden:Fact_47d32f393cdc43fc8f131674cf3a7b9b">other long term liabilities</span>. </span>The Company renewed its existing office space lease effective in March 2025 for <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Fact_2c2e81c0582f4fe993da5a46ff56f82c" contextRef="c20241231" format="ixt-sec:durwordsen">twelve months</ix:nonNumeric> at substantially the same terms.</span></div>
</ix:continuation>
      <ix:continuation id="Text_37388cf92eb84937ac64f8d14867a7475" continuedAt="Text_37388cf92eb84937ac64f8d14867a7476">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman';"><br/>
        </span> </div>
</ix:continuation>

      <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="Text_7b8bcf17c4e34ac1a2f94d50bbe049a5" contextRef="c20240101to20241231" escape="true" continuedAt="Text_4e304830c6914dd4b037266405b700731"><ix:continuation id="Text_37388cf92eb84937ac64f8d14867a7476" continuedAt="Text_37388cf92eb84937ac64f8d14867a7477">
<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">Maturity of operating lease as of December 31, 2024 in thousands:</div>
</ix:continuation></ix:nonNumeric>
      <ix:continuation id="Text_4e304830c6914dd4b037266405b700731" continuedAt="Text_4e304830c6914dd4b037266405b700732"><ix:continuation id="Text_37388cf92eb84937ac64f8d14867a7477" continuedAt="Text_37388cf92eb84937ac64f8d14867a7478">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-size: 10pt; font-family: 'Times New Roman';"><br/>
        </span> </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_37388cf92eb84937ac64f8d14867a7478" continuedAt="Text_37388cf92eb84937ac64f8d14867a7479"><ix:continuation id="Text_4e304830c6914dd4b037266405b700732">
<div style="margin-left: 27pt;">
        <table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;">


  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: top; font-size: 10pt; font-family: 'Times New Roman'; width: 88%; background-color: #CCEEFF;">2025</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; font-size: 10pt; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" id="Fact_523f4a94f97544a6a992ed83f8da5fdf" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">19</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-size: 10pt; font-family: 'Times New Roman';">Total</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div style="font-size: 10pt; font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" id="Fact_fbee34a0e51d4c9cb06b2926e6404b71" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">19</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-size: 10pt; font-family: 'Times New Roman';">Less imputed interest</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="font-size: 10pt; font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" id="Fact_2dbd53b5a092435b83526db1111fdacc" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%; padding-bottom: 4px;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-size: 10pt; font-family: 'Times New Roman';">Present value of lease liability</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div style="font-size: 10pt; font-family: 'Times New Roman';">$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div style="font-size: 10pt; font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" id="Fact_8b696bd79014406cac72ac553ba14099" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">19</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

  </tr>


</table>
         </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_37388cf92eb84937ac64f8d14867a7479" continuedAt="Text_37388cf92eb84937ac64f8d14867a74710">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman';"><br/>
        </span> </div>
</ix:continuation>
      <ix:continuation id="Text_37388cf92eb84937ac64f8d14867a74710" continuedAt="Text_37388cf92eb84937ac64f8d14867a74711">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">The discount rate used in calculating the present value of the lease payments was <ix:nonFraction name="us-gaap:LesseeOperatingLeaseDiscountRate" id="Fact_231e960a60b64de3afeefca00f9e7fec" contextRef="c20241231" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">11</ix:nonFraction>%.</div>
</ix:continuation>
      <ix:continuation id="Text_37388cf92eb84937ac64f8d14867a74711" continuedAt="Text_37388cf92eb84937ac64f8d14867a74712">
<div><span style="font-size: 10pt; font-family: 'Times New Roman';"><br/>
      </span></div>
</ix:continuation>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">F-24</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

        <div style="width: 100%;" class="BRPFPageHeader">
          <div>
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

            </div>

          </div>

        </div>

      </div>

      <ix:continuation id="Text_37388cf92eb84937ac64f8d14867a74712" continuedAt="Text_37388cf92eb84937ac64f8d14867a74713">
<div style="margin: 0px 0px 0px 12.25pt; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Legal Proceedings</div>
</ix:continuation>
      <ix:continuation id="Text_37388cf92eb84937ac64f8d14867a74713" continuedAt="Text_37388cf92eb84937ac64f8d14867a74714">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman';"><br/>
        </span> </div>
</ix:continuation>
      <ix:continuation id="Text_37388cf92eb84937ac64f8d14867a74714" continuedAt="Text_37388cf92eb84937ac64f8d14867a74715">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">The Company records accruals for such contingencies to the extent that the Company concludes that their occurrence is probable and the related damages are estimable.
        There are no pending legal proceedings.</div>
</ix:continuation>
      <ix:continuation id="Text_37388cf92eb84937ac64f8d14867a74715" continuedAt="Text_37388cf92eb84937ac64f8d14867a74716">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman';"><br/>
        </span> </div>
</ix:continuation>
      <ix:continuation id="Text_37388cf92eb84937ac64f8d14867a74716" continuedAt="Text_37388cf92eb84937ac64f8d14867a74717">
<div style="margin: 0px 0px 0px 12.25pt; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Clinical Trial and Research Contingencies</div>
</ix:continuation>
      <ix:continuation id="Text_37388cf92eb84937ac64f8d14867a74717" continuedAt="Text_37388cf92eb84937ac64f8d14867a74718">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman';"><br/>
        </span> </div>
</ix:continuation>
      <ix:continuation id="Text_37388cf92eb84937ac64f8d14867a74718">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">The Company has entered into agreements with contractors for research and development activities to further its product candidates. The contracts generally may be
        canceled at any time by providing <ix:nonNumeric name="galt:ContractCancelationNoticePeriod" id="Fact_a01cb78d6e6b4d5b931a1c828378ef7e" contextRef="c20240101to20241231" format="ixt-sec:durwordsen">thirty days</ix:nonNumeric>&#8217; notice. The Company is involved in a dispute with a contract vendor for clinical trial
        management services provided outside of the United States. The contract in question is a variable contract. The Company has accrued its estimate of the amount owed to the contract vendor. The contract vendor asserts that it is owed approximately $<ix:nonFraction name="us-gaap:LossContingencyEstimateOfPossibleLoss" id="Fact_8acf3564044746efb597b2cf35652234" contextRef="c20241231" unitRef="U001" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction> million more than the Company&#8217;s estimate. The Company disagrees with the contract vendor&#8217;s assertion, and did <ix:nonFraction name="us-gaap:LossContingencyRangeOfPossibleLossPortionNotAccrued" id="Fact_940c1fa3068842008393e607d27db558" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt-sec:numwordsen">no</ix:nonFraction>t accrue that additional amount at December 31, 2024.</div>
</ix:continuation>

      <div><br/>
      </div>

    </div>

    <div><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span></div>

  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">

    <div>
      <ix:nonNumeric name="us-gaap:InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock" id="Text_47ed3e55fa604b15b7ff1fc7dffcc887" contextRef="c20240101to20241231" escape="true" continuedAt="Text_9f3532bec01441afb13fd7b210d979871">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 27.05pt; vertical-align: top; font-weight: bold;">13.</td>

    <td style="width: auto; vertical-align: top;">
              <div style="font-weight: bold;">Galectin Sciences LLC</div>
            </td>

  </tr>


</table>
</ix:nonNumeric>
      <ix:continuation id="Text_9f3532bec01441afb13fd7b210d979871" continuedAt="Text_9f3532bec01441afb13fd7b210d979872">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>
</ix:continuation>
      <ix:continuation id="Text_9f3532bec01441afb13fd7b210d979872">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"> In January 2014, we created Galectin Sciences, LLC (the &#8220;LLC&#8221; or &#8220;Investee&#8221;), a collaborative joint venture co-owned by SBH Sciences, Inc. (&#8220;SBH&#8221;), to research and
        develop small organic molecule inhibitors of galectin-3 for oral administration. The LLC was initially capitalized with a $<ix:nonFraction name="us-gaap:PaymentsToAcquireEquityMethodInvestments" id="Fact_248b8c53384f49d7b55a1d7e23c0eb99" contextRef="c20140101to20140131_OwnershipAxis_GalectinSciencesLLCMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">400,000</ix:nonFraction> cash
        investment to fund future research and development activities, which was provided by the Company, and specific in-process research and development (&#8220;IPR&amp;D&#8221;) contributed by SBH. The estimated fair value of the IPR&amp;D contributed by SBH, on
        the date of contribution, was $<ix:nonFraction name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure" id="Fact_34e5c7c950ad4135b33abe1f7702eee0" contextRef="c20140131_CounterpartyNameAxis_SBHSciencesIncMember_FiniteLivedIntangibleAssetsByMajorClassAxis_InProcessResearchAndDevelopmentMember_OwnershipAxis_GalectinSciencesLLCMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">400,000</ix:nonFraction>. Initially, the Company and SBH have a <ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByParent" id="Fact_47874d14f02f4856a6c335ccc10fbcd4" contextRef="c20140131_CounterpartyNameAxis_SBHSciencesIncMember_OwnershipAxis_GalectinSciencesLLCMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">50</ix:nonFraction>% equity ownership interest in the LLC, with neither party having control over the LLC. Accordingly, from inception through the fourth quarter of 2014, the Company accounted
        for its investment in the LLC using the equity method of accounting. Under the equity method of accounting, the Company&#8217;s investment was initially recorded at cost with subsequent adjustments to the carrying value to recognize additional
        investments in or distributions from the Investee, as well as the Company&#8217;s share of the Investee&#8217;s earnings, losses and/or changes in capital. The estimated fair value of the IPR&amp;D contributed to the LLC was immediately expensed upon
        contribution as there was no alternative future use available at the point of contribution. The operating agreement provides that if either party does not desire to contribute its equal share of funding required after the initial capitalization,
        then the other party, providing all of the funding, will have its ownership share increased in proportion to the total amount contributed from inception. In the fourth quarter of 2014, after the LLC had expended the $<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" id="Fact_c5d89040534e4766b7e2ae9ff930da01" contextRef="c20141001to20141231_OwnershipAxis_GalectinSciencesLLCMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">400,000</ix:nonFraction> in cash, SBH decided not to contribute its share of the funding required. As a result, the Company contributed the $<ix:nonFraction name="galt:CapitalContributionExpense" id="Fact_16ec698acb62492d9ca13f5b5c588544" contextRef="c20141001to20141231_OwnershipAxis_GalectinSciencesLLCMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">73,000</ix:nonFraction> needed for the fourth quarter of 2014 expenses of the LLC and an additional $<ix:nonFraction name="galt:CapitalContributionExpense" id="Fact_0f23c496f2f845e3accb8d4b4def7ad6" contextRef="c20150101to20211231_OwnershipAxis_GalectinSciencesLLCMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">2,552,000</ix:nonFraction> in total from 2015 through 2021. The Company contributed $<ix:nonFraction name="galt:CapitalContributionExpense" id="Fact_fd0f9893cfeb4d3bafaa78a544258f05" contextRef="c20240101to20241231_OwnershipAxis_GalectinSciencesLLCMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">350,000</ix:nonFraction>
        and $<ix:nonFraction name="galt:CapitalContributionExpense" id="Fact_37e8d103ecd64fe0a6d625cc6c6f9732" contextRef="c20230101to20231231_OwnershipAxis_GalectinSciencesLLCMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">561,000</ix:nonFraction> for the LLC expenses (recorded in research and development expenses) in 2024 and 2023, and SBH has contributed a total of $<ix:nonFraction name="galt:CapitalContributionExpense" id="Fact_fc46d9c3c786410ca756397c72528520" contextRef="c20140101to20231231_CounterpartyNameAxis_SBHSciencesIncMember_OwnershipAxis_GalectinSciencesLLCMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">711,000</ix:nonFraction> since 2014. As of December 31, 2024, the Company&#8217;s ownership percentage in the LLC was <ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByParent" id="Fact_809981f6607847059facc6954c773dfb" contextRef="c20241231_OwnershipAxis_GalectinSciencesLLCMember" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">85.3</ix:nonFraction>%. The Company accounts for the interest in the LLC as a consolidated, less than wholly owned subsidiary. Because the LLC&#8217;s equity is immaterial, the value of the
        non-controlling interest is also deemed to be immaterial. The Company&#8217;s portion of the LLC&#8217;s net loss for 2014, prior to the change in accounting discussed previously, was $<ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" id="Fact_49145d3d971e4b4fb3b0328c557c4e23" contextRef="c20140101to20141231_OwnershipAxis_GalectinSciencesLLCMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">400,000</ix:nonFraction>, which includes the Company&#8217;s proportionate share of the non-cash charge associated with the contributed IPR&amp;D of $<ix:nonFraction name="galt:NonCashChargeForResearchAndDevelopmentInProcess" id="Fact_f18eb5c55fd747c1b09bd703807d7130" contextRef="c20140101to20141231_OwnershipAxis_GalectinSciencesLLCMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">200,000</ix:nonFraction>.</div>
</ix:continuation>
       </div>

    <div><br/>
    </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">

    <div>
      <ix:nonNumeric name="us-gaap:IncomeTaxDisclosureTextBlock" id="Text_030e959bff65416bac86157b76c44226" contextRef="c20240101to20241231" escape="true" continuedAt="Text_8b045f441c1e4b77b99c8e5556fcab7d1">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 24.5pt; vertical-align: top; font-weight: bold;">14.</td>

    <td style="width: auto; vertical-align: top;">
              <div style="font-weight: bold;">Income Taxes</div>
            </td>

  </tr>


</table>
</ix:nonNumeric>
      <ix:continuation id="Text_8b045f441c1e4b77b99c8e5556fcab7d1" continuedAt="Text_8b045f441c1e4b77b99c8e5556fcab7d2">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>
</ix:continuation>

      <ix:nonNumeric name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="Text_1341c291b1814f9ca30842acc2275d31" contextRef="c20240101to20241231" escape="true" continuedAt="Text_926898bb4abd42bca17e813bea2f026d1"><ix:continuation id="Text_8b045f441c1e4b77b99c8e5556fcab7d2" continuedAt="Text_8b045f441c1e4b77b99c8e5556fcab7d3">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">The components of the net deferred tax assets are as follows at December 31:</div>
</ix:continuation></ix:nonNumeric>
      <ix:continuation id="Text_926898bb4abd42bca17e813bea2f026d1" continuedAt="Text_926898bb4abd42bca17e813bea2f026d2"><ix:continuation id="Text_8b045f441c1e4b77b99c8e5556fcab7d3" continuedAt="Text_8b045f441c1e4b77b99c8e5556fcab7d4">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_8b045f441c1e4b77b99c8e5556fcab7d4" continuedAt="Text_8b045f441c1e4b77b99c8e5556fcab7d5"><ix:continuation id="Text_926898bb4abd42bca17e813bea2f026d2">
<div style="margin-left: 27pt;">
        <table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                <div style="text-align: center; font-weight: bold;"> 2024<br/>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                <div style="text-align: center; font-weight: bold;">2023<br/>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom;">
                <div style="text-align: center; font-weight: bold;">(in thousands)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Operating loss carryforwards</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">$</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" id="Fact_4d5210e2ec344051827f6a2c0be968ee" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">63,057</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" id="Fact_0aad8e6c10fb4f1c8ce69313c66c8658" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">61,427</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Tax credit carryforwards</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" id="Fact_49e57dfaaf8f4df1b61ff46cc7c9ef89" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,010</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" id="Fact_c0213871460d4a4d84aeb3a2da40b86d" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,476</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Other temporary differences</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" id="Fact_bb33a838785c410da70795469c73c6d8" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">18,276</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" id="Fact_60f0261ac273462cbbb5b282172a347e" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,533</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" id="Fact_21a18dc1821544fabe6e542a6a8ed938" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">90,343</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" id="Fact_6577aa22deba463994da18452a0cae79" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">78,436</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Less valuation allowance</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" id="Fact_fc81137b4f8a497e8aadd8224fcdd5b1" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">90,343</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" id="Fact_4b484d18b30b4be09473c30ecdc0b507" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">78,436</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Net deferred tax asset</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">$</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" id="Fact_33f206f9325e4087b6d5210ff408c48c" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" id="Fact_3714f07f9c40447bb25a6ca503a2d582" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

  </tr>


</table>
         </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_8b045f441c1e4b77b99c8e5556fcab7d5" continuedAt="Text_8b045f441c1e4b77b99c8e5556fcab7d6">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>
</ix:continuation>

      <ix:nonNumeric name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="Text_d4ec01ceef80408fa634ecc673b2c6ba" contextRef="c20240101to20241231" escape="true" continuedAt="Text_244f1604c66b461ea32ec8d684bf6ef21"><ix:continuation id="Text_8b045f441c1e4b77b99c8e5556fcab7d6" continuedAt="Text_8b045f441c1e4b77b99c8e5556fcab7d7">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">The primary factors affecting the Company&#8217;s income tax rates were as follows:</div>
</ix:continuation></ix:nonNumeric>
      <ix:continuation id="Text_244f1604c66b461ea32ec8d684bf6ef21" continuedAt="Text_244f1604c66b461ea32ec8d684bf6ef22"><ix:continuation id="Text_8b045f441c1e4b77b99c8e5556fcab7d7" continuedAt="Text_8b045f441c1e4b77b99c8e5556fcab7d8">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_8b045f441c1e4b77b99c8e5556fcab7d8" continuedAt="Text_8b045f441c1e4b77b99c8e5556fcab7d9"><ix:continuation id="Text_244f1604c66b461ea32ec8d684bf6ef22">
<div style="margin-left: 27pt;">
        <table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                <div style="text-align: center; font-weight: bold;"> 2024<br/>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                <div style="text-align: center; font-weight: bold;">2023<br/>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Tax benefit at U.S. statutory rates</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" id="Fact_261744d2345d4d2bbeae2511a9c945f9" contextRef="c20240101to20241231" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">21</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>%)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" id="Fact_bc9277459a74408ca05215eae2c363ee" contextRef="c20230101to20231231" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">21</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>%)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">State tax benefit</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" id="Fact_f7ecba4f85c444cfbe65d700ccd67c99" contextRef="c20240101to20241231" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">2.5</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div>%)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" id="Fact_37adf3f073114dcf98cdd6f8138aa939" contextRef="c20230101to20231231" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">3.4</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div>%)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Permanent differences</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" id="Fact_43262c359abc4bdcb9310335b10d305a" contextRef="c20240101to20241231" unitRef="U007" decimals="3" sign="-" scale="-2" format="ixt:num-dot-decimal">0.1</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>%</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" id="Fact_49affd9376a3440db1928a29430ea1cf" contextRef="c20230101to20231231" unitRef="U007" decimals="3" sign="-" scale="-2" format="ixt:num-dot-decimal">0.9</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>%</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Other</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" id="Fact_f92e21794dde44c588056db0e87fb56f" contextRef="c20240101to20241231" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">4.0</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div>%)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" id="Fact_d6a641daf71540dc9acfbbfc50c2be82" contextRef="c20230101to20231231" unitRef="U007" decimals="3" sign="-" scale="-2" format="ixt:num-dot-decimal">2.3</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div>%</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Changes in valuation allowance</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" id="Fact_17738fda5dd84fadbc77df34d1385aee" contextRef="c20240101to20241231" unitRef="U007" decimals="3" sign="-" scale="-2" format="ixt:num-dot-decimal">27.4</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div>%</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" id="Fact_84d502b0c4da453497cfb8d7b16e4b28" contextRef="c20230101to20231231" unitRef="U007" decimals="3" sign="-" scale="-2" format="ixt:num-dot-decimal">21.2</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div>%</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div style="font-weight: bold;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" id="Fact_5820e575f1754b378990b60c8708a1a3" contextRef="c20240101to20241231" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">0</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">
                <div style="font-weight: bold;">%</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div style="font-weight: bold;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" id="Fact_09a87882122c472493365c4432778fe6" contextRef="c20230101to20231231" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">0</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">
                <div style="font-weight: bold;">%</div>
              </td>

  </tr>


</table>
         </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_8b045f441c1e4b77b99c8e5556fcab7d9" continuedAt="Text_8b045f441c1e4b77b99c8e5556fcab7d10">
<div style="margin-left: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>
</ix:continuation>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">F-25</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

        <div style="width: 100%;" class="BRPFPageHeader">
          <div>
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic; color: rgb(0, 0, 0);"><a href="#INDEX">Index</a></div>

            </div>

          </div>

        </div>

      </div>

      <ix:continuation id="Text_8b045f441c1e4b77b99c8e5556fcab7d10" continuedAt="Text_8b045f441c1e4b77b99c8e5556fcab7d11">
<div style="margin-left: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">As of December 31, 2024, the Company has federal and state net operating loss carryforwards <span style="background-color: rgb(255, 255, 255);">totaling $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" id="Fact_4519ccf32f1d4ee49dd4d4b05b46d773" contextRef="c20241231_IncomeTaxAuthorityAxis_DomesticCountryMember_TaxPeriodAxis_ExpiringAsAResultOf2017TaxActMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">131,579,000</ix:nonFraction> and $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" id="Fact_e3aa7c410a4349d9b61eccba87b94475" contextRef="c20241231_IncomeTaxAuthorityAxis_StateAndLocalJurisdictionMember_TaxPeriodAxis_ExpiringAsAResultOf2017TaxActMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">137,878,000</ix:nonFraction>,
          respectively, which will never expire as a result of the 2017 Tax Act. As of December 31, 2023, the Company has federal and state net operating loss carryforwards totaling $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" id="Fact_9935b6bffd6f49a792755c021f1c44a3" contextRef="c20241231_IncomeTaxAuthorityAxis_DomesticCountryMember_TaxPeriodAxis_ExpiringThrough2037Member" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">120,055,000</ix:nonFraction> and $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" id="Fact_d6a1badb81b848359dcbf1e78ecba859" contextRef="c20241231_IncomeTaxAuthorityAxis_StateAndLocalJurisdictionMember_TaxPeriodAxis_ExpiringThrough2037Member" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">102,003,000</ix:nonFraction> respectively, which expire through <span style="-sec-ix-hidden:Fact_f036db385a5043f9b416f31ccdd089ed">2037</span>. In addition, the Company has federal and state research and development credits of $<ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" id="Fact_fec4137afe294dd08223f0e0f500b6d7" contextRef="c20240101to20241231_IncomeTaxAuthorityAxis_DomesticCountryMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">7,764,000</ix:nonFraction> and $<ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" id="Fact_2761ded680b04045a54b4cdc2e90a8d6" contextRef="c20240101to20241231_IncomeTaxAuthorityAxis_StateAndLocalJurisdictionMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">1,245,000</ix:nonFraction>,</span> respectively, which expire through <span style="-sec-ix-hidden:Fact_64f60f3069914649af3fc7ac5db90c6c">2042</span>. Ownership changes, as defined by Section 382 of the Internal Revenue Code, may have limited the amount of net operating loss carryforwards that
        can be utilized annually to offset future taxable income. Past and subsequent ownership changes could further affect the limitation in future years. Because of the Company&#8217;s limited operating history and its recorded losses, management has
        provided, in each of the last two years, a <ix:nonFraction name="galt:DeferredTaxAssetsValuationAllowancePercentage" id="Fact_dd185aacae904174b2d20d195a818f05" contextRef="c20241231" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction>% valuation allowance against the Company&#8217;s net deferred tax assets.</div>
</ix:continuation>
      <ix:continuation id="Text_8b045f441c1e4b77b99c8e5556fcab7d11" continuedAt="Text_8b045f441c1e4b77b99c8e5556fcab7d12">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>
</ix:continuation>
      <ix:continuation id="Text_8b045f441c1e4b77b99c8e5556fcab7d12">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">The Company is subject to taxation in the U.S. and various states. Based on the history of net operating losses all jurisdictions and tax years are open for
        examination until the operating losses are utilized or the statute of limitations expires. As of December 31, 2024 and 2023, the Company does not have any significant uncertain tax positions.</div>
</ix:continuation>

      <div><br/>
      </div>

    </div>


  </div>
<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">

    <div>
      <ix:nonNumeric name="us-gaap:SegmentReportingDisclosureTextBlock" id="Text_28aa5d5b089b4f2ea466162efefda198" contextRef="c20240101to20241231" escape="true" continuedAt="Text_8986426e4c204b5093177cfc0d67e9881">
<div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="text-align: right; vertical-align: top; width: 27pt;">
                <div style="text-align: left; font-weight: bold;"><span style="font-size: 10pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">15.</span></div>
              </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                <div style="text-align: left; font-weight: bold;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman', Times, serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: -36px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">Segments</span></div>
              </td>

  </tr>


</table>
      </div>
</ix:nonNumeric>
      <ix:continuation id="Text_8986426e4c204b5093177cfc0d67e9881" continuedAt="Text_8986426e4c204b5093177cfc0d67e9882">
<div style="margin-top: 0px; margin-bottom: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> <br/>
        </span></div>
</ix:continuation>
      <ix:continuation id="Text_8986426e4c204b5093177cfc0d67e9882" continuedAt="Text_8986426e4c204b5093177cfc0d67e9883">
<div style="margin-top: 0px; margin-bottom: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; margin-left: 18pt;"><span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Operating segments are identified as components of an entity about which separate discrete financial information is available for evaluation by the CODM, or decision-making group, in making decisions on how to allocate
          resources and assess performance. The Company&#8217;s CODM, the Chief Executive Officer, views the Company&#8217;s operations as <ix:nonFraction name="us-gaap:NumberOfOperatingSegments" id="Fact_e8f8f97f051e49deb8b94fa9d84e08ae" contextRef="c20240101to20241231" unitRef="U011" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction> operating
          segment, which is focused on creating new therapies for fibrotic disease based on targeting galectin proteins. The Company does not have revenue in the current comparative period, incurs expenses primarily in North America and manages the
          business activities on a consolidated basis.</span></div>
</ix:continuation>
      <ix:continuation id="Text_8986426e4c204b5093177cfc0d67e9883" continuedAt="Text_8986426e4c204b5093177cfc0d67e9884">
<div style="margin-top: 0px; margin-bottom: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> <br/>
        </span></div>
</ix:continuation>
      <div style="margin-top: 0px; margin-bottom: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; margin-left: 9pt;"><ix:continuation id="Text_8986426e4c204b5093177cfc0d67e9884" continuedAt="Text_8986426e4c204b5093177cfc0d67e9885">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_8986426e4c204b5093177cfc0d67e9885" continuedAt="Text_8986426e4c204b5093177cfc0d67e9886">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; margin-left: 9pt;">The accounting policies of the fibrotic disease therapeutics segment are the same
          as those described in the summary of significant accounting policies.</div>
</ix:continuation>
        <ix:continuation id="Text_8986426e4c204b5093177cfc0d67e9886" continuedAt="Text_8986426e4c204b5093177cfc0d67e9887">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify;"> <span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
          </span></div>
</ix:continuation>
        <ix:continuation id="Text_8986426e4c204b5093177cfc0d67e9887" continuedAt="Text_8986426e4c204b5093177cfc0d67e9888">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; margin-left: 9pt;">The CODM assesses performance for the fibrotic disease therapeutics segment and
          decides how to allocate resources based on net loss that also is reported on the income statement as consolidated net loss. The measure of segment assets is reported on the balance sheet as cash and cash equivalents.</div>
</ix:continuation>
        <ix:continuation id="Text_8986426e4c204b5093177cfc0d67e9888" continuedAt="Text_8986426e4c204b5093177cfc0d67e9889">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify;"> <span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
          </span></div>
</ix:continuation>
        <ix:continuation id="Text_8986426e4c204b5093177cfc0d67e9889" continuedAt="Text_8986426e4c204b5093177cfc0d67e98810">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; margin-left: 9pt;">The Company has not generated any product revenue in the current period and expects
          to continue to incur significant expenses and operating losses for the foreseeable future as the Company advances its product candidates through all stages of development and clinical trials.</div>
</ix:continuation>
        <ix:continuation id="Text_8986426e4c204b5093177cfc0d67e98810" continuedAt="Text_8986426e4c204b5093177cfc0d67e98811">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify;"> <span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
          </span></div>
</ix:continuation>
        <ix:continuation id="Text_8986426e4c204b5093177cfc0d67e98811" continuedAt="Text_8986426e4c204b5093177cfc0d67e98812">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; margin-left: 9pt;">As such, the CODM uses cash forecast models in deciding how to invest into the
          fibrotic disease therapeutics segment. Such cash forecast models are reviewed to assess the entity-wide operating results and performance. Net loss is used to monitor budget versus actual results. Monitoring budgeted versus actual results, net
          cash used in operating activities for the period and cash on hand are used in assessing performance of the segment.</div>
</ix:continuation>
        <ix:continuation id="Text_8986426e4c204b5093177cfc0d67e98812" continuedAt="Text_8986426e4c204b5093177cfc0d67e98813">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify;"> <span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
          </span></div>
</ix:continuation>

        <ix:nonNumeric name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="Text_3bdd81287ad742da82a5f28e4be8a1fb" contextRef="c20240101to20241231" escape="true" continuedAt="Text_048743c7ba724640ad34cd21d12d40891"><ix:continuation id="Text_8986426e4c204b5093177cfc0d67e98813" continuedAt="Text_8986426e4c204b5093177cfc0d67e98814">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; margin-left: 9pt;">The table below summarizes the significant expense categories regularly reviewed by
          the CODM for the years ended December 31, 2024 and 2023 (in thousands).</div>
</ix:continuation></ix:nonNumeric>
        <ix:continuation id="Text_048743c7ba724640ad34cd21d12d40891" continuedAt="Text_048743c7ba724640ad34cd21d12d40892"><ix:continuation id="Text_8986426e4c204b5093177cfc0d67e98814" continuedAt="Text_8986426e4c204b5093177cfc0d67e98815">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify;"> <span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
          </span></div>
</ix:continuation></ix:continuation>
        <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify;">
          <ix:continuation id="Text_048743c7ba724640ad34cd21d12d40892" continuedAt="Text_048743c7ba724640ad34cd21d12d40893"><ix:continuation id="Text_8986426e4c204b5093177cfc0d67e98815" continuedAt="Text_8986426e4c204b5093177cfc0d67e98816">
<table cellspacing="0" cellpadding="0" border="0" style="background-color: rgb(255, 255, 255); letter-spacing: normal; word-spacing: 0px; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: left; text-transform: none; width: 100%; border-spacing: 0;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px;">
                  <div>&#160;</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="6">
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Year Ended</div>
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">December 31,</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px;">
                  <div>&#160;</div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
                  <div style="text-align: center; font-weight: bold;"> 2024</div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
                  <div style="text-align: center; font-weight: bold;">2023</div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">
                  <div>&#160;</div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;" colspan="6">
                  <div style="text-align: center; font-weight: bold;"><span style="text-decoration: underline;">(in thousands)</span></div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
                  <div>Operating expenses:</div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;" colspan="2">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;" colspan="2">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; background-color: rgb(204, 238, 255);">
                  <div>Research and development</div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                  <div>$</div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                  <div><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_79a66d5160854c359944e1f3dda95af8" contextRef="c20240101to20241231_StatementBusinessSegmentsAxis_BusinessOperatingSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">36,571</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                  <div>$</div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                  <div><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_78887ad17e7e4384a208174f05f3dcdd" contextRef="c20230101to20231231_StatementBusinessSegmentsAxis_BusinessOperatingSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">32,130</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 2px;">
                  <div>General and administrative</div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                  <div><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" id="Fact_73d6907b69ee4313861219c6fae53215" contextRef="c20240101to20241231_StatementBusinessSegmentsAxis_BusinessOperatingSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,862</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                  <div><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" id="Fact_050dbd6a09f24c17852161a8c7bd3c8f" contextRef="c20230101to20231231_StatementBusinessSegmentsAxis_BusinessOperatingSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,942</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
                  <div>Total operating expenses</div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                  <div><ix:nonFraction name="us-gaap:OperatingExpenses" id="Fact_5cc5f41357924f03b40891875f061d48" contextRef="c20240101to20241231_StatementBusinessSegmentsAxis_BusinessOperatingSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">42,433</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                  <div><ix:nonFraction name="us-gaap:OperatingExpenses" id="Fact_a0fcc1b0af8e4d20958b24eebac78358" contextRef="c20230101to20231231_StatementBusinessSegmentsAxis_BusinessOperatingSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">38,072</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 2px;">
                  <div>Total operating loss</div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                  <div>(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_c2dd9cbc04f9471e827d12f581f3681c" contextRef="c20240101to20241231_StatementBusinessSegmentsAxis_BusinessOperatingSegmentMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">42,433</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                  <div>)</div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                  <div>(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_bf618d0777944e1fb5bace232527da60" contextRef="c20230101to20231231_StatementBusinessSegmentsAxis_BusinessOperatingSegmentMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">38,072</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                  <div>)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; background-color: rgb(204, 238, 255);">
                  <div>Other income (expense):</div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%;">
                  <div>Interest income</div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" id="Fact_17d13a3882484e3fae733321aae375fe" contextRef="c20240101to20241231_StatementBusinessSegmentsAxis_BusinessOperatingSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">336</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" id="Fact_cbef480b92ab4da29115eb832b935c3e" contextRef="c20230101to20231231_StatementBusinessSegmentsAxis_BusinessOperatingSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">230</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; background-color: rgb(204, 238, 255);">
                  <div>Interest expense</div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                  <div>(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" id="Fact_7e1aabd1b88840a6987e1c78d692f2ca" contextRef="c20240101to20241231_StatementBusinessSegmentsAxis_BusinessOperatingSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,540</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                  <div>)</div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                  <div>(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" id="Fact_3083c8ff60ef494681024c8baa5895c6" contextRef="c20230101to20231231_StatementBusinessSegmentsAxis_BusinessOperatingSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,792</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                  <div>)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 2px;">
                  <div>Change in fair value of derivatives</div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                  <div><ix:nonFraction name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" id="Fact_772e753238f946a39c76b5ced5c543ad" contextRef="c20240101to20241231_StatementBusinessSegmentsAxis_BusinessOperatingSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">590</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                  <div>(<ix:nonFraction name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" id="Fact_5d6001597b2f4d3aaa8153f5e58b59e6" contextRef="c20230101to20231231_StatementBusinessSegmentsAxis_BusinessOperatingSegmentMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">432</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                  <div>)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
                  <div>Total other expense</div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                  <div>(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" id="Fact_06652a52dd744762be01328f7c150dfd" contextRef="c20240101to20241231_StatementBusinessSegmentsAxis_BusinessOperatingSegmentMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">4,614</ix:nonFraction>)</div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                  <div>(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" id="Fact_6c36b9459b684f81bc32c269aaa3b0e9" contextRef="c20230101to20231231_StatementBusinessSegmentsAxis_BusinessOperatingSegmentMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,994</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                  <div>)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 2px;">
                  <div>Net loss</div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                  <div>$</div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                  <div>(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_dadd542f856a4a18863730365892f7a8" contextRef="c20240101to20241231_StatementBusinessSegmentsAxis_BusinessOperatingSegmentMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">47,047</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                  <div>)</div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                  <div>$</div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                  <div>(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_716483e9b90d4db6bc92f78a31be169b" contextRef="c20230101to20231231_StatementBusinessSegmentsAxis_BusinessOperatingSegmentMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">41,066</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                  <div>)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
                  <div>Preferred stock dividends</div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                  <div>(<ix:nonFraction name="us-gaap:PreferredStockDividendsAndOtherAdjustments" id="Fact_5adf93b4ec3c4e9bb81734b50bd2f8b0" contextRef="c20240101to20241231_StatementBusinessSegmentsAxis_BusinessOperatingSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">153</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                  <div>)</div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                  <div>(<ix:nonFraction name="us-gaap:PreferredStockDividendsAndOtherAdjustments" id="Fact_d9afcb2040074ecea6dbff5fb218110a" contextRef="c20230101to20231231_StatementBusinessSegmentsAxis_BusinessOperatingSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">120</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                  <div>)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 2px;">
                  <div>Warrant modification</div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                  <div><ix:nonFraction name="galt:FairValueAdjustmentOfWarrant" id="Fact_fdd6e128b16844969a9b5f78a8a2775b" contextRef="c20240101to20241231_StatementBusinessSegmentsAxis_BusinessOperatingSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                  <div>(<ix:nonFraction name="galt:FairValueAdjustmentOfWarrant" id="Fact_49228b5314014313b02b8770c077f7f4" contextRef="c20230101to20231231_StatementBusinessSegmentsAxis_BusinessOperatingSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,619</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                  <div>)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
                  <div>Net loss applicable to common stockholders</div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                  <div>$</div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                  <div>(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" id="Fact_2de2dc210f7a4c3686a1864c0de340f7" contextRef="c20240101to20241231_StatementBusinessSegmentsAxis_BusinessOperatingSegmentMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">47,200</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                  <div>)</div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                  <div>$</div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                  <div>(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" id="Fact_8448b204313a4204b52c53617e2a381d" contextRef="c20230101to20231231_StatementBusinessSegmentsAxis_BusinessOperatingSegmentMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">44,805</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                  <div>)</div>
                </td>

  </tr>


</table>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_048743c7ba724640ad34cd21d12d40893" continuedAt="Text_048743c7ba724640ad34cd21d12d40894"><ix:continuation id="Text_8986426e4c204b5093177cfc0d67e98816" continuedAt="Text_8986426e4c204b5093177cfc0d67e98817">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br class="Apple-interchange-newline"/>
          </span></div>
</ix:continuation></ix:continuation> </div>


        <ix:continuation id="Text_8986426e4c204b5093177cfc0d67e98817" continuedAt="Text_8986426e4c204b5093177cfc0d67e98818">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; margin-left: 9pt;">Other segment items included in segment loss includes interest income and interest
          expense.</div>
</ix:continuation>
        <ix:continuation id="Text_8986426e4c204b5093177cfc0d67e98818" continuedAt="Text_8986426e4c204b5093177cfc0d67e98819">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify;"><br/>
        </div>
</ix:continuation>
        <ix:continuation id="Text_8986426e4c204b5093177cfc0d67e98819" continuedAt="Text_8986426e4c204b5093177cfc0d67e98820">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; margin-left: 9pt;">The Company is a <span style="-sec-ix-hidden:Fact_600409bbedd14e1db752c48e58053e6c">single</span> operating segment and therefore the measure of segment net loss is the same as consolidated net loss and does not require reconciliation.</div>
</ix:continuation>
        <ix:continuation id="Text_8986426e4c204b5093177cfc0d67e98820" continuedAt="Text_8986426e4c204b5093177cfc0d67e98821">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify;"><br/>
        </div>
</ix:continuation>
        <ix:continuation id="Text_8986426e4c204b5093177cfc0d67e98821" continuedAt="Text_8986426e4c204b5093177cfc0d67e98822">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; margin-left: 9pt;">For the years ended December 31, 2024 and 2023, the net cash used in operating
          activities was $<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" id="Fact_25fb5f3ed0d84387a90b3ec18b0d1682" contextRef="c20240101to20241231" unitRef="U001" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal">41.8</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" id="Fact_088703719ea741dab3aa13c1dd15b714" contextRef="c20230101to20231231" unitRef="U001" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal">33.0</ix:nonFraction>
          million, respectively. <ix:continuation id="Text_048743c7ba724640ad34cd21d12d40894" continuedAt="Text_048743c7ba724640ad34cd21d12d40895"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: 400;">The

















          table below summarizes the significant asset categories regularly reviewed by the CODM for the years ended December 31, 2024 and 2023 (in thousands).</span></ix:continuation></div>
</ix:continuation>
        <ix:continuation id="Text_8986426e4c204b5093177cfc0d67e98822" continuedAt="Text_8986426e4c204b5093177cfc0d67e98823"><ix:continuation id="Text_048743c7ba724640ad34cd21d12d40895" continuedAt="Text_048743c7ba724640ad34cd21d12d40896">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify;"> <span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
          </span></div>
</ix:continuation></ix:continuation>
        <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; margin-left: 9pt;">
          <ix:continuation id="Text_8986426e4c204b5093177cfc0d67e98823"><ix:continuation id="Text_048743c7ba724640ad34cd21d12d40896">
<table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="background-color: rgb(255, 255, 255); letter-spacing: normal; word-spacing: 0px; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: left; text-transform: none; width: 100%; border-spacing: 0;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px;">
                  <div>&#160;</div>
                </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: #000000 solid 2px;">
                  <div style="text-align: center; font-weight: bold;">December 31,</div>
                </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px;">
                  <div>&#160;</div>
                </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: #000000 solid 2px;">
                  <div style="text-align: center; font-weight: bold;"> 2024</div>
                </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: #000000 solid 2px;">
                  <div style="text-align: center; font-weight: bold;">2023</div>
                </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">
                  <div>&#160;</div>
                </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">
                  <div style="text-align: center; font-weight: bold;">(in thousands)</div>
                </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; background-color: #CCEEFF;">
                  <div>Cash and cash equivalents</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div>$</div>
                </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" id="Fact_b3dcda20666c469ebf83cf4738f4ebba" contextRef="c20241231_StatementBusinessSegmentsAxis_BusinessOperatingSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,120</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div>$</div>
                </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" id="Fact_3475ea7e773b4957aedea5510b8e84c5" contextRef="c20231231_StatementBusinessSegmentsAxis_BusinessOperatingSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">25,660</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
<div>
           <br class="Apple-interchange-newline"/></div>

        </div>

      </div>

    </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">

    <div>
      <ix:nonNumeric name="us-gaap:SubsequentEventsTextBlock" id="Text_ff556bf0ded44d3090d6f92b92e30c13" contextRef="c20240101to20241231" escape="true" continuedAt="Text_063ea61236674e6ba96bcf626a5533701">
<div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="text-align: right; vertical-align: top; width: 27pt;">
                <div style="text-align: left; font-weight: bold;"><span style="font-size: 10pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">16.</span></div>
              </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                <div style="text-align: left; font-weight: bold;"><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Subsequent







































                    Event</span></div>
              </td>

  </tr>


</table>
      </div>
</ix:nonNumeric>
      <ix:continuation id="Text_063ea61236674e6ba96bcf626a5533701" continuedAt="Text_063ea61236674e6ba96bcf626a5533702">
<div>&#160;</div>
</ix:continuation>
      <ix:continuation id="Text_063ea61236674e6ba96bcf626a5533702" continuedAt="Text_063ea61236674e6ba96bcf626a5533703">
<div style="display:none;"><br/></div>
<div style="margin: 0px 0px 0px 22.5pt; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 0pt;">On March 31, 2025, the Company and Richard E. Uihlein (the &#8220;Lender&#8221;) entered into a Supplemental Line of Credit Letter
        Agreement (the &#8220;March 2025 Supplemental Credit Agreement&#8221;), pursuant to which the Lender shall provide the Company a line of credit of up to $<ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" id="Fact_9ff5590ec19e41b082eb6c32a2819584" contextRef="c20250331_CreditFacilityAxis_SupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">5.0</ix:nonFraction>
        million (the &#8220;Supplemental Line of Credit&#8221;) to finance the Company&#8217;s working capital needs. The Company may draw upon the Supplemental Line of Credit through September 30, 2025. In connection with entering into the March 2025 Supplemental Line of
        Credit, the Company agreed to extend the maturity date of the Convertible Promissory Note dated April 16, 2021 from April 16, 2025 to September 30, 2025.<br/>
        &#160;<br/>
        Each advance made pursuant to the March 2025 Supplemental Credit Agreement shall be evidenced by an unsecured, convertible promissory note (individually, a &#8220;Promissory Note,&#8221; and collectively, the &#8220;Promissory Notes&#8221;), and bear interest at the
        Applicable Federal Rate for short term loans, plus two (<ix:nonFraction name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" id="Fact_99eb0659c6b244d582c21e49a6c1296c" contextRef="c20250331to20250331_CreditFacilityAxis_SupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">2</ix:nonFraction>%) percent. Principal and interest on the Promissory Notes are due on or before
        <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" id="Fact_d7a54f584b344b389e128cb8a26f506c" contextRef="c20250331to20250331_CreditFacilityAxis_SupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" format="ixt:date-monthname-day-year-en">March 31, 2026</ix:nonNumeric>. Only with the consent of the Lender, may the Promissory Notes be prepaid, in whole or in part, at any time without
        premium or penalty, but with interest on the amount or amounts prepaid.<br/>
        &#160;<br/>
        At the election of Lender, the principal and accrued interest on Promissory Note(s) may be converted into the number of shares of the Company&#8217;s Common Stock equal to the amount of principal and accrued interest on such Promissory Note divided by
        the price equal to the closing price of the Common Stock on the date of such Promissory Note, but in no event less than $<ix:nonFraction name="us-gaap:SharePrice" id="Fact_753ae85d05ed4c0eb0df30f4d2d90cac" contextRef="c20250331_CreditFacilityAxis_SupplementalLineOfCreditMember_RangeAxis_MinimumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.00</ix:nonFraction> per share.<br/>
        &#160;<br/>
      </div>
</ix:continuation>
      <ix:continuation id="Text_063ea61236674e6ba96bcf626a5533703">
<div style="display:none;"><br/></div>
<div style="margin: 0px 0px 0px 22.5pt; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 0pt;">In connection with the March 2025 Supplemental Credit Agreement, the Company agreed to issue the Lender warrants to purchase
        up to an aggregate of <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" id="Fact_a17636b659f14fb382629a8c30cf2b65" contextRef="c20250331_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">100,000</ix:nonFraction> shares of the Company&#8217;s common stock, par value $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact_16e8af0735bc43b3a9b610610da179d0" contextRef="c20250331_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember" unitRef="U003" decimals="3" scale="0" format="ixt:num-dot-decimal">0.001</ix:nonFraction> per share (collectively, the &#8220;Warrants&#8221;).&#160; The Company shall issue to the Lender Warrants ratably, upon borrowings under the March 2025 Supplemental Line of Credit, with exercise
        prices equal to <ix:nonFraction name="galt:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock" id="Fact_962e92b51d5342af800b4e0ae2c1845d" contextRef="c20250331_CreditFacilityAxis_SupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">150</ix:nonFraction>% of the closing price of the Company&#8217;s common Stock on the date of the Promissory Note evidencing such draw, but in
        no event more than $<ix:nonFraction name="us-gaap:SharePrice" id="Fact_f8da07e5a1554ef285c8d23f3fb739da" contextRef="c20250331_CreditFacilityAxis_SupplementalLineOfCreditMember_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction> per share nor less than $<ix:nonFraction name="us-gaap:SharePrice" id="Fact_0759277438274f3cb9f267a88d183a04" contextRef="c20250331_CreditFacilityAxis_SupplementalLineOfCreditMember_RangeAxis_MinimumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.00</ix:nonFraction> per share. The Warrants expire on <ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" id="Fact_63802ca3daa149fdb3fba6c34c346c4c" contextRef="c20250331_CreditFacilityAxis_SupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember" format="ixt:date-monthname-day-year-en">July 31, 2029</ix:nonNumeric>. </div>
</ix:continuation>

      <div>&#160;</div>

      <div style="text-align: center;"><span style="font-size: 8pt;"> F-26</span><br/>
      </div>

      <div style="text-align: center;">
        <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/></div>

    </div>


  </div>
</div>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.21
<SEQUENCE>2
<FILENAME>ef20039001_ex10-21.htm
<DESCRIPTION>EXHIBIT 10.21
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc
         Document created using Broadridge PROfile 25.3.1.5296
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
  <div>
    <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Exhibit 10.21</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">MARCH 2025 SUPPLEMENTAL LINE OF CREDIT LETTER AGREEMENT</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt;">March 31, 2025</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: left; text-indent: -4.5pt; margin-left: 4.5pt; font-family: 'Times New Roman'; font-size: 10pt;">GALECTIN THERAPEUTICS, INC.</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">4960 Peachtree Industrial Blvd., Suite 240</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Norcross, Georgia 30071</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Directors and Officers of Galectin Therapeutics, Inc.:</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">This letter agreement supplements<font style="font-family: 'Times New Roman'; font-weight: bold;">&#160;</font>that certain Line of Credit Agreement, dated
      as of July 25 2022, the (&#8220;<font style="font-family: 'Times New Roman';"><u>Line of Credit Agreement</u></font>&#8221;), that certain Supplemental Line of Credit Letter Agreement, dated as of March 29, 2024, (the &#8220;Supplemental Line of Credit Agreement&#8221;),
      and that certain November 2024 Supplemental Line of Credit Agreement, dated as of November 14, 2024 (the &#8220;November 2024 Supplemental Line of Credit&#8221;) between Galectin Therapeutics, Inc., a Nevada corporation (the &#8220;<font style="font-family: 'Times New Roman';"><u>Company</u></font>&#8221;) and Richard E. Uihlein, an individual resident of the State of Illinois.&#160; This letter agreement (the &#8220;<font style="font-family: 'Times New Roman';"><u>March 2025</u></font>&#160;<font style="font-family: 'Times New Roman';"><u>Supplemental Line of Credit Agreement</u></font>&#8221;) confirms Uihlein&#8217;s commitment to provide the Company with a line of credit of $5,000,000 (the &#8220;<font style="font-family: 'Times New Roman';"><u>March 2025 Supplemental</u></font>&#160;<font style="font-family: 'Times New Roman';"><u>Line of Credit</u></font>&#8221;), which is in addition to the $60,000,000 that was established under the Line of Credit Agreement, the $10,000,000 that was established under the Supplemental Line of Credit
      Agreement, and the $6,000,000 that was established under the November Supplemental Line of Credit.&#160; The March 2025 Supplemental Line of Credit, subject to the restrictions outlined below, is available to finance the Company&#8217;s working capital needs in
      the amount of $5,000,000.</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Each advance made pursuant to the March 2025 Supplemental Line of Credit by Uihlein shall be evidenced by an unsecured Promissory Note substantially
      in the form of <font style="font-family: 'Times New Roman';"><u>Exhibit A</u></font> attached hereto (each, a &#8220;<font style="font-family: 'Times New Roman';"><u>Promissory Note</u></font>&#8221;), executed by a duly authorized officer of the Company, which
      shall represent the Company&#8217;s obligation to pay the principal amount of such advance with interest thereon.&#160; Uihlein shall make requested advances promptly after a draw is submitted by the Company. The March 2025 Supplemental Line of Credit may be
      drawn upon through September 30, 2025, through draws no more frequently than monthly.&#160; As set forth therein, the Promissory Notes shall bear interest (based upon the principal amount outstanding from time to time) payable on or before March 31, 2026,
      at the Applicable Federal Rate for short term loans published by the Internal Revenue Service as may be in effect at the time of such applicable advance, which interest rate on the date hereof is 4.22%, plus two (2%) percent. Interest on the
      Promissory Notes will compound monthly and accrue. The Promissory Notes may not be prepaid without the consent of Uihlein.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The Company may only draw on the March 2025 Supplemental Line of Credit after the Company has drawn on the maximum amount available for borrowing
      under the Line of Credit Agreement, the Supplemental Line of Credit Agreement, and the November 2024 Supplemental Line of Credit.&#160; The date and amount of any borrowing pursuant to the March 2025&#160; Supplemental Line of Credit and each payment of
      principal in respect thereof shall be (i) reflected by the Company on <font style="font-family: 'Times New Roman';"><u>Schedule 1</u></font> attached hereto, which <font style="font-family: 'Times New Roman';"><u>Schedule 1</u></font> shall be
      amended by the Company from time to time, without any further action by Uihlein, to reflect each new advance pursuant to the March 2025 Supplemental Line of Credit.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <!--PROfilePageNumberReset%Num%2%%%-->
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">At the election of Uihlein, the principal and accrued interest on a Promissory Note may be converted into the number of shares of the Company&#8217;s common
      stock (the &#8220;<font style="font-family: 'Times New Roman';"><u>Common Stock</u></font>&#8221;) equal to the amount of principal and accrued interest on such Promissory Note divided by the price equal to the closing price of the Common Stock on the date of
      such Promissory Note, but in no event less than $3.00 per share.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">In consideration for making draws under the March 2025 Supplemental Line of Credit, the Company shall issue warrants to Uihlein, exercisable to
      purchase an aggregate of 100,000 shares of Common Stock (collectively, the &#8220;<font style="font-family: 'Times New Roman';"><u>Warrants</u></font>&#8221;) in substantially the form attached hereto as <font style="font-family: 'Times New Roman';"><u>Exhibit
          B</u></font>.&#160; The Company shall issue Uihlein Warrants that are exercisable to purchase the Common Shares, ratably, at the time of the draws, with exercise prices equal to 150% of the closing price of the Common Stock on the date of the
      Promissory Note evidencing such draw, but in no event more than $10.00 per share nor less than $3.00 per share. For example, if $1,000,000 has been advanced on the March 2025 Supplemental Line of Credit in the aggregate, then the Company will issue
      Uihlein a Warrant exercisable to purchase 20,000 shares of Common Stock. The Warrants expire on July 31, 2029.</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Additionally, as consideration for entering into the March 2025 Supplemental Line of Credit, the Company agrees to extend the maturity date of the
      Unsecured Convertible Promissory Note dated April 16, 2021 from April 16, 2025 to September 30, 2025. </div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Any shares of Common Stock issued to Uihlein upon conversion of a Promissory Note shall be accompanied by registration rights whereby the Company
      shall agree to register the shares of Common Stock with the Securities and Exchange Commission (the &#8220;<font style="font-family: 'Times New Roman';"><u>SEC</u></font>&#8221;) within 180 days of the conversion of a Promissory Note.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">In the event that the Company on or after March 31, 2025 raises additional capital from at-the-market sales, other financings, exercise of warrants or
      options, from license or similar fees received from pharmaceutical or other companies or from strategic or financial partnerships or ventures (collectively, &#8220;<font style="font-family: 'Times New Roman';"><u>Other Funding</u></font>&#8221;) then Uihlein
      may, at his election, within 30 days of an Other Funding, reduce the size of the March 2025 Supplemental Line of Credit on a dollar for dollar basis determined by the amount of the Other Funding actually received, but in no event may Uihlein elect to
      reduce the size of the March 2025 Supplemental Line of Credit below the amount that is then drawn under this March 2025 Supplemental Line of Credit Agreement and provided further that Uihlein shall not reduce the size of the March 2025 Supplemental
      Line of Credit on account of Other Funding to the extent such Other Funding has resulted in reductions under the Line of Credit Agreement. Furthermore, the Company agrees that (i) in the event the Company closes on one or more Other Fundings through
      a debt financing, where terms of such debt financing is more favorable to lender than those of this March 2025 Supplemental Line of Credit Agreement, then Uihlein shall have the right to amend this March 2025 Supplemental Line of Credit Agreement so
      that the terms herein are at least as favorable as such debt financing or (ii) in the event of the Company closes on one or more Other Fundings through an equity financing, then Uihlein shall have the right to participate in such equity financing for
      up to $6,000,000, and the dollar amount by which Uihlein shall participate in such equity financing shall reduce Uihlein&#8217;s commitment under the March 2025 Supplemental Line of Credit.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The Company agrees that so long as any Promissory Note is outstanding the Company will not grant a security interest in the material assets of the
      Company to any person or entity.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">2</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">No other document shall evidence the indebtedness of Uihlein which may be created pursuant to the terms of this March 2025 Supplemental Line of Credit
      Agreement, other than the Promissory Note.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">[signatures on the following page]</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">3</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">This March 2025 Supplement Line of Credit Agreement shall be governed by, construed and interpreted in accordance with the laws of the State of
      Georgia.</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" id="zb29d18bd968a4a6e80a8900fa17a4cac" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 60%; vertical-align: top; font-size: 10pt;"><br>
          </td>
          <td style="width: 40%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: justify; font-family: 'Times New Roman';">Very truly yours,</div>
          </td>
        </tr>
        <tr>
          <td style="width: 60%; vertical-align: top; font-size: 10pt;"><br>
          </td>
          <td style="width: 40%; vertical-align: top; font-size: 10pt;"><br>
          </td>
        </tr>
        <tr>
          <td style="width: 60%; vertical-align: top; font-size: 10pt;"><br>
          </td>
          <td style="width: 40%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: justify; font-family: 'Times New Roman';">/s/ Richard E. Uihlein</div>
          </td>
        </tr>
        <tr>
          <td style="width: 60%; vertical-align: top; font-size: 10pt;"><br>
          </td>
          <td style="width: 40%; vertical-align: top; font-size: 10pt;"><br>
          </td>
        </tr>
        <tr>
          <td style="width: 60%; vertical-align: top; font-size: 10pt;"><br>
          </td>
          <td style="width: 40%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: justify; font-family: 'Times New Roman';">Richard E. Uihlein</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;"><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z06dcfa94fd834a43806d921e05e0da42" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 100%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: justify; font-family: 'Times New Roman';">Agreed and accepted as of</div>
          </td>
        </tr>
        <tr>
          <td style="width: 100%; vertical-align: top; font-size: 10pt;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 100%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: justify; font-family: 'Times New Roman';">March 31, 2025</div>
          </td>
        </tr>
        <tr>
          <td style="width: 100%; vertical-align: top; font-size: 10pt;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 100%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: justify; font-family: 'Times New Roman';">GALECTIN THERAPEUTICS, INC.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 33.33%; vertical-align: top; font-size: 10pt;" rowspan="1">&#160;&#160;&#160;</td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 3%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: justify; font-family: 'Times New Roman';">By:</div>
          </td>
          <td style="width: 32%; vertical-align: top; border-bottom: 2px solid black; font-size: 10pt;">
            <div style="text-align: justify; font-family: 'Times New Roman'; margin-left: 9pt;">/s/ Joel Lewis</div>
          </td>
          <td style="width: 65%; vertical-align: top; font-size: 10pt;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top; font-size: 10pt;" rowspan="1" colspan="2">
            <div style="text-align: justify; font-family: 'Times New Roman';">Name: Joel Lewis</div>
          </td>
          <td style="width: 65%; vertical-align: top; font-size: 10pt;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top; font-size: 10pt;" rowspan="1" colspan="2">
            <div style="text-align: left; font-family: 'Times New Roman';">Title:&#160; Chief Executive Officer</div>
          </td>
          <td style="width: 65%; vertical-align: top; font-size: 10pt;">&#160;</td>
        </tr>

    </table>
    <div style="font-size: 10pt;"><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">4</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>SCHEDULE 1</u></div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">SCHEDULE OF ADVANCES</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" id="z7e923ce89d38429db30ff8063a49ec9f" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 20%; vertical-align: bottom; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';"><u>Date</u></div>
          </td>
          <td style="width: 20%; vertical-align: bottom; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';"><u>Lender</u></div>
          </td>
          <td nowrap="nowrap" style="width: 20%; vertical-align: bottom;">
            <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Amount</div>
            <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">of</div>
            <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"><u>Advance</u></div>
          </td>
          <td nowrap="nowrap" style="width: 20%; vertical-align: bottom;">
            <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Unpaid</div>
            <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Aggregate</div>
            <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"> Principal</div>
            <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"><u>Balance</u></div>
          </td>
          <td style="width: 20%; vertical-align: bottom;">
            <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Notation</div>
            <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"><u>Made By</u></div>
          </td>
        </tr>
        <tr>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
        </tr>
        <tr>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
        </tr>
        <tr>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
        </tr>
        <tr>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
        </tr>
        <tr>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
        </tr>
        <tr>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
        </tr>
        <tr>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
        </tr>
        <tr>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
        </tr>
        <tr>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
        </tr>
        <tr>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
        </tr>
        <tr>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
        </tr>
        <tr>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
        </tr>
        <tr>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
        </tr>
        <tr>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
        </tr>
        <tr>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
        </tr>
        <tr>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
        </tr>
        <tr>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
        </tr>
        <tr>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
        </tr>
        <tr>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
        </tr>
        <tr>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
        </tr>
        <tr>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
        </tr>
        <tr>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
        </tr>
        <tr>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">__________</div>
          </td>
        </tr>

    </table>
    <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> </font><font style="font-size: 10pt;"><br>
      </font></div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>EXHIBIT A</u></div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">FORM OF CONVERTIBLE PROMISSORY NOTE</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">CONVERTIBLE PROMISSORY NOTE</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" id="z2c564910262c4cfba0a5e209ab6d4885" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 1%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;">
            <div style="text-align: justify; font-family: 'Times New Roman';">$</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);"><br>
          </td>
          <td style="width: 79%; vertical-align: top; font-size: 10pt; text-align: right; padding-bottom: 2px;">&#160;Atlanta, Georgia</td>
        </tr>

    </table>
    <div style="text-align: right; text-indent: 288pt; font-family: 'Times New Roman'; font-size: 10pt;">Dated as of ___, 2024</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">FOR VALUE RECEIVED, the undersigned, GALECTIN THERAPEUTICS, INC., a Nevada corporation (the &#8220;<font style="font-family: 'Times New Roman';"><u>Company</u></font>&#8221;),

      hereby unconditionally promises to pay to the order of Richard E. Uihlein, an individual resident of the State of Illinois (&#8220;<font style="font-family: 'Times New Roman';"><u>Lender</u></font>&#8221;), whose office address is 12575 Uline Drive, Pleasant
      Prairie, WI 53158, on [March 31, 2026], in lawful money of the United States of America and in immediately available funds, the principal amount of (a) _____________________ DOLLARS ($_______________).&#160; The Company further agrees to pay interest in
      like money at an annual rate of ______% [the Applicable Federal Rate for short term loans as may be in effect on the date of the Promissory Note as published by the Internal Revenue Service plus two (2%) percent] on the unpaid principal amount hereof
      from time to time outstanding, which shall compound monthly and accrue commencing on the date hereof and continuing until paid in full on March 31, 2026 or sooner prepaid.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">This Promissory Note is made pursuant to that certain March 2025 Supplemental Line of Credit Letter Agreement, dated as of March 31, 2024, by and
      between Lender and the Company, and the Company and the Lender are entitled to the benefits and obligations thereof.&#160; Only with the consent of Lender, this Promissory Notes may be prepaid, in whole or in part, at any time without premium or penalty,
      but with interest on the amount prepaid..</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">At the election of Lender, the principal and accrued interest on this Promissory Note may be converted into the number of shares of the Company&#8217;s
      common stock (the &#8220;<font style="font-family: 'Times New Roman';"><u>Common Stock</u></font>&#8221;) equal to the amount of principal and accrued interest on this Promissory Note divided by the price equal to the closing price of the Common Stock on the
      date of this Promissory Note.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">The Company, for itself and all other persons who now are or who may become liable for the payment of all or any part of the obligations evidenced by
      this Promissory Note, jointly, severally and irrevocably, hereby waives presentment for payment, demand, protest, notice of protest, notice of dishonor and any and all other notices and demands whatsoever.&#160; The Company shall pay all costs and
      expenses of collection, including, without limitation, reasonable attorneys&#8217; fees except to the extent limited or prohibited by law.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">No act, omission, or other failure on the part of Lender or any holder of this Note to exercise any right, remedy or recourse hereunder with respect
      to the Company, whether before or after the occurrence of a default, shall constitute waiver or release of any such right, remedy, recourse, default by such holder or on behalf of any other holder; such waiver or release to be effected only through a
      written document executed by Lender or such holder and then only to the extent specifically recited therein.&#160; A waiver or release with reference to any one event shall not be construed as continuing, as a bar to, or as a waiver or release of, any
      subsequent right, remedy or recourse as to a subsequent event.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <!--PROfilePageNumberReset%Num%2%%%-->
    <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">This Promissory Note shall be governed by, construed and interpreted in accordance with the laws of the State of Georgia.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" border="0" id="z0cd2f4f8fa6d42c89014fd23a38d1e62" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="vertical-align: top; font-size: 10pt;" colspan="3">
            <div style="text-align: justify; font-family: 'Times New Roman';">GALECTIN THERAPEUTICS, INC.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 3%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="vertical-align: top; font-size: 10pt;" colspan="2">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;">&#160;</td>
          <td style="width: 3%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;">
            <div style="text-align: justify; font-family: 'Times New Roman';">By:</div>
          </td>
          <td style="width: 32%; vertical-align: top; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 15%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;">&#160;</td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 5%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: justify; font-family: 'Times New Roman';">Name:</div>
          </td>
          <td style="width: 45%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: justify; font-family: 'Times New Roman';">Joel Lewis</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 5%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';">Title:</div>
          </td>
          <td style="width: 45%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';">Chief Executive Officer</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;"><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">2</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>EXHIBIT B</u></div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">FORM OF COMMON STOCK PURCHASE WARRANT</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">NEITHER THIS WARRANT CERTIFICATE NOR THE WARRANTS REPRESENTED HEREBY NOR ANY SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF SUCH WARRANTS, NOR ANY INTEREST IN OR
      RIGHTS UNDER SAME, HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 OR THE LAWS OF ANY STATE, AND NEITHER THIS WARRANT CERTIFICATE NOR THE WARRANTS REPRESENTED HEREBY NOR ANY SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF SUCH WARRANTS,
      NOR ANY INTEREST IN OR RIGHTS UNDER SAME, MAY BE SOLD OR OTHERWISE TRANSFERRED UNLESS REGISTERED UNDER SUCH ACT AND APPLICABLE STATE SECURITIES LAWS OR AN EXEMPTION FROM REGISTRATION IS AVAILABLE.</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt;">Warrant No. 2025-1</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">GALECTIN THERAPEUTICS, INC.</div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">COMMON STOCK PURCHASE WARRANT</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: left; text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">Galectin Therapeutics, Inc., a Nevada corporation (the &#8220;Company&#8221;), for value received and subject to the terms set forth below hereby grants to Richard
      E. Uihlein, or its registered successors and assigns (the &#8220;Holder&#8221;), the right to purchase from the Company at any time or from time to time until the date and time permitted under Section 2.1 below, ___________ (__________) fully paid and
      non-assessable shares of the Common Stock, at the purchase price of $_____ per share (the &#8220;Exercise Price&#8221;). This Warrant is issued pursuant to that certain March 2025 Supplemental Line of Credit Letter Agreement, dated as of March 31, 2025, by and
      between the Company and the Holder (the &#8220;March 2025 Supplemental Line of Credit Letter Agreement&#8221;).&#160; The Exercise Price and the number and character of such shares of Common Stock purchasable pursuant to the rights granted under this Warrant are
      subject to adjustment as provided herein.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">1. Definitions. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in the March 2025 Supplemental Line of Credit Letter Agreement. As
      used herein the following terms, unless the context otherwise requires, have the following respective meanings:</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">&#8220;Common Stock&#8221; </font><font style="font-size: 10pt;">means the Company&#8217;s common stock and stock of any other class of securities into which such securities may hereafter have been reclassified or changed into, including any stock (other than Common Stock) and other securities of the Company or
        any other Person (corporate or other) which the Holder of this Warrant at any time shall be entitled to receive, or shall have received, upon the exercise of this Warrant, in lieu of or in addition to Common Stock, or which at any time shall be
        issuable or shall have been issued in exchange for or in replacement of Common Stock pursuant to Section 3.2 hereof or otherwise.</font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;">Common Stock Equivalents</font>&#8221; means any securities of the
      Company or its subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or
      exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;">Issue Date&#8221; </font>means __________.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">3</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: left; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;">Market Value</font>&#8221; means, for any date, the price determined by
      the first of the following clauses that applies:&#160; (a) if the Common Stock is then listed or quoted on a Trading Market (other than the OTC Bulletin Board), the daily volume weighted average price of the Common Stock for such date (or the nearest
      preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg Financial L.P. (based on a Trading Day from 9:30 a.m. Eastern Time to 4:00 p.m. Eastern Time); (b) if the Common Stock is then listed or
      quoted on the OTC Bulletin Board, the average of the high and low price of the Common Stock for such date (or the nearest preceding date) on the OTC Bulletin Board; or (c) if the Common Stock is not then listed or quoted on a Trading Market and if
      prices for the Common Stock are then reported in the &#8220;Pink Sheets&#8221; published by the Pink Sheets, LLC (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so
      reported.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">&#8220;This Warrant&#8221; </font><font style="font-size: 10pt;">means, collectively, this Warrant and all other stock purchase warrants issued in exchange therefor or replacement thereof.</font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;">Trading Day</font>&#8221; means a day on which the common Stock is traded
      on a Trading Market.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;">Trading Market</font>&#8221; means any of the following markets or
      exchanges on which the common Stock is listed or quoted for trading on the date in question: the Nasdaq Stock Market, the New York Stock Exchange, the OTC Bulletin Board or the &#8220;Pink Sheets&#8221;.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">2. Exercise.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">2.1 Exercise Period. The Holder may exercise this Warrant at any time after the Issue Date and before the close of business in Norcross, Georgia on
      July 31, 2029 (the &#8220;Exercise Period&#8221;), unless earlier terminated pursuant to Section 3.2 herein.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">2.2 Exercise Procedure.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">(a) This Warrant will be deemed to have been exercised at such time as the Company has received all of the following items (the &#8220;Exercise Date&#8221;):</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; text-indent: 24.5pt; margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">(i) a completed Exercise Notice as described in Section 2.4 hereof, executed by the Person exercising all or part of the purchase
      rights represented by this Warrant (the &#8220;Purchaser&#8221;);</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; text-indent: 24.5pt; margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">(ii) this Warrant;</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; text-indent: 24.5pt; margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">(iii) if this Warrant is not registered in the name of the Purchaser, an Assignment or Assignments in the form set forth in
      Exhibit B hereto, evidencing the assignment of this Warrant to the Purchaser together with any documentation required pursuant to Section 8(a) hereof; and</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; text-indent: 24.5pt; margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">(iv) a check payable to the order of the Company in an amount equal to the product of the Exercise Price multiplied by the number
      of shares of Common Stock being purchased upon such exercise.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">(b) As soon as practicable after the exercise of this Warrant in full or in part, and in any event within ten (10) days after the Exercise Date, the
      Company at its expense will cause to be issued in the name of and delivered to the Purchaser, or as the Purchaser (upon payment by the Purchaser of any applicable transfer taxes) may direct, a certificate or certificates for the number of fully paid
      and non-assessable shares of Common Stock to which the Purchaser shall be entitled upon such exercise, together with any other stock or other securities and property (including cash, where applicable) to which the Purchaser is entitled upon exercise.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">4</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: left; text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">(c) Unless this Warrant has expired or all of the purchase rights represented hereby have been exercised, the Company at its expense will, within ten
      (10) days after the Exercise Date, issue and deliver to or upon the order of the Purchaser a new Warrant or Warrants of like tenor, in the name of the Purchaser or as the Purchaser (upon payment by the Purchaser of any applicable transfer taxes) may
      request, calling in the aggregate on the face or faces thereof for the number of shares of Common Stock remaining issuable under this Warrant.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">(d) The Common Stock issuable upon the exercise of this Warrant will be deemed to have been issued to the Purchaser on the Exercise Date, and the
      Purchaser will be deemed for all purposes to have become the record holder of such Common Stock on the Exercise Date.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">(e) The issuance of certificates for shares of Common Stock upon exercise of this Warrant will be made without charge to the Holder or the Purchaser
      for any issuance tax in respect thereof or any other cost incurred by the Company in connection with such exercise and the related issuance of shares of Common Stock.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">(f) The holder represents and warrants that at the time of any exercise of this warrant the holder is an &#8220;accredited investor,&#8221; as such term is defined
      in Rule 501 promulgated under the Securities Act and acknowledges and agrees that the Company may, in its sole discretion, (i) require, as a condition to the exercise of this Warrant, that the holder provide such written evidence that such holder is
      an accredited investor as the time of exercise, and (ii) decline to issue the shares of Common Stock issuable upon such exercise if the Company is not satisfied that this warrant may be exercised by the holder pursuant to a valid registration
      exemption from the Securities Act and any applicable state securities law.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">2.3 Acknowledgement of Continuing Obligations. The Company will, at the time of the exercise of this Warrant, upon the request of the Purchaser,
      acknowledge in writing its continuing obligation to afford to the Purchaser any rights to which the Purchaser shall continue to be entitled after such exercise in accordance with the provisions of this Warrant, provided that if the Purchaser shall
      fail to make any such request, such failure shall not affect the continuing obligation of the Company to afford to the Purchaser any such rights.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">2.4 Exercise Notice. The Exercise Notice will be substantially in the form set forth in Exhibit A hereto, except that if the shares of Common Stock
      issuable upon exercise of this Warrant are not to be issued in the name of the Purchaser, the Exercise Notice will also state the name of the Person to whom the certificates for the shares of Common Stock are to be issued, and if the number of shares
      of Common Stock to be issued does not include all the shares of Common Stock issuable hereunder, it will also state the name of the Person to whom a new Warrant for the unexercised portion of the rights hereunder is to be delivered.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">2.5 Fractional Shares. If a fractional share of Common Stock would, but for the provisions of Section 2.1 hereof, be issuable upon exercise of the
      rights represented by this Warrant, the Company will, within ten (10) days after the Exercise Date, deliver to the Purchaser a check payable to the Purchaser in lieu of such fractional share, in an amount equal to the Market Value of such fractional
      share as of the close of business on the Exercise Date.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">5</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">3. Adjustments.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">3.1 Adjustments for Stock Splits, Etc. If the Company shall at any time after the Issue Date subdivide its outstanding Common Stock, by split-up or
      otherwise, or combine its outstanding Common Stock, or issue additional shares of its capital stock in payment of a stock dividend in respect of its Common Stock, the number of shares issuable on the exercise of the unexercised portion of this
      Warrant shall forthwith be proportionately increased in the case of a subdivision or stock dividend, or proportionately decreased in the case of a combination, and the Exercise Price then applicable to shares covered by the unexercised portion of
      this Warrant shall forthwith be proportionately decreased in the case of a subdivision or stock dividend, or proportionately increased in the case of combination.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">3.2 Adjustment for Reclassification, Reorganization, Etc. In case of any reclassification, capital reorganization, or change of the outstanding Common
      Stock (other than as a result of a subdivision, combination or stock dividend), or in the case of any consolidation of the Company with, or merger of the Company into, another Person (other than a consolidation or merger in which the Company is the
      continuing corporation and which does not result in any reclassification or change of the outstanding Common Stock of the Company), or in case of any sale or conveyance to one or more Persons of the property of the Company as an entirety or
      substantially as an entirety at any time prior to the expiration of this Warrant, then, as a condition of such reclassification, reorganization, change, consolidation, merger, sale or conveyance, lawful provision shall be made, and duly executed
      documents evidencing the same from the Company or its successor shall be delivered to the Holder of this Warrant, so that the Holder of this Warrant shall have the right at any time prior to the expiration of this Warrant to purchase, at a total
      price not to exceed that payable upon the exercise of the unexercised portion of this Warrant, the kind and amount of shares of stock and other securities and property receivable upon such reclassification, reorganization, change, consolidation,
      merger, sale or conveyance by a holder of the number of shares of Common Stock of the Company as to which this Warrant was exercisable immediately prior to such reclassification, reorganization, change, consolidation, merger, sale or conveyance, and
      in any such case appropriate provision shall be made with respect to the rights and interests of the Holder of this Warrant to the end that the provisions hereof (including, without limitation, provisions for the adjustment of the Exercise Price and
      of the number of shares purchasable upon exercise of this Warrant) shall thereafter be applicable in relation to any shares of stock, and other securities and property, thereafter deliverable upon exercise hereof. If, as a consequence of any such
      transaction, solely cash, and no securities or other property of any kind, is deliverable upon exercise of this Warrant, then, in such event, the Company may terminate this Warrant by giving the Holder hereof written notice thereof. Such notice shall
      specify the date (at least thirty (30) days subsequent to the date on which notice is given) on which, at 3:00 P.M., Norcross, Georgia time, this Warrant shall terminate. Notwithstanding any such notice, this Warrant shall remain exercisable, and
      otherwise in full force and effect, until such time of termination.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">3.3 Certificate of Adjustment. Whenever the Exercise Price or the number of shares issuable hereunder is adjusted, as herein provided, the Company
      shall promptly deliver to the registered Holder of this Warrant a certificate of the Treasurer of the Company, which certificate shall state (i) the Exercise Price and the number of shares of Common Stock issuable hereunder after such adjustment,
      (ii) the facts requiring such adjustment, and (iii) the method of calculation for such adjustment and increase or decrease.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">3.4 Small Adjustments<font style="font-family: 'Times New Roman'; font-style: italic;">. </font>No adjustment in the Exercise Price shall be required
      unless such adjustment would require an increase or decrease in the Exercise Price of at least one percent; provided, however, that any adjustments which by reason of this Section 3.4 are not required to be made immediately shall be carried forward
      and taken into account at the time of exercise of this Warrant or any subsequent adjustment in the Exercise Price which, singly or in combination with any adjustment carried forward, is required to be made under Sections 3.1 or 3.2<font style="font-family: 'Times New Roman'; font-style: italic;">.</font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">6</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">4. Reservation of Stock, etc., Issuable on Exercise of Warrant<font style="font-family: 'Times New Roman'; font-style: italic;">. </font>The Company will at all times
      reserve and keep available, solely for issuance and delivery upon the exercise of this Warrant, all shares of Common Stock from time to time issuable upon the exercise of this Warrant.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">5. Disposition of This Warrant, Common Stock, Etc.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">(a) The Holder of this Warrant and any transferee hereof or of the Common Stock with respect to which this Warrant may be exercisable, by their
      acceptance hereof, hereby understand and agree that this Warrant and the Common Stock with respect to which this Warrant may be exercisable have not been registered under the Securities Act, and may not be sold, pledged, hypothecated, donated, or
      otherwise transferred (whether or not for consideration) without an effective registration statement under the Act or an opinion of counsel satisfactory to the Company and/or submission to the Company of such other evidence as may be satisfactory to
      counsel to the Company, in each such case, to the effect that any such transfer shall not be in violation of the Act. It shall be a condition to the transfer of this Warrant that any transferee thereof deliver to the Company its written agreement to
      accept and be bound by all of the terms and conditions of this Warrant.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">(b) Except to the extent the resale of the shares of Common Stock issuable upon exercise hereof are registered for resale, or may be sold to the public
      pursuant to Rule 144(b)(1) under the Securities Act, the certificates of the Company that will evidence the shares of Common Stock with respect to which this Warrant may be exercisable will be imprinted with a conspicuous legend in substantially the
      following form:</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#8220;ACT&#8221;), AND MAY NOT BE
      SOLD, PLEDGED, HYPOTHECATED, DONATED OR OTHERWISE TRANSFERRED (WHETHER OR NOT FOR CONSIDERATION) BY THE HOLDER WITHOUT AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY AND/OR SUBMISSION TO THE
      COMPANY OF SUCH OTHER EVIDENCE AS MAY BE SATISFACTORY TO COUNSEL TO THE COMPANY, IN EACH SUCH CASE, TO THE EFFECT THAT ANY SUCH TRANSFER SHALL NOT BE IN VIOLATION OF THE ACT.&#8221;</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">The Company agrees to prepare and file with the Securities Exchange Commission within 180 days from the date of issuance of any shares of Common Stock
      upon exercise of this Warrant.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">6. Rights and Obligations of Warrant Holder<font style="font-family: 'Times New Roman'; font-style: italic;">. </font>The Holder of this Warrant shall not, by virtue
      hereof, be entitled to any voting rights or other rights as a stockholder of the Company. No provision of this Warrant, in the absence of affirmative actions by the Holder to purchase Common Stock of the Company by exercising this Warrant, and no
      enumeration in this Warrant of the rights or privileges of the Holder, will give rise to any liability of such Holder for the Exercise Price of Common Stock acquirable by exercise hereof or as a stockholder of the Company.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">7. Transfer of Warrants<font style="font-family: 'Times New Roman'; font-style: italic;">. </font>Subject to compliance with the restrictions on transfer applicable to
      this Warrant referred to in Section 5 hereof, this Warrant and all rights hereunder are transferable, in whole or in part to other Lenders pursuant to the Line of Credit Letter Agreement, without charge to the registered Holder, upon surrender of
      this Warrant with a properly executed Assignment (in substantially the form attached hereto as Exhibit B), to the Company, and the Company at its expense will issue and deliver to or upon the order of the Holder hereof a new Warrant or Warrants in
      such denomination or denominations as may be requested, but otherwise of like tenor, in the name of the Holder or as the Holder (upon payment of any applicable transfer taxes) may direct.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">7</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">8. Replacement of Warrants<font style="font-family: 'Times New Roman'; font-style: italic;">. </font>Upon receipt of evidence reasonably satisfactory to the Company of the
      loss, theft, destruction or mutilation of any Warrant and, in the case of any such loss, theft or destruction, upon delivery of an indemnity agreement reasonably satisfactory in form and amount to the Company or, in the case of any such mutilation,
      upon surrender and cancellation of such Warrant, the Company at its expense will execute and deliver, in lieu thereof, a new Warrant of like tenor.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">9. Company Records<font style="font-family: 'Times New Roman'; font-style: italic;">. </font>Until this Warrant is transferred on the books of the Company, the Company may
      treat the registered Holder hereof as the absolute owner hereof for all purposes, notwithstanding any notice to the contrary.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">10.&#160; Miscellaneous.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">10.1 Notices. All notices and other communications from the Company to the Holder of this Warrant shall be mailed by first class mail, postage prepaid, to such address as
      may have been furnished to the Company in writing by such Holder, or, until an address is so furnished, to and at the address of the last Holder of this Warrant who has so furnished an address to the Company. All communications from the Holder of
      this Warrant to the Company shall be mailed by first class mail, postage prepaid, to Galectin Therapeutics, Inc., 4960 Peachtree Industrial Boulevard, Suite 240, Norcross, GA 30071, Attn: Chief Financial Officer, or such other address as may have
      been furnished to the Holder in writing by the Company.</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">10.2 Amendment and Waiver. Except as otherwise provided herein, this Warrant and any term hereof may be amended, waived, discharged or terminated only by an instrument in
      writing signed by the party against which enforcement of such amendment, waiver, discharge or termination is sought.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">10.3 Governing Law; Descriptive Headings. This Warrant shall be construed and enforced in accordance with and governed by the laws of the State of Nevada. The headings in
      this Warrant are for purposes of reference only, and shall not limit or otherwise affect any of the terms hereof.</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">[SIGNATURE ON FOLLOWING PAGE]</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">8</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Dated:&#160;&#160; ___________, 2024.</div>
    <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> </font><font style="font-size: 10pt;"><br>
      </font></div>
    <table cellspacing="0" cellpadding="0" border="0" id="z4337643e0b2c4ef18dc6e5b959feea4b" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 49.94%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="vertical-align: top; font-size: 10pt;" colspan="2">
            <div style="text-align: left; font-family: 'Times New Roman';">GALECTIN THERAPEUTICS, INC.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.94%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 5%; vertical-align: middle; font-size: 10pt;">&#160;</td>
          <td style="width: 45%; vertical-align: middle; font-size: 10pt;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 49.94%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;" rowspan="1">&#160;</td>
          <td style="width: 5%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;" rowspan="1">&#160;</td>
          <td style="width: 45%; vertical-align: bottom; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" rowspan="1"><br>
          </td>
        </tr>
        <tr>
          <td style="width: 49.94%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 5%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';">Name:</div>
          </td>
          <td style="width: 45%; vertical-align: bottom; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';">Jack W. Callicutt</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.94%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 5%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';">Title:</div>
          </td>
          <td style="width: 45%; vertical-align: bottom; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';">CFO</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;"><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">9</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">EXHIBIT A</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">EXERCISE NOTICE</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">[To be signed only upon exercise of Warrant]</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" id="z73c66938cc204e6fb00957b502d478c7" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 50%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';">To:</div>
          </td>
          <td style="width: 50%; vertical-align: bottom; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';">Date:</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: left; text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">The undersigned, the Holder of the within Warrant, pursuant to the provisions set forth in the within Warrant, hereby irrevocably elects to exercise
      the purchase rights represented by such Warrant for, and agrees to subscribe for and purchase thereunder, ___________ shares of the Common Stock covered by such Warrant and herewith makes payment of $ _____________ therefor, and requests that the
      certificates for such shares be issued in the name of, and delivered to, ___________________, whose address is: ________________________________.&#160; If said number of shares is less than all the shares covered by such Warrant, a new Warrant shall be
      registered in the name of the undersigned and delivered to the address stated below.</div>
    <div style="text-align: left; text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" id="zf950a5494d634b9593f9b1d320fdfbc0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 15%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';">Signature</div>
          </td>
          <td style="width: 5%; vertical-align: bottom; font-size: 10pt;">&#160;</td>
          <td style="width: 30%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 15%; vertical-align: middle; font-size: 10pt;">&#160;</td>
          <td style="vertical-align: middle; font-size: 10pt;" colspan="2">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 15%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 5%; vertical-align: bottom; font-size: 10pt;">&#160;</td>
          <td style="width: 30%; vertical-align: bottom; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';">(Signature must conform in all respects to name of Holder as specified on the face of the Warrant or on the form of Assignment attached as Exhibit B thereto.)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 15%; vertical-align: middle; font-size: 10pt;">&#160;</td>
          <td style="vertical-align: middle; font-size: 10pt;" colspan="2">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 15%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';">Address</div>
          </td>
          <td style="width: 5%; vertical-align: bottom; font-size: 10pt;">&#160;</td>
          <td style="width: 30%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 15%; vertical-align: middle; font-size: 10pt;">&#160;</td>
          <td style="vertical-align: middle; font-size: 10pt;" colspan="2">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 15%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 5%; vertical-align: bottom; font-size: 10pt;">&#160;</td>
          <td style="width: 30%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="vertical-align: middle; font-size: 10pt;" colspan="3">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="vertical-align: top; font-size: 10pt;" colspan="3">
            <div style="text-align: left; font-family: 'Times New Roman';">[Signature Guarantee]</div>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">10</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">EXHIBIT B</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">ASSIGNMENT</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">[To be signed only upon transfer of Warrant]</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: left; text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">For value received, the undersigned hereby sells, assigns and transfers all of the rights of the undersigned under the within Warrant with respect to
      the number of shares of the Common Stock covered thereby set forth below, unto:</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" id="z30865f1b6eca47edb26d31ee4965e459" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="vertical-align: top; font-size: 10pt;" colspan="3">
            <div style="text-align: left; font-family: 'Times New Roman'; font-style: italic;">Name of Assignee</div>
          </td>
          <td style="width: 42%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-style: italic;">Address</div>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top; font-size: 10pt;" colspan="3">&#160;</td>
          <td style="width: 42%; vertical-align: top; font-size: 10pt;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 18%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-style: italic;">No of Shares:&#160; Warrants</div>
          </td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;">&#160;</td>
          <td style="width: 42%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;">&#160;</td>
        </tr>

    </table>
    <div style="font-size: 10pt;"><br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" id="z9ff474462d934a00b8f6913b28b8d823" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 5%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;">
            <div style="text-align: left; font-family: 'Times New Roman';">Dated:</div>
          </td>
          <td style="width: 25%; vertical-align: top; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 20%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;">&#160;</td>
          <td style="width: 8%; vertical-align: bottom; font-size: 10pt; padding-bottom: 2px;">
            <div style="text-align: left; font-family: 'Times New Roman';">Signature</div>
          </td>
          <td style="width: 42%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align: middle; font-size: 10pt;" colspan="3">&#160;</td>
          <td style="width: 8%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 42%; vertical-align: top; font-size: 10pt;">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align: top; font-size: 10pt;" colspan="3">&#160;</td>
          <td style="width: 8%; vertical-align: bottom; font-size: 10pt;">&#160;</td>
          <td style="width: 42%; vertical-align: bottom; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';">(Signature must conform in all respects to name of Holder as specified on the face of the Warrant.)</div>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: middle; font-size: 10pt;" colspan="3">&#160;</td>
          <td style="width: 8%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 42%; vertical-align: top; font-size: 10pt;">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align: top; font-size: 10pt;" colspan="3">&#160;</td>
          <td style="width: 8%; vertical-align: bottom; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';">Address</div>
          </td>
          <td style="width: 42%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align: top; font-size: 10pt;" colspan="3" rowspan="1">&#160;</td>
          <td style="width: 8%; vertical-align: bottom; font-size: 10pt;" rowspan="1">&#160;</td>
          <td style="width: 42%; vertical-align: bottom; font-size: 10pt;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align: top; font-size: 10pt;" colspan="3" rowspan="1">&#160;</td>
          <td style="width: 8%; vertical-align: bottom; font-size: 10pt;" rowspan="1">&#160;</td>
          <td style="width: 42%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" rowspan="1">&#160;</td>
        </tr>

    </table>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-size: 10pt; text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">11</font></div>
    <div style="font-size: 10pt;">
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19
<SEQUENCE>3
<FILENAME>ef20039001_ex19.htm
<DESCRIPTION>EXHIBIT 19
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc
         Document created using Broadridge PROfile 25.3.1.5296
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <!--PROfilePageNumberReset%Num%1%%%--><font style="font-size: 10pt;"> </font>
  <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
  <div>
    <div style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Exhibit 19</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Galectin Therapeutics Inc.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Amended and Restated Insider Trading Policy</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Adopted by the Board of Directors on December 1, 2022</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>Purpose</u></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">This Insider Trading Policy (the &#8220;<font style="font-family: 'Times New Roman';"><u>Policy</u></font>&#8221;<font style="font-family: 'Times New Roman';"><u>),</u></font> which amends and restates the prior Insider Trading Policy adopted October 4, 2011, provides guidelines with respect to transactions in the securities of Galectin Therapeutics Inc. (the &#8220;<font style="font-family: 'Times New Roman';"><u>Company</u></font>&#8221;<font style="font-family: 'Times New Roman';"><u>)</u></font> and the handling of confidential information about the Company and the companies with which the Company
      does business. The Company's Board of Directors has adopted this Policy to promote compliance with federal, state and foreign securities laws that prohibit certain persons who are aware of material nonpublic information about a company from: (i)
      trading in securities of that company; or (ii) providing material nonpublic information to other persons who may trade on the basis of that information and to ensure that the Company&#8217;s officers and directors that are subject to reporting requirements
      pursuant to Section 16 of the Securities and Exchange Act of 1934 are in compliance with such reporting requirements.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>Persons Subject to the Policy</u></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">This Policy applies to all officers of the Company and its subsidiaries, all members of the Company's Board of Directors and all employees of the
      Company and its subsidiaries. The Company may also determine that other persons should be subject to this Policy, such as contractors or consultants who have access to material nonpublic information. This Policy also applies to family members, other
      members of a person's household and entities controlled by a person covered by this Policy, as described below.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>Transactions Subject to the Policy</u></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">This Policy applies to transactions in the Company's securities (collectively referred to in this Policy as &#8220;<font style="font-family: 'Times New Roman';"><u>Company Securities</u></font>&#8221;<font style="font-family: 'Times New Roman';"><u>),</u></font> including the Company's common stock, options to purchase common stock, or any other type of securities that the Company may issue, including
      (but not limited to) preferred stock, convertible debentures and warrants, as well as derivative securities that are not issued by the Company, such as exchange-traded put or call options or swaps relating to the Company's Securities.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>Individual Responsibility</u></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Persons subject to this Policy have ethical and legal obligations to maintain the confidentiality of information about the Company and to not engage
      in transactions in Company Securities while in possession of material nonpublic information. Each individual is responsible for making sure that he or she complies with this Policy, and that any family member, household member or entity whose
      transactions are subject to this Policy, as discussed below, also comply with this Policy. In all cases, the responsibility for determining whether an individual is in possession of material nonpublic information rests with that individual, and any
      action on the part of the Company, the Compliance Officer or any other employee or director pursuant to this Policy (or otherwise) does not in any way constitute legal advice or insulate an individual from liability under applicable securities laws.</div>
    <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">1</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Furthermore, persons subject to this Policy have ethical and legal obligations to comply with reporting requirements pursuant to Section 16 of the
      Securities and Exchange Act of 1934.&#160; Failure to comply with such reporting requirements could subject the Company to reputational damage and civil penalties from the Securities and Exchange Commission.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">You could be subject to severe legal penalties and disciplinary action by the Company for any conduct prohibited by this Policy or applicable
      securities laws, as described below in more detail under the heading &#8220;Consequences of Violations.&#8221;</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>Administration of the Policy</u></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Chief Financial Officer shall serve as the <font style="font-family: 'Times New Roman';"><u>Compliance Officer</u></font> for the purposes of
      this Policy, and in his absence, the Chief Operating Officer or another employee designated by the Compliance Officer shall be responsible for administration of this Policy. All determinations and interpretations by the Compliance Officer shall be
      final and not subject to further review.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>Statement of Policy</u></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">It is the policy of the. Company that no director, officer or other employee of the Company (or any other person designated by this Policy or by the
      Compliance Officer as subject to this Policy) who is aware of material nonpublic information relating to the Company may, directly, or indirectly through family members or other persons entities:</div>
    <div style="font-size: 10pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3ee39d5a93aa4799806a5d2b4daa334e">

        <tr>
          <td style="width: 39.6pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 32.4pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">1.</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">Engage in transactions in Company Securities, except as otherwise specified in this Policy under the headings &#8220;Transactions Under Company Plans,&#8221; &#8220;Transactions Not Involving a
              Purchase or Sale&#8221; and &#8220;Rule 10b5-1 Plans;&#8221;</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf44eb898b4e34a10a4cf9a4d3f76a6e2">

        <tr>
          <td style="width: 39.6pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 32.4pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2.</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">Recommend the purchase or sale of any Company Securities;</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb4393e0ab4b44334be3e7b639f1d15d3">

        <tr>
          <td style="width: 39.6pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 32.4pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">3.</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">Disclose material nonpublic information to persons within the Company whose jobs do not require them to have that information, or outside of the Company to other persons,
              including, but not limited to, family, friends, business associates, investors and expert consulting firms, unless any such disclosure is made in accordance with the Company's policies regarding the protection or authorized external
              disclosure of information regarding the Company; or</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd23eafeb54c1488ea2c3a21b4aa9f170">

        <tr>
          <td style="width: 39.6pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 32.4pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">4.</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">Assist anyone engaged, in the above activities.</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">In addition, it is the policy of the Company that no director, officer or other employee of the Company (or any other person designated as subject
      to this Policy) who, in the course of working for the Company, learns of material nonpublic information about a company with which the Company does business, including a customer or supplier of the Company, may trade in that company's securities
      until the information becomes public or is no longer material.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Furthermore, it is the policy of the Company that that each director, officer or affiliate of such persons that are subject to the reporting
      requirements pursuant Section 16 of the Securities and Exchange Act of 1934 comply with such reporting requirement by timely and accurately filing any required reports when engaging in a transaction of the Company&#8217;s securities that is required to be
      reported.</div>
    <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">2</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">There are no exceptions to this Policy, except as specifically noted herein. Transactions that may be necessary or justifiable for independent
      reasons (such as the need to raise money for an emergency expenditure), or small transactions, are not excepted from this Policy. The securities laws do not recognize any mitigating circumstances, and, in any event, even the appearance of an improper
      transaction must be avoided to preserve the Company's reputation for adhering to the highest standards of conduct.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>Definition of Material Nonpublic Information</u></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Material Information</u></font><font style="font-size: 10pt;">.
        Information is considered &#8220;material&#8221; if a reasonable investor would consider that information important in making a decision to buy, hold or sell securities. Any information that could be expected to affect the Company's stock price, whether it is
        positive or negative, should be considered material. There is no bright-line standard for assessing materiality; rather, materiality is based on an assessment of all of the facts and circumstances, and is often evaluated by enforcement authorities
        with the benefit of hindsight. While it is not possible to define all categories of material information, some examples of information that ordinarily would be regarded as material are:</font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z18a6779a0aa645a193fff6e0a0146f6c">

        <tr>
          <td style="width: 18pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">Projections of future earnings or losses, or other earnings guidance;</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb51e5efcd8a14b45a86fd7918e86686a">

        <tr>
          <td style="width: 18pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">Changes to previously announced earnings guidance, or the decision to suspend earnings guidance;</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7726b6a008014478abad51640c634341">

        <tr>
          <td style="width: 18pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">A pending or proposed merger, acquisition or tender offer;</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf35f6d8efbdc448abc1615bdb0d47a41">

        <tr>
          <td style="width: 18pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">A pending or proposed acquisition or disposition of a significant asset;</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z014a4682595241c6810777cd5ae85c50">

        <tr>
          <td style="width: 18pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">A pending or proposed joint venture;</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z203689897bad468ea9a8ba6a5d71cec2">

        <tr>
          <td style="width: 18pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">A Company restructuring;</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2a3931f78145444895629f9abfd691c9">

        <tr>
          <td style="width: 18pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">Significant related party transactions;</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z6205c5e2036c4db38c8d5ac2a2b28c5a">

        <tr>
          <td style="width: 18pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">A change in dividend policy, the declaration of a stock split, or an offering of additional securities;</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf7167931d4ec40909d42ffd98c95dc79">

        <tr>
          <td style="width: 18pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">Bank borrowings or other financing transactions out of the ordinary course;</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z429079be6c994fedb05098c4da724b70">

        <tr>
          <td style="width: 18pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">The establishment of a repurchase program for Company Securities;</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4ea261f0c1a94b6e95c7e0bd5fb37afc">

        <tr>
          <td style="width: 18pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">A change in the Company's pricing or cost structure;</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8274a6768e104ac78acc9be168e35956">

        <tr>
          <td style="width: 18pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">Major marketing changes;</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5487de8313a24d56b9f93aca223527bd">

        <tr>
          <td style="width: 18pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">A change in management;</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5eef36eeead44a3cba11b46d55a31122">

        <tr>
          <td style="width: 18pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">A change in auditors or notification that the auditor's reports may no longer be relied upon;</div>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">3</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zcf75d86c9a90434db23d81ab8628d9cd">

        <tr>
          <td style="width: 18pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">Development of a significant new product, process, or service;</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zedff5c2d2a9c426fadc01b9ed4783aca">

        <tr>
          <td style="width: 18pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">Pending or threatened significant litigation, or the resolution of such litigation,</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1de9c24f051240008e58876171d52296">

        <tr>
          <td style="width: 18pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">Impending bankruptcy or the existence of severe liquidity problems;</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zad811098d7d04ab593829fc7894c8525">

        <tr>
          <td style="width: 18pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">The gain or loss of a significant customer or supplier;</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc7d3b74ce6a646d6b115adfbf8d7b69d">

        <tr>
          <td style="width: 18pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">Results of clinical trials;</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb879c41f9dff4002b622cc7bbbba6ba4">

        <tr>
          <td style="width: 18pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">Prosecution of Company patents; and</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zab786a1205da47588f91164e335620e2">

        <tr>
          <td style="width: 18pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">The imposition of a ban on trading in Company Securities or the securities of another company.</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>When Information is Considered Public</u></font><font style="font-size: 10pt;">. Information that has not been disclosed to the public is generally considered to be nonpublic information. In order to establish that the information has been disclosed to the public, it may be necessary to demonstrate
        that the information has been widely disseminated. Information generally would be considered widely disseminated if it has been disclosed through the Dow Jones &#8220;broad tape,&#8221; newswire services, a broadcast on radio or television programs,
        publication in a widely-available newspaper, magazine or news website, or public disclosure documents filed with the SEC that are available on the SEC's website. By contrast, information would likely not be considered widely disseminated if it is
        available only to the Company's employees, or if it is only available to a select group of analysts, brokers and institutional investors.</font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Once information is widely disseminated, it is still necessary to afford the investing public with sufficient time to absorb the information. As a
      general rule, information should not be considered fully absorbed by the marketplace, for as long as the Company is a non-accelerated filer with the SEC, until after the second business day after the day on which the information is released. If, for
      example, the Company were to make an announcement on a Monday, you should not trade in Company Securities until Thursday. Depending on the particular circumstances, the Company may determine that a longer or shorter period should apply to the release
      of specific material nonpublic information.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><u>Transactions by Family Members and Others</u></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">This Policy applies to your family members who reside with you (including a spouse, a child, a child away at college, stepchildren, grandchildren,
      parents, stepparents, grandparents, siblings and in-laws), anyone else who lives in your household, and any family members who do not live in your household but whose transactions in Company Securities are directed by you or are subject to your
      influence or control, such as parents or children who consult with you before they trade in Company Securities (collectively referred to as &#8220;<font style="font-family: 'Times New Roman';"><u>Family Members</u></font>&#8221;<font style="font-family: 'Times New Roman';"><u>)</u></font>. You are responsible for the transactions of these other persons and therefore should make them aware of the need to confer with you before they trade in Company Securities, and you should treat all such transactions
      for the purposes of this Policy and applicable securities laws as if the transactions were for your own account. This Policy does not, however, apply to personal securities transactions of Family Members where the purchase or sale decision is made by
      a third party not controlled by, influenced by or related to you or your Family Members.</div>
    <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">4</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><u>Transactions by Entities that You Influence or Control</u></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">This Policy applies to any entities that you influence or control, including any corporations, partnerships or trusts (collectively referred to as &#8220;<font style="font-family: 'Times New Roman';"><u>Controlled Entities</u></font>&#8221;), and transactions by these Controlled Entities should be treated for the purposes of this Policy and applicable securities laws as if they were for your own account.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>Transactions Under Company Plans</u></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">This Policy does not apply in the case of the following transactions, except as specifically noted:</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"><u>Stock Option Exercises</u>.</font><font style="font-size: 10pt;"> This Policy does not apply to the exercise of an employee stock option acquired pursuant to the Company's plans, or to the exercise of a tax withholding right pursuant to which a person has elected to have the Company
        withhold shares subject to an option to satisfy tax withholding requirements. This Policy does apply, however, to any sale of stock as part of a broker-assisted cashless exercise of an option, or any other market sale for the purpose of generating
        the cash needed to pay the exercise price of an option.</font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"><u>Restricted Stock Awards</u>.</font><font style="font-size: 10pt;"> This Policy does not apply to the vesting of restricted stock, or the exercise of a tax withholding right pursuant to which you elect to have the Company withhold shares of stock to satisfy tax withholding requirements
        upon the vesting of any restricted stock. The Policy does apply, however, to any market sale of restricted stock.</font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"><u>401(k) Plan</u>.</font><font style="font-size: 10pt;"> This Policy does not apply to purchases of Company Securities in the Company's 401(k) plan resulting from your periodic contribution of money to the plan pursuant to your payroll deduction election. This Policy does apply, however, to
        certain elections you may make under the 401(k) plan; including: (a) an election to increase or decrease the percentage of your periodic contributions that will be allocated to the Company stock fund; (b) an election to make an intra-plan transfer
        of an existing account balance into or out of the Company stock fund; (c) an election to borrow money against your 401(k) plan account if the loan will result in a liquidation of some or all of your Company stock fund balance; and (d) an election
        to pre-pay a plan loan if the pre-payment will result in allocation of loan proceeds to the Company stock fund.</font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"><u>Employee Stock Purchase Plan</u>.</font><font style="font-size: 10pt;"> This Policy does not apply to purchases of Company Securities in the employee stock purchase plan resulting from your periodic contribution of money to the plan pursuant to the election you made at the time of your
        enrollment in the plan. This Policy also does not apply to purchases of Company Securities resulting from lump sum contributions to the plan, provided that you elected to participate by lump sum payment at the beginning of the applicable enrollment
        period. This Policy does apply, however, to your election to participate in the plan for any enrollment period, and to your sales of Company Securities purchased pursuant to the plan.</font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"><u>Dividend Reinvestment Plan</u>.</font><font style="font-size: 10pt;"> This Policy does not apply to purchases of Company Securities under the Company's dividend reinvestment plan resulting from your reinvestment of dividends paid on Company Securities. This Policy does apply, however, to
        voluntary purchases of Company Securities resulting from additional contributions you choose to make to the dividend reinvestment plan, and to your election to participate in the plan or increase your level of participation in the plan. This Policy
        also applies to your sale of any Company Securities purchased pursuant to the plan.</font></div>
    <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt;"> <br>
      </font></div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">5</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"><u>Other Similar Transactions</u>.</font><font style="font-size: 10pt;"> Any other purchase of Company Securities from the Company or sales of Company Securities to the Company are not subject to this Policy.</font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><u>Transactions Not Involving a Purchase or Sale</u></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Bona fide </font><font style="font-size: 10pt;">gifts of securities are
        not transactions subject to this Policy. Further, transactions in mutual funds that are invested in Company Securities are not transactions subject to this Policy.</font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><u>Special and Prohibited Transactions</u></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company has determined that there is a heightened legal risk and/or the appearance of improper or inappropriate conduct if the persons subject
      to this Policy engage in certain types of transactions. It therefore is the Company's policy that any persons covered by this Policy may not engage in any of the following transactions, or should otherwise consider the Company's preferences as
      described below:</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"><u>Short-Term Trading</u>.</font><font style="font-size: 10pt;"> Short-term trading of Company Securities may be distracting to the person and may unduly focus the person on the Company's short-term stock market performance instead of the Company's long-term business objectives. For
        these reasons, any director, officer or other employee of the Company who purchases Company Securities in the open market may not sell any Company Securities of the same class during the six months following the purchase (or vice versa).</font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"><u>Short Sales</u>.</font><font style="font-size: 10pt;"> Short sales of Company Securities (i.e., the sale of a security that the seller does not own) may evidence an expectation on the part of the seller that the securities will decline in value, and therefore have the potential to signal to the
        market that the seller lacks confidence in the Company's prospects. In addition, short sales may reduce a seller's incentive to seek to improve the Company's performance. For these reasons, short sales of Company Securities are prohibited. In
        addition, Section 16(c) of the Exchange Act prohibits officers and directors from engaging in short sales. (Short sales arising from certain types of hedging transactions are governed by the paragraph below captioned &#8220;Hedging Transactions.&#8221;)</font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"><u>Publicly-Traded Options</u>.</font><font style="font-size: 10pt;"> Given the relatively short term of publicly-traded options, transactions in options may create the appearance that a director, officer or employee is trading based on material nonpublic information and focus a director's,
        officer's or other employee's attention on short-term performance at the expense of the Company's long-term objectives. Accordingly, transactions in put options, call options or other derivative securities, on an exchange or in any other organized
        market, are prohibited by this Policy. (Option positions arising from certain types of hedging transactions are governed by the next paragraph below.)</font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"><u>Hedging Transactions</u>.</font><font style="font-size: 10pt;"> Hedging or monetization transactions can be accomplished through a number of possible mechanisms, including through the use of financial instruments such as prepaid variable forwards, equity swaps, collars and exchange
        funds. Such hedging transactions may permit a director, officer or employee to continue to own Company Securities obtained through employee benefit plans or otherwise, but without the full risks and rewards of ownership. When that occurs, the
        director, officer or employee may no longer have the same objectives as the Company's other shareholders. Therefore, the Company strongly discourages you from engaging in such transactions. Any person wishing to enter into such an arrangement must
        first submit the proposed transaction for approval by the Compliance Officer. Any request for pre-clearance of a hedging or similar arrangement must be submitted to the Compliance Officer at least two weeks prior to the proposed execution of
        documents evidencing the proposed transaction and must set forth a justification for the proposed transaction.</font></div>
    <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt;"> <br>
      </font></div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">6</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"><u>Margin Accounts and Pledged Securities</u>.</font><font style="font-size: 10pt;"> Securities held in a margin account as collateral for a margin loan may be sold by the broker without the customer's consent if the customer fails to meet a margin call. Similarly, securities pledged (or hypothecated) as
        collateral for a loan may be sold in foreclosure if the borrower defaults on the loan. Because a margin sale or foreclosure sale may occur at a time when the pledgor is aware of material nonpublic information or otherwise is not permitted to trade
        in Company Securities, directors, officers and other employees are prohibited from holding Company Securities in a margin account or otherwise pledging Company Securities as collateral for a loan. (Pledges of Company Securities arising from certain
        types of hedging transactions are governed by the paragraph above captioned &#8220;Hedging Transactions.&#8221;)&#160; Further, directors, officers and other employees are prohibited from lending Company Securities to short sellers, and from holding Company
        Securities in accounts where the Company Securities may be borrowed by short sellers.</font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"><u>Standing and Limit Orders</u>.</font><font style="font-size: 10pt;"> Standing and limit orders (except standing and limit orders under approved Rule 10b5-1 Plans, as described below) create heightened risks for insider trading violations similar to the use of margin accounts. There is no
        control over the timing of purchases or sales that result from standing instructions to a broker, and as a result the broker could execute a transaction when a director, officer or other employee is in possession of material nonpublic information.
        The Company therefore discourages placing standing or limit orders on Company Securities. If a person subject to this Policy determines that they must use a standing order or limit order, the order should be limited to short duration and should
        otherwise comply with the restrictions and procedures outlined below under the heading &#8220;Additional Procedures.&#8221;</font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><u>Additional Procedures</u></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company has established additional procedures in order to assist the Company in the administration of this Policy, to facilitate compliance with
      laws prohibiting insider trading while in possession of material nonpublic information, and to avoid the appearance of any impropriety. These additional procedures are applicable only to those individuals described below.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"><u>Pre-Clearance Procedures</u>.</font><font style="font-size: 10pt;"> The persons designated by the Compliance Officer as being subject to these procedures, as well as the Family Members and Controlled Entities of such persons, may not engage in any transaction in Company Securities without
        first obtaining pre-clearance of the transaction from the Compliance Officer. A request for pre-clearance should be submitted to the Compliance Officer at least two business days in advance of the proposed transaction. The Compliance Officer is
        under no obligation to approve a transaction submitted for pre-clearance, and may determine not to permit the transaction. If a person seeks pre-clearance and permission to engage in the transaction is denied, then he or she should refrain from
        initiating any transaction in Company Securities, and should not inform any other person of the restriction.</font></div>
    <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt;"> <br>
      </font></div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">7</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">When a request for pre-clearance is made, the requestor should carefully consider whether he or she may be aware of any material nonpublic
      information about the Company, and should describe fully those circumstances to the Compliance Officer. The requestor should also indicate whether he or she has effected any non-exempt &#8220;opposite-way&#8221; transactions within the past six months, and
      should be prepared to report the proposed transaction on an appropriate Form 4 or Form 5. The requestor should also be prepared to comply with SEC Rule 144 and file Form 144, if necessary, at the time of any sale.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"><u>Quarterly Trading Restrictions</u>.</font><font style="font-size: 10pt;"> The persons designated by the Compliance Officer as subject to this restriction (the &#8220;<font style="font-family: 'Times New Roman';"><u>Designated Persons</u></font>&#8221;<font style="font-family: 'Times New Roman';"><u>),</u></font>
        as well as their Family Members or Controlled Entities, may not conduct any transactions involving the Company's Securities (other than as specified by this Policy), during a &#8220;<font style="font-family: 'Times New Roman';"><u>Blackout Period</u></font>&#8221;
        beginning fifteen (15) days prior to the end of each fiscal quarter and ending on the second (2&#8221;) business day following the date of the public release of the Company's earnings results or financial condition for that quarter. In other words, these
        persons may only conduct transactions in Company Securities during the &#8220;Window Period&#8221; beginning on the third (3<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">rd</sup>) business day following the public release of the Company's quarterly earnings or financial condition and ending
        approximately two (2) weeks prior to the close of the next fiscal quarter.</font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; margin-left: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 12pt; font-style: italic;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Exceptions</u></font><font style="font-size: 10pt;">.</font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><u>1.</u></font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-family: 'Times New Roman';"><u>While &#8220;Development Stage&#8221; Company</u></font>: This exception applies in the following circumstances: (1) the Company presents itself in its financial statements as a development stage
          company (i.e., not earning revenue from its principal business) for the applicable reporting period, and (2) the Company does not publicly release its earnings or financial condition before it presents such information in a periodic report (10-K
          or 10-Q) to be filed with the SEC. In that case, following consultation with the Company's Chief Executive Officer, the Compliance Officer may, by written notice (including by e-mail) to the Designated Persons, (a) suspend application of the
          Blackout Period for the applicable reporting period, or (b) limit the Blackout Period to (i) the period beginning fifteen (15) days before a periodic report is filed with the SEC and ending on the second (2<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">nd</sup>) business day after the
          report is filed, or (ii) such other period as the Compliance Officer determines. If the Compliance Officer does not provide such written notice, the Blackout Period provided by (b)(i) shall apply. By way of example for a (b)(i) Blackout Period,
          if the Form 10-Q quarterly report for the second quarter is due to be filed on August 15<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup>, and the Compliance Officer does not provide written notice to the contrary, the Blackout Period begins fifteen (15) days before the due date
          and concludes on the third (3<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">rd</sup>) business day thereafter, whereupon the Window Period begins and extends until the sixteenth (16<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup>) day before the next periodic report is due to be filed.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">For avoidance of confusion, if the Company while a development stage company elects to release publicly its earnings or financial
      condition before the periodic report is filed, the Compliance Officer shall notify the Designated Persons no later than the 15<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> day before the end of the reporting period (e.g., by June 15 for the second quarter), in which case the
      Blackout Period and the Window Period shall be determined by the rule immediately following &#8220;Quarterly Trading Restrictions&#8221; above.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><u>2.</u></font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-family: 'Times New Roman';"><u>Pre-Approval</u></font>. Under certain very limited circumstances, a person subject to this restriction may be permitted to trade during a Blackout Period, but only if the Compliance
          Officer concludes that the person does not in fact possess material nonpublic information. Persons wishing to trade during a Blackout Period must contact the Compliance Officer for approval at least two business days in advance of any proposed
          transaction involving Company Securities.</font></font></div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"> <br>
        </font></font></div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">8</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"><u>Event-Specific Trading Restriction Periods</u>.</font><font style="font-size: 10pt;"> From time to time, an event may occur that is material to the Company and is known by only a few directors, officers and/or employees. So long as the event remains material and nonpublic, the persons designated by the
        Compliance Officer may not trade Company Securities. In addition, the Company's financial results may be sufficiently material in a particular fiscal quarter that, in the judgment of the Compliance Officer, designated persons should refrain from
        trading in Company Securities even sooner than the typical Blackout Period described above. In that situation, the Compliance Officer may notify these persons that they should not trade in the Company's Securities, without disclosing the reason for
        the restriction. The existence of an event-specific trading restriction period or extension of a Blackout Period will not be announced to the Company as a whole, and should not be communicated to any other person. Even if the Compliance Officer has
        not designated you as a person who should not trade due to an event-specific restriction, you should not trade while aware of material nonpublic information. Exceptions will not be granted during an event-specific trading restriction period.</font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"><u>Exceptions</u>.</font><font style="font-size: 10pt;"> The quarterly trading restrictions and event-driven trading restrictions do not apply to those transactions to which this Policy does not apply, as described above under the headings &#8220;Transactions Under Company Plans&#8221; and &#8220;Transactions Not
        Involving a Purchase or Sale.&#8221; Further, the requirement for pre-clearance, the quarterly trading restrictions and event-driven trading restrictions do not apply to transactions conducted pursuant to approved Rule 10b5-1 plans, described under the
        heading &#8220;Rule 10b5-1 Plans.&#8221;</font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>Rule 10b5-1 Plans</u></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Rule 10b5-1 under the Exchange Act provides a defense from insider trading liability under Rule 10b-5. In order to be eligible to rely on this
      defense, a person subject to this Policy must enter into a Rule 10b5-1 plan for transactions in Company Securities that meets certain conditions specified in the Rule (a &#8220;<font style="font-family: 'Times New Roman';"><u>Rule 10b5-1 Plan</u></font>&#8221;<font style="font-family: 'Times New Roman';"><u>)</u></font>. If the plan meets the requirements of Rule 10b5-1, Company Securities may be purchased or sold without regard to certain insider trading restrictions. To comply with the Policy, a Rule 10b5-1
      Plan must be approved by the Compliance Officer and meet the requirements of Rule 10b5-1 and the Company's &#8220;Guidelines for Rule 10b5-1 Plans,&#8221; which may be obtained from the Compliance Officer. In general, a Rule 10b5-1 Plan must be entered into at a
      time when the person entering into the plan is not aware of material nonpublic information. Once the plan is adopted, the person must not exercise any influence over the amount of securities to be traded, the price at which they are to be traded or
      the date of the trade. The plan must either specify the amount, pricing and timing of transactions in advance or delegate discretion on these matters to an independent third party.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Any Rule 10b5-1 Plan must be submitted for approval five days prior to the entry into the Rule 10b5-1 Plan. No further pre-approval of transactions
      conducted pursuant to the Rule 10b5-1 Plan will be required.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>Post-Termination Transactions</u></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">This Policy continues to apply to transactions in Company Securities even after termination of service to the Company. If an
      individual is in possession of material nonpublic information when his or her service terminates, that individual may not trade in Company Securities until that information has become public or is no longer material. [The pre-clearance procedures
      specified under the heading &#8220;Additional Procedures&#8221; above, however, will cease to apply to transactions in Company Securities upon the expiration of any Blackout Period or other Company-imposed trading restrictions applicable at the time of the
      termination of service.]</div>
    <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">9</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><u>Consequences of Violations</u></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The purchase or sale of securities while aware of material nonpublic information, or the disclosure of material nonpublic information to others who
      then trade in the Company's Securities, is prohibited by the federal and state laws. Insider trading violations are pursued vigorously by the SEC, U.S. Attorneys and state enforcement authorities as well as the laws of foreign jurisdictions.
      Punishment for insider trading violations is severe, and could include significant fines and imprisonment. While the regulatory authorities concentrate their efforts on the individuals who trade, or who tip inside information to others who trade, the
      federal securities laws also impose potential liability on companies and other &#8220;controlling persons&#8221; if they fail to take reasonable steps to prevent insider trading by company personnel.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">In addition, an individual's failure to comply with this Policy may subject the individual to Company imposed sanctions, including dismissal for
      cause, whether or not the employee's failure to comply results in a violation of law. Needless to say, a violation of law, or even an SEC investigation that does not result in prosecution, can tarnish a person's reputation and irreparably damage a
      career.</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><u>Company Assistance</u></div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Any person who has a question about this Policy or its application to any proposed
        transaction may obtain additional guidance from the Compliance Officer, who can be reached by telephone at (470) 299-4724 or by e-mail at</font><font style="font-size: 10pt; font-family: 'Times New Roman';">&#160;<u>callicutt@galectintherapeutics.com</u></font><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">.</font></div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"> <br>
      </font></div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">10</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><u>Certification</u></div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; margin-right: 3.6pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">All persons subject to this Policy must certify their understanding of, and intent to comply with, this Policy.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">CERTIFICATION</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">I certify that:</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za8ff61d7e734402caf8e7e39126053c8">

        <tr>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">1.</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">I have read and understand the Company's Insider Trading Policy (the &#8220;Policy&#8221;). I understand that the Compliance Officer is available to answer any questions I have regarding the
              Policy.</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;"><br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za3916284dbef4b7983d43c3537dbd711">

        <tr>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2.</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">Since date the Policy became effective, or such shorter period of time that I have been an employee of the Company, I have complied with the Policy</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;"><br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb4cec0a9b0744e9d808229c25ea511e3">

        <tr>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">3.</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">I will continue to comply with the Policy for as long as I am subject to the Policy.</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zffed48ce110941a7a94a3c0c8c8c8934">

        <tr>
          <td style="width: 8%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;">
            <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Print name:</div>
          </td>
          <td style="width: 28%; vertical-align: top; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);"><br>
          </td>
          <td style="width: 64%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;">&#160;</td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td rowspan="1" style="width: 7%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td rowspan="1" style="width: 28%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td rowspan="1" style="width: 65%; vertical-align: top; font-size: 10pt;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;">
            <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Signature:</div>
          </td>
          <td style="width: 28%; vertical-align: top; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 65%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;">&#160;</td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td rowspan="1" style="width: 4%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td rowspan="1" style="width: 31%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td rowspan="1" style="width: 65%; vertical-align: top; font-size: 10pt;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 4%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;">
            <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Date:</div>
          </td>
          <td style="width: 31%; vertical-align: top; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 65%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;">&#160;</td>
        </tr>

    </table>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-size: 10pt; text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">11</font></div>
    <div style="font-size: 10pt;">
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
  </div>
  <font style="font-size: 10pt;"> </font>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>4
<FILENAME>ef20039001_ex21-1.htm
<DESCRIPTION>EXHIBIT 21.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc
         Document created using Broadridge PROfile 25.3.1.5296
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div>
      <div>
        <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
      <div style="text-align: right; color: #000000; font-weight: bold;">Exhibit 21.1</div>
      <div style="text-align: center; color: #000000; font-weight: bold;">SUBSIDIARIES OF REGISTRANT</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000;">The following is a list of the Corporation&#8217;s subsidiaries as of December 31, 2024. The Corporation owns, directly or indirectly, 100% of the voting securities of each subsidiary,
        unless noted otherwise.</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="z72f9f0ab011b46a3abb0d92f70dbd575" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 49.01%; vertical-align: bottom; border-bottom: #000000 2px solid;">
              <div><font style="color: #000000;">&#160;</font>&#160;</div>
              <div style="color: #000000; font-weight: bold;">NAME</div>
            </td>
            <td style="width: 2%; vertical-align: bottom;">&#160;</td>
            <td style="width: 49%; vertical-align: bottom; border-bottom: #000000 2px solid;">
              <div style="color: #000000; font-weight: bold;">STATE OR JURISDICTION</div>
              <div style="color: #000000; font-weight: bold;">OF ORGANIZATION</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.01%; vertical-align: bottom;">
              <div style="color: rgb(0, 0, 0);">Galectin Therapeutics Security Corp.</div>
            </td>
            <td style="width: 2%; vertical-align: bottom;">&#160;</td>
            <td style="width: 49%; vertical-align: bottom;">
              <div style="color: rgb(0, 0, 0);">Delaware</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.01%; vertical-align: bottom;">
              <div style="color: rgb(0, 0, 0);">Galectin Sciences LLC</div>
            </td>
            <td style="width: 2%; vertical-align: bottom;">&#160;</td>
            <td style="width: 49%; vertical-align: bottom;">
              <div style="color: rgb(0, 0, 0);">Georgia</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div><br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>ef20039001_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc
         Document created using Broadridge PROfile 25.3.1.5296
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div>
      <div>
        <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
      <div style="text-align: right; color: rgb(0, 0, 0); font-weight: bold;">Exhibit 23.1</div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Consent of Independent Registered Public Accounting Firm</div>
      <div><br>
      </div>
      <div style="text-align: justify; color: rgb(0, 0, 0);">
        <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 (Nos.<font style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</font>333<font style="font-size: 10pt; font-family: 'Times New Roman';">&#8209;</font>198070, 333-225890, 333-249955 and 333-270981), and Registration Statement on Form S-3 (Nos.<font style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</font>333-194747,
          333-208674, 333-213138, 333-218112, 333-226402, 333-230085, 333-233193 and 333-271278) of our report dated March 31, 2025&#160; included in this Annual Report on Form 10-K of Galectin Therapeutics, Inc. and Subsidiaries (the &#8220;Company&#8221;) relating to the
          consolidated balance sheets of the Company as of December 31, 2024 and 2023, and the related consolidated statements of operations, changes in redeemable convertible preferred stock and stockholders&#8217; equity (deficit), and cash flows, and the
          related notes (which report expresses an unqualified opinion and contains an emphasis of matter paragraph regarding substantial doubt about the Company&#8217;s ability to continue as a going concern) for each of the two years in the period ended
          December 31, 2024.</div>
      </div>
      <div style="text-align: justify; color: rgb(0, 0, 0);"> <br>
      </div>
      <div style="color: rgb(0, 0, 0);">/s/ Cherry Bekaert LLP</div>
      <div><br>
      </div>
      <div style="color: rgb(0, 0, 0);">Atlanta, Georgia</div>
      <div style="color: #000000;">March 31, 2025</div>
      <div style="color: #000000;"> <br>
      </div>
      <div style="color: #000000;"> <br>
      </div>
      <div style="color: #000000;">
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>ef20039001_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc
         Document created using Broadridge PROfile 25.3.1.5296
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div>
      <div style="text-align: right; color: #000000; font-weight: bold;">
        <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">Exhibit 31.1</div>
      <div style="text-align: center; color: #000000; font-weight: bold;">Certification pursuant to Rule 13a-14(a) of the Securities Act of 1934</div>
      <div><br>
      </div>
      <div style="color: #000000;">I, Joel Lewis, certify that:</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="zdac077111a1242e3a822f023264e5d1d" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 27pt; vertical-align: top; color: #000000;">1.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">I have reviewed this annual report on Form 10-K of Galectin Therapeutics Inc.;</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z949495a088bb412d8f60b9a3ce7897db" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 27pt; vertical-align: top; color: #000000;">2.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which
                such statements were made, not misleading with respect to the period covered by this report;</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="zff262a2bd2d947838c39a15376d66dc9" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 27pt; vertical-align: top; color: #000000;">3.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows
                of the registrant as of, and for, the periods presented in this report;</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z512108e5c8c842bd820fbbbc0d152879" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 27pt; vertical-align: top; color: #000000;">4.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal
                control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="za6b69192aa764678a2ecb3ad94c0c8ec" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 27pt;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; color: #000000;">a)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant,
                including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z71a63706edd6433cb1777d7e18ddd29f" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 27pt;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; color: #000000;">b)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the
                reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z97355499970a45f295079edf2c8963c5" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 27pt;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; color: #000000;">c)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end
                of the period covered by this report based on such evaluation; and</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z9fe9ba9d6adc4057a9048f0a646d0aa7" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 27pt;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; color: #000000;">d)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in
                the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z4e8600aa5b714444a8a88e28bedd2bbc" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 27pt; vertical-align: top; color: #000000;">5.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the
                registrant&#8217;s board of directors (or persons performing the equivalent functions):</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z1eeb00bb265a4cc29135bb176b627642" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 27pt;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; color: #000000;">a)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record,
                process, summarize and report financial information; and</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="zf983b84d7ba34bb6b6404ba0d7989cea" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 27pt;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; color: #000000;">b)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="z78516af3815c40d8afe92540d582985d" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 49.65%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">March 31, 2025</div>
            </td>
            <td style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
              <div style="color: rgb(0, 0, 0);">/s/ Joel Lewis</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.65%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Name:</div>
            </td>
            <td style="width: 44.65%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Joel Lewis</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.65%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Title:</div>
            </td>
            <td style="width: 44.65%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Chief Executive Officer and President</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.65%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 44.65%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">(principal executive officer)</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div><br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>ef20039001_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc
         Document created using Broadridge PROfile 25.3.1.5296
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div>
      <div style="text-align: right; color: #000000; font-weight: bold;">
        <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">Exhibit 31.2</div>
      <div style="text-align: center; color: #000000; font-weight: bold;">Certification pursuant to Rule 13a-14(a) of the Securities Act of 1934</div>
      <div><br>
      </div>
      <div style="color: #000000;">I, Jack W. Callicutt, certify that:</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="zb3b4ce79c0794f96b5197e327de6cebb" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 27pt; vertical-align: top; color: #000000;">1.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">I have reviewed this annual report on Form 10-K of Galectin Therapeutics Inc.;</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z8a36dbef0a034e789dc5181ad5b9aa05" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 27pt; vertical-align: top; color: #000000;">2.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which
                such statements were made, not misleading with respect to the period covered by this report;</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z85e959dc19c64b67947c46974483c883" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 27pt; vertical-align: top; color: #000000;">3.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows
                of the registrant as of, and for, the periods presented in this report;</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="zedcaee5fb0634525aebced2a4c4370c9" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 27pt; vertical-align: top; color: #000000;">4.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal
                control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z4d58928adb884754ac42b975a7ca3439" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 27pt;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; color: #000000;">a)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant,
                including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z9b8b6a54d62c43f58092a7bc713496ae" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 27pt;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; color: #000000;">b)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the
                reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="zbdfb586bf9a243718bbc66985e3c258f" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 27pt;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; color: #000000;">c)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end
                of the period covered by this report based on such evaluation; and</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="ze2f2d63474ae4525a300c9b92d221f9c" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 27pt;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; color: #000000;">d)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in
                the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z3d1fb5a4c8fb4c7ea4f460928ddd760b" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 27pt; vertical-align: top; color: #000000;">5.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the
                registrant&#8217;s board of directors (or persons performing the equivalent functions):</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="ze26f15b86e3e447ab8c41a4bbce36188" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 27pt;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; color: #000000;">a)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record,
                process, summarize and report financial information; and</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z9ff0ca9cf8bd4550916b71acd5fab0f9" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 27pt;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; color: #000000;">b)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="z061628ee6ca147bd81d9339eb08a0706" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 49.65%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">March 31, 2025</div>
            </td>
            <td style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
              <div style="color: rgb(0, 0, 0);">/s/ Jack W. Callicutt</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.65%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Name:</div>
            </td>
            <td style="width: 44.65%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Jack W. Callicutt</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.65%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Title:</div>
            </td>
            <td style="width: 44.65%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Chief Financial Officer</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.65%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 44.65%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">(principal financial and accounting officer)</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div><br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>ef20039001_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc
         Document created using Broadridge PROfile 25.3.1.5296
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div>
      <div>
        <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
      <div style="text-align: right; color: #000000; font-weight: bold;">Exhibit 32.1</div>
      <div style="text-align: center; color: #000000; font-weight: bold;">CERTIFICATION PURSUANT TO</div>
      <div style="text-align: center; color: #000000; font-weight: bold;">18 U.S.C. SECTION 1350,</div>
      <div style="text-align: center; color: #000000; font-weight: bold;">AS ADOPTED PURSUANT TO</div>
      <div style="text-align: center; color: #000000; font-weight: bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000;">In connection with the Annual Report of Galectin Therapeutics Inc. (the &#8220;Company&#8221;) on Form 10-K for the period ended December 31, 2024 as filed with the Securities and Exchange
        Commission on the date hereof (the &#8220;Report&#8221;), I, Joel Lewis, Chief Executive Officer and President of the Company, certify, pursuant to 18 U.S.C. &#167;1350, as adopted pursuant to &#167;906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z313eabbb62c94c8bb1e1bcd27108b3cf" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 27pt; vertical-align: top; color: #000000;">(1)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="zae9ca86ae0f24efc92c7cbb7e829c1d2" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 27pt; vertical-align: top; color: #000000;">(2)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="zf341a24a3f2c4687b1cc3d670347bc2e" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 49.65%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">March 31, 2025</div>
            </td>
            <td style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
              <div style="color: rgb(0, 0, 0);">/s/ Joel Lewis</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.65%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Name:</div>
            </td>
            <td style="width: 44.65%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Joel Lewis</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.65%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Title:</div>
            </td>
            <td style="width: 44.65%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Chief Executive Officer and President</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.65%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 44.65%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">(principal executive officer)</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div><br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>ef20039001_ex32-2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc
         Document created using Broadridge PROfile 25.3.1.5296
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div>
      <div>
        <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
      <div style="text-align: right; color: #000000; font-weight: bold;">Exhibit 32.2</div>
      <div style="text-align: center; color: #000000; font-weight: bold;">CERTIFICATION PURSUANT TO</div>
      <div style="text-align: center; color: #000000; font-weight: bold;">18 U.S.C. SECTION 1350,</div>
      <div style="text-align: center; color: #000000; font-weight: bold;">AS ADOPTED PURSUANT TO</div>
      <div style="text-align: center; color: #000000; font-weight: bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000;">In connection with the Annual Report of Galectin Therapeutics Inc. (the &#8220;Company&#8221;) on Form 10-K for the period ended December 31, 2024 as filed with the Securities and Exchange
        Commission on the date hereof (the &#8220;Report&#8221;), I, Jack W. Callicutt, Chief Financial Officer, certify, pursuant to 18 U.S.C. &#167;1350, as adopted pursuant to &#167;906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="zd463ccef5f2549ce96eb5da831480372" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

          <tr>
            <td style="width: 27pt; vertical-align: top; color: #000000;">(1)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z314f486bcc954758ae79459421e68448" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

          <tr>
            <td style="width: 27pt; vertical-align: top; color: #000000;">(2)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="z7e8fc2ae35f8448bae05cabc5c9aeded" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 49.65%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">March 31, 2025</div>
            </td>
            <td colspan="2" style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="color: rgb(0, 0, 0);">/s/ Jack W. Callicutt</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.65%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Name:</div>
            </td>
            <td style="width: 44.65%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Jack W. Callicutt</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.65%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Title:</div>
            </td>
            <td style="width: 44.65%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Chief Financial Officer and President</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.65%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 44.65%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">(principal financial and accounting officer)</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div><br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>galt-20241231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 25.3.1.5296 Broadridge-->
<xs:schema targetNamespace="http://galectintherapeutics.com/20241231" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:galt="http://galectintherapeutics.com/20241231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:srt-types="http://fasb.org/srt-types/2024">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="galt-20241231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="galt-20241231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="galt-20241231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="galt-20241231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://galectintherapeutics.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
        <link:definition>010000 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
        <!--Parent Role: CONSOLIDATED BALANCE SHEETS-->
        <link:definition>010100 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/ConsolidatedStatementsOfOperations" id="ConsolidatedStatementsOfOperations">
        <link:definition>020000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" id="ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit">
        <link:definition>030000 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
        <link:definition>040000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/NatureOfBusinessBasisOfPresentationLiquidityAndGoingConcern" id="NatureOfBusinessBasisOfPresentationLiquidityAndGoingConcern">
        <link:definition>060100 - Disclosure - Nature of Business, Basis of Presentation, Liquidity, and Going Concern</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
        <link:definition>060200 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/PropertyAndEquipment" id="PropertyAndEquipment">
        <link:definition>060300 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/AccruedExpenses" id="AccruedExpenses">
        <link:definition>060400 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedParty" id="ConvertibleNotesPayableRelatedParty">
        <link:definition>060500 - Disclosure - Convertible Notes Payable - Related Party</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/FairValueOfFinancialInstruments" id="FairValueOfFinancialInstruments">
        <link:definition>060600 - Disclosure - Fair Value of Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/StockholdersEquity" id="StockholdersEquity">
        <link:definition>060700 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/Warrants" id="Warrants">
        <link:definition>060800 - Disclosure - Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/StockbasedCompensation" id="StockbasedCompensation">
        <link:definition>060900 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedParty" id="ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedParty">
        <link:definition>061000 - Disclosure - Convertible Line of Credit - Related Party and Supplemental Lines of Credit - Related Party</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/LossPerShare" id="LossPerShare">
        <link:definition>061100 - Disclosure - Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
        <link:definition>061200 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/GalectinSciencesLlc" id="GalectinSciencesLlc">
        <link:definition>061300 - Disclosure - Galectin Sciences LLC</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/IncomeTaxes" id="IncomeTaxes">
        <link:definition>061400 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/Segments" id="Segments">
        <link:definition>061500 - Disclosure - Segments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/SubsequentEvent" id="SubsequentEvent">
        <link:definition>061600 - Disclosure - Subsequent Event</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/CybersecurityRiskManagementAndStrategyDisclosure" id="CybersecurityRiskManagementAndStrategyDisclosure">
        <link:definition>061700 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/InsiderTradingArrangements" id="InsiderTradingArrangements">
        <link:definition>061800 - Disclosure - Insider Trading Arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/InsiderTradingPoliciesAndProcedures" id="InsiderTradingPoliciesAndProcedures">
        <link:definition>061900 - Disclosure - Insider Trading Policies and Procedures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
        <!--Parent Role: Summary of Significant Accounting Policies-->
        <link:definition>070200 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/PropertyAndEquipmentTables" id="PropertyAndEquipmentTables">
        <!--Parent Role: Property and Equipment-->
        <link:definition>080300 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/AccruedExpensesTables" id="AccruedExpensesTables">
        <!--Parent Role: Accrued Expenses-->
        <link:definition>080400 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsTables" id="FairValueOfFinancialInstrumentsTables">
        <!--Parent Role: Fair Value of Financial Instruments-->
        <link:definition>080600 - Disclosure - Fair Value of Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/WarrantsTables" id="WarrantsTables">
        <!--Parent Role: Warrants-->
        <link:definition>080800 - Disclosure - Warrants (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/StockbasedCompensationTables" id="StockbasedCompensationTables">
        <!--Parent Role: Stock-Based Compensation-->
        <link:definition>080900 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/LossPerShareTables" id="LossPerShareTables">
        <!--Parent Role: Loss Per Share-->
        <link:definition>081100 - Disclosure - Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
        <!--Parent Role: Commitments and Contingencies-->
        <link:definition>081200 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
        <!--Parent Role: Income Taxes-->
        <link:definition>081400 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/SegmentsTables" id="SegmentsTables">
        <!--Parent Role: Segments-->
        <link:definition>081500 - Disclosure - Segments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/NatureOfBusinessBasisOfPresentationLiquidityAndGoingConcernDetails" id="NatureOfBusinessBasisOfPresentationLiquidityAndGoingConcernDetails">
        <!--Parent Role: Nature of Business, Basis of Presentation, Liquidity, and Going Concern-->
        <link:definition>090100 - Disclosure - Nature of Business, Basis of Presentation, Liquidity, and Going Concern (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails" id="SummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails">
        <!--Parent Role: Summary of Significant Accounting Policies-->
        <link:definition>090200 - Disclosure - Summary of Significant Accounting Policies, Cash and Cash Equivalents (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" id="SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails">
        <!--Parent Role: Summary of Significant Accounting Policies-->
        <link:definition>090202 - Disclosure - Summary of Significant Accounting Policies, Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesSecurityDepositDetails" id="SummaryOfSignificantAccountingPoliciesSecurityDepositDetails">
        <!--Parent Role: Summary of Significant Accounting Policies-->
        <link:definition>090204 - Disclosure - Summary of Significant Accounting Policies, Security Deposit (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesLonglivedAssetsDetails" id="SummaryOfSignificantAccountingPoliciesLonglivedAssetsDetails">
        <!--Parent Role: Summary of Significant Accounting Policies-->
        <link:definition>090206 - Disclosure - Summary of Significant Accounting Policies, Long-Lived Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesWarrantsDetails" id="SummaryOfSignificantAccountingPoliciesWarrantsDetails">
        <!--Parent Role: Summary of Significant Accounting Policies-->
        <link:definition>090208 - Disclosure - Summary of Significant Accounting Policies, Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/PropertyAndEquipmentDetails" id="PropertyAndEquipmentDetails">
        <!--Parent Role: Property and Equipment-->
        <link:definition>090300 - Disclosure - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/AccruedExpensesDetails" id="AccruedExpensesDetails">
        <!--Parent Role: Accrued Expenses-->
        <link:definition>090400 - Disclosure - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails" id="ConvertibleNotesPayableRelatedPartyDetails">
        <!--Parent Role: Convertible Notes Payable - Related Party-->
        <link:definition>090500 - Disclosure - Convertible Notes Payable - Related Party (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueDetails" id="FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueDetails">
        <!--Parent Role: Fair Value of Financial Instruments-->
        <link:definition>090600 - Disclosure - Fair Value of Financial Instruments, Assets and Liabilities Measured at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsKeyAssumptionsDetails" id="FairValueOfFinancialInstrumentsKeyAssumptionsDetails">
        <!--Parent Role: Fair Value of Financial Instruments-->
        <link:definition>090602 - Disclosure - Fair Value of Financial Instruments, Key Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsRollForwardOfDerivativeLiabilityDetails" id="FairValueOfFinancialInstrumentsRollForwardOfDerivativeLiabilityDetails">
        <!--Parent Role: Fair Value of Financial Instruments-->
        <link:definition>090604 - Disclosure - Fair Value of Financial Instruments, Roll Forward of Derivative Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/StockholdersEquityIssuanceOfCommonStockDetails" id="StockholdersEquityIssuanceOfCommonStockDetails">
        <!--Parent Role: Stockholders' Equity-->
        <link:definition>090700 - Disclosure - Stockholders' Equity, Issuance of Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/StockholdersEquitySeries12ConvertiblePreferredStockDetails" id="StockholdersEquitySeries12ConvertiblePreferredStockDetails">
        <!--Parent Role: Stockholders' Equity-->
        <link:definition>090702 - Disclosure - Stockholders' Equity, Series A 12% Convertible Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/StockholdersEquitySeriesC6SuperDividendRedeemableConvertiblePreferredStockDetails" id="StockholdersEquitySeriesC6SuperDividendRedeemableConvertiblePreferredStockDetails">
        <!--Parent Role: Stockholders' Equity-->
        <link:definition>090704 - Disclosure - Stockholders' Equity, Series C 6% Super Dividend Redeemable Convertible Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/StockholdersEquityReturnOnInvestmentDetails" id="StockholdersEquityReturnOnInvestmentDetails">
        <!--Parent Role: Stockholders' Equity-->
        <link:definition>090706 - Disclosure - Stockholders' Equity, Return on Investment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/WarrantsSummaryOfWarrantActivityDetails" id="WarrantsSummaryOfWarrantActivityDetails">
        <!--Parent Role: Warrants-->
        <link:definition>090800 - Disclosure - Warrants, Summary of Warrant Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/WarrantsSummaryOfPurchaseWarrantsDetails" id="WarrantsSummaryOfPurchaseWarrantsDetails">
        <!--Parent Role: Warrants-->
        <link:definition>090802 - Disclosure - Warrants, Summary of Purchase Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/WarrantsSummaryOfOutstandingWarrantsIssuedInConnectionWithEquityAndDebtFinancingAndConsultantsDetails" id="WarrantsSummaryOfOutstandingWarrantsIssuedInConnectionWithEquityAndDebtFinancingAndConsultantsDetails">
        <!--Parent Role: Warrants-->
        <link:definition>090804 - Disclosure - Warrants, Summary of Outstanding Warrants Issued in Connection with Equity and Debt Financing and Consultants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/StockbasedCompensationSummaryOfStockbasedCompensationPlansDetails" id="StockbasedCompensationSummaryOfStockbasedCompensationPlansDetails">
        <!--Parent Role: Stock-Based Compensation-->
        <link:definition>090900 - Disclosure - Stock-Based Compensation, Summary of Stock-Based Compensation Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/StockbasedCompensationComponentsOfStockbasedCompensationExpenseDetails" id="StockbasedCompensationComponentsOfStockbasedCompensationExpenseDetails">
        <!--Parent Role: Stock-Based Compensation-->
        <link:definition>090902 - Disclosure - Stock-Based Compensation, Components of Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/StockbasedCompensationWeightedAverageAssumptionsUsedToDetermineFairValueOfOptionsGrantedDetails" id="StockbasedCompensationWeightedAverageAssumptionsUsedToDetermineFairValueOfOptionsGrantedDetails">
        <!--Parent Role: Stock-Based Compensation-->
        <link:definition>090904 - Disclosure - Stock-Based Compensation, Weighted Average Assumptions Used to Determine Fair Value of Options Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/StockbasedCompensationStockOptionActivityDetails" id="StockbasedCompensationStockOptionActivityDetails">
        <!--Parent Role: Stock-Based Compensation-->
        <link:definition>090906 - Disclosure - Stock-Based Compensation, Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/StockbasedCompensationOutstandingAndExercisableOptionsUnderStockBasedCompensationPlansDetails" id="StockbasedCompensationOutstandingAndExercisableOptionsUnderStockBasedCompensationPlansDetails">
        <!--Parent Role: Stock-Based Compensation-->
        <link:definition>090908 - Disclosure - Stock-Based Compensation, Outstanding and Exercisable Options under Stock Based Compensation Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/StockbasedCompensationRestrictedStockIssuancesDetails" id="StockbasedCompensationRestrictedStockIssuancesDetails">
        <!--Parent Role: Stock-Based Compensation-->
        <link:definition>090910 - Disclosure - Stock-Based Compensation, Restricted Stock Issuances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/StockbasedCompensationDeferredStockUnitsDetails" id="StockbasedCompensationDeferredStockUnitsDetails">
        <!--Parent Role: Stock-Based Compensation-->
        <link:definition>090912 - Disclosure - Stock-Based Compensation, Deferred Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedPartyDetails" id="ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedPartyDetails">
        <!--Parent Role: Convertible Line of Credit - Related Party and Supplemental Lines of Credit - Related Party-->
        <link:definition>091000 - Disclosure - Convertible Line of Credit - Related Party and Supplemental Lines of Credit - Related Party (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/LossPerShareDetails" id="LossPerShareDetails">
        <!--Parent Role: Loss Per Share-->
        <link:definition>091100 - Disclosure - Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
        <!--Parent Role: Commitments and Contingencies-->
        <link:definition>091200 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/CommitmentsAndContingenciesDetailsCalc2" id="CommitmentsAndContingenciesDetailsCalc2">
        <!--Parent Role: Commitments and Contingencies (Details)-->
        <link:definition>091202 - Disclosure - Commitments and Contingencies (Details) Calc 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/GalectinSciencesLlcDetails" id="GalectinSciencesLlcDetails">
        <!--Parent Role: Galectin Sciences LLC-->
        <link:definition>091300 - Disclosure - Galectin Sciences LLC (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/IncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" id="IncomeTaxesComponentsOfNetDeferredTaxAssetsDetails">
        <!--Parent Role: Income Taxes-->
        <link:definition>091400 - Disclosure - Income Taxes, Components of Net Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/IncomeTaxesPrimaryFactorsAffectingIncomeTaxRatesDetails" id="IncomeTaxesPrimaryFactorsAffectingIncomeTaxRatesDetails">
        <!--Parent Role: Income Taxes-->
        <link:definition>091402 - Disclosure - Income Taxes, Primary Factors Affecting Income Tax Rates (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/SegmentsSignificantExpenseCategoriesDetails" id="SegmentsSignificantExpenseCategoriesDetails">
        <!--Parent Role: Segments-->
        <link:definition>091500 - Disclosure - Segments - Significant Expense Categories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/SegmentsSignificantAssetCategoriesDetails" id="SegmentsSignificantAssetCategoriesDetails">
        <!--Parent Role: Segments-->
        <link:definition>091504 - Disclosure - Segments - Significant Asset Categories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/SubsequentEventDetails" id="SubsequentEventDetails">
        <!--Parent Role: Subsequent Event-->
        <link:definition>091600 - Disclosure - Subsequent Event (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2024" schemaLocation="https://xbrl.sec.gov/currency/2024/currency-2024.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2024" schemaLocation="https://xbrl.sec.gov/exch/2024/exch-2024.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2024" schemaLocation="https://xbrl.sec.gov/naics/2024/naics-2024.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2024" schemaLocation="https://xbrl.sec.gov/sic/2024/sic-2024.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2024" schemaLocation="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/cyd/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd" />
  <xs:element name="AccruedResearchAndDevelopmentCostsAndOtherCurrent" id="galt_AccruedResearchAndDevelopmentCostsAndOtherCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingTermAbstract" id="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingTermAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" id="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="OptionsOutstandingAbstract" id="galt_OptionsOutstandingAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="OptionsExercisableAbstract" id="galt_OptionsExercisableAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ExercisePriceRangeTwoMember" id="galt_ExercisePriceRangeTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ExercisePriceRangeThreeMember" id="galt_ExercisePriceRangeThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ExercisePriceRangeOneMember" id="galt_ExercisePriceRangeOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ExercisePriceRangeFourMember" id="galt_ExercisePriceRangeFourMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ExercisePriceRangeFiveMember" id="galt_ExercisePriceRangeFiveMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="FairValueAdjustmentOfWarrant" id="galt_FairValueAdjustmentOfWarrant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="WarrantsAbstract" id="galt_WarrantsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="CommonStockWarrantsDisclosureTextBlock" id="galt_CommonStockWarrantsDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="RestrictedStockGrantsAbstract" id="galt_RestrictedStockGrantsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne" id="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSix" id="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSix" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent" id="galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFive" id="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFive" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSeven" id="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSeven" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree" id="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo" id="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFour" id="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFour" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="BonusSharesMember" id="galt_BonusSharesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent" id="galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="MayTwentyThreeTwentyNinteenRightsOfferingWarrantsMember" id="galt_MayTwentyThreeTwentyNinteenRightsOfferingWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="March292024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" id="galt_March292024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="June282024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" id="galt_June282024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="SeptemberThirtyTwentyZeroNineSeriesBTwoTransactionOneMember" id="galt_SeptemberThirtyTwentyZeroNineSeriesBTwoTransactionOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="December292023WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" id="galt_December292023WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="AugustTwelveTwentyZeroNineSeriesBTwoTransactionOneMember" id="galt_AugustTwelveTwentyZeroNineSeriesBTwoTransactionOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="July222022WarrantsIssuedInConnectionWithRelatedPartyLineOfCreditMember" id="galt_July222022WarrantsIssuedInConnectionWithRelatedPartyLineOfCreditMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="MayTenTwentyTenSeriesBTwoTransactionTwoMember" id="galt_MayTenTwentyTenSeriesBTwoTransactionTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="AprilThirtyTwentyTenSeriesBTwoTransactionOneMember" id="galt_AprilThirtyTwentyTenSeriesBTwoTransactionOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="TwentyEighteenAndTwentySeventeenWarrantsIssuedForServicesMember" id="galt_TwentyEighteenAndTwentySeventeenWarrantsIssuedForServicesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="DecemberEightTwentyZeroNineSeriesBTwoTransactionOneMember" id="galt_DecemberEightTwentyZeroNineSeriesBTwoTransactionOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="JanuaryTwentyNineTwentyTenSeriesBTwoTransactionOneMember" id="galt_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="FebruaryTwelveTwentyZeroNineSeriesBOneTransactionMember" id="galt_FebruaryTwelveTwentyZeroNineSeriesBOneTransactionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="DecemberTwentyThreeTwentySixteenSeriesBThreeTransactionMember" id="galt_DecemberTwentyThreeTwentySixteenSeriesBThreeTransactionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="September302024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" id="galt_September302024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="SeptemberTwentyNineTwentySixteenSeriesBThreeTransactionMember" id="galt_SeptemberTwentyNineTwentySixteenSeriesBThreeTransactionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="NovemberFourTwentyZeroNineSeriesBTwoTransactionOneMember" id="galt_NovemberFourTwentyZeroNineSeriesBTwoTransactionOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="SeptemberTwentyTwoTwentySixteenSeriesBThreeTransactionMember" id="galt_SeptemberTwentyTwoTwentySixteenSeriesBThreeTransactionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired" id="galt_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired" type="xbrli:dateItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="MarchEightTwentyTenSeriesBTwoTransactionTwoMember" id="galt_MarchEightTwentyTenSeriesBTwoTransactionTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="JanuaryTwentyNineTwentyTenSeriesBTwoTransactionTwoMember" id="galt_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="MarchEightTwentyTenSeriesBTwoTransactionOneMember" id="galt_MarchEightTwentyTenSeriesBTwoTransactionOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="WarrantIssueDate" id="galt_WarrantIssueDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="AprilThirtyTwentyTenSeriesBTwoTransactionTwoMember" id="galt_AprilThirtyTwentyTenSeriesBTwoTransactionTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="MayTenTwentyTenSeriesBTwoTransactionOneMember" id="galt_MayTenTwentyTenSeriesBTwoTransactionOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="JuneThirtyTwentyZeroNineSeriesBTwoTransactionOneMember" id="galt_JuneThirtyTwentyZeroNineSeriesBTwoTransactionOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="WarrantsIssuedPrice" id="galt_WarrantsIssuedPrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="MayThirteenTwentyZeroNineSeriesBTwoTransactionOneMember" id="galt_MayThirteenTwentyZeroNineSeriesBTwoTransactionOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="VestingPercentageOfRestrictedStockUnits" id="galt_VestingPercentageOfRestrictedStockUnits" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="NumberOfDirectors" id="galt_NumberOfDirectors" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="SeriesBWarrantsMember" id="galt_SeriesBWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="NumberOfTradingDaysToBeConsideredStockClosingPriceInPurchaseAgreement" id="galt_NumberOfTradingDaysToBeConsideredStockClosingPriceInPurchaseAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ThresholdPeriodForStockClosingPriceInTenConsecutiveDaysUnderPurchaseWarrantsAgreement" id="galt_ThresholdPeriodForStockClosingPriceInTenConsecutiveDaysUnderPurchaseWarrantsAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PeriodOfPriorNoticeThatWouldBarVoluntaryExerciseOfAnyWarrants" id="galt_PeriodOfPriorNoticeThatWouldBarVoluntaryExerciseOfAnyWarrants" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ThresholdPeriodForExtensionOfExerciseDateOfPurchaseWarrantsUnderAgreement" id="galt_ThresholdPeriodForExtensionOfExerciseDateOfPurchaseWarrantsUnderAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="One0XFundLPMember" id="galt_One0XFundLPMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="One0XFundLPAnd10XCapitalManagementLLCMember" id="galt_One0XFundLPAnd10XCapitalManagementLLCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="BeneficialOwnershipPercentage" id="galt_BeneficialOwnershipPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="BeforeModificationMember" id="galt_BeforeModificationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="AfterModificationMember" id="galt_AfterModificationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="WarrantModificationIncreaseDecreaseInEquityAmount" id="galt_WarrantModificationIncreaseDecreaseInEquityAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="TemporaryEquityDividends" id="galt_TemporaryEquityDividends" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="ConvertiblePreferredStockDividends" id="galt_ConvertiblePreferredStockDividends" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="ConvertiblePreferredStockDividendsShares" id="galt_ConvertiblePreferredStockDividendsShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="TemporaryEquityDividendsShares" id="galt_TemporaryEquityDividendsShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="StockIssuedDuringPeriodValueWarrantExercise" id="galt_StockIssuedDuringPeriodValueWarrantExercise" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="StockIssuedDuringPeriodSharesWarrantExercise" id="galt_StockIssuedDuringPeriodSharesWarrantExercise" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ContingentInterestDecemberNoteMember" id="galt_ContingentInterestDecemberNoteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ContingentInterestSeptemberNoteMember" id="galt_ContingentInterestSeptemberNoteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ContingentInterestAprilNoteMember" id="galt_ContingentInterestAprilNoteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="NonQualifiedOptionsPlansMember" id="galt_NonQualifiedOptionsPlansMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="IncentiveCompensationPlanTwoThousandNineMemberMember" id="galt_IncentiveCompensationPlanTwoThousandNineMemberMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="EquityIncentivePlan2019Member" id="galt_EquityIncentivePlan2019Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ReclassificationOfAccruedBonusToAdditionalPaidInCapital" id="galt_ReclassificationOfAccruedBonusToAdditionalPaidInCapital" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit" id="galt_CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="ReturnOnInvestmentsPercentageAbstract" id="galt_ReturnOnInvestmentsPercentageAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ReturnOnInvestmentsPercentagePeriodOne" id="galt_ReturnOnInvestmentsPercentagePeriodOne" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ReturnOnInvestmentsPercentagePeriodTwo" id="galt_ReturnOnInvestmentsPercentagePeriodTwo" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ReturnOnInvestmentsPercentagePeriodEight" id="galt_ReturnOnInvestmentsPercentagePeriodEight" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ReturnOnInvestmentsPercentagePeriodSix" id="galt_ReturnOnInvestmentsPercentagePeriodSix" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ReturnOnInvestmentsPercentagePeriodSeven" id="galt_ReturnOnInvestmentsPercentagePeriodSeven" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ReturnOnInvestmentsPercentagePeriodThree" id="galt_ReturnOnInvestmentsPercentagePeriodThree" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ConvertiblePreferredStockNumberOfVotingRights" id="galt_ConvertiblePreferredStockNumberOfVotingRights" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ReturnOnInvestmentsPercentagePeriodFour" id="galt_ReturnOnInvestmentsPercentagePeriodFour" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ReturnOnInvestmentsPercentagePeriodFive" id="galt_ReturnOnInvestmentsPercentagePeriodFive" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="TwoThousandTwentyMarketAgreementMember" id="galt_TwoThousandTwentyMarketAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="TwoThousandSeventeenMarketAgreementMember" id="galt_TwoThousandSeventeenMarketAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="CommissionRate" id="galt_CommissionRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="UndesignatedCapitalStockSharesAuthorized" id="galt_UndesignatedCapitalStockSharesAuthorized" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="AggregateOfferingPrice" id="galt_AggregateOfferingPrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="SeriesBTwoConvertiblePreferredStockMember" id="galt_SeriesBTwoConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="SeriesBOneConvertiblePreferredStockMember" id="galt_SeriesBOneConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="SeriesBThreeConvertiblePreferredStockMember" id="galt_SeriesBThreeConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="UndesignatedCapitalStockValue" id="galt_UndesignatedCapitalStockValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent" id="galt_BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent" id="galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyCurrent" id="galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="UndesignatedCapitalStockSharesDesignated" id="galt_UndesignatedCapitalStockSharesDesignated" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="UndesignatedCapitalStockParValue" id="galt_UndesignatedCapitalStockParValue" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract" id="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice" id="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" id="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice" id="galt_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice" id="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="SBHSciencesIncMember" id="galt_SBHSciencesIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="NonCashChargeForResearchAndDevelopmentInProcess" id="galt_NonCashChargeForResearchAndDevelopmentInProcess" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="CapitalContributionExpense" id="galt_CapitalContributionExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="GalectinSciencesLLCMember" id="galt_GalectinSciencesLLCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="NatureOfBusinessBasisOfPresentationsAndLiquidityAbstract" id="galt_NatureOfBusinessBasisOfPresentationsAndLiquidityAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="NumberOfLineOfCredit" id="galt_NumberOfLineOfCredit" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="SupplementalLineOfCreditMember" id="galt_SupplementalLineOfCreditMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ConvertibleNotesPayableRelatedPartyAbstract" id="galt_ConvertibleNotesPayableRelatedPartyAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="NumberOfPromissoryNotesExecuted" id="galt_NumberOfPromissoryNotesExecuted" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="NumberOfLoansClosing" id="galt_NumberOfLoansClosing" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="AnnualInterestRate" id="galt_AnnualInterestRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="QuarterlyInterestRate" id="galt_QuarterlyInterestRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="AprilConvertiblePromissoryNoteMember" id="galt_AprilConvertiblePromissoryNoteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="SeptemberConvertiblePromissoryNoteMember" id="galt_SeptemberConvertiblePromissoryNoteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="FirstClosingMember" id="galt_FirstClosingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="SecondClosingMember" id="galt_SecondClosingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="DecemberConvertiblePromissoryNoteMember" id="galt_DecemberConvertiblePromissoryNoteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="NumberOfPromissoryNotesEvidencedByLoansAgreement" id="galt_NumberOfPromissoryNotesEvidencedByLoansAgreement" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" id="galt_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="SecurityDepositPolicyTextBlock" id="galt_SecurityDepositPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="AccruedExpensePolicyTextBlock" id="galt_AccruedExpensePolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ComputerAndOfficeEquipmentMember" id="galt_ComputerAndOfficeEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ClosingDaysAfterConversionRights" id="galt_ClosingDaysAfterConversionRights" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PostConversionRedemptionRightReturnOnInvestmentMultiplierAmount" id="galt_PostConversionRedemptionRightReturnOnInvestmentMultiplierAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="EquityIssuancePerShareAmount" id="galt_EquityIssuancePerShareAmount" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PostConversionDividendRightsIssued" id="galt_PostConversionDividendRightsIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="DividendPaymentScenarioTwoMember" id="galt_DividendPaymentScenarioTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="DividendAsPercentageOfNetSales" id="galt_DividendAsPercentageOfNetSales" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="NumberOfConsecutiveTradingDays" id="galt_NumberOfConsecutiveTradingDays" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ProceedsFromIssuanceOfPreferredStockNetOfIssuanceCosts" id="galt_ProceedsFromIssuanceOfPreferredStockNetOfIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="DividendPaymentScenarioOneMember" id="galt_DividendPaymentScenarioOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="CommonSharesIssuableUponConversionOfConvertibleStock" id="galt_CommonSharesIssuableUponConversionOfConvertibleStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="ClassOfWarrantOrRightIssued" id="galt_ClassOfWarrantOrRightIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="September2024PromissoryNoteMember" id="galt_September2024PromissoryNoteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="March24PromissoryNoteMember" id="galt_March24PromissoryNoteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="June2023PromissoryNoteMember" id="galt_June2023PromissoryNoteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="December2022PromissoryNoteMember" id="galt_December2022PromissoryNoteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="LineOfCreditRelatedPartyAbstract" id="galt_LineOfCreditRelatedPartyAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="DebtInstrumentAccruedInterest" id="galt_DebtInstrumentAccruedInterest" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="IssuanceOfWarrantsValue" id="galt_IssuanceOfWarrantsValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock" id="galt_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" id="galt_ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="AdditionalSupplementalLineOfCreditMember" id="galt_AdditionalSupplementalLineOfCreditMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="June2024PromissoryNoteMember" id="galt_June2024PromissoryNoteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="WarrantSixMember" id="galt_WarrantSixMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="WarrantOneMember" id="galt_WarrantOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="WarrantTwoMember" id="galt_WarrantTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="WarrantSevenMember" id="galt_WarrantSevenMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="WarrantThreeMember" id="galt_WarrantThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="WarrantFiveMember" id="galt_WarrantFiveMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="March2023PromissoryNoteMember" id="galt_March2023PromissoryNoteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="December2023PromissoryNoteMember" id="galt_December2023PromissoryNoteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="WarrantFourMember" id="galt_WarrantFourMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ExpiringThrough2037Member" id="galt_ExpiringThrough2037Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ExpiringAsAResultOf2017TaxActMember" id="galt_ExpiringAsAResultOf2017TaxActMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="DeferredTaxAssetsValuationAllowancePercentage" id="galt_DeferredTaxAssetsValuationAllowancePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="OperatingLossCarryforwardsExpirationYear" id="galt_OperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="FederalAndStateResearchAndDevelopmentCreditsExpirationYear" id="galt_FederalAndStateResearchAndDevelopmentCreditsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PercentageOfWeightedAverageStockPriceForDividendsPriorToPaymentDate" id="galt_PercentageOfWeightedAverageStockPriceForDividendsPriorToPaymentDate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfAward" id="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfAward" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ClinicalTrialAndResearchContingenciesAbstract" id="galt_ClinicalTrialAndResearchContingenciesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ContractCancelationNoticePeriod" id="galt_ContractCancelationNoticePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="NumberOfOperatingLeases" id="galt_NumberOfOperatingLeases" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="FreeRentPeriod" id="galt_FreeRentPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="BusinessOperatingSegmentMember" id="galt_BusinessOperatingSegmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>galt-20241231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 25.3.1.5296 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:type="simple" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/IncomeTaxesPrimaryFactorsAffectingIncomeTaxRatesDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#IncomeTaxesPrimaryFactorsAffectingIncomeTaxRatesDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/IncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#IncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/CommitmentsAndContingenciesDetailsCalc2" xlink:type="simple" xlink:href="galt-20241231.xsd#CommitmentsAndContingenciesDetailsCalc2" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/CommitmentsAndContingenciesDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#CommitmentsAndContingenciesDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#AccruedExpensesDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/PropertyAndEquipmentDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#PropertyAndEquipmentDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="simple" xlink:href="galt-20241231.xsd#ConsolidatedStatementsOfCashFlows" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/ConsolidatedStatementsOfOperations" xlink:type="simple" xlink:href="galt-20241231.xsd#ConsolidatedStatementsOfOperations" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="galt-20241231.xsd#ConsolidatedBalanceSheets" />
  <link:calculationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/ConsolidatedBalanceSheets">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsPayableCurrent" xlink:label="DividendsPayableCurrent" xlink:title="DividendsPayableCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="DividendsPayableCurrent" xlink:title="calculation: LiabilitiesCurrent to DividendsPayableCurrent" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="AccruedLiabilitiesCurrent" xlink:title="calculation: LiabilitiesCurrent to AccruedLiabilitiesCurrent" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="AccountsPayableCurrent" xlink:title="calculation: LiabilitiesCurrent to AccountsPayableCurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="DerivativeLiabilitiesCurrent" xlink:title="DerivativeLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="DerivativeLiabilitiesCurrent" xlink:title="calculation: LiabilitiesCurrent to DerivativeLiabilitiesCurrent" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyCurrent" xlink:label="ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyCurrent" xlink:title="ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyCurrent" xlink:title="calculation: LiabilitiesCurrent to ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyCurrent" order="4.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Liabilities" xlink:to="LiabilitiesCurrent" xlink:title="calculation: Liabilities to LiabilitiesCurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="OtherLiabilitiesNoncurrent" xlink:title="OtherLiabilitiesNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Liabilities" xlink:to="OtherLiabilitiesNoncurrent" xlink:title="calculation: Liabilities to OtherLiabilitiesNoncurrent" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent" xlink:label="ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent" xlink:title="ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Liabilities" xlink:to="ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent" xlink:title="calculation: Liabilities to ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent" order="6.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="DerivativeLiabilitiesNoncurrent" xlink:title="DerivativeLiabilitiesNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Liabilities" xlink:to="DerivativeLiabilitiesNoncurrent" xlink:title="calculation: Liabilities to DerivativeLiabilitiesNoncurrent" order="7.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent" xlink:label="BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent" xlink:title="BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Liabilities" xlink:to="BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent" xlink:title="calculation: Liabilities to BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent" order="5.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="Liabilities" xlink:title="calculation: LiabilitiesAndStockholdersEquity to Liabilities" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="TemporaryEquityCarryingAmountAttributableToParent" xlink:title="TemporaryEquityCarryingAmountAttributableToParent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="TemporaryEquityCarryingAmountAttributableToParent" xlink:title="calculation: LiabilitiesAndStockholdersEquity to TemporaryEquityCarryingAmountAttributableToParent" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="calculation: StockholdersEquity to RetainedEarningsAccumulatedDeficit" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="PreferredStockValue" xlink:title="PreferredStockValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="PreferredStockValue" xlink:title="calculation: StockholdersEquity to PreferredStockValue" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="AdditionalPaidInCapital" xlink:title="calculation: StockholdersEquity to AdditionalPaidInCapital" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_UndesignatedCapitalStockValue" xlink:label="UndesignatedCapitalStockValue" xlink:title="UndesignatedCapitalStockValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="UndesignatedCapitalStockValue" xlink:title="calculation: StockholdersEquity to UndesignatedCapitalStockValue" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="CommonStockValue" xlink:title="calculation: StockholdersEquity to CommonStockValue" order="3.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="StockholdersEquity" xlink:title="calculation: LiabilitiesAndStockholdersEquity to StockholdersEquity" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="CommitmentsAndContingencies" xlink:title="CommitmentsAndContingencies" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="CommitmentsAndContingencies" xlink:title="calculation: LiabilitiesAndStockholdersEquity to CommitmentsAndContingencies" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="OtherAssetsNoncurrent" xlink:title="OtherAssetsNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Assets" xlink:to="OtherAssetsNoncurrent" xlink:title="calculation: Assets to OtherAssetsNoncurrent" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="calculation: AssetsCurrent to CashAndCashEquivalentsAtCarryingValue" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="calculation: AssetsCurrent to PrepaidExpenseAndOtherAssetsCurrent" order="2.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Assets" xlink:to="AssetsCurrent" xlink:title="calculation: Assets to AssetsCurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Assets" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="calculation: Assets to PropertyPlantAndEquipmentNet" order="2.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/ConsolidatedStatementsOfOperations">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="PreferredStockDividendsAndOtherAdjustments" xlink:title="PreferredStockDividendsAndOtherAdjustments" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="PreferredStockDividendsAndOtherAdjustments" xlink:title="calculation: NetIncomeLossAvailableToCommonStockholdersBasic to PreferredStockDividendsAndOtherAdjustments" order="4.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="NonoperatingIncomeExpense" xlink:title="NonoperatingIncomeExpense" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="InvestmentIncomeInterest" xlink:title="InvestmentIncomeInterest" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NonoperatingIncomeExpense" xlink:to="InvestmentIncomeInterest" xlink:title="calculation: NonoperatingIncomeExpense to InvestmentIncomeInterest" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="InterestExpenseNonoperating" xlink:title="InterestExpenseNonoperating" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NonoperatingIncomeExpense" xlink:to="InterestExpenseNonoperating" xlink:title="calculation: NonoperatingIncomeExpense to InterestExpenseNonoperating" order="3.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:label="DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:title="DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NonoperatingIncomeExpense" xlink:to="DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:title="calculation: NonoperatingIncomeExpense to DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" order="1.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="NonoperatingIncomeExpense" xlink:title="calculation: NetIncomeLoss to NonoperatingIncomeExpense" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="OperatingExpenses" xlink:to="ResearchAndDevelopmentExpense" xlink:title="calculation: OperatingExpenses to ResearchAndDevelopmentExpense" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="OperatingExpenses" xlink:to="GeneralAndAdministrativeExpense" xlink:title="calculation: OperatingExpenses to GeneralAndAdministrativeExpense" order="2.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="OperatingIncomeLoss" xlink:to="OperatingExpenses" xlink:title="calculation: OperatingIncomeLoss to OperatingExpenses" order="1.0" weight="-1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="OperatingIncomeLoss" xlink:title="calculation: NetIncomeLoss to OperatingIncomeLoss" order="1.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="NetIncomeLoss" xlink:title="calculation: NetIncomeLossAvailableToCommonStockholdersBasic to NetIncomeLoss" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_FairValueAdjustmentOfWarrant" xlink:label="FairValueAdjustmentOfWarrant" xlink:title="FairValueAdjustmentOfWarrant" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="FairValueAdjustmentOfWarrant" xlink:title="calculation: NetIncomeLossAvailableToCommonStockholdersBasic to FairValueAdjustmentOfWarrant" order="3.0" weight="-1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/ConsolidatedStatementsOfCashFlows">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="NetCashProvidedByUsedInFinancingActivities" xlink:title="NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="ProceedsFromLinesOfCredit" xlink:title="ProceedsFromLinesOfCredit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="ProceedsFromLinesOfCredit" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to ProceedsFromLinesOfCredit" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="ProceedsFromWarrantExercises" xlink:title="ProceedsFromWarrantExercises" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="ProceedsFromWarrantExercises" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to ProceedsFromWarrantExercises" order="6.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="NetCashProvidedByUsedInFinancingActivities" xlink:title="calculation: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect to NetCashProvidedByUsedInFinancingActivities" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" xlink:title="NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="FairValueAdjustmentOfWarrants" xlink:title="FairValueAdjustmentOfWarrants" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="FairValueAdjustmentOfWarrants" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to FairValueAdjustmentOfWarrants" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="ShareBasedCompensation" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to ShareBasedCompensation" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="6.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaidInKindInterest" xlink:label="PaidInKindInterest" xlink:title="PaidInKindInterest" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="PaidInKindInterest" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to PaidInKindInterest" order="7.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="NetIncomeLoss" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to NetIncomeLoss" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="9.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:title="OperatingLeaseRightOfUseAssetAmortizationExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to OperatingLeaseRightOfUseAssetAmortizationExpense" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="IncreaseDecreaseInInterestPayableNet" xlink:title="IncreaseDecreaseInInterestPayableNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInInterestPayableNet" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInInterestPayableNet" order="3.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="NetCashProvidedByUsedInOperatingActivities" xlink:title="calculation: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect to NetCashProvidedByUsedInOperatingActivities" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="NetCashProvidedByUsedInInvestingActivities" xlink:title="NetCashProvidedByUsedInInvestingActivities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="NetCashProvidedByUsedInInvestingActivities" xlink:title="calculation: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect to NetCashProvidedByUsedInInvestingActivities" order="3.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/PropertyAndEquipmentDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="PropertyPlantAndEquipmentGross" xlink:title="PropertyPlantAndEquipmentGross" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="PropertyPlantAndEquipmentGross" xlink:title="calculation: PropertyPlantAndEquipmentNet to PropertyPlantAndEquipmentGross" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="calculation: PropertyPlantAndEquipmentNet to AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0" weight="-1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/AccruedExpensesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="AccruedProfessionalFeesCurrent" xlink:title="AccruedProfessionalFeesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="AccruedProfessionalFeesCurrent" xlink:title="calculation: AccruedLiabilitiesCurrent to AccruedProfessionalFeesCurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_AccruedResearchAndDevelopmentCostsAndOtherCurrent" xlink:label="AccruedResearchAndDevelopmentCostsAndOtherCurrent" xlink:title="AccruedResearchAndDevelopmentCostsAndOtherCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="AccruedResearchAndDevelopmentCostsAndOtherCurrent" xlink:title="calculation: AccruedLiabilitiesCurrent to AccruedResearchAndDevelopmentCostsAndOtherCurrent" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="EmployeeRelatedLiabilitiesCurrent" xlink:title="EmployeeRelatedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="EmployeeRelatedLiabilitiesCurrent" xlink:title="calculation: AccruedLiabilitiesCurrent to EmployeeRelatedLiabilitiesCurrent" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="OperatingLeaseLiabilityCurrent" xlink:title="OperatingLeaseLiabilityCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="OperatingLeaseLiabilityCurrent" xlink:title="calculation: AccruedLiabilitiesCurrent to OperatingLeaseLiabilityCurrent" order="3.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/CommitmentsAndContingenciesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/CommitmentsAndContingenciesDetailsCalc2">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="OperatingLeaseLiability" xlink:title="OperatingLeaseLiability" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="OperatingLeaseLiability" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to OperatingLeaseLiability" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/IncomeTaxesComponentsOfNetDeferredTaxAssetsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="DeferredTaxAssetsNet" xlink:title="DeferredTaxAssetsNet" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="DeferredTaxAssetsValuationAllowance" xlink:title="DeferredTaxAssetsValuationAllowance" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="DeferredTaxAssetsNet" xlink:to="DeferredTaxAssetsValuationAllowance" xlink:title="calculation: DeferredTaxAssetsNet to DeferredTaxAssetsValuationAllowance" order="1.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="DeferredTaxAssetsGross" xlink:title="DeferredTaxAssetsGross" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="DeferredTaxAssetsTaxCreditCarryforwards" xlink:title="DeferredTaxAssetsTaxCreditCarryforwards" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="DeferredTaxAssetsGross" xlink:to="DeferredTaxAssetsTaxCreditCarryforwards" xlink:title="calculation: DeferredTaxAssetsGross to DeferredTaxAssetsTaxCreditCarryforwards" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="DeferredTaxAssetsOperatingLossCarryforwards" xlink:title="DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="DeferredTaxAssetsGross" xlink:to="DeferredTaxAssetsOperatingLossCarryforwards" xlink:title="calculation: DeferredTaxAssetsGross to DeferredTaxAssetsOperatingLossCarryforwards" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="DeferredTaxAssetsOther" xlink:title="DeferredTaxAssetsOther" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="DeferredTaxAssetsGross" xlink:to="DeferredTaxAssetsOther" xlink:title="calculation: DeferredTaxAssetsGross to DeferredTaxAssetsOther" order="2.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="DeferredTaxAssetsNet" xlink:to="DeferredTaxAssetsGross" xlink:title="calculation: DeferredTaxAssetsNet to DeferredTaxAssetsGross" order="0.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/IncomeTaxesPrimaryFactorsAffectingIncomeTaxRatesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="EffectiveIncomeTaxRateContinuingOperations" xlink:title="EffectiveIncomeTaxRateContinuingOperations" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:title="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:title="calculation: EffectiveIncomeTaxRateContinuingOperations to EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:title="EffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:title="calculation: EffectiveIncomeTaxRateContinuingOperations to EffectiveIncomeTaxRateReconciliationNondeductibleExpense" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:title="EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:title="calculation: EffectiveIncomeTaxRateContinuingOperations to EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:title="EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:title="calculation: EffectiveIncomeTaxRateContinuingOperations to EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:title="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:title="calculation: EffectiveIncomeTaxRateContinuingOperations to EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="6.0" weight="1.0" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>galt-20241231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 25.3.1.5296 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:t1="http://xbrl.org/2005/xbrldt">
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#eedm" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/SubsequentEventDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#SubsequentEventDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/SegmentsSignificantAssetCategoriesDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#SegmentsSignificantAssetCategoriesDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/SegmentsSignificantExpenseCategoriesDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#SegmentsSignificantExpenseCategoriesDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/IncomeTaxesPrimaryFactorsAffectingIncomeTaxRatesDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#IncomeTaxesPrimaryFactorsAffectingIncomeTaxRatesDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/IncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#IncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/GalectinSciencesLlcDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#GalectinSciencesLlcDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/CommitmentsAndContingenciesDetailsCalc2" xlink:type="simple" xlink:href="galt-20241231.xsd#CommitmentsAndContingenciesDetailsCalc2" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/CommitmentsAndContingenciesDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#CommitmentsAndContingenciesDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/LossPerShareDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#LossPerShareDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedPartyDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedPartyDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/StockbasedCompensationDeferredStockUnitsDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#StockbasedCompensationDeferredStockUnitsDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/StockbasedCompensationRestrictedStockIssuancesDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#StockbasedCompensationRestrictedStockIssuancesDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/StockbasedCompensationOutstandingAndExercisableOptionsUnderStockBasedCompensationPlansDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#StockbasedCompensationOutstandingAndExercisableOptionsUnderStockBasedCompensationPlansDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/StockbasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#StockbasedCompensationStockOptionActivityDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/StockbasedCompensationWeightedAverageAssumptionsUsedToDetermineFairValueOfOptionsGrantedDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#StockbasedCompensationWeightedAverageAssumptionsUsedToDetermineFairValueOfOptionsGrantedDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/StockbasedCompensationComponentsOfStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#StockbasedCompensationComponentsOfStockbasedCompensationExpenseDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/StockbasedCompensationSummaryOfStockbasedCompensationPlansDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#StockbasedCompensationSummaryOfStockbasedCompensationPlansDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/WarrantsSummaryOfOutstandingWarrantsIssuedInConnectionWithEquityAndDebtFinancingAndConsultantsDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#WarrantsSummaryOfOutstandingWarrantsIssuedInConnectionWithEquityAndDebtFinancingAndConsultantsDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/WarrantsSummaryOfPurchaseWarrantsDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#WarrantsSummaryOfPurchaseWarrantsDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/WarrantsSummaryOfWarrantActivityDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#WarrantsSummaryOfWarrantActivityDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/StockholdersEquityReturnOnInvestmentDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#StockholdersEquityReturnOnInvestmentDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/StockholdersEquitySeriesC6SuperDividendRedeemableConvertiblePreferredStockDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#StockholdersEquitySeriesC6SuperDividendRedeemableConvertiblePreferredStockDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/StockholdersEquitySeries12ConvertiblePreferredStockDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#StockholdersEquitySeries12ConvertiblePreferredStockDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/StockholdersEquityIssuanceOfCommonStockDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#StockholdersEquityIssuanceOfCommonStockDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsRollForwardOfDerivativeLiabilityDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#FairValueOfFinancialInstrumentsRollForwardOfDerivativeLiabilityDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsKeyAssumptionsDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#FairValueOfFinancialInstrumentsKeyAssumptionsDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#ConvertibleNotesPayableRelatedPartyDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#AccruedExpensesDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/PropertyAndEquipmentDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#PropertyAndEquipmentDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesWarrantsDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#SummaryOfSignificantAccountingPoliciesWarrantsDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesLonglivedAssetsDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#SummaryOfSignificantAccountingPoliciesLonglivedAssetsDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesSecurityDepositDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#SummaryOfSignificantAccountingPoliciesSecurityDepositDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#SummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/NatureOfBusinessBasisOfPresentationLiquidityAndGoingConcernDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#NatureOfBusinessBasisOfPresentationLiquidityAndGoingConcernDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/SegmentsTables" xlink:type="simple" xlink:href="galt-20241231.xsd#SegmentsTables" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="galt-20241231.xsd#IncomeTaxesTables" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/CommitmentsAndContingenciesTables" xlink:type="simple" xlink:href="galt-20241231.xsd#CommitmentsAndContingenciesTables" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/LossPerShareTables" xlink:type="simple" xlink:href="galt-20241231.xsd#LossPerShareTables" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/StockbasedCompensationTables" xlink:type="simple" xlink:href="galt-20241231.xsd#StockbasedCompensationTables" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/WarrantsTables" xlink:type="simple" xlink:href="galt-20241231.xsd#WarrantsTables" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsTables" xlink:type="simple" xlink:href="galt-20241231.xsd#FairValueOfFinancialInstrumentsTables" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/AccruedExpensesTables" xlink:type="simple" xlink:href="galt-20241231.xsd#AccruedExpensesTables" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/PropertyAndEquipmentTables" xlink:type="simple" xlink:href="galt-20241231.xsd#PropertyAndEquipmentTables" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="galt-20241231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="simple" xlink:href="galt-20241231.xsd#CybersecurityRiskManagementAndStrategyDisclosure" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/SubsequentEvent" xlink:type="simple" xlink:href="galt-20241231.xsd#SubsequentEvent" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/Segments" xlink:type="simple" xlink:href="galt-20241231.xsd#Segments" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/IncomeTaxes" xlink:type="simple" xlink:href="galt-20241231.xsd#IncomeTaxes" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/GalectinSciencesLlc" xlink:type="simple" xlink:href="galt-20241231.xsd#GalectinSciencesLlc" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/CommitmentsAndContingencies" xlink:type="simple" xlink:href="galt-20241231.xsd#CommitmentsAndContingencies" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/LossPerShare" xlink:type="simple" xlink:href="galt-20241231.xsd#LossPerShare" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedParty" xlink:type="simple" xlink:href="galt-20241231.xsd#ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedParty" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/StockbasedCompensation" xlink:type="simple" xlink:href="galt-20241231.xsd#StockbasedCompensation" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/Warrants" xlink:type="simple" xlink:href="galt-20241231.xsd#Warrants" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/StockholdersEquity" xlink:type="simple" xlink:href="galt-20241231.xsd#StockholdersEquity" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/FairValueOfFinancialInstruments" xlink:type="simple" xlink:href="galt-20241231.xsd#FairValueOfFinancialInstruments" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedParty" xlink:type="simple" xlink:href="galt-20241231.xsd#ConvertibleNotesPayableRelatedParty" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/AccruedExpenses" xlink:type="simple" xlink:href="galt-20241231.xsd#AccruedExpenses" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/PropertyAndEquipment" xlink:type="simple" xlink:href="galt-20241231.xsd#PropertyAndEquipment" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="simple" xlink:href="galt-20241231.xsd#SummaryOfSignificantAccountingPolicies" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/NatureOfBusinessBasisOfPresentationLiquidityAndGoingConcern" xlink:type="simple" xlink:href="galt-20241231.xsd#NatureOfBusinessBasisOfPresentationLiquidityAndGoingConcern" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="simple" xlink:href="galt-20241231.xsd#ConsolidatedStatementsOfCashFlows" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="simple" xlink:href="galt-20241231.xsd#ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/ConsolidatedStatementsOfOperations" xlink:type="simple" xlink:href="galt-20241231.xsd#ConsolidatedStatementsOfOperations" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="galt-20241231.xsd#ConsolidatedBalanceSheetsParenthetical" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="galt-20241231.xsd#ConsolidatedBalanceSheets" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="galt-20241231.xsd#DocumentAndEntityInformation" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/DocumentAndEntityInformation" />
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/ConsolidatedBalanceSheets" />
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical" />
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/ConsolidatedStatementsOfOperations" />
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="definition: StatementLineItems to IncreaseDecreaseInStockholdersEquityRollForward" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockholdersEquity" xlink:title="definition: StatementLineItems to StockholdersEquity" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="SharesOutstanding" xlink:title="SharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="SharesOutstanding" xlink:title="definition: StatementLineItems to SharesOutstanding" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ConvertiblePreferredStockDividends" xlink:label="ConvertiblePreferredStockDividends" xlink:title="ConvertiblePreferredStockDividends" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ConvertiblePreferredStockDividends" xlink:title="definition: StatementLineItems to ConvertiblePreferredStockDividends" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ConvertiblePreferredStockDividendsShares" xlink:label="ConvertiblePreferredStockDividendsShares" xlink:title="ConvertiblePreferredStockDividendsShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ConvertiblePreferredStockDividendsShares" xlink:title="definition: StatementLineItems to ConvertiblePreferredStockDividendsShares" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_TemporaryEquityDividends" xlink:label="TemporaryEquityDividends" xlink:title="TemporaryEquityDividends" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="TemporaryEquityDividends" xlink:title="definition: StatementLineItems to TemporaryEquityDividends" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_TemporaryEquityDividendsShares" xlink:label="TemporaryEquityDividendsShares" xlink:title="TemporaryEquityDividendsShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="TemporaryEquityDividendsShares" xlink:title="definition: StatementLineItems to TemporaryEquityDividendsShares" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:title="StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:title="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_StockIssuedDuringPeriodValueWarrantExercise" xlink:label="StockIssuedDuringPeriodValueWarrantExercise" xlink:title="StockIssuedDuringPeriodValueWarrantExercise" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueWarrantExercise" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueWarrantExercise" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_StockIssuedDuringPeriodSharesWarrantExercise" xlink:label="StockIssuedDuringPeriodSharesWarrantExercise" xlink:title="StockIssuedDuringPeriodSharesWarrantExercise" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesWarrantExercise" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesWarrantExercise" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueStockOptionsExercised" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesStockOptionsExercised" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:title="StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:title="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:title="definition: StatementLineItems to AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_WarrantModificationIncreaseDecreaseInEquityAmount" xlink:label="WarrantModificationIncreaseDecreaseInEquityAmount" xlink:title="WarrantModificationIncreaseDecreaseInEquityAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="WarrantModificationIncreaseDecreaseInEquityAmount" xlink:title="definition: StatementLineItems to WarrantModificationIncreaseDecreaseInEquityAmount" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="definition: StatementLineItems to AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:title="StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="NetIncomeLoss" xlink:title="definition: StatementLineItems to NetIncomeLoss" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="20.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="StatementEquityComponentsAxis" xlink:title="definition: StatementTable to StatementEquityComponentsAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain_2" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain_2" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="PreferredStockMember" xlink:title="PreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="PreferredStockMember" xlink:title="definition: EquityComponentDomain to PreferredStockMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="CommonStockMember" xlink:title="definition: EquityComponentDomain to CommonStockMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="AdditionalPaidInCapitalMember" xlink:title="AdditionalPaidInCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="AdditionalPaidInCapitalMember" xlink:title="definition: EquityComponentDomain to AdditionalPaidInCapitalMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="RetainedEarningsMember" xlink:title="RetainedEarningsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="RetainedEarningsMember" xlink:title="definition: EquityComponentDomain to RetainedEarningsMember" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="StatementClassOfStockAxis" xlink:title="definition: StatementTable to StatementClassOfStockAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain_2" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain_2" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="SeriesAPreferredStockMember" xlink:title="SeriesAPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="SeriesAPreferredStockMember" xlink:title="definition: ClassOfStockDomain to SeriesAPreferredStockMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/ConsolidatedStatementsOfCashFlows" />
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/NatureOfBusinessBasisOfPresentationLiquidityAndGoingConcern" />
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPolicies" />
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/PropertyAndEquipment" />
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/AccruedExpenses" />
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedParty">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="DebtDisclosureTextBlock" xlink:title="DebtDisclosureTextBlock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtDisclosureTextBlock" xlink:title="definition: DebtInstrumentLineItems to DebtDisclosureTextBlock" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentTable" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentTable" order="2.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="LongtermDebtTypeAxis" xlink:title="LongtermDebtTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="LongtermDebtTypeAxis" xlink:title="definition: DebtInstrumentTable to LongtermDebtTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="LongtermDebtTypeDomain" xlink:title="LongtermDebtTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LongtermDebtTypeAxis" xlink:to="LongtermDebtTypeDomain" xlink:title="definition: LongtermDebtTypeAxis to LongtermDebtTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="LongtermDebtTypeDomain_2" xlink:title="LongtermDebtTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LongtermDebtTypeAxis" xlink:to="LongtermDebtTypeDomain_2" xlink:title="definition: LongtermDebtTypeAxis to LongtermDebtTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansPayableMember" xlink:label="LoansPayableMember" xlink:title="LoansPayableMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LongtermDebtTypeDomain" xlink:to="LoansPayableMember" xlink:title="definition: LongtermDebtTypeDomain to LoansPayableMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/FairValueOfFinancialInstruments" />
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/StockholdersEquity" />
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/Warrants" />
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/StockbasedCompensation" />
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedParty">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="DebtDisclosureTextBlock" xlink:title="DebtDisclosureTextBlock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtDisclosureTextBlock" xlink:title="definition: DebtInstrumentLineItems to DebtDisclosureTextBlock" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentTable" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentTable" order="2.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="LongtermDebtTypeAxis" xlink:title="LongtermDebtTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="LongtermDebtTypeAxis" xlink:title="definition: DebtInstrumentTable to LongtermDebtTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="LongtermDebtTypeDomain" xlink:title="LongtermDebtTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LongtermDebtTypeAxis" xlink:to="LongtermDebtTypeDomain" xlink:title="definition: LongtermDebtTypeAxis to LongtermDebtTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="LongtermDebtTypeDomain_2" xlink:title="LongtermDebtTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LongtermDebtTypeAxis" xlink:to="LongtermDebtTypeDomain_2" xlink:title="definition: LongtermDebtTypeAxis to LongtermDebtTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditMember" xlink:label="LineOfCreditMember" xlink:title="LineOfCreditMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LongtermDebtTypeDomain" xlink:to="LineOfCreditMember" xlink:title="definition: LongtermDebtTypeDomain to LineOfCreditMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/LossPerShare" />
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/CommitmentsAndContingencies" />
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/GalectinSciencesLlc" />
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/IncomeTaxes" />
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/Segments" />
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/SubsequentEvent" />
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/CybersecurityRiskManagementAndStrategyDisclosure" />
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/PropertyAndEquipmentTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/AccruedExpensesTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="3.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="DerivativeInstrumentRiskAxis" xlink:title="DerivativeInstrumentRiskAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="DerivativeInstrumentRiskAxis" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to DerivativeInstrumentRiskAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="DerivativeContractTypeDomain" xlink:title="DerivativeContractTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="DerivativeInstrumentRiskAxis" xlink:to="DerivativeContractTypeDomain" xlink:title="definition: DerivativeInstrumentRiskAxis to DerivativeContractTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="DerivativeContractTypeDomain_2" xlink:title="DerivativeContractTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DerivativeInstrumentRiskAxis" xlink:to="DerivativeContractTypeDomain_2" xlink:title="definition: DerivativeInstrumentRiskAxis to DerivativeContractTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ContingentInterestAprilNoteMember" xlink:label="ContingentInterestAprilNoteMember" xlink:title="ContingentInterestAprilNoteMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DerivativeContractTypeDomain" xlink:to="ContingentInterestAprilNoteMember" xlink:title="definition: DerivativeContractTypeDomain to ContingentInterestAprilNoteMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ContingentInterestSeptemberNoteMember" xlink:label="ContingentInterestSeptemberNoteMember" xlink:title="ContingentInterestSeptemberNoteMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DerivativeContractTypeDomain" xlink:to="ContingentInterestSeptemberNoteMember" xlink:title="definition: DerivativeContractTypeDomain to ContingentInterestSeptemberNoteMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ContingentInterestDecemberNoteMember" xlink:label="ContingentInterestDecemberNoteMember" xlink:title="ContingentInterestDecemberNoteMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DerivativeContractTypeDomain" xlink:to="ContingentInterestDecemberNoteMember" xlink:title="definition: DerivativeContractTypeDomain to ContingentInterestDecemberNoteMember" order="3.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/WarrantsTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/StockbasedCompensationTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/LossPerShareTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/CommitmentsAndContingenciesTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/IncomeTaxesTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/SegmentsTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/NatureOfBusinessBasisOfPresentationLiquidityAndGoingConcernDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:title="NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_NatureOfBusinessBasisOfPresentationsAndLiquidityAbstract" xlink:label="NatureOfBusinessBasisOfPresentationsAndLiquidityAbstract" xlink:title="NatureOfBusinessBasisOfPresentationsAndLiquidityAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="NatureOfBusinessBasisOfPresentationsAndLiquidityAbstract" xlink:title="definition: NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems to NatureOfBusinessBasisOfPresentationsAndLiquidityAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="definition: NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems to CashAndCashEquivalentsAtCarryingValue" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_NumberOfLineOfCredit" xlink:label="NumberOfLineOfCredit" xlink:title="NumberOfLineOfCredit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="NumberOfLineOfCredit" xlink:title="definition: NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems to NumberOfLineOfCredit" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="LineOfCreditFacilityMaximumBorrowingCapacity" xlink:title="LineOfCreditFacilityMaximumBorrowingCapacity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="LineOfCreditFacilityMaximumBorrowingCapacity" xlink:title="definition: NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems to LineOfCreditFacilityMaximumBorrowingCapacity" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:title="NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:title="definition: NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems to NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" order="5.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="definition: NewAccountingPronouncementsOrChangeInAccountingPrincipleTable to RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain_2" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain_2" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="BoardOfDirectorsChairmanMember" xlink:title="BoardOfDirectorsChairmanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyDomain" xlink:to="BoardOfDirectorsChairmanMember" xlink:title="definition: RelatedPartyDomain to BoardOfDirectorsChairmanMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="CreditFacilityAxis" xlink:title="CreditFacilityAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="CreditFacilityAxis" xlink:title="definition: NewAccountingPronouncementsOrChangeInAccountingPrincipleTable to CreditFacilityAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="CreditFacilityDomain" xlink:title="CreditFacilityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="CreditFacilityAxis" xlink:to="CreditFacilityDomain" xlink:title="definition: CreditFacilityAxis to CreditFacilityDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="CreditFacilityDomain_2" xlink:title="CreditFacilityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CreditFacilityAxis" xlink:to="CreditFacilityDomain_2" xlink:title="definition: CreditFacilityAxis to CreditFacilityDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditMember" xlink:label="LineOfCreditMember" xlink:title="LineOfCreditMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CreditFacilityDomain" xlink:to="LineOfCreditMember" xlink:title="definition: CreditFacilityDomain to LineOfCreditMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_SupplementalLineOfCreditMember" xlink:label="SupplementalLineOfCreditMember" xlink:title="SupplementalLineOfCreditMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CreditFacilityDomain" xlink:to="SupplementalLineOfCreditMember" xlink:title="definition: CreditFacilityDomain to SupplementalLineOfCreditMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="SubsequentEventTypeAxis" xlink:title="definition: NewAccountingPronouncementsOrChangeInAccountingPrincipleTable to SubsequentEventTypeAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain_2" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain_2" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="definition: SubsequentEventTypeDomain to SubsequentEventMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="PropertyPlantAndEquipmentLineItems" xlink:title="PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" xlink:title="PropertyPlantAndEquipmentAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentAbstract" xlink:title="definition: PropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="PropertyPlantAndEquipmentUsefulLife" xlink:title="PropertyPlantAndEquipmentUsefulLife" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentUsefulLife" xlink:title="definition: PropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentUsefulLife" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="definition: PropertyPlantAndEquipmentLineItems to ScheduleOfPropertyPlantAndEquipmentTable" order="3.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="PropertyPlantAndEquipmentByTypeAxis" xlink:title="definition: ScheduleOfPropertyPlantAndEquipmentTable to PropertyPlantAndEquipmentByTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain_2" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain_2" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ComputerAndOfficeEquipmentMember" xlink:label="ComputerAndOfficeEquipmentMember" xlink:title="ComputerAndOfficeEquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="ComputerAndOfficeEquipmentMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to ComputerAndOfficeEquipmentMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="FurnitureAndFixturesMember" xlink:title="FurnitureAndFixturesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="FurnitureAndFixturesMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to FurnitureAndFixturesMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesSecurityDepositDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesLonglivedAssetsDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesWarrantsDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/PropertyAndEquipmentDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="PropertyPlantAndEquipmentLineItems" xlink:title="PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="PropertyPlantAndEquipmentNetByTypeAbstract" xlink:title="PropertyPlantAndEquipmentNetByTypeAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentNetByTypeAbstract" xlink:title="definition: PropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentNetByTypeAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="DepreciationAndAmortization" xlink:title="DepreciationAndAmortization" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="DepreciationAndAmortization" xlink:title="definition: PropertyPlantAndEquipmentLineItems to DepreciationAndAmortization" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="PropertyPlantAndEquipmentGross" xlink:title="PropertyPlantAndEquipmentGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentGross" xlink:title="definition: PropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentGross" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="definition: PropertyPlantAndEquipmentLineItems to AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="definition: PropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentNet" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="definition: PropertyPlantAndEquipmentLineItems to ScheduleOfPropertyPlantAndEquipmentTable" order="6.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="PropertyPlantAndEquipmentByTypeAxis" xlink:title="definition: ScheduleOfPropertyPlantAndEquipmentTable to PropertyPlantAndEquipmentByTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain_2" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain_2" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="LeaseholdImprovementsMember" xlink:title="LeaseholdImprovementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="LeaseholdImprovementsMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to LeaseholdImprovementsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ComputerAndOfficeEquipmentMember" xlink:label="ComputerAndOfficeEquipmentMember" xlink:title="ComputerAndOfficeEquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="ComputerAndOfficeEquipmentMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to ComputerAndOfficeEquipmentMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="FurnitureAndFixturesMember" xlink:title="FurnitureAndFixturesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="FurnitureAndFixturesMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to FurnitureAndFixturesMember" order="3.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/AccruedExpensesDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ConvertibleNotesPayableRelatedPartyAbstract" xlink:label="ConvertibleNotesPayableRelatedPartyAbstract" xlink:title="ConvertibleNotesPayableRelatedPartyAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="ConvertibleNotesPayableRelatedPartyAbstract" xlink:title="definition: DebtInstrumentLineItems to ConvertibleNotesPayableRelatedPartyAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="DebtInstrumentFaceAmount" xlink:title="DebtInstrumentFaceAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentFaceAmount" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentFaceAmount" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="DebtConversionConvertedInstrumentAmount1" xlink:title="DebtConversionConvertedInstrumentAmount1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtConversionConvertedInstrumentAmount1" xlink:title="definition: DebtInstrumentLineItems to DebtConversionConvertedInstrumentAmount1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="DebtInstrumentMaturityDate" xlink:title="DebtInstrumentMaturityDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentMaturityDate" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentMaturityDate" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_NumberOfLoansClosing" xlink:label="NumberOfLoansClosing" xlink:title="NumberOfLoansClosing" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="NumberOfLoansClosing" xlink:title="definition: DebtInstrumentLineItems to NumberOfLoansClosing" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_NumberOfPromissoryNotesEvidencedByLoansAgreement" xlink:label="NumberOfPromissoryNotesEvidencedByLoansAgreement" xlink:title="NumberOfPromissoryNotesEvidencedByLoansAgreement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="NumberOfPromissoryNotesEvidencedByLoansAgreement" xlink:title="definition: DebtInstrumentLineItems to NumberOfPromissoryNotesEvidencedByLoansAgreement" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_NumberOfPromissoryNotesExecuted" xlink:label="NumberOfPromissoryNotesExecuted" xlink:title="NumberOfPromissoryNotesExecuted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="NumberOfPromissoryNotesExecuted" xlink:title="definition: DebtInstrumentLineItems to NumberOfPromissoryNotesExecuted" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="DebtInstrumentConvertibleConversionPrice1" xlink:title="DebtInstrumentConvertibleConversionPrice1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentConvertibleConversionPrice1" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentConvertibleConversionPrice1" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentInterestRateStatedPercentage" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentInterestRateStatedPercentage" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="DebtInstrumentInterestRateEffectivePercentage" xlink:title="DebtInstrumentInterestRateEffectivePercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentInterestRateEffectivePercentage" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentInterestRateEffectivePercentage" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt" xlink:label="InterestExpenseDebt" xlink:title="InterestExpenseDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="InterestExpenseDebt" xlink:title="definition: DebtInstrumentLineItems to InterestExpenseDebt" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_QuarterlyInterestRate" xlink:label="QuarterlyInterestRate" xlink:title="QuarterlyInterestRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="QuarterlyInterestRate" xlink:title="definition: DebtInstrumentLineItems to QuarterlyInterestRate" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_AnnualInterestRate" xlink:label="AnnualInterestRate" xlink:title="AnnualInterestRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="AnnualInterestRate" xlink:title="definition: DebtInstrumentLineItems to AnnualInterestRate" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="DerivativeLiabilitiesNoncurrent" xlink:title="DerivativeLiabilitiesNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DerivativeLiabilitiesNoncurrent" xlink:title="definition: DebtInstrumentLineItems to DerivativeLiabilitiesNoncurrent" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:label="DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:title="DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:title="definition: DebtInstrumentLineItems to DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="AmortizationOfFinancingCosts" xlink:title="AmortizationOfFinancingCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="AmortizationOfFinancingCosts" xlink:title="definition: DebtInstrumentLineItems to AmortizationOfFinancingCosts" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseOther" xlink:label="InterestExpenseOther" xlink:title="InterestExpenseOther" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="InterestExpenseOther" xlink:title="definition: DebtInstrumentLineItems to InterestExpenseOther" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:title="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:title="definition: DebtInstrumentLineItems to StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebt" xlink:label="RepaymentsOfDebt" xlink:title="RepaymentsOfDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="RepaymentsOfDebt" xlink:title="definition: DebtInstrumentLineItems to RepaymentsOfDebt" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentTable" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentTable" order="20.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentAxis" xlink:title="definition: DebtInstrumentTable to DebtInstrumentAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain_2" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain_2" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_AprilConvertiblePromissoryNoteMember" xlink:label="AprilConvertiblePromissoryNoteMember" xlink:title="AprilConvertiblePromissoryNoteMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="AprilConvertiblePromissoryNoteMember" xlink:title="definition: DebtInstrumentNameDomain to AprilConvertiblePromissoryNoteMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_SeptemberConvertiblePromissoryNoteMember" xlink:label="SeptemberConvertiblePromissoryNoteMember" xlink:title="SeptemberConvertiblePromissoryNoteMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="SeptemberConvertiblePromissoryNoteMember" xlink:title="definition: DebtInstrumentNameDomain to SeptemberConvertiblePromissoryNoteMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_DecemberConvertiblePromissoryNoteMember" xlink:label="DecemberConvertiblePromissoryNoteMember" xlink:title="DecemberConvertiblePromissoryNoteMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="DecemberConvertiblePromissoryNoteMember" xlink:title="definition: DebtInstrumentNameDomain to DecemberConvertiblePromissoryNoteMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_FirstClosingMember" xlink:label="FirstClosingMember" xlink:title="FirstClosingMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SeptemberConvertiblePromissoryNoteMember" xlink:to="FirstClosingMember" xlink:title="definition: SeptemberConvertiblePromissoryNoteMember to FirstClosingMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_SecondClosingMember" xlink:label="SecondClosingMember" xlink:title="SecondClosingMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SeptemberConvertiblePromissoryNoteMember" xlink:to="SecondClosingMember" xlink:title="definition: SeptemberConvertiblePromissoryNoteMember to SecondClosingMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="definition: DebtInstrumentTable to RelatedPartyTransactionsByRelatedPartyAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain_2" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain_2" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="BoardOfDirectorsChairmanMember" xlink:title="BoardOfDirectorsChairmanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyDomain" xlink:to="BoardOfDirectorsChairmanMember" xlink:title="definition: RelatedPartyDomain to BoardOfDirectorsChairmanMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="StatementScenarioAxis" xlink:title="definition: DebtInstrumentTable to StatementScenarioAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain" xlink:title="definition: StatementScenarioAxis to ScenarioUnspecifiedDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain_2" xlink:title="ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain_2" xlink:title="definition: StatementScenarioAxis to ScenarioUnspecifiedDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="ScenarioForecastMember" xlink:title="ScenarioForecastMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ScenarioUnspecifiedDomain" xlink:to="ScenarioForecastMember" xlink:title="definition: ScenarioUnspecifiedDomain to ScenarioForecastMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueNetAssetLiabilityAbstract" xlink:label="FairValueNetAssetLiabilityAbstract" xlink:title="FairValueNetAssetLiabilityAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueNetAssetLiabilityAbstract" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueNetAssetLiabilityAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="AssetsFairValueDisclosure" xlink:title="AssetsFairValueDisclosure" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="AssetsFairValueDisclosure" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to AssetsFairValueDisclosure" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="FinancialLiabilitiesFairValueDisclosure" xlink:title="FinancialLiabilitiesFairValueDisclosure" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FinancialLiabilitiesFairValueDisclosure" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FinancialLiabilitiesFairValueDisclosure" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="DerivativeLiabilitiesNoncurrent" xlink:title="DerivativeLiabilitiesNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="DerivativeLiabilitiesNoncurrent" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to DerivativeLiabilitiesNoncurrent" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="5.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="FairValueByMeasurementFrequencyAxis" xlink:title="FairValueByMeasurementFrequencyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByMeasurementFrequencyAxis" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByMeasurementFrequencyAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain" xlink:title="FairValueMeasurementFrequencyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="FairValueMeasurementFrequencyDomain" xlink:title="definition: FairValueByMeasurementFrequencyAxis to FairValueMeasurementFrequencyDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain_2" xlink:title="FairValueMeasurementFrequencyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="FairValueMeasurementFrequencyDomain_2" xlink:title="definition: FairValueByMeasurementFrequencyAxis to FairValueMeasurementFrequencyDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="FairValueMeasurementsRecurringMember" xlink:title="FairValueMeasurementsRecurringMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueMeasurementFrequencyDomain" xlink:to="FairValueMeasurementsRecurringMember" xlink:title="definition: FairValueMeasurementFrequencyDomain to FairValueMeasurementsRecurringMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="DerivativeInstrumentRiskAxis" xlink:title="DerivativeInstrumentRiskAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="DerivativeInstrumentRiskAxis" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to DerivativeInstrumentRiskAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="DerivativeContractTypeDomain" xlink:title="DerivativeContractTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="DerivativeInstrumentRiskAxis" xlink:to="DerivativeContractTypeDomain" xlink:title="definition: DerivativeInstrumentRiskAxis to DerivativeContractTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="DerivativeContractTypeDomain_2" xlink:title="DerivativeContractTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DerivativeInstrumentRiskAxis" xlink:to="DerivativeContractTypeDomain_2" xlink:title="definition: DerivativeInstrumentRiskAxis to DerivativeContractTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ContingentInterestAprilNoteMember" xlink:label="ContingentInterestAprilNoteMember" xlink:title="ContingentInterestAprilNoteMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DerivativeContractTypeDomain" xlink:to="ContingentInterestAprilNoteMember" xlink:title="definition: DerivativeContractTypeDomain to ContingentInterestAprilNoteMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ContingentInterestSeptemberNoteMember" xlink:label="ContingentInterestSeptemberNoteMember" xlink:title="ContingentInterestSeptemberNoteMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DerivativeContractTypeDomain" xlink:to="ContingentInterestSeptemberNoteMember" xlink:title="definition: DerivativeContractTypeDomain to ContingentInterestSeptemberNoteMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ContingentInterestDecemberNoteMember" xlink:label="ContingentInterestDecemberNoteMember" xlink:title="ContingentInterestDecemberNoteMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DerivativeContractTypeDomain" xlink:to="ContingentInterestDecemberNoteMember" xlink:title="definition: DerivativeContractTypeDomain to ContingentInterestDecemberNoteMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByFairValueHierarchyLevelAxis" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByFairValueHierarchyLevelAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="definition: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain_2" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain_2" xlink:title="definition: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel12And3Member" xlink:label="FairValueInputsLevel12And3Member" xlink:title="FairValueInputsLevel12And3Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel12And3Member" xlink:title="definition: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel12And3Member" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="FairValueInputsLevel1Member" xlink:title="FairValueInputsLevel1Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueInputsLevel12And3Member" xlink:to="FairValueInputsLevel1Member" xlink:title="definition: FairValueInputsLevel12And3Member to FairValueInputsLevel1Member" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="FairValueInputsLevel2Member" xlink:title="FairValueInputsLevel2Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueInputsLevel12And3Member" xlink:to="FairValueInputsLevel2Member" xlink:title="definition: FairValueInputsLevel12And3Member to FairValueInputsLevel2Member" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="FairValueInputsLevel3Member" xlink:title="FairValueInputsLevel3Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueInputsLevel12And3Member" xlink:to="FairValueInputsLevel3Member" xlink:title="definition: FairValueInputsLevel12And3Member to FairValueInputsLevel3Member" order="3.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsKeyAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueAndInputDescriptionAbstract" xlink:label="ValuationTechniqueAndInputDescriptionAbstract" xlink:title="ValuationTechniqueAndInputDescriptionAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="ValuationTechniqueAndInputDescriptionAbstract" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems to ValuationTechniqueAndInputDescriptionAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="DerivativeLiabilityMeasurementInput" xlink:title="DerivativeLiabilityMeasurementInput" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="DerivativeLiabilityMeasurementInput" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems to DerivativeLiabilityMeasurementInput" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm" xlink:label="DebtInstrumentTerm" xlink:title="DebtInstrumentTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="DebtInstrumentTerm" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems to DebtInstrumentTerm" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="4.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="MeasurementInputTypeAxis" xlink:title="MeasurementInputTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="MeasurementInputTypeAxis" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable to MeasurementInputTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="MeasurementInputTypeDomain" xlink:title="MeasurementInputTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="MeasurementInputTypeAxis" xlink:to="MeasurementInputTypeDomain" xlink:title="definition: MeasurementInputTypeAxis to MeasurementInputTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="MeasurementInputTypeDomain_2" xlink:title="MeasurementInputTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="MeasurementInputTypeAxis" xlink:to="MeasurementInputTypeDomain_2" xlink:title="definition: MeasurementInputTypeAxis to MeasurementInputTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="MeasurementInputSharePriceMember" xlink:title="MeasurementInputSharePriceMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="MeasurementInputTypeDomain" xlink:to="MeasurementInputSharePriceMember" xlink:title="definition: MeasurementInputTypeDomain to MeasurementInputSharePriceMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputConversionPriceMember" xlink:label="MeasurementInputConversionPriceMember" xlink:title="MeasurementInputConversionPriceMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="MeasurementInputTypeDomain" xlink:to="MeasurementInputConversionPriceMember" xlink:title="definition: MeasurementInputTypeDomain to MeasurementInputConversionPriceMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="MeasurementInputExpectedTermMember" xlink:title="MeasurementInputExpectedTermMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="MeasurementInputTypeDomain" xlink:to="MeasurementInputExpectedTermMember" xlink:title="definition: MeasurementInputTypeDomain to MeasurementInputExpectedTermMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="MeasurementInputRiskFreeInterestRateMember" xlink:title="MeasurementInputRiskFreeInterestRateMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="MeasurementInputTypeDomain" xlink:to="MeasurementInputRiskFreeInterestRateMember" xlink:title="definition: MeasurementInputTypeDomain to MeasurementInputRiskFreeInterestRateMember" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="MeasurementInputDiscountRateMember" xlink:title="MeasurementInputDiscountRateMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="MeasurementInputTypeDomain" xlink:to="MeasurementInputDiscountRateMember" xlink:title="definition: MeasurementInputTypeDomain to MeasurementInputDiscountRateMember" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="MeasurementInputPriceVolatilityMember" xlink:title="MeasurementInputPriceVolatilityMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="MeasurementInputTypeDomain" xlink:to="MeasurementInputPriceVolatilityMember" xlink:title="definition: MeasurementInputTypeDomain to MeasurementInputPriceVolatilityMember" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="MeasurementInputExpectedDividendRateMember" xlink:title="MeasurementInputExpectedDividendRateMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="MeasurementInputTypeDomain" xlink:to="MeasurementInputExpectedDividendRateMember" xlink:title="definition: MeasurementInputTypeDomain to MeasurementInputExpectedDividendRateMember" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="DerivativeInstrumentRiskAxis" xlink:title="DerivativeInstrumentRiskAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="DerivativeInstrumentRiskAxis" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable to DerivativeInstrumentRiskAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="DerivativeContractTypeDomain" xlink:title="DerivativeContractTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="DerivativeInstrumentRiskAxis" xlink:to="DerivativeContractTypeDomain" xlink:title="definition: DerivativeInstrumentRiskAxis to DerivativeContractTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="DerivativeContractTypeDomain_2" xlink:title="DerivativeContractTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DerivativeInstrumentRiskAxis" xlink:to="DerivativeContractTypeDomain_2" xlink:title="definition: DerivativeInstrumentRiskAxis to DerivativeContractTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ContingentInterestAprilNoteMember" xlink:label="ContingentInterestAprilNoteMember" xlink:title="ContingentInterestAprilNoteMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DerivativeContractTypeDomain" xlink:to="ContingentInterestAprilNoteMember" xlink:title="definition: DerivativeContractTypeDomain to ContingentInterestAprilNoteMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ContingentInterestSeptemberNoteMember" xlink:label="ContingentInterestSeptemberNoteMember" xlink:title="ContingentInterestSeptemberNoteMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DerivativeContractTypeDomain" xlink:to="ContingentInterestSeptemberNoteMember" xlink:title="definition: DerivativeContractTypeDomain to ContingentInterestSeptemberNoteMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ContingentInterestDecemberNoteMember" xlink:label="ContingentInterestDecemberNoteMember" xlink:title="ContingentInterestDecemberNoteMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DerivativeContractTypeDomain" xlink:to="ContingentInterestDecemberNoteMember" xlink:title="definition: DerivativeContractTypeDomain to ContingentInterestDecemberNoteMember" order="3.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsRollForwardOfDerivativeLiabilityDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="DerivativeLiabilitiesNoncurrent" xlink:title="DerivativeLiabilitiesNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="DerivativeLiabilitiesNoncurrent" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to DerivativeLiabilitiesNoncurrent" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="FairValueAdjustmentOfWarrants" xlink:title="FairValueAdjustmentOfWarrants" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueAdjustmentOfWarrants" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueAdjustmentOfWarrants" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="4.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="DerivativeInstrumentRiskAxis" xlink:title="DerivativeInstrumentRiskAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="DerivativeInstrumentRiskAxis" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to DerivativeInstrumentRiskAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="DerivativeContractTypeDomain" xlink:title="DerivativeContractTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="DerivativeInstrumentRiskAxis" xlink:to="DerivativeContractTypeDomain" xlink:title="definition: DerivativeInstrumentRiskAxis to DerivativeContractTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="DerivativeContractTypeDomain_2" xlink:title="DerivativeContractTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DerivativeInstrumentRiskAxis" xlink:to="DerivativeContractTypeDomain_2" xlink:title="definition: DerivativeInstrumentRiskAxis to DerivativeContractTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ContingentInterestAprilNoteMember" xlink:label="ContingentInterestAprilNoteMember" xlink:title="ContingentInterestAprilNoteMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DerivativeContractTypeDomain" xlink:to="ContingentInterestAprilNoteMember" xlink:title="definition: DerivativeContractTypeDomain to ContingentInterestAprilNoteMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ContingentInterestSeptemberNoteMember" xlink:label="ContingentInterestSeptemberNoteMember" xlink:title="ContingentInterestSeptemberNoteMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DerivativeContractTypeDomain" xlink:to="ContingentInterestSeptemberNoteMember" xlink:title="definition: DerivativeContractTypeDomain to ContingentInterestSeptemberNoteMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ContingentInterestDecemberNoteMember" xlink:label="ContingentInterestDecemberNoteMember" xlink:title="ContingentInterestDecemberNoteMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DerivativeContractTypeDomain" xlink:to="ContingentInterestDecemberNoteMember" xlink:title="definition: DerivativeContractTypeDomain to ContingentInterestDecemberNoteMember" order="3.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/StockholdersEquityIssuanceOfCommonStockDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="ClassOfStockLineItems" xlink:title="ClassOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" xlink:title="StockholdersEquityNoteAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="StockholdersEquityNoteAbstract" xlink:title="definition: ClassOfStockLineItems to StockholdersEquityNoteAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="CommonStockSharesAuthorized" xlink:title="definition: ClassOfStockLineItems to CommonStockSharesAuthorized" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_UndesignatedCapitalStockSharesAuthorized" xlink:label="UndesignatedCapitalStockSharesAuthorized" xlink:title="UndesignatedCapitalStockSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="UndesignatedCapitalStockSharesAuthorized" xlink:title="definition: ClassOfStockLineItems to UndesignatedCapitalStockSharesAuthorized" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="PreferredStockSharesAuthorized" xlink:title="PreferredStockSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="PreferredStockSharesAuthorized" xlink:title="definition: ClassOfStockLineItems to PreferredStockSharesAuthorized" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_AggregateOfferingPrice" xlink:label="AggregateOfferingPrice" xlink:title="AggregateOfferingPrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="AggregateOfferingPrice" xlink:title="definition: ClassOfStockLineItems to AggregateOfferingPrice" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_CommissionRate" xlink:label="CommissionRate" xlink:title="CommissionRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="CommissionRate" xlink:title="definition: ClassOfStockLineItems to CommissionRate" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="CommonStockSharesIssued" xlink:title="definition: ClassOfStockLineItems to CommonStockSharesIssued" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="ScheduleOfStockByClassTable" xlink:title="ScheduleOfStockByClassTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ClassOfStockLineItems" xlink:to="ScheduleOfStockByClassTable" xlink:title="definition: ClassOfStockLineItems to ScheduleOfStockByClassTable" order="8.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfStockByClassTable" xlink:to="StatementClassOfStockAxis" xlink:title="definition: ScheduleOfStockByClassTable to StatementClassOfStockAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain_2" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain_2" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="SeriesAPreferredStockMember" xlink:title="SeriesAPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="SeriesAPreferredStockMember" xlink:title="definition: ClassOfStockDomain to SeriesAPreferredStockMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_SeriesBOneConvertiblePreferredStockMember" xlink:label="SeriesBOneConvertiblePreferredStockMember" xlink:title="SeriesBOneConvertiblePreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="SeriesBOneConvertiblePreferredStockMember" xlink:title="definition: ClassOfStockDomain to SeriesBOneConvertiblePreferredStockMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_SeriesBTwoConvertiblePreferredStockMember" xlink:label="SeriesBTwoConvertiblePreferredStockMember" xlink:title="SeriesBTwoConvertiblePreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="SeriesBTwoConvertiblePreferredStockMember" xlink:title="definition: ClassOfStockDomain to SeriesBTwoConvertiblePreferredStockMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_SeriesBThreeConvertiblePreferredStockMember" xlink:label="SeriesBThreeConvertiblePreferredStockMember" xlink:title="SeriesBThreeConvertiblePreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="SeriesBThreeConvertiblePreferredStockMember" xlink:title="definition: ClassOfStockDomain to SeriesBThreeConvertiblePreferredStockMember" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="SeriesCPreferredStockMember" xlink:title="SeriesCPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="SeriesCPreferredStockMember" xlink:title="definition: ClassOfStockDomain to SeriesCPreferredStockMember" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfStockByClassTable" xlink:to="StatementEquityComponentsAxis" xlink:title="definition: ScheduleOfStockByClassTable to StatementEquityComponentsAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain_2" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain_2" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="CommonStockMember" xlink:title="definition: EquityComponentDomain to CommonStockMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfStockByClassTable" xlink:to="TypeOfArrangementAxis" xlink:title="definition: ScheduleOfStockByClassTable to TypeOfArrangementAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_TwoThousandTwentyMarketAgreementMember" xlink:label="TwoThousandTwentyMarketAgreementMember" xlink:title="TwoThousandTwentyMarketAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="TwoThousandTwentyMarketAgreementMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to TwoThousandTwentyMarketAgreementMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_TwoThousandSeventeenMarketAgreementMember" xlink:label="TwoThousandSeventeenMarketAgreementMember" xlink:title="TwoThousandSeventeenMarketAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="TwoThousandSeventeenMarketAgreementMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to TwoThousandSeventeenMarketAgreementMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/StockholdersEquitySeries12ConvertiblePreferredStockDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="ClassOfStockLineItems" xlink:title="ClassOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" xlink:title="StockholdersEquityNoteAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="StockholdersEquityNoteAbstract" xlink:title="definition: ClassOfStockLineItems to StockholdersEquityNoteAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="PreferredStockDividendRatePercentage" xlink:title="PreferredStockDividendRatePercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="PreferredStockDividendRatePercentage" xlink:title="definition: ClassOfStockLineItems to PreferredStockDividendRatePercentage" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="SharesIssuedPricePerShare" xlink:title="SharesIssuedPricePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="SharesIssuedPricePerShare" xlink:title="definition: ClassOfStockLineItems to SharesIssuedPricePerShare" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:title="definition: ClassOfStockLineItems to ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="definition: ClassOfStockLineItems to ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_PercentageOfWeightedAverageStockPriceForDividendsPriorToPaymentDate" xlink:label="PercentageOfWeightedAverageStockPriceForDividendsPriorToPaymentDate" xlink:title="PercentageOfWeightedAverageStockPriceForDividendsPriorToPaymentDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="PercentageOfWeightedAverageStockPriceForDividendsPriorToPaymentDate" xlink:title="definition: ClassOfStockLineItems to PercentageOfWeightedAverageStockPriceForDividendsPriorToPaymentDate" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_NumberOfConsecutiveTradingDays" xlink:label="NumberOfConsecutiveTradingDays" xlink:title="NumberOfConsecutiveTradingDays" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="NumberOfConsecutiveTradingDays" xlink:title="definition: ClassOfStockLineItems to NumberOfConsecutiveTradingDays" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="SharePrice" xlink:title="SharePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="SharePrice" xlink:title="definition: ClassOfStockLineItems to SharePrice" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="ConversionOfStockSharesIssued1" xlink:title="ConversionOfStockSharesIssued1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="ConversionOfStockSharesIssued1" xlink:title="definition: ClassOfStockLineItems to ConversionOfStockSharesIssued1" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="ConversionOfStockSharesConverted1" xlink:title="ConversionOfStockSharesConverted1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="ConversionOfStockSharesConverted1" xlink:title="definition: ClassOfStockLineItems to ConversionOfStockSharesConverted1" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="ScheduleOfStockByClassTable" xlink:title="ScheduleOfStockByClassTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ClassOfStockLineItems" xlink:to="ScheduleOfStockByClassTable" xlink:title="definition: ClassOfStockLineItems to ScheduleOfStockByClassTable" order="11.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfStockByClassTable" xlink:to="StatementClassOfStockAxis" xlink:title="definition: ScheduleOfStockByClassTable to StatementClassOfStockAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain_2" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain_2" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="SeriesAPreferredStockMember" xlink:title="SeriesAPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="SeriesAPreferredStockMember" xlink:title="definition: ClassOfStockDomain to SeriesAPreferredStockMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfStockByClassTable" xlink:to="RangeAxis" xlink:title="definition: ScheduleOfStockByClassTable to RangeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfStockByClassTable" xlink:to="StatementScenarioAxis" xlink:title="definition: ScheduleOfStockByClassTable to StatementScenarioAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain" xlink:title="definition: StatementScenarioAxis to ScenarioUnspecifiedDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain_2" xlink:title="ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain_2" xlink:title="definition: StatementScenarioAxis to ScenarioUnspecifiedDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_DividendPaymentScenarioOneMember" xlink:label="DividendPaymentScenarioOneMember" xlink:title="DividendPaymentScenarioOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ScenarioUnspecifiedDomain" xlink:to="DividendPaymentScenarioOneMember" xlink:title="definition: ScenarioUnspecifiedDomain to DividendPaymentScenarioOneMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_DividendPaymentScenarioTwoMember" xlink:label="DividendPaymentScenarioTwoMember" xlink:title="DividendPaymentScenarioTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ScenarioUnspecifiedDomain" xlink:to="DividendPaymentScenarioTwoMember" xlink:title="definition: ScenarioUnspecifiedDomain to DividendPaymentScenarioTwoMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/StockholdersEquitySeriesC6SuperDividendRedeemableConvertiblePreferredStockDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="ClassOfStockLineItems" xlink:title="ClassOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="definition: ClassOfStockLineItems to PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="StockIssuedDuringPeriodSharesNewIssues" xlink:title="definition: ClassOfStockLineItems to StockIssuedDuringPeriodSharesNewIssues" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="PreferredStockParOrStatedValuePerShare" xlink:title="PreferredStockParOrStatedValuePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="PreferredStockParOrStatedValuePerShare" xlink:title="definition: ClassOfStockLineItems to PreferredStockParOrStatedValuePerShare" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="SharesIssuedPricePerShare" xlink:title="SharesIssuedPricePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="SharesIssuedPricePerShare" xlink:title="definition: ClassOfStockLineItems to SharesIssuedPricePerShare" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="PreferredStockLiquidationPreference" xlink:title="PreferredStockLiquidationPreference" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="PreferredStockLiquidationPreference" xlink:title="definition: ClassOfStockLineItems to PreferredStockLiquidationPreference" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:title="ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:title="definition: ClassOfStockLineItems to ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="PaymentsOfStockIssuanceCosts" xlink:title="PaymentsOfStockIssuanceCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="PaymentsOfStockIssuanceCosts" xlink:title="definition: ClassOfStockLineItems to PaymentsOfStockIssuanceCosts" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ProceedsFromIssuanceOfPreferredStockNetOfIssuanceCosts" xlink:label="ProceedsFromIssuanceOfPreferredStockNetOfIssuanceCosts" xlink:title="ProceedsFromIssuanceOfPreferredStockNetOfIssuanceCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="ProceedsFromIssuanceOfPreferredStockNetOfIssuanceCosts" xlink:title="definition: ClassOfStockLineItems to ProceedsFromIssuanceOfPreferredStockNetOfIssuanceCosts" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ClassOfWarrantOrRightIssued" xlink:label="ClassOfWarrantOrRightIssued" xlink:title="ClassOfWarrantOrRightIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="ClassOfWarrantOrRightIssued" xlink:title="definition: ClassOfStockLineItems to ClassOfWarrantOrRightIssued" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="definition: ClassOfStockLineItems to ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_EquityIssuancePerShareAmount" xlink:label="EquityIssuancePerShareAmount" xlink:title="EquityIssuancePerShareAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="EquityIssuancePerShareAmount" xlink:title="definition: ClassOfStockLineItems to EquityIssuancePerShareAmount" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_CommonSharesIssuableUponConversionOfConvertibleStock" xlink:label="CommonSharesIssuableUponConversionOfConvertibleStock" xlink:title="CommonSharesIssuableUponConversionOfConvertibleStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="CommonSharesIssuableUponConversionOfConvertibleStock" xlink:title="definition: ClassOfStockLineItems to CommonSharesIssuableUponConversionOfConvertibleStock" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="CommonStockSharesOutstanding" xlink:title="definition: ClassOfStockLineItems to CommonStockSharesOutstanding" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="ConversionOfStockSharesIssued1" xlink:title="ConversionOfStockSharesIssued1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="ConversionOfStockSharesIssued1" xlink:title="definition: ClassOfStockLineItems to ConversionOfStockSharesIssued1" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="SharePrice" xlink:title="SharePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="SharePrice" xlink:title="definition: ClassOfStockLineItems to SharePrice" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_NumberOfConsecutiveTradingDays" xlink:label="NumberOfConsecutiveTradingDays" xlink:title="NumberOfConsecutiveTradingDays" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="NumberOfConsecutiveTradingDays" xlink:title="definition: ClassOfStockLineItems to NumberOfConsecutiveTradingDays" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="PreferredStockDividendRatePercentage" xlink:title="PreferredStockDividendRatePercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="PreferredStockDividendRatePercentage" xlink:title="definition: ClassOfStockLineItems to PreferredStockDividendRatePercentage" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_DividendAsPercentageOfNetSales" xlink:label="DividendAsPercentageOfNetSales" xlink:title="DividendAsPercentageOfNetSales" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="DividendAsPercentageOfNetSales" xlink:title="definition: ClassOfStockLineItems to DividendAsPercentageOfNetSales" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsPreferredStock" xlink:label="DividendsPreferredStock" xlink:title="DividendsPreferredStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="DividendsPreferredStock" xlink:title="definition: ClassOfStockLineItems to DividendsPreferredStock" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockRedemptionPricePerShare" xlink:label="PreferredStockRedemptionPricePerShare" xlink:title="PreferredStockRedemptionPricePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="PreferredStockRedemptionPricePerShare" xlink:title="definition: ClassOfStockLineItems to PreferredStockRedemptionPricePerShare" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_PostConversionDividendRightsIssued" xlink:label="PostConversionDividendRightsIssued" xlink:title="PostConversionDividendRightsIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="PostConversionDividendRightsIssued" xlink:title="definition: ClassOfStockLineItems to PostConversionDividendRightsIssued" order="21.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_PostConversionRedemptionRightReturnOnInvestmentMultiplierAmount" xlink:label="PostConversionRedemptionRightReturnOnInvestmentMultiplierAmount" xlink:title="PostConversionRedemptionRightReturnOnInvestmentMultiplierAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="PostConversionRedemptionRightReturnOnInvestmentMultiplierAmount" xlink:title="definition: ClassOfStockLineItems to PostConversionRedemptionRightReturnOnInvestmentMultiplierAmount" order="22.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ClosingDaysAfterConversionRights" xlink:label="ClosingDaysAfterConversionRights" xlink:title="ClosingDaysAfterConversionRights" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="ClosingDaysAfterConversionRights" xlink:title="definition: ClassOfStockLineItems to ClosingDaysAfterConversionRights" order="23.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="ScheduleOfStockByClassTable" xlink:title="ScheduleOfStockByClassTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ClassOfStockLineItems" xlink:to="ScheduleOfStockByClassTable" xlink:title="definition: ClassOfStockLineItems to ScheduleOfStockByClassTable" order="24.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfStockByClassTable" xlink:to="StatementClassOfStockAxis" xlink:title="definition: ScheduleOfStockByClassTable to StatementClassOfStockAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain_2" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain_2" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="SeriesCPreferredStockMember" xlink:title="SeriesCPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="SeriesCPreferredStockMember" xlink:title="definition: ClassOfStockDomain to SeriesCPreferredStockMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfStockByClassTable" xlink:to="StatementScenarioAxis" xlink:title="definition: ScheduleOfStockByClassTable to StatementScenarioAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain" xlink:title="definition: StatementScenarioAxis to ScenarioUnspecifiedDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain_2" xlink:title="ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain_2" xlink:title="definition: StatementScenarioAxis to ScenarioUnspecifiedDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_DividendPaymentScenarioOneMember" xlink:label="DividendPaymentScenarioOneMember" xlink:title="DividendPaymentScenarioOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ScenarioUnspecifiedDomain" xlink:to="DividendPaymentScenarioOneMember" xlink:title="definition: ScenarioUnspecifiedDomain to DividendPaymentScenarioOneMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_DividendPaymentScenarioTwoMember" xlink:label="DividendPaymentScenarioTwoMember" xlink:title="DividendPaymentScenarioTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ScenarioUnspecifiedDomain" xlink:to="DividendPaymentScenarioTwoMember" xlink:title="definition: ScenarioUnspecifiedDomain to DividendPaymentScenarioTwoMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfStockByClassTable" xlink:to="StatementEquityComponentsAxis" xlink:title="definition: ScheduleOfStockByClassTable to StatementEquityComponentsAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain_2" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain_2" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="CommonStockMember" xlink:title="definition: EquityComponentDomain to CommonStockMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfStockByClassTable" xlink:to="RangeAxis" xlink:title="definition: ScheduleOfStockByClassTable to RangeAxis" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/StockholdersEquityReturnOnInvestmentDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="ClassOfStockLineItems" xlink:title="ClassOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="definition: ClassOfStockLineItems to PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityAggregateAmountOfRedemptionRequirement" xlink:label="TemporaryEquityAggregateAmountOfRedemptionRequirement" xlink:title="TemporaryEquityAggregateAmountOfRedemptionRequirement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="TemporaryEquityAggregateAmountOfRedemptionRequirement" xlink:title="definition: ClassOfStockLineItems to TemporaryEquityAggregateAmountOfRedemptionRequirement" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ConvertiblePreferredStockNumberOfVotingRights" xlink:label="ConvertiblePreferredStockNumberOfVotingRights" xlink:title="ConvertiblePreferredStockNumberOfVotingRights" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="ConvertiblePreferredStockNumberOfVotingRights" xlink:title="definition: ClassOfStockLineItems to ConvertiblePreferredStockNumberOfVotingRights" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="ScheduleOfStockByClassTable" xlink:title="ScheduleOfStockByClassTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ClassOfStockLineItems" xlink:to="ScheduleOfStockByClassTable" xlink:title="definition: ClassOfStockLineItems to ScheduleOfStockByClassTable" order="4.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfStockByClassTable" xlink:to="StatementClassOfStockAxis" xlink:title="definition: ScheduleOfStockByClassTable to StatementClassOfStockAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain_2" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain_2" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="SeriesCPreferredStockMember" xlink:title="SeriesCPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="SeriesCPreferredStockMember" xlink:title="definition: ClassOfStockDomain to SeriesCPreferredStockMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/WarrantsSummaryOfWarrantActivityDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="WarrantsAndRightsOutstandingTerm" xlink:title="WarrantsAndRightsOutstandingTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="WarrantsAndRightsOutstandingTerm" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to WarrantsAndRightsOutstandingTerm" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="12.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="FinancialInstrumentAxis" xlink:title="FinancialInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="FinancialInstrumentAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to FinancialInstrumentAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FinancialInstrumentAxis" xlink:to="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="definition: FinancialInstrumentAxis to TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" xlink:title="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FinancialInstrumentAxis" xlink:to="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" xlink:title="definition: FinancialInstrumentAxis to TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="WarrantMember" xlink:title="definition: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to WarrantMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/WarrantsSummaryOfPurchaseWarrantsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="WarrantsAndRightsNoteDisclosureAbstract" xlink:title="WarrantsAndRightsNoteDisclosureAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="WarrantsAndRightsNoteDisclosureAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to WarrantsAndRightsNoteDisclosureAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ThresholdPeriodForExtensionOfExerciseDateOfPurchaseWarrantsUnderAgreement" xlink:label="ThresholdPeriodForExtensionOfExerciseDateOfPurchaseWarrantsUnderAgreement" xlink:title="ThresholdPeriodForExtensionOfExerciseDateOfPurchaseWarrantsUnderAgreement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ThresholdPeriodForExtensionOfExerciseDateOfPurchaseWarrantsUnderAgreement" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ThresholdPeriodForExtensionOfExerciseDateOfPurchaseWarrantsUnderAgreement" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ThresholdPeriodForStockClosingPriceInTenConsecutiveDaysUnderPurchaseWarrantsAgreement" xlink:label="ThresholdPeriodForStockClosingPriceInTenConsecutiveDaysUnderPurchaseWarrantsAgreement" xlink:title="ThresholdPeriodForStockClosingPriceInTenConsecutiveDaysUnderPurchaseWarrantsAgreement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ThresholdPeriodForStockClosingPriceInTenConsecutiveDaysUnderPurchaseWarrantsAgreement" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ThresholdPeriodForStockClosingPriceInTenConsecutiveDaysUnderPurchaseWarrantsAgreement" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="SharePrice" xlink:title="SharePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharePrice" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_NumberOfTradingDaysToBeConsideredStockClosingPriceInPurchaseAgreement" xlink:label="NumberOfTradingDaysToBeConsideredStockClosingPriceInPurchaseAgreement" xlink:title="NumberOfTradingDaysToBeConsideredStockClosingPriceInPurchaseAgreement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="NumberOfTradingDaysToBeConsideredStockClosingPriceInPurchaseAgreement" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to NumberOfTradingDaysToBeConsideredStockClosingPriceInPurchaseAgreement" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_BeneficialOwnershipPercentage" xlink:label="BeneficialOwnershipPercentage" xlink:title="BeneficialOwnershipPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="BeneficialOwnershipPercentage" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to BeneficialOwnershipPercentage" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_PeriodOfPriorNoticeThatWouldBarVoluntaryExerciseOfAnyWarrants" xlink:label="PeriodOfPriorNoticeThatWouldBarVoluntaryExerciseOfAnyWarrants" xlink:title="PeriodOfPriorNoticeThatWouldBarVoluntaryExerciseOfAnyWarrants" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="PeriodOfPriorNoticeThatWouldBarVoluntaryExerciseOfAnyWarrants" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to PeriodOfPriorNoticeThatWouldBarVoluntaryExerciseOfAnyWarrants" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockRedemptionPremium" xlink:label="PreferredStockRedemptionPremium" xlink:title="PreferredStockRedemptionPremium" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="PreferredStockRedemptionPremium" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to PreferredStockRedemptionPremium" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="15.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="FinancialInstrumentAxis" xlink:title="FinancialInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="FinancialInstrumentAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to FinancialInstrumentAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FinancialInstrumentAxis" xlink:to="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="definition: FinancialInstrumentAxis to TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" xlink:title="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FinancialInstrumentAxis" xlink:to="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" xlink:title="definition: FinancialInstrumentAxis to TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="WarrantMember" xlink:title="definition: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to WarrantMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="StatementEquityComponentsAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to StatementEquityComponentsAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain_2" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain_2" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="CommonStockMember" xlink:title="definition: EquityComponentDomain to CommonStockMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_SeriesBWarrantsMember" xlink:label="SeriesBWarrantsMember" xlink:title="SeriesBWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="SeriesBWarrantsMember" xlink:title="definition: EquityComponentDomain to SeriesBWarrantsMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="ClassOfWarrantOrRightAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to ClassOfWarrantOrRightAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain" xlink:title="definition: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain_2" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain_2" xlink:title="definition: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_BeforeModificationMember" xlink:label="BeforeModificationMember" xlink:title="BeforeModificationMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="BeforeModificationMember" xlink:title="definition: ClassOfWarrantOrRightDomain to BeforeModificationMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_AfterModificationMember" xlink:label="AfterModificationMember" xlink:title="AfterModificationMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="AfterModificationMember" xlink:title="definition: ClassOfWarrantOrRightDomain to AfterModificationMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to RelatedPartyTransactionsByRelatedPartyAxis" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain_2" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain_2" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_One0XFundLPAnd10XCapitalManagementLLCMember" xlink:label="One0XFundLPAnd10XCapitalManagementLLCMember" xlink:title="One0XFundLPAnd10XCapitalManagementLLCMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyDomain" xlink:to="One0XFundLPAnd10XCapitalManagementLLCMember" xlink:title="definition: RelatedPartyDomain to One0XFundLPAnd10XCapitalManagementLLCMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_One0XFundLPMember" xlink:label="One0XFundLPMember" xlink:title="One0XFundLPMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyDomain" xlink:to="One0XFundLPMember" xlink:title="definition: RelatedPartyDomain to One0XFundLPMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="RangeAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to RangeAxis" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/WarrantsSummaryOfOutstandingWarrantsIssuedInConnectionWithEquityAndDebtFinancingAndConsultantsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="ClassOfWarrantOrRightLineItems" xlink:title="ClassOfWarrantOrRightLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="WarrantsAndRightsNoteDisclosureAbstract" xlink:title="WarrantsAndRightsNoteDisclosureAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="WarrantsAndRightsNoteDisclosureAbstract" xlink:title="definition: ClassOfWarrantOrRightLineItems to WarrantsAndRightsNoteDisclosureAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="ClassOfWarrantOrRightOutstanding" xlink:title="ClassOfWarrantOrRightOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ClassOfWarrantOrRightOutstanding" xlink:title="definition: ClassOfWarrantOrRightLineItems to ClassOfWarrantOrRightOutstanding" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="definition: ClassOfWarrantOrRightLineItems to ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:title="ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:title="definition: ClassOfWarrantOrRightLineItems to ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired" xlink:label="ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired" xlink:title="ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired" xlink:title="definition: ClassOfWarrantOrRightLineItems to ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_WarrantIssueDate" xlink:label="WarrantIssueDate" xlink:title="WarrantIssueDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="WarrantIssueDate" xlink:title="definition: ClassOfWarrantOrRightLineItems to WarrantIssueDate" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_WarrantsIssuedPrice" xlink:label="WarrantsIssuedPrice" xlink:title="WarrantsIssuedPrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="WarrantsIssuedPrice" xlink:title="definition: ClassOfWarrantOrRightLineItems to WarrantsIssuedPrice" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="ClassOfWarrantOrRightTable" xlink:title="ClassOfWarrantOrRightTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ClassOfWarrantOrRightTable" xlink:title="definition: ClassOfWarrantOrRightLineItems to ClassOfWarrantOrRightTable" order="8.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ClassOfWarrantOrRightTable" xlink:to="ClassOfWarrantOrRightAxis" xlink:title="definition: ClassOfWarrantOrRightTable to ClassOfWarrantOrRightAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain" xlink:title="definition: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain_2" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain_2" xlink:title="definition: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_FebruaryTwelveTwentyZeroNineSeriesBOneTransactionMember" xlink:label="FebruaryTwelveTwentyZeroNineSeriesBOneTransactionMember" xlink:title="FebruaryTwelveTwentyZeroNineSeriesBOneTransactionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="FebruaryTwelveTwentyZeroNineSeriesBOneTransactionMember" xlink:title="definition: ClassOfWarrantOrRightDomain to FebruaryTwelveTwentyZeroNineSeriesBOneTransactionMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_MayThirteenTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:label="MayThirteenTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:title="MayThirteenTwentyZeroNineSeriesBTwoTransactionOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="MayThirteenTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:title="definition: ClassOfWarrantOrRightDomain to MayThirteenTwentyZeroNineSeriesBTwoTransactionOneMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_JuneThirtyTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:label="JuneThirtyTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:title="JuneThirtyTwentyZeroNineSeriesBTwoTransactionOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="JuneThirtyTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:title="definition: ClassOfWarrantOrRightDomain to JuneThirtyTwentyZeroNineSeriesBTwoTransactionOneMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_AugustTwelveTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:label="AugustTwelveTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:title="AugustTwelveTwentyZeroNineSeriesBTwoTransactionOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="AugustTwelveTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:title="definition: ClassOfWarrantOrRightDomain to AugustTwelveTwentyZeroNineSeriesBTwoTransactionOneMember" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_SeptemberThirtyTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:label="SeptemberThirtyTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:title="SeptemberThirtyTwentyZeroNineSeriesBTwoTransactionOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="SeptemberThirtyTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:title="definition: ClassOfWarrantOrRightDomain to SeptemberThirtyTwentyZeroNineSeriesBTwoTransactionOneMember" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_NovemberFourTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:label="NovemberFourTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:title="NovemberFourTwentyZeroNineSeriesBTwoTransactionOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="NovemberFourTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:title="definition: ClassOfWarrantOrRightDomain to NovemberFourTwentyZeroNineSeriesBTwoTransactionOneMember" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_DecemberEightTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:label="DecemberEightTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:title="DecemberEightTwentyZeroNineSeriesBTwoTransactionOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="DecemberEightTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:title="definition: ClassOfWarrantOrRightDomain to DecemberEightTwentyZeroNineSeriesBTwoTransactionOneMember" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionOneMember" xlink:label="JanuaryTwentyNineTwentyTenSeriesBTwoTransactionOneMember" xlink:title="JanuaryTwentyNineTwentyTenSeriesBTwoTransactionOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="JanuaryTwentyNineTwentyTenSeriesBTwoTransactionOneMember" xlink:title="definition: ClassOfWarrantOrRightDomain to JanuaryTwentyNineTwentyTenSeriesBTwoTransactionOneMember" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionTwoMember" xlink:label="JanuaryTwentyNineTwentyTenSeriesBTwoTransactionTwoMember" xlink:title="JanuaryTwentyNineTwentyTenSeriesBTwoTransactionTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="JanuaryTwentyNineTwentyTenSeriesBTwoTransactionTwoMember" xlink:title="definition: ClassOfWarrantOrRightDomain to JanuaryTwentyNineTwentyTenSeriesBTwoTransactionTwoMember" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_MarchEightTwentyTenSeriesBTwoTransactionOneMember" xlink:label="MarchEightTwentyTenSeriesBTwoTransactionOneMember" xlink:title="MarchEightTwentyTenSeriesBTwoTransactionOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="MarchEightTwentyTenSeriesBTwoTransactionOneMember" xlink:title="definition: ClassOfWarrantOrRightDomain to MarchEightTwentyTenSeriesBTwoTransactionOneMember" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_MarchEightTwentyTenSeriesBTwoTransactionTwoMember" xlink:label="MarchEightTwentyTenSeriesBTwoTransactionTwoMember" xlink:title="MarchEightTwentyTenSeriesBTwoTransactionTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="MarchEightTwentyTenSeriesBTwoTransactionTwoMember" xlink:title="definition: ClassOfWarrantOrRightDomain to MarchEightTwentyTenSeriesBTwoTransactionTwoMember" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_AprilThirtyTwentyTenSeriesBTwoTransactionOneMember" xlink:label="AprilThirtyTwentyTenSeriesBTwoTransactionOneMember" xlink:title="AprilThirtyTwentyTenSeriesBTwoTransactionOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="AprilThirtyTwentyTenSeriesBTwoTransactionOneMember" xlink:title="definition: ClassOfWarrantOrRightDomain to AprilThirtyTwentyTenSeriesBTwoTransactionOneMember" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_AprilThirtyTwentyTenSeriesBTwoTransactionTwoMember" xlink:label="AprilThirtyTwentyTenSeriesBTwoTransactionTwoMember" xlink:title="AprilThirtyTwentyTenSeriesBTwoTransactionTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="AprilThirtyTwentyTenSeriesBTwoTransactionTwoMember" xlink:title="definition: ClassOfWarrantOrRightDomain to AprilThirtyTwentyTenSeriesBTwoTransactionTwoMember" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_MayTenTwentyTenSeriesBTwoTransactionOneMember" xlink:label="MayTenTwentyTenSeriesBTwoTransactionOneMember" xlink:title="MayTenTwentyTenSeriesBTwoTransactionOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="MayTenTwentyTenSeriesBTwoTransactionOneMember" xlink:title="definition: ClassOfWarrantOrRightDomain to MayTenTwentyTenSeriesBTwoTransactionOneMember" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_MayTenTwentyTenSeriesBTwoTransactionTwoMember" xlink:label="MayTenTwentyTenSeriesBTwoTransactionTwoMember" xlink:title="MayTenTwentyTenSeriesBTwoTransactionTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="MayTenTwentyTenSeriesBTwoTransactionTwoMember" xlink:title="definition: ClassOfWarrantOrRightDomain to MayTenTwentyTenSeriesBTwoTransactionTwoMember" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_SeptemberTwentyTwoTwentySixteenSeriesBThreeTransactionMember" xlink:label="SeptemberTwentyTwoTwentySixteenSeriesBThreeTransactionMember" xlink:title="SeptemberTwentyTwoTwentySixteenSeriesBThreeTransactionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="SeptemberTwentyTwoTwentySixteenSeriesBThreeTransactionMember" xlink:title="definition: ClassOfWarrantOrRightDomain to SeptemberTwentyTwoTwentySixteenSeriesBThreeTransactionMember" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_SeptemberTwentyNineTwentySixteenSeriesBThreeTransactionMember" xlink:label="SeptemberTwentyNineTwentySixteenSeriesBThreeTransactionMember" xlink:title="SeptemberTwentyNineTwentySixteenSeriesBThreeTransactionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="SeptemberTwentyNineTwentySixteenSeriesBThreeTransactionMember" xlink:title="definition: ClassOfWarrantOrRightDomain to SeptemberTwentyNineTwentySixteenSeriesBThreeTransactionMember" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_DecemberTwentyThreeTwentySixteenSeriesBThreeTransactionMember" xlink:label="DecemberTwentyThreeTwentySixteenSeriesBThreeTransactionMember" xlink:title="DecemberTwentyThreeTwentySixteenSeriesBThreeTransactionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="DecemberTwentyThreeTwentySixteenSeriesBThreeTransactionMember" xlink:title="definition: ClassOfWarrantOrRightDomain to DecemberTwentyThreeTwentySixteenSeriesBThreeTransactionMember" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_TwentyEighteenAndTwentySeventeenWarrantsIssuedForServicesMember" xlink:label="TwentyEighteenAndTwentySeventeenWarrantsIssuedForServicesMember" xlink:title="TwentyEighteenAndTwentySeventeenWarrantsIssuedForServicesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="TwentyEighteenAndTwentySeventeenWarrantsIssuedForServicesMember" xlink:title="definition: ClassOfWarrantOrRightDomain to TwentyEighteenAndTwentySeventeenWarrantsIssuedForServicesMember" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_MayTwentyThreeTwentyNinteenRightsOfferingWarrantsMember" xlink:label="MayTwentyThreeTwentyNinteenRightsOfferingWarrantsMember" xlink:title="MayTwentyThreeTwentyNinteenRightsOfferingWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="MayTwentyThreeTwentyNinteenRightsOfferingWarrantsMember" xlink:title="definition: ClassOfWarrantOrRightDomain to MayTwentyThreeTwentyNinteenRightsOfferingWarrantsMember" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_July222022WarrantsIssuedInConnectionWithRelatedPartyLineOfCreditMember" xlink:label="July222022WarrantsIssuedInConnectionWithRelatedPartyLineOfCreditMember" xlink:title="July222022WarrantsIssuedInConnectionWithRelatedPartyLineOfCreditMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="July222022WarrantsIssuedInConnectionWithRelatedPartyLineOfCreditMember" xlink:title="definition: ClassOfWarrantOrRightDomain to July222022WarrantsIssuedInConnectionWithRelatedPartyLineOfCreditMember" order="21.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_December292023WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" xlink:label="December292023WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" xlink:title="December292023WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="December292023WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" xlink:title="definition: ClassOfWarrantOrRightDomain to December292023WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" order="22.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_March292024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" xlink:label="March292024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" xlink:title="March292024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="March292024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" xlink:title="definition: ClassOfWarrantOrRightDomain to March292024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" order="23.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_June282024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" xlink:label="June282024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" xlink:title="June282024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="June282024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" xlink:title="definition: ClassOfWarrantOrRightDomain to June282024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" order="24.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_September302024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" xlink:label="September302024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" xlink:title="September302024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="September302024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" xlink:title="definition: ClassOfWarrantOrRightDomain to September302024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" order="25.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/StockbasedCompensationSummaryOfStockbasedCompensationPlansDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="ShareBasedCompensationAbstract" xlink:title="ShareBasedCompensationAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="ShareBasedCompensationAbstract" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to ShareBasedCompensationAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="4.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="PlanNameAxis" xlink:title="definition: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to PlanNameAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain" xlink:title="definition: PlanNameAxis to PlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain_2" xlink:title="PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain_2" xlink:title="definition: PlanNameAxis to PlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_EquityIncentivePlan2019Member" xlink:label="EquityIncentivePlan2019Member" xlink:title="EquityIncentivePlan2019Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PlanNameDomain" xlink:to="EquityIncentivePlan2019Member" xlink:title="definition: PlanNameDomain to EquityIncentivePlan2019Member" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_IncentiveCompensationPlanTwoThousandNineMemberMember" xlink:label="IncentiveCompensationPlanTwoThousandNineMemberMember" xlink:title="IncentiveCompensationPlanTwoThousandNineMemberMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PlanNameDomain" xlink:to="IncentiveCompensationPlanTwoThousandNineMemberMember" xlink:title="definition: PlanNameDomain to IncentiveCompensationPlanTwoThousandNineMemberMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_NonQualifiedOptionsPlansMember" xlink:label="NonQualifiedOptionsPlansMember" xlink:title="NonQualifiedOptionsPlansMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PlanNameDomain" xlink:to="NonQualifiedOptionsPlansMember" xlink:title="definition: PlanNameDomain to NonQualifiedOptionsPlansMember" order="3.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/StockbasedCompensationComponentsOfStockbasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="ShareBasedCompensationAbstract" xlink:title="ShareBasedCompensationAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="ShareBasedCompensationAbstract" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to ShareBasedCompensationAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="AllocatedShareBasedCompensationExpense" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to AllocatedShareBasedCompensationExpense" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="3.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="IncomeStatementLocationAxis" xlink:title="definition: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to IncomeStatementLocationAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain_2" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain_2" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="ResearchAndDevelopmentExpenseMember" xlink:title="ResearchAndDevelopmentExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementLocationDomain" xlink:to="ResearchAndDevelopmentExpenseMember" xlink:title="definition: IncomeStatementLocationDomain to ResearchAndDevelopmentExpenseMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="GeneralAndAdministrativeExpenseMember" xlink:title="GeneralAndAdministrativeExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementLocationDomain" xlink:to="GeneralAndAdministrativeExpenseMember" xlink:title="definition: IncomeStatementLocationDomain to GeneralAndAdministrativeExpenseMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/StockbasedCompensationWeightedAverageAssumptionsUsedToDetermineFairValueOfOptionsGrantedDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfAward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfAward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfAward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfAward" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfAward" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="7.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="RangeAxis" xlink:title="definition: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to RangeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/StockbasedCompensationStockOptionActivityDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/StockbasedCompensationOutstandingAndExercisableOptionsUnderStockBasedCompensationPlansDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_OptionsOutstandingAbstract" xlink:label="OptionsOutstandingAbstract" xlink:title="OptionsOutstandingAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="OptionsOutstandingAbstract" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to OptionsOutstandingAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_OptionsExercisableAbstract" xlink:label="OptionsExercisableAbstract" xlink:title="OptionsExercisableAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="OptionsExercisableAbstract" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to OptionsExercisableAbstract" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:title="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:title="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:title="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="RangeAxis" xlink:title="definition: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to RangeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:title="definition: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:title="definition: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis to ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_2" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_2" xlink:title="definition: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis to ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ExercisePriceRangeOneMember" xlink:label="ExercisePriceRangeOneMember" xlink:title="ExercisePriceRangeOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="ExercisePriceRangeOneMember" xlink:title="definition: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to ExercisePriceRangeOneMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ExercisePriceRangeTwoMember" xlink:label="ExercisePriceRangeTwoMember" xlink:title="ExercisePriceRangeTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="ExercisePriceRangeTwoMember" xlink:title="definition: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to ExercisePriceRangeTwoMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ExercisePriceRangeThreeMember" xlink:label="ExercisePriceRangeThreeMember" xlink:title="ExercisePriceRangeThreeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="ExercisePriceRangeThreeMember" xlink:title="definition: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to ExercisePriceRangeThreeMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ExercisePriceRangeFourMember" xlink:label="ExercisePriceRangeFourMember" xlink:title="ExercisePriceRangeFourMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="ExercisePriceRangeFourMember" xlink:title="definition: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to ExercisePriceRangeFourMember" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ExercisePriceRangeFiveMember" xlink:label="ExercisePriceRangeFiveMember" xlink:title="ExercisePriceRangeFiveMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="ExercisePriceRangeFiveMember" xlink:title="definition: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to ExercisePriceRangeFiveMember" order="5.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/StockbasedCompensationRestrictedStockIssuancesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="ShareBasedCompensationAbstract" xlink:title="ShareBasedCompensationAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="ShareBasedCompensationAbstract" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to ShareBasedCompensationAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_NumberOfDirectors" xlink:label="NumberOfDirectors" xlink:title="NumberOfDirectors" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="NumberOfDirectors" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to NumberOfDirectors" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:title="StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_VestingPercentageOfRestrictedStockUnits" xlink:label="VestingPercentageOfRestrictedStockUnits" xlink:title="VestingPercentageOfRestrictedStockUnits" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="VestingPercentageOfRestrictedStockUnits" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to VestingPercentageOfRestrictedStockUnits" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="AllocatedShareBasedCompensationExpense" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to AllocatedShareBasedCompensationExpense" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="7.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="AwardTypeAxis" xlink:title="definition: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to AwardTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="RestrictedStockMember" xlink:title="RestrictedStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="RestrictedStockMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to RestrictedStockMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/StockbasedCompensationDeferredStockUnitsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="ShareBasedCompensationAbstract" xlink:title="ShareBasedCompensationAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="ShareBasedCompensationAbstract" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to ShareBasedCompensationAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_RestrictedStockGrantsAbstract" xlink:label="RestrictedStockGrantsAbstract" xlink:title="RestrictedStockGrantsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="RestrictedStockGrantsAbstract" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to RestrictedStockGrantsAbstract" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent" xlink:label="DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent" xlink:title="DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent" xlink:label="DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent" xlink:title="DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne" xlink:label="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne" xlink:title="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo" xlink:label="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo" xlink:title="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree" xlink:label="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree" xlink:title="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFour" xlink:label="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFour" xlink:title="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFour" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFour" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFour" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFive" xlink:label="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFive" xlink:title="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFive" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFive" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFive" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="CommonStockSharesSubscribedButUnissued" xlink:title="CommonStockSharesSubscribedButUnissued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="CommonStockSharesSubscribedButUnissued" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to CommonStockSharesSubscribedButUnissued" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:title="SharesPaidForTaxWithholdingForShareBasedCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to SharesPaidForTaxWithholdingForShareBasedCompensation" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:title="PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSix" xlink:label="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSix" xlink:title="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSix" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSix" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSix" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSeven" xlink:label="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSeven" xlink:title="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSeven" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSeven" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSeven" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" xlink:label="DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" xlink:title="DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued" xlink:label="DeferredCompensationArrangementWithIndividualSharesIssued" xlink:title="DeferredCompensationArrangementWithIndividualSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="DeferredCompensationArrangementWithIndividualSharesIssued" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to DeferredCompensationArrangementWithIndividualSharesIssued" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice" xlink:label="DeferredCompensationArrangementWithIndividualExercisePrice" xlink:title="DeferredCompensationArrangementWithIndividualExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="DeferredCompensationArrangementWithIndividualExercisePrice" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to DeferredCompensationArrangementWithIndividualExercisePrice" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:title="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="21.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="TitleOfIndividualAxis" xlink:title="definition: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to TitleOfIndividualAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="definition: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain_2" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain_2" xlink:title="definition: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="ChiefExecutiveOfficerMember" xlink:title="ChiefExecutiveOfficerMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="ChiefExecutiveOfficerMember" xlink:title="definition: TitleOfIndividualWithRelationshipToEntityDomain to ChiefExecutiveOfficerMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" xlink:label="DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" xlink:title="DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" xlink:title="definition: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" xlink:label="DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" xlink:title="DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" xlink:to="DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" xlink:title="definition: DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis to DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" xlink:label="DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_2" xlink:title="DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" xlink:to="DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_2" xlink:title="definition: DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis to DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredBonusMember" xlink:label="DeferredBonusMember" xlink:title="DeferredBonusMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" xlink:to="DeferredBonusMember" xlink:title="definition: DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain to DeferredBonusMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_BonusSharesMember" xlink:label="BonusSharesMember" xlink:title="BonusSharesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" xlink:to="BonusSharesMember" xlink:title="definition: DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain to BonusSharesMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedPartyDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="LineOfCreditFacilityLineItems" xlink:title="LineOfCreditFacilityLineItems" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_LineOfCreditRelatedPartyAbstract" xlink:label="LineOfCreditRelatedPartyAbstract" xlink:title="LineOfCreditRelatedPartyAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LineOfCreditFacilityLineItems" xlink:to="LineOfCreditRelatedPartyAbstract" xlink:title="definition: LineOfCreditFacilityLineItems to LineOfCreditRelatedPartyAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="LineOfCreditFacilityMaximumBorrowingCapacity" xlink:title="LineOfCreditFacilityMaximumBorrowingCapacity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LineOfCreditFacilityLineItems" xlink:to="LineOfCreditFacilityMaximumBorrowingCapacity" xlink:title="definition: LineOfCreditFacilityLineItems to LineOfCreditFacilityMaximumBorrowingCapacity" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="DebtInstrumentInterestRateIncreaseDecrease" xlink:title="DebtInstrumentInterestRateIncreaseDecrease" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LineOfCreditFacilityLineItems" xlink:to="DebtInstrumentInterestRateIncreaseDecrease" xlink:title="definition: LineOfCreditFacilityLineItems to DebtInstrumentInterestRateIncreaseDecrease" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="DebtInstrumentMaturityDate" xlink:title="DebtInstrumentMaturityDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LineOfCreditFacilityLineItems" xlink:to="DebtInstrumentMaturityDate" xlink:title="definition: LineOfCreditFacilityLineItems to DebtInstrumentMaturityDate" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="SharePrice" xlink:title="SharePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LineOfCreditFacilityLineItems" xlink:to="SharePrice" xlink:title="definition: LineOfCreditFacilityLineItems to SharePrice" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="ProceedsFromLinesOfCredit" xlink:title="ProceedsFromLinesOfCredit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LineOfCreditFacilityLineItems" xlink:to="ProceedsFromLinesOfCredit" xlink:title="definition: LineOfCreditFacilityLineItems to ProceedsFromLinesOfCredit" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LineOfCreditFacilityLineItems" xlink:to="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="definition: LineOfCreditFacilityLineItems to ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LineOfCreditFacilityLineItems" xlink:to="CommonStockParOrStatedValuePerShare" xlink:title="definition: LineOfCreditFacilityLineItems to CommonStockParOrStatedValuePerShare" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LineOfCreditFacilityLineItems" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="definition: LineOfCreditFacilityLineItems to ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="DebtInstrumentInterestRateDuringPeriod" xlink:title="DebtInstrumentInterestRateDuringPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LineOfCreditFacilityLineItems" xlink:to="DebtInstrumentInterestRateDuringPeriod" xlink:title="definition: LineOfCreditFacilityLineItems to DebtInstrumentInterestRateDuringPeriod" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LineOfCreditFacilityLineItems" xlink:to="DebtInstrumentInterestRateStatedPercentage" xlink:title="definition: LineOfCreditFacilityLineItems to DebtInstrumentInterestRateStatedPercentage" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="DebtInstrumentInterestRateEffectivePercentage" xlink:title="DebtInstrumentInterestRateEffectivePercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LineOfCreditFacilityLineItems" xlink:to="DebtInstrumentInterestRateEffectivePercentage" xlink:title="definition: LineOfCreditFacilityLineItems to DebtInstrumentInterestRateEffectivePercentage" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_DebtInstrumentAccruedInterest" xlink:label="DebtInstrumentAccruedInterest" xlink:title="DebtInstrumentAccruedInterest" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LineOfCreditFacilityLineItems" xlink:to="DebtInstrumentAccruedInterest" xlink:title="definition: LineOfCreditFacilityLineItems to DebtInstrumentAccruedInterest" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LineOfCreditFacilityLineItems" xlink:to="ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="definition: LineOfCreditFacilityLineItems to ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LineOfCreditFacilityLineItems" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock" xlink:title="definition: LineOfCreditFacilityLineItems to ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="WarrantsAndRightsOutstandingMaturityDate" xlink:title="WarrantsAndRightsOutstandingMaturityDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LineOfCreditFacilityLineItems" xlink:to="WarrantsAndRightsOutstandingMaturityDate" xlink:title="definition: LineOfCreditFacilityLineItems to WarrantsAndRightsOutstandingMaturityDate" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_IssuanceOfWarrantsValue" xlink:label="IssuanceOfWarrantsValue" xlink:title="IssuanceOfWarrantsValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LineOfCreditFacilityLineItems" xlink:to="IssuanceOfWarrantsValue" xlink:title="definition: LineOfCreditFacilityLineItems to IssuanceOfWarrantsValue" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LineOfCreditFacilityLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="definition: LineOfCreditFacilityLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LineOfCreditFacilityLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="definition: LineOfCreditFacilityLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LineOfCreditFacilityLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="definition: LineOfCreditFacilityLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LineOfCreditFacilityLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="definition: LineOfCreditFacilityLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="21.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="InterestExpense" xlink:title="InterestExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LineOfCreditFacilityLineItems" xlink:to="InterestExpense" xlink:title="definition: LineOfCreditFacilityLineItems to InterestExpense" order="22.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="LineOfCreditFacilityTable" xlink:title="LineOfCreditFacilityTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="LineOfCreditFacilityLineItems" xlink:to="LineOfCreditFacilityTable" xlink:title="definition: LineOfCreditFacilityLineItems to LineOfCreditFacilityTable" order="23.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LineOfCreditFacilityTable" xlink:to="StatementEquityComponentsAxis" xlink:title="definition: LineOfCreditFacilityTable to StatementEquityComponentsAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain_2" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain_2" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="CommonStockMember" xlink:title="definition: EquityComponentDomain to CommonStockMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LineOfCreditFacilityTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="definition: LineOfCreditFacilityTable to RelatedPartyTransactionsByRelatedPartyAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain_2" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain_2" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="BoardOfDirectorsChairmanMember" xlink:title="BoardOfDirectorsChairmanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyDomain" xlink:to="BoardOfDirectorsChairmanMember" xlink:title="definition: RelatedPartyDomain to BoardOfDirectorsChairmanMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="CreditFacilityAxis" xlink:title="CreditFacilityAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LineOfCreditFacilityTable" xlink:to="CreditFacilityAxis" xlink:title="definition: LineOfCreditFacilityTable to CreditFacilityAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="CreditFacilityDomain" xlink:title="CreditFacilityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="CreditFacilityAxis" xlink:to="CreditFacilityDomain" xlink:title="definition: CreditFacilityAxis to CreditFacilityDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="CreditFacilityDomain_2" xlink:title="CreditFacilityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CreditFacilityAxis" xlink:to="CreditFacilityDomain_2" xlink:title="definition: CreditFacilityAxis to CreditFacilityDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditMember" xlink:label="LineOfCreditMember" xlink:title="LineOfCreditMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CreditFacilityDomain" xlink:to="LineOfCreditMember" xlink:title="definition: CreditFacilityDomain to LineOfCreditMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_SupplementalLineOfCreditMember" xlink:label="SupplementalLineOfCreditMember" xlink:title="SupplementalLineOfCreditMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CreditFacilityDomain" xlink:to="SupplementalLineOfCreditMember" xlink:title="definition: CreditFacilityDomain to SupplementalLineOfCreditMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_AdditionalSupplementalLineOfCreditMember" xlink:label="AdditionalSupplementalLineOfCreditMember" xlink:title="AdditionalSupplementalLineOfCreditMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CreditFacilityDomain" xlink:to="AdditionalSupplementalLineOfCreditMember" xlink:title="definition: CreditFacilityDomain to AdditionalSupplementalLineOfCreditMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="LongtermDebtTypeAxis" xlink:title="LongtermDebtTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LineOfCreditFacilityTable" xlink:to="LongtermDebtTypeAxis" xlink:title="definition: LineOfCreditFacilityTable to LongtermDebtTypeAxis" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="LongtermDebtTypeDomain" xlink:title="LongtermDebtTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LongtermDebtTypeAxis" xlink:to="LongtermDebtTypeDomain" xlink:title="definition: LongtermDebtTypeAxis to LongtermDebtTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="LongtermDebtTypeDomain_2" xlink:title="LongtermDebtTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LongtermDebtTypeAxis" xlink:to="LongtermDebtTypeDomain_2" xlink:title="definition: LongtermDebtTypeAxis to LongtermDebtTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_December2022PromissoryNoteMember" xlink:label="December2022PromissoryNoteMember" xlink:title="December2022PromissoryNoteMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LongtermDebtTypeDomain" xlink:to="December2022PromissoryNoteMember" xlink:title="definition: LongtermDebtTypeDomain to December2022PromissoryNoteMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_March2023PromissoryNoteMember" xlink:label="March2023PromissoryNoteMember" xlink:title="March2023PromissoryNoteMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LongtermDebtTypeDomain" xlink:to="March2023PromissoryNoteMember" xlink:title="definition: LongtermDebtTypeDomain to March2023PromissoryNoteMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_June2023PromissoryNoteMember" xlink:label="June2023PromissoryNoteMember" xlink:title="June2023PromissoryNoteMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LongtermDebtTypeDomain" xlink:to="June2023PromissoryNoteMember" xlink:title="definition: LongtermDebtTypeDomain to June2023PromissoryNoteMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_December2023PromissoryNoteMember" xlink:label="December2023PromissoryNoteMember" xlink:title="December2023PromissoryNoteMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LongtermDebtTypeDomain" xlink:to="December2023PromissoryNoteMember" xlink:title="definition: LongtermDebtTypeDomain to December2023PromissoryNoteMember" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_March24PromissoryNoteMember" xlink:label="March24PromissoryNoteMember" xlink:title="March24PromissoryNoteMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LongtermDebtTypeDomain" xlink:to="March24PromissoryNoteMember" xlink:title="definition: LongtermDebtTypeDomain to March24PromissoryNoteMember" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_June2024PromissoryNoteMember" xlink:label="June2024PromissoryNoteMember" xlink:title="June2024PromissoryNoteMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LongtermDebtTypeDomain" xlink:to="June2024PromissoryNoteMember" xlink:title="definition: LongtermDebtTypeDomain to June2024PromissoryNoteMember" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_September2024PromissoryNoteMember" xlink:label="September2024PromissoryNoteMember" xlink:title="September2024PromissoryNoteMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LongtermDebtTypeDomain" xlink:to="September2024PromissoryNoteMember" xlink:title="definition: LongtermDebtTypeDomain to September2024PromissoryNoteMember" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LineOfCreditFacilityTable" xlink:to="RangeAxis" xlink:title="definition: LineOfCreditFacilityTable to RangeAxis" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="FinancialInstrumentAxis" xlink:title="FinancialInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LineOfCreditFacilityTable" xlink:to="FinancialInstrumentAxis" xlink:title="definition: LineOfCreditFacilityTable to FinancialInstrumentAxis" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FinancialInstrumentAxis" xlink:to="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="definition: FinancialInstrumentAxis to TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" xlink:title="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FinancialInstrumentAxis" xlink:to="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" xlink:title="definition: FinancialInstrumentAxis to TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="WarrantMember" xlink:title="definition: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to WarrantMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_WarrantOneMember" xlink:label="WarrantOneMember" xlink:title="WarrantOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="WarrantOneMember" xlink:title="definition: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to WarrantOneMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_WarrantTwoMember" xlink:label="WarrantTwoMember" xlink:title="WarrantTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="WarrantTwoMember" xlink:title="definition: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to WarrantTwoMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_WarrantThreeMember" xlink:label="WarrantThreeMember" xlink:title="WarrantThreeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="WarrantThreeMember" xlink:title="definition: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to WarrantThreeMember" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_WarrantFourMember" xlink:label="WarrantFourMember" xlink:title="WarrantFourMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="WarrantFourMember" xlink:title="definition: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to WarrantFourMember" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_WarrantFiveMember" xlink:label="WarrantFiveMember" xlink:title="WarrantFiveMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="WarrantFiveMember" xlink:title="definition: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to WarrantFiveMember" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_WarrantSixMember" xlink:label="WarrantSixMember" xlink:title="WarrantSixMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="WarrantSixMember" xlink:title="definition: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to WarrantSixMember" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_WarrantSevenMember" xlink:label="WarrantSevenMember" xlink:title="WarrantSevenMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="WarrantSevenMember" xlink:title="definition: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to WarrantSevenMember" order="8.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/LossPerShareDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:label="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:title="EarningsPerShareDilutedOtherDisclosuresAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to EarningsPerShareDilutedOtherDisclosuresAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="3.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="definition: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain_2" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain_2" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="WarrantMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to WarrantMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to EmployeeStockOptionMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="ConvertibleNotesPayableMember" xlink:title="ConvertibleNotesPayableMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="ConvertibleNotesPayableMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to ConvertibleNotesPayableMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditMember" xlink:label="LineOfCreditMember" xlink:title="LineOfCreditMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="LineOfCreditMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to LineOfCreditMember" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="ConvertiblePreferredStockMember" xlink:title="ConvertiblePreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="ConvertiblePreferredStockMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to ConvertiblePreferredStockMember" order="5.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/CommitmentsAndContingenciesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="LesseeLeaseDescriptionLineItems" xlink:title="LesseeLeaseDescriptionLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:label="LesseeOperatingLeaseDescriptionAbstract" xlink:title="LesseeOperatingLeaseDescriptionAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseDescriptionAbstract" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseDescriptionAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:title="OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:title="definition: LesseeLeaseDescriptionLineItems to OperatingLeaseLiabilitiesPaymentsDueAbstract" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="LesseeOperatingLeaseDiscountRate" xlink:title="LesseeOperatingLeaseDiscountRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseDiscountRate" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseDiscountRate" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ClinicalTrialAndResearchContingenciesAbstract" xlink:label="ClinicalTrialAndResearchContingenciesAbstract" xlink:title="ClinicalTrialAndResearchContingenciesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="ClinicalTrialAndResearchContingenciesAbstract" xlink:title="definition: LesseeLeaseDescriptionLineItems to ClinicalTrialAndResearchContingenciesAbstract" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ContractCancelationNoticePeriod" xlink:label="ContractCancelationNoticePeriod" xlink:title="ContractCancelationNoticePeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="ContractCancelationNoticePeriod" xlink:title="definition: LesseeLeaseDescriptionLineItems to ContractCancelationNoticePeriod" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:label="LossContingencyEstimateOfPossibleLoss" xlink:title="LossContingencyEstimateOfPossibleLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LossContingencyEstimateOfPossibleLoss" xlink:title="definition: LesseeLeaseDescriptionLineItems to LossContingencyEstimateOfPossibleLoss" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyRangeOfPossibleLossPortionNotAccrued" xlink:label="LossContingencyRangeOfPossibleLossPortionNotAccrued" xlink:title="LossContingencyRangeOfPossibleLossPortionNotAccrued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LossContingencyRangeOfPossibleLossPortionNotAccrued" xlink:title="definition: LesseeLeaseDescriptionLineItems to LossContingencyRangeOfPossibleLossPortionNotAccrued" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseLiabilityPaymentsDue" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="OperatingLeaseLiability" xlink:title="OperatingLeaseLiability" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="OperatingLeaseLiability" xlink:title="definition: LesseeLeaseDescriptionLineItems to OperatingLeaseLiability" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_NumberOfOperatingLeases" xlink:label="NumberOfOperatingLeases" xlink:title="NumberOfOperatingLeases" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="NumberOfOperatingLeases" xlink:title="definition: LesseeLeaseDescriptionLineItems to NumberOfOperatingLeases" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="LesseeOperatingLeaseTermOfContract" xlink:title="LesseeOperatingLeaseTermOfContract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseTermOfContract" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseTermOfContract" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_FreeRentPeriod" xlink:label="FreeRentPeriod" xlink:title="FreeRentPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="FreeRentPeriod" xlink:title="definition: LesseeLeaseDescriptionLineItems to FreeRentPeriod" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecurityDeposit" xlink:label="SecurityDeposit" xlink:title="SecurityDeposit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="SecurityDeposit" xlink:title="definition: LesseeLeaseDescriptionLineItems to SecurityDeposit" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="OperatingLeaseCost" xlink:title="OperatingLeaseCost" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="OperatingLeaseCost" xlink:title="definition: LesseeLeaseDescriptionLineItems to OperatingLeaseCost" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="OperatingLeaseRightOfUseAsset" xlink:title="OperatingLeaseRightOfUseAsset" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="OperatingLeaseRightOfUseAsset" xlink:title="definition: LesseeLeaseDescriptionLineItems to OperatingLeaseRightOfUseAsset" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:label="OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:title="OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:title="definition: LesseeLeaseDescriptionLineItems to OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="OperatingLeaseLiabilityCurrent" xlink:title="OperatingLeaseLiabilityCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="OperatingLeaseLiabilityCurrent" xlink:title="definition: LesseeLeaseDescriptionLineItems to OperatingLeaseLiabilityCurrent" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:title="OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:title="definition: LesseeLeaseDescriptionLineItems to OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="OperatingLeaseLiabilityNoncurrent" xlink:title="OperatingLeaseLiabilityNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="OperatingLeaseLiabilityNoncurrent" xlink:title="definition: LesseeLeaseDescriptionLineItems to OperatingLeaseLiabilityNoncurrent" order="21.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:title="OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:title="definition: LesseeLeaseDescriptionLineItems to OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" order="22.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="LesseeOperatingLeaseRenewalTerm" xlink:title="LesseeOperatingLeaseRenewalTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseRenewalTerm" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseRenewalTerm" order="23.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="LesseeLeaseDescriptionTable" xlink:title="LesseeLeaseDescriptionTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeLeaseDescriptionTable" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeLeaseDescriptionTable" order="24.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LesseeLeaseDescriptionTable" xlink:to="IncomeStatementLocationAxis" xlink:title="definition: LesseeLeaseDescriptionTable to IncomeStatementLocationAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain_2" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain_2" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="GeneralAndAdministrativeExpenseMember" xlink:title="GeneralAndAdministrativeExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementLocationDomain" xlink:to="GeneralAndAdministrativeExpenseMember" xlink:title="definition: IncomeStatementLocationDomain to GeneralAndAdministrativeExpenseMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/CommitmentsAndContingenciesDetailsCalc2" />
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/GalectinSciencesLlcDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems" xlink:label="InvestmentsInAndAdvancesToAffiliatesLineItems" xlink:title="InvestmentsInAndAdvancesToAffiliatesLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract" xlink:label="InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract" xlink:title="InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="InvestmentsInAndAdvancesToAffiliatesLineItems" xlink:to="InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract" xlink:title="definition: InvestmentsInAndAdvancesToAffiliatesLineItems to InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="PaymentsToAcquireEquityMethodInvestments" xlink:title="PaymentsToAcquireEquityMethodInvestments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="InvestmentsInAndAdvancesToAffiliatesLineItems" xlink:to="PaymentsToAcquireEquityMethodInvestments" xlink:title="definition: InvestmentsInAndAdvancesToAffiliatesLineItems to PaymentsToAcquireEquityMethodInvestments" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure" xlink:label="InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure" xlink:title="InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="InvestmentsInAndAdvancesToAffiliatesLineItems" xlink:to="InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure" xlink:title="definition: InvestmentsInAndAdvancesToAffiliatesLineItems to InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="MinorityInterestOwnershipPercentageByParent" xlink:title="MinorityInterestOwnershipPercentageByParent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="InvestmentsInAndAdvancesToAffiliatesLineItems" xlink:to="MinorityInterestOwnershipPercentageByParent" xlink:title="definition: InvestmentsInAndAdvancesToAffiliatesLineItems to MinorityInterestOwnershipPercentageByParent" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="InvestmentsInAndAdvancesToAffiliatesLineItems" xlink:to="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:title="definition: InvestmentsInAndAdvancesToAffiliatesLineItems to CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_CapitalContributionExpense" xlink:label="CapitalContributionExpense" xlink:title="CapitalContributionExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="InvestmentsInAndAdvancesToAffiliatesLineItems" xlink:to="CapitalContributionExpense" xlink:title="definition: InvestmentsInAndAdvancesToAffiliatesLineItems to CapitalContributionExpense" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="IncomeLossFromEquityMethodInvestments" xlink:title="IncomeLossFromEquityMethodInvestments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="InvestmentsInAndAdvancesToAffiliatesLineItems" xlink:to="IncomeLossFromEquityMethodInvestments" xlink:title="definition: InvestmentsInAndAdvancesToAffiliatesLineItems to IncomeLossFromEquityMethodInvestments" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_NonCashChargeForResearchAndDevelopmentInProcess" xlink:label="NonCashChargeForResearchAndDevelopmentInProcess" xlink:title="NonCashChargeForResearchAndDevelopmentInProcess" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="InvestmentsInAndAdvancesToAffiliatesLineItems" xlink:to="NonCashChargeForResearchAndDevelopmentInProcess" xlink:title="definition: InvestmentsInAndAdvancesToAffiliatesLineItems to NonCashChargeForResearchAndDevelopmentInProcess" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInvestmentsTable" xlink:label="ScheduleOfInvestmentsTable" xlink:title="ScheduleOfInvestmentsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="InvestmentsInAndAdvancesToAffiliatesLineItems" xlink:to="ScheduleOfInvestmentsTable" xlink:title="definition: InvestmentsInAndAdvancesToAffiliatesLineItems to ScheduleOfInvestmentsTable" order="9.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis" xlink:label="OwnershipAxis" xlink:title="OwnershipAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfInvestmentsTable" xlink:to="OwnershipAxis" xlink:title="definition: ScheduleOfInvestmentsTable to OwnershipAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain" xlink:label="OwnershipDomain" xlink:title="OwnershipDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="OwnershipAxis" xlink:to="OwnershipDomain" xlink:title="definition: OwnershipAxis to OwnershipDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain" xlink:label="OwnershipDomain_2" xlink:title="OwnershipDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="OwnershipAxis" xlink:to="OwnershipDomain_2" xlink:title="definition: OwnershipAxis to OwnershipDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_GalectinSciencesLLCMember" xlink:label="GalectinSciencesLLCMember" xlink:title="GalectinSciencesLLCMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OwnershipDomain" xlink:to="GalectinSciencesLLCMember" xlink:title="definition: OwnershipDomain to GalectinSciencesLLCMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="CounterpartyNameAxis" xlink:title="CounterpartyNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfInvestmentsTable" xlink:to="CounterpartyNameAxis" xlink:title="definition: ScheduleOfInvestmentsTable to CounterpartyNameAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain" xlink:title="RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain" xlink:title="definition: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain_2" xlink:title="RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain_2" xlink:title="definition: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_SBHSciencesIncMember" xlink:label="SBHSciencesIncMember" xlink:title="SBHSciencesIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RepurchaseAgreementCounterpartyNameDomain" xlink:to="SBHSciencesIncMember" xlink:title="definition: RepurchaseAgreementCounterpartyNameDomain to SBHSciencesIncMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfInvestmentsTable" xlink:to="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="definition: ScheduleOfInvestmentsTable to FiniteLivedIntangibleAssetsByMajorClassAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="definition: FiniteLivedIntangibleAssetsByMajorClassAxis to FiniteLivedIntangibleAssetsMajorClassNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="FiniteLivedIntangibleAssetsMajorClassNameDomain_2" xlink:title="FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="FiniteLivedIntangibleAssetsMajorClassNameDomain_2" xlink:title="definition: FiniteLivedIntangibleAssetsByMajorClassAxis to FiniteLivedIntangibleAssetsMajorClassNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="InProcessResearchAndDevelopmentMember" xlink:title="InProcessResearchAndDevelopmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="InProcessResearchAndDevelopmentMember" xlink:title="definition: FiniteLivedIntangibleAssetsMajorClassNameDomain to InProcessResearchAndDevelopmentMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/IncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/IncomeTaxesPrimaryFactorsAffectingIncomeTaxRatesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="OperatingLossCarryforwardsLineItems" xlink:title="OperatingLossCarryforwardsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:title="CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:title="definition: OperatingLossCarryforwardsLineItems to CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="OperatingLossCarryforwards" xlink:title="OperatingLossCarryforwards" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="OperatingLossCarryforwards" xlink:title="definition: OperatingLossCarryforwardsLineItems to OperatingLossCarryforwards" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_DeferredTaxAssetsValuationAllowancePercentage" xlink:label="DeferredTaxAssetsValuationAllowancePercentage" xlink:title="DeferredTaxAssetsValuationAllowancePercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="DeferredTaxAssetsValuationAllowancePercentage" xlink:title="definition: OperatingLossCarryforwardsLineItems to DeferredTaxAssetsValuationAllowancePercentage" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_OperatingLossCarryforwardsExpirationYear" xlink:label="OperatingLossCarryforwardsExpirationYear" xlink:title="OperatingLossCarryforwardsExpirationYear" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="OperatingLossCarryforwardsExpirationYear" xlink:title="definition: OperatingLossCarryforwardsLineItems to OperatingLossCarryforwardsExpirationYear" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="IncomeTaxReconciliationTaxCreditsResearch" xlink:title="IncomeTaxReconciliationTaxCreditsResearch" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="IncomeTaxReconciliationTaxCreditsResearch" xlink:title="definition: OperatingLossCarryforwardsLineItems to IncomeTaxReconciliationTaxCreditsResearch" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_FederalAndStateResearchAndDevelopmentCreditsExpirationYear" xlink:label="FederalAndStateResearchAndDevelopmentCreditsExpirationYear" xlink:title="FederalAndStateResearchAndDevelopmentCreditsExpirationYear" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="FederalAndStateResearchAndDevelopmentCreditsExpirationYear" xlink:title="definition: OperatingLossCarryforwardsLineItems to FederalAndStateResearchAndDevelopmentCreditsExpirationYear" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="OperatingLossCarryforwardsTable" xlink:title="OperatingLossCarryforwardsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="OperatingLossCarryforwardsTable" xlink:title="definition: OperatingLossCarryforwardsLineItems to OperatingLossCarryforwardsTable" order="7.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="IncomeTaxAuthorityAxis" xlink:title="IncomeTaxAuthorityAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="OperatingLossCarryforwardsTable" xlink:to="IncomeTaxAuthorityAxis" xlink:title="definition: OperatingLossCarryforwardsTable to IncomeTaxAuthorityAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="IncomeTaxAuthorityDomain" xlink:title="IncomeTaxAuthorityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="IncomeTaxAuthorityAxis" xlink:to="IncomeTaxAuthorityDomain" xlink:title="definition: IncomeTaxAuthorityAxis to IncomeTaxAuthorityDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="IncomeTaxAuthorityDomain_2" xlink:title="IncomeTaxAuthorityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeTaxAuthorityAxis" xlink:to="IncomeTaxAuthorityDomain_2" xlink:title="definition: IncomeTaxAuthorityAxis to IncomeTaxAuthorityDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="DomesticCountryMember" xlink:title="DomesticCountryMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeTaxAuthorityDomain" xlink:to="DomesticCountryMember" xlink:title="definition: IncomeTaxAuthorityDomain to DomesticCountryMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="StateAndLocalJurisdictionMember" xlink:title="StateAndLocalJurisdictionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeTaxAuthorityDomain" xlink:to="StateAndLocalJurisdictionMember" xlink:title="definition: IncomeTaxAuthorityDomain to StateAndLocalJurisdictionMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="TaxPeriodAxis" xlink:title="TaxPeriodAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="OperatingLossCarryforwardsTable" xlink:to="TaxPeriodAxis" xlink:title="definition: OperatingLossCarryforwardsTable to TaxPeriodAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="TaxPeriodDomain" xlink:title="TaxPeriodDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TaxPeriodAxis" xlink:to="TaxPeriodDomain" xlink:title="definition: TaxPeriodAxis to TaxPeriodDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="TaxPeriodDomain_2" xlink:title="TaxPeriodDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TaxPeriodAxis" xlink:to="TaxPeriodDomain_2" xlink:title="definition: TaxPeriodAxis to TaxPeriodDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ExpiringAsAResultOf2017TaxActMember" xlink:label="ExpiringAsAResultOf2017TaxActMember" xlink:title="ExpiringAsAResultOf2017TaxActMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TaxPeriodDomain" xlink:to="ExpiringAsAResultOf2017TaxActMember" xlink:title="definition: TaxPeriodDomain to ExpiringAsAResultOf2017TaxActMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ExpiringThrough2037Member" xlink:label="ExpiringThrough2037Member" xlink:title="ExpiringThrough2037Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TaxPeriodDomain" xlink:to="ExpiringThrough2037Member" xlink:title="definition: TaxPeriodDomain to ExpiringThrough2037Member" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/SegmentsSignificantExpenseCategoriesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="SegmentReportingInformationLineItems" xlink:title="SegmentReportingInformationLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationProfitLossAbstract" xlink:label="SegmentReportingInformationProfitLossAbstract" xlink:title="SegmentReportingInformationProfitLossAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="SegmentReportingInformationProfitLossAbstract" xlink:title="definition: SegmentReportingInformationLineItems to SegmentReportingInformationProfitLossAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="NumberOfOperatingSegments" xlink:title="NumberOfOperatingSegments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="NumberOfOperatingSegments" xlink:title="definition: SegmentReportingInformationLineItems to NumberOfOperatingSegments" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" xlink:title="NetCashProvidedByUsedInOperatingActivities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="NetCashProvidedByUsedInOperatingActivities" xlink:title="definition: SegmentReportingInformationLineItems to NetCashProvidedByUsedInOperatingActivities" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="OperatingExpensesAbstract" xlink:title="OperatingExpensesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="OperatingExpensesAbstract" xlink:title="definition: SegmentReportingInformationLineItems to OperatingExpensesAbstract" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="NonoperatingIncomeExpenseAbstract" xlink:title="NonoperatingIncomeExpenseAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="NonoperatingIncomeExpenseAbstract" xlink:title="definition: SegmentReportingInformationLineItems to NonoperatingIncomeExpenseAbstract" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="NetIncomeLoss" xlink:title="definition: SegmentReportingInformationLineItems to NetIncomeLoss" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="PreferredStockDividendsAndOtherAdjustments" xlink:title="PreferredStockDividendsAndOtherAdjustments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="PreferredStockDividendsAndOtherAdjustments" xlink:title="definition: SegmentReportingInformationLineItems to PreferredStockDividendsAndOtherAdjustments" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_FairValueAdjustmentOfWarrant" xlink:label="FairValueAdjustmentOfWarrant" xlink:title="FairValueAdjustmentOfWarrant" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="FairValueAdjustmentOfWarrant" xlink:title="definition: SegmentReportingInformationLineItems to FairValueAdjustmentOfWarrant" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="definition: SegmentReportingInformationLineItems to NetIncomeLossAvailableToCommonStockholdersBasic" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="InvestmentIncomeInterest" xlink:title="InvestmentIncomeInterest" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="InvestmentIncomeInterest" xlink:title="definition: SegmentReportingInformationLineItems to InvestmentIncomeInterest" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="InterestExpenseNonoperating" xlink:title="InterestExpenseNonoperating" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="InterestExpenseNonoperating" xlink:title="definition: SegmentReportingInformationLineItems to InterestExpenseNonoperating" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:label="DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:title="DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:title="definition: SegmentReportingInformationLineItems to DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="NonoperatingIncomeExpense" xlink:title="NonoperatingIncomeExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="NonoperatingIncomeExpense" xlink:title="definition: SegmentReportingInformationLineItems to NonoperatingIncomeExpense" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="ResearchAndDevelopmentExpense" xlink:title="definition: SegmentReportingInformationLineItems to ResearchAndDevelopmentExpense" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="GeneralAndAdministrativeExpense" xlink:title="definition: SegmentReportingInformationLineItems to GeneralAndAdministrativeExpense" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="OperatingExpenses" xlink:title="definition: SegmentReportingInformationLineItems to OperatingExpenses" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="OperatingIncomeLoss" xlink:title="definition: SegmentReportingInformationLineItems to OperatingIncomeLoss" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:title="ScheduleOfSegmentReportingInformationBySegmentTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="SegmentReportingInformationLineItems" xlink:to="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:title="definition: SegmentReportingInformationLineItems to ScheduleOfSegmentReportingInformationBySegmentTable" order="18.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="StatementBusinessSegmentsAxis" xlink:title="StatementBusinessSegmentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="StatementBusinessSegmentsAxis" xlink:title="definition: ScheduleOfSegmentReportingInformationBySegmentTable to StatementBusinessSegmentsAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="SegmentDomain" xlink:title="SegmentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementBusinessSegmentsAxis" xlink:to="SegmentDomain" xlink:title="definition: StatementBusinessSegmentsAxis to SegmentDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="SegmentDomain_2" xlink:title="SegmentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementBusinessSegmentsAxis" xlink:to="SegmentDomain_2" xlink:title="definition: StatementBusinessSegmentsAxis to SegmentDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_BusinessOperatingSegmentMember" xlink:label="BusinessOperatingSegmentMember" xlink:title="BusinessOperatingSegmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentDomain" xlink:to="BusinessOperatingSegmentMember" xlink:title="definition: SegmentDomain to BusinessOperatingSegmentMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/SegmentsSignificantAssetCategoriesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="SegmentReportingInformationLineItems" xlink:title="SegmentReportingInformationLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="definition: SegmentReportingInformationLineItems to CashAndCashEquivalentsAtCarryingValue" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:title="ScheduleOfSegmentReportingInformationBySegmentTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="SegmentReportingInformationLineItems" xlink:to="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:title="definition: SegmentReportingInformationLineItems to ScheduleOfSegmentReportingInformationBySegmentTable" order="2.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="StatementBusinessSegmentsAxis" xlink:title="StatementBusinessSegmentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="StatementBusinessSegmentsAxis" xlink:title="definition: ScheduleOfSegmentReportingInformationBySegmentTable to StatementBusinessSegmentsAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="SegmentDomain" xlink:title="SegmentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementBusinessSegmentsAxis" xlink:to="SegmentDomain" xlink:title="definition: StatementBusinessSegmentsAxis to SegmentDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="SegmentDomain_2" xlink:title="SegmentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementBusinessSegmentsAxis" xlink:to="SegmentDomain_2" xlink:title="definition: StatementBusinessSegmentsAxis to SegmentDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_BusinessOperatingSegmentMember" xlink:label="BusinessOperatingSegmentMember" xlink:title="BusinessOperatingSegmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentDomain" xlink:to="BusinessOperatingSegmentMember" xlink:title="definition: SegmentDomain to BusinessOperatingSegmentMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/SubsequentEventDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="SubsequentEventLineItems" xlink:title="SubsequentEventLineItems" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_LineOfCreditRelatedPartyAbstract" xlink:label="LineOfCreditRelatedPartyAbstract" xlink:title="LineOfCreditRelatedPartyAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="LineOfCreditRelatedPartyAbstract" xlink:title="definition: SubsequentEventLineItems to LineOfCreditRelatedPartyAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="LineOfCreditFacilityMaximumBorrowingCapacity" xlink:title="LineOfCreditFacilityMaximumBorrowingCapacity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="LineOfCreditFacilityMaximumBorrowingCapacity" xlink:title="definition: SubsequentEventLineItems to LineOfCreditFacilityMaximumBorrowingCapacity" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="DebtInstrumentInterestRateIncreaseDecrease" xlink:title="DebtInstrumentInterestRateIncreaseDecrease" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="DebtInstrumentInterestRateIncreaseDecrease" xlink:title="definition: SubsequentEventLineItems to DebtInstrumentInterestRateIncreaseDecrease" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="DebtInstrumentMaturityDate" xlink:title="DebtInstrumentMaturityDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="DebtInstrumentMaturityDate" xlink:title="definition: SubsequentEventLineItems to DebtInstrumentMaturityDate" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="SharePrice" xlink:title="SharePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="SharePrice" xlink:title="definition: SubsequentEventLineItems to SharePrice" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="definition: SubsequentEventLineItems to ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="CommonStockParOrStatedValuePerShare" xlink:title="definition: SubsequentEventLineItems to CommonStockParOrStatedValuePerShare" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock" xlink:title="definition: SubsequentEventLineItems to ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="WarrantsAndRightsOutstandingMaturityDate" xlink:title="WarrantsAndRightsOutstandingMaturityDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="WarrantsAndRightsOutstandingMaturityDate" xlink:title="definition: SubsequentEventLineItems to WarrantsAndRightsOutstandingMaturityDate" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="SubsequentEventTable" xlink:title="SubsequentEventTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="SubsequentEventLineItems" xlink:to="SubsequentEventTable" xlink:title="definition: SubsequentEventLineItems to SubsequentEventTable" order="10.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="CreditFacilityAxis" xlink:title="CreditFacilityAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="SubsequentEventTable" xlink:to="CreditFacilityAxis" xlink:title="definition: SubsequentEventTable to CreditFacilityAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="CreditFacilityDomain" xlink:title="CreditFacilityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="CreditFacilityAxis" xlink:to="CreditFacilityDomain" xlink:title="definition: CreditFacilityAxis to CreditFacilityDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="CreditFacilityDomain_2" xlink:title="CreditFacilityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CreditFacilityAxis" xlink:to="CreditFacilityDomain_2" xlink:title="definition: CreditFacilityAxis to CreditFacilityDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_SupplementalLineOfCreditMember" xlink:label="SupplementalLineOfCreditMember" xlink:title="SupplementalLineOfCreditMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CreditFacilityDomain" xlink:to="SupplementalLineOfCreditMember" xlink:title="definition: CreditFacilityDomain to SupplementalLineOfCreditMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="SubsequentEventTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="definition: SubsequentEventTable to RelatedPartyTransactionsByRelatedPartyAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain_2" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain_2" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="BoardOfDirectorsChairmanMember" xlink:title="BoardOfDirectorsChairmanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyDomain" xlink:to="BoardOfDirectorsChairmanMember" xlink:title="definition: RelatedPartyDomain to BoardOfDirectorsChairmanMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="SubsequentEventTable" xlink:to="StatementEquityComponentsAxis" xlink:title="definition: SubsequentEventTable to StatementEquityComponentsAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain_2" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain_2" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="CommonStockMember" xlink:title="definition: EquityComponentDomain to CommonStockMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="SubsequentEventTable" xlink:to="RangeAxis" xlink:title="definition: SubsequentEventTable to RangeAxis" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="SubsequentEventTable" xlink:to="SubsequentEventTypeAxis" xlink:title="definition: SubsequentEventTable to SubsequentEventTypeAxis" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain_2" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain_2" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="definition: SubsequentEventTypeDomain to SubsequentEventMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="LiabilitiesCurrentAbstract" xlink:title="LiabilitiesCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiabilitiesCurrentAbstract" xlink:to="AccruedLiabilitiesCurrent" xlink:title="definition: LiabilitiesCurrentAbstract to AccruedLiabilitiesCurrent" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="OtherAssetsNoncurrent" xlink:title="OtherAssetsNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetsAbstract" xlink:to="OtherAssetsNoncurrent" xlink:title="definition: AssetsAbstract to OtherAssetsNoncurrent" order="1.0" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>galt-20241231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 25.3.1.5296 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="InsiderTradingArrLineItems" xlink:title="InsiderTradingArrLineItems" />
    <link:label xlink:type="resource" xlink:label="ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ecd_InsiderTradingArrLineItems" xml:lang="en-US" id="ecd_InsiderTradingArrLineItems">Insider Trading Arrangements [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InsiderTradingArrLineItems" xlink:to="ecd_InsiderTradingArrLineItems" xlink:title="label: InsiderTradingArrLineItems to ecd_InsiderTradingArrLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="Rule10b51ArrAdoptedFlag" xlink:title="Rule10b51ArrAdoptedFlag" />
    <link:label xlink:type="resource" xlink:label="ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ecd_Rule10b51ArrAdoptedFlag" xml:lang="en-US" id="ecd_Rule10b51ArrAdoptedFlag">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag" xlink:title="label: Rule10b51ArrAdoptedFlag to ecd_Rule10b51ArrAdoptedFlag" />
    <link:label xlink:type="resource" xlink:label="ecd_Rule10b51ArrAdoptedFlag_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ecd_Rule10b51ArrAdoptedFlag_lbl1" xml:lang="en-US" id="ecd_Rule10b51ArrAdoptedFlag_lbl1">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag_lbl1" xlink:title="label: Rule10b51ArrAdoptedFlag to ecd_Rule10b51ArrAdoptedFlag_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="Rule10b51ArrTrmntdFlag" xlink:title="Rule10b51ArrTrmntdFlag" />
    <link:label xlink:type="resource" xlink:label="ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ecd_Rule10b51ArrTrmntdFlag" xml:lang="en-US" id="ecd_Rule10b51ArrTrmntdFlag">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag" xlink:title="label: Rule10b51ArrTrmntdFlag to ecd_Rule10b51ArrTrmntdFlag" />
    <link:label xlink:type="resource" xlink:label="ecd_Rule10b51ArrTrmntdFlag_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ecd_Rule10b51ArrTrmntdFlag_lbl1" xml:lang="en-US" id="ecd_Rule10b51ArrTrmntdFlag_lbl1">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag_lbl1" xlink:title="label: Rule10b51ArrTrmntdFlag to ecd_Rule10b51ArrTrmntdFlag_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="NonRule10b51ArrAdoptedFlag" xlink:title="NonRule10b51ArrAdoptedFlag" />
    <link:label xlink:type="resource" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ecd_NonRule10b51ArrAdoptedFlag" xml:lang="en-US" id="ecd_NonRule10b51ArrAdoptedFlag">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag" xlink:title="label: NonRule10b51ArrAdoptedFlag to ecd_NonRule10b51ArrAdoptedFlag" />
    <link:label xlink:type="resource" xlink:label="ecd_NonRule10b51ArrAdoptedFlag_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ecd_NonRule10b51ArrAdoptedFlag_lbl1" xml:lang="en-US" id="ecd_NonRule10b51ArrAdoptedFlag_lbl1">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag_lbl1" xlink:title="label: NonRule10b51ArrAdoptedFlag to ecd_NonRule10b51ArrAdoptedFlag_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="NonRule10b51ArrTrmntdFlag" xlink:title="NonRule10b51ArrTrmntdFlag" />
    <link:label xlink:type="resource" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ecd_NonRule10b51ArrTrmntdFlag" xml:lang="en-US" id="ecd_NonRule10b51ArrTrmntdFlag">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag" xlink:title="label: NonRule10b51ArrTrmntdFlag to ecd_NonRule10b51ArrTrmntdFlag" />
    <link:label xlink:type="resource" xlink:label="ecd_NonRule10b51ArrTrmntdFlag_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ecd_NonRule10b51ArrTrmntdFlag_lbl1" xml:lang="en-US" id="ecd_NonRule10b51ArrTrmntdFlag_lbl1">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag_lbl1" xlink:title="label: NonRule10b51ArrTrmntdFlag to ecd_NonRule10b51ArrTrmntdFlag_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="InsiderTradingPoliciesProcLineItems" xlink:title="InsiderTradingPoliciesProcLineItems" />
    <link:label xlink:type="resource" xlink:label="ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ecd_InsiderTradingPoliciesProcLineItems" xml:lang="en-US" id="ecd_InsiderTradingPoliciesProcLineItems">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InsiderTradingPoliciesProcLineItems" xlink:to="ecd_InsiderTradingPoliciesProcLineItems" xlink:title="label: InsiderTradingPoliciesProcLineItems to ecd_InsiderTradingPoliciesProcLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="InsiderTrdPoliciesProcAdoptedFlag" xlink:title="InsiderTrdPoliciesProcAdoptedFlag" />
    <link:label xlink:type="resource" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ecd_InsiderTrdPoliciesProcAdoptedFlag" xml:lang="en-US" id="ecd_InsiderTrdPoliciesProcAdoptedFlag">Insider Trading Policies and Procedures Adopted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InsiderTrdPoliciesProcAdoptedFlag" xlink:to="ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:title="label: InsiderTrdPoliciesProcAdoptedFlag to ecd_InsiderTrdPoliciesProcAdoptedFlag" />
    <link:label xlink:type="resource" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl1" xml:lang="en-US" id="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl1">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InsiderTrdPoliciesProcAdoptedFlag" xlink:to="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl1" xlink:title="label: InsiderTrdPoliciesProcAdoptedFlag to ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:title="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xml:lang="en-US" id="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">Accrued Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:title="label: AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock to us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl1">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl1" xlink:title="label: AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock to us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US" id="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">Less accumulated depreciation and amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="label: AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment to us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1" xml:lang="en-US" id="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1" xlink:title="label: AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment to us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdditionalPaidInCapital" xml:lang="en-US" id="us-gaap_AdditionalPaidInCapital">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:title="label: AdditionalPaidInCapital to us-gaap_AdditionalPaidInCapital" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="AmortizationOfFinancingCosts" xlink:title="AmortizationOfFinancingCosts" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AmortizationOfFinancingCosts" xml:lang="en-US" id="us-gaap_AmortizationOfFinancingCosts">Amortization of debt discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts" xlink:title="label: AmortizationOfFinancingCosts to us-gaap_AmortizationOfFinancingCosts" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="RestrictedStockMember" xlink:title="RestrictedStockMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RestrictedStockMember" xml:lang="en-US" id="us-gaap_RestrictedStockMember">Restricted Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember" xlink:title="label: RestrictedStockMember to us-gaap_RestrictedStockMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US" id="us-gaap_StatementOfFinancialPositionAbstract">CONSOLIDATED BALANCE SHEETS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract" xlink:title="label: StatementOfFinancialPositionAbstract to us-gaap_StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="EarningsPerShareBasic" xlink:title="EarningsPerShareBasic" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareBasic" xml:lang="en-US" id="us-gaap_EarningsPerShareBasic">Net loss per common share - basic (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic" xlink:title="label: EarningsPerShareBasic to us-gaap_EarningsPerShareBasic" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsAtCarryingValue">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:title="label: CashAndCashEquivalentsAtCarryingValue to us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValue1" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsAtCarryingValue1">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue1" xlink:title="label: CashAndCashEquivalentsAtCarryingValue to us-gaap_CashAndCashEquivalentsAtCarryingValue1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:label="CashAndCashEquivalentsAtCarryingValueAbstract" xlink:title="CashAndCashEquivalentsAtCarryingValueAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract">Cash and Cash Equivalents [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValueAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:title="label: CashAndCashEquivalentsAtCarryingValueAbstract to us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="CashAndCashEquivalentsPolicyTextBlock" xlink:title="CashAndCashEquivalentsPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsPolicyTextBlock">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:title="label: CashAndCashEquivalentsPolicyTextBlock to us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl1">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl1" xlink:title="label: CashAndCashEquivalentsPolicyTextBlock to us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="CashEquivalentsAtCarryingValue" xlink:title="CashEquivalentsAtCarryingValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashEquivalentsAtCarryingValue" xml:lang="en-US" id="us-gaap_CashEquivalentsAtCarryingValue">Cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" xlink:title="label: CashEquivalentsAtCarryingValue to us-gaap_CashEquivalentsAtCarryingValue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">Accounts payable, accrued expenses and other liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="label: IncreaseDecreaseInAccountsPayableAndAccruedLiabilities to us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl1">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl1" xlink:title="label: IncreaseDecreaseInAccountsPayableAndAccruedLiabilities to us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="IncreaseDecreaseInInterestPayableNet" xlink:title="IncreaseDecreaseInInterestPayableNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncreaseDecreaseInInterestPayableNet" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInInterestPayableNet">Accrued interest on convertible notes payable and convertible line of credit - related party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInInterestPayableNet" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:title="label: IncreaseDecreaseInInterestPayableNet to us-gaap_IncreaseDecreaseInInterestPayableNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl1">Increase (Decrease) in Interest Payable, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInInterestPayableNet" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl1" xlink:title="label: IncreaseDecreaseInInterestPayableNet to us-gaap_IncreaseDecreaseInInterestPayableNet_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">Prepaid expenses and other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="label: IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets to us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" xlink:title="label: IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets to us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="label: IncreaseDecreaseInOperatingCapitalAbstract to us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US" id="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="label: CommitmentsAndContingenciesDisclosureTextBlock to us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockSharesAuthorized" xml:lang="en-US" id="us-gaap_CommonStockSharesAuthorized">Common stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:title="label: CommonStockSharesAuthorized to us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockSharesIssued" xml:lang="en-US" id="us-gaap_CommonStockSharesIssued">Common stock, issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued" xlink:title="label: CommonStockSharesIssued to us-gaap_CommonStockSharesIssued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CommonStockSharesIssued1" xml:lang="en-US" id="us-gaap_CommonStockSharesIssued1">Issuance of common stock (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued1" xlink:title="label: CommonStockSharesIssued to us-gaap_CommonStockSharesIssued1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockSharesOutstanding" xml:lang="en-US" id="us-gaap_CommonStockSharesOutstanding">Common stock, outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:title="label: CommonStockSharesOutstanding to us-gaap_CommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CommonStockSharesOutstanding1" xml:lang="en-US" id="us-gaap_CommonStockSharesOutstanding1">Common stock shares outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding1" xlink:title="label: CommonStockSharesOutstanding to us-gaap_CommonStockSharesOutstanding1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockValue" xml:lang="en-US" id="us-gaap_CommonStockValue">Common stock, $0.001 par value; 150,000,000 shares authorized at December 31, 2024 and 2023, 63,157,235 and 61,852,914 issued and outstanding at December 31, 2024 and 2023, respectively</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockValue" xlink:to="us-gaap_CommonStockValue" xlink:title="label: CommonStockValue to us-gaap_CommonStockValue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="ConvertiblePreferredStockMember" xlink:title="ConvertiblePreferredStockMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConvertiblePreferredStockMember" xml:lang="en-US" id="us-gaap_ConvertiblePreferredStockMember">Convertible Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember" xlink:title="label: ConvertiblePreferredStockMember to us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_LiabilitiesCurrent" xml:lang="en-US" id="us-gaap_LiabilitiesCurrent">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent" xlink:title="label: LiabilitiesCurrent to us-gaap_LiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesCurrent_lbl1" xml:lang="en-US" id="us-gaap_LiabilitiesCurrent_lbl1">Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl1" xlink:title="label: LiabilitiesCurrent to us-gaap_LiabilitiesCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="LiabilitiesCurrentAbstract" xlink:title="LiabilitiesCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US" id="us-gaap_LiabilitiesCurrentAbstract">Current liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:title="label: LiabilitiesCurrentAbstract to us-gaap_LiabilitiesCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesCurrentAbstract_lbl1" xml:lang="en-US" id="us-gaap_LiabilitiesCurrentAbstract_lbl1">Liabilities, Current [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl1" xlink:title="label: LiabilitiesCurrentAbstract to us-gaap_LiabilitiesCurrentAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="DebtDisclosureTextBlock" xlink:title="DebtDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtDisclosureTextBlock" xml:lang="en-US" id="us-gaap_DebtDisclosureTextBlock">Convertible Line of Credit - Related Party and Supplemental Lines of Credit - Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock" xlink:title="label: DebtDisclosureTextBlock to us-gaap_DebtDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_DebtDisclosureTextBlock1" xml:lang="en-US" id="us-gaap_DebtDisclosureTextBlock1">Convertible Notes Payable - Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock1" xlink:title="label: DebtDisclosureTextBlock to us-gaap_DebtDisclosureTextBlock1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="DebtInstrumentFaceAmount" xlink:title="DebtInstrumentFaceAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US" id="us-gaap_DebtInstrumentFaceAmount">Debt financing arrangement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount" xlink:title="label: DebtInstrumentFaceAmount to us-gaap_DebtInstrumentFaceAmount" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="DebtInstrumentInterestRateDuringPeriod" xlink:title="DebtInstrumentInterestRateDuringPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentInterestRateDuringPeriod" xml:lang="en-US" id="us-gaap_DebtInstrumentInterestRateDuringPeriod">Interest rate on short term loans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:title="label: DebtInstrumentInterestRateDuringPeriod to us-gaap_DebtInstrumentInterestRateDuringPeriod" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="DebtInstrumentInterestRateEffectivePercentage" xlink:title="DebtInstrumentInterestRateEffectivePercentage" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xml:lang="en-US" id="us-gaap_DebtInstrumentInterestRateEffectivePercentage">Short term borrowing effective interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:title="label: DebtInstrumentInterestRateEffectivePercentage to us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DebtInstrumentInterestRateEffectivePercentage1" xml:lang="en-US" id="us-gaap_DebtInstrumentInterestRateEffectivePercentage1">Effective interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage1" xlink:title="label: DebtInstrumentInterestRateEffectivePercentage to us-gaap_DebtInstrumentInterestRateEffectivePercentage1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl2" xml:lang="en-US" id="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl2">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl2" xlink:title="label: DebtInstrumentInterestRateEffectivePercentage to us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US" id="us-gaap_DebtInstrumentInterestRateStatedPercentage">Short term borrowing interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:title="label: DebtInstrumentInterestRateStatedPercentage to us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentInterestRateStatedPercentage1" xml:lang="en-US" id="us-gaap_DebtInstrumentInterestRateStatedPercentage1">Interest rate compounded annually</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage1" xlink:title="label: DebtInstrumentInterestRateStatedPercentage to us-gaap_DebtInstrumentInterestRateStatedPercentage1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="DebtInstrumentMaturityDate" xlink:title="DebtInstrumentMaturityDate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DebtInstrumentMaturityDate" xml:lang="en-US" id="us-gaap_DebtInstrumentMaturityDate">Borrowings repayment due date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate" xlink:title="label: DebtInstrumentMaturityDate to us-gaap_DebtInstrumentMaturityDate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentMaturityDate1" xml:lang="en-US" id="us-gaap_DebtInstrumentMaturityDate1">Maturity date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate1" xlink:title="label: DebtInstrumentMaturityDate to us-gaap_DebtInstrumentMaturityDate1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDate2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_DebtInstrumentMaturityDate2" xml:lang="en-US" id="us-gaap_DebtInstrumentMaturityDate2">Promissory note, maturity date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate2" xlink:title="label: DebtInstrumentMaturityDate to us-gaap_DebtInstrumentMaturityDate2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentNameDomain" xml:lang="en-US" id="us-gaap_DebtInstrumentNameDomain">Debt Instrument, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:title="label: DebtInstrumentNameDomain to us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentsAbstract" xlink:label="DebtInstrumentsAbstract" xlink:title="DebtInstrumentsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentsAbstract" xml:lang="en-US" id="us-gaap_DebtInstrumentsAbstract">Convertible Notes Payable - Related Party [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentsAbstract" xlink:to="us-gaap_DebtInstrumentsAbstract" xlink:title="label: DebtInstrumentsAbstract to us-gaap_DebtInstrumentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentAxis" xml:lang="en-US" id="us-gaap_DebtInstrumentAxis">Debt Instrument [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis" xlink:title="label: DebtInstrumentAxis to us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentLineItems" xml:lang="en-US" id="us-gaap_DebtInstrumentLineItems">Debt Instrument [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems" xlink:title="label: DebtInstrumentLineItems to us-gaap_DebtInstrumentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentTable" xml:lang="en-US" id="us-gaap_DebtInstrumentTable">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable" xlink:title="label: DebtInstrumentTable to us-gaap_DebtInstrumentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued" xlink:label="DeferredCompensationArrangementWithIndividualSharesIssued" xlink:title="DeferredCompensationArrangementWithIndividualSharesIssued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued" xml:lang="en-US" id="us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued">Common stock reserved for future issuance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredCompensationArrangementWithIndividualSharesIssued" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued" xlink:title="label: DeferredCompensationArrangementWithIndividualSharesIssued to us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="DeferredTaxAssetsGross" xlink:title="DeferredTaxAssetsGross" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_DeferredTaxAssetsGross" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsGross">Deferred tax assets, gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross" xlink:title="label: DeferredTaxAssetsGross to us-gaap_DeferredTaxAssetsGross" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsGross_lbl1" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsGross_lbl1">Deferred Tax Assets, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl1" xlink:title="label: DeferredTaxAssetsGross to us-gaap_DeferredTaxAssetsGross_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="DeferredTaxAssetsNet" xlink:title="DeferredTaxAssetsNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_DeferredTaxAssetsNet" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsNet">Net deferred tax asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet" xlink:title="label: DeferredTaxAssetsNet to us-gaap_DeferredTaxAssetsNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsNet_lbl1" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsNet_lbl1">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl1" xlink:title="label: DeferredTaxAssetsNet to us-gaap_DeferredTaxAssetsNet_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="DeferredTaxAssetsOperatingLossCarryforwards" xlink:title="DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">Operating loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:title="label: DeferredTaxAssetsOperatingLossCarryforwards to us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="DeferredTaxAssetsOther" xlink:title="DeferredTaxAssetsOther" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsOther" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsOther">Other temporary differences</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther" xlink:title="label: DeferredTaxAssetsOther to us-gaap_DeferredTaxAssetsOther" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="DeferredTaxAssetsTaxCreditCarryforwards" xlink:title="DeferredTaxAssetsTaxCreditCarryforwards" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">Tax credit carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:title="label: DeferredTaxAssetsTaxCreditCarryforwards to us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="DeferredTaxAssetsValuationAllowance" xlink:title="DeferredTaxAssetsValuationAllowance" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsValuationAllowance">Less valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:title="label: DeferredTaxAssetsValuationAllowance to us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsValuationAllowance_lbl1" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsValuationAllowance_lbl1">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl1" xlink:title="label: DeferredTaxAssetsValuationAllowance to us-gaap_DeferredTaxAssetsValuationAllowance_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositAssetsAbstract" xlink:label="DepositAssetsAbstract" xlink:title="DepositAssetsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DepositAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DepositAssetsAbstract" xml:lang="en-US" id="us-gaap_DepositAssetsAbstract">Security Deposit [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepositAssetsAbstract" xlink:to="us-gaap_DepositAssetsAbstract" xlink:title="label: DepositAssetsAbstract to us-gaap_DepositAssetsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DepositAssetsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DepositAssetsAbstract_lbl1" xml:lang="en-US" id="us-gaap_DepositAssetsAbstract_lbl1">Deposit Assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepositAssetsAbstract" xlink:to="us-gaap_DepositAssetsAbstract_lbl1" xlink:title="label: DepositAssetsAbstract to us-gaap_DepositAssetsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="DepreciationAndAmortization" xlink:title="DepreciationAndAmortization" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DepreciationAndAmortization" xml:lang="en-US" id="us-gaap_DepreciationAndAmortization">Depreciation and amortization expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization" xlink:title="label: DepreciationAndAmortization to us-gaap_DepreciationAndAmortization" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:label="DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:title="DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xml:lang="en-US" id="us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet">Change in fair value of derivatives</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:to="us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:title="label: DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet to us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet1" xml:lang="en-US" id="us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet1">Change in fair value of derivative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:to="us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet1" xlink:title="label: DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet to us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet2" xml:lang="en-US" id="us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet2">Change in fair value of derivatives</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:to="us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet2" xlink:title="label: DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet to us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="DerivativeLiabilitiesCurrent" xlink:title="DerivativeLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DerivativeLiabilitiesCurrent" xml:lang="en-US" id="us-gaap_DerivativeLiabilitiesCurrent">Current portion of derivative liabilities (Note 6)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" xlink:title="label: DerivativeLiabilitiesCurrent to us-gaap_DerivativeLiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="DerivativeLiabilitiesNoncurrent" xlink:title="DerivativeLiabilitiesNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_DerivativeLiabilitiesNoncurrent" xml:lang="en-US" id="us-gaap_DerivativeLiabilitiesNoncurrent">Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeLiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:title="label: DerivativeLiabilitiesNoncurrent to us-gaap_DerivativeLiabilitiesNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_DerivativeLiabilitiesNoncurrent1" xml:lang="en-US" id="us-gaap_DerivativeLiabilitiesNoncurrent1">Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeLiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent1" xlink:title="label: DerivativeLiabilitiesNoncurrent to us-gaap_DerivativeLiabilitiesNoncurrent1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DerivativeLiabilitiesNoncurrent2" xml:lang="en-US" id="us-gaap_DerivativeLiabilitiesNoncurrent2">Derivative liabilities (Note 6)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeLiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent2" xlink:title="label: DerivativeLiabilitiesNoncurrent to us-gaap_DerivativeLiabilitiesNoncurrent2" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DerivativeLiabilitiesNoncurrent3" xml:lang="en-US" id="us-gaap_DerivativeLiabilitiesNoncurrent3">Fair value of derivative liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeLiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent3" xlink:title="label: DerivativeLiabilitiesNoncurrent to us-gaap_DerivativeLiabilitiesNoncurrent3" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_DerivativeLiabilitiesNoncurrent4" xml:lang="en-US" id="us-gaap_DerivativeLiabilitiesNoncurrent4">Derivative Liability - Contingent Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeLiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent4" xlink:title="label: DerivativeLiabilitiesNoncurrent to us-gaap_DerivativeLiabilitiesNoncurrent4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="DerivativesPolicyTextBlock" xlink:title="DerivativesPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DerivativesPolicyTextBlock" xml:lang="en-US" id="us-gaap_DerivativesPolicyTextBlock">Warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock" xlink:title="label: DerivativesPolicyTextBlock to us-gaap_DerivativesPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DerivativesPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_DerivativesPolicyTextBlock_lbl1">Derivatives, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock_lbl1" xlink:title="label: DerivativesPolicyTextBlock to us-gaap_DerivativesPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="EarningsPerShareDiluted" xlink:title="EarningsPerShareDiluted" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareDiluted" xml:lang="en-US" id="us-gaap_EarningsPerShareDiluted">Net loss per common share - diluted (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted" xlink:title="label: EarningsPerShareDiluted to us-gaap_EarningsPerShareDiluted" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="ConsolidationPolicyTextBlock" xlink:title="ConsolidationPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ConsolidationPolicyTextBlock" xml:lang="en-US" id="us-gaap_ConsolidationPolicyTextBlock">Basis of Consolidation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock" xlink:title="label: ConsolidationPolicyTextBlock to us-gaap_ConsolidationPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConsolidationPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ConsolidationPolicyTextBlock_lbl1">Consolidation, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl1" xlink:title="label: ConsolidationPolicyTextBlock to us-gaap_ConsolidationPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="IncomeLossFromEquityMethodInvestments" xlink:title="IncomeLossFromEquityMethodInvestments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeLossFromEquityMethodInvestments" xml:lang="en-US" id="us-gaap_IncomeLossFromEquityMethodInvestments">Loss from equity method investment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:title="label: IncomeLossFromEquityMethodInvestments to us-gaap_IncomeLossFromEquityMethodInvestments" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="EffectiveIncomeTaxRateContinuingOperations" xlink:title="EffectiveIncomeTaxRateContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateContinuingOperations">Income tax rate, total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:title="label: EffectiveIncomeTaxRateContinuingOperations to us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl1" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl1">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl1" xlink:title="label: EffectiveIncomeTaxRateContinuingOperations to us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:title="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">Primary Factors Affecting Income Tax Rates [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:title="label: EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract to us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl1" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl1">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl1" xlink:title="label: EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract to us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:title="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">Changes in valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:title="label: EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance to us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl1" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl1">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl1" xlink:title="label: EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance to us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:title="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">Tax benefit at U.S. statutory rates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:title="label: EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate to us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl1" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl1">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl1" xlink:title="label: EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate to us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:title="EffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">Permanent differences</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:title="label: EffectiveIncomeTaxRateReconciliationNondeductibleExpense to us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl1" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl1">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl1" xlink:title="label: EffectiveIncomeTaxRateReconciliationNondeductibleExpense to us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:title="EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:title="label: EffectiveIncomeTaxRateReconciliationOtherAdjustments to us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl1" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl1">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl1" xlink:title="label: EffectiveIncomeTaxRateReconciliationOtherAdjustments to us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:title="EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">State tax benefit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:title="label: EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes to us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl1" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl1">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl1" xlink:title="label: EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes to us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US" id="us-gaap_AllocatedShareBasedCompensationExpense">Amortized expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:title="label: AllocatedShareBasedCompensationExpense to us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_AllocatedShareBasedCompensationExpense1" xml:lang="en-US" id="us-gaap_AllocatedShareBasedCompensationExpense1">Total stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense1" xlink:title="label: AllocatedShareBasedCompensationExpense to us-gaap_AllocatedShareBasedCompensationExpense1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="label: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensation" xml:lang="en-US" id="us-gaap_ShareBasedCompensation">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation" xlink:title="label: ShareBasedCompensation to us-gaap_ShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensation_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensation_lbl1">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl1" xlink:title="label: ShareBasedCompensation to us-gaap_ShareBasedCompensation_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="ShareBasedCompensationAbstract" xlink:title="ShareBasedCompensationAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationAbstract" xml:lang="en-US" id="us-gaap_ShareBasedCompensationAbstract">Stock-Based Compensation Expense [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationAbstract" xlink:title="label: ShareBasedCompensationAbstract to us-gaap_ShareBasedCompensationAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAbstract1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationAbstract1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationAbstract1">Share-based Payment Arrangement, Noncash Expense [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationAbstract1" xlink:title="label: ShareBasedCompensationAbstract to us-gaap_ShareBasedCompensationAbstract1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">Shares issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="DomesticCountryMember" xlink:title="DomesticCountryMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DomesticCountryMember" xml:lang="en-US" id="us-gaap_DomesticCountryMember">Federal [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember" xlink:title="label: DomesticCountryMember to us-gaap_DomesticCountryMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="label: FiniteLivedIntangibleAssetsMajorClassNameDomain to us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="label: FiniteLivedIntangibleAssetsByMajorClassAxis to us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="FurnitureAndFixturesMember" xlink:title="FurnitureAndFixturesMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FurnitureAndFixturesMember" xml:lang="en-US" id="us-gaap_FurnitureAndFixturesMember">Furniture and Fixtures [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:title="label: FurnitureAndFixturesMember to us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US" id="us-gaap_GeneralAndAdministrativeExpense">General and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:title="label: GeneralAndAdministrativeExpense to us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="GeneralAndAdministrativeExpenseMember" xlink:title="GeneralAndAdministrativeExpenseMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US" id="us-gaap_GeneralAndAdministrativeExpenseMember">General and Administrative [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:title="label: GeneralAndAdministrativeExpenseMember to us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GeneralAndAdministrativeExpenseMember1" xml:lang="en-US" id="us-gaap_GeneralAndAdministrativeExpenseMember1">General and Administrative Expense [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember1" xlink:title="label: GeneralAndAdministrativeExpenseMember to us-gaap_GeneralAndAdministrativeExpenseMember1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="ImpairmentOfLongLivedAssetsHeldForUse" xlink:title="ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xml:lang="en-US" id="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">Impairment of long-lived assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:title="label: ImpairmentOfLongLivedAssetsHeldForUse to us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:title="ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xml:lang="en-US" id="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">Long-Lived Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:title="label: ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock to us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl1">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl1" xlink:title="label: ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock to us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" xlink:title="IncomeStatementAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeStatementAbstract" xml:lang="en-US" id="us-gaap_IncomeStatementAbstract">CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract" xlink:title="label: IncomeStatementAbstract to us-gaap_IncomeStatementAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="IncomeTaxDisclosureTextBlock" xlink:title="IncomeTaxDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US" id="us-gaap_IncomeTaxDisclosureTextBlock">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:title="label: IncomeTaxDisclosureTextBlock to us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="IncomeTaxPolicyTextBlock" xlink:title="IncomeTaxPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US" id="us-gaap_IncomeTaxPolicyTextBlock">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:title="label: IncomeTaxPolicyTextBlock to us-gaap_IncomeTaxPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_IncomeTaxPolicyTextBlock_lbl1">Income Tax, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl1" xlink:title="label: IncomeTaxPolicyTextBlock to us-gaap_IncomeTaxPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="IncomeTaxReconciliationTaxCreditsResearch" xlink:title="IncomeTaxReconciliationTaxCreditsResearch" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xml:lang="en-US" id="us-gaap_IncomeTaxReconciliationTaxCreditsResearch">Research and development credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:title="label: IncomeTaxReconciliationTaxCreditsResearch to us-gaap_IncomeTaxReconciliationTaxCreditsResearch" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="InterestExpense" xlink:title="InterestExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InterestExpense" xml:lang="en-US" id="us-gaap_InterestExpense">Amortization of interest expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestExpense" xlink:to="us-gaap_InterestExpense" xlink:title="label: InterestExpense to us-gaap_InterestExpense" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt" xlink:label="InterestExpenseDebt" xlink:title="InterestExpenseDebt" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_InterestExpenseDebt" xml:lang="en-US" id="us-gaap_InterestExpenseDebt">Accrued interest expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt" xlink:title="label: InterestExpenseDebt to us-gaap_InterestExpenseDebt" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebt_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InterestExpenseDebt_lbl1" xml:lang="en-US" id="us-gaap_InterestExpenseDebt_lbl1">Interest Expense, Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl1" xlink:title="label: InterestExpenseDebt to us-gaap_InterestExpenseDebt_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseOther" xlink:label="InterestExpenseOther" xlink:title="InterestExpenseOther" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestExpenseOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_InterestExpenseOther" xml:lang="en-US" id="us-gaap_InterestExpenseOther">Additional interest expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestExpenseOther" xlink:to="us-gaap_InterestExpenseOther" xlink:title="label: InterestExpenseOther to us-gaap_InterestExpenseOther" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestExpenseOther_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InterestExpenseOther_lbl1" xml:lang="en-US" id="us-gaap_InterestExpenseOther_lbl1">Interest Expense, Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestExpenseOther" xlink:to="us-gaap_InterestExpenseOther_lbl1" xlink:title="label: InterestExpenseOther to us-gaap_InterestExpenseOther_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="LeaseholdImprovementsMember" xlink:title="LeaseholdImprovementsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LeaseholdImprovementsMember" xml:lang="en-US" id="us-gaap_LeaseholdImprovementsMember">Leasehold Improvements [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:title="label: LeaseholdImprovementsMember to us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_Liabilities" xml:lang="en-US" id="us-gaap_Liabilities">Total liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Liabilities" xlink:to="us-gaap_Liabilities" xlink:title="label: Liabilities to us-gaap_Liabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_Liabilities_lbl1" xml:lang="en-US" id="us-gaap_Liabilities_lbl1">Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Liabilities" xlink:to="us-gaap_Liabilities_lbl1" xlink:title="label: Liabilities to us-gaap_Liabilities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquity">Total liabilities, redeemable convertible preferred stock and stockholders' deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" xlink:title="label: LiabilitiesAndStockholdersEquity to us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesAndStockholdersEquity_lbl1" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquity_lbl1">Liabilities and Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl1" xlink:title="label: LiabilitiesAndStockholdersEquity to us-gaap_LiabilitiesAndStockholdersEquity_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquityAbstract">LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:title="label: LiabilitiesAndStockholdersEquityAbstract to us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl1" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl1">Liabilities and Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl1" xlink:title="label: LiabilitiesAndStockholdersEquityAbstract to us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="LineOfCreditFacilityMaximumBorrowingCapacity" xlink:title="LineOfCreditFacilityMaximumBorrowingCapacity" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xml:lang="en-US" id="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">Line of credit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:title="label: LineOfCreditFacilityMaximumBorrowingCapacity to us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl1" xml:lang="en-US" id="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl1">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl1" xlink:title="label: LineOfCreditFacilityMaximumBorrowingCapacity to us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityAbstract" xlink:label="LineOfCreditFacilityAbstract" xlink:title="LineOfCreditFacilityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LineOfCreditFacilityAbstract" xml:lang="en-US" id="us-gaap_LineOfCreditFacilityAbstract">Convertible Line of Credit - Related Party and Supplemental Lines of Credit - Related Party [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LineOfCreditFacilityAbstract" xlink:to="us-gaap_LineOfCreditFacilityAbstract" xlink:title="label: LineOfCreditFacilityAbstract to us-gaap_LineOfCreditFacilityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="LineOfCreditFacilityLineItems" xlink:title="LineOfCreditFacilityLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LineOfCreditFacilityLineItems" xml:lang="en-US" id="us-gaap_LineOfCreditFacilityLineItems">Line of Credit Facility [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityLineItems" xlink:title="label: LineOfCreditFacilityLineItems to us-gaap_LineOfCreditFacilityLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="LineOfCreditFacilityTable" xlink:title="LineOfCreditFacilityTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LineOfCreditFacilityTable" xml:lang="en-US" id="us-gaap_LineOfCreditFacilityTable">Line of Credit Facility [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LineOfCreditFacilityTable" xlink:to="us-gaap_LineOfCreditFacilityTable" xlink:title="label: LineOfCreditFacilityTable to us-gaap_LineOfCreditFacilityTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditMember" xlink:label="LineOfCreditMember" xlink:title="LineOfCreditMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LineOfCreditMember" xml:lang="en-US" id="us-gaap_LineOfCreditMember">Line of Credit [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LineOfCreditMember" xlink:to="us-gaap_LineOfCreditMember" xlink:title="label: LineOfCreditMember to us-gaap_LineOfCreditMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LineOfCreditMember1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LineOfCreditMember1" xml:lang="en-US" id="us-gaap_LineOfCreditMember1">Line of Credit [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LineOfCreditMember" xlink:to="us-gaap_LineOfCreditMember1" xlink:title="label: LineOfCreditMember to us-gaap_LineOfCreditMember1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LineOfCreditMember2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_LineOfCreditMember2" xml:lang="en-US" id="us-gaap_LineOfCreditMember2">Line of Credit [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LineOfCreditMember" xlink:to="us-gaap_LineOfCreditMember2" xlink:title="label: LineOfCreditMember to us-gaap_LineOfCreditMember2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansPayableMember" xlink:label="LoansPayableMember" xlink:title="LoansPayableMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LoansPayableMember" xml:lang="en-US" id="us-gaap_LoansPayableMember">Convertible Notes Payable - Related Party [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LoansPayableMember" xlink:to="us-gaap_LoansPayableMember" xlink:title="label: LoansPayableMember to us-gaap_LoansPayableMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:label="LossContingencyEstimateOfPossibleLoss" xlink:title="LossContingencyEstimateOfPossibleLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LossContingencyEstimateOfPossibleLoss" xml:lang="en-US" id="us-gaap_LossContingencyEstimateOfPossibleLoss">Vendors disputed claim amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingencyEstimateOfPossibleLoss" xlink:to="us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:title="label: LossContingencyEstimateOfPossibleLoss to us-gaap_LossContingencyEstimateOfPossibleLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LossContingencyEstimateOfPossibleLoss_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LossContingencyEstimateOfPossibleLoss_lbl1" xml:lang="en-US" id="us-gaap_LossContingencyEstimateOfPossibleLoss_lbl1">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingencyEstimateOfPossibleLoss" xlink:to="us-gaap_LossContingencyEstimateOfPossibleLoss_lbl1" xlink:title="label: LossContingencyEstimateOfPossibleLoss to us-gaap_LossContingencyEstimateOfPossibleLoss_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="MinorityInterestOwnershipPercentageByParent" xlink:title="MinorityInterestOwnershipPercentageByParent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_MinorityInterestOwnershipPercentageByParent" xml:lang="en-US" id="us-gaap_MinorityInterestOwnershipPercentageByParent">Ownership percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinorityInterestOwnershipPercentageByParent" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:title="label: MinorityInterestOwnershipPercentageByParent to us-gaap_MinorityInterestOwnershipPercentageByParent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl1" xml:lang="en-US" id="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl1">Subsidiary, Ownership Percentage, Parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinorityInterestOwnershipPercentageByParent" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl1" xlink:title="label: MinorityInterestOwnershipPercentageByParent to us-gaap_MinorityInterestOwnershipPercentageByParent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis">Related and Nonrelated Parties [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="label: RelatedPartyTransactionsByRelatedPartyAxis to us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="NetCashProvidedByUsedInFinancingActivities" xlink:title="NetCashProvidedByUsedInFinancingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInFinancingActivities">Net cash from financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:title="label: NetCashProvidedByUsedInFinancingActivities to us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" xlink:title="label: NetCashProvidedByUsedInFinancingActivities to us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="label: NetCashProvidedByUsedInFinancingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="NetCashProvidedByUsedInInvestingActivities" xlink:title="NetCashProvidedByUsedInInvestingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInInvestingActivities">Net cash from investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:title="label: NetCashProvidedByUsedInInvestingActivities to us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="label: NetCashProvidedByUsedInInvestingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" xlink:title="NetCashProvidedByUsedInOperatingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInOperatingActivities">Net cash from operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:title="label: NetCashProvidedByUsedInOperatingActivities to us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivities1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInOperatingActivities1">Net cash used in operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities1" xlink:title="label: NetCashProvidedByUsedInOperatingActivities to us-gaap_NetCashProvidedByUsedInOperatingActivities1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl2" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl2">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl2" xlink:title="label: NetCashProvidedByUsedInOperatingActivities to us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="label: NetCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetIncomeLoss" xml:lang="en-US" id="us-gaap_NetIncomeLoss">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss" xlink:title="label: NetIncomeLoss to us-gaap_NetIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_NetIncomeLoss1" xml:lang="en-US" id="us-gaap_NetIncomeLoss1">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss1" xlink:title="label: NetIncomeLoss to us-gaap_NetIncomeLoss1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetIncomeLoss2" xml:lang="en-US" id="us-gaap_NetIncomeLoss2">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss2" xlink:title="label: NetIncomeLoss to us-gaap_NetIncomeLoss2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xml:lang="en-US" id="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">Net loss applicable to common stockholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="label: NetIncomeLossAvailableToCommonStockholdersBasic to us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl1" xml:lang="en-US" id="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl1">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl1" xlink:title="label: NetIncomeLossAvailableToCommonStockholdersBasic to us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:title="NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xml:lang="en-US" id="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:title="label: NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems to us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:title="NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xml:lang="en-US" id="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:title="label: NewAccountingPronouncementsOrChangeInAccountingPrincipleTable to us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="NonoperatingIncomeExpense" xlink:title="NonoperatingIncomeExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NonoperatingIncomeExpense" xml:lang="en-US" id="us-gaap_NonoperatingIncomeExpense">Total other expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense" xlink:title="label: NonoperatingIncomeExpense to us-gaap_NonoperatingIncomeExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NonoperatingIncomeExpense_lbl1" xml:lang="en-US" id="us-gaap_NonoperatingIncomeExpense_lbl1">Nonoperating Income (Expense)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl1" xlink:title="label: NonoperatingIncomeExpense to us-gaap_NonoperatingIncomeExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="NonoperatingIncomeExpenseAbstract" xlink:title="NonoperatingIncomeExpenseAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US" id="us-gaap_NonoperatingIncomeExpenseAbstract">Other income (expense):</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:title="label: NonoperatingIncomeExpenseAbstract to us-gaap_NonoperatingIncomeExpenseAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_NonoperatingIncomeExpenseAbstract1" xml:lang="en-US" id="us-gaap_NonoperatingIncomeExpenseAbstract1">Other income (expense) [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract1" xlink:title="label: NonoperatingIncomeExpenseAbstract to us-gaap_NonoperatingIncomeExpenseAbstract1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="OperatingLossCarryforwards" xlink:title="OperatingLossCarryforwards" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLossCarryforwards" xml:lang="en-US" id="us-gaap_OperatingLossCarryforwards">Net operating loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards" xlink:title="label: OperatingLossCarryforwards to us-gaap_OperatingLossCarryforwards" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_OperatingIncomeLoss" xml:lang="en-US" id="us-gaap_OperatingIncomeLoss">Total operating loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" xlink:title="label: OperatingIncomeLoss to us-gaap_OperatingIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingIncomeLoss_lbl1" xml:lang="en-US" id="us-gaap_OperatingIncomeLoss_lbl1">Operating Income (Loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl1" xlink:title="label: OperatingIncomeLoss to us-gaap_OperatingIncomeLoss_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xml:lang="en-US" id="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">Nature of Business, Basis of Presentation, Liquidity, and Going Concern</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:title="label: OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock to us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="PreferredStockSharesAuthorized" xlink:title="PreferredStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US" id="us-gaap_PreferredStockSharesAuthorized">Series A 12% convertible preferred stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:title="label: PreferredStockSharesAuthorized to us-gaap_PreferredStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PreferredStockSharesAuthorized1" xml:lang="en-US" id="us-gaap_PreferredStockSharesAuthorized1">Convertible preferred stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized1" xlink:title="label: PreferredStockSharesAuthorized to us-gaap_PreferredStockSharesAuthorized1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="PreferredStockSharesIssued" xlink:title="PreferredStockSharesIssued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockSharesIssued" xml:lang="en-US" id="us-gaap_PreferredStockSharesIssued">Series A 12% convertible preferred stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued" xlink:title="label: PreferredStockSharesIssued to us-gaap_PreferredStockSharesIssued" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="PreferredStockSharesOutstanding" xlink:title="PreferredStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US" id="us-gaap_PreferredStockSharesOutstanding">Series A 12% convertible preferred stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:title="label: PreferredStockSharesOutstanding to us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="PreferredStockDividendsAndOtherAdjustments" xlink:title="PreferredStockDividendsAndOtherAdjustments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_PreferredStockDividendsAndOtherAdjustments" xml:lang="en-US" id="us-gaap_PreferredStockDividendsAndOtherAdjustments">Preferred stock dividends</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockDividendsAndOtherAdjustments" xlink:to="us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:title="label: PreferredStockDividendsAndOtherAdjustments to us-gaap_PreferredStockDividendsAndOtherAdjustments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl1" xml:lang="en-US" id="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl1">Preferred Stock Dividends and Other Adjustments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockDividendsAndOtherAdjustments" xlink:to="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl1" xlink:title="label: PreferredStockDividendsAndOtherAdjustments to us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="PreferredStockParOrStatedValuePerShare" xlink:title="PreferredStockParOrStatedValuePerShare" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US" id="us-gaap_PreferredStockParOrStatedValuePerShare">Preferred stock par value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:title="label: PreferredStockParOrStatedValuePerShare to us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:title="ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock">Gross proceeds from issuance of preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:title="label: ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock to us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl1" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl1">Proceeds from Issuance of Redeemable Convertible Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl1" xlink:title="label: ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock to us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="ProceedsFromLinesOfCredit" xlink:title="ProceedsFromLinesOfCredit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ProceedsFromLinesOfCredit" xml:lang="en-US" id="us-gaap_ProceedsFromLinesOfCredit">Proceeds from lines of credit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromLinesOfCredit" xlink:to="us-gaap_ProceedsFromLinesOfCredit" xlink:title="label: ProceedsFromLinesOfCredit to us-gaap_ProceedsFromLinesOfCredit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromLinesOfCredit1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ProceedsFromLinesOfCredit1" xml:lang="en-US" id="us-gaap_ProceedsFromLinesOfCredit1">Net proceeds from convertible line of credit - related party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromLinesOfCredit" xlink:to="us-gaap_ProceedsFromLinesOfCredit1" xlink:title="label: ProceedsFromLinesOfCredit to us-gaap_ProceedsFromLinesOfCredit1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromLinesOfCredit_lbl2" xml:lang="en-US" id="us-gaap_ProceedsFromLinesOfCredit_lbl2">Proceeds from Lines of Credit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromLinesOfCredit" xlink:to="us-gaap_ProceedsFromLinesOfCredit_lbl2" xlink:title="label: ProceedsFromLinesOfCredit to us-gaap_ProceedsFromLinesOfCredit_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="PropertyPlantAndEquipmentGross" xlink:title="PropertyPlantAndEquipmentGross" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentGross">Property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:title="label: PropertyPlantAndEquipmentGross to us-gaap_PropertyPlantAndEquipmentGross" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentGross_lbl1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentGross_lbl1">Property, Plant and Equipment, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl1" xlink:title="label: PropertyPlantAndEquipmentGross to us-gaap_PropertyPlantAndEquipmentGross_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentNet">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:title="label: PropertyPlantAndEquipmentNet to us-gaap_PropertyPlantAndEquipmentNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentNet1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentNet1">Property and equipment - net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet1" xlink:title="label: PropertyPlantAndEquipmentNet to us-gaap_PropertyPlantAndEquipmentNet1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" xlink:title="PropertyPlantAndEquipmentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentAbstract" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentAbstract">Property and Equipment [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:title="label: PropertyPlantAndEquipmentAbstract to us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentAbstract1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentAbstract1">Property and Equipment [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract1" xlink:title="label: PropertyPlantAndEquipmentAbstract to us-gaap_PropertyPlantAndEquipmentAbstract1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="PropertyPlantAndEquipmentPolicyTextBlock" xlink:title="PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:title="label: PropertyPlantAndEquipmentPolicyTextBlock to us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl1">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl1" xlink:title="label: PropertyPlantAndEquipmentPolicyTextBlock to us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="PaymentsToAcquireEquityMethodInvestments" xlink:title="PaymentsToAcquireEquityMethodInvestments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PaymentsToAcquireEquityMethodInvestments" xml:lang="en-US" id="us-gaap_PaymentsToAcquireEquityMethodInvestments">Initial cash investment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquireEquityMethodInvestments" xlink:to="us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:title="label: PaymentsToAcquireEquityMethodInvestments to us-gaap_PaymentsToAcquireEquityMethodInvestments" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyDomain" xml:lang="en-US" id="us-gaap_RelatedPartyDomain">Related and Nonrelated Parties [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain" xlink:title="label: RelatedPartyDomain to us-gaap_RelatedPartyDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="ResearchAndDevelopmentExpensePolicy" xlink:title="ResearchAndDevelopmentExpensePolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpensePolicy">Research and Development Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:title="label: ResearchAndDevelopmentExpensePolicy to us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl1" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl1">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl1" xlink:title="label: ResearchAndDevelopmentExpensePolicy to us-gaap_ResearchAndDevelopmentExpensePolicy_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US" id="us-gaap_RetainedEarningsAccumulatedDeficit">Retained deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:title="label: RetainedEarningsAccumulatedDeficit to us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xml:lang="en-US" id="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">Components of Stock-Based Compensation Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:title="label: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock to us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl1">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl1" xlink:title="label: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock to us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="PropertyPlantAndEquipmentTextBlock" xlink:title="PropertyPlantAndEquipmentTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentTextBlock">Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:title="label: PropertyPlantAndEquipmentTextBlock to us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl1">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl1" xlink:title="label: PropertyPlantAndEquipmentTextBlock to us-gaap_PropertyPlantAndEquipmentTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecurityDeposit" xlink:label="SecurityDeposit" xlink:title="SecurityDeposit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SecurityDeposit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SecurityDeposit" xml:lang="en-US" id="us-gaap_SecurityDeposit">Security deposit for leased office space</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityDeposit" xlink:to="us-gaap_SecurityDeposit" xlink:title="label: SecurityDeposit to us-gaap_SecurityDeposit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SecurityDeposit1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SecurityDeposit1" xml:lang="en-US" id="us-gaap_SecurityDeposit1">Security deposit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityDeposit" xlink:to="us-gaap_SecurityDeposit1" xlink:title="label: SecurityDeposit to us-gaap_SecurityDeposit1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="SegmentReportingDisclosureTextBlock" xlink:title="SegmentReportingDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SegmentReportingDisclosureTextBlock" xml:lang="en-US" id="us-gaap_SegmentReportingDisclosureTextBlock">Segments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" xlink:title="label: SegmentReportingDisclosureTextBlock to us-gaap_SegmentReportingDisclosureTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:title="ScheduleOfSegmentReportingInformationBySegmentTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xml:lang="en-US" id="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">Summary of Significant Expense Categories and Asset Categories</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:title="label: ScheduleOfSegmentReportingInformationBySegmentTextBlock to us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="SegmentReportingInformationLineItems" xlink:title="SegmentReportingInformationLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SegmentReportingInformationLineItems" xml:lang="en-US" id="us-gaap_SegmentReportingInformationLineItems">Segment Reporting Information [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems" xlink:title="label: SegmentReportingInformationLineItems to us-gaap_SegmentReportingInformationLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:title="ScheduleOfSegmentReportingInformationBySegmentTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xml:lang="en-US" id="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:title="label: ScheduleOfSegmentReportingInformationBySegmentTable to us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="SeriesCPreferredStockMember" xlink:title="SeriesCPreferredStockMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SeriesCPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_SeriesCPreferredStockMember" xml:lang="en-US" id="us-gaap_SeriesCPreferredStockMember">Series C 6% Super Dividend Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember" xlink:title="label: SeriesCPreferredStockMember to us-gaap_SeriesCPreferredStockMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SeriesCPreferredStockMember1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SeriesCPreferredStockMember1" xml:lang="en-US" id="us-gaap_SeriesCPreferredStockMember1">Series C 6% Super Dividend Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember1" xlink:title="label: SeriesCPreferredStockMember to us-gaap_SeriesCPreferredStockMember1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="SeriesAPreferredStockMember" xlink:title="SeriesAPreferredStockMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SeriesAPreferredStockMember" xml:lang="en-US" id="us-gaap_SeriesAPreferredStockMember">Series A 12% Convertible Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember" xlink:title="label: SeriesAPreferredStockMember to us-gaap_SeriesAPreferredStockMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">Canceled/Expired (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">Restricted stock awards granted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod1">Issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl2">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">Outstanding at beginning of period (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber1">Outstanding at end of period (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl2">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">Unrecognized compensation cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:title="label: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized1" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized1">Unrecognized compensation cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized1" xlink:title="label: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xml:lang="en-US" id="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">Options Exercisable, Number of Shares (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:title="label: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions to us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xml:lang="en-US" id="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain">Exercise Price Range [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:title="label: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xml:lang="en-US" id="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">Exercise Price Range [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:title="label: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis to us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xml:lang="en-US" id="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">Options Outstanding, Number of Shares (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:title="label: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions to us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xml:lang="en-US" id="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">Maximum Exercise Price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:title="label: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit to us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">Number of shares authorized for issuance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">Stock awards, available for future grant (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">Forfeited/cancelled (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">Weighted-average grant-date fair values of options granted (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">Outstanding at end of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">Outstanding at end of period (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1">Outstanding at beginning of period (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">Outstanding at beginning of period (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1">Outstanding at beginning of period (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">Exercisable, end of period (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">Exercisable, end of period (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">Expected dividend</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1">Expected dividend rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate2">Expected dividend yield used in the option valuation model</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">Expected volatility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate1">Expected volatility of the underlying stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">Risk free interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1">Risk-free interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain">Award Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:title="ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xml:lang="en-US" id="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">Outstanding and Exercisable Options under Stock Based Compensation Plans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:title="label: ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock to us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US" id="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="label: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="SignificantAccountingPoliciesTextBlock" xlink:title="SignificantAccountingPoliciesTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US" id="us-gaap_SignificantAccountingPoliciesTextBlock">Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:title="label: SignificantAccountingPoliciesTextBlock to us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="StateAndLocalJurisdictionMember" xlink:title="StateAndLocalJurisdictionMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StateAndLocalJurisdictionMember" xml:lang="en-US" id="us-gaap_StateAndLocalJurisdictionMember">State [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember" xlink:title="label: StateAndLocalJurisdictionMember to us-gaap_StateAndLocalJurisdictionMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" xlink:title="StatementOfCashFlowsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US" id="us-gaap_StatementOfCashFlowsAbstract">CONSOLIDATED STATEMENTS OF CASH FLOWS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract" xlink:title="label: StatementOfCashFlowsAbstract to us-gaap_StatementOfCashFlowsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" xlink:title="StatementOfStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US" id="us-gaap_StatementOfStockholdersEquityAbstract">CONSOLIDATED STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract" xlink:title="label: StatementOfStockholdersEquityAbstract to us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US" id="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">Stock-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="label: ShareBasedCompensationOptionAndIncentivePlansPolicy to us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl1">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl1" xlink:title="label: ShareBasedCompensationOptionAndIncentivePlansPolicy to us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="PaymentsOfStockIssuanceCosts" xlink:title="PaymentsOfStockIssuanceCosts" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US" id="us-gaap_PaymentsOfStockIssuanceCosts">Transaction costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" xlink:title="label: PaymentsOfStockIssuanceCosts to us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockholdersEquityAbstract" xml:lang="en-US" id="us-gaap_StockholdersEquityAbstract">Stockholders' equity (deficit):</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:title="label: StockholdersEquityAbstract to us-gaap_StockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquityAbstract_lbl1" xml:lang="en-US" id="us-gaap_StockholdersEquityAbstract_lbl1">Equity, Attributable to Parent [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl1" xlink:title="label: StockholdersEquityAbstract to us-gaap_StockholdersEquityAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" xlink:title="StockholdersEquityNoteAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockholdersEquityNoteAbstract" xml:lang="en-US" id="us-gaap_StockholdersEquityNoteAbstract">Stockholders' Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract" xlink:title="label: StockholdersEquityNoteAbstract to us-gaap_StockholdersEquityNoteAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquityNoteAbstract_lbl1" xml:lang="en-US" id="us-gaap_StockholdersEquityNoteAbstract_lbl1">Stockholders' Equity Note [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl1" xlink:title="label: StockholdersEquityNoteAbstract to us-gaap_StockholdersEquityNoteAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="ClassOfWarrantOrRightOutstanding" xlink:title="ClassOfWarrantOrRightOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightOutstanding">Number outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:title="label: ClassOfWarrantOrRightOutstanding to us-gaap_ClassOfWarrantOrRightOutstanding" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="StockholdersEquityNoteDisclosureTextBlock" xlink:title="StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US" id="us-gaap_StockholdersEquityNoteDisclosureTextBlock">Stockholders' Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:title="label: StockholdersEquityNoteDisclosureTextBlock to us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">Warrants to purchase common stock (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="label: ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights to us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventTypeAxis" xml:lang="en-US" id="us-gaap_SubsequentEventTypeAxis">Subsequent Event Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:title="label: SubsequentEventTypeAxis to us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="SubsequentEventLineItems" xlink:title="SubsequentEventLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventLineItems" xml:lang="en-US" id="us-gaap_SubsequentEventLineItems">Subsequent Event [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems" xlink:title="label: SubsequentEventLineItems to us-gaap_SubsequentEventLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="SubsequentEventTable" xlink:title="SubsequentEventTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventTable" xml:lang="en-US" id="us-gaap_SubsequentEventTable">Subsequent Event [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable" xlink:title="label: SubsequentEventTable to us-gaap_SubsequentEventTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventTypeDomain" xml:lang="en-US" id="us-gaap_SubsequentEventTypeDomain">Subsequent Event Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:title="label: SubsequentEventTypeDomain to us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_AssetsCurrent" xml:lang="en-US" id="us-gaap_AssetsCurrent">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrent" xlink:to="us-gaap_AssetsCurrent" xlink:title="label: AssetsCurrent to us-gaap_AssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsCurrent_lbl1" xml:lang="en-US" id="us-gaap_AssetsCurrent_lbl1">Assets, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl1" xlink:title="label: AssetsCurrent to us-gaap_AssetsCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="AssetsCurrentAbstract" xlink:title="AssetsCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AssetsCurrentAbstract" xml:lang="en-US" id="us-gaap_AssetsCurrentAbstract">Current assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:title="label: AssetsCurrentAbstract to us-gaap_AssetsCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsCurrentAbstract_lbl1" xml:lang="en-US" id="us-gaap_AssetsCurrentAbstract_lbl1">Assets, Current [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl1" xlink:title="label: AssetsCurrentAbstract to us-gaap_AssetsCurrentAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WarrantMember" xml:lang="en-US" id="us-gaap_WarrantMember">Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantMember" xlink:to="us-gaap_WarrantMember" xlink:title="label: WarrantMember to us-gaap_WarrantMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WarrantMember1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_WarrantMember1" xml:lang="en-US" id="us-gaap_WarrantMember1">Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantMember" xlink:to="us-gaap_WarrantMember1" xlink:title="label: WarrantMember to us-gaap_WarrantMember1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US" id="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">Weighted average common and potential common shares outstanding - diluted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="label: WeightedAverageNumberOfDilutedSharesOutstanding to us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl1" xml:lang="en-US" id="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl1">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl1" xlink:title="label: WeightedAverageNumberOfDilutedSharesOutstanding to us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US" id="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">Weighted average common and potential common shares outstanding - basic (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="label: WeightedAverageNumberOfSharesOutstandingBasic to us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl1" xml:lang="en-US" id="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl1">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl1" xlink:title="label: WeightedAverageNumberOfSharesOutstandingBasic to us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockMember" xml:lang="en-US" id="us-gaap_CommonStockMember">Common Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockMember" xlink:to="us-gaap_CommonStockMember" xlink:title="label: CommonStockMember to us-gaap_CommonStockMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="label: PropertyPlantAndEquipmentDisclosureTextBlock to us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentTypeDomain">Long-Lived Tangible Asset [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:title="label: PropertyPlantAndEquipmentTypeDomain to us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpense">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:title="label: ResearchAndDevelopmentExpense to us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="ConvertibleNotesPayableMember" xlink:title="ConvertibleNotesPayableMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConvertibleNotesPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ConvertibleNotesPayableMember" xml:lang="en-US" id="us-gaap_ConvertibleNotesPayableMember">Convertible Notes Payable - Related Party [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleNotesPayableMember" xlink:to="us-gaap_ConvertibleNotesPayableMember" xlink:title="label: ConvertibleNotesPayableMember to us-gaap_ConvertibleNotesPayableMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConvertibleNotesPayableMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConvertibleNotesPayableMember_lbl1" xml:lang="en-US" id="us-gaap_ConvertibleNotesPayableMember_lbl1">Convertible Notes Payable [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleNotesPayableMember" xlink:to="us-gaap_ConvertibleNotesPayableMember_lbl1" xlink:title="label: ConvertibleNotesPayableMember to us-gaap_ConvertibleNotesPayableMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="PreferredStockMember" xlink:title="PreferredStockMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockMember" xml:lang="en-US" id="us-gaap_PreferredStockMember">Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockMember" xlink:to="us-gaap_PreferredStockMember" xlink:title="label: PreferredStockMember to us-gaap_PreferredStockMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_Assets" xml:lang="en-US" id="us-gaap_Assets">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Assets" xlink:to="us-gaap_Assets" xlink:title="label: Assets to us-gaap_Assets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Assets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_Assets_lbl1" xml:lang="en-US" id="us-gaap_Assets_lbl1">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Assets" xlink:to="us-gaap_Assets_lbl1" xlink:title="label: Assets to us-gaap_Assets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="InvestmentIncomeInterest" xlink:title="InvestmentIncomeInterest" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InvestmentIncomeInterest" xml:lang="en-US" id="us-gaap_InvestmentIncomeInterest">Interest income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest" xlink:title="label: InvestmentIncomeInterest to us-gaap_InvestmentIncomeInterest" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="OtherLiabilitiesNoncurrent" xlink:title="OtherLiabilitiesNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherLiabilitiesNoncurrent" xml:lang="en-US" id="us-gaap_OtherLiabilitiesNoncurrent">Other liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" xlink:title="label: OtherLiabilitiesNoncurrent to us-gaap_OtherLiabilitiesNoncurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockRedemptionPricePerShare" xlink:label="PreferredStockRedemptionPricePerShare" xlink:title="PreferredStockRedemptionPricePerShare" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockRedemptionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockRedemptionPricePerShare" xml:lang="en-US" id="us-gaap_PreferredStockRedemptionPricePerShare">Preferred stock redemption price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockRedemptionPricePerShare" xlink:to="us-gaap_PreferredStockRedemptionPricePerShare" xlink:title="label: PreferredStockRedemptionPricePerShare to us-gaap_PreferredStockRedemptionPricePerShare" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="IncomeTaxAuthorityDomain" xlink:title="IncomeTaxAuthorityDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxAuthorityDomain" xml:lang="en-US" id="us-gaap_IncomeTaxAuthorityDomain">Income Tax Authority [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:title="label: IncomeTaxAuthorityDomain to us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xml:lang="en-US" id="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain">Financial Instruments [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="label: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US" id="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">Stock-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="label: DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock to us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationProfitLossAbstract" xlink:label="SegmentReportingInformationProfitLossAbstract" xlink:title="SegmentReportingInformationProfitLossAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SegmentReportingInformationProfitLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SegmentReportingInformationProfitLossAbstract" xml:lang="en-US" id="us-gaap_SegmentReportingInformationProfitLossAbstract">Significant Expense Categories [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentReportingInformationProfitLossAbstract" xlink:to="us-gaap_SegmentReportingInformationProfitLossAbstract" xlink:title="label: SegmentReportingInformationProfitLossAbstract to us-gaap_SegmentReportingInformationProfitLossAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementTable" xml:lang="en-US" id="us-gaap_StatementTable">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementTable" xlink:to="us-gaap_StatementTable" xlink:title="label: StatementTable to us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesNameDomain">Antidilutive Securities, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:title="label: AntidilutiveSecuritiesNameDomain to us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AssetsAbstract" xml:lang="en-US" id="us-gaap_AssetsAbstract">ASSETS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsAbstract" xlink:to="us-gaap_AssetsAbstract" xlink:title="label: AssetsAbstract to us-gaap_AssetsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsAbstract_lbl1" xml:lang="en-US" id="us-gaap_AssetsAbstract_lbl1">Assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl1" xlink:title="label: AssetsAbstract to us-gaap_AssetsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementLineItems" xml:lang="en-US" id="us-gaap_StatementLineItems">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementLineItems" xlink:to="us-gaap_StatementLineItems" xlink:title="label: StatementLineItems to us-gaap_StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xml:lang="en-US" id="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">Roll Forward of Derivative Liability - Contingent Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:title="label: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock to us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xml:lang="en-US" id="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">Roll Forward of Derivative Liability [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:title="label: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward to us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:title="ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xml:lang="en-US" id="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">Summary of Warrants Activity, Outstanding Warrants Issued in Connection with Equity and Debt Financings and Consultants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:title="label: ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock to us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="ClassOfWarrantOrRightTable" xlink:title="ClassOfWarrantOrRightTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightTable" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightTable">Class of Warrant or Right [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable" xlink:title="label: ClassOfWarrantOrRightTable to us-gaap_ClassOfWarrantOrRightTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightAxis" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightAxis">Class of Warrant or Right [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:title="label: ClassOfWarrantOrRightAxis to us-gaap_ClassOfWarrantOrRightAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightDomain" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightDomain">Class of Warrant or Right [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:title="label: ClassOfWarrantOrRightDomain to us-gaap_ClassOfWarrantOrRightDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="OperatingLossCarryforwardsTable" xlink:title="OperatingLossCarryforwardsTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLossCarryforwardsTable" xml:lang="en-US" id="us-gaap_OperatingLossCarryforwardsTable">Operating Loss Carryforwards [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable" xlink:title="label: OperatingLossCarryforwardsTable to us-gaap_OperatingLossCarryforwardsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="OperatingLossCarryforwardsLineItems" xlink:title="OperatingLossCarryforwardsLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLossCarryforwardsLineItems" xml:lang="en-US" id="us-gaap_OperatingLossCarryforwardsLineItems">Operating Loss Carryforwards [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems" xlink:title="label: OperatingLossCarryforwardsLineItems to us-gaap_OperatingLossCarryforwardsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="FairValueInputsLevel1Member" xlink:title="FairValueInputsLevel1Member" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueInputsLevel1Member" xml:lang="en-US" id="us-gaap_FairValueInputsLevel1Member">Level 1 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member" xlink:title="label: FairValueInputsLevel1Member to us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="FairValueInputsLevel2Member" xlink:title="FairValueInputsLevel2Member" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueInputsLevel2Member" xml:lang="en-US" id="us-gaap_FairValueInputsLevel2Member">Level 2 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:title="label: FairValueInputsLevel2Member to us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="FairValueInputsLevel3Member" xlink:title="FairValueInputsLevel3Member" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueInputsLevel3Member" xml:lang="en-US" id="us-gaap_FairValueInputsLevel3Member">Level 3 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member" xlink:title="label: FairValueInputsLevel3Member to us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure" xlink:label="InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure" xlink:title="InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure" xml:lang="en-US" id="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure">Estimated fair value of asset contributed to joint venture</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure" xlink:to="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure" xlink:title="label: InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure to us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure_lbl1" xml:lang="en-US" id="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure_lbl1">Investments in Affiliates, Subsidiaries, Associates, and Joint Ventures, Fair Value Disclosure</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure" xlink:to="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure_lbl1" xlink:title="label: InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure to us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" xlink:title="EquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EquityAbstract" xml:lang="en-US" id="us-gaap_EquityAbstract">Stockholders' Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityAbstract" xlink:to="us-gaap_EquityAbstract" xlink:title="label: EquityAbstract to us-gaap_EquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="FairValueDisclosuresTextBlock" xlink:title="FairValueDisclosuresTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US" id="us-gaap_FairValueDisclosuresTextBlock">Fair Value of Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock" xlink:title="label: FairValueDisclosuresTextBlock to us-gaap_FairValueDisclosuresTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="TemporaryEquitySharesAuthorized" xlink:title="TemporaryEquitySharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TemporaryEquitySharesAuthorized" xml:lang="en-US" id="us-gaap_TemporaryEquitySharesAuthorized">Series C 6% super dividend redeemable convertible preferred stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" xlink:title="label: TemporaryEquitySharesAuthorized to us-gaap_TemporaryEquitySharesAuthorized" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="TemporaryEquitySharesIssued" xlink:title="TemporaryEquitySharesIssued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TemporaryEquitySharesIssued" xml:lang="en-US" id="us-gaap_TemporaryEquitySharesIssued">Series C 6% super dividend redeemable convertible preferred stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued" xlink:title="label: TemporaryEquitySharesIssued to us-gaap_TemporaryEquitySharesIssued" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="TemporaryEquitySharesOutstanding" xlink:title="TemporaryEquitySharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TemporaryEquitySharesOutstanding" xml:lang="en-US" id="us-gaap_TemporaryEquitySharesOutstanding">Series C 6% super dividend redeemable convertible preferred stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" xlink:title="label: TemporaryEquitySharesOutstanding to us-gaap_TemporaryEquitySharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_TemporaryEquitySharesOutstanding1" xml:lang="en-US" id="us-gaap_TemporaryEquitySharesOutstanding1">Beginning balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding1" xlink:title="label: TemporaryEquitySharesOutstanding to us-gaap_TemporaryEquitySharesOutstanding1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding2" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_TemporaryEquitySharesOutstanding2" xml:lang="en-US" id="us-gaap_TemporaryEquitySharesOutstanding2">Ending balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding2" xlink:title="label: TemporaryEquitySharesOutstanding to us-gaap_TemporaryEquitySharesOutstanding2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="PreferredStockLiquidationPreference" xlink:title="PreferredStockLiquidationPreference" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockLiquidationPreference" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PreferredStockLiquidationPreference" xml:lang="en-US" id="us-gaap_PreferredStockLiquidationPreference">Stated value of dividend payment (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockLiquidationPreference" xlink:to="us-gaap_PreferredStockLiquidationPreference" xlink:title="label: PreferredStockLiquidationPreference to us-gaap_PreferredStockLiquidationPreference" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockLiquidationPreference_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockLiquidationPreference_lbl1" xml:lang="en-US" id="us-gaap_PreferredStockLiquidationPreference_lbl1">Preferred Stock, Liquidation Preference Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockLiquidationPreference" xlink:to="us-gaap_PreferredStockLiquidationPreference_lbl1" xlink:title="label: PreferredStockLiquidationPreference to us-gaap_PreferredStockLiquidationPreference_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="ClassOfWarrantOrRightLineItems" xlink:title="ClassOfWarrantOrRightLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightLineItems" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightLineItems">Class of Warrant or Right [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" xlink:title="label: ClassOfWarrantOrRightLineItems to us-gaap_ClassOfWarrantOrRightLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfStockDomain" xml:lang="en-US" id="us-gaap_ClassOfStockDomain">Class of Stock [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain" xlink:title="label: ClassOfStockDomain to us-gaap_ClassOfStockDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="WarrantsAndRightsNoteDisclosureAbstract" xlink:title="WarrantsAndRightsNoteDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xml:lang="en-US" id="us-gaap_WarrantsAndRightsNoteDisclosureAbstract">Outstanding Warrants [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:title="label: WarrantsAndRightsNoteDisclosureAbstract to us-gaap_WarrantsAndRightsNoteDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WarrantsAndRightsNoteDisclosureAbstract1" xml:lang="en-US" id="us-gaap_WarrantsAndRightsNoteDisclosureAbstract1">Common Stock Warrants Purchase Agreement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_WarrantsAndRightsNoteDisclosureAbstract1" xlink:title="label: WarrantsAndRightsNoteDisclosureAbstract to us-gaap_WarrantsAndRightsNoteDisclosureAbstract1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="label: IncreaseDecreaseInStockholdersEquityRollForward to us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="PropertyPlantAndEquipmentNetByTypeAbstract" xlink:title="PropertyPlantAndEquipmentNetByTypeAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract">Property and Equipment [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:title="label: PropertyPlantAndEquipmentNetByTypeAbstract to us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_lbl1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_lbl1">Property, Plant and Equipment, Net, by Type [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_lbl1" xlink:title="label: PropertyPlantAndEquipmentNetByTypeAbstract to us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:title="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xml:lang="en-US" id="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">Issuance of common stock purchase warrants in connection with related party line of credit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalWarrantIssued to us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl1" xml:lang="en-US" id="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl1">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl1" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalWarrantIssued to us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="CommonStockSharesSubscribedButUnissued" xlink:title="CommonStockSharesSubscribedButUnissued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesSubscribedButUnissued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockSharesSubscribedButUnissued" xml:lang="en-US" id="us-gaap_CommonStockSharesSubscribedButUnissued">Shares unissued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesSubscribedButUnissued" xlink:to="us-gaap_CommonStockSharesSubscribedButUnissued" xlink:title="label: CommonStockSharesSubscribedButUnissued to us-gaap_CommonStockSharesSubscribedButUnissued" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="OtherAssetsNoncurrent" xlink:title="OtherAssetsNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OtherAssetsNoncurrent" xml:lang="en-US" id="us-gaap_OtherAssetsNoncurrent">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:title="label: OtherAssetsNoncurrent to us-gaap_OtherAssetsNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherAssetsNoncurrent_lbl1" xml:lang="en-US" id="us-gaap_OtherAssetsNoncurrent_lbl1">Other Assets, Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl1" xlink:title="label: OtherAssetsNoncurrent to us-gaap_OtherAssetsNoncurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="OperatingExpensesAbstract" xlink:title="OperatingExpensesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingExpensesAbstract" xml:lang="en-US" id="us-gaap_OperatingExpensesAbstract">Operating expenses:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" xlink:title="label: OperatingExpensesAbstract to us-gaap_OperatingExpensesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OperatingExpensesAbstract1" xml:lang="en-US" id="us-gaap_OperatingExpensesAbstract1">Operating expenses [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract1" xlink:title="label: OperatingExpensesAbstract to us-gaap_OperatingExpensesAbstract1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_OperatingExpenses" xml:lang="en-US" id="us-gaap_OperatingExpenses">Total operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpenses" xlink:to="us-gaap_OperatingExpenses" xlink:title="label: OperatingExpenses to us-gaap_OperatingExpenses" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingExpenses_lbl1" xml:lang="en-US" id="us-gaap_OperatingExpenses_lbl1">Operating Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl1" xlink:title="label: OperatingExpenses to us-gaap_OperatingExpenses_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">Amount excluded from calculation (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl1" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl1">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl1" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">Antidilutive Securities [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" xlink:title="EarningsPerShareAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareAbstract" xml:lang="en-US" id="us-gaap_EarningsPerShareAbstract">Loss Per Share [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract" xlink:title="label: EarningsPerShareAbstract to us-gaap_EarningsPerShareAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xml:lang="en-US" id="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:title="label: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock to us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xml:lang="en-US" id="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="label: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:label="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:title="EarningsPerShareDilutedOtherDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xml:lang="en-US" id="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract">Antidilutive Securities Excluded from Computation of Earnings Per Share [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:title="label: EarningsPerShareDilutedOtherDisclosuresAbstract to us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl1" xml:lang="en-US" id="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl1">Earnings Per Share, Diluted, Other Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl1" xlink:title="label: EarningsPerShareDilutedOtherDisclosuresAbstract to us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockRedemptionPremium" xlink:label="PreferredStockRedemptionPremium" xlink:title="PreferredStockRedemptionPremium" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockRedemptionPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PreferredStockRedemptionPremium" xml:lang="en-US" id="us-gaap_PreferredStockRedemptionPremium">Deemed dividend</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockRedemptionPremium" xlink:to="us-gaap_PreferredStockRedemptionPremium" xlink:title="label: PreferredStockRedemptionPremium to us-gaap_PreferredStockRedemptionPremium" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockRedemptionPremium_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockRedemptionPremium_lbl1" xml:lang="en-US" id="us-gaap_PreferredStockRedemptionPremium_lbl1">Preferred Stock Redemption Premium</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockRedemptionPremium" xlink:to="us-gaap_PreferredStockRedemptionPremium_lbl1" xlink:title="label: PreferredStockRedemptionPremium to us-gaap_PreferredStockRedemptionPremium_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyRangeOfPossibleLossPortionNotAccrued" xlink:label="LossContingencyRangeOfPossibleLossPortionNotAccrued" xlink:title="LossContingencyRangeOfPossibleLossPortionNotAccrued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LossContingencyRangeOfPossibleLossPortionNotAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LossContingencyRangeOfPossibleLossPortionNotAccrued" xml:lang="en-US" id="us-gaap_LossContingencyRangeOfPossibleLossPortionNotAccrued">Additional accrued amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingencyRangeOfPossibleLossPortionNotAccrued" xlink:to="us-gaap_LossContingencyRangeOfPossibleLossPortionNotAccrued" xlink:title="label: LossContingencyRangeOfPossibleLossPortionNotAccrued to us-gaap_LossContingencyRangeOfPossibleLossPortionNotAccrued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LossContingencyRangeOfPossibleLossPortionNotAccrued_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LossContingencyRangeOfPossibleLossPortionNotAccrued_lbl1" xml:lang="en-US" id="us-gaap_LossContingencyRangeOfPossibleLossPortionNotAccrued_lbl1">Loss Contingency, Range of Possible Loss, Portion Not Accrued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingencyRangeOfPossibleLossPortionNotAccrued" xlink:to="us-gaap_LossContingencyRangeOfPossibleLossPortionNotAccrued_lbl1" xlink:title="label: LossContingencyRangeOfPossibleLossPortionNotAccrued to us-gaap_LossContingencyRangeOfPossibleLossPortionNotAccrued_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementClassOfStockAxis" xml:lang="en-US" id="us-gaap_StatementClassOfStockAxis">Class of Stock [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:title="label: StatementClassOfStockAxis to us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xml:lang="en-US" id="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="label: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US" id="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable">Property, Plant and Equipment [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="label: ScheduleOfPropertyPlantAndEquipmentTable to us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US" id="us-gaap_CommonStockParOrStatedValuePerShare">Common stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:title="label: CommonStockParOrStatedValuePerShare to us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentByTypeAxis">Long-Lived Tangible Asset [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:title="label: PropertyPlantAndEquipmentByTypeAxis to us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="PropertyPlantAndEquipmentLineItems" xlink:title="PropertyPlantAndEquipmentLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentLineItems">Property, Plant and Equipment [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:title="label: PropertyPlantAndEquipmentLineItems to us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_StockholdersEquity" xml:lang="en-US" id="us-gaap_StockholdersEquity">Total stockholders' deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_StockholdersEquity1" xml:lang="en-US" id="us-gaap_StockholdersEquity1">Beginning balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity1" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity2" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_StockholdersEquity2" xml:lang="en-US" id="us-gaap_StockholdersEquity2">Ending balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity2" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity2" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquity_lbl3" xml:lang="en-US" id="us-gaap_StockholdersEquity_lbl3">Equity, Attributable to Parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl3" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity_lbl3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="PreferredStockValue" xlink:title="PreferredStockValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_PreferredStockValue" xml:lang="en-US" id="us-gaap_PreferredStockValue">Series A 12% convertible preferred stock; 1,742,500 shares authorized, 1,235,000 and 1,235,000 issued and outstanding at December 31, 2024 and 2023, respectively, liquidation value $1,235,000 at December 31, 2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockValue" xlink:to="us-gaap_PreferredStockValue" xlink:title="label: PreferredStockValue to us-gaap_PreferredStockValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockValue_lbl1" xml:lang="en-US" id="us-gaap_PreferredStockValue_lbl1">Preferred Stock, Value, Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl1" xlink:title="label: PreferredStockValue to us-gaap_PreferredStockValue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xml:lang="en-US" id="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract">Redeemable Convertible Preferred Stock [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="label: PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract to us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities" xlink:label="DerivativeLiabilities" xlink:title="DerivativeLiabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DerivativeLiabilities" xml:lang="en-US" id="us-gaap_DerivativeLiabilities">Warrant liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilities" xlink:title="label: DerivativeLiabilities to us-gaap_DerivativeLiabilities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementEquityComponentsAxis" xml:lang="en-US" id="us-gaap_StatementEquityComponentsAxis">Equity Components [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:title="label: StatementEquityComponentsAxis to us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="AdditionalPaidInCapitalMember" xlink:title="AdditionalPaidInCapitalMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US" id="us-gaap_AdditionalPaidInCapitalMember">Additional Paid-in Capital [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:title="label: AdditionalPaidInCapitalMember to us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="RetainedEarningsMember" xlink:title="RetainedEarningsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RetainedEarningsMember" xml:lang="en-US" id="us-gaap_RetainedEarningsMember">Retained Deficit [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember" xlink:title="label: RetainedEarningsMember to us-gaap_RetainedEarningsMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EquityComponentDomain" xml:lang="en-US" id="us-gaap_EquityComponentDomain">Equity Component [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain" xlink:title="label: EquityComponentDomain to us-gaap_EquityComponentDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xml:lang="en-US" id="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">Minimum Exercise Price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:title="label: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit to us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice" xlink:label="DeferredCompensationArrangementWithIndividualExercisePrice" xlink:title="DeferredCompensationArrangementWithIndividualExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice" xml:lang="en-US" id="us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice">Common Stock Weighted average Grant Date fair Value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredCompensationArrangementWithIndividualExercisePrice" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice" xlink:title="label: DeferredCompensationArrangementWithIndividualExercisePrice to us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" xlink:label="DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" xlink:title="DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" xml:lang="en-US" id="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis">Deferred Bonus and Profit Sharing Arrangements, Individual Contracts, Type of Deferred Compensation [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" xlink:title="label: DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis to us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredBonusMember" xlink:label="DeferredBonusMember" xlink:title="DeferredBonusMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredBonusMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredBonusMember" xml:lang="en-US" id="us-gaap_DeferredBonusMember">Deferred Bonus [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredBonusMember" xlink:to="us-gaap_DeferredBonusMember" xlink:title="label: DeferredBonusMember to us-gaap_DeferredBonusMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeStockOptionMember" xml:lang="en-US" id="us-gaap_EmployeeStockOptionMember">Stock Options [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:title="label: EmployeeStockOptionMember to us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaidInKindInterest" xlink:label="PaidInKindInterest" xlink:title="PaidInKindInterest" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PaidInKindInterest" xml:lang="en-US" id="us-gaap_PaidInKindInterest">Non-cash interest expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaidInKindInterest" xlink:to="us-gaap_PaidInKindInterest" xlink:title="label: PaidInKindInterest to us-gaap_PaidInKindInterest" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:title="StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">Restricted stock units valued at grant</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:title="label: StockIssuedDuringPeriodValueRestrictedStockAwardGross to us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl1" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl1">Stock Issued During Period, Value, Restricted Stock Award, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl1" xlink:title="label: StockIssuedDuringPeriodValueRestrictedStockAwardGross to us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">Issuance of common stock from exercise of stock options, net of shares withheld for exercise</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="label: StockIssuedDuringPeriodValueStockOptionsExercised to us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:title="StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">Conversion of Series A Convertible Preferred to common</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:title="label: StockIssuedDuringPeriodValueConversionOfConvertibleSecurities to us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl1" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl1">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl1" xlink:title="label: StockIssuedDuringPeriodValueConversionOfConvertibleSecurities to us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesNewIssues">Preferred stock issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:title="label: StockIssuedDuringPeriodSharesNewIssues to us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1">Stock Issued During Period, Shares, New Issues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesNewIssues to us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:title="StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">Issuance of common stock from restricted stock units (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:title="label: StockIssuedDuringPeriodSharesRestrictedStockAwardGross to us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl1" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl1">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesRestrictedStockAwardGross to us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:title="StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">Stock-based compensation expense (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:title="label: StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures to us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">Exercised (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="label: StockIssuedDuringPeriodSharesStockOptionsExercised to us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised1" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised1">Issuance of common stock from exercise of stock options, net of shares withheld for exercise (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised1" xlink:title="label: StockIssuedDuringPeriodSharesStockOptionsExercised to us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:title="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">Conversion of Series A Convertible Preferred to common (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:title="label: StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities to us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities1" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities1">Common stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities1" xlink:title="label: StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities to us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="StatementBusinessSegmentsAxis" xlink:title="StatementBusinessSegmentsAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementBusinessSegmentsAxis" xml:lang="en-US" id="us-gaap_StatementBusinessSegmentsAxis">Segments [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis" xlink:title="label: StatementBusinessSegmentsAxis to us-gaap_StatementBusinessSegmentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:title="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US" id="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">NONCASH FINANCING ACTIVITIES:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:title="label: CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">Stock Option Activity [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">Warrants Activity [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">Fair Value Assumptions Before and After Extension of warrants [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract1">Weighted Average Assumptions for Stock Options Granted [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl2">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsPreferredStock" xlink:label="DividendsPreferredStock" xlink:title="DividendsPreferredStock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DividendsPreferredStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DividendsPreferredStock" xml:lang="en-US" id="us-gaap_DividendsPreferredStock">Convertible preferred stock dividend</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DividendsPreferredStock" xlink:to="us-gaap_DividendsPreferredStock" xlink:title="label: DividendsPreferredStock to us-gaap_DividendsPreferredStock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="EarningsPerShareTextBlock" xlink:title="EarningsPerShareTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareTextBlock" xml:lang="en-US" id="us-gaap_EarningsPerShareTextBlock">Loss Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock" xlink:title="label: EarningsPerShareTextBlock to us-gaap_EarningsPerShareTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="ClassOfStockLineItems" xlink:title="ClassOfStockLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfStockLineItems" xml:lang="en-US" id="us-gaap_ClassOfStockLineItems">Class of Stock [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems" xlink:title="label: ClassOfStockLineItems to us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="ScheduleOfStockByClassTable" xlink:title="ScheduleOfStockByClassTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfStockByClassTable" xml:lang="en-US" id="us-gaap_ScheduleOfStockByClassTable">Stock, Class of Stock [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable" xlink:title="label: ScheduleOfStockByClassTable to us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="CommitmentsAndContingencies" xlink:title="CommitmentsAndContingencies" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommitmentsAndContingencies" xml:lang="en-US" id="us-gaap_CommitmentsAndContingencies">Commitments and contingencies (Note 12)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:title="label: CommitmentsAndContingencies to us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US" id="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">Adjustments to reconcile net loss to net cash from operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="label: AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="LongtermDebtTypeAxis" xlink:title="LongtermDebtTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LongtermDebtTypeAxis" xml:lang="en-US" id="us-gaap_LongtermDebtTypeAxis">Long-term Debt, Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:title="label: LongtermDebtTypeAxis to us-gaap_LongtermDebtTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeAxis1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LongtermDebtTypeAxis1" xml:lang="en-US" id="us-gaap_LongtermDebtTypeAxis1">Long-Term Debt, Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis1" xlink:title="label: LongtermDebtTypeAxis to us-gaap_LongtermDebtTypeAxis1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountsPayableCurrent" xml:lang="en-US" id="us-gaap_AccountsPayableCurrent">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent" xlink:title="label: AccountsPayableCurrent to us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US" id="us-gaap_AccruedLiabilitiesCurrent">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:title="label: AccruedLiabilitiesCurrent to us-gaap_AccruedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccruedLiabilitiesCurrent1" xml:lang="en-US" id="us-gaap_AccruedLiabilitiesCurrent1">Accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent1" xlink:title="label: AccruedLiabilitiesCurrent to us-gaap_AccruedLiabilitiesCurrent1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="AccruedProfessionalFeesCurrent" xlink:title="AccruedProfessionalFeesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccruedProfessionalFeesCurrent" xml:lang="en-US" id="us-gaap_AccruedProfessionalFeesCurrent">Legal and accounting fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" xlink:title="label: AccruedProfessionalFeesCurrent to us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsPayableCurrent" xlink:label="DividendsPayableCurrent" xlink:title="DividendsPayableCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DividendsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DividendsPayableCurrent" xml:lang="en-US" id="us-gaap_DividendsPayableCurrent">Accrued dividends payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DividendsPayableCurrent" xlink:to="us-gaap_DividendsPayableCurrent" xlink:title="label: DividendsPayableCurrent to us-gaap_DividendsPayableCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="EmployeeRelatedLiabilitiesCurrent" xlink:title="EmployeeRelatedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeRelatedLiabilitiesCurrent" xml:lang="en-US" id="us-gaap_EmployeeRelatedLiabilitiesCurrent">Accrued compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:title="label: EmployeeRelatedLiabilitiesCurrent to us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="LongtermDebtTypeDomain" xlink:title="LongtermDebtTypeDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LongtermDebtTypeDomain" xml:lang="en-US" id="us-gaap_LongtermDebtTypeDomain">Long-term Debt, Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:title="label: LongtermDebtTypeDomain to us-gaap_LongtermDebtTypeDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeDomain1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LongtermDebtTypeDomain1" xml:lang="en-US" id="us-gaap_LongtermDebtTypeDomain1">Long-Term Debt, Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain1" xlink:title="label: LongtermDebtTypeDomain to us-gaap_LongtermDebtTypeDomain1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US" id="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue to us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock" xlink:label="InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock" xlink:title="InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock" xml:lang="en-US" id="us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock">Galectin Sciences LLC</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock" xlink:to="us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock" xlink:title="label: InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock to us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US" id="us-gaap_PrepaidExpenseAndOtherAssetsCurrent">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:title="label: PrepaidExpenseAndOtherAssetsCurrent to us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityAggregateAmountOfRedemptionRequirement" xlink:label="TemporaryEquityAggregateAmountOfRedemptionRequirement" xlink:title="TemporaryEquityAggregateAmountOfRedemptionRequirement" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TemporaryEquityAggregateAmountOfRedemptionRequirement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TemporaryEquityAggregateAmountOfRedemptionRequirement" xml:lang="en-US" id="us-gaap_TemporaryEquityAggregateAmountOfRedemptionRequirement">Series C 6% super dividend redeemable convertible preferred stock, redemption value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityAggregateAmountOfRedemptionRequirement" xlink:to="us-gaap_TemporaryEquityAggregateAmountOfRedemptionRequirement" xlink:title="label: TemporaryEquityAggregateAmountOfRedemptionRequirement to us-gaap_TemporaryEquityAggregateAmountOfRedemptionRequirement" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TemporaryEquityAggregateAmountOfRedemptionRequirement1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_TemporaryEquityAggregateAmountOfRedemptionRequirement1" xml:lang="en-US" id="us-gaap_TemporaryEquityAggregateAmountOfRedemptionRequirement1">Convertible preferred stock, redemption value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityAggregateAmountOfRedemptionRequirement" xlink:to="us-gaap_TemporaryEquityAggregateAmountOfRedemptionRequirement1" xlink:title="label: TemporaryEquityAggregateAmountOfRedemptionRequirement to us-gaap_TemporaryEquityAggregateAmountOfRedemptionRequirement1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="IncreaseDecreaseInTemporaryEquityRollForward" xlink:title="IncreaseDecreaseInTemporaryEquityRollForward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:title="label: IncreaseDecreaseInTemporaryEquityRollForward to us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="TemporaryEquityLiquidationPreference" xlink:title="TemporaryEquityLiquidationPreference" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLiquidationPreference" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TemporaryEquityLiquidationPreference" xml:lang="en-US" id="us-gaap_TemporaryEquityLiquidationPreference">Series C 6% super dividend redeemable convertible preferred stock liquidation value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityLiquidationPreference" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" xlink:title="label: TemporaryEquityLiquidationPreference to us-gaap_TemporaryEquityLiquidationPreference" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="AssetsFairValueDisclosure" xlink:title="AssetsFairValueDisclosure" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AssetsFairValueDisclosure" xml:lang="en-US" id="us-gaap_AssetsFairValueDisclosure">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure" xlink:title="label: AssetsFairValueDisclosure to us-gaap_AssetsFairValueDisclosure" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsFairValueDisclosure_lbl1" xml:lang="en-US" id="us-gaap_AssetsFairValueDisclosure_lbl1">Assets, Fair Value Disclosure</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl1" xlink:title="label: AssetsFairValueDisclosure to us-gaap_AssetsFairValueDisclosure_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="SegmentDomain" xlink:title="SegmentDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SegmentDomain" xml:lang="en-US" id="us-gaap_SegmentDomain">Segments [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentDomain" xlink:to="us-gaap_SegmentDomain" xlink:title="label: SegmentDomain to us-gaap_SegmentDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TypeOfArrangementAxis" xml:lang="en-US" id="us-gaap_TypeOfArrangementAxis">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:title="label: TypeOfArrangementAxis to us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain" xlink:title="FairValueMeasurementFrequencyDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueMeasurementFrequencyDomain" xml:lang="en-US" id="us-gaap_FairValueMeasurementFrequencyDomain">Measurement Frequency [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" xlink:title="label: FairValueMeasurementFrequencyDomain to us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US" id="us-gaap_FairValueMeasurementsFairValueHierarchyDomain">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:title="label: FairValueMeasurementsFairValueHierarchyDomain to us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="FairValueMeasurementsRecurringMember" xlink:title="FairValueMeasurementsRecurringMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueMeasurementsRecurringMember" xml:lang="en-US" id="us-gaap_FairValueMeasurementsRecurringMember">Recurring [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" xlink:title="label: FairValueMeasurementsRecurringMember to us-gaap_FairValueMeasurementsRecurringMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:title="PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xml:lang="en-US" id="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">Income tax payment withholding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:title="label: PaymentsRelatedToTaxWithholdingForShareBasedCompensation to us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="ProceedsFromWarrantExercises" xlink:title="ProceedsFromWarrantExercises" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromWarrantExercises" xml:lang="en-US" id="us-gaap_ProceedsFromWarrantExercises">Net proceeds from exercise of common stock options and warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises" xlink:title="label: ProceedsFromWarrantExercises to us-gaap_ProceedsFromWarrantExercises" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:title="SharesPaidForTaxWithholdingForShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xml:lang="en-US" id="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">Shares withheld to cover income tax withholding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:title="label: SharesPaidForTaxWithholdingForShareBasedCompensation to us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" xlink:title="PayablesAndAccrualsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PayablesAndAccrualsAbstract" xml:lang="en-US" id="us-gaap_PayablesAndAccrualsAbstract">Accrued Expenses [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract" xlink:title="label: PayablesAndAccrualsAbstract to us-gaap_PayablesAndAccrualsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US" id="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">Nature of Business, Basis of Presentation, Liquidity, and Going Concern [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="label: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="PreferredStockDividendRatePercentage" xlink:title="PreferredStockDividendRatePercentage" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockDividendRatePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockDividendRatePercentage" xml:lang="en-US" id="us-gaap_PreferredStockDividendRatePercentage">Preferred stock, dividend rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockDividendRatePercentage" xlink:to="us-gaap_PreferredStockDividendRatePercentage" xlink:title="label: PreferredStockDividendRatePercentage to us-gaap_PreferredStockDividendRatePercentage" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockDividendRatePercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PreferredStockDividendRatePercentage1" xml:lang="en-US" id="us-gaap_PreferredStockDividendRatePercentage1">Preferred stock, dividend rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockDividendRatePercentage" xlink:to="us-gaap_PreferredStockDividendRatePercentage1" xlink:title="label: PreferredStockDividendRatePercentage to us-gaap_PreferredStockDividendRatePercentage1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="SharesOutstanding" xlink:title="SharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_SharesOutstanding" xml:lang="en-US" id="us-gaap_SharesOutstanding">Beginning balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesOutstanding" xlink:to="us-gaap_SharesOutstanding" xlink:title="label: SharesOutstanding to us-gaap_SharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharesOutstanding1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_SharesOutstanding1" xml:lang="en-US" id="us-gaap_SharesOutstanding1">Ending balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesOutstanding" xlink:to="us-gaap_SharesOutstanding1" xlink:title="label: SharesOutstanding to us-gaap_SharesOutstanding1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharesOutstanding_lbl2" xml:lang="en-US" id="us-gaap_SharesOutstanding_lbl2">Shares, Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl2" xlink:title="label: SharesOutstanding to us-gaap_SharesOutstanding_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebt" xlink:label="RepaymentsOfDebt" xlink:title="RepaymentsOfDebt" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RepaymentsOfDebt" xml:lang="en-US" id="us-gaap_RepaymentsOfDebt">Convertible note payable repayment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt" xlink:title="label: RepaymentsOfDebt to us-gaap_RepaymentsOfDebt" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US" id="us-gaap_FairValueByFairValueHierarchyLevelAxis">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:title="label: FairValueByFairValueHierarchyLevelAxis to us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="FairValueByMeasurementFrequencyAxis" xlink:title="FairValueByMeasurementFrequencyAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueByMeasurementFrequencyAxis" xml:lang="en-US" id="us-gaap_FairValueByMeasurementFrequencyAxis">Measurement Frequency [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:title="label: FairValueByMeasurementFrequencyAxis to us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:title="ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US" id="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">Components of Net Deferred Tax Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:title="label: ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock to us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:title="ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US" id="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">Primary Factors Affecting Income Tax Rates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:title="label: ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock to us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:title="ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xml:lang="en-US" id="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">Assets and Liabilities Measured and Recorded at Fair Value on Recurring Basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:title="label: ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock to us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:title="ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xml:lang="en-US" id="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">Accrued Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:title="label: ScheduleOfAccruedLiabilitiesTableTextBlock to us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl1">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl1" xlink:title="label: ScheduleOfAccruedLiabilitiesTableTextBlock to us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US" id="us-gaap_CommitmentsAndContingenciesDisclosureAbstract">Commitments and Contingencies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:title="label: CommitmentsAndContingenciesDisclosureAbstract to us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US" id="us-gaap_IncomeTaxDisclosureAbstract">Income Taxes [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract" xlink:title="label: IncomeTaxDisclosureAbstract to us-gaap_IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueDisclosuresAbstract" xml:lang="en-US" id="us-gaap_FairValueDisclosuresAbstract">Fair Value of Financial Instruments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract" xlink:title="label: FairValueDisclosuresAbstract to us-gaap_FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="SubsequentEventsTextBlock" xlink:title="SubsequentEventsTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventsTextBlock" xml:lang="en-US" id="us-gaap_SubsequentEventsTextBlock">Subsequent Event</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock" xlink:title="label: SubsequentEventsTextBlock to us-gaap_SubsequentEventsTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract" xlink:label="InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract" xlink:title="InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract" xml:lang="en-US" id="us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract">Investments in and Advances to Affiliates, Schedule of Investments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract" xlink:to="us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract" xlink:title="label: InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract to us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US" id="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">Stock Option Activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="label: ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock to us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US" id="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">Weighted Average Assumptions Used to Determine Fair Value of Options Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="label: ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock to us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US" id="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">Stock-Based Compensation [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="label: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:title="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xml:lang="en-US" id="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">Reclassification of accrued compensation to additional paid in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition to us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="UseOfEstimates" xlink:title="UseOfEstimates" />
    <link:label xlink:type="resource" xlink:label="us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_UseOfEstimates" xml:lang="en-US" id="us-gaap_UseOfEstimates">Use of Estimates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UseOfEstimates" xlink:to="us-gaap_UseOfEstimates" xlink:title="label: UseOfEstimates to us-gaap_UseOfEstimates" />
    <link:label xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_UseOfEstimates_lbl1" xml:lang="en-US" id="us-gaap_UseOfEstimates_lbl1">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl1" xlink:title="label: UseOfEstimates to us-gaap_UseOfEstimates_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xml:lang="en-US" id="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="label: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xml:lang="en-US" id="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:title="label: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable to us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xml:lang="en-US" id="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:title="label: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems to us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xml:lang="en-US" id="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">Key Assumptions Used in Model at Inception</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:title="label: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock to us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US" id="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="label: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="ResearchAndDevelopmentExpenseMember" xlink:title="ResearchAndDevelopmentExpenseMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpenseMember">Research and Development [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:title="label: ResearchAndDevelopmentExpenseMember to us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ResearchAndDevelopmentExpenseMember_lbl1" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpenseMember_lbl1">Research and Development Expense [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl1" xlink:title="label: ResearchAndDevelopmentExpenseMember to us-gaap_ResearchAndDevelopmentExpenseMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountingPoliciesAbstract" xml:lang="en-US" id="us-gaap_AccountingPoliciesAbstract">Summary of Significant Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:title="label: AccountingPoliciesAbstract to us-gaap_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="SegmentReportingAbstract" xlink:title="SegmentReportingAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SegmentReportingAbstract" xml:lang="en-US" id="us-gaap_SegmentReportingAbstract">Segments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract" xlink:title="label: SegmentReportingAbstract to us-gaap_SegmentReportingAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" xlink:title="SubsequentEventsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventsAbstract" xml:lang="en-US" id="us-gaap_SubsequentEventsAbstract">Subsequent Event [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract" xlink:title="label: SubsequentEventsAbstract to us-gaap_SubsequentEventsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="ConversionOfStockSharesConverted1" xlink:title="ConversionOfStockSharesConverted1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConversionOfStockSharesConverted1" xml:lang="en-US" id="us-gaap_ConversionOfStockSharesConverted1">Common stock issued upon conversion (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1" xlink:title="label: ConversionOfStockSharesConverted1 to us-gaap_ConversionOfStockSharesConverted1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="ConversionOfStockSharesIssued1" xlink:title="ConversionOfStockSharesIssued1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ConversionOfStockSharesIssued1" xml:lang="en-US" id="us-gaap_ConversionOfStockSharesIssued1">Preferred stock shares upon conversion (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1" xlink:title="label: ConversionOfStockSharesIssued1 to us-gaap_ConversionOfStockSharesIssued1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesIssued2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConversionOfStockSharesIssued2" xml:lang="en-US" id="us-gaap_ConversionOfStockSharesIssued2">Convertible preferred stock (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued2" xlink:title="label: ConversionOfStockSharesIssued1 to us-gaap_ConversionOfStockSharesIssued2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="DebtConversionConvertedInstrumentAmount1" xlink:title="DebtConversionConvertedInstrumentAmount1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtConversionConvertedInstrumentAmount1" xml:lang="en-US" id="us-gaap_DebtConversionConvertedInstrumentAmount1">Convertible note principal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:title="label: DebtConversionConvertedInstrumentAmount1 to us-gaap_DebtConversionConvertedInstrumentAmount1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:title="ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">Exercisable date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:title="label: ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable to us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl1" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl1">Class of Warrant or Right, Date from which Warrants or Rights Exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl1" xlink:title="label: ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable to us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssued1" xlink:label="StockIssued1" xlink:title="StockIssued1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockIssued1" xml:lang="en-US" id="us-gaap_StockIssued1">Payment of preferred stock dividends in common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssued1" xlink:to="us-gaap_StockIssued1" xlink:title="label: StockIssued1 to us-gaap_StockIssued1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssued1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssued1_lbl1" xml:lang="en-US" id="us-gaap_StockIssued1_lbl1">Stock Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssued1" xlink:to="us-gaap_StockIssued1_lbl1" xlink:title="label: StockIssued1 to us-gaap_StockIssued1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="DerivativeInstrumentRiskAxis" xlink:title="DerivativeInstrumentRiskAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DerivativeInstrumentRiskAxis" xml:lang="en-US" id="us-gaap_DerivativeInstrumentRiskAxis">Derivative Instrument [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" xlink:title="label: DerivativeInstrumentRiskAxis to us-gaap_DerivativeInstrumentRiskAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xml:lang="en-US" id="us-gaap_ArrangementsAndNonarrangementTransactionsMember">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:title="label: ArrangementsAndNonarrangementTransactionsMember to us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="IncomeTaxAuthorityAxis" xlink:title="IncomeTaxAuthorityAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxAuthorityAxis" xml:lang="en-US" id="us-gaap_IncomeTaxAuthorityAxis">Income Tax Authority [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:title="label: IncomeTaxAuthorityAxis to us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">Granted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:title="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xml:lang="en-US" id="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">Options Exercisable, Number of Shares (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:title="label: SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 to us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:title="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xml:lang="en-US" id="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">Options Outstanding, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:title="label: SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 to us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl1" xml:lang="en-US" id="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl1">Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl1" xlink:title="label: SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 to us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">Exercisable, end of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl1" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">Exercised (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:label="DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:title="DeferredTaxAssetsNetOfValuationAllowanceAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract">Deferred Tax Assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:title="label: DeferredTaxAssetsNetOfValuationAllowanceAbstract to us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="SharePrice" xlink:title="SharePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_SharePrice" xml:lang="en-US" id="us-gaap_SharePrice">Closing price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharePrice" xlink:to="us-gaap_SharePrice" xlink:title="label: SharePrice to us-gaap_SharePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharePrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharePrice1" xml:lang="en-US" id="us-gaap_SharePrice1">Share price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharePrice" xlink:to="us-gaap_SharePrice1" xlink:title="label: SharePrice to us-gaap_SharePrice1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharePrice2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SharePrice2" xml:lang="en-US" id="us-gaap_SharePrice2">Minimum closing price of common stock (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharePrice" xlink:to="us-gaap_SharePrice2" xlink:title="label: SharePrice to us-gaap_SharePrice2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="FinancialInstrumentAxis" xlink:title="FinancialInstrumentAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FinancialInstrumentAxis" xml:lang="en-US" id="us-gaap_FinancialInstrumentAxis">Financial Instrument [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis" xlink:title="label: FinancialInstrumentAxis to us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="TemporaryEquityCarryingAmountAttributableToParent" xlink:title="TemporaryEquityCarryingAmountAttributableToParent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xml:lang="en-US" id="us-gaap_TemporaryEquityCarryingAmountAttributableToParent">Series C 6% super dividend redeemable convertible preferred stock; 1,000 shares authorized, 176 issued and outstanding at December 31, 2024 and 2023, redemption value: $8,018,000, liquidation value: $1,760,000 at December 31, 2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:title="label: TemporaryEquityCarryingAmountAttributableToParent to us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_TemporaryEquityCarryingAmountAttributableToParent1" xml:lang="en-US" id="us-gaap_TemporaryEquityCarryingAmountAttributableToParent1">Beginning balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent1" xlink:title="label: TemporaryEquityCarryingAmountAttributableToParent to us-gaap_TemporaryEquityCarryingAmountAttributableToParent1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent2" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_TemporaryEquityCarryingAmountAttributableToParent2" xml:lang="en-US" id="us-gaap_TemporaryEquityCarryingAmountAttributableToParent2">Ending balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent2" xlink:title="label: TemporaryEquityCarryingAmountAttributableToParent to us-gaap_TemporaryEquityCarryingAmountAttributableToParent2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">Weighted Average Exercise Price [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">Granted (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">Exercised (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">Forfeited/cancelled (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:title="label: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PlanNameAxis" xml:lang="en-US" id="us-gaap_PlanNameAxis">Plan Name [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlanNameAxis" xlink:to="us-gaap_PlanNameAxis" xlink:title="label: PlanNameAxis to us-gaap_PlanNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PlanNameDomain" xml:lang="en-US" id="us-gaap_PlanNameDomain">Plan Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlanNameDomain" xlink:to="us-gaap_PlanNameDomain" xlink:title="label: PlanNameDomain to us-gaap_PlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AwardTypeAxis" xml:lang="en-US" id="us-gaap_AwardTypeAxis">Award Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis" xlink:title="label: AwardTypeAxis to us-gaap_AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventMember" xml:lang="en-US" id="us-gaap_SubsequentEventMember">Subsequent Event [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember" xlink:title="label: SubsequentEventMember to us-gaap_SubsequentEventMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeStatementLocationAxis" xml:lang="en-US" id="us-gaap_IncomeStatementLocationAxis">Statement of Income Location, Balance [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:title="label: IncomeStatementLocationAxis to us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeStatementLocationDomain" xml:lang="en-US" id="us-gaap_IncomeStatementLocationDomain">Statement of Income Location, Balance [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:title="label: IncomeStatementLocationDomain to us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" xlink:label="DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" xlink:title="DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" xml:lang="en-US" id="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense">Stock based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" xlink:title="label: DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense to us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense_lbl1" xml:lang="en-US" id="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense_lbl1">Deferred Compensation Arrangement with Individual, Allocated Share-Based Compensation Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense_lbl1" xlink:title="label: DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense to us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="PreferredStockLiquidationPreferenceValue" xlink:title="PreferredStockLiquidationPreferenceValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockLiquidationPreferenceValue" xml:lang="en-US" id="us-gaap_PreferredStockLiquidationPreferenceValue">Series A 12% convertible preferred stock, liquidation value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockLiquidationPreferenceValue" xlink:to="us-gaap_PreferredStockLiquidationPreferenceValue" xlink:title="label: PreferredStockLiquidationPreferenceValue to us-gaap_PreferredStockLiquidationPreferenceValue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US" id="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">Recent Accounting Standards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="label: NewAccountingPronouncementsPolicyPolicyTextBlock to us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="ConcentrationRiskCreditRisk" xlink:title="ConcentrationRiskCreditRisk" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US" id="us-gaap_ConcentrationRiskCreditRisk">Concentration of Credit Risk</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk" xlink:title="label: ConcentrationRiskCreditRisk to us-gaap_ConcentrationRiskCreditRisk" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConcentrationRiskCreditRisk_lbl1" xml:lang="en-US" id="us-gaap_ConcentrationRiskCreditRisk_lbl1">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl1" xlink:title="label: ConcentrationRiskCreditRisk to us-gaap_ConcentrationRiskCreditRisk_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="CreditFacilityAxis" xlink:title="CreditFacilityAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CreditFacilityAxis" xml:lang="en-US" id="us-gaap_CreditFacilityAxis">Credit Facility [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis" xlink:title="label: CreditFacilityAxis to us-gaap_CreditFacilityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="CreditFacilityDomain" xlink:title="CreditFacilityDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CreditFacilityDomain" xml:lang="en-US" id="us-gaap_CreditFacilityDomain">Credit Facility [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain" xlink:title="label: CreditFacilityDomain to us-gaap_CreditFacilityDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="PropertyPlantAndEquipmentUsefulLife" xlink:title="PropertyPlantAndEquipmentUsefulLife" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentUsefulLife">Estimated useful life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:title="label: PropertyPlantAndEquipmentUsefulLife to us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">Exercisable, end of the period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">Expected life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm2" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm2">Expected life of the options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm2" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">Unrecognized compensation cost, recognition period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="label: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:title="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xml:lang="en-US" id="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">Outstanding end of the period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:title="label: SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 to us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm3" xml:lang="en-US" id="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm3">Options Outstanding, Weighted Average Remaining Contractual Life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm3" xlink:title="label: SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 to us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="NumberOfOperatingSegments" xlink:title="NumberOfOperatingSegments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_NumberOfOperatingSegments" xml:lang="en-US" id="us-gaap_NumberOfOperatingSegments">Number of operating segment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments" xlink:title="label: NumberOfOperatingSegments to us-gaap_NumberOfOperatingSegments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NumberOfOperatingSegments_lbl1" xml:lang="en-US" id="us-gaap_NumberOfOperatingSegments_lbl1">Number of Operating Segments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl1" xlink:title="label: NumberOfOperatingSegments to us-gaap_NumberOfOperatingSegments_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="FairValueMeasurementPolicyPolicyTextBlock" xlink:title="FairValueMeasurementPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xml:lang="en-US" id="us-gaap_FairValueMeasurementPolicyPolicyTextBlock">Fair Value Measurements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:title="label: FairValueMeasurementPolicyPolicyTextBlock to us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl1">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl1" xlink:title="label: FairValueMeasurementPolicyPolicyTextBlock to us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="DebtInstrumentConvertibleConversionPrice1" xlink:title="DebtInstrumentConvertibleConversionPrice1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentConvertibleConversionPrice1" xml:lang="en-US" id="us-gaap_DebtInstrumentConvertibleConversionPrice1">Conversion price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:title="label: DebtInstrumentConvertibleConversionPrice1 to us-gaap_DebtInstrumentConvertibleConversionPrice1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="DerivativeContractTypeDomain" xlink:title="DerivativeContractTypeDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DerivativeContractTypeDomain" xml:lang="en-US" id="us-gaap_DerivativeContractTypeDomain">Derivative Contract [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeContractTypeDomain" xlink:to="us-gaap_DerivativeContractTypeDomain" xlink:title="label: DerivativeContractTypeDomain to us-gaap_DerivativeContractTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems" xlink:label="InvestmentsInAndAdvancesToAffiliatesLineItems" xlink:title="InvestmentsInAndAdvancesToAffiliatesLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems" xml:lang="en-US" id="us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems">Investments in and Advances to Affiliates [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentsInAndAdvancesToAffiliatesLineItems" xlink:to="us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems" xlink:title="label: InvestmentsInAndAdvancesToAffiliatesLineItems to us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInvestmentsTable" xlink:label="ScheduleOfInvestmentsTable" xlink:title="ScheduleOfInvestmentsTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfInvestmentsTable" xml:lang="en-US" id="us-gaap_ScheduleOfInvestmentsTable">Schedule of Investments [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfInvestmentsTable" xlink:to="us-gaap_ScheduleOfInvestmentsTable" xlink:title="label: ScheduleOfInvestmentsTable to us-gaap_ScheduleOfInvestmentsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="InProcessResearchAndDevelopmentMember" xlink:title="InProcessResearchAndDevelopmentMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InProcessResearchAndDevelopmentMember" xml:lang="en-US" id="us-gaap_InProcessResearchAndDevelopmentMember">IPR&amp;D [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InProcessResearchAndDevelopmentMember" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember" xlink:title="label: InProcessResearchAndDevelopmentMember to us-gaap_InProcessResearchAndDevelopmentMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueNetAssetLiabilityAbstract" xlink:label="FairValueNetAssetLiabilityAbstract" xlink:title="FairValueNetAssetLiabilityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueNetAssetLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueNetAssetLiabilityAbstract" xml:lang="en-US" id="us-gaap_FairValueNetAssetLiabilityAbstract">Assets and Liabilities Measured at Fair Value [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueNetAssetLiabilityAbstract" xlink:to="us-gaap_FairValueNetAssetLiabilityAbstract" xlink:title="label: FairValueNetAssetLiabilityAbstract to us-gaap_FairValueNetAssetLiabilityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">Number of shares issued upon exercise of warrant (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:title="label: ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight to us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="SharesIssuedPricePerShare" xlink:title="SharesIssuedPricePerShare" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SharesIssuedPricePerShare" xml:lang="en-US" id="us-gaap_SharesIssuedPricePerShare">Shares issued, price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare" xlink:title="label: SharesIssuedPricePerShare to us-gaap_SharesIssuedPricePerShare" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharesIssuedPricePerShare_lbl1" xml:lang="en-US" id="us-gaap_SharesIssuedPricePerShare_lbl1">Shares Issued, Price Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl1" xlink:title="label: SharesIssuedPricePerShare to us-gaap_SharesIssuedPricePerShare_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="FairValueAdjustmentOfWarrants" xlink:title="FairValueAdjustmentOfWarrants" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_FairValueAdjustmentOfWarrants" xml:lang="en-US" id="us-gaap_FairValueAdjustmentOfWarrants">Change in fair value of derivatives</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" xlink:title="label: FairValueAdjustmentOfWarrants to us-gaap_FairValueAdjustmentOfWarrants" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FairValueAdjustmentOfWarrants1" xml:lang="en-US" id="us-gaap_FairValueAdjustmentOfWarrants1">Fair Value Adjustment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants1" xlink:title="label: FairValueAdjustmentOfWarrants to us-gaap_FairValueAdjustmentOfWarrants1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueAdjustmentOfWarrants_lbl2" xml:lang="en-US" id="us-gaap_FairValueAdjustmentOfWarrants_lbl2">Fair Value Adjustment of Warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl2" xlink:title="label: FairValueAdjustmentOfWarrants to us-gaap_FairValueAdjustmentOfWarrants_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">Total fair value of options vested</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="DebtInstrumentInterestRateIncreaseDecrease" xlink:title="DebtInstrumentInterestRateIncreaseDecrease" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xml:lang="en-US" id="us-gaap_DebtInstrumentInterestRateIncreaseDecrease">Additional short term borrowing interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentInterestRateIncreaseDecrease" xlink:to="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:title="label: DebtInstrumentInterestRateIncreaseDecrease to us-gaap_DebtInstrumentInterestRateIncreaseDecrease" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm" xlink:label="DebtInstrumentTerm" xlink:title="DebtInstrumentTerm" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentTerm" xml:lang="en-US" id="us-gaap_DebtInstrumentTerm">Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm" xlink:title="label: DebtInstrumentTerm to us-gaap_DebtInstrumentTerm" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="FinancialLiabilitiesFairValueDisclosure" xlink:title="FinancialLiabilitiesFairValueDisclosure" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FinancialLiabilitiesFairValueDisclosure" xml:lang="en-US" id="us-gaap_FinancialLiabilitiesFairValueDisclosure">Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:title="label: FinancialLiabilitiesFairValueDisclosure to us-gaap_FinancialLiabilitiesFairValueDisclosure" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl1" xml:lang="en-US" id="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl1">Financial Liabilities Fair Value Disclosure</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl1" xlink:title="label: FinancialLiabilitiesFairValueDisclosure to us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">Unvested option (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">Options vested (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" xlink:label="DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" xlink:title="DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" xml:lang="en-US" id="us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain">Deferred Bonus and Profit Sharing Arrangement, Individual Contract, Type of Deferred Compensation [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" xlink:to="us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" xlink:title="label: DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain to us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="TaxPeriodAxis" xlink:title="TaxPeriodAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TaxPeriodAxis" xml:lang="en-US" id="us-gaap_TaxPeriodAxis">Tax Period [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis" xlink:title="label: TaxPeriodAxis to us-gaap_TaxPeriodAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="TaxPeriodDomain" xlink:title="TaxPeriodDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TaxPeriodDomain" xml:lang="en-US" id="us-gaap_TaxPeriodDomain">Tax Period [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxPeriodDomain" xlink:to="us-gaap_TaxPeriodDomain" xlink:title="label: TaxPeriodDomain to us-gaap_TaxPeriodDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">Exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="label: ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 to us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2">Exercise price of warrant (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2" xlink:title="label: ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 to us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:title="CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xml:lang="en-US" id="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract">Federal and Sate [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:title="label: CurrentFederalStateAndLocalTaxExpenseBenefitAbstract to us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl1" xml:lang="en-US" id="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl1">Current Federal, State and Local, Tax Expense (Benefit) [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl1" xlink:title="label: CurrentFederalStateAndLocalTaxExpenseBenefitAbstract to us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="OperatingLeaseCost" xlink:title="OperatingLeaseCost" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseCost" xml:lang="en-US" id="us-gaap_OperatingLeaseCost">Lease cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost" xlink:title="label: OperatingLeaseCost to us-gaap_OperatingLeaseCost" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="OperatingLeaseRightOfUseAsset" xlink:title="OperatingLeaseRightOfUseAsset" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US" id="us-gaap_OperatingLeaseRightOfUseAsset">Right to use lease asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" xlink:title="label: OperatingLeaseRightOfUseAsset to us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:title="OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xml:lang="en-US" id="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">Maturity of Operating Lease [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:title="label: OperatingLeaseLiabilitiesPaymentsDueAbstract to us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="LesseeOperatingLeaseDiscountRate" xlink:title="LesseeOperatingLeaseDiscountRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseDiscountRate" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseDiscountRate">Discount rate on present value of lease payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:title="label: LesseeOperatingLeaseDiscountRate to us-gaap_LesseeOperatingLeaseDiscountRate" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="LesseeLeaseDescriptionTable" xlink:title="LesseeLeaseDescriptionTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeLeaseDescriptionTable" xml:lang="en-US" id="us-gaap_LesseeLeaseDescriptionTable">Lessee, Lease, Description [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable" xlink:title="label: LesseeLeaseDescriptionTable to us-gaap_LesseeLeaseDescriptionTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="LesseeLeaseDescriptionLineItems" xlink:title="LesseeLeaseDescriptionLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeLeaseDescriptionLineItems" xml:lang="en-US" id="us-gaap_LesseeLeaseDescriptionLineItems">Lessee, Lease, Description [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" xlink:title="label: LesseeLeaseDescriptionLineItems to us-gaap_LesseeLeaseDescriptionLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:label="LesseeOperatingLeaseDescriptionAbstract" xlink:title="LesseeOperatingLeaseDescriptionAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseDescriptionAbstract" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseDescriptionAbstract">Lease Commitments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseDescriptionAbstract" xlink:to="us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:title="label: LesseeOperatingLeaseDescriptionAbstract to us-gaap_LesseeOperatingLeaseDescriptionAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect1" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect1">Amount expanded in cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect1" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">CASH AND CASH EQUIVALENTS, END OF PERIOD</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents1" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents1">CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents1" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDue to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl1">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl1" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDue to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">2025</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueYearTwo to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:title="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">Maturity of Operating Lease</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:title="label: LesseeOperatingLeaseLiabilityMaturityTableTextBlock to us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="OperatingLeaseLiability" xlink:title="OperatingLeaseLiability" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_OperatingLeaseLiability" xml:lang="en-US" id="us-gaap_OperatingLeaseLiability">Present value of lease liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability" xlink:title="label: OperatingLeaseLiability to us-gaap_OperatingLeaseLiability" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseLiability_lbl1" xml:lang="en-US" id="us-gaap_OperatingLeaseLiability_lbl1">Operating Lease, Liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl1" xlink:title="label: OperatingLeaseLiability to us-gaap_OperatingLeaseLiability_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="OperatingLeaseLiabilityCurrent" xlink:title="OperatingLeaseLiabilityCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US" id="us-gaap_OperatingLeaseLiabilityCurrent">Lease liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" xlink:title="label: OperatingLeaseLiabilityCurrent to us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseLiabilityCurrent1" xml:lang="en-US" id="us-gaap_OperatingLeaseLiabilityCurrent1">Current lease liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent1" xlink:title="label: OperatingLeaseLiabilityCurrent to us-gaap_OperatingLeaseLiabilityCurrent1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">Less imputed interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="label: LesseeOperatingLeaseLiabilityUndiscountedExcessAmount to us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="OperatingLeaseLiabilityNoncurrent" xlink:title="OperatingLeaseLiabilityNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US" id="us-gaap_OperatingLeaseLiabilityNoncurrent">Non-current lease liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:title="label: OperatingLeaseLiabilityNoncurrent to us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:title="OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xml:lang="en-US" id="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:title="label: OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList to us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList1" xml:lang="en-US" id="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList1">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList1" xlink:title="label: OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList to us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:title="OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xml:lang="en-US" id="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:title="label: OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList to us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:label="OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:title="OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xml:lang="en-US" id="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:title="label: OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList to us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesAbstract" xlink:label="InvestmentsInAndAdvancesToAffiliatesAbstract" xlink:title="InvestmentsInAndAdvancesToAffiliatesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InvestmentsInAndAdvancesToAffiliatesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InvestmentsInAndAdvancesToAffiliatesAbstract" xml:lang="en-US" id="us-gaap_InvestmentsInAndAdvancesToAffiliatesAbstract">Galectin Sciences LLC [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentsInAndAdvancesToAffiliatesAbstract" xlink:to="us-gaap_InvestmentsInAndAdvancesToAffiliatesAbstract" xlink:title="label: InvestmentsInAndAdvancesToAffiliatesAbstract to us-gaap_InvestmentsInAndAdvancesToAffiliatesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="MeasurementInputTypeAxis" xlink:title="MeasurementInputTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MeasurementInputTypeAxis" xml:lang="en-US" id="us-gaap_MeasurementInputTypeAxis">Measurement Input Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis" xlink:title="label: MeasurementInputTypeAxis to us-gaap_MeasurementInputTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputConversionPriceMember" xlink:label="MeasurementInputConversionPriceMember" xlink:title="MeasurementInputConversionPriceMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MeasurementInputConversionPriceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MeasurementInputConversionPriceMember" xml:lang="en-US" id="us-gaap_MeasurementInputConversionPriceMember">Conversion Price of Conversion Feature [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MeasurementInputConversionPriceMember" xlink:to="us-gaap_MeasurementInputConversionPriceMember" xlink:title="label: MeasurementInputConversionPriceMember to us-gaap_MeasurementInputConversionPriceMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="MeasurementInputDiscountRateMember" xlink:title="MeasurementInputDiscountRateMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MeasurementInputDiscountRateMember" xml:lang="en-US" id="us-gaap_MeasurementInputDiscountRateMember">Credit Adjusted Discount Rate [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MeasurementInputDiscountRateMember" xlink:to="us-gaap_MeasurementInputDiscountRateMember" xlink:title="label: MeasurementInputDiscountRateMember to us-gaap_MeasurementInputDiscountRateMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="MeasurementInputExpectedDividendRateMember" xlink:title="MeasurementInputExpectedDividendRateMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MeasurementInputExpectedDividendRateMember" xml:lang="en-US" id="us-gaap_MeasurementInputExpectedDividendRateMember">Dividend Rate [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:title="label: MeasurementInputExpectedDividendRateMember to us-gaap_MeasurementInputExpectedDividendRateMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="MeasurementInputExpectedTermMember" xlink:title="MeasurementInputExpectedTermMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MeasurementInputExpectedTermMember" xml:lang="en-US" id="us-gaap_MeasurementInputExpectedTermMember">Term [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember" xlink:title="label: MeasurementInputExpectedTermMember to us-gaap_MeasurementInputExpectedTermMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="MeasurementInputPriceVolatilityMember" xlink:title="MeasurementInputPriceVolatilityMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MeasurementInputPriceVolatilityMember" xml:lang="en-US" id="us-gaap_MeasurementInputPriceVolatilityMember">Volatility [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" xlink:title="label: MeasurementInputPriceVolatilityMember to us-gaap_MeasurementInputPriceVolatilityMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="MeasurementInputRiskFreeInterestRateMember" xlink:title="MeasurementInputRiskFreeInterestRateMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MeasurementInputRiskFreeInterestRateMember" xml:lang="en-US" id="us-gaap_MeasurementInputRiskFreeInterestRateMember">Risk Free Interest Rate [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:title="label: MeasurementInputRiskFreeInterestRateMember to us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="MeasurementInputSharePriceMember" xlink:title="MeasurementInputSharePriceMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MeasurementInputSharePriceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MeasurementInputSharePriceMember" xml:lang="en-US" id="us-gaap_MeasurementInputSharePriceMember">Stock Price [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MeasurementInputSharePriceMember" xlink:to="us-gaap_MeasurementInputSharePriceMember" xlink:title="label: MeasurementInputSharePriceMember to us-gaap_MeasurementInputSharePriceMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="MeasurementInputTypeDomain" xlink:title="MeasurementInputTypeDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MeasurementInputTypeDomain" xml:lang="en-US" id="us-gaap_MeasurementInputTypeDomain">Measurement Input Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain" xlink:title="label: MeasurementInputTypeDomain to us-gaap_MeasurementInputTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueAndInputDescriptionAbstract" xlink:label="ValuationTechniqueAndInputDescriptionAbstract" xlink:title="ValuationTechniqueAndInputDescriptionAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ValuationTechniqueAndInputDescriptionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ValuationTechniqueAndInputDescriptionAbstract" xml:lang="en-US" id="us-gaap_ValuationTechniqueAndInputDescriptionAbstract">Key Assumptions [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ValuationTechniqueAndInputDescriptionAbstract" xlink:to="us-gaap_ValuationTechniqueAndInputDescriptionAbstract" xlink:title="label: ValuationTechniqueAndInputDescriptionAbstract to us-gaap_ValuationTechniqueAndInputDescriptionAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="DerivativeLiabilityMeasurementInput" xlink:title="DerivativeLiabilityMeasurementInput" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DerivativeLiabilityMeasurementInput" xml:lang="en-US" id="us-gaap_DerivativeLiabilityMeasurementInput">Derivative liability, measurement input</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeLiabilityMeasurementInput" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput" xlink:title="label: DerivativeLiabilityMeasurementInput to us-gaap_DerivativeLiabilityMeasurementInput" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DerivativeLiabilityMeasurementInput_lbl1" xml:lang="en-US" id="us-gaap_DerivativeLiabilityMeasurementInput_lbl1">Derivative Liability, Measurement Input</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeLiabilityMeasurementInput" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput_lbl1" xlink:title="label: DerivativeLiabilityMeasurementInput to us-gaap_DerivativeLiabilityMeasurementInput_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="LesseeOperatingLeaseTermOfContract" xlink:title="LesseeOperatingLeaseTermOfContract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseTermOfContract" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseTermOfContract">Term of contract</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:title="label: LesseeOperatingLeaseTermOfContract to us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="LesseeOperatingLeaseRenewalTerm" xlink:title="LesseeOperatingLeaseRenewalTerm" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LesseeOperatingLeaseRenewalTerm" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseRenewalTerm">Lease renewal term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:title="label: LesseeOperatingLeaseRenewalTerm to us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl1">Lessee, Operating Lease, Renewal Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl1" xlink:title="label: LesseeOperatingLeaseRenewalTerm to us-gaap_LesseeOperatingLeaseRenewalTerm_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel12And3Member" xlink:label="FairValueInputsLevel12And3Member" xlink:title="FairValueInputsLevel12And3Member" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel12And3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueInputsLevel12And3Member" xml:lang="en-US" id="us-gaap_FairValueInputsLevel12And3Member">Fair Value, Inputs, Level 1, 2 and 3 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel12And3Member" xlink:to="us-gaap_FairValueInputsLevel12And3Member" xlink:title="label: FairValueInputsLevel12And3Member to us-gaap_FairValueInputsLevel12And3Member" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="WarrantsAndRightsOutstandingTerm" xlink:title="WarrantsAndRightsOutstandingTerm" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_WarrantsAndRightsOutstandingTerm" xml:lang="en-US" id="us-gaap_WarrantsAndRightsOutstandingTerm">Weighted average expiration term of warrants outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:title="label: WarrantsAndRightsOutstandingTerm to us-gaap_WarrantsAndRightsOutstandingTerm" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WarrantsAndRightsOutstandingTerm_lbl1" xml:lang="en-US" id="us-gaap_WarrantsAndRightsOutstandingTerm_lbl1">Warrants and Rights Outstanding, Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl1" xlink:title="label: WarrantsAndRightsOutstandingTerm to us-gaap_WarrantsAndRightsOutstandingTerm_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="WarrantsAndRightsOutstandingMaturityDate" xlink:title="WarrantsAndRightsOutstandingMaturityDate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xml:lang="en-US" id="us-gaap_WarrantsAndRightsOutstandingMaturityDate">Warrants expiry date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:title="label: WarrantsAndRightsOutstandingMaturityDate to us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:title="OperatingLeaseRightOfUseAssetAmortizationExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xml:lang="en-US" id="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">Amortization of right to use asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:title="label: OperatingLeaseRightOfUseAssetAmortizationExpense to us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentLongLivedAssetHeldForUseAbstract" xlink:label="ImpairmentLongLivedAssetHeldForUseAbstract" xlink:title="ImpairmentLongLivedAssetHeldForUseAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ImpairmentLongLivedAssetHeldForUseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ImpairmentLongLivedAssetHeldForUseAbstract" xml:lang="en-US" id="us-gaap_ImpairmentLongLivedAssetHeldForUseAbstract">Long-Lived Assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ImpairmentLongLivedAssetHeldForUseAbstract" xlink:to="us-gaap_ImpairmentLongLivedAssetHeldForUseAbstract" xlink:title="label: ImpairmentLongLivedAssetHeldForUseAbstract to us-gaap_ImpairmentLongLivedAssetHeldForUseAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="InterestExpenseNonoperating" xlink:title="InterestExpenseNonoperating" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_InterestExpenseNonoperating" xml:lang="en-US" id="us-gaap_InterestExpenseNonoperating">Interest expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating" xlink:title="label: InterestExpenseNonoperating to us-gaap_InterestExpenseNonoperating" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestExpenseNonoperating_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InterestExpenseNonoperating_lbl1" xml:lang="en-US" id="us-gaap_InterestExpenseNonoperating_lbl1">Interest Expense, Nonoperating</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_lbl1" xlink:title="label: InterestExpenseNonoperating to us-gaap_InterestExpenseNonoperating_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:label xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US" id="srt_TitleOfIndividualWithRelationshipToEntityDomain">Title and Position [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="label: TitleOfIndividualWithRelationshipToEntityDomain to srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="BoardOfDirectorsChairmanMember" xlink:title="BoardOfDirectorsChairmanMember" />
    <link:label xlink:type="resource" xlink:label="srt_BoardOfDirectorsChairmanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_BoardOfDirectorsChairmanMember" xml:lang="en-US" id="srt_BoardOfDirectorsChairmanMember">Richard E. Uihlein [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BoardOfDirectorsChairmanMember" xlink:to="srt_BoardOfDirectorsChairmanMember" xlink:title="label: BoardOfDirectorsChairmanMember to srt_BoardOfDirectorsChairmanMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="ChiefExecutiveOfficerMember" xlink:title="ChiefExecutiveOfficerMember" />
    <link:label xlink:type="resource" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_ChiefExecutiveOfficerMember" xml:lang="en-US" id="srt_ChiefExecutiveOfficerMember">Chief Executive Officer [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember" xlink:title="label: ChiefExecutiveOfficerMember to srt_ChiefExecutiveOfficerMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:label xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_ScenarioUnspecifiedDomain" xml:lang="en-US" id="srt_ScenarioUnspecifiedDomain">Scenario [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:title="label: ScenarioUnspecifiedDomain to srt_ScenarioUnspecifiedDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="ScenarioForecastMember" xlink:title="ScenarioForecastMember" />
    <link:label xlink:type="resource" xlink:label="srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_ScenarioForecastMember" xml:lang="en-US" id="srt_ScenarioForecastMember">Forecast [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember" xlink:title="label: ScenarioForecastMember to srt_ScenarioForecastMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:label xlink:type="resource" xlink:label="srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_StatementScenarioAxis" xml:lang="en-US" id="srt_StatementScenarioAxis">Scenario [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis" xlink:title="label: StatementScenarioAxis to srt_StatementScenarioAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:label xlink:type="resource" xlink:label="srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_RangeAxis" xml:lang="en-US" id="srt_RangeAxis">Statistical Measurement [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeAxis" xlink:to="srt_RangeAxis" xlink:title="label: RangeAxis to srt_RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:label xlink:type="resource" xlink:label="srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_RangeMember" xml:lang="en-US" id="srt_RangeMember">Statistical Measurement [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeMember" xlink:to="srt_RangeMember" xlink:title="label: RangeMember to srt_RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:label xlink:type="resource" xlink:label="srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_MaximumMember" xml:lang="en-US" id="srt_MaximumMember">Maximum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumMember" xlink:to="srt_MaximumMember" xlink:title="label: MaximumMember to srt_MaximumMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:label xlink:type="resource" xlink:label="srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_MinimumMember" xml:lang="en-US" id="srt_MinimumMember">Minimum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinimumMember" xlink:to="srt_MinimumMember" xlink:title="label: MinimumMember to srt_MinimumMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="CounterpartyNameAxis" xlink:title="CounterpartyNameAxis" />
    <link:label xlink:type="resource" xlink:label="srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_CounterpartyNameAxis" xml:lang="en-US" id="srt_CounterpartyNameAxis">Counterparty Name [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis" xlink:title="label: CounterpartyNameAxis to srt_CounterpartyNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain" xlink:title="RepurchaseAgreementCounterpartyNameDomain" />
    <link:label xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain" xml:lang="en-US" id="srt_RepurchaseAgreementCounterpartyNameDomain">Counterparty Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:title="label: RepurchaseAgreementCounterpartyNameDomain to srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:label xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_TitleOfIndividualAxis" xml:lang="en-US" id="srt_TitleOfIndividualAxis">Title and Position [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis" xlink:title="label: TitleOfIndividualAxis to srt_TitleOfIndividualAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis" xlink:label="OwnershipAxis" xlink:title="OwnershipAxis" />
    <link:label xlink:type="resource" xlink:label="srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_OwnershipAxis" xml:lang="en-US" id="srt_OwnershipAxis">Ownership [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OwnershipAxis" xlink:to="srt_OwnershipAxis" xlink:title="label: OwnershipAxis to srt_OwnershipAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain" xlink:label="OwnershipDomain" xlink:title="OwnershipDomain" />
    <link:label xlink:type="resource" xlink:label="srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_OwnershipDomain" xml:lang="en-US" id="srt_OwnershipDomain">Ownership [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OwnershipDomain" xlink:to="srt_OwnershipDomain" xlink:title="label: OwnershipDomain to srt_OwnershipDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:title="CybersecurityRiskManagementStrategyAndGovernanceAbstract" />
    <link:label xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xml:lang="en-US" id="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:title="label: CybersecurityRiskManagementStrategyAndGovernanceAbstract to cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:title="CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" />
    <link:label xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xml:lang="en-US" id="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:title="label: CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock to cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="CybersecurityRiskManagementProcessesIntegratedFlag" xlink:title="CybersecurityRiskManagementProcessesIntegratedFlag" />
    <link:label xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xml:lang="en-US" id="cyd_CybersecurityRiskManagementProcessesIntegratedFlag">Cybersecurity Risk Management Processes Integrated [Flag]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:title="label: CybersecurityRiskManagementProcessesIntegratedFlag to cyd_CybersecurityRiskManagementProcessesIntegratedFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:title="CybersecurityRiskManagementProcessesIntegratedTextBlock" />
    <link:label xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xml:lang="en-US" id="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">Cybersecurity Risk Management Processes Integrated [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:title="label: CybersecurityRiskManagementProcessesIntegratedTextBlock to cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:title="CybersecurityRiskManagementThirdPartyEngagedFlag" />
    <link:label xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xml:lang="en-US" id="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">Cybersecurity Risk Management Third Party Engaged [Flag]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:title="label: CybersecurityRiskManagementThirdPartyEngagedFlag to cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:title="CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" />
    <link:label xlink:type="resource" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xml:lang="en-US" id="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:title="label: CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag to cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:title="CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" />
    <link:label xlink:type="resource" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xml:lang="en-US" id="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:title="label: CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag to cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:title="CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" />
    <link:label xlink:type="resource" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xml:lang="en-US" id="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:title="label: CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock to cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:title="CybersecurityRiskBoardOfDirectorsOversightTextBlock" />
    <link:label xlink:type="resource" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xml:lang="en-US" id="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">Cybersecurity Risk Board of Directors Oversight [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:title="label: CybersecurityRiskBoardOfDirectorsOversightTextBlock to cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:title="CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
    <link:label xlink:type="resource" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xml:lang="en-US" id="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:title="label: CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock to cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:title="CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
    <link:label xlink:type="resource" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xml:lang="en-US" id="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:title="label: CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock to cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="CybersecurityRiskRoleOfManagementTextBlock" xlink:title="CybersecurityRiskRoleOfManagementTextBlock" />
    <link:label xlink:type="resource" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="cyd_CybersecurityRiskRoleOfManagementTextBlock" xml:lang="en-US" id="cyd_CybersecurityRiskRoleOfManagementTextBlock">Cybersecurity Risk Role of Management [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:title="label: CybersecurityRiskRoleOfManagementTextBlock to cyd_CybersecurityRiskRoleOfManagementTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:title="CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" />
    <link:label xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xml:lang="en-US" id="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:title="label: CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag to cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:title="CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" />
    <link:label xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xml:lang="en-US" id="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:title="label: CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock to cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:title="CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" />
    <link:label xlink:type="resource" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xml:lang="en-US" id="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:title="label: CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock to cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:title="CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" />
    <link:label xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xml:lang="en-US" id="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:title="label: CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag to cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract" xml:lang="en-US" id="dei_CoverAbstract">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract" xlink:title="label: CoverAbstract to dei_CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType" xml:lang="en-US" id="dei_DocumentType">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType" xlink:title="label: DocumentType to dei_DocumentType" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="DocumentAnnualReport" xlink:title="DocumentAnnualReport" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentAnnualReport" xml:lang="en-US" id="dei_DocumentAnnualReport">Document Annual Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport" xlink:title="label: DocumentAnnualReport to dei_DocumentAnnualReport" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="DocumentTransitionReport" xlink:title="DocumentTransitionReport" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentTransitionReport" xml:lang="en-US" id="dei_DocumentTransitionReport">Document Transition Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport" xlink:title="label: DocumentTransitionReport to dei_DocumentTransitionReport" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="DocumentFinStmtErrorCorrectionFlag" xlink:title="DocumentFinStmtErrorCorrectionFlag" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFinStmtErrorCorrectionFlag" xml:lang="en-US" id="dei_DocumentFinStmtErrorCorrectionFlag">Document Financial Statement Error Correction [Flag]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" xlink:title="label: DocumentFinStmtErrorCorrectionFlag to dei_DocumentFinStmtErrorCorrectionFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="EntityInteractiveDataCurrent" xlink:title="EntityInteractiveDataCurrent" />
    <link:label xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityInteractiveDataCurrent" xml:lang="en-US" id="dei_EntityInteractiveDataCurrent">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent" xlink:title="label: EntityInteractiveDataCurrent to dei_EntityInteractiveDataCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag" xml:lang="en-US" id="dei_AmendmentFlag">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag" xlink:title="label: AmendmentFlag to dei_AmendmentFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="IcfrAuditorAttestationFlag" xlink:title="IcfrAuditorAttestationFlag" />
    <link:label xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_IcfrAuditorAttestationFlag" xml:lang="en-US" id="dei_IcfrAuditorAttestationFlag">ICFR Auditor Attestation Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag" xlink:title="label: IcfrAuditorAttestationFlag to dei_IcfrAuditorAttestationFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus" xml:lang="en-US" id="dei_DocumentFiscalYearFocus">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate" xml:lang="en-US" id="dei_DocumentPeriodEndDate">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName" xml:lang="en-US" id="dei_EntityRegistrantName">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey" xml:lang="en-US" id="dei_EntityCentralIndexKey">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFileNumber" xml:lang="en-US" id="dei_EntityFileNumber">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFileNumber" xlink:to="dei_EntityFileNumber" xlink:title="label: EntityFileNumber to dei_EntityFileNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityTaxIdentificationNumber" xml:lang="en-US" id="dei_EntityTaxIdentificationNumber">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber" xlink:title="label: EntityTaxIdentificationNumber to dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityIncorporationStateCountryCode" xml:lang="en-US" id="dei_EntityIncorporationStateCountryCode">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:title="label: EntityIncorporationStateCountryCode to dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="CurrentFiscalYearEndDate" xlink:title="CurrentFiscalYearEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CurrentFiscalYearEndDate" xml:lang="en-US" id="dei_CurrentFiscalYearEndDate">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate" xlink:title="label: CurrentFiscalYearEndDate to dei_CurrentFiscalYearEndDate" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="EntityWellKnownSeasonedIssuer" xlink:title="EntityWellKnownSeasonedIssuer" />
    <link:label xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityWellKnownSeasonedIssuer" xml:lang="en-US" id="dei_EntityWellKnownSeasonedIssuer">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer" xlink:title="label: EntityWellKnownSeasonedIssuer to dei_EntityWellKnownSeasonedIssuer" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="EntityVoluntaryFilers" xlink:title="EntityVoluntaryFilers" />
    <link:label xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityVoluntaryFilers" xml:lang="en-US" id="dei_EntityVoluntaryFilers">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers" xlink:title="label: EntityVoluntaryFilers to dei_EntityVoluntaryFilers" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="EntityCurrentReportingStatus" xlink:title="EntityCurrentReportingStatus" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCurrentReportingStatus" xml:lang="en-US" id="dei_EntityCurrentReportingStatus">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus" xlink:title="label: EntityCurrentReportingStatus to dei_EntityCurrentReportingStatus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="EntityShellCompany" xlink:title="EntityShellCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityShellCompany" xml:lang="en-US" id="dei_EntityShellCompany">Entity Shell Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityShellCompany" xlink:to="dei_EntityShellCompany" xlink:title="label: EntityShellCompany to dei_EntityShellCompany" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="EntityFilerCategory" xlink:title="EntityFilerCategory" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFilerCategory" xml:lang="en-US" id="dei_EntityFilerCategory">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFilerCategory" xlink:to="dei_EntityFilerCategory" xlink:title="label: EntityFilerCategory to dei_EntityFilerCategory" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="EntitySmallBusiness" xlink:title="EntitySmallBusiness" />
    <link:label xlink:type="resource" xlink:label="dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntitySmallBusiness" xml:lang="en-US" id="dei_EntitySmallBusiness">Entity Small Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness" xlink:title="label: EntitySmallBusiness to dei_EntitySmallBusiness" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="EntityPublicFloat" xlink:title="EntityPublicFloat" />
    <link:label xlink:type="resource" xlink:label="dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityPublicFloat" xml:lang="en-US" id="dei_EntityPublicFloat">Entity Public Float</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityPublicFloat" xlink:to="dei_EntityPublicFloat" xlink:title="label: EntityPublicFloat to dei_EntityPublicFloat" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine1" xml:lang="en-US" id="dei_EntityAddressAddressLine1">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1" xlink:title="label: EntityAddressAddressLine1 to dei_EntityAddressAddressLine1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine2" xml:lang="en-US" id="dei_EntityAddressAddressLine2">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2" xlink:title="label: EntityAddressAddressLine2 to dei_EntityAddressAddressLine2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCityOrTown" xml:lang="en-US" id="dei_EntityAddressCityOrTown">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown" xlink:title="label: EntityAddressCityOrTown to dei_EntityAddressCityOrTown" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressStateOrProvince" xml:lang="en-US" id="dei_EntityAddressStateOrProvince">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince" xlink:title="label: EntityAddressStateOrProvince to dei_EntityAddressStateOrProvince" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressPostalZipCode" xml:lang="en-US" id="dei_EntityAddressPostalZipCode">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode" xlink:title="label: EntityAddressPostalZipCode to dei_EntityAddressPostalZipCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:label xlink:type="resource" xlink:label="dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CityAreaCode" xml:lang="en-US" id="dei_CityAreaCode">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CityAreaCode" xlink:to="dei_CityAreaCode" xlink:title="label: CityAreaCode to dei_CityAreaCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:label xlink:type="resource" xlink:label="dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LocalPhoneNumber" xml:lang="en-US" id="dei_LocalPhoneNumber">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber" xlink:title="label: LocalPhoneNumber to dei_LocalPhoneNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:label xlink:type="resource" xlink:label="dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_Security12bTitle" xml:lang="en-US" id="dei_Security12bTitle">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Security12bTitle" xlink:to="dei_Security12bTitle" xlink:title="label: Security12bTitle to dei_Security12bTitle" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_TradingSymbol" xml:lang="en-US" id="dei_TradingSymbol">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingSymbol" xlink:to="dei_TradingSymbol" xlink:title="label: TradingSymbol to dei_TradingSymbol" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:label xlink:type="resource" xlink:label="dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SecurityExchangeName" xml:lang="en-US" id="dei_SecurityExchangeName">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityExchangeName" xlink:to="dei_SecurityExchangeName" xlink:title="label: SecurityExchangeName to dei_SecurityExchangeName" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="EntityCommonStockSharesOutstanding" xlink:title="EntityCommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCommonStockSharesOutstanding" xml:lang="en-US" id="dei_EntityCommonStockSharesOutstanding">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:title="label: EntityCommonStockSharesOutstanding to dei_EntityCommonStockSharesOutstanding" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="AuditorName" xlink:title="AuditorName" />
    <link:label xlink:type="resource" xlink:label="dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AuditorName" xml:lang="en-US" id="dei_AuditorName">Auditor Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AuditorName" xlink:to="dei_AuditorName" xlink:title="label: AuditorName to dei_AuditorName" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="AuditorFirmId" xlink:title="AuditorFirmId" />
    <link:label xlink:type="resource" xlink:label="dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AuditorFirmId" xml:lang="en-US" id="dei_AuditorFirmId">Auditor Firm ID</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AuditorFirmId" xlink:to="dei_AuditorFirmId" xlink:title="label: AuditorFirmId to dei_AuditorFirmId" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="AuditorLocation" xlink:title="AuditorLocation" />
    <link:label xlink:type="resource" xlink:label="dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AuditorLocation" xml:lang="en-US" id="dei_AuditorLocation">Auditor Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AuditorLocation" xlink:to="dei_AuditorLocation" xlink:title="label: AuditorLocation to dei_AuditorLocation" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_AccruedResearchAndDevelopmentCostsAndOtherCurrent" xlink:label="AccruedResearchAndDevelopmentCostsAndOtherCurrent" xlink:title="AccruedResearchAndDevelopmentCostsAndOtherCurrent" />
    <link:label xlink:type="resource" xlink:label="galt_AccruedResearchAndDevelopmentCostsAndOtherCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_AccruedResearchAndDevelopmentCostsAndOtherCurrent_lbl" xml:lang="en-US" id="galt_AccruedResearchAndDevelopmentCostsAndOtherCurrent_lbl">Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development costs and other. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedResearchAndDevelopmentCostsAndOtherCurrent" xlink:to="galt_AccruedResearchAndDevelopmentCostsAndOtherCurrent_lbl" xlink:title="label: AccruedResearchAndDevelopmentCostsAndOtherCurrent to galt_AccruedResearchAndDevelopmentCostsAndOtherCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_AccruedResearchAndDevelopmentCostsAndOtherCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_AccruedResearchAndDevelopmentCostsAndOtherCurrent_lbl1" xml:lang="en-US" id="galt_AccruedResearchAndDevelopmentCostsAndOtherCurrent_lbl1">Accrued Research and Development Costs and Other Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedResearchAndDevelopmentCostsAndOtherCurrent" xlink:to="galt_AccruedResearchAndDevelopmentCostsAndOtherCurrent_lbl1" xlink:title="label: AccruedResearchAndDevelopmentCostsAndOtherCurrent to galt_AccruedResearchAndDevelopmentCostsAndOtherCurrent_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_AccruedResearchAndDevelopmentCostsAndOtherCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_AccruedResearchAndDevelopmentCostsAndOtherCurrent" xml:lang="en-US" id="galt_AccruedResearchAndDevelopmentCostsAndOtherCurrent">Accrued research and development costs and other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedResearchAndDevelopmentCostsAndOtherCurrent" xlink:to="galt_AccruedResearchAndDevelopmentCostsAndOtherCurrent" xlink:title="label: AccruedResearchAndDevelopmentCostsAndOtherCurrent to galt_AccruedResearchAndDevelopmentCostsAndOtherCurrent" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingTermAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingTermAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingTermAbstract" />
    <link:label xlink:type="resource" xlink:label="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingTermAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingTermAbstract_lbl1" xml:lang="en-US" id="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingTermAbstract_lbl1">Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Term [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingTermAbstract" xlink:to="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingTermAbstract_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingTermAbstract to galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingTermAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingTermAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingTermAbstract" xml:lang="en-US" id="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingTermAbstract">Weighted Average Remaining Contractual Life [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingTermAbstract" xlink:to="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingTermAbstract" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingTermAbstract to galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingTermAbstract" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" />
    <link:label xlink:type="resource" xlink:label="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl1" xml:lang="en-US" id="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl1">Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract to galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xml:lang="en-US" id="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract">Aggregate Intrinsic Value [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract to galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_OptionsOutstandingAbstract" xlink:label="OptionsOutstandingAbstract" xlink:title="OptionsOutstandingAbstract" />
    <link:label xlink:type="resource" xlink:label="galt_OptionsOutstandingAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_OptionsOutstandingAbstract_lbl1" xml:lang="en-US" id="galt_OptionsOutstandingAbstract_lbl1">Options Outstanding [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OptionsOutstandingAbstract" xlink:to="galt_OptionsOutstandingAbstract_lbl1" xlink:title="label: OptionsOutstandingAbstract to galt_OptionsOutstandingAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_OptionsExercisableAbstract" xlink:label="OptionsExercisableAbstract" xlink:title="OptionsExercisableAbstract" />
    <link:label xlink:type="resource" xlink:label="galt_OptionsExercisableAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_OptionsExercisableAbstract_lbl1" xml:lang="en-US" id="galt_OptionsExercisableAbstract_lbl1">Options Exercisable [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OptionsExercisableAbstract" xlink:to="galt_OptionsExercisableAbstract_lbl1" xlink:title="label: OptionsExercisableAbstract to galt_OptionsExercisableAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ExercisePriceRangeTwoMember" xlink:label="ExercisePriceRangeTwoMember" xlink:title="ExercisePriceRangeTwoMember" />
    <link:label xlink:type="resource" xlink:label="galt_ExercisePriceRangeTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_ExercisePriceRangeTwoMember_lbl" xml:lang="en-US" id="galt_ExercisePriceRangeTwoMember_lbl">Its represented to exercise price range two.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExercisePriceRangeTwoMember" xlink:to="galt_ExercisePriceRangeTwoMember_lbl" xlink:title="label: ExercisePriceRangeTwoMember to galt_ExercisePriceRangeTwoMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_ExercisePriceRangeTwoMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_ExercisePriceRangeTwoMember_lbl1" xml:lang="en-US" id="galt_ExercisePriceRangeTwoMember_lbl1">Exercise Price Range Two [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExercisePriceRangeTwoMember" xlink:to="galt_ExercisePriceRangeTwoMember_lbl1" xlink:title="label: ExercisePriceRangeTwoMember to galt_ExercisePriceRangeTwoMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_ExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_ExercisePriceRangeTwoMember" xml:lang="en-US" id="galt_ExercisePriceRangeTwoMember">$1.01-$3.00 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExercisePriceRangeTwoMember" xlink:to="galt_ExercisePriceRangeTwoMember" xlink:title="label: ExercisePriceRangeTwoMember to galt_ExercisePriceRangeTwoMember" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ExercisePriceRangeThreeMember" xlink:label="ExercisePriceRangeThreeMember" xlink:title="ExercisePriceRangeThreeMember" />
    <link:label xlink:type="resource" xlink:label="galt_ExercisePriceRangeThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_ExercisePriceRangeThreeMember_lbl" xml:lang="en-US" id="galt_ExercisePriceRangeThreeMember_lbl">Its represented to exercise price range three.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExercisePriceRangeThreeMember" xlink:to="galt_ExercisePriceRangeThreeMember_lbl" xlink:title="label: ExercisePriceRangeThreeMember to galt_ExercisePriceRangeThreeMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_ExercisePriceRangeThreeMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_ExercisePriceRangeThreeMember_lbl1" xml:lang="en-US" id="galt_ExercisePriceRangeThreeMember_lbl1">Exercise Price Range Three [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExercisePriceRangeThreeMember" xlink:to="galt_ExercisePriceRangeThreeMember_lbl1" xlink:title="label: ExercisePriceRangeThreeMember to galt_ExercisePriceRangeThreeMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_ExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_ExercisePriceRangeThreeMember" xml:lang="en-US" id="galt_ExercisePriceRangeThreeMember">$3.01-$5.00 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExercisePriceRangeThreeMember" xlink:to="galt_ExercisePriceRangeThreeMember" xlink:title="label: ExercisePriceRangeThreeMember to galt_ExercisePriceRangeThreeMember" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ExercisePriceRangeOneMember" xlink:label="ExercisePriceRangeOneMember" xlink:title="ExercisePriceRangeOneMember" />
    <link:label xlink:type="resource" xlink:label="galt_ExercisePriceRangeOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_ExercisePriceRangeOneMember_lbl" xml:lang="en-US" id="galt_ExercisePriceRangeOneMember_lbl">Its represented to exercise price range one.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExercisePriceRangeOneMember" xlink:to="galt_ExercisePriceRangeOneMember_lbl" xlink:title="label: ExercisePriceRangeOneMember to galt_ExercisePriceRangeOneMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_ExercisePriceRangeOneMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_ExercisePriceRangeOneMember_lbl1" xml:lang="en-US" id="galt_ExercisePriceRangeOneMember_lbl1">Exercise Price Range One [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExercisePriceRangeOneMember" xlink:to="galt_ExercisePriceRangeOneMember_lbl1" xlink:title="label: ExercisePriceRangeOneMember to galt_ExercisePriceRangeOneMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_ExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_ExercisePriceRangeOneMember" xml:lang="en-US" id="galt_ExercisePriceRangeOneMember">$0.87-$1.00 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExercisePriceRangeOneMember" xlink:to="galt_ExercisePriceRangeOneMember" xlink:title="label: ExercisePriceRangeOneMember to galt_ExercisePriceRangeOneMember" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ExercisePriceRangeFourMember" xlink:label="ExercisePriceRangeFourMember" xlink:title="ExercisePriceRangeFourMember" />
    <link:label xlink:type="resource" xlink:label="galt_ExercisePriceRangeFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_ExercisePriceRangeFourMember_lbl" xml:lang="en-US" id="galt_ExercisePriceRangeFourMember_lbl">Its represented to exercise price range four.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExercisePriceRangeFourMember" xlink:to="galt_ExercisePriceRangeFourMember_lbl" xlink:title="label: ExercisePriceRangeFourMember to galt_ExercisePriceRangeFourMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_ExercisePriceRangeFourMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_ExercisePriceRangeFourMember_lbl1" xml:lang="en-US" id="galt_ExercisePriceRangeFourMember_lbl1">Exercise Price Range Four [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExercisePriceRangeFourMember" xlink:to="galt_ExercisePriceRangeFourMember_lbl1" xlink:title="label: ExercisePriceRangeFourMember to galt_ExercisePriceRangeFourMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_ExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_ExercisePriceRangeFourMember" xml:lang="en-US" id="galt_ExercisePriceRangeFourMember">$5.01 - $8.00 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExercisePriceRangeFourMember" xlink:to="galt_ExercisePriceRangeFourMember" xlink:title="label: ExercisePriceRangeFourMember to galt_ExercisePriceRangeFourMember" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ExercisePriceRangeFiveMember" xlink:label="ExercisePriceRangeFiveMember" xlink:title="ExercisePriceRangeFiveMember" />
    <link:label xlink:type="resource" xlink:label="galt_ExercisePriceRangeFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_ExercisePriceRangeFiveMember_lbl" xml:lang="en-US" id="galt_ExercisePriceRangeFiveMember_lbl">Its represented to exercise price range five.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExercisePriceRangeFiveMember" xlink:to="galt_ExercisePriceRangeFiveMember_lbl" xlink:title="label: ExercisePriceRangeFiveMember to galt_ExercisePriceRangeFiveMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_ExercisePriceRangeFiveMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_ExercisePriceRangeFiveMember_lbl1" xml:lang="en-US" id="galt_ExercisePriceRangeFiveMember_lbl1">Exercise Price Range Five [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExercisePriceRangeFiveMember" xlink:to="galt_ExercisePriceRangeFiveMember_lbl1" xlink:title="label: ExercisePriceRangeFiveMember to galt_ExercisePriceRangeFiveMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_ExercisePriceRangeFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_ExercisePriceRangeFiveMember" xml:lang="en-US" id="galt_ExercisePriceRangeFiveMember">$8.01-$13.38 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExercisePriceRangeFiveMember" xlink:to="galt_ExercisePriceRangeFiveMember" xlink:title="label: ExercisePriceRangeFiveMember to galt_ExercisePriceRangeFiveMember" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_FairValueAdjustmentOfWarrant" xlink:label="FairValueAdjustmentOfWarrant" xlink:title="FairValueAdjustmentOfWarrant" />
    <link:label xlink:type="resource" xlink:label="galt_FairValueAdjustmentOfWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_FairValueAdjustmentOfWarrant_lbl" xml:lang="en-US" id="galt_FairValueAdjustmentOfWarrant_lbl">Amount of expense (income) related to adjustment to fair value of warrant liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAdjustmentOfWarrant" xlink:to="galt_FairValueAdjustmentOfWarrant_lbl" xlink:title="label: FairValueAdjustmentOfWarrant to galt_FairValueAdjustmentOfWarrant_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_FairValueAdjustmentOfWarrant_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_FairValueAdjustmentOfWarrant_lbl1" xml:lang="en-US" id="galt_FairValueAdjustmentOfWarrant_lbl1">Fair Value Adjustment of Warrant</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAdjustmentOfWarrant" xlink:to="galt_FairValueAdjustmentOfWarrant_lbl1" xlink:title="label: FairValueAdjustmentOfWarrant to galt_FairValueAdjustmentOfWarrant_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_FairValueAdjustmentOfWarrant" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="galt_FairValueAdjustmentOfWarrant" xml:lang="en-US" id="galt_FairValueAdjustmentOfWarrant">Warrant modification</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAdjustmentOfWarrant" xlink:to="galt_FairValueAdjustmentOfWarrant" xlink:title="label: FairValueAdjustmentOfWarrant to galt_FairValueAdjustmentOfWarrant" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_WarrantsAbstract" xlink:label="WarrantsAbstract" xlink:title="WarrantsAbstract" />
    <link:label xlink:type="resource" xlink:label="galt_WarrantsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_WarrantsAbstract_lbl1" xml:lang="en-US" id="galt_WarrantsAbstract_lbl1">Warrants [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsAbstract" xlink:to="galt_WarrantsAbstract_lbl1" xlink:title="label: WarrantsAbstract to galt_WarrantsAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_WarrantsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_WarrantsAbstract" xml:lang="en-US" id="galt_WarrantsAbstract">Warrants [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsAbstract" xlink:to="galt_WarrantsAbstract" xlink:title="label: WarrantsAbstract to galt_WarrantsAbstract" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_CommonStockWarrantsDisclosureTextBlock" xlink:label="CommonStockWarrantsDisclosureTextBlock" xlink:title="CommonStockWarrantsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="galt_CommonStockWarrantsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_CommonStockWarrantsDisclosureTextBlock_lbl" xml:lang="en-US" id="galt_CommonStockWarrantsDisclosureTextBlock_lbl">The entire disclosure for Equity warrants are instruments that bestow upon the holder of the instrument the right to buy a particular stock at a predetermined price within a stipulated time frame. ... This payment is to be adjusted against the final payment that needs to be paid in case the warrants are exercised.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockWarrantsDisclosureTextBlock" xlink:to="galt_CommonStockWarrantsDisclosureTextBlock_lbl" xlink:title="label: CommonStockWarrantsDisclosureTextBlock to galt_CommonStockWarrantsDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_CommonStockWarrantsDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_CommonStockWarrantsDisclosureTextBlock_lbl1" xml:lang="en-US" id="galt_CommonStockWarrantsDisclosureTextBlock_lbl1">Common Stock Warrants Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockWarrantsDisclosureTextBlock" xlink:to="galt_CommonStockWarrantsDisclosureTextBlock_lbl1" xlink:title="label: CommonStockWarrantsDisclosureTextBlock to galt_CommonStockWarrantsDisclosureTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_CommonStockWarrantsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_CommonStockWarrantsDisclosureTextBlock" xml:lang="en-US" id="galt_CommonStockWarrantsDisclosureTextBlock">Warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockWarrantsDisclosureTextBlock" xlink:to="galt_CommonStockWarrantsDisclosureTextBlock" xlink:title="label: CommonStockWarrantsDisclosureTextBlock to galt_CommonStockWarrantsDisclosureTextBlock" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_RestrictedStockGrantsAbstract" xlink:label="RestrictedStockGrantsAbstract" xlink:title="RestrictedStockGrantsAbstract" />
    <link:label xlink:type="resource" xlink:label="galt_RestrictedStockGrantsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_RestrictedStockGrantsAbstract_lbl1" xml:lang="en-US" id="galt_RestrictedStockGrantsAbstract_lbl1">Restricted Stock Grants [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedStockGrantsAbstract" xlink:to="galt_RestrictedStockGrantsAbstract_lbl1" xlink:title="label: RestrictedStockGrantsAbstract to galt_RestrictedStockGrantsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne" xlink:label="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne" xlink:title="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne" />
    <link:label xlink:type="resource" xlink:label="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne_lbl" xml:lang="en-US" id="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne_lbl">Percentage of underlying the outstanding whole number of DSUs credited individuals during period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne" xlink:to="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne_lbl" xlink:title="label: DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne to galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne_lbl1" xml:lang="en-US" id="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne_lbl1">Deferred Compensation Arrangement, Percentage of Deferred Share Units Shall be Issued, Period One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne" xlink:to="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne_lbl1" xlink:title="label: DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne to galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne" xml:lang="en-US" id="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne">Percentage of DSUs shall be credited on March 1, 2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne" xlink:to="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne" xlink:title="label: DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne to galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSix" xlink:label="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSix" xlink:title="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSix" />
    <link:label xlink:type="resource" xlink:label="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSix_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSix_lbl" xml:lang="en-US" id="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSix_lbl">Percentage of underlying the outstanding whole number of DSUs credited individuals during period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSix" xlink:to="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSix_lbl" xlink:title="label: DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSix to galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSix_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSix_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSix_lbl1" xml:lang="en-US" id="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSix_lbl1">Deferred Compensation Arrangement, Percentage of Deferred Share Units Shall be Issued, Period Six</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSix" xlink:to="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSix_lbl1" xlink:title="label: DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSix to galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSix_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSix" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSix" xml:lang="en-US" id="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSix">Percentage of DSUs shall be credited on March 1, 2025</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSix" xlink:to="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSix" xlink:title="label: DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSix to galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSix" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent" xlink:label="DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent" xlink:title="DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent" />
    <link:label xlink:type="resource" xlink:label="galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent_lbl" xml:lang="en-US" id="galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent_lbl">The deferred compensation arrangement with individual cash award granted paid in cash percentage.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent" xlink:to="galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent_lbl" xlink:title="label: DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent to galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent_lbl1" xml:lang="en-US" id="galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent_lbl1">Deferred Compensation Arrangement With Individual Cash Award Granted Paid in Cash Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent" xlink:to="galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent_lbl1" xlink:title="label: DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent to galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent" xml:lang="en-US" id="galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent">Percentage of base salary paid in cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent" xlink:to="galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent" xlink:title="label: DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent to galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFive" xlink:label="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFive" xlink:title="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFive" />
    <link:label xlink:type="resource" xlink:label="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFive_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFive_lbl" xml:lang="en-US" id="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFive_lbl">Percentage of underlying the outstanding whole number of DSUs credited individuals during period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFive" xlink:to="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFive_lbl" xlink:title="label: DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFive to galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFive_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFive_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFive_lbl1" xml:lang="en-US" id="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFive_lbl1">Deferred Compensation Arrangement, Percentage of Deferred Share Units Shall be Issued, Period Five</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFive" xlink:to="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFive_lbl1" xlink:title="label: DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFive to galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFive_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFive" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFive" xml:lang="en-US" id="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFive">Percentage of DSUs shall be credited on March 1, 2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFive" xlink:to="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFive" xlink:title="label: DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFive to galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFive" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSeven" xlink:label="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSeven" xlink:title="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSeven" />
    <link:label xlink:type="resource" xlink:label="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSeven_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSeven_lbl" xml:lang="en-US" id="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSeven_lbl">Percentage of underlying the outstanding whole number of DSUs credited individuals during period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSeven" xlink:to="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSeven_lbl" xlink:title="label: DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSeven to galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSeven_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSeven_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSeven_lbl1" xml:lang="en-US" id="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSeven_lbl1">Deferred Compensation Arrangement, Percentage of Deferred Share Units Shall be Issued, Period Seven</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSeven" xlink:to="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSeven_lbl1" xlink:title="label: DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSeven to galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSeven_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSeven" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSeven" xml:lang="en-US" id="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSeven">Percentage of DSUs shall be credited on January 5, 2026</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSeven" xlink:to="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSeven" xlink:title="label: DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSeven to galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSeven" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree" xlink:label="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree" xlink:title="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree" />
    <link:label xlink:type="resource" xlink:label="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree_lbl" xml:lang="en-US" id="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree_lbl">Percentage of underlying the outstanding whole number of DSUs credited individuals during period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree" xlink:to="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree_lbl" xlink:title="label: DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree to galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree_lbl1" xml:lang="en-US" id="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree_lbl1">Deferred Compensation Arrangement Percentage of Deferred Share Units Shall be Issued Period Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree" xlink:to="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree_lbl1" xlink:title="label: DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree to galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree" xml:lang="en-US" id="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree">Percentage of DSUs shall be credited on September 1, 2028</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree" xlink:to="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree" xlink:title="label: DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree to galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo" xlink:label="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo" xlink:title="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo" />
    <link:label xlink:type="resource" xlink:label="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo_lbl" xml:lang="en-US" id="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo_lbl">Percentage of underlying the outstanding whole number of DSUs credited individuals during period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo" xlink:to="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo_lbl" xlink:title="label: DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo to galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo_lbl1" xml:lang="en-US" id="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo_lbl1">Deferred Compensation Arrangement Percentage of Deferred Share Units Shall be Issued Period Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo" xlink:to="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo_lbl1" xlink:title="label: DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo to galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo" xml:lang="en-US" id="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo">Percentage of DSUs shall be credited on March 1, 2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo" xlink:to="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo" xlink:title="label: DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo to galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFour" xlink:label="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFour" xlink:title="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFour" />
    <link:label xlink:type="resource" xlink:label="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFour_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFour_lbl" xml:lang="en-US" id="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFour_lbl">Percentage of underlying the outstanding whole number of DSUs credited individuals during period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFour" xlink:to="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFour_lbl" xlink:title="label: DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFour to galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFour_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFour_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFour_lbl1" xml:lang="en-US" id="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFour_lbl1">Deferred Compensation Arrangement, Percentage of Deferred Share Units Shall be Issued, Period Four</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFour" xlink:to="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFour_lbl1" xlink:title="label: DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFour to galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFour_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFour" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFour" xml:lang="en-US" id="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFour">Percentage of DSUs shall be credited on March 1, 2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFour" xlink:to="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFour" xlink:title="label: DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFour to galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFour" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_BonusSharesMember" xlink:label="BonusSharesMember" xlink:title="BonusSharesMember" />
    <link:label xlink:type="resource" xlink:label="galt_BonusSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_BonusSharesMember_lbl" xml:lang="en-US" id="galt_BonusSharesMember_lbl">Bonus shares are additional shares given to the existing shareholders.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BonusSharesMember" xlink:to="galt_BonusSharesMember_lbl" xlink:title="label: BonusSharesMember to galt_BonusSharesMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_BonusSharesMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_BonusSharesMember_lbl1" xml:lang="en-US" id="galt_BonusSharesMember_lbl1">Bonus Shares [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BonusSharesMember" xlink:to="galt_BonusSharesMember_lbl1" xlink:title="label: BonusSharesMember to galt_BonusSharesMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_BonusSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_BonusSharesMember" xml:lang="en-US" id="galt_BonusSharesMember">Bonus Shares [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BonusSharesMember" xlink:to="galt_BonusSharesMember" xlink:title="label: BonusSharesMember to galt_BonusSharesMember" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent" xlink:label="DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent" xlink:title="DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent" />
    <link:label xlink:type="resource" xlink:label="galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent_lbl" xml:lang="en-US" id="galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent_lbl">The deferred compensation arrangement with individual cash award granted paid in deferred stock units percentage.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent" xlink:to="galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent_lbl" xlink:title="label: DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent to galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent_lbl1" xml:lang="en-US" id="galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent_lbl1">Deferred Compensation Arrangement With Individual Cash Award Granted Paid in Deferred Stock Units Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent" xlink:to="galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent_lbl1" xlink:title="label: DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent to galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent" xml:lang="en-US" id="galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent">Percentage of base salary paid in deferred stock units</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent" xlink:to="galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent" xlink:title="label: DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent to galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_MayTwentyThreeTwentyNinteenRightsOfferingWarrantsMember" xlink:label="MayTwentyThreeTwentyNinteenRightsOfferingWarrantsMember" xlink:title="MayTwentyThreeTwentyNinteenRightsOfferingWarrantsMember" />
    <link:label xlink:type="resource" xlink:label="galt_MayTwentyThreeTwentyNinteenRightsOfferingWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_MayTwentyThreeTwentyNinteenRightsOfferingWarrantsMember_lbl" xml:lang="en-US" id="galt_MayTwentyThreeTwentyNinteenRightsOfferingWarrantsMember_lbl">Name of the class or type of warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MayTwentyThreeTwentyNinteenRightsOfferingWarrantsMember" xlink:to="galt_MayTwentyThreeTwentyNinteenRightsOfferingWarrantsMember_lbl" xlink:title="label: MayTwentyThreeTwentyNinteenRightsOfferingWarrantsMember to galt_MayTwentyThreeTwentyNinteenRightsOfferingWarrantsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_MayTwentyThreeTwentyNinteenRightsOfferingWarrantsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_MayTwentyThreeTwentyNinteenRightsOfferingWarrantsMember_lbl1" xml:lang="en-US" id="galt_MayTwentyThreeTwentyNinteenRightsOfferingWarrantsMember_lbl1">May Twenty Three Twenty Ninteen Rights Offering Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MayTwentyThreeTwentyNinteenRightsOfferingWarrantsMember" xlink:to="galt_MayTwentyThreeTwentyNinteenRightsOfferingWarrantsMember_lbl1" xlink:title="label: MayTwentyThreeTwentyNinteenRightsOfferingWarrantsMember to galt_MayTwentyThreeTwentyNinteenRightsOfferingWarrantsMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_MayTwentyThreeTwentyNinteenRightsOfferingWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_MayTwentyThreeTwentyNinteenRightsOfferingWarrantsMember" xml:lang="en-US" id="galt_MayTwentyThreeTwentyNinteenRightsOfferingWarrantsMember">May 23, 2019 Rights Offering warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MayTwentyThreeTwentyNinteenRightsOfferingWarrantsMember" xlink:to="galt_MayTwentyThreeTwentyNinteenRightsOfferingWarrantsMember" xlink:title="label: MayTwentyThreeTwentyNinteenRightsOfferingWarrantsMember to galt_MayTwentyThreeTwentyNinteenRightsOfferingWarrantsMember" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_March292024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" xlink:label="March292024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" xlink:title="March292024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" />
    <link:label xlink:type="resource" xlink:label="galt_March292024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_March292024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember_lbl" xml:lang="en-US" id="galt_March292024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember_lbl">Name of the class or type of warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="March292024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" xlink:to="galt_March292024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember_lbl" xlink:title="label: March292024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember to galt_March292024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_March292024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_March292024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember_lbl1" xml:lang="en-US" id="galt_March292024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember_lbl1">March 29, 2024 Warrants Issued for Draw on Related Party Line of Credit [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="March292024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" xlink:to="galt_March292024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember_lbl1" xlink:title="label: March292024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember to galt_March292024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_March292024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_March292024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" xml:lang="en-US" id="galt_March292024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember">March 29, 2024 Warrants Issued for Draw on Related Party Line of Credit [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="March292024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" xlink:to="galt_March292024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" xlink:title="label: March292024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember to galt_March292024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_June282024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" xlink:label="June282024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" xlink:title="June282024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" />
    <link:label xlink:type="resource" xlink:label="galt_June282024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_June282024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember_lbl" xml:lang="en-US" id="galt_June282024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember_lbl">Name of the class or type of warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="June282024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" xlink:to="galt_June282024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember_lbl" xlink:title="label: June282024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember to galt_June282024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_June282024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_June282024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember_lbl1" xml:lang="en-US" id="galt_June282024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember_lbl1">June 28, 2024 Warrants Issued for Draw on Related Party Line of Credit [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="June282024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" xlink:to="galt_June282024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember_lbl1" xlink:title="label: June282024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember to galt_June282024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_June282024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_June282024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" xml:lang="en-US" id="galt_June282024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember">June 28, 2024 Warrants Issued for Draw on Related Party Line of Credit [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="June282024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" xlink:to="galt_June282024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" xlink:title="label: June282024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember to galt_June282024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_SeptemberThirtyTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:label="SeptemberThirtyTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:title="SeptemberThirtyTwentyZeroNineSeriesBTwoTransactionOneMember" />
    <link:label xlink:type="resource" xlink:label="galt_SeptemberThirtyTwentyZeroNineSeriesBTwoTransactionOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_SeptemberThirtyTwentyZeroNineSeriesBTwoTransactionOneMember_lbl" xml:lang="en-US" id="galt_SeptemberThirtyTwentyZeroNineSeriesBTwoTransactionOneMember_lbl">Name of the class or type of warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeptemberThirtyTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:to="galt_SeptemberThirtyTwentyZeroNineSeriesBTwoTransactionOneMember_lbl" xlink:title="label: SeptemberThirtyTwentyZeroNineSeriesBTwoTransactionOneMember to galt_SeptemberThirtyTwentyZeroNineSeriesBTwoTransactionOneMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_SeptemberThirtyTwentyZeroNineSeriesBTwoTransactionOneMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_SeptemberThirtyTwentyZeroNineSeriesBTwoTransactionOneMember_lbl1" xml:lang="en-US" id="galt_SeptemberThirtyTwentyZeroNineSeriesBTwoTransactionOneMember_lbl1">September Thirty Twenty Zero Nine Series B Two Transaction One [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeptemberThirtyTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:to="galt_SeptemberThirtyTwentyZeroNineSeriesBTwoTransactionOneMember_lbl1" xlink:title="label: SeptemberThirtyTwentyZeroNineSeriesBTwoTransactionOneMember to galt_SeptemberThirtyTwentyZeroNineSeriesBTwoTransactionOneMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_SeptemberThirtyTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="galt_SeptemberThirtyTwentyZeroNineSeriesBTwoTransactionOneMember" xml:lang="en-US" id="galt_SeptemberThirtyTwentyZeroNineSeriesBTwoTransactionOneMember">September 30, 2009 Series B-2 Transaction [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeptemberThirtyTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:to="galt_SeptemberThirtyTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:title="label: SeptemberThirtyTwentyZeroNineSeriesBTwoTransactionOneMember to galt_SeptemberThirtyTwentyZeroNineSeriesBTwoTransactionOneMember" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_December292023WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" xlink:label="December292023WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" xlink:title="December292023WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" />
    <link:label xlink:type="resource" xlink:label="galt_December292023WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_December292023WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember_lbl" xml:lang="en-US" id="galt_December292023WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember_lbl">Name of the class or type of warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="December292023WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" xlink:to="galt_December292023WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember_lbl" xlink:title="label: December292023WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember to galt_December292023WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_December292023WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_December292023WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember_lbl1" xml:lang="en-US" id="galt_December292023WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember_lbl1">December 29, 2023 Warrants Issued for Draw on Related Party Line of Credit [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="December292023WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" xlink:to="galt_December292023WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember_lbl1" xlink:title="label: December292023WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember to galt_December292023WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_December292023WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_December292023WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" xml:lang="en-US" id="galt_December292023WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember">December 29, 2023 Warrants Issued for Draw on Related Party Line of Credit [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="December292023WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" xlink:to="galt_December292023WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" xlink:title="label: December292023WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember to galt_December292023WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_AugustTwelveTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:label="AugustTwelveTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:title="AugustTwelveTwentyZeroNineSeriesBTwoTransactionOneMember" />
    <link:label xlink:type="resource" xlink:label="galt_AugustTwelveTwentyZeroNineSeriesBTwoTransactionOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_AugustTwelveTwentyZeroNineSeriesBTwoTransactionOneMember_lbl" xml:lang="en-US" id="galt_AugustTwelveTwentyZeroNineSeriesBTwoTransactionOneMember_lbl">Name of the class or type of warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AugustTwelveTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:to="galt_AugustTwelveTwentyZeroNineSeriesBTwoTransactionOneMember_lbl" xlink:title="label: AugustTwelveTwentyZeroNineSeriesBTwoTransactionOneMember to galt_AugustTwelveTwentyZeroNineSeriesBTwoTransactionOneMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_AugustTwelveTwentyZeroNineSeriesBTwoTransactionOneMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_AugustTwelveTwentyZeroNineSeriesBTwoTransactionOneMember_lbl1" xml:lang="en-US" id="galt_AugustTwelveTwentyZeroNineSeriesBTwoTransactionOneMember_lbl1">August Twelve Twenty Zero Nine Series B Two Transaction One [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AugustTwelveTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:to="galt_AugustTwelveTwentyZeroNineSeriesBTwoTransactionOneMember_lbl1" xlink:title="label: AugustTwelveTwentyZeroNineSeriesBTwoTransactionOneMember to galt_AugustTwelveTwentyZeroNineSeriesBTwoTransactionOneMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_AugustTwelveTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="galt_AugustTwelveTwentyZeroNineSeriesBTwoTransactionOneMember" xml:lang="en-US" id="galt_AugustTwelveTwentyZeroNineSeriesBTwoTransactionOneMember">August 12, 2009 Series B-2 Transaction [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AugustTwelveTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:to="galt_AugustTwelveTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:title="label: AugustTwelveTwentyZeroNineSeriesBTwoTransactionOneMember to galt_AugustTwelveTwentyZeroNineSeriesBTwoTransactionOneMember" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_July222022WarrantsIssuedInConnectionWithRelatedPartyLineOfCreditMember" xlink:label="July222022WarrantsIssuedInConnectionWithRelatedPartyLineOfCreditMember" xlink:title="July222022WarrantsIssuedInConnectionWithRelatedPartyLineOfCreditMember" />
    <link:label xlink:type="resource" xlink:label="galt_July222022WarrantsIssuedInConnectionWithRelatedPartyLineOfCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_July222022WarrantsIssuedInConnectionWithRelatedPartyLineOfCreditMember_lbl" xml:lang="en-US" id="galt_July222022WarrantsIssuedInConnectionWithRelatedPartyLineOfCreditMember_lbl">Name of the class or type of warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="July222022WarrantsIssuedInConnectionWithRelatedPartyLineOfCreditMember" xlink:to="galt_July222022WarrantsIssuedInConnectionWithRelatedPartyLineOfCreditMember_lbl" xlink:title="label: July222022WarrantsIssuedInConnectionWithRelatedPartyLineOfCreditMember to galt_July222022WarrantsIssuedInConnectionWithRelatedPartyLineOfCreditMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_July222022WarrantsIssuedInConnectionWithRelatedPartyLineOfCreditMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_July222022WarrantsIssuedInConnectionWithRelatedPartyLineOfCreditMember_lbl1" xml:lang="en-US" id="galt_July222022WarrantsIssuedInConnectionWithRelatedPartyLineOfCreditMember_lbl1">July 22, 2022 Warrants Issued in Connection with Related Party Line of Credit [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="July222022WarrantsIssuedInConnectionWithRelatedPartyLineOfCreditMember" xlink:to="galt_July222022WarrantsIssuedInConnectionWithRelatedPartyLineOfCreditMember_lbl1" xlink:title="label: July222022WarrantsIssuedInConnectionWithRelatedPartyLineOfCreditMember to galt_July222022WarrantsIssuedInConnectionWithRelatedPartyLineOfCreditMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_July222022WarrantsIssuedInConnectionWithRelatedPartyLineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_July222022WarrantsIssuedInConnectionWithRelatedPartyLineOfCreditMember" xml:lang="en-US" id="galt_July222022WarrantsIssuedInConnectionWithRelatedPartyLineOfCreditMember">July 22, 2022 Warrants Issued in Connection with Related Party Line of Credit [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="July222022WarrantsIssuedInConnectionWithRelatedPartyLineOfCreditMember" xlink:to="galt_July222022WarrantsIssuedInConnectionWithRelatedPartyLineOfCreditMember" xlink:title="label: July222022WarrantsIssuedInConnectionWithRelatedPartyLineOfCreditMember to galt_July222022WarrantsIssuedInConnectionWithRelatedPartyLineOfCreditMember" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_MayTenTwentyTenSeriesBTwoTransactionTwoMember" xlink:label="MayTenTwentyTenSeriesBTwoTransactionTwoMember" xlink:title="MayTenTwentyTenSeriesBTwoTransactionTwoMember" />
    <link:label xlink:type="resource" xlink:label="galt_MayTenTwentyTenSeriesBTwoTransactionTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_MayTenTwentyTenSeriesBTwoTransactionTwoMember_lbl" xml:lang="en-US" id="galt_MayTenTwentyTenSeriesBTwoTransactionTwoMember_lbl">Name of the class or type of warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MayTenTwentyTenSeriesBTwoTransactionTwoMember" xlink:to="galt_MayTenTwentyTenSeriesBTwoTransactionTwoMember_lbl" xlink:title="label: MayTenTwentyTenSeriesBTwoTransactionTwoMember to galt_MayTenTwentyTenSeriesBTwoTransactionTwoMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_MayTenTwentyTenSeriesBTwoTransactionTwoMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_MayTenTwentyTenSeriesBTwoTransactionTwoMember_lbl1" xml:lang="en-US" id="galt_MayTenTwentyTenSeriesBTwoTransactionTwoMember_lbl1">May Ten Twenty Ten Series B Two Transaction Two [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MayTenTwentyTenSeriesBTwoTransactionTwoMember" xlink:to="galt_MayTenTwentyTenSeriesBTwoTransactionTwoMember_lbl1" xlink:title="label: MayTenTwentyTenSeriesBTwoTransactionTwoMember to galt_MayTenTwentyTenSeriesBTwoTransactionTwoMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_MayTenTwentyTenSeriesBTwoTransactionTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_MayTenTwentyTenSeriesBTwoTransactionTwoMember" xml:lang="en-US" id="galt_MayTenTwentyTenSeriesBTwoTransactionTwoMember">May 10, 2010 Series B-2 Transaction [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MayTenTwentyTenSeriesBTwoTransactionTwoMember" xlink:to="galt_MayTenTwentyTenSeriesBTwoTransactionTwoMember" xlink:title="label: MayTenTwentyTenSeriesBTwoTransactionTwoMember to galt_MayTenTwentyTenSeriesBTwoTransactionTwoMember" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_AprilThirtyTwentyTenSeriesBTwoTransactionOneMember" xlink:label="AprilThirtyTwentyTenSeriesBTwoTransactionOneMember" xlink:title="AprilThirtyTwentyTenSeriesBTwoTransactionOneMember" />
    <link:label xlink:type="resource" xlink:label="galt_AprilThirtyTwentyTenSeriesBTwoTransactionOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_AprilThirtyTwentyTenSeriesBTwoTransactionOneMember_lbl" xml:lang="en-US" id="galt_AprilThirtyTwentyTenSeriesBTwoTransactionOneMember_lbl">Name of the class or type of warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AprilThirtyTwentyTenSeriesBTwoTransactionOneMember" xlink:to="galt_AprilThirtyTwentyTenSeriesBTwoTransactionOneMember_lbl" xlink:title="label: AprilThirtyTwentyTenSeriesBTwoTransactionOneMember to galt_AprilThirtyTwentyTenSeriesBTwoTransactionOneMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_AprilThirtyTwentyTenSeriesBTwoTransactionOneMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_AprilThirtyTwentyTenSeriesBTwoTransactionOneMember_lbl1" xml:lang="en-US" id="galt_AprilThirtyTwentyTenSeriesBTwoTransactionOneMember_lbl1">April Thirty Twenty Ten Series B Two Transaction One [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AprilThirtyTwentyTenSeriesBTwoTransactionOneMember" xlink:to="galt_AprilThirtyTwentyTenSeriesBTwoTransactionOneMember_lbl1" xlink:title="label: AprilThirtyTwentyTenSeriesBTwoTransactionOneMember to galt_AprilThirtyTwentyTenSeriesBTwoTransactionOneMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_AprilThirtyTwentyTenSeriesBTwoTransactionOneMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="galt_AprilThirtyTwentyTenSeriesBTwoTransactionOneMember" xml:lang="en-US" id="galt_AprilThirtyTwentyTenSeriesBTwoTransactionOneMember">April 30, 2010 Series B-2 Transaction [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AprilThirtyTwentyTenSeriesBTwoTransactionOneMember" xlink:to="galt_AprilThirtyTwentyTenSeriesBTwoTransactionOneMember" xlink:title="label: AprilThirtyTwentyTenSeriesBTwoTransactionOneMember to galt_AprilThirtyTwentyTenSeriesBTwoTransactionOneMember" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_TwentyEighteenAndTwentySeventeenWarrantsIssuedForServicesMember" xlink:label="TwentyEighteenAndTwentySeventeenWarrantsIssuedForServicesMember" xlink:title="TwentyEighteenAndTwentySeventeenWarrantsIssuedForServicesMember" />
    <link:label xlink:type="resource" xlink:label="galt_TwentyEighteenAndTwentySeventeenWarrantsIssuedForServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_TwentyEighteenAndTwentySeventeenWarrantsIssuedForServicesMember_lbl" xml:lang="en-US" id="galt_TwentyEighteenAndTwentySeventeenWarrantsIssuedForServicesMember_lbl">Name of the class or type of warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TwentyEighteenAndTwentySeventeenWarrantsIssuedForServicesMember" xlink:to="galt_TwentyEighteenAndTwentySeventeenWarrantsIssuedForServicesMember_lbl" xlink:title="label: TwentyEighteenAndTwentySeventeenWarrantsIssuedForServicesMember to galt_TwentyEighteenAndTwentySeventeenWarrantsIssuedForServicesMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_TwentyEighteenAndTwentySeventeenWarrantsIssuedForServicesMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_TwentyEighteenAndTwentySeventeenWarrantsIssuedForServicesMember_lbl1" xml:lang="en-US" id="galt_TwentyEighteenAndTwentySeventeenWarrantsIssuedForServicesMember_lbl1">Twenty Eighteen And Twenty Seventeen Warrants Issued For Services [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TwentyEighteenAndTwentySeventeenWarrantsIssuedForServicesMember" xlink:to="galt_TwentyEighteenAndTwentySeventeenWarrantsIssuedForServicesMember_lbl1" xlink:title="label: TwentyEighteenAndTwentySeventeenWarrantsIssuedForServicesMember to galt_TwentyEighteenAndTwentySeventeenWarrantsIssuedForServicesMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_TwentyEighteenAndTwentySeventeenWarrantsIssuedForServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_TwentyEighteenAndTwentySeventeenWarrantsIssuedForServicesMember" xml:lang="en-US" id="galt_TwentyEighteenAndTwentySeventeenWarrantsIssuedForServicesMember">2018 and 2017 Warrants issued for services [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TwentyEighteenAndTwentySeventeenWarrantsIssuedForServicesMember" xlink:to="galt_TwentyEighteenAndTwentySeventeenWarrantsIssuedForServicesMember" xlink:title="label: TwentyEighteenAndTwentySeventeenWarrantsIssuedForServicesMember to galt_TwentyEighteenAndTwentySeventeenWarrantsIssuedForServicesMember" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_DecemberEightTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:label="DecemberEightTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:title="DecemberEightTwentyZeroNineSeriesBTwoTransactionOneMember" />
    <link:label xlink:type="resource" xlink:label="galt_DecemberEightTwentyZeroNineSeriesBTwoTransactionOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_DecemberEightTwentyZeroNineSeriesBTwoTransactionOneMember_lbl" xml:lang="en-US" id="galt_DecemberEightTwentyZeroNineSeriesBTwoTransactionOneMember_lbl">Name of the class or type of warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DecemberEightTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:to="galt_DecemberEightTwentyZeroNineSeriesBTwoTransactionOneMember_lbl" xlink:title="label: DecemberEightTwentyZeroNineSeriesBTwoTransactionOneMember to galt_DecemberEightTwentyZeroNineSeriesBTwoTransactionOneMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_DecemberEightTwentyZeroNineSeriesBTwoTransactionOneMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_DecemberEightTwentyZeroNineSeriesBTwoTransactionOneMember_lbl1" xml:lang="en-US" id="galt_DecemberEightTwentyZeroNineSeriesBTwoTransactionOneMember_lbl1">December Eight Twenty Zero Nine Series B Two Transaction One [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DecemberEightTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:to="galt_DecemberEightTwentyZeroNineSeriesBTwoTransactionOneMember_lbl1" xlink:title="label: DecemberEightTwentyZeroNineSeriesBTwoTransactionOneMember to galt_DecemberEightTwentyZeroNineSeriesBTwoTransactionOneMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_DecemberEightTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="galt_DecemberEightTwentyZeroNineSeriesBTwoTransactionOneMember" xml:lang="en-US" id="galt_DecemberEightTwentyZeroNineSeriesBTwoTransactionOneMember">December 8, 2009 Series B-2 Transaction [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DecemberEightTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:to="galt_DecemberEightTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:title="label: DecemberEightTwentyZeroNineSeriesBTwoTransactionOneMember to galt_DecemberEightTwentyZeroNineSeriesBTwoTransactionOneMember" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionOneMember" xlink:label="JanuaryTwentyNineTwentyTenSeriesBTwoTransactionOneMember" xlink:title="JanuaryTwentyNineTwentyTenSeriesBTwoTransactionOneMember" />
    <link:label xlink:type="resource" xlink:label="galt_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionOneMember_lbl" xml:lang="en-US" id="galt_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionOneMember_lbl">Name of the class or type of warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JanuaryTwentyNineTwentyTenSeriesBTwoTransactionOneMember" xlink:to="galt_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionOneMember_lbl" xlink:title="label: JanuaryTwentyNineTwentyTenSeriesBTwoTransactionOneMember to galt_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionOneMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionOneMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionOneMember_lbl1" xml:lang="en-US" id="galt_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionOneMember_lbl1">January Twenty Nine Twenty Ten Series B Two Transaction One [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JanuaryTwentyNineTwentyTenSeriesBTwoTransactionOneMember" xlink:to="galt_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionOneMember_lbl1" xlink:title="label: JanuaryTwentyNineTwentyTenSeriesBTwoTransactionOneMember to galt_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionOneMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionOneMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="galt_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionOneMember" xml:lang="en-US" id="galt_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionOneMember">January 29, 2010 Series B-2 Transaction [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JanuaryTwentyNineTwentyTenSeriesBTwoTransactionOneMember" xlink:to="galt_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionOneMember" xlink:title="label: JanuaryTwentyNineTwentyTenSeriesBTwoTransactionOneMember to galt_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionOneMember" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_FebruaryTwelveTwentyZeroNineSeriesBOneTransactionMember" xlink:label="FebruaryTwelveTwentyZeroNineSeriesBOneTransactionMember" xlink:title="FebruaryTwelveTwentyZeroNineSeriesBOneTransactionMember" />
    <link:label xlink:type="resource" xlink:label="galt_FebruaryTwelveTwentyZeroNineSeriesBOneTransactionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_FebruaryTwelveTwentyZeroNineSeriesBOneTransactionMember_lbl" xml:lang="en-US" id="galt_FebruaryTwelveTwentyZeroNineSeriesBOneTransactionMember_lbl">Name of the class or type of warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FebruaryTwelveTwentyZeroNineSeriesBOneTransactionMember" xlink:to="galt_FebruaryTwelveTwentyZeroNineSeriesBOneTransactionMember_lbl" xlink:title="label: FebruaryTwelveTwentyZeroNineSeriesBOneTransactionMember to galt_FebruaryTwelveTwentyZeroNineSeriesBOneTransactionMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_FebruaryTwelveTwentyZeroNineSeriesBOneTransactionMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_FebruaryTwelveTwentyZeroNineSeriesBOneTransactionMember_lbl1" xml:lang="en-US" id="galt_FebruaryTwelveTwentyZeroNineSeriesBOneTransactionMember_lbl1">February Twelve Two Thousand Zero Nine Series B One Transaction Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FebruaryTwelveTwentyZeroNineSeriesBOneTransactionMember" xlink:to="galt_FebruaryTwelveTwentyZeroNineSeriesBOneTransactionMember_lbl1" xlink:title="label: FebruaryTwelveTwentyZeroNineSeriesBOneTransactionMember to galt_FebruaryTwelveTwentyZeroNineSeriesBOneTransactionMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_FebruaryTwelveTwentyZeroNineSeriesBOneTransactionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_FebruaryTwelveTwentyZeroNineSeriesBOneTransactionMember" xml:lang="en-US" id="galt_FebruaryTwelveTwentyZeroNineSeriesBOneTransactionMember">February 12, 2009 Series B-1 Transaction [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FebruaryTwelveTwentyZeroNineSeriesBOneTransactionMember" xlink:to="galt_FebruaryTwelveTwentyZeroNineSeriesBOneTransactionMember" xlink:title="label: FebruaryTwelveTwentyZeroNineSeriesBOneTransactionMember to galt_FebruaryTwelveTwentyZeroNineSeriesBOneTransactionMember" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_DecemberTwentyThreeTwentySixteenSeriesBThreeTransactionMember" xlink:label="DecemberTwentyThreeTwentySixteenSeriesBThreeTransactionMember" xlink:title="DecemberTwentyThreeTwentySixteenSeriesBThreeTransactionMember" />
    <link:label xlink:type="resource" xlink:label="galt_DecemberTwentyThreeTwentySixteenSeriesBThreeTransactionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_DecemberTwentyThreeTwentySixteenSeriesBThreeTransactionMember_lbl" xml:lang="en-US" id="galt_DecemberTwentyThreeTwentySixteenSeriesBThreeTransactionMember_lbl">Name of the class or type of warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DecemberTwentyThreeTwentySixteenSeriesBThreeTransactionMember" xlink:to="galt_DecemberTwentyThreeTwentySixteenSeriesBThreeTransactionMember_lbl" xlink:title="label: DecemberTwentyThreeTwentySixteenSeriesBThreeTransactionMember to galt_DecemberTwentyThreeTwentySixteenSeriesBThreeTransactionMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_DecemberTwentyThreeTwentySixteenSeriesBThreeTransactionMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_DecemberTwentyThreeTwentySixteenSeriesBThreeTransactionMember_lbl1" xml:lang="en-US" id="galt_DecemberTwentyThreeTwentySixteenSeriesBThreeTransactionMember_lbl1">December Twenty Three Twenty Sixteen Series B Three Transaction [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DecemberTwentyThreeTwentySixteenSeriesBThreeTransactionMember" xlink:to="galt_DecemberTwentyThreeTwentySixteenSeriesBThreeTransactionMember_lbl1" xlink:title="label: DecemberTwentyThreeTwentySixteenSeriesBThreeTransactionMember to galt_DecemberTwentyThreeTwentySixteenSeriesBThreeTransactionMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_DecemberTwentyThreeTwentySixteenSeriesBThreeTransactionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_DecemberTwentyThreeTwentySixteenSeriesBThreeTransactionMember" xml:lang="en-US" id="galt_DecemberTwentyThreeTwentySixteenSeriesBThreeTransactionMember">December 23, 2016 Series B-3 Transaction [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DecemberTwentyThreeTwentySixteenSeriesBThreeTransactionMember" xlink:to="galt_DecemberTwentyThreeTwentySixteenSeriesBThreeTransactionMember" xlink:title="label: DecemberTwentyThreeTwentySixteenSeriesBThreeTransactionMember to galt_DecemberTwentyThreeTwentySixteenSeriesBThreeTransactionMember" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_September302024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" xlink:label="September302024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" xlink:title="September302024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" />
    <link:label xlink:type="resource" xlink:label="galt_September302024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_September302024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember_lbl" xml:lang="en-US" id="galt_September302024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember_lbl">Name of the class or type of warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="September302024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" xlink:to="galt_September302024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember_lbl" xlink:title="label: September302024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember to galt_September302024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_September302024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_September302024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember_lbl1" xml:lang="en-US" id="galt_September302024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember_lbl1">September 30, 2024 Warrants Issued for Draw on Related Party Line of Credit [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="September302024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" xlink:to="galt_September302024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember_lbl1" xlink:title="label: September302024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember to galt_September302024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_September302024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_September302024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" xml:lang="en-US" id="galt_September302024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember">September 30, 2024 Warrants Issued for Draw on Related Party Line of Credit [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="September302024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" xlink:to="galt_September302024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" xlink:title="label: September302024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember to galt_September302024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_SeptemberTwentyNineTwentySixteenSeriesBThreeTransactionMember" xlink:label="SeptemberTwentyNineTwentySixteenSeriesBThreeTransactionMember" xlink:title="SeptemberTwentyNineTwentySixteenSeriesBThreeTransactionMember" />
    <link:label xlink:type="resource" xlink:label="galt_SeptemberTwentyNineTwentySixteenSeriesBThreeTransactionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_SeptemberTwentyNineTwentySixteenSeriesBThreeTransactionMember_lbl" xml:lang="en-US" id="galt_SeptemberTwentyNineTwentySixteenSeriesBThreeTransactionMember_lbl">Name of the class or type of warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeptemberTwentyNineTwentySixteenSeriesBThreeTransactionMember" xlink:to="galt_SeptemberTwentyNineTwentySixteenSeriesBThreeTransactionMember_lbl" xlink:title="label: SeptemberTwentyNineTwentySixteenSeriesBThreeTransactionMember to galt_SeptemberTwentyNineTwentySixteenSeriesBThreeTransactionMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_SeptemberTwentyNineTwentySixteenSeriesBThreeTransactionMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_SeptemberTwentyNineTwentySixteenSeriesBThreeTransactionMember_lbl1" xml:lang="en-US" id="galt_SeptemberTwentyNineTwentySixteenSeriesBThreeTransactionMember_lbl1">September Twenty Nine Twenty Sixteen Series B Three Transaction [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeptemberTwentyNineTwentySixteenSeriesBThreeTransactionMember" xlink:to="galt_SeptemberTwentyNineTwentySixteenSeriesBThreeTransactionMember_lbl1" xlink:title="label: SeptemberTwentyNineTwentySixteenSeriesBThreeTransactionMember to galt_SeptemberTwentyNineTwentySixteenSeriesBThreeTransactionMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_SeptemberTwentyNineTwentySixteenSeriesBThreeTransactionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_SeptemberTwentyNineTwentySixteenSeriesBThreeTransactionMember" xml:lang="en-US" id="galt_SeptemberTwentyNineTwentySixteenSeriesBThreeTransactionMember">September 29, 2016 Series B-3 Transaction [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeptemberTwentyNineTwentySixteenSeriesBThreeTransactionMember" xlink:to="galt_SeptemberTwentyNineTwentySixteenSeriesBThreeTransactionMember" xlink:title="label: SeptemberTwentyNineTwentySixteenSeriesBThreeTransactionMember to galt_SeptemberTwentyNineTwentySixteenSeriesBThreeTransactionMember" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_NovemberFourTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:label="NovemberFourTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:title="NovemberFourTwentyZeroNineSeriesBTwoTransactionOneMember" />
    <link:label xlink:type="resource" xlink:label="galt_NovemberFourTwentyZeroNineSeriesBTwoTransactionOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_NovemberFourTwentyZeroNineSeriesBTwoTransactionOneMember_lbl" xml:lang="en-US" id="galt_NovemberFourTwentyZeroNineSeriesBTwoTransactionOneMember_lbl">Name of the class or type of warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NovemberFourTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:to="galt_NovemberFourTwentyZeroNineSeriesBTwoTransactionOneMember_lbl" xlink:title="label: NovemberFourTwentyZeroNineSeriesBTwoTransactionOneMember to galt_NovemberFourTwentyZeroNineSeriesBTwoTransactionOneMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_NovemberFourTwentyZeroNineSeriesBTwoTransactionOneMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_NovemberFourTwentyZeroNineSeriesBTwoTransactionOneMember_lbl1" xml:lang="en-US" id="galt_NovemberFourTwentyZeroNineSeriesBTwoTransactionOneMember_lbl1">November Four Twenty Zero Nine Series B Two Transaction One [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NovemberFourTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:to="galt_NovemberFourTwentyZeroNineSeriesBTwoTransactionOneMember_lbl1" xlink:title="label: NovemberFourTwentyZeroNineSeriesBTwoTransactionOneMember to galt_NovemberFourTwentyZeroNineSeriesBTwoTransactionOneMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_NovemberFourTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="galt_NovemberFourTwentyZeroNineSeriesBTwoTransactionOneMember" xml:lang="en-US" id="galt_NovemberFourTwentyZeroNineSeriesBTwoTransactionOneMember">November 4, 2009 Series B-2 Transaction [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NovemberFourTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:to="galt_NovemberFourTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:title="label: NovemberFourTwentyZeroNineSeriesBTwoTransactionOneMember to galt_NovemberFourTwentyZeroNineSeriesBTwoTransactionOneMember" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_SeptemberTwentyTwoTwentySixteenSeriesBThreeTransactionMember" xlink:label="SeptemberTwentyTwoTwentySixteenSeriesBThreeTransactionMember" xlink:title="SeptemberTwentyTwoTwentySixteenSeriesBThreeTransactionMember" />
    <link:label xlink:type="resource" xlink:label="galt_SeptemberTwentyTwoTwentySixteenSeriesBThreeTransactionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_SeptemberTwentyTwoTwentySixteenSeriesBThreeTransactionMember_lbl" xml:lang="en-US" id="galt_SeptemberTwentyTwoTwentySixteenSeriesBThreeTransactionMember_lbl">Name of the class or type of warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeptemberTwentyTwoTwentySixteenSeriesBThreeTransactionMember" xlink:to="galt_SeptemberTwentyTwoTwentySixteenSeriesBThreeTransactionMember_lbl" xlink:title="label: SeptemberTwentyTwoTwentySixteenSeriesBThreeTransactionMember to galt_SeptemberTwentyTwoTwentySixteenSeriesBThreeTransactionMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_SeptemberTwentyTwoTwentySixteenSeriesBThreeTransactionMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_SeptemberTwentyTwoTwentySixteenSeriesBThreeTransactionMember_lbl1" xml:lang="en-US" id="galt_SeptemberTwentyTwoTwentySixteenSeriesBThreeTransactionMember_lbl1">September Twenty Two Twenty Sixteen Series B Three Transaction [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeptemberTwentyTwoTwentySixteenSeriesBThreeTransactionMember" xlink:to="galt_SeptemberTwentyTwoTwentySixteenSeriesBThreeTransactionMember_lbl1" xlink:title="label: SeptemberTwentyTwoTwentySixteenSeriesBThreeTransactionMember to galt_SeptemberTwentyTwoTwentySixteenSeriesBThreeTransactionMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_SeptemberTwentyTwoTwentySixteenSeriesBThreeTransactionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_SeptemberTwentyTwoTwentySixteenSeriesBThreeTransactionMember" xml:lang="en-US" id="galt_SeptemberTwentyTwoTwentySixteenSeriesBThreeTransactionMember">September 22, 2016 Series B-3 Transaction [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeptemberTwentyTwoTwentySixteenSeriesBThreeTransactionMember" xlink:to="galt_SeptemberTwentyTwoTwentySixteenSeriesBThreeTransactionMember" xlink:title="label: SeptemberTwentyTwoTwentySixteenSeriesBThreeTransactionMember to galt_SeptemberTwentyTwoTwentySixteenSeriesBThreeTransactionMember" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired" xlink:label="ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired" xlink:title="ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired" />
    <link:label xlink:type="resource" xlink:label="galt_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired_lbl" xml:lang="en-US" id="galt_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired_lbl">Date the warrants or rights are expired, in YYYY-MM-DD format.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired" xlink:to="galt_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired_lbl" xlink:title="label: ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired to galt_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired_lbl1" xml:lang="en-US" id="galt_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired_lbl1">Class Of Warrant Or Rights Date From Which Warrants Or Rights Expired</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired" xlink:to="galt_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired_lbl1" xlink:title="label: ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired to galt_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired" xml:lang="en-US" id="galt_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired">Expiration date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired" xlink:to="galt_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired" xlink:title="label: ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired to galt_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_MarchEightTwentyTenSeriesBTwoTransactionTwoMember" xlink:label="MarchEightTwentyTenSeriesBTwoTransactionTwoMember" xlink:title="MarchEightTwentyTenSeriesBTwoTransactionTwoMember" />
    <link:label xlink:type="resource" xlink:label="galt_MarchEightTwentyTenSeriesBTwoTransactionTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_MarchEightTwentyTenSeriesBTwoTransactionTwoMember_lbl" xml:lang="en-US" id="galt_MarchEightTwentyTenSeriesBTwoTransactionTwoMember_lbl">Name of the class or type of warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MarchEightTwentyTenSeriesBTwoTransactionTwoMember" xlink:to="galt_MarchEightTwentyTenSeriesBTwoTransactionTwoMember_lbl" xlink:title="label: MarchEightTwentyTenSeriesBTwoTransactionTwoMember to galt_MarchEightTwentyTenSeriesBTwoTransactionTwoMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_MarchEightTwentyTenSeriesBTwoTransactionTwoMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_MarchEightTwentyTenSeriesBTwoTransactionTwoMember_lbl1" xml:lang="en-US" id="galt_MarchEightTwentyTenSeriesBTwoTransactionTwoMember_lbl1">March Eight Twenty Ten Series B Two Transaction Two [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MarchEightTwentyTenSeriesBTwoTransactionTwoMember" xlink:to="galt_MarchEightTwentyTenSeriesBTwoTransactionTwoMember_lbl1" xlink:title="label: MarchEightTwentyTenSeriesBTwoTransactionTwoMember to galt_MarchEightTwentyTenSeriesBTwoTransactionTwoMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_MarchEightTwentyTenSeriesBTwoTransactionTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_MarchEightTwentyTenSeriesBTwoTransactionTwoMember" xml:lang="en-US" id="galt_MarchEightTwentyTenSeriesBTwoTransactionTwoMember">March 8, 2010 Series B-2 Transaction [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MarchEightTwentyTenSeriesBTwoTransactionTwoMember" xlink:to="galt_MarchEightTwentyTenSeriesBTwoTransactionTwoMember" xlink:title="label: MarchEightTwentyTenSeriesBTwoTransactionTwoMember to galt_MarchEightTwentyTenSeriesBTwoTransactionTwoMember" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionTwoMember" xlink:label="JanuaryTwentyNineTwentyTenSeriesBTwoTransactionTwoMember" xlink:title="JanuaryTwentyNineTwentyTenSeriesBTwoTransactionTwoMember" />
    <link:label xlink:type="resource" xlink:label="galt_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionTwoMember_lbl" xml:lang="en-US" id="galt_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionTwoMember_lbl">Name of the class or type of warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JanuaryTwentyNineTwentyTenSeriesBTwoTransactionTwoMember" xlink:to="galt_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionTwoMember_lbl" xlink:title="label: JanuaryTwentyNineTwentyTenSeriesBTwoTransactionTwoMember to galt_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionTwoMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionTwoMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionTwoMember_lbl1" xml:lang="en-US" id="galt_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionTwoMember_lbl1">January Twenty Nine Twenty Ten Series B Two Transaction Two [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JanuaryTwentyNineTwentyTenSeriesBTwoTransactionTwoMember" xlink:to="galt_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionTwoMember_lbl1" xlink:title="label: JanuaryTwentyNineTwentyTenSeriesBTwoTransactionTwoMember to galt_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionTwoMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionTwoMember" xml:lang="en-US" id="galt_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionTwoMember">January 29, 2010 Series B-2 Transaction [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JanuaryTwentyNineTwentyTenSeriesBTwoTransactionTwoMember" xlink:to="galt_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionTwoMember" xlink:title="label: JanuaryTwentyNineTwentyTenSeriesBTwoTransactionTwoMember to galt_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionTwoMember" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_MarchEightTwentyTenSeriesBTwoTransactionOneMember" xlink:label="MarchEightTwentyTenSeriesBTwoTransactionOneMember" xlink:title="MarchEightTwentyTenSeriesBTwoTransactionOneMember" />
    <link:label xlink:type="resource" xlink:label="galt_MarchEightTwentyTenSeriesBTwoTransactionOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_MarchEightTwentyTenSeriesBTwoTransactionOneMember_lbl" xml:lang="en-US" id="galt_MarchEightTwentyTenSeriesBTwoTransactionOneMember_lbl">Name of the class or type of warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MarchEightTwentyTenSeriesBTwoTransactionOneMember" xlink:to="galt_MarchEightTwentyTenSeriesBTwoTransactionOneMember_lbl" xlink:title="label: MarchEightTwentyTenSeriesBTwoTransactionOneMember to galt_MarchEightTwentyTenSeriesBTwoTransactionOneMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_MarchEightTwentyTenSeriesBTwoTransactionOneMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_MarchEightTwentyTenSeriesBTwoTransactionOneMember_lbl1" xml:lang="en-US" id="galt_MarchEightTwentyTenSeriesBTwoTransactionOneMember_lbl1">March Eight Twenty Ten Series B Two Transaction One [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MarchEightTwentyTenSeriesBTwoTransactionOneMember" xlink:to="galt_MarchEightTwentyTenSeriesBTwoTransactionOneMember_lbl1" xlink:title="label: MarchEightTwentyTenSeriesBTwoTransactionOneMember to galt_MarchEightTwentyTenSeriesBTwoTransactionOneMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_MarchEightTwentyTenSeriesBTwoTransactionOneMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="galt_MarchEightTwentyTenSeriesBTwoTransactionOneMember" xml:lang="en-US" id="galt_MarchEightTwentyTenSeriesBTwoTransactionOneMember">March 8, 2010 Series B-2 Transaction [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MarchEightTwentyTenSeriesBTwoTransactionOneMember" xlink:to="galt_MarchEightTwentyTenSeriesBTwoTransactionOneMember" xlink:title="label: MarchEightTwentyTenSeriesBTwoTransactionOneMember to galt_MarchEightTwentyTenSeriesBTwoTransactionOneMember" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_WarrantIssueDate" xlink:label="WarrantIssueDate" xlink:title="WarrantIssueDate" />
    <link:label xlink:type="resource" xlink:label="galt_WarrantIssueDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_WarrantIssueDate_lbl" xml:lang="en-US" id="galt_WarrantIssueDate_lbl">Date the warrants or rights are issued, in YYYY-MM-DD format.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantIssueDate" xlink:to="galt_WarrantIssueDate_lbl" xlink:title="label: WarrantIssueDate to galt_WarrantIssueDate_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_WarrantIssueDate_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_WarrantIssueDate_lbl1" xml:lang="en-US" id="galt_WarrantIssueDate_lbl1">Warrant Issue Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantIssueDate" xlink:to="galt_WarrantIssueDate_lbl1" xlink:title="label: WarrantIssueDate to galt_WarrantIssueDate_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_WarrantIssueDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_WarrantIssueDate" xml:lang="en-US" id="galt_WarrantIssueDate">Warrant issue date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantIssueDate" xlink:to="galt_WarrantIssueDate" xlink:title="label: WarrantIssueDate to galt_WarrantIssueDate" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_AprilThirtyTwentyTenSeriesBTwoTransactionTwoMember" xlink:label="AprilThirtyTwentyTenSeriesBTwoTransactionTwoMember" xlink:title="AprilThirtyTwentyTenSeriesBTwoTransactionTwoMember" />
    <link:label xlink:type="resource" xlink:label="galt_AprilThirtyTwentyTenSeriesBTwoTransactionTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_AprilThirtyTwentyTenSeriesBTwoTransactionTwoMember_lbl" xml:lang="en-US" id="galt_AprilThirtyTwentyTenSeriesBTwoTransactionTwoMember_lbl">Name of the class or type of warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AprilThirtyTwentyTenSeriesBTwoTransactionTwoMember" xlink:to="galt_AprilThirtyTwentyTenSeriesBTwoTransactionTwoMember_lbl" xlink:title="label: AprilThirtyTwentyTenSeriesBTwoTransactionTwoMember to galt_AprilThirtyTwentyTenSeriesBTwoTransactionTwoMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_AprilThirtyTwentyTenSeriesBTwoTransactionTwoMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_AprilThirtyTwentyTenSeriesBTwoTransactionTwoMember_lbl1" xml:lang="en-US" id="galt_AprilThirtyTwentyTenSeriesBTwoTransactionTwoMember_lbl1">April Thirty Twenty Ten Series B Two Transaction Two [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AprilThirtyTwentyTenSeriesBTwoTransactionTwoMember" xlink:to="galt_AprilThirtyTwentyTenSeriesBTwoTransactionTwoMember_lbl1" xlink:title="label: AprilThirtyTwentyTenSeriesBTwoTransactionTwoMember to galt_AprilThirtyTwentyTenSeriesBTwoTransactionTwoMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_AprilThirtyTwentyTenSeriesBTwoTransactionTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_AprilThirtyTwentyTenSeriesBTwoTransactionTwoMember" xml:lang="en-US" id="galt_AprilThirtyTwentyTenSeriesBTwoTransactionTwoMember">April 30, 2010 Series B-2 Transaction [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AprilThirtyTwentyTenSeriesBTwoTransactionTwoMember" xlink:to="galt_AprilThirtyTwentyTenSeriesBTwoTransactionTwoMember" xlink:title="label: AprilThirtyTwentyTenSeriesBTwoTransactionTwoMember to galt_AprilThirtyTwentyTenSeriesBTwoTransactionTwoMember" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_MayTenTwentyTenSeriesBTwoTransactionOneMember" xlink:label="MayTenTwentyTenSeriesBTwoTransactionOneMember" xlink:title="MayTenTwentyTenSeriesBTwoTransactionOneMember" />
    <link:label xlink:type="resource" xlink:label="galt_MayTenTwentyTenSeriesBTwoTransactionOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_MayTenTwentyTenSeriesBTwoTransactionOneMember_lbl" xml:lang="en-US" id="galt_MayTenTwentyTenSeriesBTwoTransactionOneMember_lbl">Name of the class or type of warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MayTenTwentyTenSeriesBTwoTransactionOneMember" xlink:to="galt_MayTenTwentyTenSeriesBTwoTransactionOneMember_lbl" xlink:title="label: MayTenTwentyTenSeriesBTwoTransactionOneMember to galt_MayTenTwentyTenSeriesBTwoTransactionOneMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_MayTenTwentyTenSeriesBTwoTransactionOneMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_MayTenTwentyTenSeriesBTwoTransactionOneMember_lbl1" xml:lang="en-US" id="galt_MayTenTwentyTenSeriesBTwoTransactionOneMember_lbl1">May Ten Twenty Ten Series B Two Transaction One [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MayTenTwentyTenSeriesBTwoTransactionOneMember" xlink:to="galt_MayTenTwentyTenSeriesBTwoTransactionOneMember_lbl1" xlink:title="label: MayTenTwentyTenSeriesBTwoTransactionOneMember to galt_MayTenTwentyTenSeriesBTwoTransactionOneMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_MayTenTwentyTenSeriesBTwoTransactionOneMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="galt_MayTenTwentyTenSeriesBTwoTransactionOneMember" xml:lang="en-US" id="galt_MayTenTwentyTenSeriesBTwoTransactionOneMember">May 10, 2010 Series B-2 Transaction [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MayTenTwentyTenSeriesBTwoTransactionOneMember" xlink:to="galt_MayTenTwentyTenSeriesBTwoTransactionOneMember" xlink:title="label: MayTenTwentyTenSeriesBTwoTransactionOneMember to galt_MayTenTwentyTenSeriesBTwoTransactionOneMember" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_JuneThirtyTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:label="JuneThirtyTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:title="JuneThirtyTwentyZeroNineSeriesBTwoTransactionOneMember" />
    <link:label xlink:type="resource" xlink:label="galt_JuneThirtyTwentyZeroNineSeriesBTwoTransactionOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_JuneThirtyTwentyZeroNineSeriesBTwoTransactionOneMember_lbl" xml:lang="en-US" id="galt_JuneThirtyTwentyZeroNineSeriesBTwoTransactionOneMember_lbl">Name of the class or type of warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JuneThirtyTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:to="galt_JuneThirtyTwentyZeroNineSeriesBTwoTransactionOneMember_lbl" xlink:title="label: JuneThirtyTwentyZeroNineSeriesBTwoTransactionOneMember to galt_JuneThirtyTwentyZeroNineSeriesBTwoTransactionOneMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_JuneThirtyTwentyZeroNineSeriesBTwoTransactionOneMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_JuneThirtyTwentyZeroNineSeriesBTwoTransactionOneMember_lbl1" xml:lang="en-US" id="galt_JuneThirtyTwentyZeroNineSeriesBTwoTransactionOneMember_lbl1">June Thirty Twenty Zero Nine Series B Two Transaction One [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JuneThirtyTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:to="galt_JuneThirtyTwentyZeroNineSeriesBTwoTransactionOneMember_lbl1" xlink:title="label: JuneThirtyTwentyZeroNineSeriesBTwoTransactionOneMember to galt_JuneThirtyTwentyZeroNineSeriesBTwoTransactionOneMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_JuneThirtyTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="galt_JuneThirtyTwentyZeroNineSeriesBTwoTransactionOneMember" xml:lang="en-US" id="galt_JuneThirtyTwentyZeroNineSeriesBTwoTransactionOneMember">June 30, 2009 Series B-2 Transaction [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JuneThirtyTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:to="galt_JuneThirtyTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:title="label: JuneThirtyTwentyZeroNineSeriesBTwoTransactionOneMember to galt_JuneThirtyTwentyZeroNineSeriesBTwoTransactionOneMember" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_WarrantsIssuedPrice" xlink:label="WarrantsIssuedPrice" xlink:title="WarrantsIssuedPrice" />
    <link:label xlink:type="resource" xlink:label="galt_WarrantsIssuedPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_WarrantsIssuedPrice_lbl" xml:lang="en-US" id="galt_WarrantsIssuedPrice_lbl">Issuance price per share or per unit of warrants or rights outstanding.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsIssuedPrice" xlink:to="galt_WarrantsIssuedPrice_lbl" xlink:title="label: WarrantsIssuedPrice to galt_WarrantsIssuedPrice_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_WarrantsIssuedPrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_WarrantsIssuedPrice_lbl1" xml:lang="en-US" id="galt_WarrantsIssuedPrice_lbl1">Warrants Issued Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsIssuedPrice" xlink:to="galt_WarrantsIssuedPrice_lbl1" xlink:title="label: WarrantsIssuedPrice to galt_WarrantsIssuedPrice_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_WarrantsIssuedPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_WarrantsIssuedPrice" xml:lang="en-US" id="galt_WarrantsIssuedPrice">Warrants issued price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsIssuedPrice" xlink:to="galt_WarrantsIssuedPrice" xlink:title="label: WarrantsIssuedPrice to galt_WarrantsIssuedPrice" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_MayThirteenTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:label="MayThirteenTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:title="MayThirteenTwentyZeroNineSeriesBTwoTransactionOneMember" />
    <link:label xlink:type="resource" xlink:label="galt_MayThirteenTwentyZeroNineSeriesBTwoTransactionOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_MayThirteenTwentyZeroNineSeriesBTwoTransactionOneMember_lbl" xml:lang="en-US" id="galt_MayThirteenTwentyZeroNineSeriesBTwoTransactionOneMember_lbl">Name of the class or type of warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MayThirteenTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:to="galt_MayThirteenTwentyZeroNineSeriesBTwoTransactionOneMember_lbl" xlink:title="label: MayThirteenTwentyZeroNineSeriesBTwoTransactionOneMember to galt_MayThirteenTwentyZeroNineSeriesBTwoTransactionOneMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_MayThirteenTwentyZeroNineSeriesBTwoTransactionOneMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_MayThirteenTwentyZeroNineSeriesBTwoTransactionOneMember_lbl1" xml:lang="en-US" id="galt_MayThirteenTwentyZeroNineSeriesBTwoTransactionOneMember_lbl1">May Thirteen Twenty Zero Nine Series B Two Transaction One [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MayThirteenTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:to="galt_MayThirteenTwentyZeroNineSeriesBTwoTransactionOneMember_lbl1" xlink:title="label: MayThirteenTwentyZeroNineSeriesBTwoTransactionOneMember to galt_MayThirteenTwentyZeroNineSeriesBTwoTransactionOneMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_MayThirteenTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="galt_MayThirteenTwentyZeroNineSeriesBTwoTransactionOneMember" xml:lang="en-US" id="galt_MayThirteenTwentyZeroNineSeriesBTwoTransactionOneMember">May 13, 2009 Series B-2 Transaction [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MayThirteenTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:to="galt_MayThirteenTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:title="label: MayThirteenTwentyZeroNineSeriesBTwoTransactionOneMember to galt_MayThirteenTwentyZeroNineSeriesBTwoTransactionOneMember" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_VestingPercentageOfRestrictedStockUnits" xlink:label="VestingPercentageOfRestrictedStockUnits" xlink:title="VestingPercentageOfRestrictedStockUnits" />
    <link:label xlink:type="resource" xlink:label="galt_VestingPercentageOfRestrictedStockUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_VestingPercentageOfRestrictedStockUnits_lbl" xml:lang="en-US" id="galt_VestingPercentageOfRestrictedStockUnits_lbl">'The vesting percentage of Restricted Stock Units ("RSUs") granted.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VestingPercentageOfRestrictedStockUnits" xlink:to="galt_VestingPercentageOfRestrictedStockUnits_lbl" xlink:title="label: VestingPercentageOfRestrictedStockUnits to galt_VestingPercentageOfRestrictedStockUnits_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_VestingPercentageOfRestrictedStockUnits_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_VestingPercentageOfRestrictedStockUnits_lbl1" xml:lang="en-US" id="galt_VestingPercentageOfRestrictedStockUnits_lbl1">Vesting Percentage of Restricted Stock Units</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VestingPercentageOfRestrictedStockUnits" xlink:to="galt_VestingPercentageOfRestrictedStockUnits_lbl1" xlink:title="label: VestingPercentageOfRestrictedStockUnits to galt_VestingPercentageOfRestrictedStockUnits_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_VestingPercentageOfRestrictedStockUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_VestingPercentageOfRestrictedStockUnits" xml:lang="en-US" id="galt_VestingPercentageOfRestrictedStockUnits">Vesting percentage of Restricted Stock Units</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VestingPercentageOfRestrictedStockUnits" xlink:to="galt_VestingPercentageOfRestrictedStockUnits" xlink:title="label: VestingPercentageOfRestrictedStockUnits to galt_VestingPercentageOfRestrictedStockUnits" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_NumberOfDirectors" xlink:label="NumberOfDirectors" xlink:title="NumberOfDirectors" />
    <link:label xlink:type="resource" xlink:label="galt_NumberOfDirectors_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_NumberOfDirectors_lbl" xml:lang="en-US" id="galt_NumberOfDirectors_lbl">Number of directors of the company.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfDirectors" xlink:to="galt_NumberOfDirectors_lbl" xlink:title="label: NumberOfDirectors to galt_NumberOfDirectors_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_NumberOfDirectors_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_NumberOfDirectors_lbl1" xml:lang="en-US" id="galt_NumberOfDirectors_lbl1">Number of Directors</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfDirectors" xlink:to="galt_NumberOfDirectors_lbl1" xlink:title="label: NumberOfDirectors to galt_NumberOfDirectors_lbl1" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_SeriesBWarrantsMember" xlink:label="SeriesBWarrantsMember" xlink:title="SeriesBWarrantsMember" />
    <link:label xlink:type="resource" xlink:label="galt_SeriesBWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_SeriesBWarrantsMember_lbl" xml:lang="en-US" id="galt_SeriesBWarrantsMember_lbl">Class of security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesBWarrantsMember" xlink:to="galt_SeriesBWarrantsMember_lbl" xlink:title="label: SeriesBWarrantsMember to galt_SeriesBWarrantsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_SeriesBWarrantsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_SeriesBWarrantsMember_lbl1" xml:lang="en-US" id="galt_SeriesBWarrantsMember_lbl1">Series B Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesBWarrantsMember" xlink:to="galt_SeriesBWarrantsMember_lbl1" xlink:title="label: SeriesBWarrantsMember to galt_SeriesBWarrantsMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_NumberOfTradingDaysToBeConsideredStockClosingPriceInPurchaseAgreement" xlink:label="NumberOfTradingDaysToBeConsideredStockClosingPriceInPurchaseAgreement" xlink:title="NumberOfTradingDaysToBeConsideredStockClosingPriceInPurchaseAgreement" />
    <link:label xlink:type="resource" xlink:label="galt_NumberOfTradingDaysToBeConsideredStockClosingPriceInPurchaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_NumberOfTradingDaysToBeConsideredStockClosingPriceInPurchaseAgreement_lbl" xml:lang="en-US" id="galt_NumberOfTradingDaysToBeConsideredStockClosingPriceInPurchaseAgreement_lbl">Period of specified trading days that common stock price must exceed threshold price for specified number of trading days, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfTradingDaysToBeConsideredStockClosingPriceInPurchaseAgreement" xlink:to="galt_NumberOfTradingDaysToBeConsideredStockClosingPriceInPurchaseAgreement_lbl" xlink:title="label: NumberOfTradingDaysToBeConsideredStockClosingPriceInPurchaseAgreement to galt_NumberOfTradingDaysToBeConsideredStockClosingPriceInPurchaseAgreement_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_NumberOfTradingDaysToBeConsideredStockClosingPriceInPurchaseAgreement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_NumberOfTradingDaysToBeConsideredStockClosingPriceInPurchaseAgreement_lbl1" xml:lang="en-US" id="galt_NumberOfTradingDaysToBeConsideredStockClosingPriceInPurchaseAgreement_lbl1">Number of Trading Days to be Considered Stock Closing Price in Purchase Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfTradingDaysToBeConsideredStockClosingPriceInPurchaseAgreement" xlink:to="galt_NumberOfTradingDaysToBeConsideredStockClosingPriceInPurchaseAgreement_lbl1" xlink:title="label: NumberOfTradingDaysToBeConsideredStockClosingPriceInPurchaseAgreement to galt_NumberOfTradingDaysToBeConsideredStockClosingPriceInPurchaseAgreement_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_NumberOfTradingDaysToBeConsideredStockClosingPriceInPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_NumberOfTradingDaysToBeConsideredStockClosingPriceInPurchaseAgreement" xml:lang="en-US" id="galt_NumberOfTradingDaysToBeConsideredStockClosingPriceInPurchaseAgreement">Number of consecutive trading days to be considered in purchase agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfTradingDaysToBeConsideredStockClosingPriceInPurchaseAgreement" xlink:to="galt_NumberOfTradingDaysToBeConsideredStockClosingPriceInPurchaseAgreement" xlink:title="label: NumberOfTradingDaysToBeConsideredStockClosingPriceInPurchaseAgreement to galt_NumberOfTradingDaysToBeConsideredStockClosingPriceInPurchaseAgreement" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ThresholdPeriodForStockClosingPriceInTenConsecutiveDaysUnderPurchaseWarrantsAgreement" xlink:label="ThresholdPeriodForStockClosingPriceInTenConsecutiveDaysUnderPurchaseWarrantsAgreement" xlink:title="ThresholdPeriodForStockClosingPriceInTenConsecutiveDaysUnderPurchaseWarrantsAgreement" />
    <link:label xlink:type="resource" xlink:label="galt_ThresholdPeriodForStockClosingPriceInTenConsecutiveDaysUnderPurchaseWarrantsAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_ThresholdPeriodForStockClosingPriceInTenConsecutiveDaysUnderPurchaseWarrantsAgreement_lbl" xml:lang="en-US" id="galt_ThresholdPeriodForStockClosingPriceInTenConsecutiveDaysUnderPurchaseWarrantsAgreement_lbl">Threshold period for stock closing price in ten consecutive days under purchase warrants agreement in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ThresholdPeriodForStockClosingPriceInTenConsecutiveDaysUnderPurchaseWarrantsAgreement" xlink:to="galt_ThresholdPeriodForStockClosingPriceInTenConsecutiveDaysUnderPurchaseWarrantsAgreement_lbl" xlink:title="label: ThresholdPeriodForStockClosingPriceInTenConsecutiveDaysUnderPurchaseWarrantsAgreement to galt_ThresholdPeriodForStockClosingPriceInTenConsecutiveDaysUnderPurchaseWarrantsAgreement_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_ThresholdPeriodForStockClosingPriceInTenConsecutiveDaysUnderPurchaseWarrantsAgreement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_ThresholdPeriodForStockClosingPriceInTenConsecutiveDaysUnderPurchaseWarrantsAgreement_lbl1" xml:lang="en-US" id="galt_ThresholdPeriodForStockClosingPriceInTenConsecutiveDaysUnderPurchaseWarrantsAgreement_lbl1">Threshold Period for Stock Closing Price in Ten Consecutive Days under Purchase Warrants Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ThresholdPeriodForStockClosingPriceInTenConsecutiveDaysUnderPurchaseWarrantsAgreement" xlink:to="galt_ThresholdPeriodForStockClosingPriceInTenConsecutiveDaysUnderPurchaseWarrantsAgreement_lbl1" xlink:title="label: ThresholdPeriodForStockClosingPriceInTenConsecutiveDaysUnderPurchaseWarrantsAgreement to galt_ThresholdPeriodForStockClosingPriceInTenConsecutiveDaysUnderPurchaseWarrantsAgreement_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_ThresholdPeriodForStockClosingPriceInTenConsecutiveDaysUnderPurchaseWarrantsAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_ThresholdPeriodForStockClosingPriceInTenConsecutiveDaysUnderPurchaseWarrantsAgreement" xml:lang="en-US" id="galt_ThresholdPeriodForStockClosingPriceInTenConsecutiveDaysUnderPurchaseWarrantsAgreement">Threshold period for stock closing price in 10 consecutive days under purchase warrants agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ThresholdPeriodForStockClosingPriceInTenConsecutiveDaysUnderPurchaseWarrantsAgreement" xlink:to="galt_ThresholdPeriodForStockClosingPriceInTenConsecutiveDaysUnderPurchaseWarrantsAgreement" xlink:title="label: ThresholdPeriodForStockClosingPriceInTenConsecutiveDaysUnderPurchaseWarrantsAgreement to galt_ThresholdPeriodForStockClosingPriceInTenConsecutiveDaysUnderPurchaseWarrantsAgreement" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_PeriodOfPriorNoticeThatWouldBarVoluntaryExerciseOfAnyWarrants" xlink:label="PeriodOfPriorNoticeThatWouldBarVoluntaryExerciseOfAnyWarrants" xlink:title="PeriodOfPriorNoticeThatWouldBarVoluntaryExerciseOfAnyWarrants" />
    <link:label xlink:type="resource" xlink:label="galt_PeriodOfPriorNoticeThatWouldBarVoluntaryExerciseOfAnyWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_PeriodOfPriorNoticeThatWouldBarVoluntaryExerciseOfAnyWarrants_lbl" xml:lang="en-US" id="galt_PeriodOfPriorNoticeThatWouldBarVoluntaryExerciseOfAnyWarrants_lbl">Number of prior notice days required that would bar the voluntary exercise of any warrants that would result in beneficial ownership beyond specified percentage, in P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodOfPriorNoticeThatWouldBarVoluntaryExerciseOfAnyWarrants" xlink:to="galt_PeriodOfPriorNoticeThatWouldBarVoluntaryExerciseOfAnyWarrants_lbl" xlink:title="label: PeriodOfPriorNoticeThatWouldBarVoluntaryExerciseOfAnyWarrants to galt_PeriodOfPriorNoticeThatWouldBarVoluntaryExerciseOfAnyWarrants_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_PeriodOfPriorNoticeThatWouldBarVoluntaryExerciseOfAnyWarrants_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_PeriodOfPriorNoticeThatWouldBarVoluntaryExerciseOfAnyWarrants_lbl1" xml:lang="en-US" id="galt_PeriodOfPriorNoticeThatWouldBarVoluntaryExerciseOfAnyWarrants_lbl1">Period of Prior Notice that Would Bar Voluntary Exercise of any Warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodOfPriorNoticeThatWouldBarVoluntaryExerciseOfAnyWarrants" xlink:to="galt_PeriodOfPriorNoticeThatWouldBarVoluntaryExerciseOfAnyWarrants_lbl1" xlink:title="label: PeriodOfPriorNoticeThatWouldBarVoluntaryExerciseOfAnyWarrants to galt_PeriodOfPriorNoticeThatWouldBarVoluntaryExerciseOfAnyWarrants_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_PeriodOfPriorNoticeThatWouldBarVoluntaryExerciseOfAnyWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_PeriodOfPriorNoticeThatWouldBarVoluntaryExerciseOfAnyWarrants" xml:lang="en-US" id="galt_PeriodOfPriorNoticeThatWouldBarVoluntaryExerciseOfAnyWarrants">Period of prior notice that would bar voluntary exercise of any warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodOfPriorNoticeThatWouldBarVoluntaryExerciseOfAnyWarrants" xlink:to="galt_PeriodOfPriorNoticeThatWouldBarVoluntaryExerciseOfAnyWarrants" xlink:title="label: PeriodOfPriorNoticeThatWouldBarVoluntaryExerciseOfAnyWarrants to galt_PeriodOfPriorNoticeThatWouldBarVoluntaryExerciseOfAnyWarrants" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ThresholdPeriodForExtensionOfExerciseDateOfPurchaseWarrantsUnderAgreement" xlink:label="ThresholdPeriodForExtensionOfExerciseDateOfPurchaseWarrantsUnderAgreement" xlink:title="ThresholdPeriodForExtensionOfExerciseDateOfPurchaseWarrantsUnderAgreement" />
    <link:label xlink:type="resource" xlink:label="galt_ThresholdPeriodForExtensionOfExerciseDateOfPurchaseWarrantsUnderAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_ThresholdPeriodForExtensionOfExerciseDateOfPurchaseWarrantsUnderAgreement_lbl" xml:lang="en-US" id="galt_ThresholdPeriodForExtensionOfExerciseDateOfPurchaseWarrantsUnderAgreement_lbl">Threshold period for extension of exercise date of common stock purchase warrants under purchase agreement in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ThresholdPeriodForExtensionOfExerciseDateOfPurchaseWarrantsUnderAgreement" xlink:to="galt_ThresholdPeriodForExtensionOfExerciseDateOfPurchaseWarrantsUnderAgreement_lbl" xlink:title="label: ThresholdPeriodForExtensionOfExerciseDateOfPurchaseWarrantsUnderAgreement to galt_ThresholdPeriodForExtensionOfExerciseDateOfPurchaseWarrantsUnderAgreement_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_ThresholdPeriodForExtensionOfExerciseDateOfPurchaseWarrantsUnderAgreement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_ThresholdPeriodForExtensionOfExerciseDateOfPurchaseWarrantsUnderAgreement_lbl1" xml:lang="en-US" id="galt_ThresholdPeriodForExtensionOfExerciseDateOfPurchaseWarrantsUnderAgreement_lbl1">Threshold Period for Extension of Exercise Date of Purchase Warrants under Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ThresholdPeriodForExtensionOfExerciseDateOfPurchaseWarrantsUnderAgreement" xlink:to="galt_ThresholdPeriodForExtensionOfExerciseDateOfPurchaseWarrantsUnderAgreement_lbl1" xlink:title="label: ThresholdPeriodForExtensionOfExerciseDateOfPurchaseWarrantsUnderAgreement to galt_ThresholdPeriodForExtensionOfExerciseDateOfPurchaseWarrantsUnderAgreement_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_ThresholdPeriodForExtensionOfExerciseDateOfPurchaseWarrantsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_ThresholdPeriodForExtensionOfExerciseDateOfPurchaseWarrantsUnderAgreement" xml:lang="en-US" id="galt_ThresholdPeriodForExtensionOfExerciseDateOfPurchaseWarrantsUnderAgreement">Threshold period for extension of exercise date of purchase warrants under purchase agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ThresholdPeriodForExtensionOfExerciseDateOfPurchaseWarrantsUnderAgreement" xlink:to="galt_ThresholdPeriodForExtensionOfExerciseDateOfPurchaseWarrantsUnderAgreement" xlink:title="label: ThresholdPeriodForExtensionOfExerciseDateOfPurchaseWarrantsUnderAgreement to galt_ThresholdPeriodForExtensionOfExerciseDateOfPurchaseWarrantsUnderAgreement" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_One0XFundLPMember" xlink:label="One0XFundLPMember" xlink:title="One0XFundLPMember" />
    <link:label xlink:type="resource" xlink:label="galt_One0XFundLPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_One0XFundLPMember_lbl" xml:lang="en-US" id="galt_One0XFundLPMember_lbl">Name of beneficial owner.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="One0XFundLPMember" xlink:to="galt_One0XFundLPMember_lbl" xlink:title="label: One0XFundLPMember to galt_One0XFundLPMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_One0XFundLPMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_One0XFundLPMember_lbl1" xml:lang="en-US" id="galt_One0XFundLPMember_lbl1">10X Fund L.P [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="One0XFundLPMember" xlink:to="galt_One0XFundLPMember_lbl1" xlink:title="label: One0XFundLPMember to galt_One0XFundLPMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_One0XFundLPAnd10XCapitalManagementLLCMember" xlink:label="One0XFundLPAnd10XCapitalManagementLLCMember" xlink:title="One0XFundLPAnd10XCapitalManagementLLCMember" />
    <link:label xlink:type="resource" xlink:label="galt_One0XFundLPAnd10XCapitalManagementLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_One0XFundLPAnd10XCapitalManagementLLCMember_lbl" xml:lang="en-US" id="galt_One0XFundLPAnd10XCapitalManagementLLCMember_lbl">Name of beneficial ownership entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="One0XFundLPAnd10XCapitalManagementLLCMember" xlink:to="galt_One0XFundLPAnd10XCapitalManagementLLCMember_lbl" xlink:title="label: One0XFundLPAnd10XCapitalManagementLLCMember to galt_One0XFundLPAnd10XCapitalManagementLLCMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_One0XFundLPAnd10XCapitalManagementLLCMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_One0XFundLPAnd10XCapitalManagementLLCMember_lbl1" xml:lang="en-US" id="galt_One0XFundLPAnd10XCapitalManagementLLCMember_lbl1">10X Fund L.P., and 10X Capital Management LLC [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="One0XFundLPAnd10XCapitalManagementLLCMember" xlink:to="galt_One0XFundLPAnd10XCapitalManagementLLCMember_lbl1" xlink:title="label: One0XFundLPAnd10XCapitalManagementLLCMember to galt_One0XFundLPAnd10XCapitalManagementLLCMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_BeneficialOwnershipPercentage" xlink:label="BeneficialOwnershipPercentage" xlink:title="BeneficialOwnershipPercentage" />
    <link:label xlink:type="resource" xlink:label="galt_BeneficialOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_BeneficialOwnershipPercentage_lbl" xml:lang="en-US" id="galt_BeneficialOwnershipPercentage_lbl">Beneficial ownership percentage of the outstanding shares of the Company's Class A common stock that would allow warrants to be settled in cash upon the occurrence of a tender offer or exchange offer.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BeneficialOwnershipPercentage" xlink:to="galt_BeneficialOwnershipPercentage_lbl" xlink:title="label: BeneficialOwnershipPercentage to galt_BeneficialOwnershipPercentage_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_BeneficialOwnershipPercentage_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_BeneficialOwnershipPercentage_lbl1" xml:lang="en-US" id="galt_BeneficialOwnershipPercentage_lbl1">Beneficial Ownership Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BeneficialOwnershipPercentage" xlink:to="galt_BeneficialOwnershipPercentage_lbl1" xlink:title="label: BeneficialOwnershipPercentage to galt_BeneficialOwnershipPercentage_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_BeneficialOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_BeneficialOwnershipPercentage" xml:lang="en-US" id="galt_BeneficialOwnershipPercentage">Beneficial ownership percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BeneficialOwnershipPercentage" xlink:to="galt_BeneficialOwnershipPercentage" xlink:title="label: BeneficialOwnershipPercentage to galt_BeneficialOwnershipPercentage" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_BeforeModificationMember" xlink:label="BeforeModificationMember" xlink:title="BeforeModificationMember" />
    <link:label xlink:type="resource" xlink:label="galt_BeforeModificationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_BeforeModificationMember_lbl" xml:lang="en-US" id="galt_BeforeModificationMember_lbl">Change in fair value of the warrants immediately before the modification.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BeforeModificationMember" xlink:to="galt_BeforeModificationMember_lbl" xlink:title="label: BeforeModificationMember to galt_BeforeModificationMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_BeforeModificationMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_BeforeModificationMember_lbl1" xml:lang="en-US" id="galt_BeforeModificationMember_lbl1">Before Modification [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BeforeModificationMember" xlink:to="galt_BeforeModificationMember_lbl1" xlink:title="label: BeforeModificationMember to galt_BeforeModificationMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_BeforeModificationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_BeforeModificationMember" xml:lang="en-US" id="galt_BeforeModificationMember">Before Modification [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BeforeModificationMember" xlink:to="galt_BeforeModificationMember" xlink:title="label: BeforeModificationMember to galt_BeforeModificationMember" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_AfterModificationMember" xlink:label="AfterModificationMember" xlink:title="AfterModificationMember" />
    <link:label xlink:type="resource" xlink:label="galt_AfterModificationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_AfterModificationMember_lbl" xml:lang="en-US" id="galt_AfterModificationMember_lbl">Change in fair value of the warrants immediately after the modification.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AfterModificationMember" xlink:to="galt_AfterModificationMember_lbl" xlink:title="label: AfterModificationMember to galt_AfterModificationMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_AfterModificationMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_AfterModificationMember_lbl1" xml:lang="en-US" id="galt_AfterModificationMember_lbl1">After Modification [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AfterModificationMember" xlink:to="galt_AfterModificationMember_lbl1" xlink:title="label: AfterModificationMember to galt_AfterModificationMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_AfterModificationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_AfterModificationMember" xml:lang="en-US" id="galt_AfterModificationMember">After Modification [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AfterModificationMember" xlink:to="galt_AfterModificationMember" xlink:title="label: AfterModificationMember to galt_AfterModificationMember" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_WarrantModificationIncreaseDecreaseInEquityAmount" xlink:label="WarrantModificationIncreaseDecreaseInEquityAmount" xlink:title="WarrantModificationIncreaseDecreaseInEquityAmount" />
    <link:label xlink:type="resource" xlink:label="galt_WarrantModificationIncreaseDecreaseInEquityAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_WarrantModificationIncreaseDecreaseInEquityAmount_lbl" xml:lang="en-US" id="galt_WarrantModificationIncreaseDecreaseInEquityAmount_lbl">Amount of increase (decrease) in equity for Warrants classified as equity from modification.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantModificationIncreaseDecreaseInEquityAmount" xlink:to="galt_WarrantModificationIncreaseDecreaseInEquityAmount_lbl" xlink:title="label: WarrantModificationIncreaseDecreaseInEquityAmount to galt_WarrantModificationIncreaseDecreaseInEquityAmount_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_WarrantModificationIncreaseDecreaseInEquityAmount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_WarrantModificationIncreaseDecreaseInEquityAmount_lbl1" xml:lang="en-US" id="galt_WarrantModificationIncreaseDecreaseInEquityAmount_lbl1">Warrant Modification, Increase (Decrease) in Equity, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantModificationIncreaseDecreaseInEquityAmount" xlink:to="galt_WarrantModificationIncreaseDecreaseInEquityAmount_lbl1" xlink:title="label: WarrantModificationIncreaseDecreaseInEquityAmount to galt_WarrantModificationIncreaseDecreaseInEquityAmount_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_WarrantModificationIncreaseDecreaseInEquityAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_WarrantModificationIncreaseDecreaseInEquityAmount" xml:lang="en-US" id="galt_WarrantModificationIncreaseDecreaseInEquityAmount">Warrant modification</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantModificationIncreaseDecreaseInEquityAmount" xlink:to="galt_WarrantModificationIncreaseDecreaseInEquityAmount" xlink:title="label: WarrantModificationIncreaseDecreaseInEquityAmount to galt_WarrantModificationIncreaseDecreaseInEquityAmount" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_TemporaryEquityDividends" xlink:label="TemporaryEquityDividends" xlink:title="TemporaryEquityDividends" />
    <link:label xlink:type="resource" xlink:label="galt_TemporaryEquityDividends_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_TemporaryEquityDividends_lbl" xml:lang="en-US" id="galt_TemporaryEquityDividends_lbl">Amount of paid and unpaid temporary equity dividends declared with the form of settlement in cash.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityDividends" xlink:to="galt_TemporaryEquityDividends_lbl" xlink:title="label: TemporaryEquityDividends to galt_TemporaryEquityDividends_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_TemporaryEquityDividends_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_TemporaryEquityDividends_lbl1" xml:lang="en-US" id="galt_TemporaryEquityDividends_lbl1">Temporary Equity Dividends</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityDividends" xlink:to="galt_TemporaryEquityDividends_lbl1" xlink:title="label: TemporaryEquityDividends to galt_TemporaryEquityDividends_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_TemporaryEquityDividends" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="galt_TemporaryEquityDividends" xml:lang="en-US" id="galt_TemporaryEquityDividends">Series C super dividend redeemable convertible preferred stock dividend</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityDividends" xlink:to="galt_TemporaryEquityDividends" xlink:title="label: TemporaryEquityDividends to galt_TemporaryEquityDividends" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ConvertiblePreferredStockDividends" xlink:label="ConvertiblePreferredStockDividends" xlink:title="ConvertiblePreferredStockDividends" />
    <link:label xlink:type="resource" xlink:label="galt_ConvertiblePreferredStockDividends_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_ConvertiblePreferredStockDividends_lbl" xml:lang="en-US" id="galt_ConvertiblePreferredStockDividends_lbl">Amount of paid and unpaid convertible preferred stock dividends declared with the form of settlement in cash.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertiblePreferredStockDividends" xlink:to="galt_ConvertiblePreferredStockDividends_lbl" xlink:title="label: ConvertiblePreferredStockDividends to galt_ConvertiblePreferredStockDividends_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_ConvertiblePreferredStockDividends_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_ConvertiblePreferredStockDividends_lbl1" xml:lang="en-US" id="galt_ConvertiblePreferredStockDividends_lbl1">Convertible Preferred Stock, Dividends</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertiblePreferredStockDividends" xlink:to="galt_ConvertiblePreferredStockDividends_lbl1" xlink:title="label: ConvertiblePreferredStockDividends to galt_ConvertiblePreferredStockDividends_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_ConvertiblePreferredStockDividends" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_ConvertiblePreferredStockDividends" xml:lang="en-US" id="galt_ConvertiblePreferredStockDividends">Series A 12% convertible preferred stock dividend</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertiblePreferredStockDividends" xlink:to="galt_ConvertiblePreferredStockDividends" xlink:title="label: ConvertiblePreferredStockDividends to galt_ConvertiblePreferredStockDividends" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ConvertiblePreferredStockDividendsShares" xlink:label="ConvertiblePreferredStockDividendsShares" xlink:title="ConvertiblePreferredStockDividendsShares" />
    <link:label xlink:type="resource" xlink:label="galt_ConvertiblePreferredStockDividendsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_ConvertiblePreferredStockDividendsShares_lbl" xml:lang="en-US" id="galt_ConvertiblePreferredStockDividendsShares_lbl">Number of shares of Convertible preferred stock issued as dividends during the period. Excludes stock splits.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertiblePreferredStockDividendsShares" xlink:to="galt_ConvertiblePreferredStockDividendsShares_lbl" xlink:title="label: ConvertiblePreferredStockDividendsShares to galt_ConvertiblePreferredStockDividendsShares_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_ConvertiblePreferredStockDividendsShares_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_ConvertiblePreferredStockDividendsShares_lbl1" xml:lang="en-US" id="galt_ConvertiblePreferredStockDividendsShares_lbl1">Convertible Preferred Stock Dividends, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertiblePreferredStockDividendsShares" xlink:to="galt_ConvertiblePreferredStockDividendsShares_lbl1" xlink:title="label: ConvertiblePreferredStockDividendsShares to galt_ConvertiblePreferredStockDividendsShares_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_ConvertiblePreferredStockDividendsShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_ConvertiblePreferredStockDividendsShares" xml:lang="en-US" id="galt_ConvertiblePreferredStockDividendsShares">Series A 12% convertible preferred stock dividend (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertiblePreferredStockDividendsShares" xlink:to="galt_ConvertiblePreferredStockDividendsShares" xlink:title="label: ConvertiblePreferredStockDividendsShares to galt_ConvertiblePreferredStockDividendsShares" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_TemporaryEquityDividendsShares" xlink:label="TemporaryEquityDividendsShares" xlink:title="TemporaryEquityDividendsShares" />
    <link:label xlink:type="resource" xlink:label="galt_TemporaryEquityDividendsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_TemporaryEquityDividendsShares_lbl" xml:lang="en-US" id="galt_TemporaryEquityDividendsShares_lbl">Number of shares of common stock issued as dividends for temporary equity during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityDividendsShares" xlink:to="galt_TemporaryEquityDividendsShares_lbl" xlink:title="label: TemporaryEquityDividendsShares to galt_TemporaryEquityDividendsShares_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_TemporaryEquityDividendsShares_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_TemporaryEquityDividendsShares_lbl1" xml:lang="en-US" id="galt_TemporaryEquityDividendsShares_lbl1">Temporary Equity Dividends, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityDividendsShares" xlink:to="galt_TemporaryEquityDividendsShares_lbl1" xlink:title="label: TemporaryEquityDividendsShares to galt_TemporaryEquityDividendsShares_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_TemporaryEquityDividendsShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_TemporaryEquityDividendsShares" xml:lang="en-US" id="galt_TemporaryEquityDividendsShares">Series C super dividend redeemable convertible preferred stock dividend (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityDividendsShares" xlink:to="galt_TemporaryEquityDividendsShares" xlink:title="label: TemporaryEquityDividendsShares to galt_TemporaryEquityDividendsShares" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_StockIssuedDuringPeriodValueWarrantExercise" xlink:label="StockIssuedDuringPeriodValueWarrantExercise" xlink:title="StockIssuedDuringPeriodValueWarrantExercise" />
    <link:label xlink:type="resource" xlink:label="galt_StockIssuedDuringPeriodValueWarrantExercise_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_StockIssuedDuringPeriodValueWarrantExercise_lbl" xml:lang="en-US" id="galt_StockIssuedDuringPeriodValueWarrantExercise_lbl">Equity impact of the value of stock issued from the exercise of warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueWarrantExercise" xlink:to="galt_StockIssuedDuringPeriodValueWarrantExercise_lbl" xlink:title="label: StockIssuedDuringPeriodValueWarrantExercise to galt_StockIssuedDuringPeriodValueWarrantExercise_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_StockIssuedDuringPeriodValueWarrantExercise_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_StockIssuedDuringPeriodValueWarrantExercise_lbl1" xml:lang="en-US" id="galt_StockIssuedDuringPeriodValueWarrantExercise_lbl1">Stock Issued During Period Value Warrant Exercise</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueWarrantExercise" xlink:to="galt_StockIssuedDuringPeriodValueWarrantExercise_lbl1" xlink:title="label: StockIssuedDuringPeriodValueWarrantExercise to galt_StockIssuedDuringPeriodValueWarrantExercise_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_StockIssuedDuringPeriodValueWarrantExercise" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_StockIssuedDuringPeriodValueWarrantExercise" xml:lang="en-US" id="galt_StockIssuedDuringPeriodValueWarrantExercise">Issuance of common stock from exercise of warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueWarrantExercise" xlink:to="galt_StockIssuedDuringPeriodValueWarrantExercise" xlink:title="label: StockIssuedDuringPeriodValueWarrantExercise to galt_StockIssuedDuringPeriodValueWarrantExercise" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_StockIssuedDuringPeriodSharesWarrantExercise" xlink:label="StockIssuedDuringPeriodSharesWarrantExercise" xlink:title="StockIssuedDuringPeriodSharesWarrantExercise" />
    <link:label xlink:type="resource" xlink:label="galt_StockIssuedDuringPeriodSharesWarrantExercise_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_StockIssuedDuringPeriodSharesWarrantExercise_lbl" xml:lang="en-US" id="galt_StockIssuedDuringPeriodSharesWarrantExercise_lbl">Number of new stock issued upon the exercise of warrants during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesWarrantExercise" xlink:to="galt_StockIssuedDuringPeriodSharesWarrantExercise_lbl" xlink:title="label: StockIssuedDuringPeriodSharesWarrantExercise to galt_StockIssuedDuringPeriodSharesWarrantExercise_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_StockIssuedDuringPeriodSharesWarrantExercise_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_StockIssuedDuringPeriodSharesWarrantExercise_lbl1" xml:lang="en-US" id="galt_StockIssuedDuringPeriodSharesWarrantExercise_lbl1">Stock Issued During Period Shares Warrant Exercise</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesWarrantExercise" xlink:to="galt_StockIssuedDuringPeriodSharesWarrantExercise_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesWarrantExercise to galt_StockIssuedDuringPeriodSharesWarrantExercise_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_StockIssuedDuringPeriodSharesWarrantExercise" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_StockIssuedDuringPeriodSharesWarrantExercise" xml:lang="en-US" id="galt_StockIssuedDuringPeriodSharesWarrantExercise">Issuance of common stock from exercise of warrants (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesWarrantExercise" xlink:to="galt_StockIssuedDuringPeriodSharesWarrantExercise" xlink:title="label: StockIssuedDuringPeriodSharesWarrantExercise to galt_StockIssuedDuringPeriodSharesWarrantExercise" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ContingentInterestDecemberNoteMember" xlink:label="ContingentInterestDecemberNoteMember" xlink:title="ContingentInterestDecemberNoteMember" />
    <link:label xlink:type="resource" xlink:label="galt_ContingentInterestDecemberNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_ContingentInterestDecemberNoteMember_lbl" xml:lang="en-US" id="galt_ContingentInterestDecemberNoteMember_lbl">The derivative liability of contingent interest December Note.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContingentInterestDecemberNoteMember" xlink:to="galt_ContingentInterestDecemberNoteMember_lbl" xlink:title="label: ContingentInterestDecemberNoteMember to galt_ContingentInterestDecemberNoteMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_ContingentInterestDecemberNoteMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_ContingentInterestDecemberNoteMember_lbl1" xml:lang="en-US" id="galt_ContingentInterestDecemberNoteMember_lbl1">Contingent Interest, December Note [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContingentInterestDecemberNoteMember" xlink:to="galt_ContingentInterestDecemberNoteMember_lbl1" xlink:title="label: ContingentInterestDecemberNoteMember to galt_ContingentInterestDecemberNoteMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_ContingentInterestDecemberNoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_ContingentInterestDecemberNoteMember" xml:lang="en-US" id="galt_ContingentInterestDecemberNoteMember">December Note [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContingentInterestDecemberNoteMember" xlink:to="galt_ContingentInterestDecemberNoteMember" xlink:title="label: ContingentInterestDecemberNoteMember to galt_ContingentInterestDecemberNoteMember" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ContingentInterestSeptemberNoteMember" xlink:label="ContingentInterestSeptemberNoteMember" xlink:title="ContingentInterestSeptemberNoteMember" />
    <link:label xlink:type="resource" xlink:label="galt_ContingentInterestSeptemberNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_ContingentInterestSeptemberNoteMember_lbl" xml:lang="en-US" id="galt_ContingentInterestSeptemberNoteMember_lbl">The derivative liability of contingent interest September Note.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContingentInterestSeptemberNoteMember" xlink:to="galt_ContingentInterestSeptemberNoteMember_lbl" xlink:title="label: ContingentInterestSeptemberNoteMember to galt_ContingentInterestSeptemberNoteMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_ContingentInterestSeptemberNoteMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_ContingentInterestSeptemberNoteMember_lbl1" xml:lang="en-US" id="galt_ContingentInterestSeptemberNoteMember_lbl1">Contingent Interest, September Note [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContingentInterestSeptemberNoteMember" xlink:to="galt_ContingentInterestSeptemberNoteMember_lbl1" xlink:title="label: ContingentInterestSeptemberNoteMember to galt_ContingentInterestSeptemberNoteMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_ContingentInterestSeptemberNoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_ContingentInterestSeptemberNoteMember" xml:lang="en-US" id="galt_ContingentInterestSeptemberNoteMember">September Note [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContingentInterestSeptemberNoteMember" xlink:to="galt_ContingentInterestSeptemberNoteMember" xlink:title="label: ContingentInterestSeptemberNoteMember to galt_ContingentInterestSeptemberNoteMember" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ContingentInterestAprilNoteMember" xlink:label="ContingentInterestAprilNoteMember" xlink:title="ContingentInterestAprilNoteMember" />
    <link:label xlink:type="resource" xlink:label="galt_ContingentInterestAprilNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_ContingentInterestAprilNoteMember_lbl" xml:lang="en-US" id="galt_ContingentInterestAprilNoteMember_lbl">The derivative liability of contingent interest April Note.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContingentInterestAprilNoteMember" xlink:to="galt_ContingentInterestAprilNoteMember_lbl" xlink:title="label: ContingentInterestAprilNoteMember to galt_ContingentInterestAprilNoteMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_ContingentInterestAprilNoteMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_ContingentInterestAprilNoteMember_lbl1" xml:lang="en-US" id="galt_ContingentInterestAprilNoteMember_lbl1">Contingent Interest, April Note [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContingentInterestAprilNoteMember" xlink:to="galt_ContingentInterestAprilNoteMember_lbl1" xlink:title="label: ContingentInterestAprilNoteMember to galt_ContingentInterestAprilNoteMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_ContingentInterestAprilNoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_ContingentInterestAprilNoteMember" xml:lang="en-US" id="galt_ContingentInterestAprilNoteMember">April Note [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContingentInterestAprilNoteMember" xlink:to="galt_ContingentInterestAprilNoteMember" xlink:title="label: ContingentInterestAprilNoteMember to galt_ContingentInterestAprilNoteMember" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_NonQualifiedOptionsPlansMember" xlink:label="NonQualifiedOptionsPlansMember" xlink:title="NonQualifiedOptionsPlansMember" />
    <link:label xlink:type="resource" xlink:label="galt_NonQualifiedOptionsPlansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_NonQualifiedOptionsPlansMember_lbl" xml:lang="en-US" id="galt_NonQualifiedOptionsPlansMember_lbl">Information about non qualified options Plans.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonQualifiedOptionsPlansMember" xlink:to="galt_NonQualifiedOptionsPlansMember_lbl" xlink:title="label: NonQualifiedOptionsPlansMember to galt_NonQualifiedOptionsPlansMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_NonQualifiedOptionsPlansMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_NonQualifiedOptionsPlansMember_lbl1" xml:lang="en-US" id="galt_NonQualifiedOptionsPlansMember_lbl1">Non Qualified Options Plans [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonQualifiedOptionsPlansMember" xlink:to="galt_NonQualifiedOptionsPlansMember_lbl1" xlink:title="label: NonQualifiedOptionsPlansMember to galt_NonQualifiedOptionsPlansMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_IncentiveCompensationPlanTwoThousandNineMemberMember" xlink:label="IncentiveCompensationPlanTwoThousandNineMemberMember" xlink:title="IncentiveCompensationPlanTwoThousandNineMemberMember" />
    <link:label xlink:type="resource" xlink:label="galt_IncentiveCompensationPlanTwoThousandNineMemberMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_IncentiveCompensationPlanTwoThousandNineMemberMember_lbl" xml:lang="en-US" id="galt_IncentiveCompensationPlanTwoThousandNineMemberMember_lbl">Equity Incentive Plan Agreement ("Agreement") is a legal contract between a Corporation and its employees to provide the employee with an interest in the Corporation. The purpose of an Equity Incentive Plan is to strengthen the financials of the Corporation by providing incentive stock options to its employees.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncentiveCompensationPlanTwoThousandNineMemberMember" xlink:to="galt_IncentiveCompensationPlanTwoThousandNineMemberMember_lbl" xlink:title="label: IncentiveCompensationPlanTwoThousandNineMemberMember to galt_IncentiveCompensationPlanTwoThousandNineMemberMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_IncentiveCompensationPlanTwoThousandNineMemberMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_IncentiveCompensationPlanTwoThousandNineMemberMember_lbl1" xml:lang="en-US" id="galt_IncentiveCompensationPlanTwoThousandNineMemberMember_lbl1">Incentive Compensation Plan Two thousand Nine Member [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncentiveCompensationPlanTwoThousandNineMemberMember" xlink:to="galt_IncentiveCompensationPlanTwoThousandNineMemberMember_lbl1" xlink:title="label: IncentiveCompensationPlanTwoThousandNineMemberMember to galt_IncentiveCompensationPlanTwoThousandNineMemberMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_IncentiveCompensationPlanTwoThousandNineMemberMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_IncentiveCompensationPlanTwoThousandNineMemberMember" xml:lang="en-US" id="galt_IncentiveCompensationPlanTwoThousandNineMemberMember">Incentive Compensation Plan 2009 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncentiveCompensationPlanTwoThousandNineMemberMember" xlink:to="galt_IncentiveCompensationPlanTwoThousandNineMemberMember" xlink:title="label: IncentiveCompensationPlanTwoThousandNineMemberMember to galt_IncentiveCompensationPlanTwoThousandNineMemberMember" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_EquityIncentivePlan2019Member" xlink:label="EquityIncentivePlan2019Member" xlink:title="EquityIncentivePlan2019Member" />
    <link:label xlink:type="resource" xlink:label="galt_EquityIncentivePlan2019Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_EquityIncentivePlan2019Member_lbl" xml:lang="en-US" id="galt_EquityIncentivePlan2019Member_lbl">A share-based compensation plan under which awards may be granted for officers, employees and directors of the Company and its subsidiaries.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityIncentivePlan2019Member" xlink:to="galt_EquityIncentivePlan2019Member_lbl" xlink:title="label: EquityIncentivePlan2019Member to galt_EquityIncentivePlan2019Member_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_EquityIncentivePlan2019Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_EquityIncentivePlan2019Member_lbl1" xml:lang="en-US" id="galt_EquityIncentivePlan2019Member_lbl1">Equity Incentive Plan 2019 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityIncentivePlan2019Member" xlink:to="galt_EquityIncentivePlan2019Member_lbl1" xlink:title="label: EquityIncentivePlan2019Member to galt_EquityIncentivePlan2019Member_lbl1" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ReclassificationOfAccruedBonusToAdditionalPaidInCapital" xlink:label="ReclassificationOfAccruedBonusToAdditionalPaidInCapital" xlink:title="ReclassificationOfAccruedBonusToAdditionalPaidInCapital" />
    <link:label xlink:type="resource" xlink:label="galt_ReclassificationOfAccruedBonusToAdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_ReclassificationOfAccruedBonusToAdditionalPaidInCapital_lbl" xml:lang="en-US" id="galt_ReclassificationOfAccruedBonusToAdditionalPaidInCapital_lbl">Amount reclassified from accrued compensation to excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReclassificationOfAccruedBonusToAdditionalPaidInCapital" xlink:to="galt_ReclassificationOfAccruedBonusToAdditionalPaidInCapital_lbl" xlink:title="label: ReclassificationOfAccruedBonusToAdditionalPaidInCapital to galt_ReclassificationOfAccruedBonusToAdditionalPaidInCapital_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_ReclassificationOfAccruedBonusToAdditionalPaidInCapital_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_ReclassificationOfAccruedBonusToAdditionalPaidInCapital_lbl1" xml:lang="en-US" id="galt_ReclassificationOfAccruedBonusToAdditionalPaidInCapital_lbl1">Reclassification Of Accrued Bonus To Additional Paid In Capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReclassificationOfAccruedBonusToAdditionalPaidInCapital" xlink:to="galt_ReclassificationOfAccruedBonusToAdditionalPaidInCapital_lbl1" xlink:title="label: ReclassificationOfAccruedBonusToAdditionalPaidInCapital to galt_ReclassificationOfAccruedBonusToAdditionalPaidInCapital_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_ReclassificationOfAccruedBonusToAdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_ReclassificationOfAccruedBonusToAdditionalPaidInCapital" xml:lang="en-US" id="galt_ReclassificationOfAccruedBonusToAdditionalPaidInCapital">Reclassification of accrued bonus to additional paid in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReclassificationOfAccruedBonusToAdditionalPaidInCapital" xlink:to="galt_ReclassificationOfAccruedBonusToAdditionalPaidInCapital" xlink:title="label: ReclassificationOfAccruedBonusToAdditionalPaidInCapital to galt_ReclassificationOfAccruedBonusToAdditionalPaidInCapital" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit" xlink:label="CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit" xlink:title="CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit" />
    <link:label xlink:type="resource" xlink:label="galt_CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit_lbl" xml:lang="en-US" id="galt_CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit_lbl">The fair value of common stock purchase warrants issued in connection with related party line of credit in noncash financing activities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit" xlink:to="galt_CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit_lbl" xlink:title="label: CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit to galt_CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit_lbl1" xml:lang="en-US" id="galt_CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit_lbl1">Common Stock Purchase Warrants Issued in Connection with Related Party Line of Credit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit" xlink:to="galt_CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit_lbl1" xlink:title="label: CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit to galt_CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit" xml:lang="en-US" id="galt_CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit">Common stock purchase warrants issued in connection with related party line of credit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit" xlink:to="galt_CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit" xlink:title="label: CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit to galt_CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ReturnOnInvestmentsPercentageAbstract" xlink:label="ReturnOnInvestmentsPercentageAbstract" xlink:title="ReturnOnInvestmentsPercentageAbstract" />
    <link:label xlink:type="resource" xlink:label="galt_ReturnOnInvestmentsPercentageAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_ReturnOnInvestmentsPercentageAbstract_lbl1" xml:lang="en-US" id="galt_ReturnOnInvestmentsPercentageAbstract_lbl1">Return on Investments Percentage [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReturnOnInvestmentsPercentageAbstract" xlink:to="galt_ReturnOnInvestmentsPercentageAbstract_lbl1" xlink:title="label: ReturnOnInvestmentsPercentageAbstract to galt_ReturnOnInvestmentsPercentageAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_ReturnOnInvestmentsPercentageAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_ReturnOnInvestmentsPercentageAbstract" xml:lang="en-US" id="galt_ReturnOnInvestmentsPercentageAbstract">ROI Percentage [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReturnOnInvestmentsPercentageAbstract" xlink:to="galt_ReturnOnInvestmentsPercentageAbstract" xlink:title="label: ReturnOnInvestmentsPercentageAbstract to galt_ReturnOnInvestmentsPercentageAbstract" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ReturnOnInvestmentsPercentagePeriodOne" xlink:label="ReturnOnInvestmentsPercentagePeriodOne" xlink:title="ReturnOnInvestmentsPercentagePeriodOne" />
    <link:label xlink:type="resource" xlink:label="galt_ReturnOnInvestmentsPercentagePeriodOne_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_ReturnOnInvestmentsPercentagePeriodOne_lbl" xml:lang="en-US" id="galt_ReturnOnInvestmentsPercentagePeriodOne_lbl">Return on investments percentage before second anniversary of date of issuance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReturnOnInvestmentsPercentagePeriodOne" xlink:to="galt_ReturnOnInvestmentsPercentagePeriodOne_lbl" xlink:title="label: ReturnOnInvestmentsPercentagePeriodOne to galt_ReturnOnInvestmentsPercentagePeriodOne_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_ReturnOnInvestmentsPercentagePeriodOne_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_ReturnOnInvestmentsPercentagePeriodOne_lbl1" xml:lang="en-US" id="galt_ReturnOnInvestmentsPercentagePeriodOne_lbl1">Return on Investments Percentage, Period One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReturnOnInvestmentsPercentagePeriodOne" xlink:to="galt_ReturnOnInvestmentsPercentagePeriodOne_lbl1" xlink:title="label: ReturnOnInvestmentsPercentagePeriodOne to galt_ReturnOnInvestmentsPercentagePeriodOne_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_ReturnOnInvestmentsPercentagePeriodOne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_ReturnOnInvestmentsPercentagePeriodOne" xml:lang="en-US" id="galt_ReturnOnInvestmentsPercentagePeriodOne">ROI before second anniversary of date of issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReturnOnInvestmentsPercentagePeriodOne" xlink:to="galt_ReturnOnInvestmentsPercentagePeriodOne" xlink:title="label: ReturnOnInvestmentsPercentagePeriodOne to galt_ReturnOnInvestmentsPercentagePeriodOne" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ReturnOnInvestmentsPercentagePeriodTwo" xlink:label="ReturnOnInvestmentsPercentagePeriodTwo" xlink:title="ReturnOnInvestmentsPercentagePeriodTwo" />
    <link:label xlink:type="resource" xlink:label="galt_ReturnOnInvestmentsPercentagePeriodTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_ReturnOnInvestmentsPercentagePeriodTwo_lbl" xml:lang="en-US" id="galt_ReturnOnInvestmentsPercentagePeriodTwo_lbl">Return on investments after second anniversary but before third anniversary of date of issuance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReturnOnInvestmentsPercentagePeriodTwo" xlink:to="galt_ReturnOnInvestmentsPercentagePeriodTwo_lbl" xlink:title="label: ReturnOnInvestmentsPercentagePeriodTwo to galt_ReturnOnInvestmentsPercentagePeriodTwo_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_ReturnOnInvestmentsPercentagePeriodTwo_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_ReturnOnInvestmentsPercentagePeriodTwo_lbl1" xml:lang="en-US" id="galt_ReturnOnInvestmentsPercentagePeriodTwo_lbl1">Return on Investments Percentage, Period Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReturnOnInvestmentsPercentagePeriodTwo" xlink:to="galt_ReturnOnInvestmentsPercentagePeriodTwo_lbl1" xlink:title="label: ReturnOnInvestmentsPercentagePeriodTwo to galt_ReturnOnInvestmentsPercentagePeriodTwo_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_ReturnOnInvestmentsPercentagePeriodTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_ReturnOnInvestmentsPercentagePeriodTwo" xml:lang="en-US" id="galt_ReturnOnInvestmentsPercentagePeriodTwo">ROI after second anniversary but before third anniversary of date of issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReturnOnInvestmentsPercentagePeriodTwo" xlink:to="galt_ReturnOnInvestmentsPercentagePeriodTwo" xlink:title="label: ReturnOnInvestmentsPercentagePeriodTwo to galt_ReturnOnInvestmentsPercentagePeriodTwo" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ReturnOnInvestmentsPercentagePeriodEight" xlink:label="ReturnOnInvestmentsPercentagePeriodEight" xlink:title="ReturnOnInvestmentsPercentagePeriodEight" />
    <link:label xlink:type="resource" xlink:label="galt_ReturnOnInvestmentsPercentagePeriodEight_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_ReturnOnInvestmentsPercentagePeriodEight_lbl" xml:lang="en-US" id="galt_ReturnOnInvestmentsPercentagePeriodEight_lbl">Return on investments after eighth anniversary but before ninth anniversary of date of issuance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReturnOnInvestmentsPercentagePeriodEight" xlink:to="galt_ReturnOnInvestmentsPercentagePeriodEight_lbl" xlink:title="label: ReturnOnInvestmentsPercentagePeriodEight to galt_ReturnOnInvestmentsPercentagePeriodEight_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_ReturnOnInvestmentsPercentagePeriodEight_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_ReturnOnInvestmentsPercentagePeriodEight_lbl1" xml:lang="en-US" id="galt_ReturnOnInvestmentsPercentagePeriodEight_lbl1">Return on Investments Percentage, Period Eight</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReturnOnInvestmentsPercentagePeriodEight" xlink:to="galt_ReturnOnInvestmentsPercentagePeriodEight_lbl1" xlink:title="label: ReturnOnInvestmentsPercentagePeriodEight to galt_ReturnOnInvestmentsPercentagePeriodEight_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_ReturnOnInvestmentsPercentagePeriodEight" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_ReturnOnInvestmentsPercentagePeriodEight" xml:lang="en-US" id="galt_ReturnOnInvestmentsPercentagePeriodEight">ROI after eighth anniversary but before ninth anniversary of date of issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReturnOnInvestmentsPercentagePeriodEight" xlink:to="galt_ReturnOnInvestmentsPercentagePeriodEight" xlink:title="label: ReturnOnInvestmentsPercentagePeriodEight to galt_ReturnOnInvestmentsPercentagePeriodEight" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ReturnOnInvestmentsPercentagePeriodSix" xlink:label="ReturnOnInvestmentsPercentagePeriodSix" xlink:title="ReturnOnInvestmentsPercentagePeriodSix" />
    <link:label xlink:type="resource" xlink:label="galt_ReturnOnInvestmentsPercentagePeriodSix_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_ReturnOnInvestmentsPercentagePeriodSix_lbl" xml:lang="en-US" id="galt_ReturnOnInvestmentsPercentagePeriodSix_lbl">Return on investments after sixth anniversary but before seventh anniversary of date of issuance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReturnOnInvestmentsPercentagePeriodSix" xlink:to="galt_ReturnOnInvestmentsPercentagePeriodSix_lbl" xlink:title="label: ReturnOnInvestmentsPercentagePeriodSix to galt_ReturnOnInvestmentsPercentagePeriodSix_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_ReturnOnInvestmentsPercentagePeriodSix_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_ReturnOnInvestmentsPercentagePeriodSix_lbl1" xml:lang="en-US" id="galt_ReturnOnInvestmentsPercentagePeriodSix_lbl1">Return on Investments Percentage, Period Six</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReturnOnInvestmentsPercentagePeriodSix" xlink:to="galt_ReturnOnInvestmentsPercentagePeriodSix_lbl1" xlink:title="label: ReturnOnInvestmentsPercentagePeriodSix to galt_ReturnOnInvestmentsPercentagePeriodSix_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_ReturnOnInvestmentsPercentagePeriodSix" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_ReturnOnInvestmentsPercentagePeriodSix" xml:lang="en-US" id="galt_ReturnOnInvestmentsPercentagePeriodSix">ROI after sixth anniversary but before seventh anniversary of date of issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReturnOnInvestmentsPercentagePeriodSix" xlink:to="galt_ReturnOnInvestmentsPercentagePeriodSix" xlink:title="label: ReturnOnInvestmentsPercentagePeriodSix to galt_ReturnOnInvestmentsPercentagePeriodSix" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ReturnOnInvestmentsPercentagePeriodSeven" xlink:label="ReturnOnInvestmentsPercentagePeriodSeven" xlink:title="ReturnOnInvestmentsPercentagePeriodSeven" />
    <link:label xlink:type="resource" xlink:label="galt_ReturnOnInvestmentsPercentagePeriodSeven_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_ReturnOnInvestmentsPercentagePeriodSeven_lbl" xml:lang="en-US" id="galt_ReturnOnInvestmentsPercentagePeriodSeven_lbl">Return on investments after seventh anniversary but before eighth anniversary of date of issuance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReturnOnInvestmentsPercentagePeriodSeven" xlink:to="galt_ReturnOnInvestmentsPercentagePeriodSeven_lbl" xlink:title="label: ReturnOnInvestmentsPercentagePeriodSeven to galt_ReturnOnInvestmentsPercentagePeriodSeven_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_ReturnOnInvestmentsPercentagePeriodSeven_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_ReturnOnInvestmentsPercentagePeriodSeven_lbl1" xml:lang="en-US" id="galt_ReturnOnInvestmentsPercentagePeriodSeven_lbl1">Return on Investments Percentage, Period Seven</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReturnOnInvestmentsPercentagePeriodSeven" xlink:to="galt_ReturnOnInvestmentsPercentagePeriodSeven_lbl1" xlink:title="label: ReturnOnInvestmentsPercentagePeriodSeven to galt_ReturnOnInvestmentsPercentagePeriodSeven_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_ReturnOnInvestmentsPercentagePeriodSeven" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_ReturnOnInvestmentsPercentagePeriodSeven" xml:lang="en-US" id="galt_ReturnOnInvestmentsPercentagePeriodSeven">ROI after seventh anniversary but before eighth anniversary of date of issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReturnOnInvestmentsPercentagePeriodSeven" xlink:to="galt_ReturnOnInvestmentsPercentagePeriodSeven" xlink:title="label: ReturnOnInvestmentsPercentagePeriodSeven to galt_ReturnOnInvestmentsPercentagePeriodSeven" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ReturnOnInvestmentsPercentagePeriodThree" xlink:label="ReturnOnInvestmentsPercentagePeriodThree" xlink:title="ReturnOnInvestmentsPercentagePeriodThree" />
    <link:label xlink:type="resource" xlink:label="galt_ReturnOnInvestmentsPercentagePeriodThree_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_ReturnOnInvestmentsPercentagePeriodThree_lbl" xml:lang="en-US" id="galt_ReturnOnInvestmentsPercentagePeriodThree_lbl">Return on investments after third anniversary but before fourth anniversary of date of issuance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReturnOnInvestmentsPercentagePeriodThree" xlink:to="galt_ReturnOnInvestmentsPercentagePeriodThree_lbl" xlink:title="label: ReturnOnInvestmentsPercentagePeriodThree to galt_ReturnOnInvestmentsPercentagePeriodThree_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_ReturnOnInvestmentsPercentagePeriodThree_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_ReturnOnInvestmentsPercentagePeriodThree_lbl1" xml:lang="en-US" id="galt_ReturnOnInvestmentsPercentagePeriodThree_lbl1">Return on Investments Percentage, Period Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReturnOnInvestmentsPercentagePeriodThree" xlink:to="galt_ReturnOnInvestmentsPercentagePeriodThree_lbl1" xlink:title="label: ReturnOnInvestmentsPercentagePeriodThree to galt_ReturnOnInvestmentsPercentagePeriodThree_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_ReturnOnInvestmentsPercentagePeriodThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_ReturnOnInvestmentsPercentagePeriodThree" xml:lang="en-US" id="galt_ReturnOnInvestmentsPercentagePeriodThree">ROI after third anniversary but before fourth anniversary of date of issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReturnOnInvestmentsPercentagePeriodThree" xlink:to="galt_ReturnOnInvestmentsPercentagePeriodThree" xlink:title="label: ReturnOnInvestmentsPercentagePeriodThree to galt_ReturnOnInvestmentsPercentagePeriodThree" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ConvertiblePreferredStockNumberOfVotingRights" xlink:label="ConvertiblePreferredStockNumberOfVotingRights" xlink:title="ConvertiblePreferredStockNumberOfVotingRights" />
    <link:label xlink:type="resource" xlink:label="galt_ConvertiblePreferredStockNumberOfVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_ConvertiblePreferredStockNumberOfVotingRights_lbl" xml:lang="en-US" id="galt_ConvertiblePreferredStockNumberOfVotingRights_lbl">Number of voting rights of convertible preferred stock. Includes eligibility to vote and votes per share owned.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertiblePreferredStockNumberOfVotingRights" xlink:to="galt_ConvertiblePreferredStockNumberOfVotingRights_lbl" xlink:title="label: ConvertiblePreferredStockNumberOfVotingRights to galt_ConvertiblePreferredStockNumberOfVotingRights_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_ConvertiblePreferredStockNumberOfVotingRights_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_ConvertiblePreferredStockNumberOfVotingRights_lbl1" xml:lang="en-US" id="galt_ConvertiblePreferredStockNumberOfVotingRights_lbl1">Convertible Preferred Stock, Number of Voting Rights</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertiblePreferredStockNumberOfVotingRights" xlink:to="galt_ConvertiblePreferredStockNumberOfVotingRights_lbl1" xlink:title="label: ConvertiblePreferredStockNumberOfVotingRights to galt_ConvertiblePreferredStockNumberOfVotingRights_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_ConvertiblePreferredStockNumberOfVotingRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_ConvertiblePreferredStockNumberOfVotingRights" xml:lang="en-US" id="galt_ConvertiblePreferredStockNumberOfVotingRights">Convertible preferred stock, voting rights</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertiblePreferredStockNumberOfVotingRights" xlink:to="galt_ConvertiblePreferredStockNumberOfVotingRights" xlink:title="label: ConvertiblePreferredStockNumberOfVotingRights to galt_ConvertiblePreferredStockNumberOfVotingRights" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ReturnOnInvestmentsPercentagePeriodFour" xlink:label="ReturnOnInvestmentsPercentagePeriodFour" xlink:title="ReturnOnInvestmentsPercentagePeriodFour" />
    <link:label xlink:type="resource" xlink:label="galt_ReturnOnInvestmentsPercentagePeriodFour_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_ReturnOnInvestmentsPercentagePeriodFour_lbl" xml:lang="en-US" id="galt_ReturnOnInvestmentsPercentagePeriodFour_lbl">Return on investments after fourth anniversary but before fifth anniversary of date of issuance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReturnOnInvestmentsPercentagePeriodFour" xlink:to="galt_ReturnOnInvestmentsPercentagePeriodFour_lbl" xlink:title="label: ReturnOnInvestmentsPercentagePeriodFour to galt_ReturnOnInvestmentsPercentagePeriodFour_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_ReturnOnInvestmentsPercentagePeriodFour_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_ReturnOnInvestmentsPercentagePeriodFour_lbl1" xml:lang="en-US" id="galt_ReturnOnInvestmentsPercentagePeriodFour_lbl1">Return on Investments Percentage, Period Four</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReturnOnInvestmentsPercentagePeriodFour" xlink:to="galt_ReturnOnInvestmentsPercentagePeriodFour_lbl1" xlink:title="label: ReturnOnInvestmentsPercentagePeriodFour to galt_ReturnOnInvestmentsPercentagePeriodFour_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_ReturnOnInvestmentsPercentagePeriodFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_ReturnOnInvestmentsPercentagePeriodFour" xml:lang="en-US" id="galt_ReturnOnInvestmentsPercentagePeriodFour">ROI after fourth anniversary but before fifth anniversary of date of issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReturnOnInvestmentsPercentagePeriodFour" xlink:to="galt_ReturnOnInvestmentsPercentagePeriodFour" xlink:title="label: ReturnOnInvestmentsPercentagePeriodFour to galt_ReturnOnInvestmentsPercentagePeriodFour" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ReturnOnInvestmentsPercentagePeriodFive" xlink:label="ReturnOnInvestmentsPercentagePeriodFive" xlink:title="ReturnOnInvestmentsPercentagePeriodFive" />
    <link:label xlink:type="resource" xlink:label="galt_ReturnOnInvestmentsPercentagePeriodFive_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_ReturnOnInvestmentsPercentagePeriodFive_lbl" xml:lang="en-US" id="galt_ReturnOnInvestmentsPercentagePeriodFive_lbl">Return on investments after fifth anniversary but before sixth anniversary of date of issuance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReturnOnInvestmentsPercentagePeriodFive" xlink:to="galt_ReturnOnInvestmentsPercentagePeriodFive_lbl" xlink:title="label: ReturnOnInvestmentsPercentagePeriodFive to galt_ReturnOnInvestmentsPercentagePeriodFive_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_ReturnOnInvestmentsPercentagePeriodFive_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_ReturnOnInvestmentsPercentagePeriodFive_lbl1" xml:lang="en-US" id="galt_ReturnOnInvestmentsPercentagePeriodFive_lbl1">Return on Investments Percentage, Period Five</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReturnOnInvestmentsPercentagePeriodFive" xlink:to="galt_ReturnOnInvestmentsPercentagePeriodFive_lbl1" xlink:title="label: ReturnOnInvestmentsPercentagePeriodFive to galt_ReturnOnInvestmentsPercentagePeriodFive_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_ReturnOnInvestmentsPercentagePeriodFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_ReturnOnInvestmentsPercentagePeriodFive" xml:lang="en-US" id="galt_ReturnOnInvestmentsPercentagePeriodFive">ROI after fifth anniversary but before sixth anniversary of date of issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReturnOnInvestmentsPercentagePeriodFive" xlink:to="galt_ReturnOnInvestmentsPercentagePeriodFive" xlink:title="label: ReturnOnInvestmentsPercentagePeriodFive to galt_ReturnOnInvestmentsPercentagePeriodFive" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_TwoThousandTwentyMarketAgreementMember" xlink:label="TwoThousandTwentyMarketAgreementMember" xlink:title="TwoThousandTwentyMarketAgreementMember" />
    <link:label xlink:type="resource" xlink:label="galt_TwoThousandTwentyMarketAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_TwoThousandTwentyMarketAgreementMember_lbl" xml:lang="en-US" id="galt_TwoThousandTwentyMarketAgreementMember_lbl">Agreement with a sales agent under which the Company may issue and sell shares of its common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TwoThousandTwentyMarketAgreementMember" xlink:to="galt_TwoThousandTwentyMarketAgreementMember_lbl" xlink:title="label: TwoThousandTwentyMarketAgreementMember to galt_TwoThousandTwentyMarketAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_TwoThousandTwentyMarketAgreementMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_TwoThousandTwentyMarketAgreementMember_lbl1" xml:lang="en-US" id="galt_TwoThousandTwentyMarketAgreementMember_lbl1">Two Thousand Twenty Market Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TwoThousandTwentyMarketAgreementMember" xlink:to="galt_TwoThousandTwentyMarketAgreementMember_lbl1" xlink:title="label: TwoThousandTwentyMarketAgreementMember to galt_TwoThousandTwentyMarketAgreementMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_TwoThousandTwentyMarketAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_TwoThousandTwentyMarketAgreementMember" xml:lang="en-US" id="galt_TwoThousandTwentyMarketAgreementMember">2020 Market Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TwoThousandTwentyMarketAgreementMember" xlink:to="galt_TwoThousandTwentyMarketAgreementMember" xlink:title="label: TwoThousandTwentyMarketAgreementMember to galt_TwoThousandTwentyMarketAgreementMember" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_TwoThousandSeventeenMarketAgreementMember" xlink:label="TwoThousandSeventeenMarketAgreementMember" xlink:title="TwoThousandSeventeenMarketAgreementMember" />
    <link:label xlink:type="resource" xlink:label="galt_TwoThousandSeventeenMarketAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_TwoThousandSeventeenMarketAgreementMember_lbl" xml:lang="en-US" id="galt_TwoThousandSeventeenMarketAgreementMember_lbl">Agreement with a sales agent under which the Company may issue and sell shares of its common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TwoThousandSeventeenMarketAgreementMember" xlink:to="galt_TwoThousandSeventeenMarketAgreementMember_lbl" xlink:title="label: TwoThousandSeventeenMarketAgreementMember to galt_TwoThousandSeventeenMarketAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_TwoThousandSeventeenMarketAgreementMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_TwoThousandSeventeenMarketAgreementMember_lbl1" xml:lang="en-US" id="galt_TwoThousandSeventeenMarketAgreementMember_lbl1">Two Thousand Seventeen Market Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TwoThousandSeventeenMarketAgreementMember" xlink:to="galt_TwoThousandSeventeenMarketAgreementMember_lbl1" xlink:title="label: TwoThousandSeventeenMarketAgreementMember to galt_TwoThousandSeventeenMarketAgreementMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_TwoThousandSeventeenMarketAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_TwoThousandSeventeenMarketAgreementMember" xml:lang="en-US" id="galt_TwoThousandSeventeenMarketAgreementMember">2017 Market Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TwoThousandSeventeenMarketAgreementMember" xlink:to="galt_TwoThousandSeventeenMarketAgreementMember" xlink:title="label: TwoThousandSeventeenMarketAgreementMember to galt_TwoThousandSeventeenMarketAgreementMember" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_CommissionRate" xlink:label="CommissionRate" xlink:title="CommissionRate" />
    <link:label xlink:type="resource" xlink:label="galt_CommissionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_CommissionRate_lbl" xml:lang="en-US" id="galt_CommissionRate_lbl">Percentage of commission rate to be paid to sales agent in gross proceeds from the sale of common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommissionRate" xlink:to="galt_CommissionRate_lbl" xlink:title="label: CommissionRate to galt_CommissionRate_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_CommissionRate_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_CommissionRate_lbl1" xml:lang="en-US" id="galt_CommissionRate_lbl1">Commission Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommissionRate" xlink:to="galt_CommissionRate_lbl1" xlink:title="label: CommissionRate to galt_CommissionRate_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_CommissionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_CommissionRate" xml:lang="en-US" id="galt_CommissionRate">Percentage of commission rate to be paid to sales agent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommissionRate" xlink:to="galt_CommissionRate" xlink:title="label: CommissionRate to galt_CommissionRate" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_UndesignatedCapitalStockSharesAuthorized" xlink:label="UndesignatedCapitalStockSharesAuthorized" xlink:title="UndesignatedCapitalStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="galt_UndesignatedCapitalStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_UndesignatedCapitalStockSharesAuthorized_lbl" xml:lang="en-US" id="galt_UndesignatedCapitalStockSharesAuthorized_lbl">The maximum number of undesignated capital stock permitted to be issued by an entity's charter and bylaws.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UndesignatedCapitalStockSharesAuthorized" xlink:to="galt_UndesignatedCapitalStockSharesAuthorized_lbl" xlink:title="label: UndesignatedCapitalStockSharesAuthorized to galt_UndesignatedCapitalStockSharesAuthorized_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_UndesignatedCapitalStockSharesAuthorized_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_UndesignatedCapitalStockSharesAuthorized_lbl1" xml:lang="en-US" id="galt_UndesignatedCapitalStockSharesAuthorized_lbl1">Undesignated Capital Stock, Shares Authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UndesignatedCapitalStockSharesAuthorized" xlink:to="galt_UndesignatedCapitalStockSharesAuthorized_lbl1" xlink:title="label: UndesignatedCapitalStockSharesAuthorized to galt_UndesignatedCapitalStockSharesAuthorized_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_UndesignatedCapitalStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_UndesignatedCapitalStockSharesAuthorized" xml:lang="en-US" id="galt_UndesignatedCapitalStockSharesAuthorized">Undesignated stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UndesignatedCapitalStockSharesAuthorized" xlink:to="galt_UndesignatedCapitalStockSharesAuthorized" xlink:title="label: UndesignatedCapitalStockSharesAuthorized to galt_UndesignatedCapitalStockSharesAuthorized" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_AggregateOfferingPrice" xlink:label="AggregateOfferingPrice" xlink:title="AggregateOfferingPrice" />
    <link:label xlink:type="resource" xlink:label="galt_AggregateOfferingPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_AggregateOfferingPrice_lbl" xml:lang="en-US" id="galt_AggregateOfferingPrice_lbl">Amount of aggregate offering price of common stock which can be sold from time to time through the sales agent.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AggregateOfferingPrice" xlink:to="galt_AggregateOfferingPrice_lbl" xlink:title="label: AggregateOfferingPrice to galt_AggregateOfferingPrice_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_AggregateOfferingPrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_AggregateOfferingPrice_lbl1" xml:lang="en-US" id="galt_AggregateOfferingPrice_lbl1">Aggregate Offering Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AggregateOfferingPrice" xlink:to="galt_AggregateOfferingPrice_lbl1" xlink:title="label: AggregateOfferingPrice to galt_AggregateOfferingPrice_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_AggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_AggregateOfferingPrice" xml:lang="en-US" id="galt_AggregateOfferingPrice">Aggregate offering price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AggregateOfferingPrice" xlink:to="galt_AggregateOfferingPrice" xlink:title="label: AggregateOfferingPrice to galt_AggregateOfferingPrice" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_SeriesBTwoConvertiblePreferredStockMember" xlink:label="SeriesBTwoConvertiblePreferredStockMember" xlink:title="SeriesBTwoConvertiblePreferredStockMember" />
    <link:label xlink:type="resource" xlink:label="galt_SeriesBTwoConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_SeriesBTwoConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="galt_SeriesBTwoConvertiblePreferredStockMember_lbl">Series B-2 Preferred stock that may be exchanged into common shares or other types of securities at the owner's option. Each share of the Series B-2 is entitled to dividends at the rate of 12% per annum.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesBTwoConvertiblePreferredStockMember" xlink:to="galt_SeriesBTwoConvertiblePreferredStockMember_lbl" xlink:title="label: SeriesBTwoConvertiblePreferredStockMember to galt_SeriesBTwoConvertiblePreferredStockMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_SeriesBTwoConvertiblePreferredStockMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_SeriesBTwoConvertiblePreferredStockMember_lbl1" xml:lang="en-US" id="galt_SeriesBTwoConvertiblePreferredStockMember_lbl1">Series B Two Convertible Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesBTwoConvertiblePreferredStockMember" xlink:to="galt_SeriesBTwoConvertiblePreferredStockMember_lbl1" xlink:title="label: SeriesBTwoConvertiblePreferredStockMember to galt_SeriesBTwoConvertiblePreferredStockMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_SeriesBTwoConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_SeriesBTwoConvertiblePreferredStockMember" xml:lang="en-US" id="galt_SeriesBTwoConvertiblePreferredStockMember">Series B-2 Convertible Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesBTwoConvertiblePreferredStockMember" xlink:to="galt_SeriesBTwoConvertiblePreferredStockMember" xlink:title="label: SeriesBTwoConvertiblePreferredStockMember to galt_SeriesBTwoConvertiblePreferredStockMember" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_SeriesBOneConvertiblePreferredStockMember" xlink:label="SeriesBOneConvertiblePreferredStockMember" xlink:title="SeriesBOneConvertiblePreferredStockMember" />
    <link:label xlink:type="resource" xlink:label="galt_SeriesBOneConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_SeriesBOneConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="galt_SeriesBOneConvertiblePreferredStockMember_lbl">Series B-1 Preferred stock that may be exchanged into common shares or other types of securities at the owner's option. Each share of the Series B-1 is entitled to dividends at the rate of 12% per annum.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesBOneConvertiblePreferredStockMember" xlink:to="galt_SeriesBOneConvertiblePreferredStockMember_lbl" xlink:title="label: SeriesBOneConvertiblePreferredStockMember to galt_SeriesBOneConvertiblePreferredStockMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_SeriesBOneConvertiblePreferredStockMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_SeriesBOneConvertiblePreferredStockMember_lbl1" xml:lang="en-US" id="galt_SeriesBOneConvertiblePreferredStockMember_lbl1">Series B One Convertible Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesBOneConvertiblePreferredStockMember" xlink:to="galt_SeriesBOneConvertiblePreferredStockMember_lbl1" xlink:title="label: SeriesBOneConvertiblePreferredStockMember to galt_SeriesBOneConvertiblePreferredStockMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_SeriesBOneConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_SeriesBOneConvertiblePreferredStockMember" xml:lang="en-US" id="galt_SeriesBOneConvertiblePreferredStockMember">Series B-1 Convertible Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesBOneConvertiblePreferredStockMember" xlink:to="galt_SeriesBOneConvertiblePreferredStockMember" xlink:title="label: SeriesBOneConvertiblePreferredStockMember to galt_SeriesBOneConvertiblePreferredStockMember" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_SeriesBThreeConvertiblePreferredStockMember" xlink:label="SeriesBThreeConvertiblePreferredStockMember" xlink:title="SeriesBThreeConvertiblePreferredStockMember" />
    <link:label xlink:type="resource" xlink:label="galt_SeriesBThreeConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_SeriesBThreeConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="galt_SeriesBThreeConvertiblePreferredStockMember_lbl">Series B-3 Preferred stock that may be exchanged into common shares or other types of securities at the owner's option. Each share of the Series B-3 is entitled to dividends at the rate of 8% per annum.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesBThreeConvertiblePreferredStockMember" xlink:to="galt_SeriesBThreeConvertiblePreferredStockMember_lbl" xlink:title="label: SeriesBThreeConvertiblePreferredStockMember to galt_SeriesBThreeConvertiblePreferredStockMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_SeriesBThreeConvertiblePreferredStockMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_SeriesBThreeConvertiblePreferredStockMember_lbl1" xml:lang="en-US" id="galt_SeriesBThreeConvertiblePreferredStockMember_lbl1">Series B Three Convertible Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesBThreeConvertiblePreferredStockMember" xlink:to="galt_SeriesBThreeConvertiblePreferredStockMember_lbl1" xlink:title="label: SeriesBThreeConvertiblePreferredStockMember to galt_SeriesBThreeConvertiblePreferredStockMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_SeriesBThreeConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_SeriesBThreeConvertiblePreferredStockMember" xml:lang="en-US" id="galt_SeriesBThreeConvertiblePreferredStockMember">Series B-3 Convertible Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesBThreeConvertiblePreferredStockMember" xlink:to="galt_SeriesBThreeConvertiblePreferredStockMember" xlink:title="label: SeriesBThreeConvertiblePreferredStockMember to galt_SeriesBThreeConvertiblePreferredStockMember" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_UndesignatedCapitalStockValue" xlink:label="UndesignatedCapitalStockValue" xlink:title="UndesignatedCapitalStockValue" />
    <link:label xlink:type="resource" xlink:label="galt_UndesignatedCapitalStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_UndesignatedCapitalStockValue_lbl" xml:lang="en-US" id="galt_UndesignatedCapitalStockValue_lbl">Aggregate par or stated value of shares which are not designated as common stock or preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UndesignatedCapitalStockValue" xlink:to="galt_UndesignatedCapitalStockValue_lbl" xlink:title="label: UndesignatedCapitalStockValue to galt_UndesignatedCapitalStockValue_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_UndesignatedCapitalStockValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_UndesignatedCapitalStockValue_lbl1" xml:lang="en-US" id="galt_UndesignatedCapitalStockValue_lbl1">Undesignated Capital Stock Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UndesignatedCapitalStockValue" xlink:to="galt_UndesignatedCapitalStockValue_lbl1" xlink:title="label: UndesignatedCapitalStockValue to galt_UndesignatedCapitalStockValue_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_UndesignatedCapitalStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_UndesignatedCapitalStockValue" xml:lang="en-US" id="galt_UndesignatedCapitalStockValue">Undesignated stock, $0.01 par value; 20,000,000 shares authorized at December 31, 2024 and 2023, 20,000,000 shares designated at December 31, 2024 and 2023, respectively</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UndesignatedCapitalStockValue" xlink:to="galt_UndesignatedCapitalStockValue" xlink:title="label: UndesignatedCapitalStockValue to galt_UndesignatedCapitalStockValue" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent" xlink:label="BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent" xlink:title="BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent" />
    <link:label xlink:type="resource" xlink:label="galt_BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent_lbl" xml:lang="en-US" id="galt_BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent_lbl">Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as borrowing and accrued interest under line of credit related party excluding current portion.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent" xlink:to="galt_BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent_lbl" xlink:title="label: BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent to galt_BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent_lbl1" xml:lang="en-US" id="galt_BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent_lbl1">Borrowing and Accrued Interest Under Line of Credit, Net of Debt Discount, Related Party Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent" xlink:to="galt_BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent_lbl1" xlink:title="label: BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent to galt_BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent" xml:lang="en-US" id="galt_BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent">Borrowing and accrued interest under convertible line of credit, net of debt discount - related party (Note 10)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent" xlink:to="galt_BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent" xlink:title="label: BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent to galt_BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent" xlink:label="ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent" xlink:title="ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent" />
    <link:label xlink:type="resource" xlink:label="galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent_lbl" xml:lang="en-US" id="galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent_lbl">Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as convertible notes payable and accrued interest, net of debt discount of related party excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent" xlink:to="galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent_lbl" xlink:title="label: ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent to galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent_lbl1" xml:lang="en-US" id="galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent_lbl1">Convertible Note Payable and Accrued Interest Net of Debt Discount - Related Party Non-Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent" xlink:to="galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent_lbl1" xlink:title="label: ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent to galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent" xml:lang="en-US" id="galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent">Convertible notes payable and accrued interest, net of debt discounts - related party (Note 5)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent" xlink:to="galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent" xlink:title="label: ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent to galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyCurrent" xlink:label="ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyCurrent" xlink:title="ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyCurrent" />
    <link:label xlink:type="resource" xlink:label="galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyCurrent_lbl" xml:lang="en-US" id="galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyCurrent_lbl">Carrying value as of the balance sheet date of current portion of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as convertible notes payable and accrued interest, net of debt discount of related party. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyCurrent" xlink:to="galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyCurrent_lbl" xlink:title="label: ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyCurrent to galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyCurrent_lbl1" xml:lang="en-US" id="galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyCurrent_lbl1">Convertible Note Payable And Accrued Interest Net Of Debt Discount Related Party Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyCurrent" xlink:to="galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyCurrent_lbl1" xlink:title="label: ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyCurrent to galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyCurrent_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyCurrent" xml:lang="en-US" id="galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyCurrent">Current portion of convertible notes payable and accrued interest, net of debt discounts - related party (Note 5)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyCurrent" xlink:to="galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyCurrent" xlink:title="label: ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyCurrent to galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyCurrent" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_UndesignatedCapitalStockSharesDesignated" xlink:label="UndesignatedCapitalStockSharesDesignated" xlink:title="UndesignatedCapitalStockSharesDesignated" />
    <link:label xlink:type="resource" xlink:label="galt_UndesignatedCapitalStockSharesDesignated_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_UndesignatedCapitalStockSharesDesignated_lbl" xml:lang="en-US" id="galt_UndesignatedCapitalStockSharesDesignated_lbl">Number of shares of undesignated capital stock which are designated as common stock or preferred stock by board of directors.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UndesignatedCapitalStockSharesDesignated" xlink:to="galt_UndesignatedCapitalStockSharesDesignated_lbl" xlink:title="label: UndesignatedCapitalStockSharesDesignated to galt_UndesignatedCapitalStockSharesDesignated_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_UndesignatedCapitalStockSharesDesignated_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_UndesignatedCapitalStockSharesDesignated_lbl1" xml:lang="en-US" id="galt_UndesignatedCapitalStockSharesDesignated_lbl1">Undesignated Capital Stock Shares Designated</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UndesignatedCapitalStockSharesDesignated" xlink:to="galt_UndesignatedCapitalStockSharesDesignated_lbl1" xlink:title="label: UndesignatedCapitalStockSharesDesignated to galt_UndesignatedCapitalStockSharesDesignated_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_UndesignatedCapitalStockSharesDesignated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_UndesignatedCapitalStockSharesDesignated" xml:lang="en-US" id="galt_UndesignatedCapitalStockSharesDesignated">Undesignated stock, shares designated (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UndesignatedCapitalStockSharesDesignated" xlink:to="galt_UndesignatedCapitalStockSharesDesignated" xlink:title="label: UndesignatedCapitalStockSharesDesignated to galt_UndesignatedCapitalStockSharesDesignated" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_UndesignatedCapitalStockParValue" xlink:label="UndesignatedCapitalStockParValue" xlink:title="UndesignatedCapitalStockParValue" />
    <link:label xlink:type="resource" xlink:label="galt_UndesignatedCapitalStockParValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_UndesignatedCapitalStockParValue_lbl" xml:lang="en-US" id="galt_UndesignatedCapitalStockParValue_lbl">Face amount or stated value per share of undesignated capital stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UndesignatedCapitalStockParValue" xlink:to="galt_UndesignatedCapitalStockParValue_lbl" xlink:title="label: UndesignatedCapitalStockParValue to galt_UndesignatedCapitalStockParValue_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_UndesignatedCapitalStockParValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_UndesignatedCapitalStockParValue_lbl1" xml:lang="en-US" id="galt_UndesignatedCapitalStockParValue_lbl1">Undesignated Capital Stock Par Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UndesignatedCapitalStockParValue" xlink:to="galt_UndesignatedCapitalStockParValue_lbl1" xlink:title="label: UndesignatedCapitalStockParValue to galt_UndesignatedCapitalStockParValue_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_UndesignatedCapitalStockParValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_UndesignatedCapitalStockParValue" xml:lang="en-US" id="galt_UndesignatedCapitalStockParValue">Undesignated stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UndesignatedCapitalStockParValue" xlink:to="galt_UndesignatedCapitalStockParValue" xlink:title="label: UndesignatedCapitalStockParValue to galt_UndesignatedCapitalStockParValue" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract" />
    <link:label xlink:type="resource" xlink:label="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract_lbl1" xml:lang="en-US" id="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract_lbl1">Share based Compensation Arrangement by Share based Payment Award Equity Instruments Other Than Options Weighted Average Exercise Price [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract" xlink:to="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract to galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract" xml:lang="en-US" id="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract">Weighted Average Exercise Price [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract" xlink:to="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract to galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice_lbl">Weighted average price at which option holders acquired shares granted when converting their stock options into shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice" xlink:to="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice to galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice_lbl1" xml:lang="en-US" id="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice_lbl1">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted In Period Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice" xlink:to="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice to galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice" xml:lang="en-US" id="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice">Issued (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice" xlink:to="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice to galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl">Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:to="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice to galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US" id="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl1">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:to="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice to galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US" id="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice">Outstanding at end of period (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:to="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice to galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl2" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl2" xml:lang="en-US" id="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl2">Outstanding at beginning of period (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:to="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice to galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl2" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="galt_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="galt_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl">Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="galt_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:title="label: ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice to galt_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl1" xml:lang="en-US" id="galt_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl1">Share based Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Forfeitures In Period Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="galt_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl1" xlink:title="label: ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice to galt_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice" xml:lang="en-US" id="galt_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice">Canceled/Expired (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="galt_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:title="label: ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice to galt_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl">Weighted average price at which option holders acquired shares when converting their stock options into shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice to galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl1" xml:lang="en-US" id="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl1">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercises In Period Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice to galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US" id="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice">Exercised (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice to galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_SBHSciencesIncMember" xlink:label="SBHSciencesIncMember" xlink:title="SBHSciencesIncMember" />
    <link:label xlink:type="resource" xlink:label="galt_SBHSciencesIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_SBHSciencesIncMember_lbl" xml:lang="en-US" id="galt_SBHSciencesIncMember_lbl">Name of counterparty. A counterparty is the other party that participates in a financial transaction.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBHSciencesIncMember" xlink:to="galt_SBHSciencesIncMember_lbl" xlink:title="label: SBHSciencesIncMember to galt_SBHSciencesIncMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_SBHSciencesIncMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_SBHSciencesIncMember_lbl1" xml:lang="en-US" id="galt_SBHSciencesIncMember_lbl1">SBH Sciences, Inc. [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBHSciencesIncMember" xlink:to="galt_SBHSciencesIncMember_lbl1" xlink:title="label: SBHSciencesIncMember to galt_SBHSciencesIncMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_SBHSciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_SBHSciencesIncMember" xml:lang="en-US" id="galt_SBHSciencesIncMember">SBH [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBHSciencesIncMember" xlink:to="galt_SBHSciencesIncMember" xlink:title="label: SBHSciencesIncMember to galt_SBHSciencesIncMember" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_NonCashChargeForResearchAndDevelopmentInProcess" xlink:label="NonCashChargeForResearchAndDevelopmentInProcess" xlink:title="NonCashChargeForResearchAndDevelopmentInProcess" />
    <link:label xlink:type="resource" xlink:label="galt_NonCashChargeForResearchAndDevelopmentInProcess_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_NonCashChargeForResearchAndDevelopmentInProcess_lbl" xml:lang="en-US" id="galt_NonCashChargeForResearchAndDevelopmentInProcess_lbl">The amount of non-cash charge in research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonCashChargeForResearchAndDevelopmentInProcess" xlink:to="galt_NonCashChargeForResearchAndDevelopmentInProcess_lbl" xlink:title="label: NonCashChargeForResearchAndDevelopmentInProcess to galt_NonCashChargeForResearchAndDevelopmentInProcess_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_NonCashChargeForResearchAndDevelopmentInProcess_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_NonCashChargeForResearchAndDevelopmentInProcess_lbl1" xml:lang="en-US" id="galt_NonCashChargeForResearchAndDevelopmentInProcess_lbl1">Non-cash Charge for Research and Development in Process</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonCashChargeForResearchAndDevelopmentInProcess" xlink:to="galt_NonCashChargeForResearchAndDevelopmentInProcess_lbl1" xlink:title="label: NonCashChargeForResearchAndDevelopmentInProcess to galt_NonCashChargeForResearchAndDevelopmentInProcess_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_NonCashChargeForResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_NonCashChargeForResearchAndDevelopmentInProcess" xml:lang="en-US" id="galt_NonCashChargeForResearchAndDevelopmentInProcess">Non-cash charge for in-process research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonCashChargeForResearchAndDevelopmentInProcess" xlink:to="galt_NonCashChargeForResearchAndDevelopmentInProcess" xlink:title="label: NonCashChargeForResearchAndDevelopmentInProcess to galt_NonCashChargeForResearchAndDevelopmentInProcess" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_CapitalContributionExpense" xlink:label="CapitalContributionExpense" xlink:title="CapitalContributionExpense" />
    <link:label xlink:type="resource" xlink:label="galt_CapitalContributionExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_CapitalContributionExpense_lbl" xml:lang="en-US" id="galt_CapitalContributionExpense_lbl">Capital contribution expense.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CapitalContributionExpense" xlink:to="galt_CapitalContributionExpense_lbl" xlink:title="label: CapitalContributionExpense to galt_CapitalContributionExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_CapitalContributionExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_CapitalContributionExpense_lbl1" xml:lang="en-US" id="galt_CapitalContributionExpense_lbl1">Capital Contribution Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CapitalContributionExpense" xlink:to="galt_CapitalContributionExpense_lbl1" xlink:title="label: CapitalContributionExpense to galt_CapitalContributionExpense_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_CapitalContributionExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_CapitalContributionExpense" xml:lang="en-US" id="galt_CapitalContributionExpense">Contribution for expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CapitalContributionExpense" xlink:to="galt_CapitalContributionExpense" xlink:title="label: CapitalContributionExpense to galt_CapitalContributionExpense" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_GalectinSciencesLLCMember" xlink:label="GalectinSciencesLLCMember" xlink:title="GalectinSciencesLLCMember" />
    <link:label xlink:type="resource" xlink:label="galt_GalectinSciencesLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_GalectinSciencesLLCMember_lbl" xml:lang="en-US" id="galt_GalectinSciencesLLCMember_lbl">Name of entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GalectinSciencesLLCMember" xlink:to="galt_GalectinSciencesLLCMember_lbl" xlink:title="label: GalectinSciencesLLCMember to galt_GalectinSciencesLLCMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_GalectinSciencesLLCMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_GalectinSciencesLLCMember_lbl1" xml:lang="en-US" id="galt_GalectinSciencesLLCMember_lbl1">Galectin Sciences, LLC [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GalectinSciencesLLCMember" xlink:to="galt_GalectinSciencesLLCMember_lbl1" xlink:title="label: GalectinSciencesLLCMember to galt_GalectinSciencesLLCMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_GalectinSciencesLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_GalectinSciencesLLCMember" xml:lang="en-US" id="galt_GalectinSciencesLLCMember">Galectin Sciences, LLC [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GalectinSciencesLLCMember" xlink:to="galt_GalectinSciencesLLCMember" xlink:title="label: GalectinSciencesLLCMember to galt_GalectinSciencesLLCMember" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_NatureOfBusinessBasisOfPresentationsAndLiquidityAbstract" xlink:label="NatureOfBusinessBasisOfPresentationsAndLiquidityAbstract" xlink:title="NatureOfBusinessBasisOfPresentationsAndLiquidityAbstract" />
    <link:label xlink:type="resource" xlink:label="galt_NatureOfBusinessBasisOfPresentationsAndLiquidityAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_NatureOfBusinessBasisOfPresentationsAndLiquidityAbstract_lbl1" xml:lang="en-US" id="galt_NatureOfBusinessBasisOfPresentationsAndLiquidityAbstract_lbl1">Nature of Business, Basis of Presentations and Liquidity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NatureOfBusinessBasisOfPresentationsAndLiquidityAbstract" xlink:to="galt_NatureOfBusinessBasisOfPresentationsAndLiquidityAbstract_lbl1" xlink:title="label: NatureOfBusinessBasisOfPresentationsAndLiquidityAbstract to galt_NatureOfBusinessBasisOfPresentationsAndLiquidityAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_NatureOfBusinessBasisOfPresentationsAndLiquidityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_NatureOfBusinessBasisOfPresentationsAndLiquidityAbstract" xml:lang="en-US" id="galt_NatureOfBusinessBasisOfPresentationsAndLiquidityAbstract">Nature of Business, Basis of Presentation and Liquidity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NatureOfBusinessBasisOfPresentationsAndLiquidityAbstract" xlink:to="galt_NatureOfBusinessBasisOfPresentationsAndLiquidityAbstract" xlink:title="label: NatureOfBusinessBasisOfPresentationsAndLiquidityAbstract to galt_NatureOfBusinessBasisOfPresentationsAndLiquidityAbstract" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_NumberOfLineOfCredit" xlink:label="NumberOfLineOfCredit" xlink:title="NumberOfLineOfCredit" />
    <link:label xlink:type="resource" xlink:label="galt_NumberOfLineOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_NumberOfLineOfCredit_lbl" xml:lang="en-US" id="galt_NumberOfLineOfCredit_lbl">Number of available line of credit facility borrowings.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfLineOfCredit" xlink:to="galt_NumberOfLineOfCredit_lbl" xlink:title="label: NumberOfLineOfCredit to galt_NumberOfLineOfCredit_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_NumberOfLineOfCredit_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_NumberOfLineOfCredit_lbl1" xml:lang="en-US" id="galt_NumberOfLineOfCredit_lbl1">Number of Line of Credit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfLineOfCredit" xlink:to="galt_NumberOfLineOfCredit_lbl1" xlink:title="label: NumberOfLineOfCredit to galt_NumberOfLineOfCredit_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_NumberOfLineOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_NumberOfLineOfCredit" xml:lang="en-US" id="galt_NumberOfLineOfCredit">Number of line of credit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfLineOfCredit" xlink:to="galt_NumberOfLineOfCredit" xlink:title="label: NumberOfLineOfCredit to galt_NumberOfLineOfCredit" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_SupplementalLineOfCreditMember" xlink:label="SupplementalLineOfCreditMember" xlink:title="SupplementalLineOfCreditMember" />
    <link:label xlink:type="resource" xlink:label="galt_SupplementalLineOfCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_SupplementalLineOfCreditMember_lbl" xml:lang="en-US" id="galt_SupplementalLineOfCreditMember_lbl">A supplemental contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SupplementalLineOfCreditMember" xlink:to="galt_SupplementalLineOfCreditMember_lbl" xlink:title="label: SupplementalLineOfCreditMember to galt_SupplementalLineOfCreditMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_SupplementalLineOfCreditMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_SupplementalLineOfCreditMember_lbl1" xml:lang="en-US" id="galt_SupplementalLineOfCreditMember_lbl1">Supplemental Line of Credit [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SupplementalLineOfCreditMember" xlink:to="galt_SupplementalLineOfCreditMember_lbl1" xlink:title="label: SupplementalLineOfCreditMember to galt_SupplementalLineOfCreditMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_SupplementalLineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_SupplementalLineOfCreditMember" xml:lang="en-US" id="galt_SupplementalLineOfCreditMember">Supplemental Line of Credit [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SupplementalLineOfCreditMember" xlink:to="galt_SupplementalLineOfCreditMember" xlink:title="label: SupplementalLineOfCreditMember to galt_SupplementalLineOfCreditMember" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ConvertibleNotesPayableRelatedPartyAbstract" xlink:label="ConvertibleNotesPayableRelatedPartyAbstract" xlink:title="ConvertibleNotesPayableRelatedPartyAbstract" />
    <link:label xlink:type="resource" xlink:label="galt_ConvertibleNotesPayableRelatedPartyAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_ConvertibleNotesPayableRelatedPartyAbstract_lbl1" xml:lang="en-US" id="galt_ConvertibleNotesPayableRelatedPartyAbstract_lbl1">Convertible Notes Payable, Related Party [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleNotesPayableRelatedPartyAbstract" xlink:to="galt_ConvertibleNotesPayableRelatedPartyAbstract_lbl1" xlink:title="label: ConvertibleNotesPayableRelatedPartyAbstract to galt_ConvertibleNotesPayableRelatedPartyAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_ConvertibleNotesPayableRelatedPartyAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_ConvertibleNotesPayableRelatedPartyAbstract" xml:lang="en-US" id="galt_ConvertibleNotesPayableRelatedPartyAbstract">Convertible Notes Payable - Related Party [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleNotesPayableRelatedPartyAbstract" xlink:to="galt_ConvertibleNotesPayableRelatedPartyAbstract" xlink:title="label: ConvertibleNotesPayableRelatedPartyAbstract to galt_ConvertibleNotesPayableRelatedPartyAbstract" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_NumberOfPromissoryNotesExecuted" xlink:label="NumberOfPromissoryNotesExecuted" xlink:title="NumberOfPromissoryNotesExecuted" />
    <link:label xlink:type="resource" xlink:label="galt_NumberOfPromissoryNotesExecuted_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_NumberOfPromissoryNotesExecuted_lbl" xml:lang="en-US" id="galt_NumberOfPromissoryNotesExecuted_lbl">The number of promissory notes executed under the loans agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPromissoryNotesExecuted" xlink:to="galt_NumberOfPromissoryNotesExecuted_lbl" xlink:title="label: NumberOfPromissoryNotesExecuted to galt_NumberOfPromissoryNotesExecuted_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_NumberOfPromissoryNotesExecuted_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_NumberOfPromissoryNotesExecuted_lbl1" xml:lang="en-US" id="galt_NumberOfPromissoryNotesExecuted_lbl1">Number of Promissory Notes Executed</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPromissoryNotesExecuted" xlink:to="galt_NumberOfPromissoryNotesExecuted_lbl1" xlink:title="label: NumberOfPromissoryNotesExecuted to galt_NumberOfPromissoryNotesExecuted_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_NumberOfPromissoryNotesExecuted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_NumberOfPromissoryNotesExecuted" xml:lang="en-US" id="galt_NumberOfPromissoryNotesExecuted">Number of promissory notes executed</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPromissoryNotesExecuted" xlink:to="galt_NumberOfPromissoryNotesExecuted" xlink:title="label: NumberOfPromissoryNotesExecuted to galt_NumberOfPromissoryNotesExecuted" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_NumberOfLoansClosing" xlink:label="NumberOfLoansClosing" xlink:title="NumberOfLoansClosing" />
    <link:label xlink:type="resource" xlink:label="galt_NumberOfLoansClosing_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_NumberOfLoansClosing_lbl" xml:lang="en-US" id="galt_NumberOfLoansClosing_lbl">The number of loans closing under the loans agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfLoansClosing" xlink:to="galt_NumberOfLoansClosing_lbl" xlink:title="label: NumberOfLoansClosing to galt_NumberOfLoansClosing_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_NumberOfLoansClosing_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_NumberOfLoansClosing_lbl1" xml:lang="en-US" id="galt_NumberOfLoansClosing_lbl1">Number of Loans Closing</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfLoansClosing" xlink:to="galt_NumberOfLoansClosing_lbl1" xlink:title="label: NumberOfLoansClosing to galt_NumberOfLoansClosing_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_NumberOfLoansClosing" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_NumberOfLoansClosing" xml:lang="en-US" id="galt_NumberOfLoansClosing">Number of loans closing</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfLoansClosing" xlink:to="galt_NumberOfLoansClosing" xlink:title="label: NumberOfLoansClosing to galt_NumberOfLoansClosing" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_AnnualInterestRate" xlink:label="AnnualInterestRate" xlink:title="AnnualInterestRate" />
    <link:label xlink:type="resource" xlink:label="galt_AnnualInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_AnnualInterestRate_lbl" xml:lang="en-US" id="galt_AnnualInterestRate_lbl">Contingent interest rate per annum for funds borrowed, under the debt agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AnnualInterestRate" xlink:to="galt_AnnualInterestRate_lbl" xlink:title="label: AnnualInterestRate to galt_AnnualInterestRate_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_AnnualInterestRate_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_AnnualInterestRate_lbl1" xml:lang="en-US" id="galt_AnnualInterestRate_lbl1">Annual Interest Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AnnualInterestRate" xlink:to="galt_AnnualInterestRate_lbl1" xlink:title="label: AnnualInterestRate to galt_AnnualInterestRate_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_AnnualInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_AnnualInterestRate" xml:lang="en-US" id="galt_AnnualInterestRate">Additional interest rate per annum from issuance date to maturity date period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AnnualInterestRate" xlink:to="galt_AnnualInterestRate" xlink:title="label: AnnualInterestRate to galt_AnnualInterestRate" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_QuarterlyInterestRate" xlink:label="QuarterlyInterestRate" xlink:title="QuarterlyInterestRate" />
    <link:label xlink:type="resource" xlink:label="galt_QuarterlyInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_QuarterlyInterestRate_lbl" xml:lang="en-US" id="galt_QuarterlyInterestRate_lbl">Contingent interest rate per quarter for funds borrowed, under the debt agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QuarterlyInterestRate" xlink:to="galt_QuarterlyInterestRate_lbl" xlink:title="label: QuarterlyInterestRate to galt_QuarterlyInterestRate_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_QuarterlyInterestRate_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_QuarterlyInterestRate_lbl1" xml:lang="en-US" id="galt_QuarterlyInterestRate_lbl1">Quarterly Interest Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QuarterlyInterestRate" xlink:to="galt_QuarterlyInterestRate_lbl1" xlink:title="label: QuarterlyInterestRate to galt_QuarterlyInterestRate_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_QuarterlyInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_QuarterlyInterestRate" xml:lang="en-US" id="galt_QuarterlyInterestRate">Additional interest rate per quarter</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QuarterlyInterestRate" xlink:to="galt_QuarterlyInterestRate" xlink:title="label: QuarterlyInterestRate to galt_QuarterlyInterestRate" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_AprilConvertiblePromissoryNoteMember" xlink:label="AprilConvertiblePromissoryNoteMember" xlink:title="AprilConvertiblePromissoryNoteMember" />
    <link:label xlink:type="resource" xlink:label="galt_AprilConvertiblePromissoryNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_AprilConvertiblePromissoryNoteMember_lbl" xml:lang="en-US" id="galt_AprilConvertiblePromissoryNoteMember_lbl">The type of debt instrument.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AprilConvertiblePromissoryNoteMember" xlink:to="galt_AprilConvertiblePromissoryNoteMember_lbl" xlink:title="label: AprilConvertiblePromissoryNoteMember to galt_AprilConvertiblePromissoryNoteMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_AprilConvertiblePromissoryNoteMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_AprilConvertiblePromissoryNoteMember_lbl1" xml:lang="en-US" id="galt_AprilConvertiblePromissoryNoteMember_lbl1">April Convertible Promissory Note [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AprilConvertiblePromissoryNoteMember" xlink:to="galt_AprilConvertiblePromissoryNoteMember_lbl1" xlink:title="label: AprilConvertiblePromissoryNoteMember to galt_AprilConvertiblePromissoryNoteMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_AprilConvertiblePromissoryNoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_AprilConvertiblePromissoryNoteMember" xml:lang="en-US" id="galt_AprilConvertiblePromissoryNoteMember">April 2021 Note [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AprilConvertiblePromissoryNoteMember" xlink:to="galt_AprilConvertiblePromissoryNoteMember" xlink:title="label: AprilConvertiblePromissoryNoteMember to galt_AprilConvertiblePromissoryNoteMember" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_SeptemberConvertiblePromissoryNoteMember" xlink:label="SeptemberConvertiblePromissoryNoteMember" xlink:title="SeptemberConvertiblePromissoryNoteMember" />
    <link:label xlink:type="resource" xlink:label="galt_SeptemberConvertiblePromissoryNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_SeptemberConvertiblePromissoryNoteMember_lbl" xml:lang="en-US" id="galt_SeptemberConvertiblePromissoryNoteMember_lbl">A type of debt instrument.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeptemberConvertiblePromissoryNoteMember" xlink:to="galt_SeptemberConvertiblePromissoryNoteMember_lbl" xlink:title="label: SeptemberConvertiblePromissoryNoteMember to galt_SeptemberConvertiblePromissoryNoteMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_SeptemberConvertiblePromissoryNoteMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_SeptemberConvertiblePromissoryNoteMember_lbl1" xml:lang="en-US" id="galt_SeptemberConvertiblePromissoryNoteMember_lbl1">September Convertible Promissory Note [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeptemberConvertiblePromissoryNoteMember" xlink:to="galt_SeptemberConvertiblePromissoryNoteMember_lbl1" xlink:title="label: SeptemberConvertiblePromissoryNoteMember to galt_SeptemberConvertiblePromissoryNoteMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_SeptemberConvertiblePromissoryNoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_SeptemberConvertiblePromissoryNoteMember" xml:lang="en-US" id="galt_SeptemberConvertiblePromissoryNoteMember">September 2021 Note [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeptemberConvertiblePromissoryNoteMember" xlink:to="galt_SeptemberConvertiblePromissoryNoteMember" xlink:title="label: SeptemberConvertiblePromissoryNoteMember to galt_SeptemberConvertiblePromissoryNoteMember" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_FirstClosingMember" xlink:label="FirstClosingMember" xlink:title="FirstClosingMember" />
    <link:label xlink:type="resource" xlink:label="galt_FirstClosingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_FirstClosingMember_lbl" xml:lang="en-US" id="galt_FirstClosingMember_lbl">A type of debt instrument.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FirstClosingMember" xlink:to="galt_FirstClosingMember_lbl" xlink:title="label: FirstClosingMember to galt_FirstClosingMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_FirstClosingMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_FirstClosingMember_lbl1" xml:lang="en-US" id="galt_FirstClosingMember_lbl1">First Closing [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FirstClosingMember" xlink:to="galt_FirstClosingMember_lbl1" xlink:title="label: FirstClosingMember to galt_FirstClosingMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_SecondClosingMember" xlink:label="SecondClosingMember" xlink:title="SecondClosingMember" />
    <link:label xlink:type="resource" xlink:label="galt_SecondClosingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_SecondClosingMember_lbl" xml:lang="en-US" id="galt_SecondClosingMember_lbl">A type of debt instrument.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecondClosingMember" xlink:to="galt_SecondClosingMember_lbl" xlink:title="label: SecondClosingMember to galt_SecondClosingMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_SecondClosingMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_SecondClosingMember_lbl1" xml:lang="en-US" id="galt_SecondClosingMember_lbl1">Second Closing [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecondClosingMember" xlink:to="galt_SecondClosingMember_lbl1" xlink:title="label: SecondClosingMember to galt_SecondClosingMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_DecemberConvertiblePromissoryNoteMember" xlink:label="DecemberConvertiblePromissoryNoteMember" xlink:title="DecemberConvertiblePromissoryNoteMember" />
    <link:label xlink:type="resource" xlink:label="galt_DecemberConvertiblePromissoryNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_DecemberConvertiblePromissoryNoteMember_lbl" xml:lang="en-US" id="galt_DecemberConvertiblePromissoryNoteMember_lbl">The type of debt instrument.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DecemberConvertiblePromissoryNoteMember" xlink:to="galt_DecemberConvertiblePromissoryNoteMember_lbl" xlink:title="label: DecemberConvertiblePromissoryNoteMember to galt_DecemberConvertiblePromissoryNoteMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_DecemberConvertiblePromissoryNoteMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_DecemberConvertiblePromissoryNoteMember_lbl1" xml:lang="en-US" id="galt_DecemberConvertiblePromissoryNoteMember_lbl1">December Convertible Promissory Note [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DecemberConvertiblePromissoryNoteMember" xlink:to="galt_DecemberConvertiblePromissoryNoteMember_lbl1" xlink:title="label: DecemberConvertiblePromissoryNoteMember to galt_DecemberConvertiblePromissoryNoteMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_DecemberConvertiblePromissoryNoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_DecemberConvertiblePromissoryNoteMember" xml:lang="en-US" id="galt_DecemberConvertiblePromissoryNoteMember">December 2021 Note [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DecemberConvertiblePromissoryNoteMember" xlink:to="galt_DecemberConvertiblePromissoryNoteMember" xlink:title="label: DecemberConvertiblePromissoryNoteMember to galt_DecemberConvertiblePromissoryNoteMember" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_NumberOfPromissoryNotesEvidencedByLoansAgreement" xlink:label="NumberOfPromissoryNotesEvidencedByLoansAgreement" xlink:title="NumberOfPromissoryNotesEvidencedByLoansAgreement" />
    <link:label xlink:type="resource" xlink:label="galt_NumberOfPromissoryNotesEvidencedByLoansAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_NumberOfPromissoryNotesEvidencedByLoansAgreement_lbl" xml:lang="en-US" id="galt_NumberOfPromissoryNotesEvidencedByLoansAgreement_lbl">The number of promissory notes evidenced by loans agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPromissoryNotesEvidencedByLoansAgreement" xlink:to="galt_NumberOfPromissoryNotesEvidencedByLoansAgreement_lbl" xlink:title="label: NumberOfPromissoryNotesEvidencedByLoansAgreement to galt_NumberOfPromissoryNotesEvidencedByLoansAgreement_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_NumberOfPromissoryNotesEvidencedByLoansAgreement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_NumberOfPromissoryNotesEvidencedByLoansAgreement_lbl1" xml:lang="en-US" id="galt_NumberOfPromissoryNotesEvidencedByLoansAgreement_lbl1">Number of Promissory Notes Evidenced by Loans Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPromissoryNotesEvidencedByLoansAgreement" xlink:to="galt_NumberOfPromissoryNotesEvidencedByLoansAgreement_lbl1" xlink:title="label: NumberOfPromissoryNotesEvidencedByLoansAgreement to galt_NumberOfPromissoryNotesEvidencedByLoansAgreement_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_NumberOfPromissoryNotesEvidencedByLoansAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_NumberOfPromissoryNotesEvidencedByLoansAgreement" xml:lang="en-US" id="galt_NumberOfPromissoryNotesEvidencedByLoansAgreement">Number of promissory notes evidenced by loans agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPromissoryNotesEvidencedByLoansAgreement" xlink:to="galt_NumberOfPromissoryNotesEvidencedByLoansAgreement" xlink:title="label: NumberOfPromissoryNotesEvidencedByLoansAgreement to galt_NumberOfPromissoryNotesEvidencedByLoansAgreement" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" xlink:label="PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" xlink:title="PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="galt_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock_lbl" xml:lang="en-US" id="galt_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock_lbl">Disclosure of accounting policy for prepaid expenses and other current assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" xlink:to="galt_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock_lbl" xlink:title="label: PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock to galt_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock_lbl1" xml:lang="en-US" id="galt_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock_lbl1">Prepaid Expenses and Other Current Assets [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" xlink:to="galt_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock_lbl1" xlink:title="label: PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock to galt_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" xml:lang="en-US" id="galt_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock">Prepaid Expenses and Other Current Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" xlink:to="galt_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" xlink:title="label: PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock to galt_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_SecurityDepositPolicyTextBlock" xlink:label="SecurityDepositPolicyTextBlock" xlink:title="SecurityDepositPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="galt_SecurityDepositPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_SecurityDepositPolicyTextBlock_lbl" xml:lang="en-US" id="galt_SecurityDepositPolicyTextBlock_lbl">Disclosure of accounting policy for security deposit.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityDepositPolicyTextBlock" xlink:to="galt_SecurityDepositPolicyTextBlock_lbl" xlink:title="label: SecurityDepositPolicyTextBlock to galt_SecurityDepositPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_SecurityDepositPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_SecurityDepositPolicyTextBlock_lbl1" xml:lang="en-US" id="galt_SecurityDepositPolicyTextBlock_lbl1">Security Deposit [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityDepositPolicyTextBlock" xlink:to="galt_SecurityDepositPolicyTextBlock_lbl1" xlink:title="label: SecurityDepositPolicyTextBlock to galt_SecurityDepositPolicyTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_SecurityDepositPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_SecurityDepositPolicyTextBlock" xml:lang="en-US" id="galt_SecurityDepositPolicyTextBlock">Security Deposit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityDepositPolicyTextBlock" xlink:to="galt_SecurityDepositPolicyTextBlock" xlink:title="label: SecurityDepositPolicyTextBlock to galt_SecurityDepositPolicyTextBlock" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_AccruedExpensePolicyTextBlock" xlink:label="AccruedExpensePolicyTextBlock" xlink:title="AccruedExpensePolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="galt_AccruedExpensePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_AccruedExpensePolicyTextBlock_lbl" xml:lang="en-US" id="galt_AccruedExpensePolicyTextBlock_lbl">Disclosure of accounting policy for accrued expense.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedExpensePolicyTextBlock" xlink:to="galt_AccruedExpensePolicyTextBlock_lbl" xlink:title="label: AccruedExpensePolicyTextBlock to galt_AccruedExpensePolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_AccruedExpensePolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_AccruedExpensePolicyTextBlock_lbl1" xml:lang="en-US" id="galt_AccruedExpensePolicyTextBlock_lbl1">Accrued Expense [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedExpensePolicyTextBlock" xlink:to="galt_AccruedExpensePolicyTextBlock_lbl1" xlink:title="label: AccruedExpensePolicyTextBlock to galt_AccruedExpensePolicyTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_AccruedExpensePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_AccruedExpensePolicyTextBlock" xml:lang="en-US" id="galt_AccruedExpensePolicyTextBlock">Accrued Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedExpensePolicyTextBlock" xlink:to="galt_AccruedExpensePolicyTextBlock" xlink:title="label: AccruedExpensePolicyTextBlock to galt_AccruedExpensePolicyTextBlock" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ComputerAndOfficeEquipmentMember" xlink:label="ComputerAndOfficeEquipmentMember" xlink:title="ComputerAndOfficeEquipmentMember" />
    <link:label xlink:type="resource" xlink:label="galt_ComputerAndOfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_ComputerAndOfficeEquipmentMember_lbl" xml:lang="en-US" id="galt_ComputerAndOfficeEquipmentMember_lbl">Long lived, depreciable assets in the form of computer and office equipment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComputerAndOfficeEquipmentMember" xlink:to="galt_ComputerAndOfficeEquipmentMember_lbl" xlink:title="label: ComputerAndOfficeEquipmentMember to galt_ComputerAndOfficeEquipmentMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_ComputerAndOfficeEquipmentMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_ComputerAndOfficeEquipmentMember_lbl1" xml:lang="en-US" id="galt_ComputerAndOfficeEquipmentMember_lbl1">Computer and Office Equipment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComputerAndOfficeEquipmentMember" xlink:to="galt_ComputerAndOfficeEquipmentMember_lbl1" xlink:title="label: ComputerAndOfficeEquipmentMember to galt_ComputerAndOfficeEquipmentMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_ComputerAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_ComputerAndOfficeEquipmentMember" xml:lang="en-US" id="galt_ComputerAndOfficeEquipmentMember">Computer and Office Equipment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComputerAndOfficeEquipmentMember" xlink:to="galt_ComputerAndOfficeEquipmentMember" xlink:title="label: ComputerAndOfficeEquipmentMember to galt_ComputerAndOfficeEquipmentMember" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ClosingDaysAfterConversionRights" xlink:label="ClosingDaysAfterConversionRights" xlink:title="ClosingDaysAfterConversionRights" />
    <link:label xlink:type="resource" xlink:label="galt_ClosingDaysAfterConversionRights_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_ClosingDaysAfterConversionRights_lbl" xml:lang="en-US" id="galt_ClosingDaysAfterConversionRights_lbl">Number of days for preferred stock post conversion rights in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but not limited to, weeks in a year or quarter.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClosingDaysAfterConversionRights" xlink:to="galt_ClosingDaysAfterConversionRights_lbl" xlink:title="label: ClosingDaysAfterConversionRights to galt_ClosingDaysAfterConversionRights_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_ClosingDaysAfterConversionRights_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_ClosingDaysAfterConversionRights_lbl1" xml:lang="en-US" id="galt_ClosingDaysAfterConversionRights_lbl1">Closing Days After Conversion Rights</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClosingDaysAfterConversionRights" xlink:to="galt_ClosingDaysAfterConversionRights_lbl1" xlink:title="label: ClosingDaysAfterConversionRights to galt_ClosingDaysAfterConversionRights_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_ClosingDaysAfterConversionRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_ClosingDaysAfterConversionRights" xml:lang="en-US" id="galt_ClosingDaysAfterConversionRights">Closing days after conversion rights</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClosingDaysAfterConversionRights" xlink:to="galt_ClosingDaysAfterConversionRights" xlink:title="label: ClosingDaysAfterConversionRights to galt_ClosingDaysAfterConversionRights" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_PostConversionRedemptionRightReturnOnInvestmentMultiplierAmount" xlink:label="PostConversionRedemptionRightReturnOnInvestmentMultiplierAmount" xlink:title="PostConversionRedemptionRightReturnOnInvestmentMultiplierAmount" />
    <link:label xlink:type="resource" xlink:label="galt_PostConversionRedemptionRightReturnOnInvestmentMultiplierAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_PostConversionRedemptionRightReturnOnInvestmentMultiplierAmount_lbl" xml:lang="en-US" id="galt_PostConversionRedemptionRightReturnOnInvestmentMultiplierAmount_lbl">Multiplied by the preferred stock post conversion redemption right shall be equal the applicable return on investment ("ROI") percentage.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PostConversionRedemptionRightReturnOnInvestmentMultiplierAmount" xlink:to="galt_PostConversionRedemptionRightReturnOnInvestmentMultiplierAmount_lbl" xlink:title="label: PostConversionRedemptionRightReturnOnInvestmentMultiplierAmount to galt_PostConversionRedemptionRightReturnOnInvestmentMultiplierAmount_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_PostConversionRedemptionRightReturnOnInvestmentMultiplierAmount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_PostConversionRedemptionRightReturnOnInvestmentMultiplierAmount_lbl1" xml:lang="en-US" id="galt_PostConversionRedemptionRightReturnOnInvestmentMultiplierAmount_lbl1">Post Conversion Redemption Right Return on Investment Multiplier Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PostConversionRedemptionRightReturnOnInvestmentMultiplierAmount" xlink:to="galt_PostConversionRedemptionRightReturnOnInvestmentMultiplierAmount_lbl1" xlink:title="label: PostConversionRedemptionRightReturnOnInvestmentMultiplierAmount to galt_PostConversionRedemptionRightReturnOnInvestmentMultiplierAmount_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_PostConversionRedemptionRightReturnOnInvestmentMultiplierAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_PostConversionRedemptionRightReturnOnInvestmentMultiplierAmount" xml:lang="en-US" id="galt_PostConversionRedemptionRightReturnOnInvestmentMultiplierAmount">Post conversion redemption right, return on investment multiplier amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PostConversionRedemptionRightReturnOnInvestmentMultiplierAmount" xlink:to="galt_PostConversionRedemptionRightReturnOnInvestmentMultiplierAmount" xlink:title="label: PostConversionRedemptionRightReturnOnInvestmentMultiplierAmount to galt_PostConversionRedemptionRightReturnOnInvestmentMultiplierAmount" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_EquityIssuancePerShareAmount" xlink:label="EquityIssuancePerShareAmount" xlink:title="EquityIssuancePerShareAmount" />
    <link:label xlink:type="resource" xlink:label="galt_EquityIssuancePerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_EquityIssuancePerShareAmount_lbl" xml:lang="en-US" id="galt_EquityIssuancePerShareAmount_lbl">Amount per share or per unit assigned to the consideration received of equity securities issued for development stage entities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityIssuancePerShareAmount" xlink:to="galt_EquityIssuancePerShareAmount_lbl" xlink:title="label: EquityIssuancePerShareAmount to galt_EquityIssuancePerShareAmount_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_EquityIssuancePerShareAmount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_EquityIssuancePerShareAmount_lbl1" xml:lang="en-US" id="galt_EquityIssuancePerShareAmount_lbl1">Equity Issuance Per Share Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityIssuancePerShareAmount" xlink:to="galt_EquityIssuancePerShareAmount_lbl1" xlink:title="label: EquityIssuancePerShareAmount to galt_EquityIssuancePerShareAmount_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_EquityIssuancePerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_EquityIssuancePerShareAmount" xml:lang="en-US" id="galt_EquityIssuancePerShareAmount">Common stock share conversion price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityIssuancePerShareAmount" xlink:to="galt_EquityIssuancePerShareAmount" xlink:title="label: EquityIssuancePerShareAmount to galt_EquityIssuancePerShareAmount" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_PostConversionDividendRightsIssued" xlink:label="PostConversionDividendRightsIssued" xlink:title="PostConversionDividendRightsIssued" />
    <link:label xlink:type="resource" xlink:label="galt_PostConversionDividendRightsIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_PostConversionDividendRightsIssued_lbl" xml:lang="en-US" id="galt_PostConversionDividendRightsIssued_lbl">Shares of Series C were converted into common stock and post conversion dividend rights were issued.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PostConversionDividendRightsIssued" xlink:to="galt_PostConversionDividendRightsIssued_lbl" xlink:title="label: PostConversionDividendRightsIssued to galt_PostConversionDividendRightsIssued_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_PostConversionDividendRightsIssued_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_PostConversionDividendRightsIssued_lbl1" xml:lang="en-US" id="galt_PostConversionDividendRightsIssued_lbl1">Post Conversion Dividend Rights Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PostConversionDividendRightsIssued" xlink:to="galt_PostConversionDividendRightsIssued_lbl1" xlink:title="label: PostConversionDividendRightsIssued to galt_PostConversionDividendRightsIssued_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_PostConversionDividendRightsIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_PostConversionDividendRightsIssued" xml:lang="en-US" id="galt_PostConversionDividendRightsIssued">Post conversion dividend rights (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PostConversionDividendRightsIssued" xlink:to="galt_PostConversionDividendRightsIssued" xlink:title="label: PostConversionDividendRightsIssued to galt_PostConversionDividendRightsIssued" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_DividendPaymentScenarioTwoMember" xlink:label="DividendPaymentScenarioTwoMember" xlink:title="DividendPaymentScenarioTwoMember" />
    <link:label xlink:type="resource" xlink:label="galt_DividendPaymentScenarioTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_DividendPaymentScenarioTwoMember_lbl" xml:lang="en-US" id="galt_DividendPaymentScenarioTwoMember_lbl">Dividend payment scenario.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DividendPaymentScenarioTwoMember" xlink:to="galt_DividendPaymentScenarioTwoMember_lbl" xlink:title="label: DividendPaymentScenarioTwoMember to galt_DividendPaymentScenarioTwoMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_DividendPaymentScenarioTwoMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_DividendPaymentScenarioTwoMember_lbl1" xml:lang="en-US" id="galt_DividendPaymentScenarioTwoMember_lbl1">Dividend Payment Scenario Two [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DividendPaymentScenarioTwoMember" xlink:to="galt_DividendPaymentScenarioTwoMember_lbl1" xlink:title="label: DividendPaymentScenarioTwoMember to galt_DividendPaymentScenarioTwoMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_DividendPaymentScenarioTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_DividendPaymentScenarioTwoMember" xml:lang="en-US" id="galt_DividendPaymentScenarioTwoMember">Dividend Payment Scenario Two [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DividendPaymentScenarioTwoMember" xlink:to="galt_DividendPaymentScenarioTwoMember" xlink:title="label: DividendPaymentScenarioTwoMember to galt_DividendPaymentScenarioTwoMember" />
    <link:label xlink:type="resource" xlink:label="galt_DividendPaymentScenarioTwoMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="galt_DividendPaymentScenarioTwoMember_lbl2" xml:lang="en-US" id="galt_DividendPaymentScenarioTwoMember_lbl2">Scenario 2 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DividendPaymentScenarioTwoMember" xlink:to="galt_DividendPaymentScenarioTwoMember_lbl2" xlink:title="label: DividendPaymentScenarioTwoMember to galt_DividendPaymentScenarioTwoMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_DividendAsPercentageOfNetSales" xlink:label="DividendAsPercentageOfNetSales" xlink:title="DividendAsPercentageOfNetSales" />
    <link:label xlink:type="resource" xlink:label="galt_DividendAsPercentageOfNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_DividendAsPercentageOfNetSales_lbl" xml:lang="en-US" id="galt_DividendAsPercentageOfNetSales_lbl">Net sales until the total dividends paid is equal to the initial investment as percentage of total net sales.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DividendAsPercentageOfNetSales" xlink:to="galt_DividendAsPercentageOfNetSales_lbl" xlink:title="label: DividendAsPercentageOfNetSales to galt_DividendAsPercentageOfNetSales_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_DividendAsPercentageOfNetSales_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_DividendAsPercentageOfNetSales_lbl1" xml:lang="en-US" id="galt_DividendAsPercentageOfNetSales_lbl1">Dividend as Percentage of Net Sales</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DividendAsPercentageOfNetSales" xlink:to="galt_DividendAsPercentageOfNetSales_lbl1" xlink:title="label: DividendAsPercentageOfNetSales to galt_DividendAsPercentageOfNetSales_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_DividendAsPercentageOfNetSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_DividendAsPercentageOfNetSales" xml:lang="en-US" id="galt_DividendAsPercentageOfNetSales">Dividend as percentage of net sales</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DividendAsPercentageOfNetSales" xlink:to="galt_DividendAsPercentageOfNetSales" xlink:title="label: DividendAsPercentageOfNetSales to galt_DividendAsPercentageOfNetSales" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_NumberOfConsecutiveTradingDays" xlink:label="NumberOfConsecutiveTradingDays" xlink:title="NumberOfConsecutiveTradingDays" />
    <link:label xlink:type="resource" xlink:label="galt_NumberOfConsecutiveTradingDays_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_NumberOfConsecutiveTradingDays_lbl" xml:lang="en-US" id="galt_NumberOfConsecutiveTradingDays_lbl">Number of consecutive trading days, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but not limited to, weeks in a year or quarter.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfConsecutiveTradingDays" xlink:to="galt_NumberOfConsecutiveTradingDays_lbl" xlink:title="label: NumberOfConsecutiveTradingDays to galt_NumberOfConsecutiveTradingDays_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_NumberOfConsecutiveTradingDays_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_NumberOfConsecutiveTradingDays_lbl1" xml:lang="en-US" id="galt_NumberOfConsecutiveTradingDays_lbl1">Number of Consecutive Trading Days</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfConsecutiveTradingDays" xlink:to="galt_NumberOfConsecutiveTradingDays_lbl1" xlink:title="label: NumberOfConsecutiveTradingDays to galt_NumberOfConsecutiveTradingDays_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_NumberOfConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_NumberOfConsecutiveTradingDays" xml:lang="en-US" id="galt_NumberOfConsecutiveTradingDays">Number of consecutive trading days</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfConsecutiveTradingDays" xlink:to="galt_NumberOfConsecutiveTradingDays" xlink:title="label: NumberOfConsecutiveTradingDays to galt_NumberOfConsecutiveTradingDays" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ProceedsFromIssuanceOfPreferredStockNetOfIssuanceCosts" xlink:label="ProceedsFromIssuanceOfPreferredStockNetOfIssuanceCosts" xlink:title="ProceedsFromIssuanceOfPreferredStockNetOfIssuanceCosts" />
    <link:label xlink:type="resource" xlink:label="galt_ProceedsFromIssuanceOfPreferredStockNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_ProceedsFromIssuanceOfPreferredStockNetOfIssuanceCosts_lbl" xml:lang="en-US" id="galt_ProceedsFromIssuanceOfPreferredStockNetOfIssuanceCosts_lbl">Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfPreferredStockNetOfIssuanceCosts" xlink:to="galt_ProceedsFromIssuanceOfPreferredStockNetOfIssuanceCosts_lbl" xlink:title="label: ProceedsFromIssuanceOfPreferredStockNetOfIssuanceCosts to galt_ProceedsFromIssuanceOfPreferredStockNetOfIssuanceCosts_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_ProceedsFromIssuanceOfPreferredStockNetOfIssuanceCosts_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_ProceedsFromIssuanceOfPreferredStockNetOfIssuanceCosts_lbl1" xml:lang="en-US" id="galt_ProceedsFromIssuanceOfPreferredStockNetOfIssuanceCosts_lbl1">Proceeds from Issuance of Preferred Stock, Net of Issuance Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfPreferredStockNetOfIssuanceCosts" xlink:to="galt_ProceedsFromIssuanceOfPreferredStockNetOfIssuanceCosts_lbl1" xlink:title="label: ProceedsFromIssuanceOfPreferredStockNetOfIssuanceCosts to galt_ProceedsFromIssuanceOfPreferredStockNetOfIssuanceCosts_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_ProceedsFromIssuanceOfPreferredStockNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_ProceedsFromIssuanceOfPreferredStockNetOfIssuanceCosts" xml:lang="en-US" id="galt_ProceedsFromIssuanceOfPreferredStockNetOfIssuanceCosts">Net proceeds from issuance of preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfPreferredStockNetOfIssuanceCosts" xlink:to="galt_ProceedsFromIssuanceOfPreferredStockNetOfIssuanceCosts" xlink:title="label: ProceedsFromIssuanceOfPreferredStockNetOfIssuanceCosts to galt_ProceedsFromIssuanceOfPreferredStockNetOfIssuanceCosts" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_DividendPaymentScenarioOneMember" xlink:label="DividendPaymentScenarioOneMember" xlink:title="DividendPaymentScenarioOneMember" />
    <link:label xlink:type="resource" xlink:label="galt_DividendPaymentScenarioOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_DividendPaymentScenarioOneMember_lbl" xml:lang="en-US" id="galt_DividendPaymentScenarioOneMember_lbl">Dividend payment scenario.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DividendPaymentScenarioOneMember" xlink:to="galt_DividendPaymentScenarioOneMember_lbl" xlink:title="label: DividendPaymentScenarioOneMember to galt_DividendPaymentScenarioOneMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_DividendPaymentScenarioOneMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_DividendPaymentScenarioOneMember_lbl1" xml:lang="en-US" id="galt_DividendPaymentScenarioOneMember_lbl1">Dividend Payment Scenario One [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DividendPaymentScenarioOneMember" xlink:to="galt_DividendPaymentScenarioOneMember_lbl1" xlink:title="label: DividendPaymentScenarioOneMember to galt_DividendPaymentScenarioOneMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_DividendPaymentScenarioOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_DividendPaymentScenarioOneMember" xml:lang="en-US" id="galt_DividendPaymentScenarioOneMember">Dividend Payment Scenario One [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DividendPaymentScenarioOneMember" xlink:to="galt_DividendPaymentScenarioOneMember" xlink:title="label: DividendPaymentScenarioOneMember to galt_DividendPaymentScenarioOneMember" />
    <link:label xlink:type="resource" xlink:label="galt_DividendPaymentScenarioOneMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="galt_DividendPaymentScenarioOneMember_lbl2" xml:lang="en-US" id="galt_DividendPaymentScenarioOneMember_lbl2">Scenario 1 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DividendPaymentScenarioOneMember" xlink:to="galt_DividendPaymentScenarioOneMember_lbl2" xlink:title="label: DividendPaymentScenarioOneMember to galt_DividendPaymentScenarioOneMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_CommonSharesIssuableUponConversionOfConvertibleStock" xlink:label="CommonSharesIssuableUponConversionOfConvertibleStock" xlink:title="CommonSharesIssuableUponConversionOfConvertibleStock" />
    <link:label xlink:type="resource" xlink:label="galt_CommonSharesIssuableUponConversionOfConvertibleStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_CommonSharesIssuableUponConversionOfConvertibleStock_lbl" xml:lang="en-US" id="galt_CommonSharesIssuableUponConversionOfConvertibleStock_lbl">Common stock issued per each converted share of Series C (accrued and unpaid dividends will be issued as additional shares).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonSharesIssuableUponConversionOfConvertibleStock" xlink:to="galt_CommonSharesIssuableUponConversionOfConvertibleStock_lbl" xlink:title="label: CommonSharesIssuableUponConversionOfConvertibleStock to galt_CommonSharesIssuableUponConversionOfConvertibleStock_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_CommonSharesIssuableUponConversionOfConvertibleStock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_CommonSharesIssuableUponConversionOfConvertibleStock_lbl1" xml:lang="en-US" id="galt_CommonSharesIssuableUponConversionOfConvertibleStock_lbl1">Common Shares Issuable Upon Conversion of Convertible Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonSharesIssuableUponConversionOfConvertibleStock" xlink:to="galt_CommonSharesIssuableUponConversionOfConvertibleStock_lbl1" xlink:title="label: CommonSharesIssuableUponConversionOfConvertibleStock to galt_CommonSharesIssuableUponConversionOfConvertibleStock_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_CommonSharesIssuableUponConversionOfConvertibleStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_CommonSharesIssuableUponConversionOfConvertibleStock" xml:lang="en-US" id="galt_CommonSharesIssuableUponConversionOfConvertibleStock">Common stock shares issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonSharesIssuableUponConversionOfConvertibleStock" xlink:to="galt_CommonSharesIssuableUponConversionOfConvertibleStock" xlink:title="label: CommonSharesIssuableUponConversionOfConvertibleStock to galt_CommonSharesIssuableUponConversionOfConvertibleStock" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ClassOfWarrantOrRightIssued" xlink:label="ClassOfWarrantOrRightIssued" xlink:title="ClassOfWarrantOrRightIssued" />
    <link:label xlink:type="resource" xlink:label="galt_ClassOfWarrantOrRightIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_ClassOfWarrantOrRightIssued_lbl" xml:lang="en-US" id="galt_ClassOfWarrantOrRightIssued_lbl">Number of warrants or rights issued during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightIssued" xlink:to="galt_ClassOfWarrantOrRightIssued_lbl" xlink:title="label: ClassOfWarrantOrRightIssued to galt_ClassOfWarrantOrRightIssued_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_ClassOfWarrantOrRightIssued_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_ClassOfWarrantOrRightIssued_lbl1" xml:lang="en-US" id="galt_ClassOfWarrantOrRightIssued_lbl1">Class of Warrant or Right Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightIssued" xlink:to="galt_ClassOfWarrantOrRightIssued_lbl1" xlink:title="label: ClassOfWarrantOrRightIssued to galt_ClassOfWarrantOrRightIssued_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_ClassOfWarrantOrRightIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_ClassOfWarrantOrRightIssued" xml:lang="en-US" id="galt_ClassOfWarrantOrRightIssued">Warrants issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightIssued" xlink:to="galt_ClassOfWarrantOrRightIssued" xlink:title="label: ClassOfWarrantOrRightIssued to galt_ClassOfWarrantOrRightIssued" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_September2024PromissoryNoteMember" xlink:label="September2024PromissoryNoteMember" xlink:title="September2024PromissoryNoteMember" />
    <link:label xlink:type="resource" xlink:label="galt_September2024PromissoryNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_September2024PromissoryNoteMember_lbl" xml:lang="en-US" id="galt_September2024PromissoryNoteMember_lbl">Promissory note executed on September 30, 2024 under the line of credit agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="September2024PromissoryNoteMember" xlink:to="galt_September2024PromissoryNoteMember_lbl" xlink:title="label: September2024PromissoryNoteMember to galt_September2024PromissoryNoteMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_September2024PromissoryNoteMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_September2024PromissoryNoteMember_lbl1" xml:lang="en-US" id="galt_September2024PromissoryNoteMember_lbl1">September 2024 Promissory Note [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="September2024PromissoryNoteMember" xlink:to="galt_September2024PromissoryNoteMember_lbl1" xlink:title="label: September2024PromissoryNoteMember to galt_September2024PromissoryNoteMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_September2024PromissoryNoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_September2024PromissoryNoteMember" xml:lang="en-US" id="galt_September2024PromissoryNoteMember">September 2024 Promissory Note [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="September2024PromissoryNoteMember" xlink:to="galt_September2024PromissoryNoteMember" xlink:title="label: September2024PromissoryNoteMember to galt_September2024PromissoryNoteMember" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_March24PromissoryNoteMember" xlink:label="March24PromissoryNoteMember" xlink:title="March24PromissoryNoteMember" />
    <link:label xlink:type="resource" xlink:label="galt_March24PromissoryNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_March24PromissoryNoteMember_lbl" xml:lang="en-US" id="galt_March24PromissoryNoteMember_lbl">Promissory note executed on June 30, 2023 under the line of credit agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="March24PromissoryNoteMember" xlink:to="galt_March24PromissoryNoteMember_lbl" xlink:title="label: March24PromissoryNoteMember to galt_March24PromissoryNoteMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_March24PromissoryNoteMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_March24PromissoryNoteMember_lbl1" xml:lang="en-US" id="galt_March24PromissoryNoteMember_lbl1">March 2024 Promissory Note [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="March24PromissoryNoteMember" xlink:to="galt_March24PromissoryNoteMember_lbl1" xlink:title="label: March24PromissoryNoteMember to galt_March24PromissoryNoteMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_March24PromissoryNoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_March24PromissoryNoteMember" xml:lang="en-US" id="galt_March24PromissoryNoteMember">March 2024 Promissory Note [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="March24PromissoryNoteMember" xlink:to="galt_March24PromissoryNoteMember" xlink:title="label: March24PromissoryNoteMember to galt_March24PromissoryNoteMember" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_June2023PromissoryNoteMember" xlink:label="June2023PromissoryNoteMember" xlink:title="June2023PromissoryNoteMember" />
    <link:label xlink:type="resource" xlink:label="galt_June2023PromissoryNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_June2023PromissoryNoteMember_lbl" xml:lang="en-US" id="galt_June2023PromissoryNoteMember_lbl">Promissory note executed on June 30, 2023 under the line of credit agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="June2023PromissoryNoteMember" xlink:to="galt_June2023PromissoryNoteMember_lbl" xlink:title="label: June2023PromissoryNoteMember to galt_June2023PromissoryNoteMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_June2023PromissoryNoteMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_June2023PromissoryNoteMember_lbl1" xml:lang="en-US" id="galt_June2023PromissoryNoteMember_lbl1">June 2023 Promissory Note [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="June2023PromissoryNoteMember" xlink:to="galt_June2023PromissoryNoteMember_lbl1" xlink:title="label: June2023PromissoryNoteMember to galt_June2023PromissoryNoteMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_December2022PromissoryNoteMember" xlink:label="December2022PromissoryNoteMember" xlink:title="December2022PromissoryNoteMember" />
    <link:label xlink:type="resource" xlink:label="galt_December2022PromissoryNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_December2022PromissoryNoteMember_lbl" xml:lang="en-US" id="galt_December2022PromissoryNoteMember_lbl">Promissory note executed on December 19, 2022 under the line of credit agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="December2022PromissoryNoteMember" xlink:to="galt_December2022PromissoryNoteMember_lbl" xlink:title="label: December2022PromissoryNoteMember to galt_December2022PromissoryNoteMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_December2022PromissoryNoteMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_December2022PromissoryNoteMember_lbl1" xml:lang="en-US" id="galt_December2022PromissoryNoteMember_lbl1">December 2022 Promissory Note [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="December2022PromissoryNoteMember" xlink:to="galt_December2022PromissoryNoteMember_lbl1" xlink:title="label: December2022PromissoryNoteMember to galt_December2022PromissoryNoteMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_LineOfCreditRelatedPartyAbstract" xlink:label="LineOfCreditRelatedPartyAbstract" xlink:title="LineOfCreditRelatedPartyAbstract" />
    <link:label xlink:type="resource" xlink:label="galt_LineOfCreditRelatedPartyAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_LineOfCreditRelatedPartyAbstract_lbl1" xml:lang="en-US" id="galt_LineOfCreditRelatedPartyAbstract_lbl1">Line of Credit, Related Party [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LineOfCreditRelatedPartyAbstract" xlink:to="galt_LineOfCreditRelatedPartyAbstract_lbl1" xlink:title="label: LineOfCreditRelatedPartyAbstract to galt_LineOfCreditRelatedPartyAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_LineOfCreditRelatedPartyAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_LineOfCreditRelatedPartyAbstract" xml:lang="en-US" id="galt_LineOfCreditRelatedPartyAbstract">Convertible Line of Credit - Related Party [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LineOfCreditRelatedPartyAbstract" xlink:to="galt_LineOfCreditRelatedPartyAbstract" xlink:title="label: LineOfCreditRelatedPartyAbstract to galt_LineOfCreditRelatedPartyAbstract" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_DebtInstrumentAccruedInterest" xlink:label="DebtInstrumentAccruedInterest" xlink:title="DebtInstrumentAccruedInterest" />
    <link:label xlink:type="resource" xlink:label="galt_DebtInstrumentAccruedInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_DebtInstrumentAccruedInterest_lbl" xml:lang="en-US" id="galt_DebtInstrumentAccruedInterest_lbl">Accrued, but unpaid interest on the debt instrument.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentAccruedInterest" xlink:to="galt_DebtInstrumentAccruedInterest_lbl" xlink:title="label: DebtInstrumentAccruedInterest to galt_DebtInstrumentAccruedInterest_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_DebtInstrumentAccruedInterest_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_DebtInstrumentAccruedInterest_lbl1" xml:lang="en-US" id="galt_DebtInstrumentAccruedInterest_lbl1">Debt Instrument, Accrued Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentAccruedInterest" xlink:to="galt_DebtInstrumentAccruedInterest_lbl1" xlink:title="label: DebtInstrumentAccruedInterest to galt_DebtInstrumentAccruedInterest_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_DebtInstrumentAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_DebtInstrumentAccruedInterest" xml:lang="en-US" id="galt_DebtInstrumentAccruedInterest">Accrued interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentAccruedInterest" xlink:to="galt_DebtInstrumentAccruedInterest" xlink:title="label: DebtInstrumentAccruedInterest to galt_DebtInstrumentAccruedInterest" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_IssuanceOfWarrantsValue" xlink:label="IssuanceOfWarrantsValue" xlink:title="IssuanceOfWarrantsValue" />
    <link:label xlink:type="resource" xlink:label="galt_IssuanceOfWarrantsValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_IssuanceOfWarrantsValue_lbl" xml:lang="en-US" id="galt_IssuanceOfWarrantsValue_lbl">The amount of issuance of warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuanceOfWarrantsValue" xlink:to="galt_IssuanceOfWarrantsValue_lbl" xlink:title="label: IssuanceOfWarrantsValue to galt_IssuanceOfWarrantsValue_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_IssuanceOfWarrantsValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_IssuanceOfWarrantsValue_lbl1" xml:lang="en-US" id="galt_IssuanceOfWarrantsValue_lbl1">Issuance of Warrants Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuanceOfWarrantsValue" xlink:to="galt_IssuanceOfWarrantsValue_lbl1" xlink:title="label: IssuanceOfWarrantsValue to galt_IssuanceOfWarrantsValue_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_IssuanceOfWarrantsValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_IssuanceOfWarrantsValue" xml:lang="en-US" id="galt_IssuanceOfWarrantsValue">Warrants issuance value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuanceOfWarrantsValue" xlink:to="galt_IssuanceOfWarrantsValue" xlink:title="label: IssuanceOfWarrantsValue to galt_IssuanceOfWarrantsValue" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock" />
    <link:label xlink:type="resource" xlink:label="galt_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock_lbl" xml:lang="en-US" id="galt_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock_lbl">The percentage of exercise price per share or per unit of warrants equal to common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock" xlink:to="galt_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock_lbl" xlink:title="label: ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock to galt_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock_lbl1" xml:lang="en-US" id="galt_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock_lbl1">Class of Warrant or Right, Exercise Price of Warrants or Rights, Percentage Equal to Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock" xlink:to="galt_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock_lbl1" xlink:title="label: ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock to galt_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock" xml:lang="en-US" id="galt_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock">Percentage of warrants equal to the closing price of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock" xlink:to="galt_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock" xlink:title="label: ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock to galt_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:label xlink:type="resource" xlink:label="galt_ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" id="galt_ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl">Number of securities into which the class of additional warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="galt_ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:title="label: ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights to galt_ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl1" xml:lang="en-US" id="galt_ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl1">Class of Additional Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="galt_ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl1" xlink:title="label: ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights to galt_ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US" id="galt_ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">Warrants to purchase additional common stock (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="galt_ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="label: ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights to galt_ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_AdditionalSupplementalLineOfCreditMember" xlink:label="AdditionalSupplementalLineOfCreditMember" xlink:title="AdditionalSupplementalLineOfCreditMember" />
    <link:label xlink:type="resource" xlink:label="galt_AdditionalSupplementalLineOfCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_AdditionalSupplementalLineOfCreditMember_lbl" xml:lang="en-US" id="galt_AdditionalSupplementalLineOfCreditMember_lbl">An additional supplemental contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalSupplementalLineOfCreditMember" xlink:to="galt_AdditionalSupplementalLineOfCreditMember_lbl" xlink:title="label: AdditionalSupplementalLineOfCreditMember to galt_AdditionalSupplementalLineOfCreditMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_AdditionalSupplementalLineOfCreditMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_AdditionalSupplementalLineOfCreditMember_lbl1" xml:lang="en-US" id="galt_AdditionalSupplementalLineOfCreditMember_lbl1">Additional Supplemental Line of Credit [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalSupplementalLineOfCreditMember" xlink:to="galt_AdditionalSupplementalLineOfCreditMember_lbl1" xlink:title="label: AdditionalSupplementalLineOfCreditMember to galt_AdditionalSupplementalLineOfCreditMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_June2024PromissoryNoteMember" xlink:label="June2024PromissoryNoteMember" xlink:title="June2024PromissoryNoteMember" />
    <link:label xlink:type="resource" xlink:label="galt_June2024PromissoryNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_June2024PromissoryNoteMember_lbl" xml:lang="en-US" id="galt_June2024PromissoryNoteMember_lbl">Promissory note executed on June 28, 2024 under the line of credit agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="June2024PromissoryNoteMember" xlink:to="galt_June2024PromissoryNoteMember_lbl" xlink:title="label: June2024PromissoryNoteMember to galt_June2024PromissoryNoteMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_June2024PromissoryNoteMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_June2024PromissoryNoteMember_lbl1" xml:lang="en-US" id="galt_June2024PromissoryNoteMember_lbl1">June 2024 Promissory Note [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="June2024PromissoryNoteMember" xlink:to="galt_June2024PromissoryNoteMember_lbl1" xlink:title="label: June2024PromissoryNoteMember to galt_June2024PromissoryNoteMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_June2024PromissoryNoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_June2024PromissoryNoteMember" xml:lang="en-US" id="galt_June2024PromissoryNoteMember">June 2024 Promissory Note [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="June2024PromissoryNoteMember" xlink:to="galt_June2024PromissoryNoteMember" xlink:title="label: June2024PromissoryNoteMember to galt_June2024PromissoryNoteMember" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_WarrantSixMember" xlink:label="WarrantSixMember" xlink:title="WarrantSixMember" />
    <link:label xlink:type="resource" xlink:label="galt_WarrantSixMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_WarrantSixMember_lbl" xml:lang="en-US" id="galt_WarrantSixMember_lbl">Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantSixMember" xlink:to="galt_WarrantSixMember_lbl" xlink:title="label: WarrantSixMember to galt_WarrantSixMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_WarrantSixMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_WarrantSixMember_lbl1" xml:lang="en-US" id="galt_WarrantSixMember_lbl1">Warrant Six [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantSixMember" xlink:to="galt_WarrantSixMember_lbl1" xlink:title="label: WarrantSixMember to galt_WarrantSixMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_WarrantSixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_WarrantSixMember" xml:lang="en-US" id="galt_WarrantSixMember">Warrant Six [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantSixMember" xlink:to="galt_WarrantSixMember" xlink:title="label: WarrantSixMember to galt_WarrantSixMember" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_WarrantOneMember" xlink:label="WarrantOneMember" xlink:title="WarrantOneMember" />
    <link:label xlink:type="resource" xlink:label="galt_WarrantOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_WarrantOneMember_lbl" xml:lang="en-US" id="galt_WarrantOneMember_lbl">Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantOneMember" xlink:to="galt_WarrantOneMember_lbl" xlink:title="label: WarrantOneMember to galt_WarrantOneMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_WarrantOneMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_WarrantOneMember_lbl1" xml:lang="en-US" id="galt_WarrantOneMember_lbl1">Warrant One [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantOneMember" xlink:to="galt_WarrantOneMember_lbl1" xlink:title="label: WarrantOneMember to galt_WarrantOneMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_WarrantOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_WarrantOneMember" xml:lang="en-US" id="galt_WarrantOneMember">Warrant One [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantOneMember" xlink:to="galt_WarrantOneMember" xlink:title="label: WarrantOneMember to galt_WarrantOneMember" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_WarrantTwoMember" xlink:label="WarrantTwoMember" xlink:title="WarrantTwoMember" />
    <link:label xlink:type="resource" xlink:label="galt_WarrantTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_WarrantTwoMember_lbl" xml:lang="en-US" id="galt_WarrantTwoMember_lbl">Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantTwoMember" xlink:to="galt_WarrantTwoMember_lbl" xlink:title="label: WarrantTwoMember to galt_WarrantTwoMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_WarrantTwoMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_WarrantTwoMember_lbl1" xml:lang="en-US" id="galt_WarrantTwoMember_lbl1">Warrant Two [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantTwoMember" xlink:to="galt_WarrantTwoMember_lbl1" xlink:title="label: WarrantTwoMember to galt_WarrantTwoMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_WarrantTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_WarrantTwoMember" xml:lang="en-US" id="galt_WarrantTwoMember">Warrant Two [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantTwoMember" xlink:to="galt_WarrantTwoMember" xlink:title="label: WarrantTwoMember to galt_WarrantTwoMember" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_WarrantSevenMember" xlink:label="WarrantSevenMember" xlink:title="WarrantSevenMember" />
    <link:label xlink:type="resource" xlink:label="galt_WarrantSevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_WarrantSevenMember_lbl" xml:lang="en-US" id="galt_WarrantSevenMember_lbl">Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantSevenMember" xlink:to="galt_WarrantSevenMember_lbl" xlink:title="label: WarrantSevenMember to galt_WarrantSevenMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_WarrantSevenMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_WarrantSevenMember_lbl1" xml:lang="en-US" id="galt_WarrantSevenMember_lbl1">Warrant Seven [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantSevenMember" xlink:to="galt_WarrantSevenMember_lbl1" xlink:title="label: WarrantSevenMember to galt_WarrantSevenMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_WarrantSevenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_WarrantSevenMember" xml:lang="en-US" id="galt_WarrantSevenMember">Warrant Seven [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantSevenMember" xlink:to="galt_WarrantSevenMember" xlink:title="label: WarrantSevenMember to galt_WarrantSevenMember" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_WarrantThreeMember" xlink:label="WarrantThreeMember" xlink:title="WarrantThreeMember" />
    <link:label xlink:type="resource" xlink:label="galt_WarrantThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_WarrantThreeMember_lbl" xml:lang="en-US" id="galt_WarrantThreeMember_lbl">Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantThreeMember" xlink:to="galt_WarrantThreeMember_lbl" xlink:title="label: WarrantThreeMember to galt_WarrantThreeMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_WarrantThreeMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_WarrantThreeMember_lbl1" xml:lang="en-US" id="galt_WarrantThreeMember_lbl1">Warrant Three [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantThreeMember" xlink:to="galt_WarrantThreeMember_lbl1" xlink:title="label: WarrantThreeMember to galt_WarrantThreeMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_WarrantThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_WarrantThreeMember" xml:lang="en-US" id="galt_WarrantThreeMember">Warrant Three [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantThreeMember" xlink:to="galt_WarrantThreeMember" xlink:title="label: WarrantThreeMember to galt_WarrantThreeMember" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_WarrantFiveMember" xlink:label="WarrantFiveMember" xlink:title="WarrantFiveMember" />
    <link:label xlink:type="resource" xlink:label="galt_WarrantFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_WarrantFiveMember_lbl" xml:lang="en-US" id="galt_WarrantFiveMember_lbl">Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantFiveMember" xlink:to="galt_WarrantFiveMember_lbl" xlink:title="label: WarrantFiveMember to galt_WarrantFiveMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_WarrantFiveMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_WarrantFiveMember_lbl1" xml:lang="en-US" id="galt_WarrantFiveMember_lbl1">Warrant Five [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantFiveMember" xlink:to="galt_WarrantFiveMember_lbl1" xlink:title="label: WarrantFiveMember to galt_WarrantFiveMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_March2023PromissoryNoteMember" xlink:label="March2023PromissoryNoteMember" xlink:title="March2023PromissoryNoteMember" />
    <link:label xlink:type="resource" xlink:label="galt_March2023PromissoryNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_March2023PromissoryNoteMember_lbl" xml:lang="en-US" id="galt_March2023PromissoryNoteMember_lbl">Promissory note executed on March 31, 2023 under the line of credit agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="March2023PromissoryNoteMember" xlink:to="galt_March2023PromissoryNoteMember_lbl" xlink:title="label: March2023PromissoryNoteMember to galt_March2023PromissoryNoteMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_March2023PromissoryNoteMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_March2023PromissoryNoteMember_lbl1" xml:lang="en-US" id="galt_March2023PromissoryNoteMember_lbl1">March 2023 Promissory Note [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="March2023PromissoryNoteMember" xlink:to="galt_March2023PromissoryNoteMember_lbl1" xlink:title="label: March2023PromissoryNoteMember to galt_March2023PromissoryNoteMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_December2023PromissoryNoteMember" xlink:label="December2023PromissoryNoteMember" xlink:title="December2023PromissoryNoteMember" />
    <link:label xlink:type="resource" xlink:label="galt_December2023PromissoryNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_December2023PromissoryNoteMember_lbl" xml:lang="en-US" id="galt_December2023PromissoryNoteMember_lbl">Promissory note executed on June 30, 2023 under the line of credit agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="December2023PromissoryNoteMember" xlink:to="galt_December2023PromissoryNoteMember_lbl" xlink:title="label: December2023PromissoryNoteMember to galt_December2023PromissoryNoteMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_December2023PromissoryNoteMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_December2023PromissoryNoteMember_lbl1" xml:lang="en-US" id="galt_December2023PromissoryNoteMember_lbl1">December 2023 Promissory Note [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="December2023PromissoryNoteMember" xlink:to="galt_December2023PromissoryNoteMember_lbl1" xlink:title="label: December2023PromissoryNoteMember to galt_December2023PromissoryNoteMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_December2023PromissoryNoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_December2023PromissoryNoteMember" xml:lang="en-US" id="galt_December2023PromissoryNoteMember">December 2023 Promissory Note [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="December2023PromissoryNoteMember" xlink:to="galt_December2023PromissoryNoteMember" xlink:title="label: December2023PromissoryNoteMember to galt_December2023PromissoryNoteMember" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_WarrantFourMember" xlink:label="WarrantFourMember" xlink:title="WarrantFourMember" />
    <link:label xlink:type="resource" xlink:label="galt_WarrantFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_WarrantFourMember_lbl" xml:lang="en-US" id="galt_WarrantFourMember_lbl">Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantFourMember" xlink:to="galt_WarrantFourMember_lbl" xlink:title="label: WarrantFourMember to galt_WarrantFourMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_WarrantFourMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_WarrantFourMember_lbl1" xml:lang="en-US" id="galt_WarrantFourMember_lbl1">Warrant Four [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantFourMember" xlink:to="galt_WarrantFourMember_lbl1" xlink:title="label: WarrantFourMember to galt_WarrantFourMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ExpiringThrough2037Member" xlink:label="ExpiringThrough2037Member" xlink:title="ExpiringThrough2037Member" />
    <link:label xlink:type="resource" xlink:label="galt_ExpiringThrough2037Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_ExpiringThrough2037Member_lbl" xml:lang="en-US" id="galt_ExpiringThrough2037Member_lbl">Latest expiration tax year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExpiringThrough2037Member" xlink:to="galt_ExpiringThrough2037Member_lbl" xlink:title="label: ExpiringThrough2037Member to galt_ExpiringThrough2037Member_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_ExpiringThrough2037Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_ExpiringThrough2037Member_lbl1" xml:lang="en-US" id="galt_ExpiringThrough2037Member_lbl1">Expiring Through 2037 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExpiringThrough2037Member" xlink:to="galt_ExpiringThrough2037Member_lbl1" xlink:title="label: ExpiringThrough2037Member to galt_ExpiringThrough2037Member_lbl1" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ExpiringAsAResultOf2017TaxActMember" xlink:label="ExpiringAsAResultOf2017TaxActMember" xlink:title="ExpiringAsAResultOf2017TaxActMember" />
    <link:label xlink:type="resource" xlink:label="galt_ExpiringAsAResultOf2017TaxActMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_ExpiringAsAResultOf2017TaxActMember_lbl" xml:lang="en-US" id="galt_ExpiringAsAResultOf2017TaxActMember_lbl">Expiring as a result of 2017 tax act earliest tax year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExpiringAsAResultOf2017TaxActMember" xlink:to="galt_ExpiringAsAResultOf2017TaxActMember_lbl" xlink:title="label: ExpiringAsAResultOf2017TaxActMember to galt_ExpiringAsAResultOf2017TaxActMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_ExpiringAsAResultOf2017TaxActMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_ExpiringAsAResultOf2017TaxActMember_lbl1" xml:lang="en-US" id="galt_ExpiringAsAResultOf2017TaxActMember_lbl1">Expiring as a Result of 2017 Tax Act [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExpiringAsAResultOf2017TaxActMember" xlink:to="galt_ExpiringAsAResultOf2017TaxActMember_lbl1" xlink:title="label: ExpiringAsAResultOf2017TaxActMember to galt_ExpiringAsAResultOf2017TaxActMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_DeferredTaxAssetsValuationAllowancePercentage" xlink:label="DeferredTaxAssetsValuationAllowancePercentage" xlink:title="DeferredTaxAssetsValuationAllowancePercentage" />
    <link:label xlink:type="resource" xlink:label="galt_DeferredTaxAssetsValuationAllowancePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_DeferredTaxAssetsValuationAllowancePercentage_lbl" xml:lang="en-US" id="galt_DeferredTaxAssetsValuationAllowancePercentage_lbl">The deferred tax assets valuation allowance percentage in each of the last two years.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsValuationAllowancePercentage" xlink:to="galt_DeferredTaxAssetsValuationAllowancePercentage_lbl" xlink:title="label: DeferredTaxAssetsValuationAllowancePercentage to galt_DeferredTaxAssetsValuationAllowancePercentage_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_DeferredTaxAssetsValuationAllowancePercentage_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_DeferredTaxAssetsValuationAllowancePercentage_lbl1" xml:lang="en-US" id="galt_DeferredTaxAssetsValuationAllowancePercentage_lbl1">Deferred Tax Assets Valuation Allowance Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsValuationAllowancePercentage" xlink:to="galt_DeferredTaxAssetsValuationAllowancePercentage_lbl1" xlink:title="label: DeferredTaxAssetsValuationAllowancePercentage to galt_DeferredTaxAssetsValuationAllowancePercentage_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_DeferredTaxAssetsValuationAllowancePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_DeferredTaxAssetsValuationAllowancePercentage" xml:lang="en-US" id="galt_DeferredTaxAssetsValuationAllowancePercentage">Deferred tax asset valuation allowance percentage in each of the last two years</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsValuationAllowancePercentage" xlink:to="galt_DeferredTaxAssetsValuationAllowancePercentage" xlink:title="label: DeferredTaxAssetsValuationAllowancePercentage to galt_DeferredTaxAssetsValuationAllowancePercentage" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_OperatingLossCarryforwardsExpirationYear" xlink:label="OperatingLossCarryforwardsExpirationYear" xlink:title="OperatingLossCarryforwardsExpirationYear" />
    <link:label xlink:type="resource" xlink:label="galt_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_OperatingLossCarryforwardsExpirationYear_lbl" xml:lang="en-US" id="galt_OperatingLossCarryforwardsExpirationYear_lbl">Expiration year of each operating loss carryforward included in operating loss carryforward, in YYYY format.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLossCarryforwardsExpirationYear" xlink:to="galt_OperatingLossCarryforwardsExpirationYear_lbl" xlink:title="label: OperatingLossCarryforwardsExpirationYear to galt_OperatingLossCarryforwardsExpirationYear_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_OperatingLossCarryforwardsExpirationYear_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_OperatingLossCarryforwardsExpirationYear_lbl1" xml:lang="en-US" id="galt_OperatingLossCarryforwardsExpirationYear_lbl1">Operating Loss Carryforwards Expiration Year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLossCarryforwardsExpirationYear" xlink:to="galt_OperatingLossCarryforwardsExpirationYear_lbl1" xlink:title="label: OperatingLossCarryforwardsExpirationYear to galt_OperatingLossCarryforwardsExpirationYear_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_OperatingLossCarryforwardsExpirationYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_OperatingLossCarryforwardsExpirationYear" xml:lang="en-US" id="galt_OperatingLossCarryforwardsExpirationYear">Operating loss carryforwards expiration year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLossCarryforwardsExpirationYear" xlink:to="galt_OperatingLossCarryforwardsExpirationYear" xlink:title="label: OperatingLossCarryforwardsExpirationYear to galt_OperatingLossCarryforwardsExpirationYear" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_FederalAndStateResearchAndDevelopmentCreditsExpirationYear" xlink:label="FederalAndStateResearchAndDevelopmentCreditsExpirationYear" xlink:title="FederalAndStateResearchAndDevelopmentCreditsExpirationYear" />
    <link:label xlink:type="resource" xlink:label="galt_FederalAndStateResearchAndDevelopmentCreditsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_FederalAndStateResearchAndDevelopmentCreditsExpirationYear_lbl" xml:lang="en-US" id="galt_FederalAndStateResearchAndDevelopmentCreditsExpirationYear_lbl">The federal and state research and development credits expiration year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FederalAndStateResearchAndDevelopmentCreditsExpirationYear" xlink:to="galt_FederalAndStateResearchAndDevelopmentCreditsExpirationYear_lbl" xlink:title="label: FederalAndStateResearchAndDevelopmentCreditsExpirationYear to galt_FederalAndStateResearchAndDevelopmentCreditsExpirationYear_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_FederalAndStateResearchAndDevelopmentCreditsExpirationYear_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_FederalAndStateResearchAndDevelopmentCreditsExpirationYear_lbl1" xml:lang="en-US" id="galt_FederalAndStateResearchAndDevelopmentCreditsExpirationYear_lbl1">Federal and State Research and Development Credits Expiration Year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FederalAndStateResearchAndDevelopmentCreditsExpirationYear" xlink:to="galt_FederalAndStateResearchAndDevelopmentCreditsExpirationYear_lbl1" xlink:title="label: FederalAndStateResearchAndDevelopmentCreditsExpirationYear to galt_FederalAndStateResearchAndDevelopmentCreditsExpirationYear_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_FederalAndStateResearchAndDevelopmentCreditsExpirationYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_FederalAndStateResearchAndDevelopmentCreditsExpirationYear" xml:lang="en-US" id="galt_FederalAndStateResearchAndDevelopmentCreditsExpirationYear">Federal and state research and development credits expiration year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FederalAndStateResearchAndDevelopmentCreditsExpirationYear" xlink:to="galt_FederalAndStateResearchAndDevelopmentCreditsExpirationYear" xlink:title="label: FederalAndStateResearchAndDevelopmentCreditsExpirationYear to galt_FederalAndStateResearchAndDevelopmentCreditsExpirationYear" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_PercentageOfWeightedAverageStockPriceForDividendsPriorToPaymentDate" xlink:label="PercentageOfWeightedAverageStockPriceForDividendsPriorToPaymentDate" xlink:title="PercentageOfWeightedAverageStockPriceForDividendsPriorToPaymentDate" />
    <link:label xlink:type="resource" xlink:label="galt_PercentageOfWeightedAverageStockPriceForDividendsPriorToPaymentDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_PercentageOfWeightedAverageStockPriceForDividendsPriorToPaymentDate_lbl" xml:lang="en-US" id="galt_PercentageOfWeightedAverageStockPriceForDividendsPriorToPaymentDate_lbl">Percentage of weighted average stock price for dividends prior to payment date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfWeightedAverageStockPriceForDividendsPriorToPaymentDate" xlink:to="galt_PercentageOfWeightedAverageStockPriceForDividendsPriorToPaymentDate_lbl" xlink:title="label: PercentageOfWeightedAverageStockPriceForDividendsPriorToPaymentDate to galt_PercentageOfWeightedAverageStockPriceForDividendsPriorToPaymentDate_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_PercentageOfWeightedAverageStockPriceForDividendsPriorToPaymentDate_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_PercentageOfWeightedAverageStockPriceForDividendsPriorToPaymentDate_lbl1" xml:lang="en-US" id="galt_PercentageOfWeightedAverageStockPriceForDividendsPriorToPaymentDate_lbl1">Percentage of Weighted Average Stock Price for Dividends Prior to Payment Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfWeightedAverageStockPriceForDividendsPriorToPaymentDate" xlink:to="galt_PercentageOfWeightedAverageStockPriceForDividendsPriorToPaymentDate_lbl1" xlink:title="label: PercentageOfWeightedAverageStockPriceForDividendsPriorToPaymentDate to galt_PercentageOfWeightedAverageStockPriceForDividendsPriorToPaymentDate_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_PercentageOfWeightedAverageStockPriceForDividendsPriorToPaymentDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_PercentageOfWeightedAverageStockPriceForDividendsPriorToPaymentDate" xml:lang="en-US" id="galt_PercentageOfWeightedAverageStockPriceForDividendsPriorToPaymentDate">Weighted average price percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfWeightedAverageStockPriceForDividendsPriorToPaymentDate" xlink:to="galt_PercentageOfWeightedAverageStockPriceForDividendsPriorToPaymentDate" xlink:title="label: PercentageOfWeightedAverageStockPriceForDividendsPriorToPaymentDate to galt_PercentageOfWeightedAverageStockPriceForDividendsPriorToPaymentDate" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfAward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfAward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfAward" />
    <link:label xlink:type="resource" xlink:label="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfAward_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfAward_lbl" xml:lang="en-US" id="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfAward_lbl">Refers to the terms of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but not limited to, weeks in a year or quarter.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfAward" xlink:to="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfAward_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfAward to galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfAward_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfAward_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfAward_lbl1" xml:lang="en-US" id="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfAward_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Term of Award</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfAward" xlink:to="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfAward_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfAward to galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfAward_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfAward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfAward" xml:lang="en-US" id="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfAward">Award term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfAward" xlink:to="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfAward" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfAward to galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfAward" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ClinicalTrialAndResearchContingenciesAbstract" xlink:label="ClinicalTrialAndResearchContingenciesAbstract" xlink:title="ClinicalTrialAndResearchContingenciesAbstract" />
    <link:label xlink:type="resource" xlink:label="galt_ClinicalTrialAndResearchContingenciesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_ClinicalTrialAndResearchContingenciesAbstract_lbl1" xml:lang="en-US" id="galt_ClinicalTrialAndResearchContingenciesAbstract_lbl1">Clinical Trial and Research Contingencies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClinicalTrialAndResearchContingenciesAbstract" xlink:to="galt_ClinicalTrialAndResearchContingenciesAbstract_lbl1" xlink:title="label: ClinicalTrialAndResearchContingenciesAbstract to galt_ClinicalTrialAndResearchContingenciesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ContractCancelationNoticePeriod" xlink:label="ContractCancelationNoticePeriod" xlink:title="ContractCancelationNoticePeriod" />
    <link:label xlink:type="resource" xlink:label="galt_ContractCancelationNoticePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_ContractCancelationNoticePeriod_lbl" xml:lang="en-US" id="galt_ContractCancelationNoticePeriod_lbl">Contract cancelation notice period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractCancelationNoticePeriod" xlink:to="galt_ContractCancelationNoticePeriod_lbl" xlink:title="label: ContractCancelationNoticePeriod to galt_ContractCancelationNoticePeriod_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_ContractCancelationNoticePeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_ContractCancelationNoticePeriod_lbl1" xml:lang="en-US" id="galt_ContractCancelationNoticePeriod_lbl1">Contract Cancelation Notice Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractCancelationNoticePeriod" xlink:to="galt_ContractCancelationNoticePeriod_lbl1" xlink:title="label: ContractCancelationNoticePeriod to galt_ContractCancelationNoticePeriod_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_ContractCancelationNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_ContractCancelationNoticePeriod" xml:lang="en-US" id="galt_ContractCancelationNoticePeriod">Contract cancelation notice period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractCancelationNoticePeriod" xlink:to="galt_ContractCancelationNoticePeriod" xlink:title="label: ContractCancelationNoticePeriod to galt_ContractCancelationNoticePeriod" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_NumberOfOperatingLeases" xlink:label="NumberOfOperatingLeases" xlink:title="NumberOfOperatingLeases" />
    <link:label xlink:type="resource" xlink:label="galt_NumberOfOperatingLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_NumberOfOperatingLeases_lbl" xml:lang="en-US" id="galt_NumberOfOperatingLeases_lbl">Number of operating leases during period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfOperatingLeases" xlink:to="galt_NumberOfOperatingLeases_lbl" xlink:title="label: NumberOfOperatingLeases to galt_NumberOfOperatingLeases_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_NumberOfOperatingLeases_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_NumberOfOperatingLeases_lbl1" xml:lang="en-US" id="galt_NumberOfOperatingLeases_lbl1">Number of Operating Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfOperatingLeases" xlink:to="galt_NumberOfOperatingLeases_lbl1" xlink:title="label: NumberOfOperatingLeases to galt_NumberOfOperatingLeases_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_NumberOfOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_NumberOfOperatingLeases" xml:lang="en-US" id="galt_NumberOfOperatingLeases">Number of operating leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfOperatingLeases" xlink:to="galt_NumberOfOperatingLeases" xlink:title="label: NumberOfOperatingLeases to galt_NumberOfOperatingLeases" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_FreeRentPeriod" xlink:label="FreeRentPeriod" xlink:title="FreeRentPeriod" />
    <link:label xlink:type="resource" xlink:label="galt_FreeRentPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_FreeRentPeriod_lbl" xml:lang="en-US" id="galt_FreeRentPeriod_lbl">Free rent period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FreeRentPeriod" xlink:to="galt_FreeRentPeriod_lbl" xlink:title="label: FreeRentPeriod to galt_FreeRentPeriod_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_FreeRentPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_FreeRentPeriod_lbl1" xml:lang="en-US" id="galt_FreeRentPeriod_lbl1">Free Rent Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FreeRentPeriod" xlink:to="galt_FreeRentPeriod_lbl1" xlink:title="label: FreeRentPeriod to galt_FreeRentPeriod_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_FreeRentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_FreeRentPeriod" xml:lang="en-US" id="galt_FreeRentPeriod">Free rent period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FreeRentPeriod" xlink:to="galt_FreeRentPeriod" xlink:title="label: FreeRentPeriod to galt_FreeRentPeriod" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_BusinessOperatingSegmentMember" xlink:label="BusinessOperatingSegmentMember" xlink:title="BusinessOperatingSegmentMember" />
    <link:label xlink:type="resource" xlink:label="galt_BusinessOperatingSegmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="galt_BusinessOperatingSegmentMember_lbl" xml:lang="en-US" id="galt_BusinessOperatingSegmentMember_lbl">Business operating segment which is focused on creating new therapies for fibrotic disease based on targeting galectin proteins.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessOperatingSegmentMember" xlink:to="galt_BusinessOperatingSegmentMember_lbl" xlink:title="label: BusinessOperatingSegmentMember to galt_BusinessOperatingSegmentMember_lbl" />
    <link:label xlink:type="resource" xlink:label="galt_BusinessOperatingSegmentMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="galt_BusinessOperatingSegmentMember_lbl1" xml:lang="en-US" id="galt_BusinessOperatingSegmentMember_lbl1">Business Operating Segment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessOperatingSegmentMember" xlink:to="galt_BusinessOperatingSegmentMember_lbl1" xlink:title="label: BusinessOperatingSegmentMember to galt_BusinessOperatingSegmentMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="galt_BusinessOperatingSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="galt_BusinessOperatingSegmentMember" xml:lang="en-US" id="galt_BusinessOperatingSegmentMember">Business Operating Segment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessOperatingSegmentMember" xlink:to="galt_BusinessOperatingSegmentMember" xlink:title="label: BusinessOperatingSegmentMember to galt_BusinessOperatingSegmentMember" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>galt-20241231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 25.3.1.5296 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/SubsequentEventDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#SubsequentEventDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/SegmentsSignificantAssetCategoriesDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#SegmentsSignificantAssetCategoriesDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/SegmentsSignificantExpenseCategoriesDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#SegmentsSignificantExpenseCategoriesDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/IncomeTaxesPrimaryFactorsAffectingIncomeTaxRatesDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#IncomeTaxesPrimaryFactorsAffectingIncomeTaxRatesDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/IncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#IncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/GalectinSciencesLlcDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#GalectinSciencesLlcDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/CommitmentsAndContingenciesDetailsCalc2" xlink:type="simple" xlink:href="galt-20241231.xsd#CommitmentsAndContingenciesDetailsCalc2" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/CommitmentsAndContingenciesDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#CommitmentsAndContingenciesDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/LossPerShareDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#LossPerShareDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedPartyDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedPartyDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/StockbasedCompensationDeferredStockUnitsDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#StockbasedCompensationDeferredStockUnitsDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/StockbasedCompensationRestrictedStockIssuancesDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#StockbasedCompensationRestrictedStockIssuancesDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/StockbasedCompensationOutstandingAndExercisableOptionsUnderStockBasedCompensationPlansDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#StockbasedCompensationOutstandingAndExercisableOptionsUnderStockBasedCompensationPlansDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/StockbasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#StockbasedCompensationStockOptionActivityDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/StockbasedCompensationWeightedAverageAssumptionsUsedToDetermineFairValueOfOptionsGrantedDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#StockbasedCompensationWeightedAverageAssumptionsUsedToDetermineFairValueOfOptionsGrantedDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/StockbasedCompensationComponentsOfStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#StockbasedCompensationComponentsOfStockbasedCompensationExpenseDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/StockbasedCompensationSummaryOfStockbasedCompensationPlansDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#StockbasedCompensationSummaryOfStockbasedCompensationPlansDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/WarrantsSummaryOfOutstandingWarrantsIssuedInConnectionWithEquityAndDebtFinancingAndConsultantsDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#WarrantsSummaryOfOutstandingWarrantsIssuedInConnectionWithEquityAndDebtFinancingAndConsultantsDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/WarrantsSummaryOfPurchaseWarrantsDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#WarrantsSummaryOfPurchaseWarrantsDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/WarrantsSummaryOfWarrantActivityDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#WarrantsSummaryOfWarrantActivityDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/StockholdersEquityReturnOnInvestmentDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#StockholdersEquityReturnOnInvestmentDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/StockholdersEquitySeriesC6SuperDividendRedeemableConvertiblePreferredStockDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#StockholdersEquitySeriesC6SuperDividendRedeemableConvertiblePreferredStockDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/StockholdersEquitySeries12ConvertiblePreferredStockDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#StockholdersEquitySeries12ConvertiblePreferredStockDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/StockholdersEquityIssuanceOfCommonStockDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#StockholdersEquityIssuanceOfCommonStockDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsRollForwardOfDerivativeLiabilityDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#FairValueOfFinancialInstrumentsRollForwardOfDerivativeLiabilityDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsKeyAssumptionsDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#FairValueOfFinancialInstrumentsKeyAssumptionsDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#ConvertibleNotesPayableRelatedPartyDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#AccruedExpensesDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/PropertyAndEquipmentDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#PropertyAndEquipmentDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesWarrantsDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#SummaryOfSignificantAccountingPoliciesWarrantsDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesLonglivedAssetsDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#SummaryOfSignificantAccountingPoliciesLonglivedAssetsDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesSecurityDepositDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#SummaryOfSignificantAccountingPoliciesSecurityDepositDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#SummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/NatureOfBusinessBasisOfPresentationLiquidityAndGoingConcernDetails" xlink:type="simple" xlink:href="galt-20241231.xsd#NatureOfBusinessBasisOfPresentationLiquidityAndGoingConcernDetails" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/SegmentsTables" xlink:type="simple" xlink:href="galt-20241231.xsd#SegmentsTables" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="galt-20241231.xsd#IncomeTaxesTables" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/CommitmentsAndContingenciesTables" xlink:type="simple" xlink:href="galt-20241231.xsd#CommitmentsAndContingenciesTables" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/LossPerShareTables" xlink:type="simple" xlink:href="galt-20241231.xsd#LossPerShareTables" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/StockbasedCompensationTables" xlink:type="simple" xlink:href="galt-20241231.xsd#StockbasedCompensationTables" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/WarrantsTables" xlink:type="simple" xlink:href="galt-20241231.xsd#WarrantsTables" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsTables" xlink:type="simple" xlink:href="galt-20241231.xsd#FairValueOfFinancialInstrumentsTables" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/AccruedExpensesTables" xlink:type="simple" xlink:href="galt-20241231.xsd#AccruedExpensesTables" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/PropertyAndEquipmentTables" xlink:type="simple" xlink:href="galt-20241231.xsd#PropertyAndEquipmentTables" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="galt-20241231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/InsiderTradingPoliciesAndProcedures" xlink:type="simple" xlink:href="galt-20241231.xsd#InsiderTradingPoliciesAndProcedures" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="galt-20241231.xsd#InsiderTradingArrangements" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="simple" xlink:href="galt-20241231.xsd#CybersecurityRiskManagementAndStrategyDisclosure" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/SubsequentEvent" xlink:type="simple" xlink:href="galt-20241231.xsd#SubsequentEvent" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/Segments" xlink:type="simple" xlink:href="galt-20241231.xsd#Segments" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/IncomeTaxes" xlink:type="simple" xlink:href="galt-20241231.xsd#IncomeTaxes" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/GalectinSciencesLlc" xlink:type="simple" xlink:href="galt-20241231.xsd#GalectinSciencesLlc" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/CommitmentsAndContingencies" xlink:type="simple" xlink:href="galt-20241231.xsd#CommitmentsAndContingencies" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/LossPerShare" xlink:type="simple" xlink:href="galt-20241231.xsd#LossPerShare" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedParty" xlink:type="simple" xlink:href="galt-20241231.xsd#ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedParty" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/StockbasedCompensation" xlink:type="simple" xlink:href="galt-20241231.xsd#StockbasedCompensation" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/Warrants" xlink:type="simple" xlink:href="galt-20241231.xsd#Warrants" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/StockholdersEquity" xlink:type="simple" xlink:href="galt-20241231.xsd#StockholdersEquity" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/FairValueOfFinancialInstruments" xlink:type="simple" xlink:href="galt-20241231.xsd#FairValueOfFinancialInstruments" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedParty" xlink:type="simple" xlink:href="galt-20241231.xsd#ConvertibleNotesPayableRelatedParty" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/AccruedExpenses" xlink:type="simple" xlink:href="galt-20241231.xsd#AccruedExpenses" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/PropertyAndEquipment" xlink:type="simple" xlink:href="galt-20241231.xsd#PropertyAndEquipment" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="simple" xlink:href="galt-20241231.xsd#SummaryOfSignificantAccountingPolicies" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/NatureOfBusinessBasisOfPresentationLiquidityAndGoingConcern" xlink:type="simple" xlink:href="galt-20241231.xsd#NatureOfBusinessBasisOfPresentationLiquidityAndGoingConcern" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="simple" xlink:href="galt-20241231.xsd#ConsolidatedStatementsOfCashFlows" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="simple" xlink:href="galt-20241231.xsd#ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/ConsolidatedStatementsOfOperations" xlink:type="simple" xlink:href="galt-20241231.xsd#ConsolidatedStatementsOfOperations" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="galt-20241231.xsd#ConsolidatedBalanceSheetsParenthetical" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="galt-20241231.xsd#ConsolidatedBalanceSheets" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="galt-20241231.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentType" xlink:title="presentation: CoverAbstract to DocumentType" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: CoverAbstract to AmendmentFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="DocumentAnnualReport" xlink:title="DocumentAnnualReport" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentAnnualReport" xlink:title="presentation: CoverAbstract to DocumentAnnualReport" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: CoverAbstract to DocumentPeriodEndDate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="CurrentFiscalYearEndDate" xlink:title="CurrentFiscalYearEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CurrentFiscalYearEndDate" xlink:title="presentation: CoverAbstract to CurrentFiscalYearEndDate" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalYearFocus" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalPeriodFocus" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="DocumentTransitionReport" xlink:title="DocumentTransitionReport" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentTransitionReport" xlink:title="presentation: CoverAbstract to DocumentTransitionReport" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFileNumber" xlink:title="presentation: CoverAbstract to EntityFileNumber" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: CoverAbstract to EntityRegistrantName" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: CoverAbstract to EntityCentralIndexKey" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityIncorporationStateCountryCode" xlink:title="presentation: CoverAbstract to EntityIncorporationStateCountryCode" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityTaxIdentificationNumber" xlink:title="presentation: CoverAbstract to EntityTaxIdentificationNumber" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine1" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine1" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine2" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine2" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCityOrTown" xlink:title="presentation: CoverAbstract to EntityAddressCityOrTown" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressStateOrProvince" xlink:title="presentation: CoverAbstract to EntityAddressStateOrProvince" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressPostalZipCode" xlink:title="presentation: CoverAbstract to EntityAddressPostalZipCode" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CityAreaCode" xlink:title="presentation: CoverAbstract to CityAreaCode" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="LocalPhoneNumber" xlink:title="presentation: CoverAbstract to LocalPhoneNumber" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="Security12bTitle" xlink:title="presentation: CoverAbstract to Security12bTitle" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="TradingSymbol" xlink:title="presentation: CoverAbstract to TradingSymbol" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SecurityExchangeName" xlink:title="presentation: CoverAbstract to SecurityExchangeName" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="EntityWellKnownSeasonedIssuer" xlink:title="EntityWellKnownSeasonedIssuer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityWellKnownSeasonedIssuer" xlink:title="presentation: CoverAbstract to EntityWellKnownSeasonedIssuer" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="EntityVoluntaryFilers" xlink:title="EntityVoluntaryFilers" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityVoluntaryFilers" xlink:title="presentation: CoverAbstract to EntityVoluntaryFilers" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="EntityCurrentReportingStatus" xlink:title="EntityCurrentReportingStatus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCurrentReportingStatus" xlink:title="presentation: CoverAbstract to EntityCurrentReportingStatus" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="EntityInteractiveDataCurrent" xlink:title="EntityInteractiveDataCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityInteractiveDataCurrent" xlink:title="presentation: CoverAbstract to EntityInteractiveDataCurrent" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="EntityFilerCategory" xlink:title="EntityFilerCategory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFilerCategory" xlink:title="presentation: CoverAbstract to EntityFilerCategory" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="EntitySmallBusiness" xlink:title="EntitySmallBusiness" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntitySmallBusiness" xlink:title="presentation: CoverAbstract to EntitySmallBusiness" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: CoverAbstract to EntityEmergingGrowthCompany" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="IcfrAuditorAttestationFlag" xlink:title="IcfrAuditorAttestationFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="IcfrAuditorAttestationFlag" xlink:title="presentation: CoverAbstract to IcfrAuditorAttestationFlag" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="DocumentFinStmtErrorCorrectionFlag" xlink:title="DocumentFinStmtErrorCorrectionFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFinStmtErrorCorrectionFlag" xlink:title="presentation: CoverAbstract to DocumentFinStmtErrorCorrectionFlag" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="EntityShellCompany" xlink:title="EntityShellCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityShellCompany" xlink:title="presentation: CoverAbstract to EntityShellCompany" order="32.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="EntityPublicFloat" xlink:title="EntityPublicFloat" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityPublicFloat" xlink:title="presentation: CoverAbstract to EntityPublicFloat" order="33.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="EntityCommonStockSharesOutstanding" xlink:title="EntityCommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCommonStockSharesOutstanding" xlink:title="presentation: CoverAbstract to EntityCommonStockSharesOutstanding" order="34.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="AuditorFirmId" xlink:title="AuditorFirmId" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AuditorFirmId" xlink:title="presentation: CoverAbstract to AuditorFirmId" order="35.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="AuditorName" xlink:title="AuditorName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AuditorName" xlink:title="presentation: CoverAbstract to AuditorName" order="36.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="AuditorLocation" xlink:title="AuditorLocation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AuditorLocation" xlink:title="presentation: CoverAbstract to AuditorLocation" order="37.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/ConsolidatedBalanceSheets">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="AssetsCurrentAbstract" xlink:title="AssetsCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="presentation: AssetsCurrentAbstract to CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="presentation: AssetsCurrentAbstract to PrepaidExpenseAndOtherAssetsCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="AssetsCurrent" xlink:title="presentation: AssetsCurrentAbstract to AssetsCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="AssetsCurrentAbstract" xlink:title="presentation: AssetsAbstract to AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="presentation: AssetsAbstract to PropertyPlantAndEquipmentNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="OtherAssetsNoncurrent" xlink:title="OtherAssetsNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="OtherAssetsNoncurrent" xlink:title="presentation: AssetsAbstract to OtherAssetsNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="Assets" xlink:title="presentation: AssetsAbstract to Assets" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="AssetsAbstract" xlink:title="presentation: StatementOfFinancialPositionAbstract to AssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="LiabilitiesCurrentAbstract" xlink:title="LiabilitiesCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="AccountsPayableCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to AccountsPayableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="AccruedLiabilitiesCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to AccruedLiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyCurrent" xlink:label="ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyCurrent" xlink:title="ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="DerivativeLiabilitiesCurrent" xlink:title="DerivativeLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="DerivativeLiabilitiesCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to DerivativeLiabilitiesCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsPayableCurrent" xlink:label="DividendsPayableCurrent" xlink:title="DividendsPayableCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="DividendsPayableCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to DividendsPayableCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="LiabilitiesCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to LiabilitiesCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="LiabilitiesCurrentAbstract" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to LiabilitiesCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent" xlink:label="ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent" xlink:title="ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="DerivativeLiabilitiesNoncurrent" xlink:title="DerivativeLiabilitiesNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="DerivativeLiabilitiesNoncurrent" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to DerivativeLiabilitiesNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent" xlink:label="BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent" xlink:title="BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="OtherLiabilitiesNoncurrent" xlink:title="OtherLiabilitiesNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="OtherLiabilitiesNoncurrent" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to OtherLiabilitiesNoncurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="Liabilities" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to Liabilities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="CommitmentsAndContingencies" xlink:title="CommitmentsAndContingencies" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="CommitmentsAndContingencies" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to CommitmentsAndContingencies" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="TemporaryEquityCarryingAmountAttributableToParent" xlink:title="TemporaryEquityCarryingAmountAttributableToParent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="TemporaryEquityCarryingAmountAttributableToParent" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to TemporaryEquityCarryingAmountAttributableToParent" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_UndesignatedCapitalStockValue" xlink:label="UndesignatedCapitalStockValue" xlink:title="UndesignatedCapitalStockValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="UndesignatedCapitalStockValue" xlink:title="presentation: StockholdersEquityAbstract to UndesignatedCapitalStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="PreferredStockValue" xlink:title="PreferredStockValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="PreferredStockValue" xlink:title="presentation: StockholdersEquityAbstract to PreferredStockValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockValue" xlink:title="presentation: StockholdersEquityAbstract to CommonStockValue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="AdditionalPaidInCapital" xlink:title="presentation: StockholdersEquityAbstract to AdditionalPaidInCapital" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="presentation: StockholdersEquityAbstract to RetainedEarningsAccumulatedDeficit" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="StockholdersEquity" xlink:title="presentation: StockholdersEquityAbstract to StockholdersEquity" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="StockholdersEquityAbstract" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to StockholdersEquityAbstract" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="LiabilitiesAndStockholdersEquity" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to LiabilitiesAndStockholdersEquity" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="LiabilitiesAndStockholdersEquityAbstract" xlink:title="presentation: StatementOfFinancialPositionAbstract to LiabilitiesAndStockholdersEquityAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="TemporaryEquitySharesAuthorized" xlink:title="TemporaryEquitySharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="TemporaryEquitySharesAuthorized" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to TemporaryEquitySharesAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="TemporaryEquitySharesIssued" xlink:title="TemporaryEquitySharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="TemporaryEquitySharesIssued" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to TemporaryEquitySharesIssued" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="TemporaryEquitySharesOutstanding" xlink:title="TemporaryEquitySharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="TemporaryEquitySharesOutstanding" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to TemporaryEquitySharesOutstanding" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityAggregateAmountOfRedemptionRequirement" xlink:label="TemporaryEquityAggregateAmountOfRedemptionRequirement" xlink:title="TemporaryEquityAggregateAmountOfRedemptionRequirement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="TemporaryEquityAggregateAmountOfRedemptionRequirement" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to TemporaryEquityAggregateAmountOfRedemptionRequirement" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="TemporaryEquityLiquidationPreference" xlink:title="TemporaryEquityLiquidationPreference" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="TemporaryEquityLiquidationPreference" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to TemporaryEquityLiquidationPreference" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_UndesignatedCapitalStockParValue" xlink:label="UndesignatedCapitalStockParValue" xlink:title="UndesignatedCapitalStockParValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="UndesignatedCapitalStockParValue" xlink:title="presentation: StockholdersEquityAbstract to UndesignatedCapitalStockParValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_UndesignatedCapitalStockSharesAuthorized" xlink:label="UndesignatedCapitalStockSharesAuthorized" xlink:title="UndesignatedCapitalStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="UndesignatedCapitalStockSharesAuthorized" xlink:title="presentation: StockholdersEquityAbstract to UndesignatedCapitalStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_UndesignatedCapitalStockSharesDesignated" xlink:label="UndesignatedCapitalStockSharesDesignated" xlink:title="UndesignatedCapitalStockSharesDesignated" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="UndesignatedCapitalStockSharesDesignated" xlink:title="presentation: StockholdersEquityAbstract to UndesignatedCapitalStockSharesDesignated" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="PreferredStockSharesAuthorized" xlink:title="PreferredStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="PreferredStockSharesAuthorized" xlink:title="presentation: StockholdersEquityAbstract to PreferredStockSharesAuthorized" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="PreferredStockSharesIssued" xlink:title="PreferredStockSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="PreferredStockSharesIssued" xlink:title="presentation: StockholdersEquityAbstract to PreferredStockSharesIssued" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="PreferredStockSharesOutstanding" xlink:title="PreferredStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="PreferredStockSharesOutstanding" xlink:title="presentation: StockholdersEquityAbstract to PreferredStockSharesOutstanding" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="PreferredStockLiquidationPreferenceValue" xlink:title="PreferredStockLiquidationPreferenceValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="PreferredStockLiquidationPreferenceValue" xlink:title="presentation: StockholdersEquityAbstract to PreferredStockLiquidationPreferenceValue" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockParOrStatedValuePerShare" xlink:title="presentation: StockholdersEquityAbstract to CommonStockParOrStatedValuePerShare" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockSharesAuthorized" xlink:title="presentation: StockholdersEquityAbstract to CommonStockSharesAuthorized" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockSharesIssued" xlink:title="presentation: StockholdersEquityAbstract to CommonStockSharesIssued" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockSharesOutstanding" xlink:title="presentation: StockholdersEquityAbstract to CommonStockSharesOutstanding" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="StockholdersEquityAbstract" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to StockholdersEquityAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="LiabilitiesAndStockholdersEquityAbstract" xlink:title="presentation: StatementOfFinancialPositionAbstract to LiabilitiesAndStockholdersEquityAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/ConsolidatedStatementsOfOperations">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" xlink:title="IncomeStatementAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="OperatingExpensesAbstract" xlink:title="OperatingExpensesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="ResearchAndDevelopmentExpense" xlink:title="presentation: OperatingExpensesAbstract to ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="GeneralAndAdministrativeExpense" xlink:title="presentation: OperatingExpensesAbstract to GeneralAndAdministrativeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="OperatingExpenses" xlink:title="presentation: OperatingExpensesAbstract to OperatingExpenses" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="OperatingIncomeLoss" xlink:title="presentation: OperatingExpensesAbstract to OperatingIncomeLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="OperatingExpensesAbstract" xlink:title="presentation: IncomeStatementAbstract to OperatingExpensesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="NonoperatingIncomeExpenseAbstract" xlink:title="NonoperatingIncomeExpenseAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="InvestmentIncomeInterest" xlink:title="InvestmentIncomeInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="InvestmentIncomeInterest" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to InvestmentIncomeInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="InterestExpenseNonoperating" xlink:title="InterestExpenseNonoperating" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="InterestExpenseNonoperating" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to InterestExpenseNonoperating" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:label="DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:title="DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="NonoperatingIncomeExpense" xlink:title="NonoperatingIncomeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="NonoperatingIncomeExpense" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to NonoperatingIncomeExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="NonoperatingIncomeExpenseAbstract" xlink:title="presentation: IncomeStatementAbstract to NonoperatingIncomeExpenseAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="NetIncomeLoss" xlink:title="presentation: IncomeStatementAbstract to NetIncomeLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="PreferredStockDividendsAndOtherAdjustments" xlink:title="PreferredStockDividendsAndOtherAdjustments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="PreferredStockDividendsAndOtherAdjustments" xlink:title="presentation: IncomeStatementAbstract to PreferredStockDividendsAndOtherAdjustments" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_FairValueAdjustmentOfWarrant" xlink:label="FairValueAdjustmentOfWarrant" xlink:title="FairValueAdjustmentOfWarrant" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="FairValueAdjustmentOfWarrant" xlink:title="presentation: IncomeStatementAbstract to FairValueAdjustmentOfWarrant" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="presentation: IncomeStatementAbstract to NetIncomeLossAvailableToCommonStockholdersBasic" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="EarningsPerShareBasic" xlink:title="EarningsPerShareBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="EarningsPerShareBasic" xlink:title="presentation: IncomeStatementAbstract to EarningsPerShareBasic" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="EarningsPerShareDiluted" xlink:title="EarningsPerShareDiluted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="EarningsPerShareDiluted" xlink:title="presentation: IncomeStatementAbstract to EarningsPerShareDiluted" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="presentation: IncomeStatementAbstract to WeightedAverageNumberOfSharesOutstandingBasic" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="presentation: IncomeStatementAbstract to WeightedAverageNumberOfDilutedSharesOutstanding" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" xlink:title="StatementOfStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="IncreaseDecreaseInTemporaryEquityRollForward" xlink:title="IncreaseDecreaseInTemporaryEquityRollForward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="TemporaryEquityCarryingAmountAttributableToParent" xlink:title="TemporaryEquityCarryingAmountAttributableToParent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="TemporaryEquityCarryingAmountAttributableToParent" xlink:title="presentation: IncreaseDecreaseInTemporaryEquityRollForward to TemporaryEquityCarryingAmountAttributableToParent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="TemporaryEquitySharesOutstanding" xlink:title="TemporaryEquitySharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="TemporaryEquitySharesOutstanding" xlink:title="presentation: IncreaseDecreaseInTemporaryEquityRollForward to TemporaryEquitySharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="TemporaryEquityCarryingAmountAttributableToParent_2" xlink:title="TemporaryEquityCarryingAmountAttributableToParent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="TemporaryEquityCarryingAmountAttributableToParent_2" xlink:title="presentation: IncreaseDecreaseInTemporaryEquityRollForward to TemporaryEquityCarryingAmountAttributableToParent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="TemporaryEquitySharesOutstanding_2" xlink:title="TemporaryEquitySharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="TemporaryEquitySharesOutstanding_2" xlink:title="presentation: IncreaseDecreaseInTemporaryEquityRollForward to TemporaryEquitySharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="IncreaseDecreaseInTemporaryEquityRollForward" xlink:title="presentation: StatementOfStockholdersEquityAbstract to IncreaseDecreaseInTemporaryEquityRollForward" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="PreferredStockMember" xlink:title="PreferredStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="PreferredStockMember" xlink:title="presentation: StatementEquityComponentsAxis to PreferredStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="CommonStockMember" xlink:title="presentation: StatementEquityComponentsAxis to CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="AdditionalPaidInCapitalMember" xlink:title="AdditionalPaidInCapitalMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="AdditionalPaidInCapitalMember" xlink:title="presentation: StatementEquityComponentsAxis to AdditionalPaidInCapitalMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="RetainedEarningsMember" xlink:title="RetainedEarningsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="RetainedEarningsMember" xlink:title="presentation: StatementEquityComponentsAxis to RetainedEarningsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="presentation: StatementEquityComponentsAxis to EquityComponentDomain" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementEquityComponentsAxis" xlink:title="presentation: StatementTable to StatementEquityComponentsAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="SeriesAPreferredStockMember" xlink:title="SeriesAPreferredStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="SeriesAPreferredStockMember" xlink:title="presentation: ClassOfStockDomain to SeriesAPreferredStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="presentation: StatementClassOfStockAxis to ClassOfStockDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementClassOfStockAxis" xlink:title="presentation: StatementTable to StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockholdersEquity" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="SharesOutstanding" xlink:title="SharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="SharesOutstanding" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ConvertiblePreferredStockDividends" xlink:label="ConvertiblePreferredStockDividends" xlink:title="ConvertiblePreferredStockDividends" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="ConvertiblePreferredStockDividends" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to ConvertiblePreferredStockDividends" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ConvertiblePreferredStockDividendsShares" xlink:label="ConvertiblePreferredStockDividendsShares" xlink:title="ConvertiblePreferredStockDividendsShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="ConvertiblePreferredStockDividendsShares" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to ConvertiblePreferredStockDividendsShares" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_TemporaryEquityDividends" xlink:label="TemporaryEquityDividends" xlink:title="TemporaryEquityDividends" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="TemporaryEquityDividends" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to TemporaryEquityDividends" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_TemporaryEquityDividendsShares" xlink:label="TemporaryEquityDividendsShares" xlink:title="TemporaryEquityDividendsShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="TemporaryEquityDividendsShares" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to TemporaryEquityDividendsShares" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:title="StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:title="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_StockIssuedDuringPeriodValueWarrantExercise" xlink:label="StockIssuedDuringPeriodValueWarrantExercise" xlink:title="StockIssuedDuringPeriodValueWarrantExercise" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueWarrantExercise" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueWarrantExercise" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_StockIssuedDuringPeriodSharesWarrantExercise" xlink:label="StockIssuedDuringPeriodSharesWarrantExercise" xlink:title="StockIssuedDuringPeriodSharesWarrantExercise" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodSharesWarrantExercise" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodSharesWarrantExercise" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueStockOptionsExercised" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodSharesStockOptionsExercised" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:title="StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:title="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_WarrantModificationIncreaseDecreaseInEquityAmount" xlink:label="WarrantModificationIncreaseDecreaseInEquityAmount" xlink:title="WarrantModificationIncreaseDecreaseInEquityAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="WarrantModificationIncreaseDecreaseInEquityAmount" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to WarrantModificationIncreaseDecreaseInEquityAmount" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:title="StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="NetIncomeLoss" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to NetIncomeLoss" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity_2" xlink:title="StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockholdersEquity_2" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockholdersEquity" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="SharesOutstanding_2" xlink:title="SharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="SharesOutstanding_2" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to SharesOutstanding" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="presentation: StatementLineItems to IncreaseDecreaseInStockholdersEquityRollForward" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="StatementTable" xlink:title="presentation: StatementOfStockholdersEquityAbstract to StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/ConsolidatedStatementsOfCashFlows">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" xlink:title="StatementOfCashFlowsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="NetIncomeLoss" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesAbstract to NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:title="OperatingLeaseRightOfUseAssetAmortizationExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:title="presentation: AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to OperatingLeaseRightOfUseAssetAmortizationExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ShareBasedCompensation" xlink:title="presentation: AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to ShareBasedCompensation" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaidInKindInterest" xlink:label="PaidInKindInterest" xlink:title="PaidInKindInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="PaidInKindInterest" xlink:title="presentation: AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to PaidInKindInterest" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="FairValueAdjustmentOfWarrants" xlink:title="FairValueAdjustmentOfWarrants" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="FairValueAdjustmentOfWarrants" xlink:title="presentation: AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to FairValueAdjustmentOfWarrants" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="IncreaseDecreaseInInterestPayableNet" xlink:title="IncreaseDecreaseInInterestPayableNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInInterestPayableNet" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInInterestPayableNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="presentation: AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to IncreaseDecreaseInOperatingCapitalAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesAbstract to AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" xlink:title="NetCashProvidedByUsedInOperatingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="NetCashProvidedByUsedInOperatingActivities" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesAbstract to NetCashProvidedByUsedInOperatingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="NetCashProvidedByUsedInInvestingActivities" xlink:title="NetCashProvidedByUsedInInvestingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="NetCashProvidedByUsedInInvestingActivities" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesAbstract to NetCashProvidedByUsedInInvestingActivities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="ProceedsFromLinesOfCredit" xlink:title="ProceedsFromLinesOfCredit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromLinesOfCredit" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to ProceedsFromLinesOfCredit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="ProceedsFromWarrantExercises" xlink:title="ProceedsFromWarrantExercises" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromWarrantExercises" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to ProceedsFromWarrantExercises" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="NetCashProvidedByUsedInFinancingActivities" xlink:title="NetCashProvidedByUsedInFinancingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="NetCashProvidedByUsedInFinancingActivities" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to NetCashProvidedByUsedInFinancingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:title="presentation: StatementOfCashFlowsAbstract to CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="presentation: StatementOfCashFlowsAbstract to CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:title="presentation: StatementOfCashFlowsAbstract to CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:title="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssued1" xlink:label="StockIssued1" xlink:title="StockIssued1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="StockIssued1" xlink:title="presentation: CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to StockIssued1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ReclassificationOfAccruedBonusToAdditionalPaidInCapital" xlink:label="ReclassificationOfAccruedBonusToAdditionalPaidInCapital" xlink:title="ReclassificationOfAccruedBonusToAdditionalPaidInCapital" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="ReclassificationOfAccruedBonusToAdditionalPaidInCapital" xlink:title="presentation: CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to ReclassificationOfAccruedBonusToAdditionalPaidInCapital" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit" xlink:label="CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit" xlink:title="CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit" xlink:title="presentation: CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/NatureOfBusinessBasisOfPresentationLiquidityAndGoingConcern">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPolicies">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="SignificantAccountingPoliciesTextBlock" xlink:title="SignificantAccountingPoliciesTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="SignificantAccountingPoliciesTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/PropertyAndEquipment">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" xlink:title="PropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="presentation: PropertyPlantAndEquipmentAbstract to PropertyPlantAndEquipmentDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/AccruedExpenses">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" xlink:title="PayablesAndAccrualsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:title="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:title="presentation: PayablesAndAccrualsAbstract to AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedParty">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentsAbstract" xlink:label="DebtInstrumentsAbstract" xlink:title="DebtInstrumentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="LongtermDebtTypeAxis" xlink:title="LongtermDebtTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="LongtermDebtTypeDomain" xlink:title="LongtermDebtTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansPayableMember" xlink:label="LoansPayableMember" xlink:title="LoansPayableMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongtermDebtTypeDomain" xlink:to="LoansPayableMember" xlink:title="presentation: LongtermDebtTypeDomain to LoansPayableMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongtermDebtTypeAxis" xlink:to="LongtermDebtTypeDomain" xlink:title="presentation: LongtermDebtTypeAxis to LongtermDebtTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="LongtermDebtTypeAxis" xlink:title="presentation: DebtInstrumentTable to LongtermDebtTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="DebtDisclosureTextBlock" xlink:title="DebtDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentLineItems" xlink:to="DebtDisclosureTextBlock" xlink:title="presentation: DebtInstrumentLineItems to DebtDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentLineItems" xlink:title="presentation: DebtInstrumentTable to DebtInstrumentLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentTable" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/FairValueOfFinancialInstruments">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="FairValueDisclosuresTextBlock" xlink:title="FairValueDisclosuresTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="FairValueDisclosuresTextBlock" xlink:title="presentation: FairValueDisclosuresAbstract to FairValueDisclosuresTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/StockholdersEquity">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" xlink:title="EquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="StockholdersEquityNoteDisclosureTextBlock" xlink:title="StockholdersEquityNoteDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="StockholdersEquityNoteDisclosureTextBlock" xlink:title="presentation: EquityAbstract to StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/Warrants">
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_WarrantsAbstract" xlink:label="WarrantsAbstract" xlink:title="WarrantsAbstract" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_CommonStockWarrantsDisclosureTextBlock" xlink:label="CommonStockWarrantsDisclosureTextBlock" xlink:title="CommonStockWarrantsDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAbstract" xlink:to="CommonStockWarrantsDisclosureTextBlock" xlink:title="presentation: WarrantsAbstract to CommonStockWarrantsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/StockbasedCompensation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedParty">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityAbstract" xlink:label="LineOfCreditFacilityAbstract" xlink:title="LineOfCreditFacilityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="LongtermDebtTypeAxis" xlink:title="LongtermDebtTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="LongtermDebtTypeDomain" xlink:title="LongtermDebtTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditMember" xlink:label="LineOfCreditMember" xlink:title="LineOfCreditMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongtermDebtTypeDomain" xlink:to="LineOfCreditMember" xlink:title="presentation: LongtermDebtTypeDomain to LineOfCreditMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongtermDebtTypeAxis" xlink:to="LongtermDebtTypeDomain" xlink:title="presentation: LongtermDebtTypeAxis to LongtermDebtTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="LongtermDebtTypeAxis" xlink:title="presentation: DebtInstrumentTable to LongtermDebtTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="DebtDisclosureTextBlock" xlink:title="DebtDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentLineItems" xlink:to="DebtDisclosureTextBlock" xlink:title="presentation: DebtInstrumentLineItems to DebtDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentLineItems" xlink:title="presentation: DebtInstrumentTable to DebtInstrumentLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditFacilityAbstract" xlink:to="DebtInstrumentTable" xlink:title="presentation: LineOfCreditFacilityAbstract to DebtInstrumentTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/LossPerShare">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" xlink:title="EarningsPerShareAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="EarningsPerShareTextBlock" xlink:title="EarningsPerShareTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="EarningsPerShareTextBlock" xlink:title="presentation: EarningsPerShareAbstract to EarningsPerShareTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/CommitmentsAndContingencies">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="presentation: CommitmentsAndContingenciesDisclosureAbstract to CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/GalectinSciencesLlc">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesAbstract" xlink:label="InvestmentsInAndAdvancesToAffiliatesAbstract" xlink:title="InvestmentsInAndAdvancesToAffiliatesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock" xlink:label="InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock" xlink:title="InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentsInAndAdvancesToAffiliatesAbstract" xlink:to="InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock" xlink:title="presentation: InvestmentsInAndAdvancesToAffiliatesAbstract to InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/IncomeTaxes">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="IncomeTaxDisclosureTextBlock" xlink:title="IncomeTaxDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="IncomeTaxDisclosureTextBlock" xlink:title="presentation: IncomeTaxDisclosureAbstract to IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/Segments">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="SegmentReportingAbstract" xlink:title="SegmentReportingAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="SegmentReportingDisclosureTextBlock" xlink:title="SegmentReportingDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingAbstract" xlink:to="SegmentReportingDisclosureTextBlock" xlink:title="presentation: SegmentReportingAbstract to SegmentReportingDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/SubsequentEvent">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" xlink:title="SubsequentEventsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="SubsequentEventsTextBlock" xlink:title="SubsequentEventsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsAbstract" xlink:to="SubsequentEventsTextBlock" xlink:title="presentation: SubsequentEventsAbstract to SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/CybersecurityRiskManagementAndStrategyDisclosure">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:title="CybersecurityRiskManagementStrategyAndGovernanceAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:title="CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="CybersecurityRiskManagementProcessesIntegratedFlag" xlink:title="CybersecurityRiskManagementProcessesIntegratedFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="CybersecurityRiskManagementProcessesIntegratedFlag" xlink:title="presentation: CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock to CybersecurityRiskManagementProcessesIntegratedFlag" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:title="CybersecurityRiskManagementProcessesIntegratedTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:title="presentation: CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock to CybersecurityRiskManagementProcessesIntegratedTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:title="CybersecurityRiskManagementThirdPartyEngagedFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:title="presentation: CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock to CybersecurityRiskManagementThirdPartyEngagedFlag" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:title="CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:title="presentation: CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock to CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:title="CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:title="presentation: CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock to CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:title="CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:title="presentation: CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock to CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:title="presentation: CybersecurityRiskManagementStrategyAndGovernanceAbstract to CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:title="CybersecurityRiskBoardOfDirectorsOversightTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:title="CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:title="presentation: CybersecurityRiskBoardOfDirectorsOversightTextBlock to CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:title="CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:title="presentation: CybersecurityRiskBoardOfDirectorsOversightTextBlock to CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="CybersecurityRiskRoleOfManagementTextBlock" xlink:title="CybersecurityRiskRoleOfManagementTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="CybersecurityRiskRoleOfManagementTextBlock" xlink:title="presentation: CybersecurityRiskBoardOfDirectorsOversightTextBlock to CybersecurityRiskRoleOfManagementTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:title="CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:title="presentation: CybersecurityRiskBoardOfDirectorsOversightTextBlock to CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:title="CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:title="presentation: CybersecurityRiskBoardOfDirectorsOversightTextBlock to CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:title="CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:title="presentation: CybersecurityRiskBoardOfDirectorsOversightTextBlock to CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:title="CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:title="presentation: CybersecurityRiskBoardOfDirectorsOversightTextBlock to CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:title="presentation: CybersecurityRiskManagementStrategyAndGovernanceAbstract to CybersecurityRiskBoardOfDirectorsOversightTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/InsiderTradingArrangements">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="InsiderTradingArrLineItems" xlink:title="InsiderTradingArrLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="Rule10b51ArrAdoptedFlag" xlink:title="Rule10b51ArrAdoptedFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InsiderTradingArrLineItems" xlink:to="Rule10b51ArrAdoptedFlag" xlink:title="presentation: InsiderTradingArrLineItems to Rule10b51ArrAdoptedFlag" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="NonRule10b51ArrTrmntdFlag" xlink:title="NonRule10b51ArrTrmntdFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InsiderTradingArrLineItems" xlink:to="NonRule10b51ArrTrmntdFlag" xlink:title="presentation: InsiderTradingArrLineItems to NonRule10b51ArrTrmntdFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="Rule10b51ArrTrmntdFlag" xlink:title="Rule10b51ArrTrmntdFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InsiderTradingArrLineItems" xlink:to="Rule10b51ArrTrmntdFlag" xlink:title="presentation: InsiderTradingArrLineItems to Rule10b51ArrTrmntdFlag" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="NonRule10b51ArrAdoptedFlag" xlink:title="NonRule10b51ArrAdoptedFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InsiderTradingArrLineItems" xlink:to="NonRule10b51ArrAdoptedFlag" xlink:title="presentation: InsiderTradingArrLineItems to NonRule10b51ArrAdoptedFlag" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/InsiderTradingPoliciesAndProcedures">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="InsiderTradingPoliciesProcLineItems" xlink:title="InsiderTradingPoliciesProcLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="InsiderTrdPoliciesProcAdoptedFlag" xlink:title="InsiderTrdPoliciesProcAdoptedFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InsiderTradingPoliciesProcLineItems" xlink:to="InsiderTrdPoliciesProcAdoptedFlag" xlink:title="presentation: InsiderTradingPoliciesProcLineItems to InsiderTrdPoliciesProcAdoptedFlag" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="ConsolidationPolicyTextBlock" xlink:title="ConsolidationPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ConsolidationPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to ConsolidationPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="UseOfEstimates" xlink:title="UseOfEstimates" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="UseOfEstimates" xlink:title="presentation: AccountingPoliciesAbstract to UseOfEstimates" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="FairValueMeasurementPolicyPolicyTextBlock" xlink:title="FairValueMeasurementPolicyPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="FairValueMeasurementPolicyPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to FairValueMeasurementPolicyPolicyTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="CashAndCashEquivalentsPolicyTextBlock" xlink:title="CashAndCashEquivalentsPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="CashAndCashEquivalentsPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to CashAndCashEquivalentsPolicyTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" xlink:label="PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" xlink:title="PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="PropertyPlantAndEquipmentPolicyTextBlock" xlink:title="PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="PropertyPlantAndEquipmentPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to PropertyPlantAndEquipmentPolicyTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_SecurityDepositPolicyTextBlock" xlink:label="SecurityDepositPolicyTextBlock" xlink:title="SecurityDepositPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="SecurityDepositPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to SecurityDepositPolicyTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:title="ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_AccruedExpensePolicyTextBlock" xlink:label="AccruedExpensePolicyTextBlock" xlink:title="AccruedExpensePolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="AccruedExpensePolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to AccruedExpensePolicyTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="DerivativesPolicyTextBlock" xlink:title="DerivativesPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="DerivativesPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to DerivativesPolicyTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="ResearchAndDevelopmentExpensePolicy" xlink:title="ResearchAndDevelopmentExpensePolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ResearchAndDevelopmentExpensePolicy" xlink:title="presentation: AccountingPoliciesAbstract to ResearchAndDevelopmentExpensePolicy" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="IncomeTaxPolicyTextBlock" xlink:title="IncomeTaxPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="IncomeTaxPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to IncomeTaxPolicyTextBlock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="ConcentrationRiskCreditRisk" xlink:title="ConcentrationRiskCreditRisk" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ConcentrationRiskCreditRisk" xlink:title="presentation: AccountingPoliciesAbstract to ConcentrationRiskCreditRisk" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="presentation: AccountingPoliciesAbstract to ShareBasedCompensationOptionAndIncentivePlansPolicy" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to NewAccountingPronouncementsPolicyPolicyTextBlock" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/PropertyAndEquipmentTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" xlink:title="PropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="PropertyPlantAndEquipmentTextBlock" xlink:title="PropertyPlantAndEquipmentTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="PropertyPlantAndEquipmentTextBlock" xlink:title="presentation: PropertyPlantAndEquipmentAbstract to PropertyPlantAndEquipmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/AccruedExpensesTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" xlink:title="PayablesAndAccrualsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:title="ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:title="presentation: PayablesAndAccrualsAbstract to ScheduleOfAccruedLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:title="ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:title="presentation: FairValueDisclosuresAbstract to ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="DerivativeInstrumentRiskAxis" xlink:title="DerivativeInstrumentRiskAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="DerivativeContractTypeDomain" xlink:title="DerivativeContractTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ContingentInterestAprilNoteMember" xlink:label="ContingentInterestAprilNoteMember" xlink:title="ContingentInterestAprilNoteMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DerivativeContractTypeDomain" xlink:to="ContingentInterestAprilNoteMember" xlink:title="presentation: DerivativeContractTypeDomain to ContingentInterestAprilNoteMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ContingentInterestSeptemberNoteMember" xlink:label="ContingentInterestSeptemberNoteMember" xlink:title="ContingentInterestSeptemberNoteMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DerivativeContractTypeDomain" xlink:to="ContingentInterestSeptemberNoteMember" xlink:title="presentation: DerivativeContractTypeDomain to ContingentInterestSeptemberNoteMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ContingentInterestDecemberNoteMember" xlink:label="ContingentInterestDecemberNoteMember" xlink:title="ContingentInterestDecemberNoteMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DerivativeContractTypeDomain" xlink:to="ContingentInterestDecemberNoteMember" xlink:title="presentation: DerivativeContractTypeDomain to ContingentInterestDecemberNoteMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DerivativeInstrumentRiskAxis" xlink:to="DerivativeContractTypeDomain" xlink:title="presentation: DerivativeInstrumentRiskAxis to DerivativeContractTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="DerivativeInstrumentRiskAxis" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to DerivativeInstrumentRiskAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="presentation: FairValueDisclosuresAbstract to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/WarrantsTables">
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_WarrantsAbstract" xlink:label="WarrantsAbstract" xlink:title="WarrantsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:title="ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAbstract" xlink:to="ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:title="presentation: WarrantsAbstract to ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/StockbasedCompensationTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:title="ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/LossPerShareTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" xlink:title="EarningsPerShareAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:title="presentation: EarningsPerShareAbstract to ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/CommitmentsAndContingenciesTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:title="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:title="presentation: CommitmentsAndContingenciesDisclosureAbstract to LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/IncomeTaxesTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:title="ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:title="presentation: IncomeTaxDisclosureAbstract to ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:title="ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:title="presentation: IncomeTaxDisclosureAbstract to ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/SegmentsTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="SegmentReportingAbstract" xlink:title="SegmentReportingAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:title="ScheduleOfSegmentReportingInformationBySegmentTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingAbstract" xlink:to="ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:title="presentation: SegmentReportingAbstract to ScheduleOfSegmentReportingInformationBySegmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/NatureOfBusinessBasisOfPresentationLiquidityAndGoingConcernDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:title="NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="BoardOfDirectorsChairmanMember" xlink:title="BoardOfDirectorsChairmanMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyDomain" xlink:to="BoardOfDirectorsChairmanMember" xlink:title="presentation: RelatedPartyDomain to BoardOfDirectorsChairmanMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="presentation: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="presentation: NewAccountingPronouncementsOrChangeInAccountingPrincipleTable to RelatedPartyTransactionsByRelatedPartyAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="CreditFacilityAxis" xlink:title="CreditFacilityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="CreditFacilityDomain" xlink:title="CreditFacilityDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditMember" xlink:label="LineOfCreditMember" xlink:title="LineOfCreditMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CreditFacilityDomain" xlink:to="LineOfCreditMember" xlink:title="presentation: CreditFacilityDomain to LineOfCreditMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_SupplementalLineOfCreditMember" xlink:label="SupplementalLineOfCreditMember" xlink:title="SupplementalLineOfCreditMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CreditFacilityDomain" xlink:to="SupplementalLineOfCreditMember" xlink:title="presentation: CreditFacilityDomain to SupplementalLineOfCreditMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CreditFacilityAxis" xlink:to="CreditFacilityDomain" xlink:title="presentation: CreditFacilityAxis to CreditFacilityDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="CreditFacilityAxis" xlink:title="presentation: NewAccountingPronouncementsOrChangeInAccountingPrincipleTable to CreditFacilityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="presentation: SubsequentEventTypeDomain to SubsequentEventMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="presentation: SubsequentEventTypeAxis to SubsequentEventTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="SubsequentEventTypeAxis" xlink:title="presentation: NewAccountingPronouncementsOrChangeInAccountingPrincipleTable to SubsequentEventTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:title="NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_NatureOfBusinessBasisOfPresentationsAndLiquidityAbstract" xlink:label="NatureOfBusinessBasisOfPresentationsAndLiquidityAbstract" xlink:title="NatureOfBusinessBasisOfPresentationsAndLiquidityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureOfBusinessBasisOfPresentationsAndLiquidityAbstract" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="presentation: NatureOfBusinessBasisOfPresentationsAndLiquidityAbstract to CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_NumberOfLineOfCredit" xlink:label="NumberOfLineOfCredit" xlink:title="NumberOfLineOfCredit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureOfBusinessBasisOfPresentationsAndLiquidityAbstract" xlink:to="NumberOfLineOfCredit" xlink:title="presentation: NatureOfBusinessBasisOfPresentationsAndLiquidityAbstract to NumberOfLineOfCredit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="LineOfCreditFacilityMaximumBorrowingCapacity" xlink:title="LineOfCreditFacilityMaximumBorrowingCapacity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureOfBusinessBasisOfPresentationsAndLiquidityAbstract" xlink:to="LineOfCreditFacilityMaximumBorrowingCapacity" xlink:title="presentation: NatureOfBusinessBasisOfPresentationsAndLiquidityAbstract to LineOfCreditFacilityMaximumBorrowingCapacity" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="NatureOfBusinessBasisOfPresentationsAndLiquidityAbstract" xlink:title="presentation: NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems to NatureOfBusinessBasisOfPresentationsAndLiquidityAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:title="presentation: NewAccountingPronouncementsOrChangeInAccountingPrincipleTable to NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:label="CashAndCashEquivalentsAtCarryingValueAbstract" xlink:title="CashAndCashEquivalentsAtCarryingValueAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="CashEquivalentsAtCarryingValue" xlink:title="CashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashAndCashEquivalentsAtCarryingValueAbstract" xlink:to="CashEquivalentsAtCarryingValue" xlink:title="presentation: CashAndCashEquivalentsAtCarryingValueAbstract to CashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="CashAndCashEquivalentsAtCarryingValueAbstract" xlink:title="presentation: AccountingPoliciesAbstract to CashAndCashEquivalentsAtCarryingValueAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ComputerAndOfficeEquipmentMember" xlink:label="ComputerAndOfficeEquipmentMember" xlink:title="ComputerAndOfficeEquipmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="ComputerAndOfficeEquipmentMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to ComputerAndOfficeEquipmentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="FurnitureAndFixturesMember" xlink:title="FurnitureAndFixturesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="FurnitureAndFixturesMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to FurnitureAndFixturesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="presentation: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="PropertyPlantAndEquipmentByTypeAxis" xlink:title="presentation: ScheduleOfPropertyPlantAndEquipmentTable to PropertyPlantAndEquipmentByTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="PropertyPlantAndEquipmentLineItems" xlink:title="PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" xlink:title="PropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="PropertyPlantAndEquipmentUsefulLife" xlink:title="PropertyPlantAndEquipmentUsefulLife" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="PropertyPlantAndEquipmentUsefulLife" xlink:title="presentation: PropertyPlantAndEquipmentAbstract to PropertyPlantAndEquipmentUsefulLife" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentAbstract" xlink:title="presentation: PropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="PropertyPlantAndEquipmentLineItems" xlink:title="presentation: ScheduleOfPropertyPlantAndEquipmentTable to PropertyPlantAndEquipmentLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="presentation: AccountingPoliciesAbstract to ScheduleOfPropertyPlantAndEquipmentTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesSecurityDepositDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositAssetsAbstract" xlink:label="DepositAssetsAbstract" xlink:title="DepositAssetsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecurityDeposit" xlink:label="SecurityDeposit" xlink:title="SecurityDeposit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DepositAssetsAbstract" xlink:to="SecurityDeposit" xlink:title="presentation: DepositAssetsAbstract to SecurityDeposit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="DepositAssetsAbstract" xlink:title="presentation: AccountingPoliciesAbstract to DepositAssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesLonglivedAssetsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentLongLivedAssetHeldForUseAbstract" xlink:label="ImpairmentLongLivedAssetHeldForUseAbstract" xlink:title="ImpairmentLongLivedAssetHeldForUseAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="ImpairmentOfLongLivedAssetsHeldForUse" xlink:title="ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ImpairmentLongLivedAssetHeldForUseAbstract" xlink:to="ImpairmentOfLongLivedAssetsHeldForUse" xlink:title="presentation: ImpairmentLongLivedAssetHeldForUseAbstract to ImpairmentOfLongLivedAssetsHeldForUse" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ImpairmentLongLivedAssetHeldForUseAbstract" xlink:title="presentation: AccountingPoliciesAbstract to ImpairmentLongLivedAssetHeldForUseAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesWarrantsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_WarrantsAbstract" xlink:label="WarrantsAbstract" xlink:title="WarrantsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities" xlink:label="DerivativeLiabilities" xlink:title="DerivativeLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAbstract" xlink:to="DerivativeLiabilities" xlink:title="presentation: WarrantsAbstract to DerivativeLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="WarrantsAbstract" xlink:title="presentation: AccountingPoliciesAbstract to WarrantsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/PropertyAndEquipmentDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" xlink:title="PropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="LeaseholdImprovementsMember" xlink:title="LeaseholdImprovementsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="LeaseholdImprovementsMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to LeaseholdImprovementsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ComputerAndOfficeEquipmentMember" xlink:label="ComputerAndOfficeEquipmentMember" xlink:title="ComputerAndOfficeEquipmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="ComputerAndOfficeEquipmentMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to ComputerAndOfficeEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="FurnitureAndFixturesMember" xlink:title="FurnitureAndFixturesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="FurnitureAndFixturesMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to FurnitureAndFixturesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="presentation: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="PropertyPlantAndEquipmentByTypeAxis" xlink:title="presentation: ScheduleOfPropertyPlantAndEquipmentTable to PropertyPlantAndEquipmentByTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="PropertyPlantAndEquipmentLineItems" xlink:title="PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="PropertyPlantAndEquipmentNetByTypeAbstract" xlink:title="PropertyPlantAndEquipmentNetByTypeAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="PropertyPlantAndEquipmentGross" xlink:title="PropertyPlantAndEquipmentGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="PropertyPlantAndEquipmentGross" xlink:title="presentation: PropertyPlantAndEquipmentNetByTypeAbstract to PropertyPlantAndEquipmentGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="presentation: PropertyPlantAndEquipmentNetByTypeAbstract to AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="presentation: PropertyPlantAndEquipmentNetByTypeAbstract to PropertyPlantAndEquipmentNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentNetByTypeAbstract" xlink:title="presentation: PropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentNetByTypeAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="DepreciationAndAmortization" xlink:title="DepreciationAndAmortization" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="DepreciationAndAmortization" xlink:title="presentation: PropertyPlantAndEquipmentLineItems to DepreciationAndAmortization" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="PropertyPlantAndEquipmentLineItems" xlink:title="presentation: ScheduleOfPropertyPlantAndEquipmentTable to PropertyPlantAndEquipmentLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="presentation: PropertyPlantAndEquipmentAbstract to ScheduleOfPropertyPlantAndEquipmentTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/AccruedExpensesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" xlink:title="PayablesAndAccrualsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="AccruedProfessionalFeesCurrent" xlink:title="AccruedProfessionalFeesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="AccruedProfessionalFeesCurrent" xlink:title="presentation: PayablesAndAccrualsAbstract to AccruedProfessionalFeesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="EmployeeRelatedLiabilitiesCurrent" xlink:title="EmployeeRelatedLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="EmployeeRelatedLiabilitiesCurrent" xlink:title="presentation: PayablesAndAccrualsAbstract to EmployeeRelatedLiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="OperatingLeaseLiabilityCurrent" xlink:title="OperatingLeaseLiabilityCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="OperatingLeaseLiabilityCurrent" xlink:title="presentation: PayablesAndAccrualsAbstract to OperatingLeaseLiabilityCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:title="OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:title="presentation: PayablesAndAccrualsAbstract to OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_AccruedResearchAndDevelopmentCostsAndOtherCurrent" xlink:label="AccruedResearchAndDevelopmentCostsAndOtherCurrent" xlink:title="AccruedResearchAndDevelopmentCostsAndOtherCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="AccruedResearchAndDevelopmentCostsAndOtherCurrent" xlink:title="presentation: PayablesAndAccrualsAbstract to AccruedResearchAndDevelopmentCostsAndOtherCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="AccruedLiabilitiesCurrent" xlink:title="presentation: PayablesAndAccrualsAbstract to AccruedLiabilitiesCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentsAbstract" xlink:label="DebtInstrumentsAbstract" xlink:title="DebtInstrumentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_AprilConvertiblePromissoryNoteMember" xlink:label="AprilConvertiblePromissoryNoteMember" xlink:title="AprilConvertiblePromissoryNoteMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentNameDomain" xlink:to="AprilConvertiblePromissoryNoteMember" xlink:title="presentation: DebtInstrumentNameDomain to AprilConvertiblePromissoryNoteMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_SeptemberConvertiblePromissoryNoteMember" xlink:label="SeptemberConvertiblePromissoryNoteMember" xlink:title="SeptemberConvertiblePromissoryNoteMember" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_FirstClosingMember" xlink:label="FirstClosingMember" xlink:title="FirstClosingMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SeptemberConvertiblePromissoryNoteMember" xlink:to="FirstClosingMember" xlink:title="presentation: SeptemberConvertiblePromissoryNoteMember to FirstClosingMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_SecondClosingMember" xlink:label="SecondClosingMember" xlink:title="SecondClosingMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SeptemberConvertiblePromissoryNoteMember" xlink:to="SecondClosingMember" xlink:title="presentation: SeptemberConvertiblePromissoryNoteMember to SecondClosingMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentNameDomain" xlink:to="SeptemberConvertiblePromissoryNoteMember" xlink:title="presentation: DebtInstrumentNameDomain to SeptemberConvertiblePromissoryNoteMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_DecemberConvertiblePromissoryNoteMember" xlink:label="DecemberConvertiblePromissoryNoteMember" xlink:title="DecemberConvertiblePromissoryNoteMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentNameDomain" xlink:to="DecemberConvertiblePromissoryNoteMember" xlink:title="presentation: DebtInstrumentNameDomain to DecemberConvertiblePromissoryNoteMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="presentation: DebtInstrumentAxis to DebtInstrumentNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentAxis" xlink:title="presentation: DebtInstrumentTable to DebtInstrumentAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="BoardOfDirectorsChairmanMember" xlink:title="BoardOfDirectorsChairmanMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyDomain" xlink:to="BoardOfDirectorsChairmanMember" xlink:title="presentation: RelatedPartyDomain to BoardOfDirectorsChairmanMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="presentation: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="presentation: DebtInstrumentTable to RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="ScenarioForecastMember" xlink:title="ScenarioForecastMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScenarioUnspecifiedDomain" xlink:to="ScenarioForecastMember" xlink:title="presentation: ScenarioUnspecifiedDomain to ScenarioForecastMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain" xlink:title="presentation: StatementScenarioAxis to ScenarioUnspecifiedDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="StatementScenarioAxis" xlink:title="presentation: DebtInstrumentTable to StatementScenarioAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ConvertibleNotesPayableRelatedPartyAbstract" xlink:label="ConvertibleNotesPayableRelatedPartyAbstract" xlink:title="ConvertibleNotesPayableRelatedPartyAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="DebtInstrumentFaceAmount" xlink:title="DebtInstrumentFaceAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableRelatedPartyAbstract" xlink:to="DebtInstrumentFaceAmount" xlink:title="presentation: ConvertibleNotesPayableRelatedPartyAbstract to DebtInstrumentFaceAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="DebtConversionConvertedInstrumentAmount1" xlink:title="DebtConversionConvertedInstrumentAmount1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableRelatedPartyAbstract" xlink:to="DebtConversionConvertedInstrumentAmount1" xlink:title="presentation: ConvertibleNotesPayableRelatedPartyAbstract to DebtConversionConvertedInstrumentAmount1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="DebtInstrumentMaturityDate" xlink:title="DebtInstrumentMaturityDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableRelatedPartyAbstract" xlink:to="DebtInstrumentMaturityDate" xlink:title="presentation: ConvertibleNotesPayableRelatedPartyAbstract to DebtInstrumentMaturityDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_NumberOfLoansClosing" xlink:label="NumberOfLoansClosing" xlink:title="NumberOfLoansClosing" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableRelatedPartyAbstract" xlink:to="NumberOfLoansClosing" xlink:title="presentation: ConvertibleNotesPayableRelatedPartyAbstract to NumberOfLoansClosing" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_NumberOfPromissoryNotesEvidencedByLoansAgreement" xlink:label="NumberOfPromissoryNotesEvidencedByLoansAgreement" xlink:title="NumberOfPromissoryNotesEvidencedByLoansAgreement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableRelatedPartyAbstract" xlink:to="NumberOfPromissoryNotesEvidencedByLoansAgreement" xlink:title="presentation: ConvertibleNotesPayableRelatedPartyAbstract to NumberOfPromissoryNotesEvidencedByLoansAgreement" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_NumberOfPromissoryNotesExecuted" xlink:label="NumberOfPromissoryNotesExecuted" xlink:title="NumberOfPromissoryNotesExecuted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableRelatedPartyAbstract" xlink:to="NumberOfPromissoryNotesExecuted" xlink:title="presentation: ConvertibleNotesPayableRelatedPartyAbstract to NumberOfPromissoryNotesExecuted" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="DebtInstrumentConvertibleConversionPrice1" xlink:title="DebtInstrumentConvertibleConversionPrice1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableRelatedPartyAbstract" xlink:to="DebtInstrumentConvertibleConversionPrice1" xlink:title="presentation: ConvertibleNotesPayableRelatedPartyAbstract to DebtInstrumentConvertibleConversionPrice1" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableRelatedPartyAbstract" xlink:to="DebtInstrumentInterestRateStatedPercentage" xlink:title="presentation: ConvertibleNotesPayableRelatedPartyAbstract to DebtInstrumentInterestRateStatedPercentage" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="DebtInstrumentInterestRateEffectivePercentage" xlink:title="DebtInstrumentInterestRateEffectivePercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableRelatedPartyAbstract" xlink:to="DebtInstrumentInterestRateEffectivePercentage" xlink:title="presentation: ConvertibleNotesPayableRelatedPartyAbstract to DebtInstrumentInterestRateEffectivePercentage" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt" xlink:label="InterestExpenseDebt" xlink:title="InterestExpenseDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableRelatedPartyAbstract" xlink:to="InterestExpenseDebt" xlink:title="presentation: ConvertibleNotesPayableRelatedPartyAbstract to InterestExpenseDebt" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_QuarterlyInterestRate" xlink:label="QuarterlyInterestRate" xlink:title="QuarterlyInterestRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableRelatedPartyAbstract" xlink:to="QuarterlyInterestRate" xlink:title="presentation: ConvertibleNotesPayableRelatedPartyAbstract to QuarterlyInterestRate" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_AnnualInterestRate" xlink:label="AnnualInterestRate" xlink:title="AnnualInterestRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableRelatedPartyAbstract" xlink:to="AnnualInterestRate" xlink:title="presentation: ConvertibleNotesPayableRelatedPartyAbstract to AnnualInterestRate" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="DerivativeLiabilitiesNoncurrent" xlink:title="DerivativeLiabilitiesNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableRelatedPartyAbstract" xlink:to="DerivativeLiabilitiesNoncurrent" xlink:title="presentation: ConvertibleNotesPayableRelatedPartyAbstract to DerivativeLiabilitiesNoncurrent" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:label="DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:title="DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableRelatedPartyAbstract" xlink:to="DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:title="presentation: ConvertibleNotesPayableRelatedPartyAbstract to DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" order="13.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="AmortizationOfFinancingCosts" xlink:title="AmortizationOfFinancingCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableRelatedPartyAbstract" xlink:to="AmortizationOfFinancingCosts" xlink:title="presentation: ConvertibleNotesPayableRelatedPartyAbstract to AmortizationOfFinancingCosts" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseOther" xlink:label="InterestExpenseOther" xlink:title="InterestExpenseOther" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableRelatedPartyAbstract" xlink:to="InterestExpenseOther" xlink:title="presentation: ConvertibleNotesPayableRelatedPartyAbstract to InterestExpenseOther" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:title="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableRelatedPartyAbstract" xlink:to="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:title="presentation: ConvertibleNotesPayableRelatedPartyAbstract to StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebt" xlink:label="RepaymentsOfDebt" xlink:title="RepaymentsOfDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableRelatedPartyAbstract" xlink:to="RepaymentsOfDebt" xlink:title="presentation: ConvertibleNotesPayableRelatedPartyAbstract to RepaymentsOfDebt" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentLineItems" xlink:to="ConvertibleNotesPayableRelatedPartyAbstract" xlink:title="presentation: DebtInstrumentLineItems to ConvertibleNotesPayableRelatedPartyAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentLineItems" xlink:title="presentation: DebtInstrumentTable to DebtInstrumentLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentTable" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="FairValueByMeasurementFrequencyAxis" xlink:title="FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain" xlink:title="FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="FairValueMeasurementsRecurringMember" xlink:title="FairValueMeasurementsRecurringMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementFrequencyDomain" xlink:to="FairValueMeasurementsRecurringMember" xlink:title="presentation: FairValueMeasurementFrequencyDomain to FairValueMeasurementsRecurringMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="FairValueMeasurementFrequencyDomain" xlink:title="presentation: FairValueByMeasurementFrequencyAxis to FairValueMeasurementFrequencyDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByMeasurementFrequencyAxis" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByMeasurementFrequencyAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="DerivativeInstrumentRiskAxis" xlink:title="DerivativeInstrumentRiskAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="DerivativeContractTypeDomain" xlink:title="DerivativeContractTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ContingentInterestAprilNoteMember" xlink:label="ContingentInterestAprilNoteMember" xlink:title="ContingentInterestAprilNoteMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DerivativeContractTypeDomain" xlink:to="ContingentInterestAprilNoteMember" xlink:title="presentation: DerivativeContractTypeDomain to ContingentInterestAprilNoteMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ContingentInterestSeptemberNoteMember" xlink:label="ContingentInterestSeptemberNoteMember" xlink:title="ContingentInterestSeptemberNoteMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DerivativeContractTypeDomain" xlink:to="ContingentInterestSeptemberNoteMember" xlink:title="presentation: DerivativeContractTypeDomain to ContingentInterestSeptemberNoteMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ContingentInterestDecemberNoteMember" xlink:label="ContingentInterestDecemberNoteMember" xlink:title="ContingentInterestDecemberNoteMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DerivativeContractTypeDomain" xlink:to="ContingentInterestDecemberNoteMember" xlink:title="presentation: DerivativeContractTypeDomain to ContingentInterestDecemberNoteMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DerivativeInstrumentRiskAxis" xlink:to="DerivativeContractTypeDomain" xlink:title="presentation: DerivativeInstrumentRiskAxis to DerivativeContractTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="DerivativeInstrumentRiskAxis" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to DerivativeInstrumentRiskAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel12And3Member" xlink:label="FairValueInputsLevel12And3Member" xlink:title="FairValueInputsLevel12And3Member" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="FairValueInputsLevel1Member" xlink:title="FairValueInputsLevel1Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueInputsLevel12And3Member" xlink:to="FairValueInputsLevel1Member" xlink:title="presentation: FairValueInputsLevel12And3Member to FairValueInputsLevel1Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="FairValueInputsLevel2Member" xlink:title="FairValueInputsLevel2Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueInputsLevel12And3Member" xlink:to="FairValueInputsLevel2Member" xlink:title="presentation: FairValueInputsLevel12And3Member to FairValueInputsLevel2Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="FairValueInputsLevel3Member" xlink:title="FairValueInputsLevel3Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueInputsLevel12And3Member" xlink:to="FairValueInputsLevel3Member" xlink:title="presentation: FairValueInputsLevel12And3Member to FairValueInputsLevel3Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel12And3Member" xlink:title="presentation: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel12And3Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="presentation: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByFairValueHierarchyLevelAxis" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByFairValueHierarchyLevelAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueNetAssetLiabilityAbstract" xlink:label="FairValueNetAssetLiabilityAbstract" xlink:title="FairValueNetAssetLiabilityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="AssetsFairValueDisclosure" xlink:title="AssetsFairValueDisclosure" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueNetAssetLiabilityAbstract" xlink:to="AssetsFairValueDisclosure" xlink:title="presentation: FairValueNetAssetLiabilityAbstract to AssetsFairValueDisclosure" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="FinancialLiabilitiesFairValueDisclosure" xlink:title="FinancialLiabilitiesFairValueDisclosure" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueNetAssetLiabilityAbstract" xlink:to="FinancialLiabilitiesFairValueDisclosure" xlink:title="presentation: FairValueNetAssetLiabilityAbstract to FinancialLiabilitiesFairValueDisclosure" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="DerivativeLiabilitiesNoncurrent" xlink:title="DerivativeLiabilitiesNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueNetAssetLiabilityAbstract" xlink:to="DerivativeLiabilitiesNoncurrent" xlink:title="presentation: FairValueNetAssetLiabilityAbstract to DerivativeLiabilitiesNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueNetAssetLiabilityAbstract" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueNetAssetLiabilityAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="presentation: FairValueDisclosuresAbstract to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsKeyAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="MeasurementInputTypeAxis" xlink:title="MeasurementInputTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="MeasurementInputTypeDomain" xlink:title="MeasurementInputTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="MeasurementInputSharePriceMember" xlink:title="MeasurementInputSharePriceMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MeasurementInputTypeDomain" xlink:to="MeasurementInputSharePriceMember" xlink:title="presentation: MeasurementInputTypeDomain to MeasurementInputSharePriceMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputConversionPriceMember" xlink:label="MeasurementInputConversionPriceMember" xlink:title="MeasurementInputConversionPriceMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MeasurementInputTypeDomain" xlink:to="MeasurementInputConversionPriceMember" xlink:title="presentation: MeasurementInputTypeDomain to MeasurementInputConversionPriceMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="MeasurementInputExpectedTermMember" xlink:title="MeasurementInputExpectedTermMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MeasurementInputTypeDomain" xlink:to="MeasurementInputExpectedTermMember" xlink:title="presentation: MeasurementInputTypeDomain to MeasurementInputExpectedTermMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="MeasurementInputRiskFreeInterestRateMember" xlink:title="MeasurementInputRiskFreeInterestRateMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MeasurementInputTypeDomain" xlink:to="MeasurementInputRiskFreeInterestRateMember" xlink:title="presentation: MeasurementInputTypeDomain to MeasurementInputRiskFreeInterestRateMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="MeasurementInputDiscountRateMember" xlink:title="MeasurementInputDiscountRateMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MeasurementInputTypeDomain" xlink:to="MeasurementInputDiscountRateMember" xlink:title="presentation: MeasurementInputTypeDomain to MeasurementInputDiscountRateMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="MeasurementInputPriceVolatilityMember" xlink:title="MeasurementInputPriceVolatilityMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MeasurementInputTypeDomain" xlink:to="MeasurementInputPriceVolatilityMember" xlink:title="presentation: MeasurementInputTypeDomain to MeasurementInputPriceVolatilityMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="MeasurementInputExpectedDividendRateMember" xlink:title="MeasurementInputExpectedDividendRateMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MeasurementInputTypeDomain" xlink:to="MeasurementInputExpectedDividendRateMember" xlink:title="presentation: MeasurementInputTypeDomain to MeasurementInputExpectedDividendRateMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MeasurementInputTypeAxis" xlink:to="MeasurementInputTypeDomain" xlink:title="presentation: MeasurementInputTypeAxis to MeasurementInputTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="MeasurementInputTypeAxis" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable to MeasurementInputTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="DerivativeInstrumentRiskAxis" xlink:title="DerivativeInstrumentRiskAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="DerivativeContractTypeDomain" xlink:title="DerivativeContractTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ContingentInterestAprilNoteMember" xlink:label="ContingentInterestAprilNoteMember" xlink:title="ContingentInterestAprilNoteMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DerivativeContractTypeDomain" xlink:to="ContingentInterestAprilNoteMember" xlink:title="presentation: DerivativeContractTypeDomain to ContingentInterestAprilNoteMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ContingentInterestSeptemberNoteMember" xlink:label="ContingentInterestSeptemberNoteMember" xlink:title="ContingentInterestSeptemberNoteMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DerivativeContractTypeDomain" xlink:to="ContingentInterestSeptemberNoteMember" xlink:title="presentation: DerivativeContractTypeDomain to ContingentInterestSeptemberNoteMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ContingentInterestDecemberNoteMember" xlink:label="ContingentInterestDecemberNoteMember" xlink:title="ContingentInterestDecemberNoteMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DerivativeContractTypeDomain" xlink:to="ContingentInterestDecemberNoteMember" xlink:title="presentation: DerivativeContractTypeDomain to ContingentInterestDecemberNoteMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DerivativeInstrumentRiskAxis" xlink:to="DerivativeContractTypeDomain" xlink:title="presentation: DerivativeInstrumentRiskAxis to DerivativeContractTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="DerivativeInstrumentRiskAxis" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable to DerivativeInstrumentRiskAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueAndInputDescriptionAbstract" xlink:label="ValuationTechniqueAndInputDescriptionAbstract" xlink:title="ValuationTechniqueAndInputDescriptionAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="DerivativeLiabilityMeasurementInput" xlink:title="DerivativeLiabilityMeasurementInput" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ValuationTechniqueAndInputDescriptionAbstract" xlink:to="DerivativeLiabilityMeasurementInput" xlink:title="presentation: ValuationTechniqueAndInputDescriptionAbstract to DerivativeLiabilityMeasurementInput" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm" xlink:label="DebtInstrumentTerm" xlink:title="DebtInstrumentTerm" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ValuationTechniqueAndInputDescriptionAbstract" xlink:to="DebtInstrumentTerm" xlink:title="presentation: ValuationTechniqueAndInputDescriptionAbstract to DebtInstrumentTerm" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="ValuationTechniqueAndInputDescriptionAbstract" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems to ValuationTechniqueAndInputDescriptionAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:title="presentation: FairValueDisclosuresAbstract to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsRollForwardOfDerivativeLiabilityDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="DerivativeInstrumentRiskAxis" xlink:title="DerivativeInstrumentRiskAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="DerivativeContractTypeDomain" xlink:title="DerivativeContractTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ContingentInterestAprilNoteMember" xlink:label="ContingentInterestAprilNoteMember" xlink:title="ContingentInterestAprilNoteMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DerivativeContractTypeDomain" xlink:to="ContingentInterestAprilNoteMember" xlink:title="presentation: DerivativeContractTypeDomain to ContingentInterestAprilNoteMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ContingentInterestSeptemberNoteMember" xlink:label="ContingentInterestSeptemberNoteMember" xlink:title="ContingentInterestSeptemberNoteMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DerivativeContractTypeDomain" xlink:to="ContingentInterestSeptemberNoteMember" xlink:title="presentation: DerivativeContractTypeDomain to ContingentInterestSeptemberNoteMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ContingentInterestDecemberNoteMember" xlink:label="ContingentInterestDecemberNoteMember" xlink:title="ContingentInterestDecemberNoteMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DerivativeContractTypeDomain" xlink:to="ContingentInterestDecemberNoteMember" xlink:title="presentation: DerivativeContractTypeDomain to ContingentInterestDecemberNoteMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DerivativeInstrumentRiskAxis" xlink:to="DerivativeContractTypeDomain" xlink:title="presentation: DerivativeInstrumentRiskAxis to DerivativeContractTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="DerivativeInstrumentRiskAxis" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to DerivativeInstrumentRiskAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="DerivativeLiabilitiesNoncurrent" xlink:title="DerivativeLiabilitiesNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="DerivativeLiabilitiesNoncurrent" xlink:title="presentation: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward to DerivativeLiabilitiesNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="FairValueAdjustmentOfWarrants" xlink:title="FairValueAdjustmentOfWarrants" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="FairValueAdjustmentOfWarrants" xlink:title="presentation: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward to FairValueAdjustmentOfWarrants" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="DerivativeLiabilitiesNoncurrent_2" xlink:title="DerivativeLiabilitiesNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="DerivativeLiabilitiesNoncurrent_2" xlink:title="presentation: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward to DerivativeLiabilitiesNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="presentation: FairValueDisclosuresAbstract to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/StockholdersEquityIssuanceOfCommonStockDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" xlink:title="EquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="ScheduleOfStockByClassTable" xlink:title="ScheduleOfStockByClassTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="SeriesAPreferredStockMember" xlink:title="SeriesAPreferredStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="SeriesAPreferredStockMember" xlink:title="presentation: ClassOfStockDomain to SeriesAPreferredStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_SeriesBOneConvertiblePreferredStockMember" xlink:label="SeriesBOneConvertiblePreferredStockMember" xlink:title="SeriesBOneConvertiblePreferredStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="SeriesBOneConvertiblePreferredStockMember" xlink:title="presentation: ClassOfStockDomain to SeriesBOneConvertiblePreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_SeriesBTwoConvertiblePreferredStockMember" xlink:label="SeriesBTwoConvertiblePreferredStockMember" xlink:title="SeriesBTwoConvertiblePreferredStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="SeriesBTwoConvertiblePreferredStockMember" xlink:title="presentation: ClassOfStockDomain to SeriesBTwoConvertiblePreferredStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_SeriesBThreeConvertiblePreferredStockMember" xlink:label="SeriesBThreeConvertiblePreferredStockMember" xlink:title="SeriesBThreeConvertiblePreferredStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="SeriesBThreeConvertiblePreferredStockMember" xlink:title="presentation: ClassOfStockDomain to SeriesBThreeConvertiblePreferredStockMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="SeriesCPreferredStockMember" xlink:title="SeriesCPreferredStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="SeriesCPreferredStockMember" xlink:title="presentation: ClassOfStockDomain to SeriesCPreferredStockMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="presentation: StatementClassOfStockAxis to ClassOfStockDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockByClassTable" xlink:to="StatementClassOfStockAxis" xlink:title="presentation: ScheduleOfStockByClassTable to StatementClassOfStockAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityComponentDomain" xlink:to="CommonStockMember" xlink:title="presentation: EquityComponentDomain to CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="presentation: StatementEquityComponentsAxis to EquityComponentDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockByClassTable" xlink:to="StatementEquityComponentsAxis" xlink:title="presentation: ScheduleOfStockByClassTable to StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_TwoThousandTwentyMarketAgreementMember" xlink:label="TwoThousandTwentyMarketAgreementMember" xlink:title="TwoThousandTwentyMarketAgreementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="TwoThousandTwentyMarketAgreementMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to TwoThousandTwentyMarketAgreementMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_TwoThousandSeventeenMarketAgreementMember" xlink:label="TwoThousandSeventeenMarketAgreementMember" xlink:title="TwoThousandSeventeenMarketAgreementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="TwoThousandSeventeenMarketAgreementMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to TwoThousandSeventeenMarketAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="presentation: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockByClassTable" xlink:to="TypeOfArrangementAxis" xlink:title="presentation: ScheduleOfStockByClassTable to TypeOfArrangementAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="ClassOfStockLineItems" xlink:title="ClassOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" xlink:title="StockholdersEquityNoteAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="CommonStockSharesAuthorized" xlink:title="presentation: StockholdersEquityNoteAbstract to CommonStockSharesAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_UndesignatedCapitalStockSharesAuthorized" xlink:label="UndesignatedCapitalStockSharesAuthorized" xlink:title="UndesignatedCapitalStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="UndesignatedCapitalStockSharesAuthorized" xlink:title="presentation: StockholdersEquityNoteAbstract to UndesignatedCapitalStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="PreferredStockSharesAuthorized" xlink:title="PreferredStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="PreferredStockSharesAuthorized" xlink:title="presentation: StockholdersEquityNoteAbstract to PreferredStockSharesAuthorized" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_AggregateOfferingPrice" xlink:label="AggregateOfferingPrice" xlink:title="AggregateOfferingPrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="AggregateOfferingPrice" xlink:title="presentation: StockholdersEquityNoteAbstract to AggregateOfferingPrice" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_CommissionRate" xlink:label="CommissionRate" xlink:title="CommissionRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="CommissionRate" xlink:title="presentation: StockholdersEquityNoteAbstract to CommissionRate" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="CommonStockSharesIssued" xlink:title="presentation: StockholdersEquityNoteAbstract to CommonStockSharesIssued" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockLineItems" xlink:to="StockholdersEquityNoteAbstract" xlink:title="presentation: ClassOfStockLineItems to StockholdersEquityNoteAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockByClassTable" xlink:to="ClassOfStockLineItems" xlink:title="presentation: ScheduleOfStockByClassTable to ClassOfStockLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="ScheduleOfStockByClassTable" xlink:title="presentation: EquityAbstract to ScheduleOfStockByClassTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/StockholdersEquitySeries12ConvertiblePreferredStockDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" xlink:title="EquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="ScheduleOfStockByClassTable" xlink:title="ScheduleOfStockByClassTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="SeriesAPreferredStockMember" xlink:title="SeriesAPreferredStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="SeriesAPreferredStockMember" xlink:title="presentation: ClassOfStockDomain to SeriesAPreferredStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="presentation: StatementClassOfStockAxis to ClassOfStockDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockByClassTable" xlink:to="StatementClassOfStockAxis" xlink:title="presentation: ScheduleOfStockByClassTable to StatementClassOfStockAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockByClassTable" xlink:to="RangeAxis" xlink:title="presentation: ScheduleOfStockByClassTable to RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_DividendPaymentScenarioOneMember" xlink:label="DividendPaymentScenarioOneMember" xlink:title="DividendPaymentScenarioOneMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScenarioUnspecifiedDomain" xlink:to="DividendPaymentScenarioOneMember" xlink:title="presentation: ScenarioUnspecifiedDomain to DividendPaymentScenarioOneMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_DividendPaymentScenarioTwoMember" xlink:label="DividendPaymentScenarioTwoMember" xlink:title="DividendPaymentScenarioTwoMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScenarioUnspecifiedDomain" xlink:to="DividendPaymentScenarioTwoMember" xlink:title="presentation: ScenarioUnspecifiedDomain to DividendPaymentScenarioTwoMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain" xlink:title="presentation: StatementScenarioAxis to ScenarioUnspecifiedDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockByClassTable" xlink:to="StatementScenarioAxis" xlink:title="presentation: ScheduleOfStockByClassTable to StatementScenarioAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="ClassOfStockLineItems" xlink:title="ClassOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" xlink:title="StockholdersEquityNoteAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="PreferredStockDividendRatePercentage" xlink:title="PreferredStockDividendRatePercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="PreferredStockDividendRatePercentage" xlink:title="presentation: StockholdersEquityNoteAbstract to PreferredStockDividendRatePercentage" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="SharesIssuedPricePerShare" xlink:title="SharesIssuedPricePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="SharesIssuedPricePerShare" xlink:title="presentation: StockholdersEquityNoteAbstract to SharesIssuedPricePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:title="presentation: StockholdersEquityNoteAbstract to ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="presentation: StockholdersEquityNoteAbstract to ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_PercentageOfWeightedAverageStockPriceForDividendsPriorToPaymentDate" xlink:label="PercentageOfWeightedAverageStockPriceForDividendsPriorToPaymentDate" xlink:title="PercentageOfWeightedAverageStockPriceForDividendsPriorToPaymentDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="PercentageOfWeightedAverageStockPriceForDividendsPriorToPaymentDate" xlink:title="presentation: StockholdersEquityNoteAbstract to PercentageOfWeightedAverageStockPriceForDividendsPriorToPaymentDate" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_NumberOfConsecutiveTradingDays" xlink:label="NumberOfConsecutiveTradingDays" xlink:title="NumberOfConsecutiveTradingDays" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="NumberOfConsecutiveTradingDays" xlink:title="presentation: StockholdersEquityNoteAbstract to NumberOfConsecutiveTradingDays" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="SharePrice" xlink:title="SharePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="SharePrice" xlink:title="presentation: StockholdersEquityNoteAbstract to SharePrice" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="ConversionOfStockSharesIssued1" xlink:title="ConversionOfStockSharesIssued1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="ConversionOfStockSharesIssued1" xlink:title="presentation: StockholdersEquityNoteAbstract to ConversionOfStockSharesIssued1" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="ConversionOfStockSharesConverted1" xlink:title="ConversionOfStockSharesConverted1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="ConversionOfStockSharesConverted1" xlink:title="presentation: StockholdersEquityNoteAbstract to ConversionOfStockSharesConverted1" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockLineItems" xlink:to="StockholdersEquityNoteAbstract" xlink:title="presentation: ClassOfStockLineItems to StockholdersEquityNoteAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockByClassTable" xlink:to="ClassOfStockLineItems" xlink:title="presentation: ScheduleOfStockByClassTable to ClassOfStockLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="ScheduleOfStockByClassTable" xlink:title="presentation: EquityAbstract to ScheduleOfStockByClassTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/StockholdersEquitySeriesC6SuperDividendRedeemableConvertiblePreferredStockDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" xlink:title="EquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="ScheduleOfStockByClassTable" xlink:title="ScheduleOfStockByClassTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="SeriesCPreferredStockMember" xlink:title="SeriesCPreferredStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="SeriesCPreferredStockMember" xlink:title="presentation: ClassOfStockDomain to SeriesCPreferredStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="presentation: StatementClassOfStockAxis to ClassOfStockDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockByClassTable" xlink:to="StatementClassOfStockAxis" xlink:title="presentation: ScheduleOfStockByClassTable to StatementClassOfStockAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_DividendPaymentScenarioOneMember" xlink:label="DividendPaymentScenarioOneMember" xlink:title="DividendPaymentScenarioOneMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScenarioUnspecifiedDomain" xlink:to="DividendPaymentScenarioOneMember" xlink:title="presentation: ScenarioUnspecifiedDomain to DividendPaymentScenarioOneMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_DividendPaymentScenarioTwoMember" xlink:label="DividendPaymentScenarioTwoMember" xlink:title="DividendPaymentScenarioTwoMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScenarioUnspecifiedDomain" xlink:to="DividendPaymentScenarioTwoMember" xlink:title="presentation: ScenarioUnspecifiedDomain to DividendPaymentScenarioTwoMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain" xlink:title="presentation: StatementScenarioAxis to ScenarioUnspecifiedDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockByClassTable" xlink:to="StatementScenarioAxis" xlink:title="presentation: ScheduleOfStockByClassTable to StatementScenarioAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityComponentDomain" xlink:to="CommonStockMember" xlink:title="presentation: EquityComponentDomain to CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="presentation: StatementEquityComponentsAxis to EquityComponentDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockByClassTable" xlink:to="StatementEquityComponentsAxis" xlink:title="presentation: ScheduleOfStockByClassTable to StatementEquityComponentsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockByClassTable" xlink:to="RangeAxis" xlink:title="presentation: ScheduleOfStockByClassTable to RangeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="ClassOfStockLineItems" xlink:title="ClassOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="StockIssuedDuringPeriodSharesNewIssues" xlink:title="presentation: PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract to StockIssuedDuringPeriodSharesNewIssues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="PreferredStockParOrStatedValuePerShare" xlink:title="PreferredStockParOrStatedValuePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="PreferredStockParOrStatedValuePerShare" xlink:title="presentation: PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract to PreferredStockParOrStatedValuePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="SharesIssuedPricePerShare" xlink:title="SharesIssuedPricePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="SharesIssuedPricePerShare" xlink:title="presentation: PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract to SharesIssuedPricePerShare" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="PreferredStockLiquidationPreference" xlink:title="PreferredStockLiquidationPreference" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="PreferredStockLiquidationPreference" xlink:title="presentation: PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract to PreferredStockLiquidationPreference" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:title="ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:title="presentation: PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract to ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="PaymentsOfStockIssuanceCosts" xlink:title="PaymentsOfStockIssuanceCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="PaymentsOfStockIssuanceCosts" xlink:title="presentation: PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract to PaymentsOfStockIssuanceCosts" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ProceedsFromIssuanceOfPreferredStockNetOfIssuanceCosts" xlink:label="ProceedsFromIssuanceOfPreferredStockNetOfIssuanceCosts" xlink:title="ProceedsFromIssuanceOfPreferredStockNetOfIssuanceCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="ProceedsFromIssuanceOfPreferredStockNetOfIssuanceCosts" xlink:title="presentation: PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract to ProceedsFromIssuanceOfPreferredStockNetOfIssuanceCosts" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ClassOfWarrantOrRightIssued" xlink:label="ClassOfWarrantOrRightIssued" xlink:title="ClassOfWarrantOrRightIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="ClassOfWarrantOrRightIssued" xlink:title="presentation: PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract to ClassOfWarrantOrRightIssued" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="presentation: PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract to ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_EquityIssuancePerShareAmount" xlink:label="EquityIssuancePerShareAmount" xlink:title="EquityIssuancePerShareAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="EquityIssuancePerShareAmount" xlink:title="presentation: PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract to EquityIssuancePerShareAmount" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_CommonSharesIssuableUponConversionOfConvertibleStock" xlink:label="CommonSharesIssuableUponConversionOfConvertibleStock" xlink:title="CommonSharesIssuableUponConversionOfConvertibleStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="CommonSharesIssuableUponConversionOfConvertibleStock" xlink:title="presentation: PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract to CommonSharesIssuableUponConversionOfConvertibleStock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="CommonStockSharesOutstanding" xlink:title="presentation: PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract to CommonStockSharesOutstanding" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="ConversionOfStockSharesIssued1" xlink:title="ConversionOfStockSharesIssued1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="ConversionOfStockSharesIssued1" xlink:title="presentation: PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract to ConversionOfStockSharesIssued1" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="SharePrice" xlink:title="SharePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="SharePrice" xlink:title="presentation: PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract to SharePrice" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_NumberOfConsecutiveTradingDays" xlink:label="NumberOfConsecutiveTradingDays" xlink:title="NumberOfConsecutiveTradingDays" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="NumberOfConsecutiveTradingDays" xlink:title="presentation: PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract to NumberOfConsecutiveTradingDays" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="PreferredStockDividendRatePercentage" xlink:title="PreferredStockDividendRatePercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="PreferredStockDividendRatePercentage" xlink:title="presentation: PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract to PreferredStockDividendRatePercentage" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_DividendAsPercentageOfNetSales" xlink:label="DividendAsPercentageOfNetSales" xlink:title="DividendAsPercentageOfNetSales" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="DividendAsPercentageOfNetSales" xlink:title="presentation: PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract to DividendAsPercentageOfNetSales" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsPreferredStock" xlink:label="DividendsPreferredStock" xlink:title="DividendsPreferredStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="DividendsPreferredStock" xlink:title="presentation: PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract to DividendsPreferredStock" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockRedemptionPricePerShare" xlink:label="PreferredStockRedemptionPricePerShare" xlink:title="PreferredStockRedemptionPricePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="PreferredStockRedemptionPricePerShare" xlink:title="presentation: PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract to PreferredStockRedemptionPricePerShare" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_PostConversionDividendRightsIssued" xlink:label="PostConversionDividendRightsIssued" xlink:title="PostConversionDividendRightsIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="PostConversionDividendRightsIssued" xlink:title="presentation: PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract to PostConversionDividendRightsIssued" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_PostConversionRedemptionRightReturnOnInvestmentMultiplierAmount" xlink:label="PostConversionRedemptionRightReturnOnInvestmentMultiplierAmount" xlink:title="PostConversionRedemptionRightReturnOnInvestmentMultiplierAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="PostConversionRedemptionRightReturnOnInvestmentMultiplierAmount" xlink:title="presentation: PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract to PostConversionRedemptionRightReturnOnInvestmentMultiplierAmount" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ClosingDaysAfterConversionRights" xlink:label="ClosingDaysAfterConversionRights" xlink:title="ClosingDaysAfterConversionRights" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="ClosingDaysAfterConversionRights" xlink:title="presentation: PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract to ClosingDaysAfterConversionRights" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockLineItems" xlink:to="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="presentation: ClassOfStockLineItems to PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockByClassTable" xlink:to="ClassOfStockLineItems" xlink:title="presentation: ScheduleOfStockByClassTable to ClassOfStockLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="ScheduleOfStockByClassTable" xlink:title="presentation: EquityAbstract to ScheduleOfStockByClassTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/StockholdersEquityReturnOnInvestmentDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" xlink:title="EquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ReturnOnInvestmentsPercentageAbstract" xlink:label="ReturnOnInvestmentsPercentageAbstract" xlink:title="ReturnOnInvestmentsPercentageAbstract" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ReturnOnInvestmentsPercentagePeriodOne" xlink:label="ReturnOnInvestmentsPercentagePeriodOne" xlink:title="ReturnOnInvestmentsPercentagePeriodOne" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReturnOnInvestmentsPercentageAbstract" xlink:to="ReturnOnInvestmentsPercentagePeriodOne" xlink:title="presentation: ReturnOnInvestmentsPercentageAbstract to ReturnOnInvestmentsPercentagePeriodOne" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ReturnOnInvestmentsPercentagePeriodTwo" xlink:label="ReturnOnInvestmentsPercentagePeriodTwo" xlink:title="ReturnOnInvestmentsPercentagePeriodTwo" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReturnOnInvestmentsPercentageAbstract" xlink:to="ReturnOnInvestmentsPercentagePeriodTwo" xlink:title="presentation: ReturnOnInvestmentsPercentageAbstract to ReturnOnInvestmentsPercentagePeriodTwo" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ReturnOnInvestmentsPercentagePeriodThree" xlink:label="ReturnOnInvestmentsPercentagePeriodThree" xlink:title="ReturnOnInvestmentsPercentagePeriodThree" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReturnOnInvestmentsPercentageAbstract" xlink:to="ReturnOnInvestmentsPercentagePeriodThree" xlink:title="presentation: ReturnOnInvestmentsPercentageAbstract to ReturnOnInvestmentsPercentagePeriodThree" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ReturnOnInvestmentsPercentagePeriodFour" xlink:label="ReturnOnInvestmentsPercentagePeriodFour" xlink:title="ReturnOnInvestmentsPercentagePeriodFour" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReturnOnInvestmentsPercentageAbstract" xlink:to="ReturnOnInvestmentsPercentagePeriodFour" xlink:title="presentation: ReturnOnInvestmentsPercentageAbstract to ReturnOnInvestmentsPercentagePeriodFour" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ReturnOnInvestmentsPercentagePeriodFive" xlink:label="ReturnOnInvestmentsPercentagePeriodFive" xlink:title="ReturnOnInvestmentsPercentagePeriodFive" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReturnOnInvestmentsPercentageAbstract" xlink:to="ReturnOnInvestmentsPercentagePeriodFive" xlink:title="presentation: ReturnOnInvestmentsPercentageAbstract to ReturnOnInvestmentsPercentagePeriodFive" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ReturnOnInvestmentsPercentagePeriodSix" xlink:label="ReturnOnInvestmentsPercentagePeriodSix" xlink:title="ReturnOnInvestmentsPercentagePeriodSix" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReturnOnInvestmentsPercentageAbstract" xlink:to="ReturnOnInvestmentsPercentagePeriodSix" xlink:title="presentation: ReturnOnInvestmentsPercentageAbstract to ReturnOnInvestmentsPercentagePeriodSix" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ReturnOnInvestmentsPercentagePeriodSeven" xlink:label="ReturnOnInvestmentsPercentagePeriodSeven" xlink:title="ReturnOnInvestmentsPercentagePeriodSeven" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReturnOnInvestmentsPercentageAbstract" xlink:to="ReturnOnInvestmentsPercentagePeriodSeven" xlink:title="presentation: ReturnOnInvestmentsPercentageAbstract to ReturnOnInvestmentsPercentagePeriodSeven" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ReturnOnInvestmentsPercentagePeriodEight" xlink:label="ReturnOnInvestmentsPercentagePeriodEight" xlink:title="ReturnOnInvestmentsPercentagePeriodEight" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReturnOnInvestmentsPercentageAbstract" xlink:to="ReturnOnInvestmentsPercentagePeriodEight" xlink:title="presentation: ReturnOnInvestmentsPercentageAbstract to ReturnOnInvestmentsPercentagePeriodEight" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="ReturnOnInvestmentsPercentageAbstract" xlink:title="presentation: EquityAbstract to ReturnOnInvestmentsPercentageAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="ScheduleOfStockByClassTable" xlink:title="ScheduleOfStockByClassTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="SeriesCPreferredStockMember" xlink:title="SeriesCPreferredStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="SeriesCPreferredStockMember" xlink:title="presentation: ClassOfStockDomain to SeriesCPreferredStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="presentation: StatementClassOfStockAxis to ClassOfStockDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockByClassTable" xlink:to="StatementClassOfStockAxis" xlink:title="presentation: ScheduleOfStockByClassTable to StatementClassOfStockAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="ClassOfStockLineItems" xlink:title="ClassOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityAggregateAmountOfRedemptionRequirement" xlink:label="TemporaryEquityAggregateAmountOfRedemptionRequirement" xlink:title="TemporaryEquityAggregateAmountOfRedemptionRequirement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="TemporaryEquityAggregateAmountOfRedemptionRequirement" xlink:title="presentation: PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract to TemporaryEquityAggregateAmountOfRedemptionRequirement" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ConvertiblePreferredStockNumberOfVotingRights" xlink:label="ConvertiblePreferredStockNumberOfVotingRights" xlink:title="ConvertiblePreferredStockNumberOfVotingRights" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="ConvertiblePreferredStockNumberOfVotingRights" xlink:title="presentation: PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract to ConvertiblePreferredStockNumberOfVotingRights" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockLineItems" xlink:to="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="presentation: ClassOfStockLineItems to PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockByClassTable" xlink:to="ClassOfStockLineItems" xlink:title="presentation: ScheduleOfStockByClassTable to ClassOfStockLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="ScheduleOfStockByClassTable" xlink:title="presentation: EquityAbstract to ScheduleOfStockByClassTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/WarrantsSummaryOfWarrantActivityDetails">
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_WarrantsAbstract" xlink:label="WarrantsAbstract" xlink:title="WarrantsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="FinancialInstrumentAxis" xlink:title="FinancialInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="WarrantMember" xlink:title="presentation: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to WarrantMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentAxis" xlink:to="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="presentation: FinancialInstrumentAxis to TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="FinancialInstrumentAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to FinancialInstrumentAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract" xlink:to="ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract to ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_2" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_2" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="WarrantsAndRightsOutstandingTerm" xlink:title="WarrantsAndRightsOutstandingTerm" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="WarrantsAndRightsOutstandingTerm" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to WarrantsAndRightsOutstandingTerm" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAbstract" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="presentation: WarrantsAbstract to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/WarrantsSummaryOfPurchaseWarrantsDetails">
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_WarrantsAbstract" xlink:label="WarrantsAbstract" xlink:title="WarrantsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="FinancialInstrumentAxis" xlink:title="FinancialInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="WarrantMember" xlink:title="presentation: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to WarrantMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentAxis" xlink:to="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="presentation: FinancialInstrumentAxis to TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="FinancialInstrumentAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to FinancialInstrumentAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityComponentDomain" xlink:to="CommonStockMember" xlink:title="presentation: EquityComponentDomain to CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_SeriesBWarrantsMember" xlink:label="SeriesBWarrantsMember" xlink:title="SeriesBWarrantsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityComponentDomain" xlink:to="SeriesBWarrantsMember" xlink:title="presentation: EquityComponentDomain to SeriesBWarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="presentation: StatementEquityComponentsAxis to EquityComponentDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="StatementEquityComponentsAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_BeforeModificationMember" xlink:label="BeforeModificationMember" xlink:title="BeforeModificationMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="BeforeModificationMember" xlink:title="presentation: ClassOfWarrantOrRightDomain to BeforeModificationMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_AfterModificationMember" xlink:label="AfterModificationMember" xlink:title="AfterModificationMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="AfterModificationMember" xlink:title="presentation: ClassOfWarrantOrRightDomain to AfterModificationMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain" xlink:title="presentation: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="ClassOfWarrantOrRightAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to ClassOfWarrantOrRightAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_One0XFundLPAnd10XCapitalManagementLLCMember" xlink:label="One0XFundLPAnd10XCapitalManagementLLCMember" xlink:title="One0XFundLPAnd10XCapitalManagementLLCMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyDomain" xlink:to="One0XFundLPAnd10XCapitalManagementLLCMember" xlink:title="presentation: RelatedPartyDomain to One0XFundLPAnd10XCapitalManagementLLCMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_One0XFundLPMember" xlink:label="One0XFundLPMember" xlink:title="One0XFundLPMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyDomain" xlink:to="One0XFundLPMember" xlink:title="presentation: RelatedPartyDomain to One0XFundLPMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="presentation: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to RelatedPartyTransactionsByRelatedPartyAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="RangeAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to RangeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="WarrantsAndRightsNoteDisclosureAbstract" xlink:title="WarrantsAndRightsNoteDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAndRightsNoteDisclosureAbstract" xlink:to="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="presentation: WarrantsAndRightsNoteDisclosureAbstract to ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ThresholdPeriodForExtensionOfExerciseDateOfPurchaseWarrantsUnderAgreement" xlink:label="ThresholdPeriodForExtensionOfExerciseDateOfPurchaseWarrantsUnderAgreement" xlink:title="ThresholdPeriodForExtensionOfExerciseDateOfPurchaseWarrantsUnderAgreement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAndRightsNoteDisclosureAbstract" xlink:to="ThresholdPeriodForExtensionOfExerciseDateOfPurchaseWarrantsUnderAgreement" xlink:title="presentation: WarrantsAndRightsNoteDisclosureAbstract to ThresholdPeriodForExtensionOfExerciseDateOfPurchaseWarrantsUnderAgreement" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ThresholdPeriodForStockClosingPriceInTenConsecutiveDaysUnderPurchaseWarrantsAgreement" xlink:label="ThresholdPeriodForStockClosingPriceInTenConsecutiveDaysUnderPurchaseWarrantsAgreement" xlink:title="ThresholdPeriodForStockClosingPriceInTenConsecutiveDaysUnderPurchaseWarrantsAgreement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAndRightsNoteDisclosureAbstract" xlink:to="ThresholdPeriodForStockClosingPriceInTenConsecutiveDaysUnderPurchaseWarrantsAgreement" xlink:title="presentation: WarrantsAndRightsNoteDisclosureAbstract to ThresholdPeriodForStockClosingPriceInTenConsecutiveDaysUnderPurchaseWarrantsAgreement" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="SharePrice" xlink:title="SharePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAndRightsNoteDisclosureAbstract" xlink:to="SharePrice" xlink:title="presentation: WarrantsAndRightsNoteDisclosureAbstract to SharePrice" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_NumberOfTradingDaysToBeConsideredStockClosingPriceInPurchaseAgreement" xlink:label="NumberOfTradingDaysToBeConsideredStockClosingPriceInPurchaseAgreement" xlink:title="NumberOfTradingDaysToBeConsideredStockClosingPriceInPurchaseAgreement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAndRightsNoteDisclosureAbstract" xlink:to="NumberOfTradingDaysToBeConsideredStockClosingPriceInPurchaseAgreement" xlink:title="presentation: WarrantsAndRightsNoteDisclosureAbstract to NumberOfTradingDaysToBeConsideredStockClosingPriceInPurchaseAgreement" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_BeneficialOwnershipPercentage" xlink:label="BeneficialOwnershipPercentage" xlink:title="BeneficialOwnershipPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAndRightsNoteDisclosureAbstract" xlink:to="BeneficialOwnershipPercentage" xlink:title="presentation: WarrantsAndRightsNoteDisclosureAbstract to BeneficialOwnershipPercentage" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_PeriodOfPriorNoticeThatWouldBarVoluntaryExerciseOfAnyWarrants" xlink:label="PeriodOfPriorNoticeThatWouldBarVoluntaryExerciseOfAnyWarrants" xlink:title="PeriodOfPriorNoticeThatWouldBarVoluntaryExerciseOfAnyWarrants" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAndRightsNoteDisclosureAbstract" xlink:to="PeriodOfPriorNoticeThatWouldBarVoluntaryExerciseOfAnyWarrants" xlink:title="presentation: WarrantsAndRightsNoteDisclosureAbstract to PeriodOfPriorNoticeThatWouldBarVoluntaryExerciseOfAnyWarrants" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockRedemptionPremium" xlink:label="PreferredStockRedemptionPremium" xlink:title="PreferredStockRedemptionPremium" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAndRightsNoteDisclosureAbstract" xlink:to="PreferredStockRedemptionPremium" xlink:title="presentation: WarrantsAndRightsNoteDisclosureAbstract to PreferredStockRedemptionPremium" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="WarrantsAndRightsNoteDisclosureAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to WarrantsAndRightsNoteDisclosureAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAbstract" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="presentation: WarrantsAbstract to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/WarrantsSummaryOfOutstandingWarrantsIssuedInConnectionWithEquityAndDebtFinancingAndConsultantsDetails">
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_WarrantsAbstract" xlink:label="WarrantsAbstract" xlink:title="WarrantsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="ClassOfWarrantOrRightTable" xlink:title="ClassOfWarrantOrRightTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_FebruaryTwelveTwentyZeroNineSeriesBOneTransactionMember" xlink:label="FebruaryTwelveTwentyZeroNineSeriesBOneTransactionMember" xlink:title="FebruaryTwelveTwentyZeroNineSeriesBOneTransactionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="FebruaryTwelveTwentyZeroNineSeriesBOneTransactionMember" xlink:title="presentation: ClassOfWarrantOrRightDomain to FebruaryTwelveTwentyZeroNineSeriesBOneTransactionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_MayThirteenTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:label="MayThirteenTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:title="MayThirteenTwentyZeroNineSeriesBTwoTransactionOneMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="MayThirteenTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:title="presentation: ClassOfWarrantOrRightDomain to MayThirteenTwentyZeroNineSeriesBTwoTransactionOneMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_JuneThirtyTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:label="JuneThirtyTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:title="JuneThirtyTwentyZeroNineSeriesBTwoTransactionOneMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="JuneThirtyTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:title="presentation: ClassOfWarrantOrRightDomain to JuneThirtyTwentyZeroNineSeriesBTwoTransactionOneMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_AugustTwelveTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:label="AugustTwelveTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:title="AugustTwelveTwentyZeroNineSeriesBTwoTransactionOneMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="AugustTwelveTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:title="presentation: ClassOfWarrantOrRightDomain to AugustTwelveTwentyZeroNineSeriesBTwoTransactionOneMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_SeptemberThirtyTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:label="SeptemberThirtyTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:title="SeptemberThirtyTwentyZeroNineSeriesBTwoTransactionOneMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="SeptemberThirtyTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:title="presentation: ClassOfWarrantOrRightDomain to SeptemberThirtyTwentyZeroNineSeriesBTwoTransactionOneMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_NovemberFourTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:label="NovemberFourTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:title="NovemberFourTwentyZeroNineSeriesBTwoTransactionOneMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="NovemberFourTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:title="presentation: ClassOfWarrantOrRightDomain to NovemberFourTwentyZeroNineSeriesBTwoTransactionOneMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_DecemberEightTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:label="DecemberEightTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:title="DecemberEightTwentyZeroNineSeriesBTwoTransactionOneMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="DecemberEightTwentyZeroNineSeriesBTwoTransactionOneMember" xlink:title="presentation: ClassOfWarrantOrRightDomain to DecemberEightTwentyZeroNineSeriesBTwoTransactionOneMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionOneMember" xlink:label="JanuaryTwentyNineTwentyTenSeriesBTwoTransactionOneMember" xlink:title="JanuaryTwentyNineTwentyTenSeriesBTwoTransactionOneMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="JanuaryTwentyNineTwentyTenSeriesBTwoTransactionOneMember" xlink:title="presentation: ClassOfWarrantOrRightDomain to JanuaryTwentyNineTwentyTenSeriesBTwoTransactionOneMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionTwoMember" xlink:label="JanuaryTwentyNineTwentyTenSeriesBTwoTransactionTwoMember" xlink:title="JanuaryTwentyNineTwentyTenSeriesBTwoTransactionTwoMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="JanuaryTwentyNineTwentyTenSeriesBTwoTransactionTwoMember" xlink:title="presentation: ClassOfWarrantOrRightDomain to JanuaryTwentyNineTwentyTenSeriesBTwoTransactionTwoMember" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_MarchEightTwentyTenSeriesBTwoTransactionOneMember" xlink:label="MarchEightTwentyTenSeriesBTwoTransactionOneMember" xlink:title="MarchEightTwentyTenSeriesBTwoTransactionOneMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="MarchEightTwentyTenSeriesBTwoTransactionOneMember" xlink:title="presentation: ClassOfWarrantOrRightDomain to MarchEightTwentyTenSeriesBTwoTransactionOneMember" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_MarchEightTwentyTenSeriesBTwoTransactionTwoMember" xlink:label="MarchEightTwentyTenSeriesBTwoTransactionTwoMember" xlink:title="MarchEightTwentyTenSeriesBTwoTransactionTwoMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="MarchEightTwentyTenSeriesBTwoTransactionTwoMember" xlink:title="presentation: ClassOfWarrantOrRightDomain to MarchEightTwentyTenSeriesBTwoTransactionTwoMember" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_AprilThirtyTwentyTenSeriesBTwoTransactionOneMember" xlink:label="AprilThirtyTwentyTenSeriesBTwoTransactionOneMember" xlink:title="AprilThirtyTwentyTenSeriesBTwoTransactionOneMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="AprilThirtyTwentyTenSeriesBTwoTransactionOneMember" xlink:title="presentation: ClassOfWarrantOrRightDomain to AprilThirtyTwentyTenSeriesBTwoTransactionOneMember" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_AprilThirtyTwentyTenSeriesBTwoTransactionTwoMember" xlink:label="AprilThirtyTwentyTenSeriesBTwoTransactionTwoMember" xlink:title="AprilThirtyTwentyTenSeriesBTwoTransactionTwoMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="AprilThirtyTwentyTenSeriesBTwoTransactionTwoMember" xlink:title="presentation: ClassOfWarrantOrRightDomain to AprilThirtyTwentyTenSeriesBTwoTransactionTwoMember" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_MayTenTwentyTenSeriesBTwoTransactionOneMember" xlink:label="MayTenTwentyTenSeriesBTwoTransactionOneMember" xlink:title="MayTenTwentyTenSeriesBTwoTransactionOneMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="MayTenTwentyTenSeriesBTwoTransactionOneMember" xlink:title="presentation: ClassOfWarrantOrRightDomain to MayTenTwentyTenSeriesBTwoTransactionOneMember" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_MayTenTwentyTenSeriesBTwoTransactionTwoMember" xlink:label="MayTenTwentyTenSeriesBTwoTransactionTwoMember" xlink:title="MayTenTwentyTenSeriesBTwoTransactionTwoMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="MayTenTwentyTenSeriesBTwoTransactionTwoMember" xlink:title="presentation: ClassOfWarrantOrRightDomain to MayTenTwentyTenSeriesBTwoTransactionTwoMember" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_SeptemberTwentyTwoTwentySixteenSeriesBThreeTransactionMember" xlink:label="SeptemberTwentyTwoTwentySixteenSeriesBThreeTransactionMember" xlink:title="SeptemberTwentyTwoTwentySixteenSeriesBThreeTransactionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="SeptemberTwentyTwoTwentySixteenSeriesBThreeTransactionMember" xlink:title="presentation: ClassOfWarrantOrRightDomain to SeptemberTwentyTwoTwentySixteenSeriesBThreeTransactionMember" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_SeptemberTwentyNineTwentySixteenSeriesBThreeTransactionMember" xlink:label="SeptemberTwentyNineTwentySixteenSeriesBThreeTransactionMember" xlink:title="SeptemberTwentyNineTwentySixteenSeriesBThreeTransactionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="SeptemberTwentyNineTwentySixteenSeriesBThreeTransactionMember" xlink:title="presentation: ClassOfWarrantOrRightDomain to SeptemberTwentyNineTwentySixteenSeriesBThreeTransactionMember" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_DecemberTwentyThreeTwentySixteenSeriesBThreeTransactionMember" xlink:label="DecemberTwentyThreeTwentySixteenSeriesBThreeTransactionMember" xlink:title="DecemberTwentyThreeTwentySixteenSeriesBThreeTransactionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="DecemberTwentyThreeTwentySixteenSeriesBThreeTransactionMember" xlink:title="presentation: ClassOfWarrantOrRightDomain to DecemberTwentyThreeTwentySixteenSeriesBThreeTransactionMember" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_TwentyEighteenAndTwentySeventeenWarrantsIssuedForServicesMember" xlink:label="TwentyEighteenAndTwentySeventeenWarrantsIssuedForServicesMember" xlink:title="TwentyEighteenAndTwentySeventeenWarrantsIssuedForServicesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="TwentyEighteenAndTwentySeventeenWarrantsIssuedForServicesMember" xlink:title="presentation: ClassOfWarrantOrRightDomain to TwentyEighteenAndTwentySeventeenWarrantsIssuedForServicesMember" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_MayTwentyThreeTwentyNinteenRightsOfferingWarrantsMember" xlink:label="MayTwentyThreeTwentyNinteenRightsOfferingWarrantsMember" xlink:title="MayTwentyThreeTwentyNinteenRightsOfferingWarrantsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="MayTwentyThreeTwentyNinteenRightsOfferingWarrantsMember" xlink:title="presentation: ClassOfWarrantOrRightDomain to MayTwentyThreeTwentyNinteenRightsOfferingWarrantsMember" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_July222022WarrantsIssuedInConnectionWithRelatedPartyLineOfCreditMember" xlink:label="July222022WarrantsIssuedInConnectionWithRelatedPartyLineOfCreditMember" xlink:title="July222022WarrantsIssuedInConnectionWithRelatedPartyLineOfCreditMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="July222022WarrantsIssuedInConnectionWithRelatedPartyLineOfCreditMember" xlink:title="presentation: ClassOfWarrantOrRightDomain to July222022WarrantsIssuedInConnectionWithRelatedPartyLineOfCreditMember" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_December292023WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" xlink:label="December292023WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" xlink:title="December292023WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="December292023WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" xlink:title="presentation: ClassOfWarrantOrRightDomain to December292023WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_March292024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" xlink:label="March292024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" xlink:title="March292024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="March292024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" xlink:title="presentation: ClassOfWarrantOrRightDomain to March292024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_June282024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" xlink:label="June282024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" xlink:title="June282024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="June282024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" xlink:title="presentation: ClassOfWarrantOrRightDomain to June282024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_September302024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" xlink:label="September302024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" xlink:title="September302024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="September302024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" xlink:title="presentation: ClassOfWarrantOrRightDomain to September302024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain" xlink:title="presentation: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightTable" xlink:to="ClassOfWarrantOrRightAxis" xlink:title="presentation: ClassOfWarrantOrRightTable to ClassOfWarrantOrRightAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="ClassOfWarrantOrRightLineItems" xlink:title="ClassOfWarrantOrRightLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="WarrantsAndRightsNoteDisclosureAbstract" xlink:title="WarrantsAndRightsNoteDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="ClassOfWarrantOrRightOutstanding" xlink:title="ClassOfWarrantOrRightOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAndRightsNoteDisclosureAbstract" xlink:to="ClassOfWarrantOrRightOutstanding" xlink:title="presentation: WarrantsAndRightsNoteDisclosureAbstract to ClassOfWarrantOrRightOutstanding" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAndRightsNoteDisclosureAbstract" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="presentation: WarrantsAndRightsNoteDisclosureAbstract to ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:title="ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAndRightsNoteDisclosureAbstract" xlink:to="ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:title="presentation: WarrantsAndRightsNoteDisclosureAbstract to ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired" xlink:label="ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired" xlink:title="ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAndRightsNoteDisclosureAbstract" xlink:to="ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired" xlink:title="presentation: WarrantsAndRightsNoteDisclosureAbstract to ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_WarrantIssueDate" xlink:label="WarrantIssueDate" xlink:title="WarrantIssueDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAndRightsNoteDisclosureAbstract" xlink:to="WarrantIssueDate" xlink:title="presentation: WarrantsAndRightsNoteDisclosureAbstract to WarrantIssueDate" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_WarrantsIssuedPrice" xlink:label="WarrantsIssuedPrice" xlink:title="WarrantsIssuedPrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAndRightsNoteDisclosureAbstract" xlink:to="WarrantsIssuedPrice" xlink:title="presentation: WarrantsAndRightsNoteDisclosureAbstract to WarrantsIssuedPrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="WarrantsAndRightsNoteDisclosureAbstract" xlink:title="presentation: ClassOfWarrantOrRightLineItems to WarrantsAndRightsNoteDisclosureAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightTable" xlink:to="ClassOfWarrantOrRightLineItems" xlink:title="presentation: ClassOfWarrantOrRightTable to ClassOfWarrantOrRightLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAbstract" xlink:to="ClassOfWarrantOrRightTable" xlink:title="presentation: WarrantsAbstract to ClassOfWarrantOrRightTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/StockbasedCompensationSummaryOfStockbasedCompensationPlansDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_EquityIncentivePlan2019Member" xlink:label="EquityIncentivePlan2019Member" xlink:title="EquityIncentivePlan2019Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanNameDomain" xlink:to="EquityIncentivePlan2019Member" xlink:title="presentation: PlanNameDomain to EquityIncentivePlan2019Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_IncentiveCompensationPlanTwoThousandNineMemberMember" xlink:label="IncentiveCompensationPlanTwoThousandNineMemberMember" xlink:title="IncentiveCompensationPlanTwoThousandNineMemberMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanNameDomain" xlink:to="IncentiveCompensationPlanTwoThousandNineMemberMember" xlink:title="presentation: PlanNameDomain to IncentiveCompensationPlanTwoThousandNineMemberMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_NonQualifiedOptionsPlansMember" xlink:label="NonQualifiedOptionsPlansMember" xlink:title="NonQualifiedOptionsPlansMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanNameDomain" xlink:to="NonQualifiedOptionsPlansMember" xlink:title="presentation: PlanNameDomain to NonQualifiedOptionsPlansMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain" xlink:title="presentation: PlanNameAxis to PlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="PlanNameAxis" xlink:title="presentation: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to PlanNameAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="ShareBasedCompensationAbstract" xlink:title="ShareBasedCompensationAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="presentation: ShareBasedCompensationAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="presentation: ShareBasedCompensationAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="ShareBasedCompensationAbstract" xlink:title="presentation: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to ShareBasedCompensationAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="presentation: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/StockbasedCompensationComponentsOfStockbasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="ResearchAndDevelopmentExpenseMember" xlink:title="ResearchAndDevelopmentExpenseMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationDomain" xlink:to="ResearchAndDevelopmentExpenseMember" xlink:title="presentation: IncomeStatementLocationDomain to ResearchAndDevelopmentExpenseMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="GeneralAndAdministrativeExpenseMember" xlink:title="GeneralAndAdministrativeExpenseMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationDomain" xlink:to="GeneralAndAdministrativeExpenseMember" xlink:title="presentation: IncomeStatementLocationDomain to GeneralAndAdministrativeExpenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="presentation: IncomeStatementLocationAxis to IncomeStatementLocationDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="IncomeStatementLocationAxis" xlink:title="presentation: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to IncomeStatementLocationAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="ShareBasedCompensationAbstract" xlink:title="ShareBasedCompensationAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationAbstract" xlink:to="AllocatedShareBasedCompensationExpense" xlink:title="presentation: ShareBasedCompensationAbstract to AllocatedShareBasedCompensationExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="ShareBasedCompensationAbstract" xlink:title="presentation: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to ShareBasedCompensationAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="presentation: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/StockbasedCompensationWeightedAverageAssumptionsUsedToDetermineFairValueOfOptionsGrantedDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="RangeAxis" xlink:title="presentation: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to RangeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfAward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfAward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfAward" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfAward" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfAward" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="presentation: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="presentation: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/StockbasedCompensationStockOptionActivityDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to StockIssuedDuringPeriodSharesStockOptionsExercised" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingTermAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingTermAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingTermAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:title="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingTermAbstract" xlink:to="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingTermAbstract to SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingTermAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingTermAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingTermAbstract" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingTermAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="SharePrice" xlink:title="SharePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:to="SharePrice" xlink:title="presentation: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract to SharePrice" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="presentation: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:title="presentation: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:title="presentation: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="presentation: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:title="presentation: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:title="presentation: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/StockbasedCompensationOutstandingAndExercisableOptionsUnderStockBasedCompensationPlansDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="RangeAxis" xlink:title="presentation: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to RangeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ExercisePriceRangeOneMember" xlink:label="ExercisePriceRangeOneMember" xlink:title="ExercisePriceRangeOneMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="ExercisePriceRangeOneMember" xlink:title="presentation: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to ExercisePriceRangeOneMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ExercisePriceRangeTwoMember" xlink:label="ExercisePriceRangeTwoMember" xlink:title="ExercisePriceRangeTwoMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="ExercisePriceRangeTwoMember" xlink:title="presentation: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to ExercisePriceRangeTwoMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ExercisePriceRangeThreeMember" xlink:label="ExercisePriceRangeThreeMember" xlink:title="ExercisePriceRangeThreeMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="ExercisePriceRangeThreeMember" xlink:title="presentation: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to ExercisePriceRangeThreeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ExercisePriceRangeFourMember" xlink:label="ExercisePriceRangeFourMember" xlink:title="ExercisePriceRangeFourMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="ExercisePriceRangeFourMember" xlink:title="presentation: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to ExercisePriceRangeFourMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ExercisePriceRangeFiveMember" xlink:label="ExercisePriceRangeFiveMember" xlink:title="ExercisePriceRangeFiveMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="ExercisePriceRangeFiveMember" xlink:title="presentation: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to ExercisePriceRangeFiveMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:title="presentation: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis to ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:title="presentation: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_OptionsOutstandingAbstract" xlink:label="OptionsOutstandingAbstract" xlink:title="OptionsOutstandingAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OptionsOutstandingAbstract" xlink:to="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:title="presentation: OptionsOutstandingAbstract to ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OptionsOutstandingAbstract" xlink:to="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:title="presentation: OptionsOutstandingAbstract to ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OptionsOutstandingAbstract" xlink:to="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:title="presentation: OptionsOutstandingAbstract to ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:title="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OptionsOutstandingAbstract" xlink:to="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:title="presentation: OptionsOutstandingAbstract to SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:title="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OptionsOutstandingAbstract" xlink:to="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:title="presentation: OptionsOutstandingAbstract to SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="OptionsOutstandingAbstract" xlink:title="presentation: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to OptionsOutstandingAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_OptionsExercisableAbstract" xlink:label="OptionsExercisableAbstract" xlink:title="OptionsExercisableAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OptionsExercisableAbstract" xlink:to="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:title="presentation: OptionsExercisableAbstract to ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:title="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OptionsExercisableAbstract" xlink:to="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:title="presentation: OptionsExercisableAbstract to SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="OptionsExercisableAbstract" xlink:title="presentation: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to OptionsExercisableAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="presentation: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/StockbasedCompensationRestrictedStockIssuancesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="RestrictedStockMember" xlink:title="RestrictedStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="RestrictedStockMember" xlink:title="presentation: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to RestrictedStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="presentation: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="AwardTypeAxis" xlink:title="presentation: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to AwardTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="ShareBasedCompensationAbstract" xlink:title="ShareBasedCompensationAbstract" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_NumberOfDirectors" xlink:label="NumberOfDirectors" xlink:title="NumberOfDirectors" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationAbstract" xlink:to="NumberOfDirectors" xlink:title="presentation: ShareBasedCompensationAbstract to NumberOfDirectors" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="presentation: ShareBasedCompensationAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:title="StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationAbstract" xlink:to="StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:title="presentation: ShareBasedCompensationAbstract to StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_VestingPercentageOfRestrictedStockUnits" xlink:label="VestingPercentageOfRestrictedStockUnits" xlink:title="VestingPercentageOfRestrictedStockUnits" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationAbstract" xlink:to="VestingPercentageOfRestrictedStockUnits" xlink:title="presentation: ShareBasedCompensationAbstract to VestingPercentageOfRestrictedStockUnits" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationAbstract" xlink:to="AllocatedShareBasedCompensationExpense" xlink:title="presentation: ShareBasedCompensationAbstract to AllocatedShareBasedCompensationExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="ShareBasedCompensationAbstract" xlink:title="presentation: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to ShareBasedCompensationAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="presentation: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/StockbasedCompensationDeferredStockUnitsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="ChiefExecutiveOfficerMember" xlink:title="ChiefExecutiveOfficerMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="ChiefExecutiveOfficerMember" xlink:title="presentation: TitleOfIndividualWithRelationshipToEntityDomain to ChiefExecutiveOfficerMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="presentation: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="TitleOfIndividualAxis" xlink:title="presentation: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to TitleOfIndividualAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" xlink:label="DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" xlink:title="DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" xlink:label="DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" xlink:title="DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredBonusMember" xlink:label="DeferredBonusMember" xlink:title="DeferredBonusMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" xlink:to="DeferredBonusMember" xlink:title="presentation: DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain to DeferredBonusMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_BonusSharesMember" xlink:label="BonusSharesMember" xlink:title="BonusSharesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" xlink:to="BonusSharesMember" xlink:title="presentation: DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain to BonusSharesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" xlink:to="DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" xlink:title="presentation: DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis to DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" xlink:title="presentation: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="ShareBasedCompensationAbstract" xlink:title="ShareBasedCompensationAbstract" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_RestrictedStockGrantsAbstract" xlink:label="RestrictedStockGrantsAbstract" xlink:title="RestrictedStockGrantsAbstract" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent" xlink:label="DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent" xlink:title="DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedStockGrantsAbstract" xlink:to="DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent" xlink:title="presentation: RestrictedStockGrantsAbstract to DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent" xlink:label="DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent" xlink:title="DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedStockGrantsAbstract" xlink:to="DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent" xlink:title="presentation: RestrictedStockGrantsAbstract to DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne" xlink:label="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne" xlink:title="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedStockGrantsAbstract" xlink:to="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne" xlink:title="presentation: RestrictedStockGrantsAbstract to DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo" xlink:label="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo" xlink:title="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedStockGrantsAbstract" xlink:to="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo" xlink:title="presentation: RestrictedStockGrantsAbstract to DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree" xlink:label="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree" xlink:title="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedStockGrantsAbstract" xlink:to="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree" xlink:title="presentation: RestrictedStockGrantsAbstract to DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFour" xlink:label="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFour" xlink:title="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFour" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedStockGrantsAbstract" xlink:to="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFour" xlink:title="presentation: RestrictedStockGrantsAbstract to DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFour" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFive" xlink:label="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFive" xlink:title="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFive" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedStockGrantsAbstract" xlink:to="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFive" xlink:title="presentation: RestrictedStockGrantsAbstract to DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFive" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="CommonStockSharesSubscribedButUnissued" xlink:title="CommonStockSharesSubscribedButUnissued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedStockGrantsAbstract" xlink:to="CommonStockSharesSubscribedButUnissued" xlink:title="presentation: RestrictedStockGrantsAbstract to CommonStockSharesSubscribedButUnissued" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:title="SharesPaidForTaxWithholdingForShareBasedCompensation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedStockGrantsAbstract" xlink:to="SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:title="presentation: RestrictedStockGrantsAbstract to SharesPaidForTaxWithholdingForShareBasedCompensation" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:title="PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedStockGrantsAbstract" xlink:to="PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:title="presentation: RestrictedStockGrantsAbstract to PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedStockGrantsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:title="presentation: RestrictedStockGrantsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSix" xlink:label="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSix" xlink:title="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSix" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedStockGrantsAbstract" xlink:to="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSix" xlink:title="presentation: RestrictedStockGrantsAbstract to DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSix" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSeven" xlink:label="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSeven" xlink:title="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSeven" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedStockGrantsAbstract" xlink:to="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSeven" xlink:title="presentation: RestrictedStockGrantsAbstract to DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSeven" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" xlink:label="DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" xlink:title="DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedStockGrantsAbstract" xlink:to="DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" xlink:title="presentation: RestrictedStockGrantsAbstract to DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued" xlink:label="DeferredCompensationArrangementWithIndividualSharesIssued" xlink:title="DeferredCompensationArrangementWithIndividualSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedStockGrantsAbstract" xlink:to="DeferredCompensationArrangementWithIndividualSharesIssued" xlink:title="presentation: RestrictedStockGrantsAbstract to DeferredCompensationArrangementWithIndividualSharesIssued" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice" xlink:label="DeferredCompensationArrangementWithIndividualExercisePrice" xlink:title="DeferredCompensationArrangementWithIndividualExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedStockGrantsAbstract" xlink:to="DeferredCompensationArrangementWithIndividualExercisePrice" xlink:title="presentation: RestrictedStockGrantsAbstract to DeferredCompensationArrangementWithIndividualExercisePrice" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:title="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedStockGrantsAbstract" xlink:to="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:title="presentation: RestrictedStockGrantsAbstract to AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedStockGrantsAbstract" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:title="presentation: RestrictedStockGrantsAbstract to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationAbstract" xlink:to="RestrictedStockGrantsAbstract" xlink:title="presentation: ShareBasedCompensationAbstract to RestrictedStockGrantsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="ShareBasedCompensationAbstract" xlink:title="presentation: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to ShareBasedCompensationAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="presentation: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedPartyDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityAbstract" xlink:label="LineOfCreditFacilityAbstract" xlink:title="LineOfCreditFacilityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="LineOfCreditFacilityTable" xlink:title="LineOfCreditFacilityTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityComponentDomain" xlink:to="CommonStockMember" xlink:title="presentation: EquityComponentDomain to CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="presentation: StatementEquityComponentsAxis to EquityComponentDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditFacilityTable" xlink:to="StatementEquityComponentsAxis" xlink:title="presentation: LineOfCreditFacilityTable to StatementEquityComponentsAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="BoardOfDirectorsChairmanMember" xlink:title="BoardOfDirectorsChairmanMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyDomain" xlink:to="BoardOfDirectorsChairmanMember" xlink:title="presentation: RelatedPartyDomain to BoardOfDirectorsChairmanMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="presentation: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditFacilityTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="presentation: LineOfCreditFacilityTable to RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="CreditFacilityAxis" xlink:title="CreditFacilityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="CreditFacilityDomain" xlink:title="CreditFacilityDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditMember" xlink:label="LineOfCreditMember" xlink:title="LineOfCreditMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CreditFacilityDomain" xlink:to="LineOfCreditMember" xlink:title="presentation: CreditFacilityDomain to LineOfCreditMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_SupplementalLineOfCreditMember" xlink:label="SupplementalLineOfCreditMember" xlink:title="SupplementalLineOfCreditMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CreditFacilityDomain" xlink:to="SupplementalLineOfCreditMember" xlink:title="presentation: CreditFacilityDomain to SupplementalLineOfCreditMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_AdditionalSupplementalLineOfCreditMember" xlink:label="AdditionalSupplementalLineOfCreditMember" xlink:title="AdditionalSupplementalLineOfCreditMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CreditFacilityDomain" xlink:to="AdditionalSupplementalLineOfCreditMember" xlink:title="presentation: CreditFacilityDomain to AdditionalSupplementalLineOfCreditMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CreditFacilityAxis" xlink:to="CreditFacilityDomain" xlink:title="presentation: CreditFacilityAxis to CreditFacilityDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditFacilityTable" xlink:to="CreditFacilityAxis" xlink:title="presentation: LineOfCreditFacilityTable to CreditFacilityAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="LongtermDebtTypeAxis" xlink:title="LongtermDebtTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="LongtermDebtTypeDomain" xlink:title="LongtermDebtTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_December2022PromissoryNoteMember" xlink:label="December2022PromissoryNoteMember" xlink:title="December2022PromissoryNoteMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongtermDebtTypeDomain" xlink:to="December2022PromissoryNoteMember" xlink:title="presentation: LongtermDebtTypeDomain to December2022PromissoryNoteMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_March2023PromissoryNoteMember" xlink:label="March2023PromissoryNoteMember" xlink:title="March2023PromissoryNoteMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongtermDebtTypeDomain" xlink:to="March2023PromissoryNoteMember" xlink:title="presentation: LongtermDebtTypeDomain to March2023PromissoryNoteMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_June2023PromissoryNoteMember" xlink:label="June2023PromissoryNoteMember" xlink:title="June2023PromissoryNoteMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongtermDebtTypeDomain" xlink:to="June2023PromissoryNoteMember" xlink:title="presentation: LongtermDebtTypeDomain to June2023PromissoryNoteMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_December2023PromissoryNoteMember" xlink:label="December2023PromissoryNoteMember" xlink:title="December2023PromissoryNoteMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongtermDebtTypeDomain" xlink:to="December2023PromissoryNoteMember" xlink:title="presentation: LongtermDebtTypeDomain to December2023PromissoryNoteMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_March24PromissoryNoteMember" xlink:label="March24PromissoryNoteMember" xlink:title="March24PromissoryNoteMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongtermDebtTypeDomain" xlink:to="March24PromissoryNoteMember" xlink:title="presentation: LongtermDebtTypeDomain to March24PromissoryNoteMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_June2024PromissoryNoteMember" xlink:label="June2024PromissoryNoteMember" xlink:title="June2024PromissoryNoteMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongtermDebtTypeDomain" xlink:to="June2024PromissoryNoteMember" xlink:title="presentation: LongtermDebtTypeDomain to June2024PromissoryNoteMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_September2024PromissoryNoteMember" xlink:label="September2024PromissoryNoteMember" xlink:title="September2024PromissoryNoteMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongtermDebtTypeDomain" xlink:to="September2024PromissoryNoteMember" xlink:title="presentation: LongtermDebtTypeDomain to September2024PromissoryNoteMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongtermDebtTypeAxis" xlink:to="LongtermDebtTypeDomain" xlink:title="presentation: LongtermDebtTypeAxis to LongtermDebtTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditFacilityTable" xlink:to="LongtermDebtTypeAxis" xlink:title="presentation: LineOfCreditFacilityTable to LongtermDebtTypeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditFacilityTable" xlink:to="RangeAxis" xlink:title="presentation: LineOfCreditFacilityTable to RangeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="FinancialInstrumentAxis" xlink:title="FinancialInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="WarrantMember" xlink:title="presentation: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to WarrantMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_WarrantOneMember" xlink:label="WarrantOneMember" xlink:title="WarrantOneMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="WarrantOneMember" xlink:title="presentation: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to WarrantOneMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_WarrantTwoMember" xlink:label="WarrantTwoMember" xlink:title="WarrantTwoMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="WarrantTwoMember" xlink:title="presentation: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to WarrantTwoMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_WarrantThreeMember" xlink:label="WarrantThreeMember" xlink:title="WarrantThreeMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="WarrantThreeMember" xlink:title="presentation: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to WarrantThreeMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_WarrantFourMember" xlink:label="WarrantFourMember" xlink:title="WarrantFourMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="WarrantFourMember" xlink:title="presentation: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to WarrantFourMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_WarrantFiveMember" xlink:label="WarrantFiveMember" xlink:title="WarrantFiveMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="WarrantFiveMember" xlink:title="presentation: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to WarrantFiveMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_WarrantSixMember" xlink:label="WarrantSixMember" xlink:title="WarrantSixMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="WarrantSixMember" xlink:title="presentation: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to WarrantSixMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_WarrantSevenMember" xlink:label="WarrantSevenMember" xlink:title="WarrantSevenMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="WarrantSevenMember" xlink:title="presentation: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to WarrantSevenMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentAxis" xlink:to="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="presentation: FinancialInstrumentAxis to TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditFacilityTable" xlink:to="FinancialInstrumentAxis" xlink:title="presentation: LineOfCreditFacilityTable to FinancialInstrumentAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="LineOfCreditFacilityLineItems" xlink:title="LineOfCreditFacilityLineItems" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_LineOfCreditRelatedPartyAbstract" xlink:label="LineOfCreditRelatedPartyAbstract" xlink:title="LineOfCreditRelatedPartyAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="LineOfCreditFacilityMaximumBorrowingCapacity" xlink:title="LineOfCreditFacilityMaximumBorrowingCapacity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditRelatedPartyAbstract" xlink:to="LineOfCreditFacilityMaximumBorrowingCapacity" xlink:title="presentation: LineOfCreditRelatedPartyAbstract to LineOfCreditFacilityMaximumBorrowingCapacity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="DebtInstrumentInterestRateIncreaseDecrease" xlink:title="DebtInstrumentInterestRateIncreaseDecrease" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditRelatedPartyAbstract" xlink:to="DebtInstrumentInterestRateIncreaseDecrease" xlink:title="presentation: LineOfCreditRelatedPartyAbstract to DebtInstrumentInterestRateIncreaseDecrease" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="DebtInstrumentMaturityDate" xlink:title="DebtInstrumentMaturityDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditRelatedPartyAbstract" xlink:to="DebtInstrumentMaturityDate" xlink:title="presentation: LineOfCreditRelatedPartyAbstract to DebtInstrumentMaturityDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="DebtInstrumentMaturityDate_2" xlink:title="DebtInstrumentMaturityDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditRelatedPartyAbstract" xlink:to="DebtInstrumentMaturityDate_2" xlink:title="presentation: LineOfCreditRelatedPartyAbstract to DebtInstrumentMaturityDate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="SharePrice" xlink:title="SharePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditRelatedPartyAbstract" xlink:to="SharePrice" xlink:title="presentation: LineOfCreditRelatedPartyAbstract to SharePrice" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="ProceedsFromLinesOfCredit" xlink:title="ProceedsFromLinesOfCredit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditRelatedPartyAbstract" xlink:to="ProceedsFromLinesOfCredit" xlink:title="presentation: LineOfCreditRelatedPartyAbstract to ProceedsFromLinesOfCredit" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditRelatedPartyAbstract" xlink:to="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="presentation: LineOfCreditRelatedPartyAbstract to ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditRelatedPartyAbstract" xlink:to="CommonStockParOrStatedValuePerShare" xlink:title="presentation: LineOfCreditRelatedPartyAbstract to CommonStockParOrStatedValuePerShare" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditRelatedPartyAbstract" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="presentation: LineOfCreditRelatedPartyAbstract to ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="DebtInstrumentInterestRateDuringPeriod" xlink:title="DebtInstrumentInterestRateDuringPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditRelatedPartyAbstract" xlink:to="DebtInstrumentInterestRateDuringPeriod" xlink:title="presentation: LineOfCreditRelatedPartyAbstract to DebtInstrumentInterestRateDuringPeriod" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditRelatedPartyAbstract" xlink:to="DebtInstrumentInterestRateStatedPercentage" xlink:title="presentation: LineOfCreditRelatedPartyAbstract to DebtInstrumentInterestRateStatedPercentage" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="DebtInstrumentInterestRateEffectivePercentage" xlink:title="DebtInstrumentInterestRateEffectivePercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditRelatedPartyAbstract" xlink:to="DebtInstrumentInterestRateEffectivePercentage" xlink:title="presentation: LineOfCreditRelatedPartyAbstract to DebtInstrumentInterestRateEffectivePercentage" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_DebtInstrumentAccruedInterest" xlink:label="DebtInstrumentAccruedInterest" xlink:title="DebtInstrumentAccruedInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditRelatedPartyAbstract" xlink:to="DebtInstrumentAccruedInterest" xlink:title="presentation: LineOfCreditRelatedPartyAbstract to DebtInstrumentAccruedInterest" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditRelatedPartyAbstract" xlink:to="ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="presentation: LineOfCreditRelatedPartyAbstract to ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditRelatedPartyAbstract" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock" xlink:title="presentation: LineOfCreditRelatedPartyAbstract to ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="WarrantsAndRightsOutstandingMaturityDate" xlink:title="WarrantsAndRightsOutstandingMaturityDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditRelatedPartyAbstract" xlink:to="WarrantsAndRightsOutstandingMaturityDate" xlink:title="presentation: LineOfCreditRelatedPartyAbstract to WarrantsAndRightsOutstandingMaturityDate" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_IssuanceOfWarrantsValue" xlink:label="IssuanceOfWarrantsValue" xlink:title="IssuanceOfWarrantsValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditRelatedPartyAbstract" xlink:to="IssuanceOfWarrantsValue" xlink:title="presentation: LineOfCreditRelatedPartyAbstract to IssuanceOfWarrantsValue" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditRelatedPartyAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="presentation: LineOfCreditRelatedPartyAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditRelatedPartyAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="presentation: LineOfCreditRelatedPartyAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditRelatedPartyAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="presentation: LineOfCreditRelatedPartyAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditRelatedPartyAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="presentation: LineOfCreditRelatedPartyAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="InterestExpense" xlink:title="InterestExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditRelatedPartyAbstract" xlink:to="InterestExpense" xlink:title="presentation: LineOfCreditRelatedPartyAbstract to InterestExpense" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditFacilityLineItems" xlink:to="LineOfCreditRelatedPartyAbstract" xlink:title="presentation: LineOfCreditFacilityLineItems to LineOfCreditRelatedPartyAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditFacilityTable" xlink:to="LineOfCreditFacilityLineItems" xlink:title="presentation: LineOfCreditFacilityTable to LineOfCreditFacilityLineItems" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditFacilityAbstract" xlink:to="LineOfCreditFacilityTable" xlink:title="presentation: LineOfCreditFacilityAbstract to LineOfCreditFacilityTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/LossPerShareDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" xlink:title="EarningsPerShareAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="WarrantMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to WarrantMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to EmployeeStockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="ConvertibleNotesPayableMember" xlink:title="ConvertibleNotesPayableMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="ConvertibleNotesPayableMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to ConvertibleNotesPayableMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditMember" xlink:label="LineOfCreditMember" xlink:title="LineOfCreditMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="LineOfCreditMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to LineOfCreditMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="ConvertiblePreferredStockMember" xlink:title="ConvertiblePreferredStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="ConvertiblePreferredStockMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to ConvertiblePreferredStockMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain" xlink:title="presentation: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="presentation: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:label="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:title="EarningsPerShareDilutedOtherDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="presentation: EarningsPerShareDilutedOtherDisclosuresAbstract to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:title="presentation: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to EarningsPerShareDilutedOtherDisclosuresAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="presentation: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="presentation: EarningsPerShareAbstract to ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/CommitmentsAndContingenciesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="LesseeLeaseDescriptionTable" xlink:title="LesseeLeaseDescriptionTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="GeneralAndAdministrativeExpenseMember" xlink:title="GeneralAndAdministrativeExpenseMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationDomain" xlink:to="GeneralAndAdministrativeExpenseMember" xlink:title="presentation: IncomeStatementLocationDomain to GeneralAndAdministrativeExpenseMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="presentation: IncomeStatementLocationAxis to IncomeStatementLocationDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionTable" xlink:to="IncomeStatementLocationAxis" xlink:title="presentation: LesseeLeaseDescriptionTable to IncomeStatementLocationAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="LesseeLeaseDescriptionLineItems" xlink:title="LesseeLeaseDescriptionLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:label="LesseeOperatingLeaseDescriptionAbstract" xlink:title="LesseeOperatingLeaseDescriptionAbstract" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_NumberOfOperatingLeases" xlink:label="NumberOfOperatingLeases" xlink:title="NumberOfOperatingLeases" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseDescriptionAbstract" xlink:to="NumberOfOperatingLeases" xlink:title="presentation: LesseeOperatingLeaseDescriptionAbstract to NumberOfOperatingLeases" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="LesseeOperatingLeaseTermOfContract" xlink:title="LesseeOperatingLeaseTermOfContract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseDescriptionAbstract" xlink:to="LesseeOperatingLeaseTermOfContract" xlink:title="presentation: LesseeOperatingLeaseDescriptionAbstract to LesseeOperatingLeaseTermOfContract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_FreeRentPeriod" xlink:label="FreeRentPeriod" xlink:title="FreeRentPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseDescriptionAbstract" xlink:to="FreeRentPeriod" xlink:title="presentation: LesseeOperatingLeaseDescriptionAbstract to FreeRentPeriod" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecurityDeposit" xlink:label="SecurityDeposit" xlink:title="SecurityDeposit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseDescriptionAbstract" xlink:to="SecurityDeposit" xlink:title="presentation: LesseeOperatingLeaseDescriptionAbstract to SecurityDeposit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="OperatingLeaseCost" xlink:title="OperatingLeaseCost" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseDescriptionAbstract" xlink:to="OperatingLeaseCost" xlink:title="presentation: LesseeOperatingLeaseDescriptionAbstract to OperatingLeaseCost" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="OperatingLeaseRightOfUseAsset" xlink:title="OperatingLeaseRightOfUseAsset" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseDescriptionAbstract" xlink:to="OperatingLeaseRightOfUseAsset" xlink:title="presentation: LesseeOperatingLeaseDescriptionAbstract to OperatingLeaseRightOfUseAsset" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:label="OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:title="OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseDescriptionAbstract" xlink:to="OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:title="presentation: LesseeOperatingLeaseDescriptionAbstract to OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="OperatingLeaseLiabilityCurrent" xlink:title="OperatingLeaseLiabilityCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseDescriptionAbstract" xlink:to="OperatingLeaseLiabilityCurrent" xlink:title="presentation: LesseeOperatingLeaseDescriptionAbstract to OperatingLeaseLiabilityCurrent" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:title="OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseDescriptionAbstract" xlink:to="OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:title="presentation: LesseeOperatingLeaseDescriptionAbstract to OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="OperatingLeaseLiabilityNoncurrent" xlink:title="OperatingLeaseLiabilityNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseDescriptionAbstract" xlink:to="OperatingLeaseLiabilityNoncurrent" xlink:title="presentation: LesseeOperatingLeaseDescriptionAbstract to OperatingLeaseLiabilityNoncurrent" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:title="OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseDescriptionAbstract" xlink:to="OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:title="presentation: LesseeOperatingLeaseDescriptionAbstract to OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="LesseeOperatingLeaseRenewalTerm" xlink:title="LesseeOperatingLeaseRenewalTerm" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseDescriptionAbstract" xlink:to="LesseeOperatingLeaseRenewalTerm" xlink:title="presentation: LesseeOperatingLeaseDescriptionAbstract to LesseeOperatingLeaseRenewalTerm" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseDescriptionAbstract" xlink:title="presentation: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseDescriptionAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:title="OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsDue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="OperatingLeaseLiability" xlink:title="OperatingLeaseLiability" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="OperatingLeaseLiability" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to OperatingLeaseLiability" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:title="presentation: LesseeLeaseDescriptionLineItems to OperatingLeaseLiabilitiesPaymentsDueAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="LesseeOperatingLeaseDiscountRate" xlink:title="LesseeOperatingLeaseDiscountRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseDiscountRate" xlink:title="presentation: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseDiscountRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ClinicalTrialAndResearchContingenciesAbstract" xlink:label="ClinicalTrialAndResearchContingenciesAbstract" xlink:title="ClinicalTrialAndResearchContingenciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ContractCancelationNoticePeriod" xlink:label="ContractCancelationNoticePeriod" xlink:title="ContractCancelationNoticePeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClinicalTrialAndResearchContingenciesAbstract" xlink:to="ContractCancelationNoticePeriod" xlink:title="presentation: ClinicalTrialAndResearchContingenciesAbstract to ContractCancelationNoticePeriod" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:label="LossContingencyEstimateOfPossibleLoss" xlink:title="LossContingencyEstimateOfPossibleLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClinicalTrialAndResearchContingenciesAbstract" xlink:to="LossContingencyEstimateOfPossibleLoss" xlink:title="presentation: ClinicalTrialAndResearchContingenciesAbstract to LossContingencyEstimateOfPossibleLoss" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyRangeOfPossibleLossPortionNotAccrued" xlink:label="LossContingencyRangeOfPossibleLossPortionNotAccrued" xlink:title="LossContingencyRangeOfPossibleLossPortionNotAccrued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClinicalTrialAndResearchContingenciesAbstract" xlink:to="LossContingencyRangeOfPossibleLossPortionNotAccrued" xlink:title="presentation: ClinicalTrialAndResearchContingenciesAbstract to LossContingencyRangeOfPossibleLossPortionNotAccrued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="ClinicalTrialAndResearchContingenciesAbstract" xlink:title="presentation: LesseeLeaseDescriptionLineItems to ClinicalTrialAndResearchContingenciesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionTable" xlink:to="LesseeLeaseDescriptionLineItems" xlink:title="presentation: LesseeLeaseDescriptionTable to LesseeLeaseDescriptionLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="LesseeLeaseDescriptionTable" xlink:title="presentation: CommitmentsAndContingenciesDisclosureAbstract to LesseeLeaseDescriptionTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/CommitmentsAndContingenciesDetailsCalc2" />
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/GalectinSciencesLlcDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesAbstract" xlink:label="InvestmentsInAndAdvancesToAffiliatesAbstract" xlink:title="InvestmentsInAndAdvancesToAffiliatesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInvestmentsTable" xlink:label="ScheduleOfInvestmentsTable" xlink:title="ScheduleOfInvestmentsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis" xlink:label="OwnershipAxis" xlink:title="OwnershipAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain" xlink:label="OwnershipDomain" xlink:title="OwnershipDomain" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_GalectinSciencesLLCMember" xlink:label="GalectinSciencesLLCMember" xlink:title="GalectinSciencesLLCMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OwnershipDomain" xlink:to="GalectinSciencesLLCMember" xlink:title="presentation: OwnershipDomain to GalectinSciencesLLCMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OwnershipAxis" xlink:to="OwnershipDomain" xlink:title="presentation: OwnershipAxis to OwnershipDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInvestmentsTable" xlink:to="OwnershipAxis" xlink:title="presentation: ScheduleOfInvestmentsTable to OwnershipAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="CounterpartyNameAxis" xlink:title="CounterpartyNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain" xlink:title="RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_SBHSciencesIncMember" xlink:label="SBHSciencesIncMember" xlink:title="SBHSciencesIncMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RepurchaseAgreementCounterpartyNameDomain" xlink:to="SBHSciencesIncMember" xlink:title="presentation: RepurchaseAgreementCounterpartyNameDomain to SBHSciencesIncMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain" xlink:title="presentation: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInvestmentsTable" xlink:to="CounterpartyNameAxis" xlink:title="presentation: ScheduleOfInvestmentsTable to CounterpartyNameAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="InProcessResearchAndDevelopmentMember" xlink:title="InProcessResearchAndDevelopmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="InProcessResearchAndDevelopmentMember" xlink:title="presentation: FiniteLivedIntangibleAssetsMajorClassNameDomain to InProcessResearchAndDevelopmentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="presentation: FiniteLivedIntangibleAssetsByMajorClassAxis to FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInvestmentsTable" xlink:to="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="presentation: ScheduleOfInvestmentsTable to FiniteLivedIntangibleAssetsByMajorClassAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems" xlink:label="InvestmentsInAndAdvancesToAffiliatesLineItems" xlink:title="InvestmentsInAndAdvancesToAffiliatesLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract" xlink:label="InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract" xlink:title="InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="PaymentsToAcquireEquityMethodInvestments" xlink:title="PaymentsToAcquireEquityMethodInvestments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract" xlink:to="PaymentsToAcquireEquityMethodInvestments" xlink:title="presentation: InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract to PaymentsToAcquireEquityMethodInvestments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure" xlink:label="InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure" xlink:title="InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract" xlink:to="InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure" xlink:title="presentation: InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract to InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="MinorityInterestOwnershipPercentageByParent" xlink:title="MinorityInterestOwnershipPercentageByParent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract" xlink:to="MinorityInterestOwnershipPercentageByParent" xlink:title="presentation: InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract to MinorityInterestOwnershipPercentageByParent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract" xlink:to="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:title="presentation: InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract to CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_CapitalContributionExpense" xlink:label="CapitalContributionExpense" xlink:title="CapitalContributionExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract" xlink:to="CapitalContributionExpense" xlink:title="presentation: InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract to CapitalContributionExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="IncomeLossFromEquityMethodInvestments" xlink:title="IncomeLossFromEquityMethodInvestments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract" xlink:to="IncomeLossFromEquityMethodInvestments" xlink:title="presentation: InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract to IncomeLossFromEquityMethodInvestments" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_NonCashChargeForResearchAndDevelopmentInProcess" xlink:label="NonCashChargeForResearchAndDevelopmentInProcess" xlink:title="NonCashChargeForResearchAndDevelopmentInProcess" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract" xlink:to="NonCashChargeForResearchAndDevelopmentInProcess" xlink:title="presentation: InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract to NonCashChargeForResearchAndDevelopmentInProcess" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentsInAndAdvancesToAffiliatesLineItems" xlink:to="InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract" xlink:title="presentation: InvestmentsInAndAdvancesToAffiliatesLineItems to InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInvestmentsTable" xlink:to="InvestmentsInAndAdvancesToAffiliatesLineItems" xlink:title="presentation: ScheduleOfInvestmentsTable to InvestmentsInAndAdvancesToAffiliatesLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentsInAndAdvancesToAffiliatesAbstract" xlink:to="ScheduleOfInvestmentsTable" xlink:title="presentation: InvestmentsInAndAdvancesToAffiliatesAbstract to ScheduleOfInvestmentsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/IncomeTaxesComponentsOfNetDeferredTaxAssetsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:label="DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:title="DeferredTaxAssetsNetOfValuationAllowanceAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="DeferredTaxAssetsOperatingLossCarryforwards" xlink:title="DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="DeferredTaxAssetsOperatingLossCarryforwards" xlink:title="presentation: DeferredTaxAssetsNetOfValuationAllowanceAbstract to DeferredTaxAssetsOperatingLossCarryforwards" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="DeferredTaxAssetsTaxCreditCarryforwards" xlink:title="DeferredTaxAssetsTaxCreditCarryforwards" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="DeferredTaxAssetsTaxCreditCarryforwards" xlink:title="presentation: DeferredTaxAssetsNetOfValuationAllowanceAbstract to DeferredTaxAssetsTaxCreditCarryforwards" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="DeferredTaxAssetsOther" xlink:title="DeferredTaxAssetsOther" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="DeferredTaxAssetsOther" xlink:title="presentation: DeferredTaxAssetsNetOfValuationAllowanceAbstract to DeferredTaxAssetsOther" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="DeferredTaxAssetsGross" xlink:title="DeferredTaxAssetsGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="DeferredTaxAssetsGross" xlink:title="presentation: DeferredTaxAssetsNetOfValuationAllowanceAbstract to DeferredTaxAssetsGross" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="DeferredTaxAssetsValuationAllowance" xlink:title="DeferredTaxAssetsValuationAllowance" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="DeferredTaxAssetsValuationAllowance" xlink:title="presentation: DeferredTaxAssetsNetOfValuationAllowanceAbstract to DeferredTaxAssetsValuationAllowance" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="DeferredTaxAssetsNet" xlink:title="DeferredTaxAssetsNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="DeferredTaxAssetsNet" xlink:title="presentation: DeferredTaxAssetsNetOfValuationAllowanceAbstract to DeferredTaxAssetsNet" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:title="presentation: IncomeTaxDisclosureAbstract to DeferredTaxAssetsNetOfValuationAllowanceAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/IncomeTaxesPrimaryFactorsAffectingIncomeTaxRatesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:title="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:title="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:title="presentation: EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract to EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:title="EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:title="presentation: EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract to EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:title="EffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:title="presentation: EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract to EffectiveIncomeTaxRateReconciliationNondeductibleExpense" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:title="EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:title="presentation: EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract to EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:title="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:title="presentation: EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract to EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="EffectiveIncomeTaxRateContinuingOperations" xlink:title="EffectiveIncomeTaxRateContinuingOperations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="EffectiveIncomeTaxRateContinuingOperations" xlink:title="presentation: EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract to EffectiveIncomeTaxRateContinuingOperations" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:title="presentation: IncomeTaxDisclosureAbstract to EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="OperatingLossCarryforwardsTable" xlink:title="OperatingLossCarryforwardsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="IncomeTaxAuthorityAxis" xlink:title="IncomeTaxAuthorityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="IncomeTaxAuthorityDomain" xlink:title="IncomeTaxAuthorityDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="DomesticCountryMember" xlink:title="DomesticCountryMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxAuthorityDomain" xlink:to="DomesticCountryMember" xlink:title="presentation: IncomeTaxAuthorityDomain to DomesticCountryMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="StateAndLocalJurisdictionMember" xlink:title="StateAndLocalJurisdictionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxAuthorityDomain" xlink:to="StateAndLocalJurisdictionMember" xlink:title="presentation: IncomeTaxAuthorityDomain to StateAndLocalJurisdictionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxAuthorityAxis" xlink:to="IncomeTaxAuthorityDomain" xlink:title="presentation: IncomeTaxAuthorityAxis to IncomeTaxAuthorityDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLossCarryforwardsTable" xlink:to="IncomeTaxAuthorityAxis" xlink:title="presentation: OperatingLossCarryforwardsTable to IncomeTaxAuthorityAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="TaxPeriodAxis" xlink:title="TaxPeriodAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="TaxPeriodDomain" xlink:title="TaxPeriodDomain" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ExpiringAsAResultOf2017TaxActMember" xlink:label="ExpiringAsAResultOf2017TaxActMember" xlink:title="ExpiringAsAResultOf2017TaxActMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxPeriodDomain" xlink:to="ExpiringAsAResultOf2017TaxActMember" xlink:title="presentation: TaxPeriodDomain to ExpiringAsAResultOf2017TaxActMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ExpiringThrough2037Member" xlink:label="ExpiringThrough2037Member" xlink:title="ExpiringThrough2037Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxPeriodDomain" xlink:to="ExpiringThrough2037Member" xlink:title="presentation: TaxPeriodDomain to ExpiringThrough2037Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxPeriodAxis" xlink:to="TaxPeriodDomain" xlink:title="presentation: TaxPeriodAxis to TaxPeriodDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLossCarryforwardsTable" xlink:to="TaxPeriodAxis" xlink:title="presentation: OperatingLossCarryforwardsTable to TaxPeriodAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="OperatingLossCarryforwardsLineItems" xlink:title="OperatingLossCarryforwardsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:title="CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="OperatingLossCarryforwards" xlink:title="OperatingLossCarryforwards" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="OperatingLossCarryforwards" xlink:title="presentation: CurrentFederalStateAndLocalTaxExpenseBenefitAbstract to OperatingLossCarryforwards" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_DeferredTaxAssetsValuationAllowancePercentage" xlink:label="DeferredTaxAssetsValuationAllowancePercentage" xlink:title="DeferredTaxAssetsValuationAllowancePercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="DeferredTaxAssetsValuationAllowancePercentage" xlink:title="presentation: CurrentFederalStateAndLocalTaxExpenseBenefitAbstract to DeferredTaxAssetsValuationAllowancePercentage" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_OperatingLossCarryforwardsExpirationYear" xlink:label="OperatingLossCarryforwardsExpirationYear" xlink:title="OperatingLossCarryforwardsExpirationYear" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="OperatingLossCarryforwardsExpirationYear" xlink:title="presentation: CurrentFederalStateAndLocalTaxExpenseBenefitAbstract to OperatingLossCarryforwardsExpirationYear" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="IncomeTaxReconciliationTaxCreditsResearch" xlink:title="IncomeTaxReconciliationTaxCreditsResearch" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="IncomeTaxReconciliationTaxCreditsResearch" xlink:title="presentation: CurrentFederalStateAndLocalTaxExpenseBenefitAbstract to IncomeTaxReconciliationTaxCreditsResearch" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_FederalAndStateResearchAndDevelopmentCreditsExpirationYear" xlink:label="FederalAndStateResearchAndDevelopmentCreditsExpirationYear" xlink:title="FederalAndStateResearchAndDevelopmentCreditsExpirationYear" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="FederalAndStateResearchAndDevelopmentCreditsExpirationYear" xlink:title="presentation: CurrentFederalStateAndLocalTaxExpenseBenefitAbstract to FederalAndStateResearchAndDevelopmentCreditsExpirationYear" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:title="presentation: OperatingLossCarryforwardsLineItems to CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLossCarryforwardsTable" xlink:to="OperatingLossCarryforwardsLineItems" xlink:title="presentation: OperatingLossCarryforwardsTable to OperatingLossCarryforwardsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="OperatingLossCarryforwardsTable" xlink:title="presentation: IncomeTaxDisclosureAbstract to OperatingLossCarryforwardsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/SegmentsSignificantExpenseCategoriesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="SegmentReportingAbstract" xlink:title="SegmentReportingAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:title="ScheduleOfSegmentReportingInformationBySegmentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="StatementBusinessSegmentsAxis" xlink:title="StatementBusinessSegmentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="SegmentDomain" xlink:title="SegmentDomain" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_BusinessOperatingSegmentMember" xlink:label="BusinessOperatingSegmentMember" xlink:title="BusinessOperatingSegmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentDomain" xlink:to="BusinessOperatingSegmentMember" xlink:title="presentation: SegmentDomain to BusinessOperatingSegmentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementBusinessSegmentsAxis" xlink:to="SegmentDomain" xlink:title="presentation: StatementBusinessSegmentsAxis to SegmentDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="StatementBusinessSegmentsAxis" xlink:title="presentation: ScheduleOfSegmentReportingInformationBySegmentTable to StatementBusinessSegmentsAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="SegmentReportingInformationLineItems" xlink:title="SegmentReportingInformationLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationProfitLossAbstract" xlink:label="SegmentReportingInformationProfitLossAbstract" xlink:title="SegmentReportingInformationProfitLossAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="OperatingExpensesAbstract" xlink:title="OperatingExpensesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="ResearchAndDevelopmentExpense" xlink:title="presentation: OperatingExpensesAbstract to ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="GeneralAndAdministrativeExpense" xlink:title="presentation: OperatingExpensesAbstract to GeneralAndAdministrativeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="OperatingExpenses" xlink:title="presentation: OperatingExpensesAbstract to OperatingExpenses" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="OperatingIncomeLoss" xlink:title="presentation: OperatingExpensesAbstract to OperatingIncomeLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingInformationProfitLossAbstract" xlink:to="OperatingExpensesAbstract" xlink:title="presentation: SegmentReportingInformationProfitLossAbstract to OperatingExpensesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="NonoperatingIncomeExpenseAbstract" xlink:title="NonoperatingIncomeExpenseAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="InvestmentIncomeInterest" xlink:title="InvestmentIncomeInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="InvestmentIncomeInterest" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to InvestmentIncomeInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="InterestExpenseNonoperating" xlink:title="InterestExpenseNonoperating" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="InterestExpenseNonoperating" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to InterestExpenseNonoperating" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:label="DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:title="DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="NonoperatingIncomeExpense" xlink:title="NonoperatingIncomeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="NonoperatingIncomeExpense" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to NonoperatingIncomeExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingInformationProfitLossAbstract" xlink:to="NonoperatingIncomeExpenseAbstract" xlink:title="presentation: SegmentReportingInformationProfitLossAbstract to NonoperatingIncomeExpenseAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingInformationProfitLossAbstract" xlink:to="NetIncomeLoss" xlink:title="presentation: SegmentReportingInformationProfitLossAbstract to NetIncomeLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="PreferredStockDividendsAndOtherAdjustments" xlink:title="PreferredStockDividendsAndOtherAdjustments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingInformationProfitLossAbstract" xlink:to="PreferredStockDividendsAndOtherAdjustments" xlink:title="presentation: SegmentReportingInformationProfitLossAbstract to PreferredStockDividendsAndOtherAdjustments" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_FairValueAdjustmentOfWarrant" xlink:label="FairValueAdjustmentOfWarrant" xlink:title="FairValueAdjustmentOfWarrant" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingInformationProfitLossAbstract" xlink:to="FairValueAdjustmentOfWarrant" xlink:title="presentation: SegmentReportingInformationProfitLossAbstract to FairValueAdjustmentOfWarrant" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingInformationProfitLossAbstract" xlink:to="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="presentation: SegmentReportingInformationProfitLossAbstract to NetIncomeLossAvailableToCommonStockholdersBasic" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingInformationLineItems" xlink:to="SegmentReportingInformationProfitLossAbstract" xlink:title="presentation: SegmentReportingInformationLineItems to SegmentReportingInformationProfitLossAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="NumberOfOperatingSegments" xlink:title="NumberOfOperatingSegments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingInformationLineItems" xlink:to="NumberOfOperatingSegments" xlink:title="presentation: SegmentReportingInformationLineItems to NumberOfOperatingSegments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" xlink:title="NetCashProvidedByUsedInOperatingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingInformationLineItems" xlink:to="NetCashProvidedByUsedInOperatingActivities" xlink:title="presentation: SegmentReportingInformationLineItems to NetCashProvidedByUsedInOperatingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="SegmentReportingInformationLineItems" xlink:title="presentation: ScheduleOfSegmentReportingInformationBySegmentTable to SegmentReportingInformationLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingAbstract" xlink:to="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:title="presentation: SegmentReportingAbstract to ScheduleOfSegmentReportingInformationBySegmentTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/SegmentsSignificantAssetCategoriesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="SegmentReportingAbstract" xlink:title="SegmentReportingAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:title="ScheduleOfSegmentReportingInformationBySegmentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="StatementBusinessSegmentsAxis" xlink:title="StatementBusinessSegmentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="SegmentDomain" xlink:title="SegmentDomain" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_BusinessOperatingSegmentMember" xlink:label="BusinessOperatingSegmentMember" xlink:title="BusinessOperatingSegmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentDomain" xlink:to="BusinessOperatingSegmentMember" xlink:title="presentation: SegmentDomain to BusinessOperatingSegmentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementBusinessSegmentsAxis" xlink:to="SegmentDomain" xlink:title="presentation: StatementBusinessSegmentsAxis to SegmentDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="StatementBusinessSegmentsAxis" xlink:title="presentation: ScheduleOfSegmentReportingInformationBySegmentTable to StatementBusinessSegmentsAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="SegmentReportingInformationLineItems" xlink:title="SegmentReportingInformationLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingInformationLineItems" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="presentation: SegmentReportingInformationLineItems to CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="SegmentReportingInformationLineItems" xlink:title="presentation: ScheduleOfSegmentReportingInformationBySegmentTable to SegmentReportingInformationLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingAbstract" xlink:to="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:title="presentation: SegmentReportingAbstract to ScheduleOfSegmentReportingInformationBySegmentTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/SubsequentEventDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" xlink:title="SubsequentEventsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="SubsequentEventTable" xlink:title="SubsequentEventTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="CreditFacilityAxis" xlink:title="CreditFacilityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="CreditFacilityDomain" xlink:title="CreditFacilityDomain" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_SupplementalLineOfCreditMember" xlink:label="SupplementalLineOfCreditMember" xlink:title="SupplementalLineOfCreditMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CreditFacilityDomain" xlink:to="SupplementalLineOfCreditMember" xlink:title="presentation: CreditFacilityDomain to SupplementalLineOfCreditMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CreditFacilityAxis" xlink:to="CreditFacilityDomain" xlink:title="presentation: CreditFacilityAxis to CreditFacilityDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTable" xlink:to="CreditFacilityAxis" xlink:title="presentation: SubsequentEventTable to CreditFacilityAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="BoardOfDirectorsChairmanMember" xlink:title="BoardOfDirectorsChairmanMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyDomain" xlink:to="BoardOfDirectorsChairmanMember" xlink:title="presentation: RelatedPartyDomain to BoardOfDirectorsChairmanMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="presentation: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="presentation: SubsequentEventTable to RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityComponentDomain" xlink:to="CommonStockMember" xlink:title="presentation: EquityComponentDomain to CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="presentation: StatementEquityComponentsAxis to EquityComponentDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTable" xlink:to="StatementEquityComponentsAxis" xlink:title="presentation: SubsequentEventTable to StatementEquityComponentsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTable" xlink:to="RangeAxis" xlink:title="presentation: SubsequentEventTable to RangeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="presentation: SubsequentEventTypeDomain to SubsequentEventMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="presentation: SubsequentEventTypeAxis to SubsequentEventTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTable" xlink:to="SubsequentEventTypeAxis" xlink:title="presentation: SubsequentEventTable to SubsequentEventTypeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="SubsequentEventLineItems" xlink:title="SubsequentEventLineItems" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_LineOfCreditRelatedPartyAbstract" xlink:label="LineOfCreditRelatedPartyAbstract" xlink:title="LineOfCreditRelatedPartyAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="LineOfCreditFacilityMaximumBorrowingCapacity" xlink:title="LineOfCreditFacilityMaximumBorrowingCapacity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditRelatedPartyAbstract" xlink:to="LineOfCreditFacilityMaximumBorrowingCapacity" xlink:title="presentation: LineOfCreditRelatedPartyAbstract to LineOfCreditFacilityMaximumBorrowingCapacity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="DebtInstrumentInterestRateIncreaseDecrease" xlink:title="DebtInstrumentInterestRateIncreaseDecrease" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditRelatedPartyAbstract" xlink:to="DebtInstrumentInterestRateIncreaseDecrease" xlink:title="presentation: LineOfCreditRelatedPartyAbstract to DebtInstrumentInterestRateIncreaseDecrease" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="DebtInstrumentMaturityDate" xlink:title="DebtInstrumentMaturityDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditRelatedPartyAbstract" xlink:to="DebtInstrumentMaturityDate" xlink:title="presentation: LineOfCreditRelatedPartyAbstract to DebtInstrumentMaturityDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="SharePrice" xlink:title="SharePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditRelatedPartyAbstract" xlink:to="SharePrice" xlink:title="presentation: LineOfCreditRelatedPartyAbstract to SharePrice" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditRelatedPartyAbstract" xlink:to="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="presentation: LineOfCreditRelatedPartyAbstract to ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditRelatedPartyAbstract" xlink:to="CommonStockParOrStatedValuePerShare" xlink:title="presentation: LineOfCreditRelatedPartyAbstract to CommonStockParOrStatedValuePerShare" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="galt-20241231.xsd#galt_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditRelatedPartyAbstract" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock" xlink:title="presentation: LineOfCreditRelatedPartyAbstract to ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="WarrantsAndRightsOutstandingMaturityDate" xlink:title="WarrantsAndRightsOutstandingMaturityDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditRelatedPartyAbstract" xlink:to="WarrantsAndRightsOutstandingMaturityDate" xlink:title="presentation: LineOfCreditRelatedPartyAbstract to WarrantsAndRightsOutstandingMaturityDate" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="LineOfCreditRelatedPartyAbstract" xlink:title="presentation: SubsequentEventLineItems to LineOfCreditRelatedPartyAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTable" xlink:to="SubsequentEventLineItems" xlink:title="presentation: SubsequentEventTable to SubsequentEventLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsAbstract" xlink:to="SubsequentEventTable" xlink:title="presentation: SubsequentEventsAbstract to SubsequentEventTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 03, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-31791<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">GALECTIN THERAPEUTICS INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001133416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">04-3562325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">4960 Peachtree Industrial Blvd<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Norcross<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">GA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">30071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">678<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">620-3186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 Par Value Per Share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GALT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 112<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,180,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Cherry Bekaert LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Atlanta, Georgia<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 15,120<span></span>
</td>
<td class="nump">$ 25,660<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,132<span></span>
</td>
<td class="nump">2,050<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">17,252<span></span>
</td>
<td class="nump">27,710<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other</a></td>
<td class="nump">243<span></span>
</td>
<td class="nump">490<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">17,495<span></span>
</td>
<td class="nump">28,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">5,656<span></span>
</td>
<td class="nump">6,431<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">8,204<span></span>
</td>
<td class="nump">9,182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyCurrent', window );">Current portion of convertible notes payable and accrued interest, net of debt discounts - related party (Note 5)</a></td>
<td class="nump">21,117<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Current portion of derivative liabilities (Note 6)</a></td>
<td class="nump">369<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrent', window );">Accrued dividends payable</a></td>
<td class="nump">63<span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">35,409<span></span>
</td>
<td class="nump">15,676<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent', window );">Convertible notes payable and accrued interest, net of debt discounts - related party (Note 5)</a></td>
<td class="nump">10,733<span></span>
</td>
<td class="nump">30,902<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative liabilities (Note 6)</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">1,004<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent', window );">Borrowing and accrued interest under convertible line of credit, net of debt discount - related party (Note 10)</a></td>
<td class="nump">74,376<span></span>
</td>
<td class="nump">40,839<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">120,565<span></span>
</td>
<td class="nump">88,441<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 12)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Series C 6% super dividend redeemable convertible preferred stock; 1,000 shares authorized, 176 issued and outstanding at December 31, 2024 and 2023, redemption value: $8,018,000, liquidation value: $1,760,000 at December 31, 2024</a></td>
<td class="nump">1,723<span></span>
</td>
<td class="nump">1,723<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_UndesignatedCapitalStockValue', window );">Undesignated stock, $0.01 par value; 20,000,000 shares authorized at December 31, 2024 and 2023, 20,000,000 shares designated at December 31, 2024 and 2023, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Series A 12% convertible preferred stock; 1,742,500 shares authorized, 1,235,000 and 1,235,000 issued and outstanding at December 31, 2024 and 2023, respectively, liquidation value $1,235,000 at December 31, 2024</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 150,000,000 shares authorized at December 31, 2024 and 2023, 63,157,235 and 61,852,914 issued and outstanding at December 31, 2024 and 2023, respectively</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">296,217<span></span>
</td>
<td class="nump">291,847<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained deficit</a></td>
<td class="num">(401,572)<span></span>
</td>
<td class="num">(354,372)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' deficit</a></td>
<td class="num">(104,793)<span></span>
</td>
<td class="num">(61,964)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, redeemable convertible preferred stock and stockholders' deficit</a></td>
<td class="nump">$ 17,495<span></span>
</td>
<td class="nump">$ 28,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as borrowing and accrued interest under line of credit related party excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of current portion of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as convertible notes payable and accrued interest, net of debt discount of related party. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as convertible notes payable and accrued interest, net of debt discount of related party excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_UndesignatedCapitalStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of shares which are not designated as common stock or preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_UndesignatedCapitalStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Series C 6% super dividend redeemable convertible preferred stock, shares authorized (in shares)</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Series C 6% super dividend redeemable convertible preferred stock, shares issued (in shares)</a></td>
<td class="nump">176<span></span>
</td>
<td class="nump">176<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Series C 6% super dividend redeemable convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">176<span></span>
</td>
<td class="nump">176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAggregateAmountOfRedemptionRequirement', window );">Series C 6% super dividend redeemable convertible preferred stock, redemption value</a></td>
<td class="nump">$ 8,018,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Series C 6% super dividend redeemable convertible preferred stock liquidation value</a></td>
<td class="nump">$ 1,760,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_UndesignatedCapitalStockParValue', window );">Undesignated stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_UndesignatedCapitalStockSharesAuthorized', window );">Undesignated stock, shares authorized (in shares)</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_UndesignatedCapitalStockSharesDesignated', window );">Undesignated stock, shares designated (in shares)</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Series A 12% convertible preferred stock, shares authorized (in shares)</a></td>
<td class="nump">1,742,500<span></span>
</td>
<td class="nump">1,742,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Series A 12% convertible preferred stock, shares issued (in shares)</a></td>
<td class="nump">1,235,000<span></span>
</td>
<td class="nump">1,235,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Series A 12% convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">1,235,000<span></span>
</td>
<td class="nump">1,235,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreferenceValue', window );">Series A 12% convertible preferred stock, liquidation value</a></td>
<td class="nump">$ 1,235,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">63,157,235<span></span>
</td>
<td class="nump">61,852,914<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares)</a></td>
<td class="nump">63,157,235<span></span>
</td>
<td class="nump">61,852,914<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_UndesignatedCapitalStockParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of undesignated capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_UndesignatedCapitalStockParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_UndesignatedCapitalStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of undesignated capital stock permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_UndesignatedCapitalStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_UndesignatedCapitalStockSharesDesignated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of undesignated capital stock which are designated as common stock or preferred stock by board of directors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_UndesignatedCapitalStockSharesDesignated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreferenceValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of the difference between preference in liquidation and the par or stated values of the preferred shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreferenceValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAggregateAmountOfRedemptionRequirement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount of redemption requirements for each class or type of redeemable stock classified as temporary equity for each of the five years following the latest balance sheet date. The redemption requirement does not constitute an unconditional obligation that will be settled in a variable number of shares constituting a monetary value predominantly indexed to (a) a fixed monetary amount known at inception, (b) an amount inversely correlated with the residual value of the entity, or (c) an amount determined by reference to something other than the fair value of issuer's stock. Does not include mandatorily redeemable stock. The exception is if redemption is required upon liquidation or termination of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAggregateAmountOfRedemptionRequirement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 36,571<span></span>
</td>
<td class="nump">$ 32,130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">5,862<span></span>
</td>
<td class="nump">5,942<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">42,433<span></span>
</td>
<td class="nump">38,072<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating loss</a></td>
<td class="num">(42,433)<span></span>
</td>
<td class="num">(38,072)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">338<span></span>
</td>
<td class="nump">230<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(5,540)<span></span>
</td>
<td class="num">(2,792)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Change in fair value of derivatives</a></td>
<td class="nump">588<span></span>
</td>
<td class="num">(432)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense</a></td>
<td class="num">(4,614)<span></span>
</td>
<td class="num">(2,994)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(47,047)<span></span>
</td>
<td class="num">(41,066)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsAndOtherAdjustments', window );">Preferred stock dividends</a></td>
<td class="num">(153)<span></span>
</td>
<td class="num">(120)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_FairValueAdjustmentOfWarrant', window );">Warrant modification</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,619)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss applicable to common stockholders</a></td>
<td class="num">$ (47,200)<span></span>
</td>
<td class="num">$ (44,805)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share - basic (in dollars per share)</a></td>
<td class="num">$ (0.76)<span></span>
</td>
<td class="num">$ (0.74)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share - diluted (in dollars per share)</a></td>
<td class="num">$ (0.76)<span></span>
</td>
<td class="num">$ (0.74)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common and potential common shares outstanding - basic (in shares)</a></td>
<td class="nump">62,309<span></span>
</td>
<td class="nump">60,159<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common and potential common shares outstanding - diluted (in shares)</a></td>
<td class="nump">62,309<span></span>
</td>
<td class="nump">60,159<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_FairValueAdjustmentOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_FairValueAdjustmentOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4CC<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4CC<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsAndOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsAndOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Preferred Stock [Member] </div>
<div>Series A 12% Convertible Preferred Stock [Member]</div>
</th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Deficit [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,723<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,723<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">$ 510<span></span>
</td>
<td class="nump">$ 59<span></span>
</td>
<td class="nump">$ 275,081<span></span>
</td>
<td class="num">$ (309,567)<span></span>
</td>
<td class="num">$ (33,917)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">1,260,000<span></span>
</td>
<td class="nump">59,426,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ConvertiblePreferredStockDividends', window );">Series A 12% convertible preferred stock dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="num">(50)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ConvertiblePreferredStockDividendsShares', window );">Series A 12% convertible preferred stock dividend (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_TemporaryEquityDividends', window );">Series C super dividend redeemable convertible preferred stock dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="num">(70)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_TemporaryEquityDividendsShares', window );">Series C super dividend redeemable convertible preferred stock dividend (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of Series A Convertible Preferred to common</a></td>
<td class="num">$ (10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of Series A Convertible Preferred to common (in shares)</a></td>
<td class="num">(25,000)<span></span>
</td>
<td class="nump">4,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_StockIssuedDuringPeriodValueWarrantExercise', window );">Issuance of common stock from exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">10,031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,033<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_StockIssuedDuringPeriodSharesWarrantExercise', window );">Issuance of common stock from exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,236,204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock from exercise of stock options, net of shares withheld for exercise (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of common stock purchase warrants in connection with related party line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 671<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_WarrantModificationIncreaseDecreaseInEquityAmount', window );">Warrant modification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,619<span></span>
</td>
<td class="num">(3,619)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,315<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Stock-based compensation expense (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(41,066)<span></span>
</td>
<td class="num">(41,066)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2023</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 61<span></span>
</td>
<td class="nump">291,847<span></span>
</td>
<td class="num">(354,372)<span></span>
</td>
<td class="num">(61,964)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">1,235,000<span></span>
</td>
<td class="nump">61,852,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,723<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ConvertiblePreferredStockDividends', window );">Series A 12% convertible preferred stock dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64<span></span>
</td>
<td class="num">(64)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ConvertiblePreferredStockDividendsShares', window );">Series A 12% convertible preferred stock dividend (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_TemporaryEquityDividends', window );">Series C super dividend redeemable convertible preferred stock dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89<span></span>
</td>
<td class="num">(89)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_TemporaryEquityDividendsShares', window );">Series C super dividend redeemable convertible preferred stock dividend (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_StockIssuedDuringPeriodValueWarrantExercise', window );">Issuance of common stock from exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 428<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_StockIssuedDuringPeriodSharesWarrantExercise', window );">Issuance of common stock from exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock from exercise of stock options, net of shares withheld for exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 799<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock from exercise of stock options, net of shares withheld for exercise (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">473,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">503,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of common stock from restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">378,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of common stock purchase warrants in connection with related party line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 845<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,146<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Stock-based compensation expense (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47,047)<span></span>
</td>
<td class="num">(47,047)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2024</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 62<span></span>
</td>
<td class="nump">$ 296,217<span></span>
</td>
<td class="num">$ (401,572)<span></span>
</td>
<td class="num">$ (104,793)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2024</a></td>
<td class="nump">1,235,000<span></span>
</td>
<td class="nump">63,157,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_ConvertiblePreferredStockDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid convertible preferred stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_ConvertiblePreferredStockDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_ConvertiblePreferredStockDividendsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of Convertible preferred stock issued as dividends during the period. Excludes stock splits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_ConvertiblePreferredStockDividendsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_StockIssuedDuringPeriodSharesWarrantExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued upon the exercise of warrants during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_StockIssuedDuringPeriodSharesWarrantExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_StockIssuedDuringPeriodValueWarrantExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock issued from the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_StockIssuedDuringPeriodValueWarrantExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_TemporaryEquityDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid temporary equity dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_TemporaryEquityDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_TemporaryEquityDividendsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock issued as dividends for temporary equity during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_TemporaryEquityDividendsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_WarrantModificationIncreaseDecreaseInEquityAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in equity for Warrants classified as equity from modification.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_WarrantModificationIncreaseDecreaseInEquityAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (47,047)<span></span>
</td>
<td class="num">$ (41,066)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right to use asset</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">2,447<span></span>
</td>
<td class="nump">2,261<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Non-cash interest expense</a></td>
<td class="nump">1,100<span></span>
</td>
<td class="nump">697<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of derivatives</a></td>
<td class="num">(588)<span></span>
</td>
<td class="nump">432<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(82)<span></span>
</td>
<td class="num">(90)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInterestPayableNet', window );">Accrued interest on convertible notes payable and convertible line of credit - related party</a></td>
<td class="nump">4,440<span></span>
</td>
<td class="nump">2,097<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable, accrued expenses and other liabilities</a></td>
<td class="num">(2,074)<span></span>
</td>
<td class="nump">2,671<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash from operating activities</a></td>
<td class="num">(41,767)<span></span>
</td>
<td class="num">(32,965)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash from investing activities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Net proceeds from convertible line of credit - related party</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Net proceeds from exercise of common stock options and warrants</a></td>
<td class="nump">1,227<span></span>
</td>
<td class="nump">10,033<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash from financing activities</a></td>
<td class="nump">31,227<span></span>
</td>
<td class="nump">40,033<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(10,540)<span></span>
</td>
<td class="nump">7,068<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD</a></td>
<td class="nump">25,660<span></span>
</td>
<td class="nump">18,592<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH AND CASH EQUIVALENTS, END OF PERIOD</a></td>
<td class="nump">15,120<span></span>
</td>
<td class="nump">25,660<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>NONCASH FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Payment of preferred stock dividends in common stock</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ReclassificationOfAccruedBonusToAdditionalPaidInCapital', window );">Reclassification of accrued bonus to additional paid in capital</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit', window );">Common stock purchase warrants issued in connection with related party line of credit</a></td>
<td class="nump">$ 845<span></span>
</td>
<td class="nump">$ 671<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of common stock purchase warrants issued in connection with related party line of credit in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_ReclassificationOfAccruedBonusToAdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount reclassified from accrued compensation to excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_ReclassificationOfAccruedBonusToAdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInterestPayableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInterestPayableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business, Basis of Presentation, Liquidity, and Going Concern<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Nature of Business, Basis of Presentation, Liquidity, and Going Concern [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Nature of Business, Basis of Presentation, Liquidity, and Going Concern</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 27.05pt; vertical-align: top; font-weight: bold;">1.</td>

    <td style="width: auto; vertical-align: top;">
              <div style="font-weight: bold;">Nature of Business, Basis of Presentation, Liquidity, and Going Concern<br/>
              </div>
            </td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">Galectin Therapeutics Inc. and subsidiaries (the &#8220;Company&#8221;) is a clinical stage biopharmaceutical company that is applying its leadership in galectin science and drug
        development to create new therapies for fibrotic disease and cancer. These candidates are based on the Company&#8217;s targeting of galectin proteins which are key mediators of biologic and pathologic function. These compounds also may have application
        for drugs to treat other diseases and chronic health conditions.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">The Company was founded in July 2000, was incorporated in the State of Nevada in January 2001 under the name &#8220;Pro-Pharmaceuticals, Inc.,&#8221; and changed its name to
        &#8220;Galectin Therapeutics Inc.&#8221; on May 26, 2011.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The Company has operated at a loss since its inception and has had no revenues. The Company anticipates that losses will continue for the foreseeable future. At December 31, 2024, the company had $15,120,000 of unrestricted cash and cash equivalents available to fund future operations. As of December 31, 2024, the Company has available
          borrowings under a line of credit in the amount of $6 million provided by our chairman, Richard Uihlein, (See Notes 10). Additionally,
          in March 2025, we signed a new supplemental line of credit agreement with our chairman for an additional $5 million of available
          borrowings (See Note 16). The Company believes there is sufficient cash, including availability of the two lines of credit, to fund
          currently planned operations through August 2025. To meet its future capital needs, the Company intends to raise additional capital through debt or equity financings, collaborations, partnerships or other strategic transactions. However, there
          can be no assurance that the Company will be able to complete any such transactions on acceptable terms or otherwise. The inability of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on
          the Company&#8217;s business, results of operations and financial condition.<br/>
        </span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">The Company is subject to a number of risks similar to those of clinical stage companies, including dependence on key individuals, uncertainty of product development
        and generation of revenues, dependence on outside sources of capital, risks associated with clinical trials of products, dependence on third-party collaborators for research operations, need for regulatory approval of products, risks associated
        with protection of intellectual property, and competition with larger, better-capitalized companies. Successful completion of the Company&#8217;s development program and, ultimately, the attainment of profitable operations is dependent upon future
        events, including obtaining adequate financing to fulfill its development activities and achieving a level of revenues adequate to support the Company&#8217;s cost structure. There are no assurances that the Company will be able to obtain additional
        financing on favorable terms, or at all, or successfully market its products.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 27.05pt; vertical-align: top; font-weight: bold;">2.</td>

    <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">Summary of Significant Accounting Policies</div>
          </td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
    </div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;).</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
    </div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-style: italic;">Basis of Consolidation.</span><span style="font-family: 'Times New Roman';"> The consolidated
        financial statements include the accounts of the Company and Galectin Therapeutics Security Corp., its wholly-owned subsidiary, which was incorporated in Delaware on December 23, 2003 and Galectin Sciences LLC (see Note 13). All intercompany
        transactions have been eliminated.</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
    </div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-style: italic;">Use of Estimates.</span><span style="font-family: 'Times New Roman';"> The preparation of financial
        statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and judgments that may affect the reported amounts of assets, liabilities, equity, revenue, expenses and
        related disclosure of contingent assets and liabilities. Management&#8217;s estimates and judgments include assumptions used in stock option valuations, accrued liabilities, derivative valuations, deferred income taxes and various other assumptions that
        are believed to be reasonable under the circumstances. Actual results may differ from those estimates under different assumptions or conditions.</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
    </div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-style: italic;">Fair Value Measurements</span><span style="font-family: 'Times New Roman';">. The Company has certain
        financial assets and liabilities recorded at fair value. Fair values determined by Level 1 inputs utilize observable data such as quoted prices in active markets. Fair values determined by Level 2 inputs utilize data points other than quoted prices
        in active markets that are observable either directly or indirectly. Fair values determined by Level 3 inputs utilize unobservable data points in which there is little or no market data, which require the reporting entity to develop its own
        assumptions. The estimated value of accounts payable and accrued expenses approximates their carrying value due to their short-term nature. See</span> Footnote 6 for Fair Value of Derivatives related to Convertible Notes Payable at December 31,
      2024 and 2023, which are level 3 liabilities. </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
    </div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-style: italic;">Cash and Cash Equivalents.</span><span style="font-family: 'Times New Roman';"> The Company considers
        all highly-liquid investments with original maturities of 90 days or less at the time of acquisition to be cash equivalents. The Company had no
        cash equivalents at December 31, 2024 or 2023.</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
    </div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-style: italic;">Prepaid Expenses and Other Current Assets.</span><span style="font-family: 'Times New Roman';">
        Prepaid expenses and other assets consist principally of prepaid insurance, deposits related to the NAVIGATE trial and deferred financing costs (see Note 10).</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
    </div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-style: italic;">Property and Equipment.</span><span style="font-family: 'Times New Roman';"> Property and equipment,
        including leasehold improvements, are stated at cost, net of accumulated depreciation and amortization, and are depreciated or amortized using the straight-line method over the estimated useful lives of the related assets of generally three years for computers and office equipment, five years
        for furniture and fixtures and the shorter of the useful life or life of the lease for leasehold improvements.</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
    </div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-style: italic;">Security Deposit.</span><span style="font-family: 'Times New Roman';"> At December 31, 2024 and 2023,
        the Company had a security deposit of $6,000 for leased office space included in Prepaid Expenses and Other Current Assets.</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
    </div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-style: italic;">Long-Lived Assets.</span><span style="font-family: 'Times New Roman';"> The Company reviews all
        long-lived assets for impairment whenever events or circumstances indicate the carrying amount of such assets may not be recoverable. Recoverability of assets to be held or used is measured by comparison of the carrying value of the asset to the
        future undiscounted net cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment recognized is measured by the amount by which the carrying value of the asset exceeds the discounted future cash
        flows expected to be generated by the asset. There were no impairments of long-lived assets at December 31, 2024 or 2023.</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
    </div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-style: italic;">Accrued Expenses</span><span style="font-family: 'Times New Roman';">. As part of the process of
        preparing our consolidated financial statements, we are required to estimate accrued expenses. This process involves identifying services that third parties have performed on our behalf and estimating the level of service performed and the
        associated cost incurred on these services as of each balance sheet date in our consolidated financial statements. Examples of estimated accrued expenses include professional service fees, such as those arising from the services of attorneys and
        accountants and accrued payroll expenses. In connection with these service fees, our estimates are most affected by our understanding of the status and timing of services provided relative to the actual services incurred by the service providers.
        In the event that we do not identify certain costs that have been incurred or we under- or over-estimate the level of services or costs of such services, our reported expenses for a reporting period could be understated or overstated. The date on
        which certain services commence, the level of services performed on or before a given date, and the cost of services are often subject to our judgment. We make these judgments based upon the facts and circumstances known to us in accordance with
        accounting principles generally accepted in the U.S.</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
    </div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-style: italic;">Warrants.</span><span style="font-family: 'Times New Roman';"> The Company has issued common stock
        warrants in connection with the execution of certain equity and debt financings. The fair value of warrants is determined using the Black-Scholes option-pricing model using assumptions regarding volatility of our common share price, remaining life
        of the warrant, and risk-free interest rates at each period end. There were no warrant liabilities as of December 31, 2024 or 2023.</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
    </div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-style: italic;">Research and Development Expenses.</span><span style="font-family: 'Times New Roman';"> Research and
        development expenses, including personnel costs, allocated facility costs, lab supplies, outside services, contract laboratory costs related to manufacturing drug product, clinical trials and preclinical studies are charged to research and
        development expense as incurred. The Company accounts for nonrefundable advance payments for goods and services that will be used in future research and development activities as expense when the service has been performed or when the goods have
        been received. Our current NAVIGATE clinical trial is being supported by third-party contract research organizations, or CROs, and other vendors. We accrue expenses for clinical trial activities performed by CROs based upon the estimated amount of
        work completed on each trial. For clinical trial expenses and related expenses associated with the conduct of clinical trials, the significant factors used in estimating accruals include the number of patients enrolled, the number of active
        clinical sites, and the duration for which the patients have been enrolled in the trial. We monitor patient enrollment levels and related activities to the extent possible through internal reviews, review of contractual terms and correspondence
        with CROs. We base our estimates on the best information available at the time. We monitor patient enrollment levels and related activities to the extent possible through discussions with CRO personnel and based our estimates of clinical trial
        costs on the best information available at the time. However, additional information may become available to us which will allow us to make a more accurate estimate in future periods. In that event, we may be required to record adjustments to
        research and development expenses in future periods when the actual level of activity becomes more certain.</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
    </div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-style: italic;">Income Taxes.</span><span style="font-family: 'Times New Roman';"> The Company accounts for income
        taxes in accordance with the accounting rules that requires an asset and liability approach to accounting for income taxes based upon the future expected values of the related assets and liabilities. Deferred income tax assets and liabilities are
        determined based on the differences between the financial reporting and tax bases of assets and liabilities and for tax loss and credit carry forwards and are measured using the expected tax rates estimated to be in effect when such basis
        differences reverse. Valuation allowances are established, if necessary, to reduce the deferred tax asset to the amount that will, more likely than not, be realized.</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
    </div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-style: italic;">Concentration of Credit Risk.</span><span style="font-family: 'Times New Roman';"> Financial
        instruments that subject the Company to credit risk consist of cash and cash equivalents. The Company maintains cash and cash equivalents and certificates of deposit with well-capitalized financial institutions. At times, those amounts may exceed
        federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant credit risk beyond the normal credit risk associated with commercial banking relationships. The Company has no other
        significant concentrations of credit risk.</span></div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman';"> <br/>
      </span></div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-style: italic;">Stock-Based Compensation.</span> Stock-based compensation cost is measured at the grant date based on
      the fair value of the award and is recognized as expense over the service period, which generally represents the vesting period. For awards that have performance-based vesting conditions the Company recognizes the expense over the estimated period
      that the awards are expected to be earned. The Company generally uses the Black-Scholes option-pricing model to calculate the grant date fair value of stock options. The expense recognized over the service period is required to include an estimate of
      the awards that will be forfeited.</div>

<div><br/>
      </div>

<div style="margin: 0px 0px 0px 24.45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; text-align: left;">Recently Adopted Accounting Pronouncements</div>

<div style="margin: 0px 0px 0px 24.45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; text-align: left;"> <br/>
      </div>

<div style="margin: 0px 0px 0px 24.45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">In November 2023, the FASB issued ASU 2023-07,&#160;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span>. This guidance is intended to improve reportable segment disclosure requirements through enhanced disclosures as well as clarify that
        entities with a single reportable segment are subject to new and existing segment reporting requirements. This guidance is effective for annual periods in fiscal years beginning after December 15, 2023, and interim periods within fiscal years
        beginning after December 15, 2024, with early adoption permitted. Entities must apply this guidance on a retrospective basis. Accordingly, the Company adopted this new standard for the fiscal year ended December 31, 2024. See footnote 15 for
        segment disclosures.</div>

<div style="margin: 0px 0px 0px 24.45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"> <br/>
      </div>

<div style="margin: 0px 0px 0px 24.45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; text-align: left;">Recent Accounting Pronouncements - Yet to be Adopted</div>

<div style="margin: 0px 0px 0px 24.45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; text-align: left;"> <br/>
      </div>

<div style="margin: 0px 0px 0px 24.45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">In December 2023, the FASB issued ASU 2023-09,&#160;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span>. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate
        reconciliation and income taxes paid both in the United States and in foreign jurisdictions. This guidance is effective for fiscal years beginning after December 15, 2024 on a prospective basis, with the option to apply the standard
        retrospectively, and early adoption is permitted. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements.</div>

<div style="margin: 0px 0px 0px 24.45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"> <br/>
      </div>

<div style="margin: 0px 0px 0px 24.45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">In November 2024, the FASB issued ASU 2024-03,&#160;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</span>. The amendments in ASU 2024-03 address investor requests for more
        detailed expense information and require additional disaggregated disclosures in the notes to financial statements for certain categories of expenses that are included on the face of the income statement. This guidance is effective for fiscal years
        beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated
        financial statements.</div>

<div style="margin: 0px 0px 0px 24.45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"> <br/>
      </div>

<div style="margin: 0px 0px 0px 24.45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">In November 2024, the FASB, issued ASUS 2024-04,&#160;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Debt- Debt with Conversions and Other Option.&#160;</span>ASU 2024-04 is intended to clarify requirements for determining whether certain settlements of convertible debt instruments, including convertible debt instruments with
        cash conversion features or convertible debt instruments that are not currently convertible, should be accounted for as an induced conversion. This ASU is effective for all entities for annual reporting periods beginning after December 15, 2025,
        and interim reporting periods within those annual reporting periods, with early adoption permitted. The Company is currently evaluating the potential impact of this guidance on its disclosures.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 27.05pt; vertical-align: top; font-weight: bold;">3.</td>

    <td style="width: auto; vertical-align: top;">
              <div style="font-weight: bold;">Property and Equipment</div>
            </td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">Property and equipment consist of the following at December 31:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

<div style="margin-left: 27pt;">
        <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;"> 2024<br/>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">2023<br/>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">(in thousands)</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div style="text-indent: -16.2pt; margin-left: 16.2pt;">Leasehold improvements</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>2</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>2</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                <div style="text-indent: -16.2pt; margin-left: 16.2pt;">Computer and office equipment</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>13</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>13</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
                <div style="text-indent: -16.2pt; margin-left: 16.2pt;">Furniture and fixtures</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>59</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>59</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                <div style="text-indent: -16.2pt; margin-left: 16.2pt;">Total</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>74</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>74</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
                <div style="text-indent: -16.2pt; margin-left: 16.2pt;">Less accumulated depreciation and amortization</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>(74</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>(74</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 4px;" valign="bottom">
                <div style="text-indent: -16.2pt; margin-left: 25.2pt;">Property and equipment &#8212; net</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
         </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">Depreciation and amortization expense for the years ended December 31, 2024 and 2023 was $0 and $0, respectively.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 27.05pt; vertical-align: top; font-weight: bold;">4.</td>

    <td style="width: auto; vertical-align: top;">
              <div style="font-weight: bold;">Accrued Expenses</div>
            </td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">Accrued expenses consist of the following at December 31:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

<div style="margin-left: 27pt;">
        <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">2024</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">2023</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">(in thousands)</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Legal and accounting fees</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>74</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>40</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Accrued compensation</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>1,523</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>1,129</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Lease liability </div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>19</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>46</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Accrued research and development costs and other</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div>6,588</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div>7,967</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;"><span style="text-indent: 0pt;"><span style="-sec-ix-hidden:Fact_a8602fa8d1ea4021ae045ee98e73f8f6"><span style="-sec-ix-hidden:Fact_5c08786f5dcb4bc5a62f72d8c0d8264d">Total</span></span></span></div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>8,204</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>9,182</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
         </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes Payable - Related Party<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Convertible Notes Payable - Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Convertible Notes Payable - Related Party</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 27pt; vertical-align: top; font-weight: bold;">5.</td>

    <td style="width: auto; vertical-align: top;">
              <div style="font-weight: bold;">Convertible Notes Payable &#8211; Related Party</div>
            </td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin-left: 22.5pt; font-family: 'Times New Roman'; font-size: 10pt;">On April 16, 2021, the Company and Richard E. Uihlein entered into a debt financing arrangement whereby Mr. Uihlein loaned $10,000,000 to Company. In consideration for the loan, the Company issued a convertible promissory note (the &#8220;April 2021 Note&#8221;) in the principal amount of ten million dollars.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin-left: 22.5pt; font-family: 'Times New Roman'; font-size: 10pt;">The April 2021 Note has a maturity date of April 16, 2025,
        is prepayable at the option of the Company in whole or in part at any time and is convertible into the Company&#8217;s common stock at a conversion price equal to $5.00 per share at the option of the noteholder. The April 2021 Note bears interest at the rate of two percent (2%)
        per annum, compounded annually with an effective interest rate of approximately 3%. For the years ended December 31, 2024 and 2023,
        approximately $212,000 and $207,000,
        respectively, of interest expense was accrued and included with the principal in the financial statements.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin-left: 22.5pt; font-family: 'Times New Roman'; font-size: 10pt;">The April 2021 Note also includes a contingent interest component that requires the Company to pay additional interest at a rate of two and one-half percent (2.5%) per quarter (10% per annum) (the
        &#8220;Additional Interest&#8221;) beginning on the date of issuance of this Note and ending on the maturity date, provided however, that such payment is only required if and only if the noteholder elects to convert the entire balance of the April 2021 Note
        into the Company&#8217;s common stock on or prior to maturity. As the contingent event is not based on creditworthiness, such feature is not clearly and closely related to the host instrument and accordingly must be bifurcated and recognized as a
        derivative liability and a debt discount on the April 2021 Note at its inception. The fair value of the contingent interest derivative liability was $420,000
        at note inception (April 16, 2021). The fair value of the contingent interest derivative liability was $47,000 and $431,000 and December 31, 2024 and 2023, respectively, and is recognized as a derivative liability in the consolidated balance sheet. The change in the
        fair value of the derivative liability for the years ended December 31, 2024 and 2023 of ($384,000) and $182,000, respectively, was charged to other expense/(income) for the years ended December 31, 2024 and 2023. The amortization of the original $420,000 debt discount of $105,000 and $105,000 was recorded as additional interest expense for the years ended December 31, 2024 and 2023, respectively.</div>

<div style="margin-left: 22.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-family: 'Times New Roman';"><br/>
        </span></div>

<div style="margin-left: 22.5pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman';">On May 14, 2024, Mr. Uihlein, as holder of the April 2021 Note irrevocably elected to convert the entire principal amount
          of such note, plus accrued and unpaid interest, into shares of common stock of the Company at a price of $5.00 per share, effective as
          of April 16, 2025, which is the maturity date of the April 2021 Note. The April 2021 Note will remain outstanding and accrue interest
          until maturity and no shares of common stock will be issued as a result of this election until April 16, 2025. As a result, the
          principal, plus accrued interest and related derivative liability are included in noncurrent liabilities at December 31, 2024.</span> </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin-left: 22.5pt; font-family: 'Times New Roman'; font-size: 10pt;">On September 17, 2021, the Company and Mr. Uihlein entered into a loan agreement in the aggregate of $20,000,000 (the &#8220;Loan Agreement&#8221;) to be funded in two closings
        and evidenced by two separate unsecured convertible promissory notes.&#160; The first of the two promissory notes was also executed and delivered on September 17, 2021, (the &#8220;September 2021 Note&#8221;) to evidence the first loan in the principal amount of $10,000,000.&#160; The second closing under the Loan Agreement for the remaining $10,000,000 occurred on December 20, 2021.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin-left: 22.5pt; font-family: 'Times New Roman'; font-size: 10pt;">The September 2021 Note has a maturity date of September 17, 2025,
        is prepayable at the option of the Company in whole or in part at any time and is convertible into the Company&#8217;s common stock at a conversion price equal to $8.64 per share at the option of the noteholder. The September 2021 Note bears interest at the rate of two percent (2%)
        per annum, compounded annually with an effective interest rate of approximately 3%. For the years ended December 31, 2024 and 2023,
        approximately $210,000 and $206,000,
        respectively, of interest expense was accrued and included with the principal in the financial statements.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin-left: 22.5pt; font-family: 'Times New Roman'; font-size: 10pt;">The September 2021 Note also includes a contingent interest component that requires the Company to pay additional interest at a rate of two and one-half percent (2.5%) per quarter (10% per annum) (the
        &#8220;Additional Interest&#8221;) beginning on the date of issuance of this Note and ending on the maturity date, provided however, that such payment is only required if and only if the noteholder elects to convert the entire balance of the September 2021
        Note into the Company&#8217;s common stock on or prior to maturity. As the contingent event is not based on creditworthiness, such feature is not clearly and closely related to the host instrument and accordingly must be bifurcated and recognized as a
        derivative liability and a debt discount on the September Note at its inception. The fair value of the contingent interest derivative liability was $433,000
        at note inception (September 17, 2021). The fair value of the contingent interest derivative liability was $94,000 and $169,000 and December 31, 2024 and 2023, respectively, and is recognized as a derivative liability in the consolidated balance sheet. The change in the
        fair value of the derivative liability for the years ended December 31, 2024 and 2023 of ($75,000) and $60,000, respectively, was recorded to other expense/(income) for the years ended December 31, 2024 and 2023. The amortization of the original $433,000 debt discount of $108,000 and $108,000 was recorded as additional interest expense for the years ended December 31, 2024 and 2023, respectively.</div>

<div style="margin-left: 22.5pt; font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin-left: 22.5pt; font-family: 'Times New Roman'; font-size: 10pt;">On December 20, 2021, the second of the two promissory
        notes under the Loan Agreement was executed and delivered, (the &#8220;December 2021 Note&#8221;) to evidence the second loan in the principal amount of $10,000,000.&#160;























































































        The December 2021 Note has a maturity date of December 20, 2025, is prepayable at the option of the Company in whole or in part at any
        time and is convertible into the Company&#8217;s common stock at a conversion price equal to $5.43 per share at the option of the noteholder.
        The December Note bears interest at the rate of two percent (2%) per annum, compounded annually with an effective interest rate of
        approximately 3%. For the years ended December 31, 2024 and 2023, approximately $209,000 and $204,000, respectively, of interest expense was accrued and
        included with the principal in the financial statements.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin-left: 22.5pt; font-family: 'Times New Roman'; font-size: 10pt;">The December 2021 Note also includes a contingent interest component that requires the Company to pay additional interest at a rate of two and one-half percent (2.5%) per quarter (10% per annum) (the
        &#8220;Additional Interest&#8221;) beginning on the date of issuance of this Note and ending on the maturity date, provided however, that such payment is only required if and only if the noteholder elects to convert the entire balance of the December 2021 Note
        into the Company&#8217;s common stock on or prior to maturity. As the contingent event is not based on creditworthiness, such feature is not clearly and closely related to the host instrument and accordingly must be bifurcated and recognized as a
        derivative liability and a debt discount on the December Note at its inception. The fair value of the contingent interest derivative liability was $415,000
        at note inception (December 20, 2021). The fair value of the contingent interest derivative liability was $275,000 and $404,000 at December 31, 2024 and 2023, respectively, and is recognized as a derivative liability in the consolidated balance sheet. The change in the
        fair value of the derivative liability for the years ended December 31, 2024 and 2023 of ($129,000) and $190,000, respectively was recorded to other expense/(income) for the years ended December 31, 2024 and 2023. The amortization of the original $415,000 debt discount of $104,000 and $104,000 was recorded as additional interest expense for the years ended December 31, 2024 and 2023, respectively.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin-left: 22.5pt; font-family: 'Times New Roman'; font-size: 10pt;">The Company&#8217;s contractual cash obligations related to the outstanding convertible notes payable is a repayment of the repayment of the September 2021 Note of the $10,000,000 plus accrued interest on September 17, 2025 and a repayment of the December 2021 Note of the $10,000,000 plus accrued interest on December 30, 2025, unless converted at the option of the noteholder.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value of Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 27pt; vertical-align: top; font-weight: bold;">6.</td>

    <td style="width: auto; vertical-align: top;">
              <div style="font-weight: bold;">Fair Value of Financial Instruments</div>
            </td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin: 0px 0px 0px 27pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">There were no level 1 or 2 assets or liabilities at December 31, 2024 or 2023.<br/>
        </span> </div>

<div style="margin: 0px 0px 0px 27pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span><br/>
      </div>

<div style="margin-left: 27pt; font-family: 'Times New Roman'; font-size: 10pt;">Level 3 assets and liabilities measured and recorded at fair value on a recurring basis at December 31, 2024 and 2023 were as follows:</div>

<div style="margin-left: 27pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

<div style="margin-left: 27pt;">
        <table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;">


  <tr>

    <td colspan="1" style="vertical-align: bottom; padding-left: 17%; padding-bottom: 2px;" valign="bottom">
                <div style="text-align: center; margin-left: 27pt;"><br/>
                </div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">December 31, 2024<br/>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">December 31, 2023<br/>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 68.7%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Derivative Liability &#8211; Contingent Interest April Note</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.22%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.22%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.94%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>47,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.22%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.22%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.22%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.94%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>431,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.22%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 68.7%;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Derivative Liability &#8211; Contingent Interest September Note</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.22%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.22%; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.94%; white-space: nowrap;" valign="bottom">
                <div>94,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.22%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.22%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.22%; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.94%; white-space: nowrap;" valign="bottom">
                <div>169,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.22%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 68.7%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Derivative Liability &#8211; Contingent Interest December Note</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.22%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.22%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.94%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>275,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.22%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.22%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.22%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.94%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>404,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.22%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
         </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin-left: 27pt; font-family: 'Times New Roman'; font-size: 10pt;">The April 2021 Note derivative liability &#8211; contingent interest was valued using a Monte Carlo Geometric Brownian Stock Path Model. The key assumptions used in the model
        at December 31, 2024 and 2023 are as follows:</div>

<div style="margin-left: 27pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

<div style="margin-left: 27pt;">
        <table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; width: 70%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                <div style="text-align: center; font-weight: bold;">December 31, 2024<br/>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">December 31, 2023</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 70%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Stock Price</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>1.29</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>1.66</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 70%;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Conversion Price of conversion feature</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom">
                <div>5.00</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom">
                <div>5.00</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 70%;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Term</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman'; text-indent: 25pt; text-align: right;"><span style="font-family: 'Times New Roman'; color: rgb(0, 255, 0);"> <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="text-indent: 0pt;">0.29</span> years</span><br/>
                  </span></div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="text-align: right;">1.29 years<br/>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 70%;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Risk Free Interest Rate</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';">4.37</span></div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';">%</span></div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';">4.79</span></div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';">%</span></div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 70%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Credit Adjusted Discount Rate</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';">12.43</span></div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';">%</span></div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';">12.86</span></div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';">%</span></div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 70%;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Volatility</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom">
                <div>152</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div>%</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom">
                <div>69</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div>%</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 70%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Dividend Rate</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>0</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>%</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>0</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>%</div>
              </td>

  </tr>


</table>
         </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin-left: 27pt; font-family: 'Times New Roman'; font-size: 10pt;">The roll forward of the April 2021 Note derivative liability &#8211; contingent interest is as follows:</div>

<div style="margin-left: 27pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

<div style="margin-left: 27pt;">
        <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;">


  <tr>

    <td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Balance &#8211; December 31, <span style="text-indent: 0pt;">2022</span></div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>249,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; padding-bottom: 2px;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Fair Value Adjustment</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div>182,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Balance &#8211; December 31, <span style="text-indent: 0pt;">2023</span></div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>431,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 2px;" valign="bottom">Fair Value Adjustment</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">(384,000</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">Balance &#8211; December 31, 2024</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">47,000</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

      </div>

<div style="margin-left: 27pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

<div style="margin-left: 27pt; font-family: 'Times New Roman'; font-size: 10pt;">The September 2021 Note derivative liability &#8211; contingent interest was valued using a Monte Carlo Geometric Brownian Stock Path Model. The key assumptions used in the
        model at inception, and at December 31, 2024 and 2023 are as follows:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin-left: 27pt;">
        <table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; width: 70%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                <div style="font-weight: bold;">December 31, 2024<br/>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div style="font-weight: bold;">December 31, 2023</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 70%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Stock Price</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>1.29</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>1.66</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 70%;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Conversion Price of conversion feature</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom">
                <div>8.64</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom">
                <div>8.64</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 70%;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Term</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">0.72
                years<br/>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">1.72
                years</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 70%;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Risk Free Interest Rate</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';">4.16</span></div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';">%</span></div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';">4.23</span></div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';">%</span></div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 70%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Credit Adjusted Discount Rate</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';">12.43</span></div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';">%</span></div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';">12.86</span></div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';">%</span></div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 70%;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Volatility</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom">
                <div>111</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div>%</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom">
                <div>75</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div>%</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 70%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Dividend Rate</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>0</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>%</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>0</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>%</div>
              </td>

  </tr>


</table>
         </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin-left: 27pt; font-family: 'Times New Roman'; font-size: 10pt;">The roll forward of the September 2021 Note derivative liability &#8211; contingent interest is as follows:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin-left: 27pt;">
        <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;">


  <tr>

    <td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Balance &#8211; December 31, <span style="text-indent: 0pt;">2022</span></div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>109,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; padding-bottom: 2px;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Fair Value Adjustment</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div>60,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Balance &#8211; December 31, <span style="text-indent: 0pt;">2023</span></div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>169,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 2px;" valign="bottom">Fair Value Adjustment</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">(75,000</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">Balance &#8211; December 31, 2024</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">94,000</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

      </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin-left: 27pt; font-family: 'Times New Roman'; font-size: 10pt;">The December 2021 Note derivative liability &#8211; contingent interest was valued using a Monte Carlo Geometric Brownian Stock Path Model. The key assumptions used in the
        model at inception, and at December 31, 2024 and 2023 are as follows:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin-left: 27pt;">
        <table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; width: 70%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                <div style="font-weight: bold;">December 31, 2024<br/>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div style="font-weight: bold;">December 31, 2023</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 70%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Stock Price</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>1.29</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>1.66</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 70%;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Conversion Price of conversion feature</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom">
                <div>5.43</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom">
                <div>5.43</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 70%;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Term</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman'; text-indent: 25pt; text-align: right;"><span style="font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="text-indent: 0pt;">0.97</span> years</span></div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="text-indent: 14pt;"><span style="text-indent: 0pt;">1.97</span> years</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 70%;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Risk Free Interest Rate</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';">4.16</span></div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';">%</span></div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';">4.23</span></div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';">%</span></div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 70%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Credit Adjusted Discount Rate</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';">12.43</span></div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';">%</span></div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';">12.86</span></div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';">%</span></div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 70%;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Volatility</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom">
                <div>102</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div>%</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom">
                <div>72</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div>%</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 70%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Dividend Rate</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>0</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>%</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>0</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>%</div>
              </td>

  </tr>


</table>
         </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin-left: 27pt; font-family: 'Times New Roman'; font-size: 10pt;">The roll forward of the December 2021 Note derivative liability &#8211; contingent interest is as follows:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin-left: 27pt;">
          <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;">


  <tr>

    <td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Balance &#8211; December 31, <span style="text-indent: 0pt;">2022</span></div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>214,000</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; padding-bottom: 2px;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Fair Value Adjustment</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div>190,000</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div></div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Balance &#8211; December 31, <span style="text-indent: 0pt;">2023</span></div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>404,000</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 2px;" valign="bottom">Fair Value Adjustment</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">(129,000</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">Balance &#8211; December 31, 2024</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">275,000</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
        </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 24.5pt; vertical-align: top; font-weight: bold;">7.</td>

    <td style="width: auto; vertical-align: top;">
              <div style="font-weight: bold;">Stockholders&#8217; Equity</div>
            </td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">At December 31, 2024, the Company had 150,000,000
        shares of common stock and 20,000,000 undesignated shares authorized. As of December 31, 2024, 1,742,500 shares have been designated for Series A 12% Convertible Preferred Stock, 900,000 shares have been designated for Series B-1 Convertible Preferred Stock, 2,100,000
        shares have been designated for Series B-2 Convertible Preferred Stock, 1,000 shares have been designated for Series C Super Dividend
        Convertible Preferred Stock, 2,508,000 shares have been designated for Series B-3 Convertible Preferred Stock, 12,748,500 have been designated as common stock and no shares remain undesignated. All issued and outstanding shares of Series B-1, Series B-2 and
        Series B-3 Preferred Stock were converted into Common Stock on January 19, 2019.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin-left: 24.45pt; font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">2020 At Market Issuance of Common Stock</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">On May 11, 2020, the Company entered into an At Market Issuance Sales Agreement (the &#8220;2020 At Market Agreement&#8221;) with a sales agent under which the Company may issue
        and sell shares of its common stock having an aggregate offering price of up to $40.0 million from time to time through the sales agent.
        Sales of the Company&#8217;s common stock through the sales agent, if any, will be made by any method that is deemed an &#8220;at the market&#8221; offering as defined by the U.S. Securities and Exchange Commission. The Company will pay to the sales agent a
        commission rate equal to 3.0% of the gross proceeds from the sale of any shares of common stock sold through the sales agent under the
        2020 At Market Agreement. There were no issuances of common stock under the 2020 At Market Agreement during the year ended December
        31, 2024 or 2023.<br/>
      </div>

<div><br/></div>

<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Series A 12% Convertible Preferred
        Stock &#8212; February 4, 2008 Private Placement</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">On February 4, 2008, the Company closed a private placement begun in October 2007 of its Series A 12% Convertible Preferred Stock (&#8220;Series A&#8221;) and related warrants. In this transaction, the Company sold units of securities at $6.00 per unit, each unit comprised of (i) one share of Series A Preferred,
        (ii) a warrant to purchase one share of common stock for $9.00, and (iii) a warrant to purchase one share of common stock for $12.00. Each share of the Series A is entitled to dividends at the rate of 12% per annum payable at the Company&#8217;s option in cash or shares of common stock valued at the higher of $6.00 per share or 100% of the value weighted average price of the Company&#8217;s
        share price for the 20 consecutive trading days prior to the applicable dividend payment date. Dividends are payable semi-annually on
        March 30 and September 30. The dividend paid on the initial dividend payment date is calculated from the date the Company deposited each subscription advance.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">The shares of Series A are entitled to vote as a class with the Company&#8217;s common stock and each share of Series A is convertible at any time to one-sixth of a share
        of common stock, subject to adjustment in the event of a stock dividend, stock split or combination, reclassification or similar event. The Company has the right to require conversion if the closing price of the common stock exceeds $18.00 for 15 consecutive trading days
        and a registration statement covering the resale of the shares of common stock issuable upon conversion of the Series A is then in effect. Each warrant is exercisable solely for cash beginning August 3, 2008 and expired on February 4, 2012. The
        exercise price of each warrant is adjustable in the event of a stock split or stock combination, capital reorganization, merger or similar event.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">In 2023, 25,000 shares of Series A were converted into
        4,257 shares of common stock. Prior to 2021, a total of 507,500 shares of Series A had been converted into 81,152 shares of common
        stock.</div>

<div><br/></div>

<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Series C 6% Super Dividend Redeemable
        Convertible Preferred Stock</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">On December 29, 2010, the Company designated and authorized the sale and issuance of up to 1,000 shares of Series C Super Dividend Redeemable Convertible Preferred Stock (&#8220;Series C&#8221;) with a par value of $0.01 and a stated value equal to $10,000 (the &#8220;Stated Value&#8221;).</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">On December 30, 2010, the Company sold and issued 212
        shares of Series C at a price of $10,000 per share for gross proceeds of $2,120,000. The Company incurred $47,000 of cash transaction costs resulting in
        net cash proceeds of $2,073,000. In addition, the Company issued 500 warrants exercisable at $7.20 to a placement agent which had a de minimis
        value. Additionally, in January 2011, the Company sold and issued 13 shares of Series C at a price of $10,000 per share for gross proceeds of $130,000.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">The terms of the Series C are as follows:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-style: italic;">Conversion Rights</span><span style="font-family: 'Times New Roman';">. Each holder of Series C may
          convert all, but not less than all, of his Series C shares plus accrued and unpaid dividends into Common Stock at the price of $6.00
          per share of Common Stock (&#8220;Conversion Price&#8221;), such that approximately 1,667 shares of Common Stock will be issued per each converted
          share of Series C (accrued and unpaid dividends will be issued as additional shares). At December 31, 2024 and 2023, the 176
          outstanding shares of Series C were convertible into a total of approximately 293,340 shares of Common Stock.</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">Subject to the continuing obligation to pay post conversion dividends, the Company may convert all, but not less than all, of the Series C (plus all accrued and
        unpaid dividends) into Common Stock, at the Conversion Price, upon such time that the closing price of the Common Stock is no less than $18.00
        per share for 15 consecutive trading days.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-style: italic;">Dividends</span><span style="font-family: 'Times New Roman';">. Holders of Series C shall be
          entitled to receive cumulative non-compounding dividends at the rate per share of Series C equal to the greater of (i) 6% per annum of
          the Stated Value (also defined as the &#8220;Floor&#8221;) or (ii) 2.5% of net sales until the total dividends paid is equal to the initial
          investment and 1.25% of net sales thereafter. The maximum amount each Series C shareholder will receive in dividend payments is equal
          to $100,000 (the &#8220;Maximum Payout&#8221;). For purposes of this dividend calculation, net sales shall mean gross revenues actually received by
          the Company, from the sale or licensing of the product DAVANAT<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> (GM-CT-01), less chargebacks, returns, expenses attributable to product recalls, duties, customs,
          sales tax, freight, insurance, shipping expenses, allowances and other customary deductions.</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">The dividend shall be payable in arrears semiannually on March 31 and September 30, beginning with the first such date after the original issue date; provided,
        however, that all dividends and all other distributions shall cease, and no further dividends or other distributions shall be paid, in respect of each share of Series C from and after such time that the Maximum Payout has been paid in respect of
        such share of Series C. Such dividends shall be payable at the Company&#8217;s option either in cash or in duly authorized, fully paid and non-assessable shares of Common Stock valued at the higher of (i) $3.00 per share or (ii) the average of the Common Stock trading price for the ten (10)
        consecutive trading days ending on the trading day that is immediately prior to the dividend payment date.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-style: italic;">Series C Post Conversion Dividend Right</span><span style="font-family: 'Times New Roman';">. In the
          event that any share of Series C is converted into Common Stock before the Maximum Payout is paid in respect of such converted share of Series C, then the holder shall have the right to continue to receive dividends in respect of such converted
          share of Series C equal to the remaining payout (the &#8220;Series C Preferred Stock Post Conversion Dividend Right&#8221;) which shall be equal to the Maximum Payout less the cumulative dividends received through the conversion date. One share of Series C
          Preferred Stock Post Conversion Dividend Right shall be issued for each such converted share of Series C. The holder of each Series C Preferred Stock Post Conversion Dividend Right shall receive the remaining payout on an equal basis and in
          conjunction with the then outstanding shares of Series C and all the other then outstanding Series C Post Conversion Dividend Rights, in the same manner and subject to the same terms and conditions as applicable to the payment of dividends on
          each share of Series C, except that for purposes of calculating the dividend the Floor shall not apply. The Series C Preferred Stock Post Conversion Dividend Right shall have no stated value, liquidation preference or right to any dividends or
          distributions other than the remaining payout. The Series C Preferred Stock Post Conversion Right is subject to redemption in the same manner as outstanding Series C shares.</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">At the date of issuance, the Series C have an embedded dividend right to continue to receive dividend payments after conversion to common stock (the Series C Post
        Conversion Dividend Right) which requires bifurcation. The value of this post conversion dividend right on the date of issuance was determined to be de minimis due to the fact that the payment of a dividend stream other than the 6% dividend and conversion of Series C prior to the Company achieving sales of GM-CT-01 was deemed improbable at that time. Upon a conversion of the
        Series C, the Company will be required to record a liability and the related expense during the period of conversion.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">In July 2011, 5 shares of Series C were converted into 8,334
        shares of common stock and 5 Series C Post Conversion Dividend Rights (Dividend Rights) were issued. In 2013, 24 shares of Series C were
        converted into 40,193 shares of common stock and 24 Dividend Rights were issued. In 2014, 20 shares of Series C were converted into 33,756
        shares of common stock and 20 Dividend Rights were issued. Per the terms of the Series C, these Dividend Rights shall continue to
        participate in dividends, however the Floor shall not apply. At December 31, 2016 and 2015, these Dividend Rights were determined to have a de minimis value, as the payment of a dividend is considered improbable at this time. The Company will
        continue to evaluate and assess the Series C Post Conversion Dividend Right for each reporting period.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-style: italic;">Liquidation Rights</span><span style="font-family: 'Times New Roman';">. In the event of any
          liquidation, dissolution or winding up of the Company, either voluntarily or involuntarily, the holders of Series C will receive $10,000
          per share plus accrued and unpaid dividends, payable prior and in preference to any distributions to the holders of Common Stock but after and subordinate to the Series A 12% Convertible Preferred Stock (&#8220;Series A&#8221;), Series B-1 and Series B-2, subject to the Maximum Payout.</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-style: italic;">Redemption</span><span style="font-family: 'Times New Roman';">. Upon a sale of the Company, the
          Company shall redeem all of the then outstanding shares of Series C and Series C Preferred Stock Post Conversion Rights within thirty (30)
          days after the transaction constituting the sale of the Company is closed and such closing is fully funded. The price to redeem a share of Series C and each redeemed Series C Preferred Stock Post Conversion Redemption Right shall be equal to (i)
          (A) the applicable return on investment (&#8220;ROI&#8221;) percentage, multiplied by (B) $10,000, minus (ii) the cumulative dividends received
          through the redemption date. The redemption price shall be payable at the Company&#8217;s option either in cash or in shares of common stock valued at the higher of (i) $3.00 per share or (ii) the average market price for the <span style="-sec-ix-hidden:Fact_9d42133c6fda4902871913ae7391078b">ten</span> consecutive
          trading days ending immediately prior to the date of redemption. The ROI Percentage shall mean the percentage that applies as of the redemption date, as follows:</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">ROI Percentage</span></div>

<div style="margin-left: 27pt;">
        <table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 6%; vertical-align: middle;">&#160;</td>

    <td style="width: 94%; vertical-align: middle;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>200%</div>
              </td>

    <td style="width: 94%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>before the second anniversary of the date of issuance;</div>
              </td>

  </tr>

  <tr>

    <td style="width: 6%; vertical-align: top;">
                <div>250%</div>
              </td>

    <td style="width: 94%; vertical-align: top;">
                <div>on or after the second anniversary of the date of issuance, but before the third anniversary of the date of issuance;</div>
              </td>

  </tr>

  <tr>

    <td style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="text-indent: -12pt; margin-left: 12pt;"><span style="text-indent: 0pt;">300</span>%</div>
              </td>

    <td style="width: 94%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-indent: -12pt; margin-left: 12pt;">on or after the third anniversary of the date of issuance, but before the fourth anniversary of the date of issuance;</div>
              </td>

  </tr>

  <tr>

    <td style="width: 6%; vertical-align: bottom;">
                <div style="text-indent: -12pt; margin-left: 12pt;"><span style="text-indent: 0pt;">350</span>%</div>
              </td>

    <td style="width: 94%; vertical-align: top;">
                <div style="text-indent: -12pt; margin-left: 12pt;">on or after the fourth anniversary of the date of issuance, but before the fifth anniversary of the date of issuance;</div>
              </td>

  </tr>

  <tr>

    <td style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="text-indent: -12pt; margin-left: 12pt;"><span style="text-indent: 0pt;">400</span>%</div>
              </td>

    <td style="width: 94%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-indent: -12pt; margin-left: 12pt;">on or after the fifth anniversary of the date of issuance, but before the sixth anniversary of the date of issuance;</div>
              </td>

  </tr>

  <tr>

    <td style="width: 6%; vertical-align: bottom;">
                <div style="text-indent: -12pt; margin-left: 12pt;"><span style="text-indent: 0pt;">450</span>%</div>
              </td>

    <td style="width: 94%; vertical-align: top;">
                <div style="text-indent: -12pt; margin-left: 12pt;">on or after the sixth anniversary of the date of issuance, but before the seventh anniversary of the date of issuance;</div>
              </td>

  </tr>

  <tr>

    <td style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="text-indent: -12pt; margin-left: 12pt;"><span style="text-indent: 0pt;">500</span>%</div>
              </td>

    <td style="width: 94%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-indent: -12pt; margin-left: 12pt;">on or after the seventh anniversary of the date of issuance, but before the eighth anniversary of the date of issuance; and</div>
              </td>

  </tr>

  <tr>

    <td style="width: 6%; vertical-align: bottom;">
                <div style="text-indent: -12pt; margin-left: 12pt;"><span style="text-indent: 0pt;">550</span>%</div>
              </td>

    <td style="width: 94%; vertical-align: top;">
                <div style="text-indent: -12pt; margin-left: 12pt;">on or after the eighth anniversary of the date of issuance, but before the ninth anniversary of the date of issuance.</div>
              </td>

  </tr>


</table>
      </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">Due to the redemption feature, the Company has presented the Series C outside of permanent equity, in the mezzanine of the consolidated balance sheets at December 31,
        2024 and 2023. At December 31, 2024, the Series C redemption value was $8,018,000.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-style: italic;">Voting Rights</span><span style="font-family: 'Times New Roman';">. The Series C shares have no voting rights.</span></div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_WarrantsAbstract', window );"><strong>Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_CommonStockWarrantsDisclosureTextBlock', window );">Warrants</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 27pt; vertical-align: top; font-weight: bold;">8.</td>

    <td style="width: auto; vertical-align: top;">
              <div style="font-weight: bold;">Warrants</div>
            </td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">Warrant activity is summarized as follows:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

<div style="margin-left: 27pt;">
        <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;">


  <tr>

    <td style="vertical-align: top; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom">
                <div><span style="font-weight: bold;">Warrants</span></div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="font-weight: bold;">Weighted average </div>
                <div style="font-weight: bold;">exercise price</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: top;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Outstanding at December 31, <span style="text-indent: 0pt;">2022</span></div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>11,557,964</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>4.37</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Issued</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>600,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">3.09</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Exercised</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>(2,236,204</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">4.49</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Canceled/Expired</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div>(665,267</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">4.94</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Outstanding at December 31, <span style="text-indent: 0pt;">2023</span></div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>9,256,493</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">
                <div>4.22</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Issued</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>600,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">3.70</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Exercised</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>(142,503</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">3.00</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Canceled/Expired</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div>(118,050</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">4.33</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Outstanding at December 31, <span style="text-indent: 0pt;">2024</span></div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>9,595,940</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                <div>4.21</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
      </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;<br/>
      </div>

<div><br/>
      </div>

<div style="margin-left: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">The weighted average expiration of the warrants outstanding as of December 31, 2024 is 2.2 years.</div>

<div style="margin-left: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

<div style="margin-left: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">On September 22, 2023, the Company executed an agreement with 10X Fund L.P., and 10X Capital Management LLC (which had been a related party due to having nominated a
        board member) whereby the Company extended the exercise date for a total of 5,732,253 common stock purchase warrants to the earliest of
        (a) September 30, 2026, (b) thirty days after 10X fails to vote all of the shares of common stock in the Company then owned by it in the
        manner recommended by the board of directors of the Company in any vote of the stockholders of the Company&#894; or (c) thirty days after the
        shares of common stock of the Company have a closing price of $6.00 or greater for 10 consecutive trading days. Previously, the common stock purchase warrants exercise dates would have expired at various dates from September 22, 2023 through May 10, 2025.</div>

<div style="margin-left: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

<div style="margin-left: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">Also pursuant to the terms of the agreement, the right of the 10X Fund L.P. to nominate a member of the board of directors was eliminated, and the cashless exercise
        option in certain of the common stock purchase warrants was deleted. Finally, a beneficial ownership limitation provision was added in the Series B Warrants, which would have the effect of decreasing 10X Fund&#8217;s beneficial ownership to 9.99% and would bar the voluntary exercise of any warrants that would result in 10X Fund&#8217;s ownership beyond 9.99% without at least 61 days&#8217; prior notice from 10X Fund.</div>

<div style="margin-left: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

<div style="margin-left: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">The Company has accounted for the modified terms of the warrants pursuant to ASC 815, Derivatives and Hedging, whereby the Company has recognized a deemed dividend for
        the change in fair value of the warrants immediately before and immediately after the modification. In September 2023, the Company recognized a non cash deemed dividend of $3,619,000 related to the extension of the 5,732,253 warrants. The following
        assumptions were used to value the extension of the warrants immediately before and immediately after the modification: a) immediately before the modification &#8212; an expected life range of 0 to 1.63 years, volatility range of 71% to 77%%, risk free interest rate range of 5.37% and zero dividends and&#894; b)
        immediately following the modification &#8212; an expected life of 3 years, volatility of 79%, risk free interest rate range of 4.59% and zero dividends.</div>

<div style="margin-left: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

<div style="margin-left: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">The following table summarizes information with regard to outstanding warrants issued in connection with equity and debt financings and consultants as of December 31,
        2024.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

<div style="margin-left: 27pt;">
        <table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;">


  <tr>

    <td rowspan="1" style="vertical-align: bottom; font-weight: bold; border-bottom: 2px solid rgb(0, 0, 0); text-align: left;" valign="bottom">Issued in Connection With</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: right; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">Number</div>
                <div style="text-align: center; font-weight: bold;">Outstanding<br/>
                </div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: right; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">Exercise</div>
                <div style="text-align: center; font-weight: bold;">Price</div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;Exercisable Date</td>

    <td rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;Expiration Date</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; text-align: left; width: 25.3333%; text-indent: -9pt; margin-left: 9pt; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="margin-left: 9pt"><span style="text-indent: 0pt;">February 12, 2009</span> Series B-1 Transaction $<span style="text-indent: 0pt;">3.00</span> Investor Warrants &#8211; Class B</div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>1,200,000</div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">3.00</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">February 12, 2009</td>

    <td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">September 30, 2026</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; text-align: left; width: 25.3333%; text-indent: -9pt; margin-left: 9pt;" valign="bottom">
                <div style="margin-left: 9pt"><span style="text-indent: 0pt;">May 13, 2009</span> Series B-2 Transaction $<span style="text-indent: 0pt;">3.00</span> Investor Warrants &#8211; Class B</div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">525,119</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">$ <br/>
              </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">3.00</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; white-space: nowrap;" valign="bottom">May 13, 2009</td>

    <td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; white-space: nowrap;" valign="bottom">September 30, 2026</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 25.3333%; text-indent: -9pt; margin-left: 9pt; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="margin-left: 9pt"><span style="text-indent: 0pt;">June 30, 2009</span> Series B-2 Transaction $<span style="text-indent: 0pt;">3.00</span> Investor Warrants &#8211; Class B</div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">306,547</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">$ <br/>
              </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">3.00</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">June 30, 2009</td>

    <td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">September 30, 2026</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 25.3333%; text-indent: -9pt; margin-left: 9pt;" valign="bottom">
                <div style="margin-left: 9pt"><span style="text-indent: 0pt;">August 12, 2009</span> Series B-2 Transaction $<span style="text-indent: 0pt;">3.00</span> Investor Warrants &#8211; Class B</div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">183,928</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">$ <br/>
              </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">3.00</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; white-space: nowrap;" valign="bottom">August 12, 2009</td>

    <td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; white-space: nowrap;" valign="bottom">September 30, 2026</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 25.3333%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-indent: -9pt; margin-left: 9pt;"><span style="text-indent: 0pt;">September 30, 2009</span> Series B-2 Transaction $<span style="text-indent: 0pt;">3.00</span> Investor Warrants &#8211; Class B</div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">195,922</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">$ <br/>
              </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">3.00</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">September 30, 2009</td>

    <td rowspan="1" style="vertical-align: bottom; width: 25.3333%; text-align: right; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">September 30, 2026</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 25.3333%; text-indent: -9pt; margin-left: 9pt;" valign="bottom">
                <div style="margin-left: 9pt"><span style="text-indent: 0pt;">November 4, 2009</span> Series B-2 Transaction $<span style="text-indent: 0pt;">3.00</span> Investor Warrants &#8211; Class B<br/>
                </div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">85,463</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">$ <br/>
              </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">3.00</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td rowspan="1" style="vertical-align: bottom; width: 25.3333%; text-align: right; white-space: nowrap;" valign="bottom">November 4, 2009</td>

    <td rowspan="1" style="vertical-align: bottom; width: 25.3333%; text-align: right; white-space: nowrap;" valign="bottom">September 30, 2026</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 25.3333%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="margin-left: 9pt; text-indent: -9pt;"><span style="text-indent: 0pt;">December 8, 2009</span> Series B-2 Transaction $<span style="text-indent: 0pt;">3.00</span> Investor Warrants &#8211; Class B<br/>
                </div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">110,919</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">$ <br/>
              </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">3.00</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td rowspan="1" style="vertical-align: bottom; width: 25.3333%; text-align: right; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">December 8, 2009</td>

    <td rowspan="1" style="vertical-align: bottom; width: 25.3333%; text-align: right; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">September 30, 2026</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 25.3333%;" valign="bottom">
                <div style="margin-left: 9pt; text-indent: -9pt;"><span style="text-indent: 0pt;">January 29, 2010</span> Series B-2 Transaction $<span style="text-indent: 0pt;">3.00</span> Investor Warrants &#8211; Class B<br/>
                </div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">198,664</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">$ <br/>
              </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">3.00</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td rowspan="1" style="vertical-align: bottom; width: 25.3333%; text-align: right; white-space: nowrap;" valign="bottom">January 29, 2010</td>

    <td rowspan="1" style="vertical-align: bottom; width: 25.3333%; text-align: right; white-space: nowrap;" valign="bottom">September 30, 2026</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 25.3333%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;"><span style="text-indent: 0pt;">January 29, 2010</span> Series B-2 Transaction $<span style="text-indent: 0pt;">3.00</span> Investor Warrants &#8211; Class B</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>18,003</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>3.00</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td style="vertical-align: bottom; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="text-align: right;">January 29, 2010</div>
              </td>

    <td style="vertical-align: bottom; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="text-align: right;">January 29, 2025</div>
              </td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 25.3333%;" valign="bottom">
                <div style="margin-left: 9pt; text-indent: -9pt;"><span style="text-indent: 0pt;">March 8, 2010</span> Series B-2 Transaction $<span style="text-indent: 0pt;">3.00</span> Investor Warrants &#8211; Class B<br/>
                </div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">184,132</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">$ <br/>
              </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">3.00</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td rowspan="1" style="vertical-align: bottom; width: 25.3333%; text-align: right; white-space: nowrap;" valign="bottom">March 8, 2010</td>

    <td rowspan="1" style="vertical-align: bottom; width: 25.3333%; text-align: right; white-space: nowrap;" valign="bottom">September 30, 2026</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 25.3333%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;"><span style="text-indent: 0pt;">March 8, 2010</span> Series B-2 Transaction $<span style="text-indent: 0pt;">3.00</span> Investor Warrants &#8211; Class B</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>39,202</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>3.00</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td style="vertical-align: bottom; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="text-align: right;">March 8, 2010</div>
              </td>

    <td style="vertical-align: bottom; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="text-align: right;">March 8, 2025</div>
              </td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 25.3333%;" valign="bottom">
                <div style="margin-left: 9pt; text-indent: -9pt;"><span style="text-indent: 0pt;">April 30, 2010</span> Series B-2 Transaction $<span style="text-indent: 0pt;">3.00</span> Investor Warrants &#8211; Class B<br/>
                </div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">180,689</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">$ <br/>
              </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">3.00</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td rowspan="1" style="vertical-align: bottom; width: 25.3333%; text-align: right; white-space: nowrap;" valign="bottom">April 30, 2010</td>

    <td rowspan="1" style="vertical-align: bottom; width: 25.3333%; text-align: right; white-space: nowrap;" valign="bottom">September 30, 2026</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 25.3333%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;"><span style="text-indent: 0pt;">April 30, 2010</span> Series B-2 Transaction $<span style="text-indent: 0pt;">3.00</span> Investor Warrants &#8211; Class B</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>23,503</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>3.00</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td style="vertical-align: bottom; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="text-align: right;">April 30, 2010</div>
              </td>

    <td style="vertical-align: bottom; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="text-align: right;">April 30, 2025</div>
              </td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 25.3333%;" valign="bottom">
                <div style="margin-left: 9pt; text-indent: -9pt;"><span style="text-indent: 0pt;">May 10, 2010</span> Series B-2 Transaction $<span style="text-indent: 0pt;">3.00</span> Investor Warrants &#8211; Class B<br/>
                </div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">112,631</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">$ <br/>
              </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">3.00</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td rowspan="1" style="vertical-align: bottom; width: 25.3333%; text-align: right; white-space: nowrap;" valign="bottom">May 10, 2010</td>

    <td rowspan="1" style="vertical-align: bottom; width: 25.3333%; text-align: right; white-space: nowrap;" valign="bottom">September 30, 2026</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 25.3333%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;"><span style="text-indent: 0pt;">May 10, 2010</span> Series B-2 Transaction $<span style="text-indent: 0pt;">3.00</span> Investor Warrants &#8211; Class B</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>30,535</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>3.00</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td style="vertical-align: bottom; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="text-align: right;">May 10, 2010</div>
              </td>

    <td style="vertical-align: bottom; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="text-align: right;">May 10, 2025</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 25.3333%;" valign="bottom">
                <div style="text-indent: -9pt; margin-left: 9pt;"><span style="text-indent: 0pt;">September 22, 2016</span> Series B-3 Transaction $<span style="text-indent: 0pt;">3.00</span> Investor Warrants &#8211; Class B </div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>682,572</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>3.00</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td style="vertical-align: bottom; width: 25.3333%; white-space: nowrap;" valign="bottom">
                <div style="text-align: right;">September 22, 2016</div>
              </td>

    <td style="vertical-align: bottom; width: 25.3333%; white-space: nowrap;" valign="bottom">
                <div style="text-align: right;">September 30, 2026</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 25.3333%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-indent: -9pt; margin-left: 9pt;"><span style="text-indent: 0pt;">September 29, 2016</span> Series B-3 Transaction $<span style="text-indent: 0pt;">3.00</span> Investor Warrants &#8211; Class B </div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>843,351</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>3.00</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td style="vertical-align: bottom; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="text-align: right;">September 29, 2016</div>
              </td>

    <td style="vertical-align: bottom; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="text-align: right;">September 30, 2026</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 25.3333%;" valign="bottom">
                <div style="text-indent: -9pt; margin-left: 9pt;"><span style="text-indent: 0pt;">December 23, 2016</span> Series B-3 Transaction $<span style="text-indent: 0pt;">3.00</span> Investor Warrants &#8211; Class B </div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>922,316</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>3.00</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td style="vertical-align: bottom; width: 25.3333%; white-space: nowrap;" valign="bottom">
                <div style="text-align: right;">December 23, 2016</div>
              </td>

    <td style="vertical-align: bottom; width: 25.3333%; white-space: nowrap;" valign="bottom">
                <div style="text-align: right;">September 30, 2026</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 25.3333%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">2018 and 2017 Warrants issued for services</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>290</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>5.00</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td style="vertical-align: bottom; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="text-align: right;">Various dates in 2017</div>
                <div style="text-align: right;">and 2018</div>
              </td>

    <td style="vertical-align: bottom; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="text-align: right;">Various dates in <br/>
                </div>
                <div style="text-align: right;">2025</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 25.3333%;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;"><span style="text-indent: 0pt;">May 23, 2019</span> Rights Offering warrants</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>2,622,154</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>7.00</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td style="vertical-align: bottom; width: 25.3333%; white-space: nowrap;" valign="bottom">
                <div style="text-align: right;">May 23, 2019</div>
              </td>

    <td style="vertical-align: bottom; width: 25.3333%; white-space: nowrap;" valign="bottom">
                <div style="text-align: right;">May 23, 2026</div>
              </td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; text-indent: -9pt; margin-left: 9pt; width: 25.3333%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="margin-left: 9pt;"><span style="text-indent: 0pt;">July 22, 2022</span> Warrants issued in connection with related party line of credit</div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">330,000</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">$ <br/>
              </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">5.00</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">July 22, 2022</td>

    <td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">July 31, 2029</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; text-indent: -9pt; margin-left: 9pt; width: 25.3333%;" valign="bottom">
                <div style="margin-left: 9pt;"><span style="text-indent: 0pt;">December 29, 2023</span> Warrants issued for draw on related party line of credit</div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">200,000</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">$ <br/>
              </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">3.00</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; white-space: nowrap;" valign="bottom">December 29, 2023</td>

    <td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; white-space: nowrap;" valign="bottom">July 31, 2029</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 25.3333%; text-align: left; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-indent: -9pt; margin-left: 9pt;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="text-indent: 0pt;">March 29, 2024</span> Warrants issued for draw on related party line of credit</span></div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;200,000<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">$ <br/>
              </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;3.59<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;March 29, 2024<br/>
              </td>

    <td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;July 31, 2029<br/>
              </td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 25.3333%; text-align: left;" valign="bottom">
                <div>
                  <div style="text-indent: -9pt; margin-left: 9pt;"><span style="text-indent: 0pt;">June 28, 2024</span> Warrants issued for draw on related&#160; party line of credit</div>
                </div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;200,000<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">$ <br/>
              </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;3.39<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; white-space: nowrap;" valign="bottom">&#160;June 29, 2024<br/>
              </td>

    <td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; white-space: nowrap;" valign="bottom">&#160;July 31, 2029<br/>
              </td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 25.3333%; padding-bottom: 2px; text-align: left; background-color: rgb(204, 238, 255);" valign="bottom">
                <div>
                  <div style="text-indent: -9pt; margin-left: 9pt;"><span style="text-indent: 0pt;">September 30, 2024</span> Warrants issued for draw on related party line of credit</div>
                </div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;200,000<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">$ <br/>
              </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;4.13<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;September 30, 2024<br/>
              </td>

    <td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;July 31, 2029<br/>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 25.3333%; padding-bottom: 4px;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Total Outstanding Warrants</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>9,595,940</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td style="vertical-align: bottom; width: 25.3333%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td style="vertical-align: bottom; width: 25.3333%; padding-bottom: 4px;" valign="bottom">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>

  </tr>


</table>
          </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_CommonStockWarrantsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for Equity warrants are instruments that bestow upon the holder of the instrument the right to buy a particular stock at a predetermined price within a stipulated time frame. ... This payment is to be adjusted against the final payment that needs to be paid in case the warrants are exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_CommonStockWarrantsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_WarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_WarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 24.5pt; vertical-align: top; font-weight: bold;">9.</td>

    <td style="width: auto; vertical-align: top;">
              <div style="font-weight: bold;">Stock-Based Compensation</div>
            </td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin: 0px 0px 0px 12.25pt; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Summary of Stock-Based Compensation Plans</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">At December 31, 2024, the Company has a stock-based compensation plan where the Company&#8217;s common stock has been made available for equity-based incentive grants as
        part of the Company&#8217;s compensation programs. In December 2019, the Company adopted the 2019 Omnibus Equity Incentive Plan (the &#8220;2019 Plan&#8221;) which provided originally for the issuance of up to 4,000,000 shares of the Company&#8217;s common stock, subsequently increased to 7,000,000
        in December 2021, and increased to 10,000,000 in December 2023 in the form of options, stock appreciation rights, restricted stock and
        other stock-based awards to employees, officers, directors, consultants and other eligible persons. At December 31, 2024, 4,135,213
        shares were available for future grant under the 2019 Plan. Also, the Company previously had the 2009 Incentive Compensation Plan (the &#8220;2009 Plan&#8221;) which, after amendments, provided for issuance of up to 6,733,334 shares of the Company&#8217;s common stock in the form of options, stock appreciation rights, restricted stock and other stock-based awards to employees, officers,
        directors, consultants and other eligible persons. Provisions of the 2009 Plan stipulated that no grants could be made after February 2019; however, grants made prior to that date remain outstanding for their legal term.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin: 0px 0px 0px 12.25pt; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Stock-Based Compensation</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">Following is the stock-based compensation expense related to common stock options, restricted common stock, common stock warrants and deferred stock units:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

<div style="margin-left: 27pt;">
        <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                <div style="text-align: center; font-weight: bold;">Year Ended</div>
                <div style="text-align: center; font-weight: bold;">December 31, <br/>
                </div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                <div style="text-align: center; font-weight: bold;"> 2024</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                <div style="text-align: center; font-weight: bold;">2023</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Research and development</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>1,222</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>829</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">General and administrative</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>1,225</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>1,432</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Total stock-based compensation expense</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>2,447</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>2,261</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
         </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">The fair value of the options granted is determined using the Black-Scholes option-pricing model. The following weighted average assumptions were used:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

<div style="margin-left: 27pt;">
        <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                <div style="text-align: center; font-weight: bold;"> 2024</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                <div style="text-align: center; font-weight: bold;">2023</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Risk-free interest rate</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>3.89</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>%</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>3.84</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>%</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Expected life of the options</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">
                <div style="text-align: right;">5.4 years </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">
                <div style="text-align: right;">5.7 years </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Expected volatility of the underlying stock</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>75.1</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>%</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>85.6</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>%</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Expected dividend rate</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>0</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div>%</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>0</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div>%</div>
              </td>

  </tr>


</table>

      </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">As noted above, the fair value of stock options is determined by using the Black-Scholes option pricing model. For all options granted since January 1, 2006 the
        Company has generally used option terms of between 5 to 10 years, generally with 5 to 6 years representing the estimated life of options granted to employees. The volatility of the common stock is estimated using historical volatility over a period equal to the
        expected life at the date of grant. The risk-free interest rate used in the Black-Scholes option pricing model is determined by reference to historical U.S. Treasury constant maturity rates with terms equal to the expected terms of the awards. An
        expected dividend yield of zero is used in the option valuation model, because the Company does not expect to pay any cash dividends on
        common stock in the foreseeable future. At December 31, 2024, the Company does not anticipate any option awards will be forfeited in the calculation of compensation expense due to the limited number of employees that receive stock option grants and
        the Company&#8217;s historical employee turnover; however, any forfeitures will be accounted for as incurred.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin-left: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">The following table summarizes the stock option activity in the stock-based compensation plans:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

<div style="margin-left: 27pt;">
        <table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; width: 53%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">Number of</div>
                <div style="text-align: center; font-weight: bold;">Shares</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">Weighted</div>
                <div style="text-align: center; font-weight: bold;">Average</div>
                <div style="text-align: center; font-weight: bold;">Exercise</div>
                <div style="text-align: center; font-weight: bold;">Price</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="text-align: left; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;
                <div style="text-align: center; font-weight: bold;">Weighted</div>
                <div style="text-align: center; font-weight: bold;">Average</div>
                <div style="text-align: center; font-weight: bold;">Remaining</div>
                <div style="text-align: center; font-weight: bold;">Contractual</div>
                <div style="text-align: center; font-weight: bold;">Life</div>
                <div style="text-align: center; font-weight: bold;">(in years) <br/>
                </div>
              </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;" valign="bottom">&#160;</td>

    <td rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;" valign="bottom">&#160;&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;&#160;&#160;
                <div style="text-align: center; font-weight: bold;">Aggregate</div>
                <div style="text-align: center; font-weight: bold;">Intrinsic Value</div>
                <div style="text-align: center; font-weight: bold;">(in thousands) <br/>
                </div>
              </td>

    <td style="width: 1%; padding-bottom: 2px;">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 53%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Outstanding, December 31, 2022</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>5,745,561</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>2.90</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td style="vertical-align: bottom; width: 8.95%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td style="vertical-align: bottom; width: 7.95%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 53%;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Granted</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; white-space: nowrap;" valign="bottom">
                <div>1,025,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; white-space: nowrap;" valign="bottom">
                <div>1.18</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td style="vertical-align: bottom; width: 8.95%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td style="vertical-align: bottom; width: 7.95%;" valign="bottom">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 53%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Forfeited/Cancelled</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>(436,720</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>2.23</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td style="vertical-align: bottom; width: 8.95%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td style="vertical-align: bottom; width: 7.95%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 53%; padding-bottom: 2px;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Exercised</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.01%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                <div></div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td style="vertical-align: bottom; width: 8.95%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td style="vertical-align: bottom; width: 7.95%; padding-bottom: 2px;" valign="bottom">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 53%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Outstanding, December 31, 2023</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>6,333,841</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>2.66</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td style="vertical-align: bottom; width: 8.95%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td style="vertical-align: bottom; width: 7.95%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 53%;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Granted</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; white-space: nowrap;" valign="bottom">
                <div>1,373,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; white-space: nowrap;" valign="bottom">
                <div>1.86</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td style="vertical-align: bottom; width: 8.95%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td style="vertical-align: bottom; width: 7.95%;" valign="bottom">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 53%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Forfeited/Cancelled</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>(348,750</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>6.35</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td style="vertical-align: bottom; width: 8.95%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td style="vertical-align: bottom; width: 7.95%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 53%; padding-bottom: 2px;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Exercised</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>(503,333</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.01%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>1.71</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td style="vertical-align: bottom; width: 8.95%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">&#160;</td>

    <td style="vertical-align: bottom; width: 7.95%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 53%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Outstanding, December 31, 2024</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>6,854,758<br/>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.01%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>2.39</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td style="vertical-align: bottom; width: 8.95%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div style="text-align: right;">6.27 <br/>
                </div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;$</td>

    <td style="vertical-align: bottom; width: 7.95%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div style="text-align: right;">183<br/>
                </div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 53%;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Exercisable, December 31, 2024</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; white-space: nowrap;" valign="bottom">
                <div>6,138,254<br/>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; white-space: nowrap;" valign="bottom">2.45</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td style="vertical-align: bottom; width: 8.95%; white-space: nowrap;" valign="bottom">
                <div style="text-align: right;">6.00 <br/>
                </div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;$</td>

    <td style="vertical-align: bottom; width: 7.95%; white-space: nowrap;" valign="bottom">
                <div style="text-align: right;">176 </div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
         </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">The aggregate intrinsic value in the table above represents the total pre-tax amount, net of exercise price, which would have been received by option holders if all
        option holders had exercised all options with an exercise price lower than the market price on December 31, 2024, based on the closing price of the Company&#8217;s common stock of $1.29 on that date.</div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">The weighted-average grant-date fair values of options granted during 2024 and 2023 were $1.26 and $0.85, respectively. As of December 31, 2024 and 2023,
        there were unvested options to purchase 716,504 and 1,792,080 shares of common stock, respectively. Total expected unrecognized compensation cost related to such unvested options is $775,000 at December 31, 2024, which is expected to be recognized over a weighted-average period of 1.0
        years.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">During the years ended December 31, 2024 and 2023, 1,966,167
        and 1,119,168 options became vested, respectively. The total grant date fair value of options vested during the years ended December 31,
        2024 and 2023 was $2,772,748 and $1,384,284,
        respectively.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">The following table summarizes additional information regarding outstanding and exercisable options under our stock-based compensation plans at December 31, 2024:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

<div style="margin-left: 27pt;">
        <table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; width: 39%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="10" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                <div style="text-align: center; font-weight: bold;">Options Outstanding</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                <div style="text-align: center; font-weight: bold;">Options Exercisable</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); width: 39%; white-space: nowrap;" valign="bottom">
                <div style="font-weight: bold;">Exercise</div>
                <div style="font-weight: bold;">Price (Range)</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">Number of</div>
                <div style="text-align: center; font-weight: bold;">Shares</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">Weighted</div>
                <div style="text-align: center; font-weight: bold;">Average</div>
                <div style="text-align: center; font-weight: bold;">Remaining</div>
                <div style="text-align: center; font-weight: bold;">Contractual</div>
                <div style="text-align: center; font-weight: bold;">Life</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">Weighted</div>
                <div style="text-align: center; font-weight: bold;">Average</div>
                <div style="text-align: center; font-weight: bold;">Exercise</div>
                <div style="text-align: center; font-weight: bold;">Price</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">Number of</div>
                <div style="text-align: center; font-weight: bold;">Shares</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">Weighted</div>
                <div style="text-align: center; font-weight: bold;">Average</div>
                <div style="text-align: center; font-weight: bold;">Exercise</div>
                <div style="text-align: center; font-weight: bold;">Price</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 39%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">(in years)</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 39%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div>$0.89 &#8211; 1.50</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>1,134,206</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>7.13</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>1.16</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>934,202</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>1.12</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 39%;" valign="bottom">
                <div>$1.51 &#8211; 2.50</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>3,691,315</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>6.88</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>2.02</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>3,199,815</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>2.02</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 39%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div>$2.51 &#8211; 5.00</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>1,809,237</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>4.88</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>3.48</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>1,784,237</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>3.48</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 39%; padding-bottom: 2px;" valign="bottom">
                <div>$5.01 &#8211; 6.71</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>220,000</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>3.10</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>5.92</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>220,000</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>5.92</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 39%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">&#160;&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>6,854,758<br/>
                </div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>6.27<br/>
                </div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>2.39<br/>
                </div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>6,138,254<br/>
                </div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>2.45<br/>
                </div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

      </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin: 0px 0px 0px 12.25pt; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Restricted Stock Issuances</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman';"><br/>
        </span> </div>

<div style="display:none;"><br/></div>
<div style="margin: 0px 0px 0px 24.45pt; text-indent: 0pt;"><span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In January 2024, the Company issued 408,000 restricted stock units to its employees valued at $734,000 at the date of grant. These restricted stock units would vest 100% if the Company publicly presents the results of the Interim Analysis of its NAVIGATE clinical trial on or before December 31, 2024. The Company believed it was probable that the
          vesting condition will be met and is amortized the restricted stock unit expense ratably in 2024. The vesting condition was met in December 2024. </span></div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><br/>
      </div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">In January 2024, one <span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 0px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">director elected to take a restricted stock grant in lieu of cash retainers for 2024.</span> A total of 23,256 shares of restricted stock valued at approximately $40,000
        was amortized to expense on a straight-line basis until December 31, 2024 when the stock vested in full.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">In January 2023, one <span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 0px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">director elected to take a restricted stock grant in lieu of cash retainers for 202</span>3. A total of 36,036 shares of restricted stock valued at approximately $40,000
        was amortized to expense on a straight-line basis until December 31, 2023 when the stock vested in full.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin: 0px 0px 0px 12.25pt; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Deferred Stock Units</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">In September 2020, the Company entered into an employment agreement with its new Chief Executive Officer whereby 20% of his base salary and performance bonuses will be paid in cash, and 80%
        will be paid in the form of deferred stock units (&#8220;<span style="text-decoration: underline;">DSUs</span>&#8221;) through December 31, 2022 in accordance with the terms and subject to the provisions set forth in the DSU Agreement. DSUs credited to Mr. Lewis as of any date shall be fully vested
        and nonforfeitable at all times.<span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> Pursuant to an amendment to the DSU
          Agreement in July 2022, </span><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">the
          Company shall issue the shares earned through December 31, 2022 underlying the outstanding whole number of DSUs credited to Mr. Lewis as follows: twenty five percent shall be issued on March 1, 2023, <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">fifty percent shall be issued on March 1, 2024</span> and&#160;<span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">twenty five percent </span></span>shall














            be issued on September 1, 2028. </span></span></div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
        </span> </div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="margin: 0px 0px 0px 24.45pt; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 0pt;"><span style="background-color: rgb(255, 255, 255); margin-top: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: left; text-transform: none;">On </span><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">March 1, 2024, fifty percent of the
          DSU&#8217;s were issued to Mr. Lewis in accordance with the DSU Agreement. A total of 367,800 shares were due to be issued&#894; however, 153,288 shares were withheld to cover income tax withholding of $300,445 resulting in 214,512 shares actually issued. On March 1, 2023, twenty five percent of the DSU&#8217;s were issued to Mr. Lewis in accordance with the DSU Agreement. A total of 183,900 shares were due to be issued&#894; however, 75,529 shares
          were withheld to cover income tax withholding of $156,345 resulting in 108,371 shares actually issued.</span></div>

<div style="display:none;"><br/></div>
<div style="margin: 0px 0px 0px 24.45pt; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -27pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><br/>
        <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Additionally, a 2023 DSU Agreement was
          executed in July 2022, whereby Mr. Lewis would continue to receive 20% of salary in cash and 80% in DSUs for 2023. The shares under the 2023 DSU Agreement are to be issued fifty percent on March 1, 2025 and fifty percent on January 5, 2026.</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/>
        </span></div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">For the year ended December 31, 2023, approximately $459,000 of his compensation was recorded as stock compensation expense
            representing 275,126 shares of common stock to be issued under the DSU agreement with a weighted average grant date fair value of $1.71 per share. For the year ended December 31, 2022, approximately $418,000 of his compensation was recorded as stock compensation expense representing 268,596
            shares of common stock to be issued under the DSU agreement with a weighted average grant date fair value of $1.56 per share.</span></span></div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/>
          </span></span></div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> Also, Mr. Lewis&#8217; bonus for the year ended December 31, 2022 of $210,000 (which was included in accrued compensation at
            December 31, 2022) was approved in January 2023 and represents 143,836 shares of common stock to be issued under the DSU agreement
            with a grant date fair value of $1.46 per share. The $210,000 was reclassified from accrued compensation to additional paid in capital in January 2023. Mr. Lewis&#8217; bonus for the year ended December 31, 2021 of $200,000 (which was included in accrued compensation at December 31, 2021) was approved in January 2022, and represents 103,627 shares of common stock to be issued under the DSU agreement with a grant date fair value of $1.93 per share. The $200,000 was reclassified from accrued
            compensation to additional paid in capital in January 2022.</span></span></div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/>
          </span></span></div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">There is no unrecognized compensation expense related to the DSUs.</span></span></div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Line of Credit - Related Party and Supplemental Lines of Credit - Related Party<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Convertible Line of Credit - Related Party and Supplemental Lines of Credit - Related Party</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 27.05pt; vertical-align: top; font-weight: bold;">10.</td>

    <td style="width: auto; vertical-align: top;">
              <div style="font-weight: bold;">Convertible Line of Credit &#8211; Related Party and Supplemental Lines of Credit &#8211; Related Party<br/>
              </div>
            </td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt;">On July 25, 2022, the Company and Richard E. Uihlein (the &#8220;Lender&#8221;) entered into a Line of Credit Letter Agreement (the &#8220;Credit Agreement&#8221;), pursuant
          to which the Lender shall provide the Company a line of credit of up to $60.0 million (the &#8220;Line of Credit&#8221;) to finance the Company&#8217;s
          working capital needs. The Company may draw upon the Line of Credit through July 31, 2024.</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman';"><br/>
          </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt;">Each advance made pursuant to the Credit Agreement shall be evidenced by an unsecured, convertible promissory note (individually, a &#8220;Promissory
          Note,&#8221; and collectively, the &#8220;Promissory Notes&#8221;), and bear interest at the Applicable Federal Rate for short term loans, plus two (2%)
          percent. Principal and interest on the Promissory Notes are due on or before January 31, 2026. Only with the consent of the Lender,
          may the Promissory Notes be prepaid, in whole or in part, at any time without premium or penalty, but with interest on the amount or amounts prepaid.</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman';"><br/>
          </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt;">At the election of Lender, the principal and accrued interest on Promissory Note(s) may be converted into the number of shares of the Company&#8217;s
          Common Stock equal to the amount of principal and accrued interest on such Promissory Note divided by the price equal to the closing price of the Common Stock on the date of such Promissory Note, but in no event less than $3.00 per share.</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman';"><br/>
          </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt;">In connection with the Credit Agreement, the Company agreed to issue the Lender warrants to purchase up to an aggregate of 1,700,000 shares of the Company&#8217;s common stock, par value $0.001 per share (collectively, the &#8220;Warrants&#8221;). Upon execution of the Credit Agreement, the Company issued the Lender a Warrant to purchase up to 500,000 shares of Company&#8217;s Common Stock at an exercise price of $5.00
          per share, which Warrant is exercisable upon issuance. Further, pursuant to the Credit Agreement, the Company shall issue to the Lender additional Warrants to purchase up to the remaining 1,200,000 shares of the Company&#8217;s common stock, ratably, upon borrowings under the Credit Agreement, with exercise prices equal to 150% of the closing price of the Company&#8217;s common Stock on the date of the Promissory Note evidencing such draw, but in no event more than $10.00 per share nor less than $3.00 per share. The Warrants
          expire on July 31, 2029.</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman';"><br/>
          </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt;">The fair value of the 500,000
          warrants vested at closing on July 25, 2022 was $738,000 at the date of issuance based on the following assumptions: an expected life
          of 7 years, volatility of 92%,
          risk free interest rate of 3.19% and zero
          dividends. The fair value of the vested warrants was recorded in other assets (non-current) as a deferred financing cost and will be amortized on a straight-line basis from July 25, 2022 through January 31, 2026. Amortization for the years ended
          December 31, 2024 and 2023 of $210,000 and $209,000, respectively, was recorded as interest expense.</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman';"><br/>
          </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt;">On December 19, 2022, the Company executed a $10
          million Promissory Note under the Line of Credit. The interest rate on this draw is 6.46% (Applicable Federal Rate for short term
          loans on date of draw of 4.46% plus 2%).





























































          The effective interest rate is approximately 7.1%. Accrued interest on this draw was approximately $1,399,000 and $688,000 at December 31,
          2024 and 2023, respectively. The principal and accrued interest is convertible at the option of the Lender at $3.00 per share. In
          accordance with the Credit Agreement, the Company issued the Lender a Warrant to purchase up to 200,000 shares of Company&#8217;s Common
          Stock at an exercise price of $3.00 per share, which Warrant is exercisable upon issuance.</div>

<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt;">The fair value of the 200,000
          warrants vested at closing on December 19, 2022 was $160,780 at the date of issuance based on the following assumptions: an expected
          life of 7 years, volatility of 91%,
          risk free interest rate of 4.06% and zero
          dividends. The proceeds were allocated between the Promissory Note and the warrants issued, and the amount allocated to the warrants was recorded as a debt discount netted against principal to be amortized on a straight-line basis, which is not
          materially different than the effective interest method, from December 19, 2022 through January 31, 2026. Amortization for the years ended December 31, 2024 and 2023 of $52,000 and $51,000, respectively, was recorded as interest
          expense.</div>

<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt;"> <br/>
        </div>

<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt;">On March 31, 2023, the Company executed an additional $10
          million Promissory Note under the Line of Credit. The interest rate on this draw is 6.41% (Applicable Federal Rate for short term
          loans on date of draw of 4.41% plus 2%).

















































          The effective interest rate is approximately 7.1%.&#160; Accrued interest on this draw was approximately $1,184,000 and $491,000 at December 31,
          2024 and 2023, respectively. The principal and accrued interest is convertible at the option of the Lender at $3.00 per share. In
          accordance with the Credit Agreement, the Company issued the Lender a Warrant to purchase up to 200,000 shares of Company&#8217;s Common
          Stock at an exercise price of $3.26 per share, which Warrant is exercisable upon issuance.</div>

<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt;"> <br/>
        </div>

<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt;">The fair value of the 200,000
          warrants vested at closing on March 31, 2023 was $296,680 at the date of issuance based on the following assumptions: an expected life
          of 6.33 years, volatility of 88%,
          risk free interest rate of 3.94% and zero
          dividends. The proceeds were allocated between the Promissory Note and the warrants issued, and the amount allocated to the warrants was recorded as a debt discount netted against principal amortized on a straight-line basis, which is not
          materially different than the effective interest method, from March 31, 2023 through January 31, 2026. Amortization for the year ended December 31, 2024 and 2023 of $105,000 and $79,000, respectively, was recorded as interest expense.</div>

<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt;"> <br/>
        </div>

<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt;">On June 30, 2023, the Company executed an additional $10
          million Promissory Note under the Line of Credit. The interest rate on this draw is 6.34% (Applicable Federal Rate for short term
          loans on date of draw of 4.34% plus 2%).

















































          The effective interest rate is approximately 7.1%.&#160; Accrued interest on this draw was approximately $995,000 and $321,000 at December 31,
          2024 and 2023, respectively. The principal and accrued interest is convertible at the option of the Lender at $3.00 per share. In
          accordance with the Credit Agreement, the Company issued the Lender a Warrant to purchase up to 200,000 shares of Company&#8217;s Common
          Stock at an exercise price of $3.00 per share, which Warrant is exercisable upon issuance.</div>

<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt;"> <br/>
        </div>

<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt;">The fair value of the 200,000
          warrants vested at closing on June 30, 2023 was $179,920 at the date of issuance based on the following assumptions: an expected life
          of 6.08 years, volatility of 85%,
          risk free interest rate of 3.59% and zero
          dividends. The proceeds were allocated between the Promissory Note and the warrants issued, and the amount allocated to the warrants was recorded as a debt discount netted against principal amortized on a straight-line basis, which is not
          materially different than the effective interest method, from June 30, 2023 through January 31, 2026. Amortization for the year ended December 31, 2024 and 2023 of $69,000 and $35,000, respectively, was recorded as interest expense.</div>

<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt;"> <br/>
        </div>

<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt;">On December 29, 2023, the Company executed an additional $10 million Promissory Note under the Line of Credit. The interest rate on this draw is 7.13%
          (Applicable Federal Rate for short term loans on date of draw of 5.13% plus 2%). The effective interest rate is approximately 7.5%.
          Accrued interest on this draw was approximately $737,000 at December 31, 2024. The principal and accrued interest is convertible at the
          option of the Lender at $3.00 per share. In accordance with the Credit Agreement, the Company issued the Lender a Warrant to purchase
          up to 200,000 shares of Company&#8217;s Common Stock at an exercise price of $3.00 per share, which Warrant is exercisable upon issuance.</div>

<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman', Times, serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"> <br/>
          </span></div>

<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><span style="letter-spacing: normal; text-align: left; text-indent: 0px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The fair value of the 200,000 warrants vested at closing on December 31, 2023 was $193,745 at the date of issuance based on the following assumptions: an expected life of 5.7 years,
            volatility of 79%, risk free interest rate of 4.49% and zero dividends. The proceeds were allocated between the Promissory Note and the warrants
            issued, and the amount allocated to the warrants was recorded as a debt discount netted against principal amortized on a straight-line basis, which is not materially different than the effective interest method, from December 29, 2023 through
            January 31, 2026. Amortization for the year ended December 31, 2024 of $93,000 was recorded as interest expense. On March 29, 2024,
            the Company executed an additional $10 million Promissory Note under the Line of Credit. The interest rate on this draw is 6.62% (Applicable Federal Rate for short term loans on date of draw of 4.62% plus 2%). The effective interest rate is approximately 7.1%. Accrued interest on this draw was $508,000
            at December 31, 2024. The principal and accrued interest is convertible at the option of the Lender at $3.00 per share. In accordance
            with the Credit Agreement, the Company issued the Lender a Warrant to purchase up to 200,000 shares of Company&#8217;s Common Stock at an
            exercise price of $3.59 per share, which Warrant is exercisable upon issuance.</span></div>

<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><span style="letter-spacing: normal; text-align: left; text-indent: 0px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> <br/>
          </span></div>

<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><span style="letter-spacing: normal; text-align: left; text-indent: 0px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The fair value of the 200,000 warrants vested at closing on March 29, 2024, was $277,389 at the date of issuance based on the following assumptions: an expected life of 5.33
            years, volatility of 75%, risk free interest rate of 4.19% and zero dividends. The proceeds were allocated between the
            Promissory Note and the warrants issued, and the amount allocated to the warrants was recorded as a debt discount netted against principal amortized on a straight-line basis, which is not materially different than the effective interest method,
            from March 29, 2024 through January 31, 2026. Amortization for the year ended December 31, 2024 of $114,000 was recorded as interest
            expense.<br/>
            <br/>
            On June 28, 2024, the Company executed an additional $10 million Promissory Note under the Line of Credit. The interest rate on this
            draw is 7.01% (Applicable Federal Rate for short term loans on date of draw of 5.01% plus 2%). The effective interest rate is approximately
            7.4%. Accrued interest on this draw was $336,000
            at December 31, 2024.&#160; The principal and accrued interest is convertible at the option of the Lender at $3.00 per share. In
            accordance with the Credit Agreement, the Company issued the Lender a Warrant to purchase up to 200,000 shares of Company&#8217;s Common
            Stock at an exercise price of $3.39 per share, which Warrant is exercisable upon issuance.<br/>
            <br/>
            The fair value of the 200,000 warrants vested at closing on June 28, 2024, was $260,000 at the date of issuance based on the following assumptions: an expected life of 5.03 years, volatility of 77%, risk free interest rate of 4.29% and zero dividends. The
            proceeds were allocated between the Promissory Note and the warrants issued, and the amount allocated to the warrants was recorded as a debt discount netted against principal amortized on a straight-line basis, which is not materially different
            than the effective interest method, from June 28, 2024 through January 31, 2026. Amortization for the year ended December 31, 2024 of $82,000
            was recorded as interest expense.<br/>
          </span></div>

<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><span style="letter-spacing: normal; text-align: left; text-indent: 0px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><br/>
            On March 29, 2024, the Company and Richard E. Uihlein (the &#8220;Lender&#8221;) entered into a Supplemental Line of Credit Letter Agreement (the &#8220;Supplemental Credit Agreement&#8221;), pursuant to which the Lender shall provide the Company a line of credit of
            up to $10.0 million (the &#8220;Supplemental Line of Credit&#8221;) to finance the Company&#8217;s working capital needs. The Company may draw upon the
            Supplemental Line of Credit through March 31, 2025.<br/>
            <br/>
            Each advance made pursuant to the Supplemental Credit Agreement shall be evidenced by an unsecured, convertible promissory note (individually, a &#8220;Promissory Note,&#8221; and collectively, the &#8220;Promissory Notes&#8221;), and bear interest at the Applicable
            Federal Rate for short term loans, plus two (2%) percent. Principal and interest on the Promissory Notes are due on or before January 31, 2026. Only with the consent of the Lender, may the Promissory Notes be prepaid, in whole or in part, at any time without premium or
            penalty, but with interest on the amount or amounts prepaid.<br/>
            <br/>
            At the election of Lender, the principal and accrued interest on Promissory Note(s) may be converted into the number of shares of the Company&#8217;s Common Stock equal to the amount of principal and accrued interest on such Promissory Note divided
            by the price equal to the closing price of the Common Stock on the date of such Promissory Note, but in no event less than $3.00 per
            share.<br/>
            <br/>
            In connection with the Supplemental Credit Agreement, the Company agreed to issue the Lender warrants to purchase up to an aggregate of 200,000
            shares of the Company&#8217;s common stock, par value $0.001 per share (collectively, the &#8220;Warrants&#8221;). The Company shall issue to the
            Lender Warrants ratably, upon borrowings under the Supplemental Line of Credit, with exercise prices equal to 150% of the closing
            price of the Company&#8217;s common Stock on the date of the Promissory Note evidencing such draw, but in no event more than $10.00 per
            share nor less than $3.00 per share. The Warrants expire on July 31, 2029.<br/>
            <br/>
            On September 30, 2024, the Company executed a $10 million Promissory Note under the Supplemental Line of Credit. The interest rate on
            this draw is 6.13% (Applicable Federal Rate for short term loans on date of draw of 5.01% plus 2%). The effective interest rate is approximately
            6.4%. Accrued interest on this draw was $154,000
            at December 31, 2024.&#160; The principal and accrued interest is convertible at the option of the Lender at $3.00 per share. In
            accordance with the Credit Agreement, the Company issued the Lender a Warrant to purchase up to 200,000 shares of Company&#8217;s Common
            Stock at an exercise price of $4.13 per share, which Warrant is exercisable upon issuance. The fair value of the 200,000 warrants vested at closing on September 30, 2024, was $307,780 at the date of issuance based on the following assumptions: an expected life of 4.83
            years, volatility of 78%, risk free interest rate of 3.58% and zero dividends. The proceeds were allocated between the
            Promissory Note and the warrants issued, and the amount allocated to the warrants was recorded as a debt discount netted against principal amortized on a straight-line basis, which is not materially different than the effective interest method,
            from October 1, 2024 through January 31, 2026. Amortization for the year ended December 31, 2024 of $58,000 was recorded as interest
            expense.<br/>
          </span></div>

<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><span style="letter-spacing: normal; text-align: left; text-indent: 0px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><br/>
            On November 14, 2024, the Company and Richard E. Uihlein (the &#8220;Lender&#8221;) entered into an additional Supplemental Line of Credit Letter Agreement (the &#8220;November 2024 Supplemental Credit Agreement&#8221;), pursuant to which the Lender shall provide the
            Company a line of credit of up to $6.0 million (the &#8220;November 2024 Supplemental Line of Credit&#8221;) to finance the Company&#8217;s working
            capital needs. The Company may draw upon the November 2024 Supplemental Line of Credit through March 31, 2025.<br/>
            <br/>
            Each advance made pursuant to the November 2024 Supplemental Credit Agreement shall be evidenced by an unsecured, convertible promissory note (individually, a &#8220;Promissory Note,&#8221; and collectively, the &#8220;Promissory Notes&#8221;), and bear interest at
            the Applicable Federal Rate for short term loans, plus two (2%) percent. Principal and interest on the Promissory Notes are due on or
            before March 31, 2026. Only with the consent of the Lender, may the Promissory Notes be prepaid, in whole or in part, at any time
            without premium or penalty, but with interest on the amount or amounts prepaid.<br/>
            <br/>
            At the election of Lender, the principal and accrued interest on Promissory Note(s) may be converted into the number of shares of the Company&#8217;s Common Stock equal to the amount of principal and accrued interest on such Promissory Note divided
            by the price equal to the closing price of the Common Stock on the date of such Promissory Note, but in no event less than $3.00 per
            share.<br/>
            <br/>
            In connection with the November 2024 Supplemental Credit Agreement, the Company agreed to issue the Lender warrants to purchase up to an aggregate of 120,000
            shares of the Company&#8217;s common stock, par value $0.001 per share (collectively, the &#8220;Warrants&#8221;). The Company shall issue to the
            Lender Warrants ratably, upon borrowings under the November 2024 Supplemental Line of Credit, with exercise prices equal to 150% of
            the closing price of the Company&#8217;s common Stock on the date of the Promissory Note evidencing such draw, but in no event more than $10.00
            per share nor less than $3.00 per share. The Warrants expire on July 31, 2029.<br/>
            <br/>
          </span></div>

<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The fair value
            of warrants that vest in the future based on borrowings will be computed when those borrowings occur and amortized over the remaining period through March 31, 2026</span><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">.</span> </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Loss Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Loss Per Share</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 27.05pt; vertical-align: top; font-weight: bold;">11.</td>

    <td style="width: auto; vertical-align: top;">
              <div style="font-weight: bold;">Loss Per Share</div>
            </td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">Basic net loss per common share is computed by dividing the net loss available to common stockholders by the weighted average number of common shares outstanding
        during the period. For the years ended December 31, 2024 and 2023, as the Company was in a net loss position, the diluted loss per share computations for such periods did not assume the exercise of warrants and stock options or the conversion of
        Convertible Notes, or the conversion of convertible preferred stock as they would have had an anti-dilutive effect on loss per share.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">The following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as of December 31, 2024 and 2023
        as the inclusion thereof would have been anti-dilutive:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

<div style="margin-left: 27pt;">
        <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">Year Ended</div>
                <div style="text-align: center; font-weight: bold;">December 31,</div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">2024</div>
                <div style="text-align: center; font-weight: bold;">(Shares)</div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">2023</div>
                <div style="text-align: center; font-weight: bold;">(Shares)</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Warrants to purchase shares of common stock</div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>9,595,940</div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">9,256,493</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Options to purchase shares of common stock</div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>6,854,758</div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">6,333,841</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Shares of common stock issuable upon conversion of convertible notes payable &#8211; related party</div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>7,024,053</div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">6,418,913</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; text-indent: -9pt; margin-left: 9pt; width: 76%;" valign="bottom">
                <div style="margin-left: 9pt;">Shares of common stock issuable upon conversion of convertible line of credit &#8211; related party<br/>
                </div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">25,103,873</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">13,833,356</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Shares of common stock issuable upon conversion preferred stock</div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>499,174</div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">499,174</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
                <div style="font-weight: bold;">49,077,798</div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-weight: bold; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-weight: bold; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">36,341,777</td>

    <td colspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
         </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 24.5pt; vertical-align: top; font-weight: bold; font-size: 10pt; font-family: 'Times New Roman';">12.</td>

    <td style="width: auto; vertical-align: top;">
              <div style="font-weight: bold; font-size: 10pt; font-family: 'Times New Roman';">Commitments and Contingencies</div>
            </td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman';"><br/>
        </span> </div>

<div style="margin: 0px 0px 0px 12.25pt; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Lease Commitments</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman';"><br/>
        </span> </div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">The Company has one operating lease for its office
        space which was amended effective March 1, 2022 for a term of 38 months with no residual value guarantees or material restrictive
        covenants. The amended lease provided for free rent for the first <span style="-sec-ix-hidden:Fact_5e16282e65184d8eabf15666ce8cae25">six and one-half months</span> of the lease and continues the security
        deposit of $6,000. In addition to base rental payments included in the contractual obligations table below, the Company is responsible
        for our pro-rata share of the operating expenses for the building. Our lease cost for the years ended December 31, 2024 and 2023 was $44,000
        and $44,000, respectively, and is included in general and administrative expenses. As of December 31, 2024, the right to use lease asset
        consisted of $16,000 and is included in <span style="-sec-ix-hidden:Fact_c96ca38e0f664780917ece0461c411fe">other assets</span>. Also, at December 31, 2024, current lease liability of $19,000 is included in <span style="-sec-ix-hidden:Fact_4b297d7d29a9481e88136db097de88dd">accrued expenses</span>.<span style="font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160; <span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">As of December 31, 2023, the right to use lease asset consisted of $46,000 and is included in <span style="-sec-ix-hidden:Fact_2a011c7177224f80b904fcc70e46eb35">other assets</span>.
            Also, at December 31, 2023, current lease liability of $46,000 is included in <span style="-sec-ix-hidden:Fact_3bef161157d441a4b194359a2b8c08a3">accrued expenses</span> and the noncurrent lease liability of $20,000 is included
            in <span style="-sec-ix-hidden:Fact_47d32f393cdc43fc8f131674cf3a7b9b">other long term liabilities</span>. </span>The Company renewed its existing office space lease effective in March 2025 for twelve months at substantially the same terms.</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman';"><br/>
        </span> </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">Maturity of operating lease as of December 31, 2024 in thousands:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-size: 10pt; font-family: 'Times New Roman';"><br/>
        </span> </div>

<div style="margin-left: 27pt;">
        <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;">


  <tr>

    <td rowspan="1" style="vertical-align: top; font-size: 10pt; font-family: 'Times New Roman'; width: 88%; background-color: #CCEEFF;" valign="bottom">2025</td>

    <td colspan="1" rowspan="1" style="text-align: right; font-size: 10pt; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><br/>
              </td>

    <td colspan="1" rowspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">19</td>

    <td colspan="1" rowspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-size: 10pt; font-family: 'Times New Roman';">Total</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div style="font-size: 10pt; font-family: 'Times New Roman';">19</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-size: 10pt; font-family: 'Times New Roman';">Less imputed interest</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-size: 10pt; font-family: 'Times New Roman';">-</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; padding-bottom: 4px;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-size: 10pt; font-family: 'Times New Roman';">Present value of lease liability</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                <div style="font-size: 10pt; font-family: 'Times New Roman';">$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                <div style="font-size: 10pt; font-family: 'Times New Roman';">19</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
         </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman';"><br/>
        </span> </div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">The discount rate used in calculating the present value of the lease payments was 11%.</div>

<div><span style="font-size: 10pt; font-family: 'Times New Roman';"><br/>
      </span></div>

<div style="margin: 0px 0px 0px 12.25pt; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Legal Proceedings</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman';"><br/>
        </span> </div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">The Company records accruals for such contingencies to the extent that the Company concludes that their occurrence is probable and the related damages are estimable.
        There are no pending legal proceedings.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman';"><br/>
        </span> </div>

<div style="margin: 0px 0px 0px 12.25pt; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Clinical Trial and Research Contingencies</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman';"><br/>
        </span> </div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">The Company has entered into agreements with contractors for research and development activities to further its product candidates. The contracts generally may be
        canceled at any time by providing thirty days&#8217; notice. The Company is involved in a dispute with a contract vendor for clinical trial
        management services provided outside of the United States. The contract in question is a variable contract. The Company has accrued its estimate of the amount owed to the contract vendor. The contract vendor asserts that it is owed approximately $1 million more than the Company&#8217;s estimate. The Company disagrees with the contract vendor&#8217;s assertion, and did not accrue that additional amount at December 31, 2024.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Galectin Sciences LLC<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAndAdvancesToAffiliatesAbstract', window );"><strong>Galectin Sciences LLC [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock', window );">Galectin Sciences LLC</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 27.05pt; vertical-align: top; font-weight: bold;">13.</td>

    <td style="width: auto; vertical-align: top;">
              <div style="font-weight: bold;">Galectin Sciences LLC</div>
            </td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"> In January 2014, we created Galectin Sciences, LLC (the &#8220;LLC&#8221; or &#8220;Investee&#8221;), a collaborative joint venture co-owned by SBH Sciences, Inc. (&#8220;SBH&#8221;), to research and
        develop small organic molecule inhibitors of galectin-3 for oral administration. The LLC was initially capitalized with a $400,000 cash
        investment to fund future research and development activities, which was provided by the Company, and specific in-process research and development (&#8220;IPR&amp;D&#8221;) contributed by SBH. The estimated fair value of the IPR&amp;D contributed by SBH, on
        the date of contribution, was $400,000. Initially, the Company and SBH have a 50% equity ownership interest in the LLC, with neither party having control over the LLC. Accordingly, from inception through the fourth quarter of 2014, the Company accounted
        for its investment in the LLC using the equity method of accounting. Under the equity method of accounting, the Company&#8217;s investment was initially recorded at cost with subsequent adjustments to the carrying value to recognize additional
        investments in or distributions from the Investee, as well as the Company&#8217;s share of the Investee&#8217;s earnings, losses and/or changes in capital. The estimated fair value of the IPR&amp;D contributed to the LLC was immediately expensed upon
        contribution as there was no alternative future use available at the point of contribution. The operating agreement provides that if either party does not desire to contribute its equal share of funding required after the initial capitalization,
        then the other party, providing all of the funding, will have its ownership share increased in proportion to the total amount contributed from inception. In the fourth quarter of 2014, after the LLC had expended the $400,000 in cash, SBH decided not to contribute its share of the funding required. As a result, the Company contributed the $73,000 needed for the fourth quarter of 2014 expenses of the LLC and an additional $2,552,000 in total from 2015 through 2021. The Company contributed $350,000
        and $561,000 for the LLC expenses (recorded in research and development expenses) in 2024 and 2023, and SBH has contributed a total of $711,000 since 2014. As of December 31, 2024, the Company&#8217;s ownership percentage in the LLC was 85.3%. The Company accounts for the interest in the LLC as a consolidated, less than wholly owned subsidiary. Because the LLC&#8217;s equity is immaterial, the value of the
        non-controlling interest is also deemed to be immaterial. The Company&#8217;s portion of the LLC&#8217;s net loss for 2014, prior to the change in accounting discussed previously, was $400,000, which includes the Company&#8217;s proportionate share of the non-cash charge associated with the contributed IPR&amp;D of $200,000.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAndAdvancesToAffiliatesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAndAdvancesToAffiliatesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the information summarizing investments in and advances to majority-owned subsidiaries, other controlled companies, and other affiliates. It reflects specified information about ownership, financial results from, and financial position in such entities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 24.5pt; vertical-align: top; font-weight: bold;">14.</td>

    <td style="width: auto; vertical-align: top;">
              <div style="font-weight: bold;">Income Taxes</div>
            </td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">The components of the net deferred tax assets are as follows at December 31:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

<div style="margin-left: 27pt;">
        <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="text-align: center; font-weight: bold;"> 2024<br/>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">2023<br/>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">(in thousands)</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Operating loss carryforwards</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">63,057</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>61,427</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Tax credit carryforwards</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">9,010</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>6,476</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Other temporary differences</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">18,276</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>10,533</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">90,343</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>78,436</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Less valuation allowance</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">(90,343</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>(78,436</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 4px;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Net deferred tax asset</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">&#8212;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
         </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">The primary factors affecting the Company&#8217;s income tax rates were as follows:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

<div style="margin-left: 27pt;">
        <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="text-align: center; font-weight: bold;"> 2024<br/>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">2023<br/>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Tax benefit at U.S. statutory rates</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>(21</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>%)</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>(21</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>%)</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">State tax benefit</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>(2.5</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div>%)</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>(3.4</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div>%)</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Permanent differences</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>0.1</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>%</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>0.9</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>%</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Other</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>(4.0</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div>%)</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>2.3</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div>%</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Changes in valuation allowance</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>27.4</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>%</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>21.2</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>%</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                <div style="font-weight: bold;">0</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
                <div style="font-weight: bold;">%</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                <div style="font-weight: bold;">0</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
                <div style="font-weight: bold;">%</div>
              </td>

  </tr>


</table>
         </div>

<div style="margin-left: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

<div style="margin-left: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">As of December 31, 2024, the Company has federal and state net operating loss carryforwards <span style="background-color: rgb(255, 255, 255);">totaling $131,579,000 and $137,878,000,
          respectively, which will never expire as a result of the 2017 Tax Act. As of December 31, 2023, the Company has federal and state net operating loss carryforwards totaling $120,055,000 and $102,003,000 respectively, which expire through <span style="-sec-ix-hidden:Fact_f036db385a5043f9b416f31ccdd089ed">2037</span>. In addition, the Company has federal and state research and development credits of $7,764,000 and $1,245,000,</span> respectively, which expire through <span style="-sec-ix-hidden:Fact_64f60f3069914649af3fc7ac5db90c6c">2042</span>. Ownership changes, as defined by Section 382 of the Internal Revenue Code, may have limited the amount of net operating loss carryforwards that
        can be utilized annually to offset future taxable income. Past and subsequent ownership changes could further affect the limitation in future years. Because of the Company&#8217;s limited operating history and its recorded losses, management has
        provided, in each of the last two years, a 100% valuation allowance against the Company&#8217;s net deferred tax assets.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">The Company is subject to taxation in the U.S. and various states. Based on the history of net operating losses all jurisdictions and tax years are open for
        examination until the operating losses are utilized or the statute of limitations expires. As of December 31, 2024 and 2023, the Company does not have any significant uncertain tax positions.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segments</a></td>
<td class="text">
<div>
        <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="text-align: right; vertical-align: top; width: 27pt;">
                <div style="text-align: left; font-weight: bold;"><span style="font-size: 10pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">15.</span></div>
              </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                <div style="text-align: left; font-weight: bold;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman', Times, serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: -36px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">Segments</span></div>
              </td>

  </tr>


</table>
      </div>

<div style="margin-top: 0px; margin-bottom: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> <br/>
        </span></div>

<div style="margin-top: 0px; margin-bottom: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; margin-left: 18pt;"><span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Operating segments are identified as components of an entity about which separate discrete financial information is available for evaluation by the CODM, or decision-making group, in making decisions on how to allocate
          resources and assess performance. The Company&#8217;s CODM, the Chief Executive Officer, views the Company&#8217;s operations as one operating
          segment, which is focused on creating new therapies for fibrotic disease based on targeting galectin proteins. The Company does not have revenue in the current comparative period, incurs expenses primarily in North America and manages the
          business activities on a consolidated basis.</span></div>

<div style="margin-top: 0px; margin-bottom: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> <br/>
        </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; margin-left: 9pt;">The accounting policies of the fibrotic disease therapeutics segment are the same
          as those described in the summary of significant accounting policies.</div>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify;"> <span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
          </span></div>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; margin-left: 9pt;">The CODM assesses performance for the fibrotic disease therapeutics segment and
          decides how to allocate resources based on net loss that also is reported on the income statement as consolidated net loss. The measure of segment assets is reported on the balance sheet as cash and cash equivalents.</div>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify;"> <span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
          </span></div>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; margin-left: 9pt;">The Company has not generated any product revenue in the current period and expects
          to continue to incur significant expenses and operating losses for the foreseeable future as the Company advances its product candidates through all stages of development and clinical trials.</div>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify;"> <span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
          </span></div>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; margin-left: 9pt;">As such, the CODM uses cash forecast models in deciding how to invest into the
          fibrotic disease therapeutics segment. Such cash forecast models are reviewed to assess the entity-wide operating results and performance. Net loss is used to monitor budget versus actual results. Monitoring budgeted versus actual results, net
          cash used in operating activities for the period and cash on hand are used in assessing performance of the segment.</div>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify;"> <span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
          </span></div>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; margin-left: 9pt;">The table below summarizes the significant expense categories regularly reviewed by
          the CODM for the years ended December 31, 2024 and 2023 (in thousands).</div>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify;"> <span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
          </span></div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="background-color: rgb(255, 255, 255); letter-spacing: normal; word-spacing: 0px; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: left; text-transform: none; width: 100%; border-spacing: 0;">


  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px;" valign="bottom">
                  <div>&#160;</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Year Ended</div>
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">December 31,</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px;" valign="bottom">
                  <div>&#160;</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                  <div style="text-align: center; font-weight: bold;"> 2024</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                  <div style="text-align: center; font-weight: bold;">2023</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">
                  <div>&#160;</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;"><span style="text-decoration: underline;">(in thousands)</span></div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">
                  <div>Operating expenses:</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div>Research and development</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div>$</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div>36,571</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div>$</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div>32,130</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 2px;" valign="bottom">
                  <div>General and administrative</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div>5,862</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div>5,942</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div>Total operating expenses</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div>42,433</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div>38,072</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 2px;" valign="bottom">
                  <div>Total operating loss</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div>(42,433</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div>)</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div>(38,072</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div>)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div>Other income (expense):</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%;" valign="bottom">
                  <div>Interest income</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div>336</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div>230</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div>Interest expense</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div>(5,540</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div>)</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div>(2,792</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div>)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 2px;" valign="bottom">
                  <div>Change in fair value of derivatives</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div>590</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div>(432</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div>)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div>Total other expense</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div>(4,614)</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div>(2,994</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div>)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 2px;" valign="bottom">
                  <div>Net loss</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div>$</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div>(47,047</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div>)</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div>$</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div>(41,066</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div>)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div>Preferred stock dividends</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div>(153</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div>)</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div>(120</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div>)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 2px;" valign="bottom">
                  <div>Warrant modification</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div>&#8212;</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div>(3,619</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div>)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div>Net loss applicable to common stockholders</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div>$</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div>(47,200</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div>)</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div>$</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div>(44,805</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div>)</div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br class="Apple-interchange-newline"/>
          </span></div>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; margin-left: 9pt;">Other segment items included in segment loss includes interest income and interest
          expense.</div>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify;"><br/>
        </div>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; margin-left: 9pt;">The Company is a <span style="-sec-ix-hidden:Fact_600409bbedd14e1db752c48e58053e6c">single</span> operating segment and therefore the measure of segment net loss is the same as consolidated net loss and does not require reconciliation.</div>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify;"><br/>
        </div>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; margin-left: 9pt;">For the years ended December 31, 2024 and 2023, the net cash used in operating
          activities was $41.8 million and $33.0
          million, respectively. <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: 400;">The

















          table below summarizes the significant asset categories regularly reviewed by the CODM for the years ended December 31, 2024 and 2023 (in thousands).</span></div>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify;"> <span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
          </span></div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="background-color: rgb(255, 255, 255); letter-spacing: normal; word-spacing: 0px; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: left; text-transform: none; width: 100%; border-spacing: 0;">


  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px;" valign="bottom">
                  <div>&#160;</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;">December 31,</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px;" valign="bottom">
                  <div>&#160;</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;"> 2024</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;">2023</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">
                  <div>&#160;</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;">(in thousands)</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; background-color: #CCEEFF;" valign="bottom">
                  <div>Cash and cash equivalents</div>
                </td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>$</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>15,120</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>$</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>25,660</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Event [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Event</a></td>
<td class="text">
<div>
        <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="text-align: right; vertical-align: top; width: 27pt;">
                <div style="text-align: left; font-weight: bold;"><span style="font-size: 10pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">16.</span></div>
              </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                <div style="text-align: left; font-weight: bold;"><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Subsequent







































                    Event</span></div>
              </td>

  </tr>


</table>
      </div>

<div>&#160;</div>

<div style="display:none;"><br/></div>
<div style="margin: 0px 0px 0px 22.5pt; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 0pt;">On March 31, 2025, the Company and Richard E. Uihlein (the &#8220;Lender&#8221;) entered into a Supplemental Line of Credit Letter
        Agreement (the &#8220;March 2025 Supplemental Credit Agreement&#8221;), pursuant to which the Lender shall provide the Company a line of credit of up to $5.0
        million (the &#8220;Supplemental Line of Credit&#8221;) to finance the Company&#8217;s working capital needs. The Company may draw upon the Supplemental Line of Credit through September 30, 2025. In connection with entering into the March 2025 Supplemental Line of
        Credit, the Company agreed to extend the maturity date of the Convertible Promissory Note dated April 16, 2021 from April 16, 2025 to September 30, 2025.<br/>
        &#160;<br/>
        Each advance made pursuant to the March 2025 Supplemental Credit Agreement shall be evidenced by an unsecured, convertible promissory note (individually, a &#8220;Promissory Note,&#8221; and collectively, the &#8220;Promissory Notes&#8221;), and bear interest at the
        Applicable Federal Rate for short term loans, plus two (2%) percent. Principal and interest on the Promissory Notes are due on or before
        March 31, 2026. Only with the consent of the Lender, may the Promissory Notes be prepaid, in whole or in part, at any time without
        premium or penalty, but with interest on the amount or amounts prepaid.<br/>
        &#160;<br/>
        At the election of Lender, the principal and accrued interest on Promissory Note(s) may be converted into the number of shares of the Company&#8217;s Common Stock equal to the amount of principal and accrued interest on such Promissory Note divided by
        the price equal to the closing price of the Common Stock on the date of such Promissory Note, but in no event less than $3.00 per share.<br/>
        &#160;<br/>
      </div>

<div style="display:none;"><br/></div>
<div style="margin: 0px 0px 0px 22.5pt; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 0pt;">In connection with the March 2025 Supplemental Credit Agreement, the Company agreed to issue the Lender warrants to purchase
        up to an aggregate of 100,000 shares of the Company&#8217;s common stock, par value $0.001 per share (collectively, the &#8220;Warrants&#8221;).&#160; The Company shall issue to the Lender Warrants ratably, upon borrowings under the March 2025 Supplemental Line of Credit, with exercise
        prices equal to 150% of the closing price of the Company&#8217;s common Stock on the date of the Promissory Note evidencing such draw, but in
        no event more than $10.00 per share nor less than $3.00 per share. The Warrants expire on July 31, 2029. </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text">
<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Risk management and strategy</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
            </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 24.3pt; font-family: 'Times New Roman'; font-size: 10pt;">We have policies and processes designed to protect our information technology systems, which are managed by outside consultants.&#160; Our cybersecurity consultants resolve issues in a timely manner in the event of a cybersecurity threat or
              incident.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
            </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 24.3pt; font-family: 'Times New Roman'; font-size: 10pt;">As part of our broader risk management framework, from time to time, we seek to identify potential cybersecurity risks to our business and improve our policies
              and processes to address such risks. We have designed our business applications to minimize the impact that cybersecurity incidents could have on our business and have identified back-up systems where appropriate. We seek to further mitigate
              cybersecurity risks through a combination of monitoring and detection activities, use of anti-malware applications, employee training, quality reviews and communication and reporting structures, among other processes. We have an incident
              response plan in place that outlines containment, eradication and recovery plans in the event of a cybersecurity threat or incident.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
            </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 24.3pt; font-family: 'Times New Roman'; font-size: 10pt;">We engage a third-party consultant to assist us with designing controls and our cybersecurity risk management framework. We are also engaging with a third party to perform penetration testing. We also retain third parties to assist with the monitoring and detection of cybersecurity
              threats and responding to any cybersecurity threats or incidents.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
            </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 24.3pt; font-family: 'Times New Roman'; font-size: 10pt;">With respect to third parties that manage or use our information technology or data, we obtain reports to assess the security of their systems and processes. We engage in ongoing monitoring of third-party providers to ensure compliance with our cybersecurity standards.<br/>
            </div>

<div><br/></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 24.3pt; font-family: 'Times New Roman'; font-size: 10pt;">We have not encountered cybersecurity threats or incidents that have had a material impact on our business.<br/>
            </div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-indent: 24.3pt; font-family: 'Times New Roman'; font-size: 10pt;">We have policies and processes designed to protect our information technology systems, which are managed by outside consultants.&#160; Our cybersecurity consultants resolve issues in a timely manner in the event of a cybersecurity threat or
              incident.</div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-indent: 24.3pt; font-family: 'Times New Roman'; font-size: 10pt;">We have not encountered cybersecurity threats or incidents that have had a material impact on our business.<br/>
            </div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text">
<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Cybersecurity Governance</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
            </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 24.3pt; font-family: 'Times New Roman'; font-size: 10pt;">Our Nomination and Corporate Governance Committee has specific oversight responsibility for cybersecurity The Nomination and Corporate Governance Committee
              reviews and discusses with management our policies, practices and risks related to information security and cybersecurity.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
            </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 24.3pt; font-family: 'Times New Roman'; font-size: 10pt;">Our chief financial officer has primary responsibility for assessing, monitoring and managing cybersecurity risks. We utilize cybersecurity consultants to monitor and
              report cybersecurity threats or incidents to our chief financial officer and to resolve issues arising from such threats or incidents.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
            </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 24.3pt; font-family: 'Times New Roman'; font-size: 10pt;">Our chief financial officer updates the Nomination and Corporate Governance Committee on any risks related to cybersecurity as needed.<br/>
            </div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-indent: 24.3pt; font-family: 'Times New Roman'; font-size: 10pt;">Our Nomination and Corporate Governance Committee has specific oversight responsibility for cybersecurity The Nomination and Corporate Governance Committee
              reviews and discusses with management our policies, practices and risks related to information security and cybersecurity.</div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-indent: 24.3pt; font-family: 'Times New Roman'; font-size: 10pt;">Our chief financial officer updates the Nomination and Corporate Governance Committee on any risks related to cybersecurity as needed.<br/>
            </div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-indent: 24.3pt; font-family: 'Times New Roman'; font-size: 10pt;">Our chief financial officer has primary responsibility for assessing, monitoring and managing cybersecurity risks. We utilize cybersecurity consultants to monitor and
              report cybersecurity threats or incidents to our chief financial officer and to resolve issues arising from such threats or incidents.</div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-indent: 24.3pt; font-family: 'Times New Roman'; font-size: 10pt;">Our chief financial officer has primary responsibility for assessing, monitoring and managing cybersecurity risks. We utilize cybersecurity consultants to monitor and
              report cybersecurity threats or incidents to our chief financial officer and to resolve issues arising from such threats or incidents.</div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-indent: 24.3pt; font-family: 'Times New Roman'; font-size: 10pt;">Our chief financial officer updates the Nomination and Corporate Governance Committee on any risks related to cybersecurity as needed.<br/>
            </div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingArrLineItems', window );"><strong>Insider Trading Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingArrLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingArrLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of Consolidation</a></td>
<td class="text">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-style: italic;">Basis of Consolidation.</span><span style="font-family: 'Times New Roman';"> The consolidated
        financial statements include the accounts of the Company and Galectin Therapeutics Security Corp., its wholly-owned subsidiary, which was incorporated in Delaware on December 23, 2003 and Galectin Sciences LLC (see Note 13). All intercompany
        transactions have been eliminated.</span></div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-style: italic;">Use of Estimates.</span><span style="font-family: 'Times New Roman';"> The preparation of financial
        statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and judgments that may affect the reported amounts of assets, liabilities, equity, revenue, expenses and
        related disclosure of contingent assets and liabilities. Management&#8217;s estimates and judgments include assumptions used in stock option valuations, accrued liabilities, derivative valuations, deferred income taxes and various other assumptions that
        are believed to be reasonable under the circumstances. Actual results may differ from those estimates under different assumptions or conditions.</span></div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-style: italic;">Fair Value Measurements</span><span style="font-family: 'Times New Roman';">. The Company has certain
        financial assets and liabilities recorded at fair value. Fair values determined by Level 1 inputs utilize observable data such as quoted prices in active markets. Fair values determined by Level 2 inputs utilize data points other than quoted prices
        in active markets that are observable either directly or indirectly. Fair values determined by Level 3 inputs utilize unobservable data points in which there is little or no market data, which require the reporting entity to develop its own
        assumptions. The estimated value of accounts payable and accrued expenses approximates their carrying value due to their short-term nature. See</span> Footnote 6 for Fair Value of Derivatives related to Convertible Notes Payable at December 31,
      2024 and 2023, which are level 3 liabilities. </div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-style: italic;">Cash and Cash Equivalents.</span><span style="font-family: 'Times New Roman';"> The Company considers
        all highly-liquid investments with original maturities of 90 days or less at the time of acquisition to be cash equivalents. The Company had no
        cash equivalents at December 31, 2024 or 2023.</span></div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-style: italic;">Prepaid Expenses and Other Current Assets.</span><span style="font-family: 'Times New Roman';">
        Prepaid expenses and other assets consist principally of prepaid insurance, deposits related to the NAVIGATE trial and deferred financing costs (see Note 10).</span></div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-style: italic;">Property and Equipment.</span><span style="font-family: 'Times New Roman';"> Property and equipment,
        including leasehold improvements, are stated at cost, net of accumulated depreciation and amortization, and are depreciated or amortized using the straight-line method over the estimated useful lives of the related assets of generally three years for computers and office equipment, five years
        for furniture and fixtures and the shorter of the useful life or life of the lease for leasehold improvements.</span></div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_SecurityDepositPolicyTextBlock', window );">Security Deposit</a></td>
<td class="text">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-style: italic;">Security Deposit.</span><span style="font-family: 'Times New Roman';"> At December 31, 2024 and 2023,
        the Company had a security deposit of $6,000 for leased office space included in Prepaid Expenses and Other Current Assets.</span></div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Long-Lived Assets</a></td>
<td class="text">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-style: italic;">Long-Lived Assets.</span><span style="font-family: 'Times New Roman';"> The Company reviews all
        long-lived assets for impairment whenever events or circumstances indicate the carrying amount of such assets may not be recoverable. Recoverability of assets to be held or used is measured by comparison of the carrying value of the asset to the
        future undiscounted net cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment recognized is measured by the amount by which the carrying value of the asset exceeds the discounted future cash
        flows expected to be generated by the asset. There were no impairments of long-lived assets at December 31, 2024 or 2023.</span></div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_AccruedExpensePolicyTextBlock', window );">Accrued Expenses</a></td>
<td class="text">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-style: italic;">Accrued Expenses</span><span style="font-family: 'Times New Roman';">. As part of the process of
        preparing our consolidated financial statements, we are required to estimate accrued expenses. This process involves identifying services that third parties have performed on our behalf and estimating the level of service performed and the
        associated cost incurred on these services as of each balance sheet date in our consolidated financial statements. Examples of estimated accrued expenses include professional service fees, such as those arising from the services of attorneys and
        accountants and accrued payroll expenses. In connection with these service fees, our estimates are most affected by our understanding of the status and timing of services provided relative to the actual services incurred by the service providers.
        In the event that we do not identify certain costs that have been incurred or we under- or over-estimate the level of services or costs of such services, our reported expenses for a reporting period could be understated or overstated. The date on
        which certain services commence, the level of services performed on or before a given date, and the cost of services are often subject to our judgment. We make these judgments based upon the facts and circumstances known to us in accordance with
        accounting principles generally accepted in the U.S.</span></div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Warrants</a></td>
<td class="text">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-style: italic;">Warrants.</span><span style="font-family: 'Times New Roman';"> The Company has issued common stock
        warrants in connection with the execution of certain equity and debt financings. The fair value of warrants is determined using the Black-Scholes option-pricing model using assumptions regarding volatility of our common share price, remaining life
        of the warrant, and risk-free interest rates at each period end. There were no warrant liabilities as of December 31, 2024 or 2023.</span></div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-style: italic;">Research and Development Expenses.</span><span style="font-family: 'Times New Roman';"> Research and
        development expenses, including personnel costs, allocated facility costs, lab supplies, outside services, contract laboratory costs related to manufacturing drug product, clinical trials and preclinical studies are charged to research and
        development expense as incurred. The Company accounts for nonrefundable advance payments for goods and services that will be used in future research and development activities as expense when the service has been performed or when the goods have
        been received. Our current NAVIGATE clinical trial is being supported by third-party contract research organizations, or CROs, and other vendors. We accrue expenses for clinical trial activities performed by CROs based upon the estimated amount of
        work completed on each trial. For clinical trial expenses and related expenses associated with the conduct of clinical trials, the significant factors used in estimating accruals include the number of patients enrolled, the number of active
        clinical sites, and the duration for which the patients have been enrolled in the trial. We monitor patient enrollment levels and related activities to the extent possible through internal reviews, review of contractual terms and correspondence
        with CROs. We base our estimates on the best information available at the time. We monitor patient enrollment levels and related activities to the extent possible through discussions with CRO personnel and based our estimates of clinical trial
        costs on the best information available at the time. However, additional information may become available to us which will allow us to make a more accurate estimate in future periods. In that event, we may be required to record adjustments to
        research and development expenses in future periods when the actual level of activity becomes more certain.</span></div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-style: italic;">Income Taxes.</span><span style="font-family: 'Times New Roman';"> The Company accounts for income
        taxes in accordance with the accounting rules that requires an asset and liability approach to accounting for income taxes based upon the future expected values of the related assets and liabilities. Deferred income tax assets and liabilities are
        determined based on the differences between the financial reporting and tax bases of assets and liabilities and for tax loss and credit carry forwards and are measured using the expected tax rates estimated to be in effect when such basis
        differences reverse. Valuation allowances are established, if necessary, to reduce the deferred tax asset to the amount that will, more likely than not, be realized.</span></div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-style: italic;">Concentration of Credit Risk.</span><span style="font-family: 'Times New Roman';"> Financial
        instruments that subject the Company to credit risk consist of cash and cash equivalents. The Company maintains cash and cash equivalents and certificates of deposit with well-capitalized financial institutions. At times, those amounts may exceed
        federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant credit risk beyond the normal credit risk associated with commercial banking relationships. The Company has no other
        significant concentrations of credit risk.</span></div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman';"> <br/>
      </span></div>

<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-style: italic;">Stock-Based Compensation.</span> Stock-based compensation cost is measured at the grant date based on
      the fair value of the award and is recognized as expense over the service period, which generally represents the vesting period. For awards that have performance-based vesting conditions the Company recognizes the expense over the estimated period
      that the awards are expected to be earned. The Company generally uses the Black-Scholes option-pricing model to calculate the grant date fair value of stock options. The expense recognized over the service period is required to include an estimate of
      the awards that will be forfeited.</div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Standards</a></td>
<td class="text">
<div><br/>
      </div>

<div style="margin: 0px 0px 0px 24.45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; text-align: left;">Recently Adopted Accounting Pronouncements</div>

<div style="margin: 0px 0px 0px 24.45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; text-align: left;"> <br/>
      </div>

<div style="margin: 0px 0px 0px 24.45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">In November 2023, the FASB issued ASU 2023-07,&#160;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span>. This guidance is intended to improve reportable segment disclosure requirements through enhanced disclosures as well as clarify that
        entities with a single reportable segment are subject to new and existing segment reporting requirements. This guidance is effective for annual periods in fiscal years beginning after December 15, 2023, and interim periods within fiscal years
        beginning after December 15, 2024, with early adoption permitted. Entities must apply this guidance on a retrospective basis. Accordingly, the Company adopted this new standard for the fiscal year ended December 31, 2024. See footnote 15 for
        segment disclosures.</div>

<div style="margin: 0px 0px 0px 24.45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"> <br/>
      </div>

<div style="margin: 0px 0px 0px 24.45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; text-align: left;">Recent Accounting Pronouncements - Yet to be Adopted</div>

<div style="margin: 0px 0px 0px 24.45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; text-align: left;"> <br/>
      </div>

<div style="margin: 0px 0px 0px 24.45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">In December 2023, the FASB issued ASU 2023-09,&#160;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span>. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate
        reconciliation and income taxes paid both in the United States and in foreign jurisdictions. This guidance is effective for fiscal years beginning after December 15, 2024 on a prospective basis, with the option to apply the standard
        retrospectively, and early adoption is permitted. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements.</div>

<div style="margin: 0px 0px 0px 24.45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"> <br/>
      </div>

<div style="margin: 0px 0px 0px 24.45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">In November 2024, the FASB issued ASU 2024-03,&#160;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</span>. The amendments in ASU 2024-03 address investor requests for more
        detailed expense information and require additional disaggregated disclosures in the notes to financial statements for certain categories of expenses that are included on the face of the income statement. This guidance is effective for fiscal years
        beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated
        financial statements.</div>

<div style="margin: 0px 0px 0px 24.45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"> <br/>
      </div>

<div style="margin: 0px 0px 0px 24.45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">In November 2024, the FASB, issued ASUS 2024-04,&#160;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Debt- Debt with Conversions and Other Option.&#160;</span>ASU 2024-04 is intended to clarify requirements for determining whether certain settlements of convertible debt instruments, including convertible debt instruments with
        cash conversion features or convertible debt instruments that are not currently convertible, should be accounted for as an induced conversion. This ASU is effective for all entities for annual reporting periods beginning after December 15, 2025,
        and interim reporting periods within those annual reporting periods, with early adoption permitted. The Company is currently evaluating the potential impact of this guidance on its disclosures.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_AccruedExpensePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accrued expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_AccruedExpensePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_SecurityDepositPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for security deposit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_SecurityDepositPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property and Equipment</a></td>
<td class="text">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">Property and equipment consist of the following at December 31:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

<div style="margin-left: 27pt;">
        <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;"> 2024<br/>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">2023<br/>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">(in thousands)</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div style="text-indent: -16.2pt; margin-left: 16.2pt;">Leasehold improvements</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>2</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>2</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                <div style="text-indent: -16.2pt; margin-left: 16.2pt;">Computer and office equipment</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>13</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>13</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
                <div style="text-indent: -16.2pt; margin-left: 16.2pt;">Furniture and fixtures</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>59</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>59</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                <div style="text-indent: -16.2pt; margin-left: 16.2pt;">Total</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>74</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>74</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
                <div style="text-indent: -16.2pt; margin-left: 16.2pt;">Less accumulated depreciation and amortization</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>(74</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>(74</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 4px;" valign="bottom">
                <div style="text-indent: -16.2pt; margin-left: 25.2pt;">Property and equipment &#8212; net</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
         </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued Expenses</a></td>
<td class="text">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">Accrued expenses consist of the following at December 31:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

<div style="margin-left: 27pt;">
        <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">2024</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">2023</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">(in thousands)</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Legal and accounting fees</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>74</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>40</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Accrued compensation</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>1,523</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>1,129</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Lease liability </div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>19</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>46</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Accrued research and development costs and other</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div>6,588</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div>7,967</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;"><span style="text-indent: 0pt;"><span style="-sec-ix-hidden:Fact_a8602fa8d1ea4021ae045ee98e73f8f6"><span style="-sec-ix-hidden:Fact_5c08786f5dcb4bc5a62f72d8c0d8264d">Total</span></span></span></div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>8,204</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>9,182</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
         </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value of Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Assets and Liabilities Measured and Recorded at Fair Value on Recurring Basis</a></td>
<td class="text">
<div style="margin-left: 27pt; font-family: 'Times New Roman'; font-size: 10pt;">Level 3 assets and liabilities measured and recorded at fair value on a recurring basis at December 31, 2024 and 2023 were as follows:</div>

<div style="margin-left: 27pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

<div style="margin-left: 27pt;">
        <table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;">


  <tr>

    <td colspan="1" style="vertical-align: bottom; padding-left: 17%; padding-bottom: 2px;" valign="bottom">
                <div style="text-align: center; margin-left: 27pt;"><br/>
                </div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">December 31, 2024<br/>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">December 31, 2023<br/>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 68.7%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Derivative Liability &#8211; Contingent Interest April Note</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.22%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.22%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.94%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>47,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.22%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.22%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.22%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.94%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>431,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.22%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 68.7%;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Derivative Liability &#8211; Contingent Interest September Note</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.22%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.22%; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.94%; white-space: nowrap;" valign="bottom">
                <div>94,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.22%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.22%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.22%; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.94%; white-space: nowrap;" valign="bottom">
                <div>169,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.22%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 68.7%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Derivative Liability &#8211; Contingent Interest December Note</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.22%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.22%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.94%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>275,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.22%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.22%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.22%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.94%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>404,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.22%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
         </div>
<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=galt_ContingentInterestAprilNoteMember', window );">April Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Key Assumptions Used in Model at Inception</a></td>
<td class="text">
<div style="margin-left: 27pt; font-family: 'Times New Roman'; font-size: 10pt;">The April 2021 Note derivative liability &#8211; contingent interest was valued using a Monte Carlo Geometric Brownian Stock Path Model. The key assumptions used in the model
        at December 31, 2024 and 2023 are as follows:</div>

<div style="margin-left: 27pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

<div style="margin-left: 27pt;">
        <table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; width: 70%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                <div style="text-align: center; font-weight: bold;">December 31, 2024<br/>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">December 31, 2023</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 70%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Stock Price</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>1.29</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>1.66</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 70%;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Conversion Price of conversion feature</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom">
                <div>5.00</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom">
                <div>5.00</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 70%;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Term</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman'; text-indent: 25pt; text-align: right;"><span style="font-family: 'Times New Roman'; color: rgb(0, 255, 0);"> <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="text-indent: 0pt;">0.29</span> years</span><br/>
                  </span></div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="text-align: right;">1.29 years<br/>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 70%;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Risk Free Interest Rate</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';">4.37</span></div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';">%</span></div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';">4.79</span></div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';">%</span></div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 70%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Credit Adjusted Discount Rate</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';">12.43</span></div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';">%</span></div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';">12.86</span></div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';">%</span></div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 70%;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Volatility</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom">
                <div>152</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div>%</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom">
                <div>69</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div>%</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 70%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Dividend Rate</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>0</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>%</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>0</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>%</div>
              </td>

  </tr>


</table>
         </div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Roll Forward of Derivative Liability - Contingent Interest</a></td>
<td class="text">
<div style="margin-left: 27pt; font-family: 'Times New Roman'; font-size: 10pt;">The roll forward of the April 2021 Note derivative liability &#8211; contingent interest is as follows:</div>

<div style="margin-left: 27pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

<div style="margin-left: 27pt;">
        <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;">


  <tr>

    <td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Balance &#8211; December 31, <span style="text-indent: 0pt;">2022</span></div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>249,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; padding-bottom: 2px;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Fair Value Adjustment</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div>182,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Balance &#8211; December 31, <span style="text-indent: 0pt;">2023</span></div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>431,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 2px;" valign="bottom">Fair Value Adjustment</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">(384,000</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">Balance &#8211; December 31, 2024</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">47,000</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

      </div>
<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=galt_ContingentInterestSeptemberNoteMember', window );">September Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Key Assumptions Used in Model at Inception</a></td>
<td class="text">
<div style="margin-left: 27pt; font-family: 'Times New Roman'; font-size: 10pt;">The September 2021 Note derivative liability &#8211; contingent interest was valued using a Monte Carlo Geometric Brownian Stock Path Model. The key assumptions used in the
        model at inception, and at December 31, 2024 and 2023 are as follows:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin-left: 27pt;">
        <table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; width: 70%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                <div style="font-weight: bold;">December 31, 2024<br/>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div style="font-weight: bold;">December 31, 2023</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 70%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Stock Price</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>1.29</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>1.66</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 70%;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Conversion Price of conversion feature</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom">
                <div>8.64</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom">
                <div>8.64</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 70%;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Term</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">0.72
                years<br/>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">1.72
                years</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 70%;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Risk Free Interest Rate</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';">4.16</span></div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';">%</span></div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';">4.23</span></div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';">%</span></div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 70%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Credit Adjusted Discount Rate</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';">12.43</span></div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';">%</span></div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';">12.86</span></div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';">%</span></div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 70%;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Volatility</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom">
                <div>111</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div>%</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom">
                <div>75</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div>%</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 70%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Dividend Rate</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>0</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>%</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>0</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>%</div>
              </td>

  </tr>


</table>
         </div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Roll Forward of Derivative Liability - Contingent Interest</a></td>
<td class="text">
<div style="margin-left: 27pt; font-family: 'Times New Roman'; font-size: 10pt;">The roll forward of the September 2021 Note derivative liability &#8211; contingent interest is as follows:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin-left: 27pt;">
        <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;">


  <tr>

    <td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Balance &#8211; December 31, <span style="text-indent: 0pt;">2022</span></div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>109,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; padding-bottom: 2px;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Fair Value Adjustment</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div>60,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Balance &#8211; December 31, <span style="text-indent: 0pt;">2023</span></div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>169,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 2px;" valign="bottom">Fair Value Adjustment</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">(75,000</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">Balance &#8211; December 31, 2024</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">94,000</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

      </div>
<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=galt_ContingentInterestDecemberNoteMember', window );">December Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Key Assumptions Used in Model at Inception</a></td>
<td class="text">
<div style="margin-left: 27pt; font-family: 'Times New Roman'; font-size: 10pt;">The December 2021 Note derivative liability &#8211; contingent interest was valued using a Monte Carlo Geometric Brownian Stock Path Model. The key assumptions used in the
        model at inception, and at December 31, 2024 and 2023 are as follows:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin-left: 27pt;">
        <table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; width: 70%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                <div style="font-weight: bold;">December 31, 2024<br/>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div style="font-weight: bold;">December 31, 2023</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 70%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Stock Price</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>1.29</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>1.66</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 70%;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Conversion Price of conversion feature</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom">
                <div>5.43</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom">
                <div>5.43</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 70%;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Term</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman'; text-indent: 25pt; text-align: right;"><span style="font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="text-indent: 0pt;">0.97</span> years</span></div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="text-indent: 14pt;"><span style="text-indent: 0pt;">1.97</span> years</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 70%;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Risk Free Interest Rate</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';">4.16</span></div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';">%</span></div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';">4.23</span></div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';">%</span></div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 70%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Credit Adjusted Discount Rate</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';">12.43</span></div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';">%</span></div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';">12.86</span></div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';">%</span></div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 70%;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Volatility</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom">
                <div>102</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div>%</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom">
                <div>72</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div>%</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 70%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Dividend Rate</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>0</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>%</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>0</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>%</div>
              </td>

  </tr>


</table>
         </div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Roll Forward of Derivative Liability - Contingent Interest</a></td>
<td class="text">
<div style="margin-left: 27pt; font-family: 'Times New Roman'; font-size: 10pt;">The roll forward of the December 2021 Note derivative liability &#8211; contingent interest is as follows:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="margin-left: 27pt;">
          <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;">


  <tr>

    <td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Balance &#8211; December 31, <span style="text-indent: 0pt;">2022</span></div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>214,000</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; padding-bottom: 2px;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Fair Value Adjustment</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div>190,000</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div></div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Balance &#8211; December 31, <span style="text-indent: 0pt;">2023</span></div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>404,000</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 2px;" valign="bottom">Fair Value Adjustment</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">(129,000</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">Balance &#8211; December 31, 2024</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">275,000</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
        </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=galt_ContingentInterestAprilNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=galt_ContingentInterestAprilNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=galt_ContingentInterestSeptemberNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=galt_ContingentInterestSeptemberNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=galt_ContingentInterestDecemberNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=galt_ContingentInterestDecemberNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_WarrantsAbstract', window );"><strong>Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Summary of Warrants Activity, Outstanding Warrants Issued in Connection with Equity and Debt Financings and Consultants</a></td>
<td class="text">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">Warrant activity is summarized as follows:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

<div style="margin-left: 27pt;">
        <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;">


  <tr>

    <td style="vertical-align: top; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom">
                <div><span style="font-weight: bold;">Warrants</span></div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="font-weight: bold;">Weighted average </div>
                <div style="font-weight: bold;">exercise price</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: top;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Outstanding at December 31, <span style="text-indent: 0pt;">2022</span></div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>11,557,964</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>4.37</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Issued</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>600,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">3.09</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Exercised</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>(2,236,204</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">4.49</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Canceled/Expired</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div>(665,267</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">4.94</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Outstanding at December 31, <span style="text-indent: 0pt;">2023</span></div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>9,256,493</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">
                <div>4.22</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Issued</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>600,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">3.70</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Exercised</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>(142,503</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">3.00</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Canceled/Expired</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div>(118,050</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">4.33</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Outstanding at December 31, <span style="text-indent: 0pt;">2024</span></div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>9,595,940</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                <div>4.21</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
      </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;<br/>
      </div>

<div style="margin-left: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">The following table summarizes information with regard to outstanding warrants issued in connection with equity and debt financings and consultants as of December 31,
        2024.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

<div style="margin-left: 27pt;">
        <table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;">


  <tr>

    <td rowspan="1" style="vertical-align: bottom; font-weight: bold; border-bottom: 2px solid rgb(0, 0, 0); text-align: left;" valign="bottom">Issued in Connection With</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: right; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">Number</div>
                <div style="text-align: center; font-weight: bold;">Outstanding<br/>
                </div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: right; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">Exercise</div>
                <div style="text-align: center; font-weight: bold;">Price</div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;Exercisable Date</td>

    <td rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;Expiration Date</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; text-align: left; width: 25.3333%; text-indent: -9pt; margin-left: 9pt; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="margin-left: 9pt"><span style="text-indent: 0pt;">February 12, 2009</span> Series B-1 Transaction $<span style="text-indent: 0pt;">3.00</span> Investor Warrants &#8211; Class B</div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>1,200,000</div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">3.00</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">February 12, 2009</td>

    <td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">September 30, 2026</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; text-align: left; width: 25.3333%; text-indent: -9pt; margin-left: 9pt;" valign="bottom">
                <div style="margin-left: 9pt"><span style="text-indent: 0pt;">May 13, 2009</span> Series B-2 Transaction $<span style="text-indent: 0pt;">3.00</span> Investor Warrants &#8211; Class B</div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">525,119</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">$ <br/>
              </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">3.00</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; white-space: nowrap;" valign="bottom">May 13, 2009</td>

    <td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; white-space: nowrap;" valign="bottom">September 30, 2026</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 25.3333%; text-indent: -9pt; margin-left: 9pt; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="margin-left: 9pt"><span style="text-indent: 0pt;">June 30, 2009</span> Series B-2 Transaction $<span style="text-indent: 0pt;">3.00</span> Investor Warrants &#8211; Class B</div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">306,547</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">$ <br/>
              </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">3.00</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">June 30, 2009</td>

    <td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">September 30, 2026</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 25.3333%; text-indent: -9pt; margin-left: 9pt;" valign="bottom">
                <div style="margin-left: 9pt"><span style="text-indent: 0pt;">August 12, 2009</span> Series B-2 Transaction $<span style="text-indent: 0pt;">3.00</span> Investor Warrants &#8211; Class B</div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">183,928</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">$ <br/>
              </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">3.00</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; white-space: nowrap;" valign="bottom">August 12, 2009</td>

    <td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; white-space: nowrap;" valign="bottom">September 30, 2026</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 25.3333%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-indent: -9pt; margin-left: 9pt;"><span style="text-indent: 0pt;">September 30, 2009</span> Series B-2 Transaction $<span style="text-indent: 0pt;">3.00</span> Investor Warrants &#8211; Class B</div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">195,922</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">$ <br/>
              </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">3.00</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">September 30, 2009</td>

    <td rowspan="1" style="vertical-align: bottom; width: 25.3333%; text-align: right; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">September 30, 2026</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 25.3333%; text-indent: -9pt; margin-left: 9pt;" valign="bottom">
                <div style="margin-left: 9pt"><span style="text-indent: 0pt;">November 4, 2009</span> Series B-2 Transaction $<span style="text-indent: 0pt;">3.00</span> Investor Warrants &#8211; Class B<br/>
                </div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">85,463</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">$ <br/>
              </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">3.00</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td rowspan="1" style="vertical-align: bottom; width: 25.3333%; text-align: right; white-space: nowrap;" valign="bottom">November 4, 2009</td>

    <td rowspan="1" style="vertical-align: bottom; width: 25.3333%; text-align: right; white-space: nowrap;" valign="bottom">September 30, 2026</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 25.3333%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="margin-left: 9pt; text-indent: -9pt;"><span style="text-indent: 0pt;">December 8, 2009</span> Series B-2 Transaction $<span style="text-indent: 0pt;">3.00</span> Investor Warrants &#8211; Class B<br/>
                </div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">110,919</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">$ <br/>
              </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">3.00</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td rowspan="1" style="vertical-align: bottom; width: 25.3333%; text-align: right; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">December 8, 2009</td>

    <td rowspan="1" style="vertical-align: bottom; width: 25.3333%; text-align: right; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">September 30, 2026</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 25.3333%;" valign="bottom">
                <div style="margin-left: 9pt; text-indent: -9pt;"><span style="text-indent: 0pt;">January 29, 2010</span> Series B-2 Transaction $<span style="text-indent: 0pt;">3.00</span> Investor Warrants &#8211; Class B<br/>
                </div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">198,664</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">$ <br/>
              </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">3.00</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td rowspan="1" style="vertical-align: bottom; width: 25.3333%; text-align: right; white-space: nowrap;" valign="bottom">January 29, 2010</td>

    <td rowspan="1" style="vertical-align: bottom; width: 25.3333%; text-align: right; white-space: nowrap;" valign="bottom">September 30, 2026</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 25.3333%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;"><span style="text-indent: 0pt;">January 29, 2010</span> Series B-2 Transaction $<span style="text-indent: 0pt;">3.00</span> Investor Warrants &#8211; Class B</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>18,003</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>3.00</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td style="vertical-align: bottom; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="text-align: right;">January 29, 2010</div>
              </td>

    <td style="vertical-align: bottom; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="text-align: right;">January 29, 2025</div>
              </td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 25.3333%;" valign="bottom">
                <div style="margin-left: 9pt; text-indent: -9pt;"><span style="text-indent: 0pt;">March 8, 2010</span> Series B-2 Transaction $<span style="text-indent: 0pt;">3.00</span> Investor Warrants &#8211; Class B<br/>
                </div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">184,132</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">$ <br/>
              </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">3.00</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td rowspan="1" style="vertical-align: bottom; width: 25.3333%; text-align: right; white-space: nowrap;" valign="bottom">March 8, 2010</td>

    <td rowspan="1" style="vertical-align: bottom; width: 25.3333%; text-align: right; white-space: nowrap;" valign="bottom">September 30, 2026</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 25.3333%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;"><span style="text-indent: 0pt;">March 8, 2010</span> Series B-2 Transaction $<span style="text-indent: 0pt;">3.00</span> Investor Warrants &#8211; Class B</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>39,202</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>3.00</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td style="vertical-align: bottom; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="text-align: right;">March 8, 2010</div>
              </td>

    <td style="vertical-align: bottom; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="text-align: right;">March 8, 2025</div>
              </td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 25.3333%;" valign="bottom">
                <div style="margin-left: 9pt; text-indent: -9pt;"><span style="text-indent: 0pt;">April 30, 2010</span> Series B-2 Transaction $<span style="text-indent: 0pt;">3.00</span> Investor Warrants &#8211; Class B<br/>
                </div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">180,689</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">$ <br/>
              </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">3.00</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td rowspan="1" style="vertical-align: bottom; width: 25.3333%; text-align: right; white-space: nowrap;" valign="bottom">April 30, 2010</td>

    <td rowspan="1" style="vertical-align: bottom; width: 25.3333%; text-align: right; white-space: nowrap;" valign="bottom">September 30, 2026</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 25.3333%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;"><span style="text-indent: 0pt;">April 30, 2010</span> Series B-2 Transaction $<span style="text-indent: 0pt;">3.00</span> Investor Warrants &#8211; Class B</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>23,503</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>3.00</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td style="vertical-align: bottom; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="text-align: right;">April 30, 2010</div>
              </td>

    <td style="vertical-align: bottom; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="text-align: right;">April 30, 2025</div>
              </td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 25.3333%;" valign="bottom">
                <div style="margin-left: 9pt; text-indent: -9pt;"><span style="text-indent: 0pt;">May 10, 2010</span> Series B-2 Transaction $<span style="text-indent: 0pt;">3.00</span> Investor Warrants &#8211; Class B<br/>
                </div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">112,631</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">$ <br/>
              </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">3.00</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td rowspan="1" style="vertical-align: bottom; width: 25.3333%; text-align: right; white-space: nowrap;" valign="bottom">May 10, 2010</td>

    <td rowspan="1" style="vertical-align: bottom; width: 25.3333%; text-align: right; white-space: nowrap;" valign="bottom">September 30, 2026</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 25.3333%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;"><span style="text-indent: 0pt;">May 10, 2010</span> Series B-2 Transaction $<span style="text-indent: 0pt;">3.00</span> Investor Warrants &#8211; Class B</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>30,535</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>3.00</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td style="vertical-align: bottom; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="text-align: right;">May 10, 2010</div>
              </td>

    <td style="vertical-align: bottom; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="text-align: right;">May 10, 2025</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 25.3333%;" valign="bottom">
                <div style="text-indent: -9pt; margin-left: 9pt;"><span style="text-indent: 0pt;">September 22, 2016</span> Series B-3 Transaction $<span style="text-indent: 0pt;">3.00</span> Investor Warrants &#8211; Class B </div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>682,572</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>3.00</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td style="vertical-align: bottom; width: 25.3333%; white-space: nowrap;" valign="bottom">
                <div style="text-align: right;">September 22, 2016</div>
              </td>

    <td style="vertical-align: bottom; width: 25.3333%; white-space: nowrap;" valign="bottom">
                <div style="text-align: right;">September 30, 2026</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 25.3333%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-indent: -9pt; margin-left: 9pt;"><span style="text-indent: 0pt;">September 29, 2016</span> Series B-3 Transaction $<span style="text-indent: 0pt;">3.00</span> Investor Warrants &#8211; Class B </div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>843,351</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>3.00</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td style="vertical-align: bottom; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="text-align: right;">September 29, 2016</div>
              </td>

    <td style="vertical-align: bottom; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="text-align: right;">September 30, 2026</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 25.3333%;" valign="bottom">
                <div style="text-indent: -9pt; margin-left: 9pt;"><span style="text-indent: 0pt;">December 23, 2016</span> Series B-3 Transaction $<span style="text-indent: 0pt;">3.00</span> Investor Warrants &#8211; Class B </div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>922,316</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>3.00</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td style="vertical-align: bottom; width: 25.3333%; white-space: nowrap;" valign="bottom">
                <div style="text-align: right;">December 23, 2016</div>
              </td>

    <td style="vertical-align: bottom; width: 25.3333%; white-space: nowrap;" valign="bottom">
                <div style="text-align: right;">September 30, 2026</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 25.3333%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">2018 and 2017 Warrants issued for services</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>290</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>5.00</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td style="vertical-align: bottom; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="text-align: right;">Various dates in 2017</div>
                <div style="text-align: right;">and 2018</div>
              </td>

    <td style="vertical-align: bottom; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="text-align: right;">Various dates in <br/>
                </div>
                <div style="text-align: right;">2025</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 25.3333%;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;"><span style="text-indent: 0pt;">May 23, 2019</span> Rights Offering warrants</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>2,622,154</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>7.00</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td style="vertical-align: bottom; width: 25.3333%; white-space: nowrap;" valign="bottom">
                <div style="text-align: right;">May 23, 2019</div>
              </td>

    <td style="vertical-align: bottom; width: 25.3333%; white-space: nowrap;" valign="bottom">
                <div style="text-align: right;">May 23, 2026</div>
              </td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; text-indent: -9pt; margin-left: 9pt; width: 25.3333%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="margin-left: 9pt;"><span style="text-indent: 0pt;">July 22, 2022</span> Warrants issued in connection with related party line of credit</div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">330,000</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">$ <br/>
              </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">5.00</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">July 22, 2022</td>

    <td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">July 31, 2029</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; text-indent: -9pt; margin-left: 9pt; width: 25.3333%;" valign="bottom">
                <div style="margin-left: 9pt;"><span style="text-indent: 0pt;">December 29, 2023</span> Warrants issued for draw on related party line of credit</div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">200,000</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">$ <br/>
              </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">3.00</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; white-space: nowrap;" valign="bottom">December 29, 2023</td>

    <td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; white-space: nowrap;" valign="bottom">July 31, 2029</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 25.3333%; text-align: left; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-indent: -9pt; margin-left: 9pt;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="text-indent: 0pt;">March 29, 2024</span> Warrants issued for draw on related party line of credit</span></div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;200,000<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">$ <br/>
              </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;3.59<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;March 29, 2024<br/>
              </td>

    <td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;July 31, 2029<br/>
              </td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 25.3333%; text-align: left;" valign="bottom">
                <div>
                  <div style="text-indent: -9pt; margin-left: 9pt;"><span style="text-indent: 0pt;">June 28, 2024</span> Warrants issued for draw on related&#160; party line of credit</div>
                </div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;200,000<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">$ <br/>
              </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;3.39<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; white-space: nowrap;" valign="bottom">&#160;June 29, 2024<br/>
              </td>

    <td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; white-space: nowrap;" valign="bottom">&#160;July 31, 2029<br/>
              </td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 25.3333%; padding-bottom: 2px; text-align: left; background-color: rgb(204, 238, 255);" valign="bottom">
                <div>
                  <div style="text-indent: -9pt; margin-left: 9pt;"><span style="text-indent: 0pt;">September 30, 2024</span> Warrants issued for draw on related party line of credit</div>
                </div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;200,000<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">$ <br/>
              </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;4.13<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;September 30, 2024<br/>
              </td>

    <td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;July 31, 2029<br/>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 25.3333%; padding-bottom: 4px;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Total Outstanding Warrants</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>9,595,940</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td style="vertical-align: bottom; width: 25.3333%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td style="vertical-align: bottom; width: 25.3333%; padding-bottom: 4px;" valign="bottom">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>

  </tr>


</table>
          </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_WarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_WarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Components of Stock-Based Compensation Expense</a></td>
<td class="text">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">Following is the stock-based compensation expense related to common stock options, restricted common stock, common stock warrants and deferred stock units:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

<div style="margin-left: 27pt;">
        <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                <div style="text-align: center; font-weight: bold;">Year Ended</div>
                <div style="text-align: center; font-weight: bold;">December 31, <br/>
                </div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                <div style="text-align: center; font-weight: bold;"> 2024</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                <div style="text-align: center; font-weight: bold;">2023</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Research and development</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>1,222</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>829</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">General and administrative</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>1,225</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>1,432</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Total stock-based compensation expense</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>2,447</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>2,261</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
         </div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Weighted Average Assumptions Used to Determine Fair Value of Options Granted</a></td>
<td class="text">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">The fair value of the options granted is determined using the Black-Scholes option-pricing model. The following weighted average assumptions were used:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

<div style="margin-left: 27pt;">
        <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                <div style="text-align: center; font-weight: bold;"> 2024</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                <div style="text-align: center; font-weight: bold;">2023</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Risk-free interest rate</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>3.89</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>%</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>3.84</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>%</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Expected life of the options</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">
                <div style="text-align: right;">5.4 years </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">
                <div style="text-align: right;">5.7 years </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Expected volatility of the underlying stock</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>75.1</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>%</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>85.6</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>%</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Expected dividend rate</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>0</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div>%</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>0</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div>%</div>
              </td>

  </tr>


</table>

      </div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Stock Option Activity</a></td>
<td class="text">
<div style="margin-left: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">The following table summarizes the stock option activity in the stock-based compensation plans:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

<div style="margin-left: 27pt;">
        <table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; width: 53%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">Number of</div>
                <div style="text-align: center; font-weight: bold;">Shares</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">Weighted</div>
                <div style="text-align: center; font-weight: bold;">Average</div>
                <div style="text-align: center; font-weight: bold;">Exercise</div>
                <div style="text-align: center; font-weight: bold;">Price</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="text-align: left; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;
                <div style="text-align: center; font-weight: bold;">Weighted</div>
                <div style="text-align: center; font-weight: bold;">Average</div>
                <div style="text-align: center; font-weight: bold;">Remaining</div>
                <div style="text-align: center; font-weight: bold;">Contractual</div>
                <div style="text-align: center; font-weight: bold;">Life</div>
                <div style="text-align: center; font-weight: bold;">(in years) <br/>
                </div>
              </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;" valign="bottom">&#160;</td>

    <td rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;" valign="bottom">&#160;&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;&#160;&#160;
                <div style="text-align: center; font-weight: bold;">Aggregate</div>
                <div style="text-align: center; font-weight: bold;">Intrinsic Value</div>
                <div style="text-align: center; font-weight: bold;">(in thousands) <br/>
                </div>
              </td>

    <td style="width: 1%; padding-bottom: 2px;">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 53%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Outstanding, December 31, 2022</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>5,745,561</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>2.90</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td style="vertical-align: bottom; width: 8.95%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td style="vertical-align: bottom; width: 7.95%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 53%;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Granted</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; white-space: nowrap;" valign="bottom">
                <div>1,025,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; white-space: nowrap;" valign="bottom">
                <div>1.18</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td style="vertical-align: bottom; width: 8.95%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td style="vertical-align: bottom; width: 7.95%;" valign="bottom">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 53%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Forfeited/Cancelled</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>(436,720</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>2.23</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td style="vertical-align: bottom; width: 8.95%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td style="vertical-align: bottom; width: 7.95%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 53%; padding-bottom: 2px;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Exercised</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.01%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                <div></div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td style="vertical-align: bottom; width: 8.95%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td style="vertical-align: bottom; width: 7.95%; padding-bottom: 2px;" valign="bottom">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 53%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Outstanding, December 31, 2023</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>6,333,841</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>2.66</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td style="vertical-align: bottom; width: 8.95%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td style="vertical-align: bottom; width: 7.95%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 53%;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Granted</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; white-space: nowrap;" valign="bottom">
                <div>1,373,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; white-space: nowrap;" valign="bottom">
                <div>1.86</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td style="vertical-align: bottom; width: 8.95%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td style="vertical-align: bottom; width: 7.95%;" valign="bottom">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 53%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Forfeited/Cancelled</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>(348,750</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>6.35</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td style="vertical-align: bottom; width: 8.95%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td style="vertical-align: bottom; width: 7.95%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 53%; padding-bottom: 2px;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Exercised</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>(503,333</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.01%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>1.71</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td style="vertical-align: bottom; width: 8.95%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">&#160;</td>

    <td style="vertical-align: bottom; width: 7.95%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 53%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Outstanding, December 31, 2024</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>6,854,758<br/>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.01%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>2.39</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td style="vertical-align: bottom; width: 8.95%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div style="text-align: right;">6.27 <br/>
                </div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;$</td>

    <td style="vertical-align: bottom; width: 7.95%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div style="text-align: right;">183<br/>
                </div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 53%;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Exercisable, December 31, 2024</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; white-space: nowrap;" valign="bottom">
                <div>6,138,254<br/>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; white-space: nowrap;" valign="bottom">2.45</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td style="vertical-align: bottom; width: 8.95%; white-space: nowrap;" valign="bottom">
                <div style="text-align: right;">6.00 <br/>
                </div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;$</td>

    <td style="vertical-align: bottom; width: 7.95%; white-space: nowrap;" valign="bottom">
                <div style="text-align: right;">176 </div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
         </div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Outstanding and Exercisable Options under Stock Based Compensation Plans</a></td>
<td class="text">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">The following table summarizes additional information regarding outstanding and exercisable options under our stock-based compensation plans at December 31, 2024:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

<div style="margin-left: 27pt;">
        <table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; width: 39%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="10" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                <div style="text-align: center; font-weight: bold;">Options Outstanding</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                <div style="text-align: center; font-weight: bold;">Options Exercisable</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); width: 39%; white-space: nowrap;" valign="bottom">
                <div style="font-weight: bold;">Exercise</div>
                <div style="font-weight: bold;">Price (Range)</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">Number of</div>
                <div style="text-align: center; font-weight: bold;">Shares</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">Weighted</div>
                <div style="text-align: center; font-weight: bold;">Average</div>
                <div style="text-align: center; font-weight: bold;">Remaining</div>
                <div style="text-align: center; font-weight: bold;">Contractual</div>
                <div style="text-align: center; font-weight: bold;">Life</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">Weighted</div>
                <div style="text-align: center; font-weight: bold;">Average</div>
                <div style="text-align: center; font-weight: bold;">Exercise</div>
                <div style="text-align: center; font-weight: bold;">Price</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">Number of</div>
                <div style="text-align: center; font-weight: bold;">Shares</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">Weighted</div>
                <div style="text-align: center; font-weight: bold;">Average</div>
                <div style="text-align: center; font-weight: bold;">Exercise</div>
                <div style="text-align: center; font-weight: bold;">Price</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 39%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">(in years)</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 39%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div>$0.89 &#8211; 1.50</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>1,134,206</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>7.13</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>1.16</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>934,202</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>1.12</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 39%;" valign="bottom">
                <div>$1.51 &#8211; 2.50</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>3,691,315</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>6.88</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>2.02</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>3,199,815</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>2.02</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 39%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div>$2.51 &#8211; 5.00</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>1,809,237</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>4.88</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>3.48</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>1,784,237</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>3.48</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 39%; padding-bottom: 2px;" valign="bottom">
                <div>$5.01 &#8211; 6.71</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>220,000</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>3.10</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>5.92</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>220,000</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>5.92</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 39%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">&#160;&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>6,854,758<br/>
                </div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>6.27<br/>
                </div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>2.39<br/>
                </div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>6,138,254<br/>
                </div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>2.45<br/>
                </div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

      </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Loss Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">The following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as of December 31, 2024 and 2023
        as the inclusion thereof would have been anti-dilutive:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

<div style="margin-left: 27pt;">
        <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">Year Ended</div>
                <div style="text-align: center; font-weight: bold;">December 31,</div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">2024</div>
                <div style="text-align: center; font-weight: bold;">(Shares)</div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">2023</div>
                <div style="text-align: center; font-weight: bold;">(Shares)</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Warrants to purchase shares of common stock</div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>9,595,940</div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">9,256,493</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Options to purchase shares of common stock</div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>6,854,758</div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">6,333,841</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Shares of common stock issuable upon conversion of convertible notes payable &#8211; related party</div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>7,024,053</div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">6,418,913</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; text-indent: -9pt; margin-left: 9pt; width: 76%;" valign="bottom">
                <div style="margin-left: 9pt;">Shares of common stock issuable upon conversion of convertible line of credit &#8211; related party<br/>
                </div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">25,103,873</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">13,833,356</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Shares of common stock issuable upon conversion preferred stock</div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>499,174</div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">499,174</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
                <div style="font-weight: bold;">49,077,798</div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-weight: bold; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-weight: bold; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">36,341,777</td>

    <td colspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
         </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Maturity of Operating Lease</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">Maturity of operating lease as of December 31, 2024 in thousands:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-size: 10pt; font-family: 'Times New Roman';"><br/>
        </span> </div>

<div style="margin-left: 27pt;">
        <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;">


  <tr>

    <td rowspan="1" style="vertical-align: top; font-size: 10pt; font-family: 'Times New Roman'; width: 88%; background-color: #CCEEFF;" valign="bottom">2025</td>

    <td colspan="1" rowspan="1" style="text-align: right; font-size: 10pt; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><br/>
              </td>

    <td colspan="1" rowspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">19</td>

    <td colspan="1" rowspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-size: 10pt; font-family: 'Times New Roman';">Total</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div style="font-size: 10pt; font-family: 'Times New Roman';">19</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-size: 10pt; font-family: 'Times New Roman';">Less imputed interest</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="font-size: 10pt; font-family: 'Times New Roman';">-</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; padding-bottom: 4px;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-size: 10pt; font-family: 'Times New Roman';">Present value of lease liability</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                <div style="font-size: 10pt; font-family: 'Times New Roman';">$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                <div style="font-size: 10pt; font-family: 'Times New Roman';">19</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
         </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Components of Net Deferred Tax Assets</a></td>
<td class="text">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">The components of the net deferred tax assets are as follows at December 31:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

<div style="margin-left: 27pt;">
        <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="text-align: center; font-weight: bold;"> 2024<br/>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">2023<br/>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">(in thousands)</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Operating loss carryforwards</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">63,057</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>61,427</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Tax credit carryforwards</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">9,010</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>6,476</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Other temporary differences</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">18,276</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>10,533</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">90,343</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>78,436</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Less valuation allowance</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">(90,343</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>(78,436</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 4px;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Net deferred tax asset</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">&#8212;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
         </div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Primary Factors Affecting Income Tax Rates</a></td>
<td class="text">
<div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;">The primary factors affecting the Company&#8217;s income tax rates were as follows:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

<div style="margin-left: 27pt;">
        <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="text-align: center; font-weight: bold;"> 2024<br/>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">2023<br/>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Tax benefit at U.S. statutory rates</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>(21</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>%)</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>(21</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>%)</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">State tax benefit</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>(2.5</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div>%)</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>(3.4</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div>%)</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Permanent differences</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>0.1</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>%</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>0.9</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>%</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Other</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>(4.0</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div>%)</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>2.3</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div>%</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Changes in valuation allowance</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>27.4</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>%</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>21.2</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>%</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                <div style="font-weight: bold;">0</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
                <div style="font-weight: bold;">%</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                <div style="font-weight: bold;">0</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
                <div style="font-weight: bold;">%</div>
              </td>

  </tr>


</table>
         </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Summary of Significant Expense Categories and Asset Categories</a></td>
<td class="text">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; margin-left: 9pt;">The table below summarizes the significant expense categories regularly reviewed by
          the CODM for the years ended December 31, 2024 and 2023 (in thousands).</div>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify;"> <span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
          </span></div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="background-color: rgb(255, 255, 255); letter-spacing: normal; word-spacing: 0px; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: left; text-transform: none; width: 100%; border-spacing: 0;">


  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px;" valign="bottom">
                  <div>&#160;</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Year Ended</div>
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">December 31,</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px;" valign="bottom">
                  <div>&#160;</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                  <div style="text-align: center; font-weight: bold;"> 2024</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                  <div style="text-align: center; font-weight: bold;">2023</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">
                  <div>&#160;</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;"><span style="text-decoration: underline;">(in thousands)</span></div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">
                  <div>Operating expenses:</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div>Research and development</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div>$</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div>36,571</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div>$</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div>32,130</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 2px;" valign="bottom">
                  <div>General and administrative</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div>5,862</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div>5,942</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div>Total operating expenses</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div>42,433</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div>38,072</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 2px;" valign="bottom">
                  <div>Total operating loss</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div>(42,433</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div>)</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div>(38,072</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div>)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div>Other income (expense):</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%;" valign="bottom">
                  <div>Interest income</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div>336</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div>230</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div>Interest expense</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div>(5,540</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div>)</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div>(2,792</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div>)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 2px;" valign="bottom">
                  <div>Change in fair value of derivatives</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div>590</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div>(432</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div>)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div>Total other expense</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div>(4,614)</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div>(2,994</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div>)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 2px;" valign="bottom">
                  <div>Net loss</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div>$</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div>(47,047</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div>)</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div>$</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div>(41,066</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div>)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div>Preferred stock dividends</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div>(153</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div>)</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div>(120</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div>)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 2px;" valign="bottom">
                  <div>Warrant modification</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div>&#8212;</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div>(3,619</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div>)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div>Net loss applicable to common stockholders</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div>$</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div>(47,200</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div>)</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div>$</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div>(44,805</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div>)</div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br class="Apple-interchange-newline"/>
          </span></div>
<span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: 400;">The

















          table below summarizes the significant asset categories regularly reviewed by the CODM for the years ended December 31, 2024 and 2023 (in thousands).</span>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify;"> <span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
          </span></div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="background-color: rgb(255, 255, 255); letter-spacing: normal; word-spacing: 0px; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: left; text-transform: none; width: 100%; border-spacing: 0;">


  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px;" valign="bottom">
                  <div>&#160;</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;">December 31,</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px;" valign="bottom">
                  <div>&#160;</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;"> 2024</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;">2023</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">
                  <div>&#160;</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;">(in thousands)</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; background-color: #CCEEFF;" valign="bottom">
                  <div>Cash and cash equivalents</div>
                </td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>$</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>15,120</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>$</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>25,660</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business, Basis of Presentation, Liquidity, and Going Concern (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>LineofCredit</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 29, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 25, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_NatureOfBusinessBasisOfPresentationsAndLiquidityAbstract', window );"><strong>Nature of Business, Basis of Presentation and Liquidity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 15,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_NumberOfLineOfCredit', window );">Number of line of credit | LineofCredit</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember', window );">Richard E. Uihlein [Member] | Line of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_NatureOfBusinessBasisOfPresentationsAndLiquidityAbstract', window );"><strong>Nature of Business, Basis of Presentation and Liquidity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit</a></td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember', window );">Richard E. Uihlein [Member] | Supplemental Line of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_NatureOfBusinessBasisOfPresentationsAndLiquidityAbstract', window );"><strong>Nature of Business, Basis of Presentation and Liquidity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember', window );">Richard E. Uihlein [Member] | Supplemental Line of Credit [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_NatureOfBusinessBasisOfPresentationsAndLiquidityAbstract', window );"><strong>Nature of Business, Basis of Presentation and Liquidity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_NatureOfBusinessBasisOfPresentationsAndLiquidityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_NatureOfBusinessBasisOfPresentationsAndLiquidityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_NumberOfLineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of available line of credit facility borrowings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_NumberOfLineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=galt_SupplementalLineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=galt_SupplementalLineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies, Cash and Cash Equivalents (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies, Property and Equipment (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=galt_ComputerAndOfficeEquipmentMember', window );">Computer and Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=galt_ComputerAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=galt_ComputerAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies, Security Deposit (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositAssetsAbstract', window );"><strong>Security Deposit [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit for leased office space</a></td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies, Long-Lived Assets (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentLongLivedAssetHeldForUseAbstract', window );"><strong>Long-Lived Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentLongLivedAssetHeldForUseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentLongLivedAssetHeldForUseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies, Warrants (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_WarrantsAbstract', window );"><strong>Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Warrant liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_WarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_WarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 28: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Property and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">$ 74,000<span></span>
</td>
<td class="nump">$ 74,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
<td class="num">(74,000)<span></span>
</td>
<td class="num">(74,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment - net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Property and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=galt_ComputerAndOfficeEquipmentMember', window );">Computer and Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Property and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">13,000<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Property and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">$ 59,000<span></span>
</td>
<td class="nump">$ 59,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=galt_ComputerAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=galt_ComputerAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Legal and accounting fees</a></td>
<td class="nump">$ 74,000<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">1,523,000<span></span>
</td>
<td class="nump">1,129,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liability</a></td>
<td class="nump">$ 19,000<span></span>
</td>
<td class="nump">$ 46,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Total<span></span>
</td>
<td class="text">Total<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_AccruedResearchAndDevelopmentCostsAndOtherCurrent', window );">Accrued research and development costs and other</a></td>
<td class="nump">$ 6,588,000<span></span>
</td>
<td class="nump">$ 7,967,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 8,204,000<span></span>
</td>
<td class="nump">$ 9,182,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_AccruedResearchAndDevelopmentCostsAndOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development costs and other. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_AccruedResearchAndDevelopmentCostsAndOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes Payable - Related Party (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 17, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 14, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 20, 2021 </div>
<div>USD ($) </div>
<div>PromissoryNote </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 17, 2021 </div>
<div>USD ($) </div>
<div>loan </div>
<div>PromissoryNote</div>
</th>
<th class="th">
<div>Apr. 16, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ConvertibleNotesPayableRelatedPartyAbstract', window );"><strong>Convertible Notes Payable - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Fair value of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,000<span></span>
</td>
<td class="nump">$ 1,004,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Change in fair value of derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(588,000)<span></span>
</td>
<td class="nump">432,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=galt_AprilConvertiblePromissoryNoteMember', window );">April 2021 Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ConvertibleNotesPayableRelatedPartyAbstract', window );"><strong>Convertible Notes Payable - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Change in fair value of derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(384,000)<span></span>
</td>
<td class="nump">182,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">420,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseOther', window );">Additional interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105,000<span></span>
</td>
<td class="nump">105,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=galt_AprilConvertiblePromissoryNoteMember', window );">April 2021 Note [Member] | Richard E. Uihlein [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ConvertibleNotesPayableRelatedPartyAbstract', window );"><strong>Convertible Notes Payable - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt financing arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Convertible note principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 16,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 16,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate compounded annually</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Accrued interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 212,000<span></span>
</td>
<td class="nump">207,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_QuarterlyInterestRate', window );">Additional interest rate per quarter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_AnnualInterestRate', window );">Additional interest rate per annum from issuance date to maturity date period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Fair value of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 420,000<span></span>
</td>
<td class="nump">47,000<span></span>
</td>
<td class="nump">431,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Common stock, shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=galt_SeptemberConvertiblePromissoryNoteMember', window );">September 2021 Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ConvertibleNotesPayableRelatedPartyAbstract', window );"><strong>Convertible Notes Payable - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Change in fair value of derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(75,000)<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">433,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseOther', window );">Additional interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 108,000<span></span>
</td>
<td class="nump">108,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=galt_SeptemberConvertiblePromissoryNoteMember', window );">September 2021 Note [Member] | Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ConvertibleNotesPayableRelatedPartyAbstract', window );"><strong>Convertible Notes Payable - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Convertible note payable repayment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=galt_SeptemberConvertiblePromissoryNoteMember', window );">September 2021 Note [Member] | Richard E. Uihlein [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ConvertibleNotesPayableRelatedPartyAbstract', window );"><strong>Convertible Notes Payable - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt financing arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep. 17,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_NumberOfLoansClosing', window );">Number of loans closing | loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_NumberOfPromissoryNotesEvidencedByLoansAgreement', window );">Number of promissory notes evidenced by loans agreement | PromissoryNote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_NumberOfPromissoryNotesExecuted', window );">Number of promissory notes executed | PromissoryNote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate compounded annually</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Accrued interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210,000<span></span>
</td>
<td class="nump">206,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_QuarterlyInterestRate', window );">Additional interest rate per quarter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_AnnualInterestRate', window );">Additional interest rate per annum from issuance date to maturity date period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Fair value of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 433,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,000<span></span>
</td>
<td class="nump">169,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=galt_FirstClosingMember', window );">First Closing [Member] | Richard E. Uihlein [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ConvertibleNotesPayableRelatedPartyAbstract', window );"><strong>Convertible Notes Payable - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt financing arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=galt_SecondClosingMember', window );">Second Closing [Member] | Richard E. Uihlein [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ConvertibleNotesPayableRelatedPartyAbstract', window );"><strong>Convertible Notes Payable - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt financing arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=galt_DecemberConvertiblePromissoryNoteMember', window );">December 2021 Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ConvertibleNotesPayableRelatedPartyAbstract', window );"><strong>Convertible Notes Payable - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Convertible note principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 20,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_NumberOfPromissoryNotesEvidencedByLoansAgreement', window );">Number of promissory notes evidenced by loans agreement | PromissoryNote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate compounded annually</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Accrued interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">209,000<span></span>
</td>
<td class="nump">204,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_QuarterlyInterestRate', window );">Additional interest rate per quarter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_AnnualInterestRate', window );">Additional interest rate per annum from issuance date to maturity date period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Fair value of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 415,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">275,000<span></span>
</td>
<td class="nump">404,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Change in fair value of derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(129,000)<span></span>
</td>
<td class="nump">190,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">415,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseOther', window );">Additional interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104,000<span></span>
</td>
<td class="nump">$ 104,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=galt_DecemberConvertiblePromissoryNoteMember', window );">December 2021 Note [Member] | Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ConvertibleNotesPayableRelatedPartyAbstract', window );"><strong>Convertible Notes Payable - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Convertible note payable repayment</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_AnnualInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent interest rate per annum for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_AnnualInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_ConvertibleNotesPayableRelatedPartyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_ConvertibleNotesPayableRelatedPartyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_NumberOfLoansClosing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of loans closing under the loans agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_NumberOfLoansClosing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_NumberOfPromissoryNotesEvidencedByLoansAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of promissory notes evidenced by loans agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_NumberOfPromissoryNotesEvidencedByLoansAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_NumberOfPromissoryNotesExecuted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of promissory notes executed under the loans agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_NumberOfPromissoryNotesExecuted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_QuarterlyInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent interest rate per quarter for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_QuarterlyInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4CC<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4CC<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=galt_AprilConvertiblePromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=galt_AprilConvertiblePromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=galt_SeptemberConvertiblePromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=galt_SeptemberConvertiblePromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=galt_FirstClosingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=galt_FirstClosingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=galt_SecondClosingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=galt_SecondClosingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=galt_DecemberConvertiblePromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=galt_DecemberConvertiblePromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Instruments, Assets and Liabilities Measured at Fair Value (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Assets and Liabilities Measured at Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative Liability - Contingent Interest</a></td>
<td class="nump">$ 47,000<span></span>
</td>
<td class="nump">$ 1,004,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=galt_ContingentInterestAprilNoteMember', window );">April Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Assets and Liabilities Measured at Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative Liability - Contingent Interest</a></td>
<td class="nump">47,000<span></span>
</td>
<td class="nump">431,000<span></span>
</td>
<td class="nump">$ 249,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=galt_ContingentInterestSeptemberNoteMember', window );">September Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Assets and Liabilities Measured at Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative Liability - Contingent Interest</a></td>
<td class="nump">94,000<span></span>
</td>
<td class="nump">169,000<span></span>
</td>
<td class="nump">109,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=galt_ContingentInterestDecemberNoteMember', window );">December Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Assets and Liabilities Measured at Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative Liability - Contingent Interest</a></td>
<td class="nump">275,000<span></span>
</td>
<td class="nump">404,000<span></span>
</td>
<td class="nump">$ 214,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring [Member] | Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Assets and Liabilities Measured at Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring [Member] | Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Assets and Liabilities Measured at Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring [Member] | April Note [Member] | Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Assets and Liabilities Measured at Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative Liability - Contingent Interest</a></td>
<td class="nump">47,000<span></span>
</td>
<td class="nump">431,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring [Member] | September Note [Member] | Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Assets and Liabilities Measured at Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative Liability - Contingent Interest</a></td>
<td class="nump">94,000<span></span>
</td>
<td class="nump">169,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring [Member] | December Note [Member] | Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Assets and Liabilities Measured at Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative Liability - Contingent Interest</a></td>
<td class="nump">$ 275,000<span></span>
</td>
<td class="nump">$ 404,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetAssetLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetAssetLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=galt_ContingentInterestAprilNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=galt_ContingentInterestAprilNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=galt_ContingentInterestSeptemberNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=galt_ContingentInterestSeptemberNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=galt_ContingentInterestDecemberNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=galt_ContingentInterestDecemberNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments, Key Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Stock Price [Member] | April Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAndInputDescriptionAbstract', window );"><strong>Key Assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">1.29<span></span>
</td>
<td class="nump">1.66<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Stock Price [Member] | September Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAndInputDescriptionAbstract', window );"><strong>Key Assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">1.29<span></span>
</td>
<td class="nump">1.66<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Stock Price [Member] | December Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAndInputDescriptionAbstract', window );"><strong>Key Assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">1.29<span></span>
</td>
<td class="nump">1.66<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputConversionPriceMember', window );">Conversion Price of Conversion Feature [Member] | April Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAndInputDescriptionAbstract', window );"><strong>Key Assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputConversionPriceMember', window );">Conversion Price of Conversion Feature [Member] | September Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAndInputDescriptionAbstract', window );"><strong>Key Assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">8.64<span></span>
</td>
<td class="nump">8.64<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputConversionPriceMember', window );">Conversion Price of Conversion Feature [Member] | December Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAndInputDescriptionAbstract', window );"><strong>Key Assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">5.43<span></span>
</td>
<td class="nump">5.43<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Term [Member] | April Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAndInputDescriptionAbstract', window );"><strong>Key Assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term</a></td>
<td class="text">3 months 14 days<span></span>
</td>
<td class="text">1 year 3 months 14 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Term [Member] | September Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAndInputDescriptionAbstract', window );"><strong>Key Assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term</a></td>
<td class="text">8 months 19 days<span></span>
</td>
<td class="text">1 year 8 months 19 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Term [Member] | December Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAndInputDescriptionAbstract', window );"><strong>Key Assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term</a></td>
<td class="text">11 months 19 days<span></span>
</td>
<td class="text">1 year 11 months 19 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk Free Interest Rate [Member] | April Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAndInputDescriptionAbstract', window );"><strong>Key Assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">0.0437<span></span>
</td>
<td class="nump">0.0479<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk Free Interest Rate [Member] | September Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAndInputDescriptionAbstract', window );"><strong>Key Assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">0.0416<span></span>
</td>
<td class="nump">0.0423<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk Free Interest Rate [Member] | December Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAndInputDescriptionAbstract', window );"><strong>Key Assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">0.0416<span></span>
</td>
<td class="nump">0.0423<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Credit Adjusted Discount Rate [Member] | April Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAndInputDescriptionAbstract', window );"><strong>Key Assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">0.1243<span></span>
</td>
<td class="nump">0.1286<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Credit Adjusted Discount Rate [Member] | September Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAndInputDescriptionAbstract', window );"><strong>Key Assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">0.1243<span></span>
</td>
<td class="nump">0.1286<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Credit Adjusted Discount Rate [Member] | December Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAndInputDescriptionAbstract', window );"><strong>Key Assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">0.1243<span></span>
</td>
<td class="nump">0.1286<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility [Member] | April Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAndInputDescriptionAbstract', window );"><strong>Key Assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">1.52<span></span>
</td>
<td class="nump">0.69<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility [Member] | September Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAndInputDescriptionAbstract', window );"><strong>Key Assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">1.11<span></span>
</td>
<td class="nump">0.75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility [Member] | December Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAndInputDescriptionAbstract', window );"><strong>Key Assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">1.02<span></span>
</td>
<td class="nump">0.72<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend Rate [Member] | April Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAndInputDescriptionAbstract', window );"><strong>Key Assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend Rate [Member] | September Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAndInputDescriptionAbstract', window );"><strong>Key Assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend Rate [Member] | December Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAndInputDescriptionAbstract', window );"><strong>Key Assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAndInputDescriptionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAndInputDescriptionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=galt_ContingentInterestAprilNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=galt_ContingentInterestAprilNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=galt_ContingentInterestSeptemberNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=galt_ContingentInterestSeptemberNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=galt_ContingentInterestDecemberNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=galt_ContingentInterestDecemberNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputConversionPriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputConversionPriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments, Roll Forward of Derivative Liability (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Roll Forward of Derivative Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Balance</a></td>
<td class="nump">$ 1,004,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair Value Adjustment</a></td>
<td class="num">(588,000)<span></span>
</td>
<td class="nump">$ 432,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Balance</a></td>
<td class="nump">47,000<span></span>
</td>
<td class="nump">1,004,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=galt_ContingentInterestAprilNoteMember', window );">April Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Roll Forward of Derivative Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Balance</a></td>
<td class="nump">431,000<span></span>
</td>
<td class="nump">249,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair Value Adjustment</a></td>
<td class="num">(384,000)<span></span>
</td>
<td class="nump">182,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Balance</a></td>
<td class="nump">47,000<span></span>
</td>
<td class="nump">431,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=galt_ContingentInterestSeptemberNoteMember', window );">September Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Roll Forward of Derivative Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Balance</a></td>
<td class="nump">169,000<span></span>
</td>
<td class="nump">109,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair Value Adjustment</a></td>
<td class="num">(75,000)<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Balance</a></td>
<td class="nump">94,000<span></span>
</td>
<td class="nump">169,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=galt_ContingentInterestDecemberNoteMember', window );">December Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Roll Forward of Derivative Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Balance</a></td>
<td class="nump">404,000<span></span>
</td>
<td class="nump">214,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair Value Adjustment</a></td>
<td class="num">(129,000)<span></span>
</td>
<td class="nump">190,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Balance</a></td>
<td class="nump">$ 275,000<span></span>
</td>
<td class="nump">$ 404,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=galt_ContingentInterestAprilNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=galt_ContingentInterestAprilNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=galt_ContingentInterestSeptemberNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=galt_ContingentInterestSeptemberNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=galt_ContingentInterestDecemberNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=galt_ContingentInterestDecemberNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity, Issuance of Common Stock (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_UndesignatedCapitalStockSharesAuthorized', window );">Undesignated stock, shares authorized (in shares)</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Convertible preferred stock, shares authorized (in shares)</a></td>
<td class="nump">1,742,500<span></span>
</td>
<td class="nump">1,742,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Issuance of common stock (in shares)</a></td>
<td class="nump">63,157,235<span></span>
</td>
<td class="nump">61,852,914<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=galt_TwoThousandTwentyMarketAgreementMember', window );">2020 Market Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_AggregateOfferingPrice', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_CommissionRate', window );">Percentage of commission rate to be paid to sales agent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Issuance of common stock (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Convertible preferred stock, shares authorized (in shares)</a></td>
<td class="nump">12,748,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A 12% Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Convertible preferred stock, shares authorized (in shares)</a></td>
<td class="nump">1,742,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=galt_SeriesBOneConvertiblePreferredStockMember', window );">Series B-1 Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Convertible preferred stock, shares authorized (in shares)</a></td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=galt_SeriesBTwoConvertiblePreferredStockMember', window );">Series B-2 Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Convertible preferred stock, shares authorized (in shares)</a></td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=galt_SeriesBThreeConvertiblePreferredStockMember', window );">Series B-3 Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Convertible preferred stock, shares authorized (in shares)</a></td>
<td class="nump">2,508,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C 6% Super Dividend Redeemable Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Convertible preferred stock, shares authorized (in shares)</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_AggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of aggregate offering price of common stock which can be sold from time to time through the sales agent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_AggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_CommissionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of commission rate to be paid to sales agent in gross proceeds from the sale of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_CommissionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_UndesignatedCapitalStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of undesignated capital stock permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_UndesignatedCapitalStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=galt_TwoThousandTwentyMarketAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=galt_TwoThousandTwentyMarketAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=galt_SeriesBOneConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=galt_SeriesBOneConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=galt_SeriesBTwoConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=galt_SeriesBTwoConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=galt_SeriesBThreeConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=galt_SeriesBThreeConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity, Series A 12% Convertible Preferred Stock (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 04, 2008</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.29<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A 12% Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred stock, dividend rate</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price (in dollars per share)</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares issued upon exercise of warrant (in shares)</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_PercentageOfWeightedAverageStockPriceForDividendsPriorToPaymentDate', window );">Weighted average price percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Convertible preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">507,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Common stock issued upon conversion (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,257<span></span>
</td>
<td class="nump">81,152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A 12% Convertible Preferred Stock [Member] | Scenario 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrant (in dollars per share)</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_NumberOfConsecutiveTradingDays', window );">Number of consecutive trading days</a></td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A 12% Convertible Preferred Stock [Member] | Scenario 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrant (in dollars per share)</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_NumberOfConsecutiveTradingDays', window );">Number of consecutive trading days</a></td>
<td class="text">15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A 12% Convertible Preferred Stock [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="nump">$ 18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_NumberOfConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of consecutive trading days, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but not limited to, weeks in a year or quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_NumberOfConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_PercentageOfWeightedAverageStockPriceForDividendsPriorToPaymentDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of weighted average stock price for dividends prior to payment date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_PercentageOfWeightedAverageStockPriceForDividendsPriorToPaymentDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=galt_DividendPaymentScenarioOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=galt_DividendPaymentScenarioOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=galt_DividendPaymentScenarioTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=galt_DividendPaymentScenarioTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity, Series C 6% Super Dividend Redeemable Convertible Preferred Stock (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
<th class="th"><div>Jul. 31, 2011</div></th>
<th class="th"><div>Dec. 30, 2010</div></th>
<th class="th"><div>Dec. 29, 2010</div></th>
<th class="th"><div>Jan. 31, 2011</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Redeemable Convertible Preferred Stock [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,157,235<span></span>
</td>
<td class="nump">61,852,914<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Minimum closing price of common stock (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C 6% Super Dividend Redeemable Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Redeemable Convertible Preferred Stock [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Preferred stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreference', window );">Stated value of dividend payment (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Gross proceeds from issuance of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ProceedsFromIssuanceOfPreferredStockNetOfIssuanceCosts', window );">Net proceeds from issuance of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,073,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ClassOfWarrantOrRightIssued', window );">Warrants issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrant (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_EquityIssuancePerShareAmount', window );">Common stock share conversion price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_CommonSharesIssuableUponConversionOfConvertibleStock', window );">Common stock shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Preferred stock shares upon conversion (in shares)</a></td>
<td class="nump">33,756<span></span>
</td>
<td class="nump">40,193<span></span>
</td>
<td class="nump">8,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">293,340<span></span>
</td>
<td class="nump">293,340<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_NumberOfConsecutiveTradingDays', window );">Number of consecutive trading days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred stock, dividend rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockRedemptionPricePerShare', window );">Preferred stock redemption price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_PostConversionDividendRightsIssued', window );">Post conversion dividend rights (in shares)</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_PostConversionRedemptionRightReturnOnInvestmentMultiplierAmount', window );">Post conversion redemption right, return on investment multiplier amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ClosingDaysAfterConversionRights', window );">Closing days after conversion rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C 6% Super Dividend Redeemable Convertible Preferred Stock [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Redeemable Convertible Preferred Stock [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Preferred stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreference', window );">Stated value of dividend payment (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Convertible preferred stock dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C 6% Super Dividend Redeemable Convertible Preferred Stock [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Redeemable Convertible Preferred Stock [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176<span></span>
</td>
<td class="nump">176<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Minimum closing price of common stock (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C 6% Super Dividend Redeemable Convertible Preferred Stock [Member] | Dividend Payment Scenario One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Redeemable Convertible Preferred Stock [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_DividendAsPercentageOfNetSales', window );">Dividend as percentage of net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C 6% Super Dividend Redeemable Convertible Preferred Stock [Member] | Dividend Payment Scenario Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Redeemable Convertible Preferred Stock [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_DividendAsPercentageOfNetSales', window );">Dividend as percentage of net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_ClassOfWarrantOrRightIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_ClassOfWarrantOrRightIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_ClosingDaysAfterConversionRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of days for preferred stock post conversion rights in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but not limited to, weeks in a year or quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_ClosingDaysAfterConversionRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_CommonSharesIssuableUponConversionOfConvertibleStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock issued per each converted share of Series C (accrued and unpaid dividends will be issued as additional shares).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_CommonSharesIssuableUponConversionOfConvertibleStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_DividendAsPercentageOfNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net sales until the total dividends paid is equal to the initial investment as percentage of total net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_DividendAsPercentageOfNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_EquityIssuancePerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount per share or per unit assigned to the consideration received of equity securities issued for development stage entities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_EquityIssuancePerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_NumberOfConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of consecutive trading days, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but not limited to, weeks in a year or quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_NumberOfConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_PostConversionDividendRightsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares of Series C were converted into common stock and post conversion dividend rights were issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_PostConversionDividendRightsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_PostConversionRedemptionRightReturnOnInvestmentMultiplierAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Multiplied by the preferred stock post conversion redemption right shall be equal the applicable return on investment ("ROI") percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_PostConversionRedemptionRightReturnOnInvestmentMultiplierAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_ProceedsFromIssuanceOfPreferredStockNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_ProceedsFromIssuanceOfPreferredStockNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -SubTopic 405<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477787/942-405-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockRedemptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-5<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockRedemptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=galt_DividendPaymentScenarioOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=galt_DividendPaymentScenarioOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=galt_DividendPaymentScenarioTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=galt_DividendPaymentScenarioTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity, Return on Investment (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>Rights</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ReturnOnInvestmentsPercentageAbstract', window );"><strong>ROI Percentage [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ReturnOnInvestmentsPercentagePeriodOne', window );">ROI before second anniversary of date of issuance</a></td>
<td class="nump">200.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ReturnOnInvestmentsPercentagePeriodTwo', window );">ROI after second anniversary but before third anniversary of date of issuance</a></td>
<td class="nump">250.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ReturnOnInvestmentsPercentagePeriodThree', window );">ROI after third anniversary but before fourth anniversary of date of issuance</a></td>
<td class="nump">300.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ReturnOnInvestmentsPercentagePeriodFour', window );">ROI after fourth anniversary but before fifth anniversary of date of issuance</a></td>
<td class="nump">350.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ReturnOnInvestmentsPercentagePeriodFive', window );">ROI after fifth anniversary but before sixth anniversary of date of issuance</a></td>
<td class="nump">400.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ReturnOnInvestmentsPercentagePeriodSix', window );">ROI after sixth anniversary but before seventh anniversary of date of issuance</a></td>
<td class="nump">450.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ReturnOnInvestmentsPercentagePeriodSeven', window );">ROI after seventh anniversary but before eighth anniversary of date of issuance</a></td>
<td class="nump">500.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ReturnOnInvestmentsPercentagePeriodEight', window );">ROI after eighth anniversary but before ninth anniversary of date of issuance</a></td>
<td class="nump">550.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Redeemable Convertible Preferred Stock [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAggregateAmountOfRedemptionRequirement', window );">Convertible preferred stock, redemption value</a></td>
<td class="nump">$ 8,018,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C 6% Super Dividend Redeemable Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Redeemable Convertible Preferred Stock [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAggregateAmountOfRedemptionRequirement', window );">Convertible preferred stock, redemption value</a></td>
<td class="nump">$ 8,018,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ConvertiblePreferredStockNumberOfVotingRights', window );">Convertible preferred stock, voting rights | Rights</a></td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_ConvertiblePreferredStockNumberOfVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of voting rights of convertible preferred stock. Includes eligibility to vote and votes per share owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_ConvertiblePreferredStockNumberOfVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_ReturnOnInvestmentsPercentageAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_ReturnOnInvestmentsPercentageAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_ReturnOnInvestmentsPercentagePeriodEight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Return on investments after eighth anniversary but before ninth anniversary of date of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_ReturnOnInvestmentsPercentagePeriodEight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_ReturnOnInvestmentsPercentagePeriodFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Return on investments after fifth anniversary but before sixth anniversary of date of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_ReturnOnInvestmentsPercentagePeriodFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_ReturnOnInvestmentsPercentagePeriodFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Return on investments after fourth anniversary but before fifth anniversary of date of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_ReturnOnInvestmentsPercentagePeriodFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_ReturnOnInvestmentsPercentagePeriodOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Return on investments percentage before second anniversary of date of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_ReturnOnInvestmentsPercentagePeriodOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_ReturnOnInvestmentsPercentagePeriodSeven">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Return on investments after seventh anniversary but before eighth anniversary of date of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_ReturnOnInvestmentsPercentagePeriodSeven</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_ReturnOnInvestmentsPercentagePeriodSix">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Return on investments after sixth anniversary but before seventh anniversary of date of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_ReturnOnInvestmentsPercentagePeriodSix</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_ReturnOnInvestmentsPercentagePeriodThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Return on investments after third anniversary but before fourth anniversary of date of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_ReturnOnInvestmentsPercentagePeriodThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_ReturnOnInvestmentsPercentagePeriodTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Return on investments after second anniversary but before third anniversary of date of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_ReturnOnInvestmentsPercentagePeriodTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAggregateAmountOfRedemptionRequirement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount of redemption requirements for each class or type of redeemable stock classified as temporary equity for each of the five years following the latest balance sheet date. The redemption requirement does not constitute an unconditional obligation that will be settled in a variable number of shares constituting a monetary value predominantly indexed to (a) a fixed monetary amount known at inception, (b) an amount inversely correlated with the residual value of the entity, or (c) an amount determined by reference to something other than the fair value of issuer's stock. Does not include mandatorily redeemable stock. The exception is if redemption is required upon liquidation or termination of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAggregateAmountOfRedemptionRequirement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants, Summary of Warrant Activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract', window );"><strong>Weighted Average Exercise Price [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of period (in dollars per share)</a></td>
<td class="nump">$ 4.22<span></span>
</td>
<td class="nump">$ 4.37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice', window );">Issued (in dollars per share)</a></td>
<td class="nump">3.7<span></span>
</td>
<td class="nump">3.09<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">4.49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Canceled/Expired (in dollars per share)</a></td>
<td class="nump">4.33<span></span>
</td>
<td class="nump">4.94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of period (in dollars per share)</a></td>
<td class="nump">$ 4.21<span></span>
</td>
<td class="nump">$ 4.22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Weighted average expiration term of warrants outstanding</a></td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Warrants Activity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at beginning of period (in shares)</a></td>
<td class="nump">9,256,493<span></span>
</td>
<td class="nump">11,557,964<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Issued (in shares)</a></td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(142,503)<span></span>
</td>
<td class="num">(2,236,204)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Canceled/Expired (in shares)</a></td>
<td class="num">(118,050)<span></span>
</td>
<td class="num">(665,267)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at end of period (in shares)</a></td>
<td class="nump">9,595,940<span></span>
</td>
<td class="nump">9,256,493<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares granted when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants, Summary of Purchase Warrants (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 22, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Common Stock Warrants Purchase Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Closing price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockRedemptionPremium', window );">Deemed dividend</a></td>
<td class="nump">$ 3,619,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair Value Assumptions Before and After Extension of warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 4 months 24 days<span></span>
</td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.10%<span></span>
</td>
<td class="nump">85.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.89%<span></span>
</td>
<td class="nump">3.84%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Common Stock Warrants Purchase Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_NumberOfTradingDaysToBeConsideredStockClosingPriceInPurchaseAgreement', window );">Number of consecutive trading days to be considered in purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair Value Assumptions Before and After Extension of warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair Value Assumptions Before and After Extension of warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=galt_One0XFundLPMember', window );">10X Fund L.P [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Common Stock Warrants Purchase Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_PeriodOfPriorNoticeThatWouldBarVoluntaryExerciseOfAnyWarrants', window );">Period of prior notice that would bar voluntary exercise of any warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">61 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | 10X Fund L.P., and 10X Capital Management LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Common Stock Warrants Purchase Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock (in shares)</a></td>
<td class="nump">5,732,253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,732,253<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ThresholdPeriodForExtensionOfExerciseDateOfPurchaseWarrantsUnderAgreement', window );">Threshold period for extension of exercise date of purchase warrants under purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ThresholdPeriodForStockClosingPriceInTenConsecutiveDaysUnderPurchaseWarrantsAgreement', window );">Threshold period for stock closing price in 10 consecutive days under purchase warrants agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | 10X Fund L.P., and 10X Capital Management LLC [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Common Stock Warrants Purchase Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Closing price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=galt_SeriesBWarrantsMember', window );">Series B Warrants [Member] | 10X Fund L.P [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Common Stock Warrants Purchase Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_BeneficialOwnershipPercentage', window );">Beneficial ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair Value Assumptions Before and After Extension of warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 9 months 29 days<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78.00%<span></span>
</td>
<td class="nump">92.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.58%<span></span>
</td>
<td class="nump">3.19%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember', window );">Warrants [Member] | Before Modification [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair Value Assumptions Before and After Extension of warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.37%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember', window );">Warrants [Member] | Before Modification [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair Value Assumptions Before and After Extension of warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">0 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember', window );">Warrants [Member] | Before Modification [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair Value Assumptions Before and After Extension of warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 7 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember', window );">Warrants [Member] | After Modification [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair Value Assumptions Before and After Extension of warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.59%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_BeneficialOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Beneficial ownership percentage of the outstanding shares of the Company's Class A common stock that would allow warrants to be settled in cash upon the occurrence of a tender offer or exchange offer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_BeneficialOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_NumberOfTradingDaysToBeConsideredStockClosingPriceInPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of specified trading days that common stock price must exceed threshold price for specified number of trading days, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_NumberOfTradingDaysToBeConsideredStockClosingPriceInPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_PeriodOfPriorNoticeThatWouldBarVoluntaryExerciseOfAnyWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of prior notice days required that would bar the voluntary exercise of any warrants that would result in beneficial ownership beyond specified percentage, in P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_PeriodOfPriorNoticeThatWouldBarVoluntaryExerciseOfAnyWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_ThresholdPeriodForExtensionOfExerciseDateOfPurchaseWarrantsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold period for extension of exercise date of common stock purchase warrants under purchase agreement in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_ThresholdPeriodForExtensionOfExerciseDateOfPurchaseWarrantsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_ThresholdPeriodForStockClosingPriceInTenConsecutiveDaysUnderPurchaseWarrantsAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold period for stock closing price in ten consecutive days under purchase warrants agreement in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_ThresholdPeriodForStockClosingPriceInTenConsecutiveDaysUnderPurchaseWarrantsAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockRedemptionPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The excess of (1) fair value of the consideration transferred to the holders of the preferred stock over (2) the carrying amount of the preferred stock in the registrant's balance sheet, during the accounting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480408/260-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockRedemptionPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=galt_One0XFundLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=galt_One0XFundLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=galt_One0XFundLPAnd10XCapitalManagementLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=galt_One0XFundLPAnd10XCapitalManagementLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=galt_SeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=galt_SeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=galt_BeforeModificationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=galt_BeforeModificationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=galt_AfterModificationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=galt_AfterModificationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants, Summary of Outstanding Warrants Issued in Connection with Equity and Debt Financing and Consultants (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Outstanding Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number outstanding (in shares) | shares</a></td>
<td class="nump">9,595,940<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=galt_FebruaryTwelveTwentyZeroNineSeriesBOneTransactionMember', window );">February 12, 2009 Series B-1 Transaction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Outstanding Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number outstanding (in shares) | shares</a></td>
<td class="nump">1,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Exercisable date</a></td>
<td class="text">Feb. 12,  2009<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired', window );">Expiration date</a></td>
<td class="text">Sep. 30,  2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_WarrantIssueDate', window );">Warrant issue date</a></td>
<td class="text">Feb. 12,  2009<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_WarrantsIssuedPrice', window );">Warrants issued price (in dollars per share)</a></td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=galt_MayThirteenTwentyZeroNineSeriesBTwoTransactionOneMember', window );">May 13, 2009 Series B-2 Transaction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Outstanding Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number outstanding (in shares) | shares</a></td>
<td class="nump">525,119<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Exercisable date</a></td>
<td class="text">May 13,  2009<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired', window );">Expiration date</a></td>
<td class="text">Sep. 30,  2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_WarrantIssueDate', window );">Warrant issue date</a></td>
<td class="text">May 13,  2009<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_WarrantsIssuedPrice', window );">Warrants issued price (in dollars per share)</a></td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=galt_JuneThirtyTwentyZeroNineSeriesBTwoTransactionOneMember', window );">June 30, 2009 Series B-2 Transaction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Outstanding Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number outstanding (in shares) | shares</a></td>
<td class="nump">306,547<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Exercisable date</a></td>
<td class="text">Jun. 30,  2009<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired', window );">Expiration date</a></td>
<td class="text">Sep. 30,  2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_WarrantIssueDate', window );">Warrant issue date</a></td>
<td class="text">Jun. 30,  2009<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_WarrantsIssuedPrice', window );">Warrants issued price (in dollars per share)</a></td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=galt_AugustTwelveTwentyZeroNineSeriesBTwoTransactionOneMember', window );">August 12, 2009 Series B-2 Transaction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Outstanding Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number outstanding (in shares) | shares</a></td>
<td class="nump">183,928<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Exercisable date</a></td>
<td class="text">Aug. 12,  2009<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired', window );">Expiration date</a></td>
<td class="text">Sep. 30,  2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_WarrantIssueDate', window );">Warrant issue date</a></td>
<td class="text">Aug. 12,  2009<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_WarrantsIssuedPrice', window );">Warrants issued price (in dollars per share)</a></td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=galt_SeptemberThirtyTwentyZeroNineSeriesBTwoTransactionOneMember', window );">September 30, 2009 Series B-2 Transaction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Outstanding Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number outstanding (in shares) | shares</a></td>
<td class="nump">195,922<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Exercisable date</a></td>
<td class="text">Sep. 30,  2009<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired', window );">Expiration date</a></td>
<td class="text">Sep. 30,  2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_WarrantIssueDate', window );">Warrant issue date</a></td>
<td class="text">Sep. 30,  2009<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_WarrantsIssuedPrice', window );">Warrants issued price (in dollars per share)</a></td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=galt_NovemberFourTwentyZeroNineSeriesBTwoTransactionOneMember', window );">November 4, 2009 Series B-2 Transaction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Outstanding Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number outstanding (in shares) | shares</a></td>
<td class="nump">85,463<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Exercisable date</a></td>
<td class="text">Nov.  04,  2009<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired', window );">Expiration date</a></td>
<td class="text">Sep. 30,  2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_WarrantIssueDate', window );">Warrant issue date</a></td>
<td class="text">Nov.  04,  2009<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_WarrantsIssuedPrice', window );">Warrants issued price (in dollars per share)</a></td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=galt_DecemberEightTwentyZeroNineSeriesBTwoTransactionOneMember', window );">December 8, 2009 Series B-2 Transaction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Outstanding Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number outstanding (in shares) | shares</a></td>
<td class="nump">110,919<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Exercisable date</a></td>
<td class="text">Dec.  08,  2009<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired', window );">Expiration date</a></td>
<td class="text">Sep. 30,  2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_WarrantIssueDate', window );">Warrant issue date</a></td>
<td class="text">Dec.  08,  2009<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_WarrantsIssuedPrice', window );">Warrants issued price (in dollars per share)</a></td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=galt_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionOneMember', window );">January 29, 2010 Series B-2 Transaction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Outstanding Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number outstanding (in shares) | shares</a></td>
<td class="nump">198,664<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Exercisable date</a></td>
<td class="text">Jan. 29,  2010<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired', window );">Expiration date</a></td>
<td class="text">Sep. 30,  2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_WarrantIssueDate', window );">Warrant issue date</a></td>
<td class="text">Jan. 29,  2010<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_WarrantsIssuedPrice', window );">Warrants issued price (in dollars per share)</a></td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=galt_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionTwoMember', window );">January 29, 2010 Series B-2 Transaction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Outstanding Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number outstanding (in shares) | shares</a></td>
<td class="nump">18,003<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Exercisable date</a></td>
<td class="text">Jan. 29,  2010<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired', window );">Expiration date</a></td>
<td class="text">Jan. 29,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_WarrantIssueDate', window );">Warrant issue date</a></td>
<td class="text">Jan. 29,  2010<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_WarrantsIssuedPrice', window );">Warrants issued price (in dollars per share)</a></td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=galt_MarchEightTwentyTenSeriesBTwoTransactionOneMember', window );">March 8, 2010 Series B-2 Transaction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Outstanding Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number outstanding (in shares) | shares</a></td>
<td class="nump">184,132<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Exercisable date</a></td>
<td class="text">Mar.  08,  2010<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired', window );">Expiration date</a></td>
<td class="text">Sep. 30,  2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_WarrantIssueDate', window );">Warrant issue date</a></td>
<td class="text">Mar.  08,  2010<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_WarrantsIssuedPrice', window );">Warrants issued price (in dollars per share)</a></td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=galt_MarchEightTwentyTenSeriesBTwoTransactionTwoMember', window );">March 8, 2010 Series B-2 Transaction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Outstanding Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number outstanding (in shares) | shares</a></td>
<td class="nump">39,202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Exercisable date</a></td>
<td class="text">Mar.  08,  2010<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired', window );">Expiration date</a></td>
<td class="text">Mar.  08,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_WarrantIssueDate', window );">Warrant issue date</a></td>
<td class="text">Mar.  08,  2010<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_WarrantsIssuedPrice', window );">Warrants issued price (in dollars per share)</a></td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=galt_AprilThirtyTwentyTenSeriesBTwoTransactionOneMember', window );">April 30, 2010 Series B-2 Transaction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Outstanding Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number outstanding (in shares) | shares</a></td>
<td class="nump">180,689<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Exercisable date</a></td>
<td class="text">Apr. 30,  2010<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired', window );">Expiration date</a></td>
<td class="text">Sep. 30,  2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_WarrantIssueDate', window );">Warrant issue date</a></td>
<td class="text">Apr. 30,  2010<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_WarrantsIssuedPrice', window );">Warrants issued price (in dollars per share)</a></td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=galt_AprilThirtyTwentyTenSeriesBTwoTransactionTwoMember', window );">April 30, 2010 Series B-2 Transaction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Outstanding Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number outstanding (in shares) | shares</a></td>
<td class="nump">23,503<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Exercisable date</a></td>
<td class="text">Apr. 30,  2010<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired', window );">Expiration date</a></td>
<td class="text">Apr. 30,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_WarrantIssueDate', window );">Warrant issue date</a></td>
<td class="text">Apr. 30,  2010<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_WarrantsIssuedPrice', window );">Warrants issued price (in dollars per share)</a></td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=galt_MayTenTwentyTenSeriesBTwoTransactionOneMember', window );">May 10, 2010 Series B-2 Transaction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Outstanding Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number outstanding (in shares) | shares</a></td>
<td class="nump">112,631<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Exercisable date</a></td>
<td class="text">May 10,  2010<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired', window );">Expiration date</a></td>
<td class="text">Sep. 30,  2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_WarrantIssueDate', window );">Warrant issue date</a></td>
<td class="text">May 10,  2010<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_WarrantsIssuedPrice', window );">Warrants issued price (in dollars per share)</a></td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=galt_MayTenTwentyTenSeriesBTwoTransactionTwoMember', window );">May 10, 2010 Series B-2 Transaction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Outstanding Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number outstanding (in shares) | shares</a></td>
<td class="nump">30,535<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Exercisable date</a></td>
<td class="text">May 10,  2010<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired', window );">Expiration date</a></td>
<td class="text">May 10,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_WarrantIssueDate', window );">Warrant issue date</a></td>
<td class="text">May 10,  2010<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_WarrantsIssuedPrice', window );">Warrants issued price (in dollars per share)</a></td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=galt_SeptemberTwentyTwoTwentySixteenSeriesBThreeTransactionMember', window );">September 22, 2016 Series B-3 Transaction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Outstanding Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number outstanding (in shares) | shares</a></td>
<td class="nump">682,572<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Exercisable date</a></td>
<td class="text">Sep. 22,  2016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired', window );">Expiration date</a></td>
<td class="text">Sep. 30,  2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_WarrantIssueDate', window );">Warrant issue date</a></td>
<td class="text">Sep. 22,  2016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_WarrantsIssuedPrice', window );">Warrants issued price (in dollars per share)</a></td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=galt_SeptemberTwentyNineTwentySixteenSeriesBThreeTransactionMember', window );">September 29, 2016 Series B-3 Transaction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Outstanding Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number outstanding (in shares) | shares</a></td>
<td class="nump">843,351<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Exercisable date</a></td>
<td class="text">Sep. 29,  2016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired', window );">Expiration date</a></td>
<td class="text">Sep. 30,  2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_WarrantIssueDate', window );">Warrant issue date</a></td>
<td class="text">Sep. 29,  2016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_WarrantsIssuedPrice', window );">Warrants issued price (in dollars per share)</a></td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=galt_DecemberTwentyThreeTwentySixteenSeriesBThreeTransactionMember', window );">December 23, 2016 Series B-3 Transaction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Outstanding Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number outstanding (in shares) | shares</a></td>
<td class="nump">922,316<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Exercisable date</a></td>
<td class="text">Dec. 23,  2016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired', window );">Expiration date</a></td>
<td class="text">Sep. 30,  2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_WarrantIssueDate', window );">Warrant issue date</a></td>
<td class="text">Dec. 23,  2016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_WarrantsIssuedPrice', window );">Warrants issued price (in dollars per share)</a></td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=galt_TwentyEighteenAndTwentySeventeenWarrantsIssuedForServicesMember', window );">2018 and 2017 Warrants issued for services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Outstanding Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number outstanding (in shares) | shares</a></td>
<td class="nump">290<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=galt_MayTwentyThreeTwentyNinteenRightsOfferingWarrantsMember', window );">May 23, 2019 Rights Offering warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Outstanding Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number outstanding (in shares) | shares</a></td>
<td class="nump">2,622,154<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Exercisable date</a></td>
<td class="text">May 23,  2019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired', window );">Expiration date</a></td>
<td class="text">May 23,  2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_WarrantIssueDate', window );">Warrant issue date</a></td>
<td class="text">May 23,  2019<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=galt_July222022WarrantsIssuedInConnectionWithRelatedPartyLineOfCreditMember', window );">July 22, 2022 Warrants Issued in Connection with Related Party Line of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Outstanding Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number outstanding (in shares) | shares</a></td>
<td class="nump">330,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Exercisable date</a></td>
<td class="text">Jul. 22,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired', window );">Expiration date</a></td>
<td class="text">Jul. 31,  2029<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_WarrantIssueDate', window );">Warrant issue date</a></td>
<td class="text">Jul. 22,  2022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=galt_December292023WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember', window );">December 29, 2023 Warrants Issued for Draw on Related Party Line of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Outstanding Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number outstanding (in shares) | shares</a></td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Exercisable date</a></td>
<td class="text">Dec. 29,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired', window );">Expiration date</a></td>
<td class="text">Jul. 31,  2029<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_WarrantIssueDate', window );">Warrant issue date</a></td>
<td class="text">Dec. 29,  2023<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=galt_March292024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember', window );">March 29, 2024 Warrants Issued for Draw on Related Party Line of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Outstanding Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number outstanding (in shares) | shares</a></td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 3.59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Exercisable date</a></td>
<td class="text">Mar. 29,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired', window );">Expiration date</a></td>
<td class="text">Jul. 31,  2029<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_WarrantIssueDate', window );">Warrant issue date</a></td>
<td class="text">Mar. 29,  2024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=galt_June282024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember', window );">June 28, 2024 Warrants Issued for Draw on Related Party Line of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Outstanding Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number outstanding (in shares) | shares</a></td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 3.39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Exercisable date</a></td>
<td class="text">Jun. 29,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired', window );">Expiration date</a></td>
<td class="text">Jul. 31,  2029<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_WarrantIssueDate', window );">Warrant issue date</a></td>
<td class="text">Jun. 28,  2024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=galt_September302024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember', window );">September 30, 2024 Warrants Issued for Draw on Related Party Line of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Outstanding Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number outstanding (in shares) | shares</a></td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 4.13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Exercisable date</a></td>
<td class="text">Sep. 30,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired', window );">Expiration date</a></td>
<td class="text">Jul. 31,  2029<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_WarrantIssueDate', window );">Warrant issue date</a></td>
<td class="text">Sep. 30,  2024<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the warrants or rights are expired, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_WarrantIssueDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the warrants or rights are issued, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_WarrantIssueDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_WarrantsIssuedPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_WarrantsIssuedPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the warrants or rights are exercisable, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=galt_FebruaryTwelveTwentyZeroNineSeriesBOneTransactionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=galt_FebruaryTwelveTwentyZeroNineSeriesBOneTransactionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=galt_MayThirteenTwentyZeroNineSeriesBTwoTransactionOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=galt_MayThirteenTwentyZeroNineSeriesBTwoTransactionOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=galt_JuneThirtyTwentyZeroNineSeriesBTwoTransactionOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=galt_JuneThirtyTwentyZeroNineSeriesBTwoTransactionOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=galt_AugustTwelveTwentyZeroNineSeriesBTwoTransactionOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=galt_AugustTwelveTwentyZeroNineSeriesBTwoTransactionOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=galt_SeptemberThirtyTwentyZeroNineSeriesBTwoTransactionOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=galt_SeptemberThirtyTwentyZeroNineSeriesBTwoTransactionOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=galt_NovemberFourTwentyZeroNineSeriesBTwoTransactionOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=galt_NovemberFourTwentyZeroNineSeriesBTwoTransactionOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=galt_DecemberEightTwentyZeroNineSeriesBTwoTransactionOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=galt_DecemberEightTwentyZeroNineSeriesBTwoTransactionOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=galt_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=galt_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=galt_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=galt_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=galt_MarchEightTwentyTenSeriesBTwoTransactionOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=galt_MarchEightTwentyTenSeriesBTwoTransactionOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=galt_MarchEightTwentyTenSeriesBTwoTransactionTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=galt_MarchEightTwentyTenSeriesBTwoTransactionTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=galt_AprilThirtyTwentyTenSeriesBTwoTransactionOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=galt_AprilThirtyTwentyTenSeriesBTwoTransactionOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=galt_AprilThirtyTwentyTenSeriesBTwoTransactionTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=galt_AprilThirtyTwentyTenSeriesBTwoTransactionTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=galt_MayTenTwentyTenSeriesBTwoTransactionOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=galt_MayTenTwentyTenSeriesBTwoTransactionOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=galt_MayTenTwentyTenSeriesBTwoTransactionTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=galt_MayTenTwentyTenSeriesBTwoTransactionTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=galt_SeptemberTwentyTwoTwentySixteenSeriesBThreeTransactionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=galt_SeptemberTwentyTwoTwentySixteenSeriesBThreeTransactionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=galt_SeptemberTwentyNineTwentySixteenSeriesBThreeTransactionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=galt_SeptemberTwentyNineTwentySixteenSeriesBThreeTransactionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=galt_DecemberTwentyThreeTwentySixteenSeriesBThreeTransactionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=galt_DecemberTwentyThreeTwentySixteenSeriesBThreeTransactionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=galt_TwentyEighteenAndTwentySeventeenWarrantsIssuedForServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=galt_TwentyEighteenAndTwentySeventeenWarrantsIssuedForServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=galt_MayTwentyThreeTwentyNinteenRightsOfferingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=galt_MayTwentyThreeTwentyNinteenRightsOfferingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=galt_July222022WarrantsIssuedInConnectionWithRelatedPartyLineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=galt_July222022WarrantsIssuedInConnectionWithRelatedPartyLineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=galt_December292023WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=galt_December292023WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=galt_March292024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=galt_March292024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=galt_June282024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=galt_June282024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=galt_September302024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=galt_September302024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stock-Based Compensation, Summary of Stock-Based Compensation Plans (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=galt_EquityIncentivePlan2019Member', window );">Equity Incentive Plan 2019 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Stock-Based Compensation Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">7,000,000<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Stock awards, available for future grant (in shares)</a></td>
<td class="nump">4,135,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=galt_IncentiveCompensationPlanTwoThousandNineMemberMember', window );">Incentive Compensation Plan 2009 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Stock-Based Compensation Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized for issuance (in shares)</a></td>
<td class="nump">6,733,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=galt_EquityIncentivePlan2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=galt_EquityIncentivePlan2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=galt_IncentiveCompensationPlanTwoThousandNineMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=galt_IncentiveCompensationPlanTwoThousandNineMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation, Components of Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Stock-Based Compensation Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 2,447<span></span>
</td>
<td class="nump">$ 2,261<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Stock-Based Compensation Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">1,222<span></span>
</td>
<td class="nump">829<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Stock-Based Compensation Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 1,225<span></span>
</td>
<td class="nump">$ 1,432<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation, Weighted Average Assumptions Used to Determine Fair Value of Options Granted (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted Average Assumptions for Stock Options Granted [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.89%<span></span>
</td>
<td class="nump">3.84%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of the options</a></td>
<td class="text">5 years 4 months 24 days<span></span>
</td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility of the underlying stock</a></td>
<td class="nump">75.10%<span></span>
</td>
<td class="nump">85.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield used in the option valuation model</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted Average Assumptions for Stock Options Granted [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of the options</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfAward', window );">Award term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted Average Assumptions for Stock Options Granted [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of the options</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfAward', window );">Award term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Refers to the terms of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but not limited to, weeks in a year or quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation, Stock Option Activity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Stock Option Activity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of period (in shares)</a></td>
<td class="nump">6,333,841<span></span>
</td>
<td class="nump">5,745,561<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">1,373,000<span></span>
</td>
<td class="nump">1,025,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited/cancelled (in shares)</a></td>
<td class="num">(348,750)<span></span>
</td>
<td class="num">(436,720)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(503,333)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of period (in shares)</a></td>
<td class="nump">6,854,758<span></span>
</td>
<td class="nump">6,333,841<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable, end of period (in shares)</a></td>
<td class="nump">6,138,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of period (in dollars per share)</a></td>
<td class="nump">$ 2.66<span></span>
</td>
<td class="nump">$ 2.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">1.86<span></span>
</td>
<td class="nump">1.18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited/cancelled (in dollars per share)</a></td>
<td class="nump">6.35<span></span>
</td>
<td class="nump">2.23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">1.71<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of period (in dollars per share)</a></td>
<td class="nump">2.39<span></span>
</td>
<td class="nump">2.66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, end of period (in dollars per share)</a></td>
<td class="nump">$ 2.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingTermAbstract', window );"><strong>Weighted Average Remaining Contractual Life [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Outstanding end of the period</a></td>
<td class="text">6 years 3 months 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable, end of the period</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding at end of period</a></td>
<td class="nump">$ 183,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable, end of period</a></td>
<td class="nump">$ 176,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract', window );"><strong>Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Closing price (in dollars per share)</a></td>
<td class="nump">$ 1.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair values of options granted (in dollars per share)</a></td>
<td class="nump">$ 1.26<span></span>
</td>
<td class="nump">$ 0.85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Unvested option (in shares)</a></td>
<td class="nump">716,504<span></span>
</td>
<td class="nump">1,792,080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 775,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation cost, recognition period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Options vested (in shares)</a></td>
<td class="nump">1,966,167<span></span>
</td>
<td class="nump">1,119,168<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Total fair value of options vested</a></td>
<td class="nump">$ 2,772,748<span></span>
</td>
<td class="nump">$ 1,384,284<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation, Outstanding and Exercisable Options under Stock Based Compensation Plans (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_OptionsOutstandingAbstract', window );"><strong>Options Outstanding [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Number of Shares (in shares) | shares</a></td>
<td class="nump">6,854,758<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life</a></td>
<td class="text">6 years 3 months 7 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options Outstanding, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 2.39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_OptionsExercisableAbstract', window );"><strong>Options Exercisable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Number of Shares (in shares) | shares</a></td>
<td class="nump">6,138,254<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable, Number of Shares (in dollars per share)</a></td>
<td class="nump">$ 2.45<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=galt_ExercisePriceRangeOneMember', window );">$0.87-$1.00 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_OptionsOutstandingAbstract', window );"><strong>Options Outstanding [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Number of Shares (in shares) | shares</a></td>
<td class="nump">1,134,206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life</a></td>
<td class="text">7 years 1 month 17 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options Outstanding, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 1.16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_OptionsExercisableAbstract', window );"><strong>Options Exercisable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Number of Shares (in shares) | shares</a></td>
<td class="nump">934,202<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable, Number of Shares (in dollars per share)</a></td>
<td class="nump">$ 1.12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=galt_ExercisePriceRangeTwoMember', window );">$1.01-$3.00 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_OptionsOutstandingAbstract', window );"><strong>Options Outstanding [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Number of Shares (in shares) | shares</a></td>
<td class="nump">3,691,315<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life</a></td>
<td class="text">6 years 10 months 17 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options Outstanding, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 2.02<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_OptionsExercisableAbstract', window );"><strong>Options Exercisable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Number of Shares (in shares) | shares</a></td>
<td class="nump">3,199,815<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable, Number of Shares (in dollars per share)</a></td>
<td class="nump">$ 2.02<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=galt_ExercisePriceRangeThreeMember', window );">$3.01-$5.00 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_OptionsOutstandingAbstract', window );"><strong>Options Outstanding [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Number of Shares (in shares) | shares</a></td>
<td class="nump">1,809,237<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life</a></td>
<td class="text">4 years 10 months 17 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options Outstanding, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 3.48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_OptionsExercisableAbstract', window );"><strong>Options Exercisable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Number of Shares (in shares) | shares</a></td>
<td class="nump">1,784,237<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable, Number of Shares (in dollars per share)</a></td>
<td class="nump">$ 3.48<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=galt_ExercisePriceRangeFourMember', window );">$5.01 - $8.00 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_OptionsOutstandingAbstract', window );"><strong>Options Outstanding [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Number of Shares (in shares) | shares</a></td>
<td class="nump">220,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life</a></td>
<td class="text">3 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options Outstanding, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 5.92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_OptionsExercisableAbstract', window );"><strong>Options Exercisable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Number of Shares (in shares) | shares</a></td>
<td class="nump">220,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable, Number of Shares (in dollars per share)</a></td>
<td class="nump">$ 5.92<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | $0.87-$1.00 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_OptionsOutstandingAbstract', window );"><strong>Options Outstanding [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Minimum Exercise Price (in dollars per share)</a></td>
<td class="nump">0.89<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | $1.01-$3.00 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_OptionsOutstandingAbstract', window );"><strong>Options Outstanding [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Minimum Exercise Price (in dollars per share)</a></td>
<td class="nump">1.51<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | $3.01-$5.00 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_OptionsOutstandingAbstract', window );"><strong>Options Outstanding [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Minimum Exercise Price (in dollars per share)</a></td>
<td class="nump">2.51<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | $5.01 - $8.00 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_OptionsOutstandingAbstract', window );"><strong>Options Outstanding [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Minimum Exercise Price (in dollars per share)</a></td>
<td class="nump">5.01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | $0.87-$1.00 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_OptionsOutstandingAbstract', window );"><strong>Options Outstanding [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Maximum Exercise Price (in dollars per share)</a></td>
<td class="nump">1.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | $1.01-$3.00 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_OptionsOutstandingAbstract', window );"><strong>Options Outstanding [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Maximum Exercise Price (in dollars per share)</a></td>
<td class="nump">2.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | $3.01-$5.00 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_OptionsOutstandingAbstract', window );"><strong>Options Outstanding [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Maximum Exercise Price (in dollars per share)</a></td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | $5.01 - $8.00 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_OptionsOutstandingAbstract', window );"><strong>Options Outstanding [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Maximum Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 6.71<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_OptionsExercisableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_OptionsExercisableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_OptionsOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_OptionsOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=galt_ExercisePriceRangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=galt_ExercisePriceRangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=galt_ExercisePriceRangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=galt_ExercisePriceRangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=galt_ExercisePriceRangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=galt_ExercisePriceRangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=galt_ExercisePriceRangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=galt_ExercisePriceRangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation, Restricted Stock Issuances (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>Director </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>Director </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-based Payment Arrangement, Noncash Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Amortized expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,447,000<span></span>
</td>
<td class="nump">$ 2,261,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-based Payment Arrangement, Noncash Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_NumberOfDirectors', window );">Number of Directors | Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock awards granted (in shares) | shares</a></td>
<td class="nump">408,000<span></span>
</td>
<td class="nump">36,036<span></span>
</td>
<td class="nump">23,256<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Restricted stock units valued at grant</a></td>
<td class="nump">$ 734,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_VestingPercentageOfRestrictedStockUnits', window );">Vesting percentage of Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Amortized expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_NumberOfDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of directors of the company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_NumberOfDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_VestingPercentageOfRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>'The vesting percentage of Restricted Stock Units ("RSUs") granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_VestingPercentageOfRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation, Deferred Stock Units (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_RestrictedStockGrantsAbstract', window );"><strong>Restricted Stock Grants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 775,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_RestrictedStockGrantsAbstract', window );"><strong>Restricted Stock Grants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense', window );">Stock based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 459,000<span></span>
</td>
<td class="nump">$ 418,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer [Member] | Deferred Bonus [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_RestrictedStockGrantsAbstract', window );"><strong>Restricted Stock Grants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent', window );">Percentage of base salary paid in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent', window );">Percentage of base salary paid in deferred stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne', window );">Percentage of DSUs shall be credited on March 1, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo', window );">Percentage of DSUs shall be credited on March 1, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree', window );">Percentage of DSUs shall be credited on September 1, 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFour', window );">Percentage of DSUs shall be credited on March 1, 2024</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFive', window );">Percentage of DSUs shall be credited on March 1, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscribedButUnissued', window );">Shares unissued (in shares)</a></td>
<td class="nump">367,800<span></span>
</td>
<td class="nump">183,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Shares withheld to cover income tax withholding (in shares)</a></td>
<td class="nump">153,288<span></span>
</td>
<td class="nump">75,529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Income tax payment withholding</a></td>
<td class="nump">$ 300,445<span></span>
</td>
<td class="nump">$ 156,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Shares issued (in shares)</a></td>
<td class="nump">214,512<span></span>
</td>
<td class="nump">108,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSix', window );">Percentage of DSUs shall be credited on March 1, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSeven', window );">Percentage of DSUs shall be credited on January 5, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">275,126<span></span>
</td>
<td class="nump">268,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice', window );">Common Stock Weighted average Grant Date fair Value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.71<span></span>
</td>
<td class="nump">$ 1.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer [Member] | Bonus Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_RestrictedStockGrantsAbstract', window );"><strong>Restricted Stock Grants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense', window );">Stock based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,836<span></span>
</td>
<td class="nump">103,627<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice', window );">Common Stock Weighted average Grant Date fair Value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.46<span></span>
</td>
<td class="nump">$ 1.93<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Reclassification of accrued compensation to additional paid in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of underlying the outstanding whole number of DSUs credited individuals during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of underlying the outstanding whole number of DSUs credited individuals during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of underlying the outstanding whole number of DSUs credited individuals during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSeven">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of underlying the outstanding whole number of DSUs credited individuals during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSeven</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSix">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of underlying the outstanding whole number of DSUs credited individuals during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSix</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of underlying the outstanding whole number of DSUs credited individuals during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of underlying the outstanding whole number of DSUs credited individuals during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The deferred compensation arrangement with individual cash award granted paid in cash percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The deferred compensation arrangement with individual cash award granted paid in deferred stock units percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_RestrictedStockGrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_RestrictedStockGrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesSubscribedButUnissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesSubscribedButUnissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense recognized from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments), awarded to key employees or individuals. Excludes amount related to plans that cover generally all employees (for example, but not limited to, qualified pension plans).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The per share price that the individual must pay to acquire shares under the deferred compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued pursuant to the terms of a deferred compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis=us-gaap_DeferredBonusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis=us-gaap_DeferredBonusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis=galt_BonusSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis=galt_BonusSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Line of Credit - Related Party and Supplemental Lines of Credit - Related Party (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Nov. 14, 2024</div></th>
<th class="th"><div>Jun. 28, 2024</div></th>
<th class="th"><div>Mar. 29, 2024</div></th>
<th class="th"><div>Dec. 29, 2023</div></th>
<th class="th"><div>Dec. 19, 2022</div></th>
<th class="th"><div>Jul. 25, 2022</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_LineOfCreditRelatedPartyAbstract', window );"><strong>Convertible Line of Credit - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from lines of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 4 months 24 days<span></span>
</td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.10%<span></span>
</td>
<td class="nump">85.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.89%<span></span>
</td>
<td class="nump">3.84%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_LineOfCreditRelatedPartyAbstract', window );"><strong>Convertible Line of Credit - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_IssuanceOfWarrantsValue', window );">Warrants issuance value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 738,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 9 months 29 days<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78.00%<span></span>
</td>
<td class="nump">92.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.58%<span></span>
</td>
<td class="nump">3.19%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Amortization of interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210,000<span></span>
</td>
<td class="nump">$ 209,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=galt_WarrantOneMember', window );">Warrant One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_LineOfCreditRelatedPartyAbstract', window );"><strong>Convertible Line of Credit - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_IssuanceOfWarrantsValue', window );">Warrants issuance value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 160,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.06%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Amortization of interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,000<span></span>
</td>
<td class="nump">51,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=galt_WarrantTwoMember', window );">Warrant Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_LineOfCreditRelatedPartyAbstract', window );"><strong>Convertible Line of Credit - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_IssuanceOfWarrantsValue', window );">Warrants issuance value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 260,000<span></span>
</td>
<td class="nump">$ 277,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 179,920<span></span>
</td>
<td class="nump">$ 296,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 193,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 10 days<span></span>
</td>
<td class="text">5 years 3 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">6 years 3 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77.00%<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="nump">88.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.29%<span></span>
</td>
<td class="nump">4.19%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.59%<span></span>
</td>
<td class="nump">3.94%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.49%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Amortization of interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105,000<span></span>
</td>
<td class="nump">79,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=galt_WarrantThreeMember', window );">Warrant Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_LineOfCreditRelatedPartyAbstract', window );"><strong>Convertible Line of Credit - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Amortization of interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,000<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=galt_WarrantFourMember', window );">Warrant Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_LineOfCreditRelatedPartyAbstract', window );"><strong>Convertible Line of Credit - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Amortization of interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=galt_WarrantFiveMember', window );">Warrant Five [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_LineOfCreditRelatedPartyAbstract', window );"><strong>Convertible Line of Credit - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Amortization of interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=galt_WarrantSixMember', window );">Warrant Six [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_LineOfCreditRelatedPartyAbstract', window );"><strong>Convertible Line of Credit - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Amortization of interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=galt_WarrantSevenMember', window );">Warrant Seven [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_LineOfCreditRelatedPartyAbstract', window );"><strong>Convertible Line of Credit - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Amortization of interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_LineOfCreditRelatedPartyAbstract', window );"><strong>Convertible Line of Credit - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_LineOfCreditRelatedPartyAbstract', window );"><strong>Convertible Line of Credit - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember', window );">Richard E. Uihlein [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_LineOfCreditRelatedPartyAbstract', window );"><strong>Convertible Line of Credit - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock', window );">Percentage of warrants equal to the closing price of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrants expiry date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 31,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember', window );">Richard E. Uihlein [Member] | Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_LineOfCreditRelatedPartyAbstract', window );"><strong>Convertible Line of Credit - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrant (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember', window );">Richard E. Uihlein [Member] | Warrant One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_LineOfCreditRelatedPartyAbstract', window );"><strong>Convertible Line of Credit - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrant (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.39<span></span>
</td>
<td class="nump">$ 3.59<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 3.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember', window );">Richard E. Uihlein [Member] | Line of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_LineOfCreditRelatedPartyAbstract', window );"><strong>Convertible Line of Credit - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease', window );">Additional short term borrowing interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Promissory note, maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 31,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Borrowings repayment due date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 31,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from lines of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest rate on short term loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.01%<span></span>
</td>
<td class="nump">6.62%<span></span>
</td>
<td class="nump">7.13%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Short term borrowing interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.01%<span></span>
</td>
<td class="nump">4.62%<span></span>
</td>
<td class="nump">5.13%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Short term borrowing effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.40%<span></span>
</td>
<td class="nump">7.10%<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember', window );">Richard E. Uihlein [Member] | Line of Credit [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_LineOfCreditRelatedPartyAbstract', window );"><strong>Convertible Line of Credit - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember', window );">Richard E. Uihlein [Member] | Line of Credit [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_LineOfCreditRelatedPartyAbstract', window );"><strong>Convertible Line of Credit - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember', window );">Richard E. Uihlein [Member] | Line of Credit [Member] | December 2022 Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_LineOfCreditRelatedPartyAbstract', window );"><strong>Convertible Line of Credit - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease', window );">Additional short term borrowing interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from lines of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest rate on short term loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.46%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Short term borrowing interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.46%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Short term borrowing effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_DebtInstrumentAccruedInterest', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,399,000<span></span>
</td>
<td class="nump">688,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember', window );">Richard E. Uihlein [Member] | Line of Credit [Member] | March 2023 Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_LineOfCreditRelatedPartyAbstract', window );"><strong>Convertible Line of Credit - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease', window );">Additional short term borrowing interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from lines of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest rate on short term loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.41%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Short term borrowing interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.41%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Short term borrowing effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_DebtInstrumentAccruedInterest', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,184,000<span></span>
</td>
<td class="nump">491,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember', window );">Richard E. Uihlein [Member] | Line of Credit [Member] | June 2023 Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_LineOfCreditRelatedPartyAbstract', window );"><strong>Convertible Line of Credit - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease', window );">Additional short term borrowing interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from lines of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest rate on short term loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.34%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Short term borrowing interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.34%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Short term borrowing effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_DebtInstrumentAccruedInterest', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">995,000<span></span>
</td>
<td class="nump">$ 321,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember', window );">Richard E. Uihlein [Member] | Line of Credit [Member] | December 2023 Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_LineOfCreditRelatedPartyAbstract', window );"><strong>Convertible Line of Credit - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_DebtInstrumentAccruedInterest', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">737,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember', window );">Richard E. Uihlein [Member] | Line of Credit [Member] | March 2024 Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_LineOfCreditRelatedPartyAbstract', window );"><strong>Convertible Line of Credit - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_DebtInstrumentAccruedInterest', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">508,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember', window );">Richard E. Uihlein [Member] | Line of Credit [Member] | June 2024 Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_LineOfCreditRelatedPartyAbstract', window );"><strong>Convertible Line of Credit - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_DebtInstrumentAccruedInterest', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">336,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember', window );">Richard E. Uihlein [Member] | Line of Credit [Member] | September 2024 Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_LineOfCreditRelatedPartyAbstract', window );"><strong>Convertible Line of Credit - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_DebtInstrumentAccruedInterest', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 154,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember', window );">Richard E. Uihlein [Member] | Supplemental Line of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_LineOfCreditRelatedPartyAbstract', window );"><strong>Convertible Line of Credit - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease', window );">Additional short term borrowing interest rate</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Promissory note, maturity date</a></td>
<td class="text">Mar. 31,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 31,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Borrowings repayment due date</a></td>
<td class="text">Mar. 31,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 31,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from lines of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrant (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest rate on short term loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.13%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Short term borrowing interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.01%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Short term borrowing effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock', window );">Percentage of warrants equal to the closing price of common stock</a></td>
<td class="nump">150.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrants expiry date</a></td>
<td class="text">Jul. 31,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 31,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_IssuanceOfWarrantsValue', window );">Warrants issuance value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 307,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember', window );">Richard E. Uihlein [Member] | Supplemental Line of Credit [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_LineOfCreditRelatedPartyAbstract', window );"><strong>Convertible Line of Credit - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember', window );">Richard E. Uihlein [Member] | Supplemental Line of Credit [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_LineOfCreditRelatedPartyAbstract', window );"><strong>Convertible Line of Credit - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember', window );">Richard E. Uihlein [Member] | Additional Supplemental Line of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_LineOfCreditRelatedPartyAbstract', window );"><strong>Convertible Line of Credit - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease', window );">Additional short term borrowing interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Promissory note, maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 31,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Borrowings repayment due date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 31,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock', window );">Percentage of warrants equal to the closing price of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrants expiry date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 31,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember', window );">Richard E. Uihlein [Member] | Additional Supplemental Line of Credit [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_LineOfCreditRelatedPartyAbstract', window );"><strong>Convertible Line of Credit - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember', window );">Richard E. Uihlein [Member] | Additional Supplemental Line of Credit [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_LineOfCreditRelatedPartyAbstract', window );"><strong>Convertible Line of Credit - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Richard E. Uihlein [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_LineOfCreditRelatedPartyAbstract', window );"><strong>Convertible Line of Credit - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock (in shares)</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Richard E. Uihlein [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_LineOfCreditRelatedPartyAbstract', window );"><strong>Convertible Line of Credit - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase additional common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of additional warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of exercise price per share or per unit of warrants equal to common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_DebtInstrumentAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued, but unpaid interest on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_DebtInstrumentAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_IssuanceOfWarrantsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of issuance of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_IssuanceOfWarrantsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_LineOfCreditRelatedPartyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_LineOfCreditRelatedPartyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Incremental percentage increase (decrease) in the stated rate on a debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=galt_WarrantOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=galt_WarrantOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=galt_WarrantTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=galt_WarrantTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=galt_WarrantThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=galt_WarrantThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=galt_WarrantFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=galt_WarrantFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=galt_WarrantFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=galt_WarrantFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=galt_WarrantSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=galt_WarrantSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=galt_WarrantSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=galt_WarrantSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=galt_December2022PromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=galt_December2022PromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=galt_March2023PromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=galt_March2023PromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=galt_June2023PromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=galt_June2023PromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=galt_December2023PromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=galt_December2023PromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=galt_March24PromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=galt_March24PromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=galt_June2024PromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=galt_June2024PromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=galt_September2024PromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=galt_September2024PromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=galt_SupplementalLineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=galt_SupplementalLineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=galt_AdditionalSupplementalLineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=galt_AdditionalSupplementalLineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Amount excluded from calculation (in shares)</a></td>
<td class="nump">49,077,798<span></span>
</td>
<td class="nump">36,341,777<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Amount excluded from calculation (in shares)</a></td>
<td class="nump">9,595,940<span></span>
</td>
<td class="nump">9,256,493<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Amount excluded from calculation (in shares)</a></td>
<td class="nump">6,854,758<span></span>
</td>
<td class="nump">6,333,841<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes Payable - Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Amount excluded from calculation (in shares)</a></td>
<td class="nump">7,024,053<span></span>
</td>
<td class="nump">6,418,913<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_LineOfCreditMember', window );">Line of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Amount excluded from calculation (in shares)</a></td>
<td class="nump">25,103,873<span></span>
</td>
<td class="nump">13,833,356<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Amount excluded from calculation (in shares)</a></td>
<td class="nump">499,174<span></span>
</td>
<td class="nump">499,174<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>Lease</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescriptionAbstract', window );"><strong>Lease Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_NumberOfOperatingLeases', window );">Number of operating leases | Lease</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Term of contract</a></td>
<td class="text">38 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_FreeRentPeriod', window );">Free rent period</a></td>
<td class="text">6 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right to use lease asset</a></td>
<td class="nump">$ 16,000<span></span>
</td>
<td class="nump">$ 46,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Other Assets, Noncurrent<span></span>
</td>
<td class="text">Other Assets, Noncurrent<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current lease liability</a></td>
<td class="nump">$ 19,000<span></span>
</td>
<td class="nump">$ 46,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Accrued expenses<span></span>
</td>
<td class="text">Accrued expenses<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Other liabilities<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease renewal term</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Maturity of Operating Lease [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">$ 19,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">19,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liability</a></td>
<td class="nump">$ 19,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Discount rate on present value of lease payments</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ClinicalTrialAndResearchContingenciesAbstract', window );"><strong>Clinical Trial and Research Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ContractCancelationNoticePeriod', window );">Contract cancelation notice period</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Vendors disputed claim amount</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyRangeOfPossibleLossPortionNotAccrued', window );">Additional accrued amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescriptionAbstract', window );"><strong>Lease Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Lease cost</a></td>
<td class="nump">$ 44,000<span></span>
</td>
<td class="nump">$ 44,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_ClinicalTrialAndResearchContingenciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_ClinicalTrialAndResearchContingenciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_ContractCancelationNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract cancelation notice period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_ContractCancelationNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_FreeRentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Free rent period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_FreeRentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_NumberOfOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating leases during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_NumberOfOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescriptionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescriptionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyRangeOfPossibleLossPortionNotAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum amount of estimated loss and the amount recorded as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyRangeOfPossibleLossPortionNotAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Galectin Sciences LLC (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">84 Months Ended</th>
<th class="th" colspan="1">120 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract', window );"><strong>Investments in and Advances to Affiliates, Schedule of Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Amount expanded in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (10,540,000)<span></span>
</td>
<td class="nump">$ 7,068,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=galt_GalectinSciencesLLCMember', window );">Galectin Sciences, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract', window );"><strong>Investments in and Advances to Affiliates, Schedule of Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Initial cash investment</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Amount expanded in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_CapitalContributionExpense', window );">Contribution for expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73,000<span></span>
</td>
<td class="nump">$ 350,000<span></span>
</td>
<td class="nump">$ 561,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,552,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss from equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_NonCashChargeForResearchAndDevelopmentInProcess', window );">Non-cash charge for in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=galt_GalectinSciencesLLCMember', window );">Galectin Sciences, LLC [Member] | SBH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract', window );"><strong>Investments in and Advances to Affiliates, Schedule of Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_CapitalContributionExpense', window );">Contribution for expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 711,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=galt_GalectinSciencesLLCMember', window );">Galectin Sciences, LLC [Member] | SBH [Member] | IPR&amp;D [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract', window );"><strong>Investments in and Advances to Affiliates, Schedule of Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure', window );">Estimated fair value of asset contributed to joint venture</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_CapitalContributionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capital contribution expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_CapitalContributionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_NonCashChargeForResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-cash charge in research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_NonCashChargeForResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investments in an entity not consolidated. Includes, but is not limited to, investments in an entity that is affiliated with the reporting entity by means of direct or indirect ownership, an entity in which the reporting entity shares control of the entity with another party or group, an entity which the company has significant influence, but does not have control and subsidiaries that are not required to be consolidated and are accounted for using the equity or cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=galt_GalectinSciencesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=galt_GalectinSciencesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=galt_SBHSciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=galt_SBHSciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes, Components of Net Deferred Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract', window );"><strong>Deferred Tax Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 63,057<span></span>
</td>
<td class="nump">$ 61,427<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credit carryforwards</a></td>
<td class="nump">9,010<span></span>
</td>
<td class="nump">6,476<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other temporary differences</a></td>
<td class="nump">18,276<span></span>
</td>
<td class="nump">10,533<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax assets, gross</a></td>
<td class="nump">90,343<span></span>
</td>
<td class="nump">78,436<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less valuation allowance</a></td>
<td class="num">(90,343)<span></span>
</td>
<td class="num">(78,436)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax asset</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes, Primary Factors Affecting Income Tax Rates (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Primary Factors Affecting Income Tax Rates [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Tax benefit at U.S. statutory rates</a></td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(21.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax benefit</a></td>
<td class="num">(2.50%)<span></span>
</td>
<td class="num">(3.40%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Permanent differences</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(4.00%)<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Changes in valuation allowance</a></td>
<td class="nump">27.40%<span></span>
</td>
<td class="nump">21.20%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Income tax rate, total</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Federal and Sate [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_DeferredTaxAssetsValuationAllowancePercentage', window );">Deferred tax asset valuation allowance percentage in each of the last two years</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_OperatingLossCarryforwardsExpirationYear', window );">Operating loss carryforwards expiration year</a></td>
<td class="text">2037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_FederalAndStateResearchAndDevelopmentCreditsExpirationYear', window );">Federal and state research and development credits expiration year</a></td>
<td class="text">2042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Federal and Sate [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research and development credits</a></td>
<td class="nump">$ 7,764,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member] | Expiring as a Result of 2017 Tax Act [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Federal and Sate [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">131,579,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member] | Expiring Through 2037 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Federal and Sate [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">120,055,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Federal and Sate [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research and development credits</a></td>
<td class="nump">1,245,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State [Member] | Expiring as a Result of 2017 Tax Act [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Federal and Sate [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">137,878,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State [Member] | Expiring Through 2037 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Federal and Sate [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 102,003,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_DeferredTaxAssetsValuationAllowancePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The deferred tax assets valuation allowance percentage in each of the last two years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_DeferredTaxAssetsValuationAllowancePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_FederalAndStateResearchAndDevelopmentCreditsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The federal and state research and development credits expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_FederalAndStateResearchAndDevelopmentCreditsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration year of each operating loss carryforward included in operating loss carryforward, in YYYY format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=galt_ExpiringAsAResultOf2017TaxActMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=galt_ExpiringAsAResultOf2017TaxActMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=galt_ExpiringThrough2037Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=galt_ExpiringThrough2037Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments - Significant Expense Categories (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 36,571<span></span>
</td>
<td class="nump">$ 32,130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">5,862<span></span>
</td>
<td class="nump">5,942<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">42,433<span></span>
</td>
<td class="nump">38,072<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating loss</a></td>
<td class="num">(42,433)<span></span>
</td>
<td class="num">(38,072)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">338<span></span>
</td>
<td class="nump">230<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(5,540)<span></span>
</td>
<td class="num">(2,792)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Change in fair value of derivatives</a></td>
<td class="nump">588<span></span>
</td>
<td class="num">(432)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense</a></td>
<td class="num">(4,614)<span></span>
</td>
<td class="num">(2,994)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(47,047)<span></span>
</td>
<td class="num">(41,066)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsAndOtherAdjustments', window );">Preferred stock dividends</a></td>
<td class="num">(153)<span></span>
</td>
<td class="num">(120)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_FairValueAdjustmentOfWarrant', window );">Warrant modification</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,619)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss applicable to common stockholders</a></td>
<td class="num">$ (47,200)<span></span>
</td>
<td class="num">(44,805)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">$ (41,767)<span></span>
</td>
<td class="num">(32,965)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=galt_BusinessOperatingSegmentMember', window );">Business Operating Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">36,571<span></span>
</td>
<td class="nump">32,130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">5,862<span></span>
</td>
<td class="nump">5,942<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">42,433<span></span>
</td>
<td class="nump">38,072<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating loss</a></td>
<td class="num">(42,433)<span></span>
</td>
<td class="num">(38,072)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">336<span></span>
</td>
<td class="nump">230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(5,540)<span></span>
</td>
<td class="num">(2,792)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Change in fair value of derivatives</a></td>
<td class="nump">590<span></span>
</td>
<td class="num">(432)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense</a></td>
<td class="num">(4,614)<span></span>
</td>
<td class="num">(2,994)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(47,047)<span></span>
</td>
<td class="num">(41,066)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsAndOtherAdjustments', window );">Preferred stock dividends</a></td>
<td class="num">(153)<span></span>
</td>
<td class="num">(120)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_FairValueAdjustmentOfWarrant', window );">Warrant modification</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,619)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss applicable to common stockholders</a></td>
<td class="num">$ (47,200)<span></span>
</td>
<td class="num">$ (44,805)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_FairValueAdjustmentOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_FairValueAdjustmentOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4CC<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4CC<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsAndOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsAndOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=galt_BusinessOperatingSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=galt_BusinessOperatingSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Segments - Significant Asset Categories (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 15,120<span></span>
</td>
<td class="nump">$ 25,660<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=galt_BusinessOperatingSegmentMember', window );">Business Operating Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 15,120<span></span>
</td>
<td class="nump">$ 25,660<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=galt_BusinessOperatingSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=galt_BusinessOperatingSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 29, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 28, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 29, 2023</div></th>
<th class="th"><div>Dec. 19, 2022</div></th>
<th class="th"><div>Jul. 25, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_LineOfCreditRelatedPartyAbstract', window );"><strong>Convertible Line of Credit - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember', window );">Richard E. Uihlein [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_LineOfCreditRelatedPartyAbstract', window );"><strong>Convertible Line of Credit - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock', window );">Percentage of warrants equal to the closing price of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrants expiry date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 31,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember', window );">Richard E. Uihlein [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_LineOfCreditRelatedPartyAbstract', window );"><strong>Convertible Line of Credit - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock (in shares)</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember', window );">Richard E. Uihlein [Member] | Common Stock [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_LineOfCreditRelatedPartyAbstract', window );"><strong>Convertible Line of Credit - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=galt_SupplementalLineOfCreditMember', window );">Supplemental Line of Credit [Member] | Richard E. Uihlein [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_LineOfCreditRelatedPartyAbstract', window );"><strong>Convertible Line of Credit - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease', window );">Additional short term borrowing interest rate</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Promissory note, maturity date</a></td>
<td class="text">Mar. 31,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 31,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock', window );">Percentage of warrants equal to the closing price of common stock</a></td>
<td class="nump">150.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrants expiry date</a></td>
<td class="text">Jul. 31,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 31,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=galt_SupplementalLineOfCreditMember', window );">Supplemental Line of Credit [Member] | Richard E. Uihlein [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_LineOfCreditRelatedPartyAbstract', window );"><strong>Convertible Line of Credit - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit</a></td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=galt_SupplementalLineOfCreditMember', window );">Supplemental Line of Credit [Member] | Richard E. Uihlein [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_LineOfCreditRelatedPartyAbstract', window );"><strong>Convertible Line of Credit - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=galt_SupplementalLineOfCreditMember', window );">Supplemental Line of Credit [Member] | Richard E. Uihlein [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_galt_LineOfCreditRelatedPartyAbstract', window );"><strong>Convertible Line of Credit - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of exercise price per share or per unit of warrants equal to common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_galt_LineOfCreditRelatedPartyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">galt_LineOfCreditRelatedPartyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>galt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Incremental percentage increase (decrease) in the stated rate on a debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=galt_SupplementalLineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=galt_SupplementalLineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>86
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( % ^?UI&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( % ^?UK^11E.\0   "L"   1
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MB/>Y@!$MC_%[9"S!;1 NB,<SP E4>:#OCKCZ\%X+T&@4,*56!5B& 1MW\0N
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MYDWDN:$U??BRR;!M0X%R:C!D&O7&WH#EZ'BJ56['M?'Z$E:A';<@MG%[FO9
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M5HT3$GP&'?@)( >Y!D#C]R_O6.!T"H=V4GV=)H>67KNY7]R"Q=WT?K2:S;^
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M>LZYN-U("**3*Y.;[N:^BP:M E%M4RM&S1^');EI\<UCC,DY6 +(ZUN*:)R
MEH1!8KUVJ9<OMFEUFJ+L1PD,B:HCCU^R_F5(D8K8>>P+V'1HW[C2KOZ(G:ZM
MKPY?U+J\&)^7*)O(Q;AI&E/?2 O6KH)19?&P%?=FJ3W'(!!8QR[Q"X*)A"NR
M(#>@-%"A:P:NBE&X%2EP$V_B! "?B_&"*DH>7B$4E!<PB(*9R7E-4^WGMT1G
MIY47L+TGJWV$SVA?2EOV4OI'SNRO.NP:+BFJP9(<8"/5E_M@+Y ):XG1$15H
MKA08UZ5H*+VI]1Q.O=G45D(W4LTQ"&8:*=' FA;2>-#YM'78UZQUTY)GMYQL
M*]^2F[JJ+:'/$I4^RKI:^AWQ?6H3\N,0P7.*L1)V6@I)_Q5YE>Y1<M?!NUYZ
MP2U\XU&L-Y5TU=4EQQ12@T0G+5DZ5PE;N^EZ:Y$\YJ8;>:4":,B8&C+&4XW.
MX)E-JGIW()SB3Z;2/23Y?IEP0R!=\"IHRE!Y-%'OR9]3?=XUD;O:I<":&ZX\
M8%(!8,X@*#S&5'A<]_;LY'!^J9O4RY$+H OX^#Z,!KTO$+)RR#D$<I)==V%]
MCXF!(GH9P0:1W<?#0<V0Z_R";N"X&J]-%,#FF&/B$_7ZYH$[[7IVR_YA7Q5U
M8$:S.W@G0]FN?TH""8/K"')L2-_YP: N8V604P]G]DW+44Y3 :QB-S,-52*Y
M<N\7R""LZ&/!1A/Z/%2U:>"]8 _)Q7M'=C _3P=D_$^ZHJ3DT-AB>]J45K+#
M<I;<5=K =*DR,5>1UJ+/#)9""(VV:Y<K <:&IZG< X[2ASR&]JFD(91/"<_!
M=P,,7U&B+M@6Y!+,)KG%7N&5/&1NN)*5FV.>/UQJ6TLX]^.D_ZNLU 6U7+6F
M<1?8'F L$16WWA-@W[F*5#%]FV"_N"VUS7"+2N;-%.>#;=0*SPT/T'L*4DFD
M^QT",LH 6WJ6+RTTU.4YGLG+^D@<0)UD.2F<&1*YV.0V20[=Z91D8 TN?V_S
M;#"ZXDZX'/0&>^?U8)A\J"OGDLFRO$%$2,4(L<E:^$37"/?D!+EM*.2VX6:Q
M-;QXHR#W;9U30G<)I)O4+ ^G]M<RH&6L<D,*_:'IBF._*!3QNWXZ#;9O'WO=
MN-%Y>?,6Y:X[!>388C@N%Z=M4JLO]QR4_^8F;DVR0=_W];4[ Q2.(0*#&ZR;
MY]$P#<+3VMJ%A /@U4890=!;5$PI_W*KE:<7?578SQE 1NJP/FVDT0@@4.[8
MV'>X(9G3+6PQ%(NNTGQ 2'W)EU 2%E*"T^F@B_"Q:(6!U7:A4 6C7>6[4O9P
M) T!^6YDVVF[:^4DCW4EQ$B<M+87AN>4<!VT:*-T9T67$\CM9PXL$&CF OM,
ME/01A2A27G?9:9L0?3NX7>SZD8&S@Y&D8ZICNY$UP5$>_=\_9Z?ZF"(JW+U!
M'B+P.$LFM,OC2(ZBK:GK<:DW-HJ0 T<B*6QLTY7(:62@X\S+K7^Z&"6(D5E4
ML3!5:G1XP,[7BVM[6V=#W2_YB^<[:1J-7+/G2:3+C"%C >.VW"+B+<_<TG87
MQ+.&9<!0I7-S[5*.;@B'ZYVW^P4']Z:>)9_KYH(QA?M_B+^RFUNED,JKV&%@
MZ".27?I#)^J<NKCQ"PYIH@5P33\[^&AH'Y1W6CEN$H<_L/"NP><RW5<"Z'^E
M437?]M/TF65\?7K^(O>,I^>?^<UX^G"DS@UWN3@A(\.#3VYC2S5[-/W^L7HS
M&'R3.F49YZ>\\V5W?QT2G_=P-U;_DCA#[&19W@Q_G_ 5CG\:[:2(S.S#D]N8
M[5?N,+FGH9,[SSL93X^[\\[SR(POW6=/>H61J;Q9T0_44,S)\K0H-7]TO%XN
MJ<UE=!AR\^"\G4?1^&PZ9CGV5L--]GGHAZ=W"S,:2'.>Q,'KEVCRQ_Q_*H1<
M0Y#*#MG?(KS?B./=]K.DP\&OS! 52_XM'<UO8'+YP5GWM/NYWJG\2JU?+K_U
M>X=FD4"J-@MLG4X>_G" 6.#?S\D7:(9_LS9W,;HU?UP9#2BA!7B_<"[F+W1
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M@'8*N%\H93>,.Z#[I4S^ U!+ P04    " !0/G]:T)BE5Y<"  "T!0  &0
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M=]L):-5-Y_)H,O(=)X)TWQTJ\>RXV0A/GDC?V;:&3%!SRHL'ZA!KEIBBRN_
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MQFE1D9>0D_/>K=N[5.LF1RB+[^.ZH)J%W9=M]!Q;B\2I];YV@XME<J=2I9Q
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MLDRDD]-,1''J3A-B8N)%R8")B\0GO!KA2>!-@_N9B,%$FL2@E#(3T0SDPJD
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M +Q?2B1S>4,*ZF^]S_\'4$L#!!0    ( % ^?UJ=,.TS$P0  +,)   9
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M>3; ^]*YV"\XP'#37OT#4$L#!!0    ( % ^?UJ*N+:3=P8  +T/   9
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MV%TJA4J%9>_?7Y]-'%R3P22-;JZ"F_D#;F9S]D$KEUOV5F4B&SJ8 %,+;-X
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M8<@ XVNM7?-" =H;^\7?4$L#!!0    ( % ^?UJ'G;C@900  ,T)   9
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MI"T;SI.P"\M/0W[SN/6;QX-6_UI;KWZ%<(SZ$5N!0ED)I]SGBP@I<:,&Q#;
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M.-=I9KYL[WT%=5\41]R-U3\$, &"S5[>].\6?H+C;T>J'^L;9I\\.L5L-_*
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M%)0-P/-"2K-?V 1]=U[]!E!+ P04    " !0/G]:''('#F\%  #S&   &0
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M/X#H0@*OKZREG1,(^B<U^P-02P,$%     @ 4#Y_6NB*D+1U P  N@<  !D
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M;W)K<VAE971S+W-H965T,S8N>&ULQ9E;;Z,X%,>_BL6.5C-252X)]+))I";
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MD]U7&/Q<.[Y,<NV?J!MJ XRR5AM9#V"KH&:B?].GH0\G@/GB#" < .%K =$
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M"HP/</Y":SP8?@B&-R_[!U!+ P04    " !0/G]:_[(KHWL#  "L#P  &0
M 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6RU5VU/VS 0_BM6-DU,&N2M+\#:
M2M""AC0T!&+[@/;!3:ZM11('VVG+?OUL)TT3".Z*LB^M[=P]>9[SV;D;K"A[
MY L @=9QE/"AM1 B/;5M'BP@QOR(II#()S/*8BSDE,UMGC+ H7:*(]MSG)X=
M8Y)8HX%>NV&C <U$1!*X88AG<8S9\SE$=#6T7&NS<$OF"Z$6[-$@Q7.X W&?
MWC YLTN4D,20<$(3Q& VM,[<T[';4P[:XB>!%:^,D9(RI?113:["H>4H1A!!
M(!0$EG]+&$,4*23)XZD M<IW*L?J>(-^J<5+,5/,84RC7R04BZ%U;*$09CB+
MQ"U=?8-"4%?A!33B^A>M<MM.WT)!Q@6-"V?)("9)_H_712 J#E)HLX-7.'@O
M'3IO./B%@Z^%YLRTK D6>#1@=(68LI9H:J!CH[VE&I*H;;P33#XETD^,;IC,
M"":>$4Y"=/&4D53ND4 '$Q"81/PS.D3W=Q-T\/'SP!;R?<K+#@KL\QS;>P/;
M]= U3<2"HXLDA+ .8$NB)5MOP_;<,R).(#A"OOL%>8[7:2 T_G=WWT#'+X/G
M:SQ_O^ ]G$VY8#)!?S?%+(?L-$.J4WO*4QS T)+'D@-;@C7Z],'M.5^;]+8$
M5E/?*=5W3.AU];!1WR0YQ^EJ''6O+$?]CN,X WM9U;++JD:R6Y+L&DE^!\[E
M71%D<19A :$\XC(4 <'Y)2*9XY@R0?[HA2;R.7ZO0NNPB?U.LQK]7DF_]XX8
MRT.90&.D>Z]8O.1ILJA1[)<4^T:*$U- $:SE!X=#$]?^3JXFBQK7XY+K\8YL
MD#?^@D8ANHI31I>@HLG1PS7$4V"-Q]4(N.]Q;0FLIOVDU'[2_F5UTJ;ZEL!J
MZEUG^Z%S6KJN"J!JWGFO#_PNJSK-RO?8-=(<TSC-!#!-\\=L1@*H[I8A4\W
M^VY66VCU,'C;,'CM9VN!V58$6D*K1V!;6[C&C_<^^>J_RD37;TC8769UHMLR
MP#77 9<92XC(&&BFEV2MQN9+U8RX]T:UA%;7OZTPW.Y_2%5CV;)W!%I"JT=@
M6Z2X[ZE2&F7W7A5YW9.&5-UEEA.U*WU/#&RNVT&. IHE(F\JRM6\Y3Q7+:?J
MFUZLRU;T3#=@]A8F[V.O,9N3A*,(9A+2.>I+3BQO#?.)H*GNKJ94R%Y-#Q>R
MG0:F#.3S&:5B,U$O*!OTT5]02P,$%     @ 4#Y_6M#N(3CO @  GP@  !D
M  !X;"]W;W)K<VAE971S+W-H965T-#,N>&ULK59=;]HP%/TK5C9-K<2:#R"$
M#B*UT&J3.@V5=7NH]F"2"UAU[,QV@/[[V0YDH 3&IKTDMG//\3G7OG8&:RY>
MY!) H4U&F1PZ2Z7R:]>5R1(R+*]X#DQ_F7.18:6[8N'*7 !.+2BC;N!YH9MA
MPIQX8,<F(A[P0E'"8"*0++(,B]=;H'P]='QG-_!(%DME!MQXD.,%3$$]Y1.A
M>V[%DI(,F"2<(0'SH7/C7X\B$V\#OA%8R[TV,DYFG+^8SJ=TZ'A&$%!(E&'
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M9JA)B;S)D@\4/V1]B@U7BB?9Y9[@F ACH.]ON3Y8BH%9H&QUS?\'4$L#!!0
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M^#@?-[R5J;.8<4XN_B5,!JQ<!O1M=Q=H-"XG\[>$UN1?>11H-BEV'^_PT(5
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MU5:J-*Z#\Q;$85+]#3[7.Z(58$W?"+#K /O8 *<.<(X-F-8!TV,#9G7 [-B
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M)P.N-ZCW$6/R.-$&ZEN>_S=02P,$%     @ 4#Y_6M9!&J/V P  .0\  !D
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M_7UY@&(.PEJ3W1C7%N7W0COVN-/LL;L][3UN._O+D\Y;I$]$^N%G]@#@=PW
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M_2 PBA'0DPUKK@O$LXP W8>BQ4#"=0R$[M>R^5A@Y"#@Y(#E.@9!S'6!D86
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M]_*QR!=%U7Y __V^+)O]FW8'A[7 ;_X/4$L#!!0    ( % ^?UKHYT\[)@,
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M.%FKUF-.N&ADU# 6S2Q0:2"^+PGAKQ/9S=3ML?\;4$L#!!0    ( % ^?UH
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M0Y'AZ5#4Q/<]^6XC@-/])4C<4=)7N-=S\U&1K\9>"W('&B32 O*),DF^4;X
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MR0RO4O%(-W^0BI"G_$4TY<4OV%2V=@]$*RYH5@V6"+(D+__Q2Q6(O0'(/3
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ME7NFRP\\W17[E.]3SM.X>+MEP9IE\@#Q]TV:\L,'Z:#>N;[\#U!+ P04
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MY1:0IXUZP[>Y6ME#(TBHEJ":0#6):@K5-*H95+.HYE#-HUI*:>4.D0>:>N%
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MH3*:K!V1^.LC\4J7C];'0Z&M3DJEB8A?$PV*;3"*0!"PQ/9\E G-(^;91>X
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MPFC,I'D!?A\)H1<W9H#RVU#O/U!+ P04    " !0/G]:[[G.2;L%  "J,
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M63K#?C[[S*0LV[E<)%5G5W;.(,@^2_5*J&]R16,\<4"T5(;]7/:<:<2VV\Q
M?,PXT@*9TR@W77ZUP!N1F8*"5S?NM0%F+Q@-TT7?)[BK*!J'0P=\2W'8SW'O
M=_FCJ213\Y;G5-UWHO\\'>@<]^FLV^+XI_Y!9L"6&+&7>:K,+)G:H)TR6]V<
M<3;"2GRE.G4<;V,@*7@4]PIT#&PI,HE=2;&DAOVL-M\I\\;L*=MP-YE 7][Q
M,F$@J_N]GDOKE_)V+(@L>Y+PLEJ#>-GXW.@OY>TX>DO,Q$_,Y^@-TB=:2'!
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M9C,#FQN+UFH8-U6<*ZE7F<:I= ZYKHE"\I[,6<[9BF64*W*)J#MH0A7D0C)
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MBX<;&JPIRQ<0[]^E*7]ZDC=037B^^#]02P,$%     @ 4#Y_6B\E&K]7 P
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M;%!+ 0(4 Q0    ( % ^?UK^11E.\0   "L"   1              "  <,
M  !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( % ^?UJ97)PC$ 8  )PG
M   3              "  >,!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#
M%     @ 4#Y_6OHJ%7K7!P  4S,  !@              ("!) @  'AL+W=O
M<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( % ^?UHV<M;,>@8  ((;
M   8              " @3$0  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q0
M2P$"% ,4    " !0/G]:-WU3(U4$  !,$P  &               @('A%@
M>&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ 4#Y_6G7'A>>I
M!   21$  !@              ("!;!L  'AL+W=O<FMS:&5E=',O<VAE970T
M+GAM;%!+ 0(4 Q0    ( % ^?UHM82;;,@D  .=+   8              "
M@4L@  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " !0/G]:
MF3E'FAT&  !I&   &               @(&S*0  >&PO=V]R:W-H965T<R]S
M:&5E=#8N>&UL4$L! A0#%     @ 4#Y_6H2& KA4!P  0A$  !@
M     ("!!C   'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    (
M % ^?UHSK(-X1 \  - H   8              " @9 W  !X;"]W;W)K<VAE
M971S+W-H965T."YX;6Q02P$"% ,4    " !0/G]:I7 P+]$"  !>!@  &
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M970Q,RYX;6Q02P$"% ,4    " !0/G]:8;><$*L(  !Q%P  &0
M    @(%D:P  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    (
M % ^?UIL2"!I[ T  *TH   9              " @49T  !X;"]W;W)K<VAE
M971S+W-H965T,34N>&UL4$L! A0#%     @ 4#Y_6E S&N#B"0  ]RT  !D
M             ("!:8(  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"
M% ,4    " !0/G]:G3#M,Q,$  "S"0  &0              @(&"C   >&PO
M=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( % ^?UI[DW*B_00
M '4+   9              " @<R0  !X;"]W;W)K<VAE971S+W-H965T,3@N
M>&UL4$L! A0#%     @ 4#Y_6HJXMI-W!@  O0\  !D              ("!
M )8  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " !0/G]:
MAYVXX&4$  #-"0  &0              @(&NG   >&PO=V]R:W-H965T<R]S
M:&5E=#(P+GAM;%!+ 0(4 Q0    ( % ^?UJQRVE2[08  &\0   9
M      " @4JA  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%
M  @ 4#Y_6@#T HXG!   !0H  !D              ("!;J@  'AL+W=O<FMS
M:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " !0/G]:=KM5\5<'  "V'P
M&0              @(',K   >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+
M 0(4 Q0    ( % ^?UK:WSFS10(  ) &   9              " @5JT  !X
M;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ 4#Y_6L?&A)80
M @  W 0  !D              ("!UK8  'AL+W=O<FMS:&5E=',O<VAE970R
M-2YX;6Q02P$"% ,4    " !0/G]:"S\YBAT0  "4+P  &0
M@($=N0  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( % ^
M?UK+*5C+IP(  /$%   9              " @7')  !X;"]W;W)K<VAE971S
M+W-H965T,C<N>&UL4$L! A0#%     @ 4#Y_6ATU=.V< @  J04  !D
M         ("!3\P  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4
M    " !0/G]:''('#F\%  #S&   &0              @($BSP  >&PO=V]R
M:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( % ^?UJBO$L_&P4  '<.
M   9              " @<C4  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL
M4$L! A0#%     @ 4#Y_6H'$5C&?!0  A0X  !D              ("!&MH
M 'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " !0/G]:5AK?
M;&4#  #$!P  &0              @('PWP  >&PO=V]R:W-H965T<R]S:&5E
M=#,R+GAM;%!+ 0(4 Q0    ( % ^?UK#C*EZ9P(  %X%   9
M  " @8SC  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @
M4#Y_6NB*D+1U P  N@<  !D              ("!*N8  'AL+W=O<FMS:&5E
M=',O<VAE970S-"YX;6Q02P$"% ,4    " !0/G]:+5UKX-,#  "."   &0
M            @('6Z0  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4
M Q0    ( % ^?UJ<A0(!/ 0  ",<   9              " @>#M  !X;"]W
M;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ 4#Y_6@I!@\(C @
M'@4  !D              ("!4_(  'AL+W=O<FMS:&5E=',O<VAE970S-RYX
M;6Q02P$"% ,4    " !0/G]: C <'%T"  #R!@  &0              @(&M
M]   >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( % ^?UK9
M=R0A, (  "H%   9              " @4'W  !X;"]W;W)K<VAE971S+W-H
M965T,SDN>&UL4$L! A0#%     @ 4#Y_6F8HHRED @  P@4  !D
M     ("!J/D  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( % ^?UI\D>E@Q@0  * E   9              "
M@;P3 0!X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ 4#Y_
M6N=4@<HF!P  ]3X  !D              ("!N1@! 'AL+W=O<FMS:&5E=',O
M<VAE970T-BYX;6Q02P$"% ,4    " !0/G]:AVH;R],#  #V$@  &0
M        @($6( $ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0
M   ( % ^?UI[9EE@P 0   T>   9              " @2 D 0!X;"]W;W)K
M<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ 4#Y_6BZ-IM]"!0  C24
M !D              ("!%RD! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q0
M2P$"% ,4    " !0/G]:+J0_>MD)  !O;P  &0              @(&0+@$
M>&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( % ^?UK!8XS-
MH@,  /$-   9              " @: X 0!X;"]W;W)K<VAE971S+W-H965T
M-3$N>&UL4$L! A0#%     @ 4#Y_6M9!&J/V P  .0\  !D
M ("!>3P! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4    " !0
M/G]:1Z%1'"D*  "L:@  &0              @(&F0 $ >&PO=V]R:W-H965T
M<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( % ^?UI"\:M$8PT  !=\   9
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M970U."YX;6Q02P$"% ,4    " !0/G]:4B5=S'P&  #%+@  &0
M    @(%;:0$ >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    (
M % ^?UJ1>#G9K@,  "8/   9              " @0YP 0!X;"]W;W)K<VAE
M971S+W-H965T-C N>&UL4$L! A0#%     @ 4#Y_6JP:5;O%!@  TB\  !D
M             ("!\W,! 'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6Q02P$"
M% ,4    " !0/G]:;0JY%HTC  !OF@( &0              @('O>@$ >&PO
M=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4 Q0    ( % ^?UJ;7!?M  0
M )<4   9              " @;.> 0!X;"]W;W)K<VAE971S+W-H965T-C,N
M>&UL4$L! A0#%     @ 4#Y_6JL"[3)U!0  )QH  !D              ("!
MZJ(! 'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6Q02P$"% ,4    " !0/G]:
M[[G.2;L%  "J,   &0              @(&6J $ >&PO=V]R:W-H965T<R]S
M:&5E=#8U+GAM;%!+ 0(4 Q0    ( % ^?UIF[;C,Y@(  &<(   9
M      " @8BN 0!X;"]W;W)K<VAE971S+W-H965T-C8N>&UL4$L! A0#%
M  @ 4#Y_6L>;22=K!0  UQX  !D              ("!I;$! 'AL+W=O<FMS
M:&5E=',O<VAE970V-RYX;6Q02P$"% ,4    " !0/G]:WL2_8)@%  "$&@
M&0              @(%'MP$ >&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;%!+
M 0(4 Q0    ( % ^?UK/.N,JA0(  -4'   9              " @1:] 0!X
M;"]W;W)K<VAE971S+W-H965T-CDN>&UL4$L! A0#%     @ 4#Y_6EW.^S5P
M"0  _'P  !D              ("!TK\! 'AL+W=O<FMS:&5E=',O<VAE970W
M,"YX;6Q02P$"% ,4    " !0/G]:+R4:OU<#  "N%0  #0
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:+GAM;%!+!08     3@!. %D5  !#V $    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>385</ContextCount>
  <ElementCount>387</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>114</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="ef20039001_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ef20039001_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>010000 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ef20039001_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>010100 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ef20039001_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>020000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/ConsolidatedStatementsOfOperations</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ef20039001_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>030000 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ef20039001_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>040000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ef20039001_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>060100 - Disclosure - Nature of Business, Basis of Presentation, Liquidity, and Going Concern</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/NatureOfBusinessBasisOfPresentationLiquidityAndGoingConcern</Role>
      <ShortName>Nature of Business, Basis of Presentation, Liquidity, and Going Concern</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ef20039001_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>060200 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ef20039001_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>060300 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/PropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ef20039001_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>060400 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ef20039001_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>060500 - Disclosure - Convertible Notes Payable - Related Party</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedParty</Role>
      <ShortName>Convertible Notes Payable - Related Party</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ef20039001_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>060600 - Disclosure - Fair Value of Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/FairValueOfFinancialInstruments</Role>
      <ShortName>Fair Value of Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ef20039001_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>060700 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ef20039001_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>060800 - Disclosure - Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/Warrants</Role>
      <ShortName>Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ef20039001_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>060900 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/StockbasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ef20039001_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>061000 - Disclosure - Convertible Line of Credit - Related Party and Supplemental Lines of Credit - Related Party</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedParty</Role>
      <ShortName>Convertible Line of Credit - Related Party and Supplemental Lines of Credit - Related Party</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ef20039001_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>061100 - Disclosure - Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/LossPerShare</Role>
      <ShortName>Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ef20039001_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>061200 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ef20039001_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>061300 - Disclosure - Galectin Sciences LLC</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/GalectinSciencesLlc</Role>
      <ShortName>Galectin Sciences LLC</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ef20039001_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>061400 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ef20039001_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>061500 - Disclosure - Segments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/Segments</Role>
      <ShortName>Segments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ef20039001_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>061600 - Disclosure - Subsequent Event</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/SubsequentEvent</Role>
      <ShortName>Subsequent Event</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ef20039001_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>061700 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ef20039001_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>061800 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ef20039001_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>061900 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/InsiderTradingPoliciesAndProcedures</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="ef20039001_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>070200 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ef20039001_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>080300 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://galectintherapeutics.com/role/PropertyAndEquipment</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ef20039001_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>080400 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://galectintherapeutics.com/role/AccruedExpenses</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ef20039001_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>080600 - Disclosure - Fair Value of Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsTables</Role>
      <ShortName>Fair Value of Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://galectintherapeutics.com/role/FairValueOfFinancialInstruments</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ef20039001_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>080800 - Disclosure - Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/WarrantsTables</Role>
      <ShortName>Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://galectintherapeutics.com/role/Warrants</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ef20039001_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>080900 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/StockbasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://galectintherapeutics.com/role/StockbasedCompensation</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ef20039001_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>081100 - Disclosure - Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/LossPerShareTables</Role>
      <ShortName>Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://galectintherapeutics.com/role/LossPerShare</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ef20039001_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>081200 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://galectintherapeutics.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ef20039001_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>081400 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://galectintherapeutics.com/role/IncomeTaxes</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ef20039001_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>081500 - Disclosure - Segments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/SegmentsTables</Role>
      <ShortName>Segments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://galectintherapeutics.com/role/Segments</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ef20039001_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>090100 - Disclosure - Nature of Business, Basis of Presentation, Liquidity, and Going Concern (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/NatureOfBusinessBasisOfPresentationLiquidityAndGoingConcernDetails</Role>
      <ShortName>Nature of Business, Basis of Presentation, Liquidity, and Going Concern (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://galectintherapeutics.com/role/NatureOfBusinessBasisOfPresentationLiquidityAndGoingConcern</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ef20039001_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>090200 - Disclosure - Summary of Significant Accounting Policies, Cash and Cash Equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies, Cash and Cash Equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="ef20039001_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>090202 - Disclosure - Summary of Significant Accounting Policies, Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails</Role>
      <ShortName>Summary of Significant Accounting Policies, Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="ef20039001_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>090204 - Disclosure - Summary of Significant Accounting Policies, Security Deposit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesSecurityDepositDetails</Role>
      <ShortName>Summary of Significant Accounting Policies, Security Deposit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="ef20039001_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>090206 - Disclosure - Summary of Significant Accounting Policies, Long-Lived Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesLonglivedAssetsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies, Long-Lived Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="ef20039001_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>090208 - Disclosure - Summary of Significant Accounting Policies, Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesWarrantsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies, Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="ef20039001_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>090300 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/PropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://galectintherapeutics.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="ef20039001_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>090400 - Disclosure - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/AccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://galectintherapeutics.com/role/AccruedExpensesTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="ef20039001_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>090500 - Disclosure - Convertible Notes Payable - Related Party (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails</Role>
      <ShortName>Convertible Notes Payable - Related Party (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedParty</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="ef20039001_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>090600 - Disclosure - Fair Value of Financial Instruments, Assets and Liabilities Measured at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueDetails</Role>
      <ShortName>Fair Value of Financial Instruments, Assets and Liabilities Measured at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ef20039001_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>090602 - Disclosure - Fair Value of Financial Instruments, Key Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsKeyAssumptionsDetails</Role>
      <ShortName>Fair Value of Financial Instruments, Key Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="ef20039001_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>090604 - Disclosure - Fair Value of Financial Instruments, Roll Forward of Derivative Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsRollForwardOfDerivativeLiabilityDetails</Role>
      <ShortName>Fair Value of Financial Instruments, Roll Forward of Derivative Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="ef20039001_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>090700 - Disclosure - Stockholders' Equity, Issuance of Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/StockholdersEquityIssuanceOfCommonStockDetails</Role>
      <ShortName>Stockholders' Equity, Issuance of Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="ef20039001_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>090702 - Disclosure - Stockholders' Equity, Series A 12% Convertible Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/StockholdersEquitySeries12ConvertiblePreferredStockDetails</Role>
      <ShortName>Stockholders' Equity, Series A 12% Convertible Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="ef20039001_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>090704 - Disclosure - Stockholders' Equity, Series C 6% Super Dividend Redeemable Convertible Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/StockholdersEquitySeriesC6SuperDividendRedeemableConvertiblePreferredStockDetails</Role>
      <ShortName>Stockholders' Equity, Series C 6% Super Dividend Redeemable Convertible Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="ef20039001_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>090706 - Disclosure - Stockholders' Equity, Return on Investment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/StockholdersEquityReturnOnInvestmentDetails</Role>
      <ShortName>Stockholders' Equity, Return on Investment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="ef20039001_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>090800 - Disclosure - Warrants, Summary of Warrant Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/WarrantsSummaryOfWarrantActivityDetails</Role>
      <ShortName>Warrants, Summary of Warrant Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="ef20039001_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>090802 - Disclosure - Warrants, Summary of Purchase Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/WarrantsSummaryOfPurchaseWarrantsDetails</Role>
      <ShortName>Warrants, Summary of Purchase Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="ef20039001_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>090804 - Disclosure - Warrants, Summary of Outstanding Warrants Issued in Connection with Equity and Debt Financing and Consultants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/WarrantsSummaryOfOutstandingWarrantsIssuedInConnectionWithEquityAndDebtFinancingAndConsultantsDetails</Role>
      <ShortName>Warrants, Summary of Outstanding Warrants Issued in Connection with Equity and Debt Financing and Consultants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="ef20039001_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>090900 - Disclosure - Stock-Based Compensation, Summary of Stock-Based Compensation Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/StockbasedCompensationSummaryOfStockbasedCompensationPlansDetails</Role>
      <ShortName>Stock-Based Compensation, Summary of Stock-Based Compensation Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="ef20039001_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>090902 - Disclosure - Stock-Based Compensation, Components of Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/StockbasedCompensationComponentsOfStockbasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation, Components of Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="ef20039001_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>090904 - Disclosure - Stock-Based Compensation, Weighted Average Assumptions Used to Determine Fair Value of Options Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/StockbasedCompensationWeightedAverageAssumptionsUsedToDetermineFairValueOfOptionsGrantedDetails</Role>
      <ShortName>Stock-Based Compensation, Weighted Average Assumptions Used to Determine Fair Value of Options Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="ef20039001_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>090906 - Disclosure - Stock-Based Compensation, Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/StockbasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation, Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="ef20039001_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>090908 - Disclosure - Stock-Based Compensation, Outstanding and Exercisable Options under Stock Based Compensation Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/StockbasedCompensationOutstandingAndExercisableOptionsUnderStockBasedCompensationPlansDetails</Role>
      <ShortName>Stock-Based Compensation, Outstanding and Exercisable Options under Stock Based Compensation Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="ef20039001_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>090910 - Disclosure - Stock-Based Compensation, Restricted Stock Issuances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/StockbasedCompensationRestrictedStockIssuancesDetails</Role>
      <ShortName>Stock-Based Compensation, Restricted Stock Issuances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="ef20039001_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>090912 - Disclosure - Stock-Based Compensation, Deferred Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/StockbasedCompensationDeferredStockUnitsDetails</Role>
      <ShortName>Stock-Based Compensation, Deferred Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="ef20039001_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>091000 - Disclosure - Convertible Line of Credit - Related Party and Supplemental Lines of Credit - Related Party (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedPartyDetails</Role>
      <ShortName>Convertible Line of Credit - Related Party and Supplemental Lines of Credit - Related Party (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedParty</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="ef20039001_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>091100 - Disclosure - Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/LossPerShareDetails</Role>
      <ShortName>Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://galectintherapeutics.com/role/LossPerShareTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="ef20039001_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>091200 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://galectintherapeutics.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="ef20039001_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>091300 - Disclosure - Galectin Sciences LLC (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/GalectinSciencesLlcDetails</Role>
      <ShortName>Galectin Sciences LLC (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://galectintherapeutics.com/role/GalectinSciencesLlc</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="ef20039001_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>091400 - Disclosure - Income Taxes, Components of Net Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/IncomeTaxesComponentsOfNetDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes, Components of Net Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="ef20039001_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>091402 - Disclosure - Income Taxes, Primary Factors Affecting Income Tax Rates (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/IncomeTaxesPrimaryFactorsAffectingIncomeTaxRatesDetails</Role>
      <ShortName>Income Taxes, Primary Factors Affecting Income Tax Rates (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="ef20039001_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>091500 - Disclosure - Segments - Significant Expense Categories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/SegmentsSignificantExpenseCategoriesDetails</Role>
      <ShortName>Segments - Significant Expense Categories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="ef20039001_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>091504 - Disclosure - Segments - Significant Asset Categories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/SegmentsSignificantAssetCategoriesDetails</Role>
      <ShortName>Segments - Significant Asset Categories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="ef20039001_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>091600 - Disclosure - Subsequent Event (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/SubsequentEventDetails</Role>
      <ShortName>Subsequent Event (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://galectintherapeutics.com/role/SubsequentEvent</ParentRole>
      <Position>70</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="ef20039001_10k.htm">ef20039001_10k.htm</File>
    <File>galt-20241231.xsd</File>
    <File>galt-20241231_cal.xml</File>
    <File>galt-20241231_def.xml</File>
    <File>galt-20241231_lab.xml</File>
    <File>galt-20241231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="899">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="15">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="5">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>93
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ef20039001_10k.htm": {
   "nsprefix": "galt",
   "nsuri": "http://galectintherapeutics.com/20241231",
   "dts": {
    "inline": {
     "local": [
      "ef20039001_10k.htm"
     ]
    },
    "schema": {
     "local": [
      "galt-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2004/ref-2004-08-10.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/currency/2024/currency-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/exch/2024/exch-2024.xsd",
      "https://xbrl.sec.gov/naics/2024/naics-2024.xsd",
      "https://xbrl.sec.gov/sic/2024/sic-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "galt-20241231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "galt-20241231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "galt-20241231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "galt-20241231_pre.xml"
     ]
    }
   },
   "keyStandard": 302,
   "keyCustom": 85,
   "axisStandard": 30,
   "axisCustom": 0,
   "memberStandard": 38,
   "memberCustom": 73,
   "hidden": {
    "total": 18,
    "http://galectintherapeutics.com/20241231": 4,
    "http://fasb.org/us-gaap/2024": 8,
    "http://xbrl.sec.gov/dei/2024": 6
   },
   "contextCount": 385,
   "entityCount": 1,
   "segmentCount": 114,
   "elementCount": 670,
   "unitCount": 11,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 899,
    "http://xbrl.sec.gov/dei/2024": 38,
    "http://xbrl.sec.gov/cyd/2024": 15,
    "http://xbrl.sec.gov/ecd/2024": 5
   },
   "report": {
    "R1": {
     "role": "http://galectintherapeutics.com/role/DocumentAndEntityInformation",
     "longName": "000100 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://galectintherapeutics.com/role/ConsolidatedBalanceSheets",
     "longName": "010000 - Statement - CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c20241231",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20241231",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://galectintherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
     "longName": "010100 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c20241231",
      "name": "us-gaap:TemporaryEquitySharesAuthorized",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "us-gaap:TemporaryEquitySharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20241231",
      "name": "us-gaap:TemporaryEquitySharesAuthorized",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "us-gaap:TemporaryEquitySharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://galectintherapeutics.com/role/ConsolidatedStatementsOfOperations",
     "longName": "020000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:EarningsPerShareBasic",
      "unitRef": "U003",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "us-gaap:EarningsPerShareDiluted",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://galectintherapeutics.com/role/ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
     "longName": "030000 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)",
     "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c20221231",
      "name": "us-gaap:TemporaryEquityCarryingAmountAttributableToParent",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20221231",
      "name": "us-gaap:TemporaryEquityCarryingAmountAttributableToParent",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://galectintherapeutics.com/role/ConsolidatedStatementsOfCashFlows",
     "longName": "040000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://galectintherapeutics.com/role/NatureOfBusinessBasisOfPresentationLiquidityAndGoingConcern",
     "longName": "060100 - Disclosure - Nature of Business, Basis of Presentation, Liquidity, and Going Concern",
     "shortName": "Nature of Business, Basis of Presentation, Liquidity, and Going Concern",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPolicies",
     "longName": "060200 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://galectintherapeutics.com/role/PropertyAndEquipment",
     "longName": "060300 - Disclosure - Property and Equipment",
     "shortName": "Property and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://galectintherapeutics.com/role/AccruedExpenses",
     "longName": "060400 - Disclosure - Accrued Expenses",
     "shortName": "Accrued Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedParty",
     "longName": "060500 - Disclosure - Convertible Notes Payable - Related Party",
     "shortName": "Convertible Notes Payable - Related Party",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c20240101to20241231_LongtermDebtTypeAxis_LoansPayableMember",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231_LongtermDebtTypeAxis_LoansPayableMember",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://galectintherapeutics.com/role/FairValueOfFinancialInstruments",
     "longName": "060600 - Disclosure - Fair Value of Financial Instruments",
     "shortName": "Fair Value of Financial Instruments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://galectintherapeutics.com/role/StockholdersEquity",
     "longName": "060700 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://galectintherapeutics.com/role/Warrants",
     "longName": "060800 - Disclosure - Warrants",
     "shortName": "Warrants",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "galt:CommonStockWarrantsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "galt:CommonStockWarrantsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://galectintherapeutics.com/role/StockbasedCompensation",
     "longName": "060900 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedParty",
     "longName": "061000 - Disclosure - Convertible Line of Credit - Related Party and Supplemental Lines of Credit - Related Party",
     "shortName": "Convertible Line of Credit - Related Party and Supplemental Lines of Credit - Related Party",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c20240101to20241231_LongtermDebtTypeAxis_LineOfCreditMember",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231_LongtermDebtTypeAxis_LineOfCreditMember",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://galectintherapeutics.com/role/LossPerShare",
     "longName": "061100 - Disclosure - Loss Per Share",
     "shortName": "Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://galectintherapeutics.com/role/CommitmentsAndContingencies",
     "longName": "061200 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://galectintherapeutics.com/role/GalectinSciencesLlc",
     "longName": "061300 - Disclosure - Galectin Sciences LLC",
     "shortName": "Galectin Sciences LLC",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://galectintherapeutics.com/role/IncomeTaxes",
     "longName": "061400 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://galectintherapeutics.com/role/Segments",
     "longName": "061500 - Disclosure - Segments",
     "shortName": "Segments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://galectintherapeutics.com/role/SubsequentEvent",
     "longName": "061600 - Disclosure - Subsequent Event",
     "shortName": "Subsequent Event",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://galectintherapeutics.com/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "061700 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://galectintherapeutics.com/role/InsiderTradingArrangements",
     "longName": "061800 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c20241001to20241231",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20241001to20241231",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://galectintherapeutics.com/role/InsiderTradingPoliciesAndProcedures",
     "longName": "061900 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c20241001to20241231",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20241001to20241231",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "070200 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://galectintherapeutics.com/role/PropertyAndEquipmentTables",
     "longName": "080300 - Disclosure - Property and Equipment (Tables)",
     "shortName": "Property and Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://galectintherapeutics.com/role/AccruedExpensesTables",
     "longName": "080400 - Disclosure - Accrued Expenses (Tables)",
     "shortName": "Accrued Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsTables",
     "longName": "080600 - Disclosure - Fair Value of Financial Instruments (Tables)",
     "shortName": "Fair Value of Financial Instruments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://galectintherapeutics.com/role/WarrantsTables",
     "longName": "080800 - Disclosure - Warrants (Tables)",
     "shortName": "Warrants (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://galectintherapeutics.com/role/StockbasedCompensationTables",
     "longName": "080900 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://galectintherapeutics.com/role/LossPerShareTables",
     "longName": "081100 - Disclosure - Loss Per Share (Tables)",
     "shortName": "Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://galectintherapeutics.com/role/CommitmentsAndContingenciesTables",
     "longName": "081200 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://galectintherapeutics.com/role/IncomeTaxesTables",
     "longName": "081400 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://galectintherapeutics.com/role/SegmentsTables",
     "longName": "081500 - Disclosure - Segments (Tables)",
     "shortName": "Segments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://galectintherapeutics.com/role/NatureOfBusinessBasisOfPresentationLiquidityAndGoingConcernDetails",
     "longName": "090100 - Disclosure - Nature of Business, Basis of Presentation, Liquidity, and Going Concern (Details)",
     "shortName": "Nature of Business, Basis of Presentation, Liquidity, and Going Concern (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c20241231",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "galt:NumberOfLineOfCredit",
      "unitRef": "U004",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails",
     "longName": "090200 - Disclosure - Summary of Significant Accounting Policies, Cash and Cash Equivalents (Details)",
     "shortName": "Summary of Significant Accounting Policies, Cash and Cash Equivalents (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c20241231",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20241231",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails",
     "longName": "090202 - Disclosure - Summary of Significant Accounting Policies, Property and Equipment (Details)",
     "shortName": "Summary of Significant Accounting Policies, Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c20241231_PropertyPlantAndEquipmentByTypeAxis_ComputerAndOfficeEquipmentMember",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20241231_PropertyPlantAndEquipmentByTypeAxis_ComputerAndOfficeEquipmentMember",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesSecurityDepositDetails",
     "longName": "090204 - Disclosure - Summary of Significant Accounting Policies, Security Deposit (Details)",
     "shortName": "Summary of Significant Accounting Policies, Security Deposit (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c20241231",
      "name": "us-gaap:SecurityDeposit",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "us-gaap:SecurityDeposit",
       "span",
       "div",
       "ix:continuation",
       "galt:SecurityDepositPolicyTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R40": {
     "role": "http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesLonglivedAssetsDetails",
     "longName": "090206 - Disclosure - Summary of Significant Accounting Policies, Long-Lived Assets (Details)",
     "shortName": "Summary of Significant Accounting Policies, Long-Lived Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesWarrantsDetails",
     "longName": "090208 - Disclosure - Summary of Significant Accounting Policies, Warrants (Details)",
     "shortName": "Summary of Significant Accounting Policies, Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c20241231",
      "name": "us-gaap:DerivativeLiabilities",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "us-gaap:DerivativeLiabilities",
       "span",
       "div",
       "ix:continuation",
       "us-gaap:DerivativesPolicyTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20241231",
      "name": "us-gaap:DerivativeLiabilities",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "us-gaap:DerivativeLiabilities",
       "span",
       "div",
       "ix:continuation",
       "us-gaap:DerivativesPolicyTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://galectintherapeutics.com/role/PropertyAndEquipmentDetails",
     "longName": "090300 - Disclosure - Property and Equipment (Details)",
     "shortName": "Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c20241231",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20241231",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://galectintherapeutics.com/role/AccruedExpensesDetails",
     "longName": "090400 - Disclosure - Accrued Expenses (Details)",
     "shortName": "Accrued Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c20241231",
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20241231",
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails",
     "longName": "090500 - Disclosure - Convertible Notes Payable - Related Party (Details)",
     "shortName": "Convertible Notes Payable - Related Party (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c20241231",
      "name": "us-gaap:DerivativeLiabilitiesNoncurrent",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember",
      "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueDetails",
     "longName": "090600 - Disclosure - Fair Value of Financial Instruments, Assets and Liabilities Measured at Fair Value (Details)",
     "shortName": "Fair Value of Financial Instruments, Assets and Liabilities Measured at Fair Value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c20241231",
      "name": "us-gaap:DerivativeLiabilitiesNoncurrent",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "us-gaap:FinancialLiabilitiesFairValueDisclosure",
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsKeyAssumptionsDetails",
     "longName": "090602 - Disclosure - Fair Value of Financial Instruments, Key Assumptions (Details)",
     "shortName": "Fair Value of Financial Instruments, Key Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c20241231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputSharePriceMember",
      "name": "us-gaap:DerivativeLiabilityMeasurementInput",
      "unitRef": "U007",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20241231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputSharePriceMember",
      "name": "us-gaap:DerivativeLiabilityMeasurementInput",
      "unitRef": "U007",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsRollForwardOfDerivativeLiabilityDetails",
     "longName": "090604 - Disclosure - Fair Value of Financial Instruments, Roll Forward of Derivative Liability (Details)",
     "shortName": "Fair Value of Financial Instruments, Roll Forward of Derivative Liability (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c20231231",
      "name": "us-gaap:DerivativeLiabilitiesNoncurrent",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember",
      "name": "us-gaap:FairValueAdjustmentOfWarrants",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://galectintherapeutics.com/role/StockholdersEquityIssuanceOfCommonStockDetails",
     "longName": "090700 - Disclosure - Stockholders' Equity, Issuance of Common Stock (Details)",
     "shortName": "Stockholders' Equity, Issuance of Common Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c20241231",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20231231_TypeOfArrangementAxis_TwoThousandTwentyMarketAgreementMember",
      "name": "galt:AggregateOfferingPrice",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://galectintherapeutics.com/role/StockholdersEquitySeries12ConvertiblePreferredStockDetails",
     "longName": "090702 - Disclosure - Stockholders' Equity, Series A 12% Convertible Preferred Stock (Details)",
     "shortName": "Stockholders' Equity, Series A 12% Convertible Preferred Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c20241231",
      "name": "us-gaap:SharePrice",
      "unitRef": "U003",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20080204to20080204_StatementClassOfStockAxis_SeriesAPreferredStockMember",
      "name": "us-gaap:PreferredStockDividendRatePercentage",
      "unitRef": "U007",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://galectintherapeutics.com/role/StockholdersEquitySeriesC6SuperDividendRedeemableConvertiblePreferredStockDetails",
     "longName": "090704 - Disclosure - Stockholders' Equity, Series C 6% Super Dividend Redeemable Convertible Preferred Stock (Details)",
     "shortName": "Stockholders' Equity, Series C 6% Super Dividend Redeemable Convertible Preferred Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c20241231",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "us-gaap:CommonStockSharesIssued",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20101230to20101230_StatementClassOfStockAxis_SeriesCPreferredStockMember",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://galectintherapeutics.com/role/StockholdersEquityReturnOnInvestmentDetails",
     "longName": "090706 - Disclosure - Stockholders' Equity, Return on Investment (Details)",
     "shortName": "Stockholders' Equity, Return on Investment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "galt:ReturnOnInvestmentsPercentagePeriodOne",
      "unitRef": "U007",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "galt:ReturnOnInvestmentsPercentagePeriodOne",
      "unitRef": "U007",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://galectintherapeutics.com/role/WarrantsSummaryOfWarrantActivityDetails",
     "longName": "090800 - Disclosure - Warrants, Summary of Warrant Activity (Details)",
     "shortName": "Warrants, Summary of Warrant Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c20231231",
      "name": "galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice",
      "unitRef": "U003",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20221231",
      "name": "galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice",
      "unitRef": "U003",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://galectintherapeutics.com/role/WarrantsSummaryOfPurchaseWarrantsDetails",
     "longName": "090802 - Disclosure - Warrants, Summary of Purchase Warrants (Details)",
     "shortName": "Warrants, Summary of Purchase Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c20241231",
      "name": "us-gaap:SharePrice",
      "unitRef": "U003",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20230901to20230930",
      "name": "us-gaap:PreferredStockRedemptionPremium",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://galectintherapeutics.com/role/WarrantsSummaryOfOutstandingWarrantsIssuedInConnectionWithEquityAndDebtFinancingAndConsultantsDetails",
     "longName": "090804 - Disclosure - Warrants, Summary of Outstanding Warrants Issued in Connection with Equity and Debt Financing and Consultants (Details)",
     "shortName": "Warrants, Summary of Outstanding Warrants Issued in Connection with Equity and Debt Financing and Consultants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c20241231",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20241231",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://galectintherapeutics.com/role/StockbasedCompensationSummaryOfStockbasedCompensationPlansDetails",
     "longName": "090900 - Disclosure - Stock-Based Compensation, Summary of Stock-Based Compensation Plans (Details)",
     "shortName": "Stock-Based Compensation, Summary of Stock-Based Compensation Plans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c20231231_PlanNameAxis_EquityIncentivePlan2019Member",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20231231_PlanNameAxis_EquityIncentivePlan2019Member",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://galectintherapeutics.com/role/StockbasedCompensationComponentsOfStockbasedCompensationExpenseDetails",
     "longName": "090902 - Disclosure - Stock-Based Compensation, Components of Stock-Based Compensation Expense (Details)",
     "shortName": "Stock-Based Compensation, Components of Stock-Based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://galectintherapeutics.com/role/StockbasedCompensationWeightedAverageAssumptionsUsedToDetermineFairValueOfOptionsGrantedDetails",
     "longName": "090904 - Disclosure - Stock-Based Compensation, Weighted Average Assumptions Used to Determine Fair Value of Options Granted (Details)",
     "shortName": "Stock-Based Compensation, Weighted Average Assumptions Used to Determine Fair Value of Options Granted (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "U007",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231_RangeAxis_MinimumMember",
      "name": "galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfAward",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://galectintherapeutics.com/role/StockbasedCompensationStockOptionActivityDetails",
     "longName": "090906 - Disclosure - Stock-Based Compensation, Stock Option Activity (Details)",
     "shortName": "Stock-Based Compensation, Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c20231231",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20221231",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://galectintherapeutics.com/role/StockbasedCompensationOutstandingAndExercisableOptionsUnderStockBasedCompensationPlansDetails",
     "longName": "090908 - Disclosure - Stock-Based Compensation, Outstanding and Exercisable Options under Stock Based Compensation Plans (Details)",
     "shortName": "Stock-Based Compensation, Outstanding and Exercisable Options under Stock Based Compensation Plans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c20241231",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20241231",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://galectintherapeutics.com/role/StockbasedCompensationRestrictedStockIssuancesDetails",
     "longName": "090910 - Disclosure - Stock-Based Compensation, Restricted Stock Issuances (Details)",
     "shortName": "Stock-Based Compensation, Restricted Stock Issuances (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20241231_AwardTypeAxis_RestrictedStockMember",
      "name": "galt:NumberOfDirectors",
      "unitRef": "U009",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://galectintherapeutics.com/role/StockbasedCompensationDeferredStockUnitsDetails",
     "longName": "090912 - Disclosure - Stock-Based Compensation, Deferred Stock Units (Details)",
     "shortName": "Stock-Based Compensation, Deferred Stock Units (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c20241231",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20230101to20231231_TitleOfIndividualAxis_ChiefExecutiveOfficerMember",
      "name": "us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedPartyDetails",
     "longName": "091000 - Disclosure - Convertible Line of Credit - Related Party and Supplemental Lines of Credit - Related Party (Details)",
     "shortName": "Convertible Line of Credit - Related Party and Supplemental Lines of Credit - Related Party (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c20241231",
      "name": "us-gaap:SharePrice",
      "unitRef": "U003",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20220725to20220725_FinancialInstrumentAxis_WarrantMember",
      "name": "galt:IssuanceOfWarrantsValue",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://galectintherapeutics.com/role/LossPerShareDetails",
     "longName": "091100 - Disclosure - Loss Per Share (Details)",
     "shortName": "Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://galectintherapeutics.com/role/CommitmentsAndContingenciesDetails",
     "longName": "091200 - Disclosure - Commitments and Contingencies (Details)",
     "shortName": "Commitments and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "galt:NumberOfOperatingLeases",
      "unitRef": "U010",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "galt:NumberOfOperatingLeases",
      "unitRef": "U010",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://galectintherapeutics.com/role/GalectinSciencesLlcDetails",
     "longName": "091300 - Disclosure - Galectin Sciences LLC (Details)",
     "shortName": "Galectin Sciences LLC (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20140101to20140131_OwnershipAxis_GalectinSciencesLLCMember",
      "name": "us-gaap:PaymentsToAcquireEquityMethodInvestments",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "unique": true
     }
    },
    "R66": {
     "role": "http://galectintherapeutics.com/role/IncomeTaxesComponentsOfNetDeferredTaxAssetsDetails",
     "longName": "091400 - Disclosure - Income Taxes, Components of Net Deferred Tax Assets (Details)",
     "shortName": "Income Taxes, Components of Net Deferred Tax Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c20241231",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20241231",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://galectintherapeutics.com/role/IncomeTaxesPrimaryFactorsAffectingIncomeTaxRatesDetails",
     "longName": "091402 - Disclosure - Income Taxes, Primary Factors Affecting Income Tax Rates (Details)",
     "shortName": "Income Taxes, Primary Factors Affecting Income Tax Rates (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U007",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U007",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://galectintherapeutics.com/role/SegmentsSignificantExpenseCategoriesDetails",
     "longName": "091500 - Disclosure - Segments - Significant Expense Categories (Details)",
     "shortName": "Segments - Significant Expense Categories (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231_StatementBusinessSegmentsAxis_BusinessOperatingSegmentMember",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "unique": true
     }
    },
    "R69": {
     "role": "http://galectintherapeutics.com/role/SegmentsSignificantAssetCategoriesDetails",
     "longName": "091504 - Disclosure - Segments - Significant Asset Categories (Details)",
     "shortName": "Segments - Significant Asset Categories (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c20241231",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20241231_StatementBusinessSegmentsAxis_BusinessOperatingSegmentMember",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "unique": true
     }
    },
    "R70": {
     "role": "http://galectintherapeutics.com/role/SubsequentEventDetails",
     "longName": "091600 - Disclosure - Subsequent Event (Details)",
     "shortName": "Subsequent Event (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c20241231",
      "name": "us-gaap:SharePrice",
      "unitRef": "U003",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20039001_10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://galectintherapeutics.com/role/AccruedExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Expenses",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r70",
      "r75",
      "r1053"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r906"
     ]
    },
    "galt_AccruedExpensePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "AccruedExpensePolicyTextBlock",
     "presentation": [
      "http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accrued expense.",
        "label": "Accrued Expense [Policy Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://galectintherapeutics.com/role/AccruedExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/AccruedExpensesDetails",
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://galectintherapeutics.com/role/AccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal and accounting fees",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "galt_AccruedResearchAndDevelopmentCostsAndOtherCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "AccruedResearchAndDevelopmentCostsAndOtherCurrent",
     "crdr": "credit",
     "calculation": {
      "http://galectintherapeutics.com/role/AccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development costs and other. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Research and Development Costs and Other Current",
        "terseLabel": "Accrued research and development costs and other"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://galectintherapeutics.com/role/PropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less accumulated depreciation and amortization",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r148",
      "r652"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r906",
      "r1128"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r698",
      "r982",
      "r983",
      "r984",
      "r986",
      "r1061",
      "r1129"
     ]
    },
    "galt_AdditionalSupplementalLineOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "AdditionalSupplementalLineOfCreditMember",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An additional supplemental contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Additional Supplemental Line of Credit [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationDeferredStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reclassification of accrued compensation to additional paid in capital",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation expense",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r54",
      "r415"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of common stock purchase warrants in connection with related party line of credit",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r35",
      "r107"
     ]
    },
    "galt_AfterModificationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "AfterModificationMember",
     "presentation": [
      "http://galectintherapeutics.com/role/WarrantsSummaryOfPurchaseWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in fair value of the warrants immediately after the modification.",
        "label": "After Modification [Member]",
        "terseLabel": "After Modification [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "galt_AggregateOfferingPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "AggregateOfferingPrice",
     "crdr": "credit",
     "presentation": [
      "http://galectintherapeutics.com/role/StockholdersEquityIssuanceOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of aggregate offering price of common stock which can be sold from time to time through the sales agent.",
        "label": "Aggregate Offering Price",
        "terseLabel": "Aggregate offering price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationComponentsOfStockbasedCompensationExpenseDetails",
      "http://galectintherapeutics.com/role/StockbasedCompensationRestrictedStockIssuancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortized expense",
        "verboseLabel": "Total stock-based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r447",
      "r457"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfFinancingCosts",
     "crdr": "debit",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of debt discount",
        "documentation": "Amount of amortization expense attributable to debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r377",
      "r977",
      "r1080"
     ]
    },
    "galt_AnnualInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "AnnualInterestRate",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent interest rate per annum for funds borrowed, under the debt agreement.",
        "label": "Annual Interest Rate",
        "terseLabel": "Additional interest rate per annum from issuance date to maturity date period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://galectintherapeutics.com/role/LossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount excluded from calculation (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r209"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://galectintherapeutics.com/role/LossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://galectintherapeutics.com/role/LossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://galectintherapeutics.com/role/LossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "galt_AprilConvertiblePromissoryNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "AprilConvertiblePromissoryNoteMember",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of debt instrument.",
        "label": "April Convertible Promissory Note [Member]",
        "terseLabel": "April 2021 Note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "galt_AprilThirtyTwentyTenSeriesBTwoTransactionOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "AprilThirtyTwentyTenSeriesBTwoTransactionOneMember",
     "presentation": [
      "http://galectintherapeutics.com/role/WarrantsSummaryOfOutstandingWarrantsIssuedInConnectionWithEquityAndDebtFinancingAndConsultantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrants.",
        "label": "April Thirty Twenty Ten Series B Two Transaction One [Member]",
        "verboseLabel": "April 30, 2010 Series B-2 Transaction [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "galt_AprilThirtyTwentyTenSeriesBTwoTransactionTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "AprilThirtyTwentyTenSeriesBTwoTransactionTwoMember",
     "presentation": [
      "http://galectintherapeutics.com/role/WarrantsSummaryOfOutstandingWarrantsIssuedInConnectionWithEquityAndDebtFinancingAndConsultantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrants.",
        "label": "April Thirty Twenty Ten Series B Two Transaction Two [Member]",
        "terseLabel": "April 30, 2010 Series B-2 Transaction [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://galectintherapeutics.com/role/StockholdersEquityIssuanceOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r511"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r126",
      "r150",
      "r174",
      "r214",
      "r222",
      "r241",
      "r245",
      "r285",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r512",
      "r514",
      "r564",
      "r642",
      "r739",
      "r870",
      "r871",
      "r906",
      "r919",
      "r1021",
      "r1022",
      "r1086"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r155",
      "r174",
      "r285",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r512",
      "r514",
      "r564",
      "r906",
      "r1021",
      "r1022",
      "r1086"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r541",
      "r542",
      "r892"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r923",
      "r924",
      "r937"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r923",
      "r924",
      "r937"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r923",
      "r924",
      "r937"
     ]
    },
    "galt_AugustTwelveTwentyZeroNineSeriesBTwoTransactionOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "AugustTwelveTwentyZeroNineSeriesBTwoTransactionOneMember",
     "presentation": [
      "http://galectintherapeutics.com/role/WarrantsSummaryOfOutstandingWarrantsIssuedInConnectionWithEquityAndDebtFinancingAndConsultantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrants.",
        "label": "August Twelve Twenty Zero Nine Series B Two Transaction One [Member]",
        "verboseLabel": "August 12, 2009 Series B-2 Transaction [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationRestrictedStockIssuancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r418",
      "r419",
      "r420",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446"
     ]
    },
    "galt_BeforeModificationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "BeforeModificationMember",
     "presentation": [
      "http://galectintherapeutics.com/role/WarrantsSummaryOfPurchaseWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in fair value of the warrants immediately before the modification.",
        "label": "Before Modification [Member]",
        "terseLabel": "Before Modification [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "galt_BeneficialOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "BeneficialOwnershipPercentage",
     "presentation": [
      "http://galectintherapeutics.com/role/WarrantsSummaryOfPurchaseWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Beneficial ownership percentage of the outstanding shares of the Company's Class A common stock that would allow warrants to be settled in cash upon the occurrence of a tender offer or exchange offer.",
        "label": "Beneficial Ownership Percentage",
        "terseLabel": "Beneficial ownership percentage"
       }
      }
     },
     "auth_ref": []
    },
    "srt_BoardOfDirectorsChairmanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "BoardOfDirectorsChairmanMember",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedPartyDetails",
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails",
      "http://galectintherapeutics.com/role/NatureOfBusinessBasisOfPresentationLiquidityAndGoingConcernDetails",
      "http://galectintherapeutics.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Richard E. Uihlein [Member]"
       }
      }
     },
     "auth_ref": [
      "r995"
     ]
    },
    "galt_BonusSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "BonusSharesMember",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationDeferredStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bonus shares are additional shares given to the existing shareholders.",
        "label": "Bonus Shares [Member]",
        "terseLabel": "Bonus Shares [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "galt_BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as borrowing and accrued interest under line of credit related party excluding current portion.",
        "label": "Borrowing and Accrued Interest Under Line of Credit, Net of Debt Discount, Related Party Noncurrent",
        "terseLabel": "Borrowing and accrued interest under convertible line of credit, net of debt discount - related party (Note 10)"
       }
      }
     },
     "auth_ref": []
    },
    "galt_BusinessOperatingSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "BusinessOperatingSegmentMember",
     "presentation": [
      "http://galectintherapeutics.com/role/SegmentsSignificantAssetCategoriesDetails",
      "http://galectintherapeutics.com/role/SegmentsSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business operating segment which is focused on creating new therapies for fibrotic disease based on targeting galectin proteins.",
        "label": "Business Operating Segment [Member]",
        "terseLabel": "Business Operating Segment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "galt_CapitalContributionExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "CapitalContributionExpense",
     "crdr": "credit",
     "presentation": [
      "http://galectintherapeutics.com/role/GalectinSciencesLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capital contribution expense.",
        "label": "Capital Contribution Expense",
        "terseLabel": "Contribution for expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://galectintherapeutics.com/role/NatureOfBusinessBasisOfPresentationLiquidityAndGoingConcernDetails",
      "http://galectintherapeutics.com/role/SegmentsSignificantAssetCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r146",
      "r858"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValueAbstract",
     "presentation": [
      "http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "CASH AND CASH EQUIVALENTS, END OF PERIOD",
        "periodStartLabel": "CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r91",
      "r169"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfCashFlows",
      "http://galectintherapeutics.com/role/GalectinSciencesLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS",
        "label": "Amount expanded in cash",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r91"
     ]
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash equivalents",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r968",
      "r1095"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NONCASH FINANCING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ChiefExecutiveOfficerMember",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationDeferredStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]"
       }
      }
     },
     "auth_ref": [
      "r995"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "galt_ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of additional warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Additional Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Warrants to purchase additional common stock (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://galectintherapeutics.com/role/StockholdersEquityIssuanceOfCommonStockDetails",
      "http://galectintherapeutics.com/role/StockholdersEquityReturnOnInvestmentDetails",
      "http://galectintherapeutics.com/role/StockholdersEquitySeries12ConvertiblePreferredStockDetails",
      "http://galectintherapeutics.com/role/StockholdersEquitySeriesC6SuperDividendRedeemableConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r152",
      "r153",
      "r154",
      "r174",
      "r202",
      "r203",
      "r206",
      "r208",
      "r216",
      "r217",
      "r285",
      "r346",
      "r348",
      "r349",
      "r350",
      "r353",
      "r354",
      "r385",
      "r386",
      "r389",
      "r392",
      "r399",
      "r564",
      "r692",
      "r693",
      "r694",
      "r695",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r727",
      "r748",
      "r766",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r957",
      "r978",
      "r987"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://galectintherapeutics.com/role/StockholdersEquityIssuanceOfCommonStockDetails",
      "http://galectintherapeutics.com/role/StockholdersEquityReturnOnInvestmentDetails",
      "http://galectintherapeutics.com/role/StockholdersEquitySeries12ConvertiblePreferredStockDetails",
      "http://galectintherapeutics.com/role/StockholdersEquitySeriesC6SuperDividendRedeemableConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r153",
      "r154",
      "r216",
      "r385",
      "r386",
      "r387",
      "r389",
      "r392",
      "r397",
      "r399",
      "r692",
      "r693",
      "r694",
      "r695",
      "r884",
      "r957",
      "r978"
     ]
    },
    "us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable",
     "presentation": [
      "http://galectintherapeutics.com/role/WarrantsSummaryOfOutstandingWarrantsIssuedInConnectionWithEquityAndDebtFinancingAndConsultantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable date",
        "label": "Class of Warrant or Right, Date from which Warrants or Rights Exercisable",
        "documentation": "Date the warrants or rights are exercisable, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r400"
     ]
    },
    "galt_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired": {
     "xbrltype": "dateItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired",
     "presentation": [
      "http://galectintherapeutics.com/role/WarrantsSummaryOfOutstandingWarrantsIssuedInConnectionWithEquityAndDebtFinancingAndConsultantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date the warrants or rights are expired, in YYYY-MM-DD format.",
        "label": "Class Of Warrant Or Rights Date From Which Warrants Or Rights Expired",
        "terseLabel": "Expiration date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://galectintherapeutics.com/role/WarrantsSummaryOfOutstandingWarrantsIssuedInConnectionWithEquityAndDebtFinancingAndConsultantsDetails",
      "http://galectintherapeutics.com/role/WarrantsSummaryOfPurchaseWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://galectintherapeutics.com/role/WarrantsSummaryOfOutstandingWarrantsIssuedInConnectionWithEquityAndDebtFinancingAndConsultantsDetails",
      "http://galectintherapeutics.com/role/WarrantsSummaryOfPurchaseWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedPartyDetails",
      "http://galectintherapeutics.com/role/StockholdersEquitySeries12ConvertiblePreferredStockDetails",
      "http://galectintherapeutics.com/role/StockholdersEquitySeriesC6SuperDividendRedeemableConvertiblePreferredStockDetails",
      "http://galectintherapeutics.com/role/WarrantsSummaryOfOutstandingWarrantsIssuedInConnectionWithEquityAndDebtFinancingAndConsultantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price (in dollars per share)",
        "label": "Exercise price of warrant (in dollars per share)",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r400"
     ]
    },
    "galt_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock": {
     "xbrltype": "percentItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedPartyDetails",
      "http://galectintherapeutics.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of exercise price per share or per unit of warrants equal to common stock.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights, Percentage Equal to Common Stock",
        "terseLabel": "Percentage of warrants equal to the closing price of common stock"
       }
      }
     },
     "auth_ref": []
    },
    "galt_ClassOfWarrantOrRightIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "ClassOfWarrantOrRightIssued",
     "presentation": [
      "http://galectintherapeutics.com/role/StockholdersEquitySeriesC6SuperDividendRedeemableConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights issued during the period.",
        "label": "Class of Warrant or Right Issued",
        "terseLabel": "Warrants issued (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://galectintherapeutics.com/role/WarrantsSummaryOfOutstandingWarrantsIssuedInConnectionWithEquityAndDebtFinancingAndConsultantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://galectintherapeutics.com/role/StockholdersEquitySeries12ConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares issued upon exercise of warrant (in shares)",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedPartyDetails",
      "http://galectintherapeutics.com/role/SubsequentEventDetails",
      "http://galectintherapeutics.com/role/WarrantsSummaryOfPurchaseWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants to purchase common stock (in shares)",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r400"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://galectintherapeutics.com/role/WarrantsSummaryOfOutstandingWarrantsIssuedInConnectionWithEquityAndDebtFinancingAndConsultantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number outstanding (in shares)",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://galectintherapeutics.com/role/WarrantsSummaryOfOutstandingWarrantsIssuedInConnectionWithEquityAndDebtFinancingAndConsultantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "galt_ClinicalTrialAndResearchContingenciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "ClinicalTrialAndResearchContingenciesAbstract",
     "presentation": [
      "http://galectintherapeutics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical Trial and Research Contingencies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "galt_ClosingDaysAfterConversionRights": {
     "xbrltype": "durationItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "ClosingDaysAfterConversionRights",
     "presentation": [
      "http://galectintherapeutics.com/role/StockholdersEquitySeriesC6SuperDividendRedeemableConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of days for preferred stock post conversion rights in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but not limited to, weeks in a year or quarter.",
        "label": "Closing Days After Conversion Rights",
        "terseLabel": "Closing days after conversion rights"
       }
      }
     },
     "auth_ref": []
    },
    "galt_CommissionRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "CommissionRate",
     "presentation": [
      "http://galectintherapeutics.com/role/StockholdersEquityIssuanceOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of commission rate to be paid to sales agent in gross proceeds from the sale of common stock.",
        "label": "Commission Rate",
        "terseLabel": "Percentage of commission rate to be paid to sales agent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and contingencies (Note 12)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r119",
      "r644",
      "r726"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://galectintherapeutics.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r336",
      "r337",
      "r854",
      "r1011",
      "r1016"
     ]
    },
    "galt_CommonSharesIssuableUponConversionOfConvertibleStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "CommonSharesIssuableUponConversionOfConvertibleStock",
     "presentation": [
      "http://galectintherapeutics.com/role/StockholdersEquitySeriesC6SuperDividendRedeemableConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock issued per each converted share of Series C (accrued and unpaid dividends will be issued as additional shares).",
        "label": "Common Shares Issuable Upon Conversion of Convertible Stock",
        "terseLabel": "Common stock shares issued (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedPartyDetails",
      "http://galectintherapeutics.com/role/StockholdersEquityIssuanceOfCommonStockDetails",
      "http://galectintherapeutics.com/role/StockholdersEquitySeriesC6SuperDividendRedeemableConvertiblePreferredStockDetails",
      "http://galectintherapeutics.com/role/SubsequentEventDetails",
      "http://galectintherapeutics.com/role/WarrantsSummaryOfPurchaseWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r910",
      "r911",
      "r912",
      "r914",
      "r915",
      "r916",
      "r917",
      "r982",
      "r983",
      "r986",
      "r1061",
      "r1126",
      "r1129"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedPartyDetails",
      "http://galectintherapeutics.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "galt_CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit",
     "crdr": "credit",
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of common stock purchase warrants issued in connection with related party line of credit in noncash financing activities.",
        "label": "Common Stock Purchase Warrants Issued in Connection with Related Party Line of Credit",
        "terseLabel": "Common stock purchase warrants issued in connection with related party line of credit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://galectintherapeutics.com/role/StockholdersEquityIssuanceOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized (in shares)",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r727"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://galectintherapeutics.com/role/StockholdersEquityIssuanceOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, issued (in shares)",
        "terseLabel": "Issuance of common stock (in shares)",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://galectintherapeutics.com/role/StockholdersEquitySeriesC6SuperDividendRedeemableConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, outstanding (in shares)",
        "terseLabel": "Common stock shares outstanding (in shares)",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r80",
      "r727",
      "r745",
      "r1129",
      "r1130"
     ]
    },
    "us-gaap_CommonStockSharesSubscribedButUnissued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesSubscribedButUnissued",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationDeferredStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares unissued (in shares)",
        "documentation": "Amount of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, $0.001 par value; 150,000,000 shares authorized at December 31, 2024 and 2023, 63,157,235 and 61,852,914 issued and outstanding at December 31, 2024 and 2023, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r646",
      "r906"
     ]
    },
    "galt_CommonStockWarrantsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "CommonStockWarrantsDisclosureTextBlock",
     "presentation": [
      "http://galectintherapeutics.com/role/Warrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for Equity warrants are instruments that bestow upon the holder of the instrument the right to buy a particular stock at a predetermined price within a stipulated time frame. ... This payment is to be adjusted against the final payment that needs to be paid in case the warrants are exercised.",
        "label": "Common Stock Warrants Disclosure [Text Block]",
        "terseLabel": "Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "galt_ComputerAndOfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "ComputerAndOfficeEquipmentMember",
     "presentation": [
      "http://galectintherapeutics.com/role/PropertyAndEquipmentDetails",
      "http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets in the form of computer and office equipment.",
        "label": "Computer and Office Equipment [Member]",
        "terseLabel": "Computer and Office Equipment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration of Credit Risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r129"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r862"
     ]
    },
    "galt_ContingentInterestAprilNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "ContingentInterestAprilNoteMember",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueDetails",
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsKeyAssumptionsDetails",
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsRollForwardOfDerivativeLiabilityDetails",
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The derivative liability of contingent interest April Note.",
        "label": "Contingent Interest, April Note [Member]",
        "terseLabel": "April Note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "galt_ContingentInterestDecemberNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "ContingentInterestDecemberNoteMember",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueDetails",
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsKeyAssumptionsDetails",
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsRollForwardOfDerivativeLiabilityDetails",
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The derivative liability of contingent interest December Note.",
        "label": "Contingent Interest, December Note [Member]",
        "terseLabel": "December Note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "galt_ContingentInterestSeptemberNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "ContingentInterestSeptemberNoteMember",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueDetails",
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsKeyAssumptionsDetails",
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsRollForwardOfDerivativeLiabilityDetails",
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The derivative liability of contingent interest September Note.",
        "label": "Contingent Interest, September Note [Member]",
        "terseLabel": "September Note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "galt_ContractCancelationNoticePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "ContractCancelationNoticePeriod",
     "presentation": [
      "http://galectintherapeutics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract cancelation notice period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Contract Cancelation Notice Period",
        "terseLabel": "Contract cancelation notice period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockSharesConverted1",
     "presentation": [
      "http://galectintherapeutics.com/role/StockholdersEquitySeries12ConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued upon conversion (in shares)",
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r21"
     ]
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockSharesIssued1",
     "presentation": [
      "http://galectintherapeutics.com/role/StockholdersEquitySeries12ConvertiblePreferredStockDetails",
      "http://galectintherapeutics.com/role/StockholdersEquitySeriesC6SuperDividendRedeemableConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock shares upon conversion (in shares)",
        "label": "Convertible preferred stock (in shares)",
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r21"
     ]
    },
    "galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyCurrent",
     "crdr": "credit",
     "calculation": {
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of current portion of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as convertible notes payable and accrued interest, net of debt discount of related party. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.",
        "label": "Convertible Note Payable And Accrued Interest Net Of Debt Discount Related Party Current",
        "terseLabel": "Current portion of convertible notes payable and accrued interest, net of debt discounts - related party (Note 5)"
       }
      }
     },
     "auth_ref": []
    },
    "galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent",
     "crdr": "credit",
     "calculation": {
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as convertible notes payable and accrued interest, net of debt discount of related party excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.",
        "label": "Convertible Note Payable and Accrued Interest Net of Debt Discount - Related Party Non-Current",
        "terseLabel": "Convertible notes payable and accrued interest, net of debt discounts - related party (Note 5)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleNotesPayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleNotesPayableMember",
     "presentation": [
      "http://galectintherapeutics.com/role/LossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Notes Payable - Related Party [Member]",
        "label": "Convertible Notes Payable [Member]",
        "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r117"
     ]
    },
    "galt_ConvertibleNotesPayableRelatedPartyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "ConvertibleNotesPayableRelatedPartyAbstract",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Notes Payable, Related Party [Abstract]",
        "terseLabel": "Convertible Notes Payable - Related Party [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "galt_ConvertiblePreferredStockDividends": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "ConvertiblePreferredStockDividends",
     "crdr": "debit",
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid convertible preferred stock dividends declared with the form of settlement in cash.",
        "label": "Convertible Preferred Stock, Dividends",
        "terseLabel": "Series A 12% convertible preferred stock dividend"
       }
      }
     },
     "auth_ref": []
    },
    "galt_ConvertiblePreferredStockDividendsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "ConvertiblePreferredStockDividendsShares",
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of Convertible preferred stock issued as dividends during the period. Excludes stock splits.",
        "label": "Convertible Preferred Stock Dividends, Shares",
        "terseLabel": "Series A 12% convertible preferred stock dividend (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertiblePreferredStockMember",
     "presentation": [
      "http://galectintherapeutics.com/role/LossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock [Member]",
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r386",
      "r389",
      "r914",
      "r915",
      "r916",
      "r917"
     ]
    },
    "galt_ConvertiblePreferredStockNumberOfVotingRights": {
     "xbrltype": "integerItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "ConvertiblePreferredStockNumberOfVotingRights",
     "presentation": [
      "http://galectintherapeutics.com/role/StockholdersEquityReturnOnInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of voting rights of convertible preferred stock. Includes eligibility to vote and votes per share owned.",
        "label": "Convertible Preferred Stock, Number of Voting Rights",
        "terseLabel": "Convertible preferred stock, voting rights"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://galectintherapeutics.com/role/GalectinSciencesLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r176",
      "r177",
      "r359",
      "r387",
      "r595",
      "r615",
      "r641",
      "r859",
      "r861"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedPartyDetails",
      "http://galectintherapeutics.com/role/NatureOfBusinessBasisOfPresentationLiquidityAndGoingConcernDetails",
      "http://galectintherapeutics.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r345",
      "r1019"
     ]
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedPartyDetails",
      "http://galectintherapeutics.com/role/NatureOfBusinessBasisOfPresentationLiquidityAndGoingConcernDetails",
      "http://galectintherapeutics.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r345",
      "r1019",
      "r1020"
     ]
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract",
     "presentation": [
      "http://galectintherapeutics.com/role/IncomeTaxesPrimaryFactorsAffectingIncomeTaxRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal and Sate [Abstract]",
        "label": "Current Federal, State and Local, Tax Expense (Benefit) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://galectintherapeutics.com/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r932",
      "r949"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://galectintherapeutics.com/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r932",
      "r949"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://galectintherapeutics.com/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r934",
      "r951"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://galectintherapeutics.com/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r936",
      "r953"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://galectintherapeutics.com/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r934",
      "r951"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://galectintherapeutics.com/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r927",
      "r944"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://galectintherapeutics.com/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r928",
      "r945"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://galectintherapeutics.com/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r928",
      "r945"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r926",
      "r943"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://galectintherapeutics.com/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r929",
      "r946"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://galectintherapeutics.com/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r931",
      "r948"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://galectintherapeutics.com/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r931",
      "r948"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://galectintherapeutics.com/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r932",
      "r949"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://galectintherapeutics.com/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r935",
      "r952"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://galectintherapeutics.com/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r933",
      "r950"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://galectintherapeutics.com/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r930",
      "r947"
     ]
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "crdr": "credit",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible note principal",
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r21"
     ]
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedParty",
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedParty"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Line of Credit - Related Party and Supplemental Lines of Credit - Related Party",
        "verboseLabel": "Convertible Notes Payable - Related Party",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r171",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r344",
      "r345",
      "r355",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r371",
      "r378",
      "r379",
      "r381",
      "r573"
     ]
    },
    "galt_DebtInstrumentAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "DebtInstrumentAccruedInterest",
     "crdr": "credit",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued, but unpaid interest on the debt instrument.",
        "label": "Debt Instrument, Accrued Interest",
        "terseLabel": "Accrued interest"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r69",
      "r70",
      "r117",
      "r118",
      "r179",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r362",
      "r367",
      "r368",
      "r369",
      "r370",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r903",
      "r979",
      "r1012",
      "r1013",
      "r1014",
      "r1079",
      "r1081"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion price (in dollars per share)",
        "documentation": "The price per share of the conversion feature embedded in the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r358"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt financing arrangement",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r356",
      "r573",
      "r574",
      "r880",
      "r881",
      "r903"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest rate on short term loans",
        "documentation": "The average effective interest rate during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r374",
      "r1079"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedPartyDetails",
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Short term borrowing effective interest rate",
        "terseLabel": "Effective interest rate",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r382",
      "r573",
      "r574",
      "r903"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateIncreaseDecrease": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateIncreaseDecrease",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedPartyDetails",
      "http://galectintherapeutics.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional short term borrowing interest rate",
        "documentation": "Incremental percentage increase (decrease) in the stated rate on a debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedPartyDetails",
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short term borrowing interest rate",
        "label": "Interest rate compounded annually",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r357"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedParty",
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedParty",
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r362",
      "r367",
      "r368",
      "r369",
      "r370",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r380",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r903",
      "r979",
      "r1079",
      "r1081"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentMaturityDate",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedPartyDetails",
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails",
      "http://galectintherapeutics.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings repayment due date",
        "label": "Maturity date",
        "verboseLabel": "Promissory note, maturity date",
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r879",
      "r1066",
      "r1067"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r179",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r362",
      "r367",
      "r368",
      "r369",
      "r370",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r903",
      "r979",
      "r1012",
      "r1013",
      "r1014",
      "r1079",
      "r1081"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedParty",
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedParty",
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r39",
      "r43",
      "r64",
      "r105",
      "r106",
      "r179",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r362",
      "r367",
      "r368",
      "r369",
      "r370",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r380",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r903",
      "r979",
      "r1079",
      "r1081"
     ]
    },
    "us-gaap_DebtInstrumentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTerm",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsKeyAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term",
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Notes Payable - Related Party [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "galt_December2022PromissoryNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "December2022PromissoryNoteMember",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Promissory note executed on December 19, 2022 under the line of credit agreement.",
        "label": "December 2022 Promissory Note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "galt_December2023PromissoryNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "December2023PromissoryNoteMember",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Promissory note executed on June 30, 2023 under the line of credit agreement.",
        "label": "December 2023 Promissory Note [Member]",
        "terseLabel": "December 2023 Promissory Note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "galt_December292023WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "December292023WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember",
     "presentation": [
      "http://galectintherapeutics.com/role/WarrantsSummaryOfOutstandingWarrantsIssuedInConnectionWithEquityAndDebtFinancingAndConsultantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrants.",
        "label": "December 29, 2023 Warrants Issued for Draw on Related Party Line of Credit [Member]",
        "terseLabel": "December 29, 2023 Warrants Issued for Draw on Related Party Line of Credit [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "galt_DecemberConvertiblePromissoryNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "DecemberConvertiblePromissoryNoteMember",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of debt instrument.",
        "label": "December Convertible Promissory Note [Member]",
        "terseLabel": "December 2021 Note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "galt_DecemberEightTwentyZeroNineSeriesBTwoTransactionOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "DecemberEightTwentyZeroNineSeriesBTwoTransactionOneMember",
     "presentation": [
      "http://galectintherapeutics.com/role/WarrantsSummaryOfOutstandingWarrantsIssuedInConnectionWithEquityAndDebtFinancingAndConsultantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrants.",
        "label": "December Eight Twenty Zero Nine Series B Two Transaction One [Member]",
        "verboseLabel": "December 8, 2009 Series B-2 Transaction [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "galt_DecemberTwentyThreeTwentySixteenSeriesBThreeTransactionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "DecemberTwentyThreeTwentySixteenSeriesBThreeTransactionMember",
     "presentation": [
      "http://galectintherapeutics.com/role/WarrantsSummaryOfOutstandingWarrantsIssuedInConnectionWithEquityAndDebtFinancingAndConsultantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrants.",
        "label": "December Twenty Three Twenty Sixteen Series B Three Transaction [Member]",
        "terseLabel": "December 23, 2016 Series B-3 Transaction [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationDeferredStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Bonus and Profit Sharing Arrangement, Individual Contract, Type of Deferred Compensation [Domain]",
        "documentation": "Deferred compensation that is not equivalent to a defined benefit pension plan or a defined benefit other postretirement benefit plan. Includes, but is not limited to, employment contracts with one or more selected officers or key employees. Excludes equity-based compensation plans, defined benefit pension plans and defined benefit other postretirement benefit plans."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r108"
     ]
    },
    "us-gaap_DeferredBonusMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredBonusMember",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationDeferredStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Bonus [Member]",
        "documentation": "Contractual arrangement whereby employee is entitled to receive future bonus, subject to vesting and other restrictions as defined in agreement, in addition to employee's regular salary and profit sharing. Includes, but is not limited to, discretionary or fixed formula employer contribution based on individual, group, and entity-wide performance goals or other factors."
       }
      }
     },
     "auth_ref": []
    },
    "galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFive": {
     "xbrltype": "percentItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFive",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationDeferredStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of underlying the outstanding whole number of DSUs credited individuals during period.",
        "label": "Deferred Compensation Arrangement, Percentage of Deferred Share Units Shall be Issued, Period Five",
        "verboseLabel": "Percentage of DSUs shall be credited on March 1, 2023"
       }
      }
     },
     "auth_ref": []
    },
    "galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFour": {
     "xbrltype": "percentItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFour",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationDeferredStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of underlying the outstanding whole number of DSUs credited individuals during period.",
        "label": "Deferred Compensation Arrangement, Percentage of Deferred Share Units Shall be Issued, Period Four",
        "verboseLabel": "Percentage of DSUs shall be credited on March 1, 2024"
       }
      }
     },
     "auth_ref": []
    },
    "galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne": {
     "xbrltype": "percentItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationDeferredStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of underlying the outstanding whole number of DSUs credited individuals during period.",
        "label": "Deferred Compensation Arrangement, Percentage of Deferred Share Units Shall be Issued, Period One",
        "terseLabel": "Percentage of DSUs shall be credited on March 1, 2023"
       }
      }
     },
     "auth_ref": []
    },
    "galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSeven": {
     "xbrltype": "percentItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSeven",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationDeferredStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of underlying the outstanding whole number of DSUs credited individuals during period.",
        "label": "Deferred Compensation Arrangement, Percentage of Deferred Share Units Shall be Issued, Period Seven",
        "terseLabel": "Percentage of DSUs shall be credited on January 5, 2026"
       }
      }
     },
     "auth_ref": []
    },
    "galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSix": {
     "xbrltype": "percentItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSix",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationDeferredStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of underlying the outstanding whole number of DSUs credited individuals during period.",
        "label": "Deferred Compensation Arrangement, Percentage of Deferred Share Units Shall be Issued, Period Six",
        "terseLabel": "Percentage of DSUs shall be credited on March 1, 2025"
       }
      }
     },
     "auth_ref": []
    },
    "galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree": {
     "xbrltype": "percentItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationDeferredStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of underlying the outstanding whole number of DSUs credited individuals during period.",
        "label": "Deferred Compensation Arrangement Percentage of Deferred Share Units Shall be Issued Period Three",
        "terseLabel": "Percentage of DSUs shall be credited on September 1, 2028"
       }
      }
     },
     "auth_ref": []
    },
    "galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo": {
     "xbrltype": "percentItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationDeferredStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of underlying the outstanding whole number of DSUs credited individuals during period.",
        "label": "Deferred Compensation Arrangement Percentage of Deferred Share Units Shall be Issued Period Two",
        "terseLabel": "Percentage of DSUs shall be credited on March 1, 2024"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationDeferredStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock based compensation expense",
        "label": "Deferred Compensation Arrangement with Individual, Allocated Share-Based Compensation Expense",
        "documentation": "Amount of expense recognized from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments), awarded to key employees or individuals. Excludes amount related to plans that cover generally all employees (for example, but not limited to, qualified pension plans)."
       }
      }
     },
     "auth_ref": []
    },
    "galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationDeferredStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The deferred compensation arrangement with individual cash award granted paid in cash percentage.",
        "label": "Deferred Compensation Arrangement With Individual Cash Award Granted Paid in Cash Percent",
        "terseLabel": "Percentage of base salary paid in cash"
       }
      }
     },
     "auth_ref": []
    },
    "galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationDeferredStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The deferred compensation arrangement with individual cash award granted paid in deferred stock units percentage.",
        "label": "Deferred Compensation Arrangement With Individual Cash Award Granted Paid in Deferred Stock Units Percent",
        "terseLabel": "Percentage of base salary paid in deferred stock units"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationDeferredStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Bonus and Profit Sharing Arrangements, Individual Contracts, Type of Deferred Compensation [Axis]",
        "documentation": "Information by type of deferred compensation that is not equivalent to a defined benefit pension plan or a defined benefit other postretirement benefit plan. Includes, but is not limited to, employment contracts with one or more selected officers or key employees. Excludes equity-based compensation plans, defined benefit pension plans and defined benefit other postretirement benefit plans."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r108"
     ]
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCompensationArrangementWithIndividualExercisePrice",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationDeferredStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Weighted average Grant Date fair Value (in dollars per share)",
        "documentation": "The per share price that the individual must pay to acquire shares under the deferred compensation arrangement."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCompensationArrangementWithIndividualSharesIssued",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationDeferredStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock reserved for future issuance (in shares)",
        "documentation": "Number of shares issued pursuant to the terms of a deferred compensation arrangement."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://galectintherapeutics.com/role/IncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/IncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred tax assets, gross",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r477"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://galectintherapeutics.com/role/IncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/IncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax asset",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1058"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNetOfValuationAllowanceAbstract",
     "presentation": [
      "http://galectintherapeutics.com/role/IncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://galectintherapeutics.com/role/IncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/IncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1060"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://galectintherapeutics.com/role/IncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/IncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other temporary differences",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1060"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://galectintherapeutics.com/role/IncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/IncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax credit carryforwards",
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1060"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://galectintherapeutics.com/role/IncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/IncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r478"
     ]
    },
    "galt_DeferredTaxAssetsValuationAllowancePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "DeferredTaxAssetsValuationAllowancePercentage",
     "presentation": [
      "http://galectintherapeutics.com/role/IncomeTaxesPrimaryFactorsAffectingIncomeTaxRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The deferred tax assets valuation allowance percentage in each of the last two years.",
        "label": "Deferred Tax Assets Valuation Allowance Percentage",
        "terseLabel": "Deferred tax asset valuation allowance percentage in each of the last two years"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepositAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepositAssetsAbstract",
     "presentation": [
      "http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesSecurityDepositDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Deposit [Abstract]",
        "label": "Deposit Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://galectintherapeutics.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation and amortization expense",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r32"
     ]
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeContractTypeDomain",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueDetails",
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsKeyAssumptionsDetails",
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsRollForwardOfDerivativeLiabilityDetails",
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Contract [Domain]",
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "auth_ref": [
      "r716",
      "r718",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r740",
      "r741",
      "r742",
      "r743",
      "r754",
      "r755",
      "r756",
      "r757",
      "r760",
      "r761",
      "r762",
      "r763",
      "r820",
      "r821",
      "r824",
      "r826",
      "r910",
      "r912",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1075",
      "r1076"
     ]
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueDetails",
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsKeyAssumptionsDetails",
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsRollForwardOfDerivativeLiabilityDetails",
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instrument [Axis]",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r60",
      "r62",
      "r115",
      "r716",
      "r718",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r740",
      "r741",
      "r742",
      "r743",
      "r754",
      "r755",
      "r756",
      "r757",
      "r760",
      "r761",
      "r762",
      "r763",
      "r820",
      "r821",
      "r824",
      "r826",
      "r861",
      "r910",
      "r912",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1075",
      "r1076"
     ]
    },
    "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
     "crdr": "credit",
     "calculation": {
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfOperations",
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails",
      "http://galectintherapeutics.com/role/SegmentsSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of derivatives",
        "negatedLabel": "Change in fair value of derivative",
        "terseLabel": "Change in fair value of derivatives",
        "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r960"
     ]
    },
    "us-gaap_DerivativeLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant liabilities",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r157",
      "r541",
      "r542",
      "r553",
      "r563",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r740",
      "r742",
      "r743",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r861",
      "r1065",
      "r1066",
      "r1067",
      "r1127"
     ]
    },
    "us-gaap_DerivativeLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current portion of derivative liabilities (Note 6)",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r156"
     ]
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails",
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueDetails",
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsRollForwardOfDerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "label": "Derivative liabilities (Note 6)",
        "terseLabel": "Fair value of derivative liability",
        "verboseLabel": "Derivative Liability - Contingent Interest",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r156"
     ]
    },
    "us-gaap_DerivativeLiabilityMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilityMeasurementInput",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsKeyAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative liability, measurement input",
        "label": "Derivative Liability, Measurement Input",
        "documentation": "Value of input used to measure derivative liability."
       }
      }
     },
     "auth_ref": [
      "r543",
      "r544",
      "r545"
     ]
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativesPolicyTextBlock",
     "presentation": [
      "http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "label": "Derivatives, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r56",
      "r57",
      "r58",
      "r63",
      "r178",
      "r196"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r413",
      "r417",
      "r448",
      "r449",
      "r451",
      "r889"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "galt_DividendAsPercentageOfNetSales": {
     "xbrltype": "percentItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "DividendAsPercentageOfNetSales",
     "presentation": [
      "http://galectintherapeutics.com/role/StockholdersEquitySeriesC6SuperDividendRedeemableConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net sales until the total dividends paid is equal to the initial investment as percentage of total net sales.",
        "label": "Dividend as Percentage of Net Sales",
        "terseLabel": "Dividend as percentage of net sales"
       }
      }
     },
     "auth_ref": []
    },
    "galt_DividendPaymentScenarioOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "DividendPaymentScenarioOneMember",
     "presentation": [
      "http://galectintherapeutics.com/role/StockholdersEquitySeries12ConvertiblePreferredStockDetails",
      "http://galectintherapeutics.com/role/StockholdersEquitySeriesC6SuperDividendRedeemableConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dividend payment scenario.",
        "label": "Dividend Payment Scenario One [Member]",
        "terseLabel": "Dividend Payment Scenario One [Member]",
        "verboseLabel": "Scenario 1 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "galt_DividendPaymentScenarioTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "DividendPaymentScenarioTwoMember",
     "presentation": [
      "http://galectintherapeutics.com/role/StockholdersEquitySeries12ConvertiblePreferredStockDetails",
      "http://galectintherapeutics.com/role/StockholdersEquitySeriesC6SuperDividendRedeemableConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dividend payment scenario.",
        "label": "Dividend Payment Scenario Two [Member]",
        "terseLabel": "Dividend Payment Scenario Two [Member]",
        "verboseLabel": "Scenario 2 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DividendsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DividendsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued dividends payable",
        "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_DividendsPreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DividendsPreferredStock",
     "crdr": "debit",
     "presentation": [
      "http://galectintherapeutics.com/role/StockholdersEquitySeriesC6SuperDividendRedeemableConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible preferred stock dividend",
        "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK)."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r107"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r923",
      "r924",
      "r937"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r923",
      "r924",
      "r937",
      "r939"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://galectintherapeutics.com/role/IncomeTaxesPrimaryFactorsAffectingIncomeTaxRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r464"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per common share - basic (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r199",
      "r202",
      "r206",
      "r207",
      "r208",
      "r212",
      "r501",
      "r510",
      "r538",
      "r539",
      "r639",
      "r658",
      "r863"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per common share - diluted (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r202",
      "r206",
      "r207",
      "r208",
      "r212",
      "r501",
      "r510",
      "r538",
      "r539",
      "r639",
      "r658",
      "r863"
     ]
    },
    "us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDilutedOtherDisclosuresAbstract",
     "presentation": [
      "http://galectintherapeutics.com/role/LossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Abstract]",
        "label": "Earnings Per Share, Diluted, Other Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://galectintherapeutics.com/role/LossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Per Share",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r209",
      "r210",
      "r211"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://galectintherapeutics.com/role/IncomeTaxesPrimaryFactorsAffectingIncomeTaxRatesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/IncomeTaxesPrimaryFactorsAffectingIncomeTaxRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income tax rate, total",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r464",
      "r891"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "presentation": [
      "http://galectintherapeutics.com/role/IncomeTaxesPrimaryFactorsAffectingIncomeTaxRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Primary Factors Affecting Income Tax Rates [Abstract]",
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://galectintherapeutics.com/role/IncomeTaxesPrimaryFactorsAffectingIncomeTaxRatesDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/IncomeTaxesPrimaryFactorsAffectingIncomeTaxRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Tax benefit at U.S. statutory rates",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r464",
      "r489",
      "r891"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://galectintherapeutics.com/role/IncomeTaxesPrimaryFactorsAffectingIncomeTaxRatesDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/IncomeTaxesPrimaryFactorsAffectingIncomeTaxRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Changes in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r468",
      "r891",
      "r981",
      "r1054"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "calculation": {
      "http://galectintherapeutics.com/role/IncomeTaxesPrimaryFactorsAffectingIncomeTaxRatesDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/IncomeTaxesPrimaryFactorsAffectingIncomeTaxRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Permanent differences",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r469",
      "r470",
      "r981",
      "r1054"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://galectintherapeutics.com/role/IncomeTaxesPrimaryFactorsAffectingIncomeTaxRatesDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/IncomeTaxesPrimaryFactorsAffectingIncomeTaxRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r891",
      "r981",
      "r1054",
      "r1055"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://galectintherapeutics.com/role/IncomeTaxesPrimaryFactorsAffectingIncomeTaxRatesDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/IncomeTaxesPrimaryFactorsAffectingIncomeTaxRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "State tax benefit",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r467",
      "r891",
      "r981",
      "r1054"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://galectintherapeutics.com/role/AccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued compensation",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationComponentsOfStockbasedCompensationExpenseDetails",
      "http://galectintherapeutics.com/role/StockbasedCompensationDeferredStockUnitsDetails",
      "http://galectintherapeutics.com/role/StockbasedCompensationOutstandingAndExercisableOptionsUnderStockBasedCompensationPlansDetails",
      "http://galectintherapeutics.com/role/StockbasedCompensationRestrictedStockIssuancesDetails",
      "http://galectintherapeutics.com/role/StockbasedCompensationSummaryOfStockbasedCompensationPlansDetails",
      "http://galectintherapeutics.com/role/StockbasedCompensationWeightedAverageAssumptionsUsedToDetermineFairValueOfOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationDeferredStockUnitsDetails",
      "http://galectintherapeutics.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation cost",
        "label": "Unrecognized compensation cost",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r450"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized compensation cost, recognition period",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r450"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://galectintherapeutics.com/role/LossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r954"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedPartyDetails",
      "http://galectintherapeutics.com/role/StockholdersEquityIssuanceOfCommonStockDetails",
      "http://galectintherapeutics.com/role/StockholdersEquitySeriesC6SuperDividendRedeemableConvertiblePreferredStockDetails",
      "http://galectintherapeutics.com/role/SubsequentEventDetails",
      "http://galectintherapeutics.com/role/WarrantsSummaryOfPurchaseWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r138",
      "r161",
      "r162",
      "r163",
      "r180",
      "r181",
      "r182",
      "r185",
      "r192",
      "r194",
      "r196",
      "r215",
      "r289",
      "r295",
      "r323",
      "r402",
      "r484",
      "r485",
      "r497",
      "r498",
      "r499",
      "r502",
      "r509",
      "r510",
      "r519",
      "r521",
      "r522",
      "r523",
      "r524",
      "r526",
      "r537",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r576",
      "r578",
      "r592",
      "r656",
      "r676",
      "r677",
      "r678",
      "r698",
      "r766"
     ]
    },
    "galt_EquityIncentivePlan2019Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "EquityIncentivePlan2019Member",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationSummaryOfStockbasedCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A share-based compensation plan under which awards may be granted for officers, employees and directors of the Company and its subsidiaries.",
        "label": "Equity Incentive Plan 2019 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "galt_EquityIssuancePerShareAmount": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "EquityIssuancePerShareAmount",
     "presentation": [
      "http://galectintherapeutics.com/role/StockholdersEquitySeriesC6SuperDividendRedeemableConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount per share or per unit assigned to the consideration received of equity securities issued for development stage entities.",
        "label": "Equity Issuance Per Share Amount",
        "terseLabel": "Common stock share conversion price (in dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "galt_ExercisePriceRangeFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "ExercisePriceRangeFiveMember",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationOutstandingAndExercisableOptionsUnderStockBasedCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Its represented to exercise price range five.",
        "label": "Exercise Price Range Five [Member]",
        "terseLabel": "$8.01-$13.38 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "galt_ExercisePriceRangeFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "ExercisePriceRangeFourMember",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationOutstandingAndExercisableOptionsUnderStockBasedCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Its represented to exercise price range four.",
        "label": "Exercise Price Range Four [Member]",
        "terseLabel": "$5.01 - $8.00 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "galt_ExercisePriceRangeOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "ExercisePriceRangeOneMember",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationOutstandingAndExercisableOptionsUnderStockBasedCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Its represented to exercise price range one.",
        "label": "Exercise Price Range One [Member]",
        "terseLabel": "$0.87-$1.00 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "galt_ExercisePriceRangeThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "ExercisePriceRangeThreeMember",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationOutstandingAndExercisableOptionsUnderStockBasedCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Its represented to exercise price range three.",
        "label": "Exercise Price Range Three [Member]",
        "terseLabel": "$3.01-$5.00 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "galt_ExercisePriceRangeTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "ExercisePriceRangeTwoMember",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationOutstandingAndExercisableOptionsUnderStockBasedCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Its represented to exercise price range two.",
        "label": "Exercise Price Range Two [Member]",
        "terseLabel": "$1.01-$3.00 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "galt_ExpiringAsAResultOf2017TaxActMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "ExpiringAsAResultOf2017TaxActMember",
     "presentation": [
      "http://galectintherapeutics.com/role/IncomeTaxesPrimaryFactorsAffectingIncomeTaxRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiring as a result of 2017 tax act earliest tax year.",
        "label": "Expiring as a Result of 2017 Tax Act [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "galt_ExpiringThrough2037Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "ExpiringThrough2037Member",
     "presentation": [
      "http://galectintherapeutics.com/role/IncomeTaxesPrimaryFactorsAffectingIncomeTaxRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Latest expiration tax year.",
        "label": "Expiring Through 2037 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "galt_FairValueAdjustmentOfWarrant": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "FairValueAdjustmentOfWarrant",
     "crdr": "debit",
     "calculation": {
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfOperations",
      "http://galectintherapeutics.com/role/SegmentsSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment of Warrant",
        "negatedLabel": "Warrant modification"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfCashFlows",
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsRollForwardOfDerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Change in fair value of derivatives",
        "terseLabel": "Fair Value Adjustment",
        "label": "Fair Value Adjustment of Warrants",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r6"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueDetails",
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsRollForwardOfDerivativeLiabilityDetails",
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r541",
      "r542",
      "r553",
      "r892"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueDetails",
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsRollForwardOfDerivativeLiabilityDetails",
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r541",
      "r542",
      "r553",
      "r892"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsKeyAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r543",
      "r544",
      "r545",
      "r896"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsKeyAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r543",
      "r544",
      "r545",
      "r896"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Key Assumptions Used in Model at Inception",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r543",
      "r544",
      "r896"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r369",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r540",
      "r542",
      "r543",
      "r544",
      "r545",
      "r552",
      "r553",
      "r555",
      "r602",
      "r603",
      "r604",
      "r880",
      "r881",
      "r885",
      "r886",
      "r887",
      "r892",
      "r896"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r541",
      "r542",
      "r543",
      "r545",
      "r892",
      "r1066",
      "r1077"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r548",
      "r550",
      "r551",
      "r552",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r638",
      "r892",
      "r897"
     ]
    },
    "us-gaap_FairValueInputsLevel12And3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel12And3Member",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1, 2 and 3 [Member]",
        "documentation": "Fair value measurement input including quoted price in active market for identical asset or liability reporting entity can access at measurement date (level 1), input other than quoted price included within level 1 either directly or indirectly observable for asset or liability (level 2) and unobservable input reflecting entity's own assumption (level 3)."
       }
      }
     },
     "auth_ref": [
      "r892",
      "r1026",
      "r1064",
      "r1075"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r369",
      "r404",
      "r409",
      "r542",
      "r553",
      "r602",
      "r885",
      "r886",
      "r887",
      "r892"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r369",
      "r404",
      "r409",
      "r542",
      "r543",
      "r553",
      "r603",
      "r880",
      "r881",
      "r885",
      "r886",
      "r887",
      "r892"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r369",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r542",
      "r543",
      "r544",
      "r545",
      "r553",
      "r604",
      "r880",
      "r881",
      "r885",
      "r886",
      "r887",
      "r892",
      "r896"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsRollForwardOfDerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Roll Forward of Derivative Liability [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Roll Forward of Derivative Liability - Contingent Interest",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r546",
      "r549",
      "r554"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r541",
      "r542",
      "r543",
      "r545",
      "r892",
      "r1066",
      "r1077"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r369",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r540",
      "r542",
      "r543",
      "r544",
      "r545",
      "r552",
      "r553",
      "r555",
      "r602",
      "r603",
      "r604",
      "r880",
      "r881",
      "r885",
      "r886",
      "r887",
      "r892",
      "r896"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r892",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1077"
     ]
    },
    "us-gaap_FairValueNetAssetLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueNetAssetLiabilityAbstract",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets and Liabilities Measured at Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "galt_FebruaryTwelveTwentyZeroNineSeriesBOneTransactionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "FebruaryTwelveTwentyZeroNineSeriesBOneTransactionMember",
     "presentation": [
      "http://galectintherapeutics.com/role/WarrantsSummaryOfOutstandingWarrantsIssuedInConnectionWithEquityAndDebtFinancingAndConsultantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrants.",
        "label": "February Twelve Two Thousand Zero Nine Series B One Transaction Member",
        "terseLabel": "February 12, 2009 Series B-1 Transaction [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "galt_FederalAndStateResearchAndDevelopmentCreditsExpirationYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "FederalAndStateResearchAndDevelopmentCreditsExpirationYear",
     "presentation": [
      "http://galectintherapeutics.com/role/IncomeTaxesPrimaryFactorsAffectingIncomeTaxRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The federal and state research and development credits expiration year.",
        "label": "Federal and State Research and Development Credits Expiration Year",
        "terseLabel": "Federal and state research and development credits expiration year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedPartyDetails",
      "http://galectintherapeutics.com/role/WarrantsSummaryOfPurchaseWarrantsDetails",
      "http://galectintherapeutics.com/role/WarrantsSummaryOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r380",
      "r397",
      "r527",
      "r560",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r657",
      "r876",
      "r892",
      "r894",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r907",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1062",
      "r1065",
      "r1066",
      "r1067",
      "r1074",
      "r1077"
     ]
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities",
        "label": "Financial Liabilities Fair Value Disclosure",
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities."
       }
      }
     },
     "auth_ref": [
      "r1063",
      "r1064",
      "r1074"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://galectintherapeutics.com/role/GalectinSciencesLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r633",
      "r637",
      "r857"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://galectintherapeutics.com/role/GalectinSciencesLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r857"
     ]
    },
    "galt_FirstClosingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "FirstClosingMember",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A type of debt instrument.",
        "label": "First Closing [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "galt_FreeRentPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "FreeRentPeriod",
     "presentation": [
      "http://galectintherapeutics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Free rent period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Free Rent Period",
        "terseLabel": "Free rent period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://galectintherapeutics.com/role/PropertyAndEquipmentDetails",
      "http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "galt_GalectinSciencesLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "GalectinSciencesLLCMember",
     "presentation": [
      "http://galectintherapeutics.com/role/GalectinSciencesLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of entity.",
        "label": "Galectin Sciences, LLC [Member]",
        "terseLabel": "Galectin Sciences, LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfOperations",
      "http://galectintherapeutics.com/role/SegmentsSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r750"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://galectintherapeutics.com/role/CommitmentsAndContingenciesDetails",
      "http://galectintherapeutics.com/role/StockbasedCompensationComponentsOfStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and Administrative [Member]",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r923",
      "r924",
      "r937"
     ]
    },
    "us-gaap_ImpairmentLongLivedAssetHeldForUseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentLongLivedAssetHeldForUseAbstract",
     "presentation": [
      "http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesLonglivedAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "crdr": "debit",
     "presentation": [
      "http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesLonglivedAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of long-lived assets",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r31",
      "r98",
      "r893"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r99"
     ]
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InProcessResearchAndDevelopmentMember",
     "presentation": [
      "http://galectintherapeutics.com/role/GalectinSciencesLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IPR&amp;D [Member]",
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process."
       }
      }
     },
     "auth_ref": [
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010"
     ]
    },
    "galt_IncentiveCompensationPlanTwoThousandNineMemberMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "IncentiveCompensationPlanTwoThousandNineMemberMember",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationSummaryOfStockbasedCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Incentive Plan Agreement (\"Agreement\") is a legal contract between a Corporation and its employees to provide the employee with an interest in the Corporation. The purpose of an Equity Incentive Plan is to strengthen the financials of the Corporation by providing incentive stock options to its employees.",
        "label": "Incentive Compensation Plan Two thousand Nine Member [Member]",
        "terseLabel": "Incentive Compensation Plan 2009 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromEquityMethodInvestments",
     "crdr": "credit",
     "presentation": [
      "http://galectintherapeutics.com/role/GalectinSciencesLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss from equity method investment",
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r86",
      "r121",
      "r214",
      "r229",
      "r245",
      "r284",
      "r654"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://galectintherapeutics.com/role/CommitmentsAndContingenciesDetails",
      "http://galectintherapeutics.com/role/StockbasedCompensationComponentsOfStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r324",
      "r331",
      "r333",
      "r547",
      "r549",
      "r554",
      "r671",
      "r673",
      "r751",
      "r857",
      "r895",
      "r1097"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://galectintherapeutics.com/role/CommitmentsAndContingenciesDetails",
      "http://galectintherapeutics.com/role/StockbasedCompensationComponentsOfStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r333",
      "r547",
      "r549",
      "r554",
      "r671",
      "r673",
      "r751",
      "r857",
      "r895",
      "r1097"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://galectintherapeutics.com/role/IncomeTaxesPrimaryFactorsAffectingIncomeTaxRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r464",
      "r465",
      "r474",
      "r481",
      "r891",
      "r1059"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://galectintherapeutics.com/role/IncomeTaxesPrimaryFactorsAffectingIncomeTaxRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r464",
      "r465",
      "r474",
      "r481",
      "r891",
      "r1059"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://galectintherapeutics.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r461",
      "r464",
      "r471",
      "r472",
      "r473",
      "r475",
      "r480",
      "r490",
      "r491",
      "r492",
      "r493",
      "r697",
      "r891"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r462",
      "r463",
      "r475",
      "r476",
      "r479",
      "r483",
      "r691"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "crdr": "credit",
     "presentation": [
      "http://galectintherapeutics.com/role/IncomeTaxesPrimaryFactorsAffectingIncomeTaxRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development credits",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r891",
      "r1054",
      "r1056"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable, accrued expenses and other liabilities",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInInterestPayableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInInterestPayableNet",
     "crdr": "debit",
     "calculation": {
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued interest on convertible notes payable and convertible line of credit - related party",
        "label": "Increase (Decrease) in Interest Payable, Net",
        "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r940"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r925",
      "r942"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://galectintherapeutics.com/role/InsiderTradingPoliciesAndProcedures"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r925",
      "r942"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of interest expense",
        "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r222",
      "r226",
      "r232",
      "r245",
      "r572",
      "r870",
      "r871"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued interest expense",
        "label": "Interest Expense, Debt",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r375",
      "r383",
      "r882",
      "r883"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfOperations",
      "http://galectintherapeutics.com/role/SegmentsSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest Expense, Nonoperating",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r974"
     ]
    },
    "us-gaap_InterestExpenseOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseOther",
     "crdr": "debit",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional interest expense",
        "label": "Interest Expense, Other",
        "documentation": "Amount of interest expense classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfOperations",
      "http://galectintherapeutics.com/role/SegmentsSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r225",
      "r245",
      "r870",
      "r973"
     ]
    },
    "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://galectintherapeutics.com/role/GalectinSciencesLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated fair value of asset contributed to joint venture",
        "label": "Investments in Affiliates, Subsidiaries, Associates, and Joint Ventures, Fair Value Disclosure",
        "documentation": "Fair value portion of investments in an entity not consolidated. Includes, but is not limited to, investments in an entity that is affiliated with the reporting entity by means of direct or indirect ownership, an entity in which the reporting entity shares control of the entity with another party or group, an entity which the company has significant influence, but does not have control and subsidiaries that are not required to be consolidated and are accounted for using the equity or cost method."
       }
      }
     },
     "auth_ref": [
      "r1063",
      "r1064",
      "r1074"
     ]
    },
    "us-gaap_InvestmentsInAndAdvancesToAffiliatesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsInAndAdvancesToAffiliatesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Galectin Sciences LLC [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsInAndAdvancesToAffiliatesLineItems",
     "presentation": [
      "http://galectintherapeutics.com/role/GalectinSciencesLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments in and Advances to Affiliates [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract",
     "presentation": [
      "http://galectintherapeutics.com/role/GalectinSciencesLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments in and Advances to Affiliates, Schedule of Investments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock",
     "presentation": [
      "http://galectintherapeutics.com/role/GalectinSciencesLlc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Galectin Sciences LLC",
        "documentation": "The entire disclosure for the information summarizing investments in and advances to majority-owned subsidiaries, other controlled companies, and other affiliates. It reflects specified information about ownership, financial results from, and financial position in such entities."
       }
      }
     },
     "auth_ref": [
      "r835",
      "r840",
      "r841"
     ]
    },
    "galt_IssuanceOfWarrantsValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "IssuanceOfWarrantsValue",
     "crdr": "credit",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of issuance of warrants.",
        "label": "Issuance of Warrants Value",
        "terseLabel": "Warrants issuance value"
       }
      }
     },
     "auth_ref": []
    },
    "galt_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "JanuaryTwentyNineTwentyTenSeriesBTwoTransactionOneMember",
     "presentation": [
      "http://galectintherapeutics.com/role/WarrantsSummaryOfOutstandingWarrantsIssuedInConnectionWithEquityAndDebtFinancingAndConsultantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrants.",
        "label": "January Twenty Nine Twenty Ten Series B Two Transaction One [Member]",
        "verboseLabel": "January 29, 2010 Series B-2 Transaction [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "galt_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "JanuaryTwentyNineTwentyTenSeriesBTwoTransactionTwoMember",
     "presentation": [
      "http://galectintherapeutics.com/role/WarrantsSummaryOfOutstandingWarrantsIssuedInConnectionWithEquityAndDebtFinancingAndConsultantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrants.",
        "label": "January Twenty Nine Twenty Ten Series B Two Transaction Two [Member]",
        "terseLabel": "January 29, 2010 Series B-2 Transaction [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "galt_July222022WarrantsIssuedInConnectionWithRelatedPartyLineOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "July222022WarrantsIssuedInConnectionWithRelatedPartyLineOfCreditMember",
     "presentation": [
      "http://galectintherapeutics.com/role/WarrantsSummaryOfOutstandingWarrantsIssuedInConnectionWithEquityAndDebtFinancingAndConsultantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrants.",
        "label": "July 22, 2022 Warrants Issued in Connection with Related Party Line of Credit [Member]",
        "terseLabel": "July 22, 2022 Warrants Issued in Connection with Related Party Line of Credit [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "galt_June2023PromissoryNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "June2023PromissoryNoteMember",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Promissory note executed on June 30, 2023 under the line of credit agreement.",
        "label": "June 2023 Promissory Note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "galt_June2024PromissoryNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "June2024PromissoryNoteMember",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Promissory note executed on June 28, 2024 under the line of credit agreement.",
        "label": "June 2024 Promissory Note [Member]",
        "terseLabel": "June 2024 Promissory Note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "galt_June282024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "June282024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember",
     "presentation": [
      "http://galectintherapeutics.com/role/WarrantsSummaryOfOutstandingWarrantsIssuedInConnectionWithEquityAndDebtFinancingAndConsultantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrants.",
        "label": "June 28, 2024 Warrants Issued for Draw on Related Party Line of Credit [Member]",
        "terseLabel": "June 28, 2024 Warrants Issued for Draw on Related Party Line of Credit [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "galt_JuneThirtyTwentyZeroNineSeriesBTwoTransactionOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "JuneThirtyTwentyZeroNineSeriesBTwoTransactionOneMember",
     "presentation": [
      "http://galectintherapeutics.com/role/WarrantsSummaryOfOutstandingWarrantsIssuedInConnectionWithEquityAndDebtFinancingAndConsultantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrants.",
        "label": "June Thirty Twenty Zero Nine Series B Two Transaction One [Member]",
        "verboseLabel": "June 30, 2009 Series B-2 Transaction [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://galectintherapeutics.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r585"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://galectintherapeutics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r582",
      "r586"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://galectintherapeutics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r582",
      "r586"
     ]
    },
    "us-gaap_LesseeOperatingLeaseDescriptionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseDescriptionAbstract",
     "presentation": [
      "http://galectintherapeutics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Commitments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseDiscountRate",
     "presentation": [
      "http://galectintherapeutics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discount rate on present value of lease payments",
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments."
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://galectintherapeutics.com/role/CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturity of Operating Lease",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1083"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://galectintherapeutics.com/role/CommitmentsAndContingenciesDetailsCalc2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://galectintherapeutics.com/role/CommitmentsAndContingenciesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r584"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://galectintherapeutics.com/role/CommitmentsAndContingenciesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r584"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://galectintherapeutics.com/role/CommitmentsAndContingenciesDetailsCalc2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Less imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r584"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://galectintherapeutics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease renewal term",
        "label": "Lessee, Operating Lease, Renewal Term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1082"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://galectintherapeutics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term of contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1082"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r69",
      "r70",
      "r71",
      "r74",
      "r75",
      "r76",
      "r77",
      "r174",
      "r285",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r513",
      "r514",
      "r515",
      "r564",
      "r725",
      "r864",
      "r919",
      "r1021",
      "r1086",
      "r1087"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities, redeemable convertible preferred stock and stockholders' deficit",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r120",
      "r649",
      "r906",
      "r980",
      "r1000",
      "r1078"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r145",
      "r174",
      "r285",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r513",
      "r514",
      "r515",
      "r564",
      "r906",
      "r1021",
      "r1086",
      "r1087"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Line of Credit - Related Party and Supplemental Lines of Credit - Related Party [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityLineItems",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r345",
      "r979",
      "r1019"
     ]
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedPartyDetails",
      "http://galectintherapeutics.com/role/NatureOfBusinessBasisOfPresentationLiquidityAndGoingConcernDetails",
      "http://galectintherapeutics.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of credit",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r73"
     ]
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityTable",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility [Table]",
        "documentation": "Disclosure of information about short-term and long-term contractual arrangements with lender under which borrowing can occur up to maximum amount. Includes, but is not limited to, letter of credit, standby letter of credit, and revolving credit arrangement."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r73",
      "r345",
      "r979",
      "r1019"
     ]
    },
    "us-gaap_LineOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditMember",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedParty",
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedPartyDetails",
      "http://galectintherapeutics.com/role/LossPerShareDetails",
      "http://galectintherapeutics.com/role/NatureOfBusinessBasisOfPresentationLiquidityAndGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit [Member]",
        "label": "Line of Credit [Member]",
        "verboseLabel": "Line of Credit [Member]",
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars."
       }
      }
     },
     "auth_ref": []
    },
    "galt_LineOfCreditRelatedPartyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "LineOfCreditRelatedPartyAbstract",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedPartyDetails",
      "http://galectintherapeutics.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit, Related Party [Abstract]",
        "terseLabel": "Convertible Line of Credit - Related Party [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LoansPayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LoansPayableMember",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedParty"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Notes Payable - Related Party [Member]",
        "documentation": "Borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedParty",
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedPartyDetails",
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedParty"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r1012",
      "r1013",
      "r1014"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedParty",
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedPartyDetails",
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedParty"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r34",
      "r1012",
      "r1013",
      "r1014"
     ]
    },
    "us-gaap_LossContingencyEstimateOfPossibleLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyEstimateOfPossibleLoss",
     "crdr": "debit",
     "presentation": [
      "http://galectintherapeutics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vendors disputed claim amount",
        "label": "Loss Contingency, Estimate of Possible Loss",
        "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r339",
      "r342",
      "r343",
      "r458",
      "r878"
     ]
    },
    "us-gaap_LossContingencyRangeOfPossibleLossPortionNotAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyRangeOfPossibleLossPortionNotAccrued",
     "crdr": "debit",
     "presentation": [
      "http://galectintherapeutics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional accrued amount",
        "label": "Loss Contingency, Range of Possible Loss, Portion Not Accrued",
        "documentation": "The difference between the maximum amount of estimated loss and the amount recorded as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r1017",
      "r1018"
     ]
    },
    "galt_March2023PromissoryNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "March2023PromissoryNoteMember",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Promissory note executed on March 31, 2023 under the line of credit agreement.",
        "label": "March 2023 Promissory Note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "galt_March24PromissoryNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "March24PromissoryNoteMember",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Promissory note executed on June 30, 2023 under the line of credit agreement.",
        "label": "March 2024 Promissory Note [Member]",
        "terseLabel": "March 2024 Promissory Note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "galt_March292024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "March292024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember",
     "presentation": [
      "http://galectintherapeutics.com/role/WarrantsSummaryOfOutstandingWarrantsIssuedInConnectionWithEquityAndDebtFinancingAndConsultantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrants.",
        "label": "March 29, 2024 Warrants Issued for Draw on Related Party Line of Credit [Member]",
        "terseLabel": "March 29, 2024 Warrants Issued for Draw on Related Party Line of Credit [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "galt_MarchEightTwentyTenSeriesBTwoTransactionOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "MarchEightTwentyTenSeriesBTwoTransactionOneMember",
     "presentation": [
      "http://galectintherapeutics.com/role/WarrantsSummaryOfOutstandingWarrantsIssuedInConnectionWithEquityAndDebtFinancingAndConsultantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrants.",
        "label": "March Eight Twenty Ten Series B Two Transaction One [Member]",
        "verboseLabel": "March 8, 2010 Series B-2 Transaction [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "galt_MarchEightTwentyTenSeriesBTwoTransactionTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "MarchEightTwentyTenSeriesBTwoTransactionTwoMember",
     "presentation": [
      "http://galectintherapeutics.com/role/WarrantsSummaryOfOutstandingWarrantsIssuedInConnectionWithEquityAndDebtFinancingAndConsultantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrants.",
        "label": "March Eight Twenty Ten Series B Two Transaction Two [Member]",
        "terseLabel": "March 8, 2010 Series B-2 Transaction [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedPartyDetails",
      "http://galectintherapeutics.com/role/StockbasedCompensationOutstandingAndExercisableOptionsUnderStockBasedCompensationPlansDetails",
      "http://galectintherapeutics.com/role/StockbasedCompensationWeightedAverageAssumptionsUsedToDetermineFairValueOfOptionsGrantedDetails",
      "http://galectintherapeutics.com/role/StockholdersEquitySeriesC6SuperDividendRedeemableConvertiblePreferredStockDetails",
      "http://galectintherapeutics.com/role/SubsequentEventDetails",
      "http://galectintherapeutics.com/role/WarrantsSummaryOfPurchaseWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r338",
      "r339",
      "r340",
      "r341",
      "r411",
      "r458",
      "r545",
      "r631",
      "r670",
      "r672",
      "r686",
      "r717",
      "r718",
      "r775",
      "r794",
      "r799",
      "r800",
      "r836",
      "r855",
      "r856",
      "r875",
      "r884",
      "r888",
      "r896",
      "r897",
      "r901",
      "r902",
      "r908",
      "r1023",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093"
     ]
    },
    "galt_MayTenTwentyTenSeriesBTwoTransactionOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "MayTenTwentyTenSeriesBTwoTransactionOneMember",
     "presentation": [
      "http://galectintherapeutics.com/role/WarrantsSummaryOfOutstandingWarrantsIssuedInConnectionWithEquityAndDebtFinancingAndConsultantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrants.",
        "label": "May Ten Twenty Ten Series B Two Transaction One [Member]",
        "verboseLabel": "May 10, 2010 Series B-2 Transaction [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "galt_MayTenTwentyTenSeriesBTwoTransactionTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "MayTenTwentyTenSeriesBTwoTransactionTwoMember",
     "presentation": [
      "http://galectintherapeutics.com/role/WarrantsSummaryOfOutstandingWarrantsIssuedInConnectionWithEquityAndDebtFinancingAndConsultantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrants.",
        "label": "May Ten Twenty Ten Series B Two Transaction Two [Member]",
        "terseLabel": "May 10, 2010 Series B-2 Transaction [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "galt_MayThirteenTwentyZeroNineSeriesBTwoTransactionOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "MayThirteenTwentyZeroNineSeriesBTwoTransactionOneMember",
     "presentation": [
      "http://galectintherapeutics.com/role/WarrantsSummaryOfOutstandingWarrantsIssuedInConnectionWithEquityAndDebtFinancingAndConsultantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrants.",
        "label": "May Thirteen Twenty Zero Nine Series B Two Transaction One [Member]",
        "verboseLabel": "May 13, 2009 Series B-2 Transaction [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "galt_MayTwentyThreeTwentyNinteenRightsOfferingWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "MayTwentyThreeTwentyNinteenRightsOfferingWarrantsMember",
     "presentation": [
      "http://galectintherapeutics.com/role/WarrantsSummaryOfOutstandingWarrantsIssuedInConnectionWithEquityAndDebtFinancingAndConsultantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrants.",
        "label": "May Twenty Three Twenty Ninteen Rights Offering Warrants [Member]",
        "terseLabel": "May 23, 2019 Rights Offering warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputConversionPriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputConversionPriceMember",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsKeyAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion Price of Conversion Feature [Member]",
        "documentation": "Measurement input using price per share at which convertible share can be converted into common stock."
       }
      }
     },
     "auth_ref": [
      "r1065",
      "r1066",
      "r1067"
     ]
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputDiscountRateMember",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsKeyAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Adjusted Discount Rate [Member]",
        "documentation": "Measurement input using interest rate to determine present value of future cash flows."
       }
      }
     },
     "auth_ref": [
      "r1065",
      "r1066",
      "r1067"
     ]
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedDividendRateMember",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsKeyAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend Rate [Member]",
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
       }
      }
     },
     "auth_ref": [
      "r1065",
      "r1066",
      "r1067"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsKeyAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term [Member]",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r1065",
      "r1066",
      "r1067"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsKeyAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r896",
      "r1065",
      "r1066",
      "r1067"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsKeyAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r1065",
      "r1066",
      "r1067"
     ]
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputSharePriceMember",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsKeyAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price [Member]",
        "documentation": "Measurement input using share price of saleable stock."
       }
      }
     },
     "auth_ref": [
      "r1065",
      "r1066",
      "r1067"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsKeyAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r543",
      "r544",
      "r545",
      "r896"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsKeyAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r543",
      "r544",
      "r545",
      "r896"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedPartyDetails",
      "http://galectintherapeutics.com/role/StockbasedCompensationOutstandingAndExercisableOptionsUnderStockBasedCompensationPlansDetails",
      "http://galectintherapeutics.com/role/StockbasedCompensationWeightedAverageAssumptionsUsedToDetermineFairValueOfOptionsGrantedDetails",
      "http://galectintherapeutics.com/role/StockholdersEquitySeries12ConvertiblePreferredStockDetails",
      "http://galectintherapeutics.com/role/SubsequentEventDetails",
      "http://galectintherapeutics.com/role/WarrantsSummaryOfPurchaseWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r338",
      "r339",
      "r340",
      "r341",
      "r411",
      "r458",
      "r545",
      "r631",
      "r670",
      "r672",
      "r686",
      "r717",
      "r718",
      "r775",
      "r794",
      "r799",
      "r800",
      "r836",
      "r855",
      "r856",
      "r875",
      "r884",
      "r888",
      "r896",
      "r897",
      "r901",
      "r908",
      "r1023",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093"
     ]
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "presentation": [
      "http://galectintherapeutics.com/role/GalectinSciencesLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership percentage",
        "label": "Subsidiary, Ownership Percentage, Parent",
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage."
       }
      }
     },
     "auth_ref": []
    },
    "galt_NatureOfBusinessBasisOfPresentationsAndLiquidityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "NatureOfBusinessBasisOfPresentationsAndLiquidityAbstract",
     "presentation": [
      "http://galectintherapeutics.com/role/NatureOfBusinessBasisOfPresentationLiquidityAndGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Business, Basis of Presentations and Liquidity [Abstract]",
        "terseLabel": "Nature of Business, Basis of Presentation and Liquidity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash from financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net cash from investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfCashFlows",
      "http://galectintherapeutics.com/role/SegmentsSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash from operating activities",
        "terseLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r92",
      "r93"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0,
       "order": 1.0
      },
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfCashFlows",
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfOperations",
      "http://galectintherapeutics.com/role/SegmentsSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "terseLabel": "Net loss",
        "label": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r93",
      "r122",
      "r143",
      "r158",
      "r159",
      "r163",
      "r174",
      "r184",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r195",
      "r196",
      "r204",
      "r285",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r501",
      "r510",
      "r539",
      "r564",
      "r655",
      "r747",
      "r764",
      "r765",
      "r918",
      "r1021"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "calculation": {
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfOperations",
      "http://galectintherapeutics.com/role/SegmentsSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss applicable to common stockholders",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r188",
      "r189",
      "r190",
      "r191",
      "r199",
      "r200",
      "r205",
      "r208",
      "r510"
     ]
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "presentation": [
      "http://galectintherapeutics.com/role/NatureOfBusinessBasisOfPresentationLiquidityAndGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r190",
      "r197",
      "r212",
      "r251",
      "r252",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r322",
      "r323",
      "r332",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r561",
      "r562",
      "r575",
      "r576",
      "r577",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r634",
      "r635",
      "r636",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r689"
     ]
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "presentation": [
      "http://galectintherapeutics.com/role/NatureOfBusinessBasisOfPresentationLiquidityAndGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "documentation": "Disclosure of information about change in accounting principle or amendment to accounting standards or both. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards and other change in accounting principle."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r190",
      "r197",
      "r212",
      "r251",
      "r252",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r322",
      "r323",
      "r332",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r561",
      "r562",
      "r575",
      "r576",
      "r577",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r634",
      "r635",
      "r636",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r689"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recent Accounting Standards",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "galt_NonCashChargeForResearchAndDevelopmentInProcess": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "NonCashChargeForResearchAndDevelopmentInProcess",
     "crdr": "debit",
     "presentation": [
      "http://galectintherapeutics.com/role/GalectinSciencesLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of non-cash charge in research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Non-cash Charge for Research and Development in Process",
        "terseLabel": "Non-cash charge for in-process research and development"
       }
      }
     },
     "auth_ref": []
    },
    "galt_NonQualifiedOptionsPlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "NonQualifiedOptionsPlansMember",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationSummaryOfStockbasedCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about non qualified options Plans.",
        "label": "Non Qualified Options Plans [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://galectintherapeutics.com/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r941"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://galectintherapeutics.com/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r941"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfOperations",
      "http://galectintherapeutics.com/role/SegmentsSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other expense",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfOperations",
      "http://galectintherapeutics.com/role/SegmentsSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income (expense):",
        "terseLabel": "Other income (expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "galt_NovemberFourTwentyZeroNineSeriesBTwoTransactionOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "NovemberFourTwentyZeroNineSeriesBTwoTransactionOneMember",
     "presentation": [
      "http://galectintherapeutics.com/role/WarrantsSummaryOfOutstandingWarrantsIssuedInConnectionWithEquityAndDebtFinancingAndConsultantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrants.",
        "label": "November Four Twenty Zero Nine Series B Two Transaction One [Member]",
        "verboseLabel": "November 4, 2009 Series B-2 Transaction [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "galt_NumberOfConsecutiveTradingDays": {
     "xbrltype": "durationItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "NumberOfConsecutiveTradingDays",
     "presentation": [
      "http://galectintherapeutics.com/role/StockholdersEquitySeries12ConvertiblePreferredStockDetails",
      "http://galectintherapeutics.com/role/StockholdersEquitySeriesC6SuperDividendRedeemableConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of consecutive trading days, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but not limited to, weeks in a year or quarter.",
        "label": "Number of Consecutive Trading Days",
        "terseLabel": "Number of consecutive trading days"
       }
      }
     },
     "auth_ref": []
    },
    "galt_NumberOfDirectors": {
     "xbrltype": "integerItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "NumberOfDirectors",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationRestrictedStockIssuancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of directors of the company.",
        "label": "Number of Directors"
       }
      }
     },
     "auth_ref": []
    },
    "galt_NumberOfLineOfCredit": {
     "xbrltype": "integerItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "NumberOfLineOfCredit",
     "presentation": [
      "http://galectintherapeutics.com/role/NatureOfBusinessBasisOfPresentationLiquidityAndGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of available line of credit facility borrowings.",
        "label": "Number of Line of Credit",
        "terseLabel": "Number of line of credit"
       }
      }
     },
     "auth_ref": []
    },
    "galt_NumberOfLoansClosing": {
     "xbrltype": "integerItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "NumberOfLoansClosing",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of loans closing under the loans agreement.",
        "label": "Number of Loans Closing",
        "terseLabel": "Number of loans closing"
       }
      }
     },
     "auth_ref": []
    },
    "galt_NumberOfOperatingLeases": {
     "xbrltype": "integerItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "NumberOfOperatingLeases",
     "presentation": [
      "http://galectintherapeutics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating leases during period.",
        "label": "Number of Operating Leases",
        "terseLabel": "Number of operating leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://galectintherapeutics.com/role/SegmentsSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segment",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r871",
      "r990"
     ]
    },
    "galt_NumberOfPromissoryNotesEvidencedByLoansAgreement": {
     "xbrltype": "integerItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "NumberOfPromissoryNotesEvidencedByLoansAgreement",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of promissory notes evidenced by loans agreement.",
        "label": "Number of Promissory Notes Evidenced by Loans Agreement",
        "terseLabel": "Number of promissory notes evidenced by loans agreement"
       }
      }
     },
     "auth_ref": []
    },
    "galt_NumberOfPromissoryNotesExecuted": {
     "xbrltype": "integerItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "NumberOfPromissoryNotesExecuted",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of promissory notes executed under the loans agreement.",
        "label": "Number of Promissory Notes Executed",
        "terseLabel": "Number of promissory notes executed"
       }
      }
     },
     "auth_ref": []
    },
    "galt_NumberOfTradingDaysToBeConsideredStockClosingPriceInPurchaseAgreement": {
     "xbrltype": "durationItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "NumberOfTradingDaysToBeConsideredStockClosingPriceInPurchaseAgreement",
     "presentation": [
      "http://galectintherapeutics.com/role/WarrantsSummaryOfPurchaseWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of specified trading days that common stock price must exceed threshold price for specified number of trading days, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Number of Trading Days to be Considered Stock Closing Price in Purchase Agreement",
        "terseLabel": "Number of consecutive trading days to be considered in purchase agreement"
       }
      }
     },
     "auth_ref": []
    },
    "galt_One0XFundLPAnd10XCapitalManagementLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "One0XFundLPAnd10XCapitalManagementLLCMember",
     "presentation": [
      "http://galectintherapeutics.com/role/WarrantsSummaryOfPurchaseWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of beneficial ownership entity.",
        "label": "10X Fund L.P., and 10X Capital Management LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "galt_One0XFundLPMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "One0XFundLPMember",
     "presentation": [
      "http://galectintherapeutics.com/role/WarrantsSummaryOfPurchaseWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of beneficial owner.",
        "label": "10X Fund L.P [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfOperations",
      "http://galectintherapeutics.com/role/SegmentsSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfOperations",
      "http://galectintherapeutics.com/role/SegmentsSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:",
        "terseLabel": "Operating expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfOperations",
      "http://galectintherapeutics.com/role/SegmentsSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating loss",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r865",
      "r989",
      "r991",
      "r992",
      "r993",
      "r994"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://galectintherapeutics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r583",
      "r905"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://galectintherapeutics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturity of Operating Lease [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://galectintherapeutics.com/role/CommitmentsAndContingenciesDetailsCalc2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Present value of lease liability",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r580"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://galectintherapeutics.com/role/AccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/AccruedExpensesDetails",
      "http://galectintherapeutics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liability",
        "label": "Current lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r580"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://galectintherapeutics.com/role/AccruedExpensesDetails",
      "http://galectintherapeutics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]",
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r581"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://galectintherapeutics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r580"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://galectintherapeutics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r581"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://galectintherapeutics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right to use lease asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r579"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of right to use asset",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r977"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://galectintherapeutics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]",
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset."
       }
      }
     },
     "auth_ref": [
      "r581"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://galectintherapeutics.com/role/IncomeTaxesPrimaryFactorsAffectingIncomeTaxRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r482"
     ]
    },
    "galt_OperatingLossCarryforwardsExpirationYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "OperatingLossCarryforwardsExpirationYear",
     "presentation": [
      "http://galectintherapeutics.com/role/IncomeTaxesPrimaryFactorsAffectingIncomeTaxRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration year of each operating loss carryforward included in operating loss carryforward, in YYYY format.",
        "label": "Operating Loss Carryforwards Expiration Year",
        "terseLabel": "Operating loss carryforwards expiration year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://galectintherapeutics.com/role/IncomeTaxesPrimaryFactorsAffectingIncomeTaxRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r482"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://galectintherapeutics.com/role/IncomeTaxesPrimaryFactorsAffectingIncomeTaxRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Disclosure of information about operating loss carryforward. Includes, but is not limited to, tax authority, amount and expiration date of operating loss carryforward, and likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r482"
     ]
    },
    "galt_OptionsExercisableAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "OptionsExercisableAbstract",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationOutstandingAndExercisableOptionsUnderStockBasedCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Exercisable [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "galt_OptionsOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "OptionsOutstandingAbstract",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationOutstandingAndExercisableOptionsUnderStockBasedCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Outstanding [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Business, Basis of Presentation, Liquidity, and Going Concern [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://galectintherapeutics.com/role/NatureOfBusinessBasisOfPresentationLiquidityAndGoingConcern"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Business, Basis of Presentation, Liquidity, and Going Concern",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r114",
      "r687",
      "r688"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r149"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other liabilities",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://galectintherapeutics.com/role/GalectinSciencesLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "OwnershipDomain",
     "presentation": [
      "http://galectintherapeutics.com/role/GalectinSciencesLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaidInKindInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaidInKindInterest",
     "crdr": "debit",
     "calculation": {
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash interest expense",
        "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://galectintherapeutics.com/role/StockholdersEquitySeriesC6SuperDividendRedeemableConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationDeferredStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income tax payment withholding",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r166"
     ]
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "crdr": "credit",
     "presentation": [
      "http://galectintherapeutics.com/role/GalectinSciencesLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial cash investment",
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "galt_PercentageOfWeightedAverageStockPriceForDividendsPriorToPaymentDate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "PercentageOfWeightedAverageStockPriceForDividendsPriorToPaymentDate",
     "presentation": [
      "http://galectintherapeutics.com/role/StockholdersEquitySeries12ConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of weighted average stock price for dividends prior to payment date.",
        "label": "Percentage of Weighted Average Stock Price for Dividends Prior to Payment Date",
        "terseLabel": "Weighted average price percentage"
       }
      }
     },
     "auth_ref": []
    },
    "galt_PeriodOfPriorNoticeThatWouldBarVoluntaryExerciseOfAnyWarrants": {
     "xbrltype": "durationItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "PeriodOfPriorNoticeThatWouldBarVoluntaryExerciseOfAnyWarrants",
     "presentation": [
      "http://galectintherapeutics.com/role/WarrantsSummaryOfPurchaseWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of prior notice days required that would bar the voluntary exercise of any warrants that would result in beneficial ownership beyond specified percentage, in P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Period of Prior Notice that Would Bar Voluntary Exercise of any Warrants",
        "terseLabel": "Period of prior notice that would bar voluntary exercise of any warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationSummaryOfStockbasedCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationSummaryOfStockbasedCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052"
     ]
    },
    "galt_PostConversionDividendRightsIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "PostConversionDividendRightsIssued",
     "presentation": [
      "http://galectintherapeutics.com/role/StockholdersEquitySeriesC6SuperDividendRedeemableConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of Series C were converted into common stock and post conversion dividend rights were issued.",
        "label": "Post Conversion Dividend Rights Issued",
        "terseLabel": "Post conversion dividend rights (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "galt_PostConversionRedemptionRightReturnOnInvestmentMultiplierAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "PostConversionRedemptionRightReturnOnInvestmentMultiplierAmount",
     "crdr": "credit",
     "presentation": [
      "http://galectintherapeutics.com/role/StockholdersEquitySeriesC6SuperDividendRedeemableConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Multiplied by the preferred stock post conversion redemption right shall be equal the applicable return on investment (\"ROI\") percentage.",
        "label": "Post Conversion Redemption Right Return on Investment Multiplier Amount",
        "terseLabel": "Post conversion redemption right, return on investment multiplier amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockDividendRatePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockDividendRatePercentage",
     "presentation": [
      "http://galectintherapeutics.com/role/StockholdersEquitySeries12ConvertiblePreferredStockDetails",
      "http://galectintherapeutics.com/role/StockholdersEquitySeriesC6SuperDividendRedeemableConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, dividend rate",
        "terseLabel": "Preferred stock, dividend rate",
        "documentation": "The percentage rate used to calculate dividend payments on preferred stock."
       }
      }
     },
     "auth_ref": [
      "r386",
      "r776",
      "r795",
      "r798",
      "r837"
     ]
    },
    "us-gaap_PreferredStockDividendsAndOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockDividendsAndOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfOperations",
      "http://galectintherapeutics.com/role/SegmentsSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Preferred stock dividends",
        "label": "Preferred Stock Dividends and Other Adjustments",
        "documentation": "The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r956",
      "r988"
     ]
    },
    "us-gaap_PreferredStockLiquidationPreference": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockLiquidationPreference",
     "presentation": [
      "http://galectintherapeutics.com/role/StockholdersEquitySeriesC6SuperDividendRedeemableConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stated value of dividend payment (in dollars per share)",
        "label": "Preferred Stock, Liquidation Preference Per Share",
        "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r40",
      "r79",
      "r978",
      "r1024"
     ]
    },
    "us-gaap_PreferredStockLiquidationPreferenceValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockLiquidationPreferenceValue",
     "crdr": "credit",
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A 12% convertible preferred stock, liquidation value",
        "documentation": "Value of the difference between preference in liquidation and the par or stated values of the preferred shares."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r389",
      "r401"
     ]
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r910",
      "r911",
      "r914",
      "r915",
      "r916",
      "r917",
      "r1126",
      "r1129"
     ]
    },
    "us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "presentation": [
      "http://galectintherapeutics.com/role/StockholdersEquityReturnOnInvestmentDetails",
      "http://galectintherapeutics.com/role/StockholdersEquitySeriesC6SuperDividendRedeemableConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redeemable Convertible Preferred Stock [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://galectintherapeutics.com/role/StockholdersEquitySeriesC6SuperDividendRedeemableConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r385"
     ]
    },
    "us-gaap_PreferredStockRedemptionPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockRedemptionPremium",
     "crdr": "debit",
     "presentation": [
      "http://galectintherapeutics.com/role/WarrantsSummaryOfPurchaseWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deemed dividend",
        "label": "Preferred Stock Redemption Premium",
        "documentation": "The excess of (1) fair value of the consideration transferred to the holders of the preferred stock over (2) the carrying amount of the preferred stock in the registrant's balance sheet, during the accounting period."
       }
      }
     },
     "auth_ref": [
      "r213"
     ]
    },
    "us-gaap_PreferredStockRedemptionPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockRedemptionPricePerShare",
     "presentation": [
      "http://galectintherapeutics.com/role/StockholdersEquitySeriesC6SuperDividendRedeemableConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock redemption price (in dollars per share)",
        "documentation": "The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r39",
      "r42"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://galectintherapeutics.com/role/StockholdersEquityIssuanceOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A 12% convertible preferred stock, shares authorized (in shares)",
        "terseLabel": "Convertible preferred stock, shares authorized (in shares)",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r727"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A 12% convertible preferred stock, shares issued (in shares)",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r385"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A 12% convertible preferred stock, shares outstanding (in shares)",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r727",
      "r745",
      "r1129",
      "r1130"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Series A 12% convertible preferred stock; 1,742,500 shares authorized, 1,235,000 and 1,235,000 issued and outstanding at December 31, 2024 and 2023, respectively, liquidation value $1,235,000 at December 31, 2024",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r645",
      "r906"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r972"
     ]
    },
    "galt_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock",
     "presentation": [
      "http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for prepaid expenses and other current assets.",
        "label": "Prepaid Expenses and Other Current Assets [Policy Text Block]",
        "terseLabel": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "auth_ref": []
    },
    "galt_ProceedsFromIssuanceOfPreferredStockNetOfIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "ProceedsFromIssuanceOfPreferredStockNetOfIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://galectintherapeutics.com/role/StockholdersEquitySeriesC6SuperDividendRedeemableConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.",
        "label": "Proceeds from Issuance of Preferred Stock, Net of Issuance Costs",
        "terseLabel": "Net proceeds from issuance of preferred stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock",
     "crdr": "debit",
     "presentation": [
      "http://galectintherapeutics.com/role/StockholdersEquitySeriesC6SuperDividendRedeemableConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross proceeds from issuance of preferred stock",
        "label": "Proceeds from Issuance of Redeemable Convertible Preferred Stock",
        "documentation": "The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromLinesOfCredit",
     "crdr": "debit",
     "calculation": {
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfCashFlows",
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from lines of credit",
        "terseLabel": "Net proceeds from convertible line of credit - related party",
        "label": "Proceeds from Lines of Credit",
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r979"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net proceeds from exercise of common stock options and warrants",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r975"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "presentation": [
      "http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment [Abstract]",
        "terseLabel": "Property and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://galectintherapeutics.com/role/PropertyAndEquipmentDetails",
      "http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r585"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://galectintherapeutics.com/role/PropertyAndEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r130",
      "r133",
      "r134"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://galectintherapeutics.com/role/PropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r147",
      "r653"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://galectintherapeutics.com/role/PropertyAndEquipmentDetails",
      "http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r585"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://galectintherapeutics.com/role/PropertyAndEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://galectintherapeutics.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "totalLabel": "Property and equipment - net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r585",
      "r640",
      "r653",
      "r906"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNetByTypeAbstract",
     "presentation": [
      "http://galectintherapeutics.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment [Abstract]",
        "label": "Property, Plant and Equipment, Net, by Type [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r130",
      "r133",
      "r651"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://galectintherapeutics.com/role/PropertyAndEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://galectintherapeutics.com/role/PropertyAndEquipmentDetails",
      "http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r585"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimated useful life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "galt_QuarterlyInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "QuarterlyInterestRate",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent interest rate per quarter for funds borrowed, under the debt agreement.",
        "label": "Quarterly Interest Rate",
        "terseLabel": "Additional interest rate per quarter"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedPartyDetails",
      "http://galectintherapeutics.com/role/StockbasedCompensationOutstandingAndExercisableOptionsUnderStockBasedCompensationPlansDetails",
      "http://galectintherapeutics.com/role/StockbasedCompensationWeightedAverageAssumptionsUsedToDetermineFairValueOfOptionsGrantedDetails",
      "http://galectintherapeutics.com/role/StockholdersEquitySeries12ConvertiblePreferredStockDetails",
      "http://galectintherapeutics.com/role/StockholdersEquitySeriesC6SuperDividendRedeemableConvertiblePreferredStockDetails",
      "http://galectintherapeutics.com/role/SubsequentEventDetails",
      "http://galectintherapeutics.com/role/WarrantsSummaryOfPurchaseWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r338",
      "r339",
      "r340",
      "r341",
      "r403",
      "r411",
      "r443",
      "r444",
      "r445",
      "r458",
      "r545",
      "r605",
      "r614",
      "r631",
      "r670",
      "r672",
      "r686",
      "r717",
      "r718",
      "r775",
      "r794",
      "r799",
      "r800",
      "r836",
      "r855",
      "r856",
      "r875",
      "r884",
      "r888",
      "r896",
      "r897",
      "r901",
      "r902",
      "r908",
      "r912",
      "r1015",
      "r1023",
      "r1066",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedPartyDetails",
      "http://galectintherapeutics.com/role/StockbasedCompensationOutstandingAndExercisableOptionsUnderStockBasedCompensationPlansDetails",
      "http://galectintherapeutics.com/role/StockbasedCompensationWeightedAverageAssumptionsUsedToDetermineFairValueOfOptionsGrantedDetails",
      "http://galectintherapeutics.com/role/StockholdersEquitySeries12ConvertiblePreferredStockDetails",
      "http://galectintherapeutics.com/role/StockholdersEquitySeriesC6SuperDividendRedeemableConvertiblePreferredStockDetails",
      "http://galectintherapeutics.com/role/SubsequentEventDetails",
      "http://galectintherapeutics.com/role/WarrantsSummaryOfPurchaseWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r338",
      "r339",
      "r340",
      "r341",
      "r403",
      "r411",
      "r443",
      "r444",
      "r445",
      "r458",
      "r545",
      "r605",
      "r614",
      "r631",
      "r670",
      "r672",
      "r686",
      "r717",
      "r718",
      "r775",
      "r794",
      "r799",
      "r800",
      "r836",
      "r855",
      "r856",
      "r875",
      "r884",
      "r888",
      "r896",
      "r897",
      "r901",
      "r902",
      "r908",
      "r912",
      "r1015",
      "r1023",
      "r1066",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093"
     ]
    },
    "galt_ReclassificationOfAccruedBonusToAdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "ReclassificationOfAccruedBonusToAdditionalPaidInCapital",
     "crdr": "credit",
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount reclassified from accrued compensation to excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Reclassification Of Accrued Bonus To Additional Paid In Capital",
        "terseLabel": "Reclassification of accrued bonus to additional paid in capital"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedPartyDetails",
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails",
      "http://galectintherapeutics.com/role/NatureOfBusinessBasisOfPresentationLiquidityAndGoingConcernDetails",
      "http://galectintherapeutics.com/role/SubsequentEventDetails",
      "http://galectintherapeutics.com/role/WarrantsSummaryOfPurchaseWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r410",
      "r593",
      "r594",
      "r643",
      "r650",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r744",
      "r746",
      "r771"
     ]
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedPartyDetails",
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails",
      "http://galectintherapeutics.com/role/NatureOfBusinessBasisOfPresentationLiquidityAndGoingConcernDetails",
      "http://galectintherapeutics.com/role/SubsequentEventDetails",
      "http://galectintherapeutics.com/role/WarrantsSummaryOfPurchaseWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r410",
      "r593",
      "r594",
      "r643",
      "r650",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r744",
      "r746",
      "r771",
      "r1085"
     ]
    },
    "us-gaap_RepaymentsOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible note payable repayment",
        "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation."
       }
      }
     },
     "auth_ref": [
      "r976"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://galectintherapeutics.com/role/GalectinSciencesLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r176",
      "r177",
      "r359",
      "r387",
      "r595",
      "r615",
      "r641",
      "r860",
      "r861"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfOperations",
      "http://galectintherapeutics.com/role/SegmentsSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r460",
      "r857",
      "r870",
      "r1094"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationComponentsOfStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development [Member]",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Expenses",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "galt_RestrictedStockGrantsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "RestrictedStockGrantsAbstract",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationDeferredStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Grants [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationRestrictedStockIssuancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r107",
      "r648",
      "r680",
      "r685",
      "r696",
      "r728",
      "r906"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Deficit [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r180",
      "r181",
      "r182",
      "r185",
      "r192",
      "r194",
      "r196",
      "r289",
      "r295",
      "r323",
      "r484",
      "r485",
      "r497",
      "r498",
      "r499",
      "r502",
      "r509",
      "r510",
      "r519",
      "r522",
      "r523",
      "r526",
      "r537",
      "r576",
      "r578",
      "r676",
      "r678",
      "r698",
      "r1129"
     ]
    },
    "galt_ReturnOnInvestmentsPercentageAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "ReturnOnInvestmentsPercentageAbstract",
     "presentation": [
      "http://galectintherapeutics.com/role/StockholdersEquityReturnOnInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Return on Investments Percentage [Abstract]",
        "terseLabel": "ROI Percentage [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "galt_ReturnOnInvestmentsPercentagePeriodEight": {
     "xbrltype": "percentItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "ReturnOnInvestmentsPercentagePeriodEight",
     "presentation": [
      "http://galectintherapeutics.com/role/StockholdersEquityReturnOnInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Return on investments after eighth anniversary but before ninth anniversary of date of issuance.",
        "label": "Return on Investments Percentage, Period Eight",
        "terseLabel": "ROI after eighth anniversary but before ninth anniversary of date of issuance"
       }
      }
     },
     "auth_ref": []
    },
    "galt_ReturnOnInvestmentsPercentagePeriodFive": {
     "xbrltype": "percentItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "ReturnOnInvestmentsPercentagePeriodFive",
     "presentation": [
      "http://galectintherapeutics.com/role/StockholdersEquityReturnOnInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Return on investments after fifth anniversary but before sixth anniversary of date of issuance.",
        "label": "Return on Investments Percentage, Period Five",
        "terseLabel": "ROI after fifth anniversary but before sixth anniversary of date of issuance"
       }
      }
     },
     "auth_ref": []
    },
    "galt_ReturnOnInvestmentsPercentagePeriodFour": {
     "xbrltype": "percentItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "ReturnOnInvestmentsPercentagePeriodFour",
     "presentation": [
      "http://galectintherapeutics.com/role/StockholdersEquityReturnOnInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Return on investments after fourth anniversary but before fifth anniversary of date of issuance.",
        "label": "Return on Investments Percentage, Period Four",
        "terseLabel": "ROI after fourth anniversary but before fifth anniversary of date of issuance"
       }
      }
     },
     "auth_ref": []
    },
    "galt_ReturnOnInvestmentsPercentagePeriodOne": {
     "xbrltype": "percentItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "ReturnOnInvestmentsPercentagePeriodOne",
     "presentation": [
      "http://galectintherapeutics.com/role/StockholdersEquityReturnOnInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Return on investments percentage before second anniversary of date of issuance.",
        "label": "Return on Investments Percentage, Period One",
        "terseLabel": "ROI before second anniversary of date of issuance"
       }
      }
     },
     "auth_ref": []
    },
    "galt_ReturnOnInvestmentsPercentagePeriodSeven": {
     "xbrltype": "percentItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "ReturnOnInvestmentsPercentagePeriodSeven",
     "presentation": [
      "http://galectintherapeutics.com/role/StockholdersEquityReturnOnInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Return on investments after seventh anniversary but before eighth anniversary of date of issuance.",
        "label": "Return on Investments Percentage, Period Seven",
        "terseLabel": "ROI after seventh anniversary but before eighth anniversary of date of issuance"
       }
      }
     },
     "auth_ref": []
    },
    "galt_ReturnOnInvestmentsPercentagePeriodSix": {
     "xbrltype": "percentItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "ReturnOnInvestmentsPercentagePeriodSix",
     "presentation": [
      "http://galectintherapeutics.com/role/StockholdersEquityReturnOnInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Return on investments after sixth anniversary but before seventh anniversary of date of issuance.",
        "label": "Return on Investments Percentage, Period Six",
        "terseLabel": "ROI after sixth anniversary but before seventh anniversary of date of issuance"
       }
      }
     },
     "auth_ref": []
    },
    "galt_ReturnOnInvestmentsPercentagePeriodThree": {
     "xbrltype": "percentItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "ReturnOnInvestmentsPercentagePeriodThree",
     "presentation": [
      "http://galectintherapeutics.com/role/StockholdersEquityReturnOnInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Return on investments after third anniversary but before fourth anniversary of date of issuance.",
        "label": "Return on Investments Percentage, Period Three",
        "terseLabel": "ROI after third anniversary but before fourth anniversary of date of issuance"
       }
      }
     },
     "auth_ref": []
    },
    "galt_ReturnOnInvestmentsPercentagePeriodTwo": {
     "xbrltype": "percentItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "ReturnOnInvestmentsPercentagePeriodTwo",
     "presentation": [
      "http://galectintherapeutics.com/role/StockholdersEquityReturnOnInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Return on investments after second anniversary but before third anniversary of date of issuance.",
        "label": "Return on Investments Percentage, Period Two",
        "terseLabel": "ROI after second anniversary but before third anniversary of date of issuance"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://galectintherapeutics.com/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r941"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://galectintherapeutics.com/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r941"
     ]
    },
    "galt_SBHSciencesIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "SBHSciencesIncMember",
     "presentation": [
      "http://galectintherapeutics.com/role/GalectinSciencesLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of counterparty. A counterparty is the other party that participates in a financial transaction.",
        "label": "SBH Sciences, Inc. [Member]",
        "terseLabel": "SBH [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]"
       }
      }
     },
     "auth_ref": [
      "r412",
      "r985"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails",
      "http://galectintherapeutics.com/role/StockholdersEquitySeries12ConvertiblePreferredStockDetails",
      "http://galectintherapeutics.com/role/StockholdersEquitySeriesC6SuperDividendRedeemableConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r197",
      "r412",
      "r958",
      "r985"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://galectintherapeutics.com/role/AccruedExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Expenses",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://galectintherapeutics.com/role/LossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://galectintherapeutics.com/role/LossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://galectintherapeutics.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Net Deferred Tax Assets",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1058"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://galectintherapeutics.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Primary Factors Affecting Income Tax Rates",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r466",
      "r891",
      "r1054"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationComponentsOfStockbasedCompensationExpenseDetails",
      "http://galectintherapeutics.com/role/StockbasedCompensationDeferredStockUnitsDetails",
      "http://galectintherapeutics.com/role/StockbasedCompensationOutstandingAndExercisableOptionsUnderStockBasedCompensationPlansDetails",
      "http://galectintherapeutics.com/role/StockbasedCompensationRestrictedStockIssuancesDetails",
      "http://galectintherapeutics.com/role/StockbasedCompensationSummaryOfStockbasedCompensationPlansDetails",
      "http://galectintherapeutics.com/role/StockbasedCompensationWeightedAverageAssumptionsUsedToDetermineFairValueOfOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Components of Stock-Based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets and Liabilities Measured and Recorded at Fair Value on Recurring Basis",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1063",
      "r1064"
     ]
    },
    "us-gaap_ScheduleOfInvestmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfInvestmentsTable",
     "presentation": [
      "http://galectintherapeutics.com/role/GalectinSciencesLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Investments [Table]",
        "documentation": "Disclosure of information about investments owned by investment company."
       }
      }
     },
     "auth_ref": [
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://galectintherapeutics.com/role/PropertyAndEquipmentDetails",
      "http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r585"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://galectintherapeutics.com/role/SegmentsSignificantAssetCategoriesDetails",
      "http://galectintherapeutics.com/role/SegmentsSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r30"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://galectintherapeutics.com/role/SegmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Expense Categories and Asset Categories",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r30"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://galectintherapeutics.com/role/WarrantsSummaryOfPurchaseWarrantsDetails",
      "http://galectintherapeutics.com/role/WarrantsSummaryOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r414",
      "r416",
      "r418",
      "r419",
      "r420",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding and Exercisable Options under Stock Based Compensation Plans",
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option Activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r12",
      "r109"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Assumptions Used to Determine Fair Value of Options Granted",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://galectintherapeutics.com/role/StockholdersEquityIssuanceOfCommonStockDetails",
      "http://galectintherapeutics.com/role/StockholdersEquityReturnOnInvestmentDetails",
      "http://galectintherapeutics.com/role/StockholdersEquitySeries12ConvertiblePreferredStockDetails",
      "http://galectintherapeutics.com/role/StockholdersEquitySeriesC6SuperDividendRedeemableConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r37",
      "r39",
      "r40",
      "r41",
      "r43",
      "r103",
      "r105",
      "r106",
      "r107",
      "r152",
      "r153",
      "r154",
      "r216",
      "r385",
      "r386",
      "r387",
      "r389",
      "r392",
      "r397",
      "r399",
      "r692",
      "r693",
      "r694",
      "r695",
      "r884",
      "r957",
      "r978"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://galectintherapeutics.com/role/WarrantsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Warrants Activity, Outstanding Warrants Issued in Connection with Equity and Debt Financings and Consultants",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "galt_SecondClosingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "SecondClosingMember",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A type of debt instrument.",
        "label": "Second Closing [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "us-gaap_SecurityDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SecurityDeposit",
     "crdr": "debit",
     "presentation": [
      "http://galectintherapeutics.com/role/CommitmentsAndContingenciesDetails",
      "http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesSecurityDepositDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security deposit for leased office space",
        "label": "Security deposit",
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease."
       }
      }
     },
     "auth_ref": [
      "r969"
     ]
    },
    "galt_SecurityDepositPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "SecurityDepositPolicyTextBlock",
     "presentation": [
      "http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for security deposit.",
        "label": "Security Deposit [Policy Text Block]",
        "terseLabel": "Security Deposit"
       }
      }
     },
     "auth_ref": []
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentDomain",
     "presentation": [
      "http://galectintherapeutics.com/role/SegmentsSignificantAssetCategoriesDetails",
      "http://galectintherapeutics.com/role/SegmentsSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r124",
      "r125",
      "r126",
      "r214",
      "r219",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r233",
      "r234",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r245",
      "r246",
      "r247",
      "r250",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r321",
      "r334",
      "r335",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r867",
      "r870",
      "r871",
      "r877",
      "r909",
      "r1096",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://galectintherapeutics.com/role/Segments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r214",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r235",
      "r237",
      "r238",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r866",
      "r868",
      "r869",
      "r870",
      "r872",
      "r873",
      "r874"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://galectintherapeutics.com/role/SegmentsSignificantAssetCategoriesDetails",
      "http://galectintherapeutics.com/role/SegmentsSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingInformationProfitLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingInformationProfitLossAbstract",
     "presentation": [
      "http://galectintherapeutics.com/role/SegmentsSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Expense Categories [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "galt_September2024PromissoryNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "September2024PromissoryNoteMember",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Promissory note executed on September 30, 2024 under the line of credit agreement.",
        "label": "September 2024 Promissory Note [Member]",
        "terseLabel": "September 2024 Promissory Note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "galt_September302024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "September302024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember",
     "presentation": [
      "http://galectintherapeutics.com/role/WarrantsSummaryOfOutstandingWarrantsIssuedInConnectionWithEquityAndDebtFinancingAndConsultantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrants.",
        "label": "September 30, 2024 Warrants Issued for Draw on Related Party Line of Credit [Member]",
        "terseLabel": "September 30, 2024 Warrants Issued for Draw on Related Party Line of Credit [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "galt_SeptemberConvertiblePromissoryNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "SeptemberConvertiblePromissoryNoteMember",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A type of debt instrument.",
        "label": "September Convertible Promissory Note [Member]",
        "terseLabel": "September 2021 Note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "galt_SeptemberThirtyTwentyZeroNineSeriesBTwoTransactionOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "SeptemberThirtyTwentyZeroNineSeriesBTwoTransactionOneMember",
     "presentation": [
      "http://galectintherapeutics.com/role/WarrantsSummaryOfOutstandingWarrantsIssuedInConnectionWithEquityAndDebtFinancingAndConsultantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrants.",
        "label": "September Thirty Twenty Zero Nine Series B Two Transaction One [Member]",
        "verboseLabel": "September 30, 2009 Series B-2 Transaction [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "galt_SeptemberTwentyNineTwentySixteenSeriesBThreeTransactionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "SeptemberTwentyNineTwentySixteenSeriesBThreeTransactionMember",
     "presentation": [
      "http://galectintherapeutics.com/role/WarrantsSummaryOfOutstandingWarrantsIssuedInConnectionWithEquityAndDebtFinancingAndConsultantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrants.",
        "label": "September Twenty Nine Twenty Sixteen Series B Three Transaction [Member]",
        "terseLabel": "September 29, 2016 Series B-3 Transaction [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "galt_SeptemberTwentyTwoTwentySixteenSeriesBThreeTransactionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "SeptemberTwentyTwoTwentySixteenSeriesBThreeTransactionMember",
     "presentation": [
      "http://galectintherapeutics.com/role/WarrantsSummaryOfOutstandingWarrantsIssuedInConnectionWithEquityAndDebtFinancingAndConsultantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrants.",
        "label": "September Twenty Two Twenty Sixteen Series B Three Transaction [Member]",
        "terseLabel": "September 22, 2016 Series B-3 Transaction [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesAPreferredStockMember",
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://galectintherapeutics.com/role/StockholdersEquityIssuanceOfCommonStockDetails",
      "http://galectintherapeutics.com/role/StockholdersEquitySeries12ConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A 12% Convertible Preferred Stock [Member]",
        "documentation": "Series A preferred stock."
       }
      }
     },
     "auth_ref": [
      "r970",
      "r971",
      "r1025"
     ]
    },
    "galt_SeriesBOneConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "SeriesBOneConvertiblePreferredStockMember",
     "presentation": [
      "http://galectintherapeutics.com/role/StockholdersEquityIssuanceOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B-1 Preferred stock that may be exchanged into common shares or other types of securities at the owner's option. Each share of the Series B-1 is entitled to dividends at the rate of 12% per annum.",
        "label": "Series B One Convertible Preferred Stock [Member]",
        "terseLabel": "Series B-1 Convertible Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "galt_SeriesBThreeConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "SeriesBThreeConvertiblePreferredStockMember",
     "presentation": [
      "http://galectintherapeutics.com/role/StockholdersEquityIssuanceOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B-3 Preferred stock that may be exchanged into common shares or other types of securities at the owner's option. Each share of the Series B-3 is entitled to dividends at the rate of 8% per annum.",
        "label": "Series B Three Convertible Preferred Stock [Member]",
        "terseLabel": "Series B-3 Convertible Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "galt_SeriesBTwoConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "SeriesBTwoConvertiblePreferredStockMember",
     "presentation": [
      "http://galectintherapeutics.com/role/StockholdersEquityIssuanceOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B-2 Preferred stock that may be exchanged into common shares or other types of securities at the owner's option. Each share of the Series B-2 is entitled to dividends at the rate of 12% per annum.",
        "label": "Series B Two Convertible Preferred Stock [Member]",
        "terseLabel": "Series B-2 Convertible Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "galt_SeriesBWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "SeriesBWarrantsMember",
     "presentation": [
      "http://galectintherapeutics.com/role/WarrantsSummaryOfPurchaseWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Series B Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesCPreferredStockMember",
     "presentation": [
      "http://galectintherapeutics.com/role/StockholdersEquityIssuanceOfCommonStockDetails",
      "http://galectintherapeutics.com/role/StockholdersEquityReturnOnInvestmentDetails",
      "http://galectintherapeutics.com/role/StockholdersEquitySeriesC6SuperDividendRedeemableConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Series C 6% Super Dividend Redeemable Convertible Preferred Stock [Member]",
        "label": "Series C 6% Super Dividend Redeemable Convertible Preferred Stock [Member]",
        "documentation": "Series C preferred stock."
       }
      }
     },
     "auth_ref": [
      "r970",
      "r971",
      "r1025"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ShareBasedCompensationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAbstract",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationComponentsOfStockbasedCompensationExpenseDetails",
      "http://galectintherapeutics.com/role/StockbasedCompensationDeferredStockUnitsDetails",
      "http://galectintherapeutics.com/role/StockbasedCompensationRestrictedStockIssuancesDetails",
      "http://galectintherapeutics.com/role/StockbasedCompensationSummaryOfStockbasedCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation Expense [Abstract]",
        "terseLabel": "Share-based Payment Arrangement, Noncash Expense [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://galectintherapeutics.com/role/WarrantsSummaryOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercises In Period Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://galectintherapeutics.com/role/WarrantsSummaryOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Canceled/Expired (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r435"
     ]
    },
    "galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://galectintherapeutics.com/role/WarrantsSummaryOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares granted when converting their stock options into shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted In Period Weighted Average Exercise Price",
        "terseLabel": "Issued (in dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationRestrictedStockIssuancesDetails",
      "http://galectintherapeutics.com/role/WarrantsSummaryOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock awards granted (in shares)",
        "verboseLabel": "Issued (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r433"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://galectintherapeutics.com/role/WarrantsSummaryOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding at beginning of period (in shares)",
        "periodEndLabel": "Outstanding at end of period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r430",
      "r431"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://galectintherapeutics.com/role/WarrantsSummaryOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Activity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://galectintherapeutics.com/role/WarrantsSummaryOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at end of period (in dollars per share)",
        "periodStartLabel": "Outstanding at beginning of period (in dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract",
     "presentation": [
      "http://galectintherapeutics.com/role/WarrantsSummaryOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share based Compensation Arrangement by Share based Payment Award Equity Instruments Other Than Options Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationWeightedAverageAssumptionsUsedToDetermineFairValueOfOptionsGrantedDetails",
      "http://galectintherapeutics.com/role/WarrantsSummaryOfPurchaseWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fair Value Assumptions Before and After Extension of warrants [Abstract]",
        "terseLabel": "Weighted Average Assumptions for Stock Options Granted [Abstract]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedPartyDetails",
      "http://galectintherapeutics.com/role/StockbasedCompensationWeightedAverageAssumptionsUsedToDetermineFairValueOfOptionsGrantedDetails",
      "http://galectintherapeutics.com/role/WarrantsSummaryOfPurchaseWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend",
        "label": "Expected dividend rate",
        "verboseLabel": "Expected dividend yield used in the option valuation model",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r444"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedPartyDetails",
      "http://galectintherapeutics.com/role/StockbasedCompensationWeightedAverageAssumptionsUsedToDetermineFairValueOfOptionsGrantedDetails",
      "http://galectintherapeutics.com/role/WarrantsSummaryOfPurchaseWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Expected volatility of the underlying stock",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r443"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedPartyDetails",
      "http://galectintherapeutics.com/role/StockbasedCompensationWeightedAverageAssumptionsUsedToDetermineFairValueOfOptionsGrantedDetails",
      "http://galectintherapeutics.com/role/WarrantsSummaryOfPurchaseWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk free interest rate",
        "label": "Risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r445"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://galectintherapeutics.com/role/WarrantsSummaryOfPurchaseWarrantsDetails",
      "http://galectintherapeutics.com/role/WarrantsSummaryOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r414",
      "r416",
      "r418",
      "r419",
      "r420",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "presentation": [
      "http://galectintherapeutics.com/role/WarrantsSummaryOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised",
        "documentation": "Number of non-option equity instruments exercised by participants."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationSummaryOfStockbasedCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares authorized for issuance (in shares)",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r890"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationSummaryOfStockbasedCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock awards, available for future grant (in shares)",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercisable, end of period (in shares)",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r424"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercisable, end of period (in dollars per share)",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r424"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited/cancelled (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r428"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r426"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average grant-date fair values of options granted (in dollars per share)",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding at end of period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Outstanding at end of period (in shares)",
        "periodStartLabel": "Outstanding at beginning of period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r422",
      "r423"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option Activity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding at beginning of period (in dollars per share)",
        "periodEndLabel": "Outstanding at beginning of period (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r422",
      "r423"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingTermAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingTermAbstract",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Term [Abstract]",
        "terseLabel": "Weighted Average Remaining Contractual Life [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationDeferredStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued (in shares)",
        "documentation": "Number of shares issued under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfAward": {
     "xbrltype": "durationItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfAward",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationWeightedAverageAssumptionsUsedToDetermineFairValueOfOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Refers to the terms of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but not limited to, weeks in a year or quarter.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Term of Award",
        "terseLabel": "Award term"
       }
      }
     },
     "auth_ref": []
    },
    "galt_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://galectintherapeutics.com/role/WarrantsSummaryOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share based Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Forfeitures In Period Weighted Average Exercise Price",
        "terseLabel": "Canceled/Expired (in dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationRestrictedStockIssuancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r418",
      "r419",
      "r420",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercised (in dollars per share)",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forfeited/cancelled (in dollars per share)",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r428"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted (in dollars per share)",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r426"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r413",
      "r421",
      "r440",
      "r441",
      "r442",
      "r443",
      "r446",
      "r452",
      "r453",
      "r454",
      "r455"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationOutstandingAndExercisableOptionsUnderStockBasedCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range [Axis]",
        "documentation": "Information by range of option prices pertaining to options granted."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationOutstandingAndExercisableOptionsUnderStockBasedCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range [Domain]",
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationOutstandingAndExercisableOptionsUnderStockBasedCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum Exercise Price (in dollars per share)",
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationOutstandingAndExercisableOptionsUnderStockBasedCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Exercisable, Number of Shares (in shares)",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationOutstandingAndExercisableOptionsUnderStockBasedCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Outstanding, Number of Shares (in shares)",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r111"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationOutstandingAndExercisableOptionsUnderStockBasedCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Exercise Price (in dollars per share)",
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharePrice",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedPartyDetails",
      "http://galectintherapeutics.com/role/StockbasedCompensationStockOptionActivityDetails",
      "http://galectintherapeutics.com/role/StockholdersEquitySeries12ConvertiblePreferredStockDetails",
      "http://galectintherapeutics.com/role/StockholdersEquitySeriesC6SuperDividendRedeemableConvertiblePreferredStockDetails",
      "http://galectintherapeutics.com/role/SubsequentEventDetails",
      "http://galectintherapeutics.com/role/WarrantsSummaryOfPurchaseWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Closing price (in dollars per share)",
        "label": "Share price (in dollars per share)",
        "terseLabel": "Minimum closing price of common stock (in dollars per share)",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedPartyDetails",
      "http://galectintherapeutics.com/role/StockbasedCompensationWeightedAverageAssumptionsUsedToDetermineFairValueOfOptionsGrantedDetails",
      "http://galectintherapeutics.com/role/WarrantsSummaryOfPurchaseWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected life",
        "label": "Expected life of the options",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r442"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable, end of period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercisable, end of the period",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unvested option (in shares)",
        "documentation": "Number of non-vested options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total fair value of options vested",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options vested (in shares)",
        "documentation": "Number of options vested."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationOutstandingAndExercisableOptionsUnderStockBasedCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Exercisable, Number of Shares (in dollars per share)",
        "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationOutstandingAndExercisableOptionsUnderStockBasedCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options Outstanding, Weighted Average Exercise Price (in dollars per share)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price",
        "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r111"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationOutstandingAndExercisableOptionsUnderStockBasedCompensationPlansDetails",
      "http://galectintherapeutics.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding end of the period",
        "terseLabel": "Options Outstanding, Weighted Average Remaining Contractual Life",
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://galectintherapeutics.com/role/StockholdersEquitySeries12ConvertiblePreferredStockDetails",
      "http://galectintherapeutics.com/role/StockholdersEquitySeriesC6SuperDividendRedeemableConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued, price (in dollars per share)",
        "label": "Shares Issued, Price Per Share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationDeferredStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares withheld to cover income tax withholding (in shares)",
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r170"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://galectintherapeutics.com/role/IncomeTaxesPrimaryFactorsAffectingIncomeTaxRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State [Member]",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r464"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://galectintherapeutics.com/role/SegmentsSignificantAssetCategoriesDetails",
      "http://galectintherapeutics.com/role/SegmentsSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r124",
      "r125",
      "r126",
      "r142",
      "r214",
      "r219",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r233",
      "r234",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r245",
      "r246",
      "r247",
      "r250",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r321",
      "r325",
      "r334",
      "r335",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r867",
      "r870",
      "r871",
      "r877",
      "r909",
      "r1096",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://galectintherapeutics.com/role/StockholdersEquityIssuanceOfCommonStockDetails",
      "http://galectintherapeutics.com/role/StockholdersEquityReturnOnInvestmentDetails",
      "http://galectintherapeutics.com/role/StockholdersEquitySeries12ConvertiblePreferredStockDetails",
      "http://galectintherapeutics.com/role/StockholdersEquitySeriesC6SuperDividendRedeemableConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r152",
      "r153",
      "r154",
      "r174",
      "r202",
      "r203",
      "r206",
      "r208",
      "r216",
      "r217",
      "r285",
      "r346",
      "r348",
      "r349",
      "r350",
      "r353",
      "r354",
      "r385",
      "r386",
      "r389",
      "r392",
      "r399",
      "r564",
      "r692",
      "r693",
      "r694",
      "r695",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r727",
      "r748",
      "r766",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r957",
      "r978",
      "r987"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedPartyDetails",
      "http://galectintherapeutics.com/role/StockholdersEquityIssuanceOfCommonStockDetails",
      "http://galectintherapeutics.com/role/StockholdersEquitySeriesC6SuperDividendRedeemableConvertiblePreferredStockDetails",
      "http://galectintherapeutics.com/role/SubsequentEventDetails",
      "http://galectintherapeutics.com/role/WarrantsSummaryOfPurchaseWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r80",
      "r83",
      "r84",
      "r138",
      "r161",
      "r162",
      "r163",
      "r180",
      "r181",
      "r182",
      "r185",
      "r192",
      "r194",
      "r196",
      "r215",
      "r289",
      "r295",
      "r323",
      "r402",
      "r484",
      "r485",
      "r497",
      "r498",
      "r499",
      "r502",
      "r509",
      "r510",
      "r519",
      "r521",
      "r522",
      "r523",
      "r524",
      "r526",
      "r537",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r576",
      "r578",
      "r592",
      "r656",
      "r676",
      "r677",
      "r678",
      "r698",
      "r766"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r181",
      "r182",
      "r215",
      "r578",
      "r632",
      "r690",
      "r709",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r727",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r746",
      "r749",
      "r750",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r766",
      "r913"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF CASH FLOWS [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED BALANCE SHEETS [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails",
      "http://galectintherapeutics.com/role/StockholdersEquitySeries12ConvertiblePreferredStockDetails",
      "http://galectintherapeutics.com/role/StockholdersEquitySeriesC6SuperDividendRedeemableConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r197",
      "r412",
      "r958",
      "r959",
      "r985"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r181",
      "r182",
      "r215",
      "r253",
      "r578",
      "r632",
      "r690",
      "r709",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r727",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r746",
      "r749",
      "r750",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r766",
      "r913"
     ]
    },
    "us-gaap_StockIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssued1",
     "crdr": "credit",
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment of preferred stock dividends in common stock",
        "label": "Stock Issued",
        "documentation": "The fair value of stock issued in noncash financing activities."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r21"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Series A Convertible Preferred to common (in shares)",
        "verboseLabel": "Common stock, shares issued (in shares)",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r39",
      "r80",
      "r83",
      "r107",
      "r372"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://galectintherapeutics.com/role/StockholdersEquitySeriesC6SuperDividendRedeemableConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred stock issued (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r79",
      "r80",
      "r107",
      "r692",
      "r766",
      "r849"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock from restricted stock units (in shares)",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r107"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation expense (in shares)",
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r79",
      "r80",
      "r107"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://galectintherapeutics.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Exercised (in shares)",
        "label": "Issuance of common stock from exercise of stock options, net of shares withheld for exercise (in shares)",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r79",
      "r80",
      "r107",
      "r427"
     ]
    },
    "galt_StockIssuedDuringPeriodSharesWarrantExercise": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesWarrantExercise",
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued upon the exercise of warrants during the period.",
        "label": "Stock Issued During Period Shares Warrant Exercise",
        "terseLabel": "Issuance of common stock from exercise of warrants (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of Series A Convertible Preferred to common",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r80",
      "r83",
      "r84",
      "r107"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "crdr": "credit",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationRestrictedStockIssuancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock units valued at grant",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r79",
      "r80",
      "r107"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock from exercise of stock options, net of shares withheld for exercise",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r80",
      "r83",
      "r84",
      "r107"
     ]
    },
    "galt_StockIssuedDuringPeriodValueWarrantExercise": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "StockIssuedDuringPeriodValueWarrantExercise",
     "crdr": "credit",
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock issued from the exercise of warrants.",
        "label": "Stock Issued During Period Value Warrant Exercise",
        "terseLabel": "Issuance of common stock from exercise of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders' deficit",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r83",
      "r84",
      "r95",
      "r729",
      "r745",
      "r767",
      "r768",
      "r906",
      "r919",
      "r980",
      "r1000",
      "r1078",
      "r1129"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' equity (deficit):",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteAbstract",
     "presentation": [
      "http://galectintherapeutics.com/role/StockholdersEquityIssuanceOfCommonStockDetails",
      "http://galectintherapeutics.com/role/StockholdersEquitySeries12ConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity [Abstract]",
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://galectintherapeutics.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r173",
      "r384",
      "r386",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r398",
      "r402",
      "r528",
      "r769",
      "r770",
      "r853"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://galectintherapeutics.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r571",
      "r597"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://galectintherapeutics.com/role/NatureOfBusinessBasisOfPresentationLiquidityAndGoingConcernDetails",
      "http://galectintherapeutics.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r571",
      "r597"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://galectintherapeutics.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r571",
      "r597"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://galectintherapeutics.com/role/NatureOfBusinessBasisOfPresentationLiquidityAndGoingConcernDetails",
      "http://galectintherapeutics.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r571",
      "r597"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://galectintherapeutics.com/role/NatureOfBusinessBasisOfPresentationLiquidityAndGoingConcernDetails",
      "http://galectintherapeutics.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r571",
      "r597"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://galectintherapeutics.com/role/SubsequentEvent"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r596",
      "r598"
     ]
    },
    "galt_SupplementalLineOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "SupplementalLineOfCreditMember",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedPartyDetails",
      "http://galectintherapeutics.com/role/NatureOfBusinessBasisOfPresentationLiquidityAndGoingConcernDetails",
      "http://galectintherapeutics.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A supplemental contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Supplemental Line of Credit [Member]",
        "terseLabel": "Supplemental Line of Credit [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxPeriodAxis",
     "presentation": [
      "http://galectintherapeutics.com/role/IncomeTaxesPrimaryFactorsAffectingIncomeTaxRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Axis]",
        "documentation": "Information by period subject to enacted tax law."
       }
      }
     },
     "auth_ref": [
      "r1057"
     ]
    },
    "us-gaap_TaxPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxPeriodDomain",
     "presentation": [
      "http://galectintherapeutics.com/role/IncomeTaxesPrimaryFactorsAffectingIncomeTaxRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Domain]",
        "documentation": "Identified tax period."
       }
      }
     },
     "auth_ref": [
      "r1057"
     ]
    },
    "us-gaap_TemporaryEquityAggregateAmountOfRedemptionRequirement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityAggregateAmountOfRedemptionRequirement",
     "crdr": "credit",
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://galectintherapeutics.com/role/StockholdersEquityReturnOnInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series C 6% super dividend redeemable convertible preferred stock, redemption value",
        "terseLabel": "Convertible preferred stock, redemption value",
        "documentation": "Aggregate amount of redemption requirements for each class or type of redeemable stock classified as temporary equity for each of the five years following the latest balance sheet date. The redemption requirement does not constitute an unconditional obligation that will be settled in a variable number of shares constituting a monetary value predominantly indexed to (a) a fixed monetary amount known at inception, (b) an amount inversely correlated with the residual value of the entity, or (c) an amount determined by reference to something other than the fair value of issuer's stock. Does not include mandatorily redeemable stock. The exception is if redemption is required upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series C 6% super dividend redeemable convertible preferred stock; 1,000 shares authorized, 176 issued and outstanding at December 31, 2024 and 2023, redemption value: $8,018,000, liquidation value: $1,760,000 at December 31, 2024",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r348",
      "r349",
      "r350",
      "r353",
      "r354",
      "r456",
      "r647"
     ]
    },
    "galt_TemporaryEquityDividends": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "TemporaryEquityDividends",
     "crdr": "debit",
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid temporary equity dividends declared with the form of settlement in cash.",
        "label": "Temporary Equity Dividends",
        "negatedLabel": "Series C super dividend redeemable convertible preferred stock dividend"
       }
      }
     },
     "auth_ref": []
    },
    "galt_TemporaryEquityDividendsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "TemporaryEquityDividendsShares",
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock issued as dividends for temporary equity during the period.",
        "label": "Temporary Equity Dividends, Shares",
        "terseLabel": "Series C super dividend redeemable convertible preferred stock dividend (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityLiquidationPreference": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityLiquidationPreference",
     "crdr": "credit",
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series C 6% super dividend redeemable convertible preferred stock liquidation value",
        "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquitySharesAuthorized",
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series C 6% super dividend redeemable convertible preferred stock, shares authorized (in shares)",
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquitySharesIssued",
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series C 6% super dividend redeemable convertible preferred stock, shares issued (in shares)",
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquitySharesOutstanding",
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series C 6% super dividend redeemable convertible preferred stock, shares outstanding (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "galt_ThresholdPeriodForExtensionOfExerciseDateOfPurchaseWarrantsUnderAgreement": {
     "xbrltype": "durationItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "ThresholdPeriodForExtensionOfExerciseDateOfPurchaseWarrantsUnderAgreement",
     "presentation": [
      "http://galectintherapeutics.com/role/WarrantsSummaryOfPurchaseWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold period for extension of exercise date of common stock purchase warrants under purchase agreement in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Threshold Period for Extension of Exercise Date of Purchase Warrants under Agreement",
        "terseLabel": "Threshold period for extension of exercise date of purchase warrants under purchase agreement"
       }
      }
     },
     "auth_ref": []
    },
    "galt_ThresholdPeriodForStockClosingPriceInTenConsecutiveDaysUnderPurchaseWarrantsAgreement": {
     "xbrltype": "durationItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "ThresholdPeriodForStockClosingPriceInTenConsecutiveDaysUnderPurchaseWarrantsAgreement",
     "presentation": [
      "http://galectintherapeutics.com/role/WarrantsSummaryOfPurchaseWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold period for stock closing price in ten consecutive days under purchase warrants agreement in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Threshold Period for Stock Closing Price in Ten Consecutive Days under Purchase Warrants Agreement",
        "terseLabel": "Threshold period for stock closing price in 10 consecutive days under purchase warrants agreement"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationDeferredStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r995",
      "r1084"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationDeferredStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedPartyDetails",
      "http://galectintherapeutics.com/role/WarrantsSummaryOfPurchaseWarrantsDetails",
      "http://galectintherapeutics.com/role/WarrantsSummaryOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r380",
      "r397",
      "r527",
      "r560",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r657",
      "r892",
      "r894",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r907",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1062",
      "r1065",
      "r1066",
      "r1067",
      "r1074",
      "r1077"
     ]
    },
    "galt_TwentyEighteenAndTwentySeventeenWarrantsIssuedForServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "TwentyEighteenAndTwentySeventeenWarrantsIssuedForServicesMember",
     "presentation": [
      "http://galectintherapeutics.com/role/WarrantsSummaryOfOutstandingWarrantsIssuedInConnectionWithEquityAndDebtFinancingAndConsultantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrants.",
        "label": "Twenty Eighteen And Twenty Seventeen Warrants Issued For Services [Member]",
        "terseLabel": "2018 and 2017 Warrants issued for services [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "galt_TwoThousandSeventeenMarketAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "TwoThousandSeventeenMarketAgreementMember",
     "presentation": [
      "http://galectintherapeutics.com/role/StockholdersEquityIssuanceOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement with a sales agent under which the Company may issue and sell shares of its common stock.",
        "label": "Two Thousand Seventeen Market Agreement [Member]",
        "terseLabel": "2017 Market Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "galt_TwoThousandTwentyMarketAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "TwoThousandTwentyMarketAgreementMember",
     "presentation": [
      "http://galectintherapeutics.com/role/StockholdersEquityIssuanceOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement with a sales agent under which the Company may issue and sell shares of its common stock.",
        "label": "Two Thousand Twenty Market Agreement [Member]",
        "terseLabel": "2020 Market Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://galectintherapeutics.com/role/StockholdersEquityIssuanceOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r511"
     ]
    },
    "galt_UndesignatedCapitalStockParValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "UndesignatedCapitalStockParValue",
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of undesignated capital stock.",
        "label": "Undesignated Capital Stock Par Value",
        "terseLabel": "Undesignated stock, par value (in dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "galt_UndesignatedCapitalStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "UndesignatedCapitalStockSharesAuthorized",
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://galectintherapeutics.com/role/StockholdersEquityIssuanceOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of undesignated capital stock permitted to be issued by an entity's charter and bylaws.",
        "label": "Undesignated Capital Stock, Shares Authorized",
        "terseLabel": "Undesignated stock, shares authorized (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "galt_UndesignatedCapitalStockSharesDesignated": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "UndesignatedCapitalStockSharesDesignated",
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of undesignated capital stock which are designated as common stock or preferred stock by board of directors.",
        "label": "Undesignated Capital Stock Shares Designated",
        "terseLabel": "Undesignated stock, shares designated (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "galt_UndesignatedCapitalStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "UndesignatedCapitalStockValue",
     "crdr": "credit",
     "calculation": {
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of shares which are not designated as common stock or preferred stock.",
        "label": "Undesignated Capital Stock Value",
        "terseLabel": "Undesignated stock, $0.01 par value; 20,000,000 shares authorized at December 31, 2024 and 2023, 20,000,000 shares designated at December 31, 2024 and 2023, respectively"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r27",
      "r127",
      "r128",
      "r131",
      "r132"
     ]
    },
    "us-gaap_ValuationTechniqueAndInputDescriptionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationTechniqueAndInputDescriptionAbstract",
     "presentation": [
      "http://galectintherapeutics.com/role/FairValueOfFinancialInstrumentsKeyAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Key Assumptions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "galt_VestingPercentageOfRestrictedStockUnits": {
     "xbrltype": "percentItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "VestingPercentageOfRestrictedStockUnits",
     "presentation": [
      "http://galectintherapeutics.com/role/StockbasedCompensationRestrictedStockIssuancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "'The vesting percentage of Restricted Stock Units (\"RSUs\") granted.",
        "label": "Vesting Percentage of Restricted Stock Units",
        "terseLabel": "Vesting percentage of Restricted Stock Units"
       }
      }
     },
     "auth_ref": []
    },
    "galt_WarrantFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "WarrantFiveMember",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant Five [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "galt_WarrantFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "WarrantFourMember",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant Four [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "galt_WarrantIssueDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "WarrantIssueDate",
     "presentation": [
      "http://galectintherapeutics.com/role/WarrantsSummaryOfOutstandingWarrantsIssuedInConnectionWithEquityAndDebtFinancingAndConsultantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date the warrants or rights are issued, in YYYY-MM-DD format.",
        "label": "Warrant Issue Date",
        "terseLabel": "Warrant issue date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedPartyDetails",
      "http://galectintherapeutics.com/role/LossPerShareDetails",
      "http://galectintherapeutics.com/role/WarrantsSummaryOfPurchaseWarrantsDetails",
      "http://galectintherapeutics.com/role/WarrantsSummaryOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants [Member]",
        "terseLabel": "Warrants [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r910",
      "r911",
      "r914",
      "r915",
      "r916",
      "r917"
     ]
    },
    "galt_WarrantModificationIncreaseDecreaseInEquityAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "WarrantModificationIncreaseDecreaseInEquityAmount",
     "crdr": "credit",
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in equity for Warrants classified as equity from modification.",
        "label": "Warrant Modification, Increase (Decrease) in Equity, Amount",
        "terseLabel": "Warrant modification"
       }
      }
     },
     "auth_ref": []
    },
    "galt_WarrantOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "WarrantOneMember",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant One [Member]",
        "terseLabel": "Warrant One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "galt_WarrantSevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "WarrantSevenMember",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant Seven [Member]",
        "terseLabel": "Warrant Seven [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "galt_WarrantSixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "WarrantSixMember",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant Six [Member]",
        "terseLabel": "Warrant Six [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "galt_WarrantThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "WarrantThreeMember",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant Three [Member]",
        "terseLabel": "Warrant Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "galt_WarrantTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "WarrantTwoMember",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant Two [Member]",
        "terseLabel": "Warrant Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "galt_WarrantsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "WarrantsAbstract",
     "presentation": [
      "http://galectintherapeutics.com/role/SummaryOfSignificantAccountingPoliciesWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants [Abstract]",
        "terseLabel": "Warrants [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsNoteDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsNoteDisclosureAbstract",
     "presentation": [
      "http://galectintherapeutics.com/role/WarrantsSummaryOfOutstandingWarrantsIssuedInConnectionWithEquityAndDebtFinancingAndConsultantsDetails",
      "http://galectintherapeutics.com/role/WarrantsSummaryOfPurchaseWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Warrants [Abstract]",
        "label": "Common Stock Warrants Purchase Agreement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "presentation": [
      "http://galectintherapeutics.com/role/ConvertibleLineOfCreditRelatedPartyAndSupplementalLinesOfCreditRelatedPartyDetails",
      "http://galectintherapeutics.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants expiry date",
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r1065",
      "r1066",
      "r1067"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://galectintherapeutics.com/role/WarrantsSummaryOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average expiration term of warrants outstanding",
        "label": "Warrants and Rights Outstanding, Term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1065",
      "r1066",
      "r1067"
     ]
    },
    "galt_WarrantsIssuedPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://galectintherapeutics.com/20241231",
     "localname": "WarrantsIssuedPrice",
     "presentation": [
      "http://galectintherapeutics.com/role/WarrantsSummaryOfOutstandingWarrantsIssuedInConnectionWithEquityAndDebtFinancingAndConsultantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance price per share or per unit of warrants or rights outstanding.",
        "label": "Warrants Issued Price",
        "terseLabel": "Warrants issued price (in dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average common and potential common shares outstanding - diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r208"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://galectintherapeutics.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average common and potential common shares outstanding - basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r208"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481766/480-10-25-13"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-11"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "710",
   "SubTopic": "10",
   "Section": "25",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483070/710-10-25-11"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-5"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483043/710-10-30-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(n))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-6"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480408/260-10-S99-2"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.E.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-2"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-3"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column B)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5A",
   "Subparagraph": "(SX 210.12-13A(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 5)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CC",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CC"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>94
<FILENAME>0001140361-25-011169-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001140361-25-011169-xbrl.zip
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M\;EK=8LW^,T=CN)GHUZO>#%%X\]<SJPO "W\\MQSFO,$*[BBX"/+5WOO_O@
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M]7ZG!?AH64UN 1_K.#T;>%F_;K?J]BKQU7_PN=!JEGME=_PUR'+CMX'I!'B
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M4!."U2+"F&DLV 'H1:"F ?- 6A7151=^ 8XCLM6%OJ0OBJ'3*/"<$Q"G"5_
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M< 1N8 QL&'*) %3E>"8*TAA5ROCJ5Y4VFB).26WZW<)^;0;2VYXHV1P'Z:'
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M=N[ZT8GL-(BK?.<S&I++,!Z'WX,[\((A]E:'34T8+"=^'4Q]X2P]->#Z< :
MCQV#<6"=$=CV-,0FI2=P,<P!=E=C#\SUB%=./'0YP;N=J8WV5H27+5K#8[O
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M%86\F?>-W-V<$'I_/?OK]6]G]Y?B;TJP(410'PA@E]3_5TPP2HCBZN*,RBA
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M!?7>CT=1:@W/!(\'=1!@ ]L,(CN8T,P6Y)NX6DQ!#?+E$) 0#Y*%3M7=PT[
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M)#N5F@%X/O63R .9'CQSU4Y CC.5:Y=+9<MFW D_#6X370-2"Z1O;-T&(5\
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M&,?8<^)@GL 4N=4Z6E8>*8?M]71-CH,8EQ(F)_ 1K; '-IL0?%J4!DDYT?9
MZP\/D+YC6^]D1?BC0JT,1LD%H@"A/S&20^EH!<AA0V 'B*15+XZ#\G@?!)C$
M$N!*B8+@)P8E(,KDX\OH'E66)?.JT2FLI8!_Y2PUA?@9*2$L6W-<6D8[TRU
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M6@L4B ] 7,RZ%U7MM> 0!D?IH*3(V)5:9MP2BCH2.@I1<+8AEB(PQ@NE1QZ
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MNN:^BY)O/^S.LEG@)21ABM>XXL((WI'%PI)71'"'EFP;BT05MU6U[%".HSZ
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M?Y+VYR#ZU =(MY!8Q"P8K;<_A)KX'%\CD2YX$F'#MW4S_Z!57;I=K+ZZ!->
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MGT3BGK8;U[+*/,O-LW8Y\X-=((11=7L_?JTHTHA5C**][Q,::XI^HJ]^ER>
M92_)&)=<M4U@7K,749%E].=S ;=SE3/DF>;^;-2P:C3)KN+O(K@JQ4DN9SF_
M@5<[QVY!Q(+-9XCN@G&^!"#4^VV:#,U9Y8Z*#2Q216'@7)5O#2Y0EJO \,W
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MRRKGV::/#RZKZ\>'&@IRIBB778(K4Q[%M$/<FY"H[D2T"6K?+D>'24TP#!U
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M EN/CCCC]93VL]UM11/7X"@U)B8RHL;Q^^!GZ$E>6>\DC7.!D"K K$*-$^>
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MZ(_!;@W:Q[AEGS)=/CCD9-@(QB6)@4=1.[?WIR4)[)&>=4N-[P\U+G?]V>'
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M0W9?0<1B629N[<*Y7X<X@/C[\<H=8;":PI]-LM!'_/*'_WK]]<'1>?A">&\
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M"VO-P</^XQ.A.+(V0WPH9# <$^AZ5:Z$L)X"':5&2TG !Q\@3HV:4\J+"CS
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MQ$."?OP  H-?AO"=S_#)G!A7BM5'XWTC@/<&T&^$]!Y_<D3O1T%U^]ODA[8
M/% #P'W"_X_'T?][0/$/@/R_-]R_WY2V#O63.[[1"&HX_.>@@6QT 0ZP^/T_
MW>!7QK19U]2*,SN9/SUZ,FNH\<C-5LYH+[KWWDU"HY'=<4/M2/"C63L[/7_Z
M9/:C/VI=MK5WMZ_+O&N8_N&K]55^./?NNE[6%;6 ??LBUGGYGN2<627SH*T.
M\!^S1=84?66]DR?IDQ7E['OO4Z%:]F*.!^V"LNUB%PD#N38,E5@D(F)O(?3,
M6*2 @"5K?24N&Y6!W7?OI< =Y;<:82#$JRW<NG!,[TZ<RG[5(ZHF?N:BU>9]
M[;1LD!D)'?^''S#!MWJ^D\GS?::>[^0WX_G^YB[\*D=0[LAV?J4.\-40\6A9
M\;UW<.^91@<\.T#N4>S) LN,':'^3K.2D54U%Z#"6)2?YAHWBSSXOZ\QC-LX
MC**36RMG.<G;^G<HKHJ\8^G1 !G.+BYJ1TA"_\R5#)FH1VHE;3XBWTN/&V-L
MZ@$OE(^$^2:9@N%A7-/IY)H^4]=T^IMQ3=\5?@-_DZV</]I]733:__SY.:B1
MQLM6$;K^+A^R\!Z6[/%72/5X_&24ZO%^B!X_,YK'CR=Y'.N1O6^"QU\#O>/'
M9$)N718W6Z_VH_+>^..+G]Z^?CVR-](?9J]?W^<>?#;MP9_I'GSVV]F#62J'
M#KP1E1;TV%XR;<TW__0'X]W<?X,3LV^,,/AW4&KDD_IK*E#5LQ\[?Q+/&J8(
MX]_.W@1%HU_!]OY#G[%GX</W,G#[^(\!R'CQYNL7_SE[F3'AM(QD!V%&(&IW
M&S_PLV]?_.UMI&RAKRTO9\<G<VAX?5#H,/ZX=Q9E^ZM(R%4KG5?,XP,=V%[@
M1J_<HNZH8'O\G%[X^ S'-G]H@FS5T<E3%H"ZC(]&#4*L\S=0;9I])2Q6^[7@
M<""#AMJ"M!FA)Y@)STY=O4O(4GT,LO$1J%)=14VJA2O=JJ!3EQ[6XN-!G8MO
M7S16T\J?^$!Y17.?E;TKRDO)=1YSTK^F ZDK\^:!ICF@2DEH:;;-B 8L:RYG
MN=Y7P:$#!JR\8JT#/WK+8DN5H6VV0Y7^]M_+P5I$23AEUU%S&Q_J_854L/OF
MZUCZJDJ9 Y%,S6IJP?&F,78"-P1>MNW03S*9U#(P866\ZOT[=9!*X6(])3&$
M^VJH:0EJ+D(:%&@!=6MWE<6FMWL)*YY.8<5G&E8\_<V$%?_/3XXR[R[_?S^?
M[?[6A?%L6AB?Z<)X]IM9&!'?$8+LKQF0JQO+BS);[ZBX1N%3V'Q>)IO/3S'_
M^T/(_WX^*^W&H*4WOZ^J^MIO@@=_JRK0?X*OT%*RW4_$TLLY&-Y.J@Q<%J1=
M"V)+@VN>2Y"AJD\/.'?:- _&4(S'6L:C">-!04/N U.B4^!3QAONII7).C[Z
M1DDQXVEK]LU[EC>>O6 "V:/SD],Y5*M89X!U;#F6_3DT')+4[(I"NWI!8'3(
MU^8<NOO8BTZ+^Y_S< ;->_/@S$/KB.N22R84^($=%_6:N?VN'XBE0_"%0"R&
MA[F6.OQ?I/ZA-)W[JK_S(26NH6,WQ1P>A!CJ!89>_L/2!_2+E%%BIZP-U]YE
M-TH3RD5N]S[;@.L6E,1/OHSO,,<G1U_J7ZBO>C/V.4I*_4_] _\\\C$Q=Y?Y
MX,OKK.Q_)H5O_91>3?X"#N+^UYM+^ZF,M?P-#!SZ??_.\K&/7@_UTQ?KM9E8
M%6O'Z<C,-RD]Q=5'D7,@+O;C+ ;'M3;A&;'4&2".:(2L/,R[%.=L@9!'%!#9
M.!W"7PN>X1VKUH:C!8X3<UCK?E-7 XQ$R^;-J.970T96R"YP1H@"Q^8; S70
MVW]A=05$,<#_C/7BF=YL^&LTENB=+$I"R4-<3>8OS.P]@G=ZJ, G(_<HEC(
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MTS7S3ZP R1JV7G!+]BFF^C.@6E(O'P9(Q!FF0ZK5PQH0U$MX+>0Y5TM6WN%
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M:&ISW;?6T)-H)6(/?B"D)B(ZH-N>ES/O#='%P:+$6-1F=ND(KJOGP6!VI>W
MO_ O?^"C\'P%SD</X!9P*^.".$]KUQ&_F$('U:@N+L&KT\]58QP+=>"TZA@%
M.MQ&5WZ #[ /U=M'U=W1;R5O$TQ\<A6T,^/<.B=Q$81@^(.]USGIP&+DZ:BX
M0N+[2#I+2YB1+D3NB0M+= 9J:LHK8$PJTA(<M+#]1^"S'X,L^!JK(LT=[Y&\
M<Z.(X(.-'BQM?@XZ**-'Z5,AG<"UB/"+R=Y*<" #9?TDZL"#K<5U[(($A/J<
MY@7O1!BAM+#WH#N-!Y2$H4TBD[)FM?%E[WM_?, _S=WSZNP=IER^JJ+C[L&8
M74_KX;][?L*:]\T9"!M(##9MP/LYE88M'GP 75OA-#P7+Y^^\SR8@1[ROB01
M-9PN9A6?B];"OENK:IG]4O>+I;'J<1DUK \,-=C0IU3OC-T*'+WS+9A#?5]%
M9.;5RKJ]8N]:5=>JX1;[/LBYCH?/%VHFLK'&1+.*7=A-"]P3$.L9V+&APZ<D
MZFA)R.<4[(M\335]6HU#BKCD.N28.$?'.J/<:JL:O'$,/([&O%;D5Z'J"DHP
MQC@%19'3?V'+=([Q#^#ANSF8,_B@09I^%38D7!GJ#".G@L4#7II.9N;0C-.\
MX*<62!?%1A=X5J![)M[.&7T:5/I?@8Y&?$I3T0R\9[)A3UGV0;613?P\#OZK
M/O_9P4,$5C6%1JNQ-PREHE^*DBC=W+WS-"Z%BXG\#KJY%+$HL:@S#Q>96!A7
M^PI3]CXKZMN=)N[%K3?!F%@]B;-U:559=."@HWN,O%):#00A4CN9_B#X;9FW
M/?$4^"SC'+2V_/'A:QR,TTE0T07O,B/-MPW U$,HMM'SNF$1^\VYL$C+?'H;
MYM-G+?-IRWQZS\RG=W#ONK6U)+\-63XTO#&Y-PPFBA15+82]Z#9-W&P-<>]U
M.\0&S<$A7U\)< VM>>.^0S?7=@)S@P?GV&V+R0KM)0#7Q1?LZ*##60'%2B@4
MDDK/OVB*43OLH3;\2L\6]S@L\8.@+W-LKP%&%D;,3%A#1S5TB+1[9'P"Q!:S
M'4K+RP%25W'K]:*[%-/'7O^P47N#'T2]"IW$JLF'B<<5\ 7*K4'PNNL[Z0BZ
M.^".3&=T-=+[:#EH-7QGC&ZVY'/PC;,-]M&T[.(-GY)A.=,Q,\I'Z470=^VA
MF-/X*/>[+U2<HJ/%;I'W.2V'8V5NZF?R[5['.T&-B+G#A*GYP9@;8C?5)=._
MPLY9Y/QRQA&.,AE4%&6TRY\IS)'I;2Z";P&',>U:3")TOSC$44OP6H-[E XY
MF(ZB #II-U&@G8BRDI6,L2S@?G4>3CX)ZF[E4;<!L^-TE5MO1[?GC=!GOPQ
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M""HWYQOJ.;9VSL<HN^5D$ 6H_$/\ Q_W7DV#6-]+->6N5VF-B&*S$X:M8:O
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MO$9_&!4:>+A BF!=5U] ,1DQ$@&K3_OB6)$CH@O2@A0&L]RR0 FV$(D+W4_
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MFY>X0^WS;XU!79R)KR 74-O)Y.$/HPQQ#XT!+T%&+M!&NPW],2?^%D=?T8G
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M)6.#BK0R;4RF:MPDP@S'&3V]&'*,5G;R?O3:HL/#1U]8M+3(01-\+'_2[18
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M#D1,+;+^%&+R14RW+(B)64U=36]UUK6:.IVNTGF[1%"O+ A"[S,ZOU*D!ZH
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M@4IG4>DLBDMVG\ZBUTY+=07.?J:SZ">-%L942E4(1S&92F=1 "L@;K3[$2J
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M-V'&,F O&@'WN5SF!RZG"16GTEQPS1#O*<;%=4?;C8Y&IF5RT8$?<=IROV$
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M;VQ.HP:!>N)@QP:K3,[&('<F,,RU22I7-X1#QN)NWF9L:6=S3Z_OYLV*U=V
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M')DI.VD4 %1H+EWQ%YHBO^,-LI9E&H'O*Q=TO[R"3O-4:]7;E?0**DSKG0]
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M_*B@N 2*C;) $<!B!4/F<="-',MR7F IB!U,!LP%MY-X8PI Q-^<P(693":
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MTI^=S<<VQ)@P\<RR0M**%(WD[%(9I?A;,,6FOM/KM3H!9K,P"+%P7,D)16L
M#8Q,FX8B*2TT7ASW3R2](<^WV8P- 52/L9'A2<RA2U]F"</+%M(?@[GV-):4
ME)!IST%F,2Y2N65S* FM.I$&MAUACD5ZZ/"9K]*$ F7BI)R;<1H!@K;(YPS)
M"HWPX!#, 8^G&(&+N33QW&&@_\3T/,=]Y;G*Y!!E);P:8(HGGKB1]+V;/7<#
MSVF2J)P38!+\GO=GAJ_$0#%[2:(-7_5F*!4BB;J1.,;4&2X%88I@S^  +]F0
M%W*X%ZF/B%Z0*^!ON!-B.3RG9VH%'D\*/6Q\?Q26+*J1.Q DJ,<L>1!'=B&!
MDYJ0QX7K,&!$U!D:L!'JI01T.N6&SJT-.A!K"O'Y8:(3 D+J%<'Z&N>@S.D/
M$ ML2LVA)E2\ XO/=2>7TAJ2AML"X #P7C!9"]Z8F%AVR85EMZGEOXJ#37P4
MZ16G$W">N#X6OWEAAS72%V1G'$91NCL,/1PV?CM-T),:AANP)%U3DSKTCL*S
MVQ+RH0!>5,PI2RPE$H)!=4/_LH5P0J,UAL8S>%/C$S6R9$ZSF" P?=B%7 1.
M2\OQ4#*&V]OA.&?CDDL\1";!&67T)B@#Y 3]RYX1&A;S/&%Y?=>LU>O(.6(M
MRHWS*WXRPA90F0%^J5Q,J6_\F)_DYRD_<=T896+#EU%^O%!^:%H]P9M/<I$;
M]7JJ2-.J\XX:LA*&(*#/[T"3UG5<<TEHW@PY7"A,?Y<C"\5G4C,*N2^GX\1G
M%+Y'7(KN$33*E2<XYB[/U?1DXN0*;:J)E8XRF#@6O1E#Z.WZ]^$:+,)KUL)D
MX3<&_33+2+7&S^D@R-$:F$?VS*?@%DL,VMR-6 Q\OJ;1BK&O4ZS3!H/[)0#9
M*M7 :?'LL2I-7D0!5C//)LG0,D$?+.$;\ ^XK-1;>1C#P%9# )B)QTK6,(PC
M?S_;0(X&BP-=+A0V,9<W-90["^SD)</;BM4<K<Y:UO/:HUG'EIYSP.:RW(M'
M[VIS>@.\;&I<1[0HR,BNB'D=+<M",YM4UY0M.T.D+.W=V-@1 LIB:^_>RBXC
M5A88VAM(S"V8W1%6TN:WWMB.^5T*PWMM13PKBEF<.5Y&0SQ:AGF#/*>MGGCZ
MU2RH?X5RQX(U$]L^5[9G(DWOHDV46>;CMF/4-XX !C_Q-G_] "SO[/8!C[G/
M3%Y","N^RC>&'+3;X8_9PXZ;3#8SHMG"8XAY/.R&<7O<O\!Z-WP@KB V/&+Z
M63M ? RR2G%\$+/]GL_A4,[C0\E>^+<$_M<ALQC#.4,#"*SN4$<NV[/,8^\H
M@RJXT&([!V4H+W$H-K.0%)(P;FP?4I"'%WV7($FV%<GSL[!V$C-QEV96:C:V
M<V:]UHBH3RU]!S,<C,:;%N/%9H=RZ:+-(SX,N8N5'(7#N^/LCX?G^<W*W$Z4
M@C=SJRNRB;&KD2E+ J"TN.D_G/?_(2486)1_,K!2%RPFK\<[&ZH8Y+D+#E-_
MPL!IT\A],, ;/9&I$Z6BP)KDW.'R8US0NNT(H,B"3T^XF2;<M8AO0FF%JX!
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M0+&6PHLX)8Q:)2(LK$0 "X]53.1UTJ"X^"%I,@$K )G%8U.*F@<T;-9BI/"
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M :VD'2<CF5>V9V(YP4>7HG@B=PX(T-?BPPD*0@D(@8U=RM,5"0PU]./(%1@
MC$SJXFT;((86G[]3\>"=PJI9VYTKNSZNFL>S(VJ>S'0Y R2YK^0S^Y/"$,CU
M]1VX7#8QP83#4MWXE,LO@6&X@SD-!B#'"#4,&)6/@FUDNA.%OIVBKZE7 7W-
M2*J=86\CZ(];5W>!ZP54E).Z#\#*UYOT6&\=TB.$)\8''F8W#EU\-<;4?F*D
M;W#TZJ?-ED+?KM'7J 3Z&@I]>XB^1DW_:_G1UU@M^_0>^:WV4#NK(>+XMWJS
M+2XUZP^=*09@XX^'#YW6.Q%2J3N@-O..;[]:[%6"-#%$_ ^&U5"@W35H&Y4
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M]YPDN<K]BW^"0W!>(Y?W%Q=?^GNYAZ"$_^Z%/WL&'P!AAG>34K5/4&)QHS1
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MUI()-[8VWPWG.#NB]&T3Z&UO!K.\O<8&LTD:QREAL(9$6HV&3#6TL16^QLC
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M P^?^1X!S ?,M.?_S]Z;=C5R9/G#[_TILJM[GK;/$>78%]M=YU! V?RG&AC
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M4'D>LQ3^H7JC>L1.:Z.D(^$_)PD@5$&-+>7&2*D,EJ8AUE5&N+)1OSN^]CL
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M^&6J%;[[U=F]?[M\,#XN#='/+<*3MJD(B6?:RC->,6NY409@32 DV@'I/;'
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M(^2Q:(>?^>%F<JBIP,@.$582:<D22?"=X+L!O@WW0F!"C*)!NZ=:RF"6<,V
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MP [E37K4[B#4$READ^=1$KPE*W%=Z_(2Q#,.":>%UCZ8B3K\P0FTFEODL*8
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M3I0GXR)OD\>4*QX?&Y'C@0#=.#IPZN^)M3%-@>'&"VP1$3)L.5#4 ,D"IA-
MW1.CVZ2^LL<G'Z9+"V:6=J]P)BYO3%,I7/_-N^&7P?S:1D8I;CFE,T'HVOJ:
M49Z'10KZ[TU/]2/#W<)V6)F@;WRZRO9'GT;%L&3-L.[!UG)N6 KI"NFK+.3
MJ<X6LYC>#7./-EIX<JYB_YT:*TZ^-GF,=3J =UY*E[ UTR+XX99!@PE;5F76
MA+]CJDI_; 87\2MC:RY(J\ !T5@<UCCC;?;;X$N@CKPS)H_Z[ ,VZ!@FRU11
MC/)H[8ZUA_H42A4B?&HBXZ(ZT'/#:"%_"W06,*O^M*B(*Q-UE_'G77Y].\(O
M807&E!OF-DN!DZ>%!PST4$63_I:$?6GG-MWYRY7KE^L>9?1@U+.5$1SLX?"!
M&.-3-DP]++PK"QIF-:LX:[3<]=1Y%L3_J#<L":A&%%$)N(T@3HWDM[-^L]E
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MJ"XU+CK+_3HT]VIJ!S_=#OXYO!^YX7B0ZE("!@W'\\E !:FKYP,_'*NQ257
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M)I)TE)E36TK,C(>FW1BB T?8M/>A\38^-'$:']I@J:YHQ_W+3L;H9FQ6#YT
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MB@=3@3DNC2-*"$TL9UXBX*FS5NN^BMEKCLC6')%U$KYVXFZ7(K)LCO0\0X3
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MQ>;R3>^23*O_%#AYVODZ><-JZ@:?XU_;%>,: 1M^_@RW:UHTP'.F&(3A#Q%
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M293@F:C*T63_],"Z#]D3+)CA2DF+".&"!7.7FY@U1AFR!N3&X'Y]@#P</X'
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MG!1!E\  "0TTI) QKP%GHJO*UIXS+/0$ACI='N_Z.YSD.O3OZTL]>%Y]>)^
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M,30P*%Y,0]L#1>MT(_IHON/O)7EA_U2J*[T_)WIG5ELJ'#($2J*I%E(P$3B
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M+I\D7-+>T?>#-TY/DP,HMK,)&XHCW3]%Q?;]2!G7*'X[@9#*=@+8&4X_4R>
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M-PW6#H-^:<(7T" G=S.Y'X3)DK 70GU4S.4&+>W">&KZP^5H\&<Y)-W)AT&
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M>DB60DF#R6P%^VF8/W>AVN=4>DK=W6BD+-XU4[;CNKO1T%:\/K6U1>_S$LF
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M /G($<,"L9$9Q% @2DLJ0TCMUP)8"@VR<+IG"%PQ0=_"Y+O]!<%Q9)!&7/
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ML8"WAG_/'R8[TJ;8\0QG"2BT_PCG#XN=!&(#!RM)@C2&6!8]43)J1;SDP9G
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M,&OD)$JM!75!,YUF*U-ML8@JN>N".RJ0=\)#O(7/SQ,^)THP0Z0&FE0,*:0
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M[^D!6'[R 9;R_6#D_E%8B.G/_Y762<,CDL1;!CA5A=2L*W!&A>%&[H:GK[(
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M/IF<II#Q #Z_1'3P1J7-J90JY(.-T6J.F"12:6RE0\EOJ#!%;@^=]0R5RI=
MI2\7["\4S:?1 (AKD#I'ENHF;[8U>$J1BCPYZF:QWRSV*[38YQ3^]P6!K[L
M% U.2.=HY$Q;K#P(0^DEB$(A%-E'2V^UV>G^-KOD=V?*/[@RF_TF4#J\[)M
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M4J;\<I9]B_K=UG.+^KV4J-^MGJR5174B:?\:ZE>.JB?C7*:Q"!1Q*5F4PK"
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MBL?Y%-?T(F*V$C$'#3,I*[SCFF,O+(M$:FZIC@1+@S'V_LA]B5[LFQ<!\B)
MMA4@QX\AF<"#))PQC",CVJO(G*?.$B]P\)&=IE1YP223%1TS8L32BEM4456/
M<S0YN?FRCRU-SW?E"^(4%M[Q@SL03POR]'0?9BMUL9?G.QE8^J#;W:AH@Z;<
M$FR8B-9B)9$3B@3K=,"K%,A.4**X4)Q=2%[("[##OQ0V\$1$_?F<X_-=^8L$
MVK,$.A>_O5-1:QHY\Q0Q$XD%PSDE:1IIF0BAU&I\WF__8.<K(I?<Z"^BYYFO
M_'A'\Z3:AQ];0)U7<$!:%)3C2'*)6#3$<BLLIL%%#G*+K>HCMJ-6"71Y*.B+
M''ON*W^!4$_(B'LPMN !$M&("';(,^^4"8X':RU)@"GH57T =F3$8=A$PMF+
M!'I9^0N2.C<Y=?P01AI.9YQ70CG"B#3&"V&1=H8&(239,W)BA3Z*SU-N%:(1
MTQ__ .\DTL[>_,/<KN0]3&3J]N],'999?&7RC877,R-\ O+^PPL6)1<..1$8
MQ503K"460L,.H$ IK?48?!.X:KSIMPB<CG0:)GL>X1*7T=QT>_??=O[/I^Y-
M&'5^"5\ZOPYN3/__?-?)[X^ ]6'_T>T8=JS)$"L?>/)^NI/KF1'PX9M?/[[[
M"*S_9AC,/U_#/U.ZNUXPPTSNZ^\Z-V8(=L7E>'!;WW'RRH3D]3*F>U^Z1X43
MYF[2E$HNP!$:IF=)+-AB*U1:5X/79F(K?^A+/NR)R^"T]2;?3'>9OO;J^W>7
M6/WU+VD!DZC=@X^4MVWZ-+?PRJ5-+UV:",_R;<?TOIC[T;SP^^OU</*%6NS6
M1PFE8U/8]DH>YW<GAPXA.';7]0/EL%[QN<MG</K^J[^4'[)>7?-FKQ:?_-^#
M@:7//]B2]&E>K4GJ7H@;D<H.>GY9<SQ\U6T9ILD&W3%<RI57!GQI.M?#),S_
M^/Z7']_^UZOOWX/>^?K7OYBE76R<PC^L?F7^]X7?VHL@TDH$T041-&$]5+%>
M_HO)%>&WV^UQ)2U*FURB]*]A- ;E"RJYD_5YY_UH=)?\&*.U0JW]AM%6&\8>
M+[.WD'.O%E1^+:/6R_KVV\):;0M?V!;?'=WVS'U"+V'R%)-%KV$WP@#Z).[)
MA[P+AZT_3I_8=N]601'.,PJ90)&BDE@MHU:Q]YQZ^6R&7=-O7"\_RG@(^#2!
MOO1ZWI;W_<Y_&"#1\+Z3P.-%9WP=.@GRFOY]IPMG  Y$&XO^]7"8D.\-[-R;
M^]E'/IK[]-+K+V;HW_[KKCN^?]^'@W>77AQ]@'L//UV;?@V2_PTN,1Z][W\,
MP^[ S_?5TE$*@24F3%&MX <%_(&HQECRAZ?((TSQ/_("/MW?5LDYL\.?S_X.
M<_T84L5<O\YP)F]&6=ZDFXTZXT$G_2?<W/8&]P&X"7!R(H$9=];5)J>KO,\$
M^_%N"*"XVK6_I^\O/%]^^'\;#D9--PGA2BK83XF18RPJXUV(F!K*N+=!/#R$
MK=V>XG9[*BDK[REL4N)>;\:A,XB=WQ/[7'4^78=16+7?7P9W/3!&X,T57/Z[
MZ8V__3N\7^UH@HJ 03[$A<?[6[I:T^--A%$!$Z-T8%P[V-EHG;(&1<MY<7+&
M0D'-UKLIRU;>)5G7]*2PE7_J=..<)+@%D[SK>O #;&0ZJ_E=^/FN!S\/J@^_
M3S"Z>]-YW3>]^U$WOYXV^9?7?W__;Z\_O04DU^TGBZX#SP+_PB8/AAT;8'FA
M\V-P^:$Z%%]D490I-UV #;UN^ S4ZXX[7\P(UC&PR>B"&U=D;\"=SQ6YTA;[
M;J;EEVZO!Y?HW(1QQ_3A(J..N1F >0DV_.1)EMFC$[XF>0;OFF3@@3SL-U96
MN NL*]T!/C9]FNKS\\!^'SJ3M]*9HHB]+A.>_7:F!;<&7?M1>X_0<G-*>R^K
M:XM)6SW.E)^VL;W;\Y9HQ5ORF?#6$H)Z0)%, A8_=H?!C0?#N3B%E9)$$@'5
M!!88 66A4O,M1KVA6;POJ@S:3E'HIJ)X_\N[%8HW9X. MO@R&'H0^:^^A\==
MUKG+<+C>MTLPC<WX#@1K>5\OG;EMO-4+8U >V1\'0G5AT^?,[ 5,OIQ87'TQ
M+7MVN?RY_$UX],$PGX"I60A[TYW>J_%^S2_3]R<6!;P"BBQT_E>G>W,+6@2>
M!IZM-S#C*5/XFL"=T M9JP"P&YM_AHY95C49IR2E 1KN+NE,9T;7\+&Q@9L,
M1XDFE1J9F%ZOX6KCI#_CZ4%SQ:R*%-LT]8\9P0T!_!@%9X)C:4QA4@.= I^6
M_-RV#(=>$"Z6.7J4??QI<Y<H-0/CYA8 R%>XT#@ +E@#S5_W>@-GTB,4Z?&V
M0AG-8DH'?Y0'("XB(X[:)%$QHL%1X:@IM'MX]":VQ.*L7,HT!6,)$C60UF *
MJ6"3#.SJT"01?9F/DS4),]Z!HNDMHT$XY*&?H5I-"GBDA ;[G7C7ZUWM4?O)
M5MI/'=:QWO[Q5*O'T\]2N=/6RIVAH*AW/@ADF31>*Q20B3PBI7QD*V<?ORCW
MYZ'<:]5.KTY:N0=%O#;"\$ YLT;K:"D!9N;,(&N,W8-7H^T@0'&!Z(DJ]X!E
M$J>>8,G@OXI@H1BAEI!(=7$,^F,W\<25.SV><M=MM!]#9Z+<&6KU>/@D(G(_
MAAB&PVD\+GM8][A5K?(GV('S)]H_7JO8+"O'9A\+\S*L^BW<CJ<N4C0?=\KY
M&%D @% !!%*%0Y*NZIC?AR%KM\Z7[O@ZNY?[<*L?KKLA=MY^#>YNW/T<.A]B
M[#JX-@B68;#W#\&V"9^MT*+_";=YWX<]Z/H[T_L!M'<=/@$=F?1JU[_OIU?K
MX$ SHF)]P,0QHZQD)HEV0B5!/F*E4@'ALJ G4T%/LJ#?:FEOO[K>7<J&6M+Z
MH]=]_W$ \CB, ;ED:!#Z(<+>O;E/:@0@:^E&2;E,WG@SZ-^-ZI:DG[KC'GQG
M=N?\R4R!*0'J_=]EG(*4PA2@R*]!KZ1$O<[(]!).3_[]VS#,U^H[T#QIZ<"1
MDQC +9 LJ98$Q"[RI_?+')-+S.)$RZP2D$6":8Z#LTP@IKRG0<H8@PV1HT*A
MZ0NK/, JJL J,]2RP =)\*2K)5[R$YW3C!%^DUH-$_3=G#6T8$Y\"Y_U89B@
M3E)=O_UM5"/Z_%W\W9_A-F#7_GZ]!'Y(6H-Q<"&?V36+M;0F$($WH\R?HSO[
MWV!H9#,#W@!P^KD[2D"],PKCM/8D"*L'@3MW7D]$Y%7Z==1Q\$#=VDSY>7C5
M^2E\2?&OC(*3M,WQ4@#&U;8DQ'5?([#IGJ55P&["K6+HYF3'C)/A&^,D[:_F
MMN;009*B.^ Q)F?1%["Q(;J9#^. YFKGX]TPY3)E!@(R@73K^ZQ":X8"+FE$
M3Z?LDWCJ/^YZV?-!+J8QIZ<52IN/'$\ 2'4:<OI+99949F,PPWX.&*\ZRI40
MN$]AX?2UP:R"#MAG *>FGWU$Z>0]?#3C ,S*+Z-O'Z&;FMD*4QV4GB/KH-_2
M$[X)5<)(9>A_Z#?-5.[ V.<,6QP9XRXH[2(17H9(& ##0CCJV2NB):?:^ NL
M^[X3$R)=TDBW%7UFDK?.M@(B_VR&[KI3&\<7G2=VY [(TI^^#.;+4#V6%,N@
M+(L**6&$]#I0+92UI2[]+RR]R-*Q&X&CVS(SFX0P02C6I19/C+=?'N>4'^>
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MN]8Y>J>C?!UZ^;B[ 9 8CKH;W  3F*_5FQ7YTIE>DW@TV;M?0R^E'WT:;,\
MQE-): A.F31B5\$93QG;D2%N.8X/UU$^709HF2Y%$;I@A98I=9E<HBK(]3TE
M]56BH-+UA<R]2%2PP2J6_J=3VRN%@82,:TZC(Z5.QL^!TFU+!S"[X'BYW?[D
MJ%?-6GN3 NJKSH=EG_X!01_L08,5--68"1RC\X1YSHQTCDI-F43>"E?HAT:?
M+@/LTQ-55\6>!>"32D7-0#(XR1D*1FL5M R2>4F#LP5+X DS15L H.B%/FG
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MK1?Q*0QOFHX3*JBV07 +>($19RRE7G-DJ3,>:5IPG"R6EFQ(H,7J/7\W3,@
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MO8E9#>9T?]#LW9QB!<-NZJ()=XLQI'3!JKAN7(X5W83Q]0">+6<!+N. ]IF
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M_1QS'+Y<7FFL)0M*",40,98KI6@P'OZR((M]?^DY1^X+Y5NM(_?[#T&V&M=
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M,87=K [E\JN%?5]X9>GW]BF^NDV*+T,O*;[GD^);3$)83!IM^DX30/D5T %
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MA#JTG!ZXCCI@Y!328F>9$9UO5L+IR0F8P.AY<Z5"_O5Q'2S9*_7IG5PCA=L
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M#G/]C-N%6<;%U3B'JVU^'0S'P-. >\-I$4QNQ\'6(\W59'Y6^?OJW?C@]R.
M/EG8-[;\V42KU"H21ZF.%06#)A)4T]#R5,8ZI&FLUZ"5MV<>';<6D2AI(A&=
M =$9W>9M6,&AO_X8W("Y"^,_!W[)1CJ[@2UJ%NH&%3@L$T$@<V"IJ<7O83.5
MKW2;FVF;K,_%[?NMXN,WL![--M2)C+@#*:(8A_^)%!N-:B4DC5U$.K]=S7U
MX#F[AM%>X3J<&7EWAMGU9W;TXM6"ZA(O*Z;GP<?1\*Z$5-P$K Q$>*C0KM0(
M!A[*6_=((3+8&YD!7(#2<WLU!D8<([L&-S"5 ;(K NP$=#'_EO%T7ID-=UYG
MTVN\_L:.Y' "J*"FDW(TR^0AK\%.F>"UY6]%_>(=<//"8T9@AY4$@=G5,\//
M;Q;H4FJ=3^TB?2[-^V7QHU\296N,K+4Y7Y<T];B.=9B@%,(BS43'H@@M>ZL$
MOKD*!B?A_=43ZKFZ'8963&%[5R21[\2.D#Y;@VJB(#@67J6'8RPUK;Z:CW0^
MLFK]:R'8]KYRVV#/1R! O_HZ?5M@I0C(DRV:X1=<HD_X\N815!&35D2&1-9P
M30!6C6/$<4--2K1<QYJ',"2ZX?R%OV4C5$=/BZNL'5?)MEJF\Y:68XBK)85M
MY8#367Y/QHAK42'WT9?6J8O !%/;-)YNR[:O!7X)RAF8A<5<:)6V$C"%O(0G
M7%8<M254@?[ 63O9C_EG=.=\\!#ST7U!5<U7XKT&/0Q+]:KKBNK"9H6>#).8
MQ0HT%!=R!Q*/QC250C.B'86/UW'5$6VC.AR"09?)'2XGT$D=#FGTFFKC'=KD
M';(S[X2$#$@;^VP&YV9CT@'*,@Q^P%9O@;/&'&!5/N9^QL:'DS[9W(-=8T?"
MV KI2,(BI3E33*8J#@G\9V"O4M-R5%&G=F0!S=C..T( S<(-<!:\7&LHU-1=
M&PCG)=8MF)VE95,QYKC)F_7=02[1:0>/]I:IJCT0!<P.K]O!FIQ9D:4Q^@U4
MW*S!Z%Z:%G-)NZ%Y="M_OZT>Z 7C[,L94W\J-6IY:=_B&Q;:M#4-DIC:E*HH
M-!'C5#I!B.*62$MU*'C4TIJM WKM,<R0,%KE][_6G+Y.XVEC_U8-J$41KJUH
MWZ$#%23T>]1:T8PJ9MK1==FSXT#MR DC26(C&481MXZ*2 M#F6-.)2PU+<DW
M1]".2F==)[6CD&Q6CS"P<$^%E"112I.$@\Q,N&-:I8[&B13"A())<DQ'Y+-0
M2#T@S^#6?KO!5C*PU!NM]OKZBY$I8>[C=%),P.X!KEICP\=,$*HE,U*&/'5&
M 0_(6#,._\6:']-0>'C+_;^F8)E7AGNZ:KAO4^IKW7XE -3X8D->]/KXK/ *
M=?#N#-T)92!MU=;8]25SA\[5+(Q]584L::/&L\Y%:$O]J+]JR^XN0^QUV>9"
ME:T/JM8?Y>4KRT#K8CI&:\)%_4.-S1W^O)I<#U_]?U!+ P04    " !0/G]:
M!=/N?O8V  #VD0$ %@   &5F,C P,SDP,#%?97@Q,"TR,2YH=&WM??MOVTB2
M\.\'W/_0ZYWLV8"LZ&7'3B8!%$=)O)]C&Y8SV<%@<6B1+8L;BM3P84?[UW]5
MU0\V*4J69-FQ]CBXV\@2V5U=7>^JKOYUE(S]=__]7XS].A+<I4_P.?$27[S[
M]:7\5WWYE_U]=N8Y(HB%RY+P-7L?A=R-//=&L(]>P /'XS[KAWZ:>&$0U]AI
MX,A7Z;\/H9..19 P)Q(\@2'2V MN[$$NKRZ&GB]8ZZ#>KC?K!ZWC0^O]DW R
MC;R;4<*:Q\<';)^U&JT#^_7]?;F0EVHEOPY"=\H&-T[HA]';G;\.Z;\=%B=3
M7[S=&89!LC_D8\^?OF;_<^V-1<S.Q1V["L<\^)\WC'Z/O7^+UZS9F"1O6")^
M)/O<]VZ"U\P70_B&1G[-_MJ@_][L*$1&+ CC$7=A$O5AA]%[;W< >XF(# PC
M@0MZS3J3'S.CL0%WOM]$81JX^\6?;%#DD&_8F$<W7K"/D+UF/$U"\U4D)Y'?
M#<+(%3!6$ 9"0^QZMWJ3X:,&SIZ$AE X605G],6=6N4@]%V8LO=CY T\V,9&
MO=7\]67YY,61=M[].HCT<W/>*</*1B#^TKTZ^2SIK?_U\O*L]Z5W?MT]8V>G
MYSUV\9&=7/4^G%ZSL][U=>^*=3]=]>B)QUK;FIL!Z^"1,V+M9HW6\EC@2=Z@
M;[S A7UXS?8[]0-$;HY&U7>K+^-3]ZQW<GUZSJX_]ZZZE[VOUZ<G?1 WYR?U
M9>#[5QHGWG"ZSLR=X\,&NQ3<&261$"#@7!@K0K'WWK]UZS763[T$!%BG\<B
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M*S WS#H%<M*8P*&!EB:XRE$4IC<CUA>31$J5=D-Z<37S&SX>@U_/QF$$Q$3
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MQOT[/HVM0>8%XM4($@**O+,&1M_O/#<9(2B-%SI(OJ^^ S[0@?K6BH%Z&P]
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M^U:05Y!O+>05^U:05Y!O+>05^U:05Y!O+>2_KG+EQ4PS^[+K(ZR%W0\IT]=
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MGGPVH]?,6*<P 0QV#1_8Q97FE*O33Y\!AJ_G'P#F?O=+K\8^=W_KL?>]WCE
M]NFTCV]]4 _@5/W>R=>KT^M3@*M[<HT3-H_;;:96==;]1O 2]->PWAI\_,">
M&U;T\LN14X:5+]W? 2FL?W'V 9^XP.5\P[&O8<3^Q]Z5Q-)9K]^?Q1M-CMA"
M7'0O+\]@T0@I8<C&J$0?PH3 ?[F\/H6E?+RZ^*+&O.K2-X#$[F_=TS,<9(4
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M9,Q6F<4#.TB>&]7#6=MM;\*E>MVDJ><B]-EO .R O<PM7HBG7+M\#AS=.JL
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MJ>%2 Y'+'.A/O[X<A.Z4/HR2L0\?_C]02P,$%     @ 4#Y_6B[5=+@%-
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M7HU]/:+/RIP87X_WH)%2XAP>"5&ND65Y@6=DGOB^["((2U':"ZL01O4EPE7
M=:WRBJ=.%<A6DN=.)%RZ2'L! 02M$'8 ")KY-Y6*:X054>$XS <C650"+FXM
MBQ*O]WJ9!Z* $:[QW[ L. 59X)D (U_7(2RDXW2$/HM-D, "GP6GZLQLOM*
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M^BG\1J]=JU*>L5I*I#"C$:^!3*-(!I=5@P[)>"#B*Y@5AU<HK+%RZ1\3*GQ
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M*X8Q1IA05$U(_'H@_)6I W$1O&V.)G;&R://\@I$-Z$C"T",O":7\,:*IK
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M^VN?]Q =@:9"[X\_A'F\H3^6U2J%/_X_4$L#!!0    ( % ^?UIVM7'>:@,
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M?/!_^UQ^:R[KZ^75U;G]CPWN8OC?&_\!4$L#!!0    ( %$^?UHN=/GH% D
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M-Z#>H?A:BK47VYBD&:ZI6M^8RJU^L]-^M9MXS^'8[T33J+HPM/<ZWL_4VAD
M*^<$RAB58/BECY"I6+ MX=8O>+3X;X7W'-5/L].-"\=SF'D(E]OKAC/<*V4<
M\MQN2;)]3]GGN"J36H=ET7=[#'/[#O%RSF&O._?_^HB^ N30SCU.M<"ZF6+A
MY$\>5J6'3_[+PKC']+][SO%>QG/.NEVUSD[MTUG16+T/_@U02P,$%     @
M43Y_6B>4.>4*!0  +Q0  !4   !E9C(P,#,Y,# Q7V5X,S(M,BYH=&WE6%MO
MVS84?A^P_W#FH&T"V(XD2XXO20#7<;9L71S$#K8]4B1E<Y5(C:*:N+]^AY(5
MNZZW.9D[9*A@(+R(Y_J=[S ZG9LD/O_V&X#3.2>L&.'8"!/S\]/C\N]R\;M&
M ]X)RF7&&1C5@[=:$:8%FW&X%))(*D@,$Q7G1BB9U>%*TO)H\5PHFB=<&J":
M$X,B\DS(V;J0F]MQ)&(.7M!L-=UFX'7;:^>'*EUH,9L;<+O= !K@.5ZP?KS1
M*!TY7GIR&BJV@'!&5:ST6>T@*IX:9&81\[-:I*1I1"01\:(';Z8BX1E<\WNX
M50F1;_I0[&?B(^^!ZZ2F#X8_F :)Q4SV(.81KA22>W#@%$^_5NIGXD,5LM5P
M8V+CK4&J;$X8VK(<U* 0?U;#(!NN'TV=<^MW#_STX3.E$!+Z?J95+EEC<VO=
MXE)D'Q*B9T(VK ,](+E1CTNZ5%*NA4HSCK*DDAP=PZAN^E(9MZZD$/&YB44H
M[Y=.A"IF*''T,!>A,-#RFMYNPBL/=I$^'-U.KRZOAH/IU?@:;NYN)W>#ZRE,
MQ_M7Y7;@KCEI#ILP&0T+=6XK<.K[5S28P.!B?#,=77Q9ARHWNDX;QI<P_6$$
MD\'MV\'U:-(8__IN]!L,AE.[XSG.EM2=GX9ZM;"3=;_GF1'18@E8(1E:VX-6
M.]U68U<2UZ3DU+(,W LS!S/G,) R1_JYY:G2!E0$WY/8OB-A.N>:I!Q9B6:6
MDYIP: ^\/NAXGM,?JB0E<E',W/X1H,Q+I1.L^<9/&!Y="$^Y%HH!1\L87'#*
MDY!K:+EU2T(^D PL<;&5-1-.<RV,0$XADL'H@<Z)G/%5^:/:1&29=0%_]@A#
M4@0TE:/MZP:6'E7V(:O6X4<L>?BE"4,2QX+FQM1A.!<\6J/A<10A5>LZ9E[;
MV-8AS766$^1?HV"%V=<';OND7R#6ND&82BTWK[]<OF+1@)85SA$=$LFSQO@A
MY@L8T"+>%@UUW"=H#9Y*%O!>JGN,RHSWGH820T+L I3'<982BDWBK.;4BGE*
M&*OF@IW5/C*_W:*41T'D!7Z7\FZ;AP$CG9;K=YS6B?=\MK\7S,SMQ'FU"_4#
MC4F6G=4N)C>7[T1FIM:'VAK?KW4R]%"?K\_M"JLL72KV3JP5'VSV*(DKY4:E
M6TKBT#W"7LW^469)[5ME;BO'VH; 3PMX:86>A8>('?L[PA-8;%4-1GD<+]#8
M)(UM'3S6AN9_Y$)S>Q?(+' FRU)V6X<$ZT^#&QRRHT>PK2JIJJ(*<6ZWY?=M
M?7V*GPI3&P'!!;TE'[AL4_4EP(D@C/Q..Z2T&_@G08?PDZX?='W/Y>V.[W>^
M$G!Z+PJ<0B*I)Z1 '/810X1$OA,E!U?()4(C=%/-,PO2NMU&JL6+$C91RZZX
MD2)JLWIQ*GID713(1"':LCZ^E<<%4A4VD$)E5L%ZV7::+P^ZY<UOA>(3WHFH
M1W@KB"QH0\*=@)*0!K1+./;#/:&X5&NOL#%),WRG&NU\\7X>E/UNLQV\V@Z\
MYV#L9Z+IO+H:!#NEMS0+Q6%:\/*_:EI;BV$9J% 9HQ(LQ?0!,A4+MFG(TTT_
MSHX_OUH\!Z#[B+R]=3C]G9ACG^F[)LGF=>5OL[;ADK]?,'WMV9C:[P\O)QU_
M<<DNR/X&V5[8?US^UREZ@I!]!_<PU0+#FF)<5PW51I90JG)I[,<B50;\Z+_L
MFCML_[NO.M[+^*JS&E>CTV/[!:T8+#\3_@E02P,$%     @ 43Y_6E;QV6$"
M&P  *4@! !$   !G86QT+3(P,C0Q,C,Q+GAS9.T]:W/C-I+?K^K^ \]56YNK
M&K_DF4D\E<F6+,L396U+D329W?NR!9.0A T%*@!I6_?K#P )"B3!MV3#%WZR
M3#0:_0+00 .-'__VO':M1T@H\O#GH_.3LR,+8MMS$%Y^/@KH,: V0D=_^^D_
M_^/'_SH^_@(Q),"'CO6PM:Z(!QR"G"6T)M/Q KG0ZGTXN3@Y/_G0N_RH%!\?
M\^K/]!.U5W -+!^0)?3OP1K2#;#AYZ.5[V\^G9XN@0MM'V%_Q1K9P,!'-CVQ
MO?5I[ZSW_KQW<<YH<^$:8O_&(^MKN "!ZW\^^B, +EH@Z!Q9C!E,/SW3&.73
MT]/)T\6)1Y8,R=GYZ3_N;F>"" G+VO3K$!#6<A'^/='&\P-Q92L7I[SX 5 8
M$Y2!CV@ZO[R\/!6E,2A#A I0(TQ]@&VHPCL[#E3@#Z=AH01U($K"46B?++W'
M4U8@.(P!?7+L;S>0ZNE@Q:>\F-?I'9]='._DP@PF67$!Z(.H)$L2#5'BY\''
M16$%9D"6Q4T(8.SYP&?6*CY%'S<;A!=>](5]XQ+])+4PA0M+R/@31_CYB*+U
MQN4"%-]6!"X^'W$S.)9:_M>&P!-&H00AG@L+5,*+3UD5R@Q34':[:UBB ,3.
M8,G8 $/B;2#Q$>-Z9T*G>V/+!FY=ME@5.W"-YLJ!B[I<L2H((Y.9<L%#7:98
M%>@>EA^.9\XXL/B/K]-1^< I*+OV[("/VGWL#+&/_.V(=5:R%E9U9"'G\U$A
M1$R$)&.GOI_.V*!^=F8=6Q*#^A-@QPK160J^'T_32-+X PJ=,?Y)_$[WZZAV
M!%)4,]5UJE=,6J>^7O15*F0_>AIXF'HN<O@$?P5</LW,5A#Z-%12?G&AAIA^
MA(9F3(@P4M%@?#\;WXZN^_/AM775O^W?#X;6[.?A<#[KU%-;/1- (*_#P(%;
MHJLDK,HH<^_"0FO*6OM4I"/AT!5I_+R.QJWO$D3]=V<!52P@%BX=+\8;[I4S
M>C0]-0>N4(&]LBX[F[,_=\-[IKSQC36>#*?]^8@!=*JKJ[K!"N EI",\A0YD
MZY('%S+01SX5LY\3YAI 0G@5S_Z=S8[B[\IS';9B&_X1L*F-+8.0C?QBQ>^M
ME4*SN:AG-H.?^_=?AC-K=&]-A]?#X5W_ZG;(*_PVG,Y'_/=D.KP93J>BYGCP
M=ZM_'_WZ>7Q[/9S._FH-?_TZFO_3^NYZ>#,:C.;=V%'?  %=W;C>4\G0L0,K
M-('W-4V@/_O9NKD=?^M&CES%W0,_('"\N HHPI#2*T 14\@D(0+621W635G?
M_>(AO&1:M"&)G.LV" J5_5'ZWHC:KD=9(^R?L#7+6UBRO7>6:)%_4MM\9\6M
MOA.NNFC8BEKN["'/'F;!>@W(=KR8H25&;%@&;-UDVU[ 5CIX.6&=UV:KN%#U
M%6%+M-S+:CE"S'6JH+9VN"V)O%-DGB(GX9*;]SD^R6[X<!FJ35M2HJ2+K)(D
MFG A+!%U"LE3"+->$D!G^+R!F,HNE/Y8HH;W635$&"R)HE- @8\B?=)[SX=L
ML;KEKNH4NMP=8:M$?QM[*:6 )8KZD%64@M42:*T(+RN+4%L"=Z?!/ W> $1^
M V[ W(T;A &V$7!'F/I$[,A%7:H,J$1S'[.:XQ@M@9+/2#%22\':Z2S7H<BL
M]B+G(?N]1#/?:QP%!<E?K1!-IXH\57P#A("XG\3_E8C]AZS89=5.U(56S\,<
MSL!;\XE9"4?DE)6HX3+'^H^O."9+1=6II8(+P%IF,\2 0+9$5&=VOD$5;#;A
M20# 0UZ0ZN RKD)KA,4&<'Y6[%)PO'QZ"A&G?0KAI*MD"'B:7Z&SH3P;NO4H
MG4 R6P$"0R-(?"G1HF9/@U>W6'U+(.@$G]]YUVOD"W>+]2EF^WPG .+=?D01
M0(E:-)L0"C;1>Q+X.BWE:>E+5#IC8L(VI+>N'6I'5U"B%<VN@\1B2336[>V@
MTT:>-D:8_81S\"S[B/JA1/J:S8:PMB6J=T+/=?[@4EF/QO^5B%NS92"K=J+.
MWZY^H/"/@+$[?(PW.-,?2P2O6?'O,%@"1:> W$EY^\#6WM ."%MZ3Q']_0Y@
ML(31<:N9S\_S+K<[X48S==U:)2K4; TDFK!X&]:ND= =CII1ZG5ZSI](*'(@
MF1/ #V_W^?H_%&4\K^26E^A.L[\0(;,B;):*KE-1-17)"!GK3Q/BV=!AHM7J
M2@]8HC3-;D1::1*OZ&L[S)W^VH5>FX1@M:'8](F\ZD'7D@-ZW[<+Z5K?R5_=
M>9M:T=TY#R;1_!AO5%YD _J8;HF^?Z@>';:^"XGH-%LU3*PJ55]4I,]T<+A4
MDQ4"S)T.V\8I59U6 RW2<87H9*G:FP4].TNH'')359[Z5J1;"5JJP((@7:>E
MAM$Z56>%$(5>54Z,KE2C->)]G89K!6U4O6J^%VDS&:HITV%YL*?37)NHCZK(
M<K BO1;&>DK57#=XU&F]3MQ"U7+V<Y%6U6A%J1)+HAV=SBJ'/1+S9O);X4P9
M@99JJB!0TFGID!<^KJ$/D$M;W_N0>(JL84\7/4J,Z?* =TRL[R(^.V-LN>7)
M;X?Q29W]X3M)CPPEZ^L):]P'HA?9'+ULMSGZSN+$ARX%_Z&PT=G;WK;8-9NG
M#:RM",V+V5JOC:WE;>)VAK8?0YM%X>EKN/$H:F)C.1A>S+S>MS$O2;P54=\9
MUKX,Z];#2Q<]0J=/*6PT5>9@>#'#^MC&L#CQQ[><>BLDO[.L?5F6W%5N8%+I
MJB]F2S^TL:7=-GIG0DVBT@E#:>H2-8I+7]:)2W?*K1F83N@UIVR/H>G+:J'I
M3HU[N 6=4&T-^.(=]HJWGTOMH,W5ZLY 6A]>"!TJ-H#?(O" 7,23.MY!P#7A
M]/VX<L*&]HORL(<A+AL>AG@G74T^L2B,6)(3"_@JGLX2VUKBW^&6B3Q8;SAI
MM([!Z6L>WJXRFS&5[(I1:RGD=I;3VG*83MT;CSP!XHP7UY"@1\;<(Y2]=EO'
MEJKB.KQU9?9B*ED7I]^*&.!@.Q;B4:R;-AOEN1BQ/LM3HXX7_#2 AP5$<MU<
MKT[I.:-4)HQ2FZF84>.=)<D2]\4%82%@9QA-#&/&NABDY[W<))DE1E*Y_@$,
M)AM/T!I,2*+5M\Y[?TFXYS&AG0&U-:#!QUFP@>0:/2('8J="\M5*=M4<[0',
M+1M?*#*W@?7Q+Y:@WI+D6SOZ.SO<MQU.H1\0/,8C)E?J9\.D-2H<P':R(02M
M[80T66Q*VU'5F4/UH^WQYG_TH<^J/*:=Z*K 1690\3#\9=%A^'?JWG_TT9)$
M=%IOH/5)0.P5H% ;&*H,O2>]9[P3K=XE$5ULIXWBQX'/'XOB=WUE&5\F0&>$
MV42+.2H/?T/^*AQH^]BYA@]^M K%R_"4-@U<O]QJ#M+4GDPNXZ%H34[A8&=U
M(0\6PM:."^N)L1'-36(KD7-BQ:S(P^22F<YRF][NV<6LM<43%Z3V%-NC*?5Q
MZM\3NJQS3RAAD;F7B03)G5TUM2O^V\-0/&N@AXBBE16,JS:N UF8?M&OM; =
MR85&%M'=F5E3,_L&T7+E0Z?/5K1@"97XP%<&.?>87"%9(PR5[>MQ"/"%SS[0
MJ6!_^VOD0(:IWQ[0&J;DQ8J82814.#N6[UDQ0ZF]\X@I*^*J,]O&LR[_&DI3
MNTZL7>M AJ7?.]#/J6+_**2N6TJVMA#%4^:GQ)XAL1'EVW=1'_R*'4A$U:NF
M/MN^FCB0[66/*^;:GKJL$ ?:=KS$8U; N8FLM'/W]FVN4TA]@FP_V@J7@;(J
M9EA6]3#F=5YCN;"C,+*?F,;.8)H:S+4:.?G*"*MB*OF5#F0D-3S^ZV0@15#7
MF<>+YJ+/.["Y+[Q5#W;>[C<'?9F=OG!*_,ZHZ^5925BEKJ#(K&IE6KFLDFFE
M4UZ+5"NI$:84KGC$:)YLY;)!LI5.\>T5/V \]:IJ/P1N; ([C54PAHRC4A&U
MQ8FT>IU-U'C'(3$(%)07:5[[?D.IGJL^!-%U]EJIE=3XPCWTI2?/RC3WAAO4
M*S*$&LF9+LN2,Z7##HRFW;*$072W@)M8QX0@'BR\ ;;O$=I?+$2U90PQ9:YQ
MKHG4JKQ'.\G,!TD[B<BR(KJLF# %SA*T=<92/>.7<HDZ"NP-^,L*'DE[CG4J
M%.YL5,L5=EF8*^PX<?E;1B1WA'06T,@"Q%A;7?\YX'O2?C9 J->^H*+3?3W=
M)Y_9266$T)85:C7UYDZI=BN\V_.G4../I\_T$]AL$%YXXE/X 6,O9"#\QCXA
MYB,1W\)@#>D&V##6\P+0AQ./+$\#>KP$8'/*UE7OCRQJK^ :W'JV0!-"4P;^
M_$#<$VV=4^CZ5'XYYE].GJES9)V6TR"04FB?++W'4P>B*C2DP?F/%JV*[!]D
M6Z=EM8K\IPT% 7-9L5V/!+5._%\+(N"SO:I#0 PO?K5H& ,VOM1I>5<A_-FB
M;8KL.BU+</ZC7JM/3T\G A7O.[VSL\MP,,5PR7>:]<VGJ[F$)&H=<SS'Y[WC
M\X_MZ?!KT^ W:3\I3G]#:HE?PHM?[11P<8HP#Z+;L!KCH@K_[UC6X^Q?</8O
MSAM3\?Z4P$5E @0T;_;]\=D/Q^=G]:0>(?D@_G,JZENIP!O^4+E)=:+PV:Q5
MJ8<7SRX"3=MN!X@M['?!EH+'\'GC @S8FE L6:MW 17+<(>D28^(>:;$KR4C
M"1_*A_U73S0JG@8:RK;>5CV.3TXY#HZV=\RZUL5Y/C%E-<7_M.%,:#NU)L((
MG/]HXP1L:[4JP?D/;:LP#'"*9N-435/FX#+;78F[$H_0]40>K(%'Q:[^F'O\
M ^%*1&]JLJ6 _Z\&=;GT/Q]Q@M&GM<?F"D"V(Q^NN?_*&&3^NH_\@+/WA7C!
M1H(B!G)D8>2Z_"S3YR.?M7MD 09-6$?[?+0 +F4?0N -),ASYJ*E<$SV9=$#
M</D(_?G(%B'=?+&((&'FN)?R\.#5=@<R 5OQ5*5(^A >LTH=E9TRO3%W'B_G
MD*S[$=F*)%^F.57X_"0/7NY!].'_6<D[ 1%,'$[&_>62"(=GA#DSS/42!W0/
M(-[2E@R3;$2V>K Q*Y0B(#/Y48XSYO.C!3*,GXA&."'(AE-NA/,G[PZN'R!1
M&"J$"CEB$UPXO7YR/-[E3>-J12"LPI<*]R8X&^,J?"E0;X*K&R\@%=A2P=X&
M7^BQBKI4, /YBF_5])U_!V%B@OCBO,)7,=A+.V [ME(>F ,?BAPP>2M6,]!G
MBPP;WI5<3?'%]GA;>@Z?_2N7%2D<5:V0-DI?%KV,!O/X39U<_Y*GN!(XP[0H
M3PSDN(P3-GKPF  ;Y1?Q>6SN1(H3S^R7ZU[!\$KW1+3+)@-%%@?!GK:/38CE
M1198+R7&&7H^H!@%]C<H1I[M8,2<^$?D!, 5#]OP]4MT07$"$,^-P+Y& JDN
MP=J(7T%X+]^7N:=P0"L,T;]!,ZS?W^ CQ(?LSR'^/X,HQ2+J@**,\/\I1/GD
M'5*0'/N?08Q\G7C(45*@-U&05QX.J*"=9I:=FC(#UYI[\ JREQ0/XGP4-&.D
M*W('MO,G]N]6C*?ASWO$^(%XRC?QZ7C!&%)26V4LJ#$& ^WLC@>.>I<\3I5,
MY77CD6L"GL98O8!XJUQ@U(BE+2H#Y?-+@&'OAWV(IS4F Z4S@QM?4#=?(49U
MV!7^!Q*/=0<8)H&]8K/MG+%+@<BGIMNW;87%0*E<0UL0)_K"15N[V0LV Z74
M#Y8!]9FRW4?8T'":HS!0'K\$[K;7XP<EBG,JUAAP]H/00%GQ&1CB:!*&6*MM
M742O9CT#.>]O"'+5<3*/#6U_:5#90!F$M _%B0N(^]@)/XBM!OXE,T8R'A^1
MK5D+M,9DH'3D?"&X:CBPML!AH$1^ 3@ 9!L[ZK!^SVF.PD!YW, '$G&3-W$R
M!A1V,N)HC.%@TFBU-QT:>V9--T//?!"0&A8%!4)IB<= 0XD=\XNS?:R ]H/.
M9#FEQX>:%M02CX&2N?<>!7%\J[#A7-0<A8'R2&F8D[X'0ZF)QD"Y#%Q :7Q*
M9DSX/AKUK]E <$.\];<5LE=RN @+?3I\WB#";^CL3G&T0**>?7#X0=-7WJ,D
M]DIQONJM<6K7-= @:CI<.D$T1V&@/*IJ53>"-JAKH 2BKBN\!=ZGLP?2E"*S
MNG/E=;?.C)M4-E!]5;9>],9;JYZ!G/.-_U;[XTT1&"B+I,\O3OYJ#I8F2C5!
M1!&]?>T9>BM4 J5MUM9J8PP&JO4W2'G2'O4$0>JLJ0@,*]Q7KF%D#/D^X*H8
M+ZZ9\R@2%ZGKE6R9.AOQ./$2DE<]'A%96&Z .Z?<0,.3PF8]A5^@N@9;.O>N
M^-.8%#E0GDH8N![EQL8'E!&6SXWUEVQYM$Z>A]@3OH3[$3'QNA;+UX*4O[4H
MC^X0#2=L?N6<0CO@[TUSYD7J_?0C<3K!'0B_>8*,3GLO&$L>N?=\QMA\!?QO
M7N Z5X#\YKD!YG<ZY.V6\:*/MY(S16 M\9@GF*P%#)]]R/H-F[P6D@ONG6=?
M'1164,VJ&N,T3V!L2C_[QTV G=M)9@36E!DX^BI4]K%S?O:/ =@@'[AW (/P
M -GM[:"(M_):!G)]!3%<(!L!=_R$(:$KM-FY,>I!PV*X5W!LRL]-PH5'X)WG
MB#QLVJW'?! #5=5?^) 4LI,+82 WT="F4CO"-H& /S@7_AWAZ,G--<]]E5U:
MU:FKCIBO>E.Q+%?$'/(\'GRN%/3+I\;5V38?Q!@N2^YCYK_VKF&W"O#_'\;#
MP]RUV)=55"%0\>V5G:@<.\VP6 9H&F/QDTK0N0Y(N/)GU<4]Z6ALDOZ<NA"M
M4\L8@R[-;:/G*E1=;6'D5#/- .*\__X(LRD74E^>EV"+G^SN6#5P R?I+.%Q
ML+8BHUKX-\&I"%54Y#(#:R"']Q[^-0 N\YB@S$0DGN?3G%$H!C20-^;]L7_0
M(TP_I\CWG5=>0 %V^&YTR$*&XV;5#91#.'_&[' 6>F?GE]EL)<5P!G(VA38_
M$!'[^^-%E"].W(";>WW'$?F-@2MOD8ME>")?1$,,;V8J5A)_I#>0ZAV6UR<3
M:8OSS<AQ"OV X#%;4S[",.4-W>UU:#.15()/.#&OGY&DD&I=DI&J%8P,<E4@
M/GE/NVJ%M\JM.$)3C]^HREOE.)GKI6J%-\MM*A=&]2IOE>-TRHKJ58SD.'??
M1X9U?_/X*B0\^EEEOTA?[X7#^7O1="H51.4:1NJY"O7)!$&5:QC)K[*F"H\*
MW0'R._3CZ*;F7ENU"@:N6A32XVMX-=@MJV,@Q^*%3,ICVM/DL=9T@8D10QYF
MIVB)^0(F6OZ)D3/<E>P'_LHCZ'\3Q_2K5WG9/<Q27N,LU#*_1_K\8A[ 2R_C
M&B==CT\>YLZ(>6?%JM0QL._M+BO6YKA*'7,Y%FY<?2U7JF4@UWECCH@D51B;
M(KBWTI&O/$*\)YY1'CO1EIW<=Q?GHM1=IGOH\WQ?#S[/>,LC_^IVU+V'[<RS
M$P?!_E9$JU@_CUY,P%9DNL](HHSQ[&L>>\?\IQ+I@>3YYH19[%U=QV65'3*U
MBF$.61[A3'-5!_8=J,:[/O@]D_*3^DT?3I'A*D9"():[XAF@^0I@_8LUB63\
M^WS!94^$&!8).)PXHMR*(QSN2A1)YT744XN>U^A#KZDLY>V>5U=495K>]$#W
M4%LN-QY90,8,GZP.TZE>@*8_6\>2[!]*90>GR%"%7?T\LQ%DCB1CP\ZN\K7%
M!B[G^2H'T-6 292_AD3T+R R31&/\9*XG5FWIC%',,J.28=.+3]H1]"#(&CX
MS'M 8D>Y ,@81LM6.%^ R\_.8&FJNCM&!3 FFC/@4\%X<150A)G5L=$)47XU
M</?J/64&>HO8(.7P&QI9_[PY"L,\:QERS3E<I2\V+B(["S:;\ -PBW.BE0 :
M:*VI?14:;:RHNR8: ZU5RU";9),"#\AY9"M88%.^'22W4DHAC;/4N$-Y -/H
MNK:NOR6*C>.BCW$ 7+FCEXJCZ@I-C*7^&K!> (F[S>$CI]Q$5L3I_D2@2.T/
M^AQ'I> &CH7Q78WJO%:O8B"_-XA0/QH&LEEA-84&\C"#MH>=/":TI09R(:]#
M53>\RC4,Y#9O7A6W'FWH7&W%!%64TJ5Z5>-F-^;%;P!RHJ4:]^/%[D04F^I3
M"GTZ\5QD;W6/FS:JG;8!0UXZ9;TS(/R^*]RP#NKG,UT&:"A_46@RTE4^>R5P
MAG+']^28&TRX"2X6R(9\UVVC/=)7#FK@*!7-&CRQD<@K$8ZTX@!?YLAQ*:@Z
M"IF1L&;BL>E]1R=TX%KLC0J*LR=L[P+71QL7,26FLU&TQO1F-JNB?65* PX_
MB7:!,P(I!C-S,SFI1)F!(#3?\*);KL;UP"][NJ""BQ51&<4)9FQ5!5A]79+6
M<E #ARM)=%\Y"S]>W$-_!MQ$LHDRP%=8@59W&96,<TI6/XV#F =HX$#,@Q/0
MH3RMN1PSQ%ZO>G6%GVJ2A0/6^Q+)YQHB,&;8+0F&Y'1'[5,WI: &]MSHBG$X
M1G(5,?Q?-Q[>C;#"G.4R3^@S>T.Y9O67'9Y+MYATV?[]S+Q3"&7:A!-O#?'G
M4:IN(^7#&FBXX1NA9;P50AG(E7C:\ZQW4<)6,9B!?,5/3Y[U>A4WE_)!#>1/
M#;B5A*_*00V+6?$#S;OC+*DCSPG%%<*]](S?]-CSSHN1N3;2)X!S(8QQ:DK/
MR>OFLL2YHQUO\H&;G</.EIC G7M*=I*R:;(5:A.C4A&7N[0U27[E0B#:.T20
M#H#K\AWB-.M9R>T#IVGNR(ZGRL<9JE<Q<#J(YN<R[Z08S$"^(DN;H><,+]DB
M<^G7K=ZR1>;2K]LWRA:92[^X6I]K06JAN3R("ZRY6E +S>6!)ZK(8T$M,Y"#
M<&%7OE(J@3.0,V7]4\9<.:B!_$G[\H)L+DA-F8$<B*<>V:J,]7(O6#+KNO@^
MF^0Q'\9@COJT/X4T</WQHG=V_OT<//?MK&M6"=I +J^C36E.J#BKP)=MX;4.
MU_6>HGA9]OF%FO5,7*^,&33@F:=N/<K6#81L%Q[AMU7"=TL%,_^$(/&X1N4J
MZFICR3^][F+C!CJ,<K>/G9D/?*B_EQ$N(?*Y;X/$,'FHD;;45:/PXC)?E/-'
MLV7F=_&0T-R+XABI%S+W@LW(,%_C&U]S2-9LW<Y_[N,"60*=>2'#@8LPLH$[
M)TCT#]DUXL3<-H)4=VR_7CW#-D'%12>&8\!'>U< AT]MA5?X4@G*"R'-4ZG<
M6MH-^?P5%UUD.P.A,F/$"<<;MO*:LG\S>DD7F*<&>>,J%O(,+K5'VLH 7]GW
M^O&4L4;M%5R#G_X/4$L#!!0    ( %$^?UK[Q3*B6PT  #>O   5    9V%L
M="TR,#(T,3(S,5]C86PN>&UL[5U9<]LX$G[?JOT/6L^SK-A.9BNI>*84'UG7
M>FV5D^SQ- 63D(T=DM" D&WMKU^ !"4>."G*@#+SXD-J-/KXNM$X"'[\^25-
M1D^0Y AGIP='AV\.1C"+<(RRA].#93X&>830P<\__?E/'_\R'G^&&22 PGAT
MOQI](AC$!,4/<#2[NYVC!(Z.WQV>'!X=OCM^_V/MZ_&8-T]0]NL'_N,>Y'#$
MNLWR#R\Y.CUXI'3Q83)Y?GX^?#XYQ.1A<OSFS='DW_^X_A(]PA2,4993D$7P
M8,3H/^3%A]<X K20N=;\Y9XD%8.3R;HO)07_;UR1C?E'XZ/C\<G1X4L>'P@1
M^=<6G53D+QUZH=/1^_?O)\6W:U+&"&E8K]5FUAN-2OL!$A&<P#LX'XD_O]U=
ME3QRQJ3&X/AD(B@F^3)-"V.-$84IZ[Y@15<+>'J0HW21P.JS1P+G&VXMD1C'
M""31,BEY'1T6=OJAS7U2$[>2M2$HX_P $AA1E-%'!J<%7%(4Y8<13B>%O%<,
M@"G\"EY@/B,H!61U"2**23Z=SXMF#VN*.P;&_!Q2@)+<K!CKEC(W'[\].BZ=
M_$/OK@;5\@RG"YS!C.:W\QM(S^$<$@)C]MTTSR$=2$'K7K;7C765(IKROJ99
M?(8S;DF65]#:@F<,2<=]%+)F_1I:[$:!(62?1A%9POCB90&S?"MY59RVEW%&
M\ (2NF)FN/AMB1;<)EL(JF4W!!JR'"<HYL/?%\I^IF4HG8'\\3+!SSW!8&2Z
M.\EO%WPP9YE[4-'K7(>5_1-(^'CXY1&R;+6MR"UF=4EKH]PU^[_1$7RA,(MA
M7'7%A=Q:E:+OJO<$1XT>$U[I8"(?HHOA>0[R^V*,9O7: P +/E:_G<"$YM4G
MA1D*$X@/?KE&X!XEB+*LP^+E"\71KX\XB5DAR&.'KJKN$G /D],#6W***+>'
MF7SB5V>U>FI-O M]MF3C=4;5LK<(NBJL"7QH<HZ>4,R")Y^!%;A/H%P= Y70
M24G55*P6R5/2U)$5QQ5/42?W*Z/G!*=:)V!;G6K"?AAU&8XH'BD98<*"Z_3@
MA,_?GB%Z>*1B,N?#T:)B,"+72"<,HZ$+TMVV>EDX7,-*N/PX%)?C)1O^M:&M
M)]HX6TH4JJ?-&MFY6<I'^/@H"!^?0X*>F!I/T!C9-J15)M>2!NEU!^UL<KJ6
MFT# NR$0T"V(^2>_L+KTB<V;$ />#:908)#5;2+Y7&44$IC3&TAOY^?PGIZC
MO(#K'4QX+3L#;-(EQ\$N6 O+#LLZ2)SMT'H6N!RV=X'CMP8<^[!\W>2] YI;
M3!._863P6SXQK4EY@[-(&K=F0F$.'6%8GK562>=A'1-+A'O/U$SF'2;K+O<A
M\W6=>UCPVJWQ=)@<O&<!Y!^#2%G2ZDB9MRRI=:5GN!G,33D=9(R<! 3^NL-<
M]@D3@I]1]M!%ZK<LYEDV@[?S,P)C9(2N' P[[$'8>"<]A 6ZW1M1!]2=]&XY
MI?)A>?W:.M8M5*O,*&79JE8#*U._PG2!"2"K4M@S0,B*8R#E7IU22M#]DO)!
M[BMFSNT&?N_VPI0]VN\!=+:UBC/ >G08U#*V<5/,N T6RL;7'=\%SV!\ 4C&
M/)"S5+I,ET5V/(=S%*%V!-DW$)K:-/ 4(_JH<-:T$09RX-OP'')=;VM\S(@X
M"U3H\T^0+&$+$!H*81<I19 N-^MBX6,ID["V9&)6%#$-0#(#B)5-9V"!*$C:
M>S)ZJFI31D45I(/M=+)PLI+1*ZSU\/HV1P\9SQJB7V5T6M$*M0VT03K413\+
MMQK8!54+\].".%-Z7O7U>M&M_760_C5H8>'2+@?+4C+(4MU86#K7XC*.0R:Q
M07"N.!4K@;R!LH9^)>4>P,!>4V<\:%F'5<849]/;54OCPZI($1]ZVUDK!=!O
MJJEHZOMI71I/8&V9&=OIT !C2;O>.^LV#6K*7XJG.+TD^ZX!/:^G*_F)<1[*
M[!</\R>0%,%-JV47:?7@TJ9*JG9MO")6=I:BAZH2(-?/1]AQ#*J:9+/6!9O)
MB&<YF/2UH)2CWJ'%9B' W"(T>+BKJ0>'%3_+<=9CNG<T0#%GENH8"OS+)X1F
M"<AH_3&A&]C%O9ET#7@=:3"^=-!(X5H]!P.:/T[:!KAF_[_N4S>*QY0\()%9
MK'PR\QKG^?0)H*3<"*G-8T7-_@GD*&J!LV=KX5WGUOZ7I-?//:PS:?S?95[.
M7[0KU38-I0O8^H:>@KJOWSN+W@YF:>0"1P&Z"^7ZCF4K$F-OHT5#65T$ZN++
MD^@XPV5^JQY@%Y5(6PT37:62FLZ'>E?9$RQ!4PI3G0EI:6<B$\JIR7R%N=$K
MV%JY9OBJ&/- 53,,:CVH$DM(7E>IXWXCY1H!&LJP06"KH@L.-#QEJS7^,O3F
M'.-5EE.R+(:1&TS/U]L[T_QO,'XHU%P3? 8HXZFY6_0/QJ]SP+0WOY#1-[2Y
M[#$Z0,^6$U,_M5W=RK9CM+I0XQ;3< DJO=\VA9247AJ*:A%=1N%5F>KR%)4J
M[>_;BFR^]W-\+(<,PGRU\QP^P007DWYY16E%NSXTIJ7U%(AJIV W]1H!V>%:
M'A33<@MJ[:R\^BWA!['C%&6(9=4B <MA8$DM+&6D#A$*;BJ:P6#D%]IRL2X1
M8W-RDUND.6I)>,B"0E:!^A^XS0.5?LB6M@^Z;'%;DM*MH6R[ZM3B/60F59S7
MNP2(%%M^FQ6MV_F_ "&@LZ=F0RKLH"?=/Y\[J+XM!/1=F2:RH6U7;"Z$\W2V
MH+7/S4H72E!4G* L]L&;']0H9VRNAF/F/0)!#L]A^?OB)4J6<9'9HT>0/4!^
MO>9%<>FFY)#"ZW=>.^WPFIU[6N?F@L\(YFOS\:?5MYP_9G>),I!%_($=AM8G
MV:UI[@TW*^36#3WM$T<0QODE2W<LN&%>/6/8W236TVUVB%5T_E*XJ^NPO;[M
MU&W9E=AC5G41V",S&SG%H'+Q DF$NK-\&U()4+JD>XL5@]8#P:7;B^5-!J]F
M24]#&=XB53=\\[KRBSK>6NZ@UC$5@J_G=*Z#JJ:A?E"5-O1A$5T]WC:"%:W%
M%"FXI*ESHV%ZU"=K2KHS38T4QS#\/87]" ADDSJ63W#*%X$*C5MXT1-53V,K
MB/8*(5::;@$-%?^@DFM[$+G*6A=H;JX+4=_YO!V3]<F!?DSV"G.#6&H+3/;M
M/ZB+K,HGB/^.LEAQ6DE-4$T.) 1[A2.CAEM@1,9[R%NLPCQ-&+C#75;X'7R]
MP\7]'0Q-XE&0ZG4[TD="C$.3"Q/ET&3'9*\0-HBE!AV:[/H7F'T?QCFZM7+7
M7(<[+L[MG.E=2#M-,:'H?X5YY)O]?9NW3[E8-]\KB&YIG2W Z=YS4$NLW=BJ
MAG91]G4/<+HT4:9)69.]0EP/*PR: F6]A78=1W!+L>8%OC"78J5R!U62*00O
MGW?HL12K::A?BI4V_ /_ME8-$_]2N0W9SM?A$MT;$G^7CV-[UO,SZ:X%V!&;
M=!7$GI*+E;=TCZ3+=&V$OZX'[:/J@K,(T#=!#%"-^T$7!$:HT)+]G<#"65E<
MK]:5NK60-#3;S0NZ!F(;.#IW9#\G' \G@^G<M*\Q2?%ZX=_3:PM?53T&D3G,
M<\1O-;V$!AT-Q$U%E<2^KD Q^@D[*MJ\%T7%OO;>1B7;5SB0+D20/V-TAG.Z
MOH-!"P'W]DU4N+3? Z#T-H<S=EQZ"NK$QD6Z2/ *0O'^#6,^M:87EK2@#QE(
MKNK: \>"<U#'.)KKTY6XBE=)VA%+MQ2ZQ"'CPTE1>W"8V :Z9*&YJ-9CJ7C-
M!G4(%2:=@54A[WGGODW79M4+W*V;>7E!O:5T_V&CV==GW-,DK=:.EEFW]G7K
MLZOC\;:6:=X(;<FJ>"V4:[?!WOMG2AQGK./C/[*'W^RAD,MN\+<;]?<JZNTT
M[1W=2O9![=AI-?J6Q>(%?WS5*&*DY1O%7*+%Q,,F=-0\]@AN0UAI-T.-NG/#
MVKVO :<\DO@5O+"R&Z<+G)4/;M] 6IT%8]^5Y[\\5JX=662WH*E)UA>;R4C\
M7 '7DH0_UU(&6Y+@9Y!%[6'4H85*6UD+3T&O=1;NHVTCG&7LRPO8+-C:7M7B
M"2FRW5<]D0H/TMU63UJQ/\H'IHOW$,PQ>08D-JJI;Z726]4JE%AH.D\6#59Z
MZR.BZ$0:$RKF0=5:':DWXS'3RPE$YI8J(.E:[@^8K/7O"RA=!T&=:.A*SFLF
M(W[J1$JHE$1[A J)5KT!4/(*[28XYR+$>+['NNZP.\\3P)Q@1E *R.H21"S<
M\FEQK'!]MQNCX(<-?4X,RH..Q8VZ-8G*=;,E$[3VOHS6]IUSPVH?SZ&AEWU,
MJ7QW,,)9Q*:H95S12QCS:QOY75U+)L.J06QEJEX<M39TY.@I:_0 #MZ%#1N)
MQUZH8L=U"&&"&KEM-+K!/!TN&=E]HKC_=5LV#O"6L_GN,&UAK1T#62Y!4"<*
M;-0H;E6<9O$UDR"I#= ]$&QBY8!B-:OO#LF65MLQFM52!#4]MU'%\$:L;5@X
M(#B8MV3M#KDNK\H:'K%V[\L*&JEGQ7-55YG[JOV.N#O@VXG[=P?]_K;=<50X
M"6:X$4BY3""^X#_N00Y_^C]02P,$%     @ 43Y_6L1Q>SOD70  ;'H& !4
M  !G86QT+3(P,C0Q,C,Q7V1E9BYX;6SM?5EW(S>RYON<,__!XWFVRU7NS7UN
MSQQJ\U5?E:B15/:=>?')(D$IVV1"SD4EWE\_0"YD+H$=2"!9^=#M$C,0B$!\
M  ) (/!O__MMM_WF%:59C)-_?/O^^Q^^_08E*[R.DZ=_?%MDWT79*HZ__=__
MZ[__MW_[']]]]S-*4!KE:/W-Y_TW9RF.UFF\?D+?W-TO-_$6??/AS]__^/W[
M[__\X:>_M#Y_]QTMOHV3W_]._^]SE*%O2+5)]O>W+/['M\]Y_O+W=^^^?/GR
M_9<?O\?IT[L//_SP_MU_?KQY6#VC7?1=G&1YE*S0M]\0^K]GY8\W>!7EI<RM
MXF^?TVW#X,=WA[J8%/2O[QJR[^A/W[W_\-V/[[]_R];?UB+2SQ*5-.1O _I:
MI_<__?33N_+K@90PBCFL6VJ7]/G[ W&;\,_E7^O\6]+(WWQ3-7.*M^@>;;ZA
M__UT?WTHMXFRSV4Y8MFG*'IY1PG>(;3>O;M\RU&2Q9^WZ#(I=M3*I'5OXBS/
M2/TETWS_@O[Q;1;O7K:H^>TY19N*>]:(-:CCPP\?_O0.;?.,_D(KS+ZC/]%&
M_I^TZF^_>2<A^E.T1:L\3O)G(ML+*O)XE7V_PKM*A8?B<X;^*%"27[Z2_[M
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M[MZ\O3#7,HG%8)" /O;#6^N/+HW5NN0AUVDY<LOTP&[Q)E:OW"K/W_^=)I%
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MY>8B3M&*<,S((!:GNR@!#Y_DB.O6$1%[6@QP^C-6U)!E_^.QDHB=[][>73H
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MA9?WHKL76__F[]B^>4:YEK3MX@^<#2GB8](@+G&HME524O*J)9]CC8&? L-
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MM]LKG-)"MJQ@5+FIQ30K]Q5:90_IV+/%.M.JL5J'=$HCJN,F:-"=%K\BNJF
MUHM7,F$\H4XZ4<:N=QC".._C<L+,?=ZV1:<T!LBIY]O;;]R^19.-HI4*\A&E
MNU[_EB6O[24F/XD^HM@J]E$L%L!P7WCTN:>E *\CC3;]*,KC? :2EN<D.E@
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MZ3TGI:>83CBEAE+S^$EIZS@I2W.QX").R>B$TWZ'9'ZO&P7X?GHP$36"8V0
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M%:X31Z1V ]K$KHH0#<J];80REK7G19JBP3Z5'#%_ ^% /#6H"=2ULYUPX-T
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MD=6IL(ZBH$F/4Z$40\.>*3#SXW.*BZ?G#S_\^%>N<9ET/9,"=.$:4J24I/D
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M")?5(%+ZW%UL<X0;8$\(A_]>/:Z.; 1 B7U-3%1J,F" CT36<P0TPT?G^]L
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MA3Y[5%'DARJ71;&5TZ0KQ:-((V6;'EWOUJFQ,Z]%BUJK1XF4_AHP#WHU*>(
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M?:2G6URB0;)QOD#](5@"AB3A^U3JK*$R7HDZ:TSS(CXP%*('X@4LJG^&<XI
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M9/5=I5]<2#K&U*SO/K%UY&L$V[&T4HRIRN9U0N=XRDX3(=.G+%VFBQ@79;%
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M$=CB%N9TF#Y?H^U@+&S59K.@8\>FZ72VS3>STO6P52+AC+<5'U'U7QSG*SU
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MU]X[F496*R41Q4X+#J*?XQ5<E+@;<[]((5$&5U>G?D.B150B%[CHAC5SN^W
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MMIKCNLCA[UO<O7YEQFD-C?JS*&D8TD:C5*8D4G,EHI2*A:CU#.P>!M)$Z&
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MLQ^=/<WMD913K<D;-SXO>_.5=N_Q88(\[ASO%+[#_$ =9L& 6C).T.":L5H
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MC1^+^:QY?<P8M])R/H=R0XQNQX^:D PK2C/Z++KWQ11=\X5T3>LDLS-#+E6
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MB"WH]"C1_O1=*U P5"9@ A-O^/^ZQ$F4QN27)-OB9;R.\4H8Q8W2E:^OH'-
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M2A$&>C#_0_"_!CDF8$6^/+&W3!7P^P?EDRWS75!*_7KGD'-GT$;ERU&;9^"
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MM0CJRI>*+O*'HD]Q^G2U$N.H^ZR+I.J9.Y:Z6@#05 L<P5-)5R.*_8VN+H(
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MS!QJ)H4Q] 1[Q)2O47F@Q!9-LA&9$@7K4JTQI#T6&X,(?!P>O*./4;BMQ 9
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MV#_LZ(0'\3%'8Y&#PXV6C9K-/F /]ELWP8]EM _Q<P$'>5XI$,L9.:(_D^D
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MBE*RJL,H":L' Q5JFBJ04BDWM5:YK%8J)\$OW="I+J4E,MS@,C=60!LQYE$
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MC$+L=;Q<\.0J>"I&\P[DS%? ;BL>O"-.R;BP-R><#?]HW3(26W)[[N# N14
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MBMM,(O2B6A#T7?850/!*M/J5?9GLV6VYPQ>-\6&W2<W;7,W*?A&E.!3CZ16
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M,OT>#/VMF/3H:'FD'F)#03<11/BL@O2BK>'@'F8KJC?ETC2F8]!XB <9;41
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M@!C7R]<HVX#B-L-)M, 6SS1;;TUWE\W48&"2F=]MVER%K$4*98:)<WW+%HN
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M^7V8^R(<1(B44H0#A5V047B,-VJIN)"BY;\"' Y>5)15Q(Z =9!QUOVW::D
MXA,Q7@$.!S)2ZBEBA<4SR/2Y/26OX!;IU@]<X-&0L 4ZC?\(D5%.$2 ,EH9S
MY;HP9G<1 =5FY PK5CSKW$E<7D'.ZXXZ7:91432+5=[*AD777]4,Z9Q,6UM2
M4%T'FX!,7"D$3AH*Y#AWE,0238*2-!:/TEEGYC0)5-&NVYV'7*LNS>-FN$.[
M\(?,W@HEH,_PAWV>U=*&PNL,S,<>3@1N4'HH&?()<DEXU.<.33QOT8_,\6-
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M&"S?%802&\\FH*KB+O*]*\=]M*6'NXO(J%JUR0S.5G9YDK8Z\0-RF4E1P/R
MNS,U8%2E"!D6I(HX3'8A: ^HI74_"0:]DFJ8D&+N[,R.]88\V)65:&KX42UV
MS(TB6\R<AC=)7I27*5IY9!MZ\#23@ 1-4PC<G7:I6AY*:-@[W9*LH@J7IK#V
MZ*;&$UC!+.:U/H?BE-!G2!%4^XMUU < E7>XYYDRPXBF\Y,?2N0K<':WA='?
MKL!*8S11+'6<6DF6\AI,>KK+8TF:?^ O*G+6%U!ZMLXS*[FTPF85[DT5WD)S
M8#WA'10*MZ'A KY=TMX8><ZCK(A66/'BXM#^0ED#JQ=L[*M2T+5%J*ME-@%%
M0^-7OXN\;&F!?CMI@'[Y[0)&>;Q<7R4Y6"&.Q>4KSG<49=2Q2HZXT4I$[*S#
M<]H#*NK8[?M#QKCKBQB&ZSDUNC24Z YLH_(KP<:F,0_7P(*A2=NE2@U9*MS]
M"181N+OCP>S3"F11GD#*2,6E(>MB.LUD:C2U_IP5.[!*U@F(J4./D.Z8C(9)
M-[5*-Q#YR:B@9Y/@$_64Z1,Y#-(6M0*45*T?B<W@6T<!T_F%ZPWY_1+*H[UG
M11K;M@4I[,(UHF!(D?%]4J,'@Y'A+!(N3L7N&-?H!534,[&[41?FF1EZA$?:
MK+>@U4L>\_8HE'3?AC?1"BRV.-,@MQ&'9-16;).Y>_59H^T&VQM,A;M]7J&N
MX>9'NXX@MT"P.K4%<#A^8PL0M[9W*NT^4:"E4JP%-;EB(4)/PR"CH2A7IS]+
M&FTO]R4JZ]<ID"FX?HY&2/5T7<(0 2>EM$%OUZW%Q?2',4NXW^/U ,X@CY;V
MS1%F#R0\DL92=)+0@"&AZ"A(T/G[%OA-I.P>D177;TD,LA6(+PZ5_(M-#@ E
M48MN\1Z2Y(N'BC)- QE!H'S=SF+"%='Y#E;[\A3Z*P!CCUJ O2/UN4"-KKX5
M9!VK&A$G[CQ31WLD;]GE-(-\R),5H,WTE<I1YUK<<J$!4M<D!F=BW$H;D/XU
MX-G^;8;Z"RC*1V2+:O<M?@#Y"AMOPY_]RQ2D(I1?,&R(*AC%($;YM38@_=N9
M@/1ZO<87<]Z !DXY9850I98]'[2*36,)L-2*&\S^/;S1GZC6))?!>O?@R:$@
M#][1*$*#FEC-48"BLF]@\Z,OJX__M4=B@SP]M '?@P.7IK$4@R8T2,BH.@H4
MC K(IJPW5X@66;:/4@XHV 3D:AF%(#0X")4<A04:=P*$ !^VH#X#=P^S%?7B
MNB0U[U&]-G5HR%)3?^3$1E 5P5R F6Q.NK5N@".C7($BV638'(OBWT&\2;)-
MB^"G*,GN8%$,$Q ;XS? K3:_<)%MQH2&L*\M#.D=*L<9WN3>;J>#/:;LR395
MMI3^@"Y!2H9V+FEH@%50?-QPSZV'P$SC7,+A)DAOC5-EW^$O)CLD]-5D0Q(:
MCB04-;F>;/@3W 1X#/%4PM7OMT6Q!_'5/L=/XR)O#>.G5]0RQ6DK>[EN&>H)
MK'#8P?!I9C/,CE'PXYB%!EVCQAL%\K&2D.Z@<>"!V+U IQWB$>RB0S4#6:XI
MVW*LS\?;=OW/H<%0H. H8 UY$ZB8.G9P%NQ^1WMU0#_DF1<&?]=^>D"I"ALY
M<ORY7B 7(Z]QH_IN\)Z 1EB57W"E)OD39T7C&:]@'^2<RXL -U&2_Q*E>]#*
MO-HV0%& *@%F:X_G"XB*/5)S41X+.TSY=Y(A*58IQ)*Q\O[)D)(T3EQ2)^_[
M$HEX3;+,'O&D!4]P$,$]S'+RZT54) 4M;Z!QOGT+CN?KU-P7AT;8ZBY&#O[8
M@VQ%2]B@4*)O(EX)I\K3Q*)>G%4HT5>>5\(7Y8LC3.E9X12*<-0?%G$VM*JT
M)]0R0'?<E:BORB G54^XMTU5? C#[/Q>Q[ ZNSJ6U0?5G('1C8V 4&<T8#3-
M6*$Z#<@3)M"[A<.#F,>D^)V:5%A,RCE>.Y&ZU1.MCJM9:/O9>X:>;-*!GC12
MHS>L\=,/K?BW*@$N,\>?-/WI-K6(WN$B5:(YH+K._74KNY9F3T7$W;=LPT.1
MCZDN%8##*<,$#[5,@  2ZSX61-0:?,LS.A2;Y+E4P!&["!-&M"(!HDBH^5@0
MT2H(/L&HQ%P#*HW5+"L/*^@&J- 8SW-U0&\%X<S0XB2=+T60Z15:ZX[CC_^>
M@!RU\^OA#K^RQ-]'DR@TW$KC%O)F0VDHI?2^FK L;XN)7=:I:6ZSW;XLJH;Z
M]!EUDQ_X^VP"\KX!F.3>Z"ROKKRFSN<<TLT%571EN&!&'9WM#QKO(+<]:!I]
MEL;09VD,?0X>0W1=S6#H\_@5CV<8DG>[\AZ7X6P#PA!=5S,8^F'\BL>;.;G2
M'(7E\]G#N?C$B%DK<Q3HU'8&RR*Y.3/KQ$YR8LD\1.+4S3R]8]=Y!LUAZ41)
M?ETTS:$25YX@4]B:L-0=(_&M%=X&HV[N1B79-6?Z>U!66AP?"Q>%=0D+](W$
M*>#D5E759I30LY["0CIRGXI-Y]XUBAL+RFO*<'/,.JI[4VS>SH["QG<>$L/9
MZO9B0"F6.CYU*5DJ$+#I64$'>M(U.3M*FV_M3P"X,9?UY8 F>T=?8W+&N]84
MV%1[.)F"&K,*\U/MN_:M&!EYYA43?<5D8:(]Q<+*C-CAWN^1NJ]AJ)W%5X-X
MTIAJM@]RJ^@_P0$9:;_=50^DS9>'@MC.P.4KH#R#U6N6_+$'UNX3B:HRN-G!
MKLI%.[4V1JM=:ART0PF1$)$U]F&3^:(;->9!3,C1SV4T0U^>*KM E3&9>JPF
M2\[0=DCN;*"6:#&HK&]W]&57@<=>,>L@C_G[:O7R<$NABEN& 2U&F<#P):/Y
M&) Q^ <9#-#7#2<#6I4@?@;Y5@IF[ (,C-$*! 8PH<YCT$5C'N116E\Q'--Z
MDP/03E J!3%Q00;4> 4#@YRT#<9 CU>)X=T$-Q#$ZS+\;)TT]-@%&)"C%0@,
M:D*=QT",QES_!26/H%5-!7Z!*;(*WIN50A>W# -@C#*!84Q&\S$P8_#7?V+)
M(Z21"<)54CU*%DL[,W%!P92-5C PX$G;P,04CE:)X0>4'!N\'UTHO84C-B\)
M'N2Q_-CG7L+=4D:#3!(NR!*.U:1S+@IFL,.<BV+.1>'J$OB<BV+.13'GHIAS
M4<RY*.9<%',NBFGG[D[34_#F[^><L<*LR>XL7@62J<YNP,R=VPM#0XF0W/4N
M,RA6>5)%F3&BNK3*-M94+.M'%/ZAO^AFKMB$)9C1^)02SIRT7@-3@_-%AN@Z
M7Z6*Z;'ZE K#O9G42Y\/\NT >2P"Z@O5-4&(N!*H.1I&0_Z&A^+PYUC# 1*.
M&PLFF7C=M>^#*$H[3[-%T^R)YV+33M7M*W<&^4LFN&8B&=D^_<T3MF#G?AGE
M$:;I#<R_1GF,G_ :3,+FZRE!K+KGMVWF@\KYH'(^J)P/*N>#ROF@<CZHG \J
MYX/*^:!R3IH?7!CAG'K0?>I!ON25J#]G\*4 ^1M&8GUK"JQ@MD*E*IQ?1NEJ
MGU8_MC886,UAN[Y^$]FKSX]3S@^5:\PZ>$RE*K,EJ$JF,XVQ8(=8P_BIC/+2
M96;'HWN-_WM?E'B@6ZY_C?(\RDJVF^?0#MPVE?9CP%O%8 [ +1!OSA)94?_V
M>?;=&KY[8#:/O;?&TK;VWM=9['IY:S]3Y42SR*D27=I39U[*SWDR67DR0PZ2
MFO-D!A::\%3"U>^O,$5J%-=_[)/R<%L4^RA;@>7Z$FZW,*LH'(8@U%(Q@@[H
M'QM4]#^ZF%\^K5Y!O$^1-2L[7APNTZB@A@I(4#9Z<2F=*(EP6<4(5X(T8E'.
M\H5T1$$VG0OUVE)0S^[9!.24B4+@I*'05!3YP@?BJ2J!J$=I$I2DL7B4SD8D
M3I- %>VZ(\N0*QY/N-Q<G  P3E1K.2^6&:@3!Y8)\AC26% HUT&&5#FO<:*N
MN3QJI'C[=C3?B/[\%6H!2;Y<%T@RY?P&DK+F"D"2X6WC?-X$D!"1GD]2*=D#
MDU1)S^&DKKT*H*2XZZ=C=+WU6ZMY*0TV+F4'7 Q*K\$DHYT\>!C<#"=8G-"$
MXJ4+E%@'= W(Y%D%7%%XA;MK*+.XA?(+Q)X=V<PK1+*9!AF><]2GWM^XA-L=
MS/ ]$MZ*FT?;7W73:5VHVI.$NOCFTG1V@@8T3C833IMJC!A6QO=CP.K@N[->
MS3<]%"O3[<=4=G7PZ8!-P*Y0JDM".6 S!A0::VQ(!LN C:DXKDBX0;VQA<XX
MR PT..1XN5[@V(Y-I1ME7.'2-(9DT#AYU_@D1%&?YD2GOSRCGXIHA=N[H+ID
MS=+D#635TN:6U\]?X?,KW!=1%C]_1;4=OD3Y[Z!<;-#"#M=.U5:M$&EKR4+.
M'(5N&T)-@W2]B&+MV+/(UNK;_:^6W$_@#0D*0*8(.[ER0^2)R@4./B6SF,2?
MJ&(;V],3M@Y_+(-C_7^W):B558_!JU9R]I,VF3F&TF2-P3#(-XW:>QEWC+LV
M7!K*R?2=V[LOPU 4?+60$?@A1WS<V> 3.]X'J-X*+!;[\A7FR3]!_XZ.!.5P
M;V!(Z7#!*]544$73_KJ75T-O!V'(V:,C^I^S&!3))D.KRO@RVB5EE,I 1+58
M8T7Y8@& 1],&JDB2KR;<2Q'=PQL!]N2(&VN+B / F9*^JN@2,??M '^Q08N!
M#>H+RS62)<DVU7M7_?T3+A'9)F$0!8 (*?U4D<!BZNR\G9FF8[M-"OP&+7Y<
MBC)U&7YLS5;:'P-H::X^.G.2-C/]PW'7X\5@=H5CR,7SV"X5:PY+J *!AUC#
MT7-7PE7_$4$O]EWXRU.HN,9CQZ;<M>]VB7C:V$[U;VM%9F= :6N%P=#P6[V3
M'VW3.KG\/0W:Z7:[8W,YG>'-HCHT[--G9DSA?,MHOF4TWS*:;QG-MXP<WS*:
M VN#,=\<6,OW6T5>MGP6^NWDK] OOSWBLT#*(#+X>V.@UM\G%9'J/BE?VF*.
M""C2$O1+DB7;_9;^!#SM&WGEO?O-65^BF1/R1>_VEQ:#ZG7I;L%PG<RP,T >
M^"A&(<ZW4RA<@TAZ79834?*R+2;^A),*/,%Q9'A:@2S*$\B;IM-H^E/T+LUD
M:C2U_IP5.[!*U@F(J3-S(=UQ2<6D,[<A?Y6\)3%:M#]$A[;EEAE]#)$E)QG-
MA.0..Z6H%:"RNOV>RJBARB FY*SO[]Y _@(M'-XP9'[^"E6P,B#G8Z5%'B16
M6.J.QTJ+L[ZKYV'%Q;J.ZMZAO--D+.W:;.O-5":[LY]GR RE>BN[+L,Y4G*.
ME'0=C41<)SXS?P#Y"F-ZT]_E5BE"C4QB%0G@$%I#]W%12JPJPGTIN'W,7H7=
M(+6JO_6[EHB.]"HV70" DM52%44<ON&&3C:C1),:>YD_)IO7\GZ/)W5H[, I
M)*LLDY=1FH+XXG =K5Z[M/21:3R_[B@VAE\ D#5M->60G?'UASS7ZNIR_8X&
MA:0 51\_98UOOA:?9! ORX.'<C&/4)&M:!TC:!;7:3CX9\P^QVE:@B0%6$ 0
M+]!"&?VA4K]2X@;F9"I3H#_ _!DVZ_.K862K08YD FJ"8P (-F\YY>FK"0F<
M1>LR($Y&ETN8%6B P2\9/.=1G&2;J^C07^_*$3?F%1$'@#DE?57A)&)N(TQW
MPG40[4;'\$-[I1/.S0VF'EIKF>X-C;^&-7.K8C+Q981FBZN].AM,T:2(3R^L
M<HD#@(F2ONKA_7SF#9S^=@YP:B)_I1$UI.>#JDT?+JZ86AN"5IM_@ZZ_AW<V
M,E\?F:^/> O.^?J(K>LCEW]]VN_ <6WV"&( MECG^5;)?*MDOE5R[K=*YG3M
MTZ=K-QRP-E\N"646,U\N$;BO.0RZ.PN8PZ#G,&B+8=!V3D[F(.CS"X+V8S=E
M#H$^UQ!H#ZY@S2_&S"_&]/-JS2_&S"_&S"_&G,&+,1Z$?<Z)$Z9+G!"]LQ,G
MT+Z1Q G=;]XE3N"(SD^<T"T8KK.9$R=XE3AATE#D^>*BZ"K?\4)$%97R$.6_
M1.D>++)XB8^$KY)BE<)BCS-@TP]0#7&C7@#4X.;L)F@=*G:UK[)$ [14C6NI
M[\'7ZM-PB:=2J'TS5**0,]=B"@U0TT!=WS12FF.LD804#M-*&'8(R##+O)H@
MQY6!&-<NU0I1NS>[T#G@5\M QO$K*T686VH?X(JP28^J=8?8A!,57C*>_BT-
MPU[S+OECG\25R>H/(!M<V% H0?67C!+G $UUTUCVE P1G#W\80"N< 5 7-R@
MIL,],<KPC5&)R,T!B$?R.4);F\]Y -Z,&2UT VW!PGT[I3G])@MTHO<E+,K^
MNDV&E$"<2WH6*)8WAGF@<NO6O^]I_MX[M4?U+ #*Y9H+NU%,N#Y7S.0LH&K"
M@!-Y6[%4^M=;+3U 1LM.07^ 2DS)RQ_B_"$J@Y"4-X5QW'&KUK_LZGH<GU/?
M^ GJ4;EQ;,%=.GF.J7NY8QQL':A 1@&R?[+8PGU&O]+&)^T$6+%(SP&."L8P
MCCI^W0VX?O1F"*^CM8Y;=7BQ]_,.9NW[ZZW%'VUO8 R+;IR<(HMS0*H!XYGW
MFUHRD;.$ )..#I[Y7.[+HHPRG$B('?'))&4]I]HA/2/PRAC#%D@9=1,PAIC&
M]..E S(*2>U\049 *950Z%. !U^!)B0S?9 JSEAFZN2TF]+LDS>OSG_ ;(<&
M030B':(!8$GF2_P4XF%.-_',QWRJP-K9O,9;!L8/YP6/'7SRX=2'R+@HVIEN
M[T'Y%*6#8% YXMYE9A;Q.6!.R2#&T2:JG>!L^N.7T<ZQE4Z9$^0AH.H!<4!U
M3@CDF\ :] ;5$LR%E8*TJP6.(MGNZI@J=K2F4AGJ:,PL<P[ U#&/Y?&8*00!
MK0\G* ^P*$^K\N,4HCKKH9Y4RQ<@()0H<!8(5#6,>?A)2$"PY\T!2U?H4Y^I
MQ'X$Y3[/EMDM^EZ4.+#IRSXMDUV:@)QZRF>(&Q6Z&MS.#]=C36H9]!KBD5A[
M;Y(^72(MFQV'Q1I5T=*NZLJ#R PY\F,0AHC\'$"K:!0+H16B^@GL0LT@)<QQ
M;JHUE9*@CZ[T[.^O3YP@76.GU+4AYP3IYA.D#P?BCYKZG#'H#PW4VF5CB*I4
MAB21D2LSD6+UM?%EUM_L4"LDHUJKD+N4*TKM!37-T'4]4G56*4DDZ_(M1:J$
MW,]?H3J^6H7D\545.BM\#<U@#U]57<[>5QZ!+\1 PX-UBBE@K"YV7BBCF,(B
MSNK:G%VRUT?:#=P/\L6IE9+'65WJK&!&,80]E-65.;L:/P)DR9N&-VN74@!9
M5>J\0#8TA$60597Y]N"OA.!/R;LZQEJ%Y"%6%3HKA W-8 ]@55W.G@D>@2_P
M!OK)M56+*6"L+G9>**.8PB+.ZMI\N\$M(?DUWM!71UJGF#S2FF)GA32:*>PA
MK:G-QG5N+S:I=78%1=O5DCR=[0W-[TG.[TG.[TG2*>?W).?W)(E!Y_<DY_<D
MIW7$=W-V^#D[/,6@SV"[@WF4'YK)YF:3@PWJ!G547IU:L0GD X@BK_I'SXRC
M>#3&T^1Q#C%R)LQG/'!.4RC?3J69^4")47Z!99)MZ &=.F4[*0RDRYX#C,>8
MRWS<IYHP@;\B.L> ACF+G3@&U-3S"5YLKTT; SK6=.YB0$GBP*?]=HN&\V,F
MP04J\H8LH1__R1AR286,.3?K<]-8P\^.MR&QN[J("A#C9QA!5C2HS_'+8=4&
M[,7A1--D?5Y\C?)8L&EIAN]PBW,L7Q?FODFR*%LE47J;H5;?5R(-MT,%5(TI
MF%1.5E?([ 7R&04:YYY _I:LT*1CN:;(6#PC,0KZ)^HFJ@W69"UFE+4+NS=>
MA+I52_W6]3[.MV.M-"[DZ]X=)DU*@ ?97LWA3NU$7@A:[9K=1F+(4JW?C<H0
M;G.9'W&A[$C$G+F/$P2W+E. (/>IA09AV8.UJ6V.83M%X$B&05FV20Y]\@35
M*OWY-<J6U:9?<0^K$ 00/\(TO8$Y+F2J%495/K;%-"L_T]:M=VVF;]ANO=.U
M*:G7W7CEIM- =ZW:&R8GU?^8Q'0:O?5'YUT=G%E&>>DZMZX54_U4;?K<9G5H
MX&3^AEZM=7?3KW;V-E.UZ?DZF[[:^AO7[I_\UK82,GMMCH&YR',ZQGR+0E5C
M_8E45;,/L=EVP?H-*54U;N#^6/N*K H*B4/T%<*V0.9?@P1I-_FTA%FS]9D)
MI>;9L4S8LL'Z&1W-->YD?P"WX\G>RV^?Y]V7LW YHG8]7Y?#VG_1N)]?[[]<
M9W27$P)"AT<;TZ".O45O"'AW[9C#J15R<=[&B+NRI_JO (?)@GCQ!O)H SHO
MTS*BO/P0QOK()2=,"&W<>I60I]1DS:PHC_66EI8GO)'!;)>S.JKHH6*J&8Z,
MG>P.4M+V<7P2-;E[JW;'3VM/+UR<ADS3G$S)RC2[.E]:XH.Z.R4;^9;0U)Y9
MB.*%5^Y.2RKK#D]1JMGE^=,6']3I*5K)M^RZLH9YT3UAP'=(+3J^R>12='T3
MR#4[/Y]:XRS<WP1V\BWSLP>K?[_V\"8\:9QW\7R8Y^GB(E0G9W\?;S[1M(]:
MC8.GL$XXY11TMHUBZE(XOA%;Y_UI];)GD&]9B2H$Y/W$%4SR,^EABG:QT0?$
M(MA8]89^:]D@#*Q?<#8A:[A9CY@Y<J -:- :LR]!+T_2V)J#?UF3V.>85>EA
MGZ]>D;;DPYQ6:4ZK-*=5FM,JM4PXIU6:TRK-:94833.G50JJN>:T2@&D52+/
M&=0[/]@J,,-VX#TUPZ/M/S=#IW6A:D\2ZLC.I>F\*S^@<?)X ]QN8<9^<8;Y
M_9B!?/#=<19?ENFA6!E:"M\>NSKK]X"-3Q<TJG=O+LA2C/..$(.F\X+0@,;?
MUI512K*%&:S"W>J1<[Q0SGTQ7@VBL<;&9+"<9R7TIX8DAD:;.Z)\,0SW@$D?
M*&IZ\S*O-O,ILQ,A7?>A(AJ=-^KQ7L3C4?)4'#%/88Q5%V -<_ %QLDZ655@
MI0Y7(K)&:#:9ZR<SN!:'T@I27\2@\<8]F<W3M]=S%FO$5P@" 55C(B:5[Q"0
M4T\) 4R6Y_$.#<=/0Q5?)V'3WB.(=*;SA(;VZHQP-+4XF>&(H']R[W B\PA2
MG(_F(<K+0[5%&*VJD)J+0_L+96:C7O#X1+E\0=<6H4YYV 04#<U/<)89^//_
MOMEG\=W#(HL__?E_7T:[I(S2+U$6U2B^N[ND#G<:)1N-E$HZ?%F>V3!PC/9=
M=S*L!?L%)>X>;>VTY!9A1H2,<-K?1"N'OX&CX<&AA/=CVY%?";8OC?D\!P(L
M^RN-NQ8G12HRZ5]J,3U+*O*R-1] OYWF NB7WQZQ_K2)3__O9-0__7U2$:EN
MF_*E+2;=5=L3]$N2)=O]EBHJ]5LC;.^;.U=),2?DB]YS@R<&N,/T"OIS2"MJ
MQ^B=W8ZT;Z0=N]^\:T>.Z/QV[!8,>"XP<&J0YT0H1CD.X>U"\]@-!@:=>&@^
M5:E_XVI^8>L,7]@:7$6YAR4XO68MBM:6*\6Z8L0JY<UAU_'1;[#:YTF9@.(R
M2E,07QR(+@VAU(F?.C?>H9D*-_<W022!PMK>U38=XUH(7QSF%J^*&!YM[SRC
MK\4K3.,ZW\ -S*_QU9$"V62Y)O<DK] 2;7@/Y.<,:;'8Y*!R8CV4&^=+(LW-
M\0T)^;;,J=T'# KD6_:RH6I5V-TE,D*2;:H[P[?9,\@N85:@SEXF;TC10ZU6
M7U?Y[F&P#F97,5)'V-W&O)D-=B$CPCG+BF5F*L_,X\+,(.4ZKXD&+ID*:8.I
MS5%_!W7T^V@,ETHF1\]YA"^R8Q@_PPN D9T@64%,03Z!.,N%&N79F-\0SY"@
M:,.,VB@V)(S^1H:=&<4%R, ZP;=OEE\S5,-KLD,^?X5-M.G[.BG:8_ AES8D
M&*JHK0TO024-;/[B"VSJ>0&:0*-_<J05@OOS:U3^"O=I?!'EO\!TCR3/#V2Z
MO5POLN-JLP<K([P:^X_D%1(L39I-&[8CA6A@_=?P)H0/1-K*[3^"&&RK?$[H
M[]MDW\]J)$E-0"RB#@JF2JKK U%430.UOP4:Y&LYFY343O@D2:58DOASSCS%
M"=!-E.2_1.D>+(IB7R,9F^@+*%]A#%.X.9A^ DJ]QK%G2"HU.FN\%XULNC3%
MKM]W8%6"&"=*^T1K,ZL5M9O*4D7A>48-Q,,)&\N0MY77\KA78TD[9_>L_'+C
MQ"IH;HS8I$EY>(Q*8^FAU6NTX<99-7XH)S%I\[GS%K;5##?UK5'S/";%[S<Y
M +<94@L4I6VGP:O/ALN@US<[##M-%[Z[H"L9^ FC:5]ZE;PE,4!+ZXEF&+3Z
M;,XONO7-SL).TX7O+.A*VGBC)@344;<$I]\X\NJ=!A4M]&>DO""&T"\(?-!$
M]QI'LJ[OAQSWW.=$]Z$DNF\_3=1\NT6."K_">PFS#%1W5G]-RM<Z3QGR7%?@
MI6PRJV8;]#L.5-FGY9PE7^4F!2WMO9B0=__!86+Z.>^;KWG?;L!+OD?]_/DK
M2-\ ^G]6'OX/R.$]&FV:W)O+#+1NIU,OL8[D0IX<T.7B5_ZK80X-,^91RCBF
M7:5O*>F^1(?GUR0O <BH6CQ_A2TMD$Z,6]:CN!SO8VMR\1V@9LRC!%#M*NTL
M@<9 ]#_VJ"=A70XC$#J.2=,"NDQ\QZ<1XRC!4[=&_5U@6^A<[#?[HN2, W+X
M',N&9 759N,[1@T92"VOJ':=_MV&>0*[LA)NM"LUP.F8>7\$)]\!:\Y,2I@=
M5:W^'19KE[C@6R7;#=SG(S [E@VYJJ7-QG>T&C*0$E3UZ]3?H;6%TRNPJF2[
MKK:"]($ZFD_3$"/X^ Y54R92PNJ(2O6OPEA;4459LWF!U, JU#\]@TQM3362
M#5E5:;/Q':F&#*2VLM*N4_\>C2<X1;^9P.F C1Y.6VS.#*<L ]G$::O.!J=_
M]V<+-5^]ML8%53>J7?ZX;:I<WG= CC6)XE:I<F4-!'_TQU7**L'RD=KE%4$8
MD%<<:Q(K(!SZP4_>G"4M=GF2MK<=5#VA/@.R_:G!P'<8CC:*VI:G1FT$B!Z=
M&4FKP?*'^@Q4H1B01QQM%#M0I/C$Z:\)<,[7R1&L^L10HVSK+%VAK._(&V,*
MY7-SA8H(WCPZZ)'1@#T+U"BK@+B ?-T84QA'',7#>9-G['3@5*N !*]^>$K>
M<?0)T0?Q$,:YF6 U.%K48>4[. T:2O-P4:=> EUO<IWUU#GM0HW'KAXO.GA5
M>06&WE&F&@-?U8H)?J=/:B8X=&QZ8R6V+GZ-\.H=/FKR\AV_)DVE=0BI63'!
MK]%,::.2GE?"5[M>2/I%%C?:@#?T#_I+]T(,SE4-\K=D!0HJ@@UQ(XG,QW+S
M'<5FS:6$X]%5$R1[= 9T&'1*-+Q@9>KD=\LUDK%UQXNY_!K!I;40T^+B.V+-
MF$=Y<:95)4&HQA&1'83^QSX]?/Z,_OZ9?\VP_3;F'9H@+=>72/"D9$35FV1Z
MC+(WP]1W.%LQGF(4OAD)2%2^-R=19*+T^4?T[8?!<'*51U^7F1+2#7+L39)'
M<?0=X^;-IC5A'E4]0;<W;P559\652O]B MJFV+4C 4:Q\QW4A@VF'B<PJFX"
M9V^.R/!=L,]_-X5F0]Q:-_Y&<?,=RV;-I7P'<%35!,E&TSP9V4_^X<^FX&R2
M97]W>11+WX%MP7!Z>\VCZB<0-WK:Y[JQ^B]ZRV?MD&@!\N(WEVFX+X!+Y*AA
M653XQ#>;-].@G3>\PWK!@:K/'>-];CEB7FZ9%O'\KK9OV:!:2;AD&IY"SFOZ
M#KG[W' CG[YF*Z_]Q(^XGO/Q,.2]K.HAP>/'XSO=_1=$1O'@@5+,(WBD*IK)
M+'S%E8>;_IZF<%'BA[=O4 /^^IJL7OOZ-N:0S+JGSHP#=15FH6->VW!&P:\B
MA;.\[HPUO)8^NR0_90,=@^L.HS&8;AB=/9YI!IL6RXT$-E*.&\C<6NTW7 T?
M"6!][D[A6Y]#0I) .6U\#/GZ]NAS=YN)]JP]AZ*W?.M0!-C\'!7'(J#+VL83
MSJZWE(9[&X8>%^77-M'#H?[:76XKC[7S-'H_K\58?WGB>H_T""#9A:)>6GL>
MJ^#SU%>/+0^>BSQFK:=_?DBC;$0.^M'KTI.36*[;<C6G+)>P*(O!(Y>LW/9F
MF)%@GY',G+Q;=7RVX7J[2^$!@"8,E_&*0UJ)@>]'KA_!"FZRY)](E>H9^4H_
M6LI]JW60\TX[=3AYFQYUL/MH"RBY_6F?R*OSG4\NY:8F[:=_[,EN/C5__9[&
M;;9"/2UY [BBSW_^]"/U%%Z*MI%80.ML5&28&:IIUQT6NSSQH"C@Y6(?G]'^
M1QG[(QB^U?@*]T64Q?B&6"TZ%19C6#3VU&/A(8@,V$*$+;TJG&VS,S/:9O]K
M'Z7).@'QLGZ.K)HW,?+6RA ?L]/RB3U$C9)^(GR(F.EO-;M>T5 '=R@8.NGF
M(O$Q_:+AAL38G4-"[M2J:V,KDK0;*^!P&S,6&6Q\D F:'>YD2F>:NT?/$-,7
MOW+$_ > W2Y>==^!O-_CP:)YJK!8[,M7F..&E#/0>/YC'U5F\_?M.5N3[Q]+
M6K7GKKERC7I-E"U/D,[;E!W>HB3%8]H-S'_"FZ:6.A6K&L-]:UC-!^IB AN[
MZFE#L<(]Q[ UJ6&C0.8 S[!4G,8W<-#GN@FMKTWL3GPG6MX85R+</F_HU E.
M<[32Q<<XV;LOA1N5^4Q/8_'/,,,V9!W(7K_C'\%\)#L?R<Y'LG::Y#9#O10\
MH3Y?35/O&D$I)[02E*=#(3:E1TI2CW.E:/F*CCCL':WJ(_+@.,?"(HNOP!M(
MX0Y+UCA2ZAF-0HE&;:D2SJ8@<@T(=13OSA>X%>'I@%0%SEY4'PVUGT"&!OL4
M:;>(MTF6X)$%'V_RP*94IK&Z9!G_ :>CO"+D)*NP<:CLWN+]XT455RYE9W+X
M*& \K_>9ZWWY2<1$:W>N0$%N=L\GE?-)Y83:-JT!8KIPS<#3TUJM$'F22+)0
M *<86OJKGDG(5J+OY7AOP,P'#?-!@T<3C_F@83YHF \:/N9!PZ^@2M4?+]!X
M%6W HBCVVSJ^]F=$^0RO %K5HM4RN(F2_)<HW2.[-@&XU2$\B.<3B/D$8CZ!
M4&B2(B];S8%^.S4%^N6W1QP60SEC&/R=[#B?_CZIB/0-\^&7MICT_4A[@GY)
MLF2[W])S8].^D437W6_.1G*:.2%?].YPVF)0I9CN%O1G#T?4CM$[NQUIWXX)
MR]^];D>.Z/QV[!8,=ZHZ=&J0YT0H1B'[SIU"\V*/N=AC#2,3+=-:U?OC?>8=
MY.!WD,71Q,<%3&N-L\CB+Z!\A3%,X>:@M@UMH\:Q4>PJ-0;?>(])\?M-#L M
M6H4BYU4^#E.A35:?C8:CU^?;#KZ5;C#F,H-FTTF=()A4=M35"'DE@QQE3ULC
M?+N\R-@%'^:L2A _@WS;S\%LOZ*V9[!4T8=R"5,TECM?8$D[PPO$ "<+Q""_
MP!2Q29/R8'NZP*_1QH2!5>.'\@^3-E_XDP:6FH83J@3L,:Z2MR0&63R5OZ#5
M9]-;=.N;?86=ICL?3]%54C\WNO&L;]K:XDG2<EW]:*J#4UB.[<,=EG,WU6Z
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MXH=E@4GPTZK<M_<VB83XA38N@H8$/0RU"<X614PK3(.C=O6^G:XU,N)'RWA
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M7+>('X])3G[]'U!+ 0(4 Q0    ( % ^?UIL%D E\E,# #U/(P 2
M      "  0    !E9C(P,#,Y,# Q7S$P:RYH=&U02P$"% ,4    " !0/G]:
M!=/N?O8V  #VD0$ %@              @ $B5 , 968R,# S.3 P,5]E>#$P
M+3(Q+FAT;5!+ 0(4 Q0    ( % ^?UHNU72X!30  &8\ 0 3
M  "  4R+ P!E9C(P,#,Y,# Q7V5X,3DN:'1M4$L! A0#%     @ 4#Y_6G:U
M<=YJ P  >@P  !4              ( !@K\# &5F,C P,SDP,#%?97@R,2TQ
M+FAT;5!+ 0(4 Q0    ( %$^?UIVQX 9(00  (0+   5              "
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M !4              ( !CFT% &=A;'0M,C R-#$R,S%?<')E+GAM;%!+!08
1    #@ . *(#  #_]04    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>ef20039001_10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:galt="http://galectintherapeutics.com/20241231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="galt-20241231.xsd" xlink:type="simple"/>
    <context id="c20240101to20241231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c20250303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
        </entity>
        <period>
            <instant>2025-03-03</instant>
        </period>
    </context>
    <context id="c20241231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20231231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20230101to20231231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20221231_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20221231_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20221231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20240101to20241231_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20230101to20231231_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20230101to20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20230101to20231231_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20230101to20231231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20231231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20241231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20231231_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20241231_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20231231_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20241231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20240101to20241231_LongtermDebtTypeAxis_LoansPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_LongtermDebtTypeAxis_LineOfCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20241001to20241231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20241231_CreditFacilityAxis_LineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20250331_CreditFacilityAxis_SupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_SubsequentEventTypeAxis_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">galt:SupplementalLineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c20241231_PropertyPlantAndEquipmentByTypeAxis_ComputerAndOfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">galt:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20231231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20231231_PropertyPlantAndEquipmentByTypeAxis_ComputerAndOfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">galt:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20231231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20210416_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:AprilConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-16</instant>
        </period>
    </context>
    <context id="c20210917_DebtInstrumentAxis_FirstClosingMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:FirstClosingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-17</instant>
        </period>
    </context>
    <context id="c20211220_DebtInstrumentAxis_SecondClosingMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:SecondClosingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-20</instant>
        </period>
    </context>
    <context id="c20210917_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:SeptemberConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-17</instant>
        </period>
    </context>
    <context id="c20210416to20210416_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:AprilConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-16</startDate>
            <endDate>2021-04-16</endDate>
        </period>
    </context>
    <context id="c20211220to20211220_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:DecemberConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-20</startDate>
            <endDate>2021-12-20</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:SeptemberConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240514to20240514_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:AprilConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-14</startDate>
            <endDate>2024-05-14</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:AprilConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20210917to20210917_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:SeptemberConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-17</startDate>
            <endDate>2021-09-17</endDate>
        </period>
    </context>
    <context id="c20240514_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:AprilConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-14</instant>
        </period>
    </context>
    <context id="c20241231_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:AprilConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20211220_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:DecemberConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-20</instant>
        </period>
    </context>
    <context id="c20241231_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:SeptemberConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20230101to20231231_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:DecemberConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20230101to20231231_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:SeptemberConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:DecemberConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20230101to20231231_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:AprilConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20231231_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:SeptemberConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20231231_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:DecemberConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20231231_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:AprilConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20241231_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:DecemberConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20230101to20231231_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:SeptemberConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:AprilConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20230101to20231231_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:AprilConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:SeptemberConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20250917to20250917_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_StatementScenarioAxis_ScenarioForecastMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:SeptemberConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-17</startDate>
            <endDate>2025-09-17</endDate>
        </period>
    </context>
    <context id="c20251230to20251230_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember_StatementScenarioAxis_ScenarioForecastMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">galt:DecemberConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-12-30</startDate>
            <endDate>2025-12-30</endDate>
        </period>
    </context>
    <context id="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputSharePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputDiscountRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputConversionPriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputConversionPriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputConversionPriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputConversionPriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputDiscountRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputSharePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputSharePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputSharePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputDiscountRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputConversionPriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputConversionPriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputConversionPriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputConversionPriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputDiscountRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputDiscountRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputDiscountRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputSharePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputConversionPriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputConversionPriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputConversionPriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputConversionPriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputSharePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20230101to20231231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20230101to20231231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20230101to20231231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20230101to20231231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20230101to20231231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20230101to20231231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestSeptemberNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestAprilNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">galt:ContingentInterestDecemberNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_StatementClassOfStockAxis_SeriesBOneConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">galt:SeriesBOneConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_StatementClassOfStockAxis_SeriesBTwoConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">galt:SeriesBTwoConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_StatementClassOfStockAxis_SeriesBThreeConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">galt:SeriesBThreeConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_StatementClassOfStockAxis_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_StatementClassOfStockAxis_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20231231_TypeOfArrangementAxis_TwoThousandTwentyMarketAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">galt:TwoThousandTwentyMarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20241231_TypeOfArrangementAxis_TwoThousandTwentyMarketAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">galt:TwoThousandTwentyMarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20080204to20080204_StatementClassOfStockAxis_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2008-02-04</startDate>
            <endDate>2008-02-04</endDate>
        </period>
    </context>
    <context id="c20080204_StatementClassOfStockAxis_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2008-02-04</instant>
        </period>
    </context>
    <context id="c20080204_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementScenarioAxis_DividendPaymentScenarioOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">galt:DividendPaymentScenarioOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2008-02-04</instant>
        </period>
    </context>
    <context id="c20080204_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementScenarioAxis_DividendPaymentScenarioTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">galt:DividendPaymentScenarioTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2008-02-04</instant>
        </period>
    </context>
    <context id="c20080204to20080204_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementScenarioAxis_DividendPaymentScenarioOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">galt:DividendPaymentScenarioOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2008-02-04</startDate>
            <endDate>2008-02-04</endDate>
        </period>
    </context>
    <context id="c20080204to20080204_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementScenarioAxis_DividendPaymentScenarioTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">galt:DividendPaymentScenarioTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2008-02-04</startDate>
            <endDate>2008-02-04</endDate>
        </period>
    </context>
    <context id="c20080204_RangeAxis_MinimumMember_StatementClassOfStockAxis_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2008-02-04</instant>
        </period>
    </context>
    <context id="c20230101to20231231_StatementClassOfStockAxis_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20200101to20201231_StatementClassOfStockAxis_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c20110101to20110131_StatementClassOfStockAxis_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2011-01-01</startDate>
            <endDate>2011-01-31</endDate>
        </period>
    </context>
    <context id="c20101230to20101230_StatementClassOfStockAxis_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2010-12-30</startDate>
            <endDate>2010-12-30</endDate>
        </period>
    </context>
    <context id="c20101229to20101229_RangeAxis_MaximumMember_StatementClassOfStockAxis_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2010-12-29</startDate>
            <endDate>2010-12-29</endDate>
        </period>
    </context>
    <context id="c20101229_StatementClassOfStockAxis_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2010-12-29</instant>
        </period>
    </context>
    <context id="c20101230_StatementClassOfStockAxis_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2010-12-30</instant>
        </period>
    </context>
    <context id="c20110131_StatementClassOfStockAxis_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2011-01-31</instant>
        </period>
    </context>
    <context id="c20101229_RangeAxis_MaximumMember_StatementClassOfStockAxis_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2010-12-29</instant>
        </period>
    </context>
    <context id="c20241231_StatementClassOfStockAxis_SeriesCPreferredStockMember_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20231231_StatementClassOfStockAxis_SeriesCPreferredStockMember_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20131231to20131231_StatementClassOfStockAxis_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-12-31</startDate>
            <endDate>2013-12-31</endDate>
        </period>
    </context>
    <context id="c20110731to20110731_StatementClassOfStockAxis_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2011-07-31</startDate>
            <endDate>2011-07-31</endDate>
        </period>
    </context>
    <context id="c20230101to20231231_StatementClassOfStockAxis_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20141231to20141231_StatementClassOfStockAxis_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-12-31</startDate>
            <endDate>2014-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_StatementClassOfStockAxis_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20101230_StatementClassOfStockAxis_SeriesCPreferredStockMember_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2010-12-30</instant>
        </period>
    </context>
    <context id="c20101230to20101230_StatementClassOfStockAxis_SeriesCPreferredStockMember_StatementScenarioAxis_DividendPaymentScenarioOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">galt:DividendPaymentScenarioOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2010-12-30</startDate>
            <endDate>2010-12-30</endDate>
        </period>
    </context>
    <context id="c20101230to20101230_StatementClassOfStockAxis_SeriesCPreferredStockMember_StatementScenarioAxis_DividendPaymentScenarioTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">galt:DividendPaymentScenarioTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2010-12-30</startDate>
            <endDate>2010-12-30</endDate>
        </period>
    </context>
    <context id="c20101230to20101230_RangeAxis_MaximumMember_StatementClassOfStockAxis_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2010-12-30</startDate>
            <endDate>2010-12-30</endDate>
        </period>
    </context>
    <context id="c20221231_FinancialInstrumentAxis_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20230101to20231231_FinancialInstrumentAxis_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_FinancialInstrumentAxis_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20241231_FinancialInstrumentAxis_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20231231_FinancialInstrumentAxis_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20230930_RelatedPartyTransactionsByRelatedPartyAxis_One0XFundLPAnd10XCapitalManagementLLCMember_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">galt:One0XFundLPAnd10XCapitalManagementLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c20230922_RelatedPartyTransactionsByRelatedPartyAxis_One0XFundLPAnd10XCapitalManagementLLCMember_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">galt:One0XFundLPAnd10XCapitalManagementLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-22</instant>
        </period>
    </context>
    <context id="c20240101to20241231_RelatedPartyTransactionsByRelatedPartyAxis_One0XFundLPAnd10XCapitalManagementLLCMember_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">galt:One0XFundLPAnd10XCapitalManagementLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20241231_RangeAxis_MinimumMember_RelatedPartyTransactionsByRelatedPartyAxis_One0XFundLPAnd10XCapitalManagementLLCMember_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">galt:One0XFundLPAnd10XCapitalManagementLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20240101to20241231_RangeAxis_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20241231_RelatedPartyTransactionsByRelatedPartyAxis_One0XFundLPMember_StatementEquityComponentsAxis_SeriesBWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">galt:One0XFundLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">galt:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20240101to20241231_RelatedPartyTransactionsByRelatedPartyAxis_One0XFundLPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">galt:One0XFundLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20230901to20230930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
        </entity>
        <period>
            <startDate>2023-09-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_ClassOfWarrantOrRightAxis_AfterModificationMember_FinancialInstrumentAxis_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:AfterModificationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_ClassOfWarrantOrRightAxis_BeforeModificationMember_FinancialInstrumentAxis_WarrantMember_RangeAxis_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:BeforeModificationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_ClassOfWarrantOrRightAxis_BeforeModificationMember_FinancialInstrumentAxis_WarrantMember_RangeAxis_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:BeforeModificationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_ClassOfWarrantOrRightAxis_BeforeModificationMember_FinancialInstrumentAxis_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:BeforeModificationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20241231_ClassOfWarrantOrRightAxis_DecemberTwentyThreeTwentySixteenSeriesBThreeTransactionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:DecemberTwentyThreeTwentySixteenSeriesBThreeTransactionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_ClassOfWarrantOrRightAxis_AprilThirtyTwentyTenSeriesBTwoTransactionTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:AprilThirtyTwentyTenSeriesBTwoTransactionTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_ClassOfWarrantOrRightAxis_SeptemberThirtyTwentyZeroNineSeriesBTwoTransactionOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:SeptemberThirtyTwentyZeroNineSeriesBTwoTransactionOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_ClassOfWarrantOrRightAxis_MarchEightTwentyTenSeriesBTwoTransactionTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:MarchEightTwentyTenSeriesBTwoTransactionTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_ClassOfWarrantOrRightAxis_December292023WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:December292023WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_ClassOfWarrantOrRightAxis_AugustTwelveTwentyZeroNineSeriesBTwoTransactionOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:AugustTwelveTwentyZeroNineSeriesBTwoTransactionOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_ClassOfWarrantOrRightAxis_SeptemberTwentyTwoTwentySixteenSeriesBThreeTransactionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:SeptemberTwentyTwoTwentySixteenSeriesBThreeTransactionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_ClassOfWarrantOrRightAxis_DecemberEightTwentyZeroNineSeriesBTwoTransactionOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:DecemberEightTwentyZeroNineSeriesBTwoTransactionOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_ClassOfWarrantOrRightAxis_AprilThirtyTwentyTenSeriesBTwoTransactionOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:AprilThirtyTwentyTenSeriesBTwoTransactionOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_ClassOfWarrantOrRightAxis_September302024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:September302024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_ClassOfWarrantOrRightAxis_MayTenTwentyTenSeriesBTwoTransactionOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:MayTenTwentyTenSeriesBTwoTransactionOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_ClassOfWarrantOrRightAxis_SeptemberTwentyNineTwentySixteenSeriesBThreeTransactionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:SeptemberTwentyNineTwentySixteenSeriesBThreeTransactionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_ClassOfWarrantOrRightAxis_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:JanuaryTwentyNineTwentyTenSeriesBTwoTransactionOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_ClassOfWarrantOrRightAxis_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:JanuaryTwentyNineTwentyTenSeriesBTwoTransactionTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_ClassOfWarrantOrRightAxis_June282024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:June282024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_ClassOfWarrantOrRightAxis_TwentyEighteenAndTwentySeventeenWarrantsIssuedForServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:TwentyEighteenAndTwentySeventeenWarrantsIssuedForServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_ClassOfWarrantOrRightAxis_MayTenTwentyTenSeriesBTwoTransactionTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:MayTenTwentyTenSeriesBTwoTransactionTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_ClassOfWarrantOrRightAxis_NovemberFourTwentyZeroNineSeriesBTwoTransactionOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:NovemberFourTwentyZeroNineSeriesBTwoTransactionOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_ClassOfWarrantOrRightAxis_July222022WarrantsIssuedInConnectionWithRelatedPartyLineOfCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:July222022WarrantsIssuedInConnectionWithRelatedPartyLineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_ClassOfWarrantOrRightAxis_March292024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:March292024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_ClassOfWarrantOrRightAxis_MarchEightTwentyTenSeriesBTwoTransactionOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:MarchEightTwentyTenSeriesBTwoTransactionOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_ClassOfWarrantOrRightAxis_MayTwentyThreeTwentyNinteenRightsOfferingWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:MayTwentyThreeTwentyNinteenRightsOfferingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_ClassOfWarrantOrRightAxis_FebruaryTwelveTwentyZeroNineSeriesBOneTransactionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:FebruaryTwelveTwentyZeroNineSeriesBOneTransactionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_ClassOfWarrantOrRightAxis_JuneThirtyTwentyZeroNineSeriesBTwoTransactionOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:JuneThirtyTwentyZeroNineSeriesBTwoTransactionOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_ClassOfWarrantOrRightAxis_MayThirteenTwentyZeroNineSeriesBTwoTransactionOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:MayThirteenTwentyZeroNineSeriesBTwoTransactionOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20240101to20241231_ClassOfWarrantOrRightAxis_SeptemberTwentyTwoTwentySixteenSeriesBThreeTransactionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:SeptemberTwentyTwoTwentySixteenSeriesBThreeTransactionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_ClassOfWarrantOrRightAxis_MayTenTwentyTenSeriesBTwoTransactionTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:MayTenTwentyTenSeriesBTwoTransactionTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_ClassOfWarrantOrRightAxis_NovemberFourTwentyZeroNineSeriesBTwoTransactionOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:NovemberFourTwentyZeroNineSeriesBTwoTransactionOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_ClassOfWarrantOrRightAxis_July222022WarrantsIssuedInConnectionWithRelatedPartyLineOfCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:July222022WarrantsIssuedInConnectionWithRelatedPartyLineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_ClassOfWarrantOrRightAxis_MayTwentyThreeTwentyNinteenRightsOfferingWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:MayTwentyThreeTwentyNinteenRightsOfferingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_ClassOfWarrantOrRightAxis_December292023WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:December292023WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_ClassOfWarrantOrRightAxis_MayTenTwentyTenSeriesBTwoTransactionOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:MayTenTwentyTenSeriesBTwoTransactionOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_ClassOfWarrantOrRightAxis_SeptemberThirtyTwentyZeroNineSeriesBTwoTransactionOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:SeptemberThirtyTwentyZeroNineSeriesBTwoTransactionOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_ClassOfWarrantOrRightAxis_MarchEightTwentyTenSeriesBTwoTransactionTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:MarchEightTwentyTenSeriesBTwoTransactionTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_ClassOfWarrantOrRightAxis_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:JanuaryTwentyNineTwentyTenSeriesBTwoTransactionOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_ClassOfWarrantOrRightAxis_September302024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:September302024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_ClassOfWarrantOrRightAxis_March292024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:March292024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_ClassOfWarrantOrRightAxis_AprilThirtyTwentyTenSeriesBTwoTransactionOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:AprilThirtyTwentyTenSeriesBTwoTransactionOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_ClassOfWarrantOrRightAxis_MayThirteenTwentyZeroNineSeriesBTwoTransactionOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:MayThirteenTwentyZeroNineSeriesBTwoTransactionOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_ClassOfWarrantOrRightAxis_SeptemberTwentyNineTwentySixteenSeriesBThreeTransactionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:SeptemberTwentyNineTwentySixteenSeriesBThreeTransactionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_ClassOfWarrantOrRightAxis_DecemberEightTwentyZeroNineSeriesBTwoTransactionOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:DecemberEightTwentyZeroNineSeriesBTwoTransactionOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_ClassOfWarrantOrRightAxis_June282024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:June282024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_ClassOfWarrantOrRightAxis_MarchEightTwentyTenSeriesBTwoTransactionOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:MarchEightTwentyTenSeriesBTwoTransactionOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_ClassOfWarrantOrRightAxis_DecemberTwentyThreeTwentySixteenSeriesBThreeTransactionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:DecemberTwentyThreeTwentySixteenSeriesBThreeTransactionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_ClassOfWarrantOrRightAxis_AugustTwelveTwentyZeroNineSeriesBTwoTransactionOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:AugustTwelveTwentyZeroNineSeriesBTwoTransactionOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_ClassOfWarrantOrRightAxis_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:JanuaryTwentyNineTwentyTenSeriesBTwoTransactionTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_ClassOfWarrantOrRightAxis_JuneThirtyTwentyZeroNineSeriesBTwoTransactionOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:JuneThirtyTwentyZeroNineSeriesBTwoTransactionOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_ClassOfWarrantOrRightAxis_AprilThirtyTwentyTenSeriesBTwoTransactionTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:AprilThirtyTwentyTenSeriesBTwoTransactionTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_ClassOfWarrantOrRightAxis_FebruaryTwelveTwentyZeroNineSeriesBOneTransactionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">galt:FebruaryTwelveTwentyZeroNineSeriesBOneTransactionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20231231_PlanNameAxis_EquityIncentivePlan2019Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">galt:EquityIncentivePlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20211231_PlanNameAxis_EquityIncentivePlan2019Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">galt:EquityIncentivePlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20191231_PlanNameAxis_EquityIncentivePlan2019Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">galt:EquityIncentivePlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20241231_PlanNameAxis_IncentiveCompensationPlanTwoThousandNineMemberMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">galt:IncentiveCompensationPlanTwoThousandNineMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_PlanNameAxis_EquityIncentivePlan2019Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">galt:EquityIncentivePlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20230101to20231231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20230101to20231231_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_RangeAxis_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_RangeAxis_MinimumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">galt:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_RangeAxis_MinimumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">galt:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_RangeAxis_MinimumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">galt:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_RangeAxis_MinimumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">galt:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_RangeAxis_MaximumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">galt:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_RangeAxis_MaximumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">galt:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_RangeAxis_MaximumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">galt:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_RangeAxis_MaximumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">galt:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">galt:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">galt:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">galt:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">galt:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">galt:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">galt:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">galt:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">galt:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20241231_AwardTypeAxis_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20231231_AwardTypeAxis_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20230101to20231231_AwardTypeAxis_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20240131_AwardTypeAxis_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_AwardTypeAxis_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20230101to20231231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis">us-gaap:DeferredBonusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis">us-gaap:DeferredBonusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20221231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis">us-gaap:DeferredBonusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20241231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis">us-gaap:DeferredBonusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20231231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis">us-gaap:DeferredBonusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20240101to20241231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis">us-gaap:DeferredBonusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20210101to20211231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_BonusSharesMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis">galt:BonusSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c20230101to20231231_TitleOfIndividualAxis_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_TitleOfIndividualAxis_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_BonusSharesMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis">galt:BonusSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20230101to20231231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_BonusSharesMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis">galt:BonusSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20241231_TitleOfIndividualAxis_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20220725_CreditFacilityAxis_LineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-25</instant>
        </period>
    </context>
    <context id="c20240329_CreditFacilityAxis_SupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">galt:SupplementalLineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-29</instant>
        </period>
    </context>
    <context id="c20241114_CreditFacilityAxis_AdditionalSupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">galt:AdditionalSupplementalLineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-14</instant>
        </period>
    </context>
    <context id="c20231229to20231229_CreditFacilityAxis_LineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-29</startDate>
            <endDate>2023-12-29</endDate>
        </period>
    </context>
    <context id="c20241113to20241114_CreditFacilityAxis_AdditionalSupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">galt:AdditionalSupplementalLineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-13</startDate>
            <endDate>2024-11-14</endDate>
        </period>
    </context>
    <context id="c20240329to20240329_CreditFacilityAxis_LineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-29</startDate>
            <endDate>2024-03-29</endDate>
        </period>
    </context>
    <context id="c20240628to20240628_CreditFacilityAxis_LineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-28</startDate>
            <endDate>2024-06-28</endDate>
        </period>
    </context>
    <context id="c20240401to20240630_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_June2023PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">galt:June2023PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c20240329to20240329_CreditFacilityAxis_SupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">galt:SupplementalLineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-29</startDate>
            <endDate>2024-03-29</endDate>
        </period>
    </context>
    <context id="c20240101to20240331_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_March2023PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">galt:March2023PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c20220725to20220725_CreditFacilityAxis_LineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-25</startDate>
            <endDate>2022-07-25</endDate>
        </period>
    </context>
    <context id="c20240328to20240930_CreditFacilityAxis_SupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">galt:SupplementalLineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-28</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c20221219to20221219_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_December2022PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">galt:December2022PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-19</startDate>
            <endDate>2022-12-19</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_CreditFacilityAxis_SupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">galt:SupplementalLineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240630_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_June2023PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">galt:June2023PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c20241231_CreditFacilityAxis_SupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">galt:SupplementalLineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_CreditFacilityAxis_SupplementalLineOfCreditMember_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">galt:SupplementalLineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241114_CreditFacilityAxis_AdditionalSupplementalLineOfCreditMember_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">galt:AdditionalSupplementalLineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-14</instant>
        </period>
    </context>
    <context id="c20231229_CreditFacilityAxis_LineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-29</instant>
        </period>
    </context>
    <context id="c20241114_CreditFacilityAxis_AdditionalSupplementalLineOfCreditMember_RangeAxis_MinimumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">galt:AdditionalSupplementalLineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-14</instant>
        </period>
    </context>
    <context id="c20220725_CreditFacilityAxis_LineOfCreditMember_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-25</instant>
        </period>
    </context>
    <context id="c20241231_CreditFacilityAxis_SupplementalLineOfCreditMember_RangeAxis_MinimumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">galt:SupplementalLineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20240329_CreditFacilityAxis_LineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-29</instant>
        </period>
    </context>
    <context id="c20240628_CreditFacilityAxis_LineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-28</instant>
        </period>
    </context>
    <context id="c20220725_CreditFacilityAxis_LineOfCreditMember_RangeAxis_MinimumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-25</instant>
        </period>
    </context>
    <context id="c20241231_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_December2022PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">galt:December2022PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20240331_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_March2023PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">galt:March2023PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c20220725_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-25</instant>
        </period>
    </context>
    <context id="c20220725_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-25</instant>
        </period>
    </context>
    <context id="c20221219_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-19</instant>
        </period>
    </context>
    <context id="c20240628_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-28</instant>
        </period>
    </context>
    <context id="c20240329_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-29</instant>
        </period>
    </context>
    <context id="c20240630_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c20231229_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-29</instant>
        </period>
    </context>
    <context id="c20240930_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c20240331_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c20241231_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20220725_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-25</instant>
        </period>
    </context>
    <context id="c20231229_FinancialInstrumentAxis_WarrantOneMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">galt:WarrantOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-29</instant>
        </period>
    </context>
    <context id="c20240331_FinancialInstrumentAxis_WarrantOneMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">galt:WarrantOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c20240329_FinancialInstrumentAxis_WarrantOneMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">galt:WarrantOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-29</instant>
        </period>
    </context>
    <context id="c20221219_FinancialInstrumentAxis_WarrantOneMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">galt:WarrantOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-19</instant>
        </period>
    </context>
    <context id="c20240930_CreditFacilityAxis_SupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">galt:SupplementalLineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c20240630_FinancialInstrumentAxis_WarrantOneMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">galt:WarrantOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c20240628_FinancialInstrumentAxis_WarrantOneMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">galt:WarrantOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-28</instant>
        </period>
    </context>
    <context id="c20220725_FinancialInstrumentAxis_WarrantMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-25</instant>
        </period>
    </context>
    <context id="c20221219_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_December2022PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">galt:December2022PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-19</instant>
        </period>
    </context>
    <context id="c20241231_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_September2024PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">galt:September2024PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_March24PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">galt:March24PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20231231_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_June2023PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">galt:June2023PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20231231_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_March2023PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">galt:March2023PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20241231_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_March2023PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">galt:March2023PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20231231_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_December2022PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">galt:December2022PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20241231_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_June2023PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">galt:June2023PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_December2023PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">galt:December2023PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_June2024PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">galt:June2024PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20220725to20220725_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-25</startDate>
            <endDate>2022-07-25</endDate>
        </period>
    </context>
    <context id="c20241231_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20240101to20241231_FinancialInstrumentAxis_WarrantTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">galt:WarrantTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20221219to20221219_FinancialInstrumentAxis_WarrantOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">galt:WarrantOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-19</startDate>
            <endDate>2022-12-19</endDate>
        </period>
    </context>
    <context id="c20240101to20240331_FinancialInstrumentAxis_WarrantTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">galt:WarrantTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c20240329to20240329_FinancialInstrumentAxis_WarrantTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">galt:WarrantTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-29</startDate>
            <endDate>2024-03-29</endDate>
        </period>
    </context>
    <context id="c20240401to20240630_FinancialInstrumentAxis_WarrantTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">galt:WarrantTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c20240628to20240628_FinancialInstrumentAxis_WarrantTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">galt:WarrantTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-28</startDate>
            <endDate>2024-06-28</endDate>
        </period>
    </context>
    <context id="c20220725to20220725_FinancialInstrumentAxis_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-25</startDate>
            <endDate>2022-07-25</endDate>
        </period>
    </context>
    <context id="c20240328to20240930_FinancialInstrumentAxis_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-28</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_FinancialInstrumentAxis_WarrantOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">galt:WarrantOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20230101to20231231_FinancialInstrumentAxis_WarrantThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">galt:WarrantThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20230101to20231231_FinancialInstrumentAxis_WarrantTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">galt:WarrantTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20230101to20231231_FinancialInstrumentAxis_WarrantOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">galt:WarrantOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_FinancialInstrumentAxis_WarrantThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">galt:WarrantThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_FinancialInstrumentAxis_WarrantSevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">galt:WarrantSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_FinancialInstrumentAxis_WarrantFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">galt:WarrantFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_FinancialInstrumentAxis_WarrantSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">galt:WarrantSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_FinancialInstrumentAxis_WarrantFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">galt:WarrantFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20230101to20231231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20230101to20231231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertibleNotesPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20230101to20231231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertibleNotesPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_LineOfCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20230101to20231231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20230101to20231231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_LineOfCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20140101to20140131_OwnershipAxis_GalectinSciencesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">galt:GalectinSciencesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-01-31</endDate>
        </period>
    </context>
    <context id="c20140131_CounterpartyNameAxis_SBHSciencesIncMember_FiniteLivedIntangibleAssetsByMajorClassAxis_InProcessResearchAndDevelopmentMember_OwnershipAxis_GalectinSciencesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">galt:SBHSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">galt:GalectinSciencesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-01-31</instant>
        </period>
    </context>
    <context id="c20241231_OwnershipAxis_GalectinSciencesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">galt:GalectinSciencesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20140131_CounterpartyNameAxis_SBHSciencesIncMember_OwnershipAxis_GalectinSciencesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">galt:SBHSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">galt:GalectinSciencesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-01-31</instant>
        </period>
    </context>
    <context id="c20141001to20141231_OwnershipAxis_GalectinSciencesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">galt:GalectinSciencesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-10-01</startDate>
            <endDate>2014-12-31</endDate>
        </period>
    </context>
    <context id="c20230101to20231231_OwnershipAxis_GalectinSciencesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">galt:GalectinSciencesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20150101to20211231_OwnershipAxis_GalectinSciencesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">galt:GalectinSciencesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_OwnershipAxis_GalectinSciencesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">galt:GalectinSciencesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20140101to20231231_CounterpartyNameAxis_SBHSciencesIncMember_OwnershipAxis_GalectinSciencesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">galt:SBHSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">galt:GalectinSciencesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20140101to20141231_OwnershipAxis_GalectinSciencesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">galt:GalectinSciencesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-12-31</endDate>
        </period>
    </context>
    <context id="c20241231_IncomeTaxAuthorityAxis_DomesticCountryMember_TaxPeriodAxis_ExpiringAsAResultOf2017TaxActMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">galt:ExpiringAsAResultOf2017TaxActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_IncomeTaxAuthorityAxis_DomesticCountryMember_TaxPeriodAxis_ExpiringThrough2037Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">galt:ExpiringThrough2037Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_IncomeTaxAuthorityAxis_StateAndLocalJurisdictionMember_TaxPeriodAxis_ExpiringAsAResultOf2017TaxActMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">galt:ExpiringAsAResultOf2017TaxActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_IncomeTaxAuthorityAxis_StateAndLocalJurisdictionMember_TaxPeriodAxis_ExpiringThrough2037Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">galt:ExpiringThrough2037Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20240101to20241231_IncomeTaxAuthorityAxis_StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_IncomeTaxAuthorityAxis_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_StatementBusinessSegmentsAxis_BusinessOperatingSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">galt:BusinessOperatingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20230101to20231231_StatementBusinessSegmentsAxis_BusinessOperatingSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">galt:BusinessOperatingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20231231_StatementBusinessSegmentsAxis_BusinessOperatingSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">galt:BusinessOperatingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20241231_StatementBusinessSegmentsAxis_BusinessOperatingSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">galt:BusinessOperatingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20250331to20250331_CreditFacilityAxis_SupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">galt:SupplementalLineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-31</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c20250331_CreditFacilityAxis_SupplementalLineOfCreditMember_RangeAxis_MinimumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">galt:SupplementalLineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c20250331_CreditFacilityAxis_SupplementalLineOfCreditMember_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">galt:SupplementalLineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c20250331_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c20250331_CreditFacilityAxis_SupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">galt:SupplementalLineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <unit id="U001">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U002">
        <measure>shares</measure>
    </unit>
    <unit id="U003">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U004">
        <measure>galt:LineofCredit</measure>
    </unit>
    <unit id="U005">
        <measure>galt:loan</measure>
    </unit>
    <unit id="U006">
        <measure>galt:PromissoryNote</measure>
    </unit>
    <unit id="U007">
        <measure>pure</measure>
    </unit>
    <unit id="U008">
        <measure>galt:Rights</measure>
    </unit>
    <unit id="U009">
        <measure>galt:Director</measure>
    </unit>
    <unit id="U010">
        <measure>galt:Lease</measure>
    </unit>
    <unit id="U011">
        <measure>galt:Segment</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="c20240101to20241231"
      id="Fact_8d49a8eb31cb48aeb750f62f1c79329e">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="c20240101to20241231"
      id="Fact_5c46843e57324b84ba22d20b5c7120f2">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="c20240101to20241231"
      id="Fact_e9ef3d473ff54310a354df04f49ab23d">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="c20240101to20241231"
      id="Fact_2ee2ac31eca347aabd9c7dba5f9cd928">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="c20240101to20241231"
      id="Fact_d3a041f1810748ec875770cb1cd2eb88">0001133416</dei:EntityCentralIndexKey>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="c20231231"
      id="Fact_3bef161157d441a4b194359a2b8c08a3">http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="c20231231"
      id="Fact_a8602fa8d1ea4021ae045ee98e73f8f6">http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="c20241231"
      id="Fact_4b297d7d29a9481e88136db097de88dd">http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="c20241231"
      id="Fact_5c08786f5dcb4bc5a62f72d8c0d8264d">http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <galt:FreeRentPeriod
      contextRef="c20240101to20241231"
      id="Fact_5e16282e65184d8eabf15666ce8cae25">P6M15D</galt:FreeRentPeriod>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="c20231231"
      id="Fact_2a011c7177224f80b904fcc70e46eb35">http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="c20241231"
      id="Fact_c96ca38e0f664780917ece0461c411fe">http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="c20231231"
      id="Fact_47d32f393cdc43fc8f131674cf3a7b9b">http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c20240101to20241231"
      decimals="INF"
      id="Fact_600409bbedd14e1db752c48e58053e6c"
      unitRef="U011">1</us-gaap:NumberOfOperatingSegments>
    <dei:AuditorFirmId
      contextRef="c20240101to20241231"
      id="Fact_8aa86162ab1a4132867b6ccb28da17b8">677</dei:AuditorFirmId>
    <galt:NumberOfConsecutiveTradingDays
      contextRef="c20240101to20241231_StatementClassOfStockAxis_SeriesCPreferredStockMember"
      id="Fact_9d42133c6fda4902871913ae7391078b">P10D</galt:NumberOfConsecutiveTradingDays>
    <galt:OperatingLossCarryforwardsExpirationYear
      contextRef="c20240101to20241231"
      id="Fact_f036db385a5043f9b416f31ccdd089ed">2037</galt:OperatingLossCarryforwardsExpirationYear>
    <galt:FederalAndStateResearchAndDevelopmentCreditsExpirationYear
      contextRef="c20240101to20241231"
      id="Fact_64f60f3069914649af3fc7ac5db90c6c">2042</galt:FederalAndStateResearchAndDevelopmentCreditsExpirationYear>
    <dei:DocumentType
      contextRef="c20240101to20241231"
      id="Fact_1d39da308fee4509978fb7b40ff088db">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="c20240101to20241231"
      id="Fact_fddfb87ae304439aa691840231dd694e">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="c20240101to20241231"
      id="Fact_c5c2f5a79dfb4096a2f424028c306a06">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="c20240101to20241231"
      id="Fact_18e8f5f4b4bf470eb157dbdda1d79885">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="c20240101to20241231"
      id="Fact_21754fde14a747e1bc18ab04ee5e8ed7">001-31791</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="c20240101to20241231"
      id="Fact_953eabfdf9874804aff1aa19f6b0881e">GALECTIN THERAPEUTICS INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="c20240101to20241231"
      id="Fact_4f057a264fa44629bc712c8aaeb63d51">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="c20240101to20241231"
      id="Fact_a442f07f6924441883c9389d925957cf">04-3562325</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="c20240101to20241231"
      id="Fact_9b1b374e479a45eeb77ceeb840774e47">4960 Peachtree Industrial Blvd</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="c20240101to20241231"
      id="Fact_beabffa1284d4dc2b257ff74043b19a9">Suite 240</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="c20240101to20241231"
      id="Fact_b6a5751053ab4b6e8455e9314eedd6ec">Norcross</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="c20240101to20241231"
      id="Fact_71fa7d70e9d84d95a135b27a805d60f1">GA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="c20240101to20241231"
      id="Fact_0262fd809588421c8d8ffa119dbcbf89">30071</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="c20240101to20241231"
      id="Fact_955ba63ee38743d286f46c8419e7f2e9">678</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="c20240101to20241231"
      id="Fact_582e971dca4d431d9d5556d352f9f3a3">620-3186</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="c20240101to20241231"
      id="Fact_d2ee777d449841ffad449d4a32fd62d3">Common Stock, $0.001 Par Value Per Share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20240101to20241231"
      id="Fact_c0855df1a74b4623ae0742076a8ea271">GALT</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="c20240101to20241231"
      id="Fact_07ceb375ec1a49848e09aac01b59ce8e">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="c20240101to20241231"
      id="Fact_a04a1a5f92fd410f9d24b8ef4ad816f5">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="c20240101to20241231"
      id="Fact_08a13c58f71942ca9915f7e6f545f138">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="c20240101to20241231"
      id="Fact_b5f0b75412224e21a57d9cf92b0c50cc">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="c20240101to20241231"
      id="Fact_5e82b61e4c584356b6c36644bdc3f734">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="c20240101to20241231"
      id="Fact_90e8a6e744cd4a68b69b96e8f06ee0de">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="c20240101to20241231"
      id="Fact_854f2798404642e586e7572f74f65334">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20240101to20241231"
      id="Fact_bda773c3412c4710ac19396fa4a115d5">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="c20240101to20241231"
      id="Fact_bb55b33498bc4a509bfed4d47ced5f6b">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="c20240101to20241231"
      id="Fact_36b3ac4ee47645f9b1bee69e6d59d745">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="c20240101to20241231"
      id="Fact_fcbad44f818c474781665b0b63606aeb">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="c20240630"
      decimals="-6"
      id="Fact_7d3fc79be079490ab4b65a286b372783"
      unitRef="U001">112000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="c20250303"
      decimals="INF"
      id="Fact_9146d9ca18fb4c9eaadd1077bdf89fc1"
      unitRef="U002">63180491</dei:EntityCommonStockSharesOutstanding>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock
      contextRef="c20240101to20241231"
      id="Text_3b8ad099d87f4e5cb733d4babc97962b">
&lt;div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Risk management and strategy&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
            &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.3pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;We have policies and processes designed to protect our information technology systems, which are managed by outside consultants.&#160; Our cybersecurity consultants resolve issues in a timely manner in the event of a cybersecurity threat or
              incident.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
            &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.3pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;As part of our broader risk management framework, from time to time, we seek to identify potential cybersecurity risks to our business and improve our policies
              and processes to address such risks. We have designed our business applications to minimize the impact that cybersecurity incidents could have on our business and have identified back-up systems where appropriate. We seek to further mitigate
              cybersecurity risks through a combination of monitoring and detection activities, use of anti-malware applications, employee training, quality reviews and communication and reporting structures, among other processes. We have an incident
              response plan in place that outlines containment, eradication and recovery plans in the event of a cybersecurity threat or incident.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
            &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.3pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;We engage a third-party consultant to assist us with designing controls and our cybersecurity risk management framework. We are also engaging with a third party to perform penetration testing. We also retain third parties to assist with the monitoring and detection of cybersecurity
              threats and responding to any cybersecurity threats or incidents.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
            &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.3pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;With respect to third parties that manage or use our information technology or data, we obtain reports to assess the security of their systems and processes. We engage in ongoing monitoring of third-party providers to ensure compliance with our cybersecurity standards.&lt;br/&gt;
            &lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.3pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;We have not encountered cybersecurity threats or incidents that have had a material impact on our business.&lt;br/&gt;
            &lt;/div&gt;
</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock
      contextRef="c20240101to20241231"
      id="Text_5d70e5104c8f434294818c951b222848">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.3pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;We have policies and processes designed to protect our information technology systems, which are managed by outside consultants.&#160; Our cybersecurity consultants resolve issues in a timely manner in the event of a cybersecurity threat or
              incident.&lt;/div&gt;
</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag
      contextRef="c20240101to20241231"
      id="Fact_33ee45c031f84a49b187379990f32ab0">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag
      contextRef="c20240101to20241231"
      id="Fact_e496bc4be127456d8e33d49401e5cfe3">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag
      contextRef="c20240101to20241231"
      id="Fact_f325eaa8b5894dcba9d3d35eb2547d59">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock
      contextRef="c20240101to20241231"
      id="Text_ef625999d8304a4fa97dca43ce0e8714">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.3pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;We have not encountered cybersecurity threats or incidents that have had a material impact on our business.&lt;br/&gt;
            &lt;/div&gt;
</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag
      contextRef="c20240101to20241231"
      id="Fact_541575825c4e4cce88420c9e71066a92">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock
      contextRef="c20240101to20241231"
      id="Text_4c79b204119d48098ed2777c5a1222c4">
&lt;div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Cybersecurity Governance&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
            &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.3pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Our Nomination and Corporate Governance Committee has specific oversight responsibility for cybersecurity The Nomination and Corporate Governance Committee
              reviews and discusses with management our policies, practices and risks related to information security and cybersecurity.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
            &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.3pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Our chief financial officer has primary responsibility for assessing, monitoring and managing cybersecurity risks. We utilize cybersecurity consultants to monitor and
              report cybersecurity threats or incidents to our chief financial officer and to resolve issues arising from such threats or incidents.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
            &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.3pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Our chief financial officer updates the Nomination and Corporate Governance Committee on any risks related to cybersecurity as needed.&lt;br/&gt;
            &lt;/div&gt;
</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="c20240101to20241231"
      id="Text_3c237d91d5214797a307ee045d99e83d">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.3pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Our Nomination and Corporate Governance Committee has specific oversight responsibility for cybersecurity The Nomination and Corporate Governance Committee
              reviews and discusses with management our policies, practices and risks related to information security and cybersecurity.&lt;/div&gt;
</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock
      contextRef="c20240101to20241231"
      id="Text_86e7cc5936864b40be4f2bbbcd19eacc">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.3pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Our chief financial officer has primary responsibility for assessing, monitoring and managing cybersecurity risks. We utilize cybersecurity consultants to monitor and
              report cybersecurity threats or incidents to our chief financial officer and to resolve issues arising from such threats or incidents.&lt;/div&gt;
</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock
      contextRef="c20240101to20241231"
      id="Text_6d34d35cd2ac4f249b3b3c15bf2d98d8">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.3pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Our chief financial officer has primary responsibility for assessing, monitoring and managing cybersecurity risks. We utilize cybersecurity consultants to monitor and
              report cybersecurity threats or incidents to our chief financial officer and to resolve issues arising from such threats or incidents.&lt;/div&gt;
</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag
      contextRef="c20240101to20241231"
      id="Fact_61e6c7aae9134630a2630c17aba697ec">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="c20240101to20241231"
      id="Text_d3cbcebe11d74b7f9430dbc1a6471221">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.3pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Our chief financial officer updates the Nomination and Corporate Governance Committee on any risks related to cybersecurity as needed.&lt;br/&gt;
            &lt;/div&gt;
</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock
      contextRef="c20240101to20241231"
      id="Text_815c0823911d4a2fbf14e7ef0aa9d580">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.3pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Our chief financial officer updates the Nomination and Corporate Governance Committee on any risks related to cybersecurity as needed.&lt;br/&gt;
            &lt;/div&gt;
</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag
      contextRef="c20240101to20241231"
      id="Fact_5c80d41dfe4f4b08908f5c9373143a8e">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="c20241001to20241231"
      id="Fact_95a3b0644e3c49be8f3d8a96abeebfe2">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="c20241001to20241231"
      id="Fact_60a65f9e8aa04f079cf26741c3eebaed">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="c20241001to20241231"
      id="Fact_82bcbca26a994112b0f83d21a601a927">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="c20241001to20241231"
      id="Fact_77b30304038a4d8eabd7f4fc1c91f703">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag
      contextRef="c20241001to20241231"
      id="Fact_c1d19b1eecaa418ba1f794f7525c7d7b">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <dei:AuditorName
      contextRef="c20240101to20241231"
      id="Fact_901026108d70446cb6a2d7a5ab388d9a">Cherry Bekaert LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="c20240101to20241231"
      id="Fact_fc0377fc4feb48dea7e2d988c4739741">Atlanta, Georgia</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="c20241231"
      decimals="-3"
      id="Fact_bbca9e4a9ee94045a1b3d57cc99ac39c"
      unitRef="U001">15120000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="c20231231"
      decimals="-3"
      id="Fact_cd78e6af80e44c1c9bc4e9b5517e5f91"
      unitRef="U001">25660000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="c20241231"
      decimals="-3"
      id="Fact_4c65d4385b7c4217a3f492cfff23ae3a"
      unitRef="U001">2132000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_77fd02ab7d424de4b34c4096b176aceb"
      unitRef="U001">2050000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="c20241231"
      decimals="-3"
      id="Fact_1576b3cff5fb4d54a475fdce8e724783"
      unitRef="U001">17252000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_43ca7f4e57634d5383232c31c02f3848"
      unitRef="U001">27710000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="c20241231"
      decimals="-3"
      id="Fact_bffe5b1ce0ab4e5a909b42c22780024f"
      unitRef="U001">0</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="c20231231"
      decimals="-3"
      id="Fact_fa6dd7cac03b4114be09ff4d0c38dec3"
      unitRef="U001">0</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="c20241231"
      decimals="-3"
      id="Fact_497c39140ad345fa82f8de407a0c08de"
      unitRef="U001">243000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_5675bb4cad404edcad20cdd5ddcdb93a"
      unitRef="U001">490000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="c20241231"
      decimals="-3"
      id="Fact_88c758354ccf4fef83505a018c2f0ed0"
      unitRef="U001">17495000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="c20231231"
      decimals="-3"
      id="Fact_885a1d27eea24105bb05dfac97350eb2"
      unitRef="U001">28200000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="c20241231"
      decimals="-3"
      id="Fact_ddd9c3d55edb4e6f815a5260cdf498ed"
      unitRef="U001">5656000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_04ca153660d4427e83e4343c04e71791"
      unitRef="U001">6431000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="c20241231"
      decimals="-3"
      id="Fact_7198922d3f0d43708a6967569de22f21"
      unitRef="U001">8204000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_18f3f8f8bd2c4f828adc74491c226d86"
      unitRef="U001">9182000</us-gaap:AccruedLiabilitiesCurrent>
    <galt:ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyCurrent
      contextRef="c20241231"
      decimals="-3"
      id="Fact_982d13b386654698a996f80b90339db3"
      unitRef="U001">21117000</galt:ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyCurrent>
    <galt:ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyCurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_a965e3ea878d43c9879164f6c484afc7"
      unitRef="U001">0</galt:ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="c20241231"
      decimals="-3"
      id="Fact_7933d7fa11d74009b9137b8217447020"
      unitRef="U001">369000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_5469c02469f4437ab8812e10d59badee"
      unitRef="U001">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="c20241231"
      decimals="-3"
      id="Fact_0b2a760b84364a7a8a490208fe743549"
      unitRef="U001">63000</us-gaap:DividendsPayableCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_dee0d8e202754f529c69ce08b79abd5b"
      unitRef="U001">63000</us-gaap:DividendsPayableCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="c20241231"
      decimals="-3"
      id="Fact_aef721c9a6584cddac579602c463f775"
      unitRef="U001">35409000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_ff1d4830a1ce490a9bef12e2bd52f090"
      unitRef="U001">15676000</us-gaap:LiabilitiesCurrent>
    <galt:ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent
      contextRef="c20241231"
      decimals="-3"
      id="Fact_3b21ee8e01d14a0c9d84995d050d74e5"
      unitRef="U001">10733000</galt:ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent>
    <galt:ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_3282f47d80c94d4c91728230f2d2d23c"
      unitRef="U001">30902000</galt:ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="c20241231"
      decimals="-3"
      id="Fact_1b28fec860e94ab69fff62381d387edf"
      unitRef="U001">47000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_60f5420e19f84873a6d755a8d72b2f99"
      unitRef="U001">1004000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <galt:BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent
      contextRef="c20241231"
      decimals="-3"
      id="Fact_02b53b63f3af45edabf1f7a488504fc8"
      unitRef="U001">74376000</galt:BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent>
    <galt:BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_77bd1182e43642b2b5ff1e2e6986a1de"
      unitRef="U001">40839000</galt:BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="c20241231"
      decimals="-3"
      id="Fact_cb594bdfa02c46538b17609f6a84d3d8"
      unitRef="U001">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_365546d0d7fc47498dbd9618394a14c9"
      unitRef="U001">20000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="c20241231"
      decimals="-3"
      id="Fact_f8b2211ecfd44328938316119df04c0f"
      unitRef="U001">120565000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="c20231231"
      decimals="-3"
      id="Fact_f38a12ebb5734a93a0cc22d830a4fa4c"
      unitRef="U001">88441000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c20241231"
      id="Fact_fff5fbc7fbf24f2dac3658bc72b91145"
      unitRef="U001"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c20231231"
      id="Fact_13b532b1af064425868750deae19da4d"
      unitRef="U001"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="c20231231"
      decimals="0"
      id="Fact_a6b80c15a58f48888fa994d92343b0bc"
      unitRef="U002">1000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="c20241231"
      decimals="0"
      id="Fact_ae7a40d2cea84c0899acd9d8dee394a3"
      unitRef="U002">1000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c20231231"
      decimals="0"
      id="Fact_142b696c418b481585ef3986e174fe72"
      unitRef="U002">176</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c20241231"
      decimals="0"
      id="Fact_8b7d057252e1455380c977f85d38f644"
      unitRef="U002">176</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="c20231231"
      decimals="0"
      id="Fact_75058e81a86f41c18252dd1e0831d4a0"
      unitRef="U002">176</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="c20241231"
      decimals="0"
      id="Fact_1c5b94f5e7734b64bb9e35d5c28ee441"
      unitRef="U002">176</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquityAggregateAmountOfRedemptionRequirement
      contextRef="c20241231"
      decimals="0"
      id="Fact_37805c8bc3d64de19446724331e8eb6b"
      unitRef="U001">8018000</us-gaap:TemporaryEquityAggregateAmountOfRedemptionRequirement>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="c20241231"
      decimals="0"
      id="Fact_d3ffbdd803ed443292a2a5cbe3c3ad67"
      unitRef="U001">1760000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="c20241231"
      decimals="-3"
      id="Fact_1ef31a93785748fcbff533e50235f114"
      unitRef="U001">1723000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_2a02a2161fdc4c44b23a7cdd3e96e92e"
      unitRef="U001">1723000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <galt:UndesignatedCapitalStockParValue
      contextRef="c20231231"
      decimals="2"
      id="Fact_bd6d6bee829048a0ac65480a4105c591"
      unitRef="U003">0.01</galt:UndesignatedCapitalStockParValue>
    <galt:UndesignatedCapitalStockParValue
      contextRef="c20241231"
      decimals="2"
      id="Fact_4977a342dc974770b077501cdeb4a06f"
      unitRef="U003">0.01</galt:UndesignatedCapitalStockParValue>
    <galt:UndesignatedCapitalStockSharesAuthorized
      contextRef="c20231231"
      decimals="0"
      id="Fact_42a7f1152bf94d03a3ca821c2ea48ee8"
      unitRef="U002">20000000</galt:UndesignatedCapitalStockSharesAuthorized>
    <galt:UndesignatedCapitalStockSharesAuthorized
      contextRef="c20241231"
      decimals="0"
      id="Fact_9a6fe323594e4b088638118d810150e1"
      unitRef="U002">20000000</galt:UndesignatedCapitalStockSharesAuthorized>
    <galt:UndesignatedCapitalStockSharesDesignated
      contextRef="c20231231"
      decimals="0"
      id="Fact_bb49bd5d0ec64f51ab62e56d06d224da"
      unitRef="U002">20000000</galt:UndesignatedCapitalStockSharesDesignated>
    <galt:UndesignatedCapitalStockSharesDesignated
      contextRef="c20241231"
      decimals="0"
      id="Fact_ab604681a2b647abb26c38c48f148f87"
      unitRef="U002">20000000</galt:UndesignatedCapitalStockSharesDesignated>
    <galt:UndesignatedCapitalStockValue
      contextRef="c20241231"
      decimals="-3"
      id="Fact_4924f7f276b1452184d94ee92b435427"
      unitRef="U001">0</galt:UndesignatedCapitalStockValue>
    <galt:UndesignatedCapitalStockValue
      contextRef="c20231231"
      decimals="-3"
      id="Fact_98e3289c235d4c33bab0a3e64ce46529"
      unitRef="U001">0</galt:UndesignatedCapitalStockValue>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c20231231"
      decimals="0"
      id="Fact_0c8041630b12436dae0237398190c89d"
      unitRef="U002">1742500</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c20241231"
      decimals="0"
      id="Fact_6aaf538e1dae41f984a96bdc2804ff4a"
      unitRef="U002">1742500</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c20241231"
      decimals="0"
      id="Fact_a65882718f254f6f8618ddce54a58a8c"
      unitRef="U002">1235000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c20241231"
      decimals="0"
      id="Fact_6a9c5078cc494cfbb3daba52fdd9a056"
      unitRef="U002">1235000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c20231231"
      decimals="0"
      id="Fact_484dcd99f8ef4c0a8b076da6e8a4287a"
      unitRef="U002">1235000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c20231231"
      decimals="0"
      id="Fact_360a8fda2d0e4b62b8d77c07ec32cfad"
      unitRef="U002">1235000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockLiquidationPreferenceValue
      contextRef="c20241231"
      decimals="-3"
      id="Fact_7318283e140343bbb6823dd12ca10091"
      unitRef="U001">1235000000</us-gaap:PreferredStockLiquidationPreferenceValue>
    <us-gaap:PreferredStockValue
      contextRef="c20241231"
      decimals="-3"
      id="Fact_62563c5aceb1491d87cc3c3dac37aa26"
      unitRef="U001">500000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="c20231231"
      decimals="-3"
      id="Fact_313563c914b34c118f368ab06eae96c6"
      unitRef="U001">500000</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c20231231"
      decimals="3"
      id="Fact_95b7426ec1544df5bb84d192c3ff410d"
      unitRef="U003">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c20241231"
      decimals="3"
      id="Fact_ec67611e468e4149bf52d270d7c65614"
      unitRef="U003">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c20241231"
      decimals="0"
      id="Fact_d25b7fc87d0c4bc499950bc8f2899a04"
      unitRef="U002">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c20231231"
      decimals="0"
      id="Fact_6759c49cd8114b11953310e387f6b016"
      unitRef="U002">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c20241231"
      decimals="0"
      id="Fact_b2090e5612144a4f91754172bfc48860"
      unitRef="U002">63157235</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c20241231"
      decimals="0"
      id="Fact_4011c44b62884958b8888c91ec932024"
      unitRef="U002">63157235</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c20231231"
      decimals="0"
      id="Fact_d3d1e3b12e4b4387aba22cf738dc2cd0"
      unitRef="U002">61852914</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c20231231"
      decimals="0"
      id="Fact_a9f5c35c00fe4a0cadb7f3c906e31ecd"
      unitRef="U002">61852914</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="c20241231"
      decimals="-3"
      id="Fact_40b2da82d2c846f6baecaa21989eea2a"
      unitRef="U001">62000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="c20231231"
      decimals="-3"
      id="Fact_1be985dca9d54962bc927d3ecb4d1dac"
      unitRef="U001">61000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="c20241231"
      decimals="-3"
      id="Fact_1e55a9f7daa94d2eb9face6dedbae45c"
      unitRef="U001">296217000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="c20231231"
      decimals="-3"
      id="Fact_f5e7d8f294404b0699473fcb238c1747"
      unitRef="U001">291847000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="c20241231"
      decimals="-3"
      id="Fact_358920cc6ea84fcda9afd39b3ebdb18f"
      unitRef="U001">-401572000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="c20231231"
      decimals="-3"
      id="Fact_56d738c77d6148668b8bf6f7de93b5be"
      unitRef="U001">-354372000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="c20241231"
      decimals="-3"
      id="Fact_305370a981e34253914babe9eedf1c6e"
      unitRef="U001">-104793000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20231231"
      decimals="-3"
      id="Fact_4e41920def004bcd8011d0f39fac11af"
      unitRef="U001">-61964000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="c20241231"
      decimals="-3"
      id="Fact_097b0c69ec7e4542bffa879e41974a4e"
      unitRef="U001">17495000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="c20231231"
      decimals="-3"
      id="Fact_54b1f80104884777b1173d20a4777fe6"
      unitRef="U001">28200000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_c7e8bde7f8544a12a7651d0e8617eef9"
      unitRef="U001">36571000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_73d3766bbdfd4ccc94527b4ed056b1cc"
      unitRef="U001">32130000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_708f1f29ad664bc799b8cd5f369872d8"
      unitRef="U001">5862000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_0103e2e8df6e449e86f0fbacc18c94bb"
      unitRef="U001">5942000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_e84e796fe00c4cd18da7b60ff7439ed1"
      unitRef="U001">42433000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_56e43da523ac46329e6f1012b8cb01bf"
      unitRef="U001">38072000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_fe7750176f83440fbf05029b10f16685"
      unitRef="U001">-42433000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_6e78d032a8094674ad40a950be5a6973"
      unitRef="U001">-38072000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_319661290cfe4f5a8b25ff7f8fc2b031"
      unitRef="U001">338000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_ba5b66ff13a84069a4ea924716baf4d5"
      unitRef="U001">230000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpenseNonoperating
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_119ebc778e4a4c3a8ccb01fbd9de95b8"
      unitRef="U001">5540000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_c6b63b7dbae44a72ba197ad2a339f887"
      unitRef="U001">2792000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_334fb373b5d24970a2f6861cb96088d2"
      unitRef="U001">588000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_df6dec1129f74e7397aed70b100013b1"
      unitRef="U001">-432000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_3ba3ab21b0534fe1b40070455c912f9d"
      unitRef="U001">-4614000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_0adcbe74280448c9824b47ca74ecacf8"
      unitRef="U001">-2994000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_89ff8c69f7fe4a7c9d56dc5fb14e0d89"
      unitRef="U001">-47047000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_58c1ddfe88c5468fa46d1b79a74cca2c"
      unitRef="U001">-41066000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_ba4ac9d52d7b4d19a9ddb1512788bea6"
      unitRef="U001">153000</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_50a7a24246b34425b3a23afdbfd28c4d"
      unitRef="U001">120000</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <galt:FairValueAdjustmentOfWarrant
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_2c30dad60e854ab3a6b95ce386a94388"
      unitRef="U001">0</galt:FairValueAdjustmentOfWarrant>
    <galt:FairValueAdjustmentOfWarrant
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_9bf3db2c0a0d4f97adcf9a6ec7eaa5dd"
      unitRef="U001">3619000</galt:FairValueAdjustmentOfWarrant>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_2f49fad7c5a849dabfab00fa2ace30c9"
      unitRef="U001">-47200000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_7c5ca9d4558049c3b2e8a7b142901bda"
      unitRef="U001">-44805000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20240101to20241231"
      decimals="2"
      id="Fact_aaf0b80d115441a296d54e7ae8f4e88a"
      unitRef="U003">-0.76</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20240101to20241231"
      decimals="2"
      id="Fact_742dd2241498481da149fbd263314de2"
      unitRef="U003">-0.76</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20230101to20231231"
      decimals="2"
      id="Fact_941b465d135a4e348d28242bdf11dc98"
      unitRef="U003">-0.74</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20230101to20231231"
      decimals="2"
      id="Fact_231d72b27d434d0e851bd47e049f1d78"
      unitRef="U003">-0.74</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_dd1d17180cf1486789587fdff9364463"
      unitRef="U002">62309000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_ef8c8ef405014a59934833c645da0812"
      unitRef="U002">62309000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_459fb8f6c3b14ca4a3662af73b76fb53"
      unitRef="U002">60159000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_fdd2c146ea0f4ef6ad779dc61d535609"
      unitRef="U002">60159000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c20221231"
      decimals="0"
      id="Fact_57260f8149784c33a75d0826024e9db5"
      unitRef="U002">176</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="c20221231"
      decimals="-3"
      id="Fact_a65e9609ac4c43e894b8f6c01ac4bec5"
      unitRef="U001">1723000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c20231231"
      decimals="0"
      id="Fact_8dded3da2fb94045890683f7ccced236"
      unitRef="U002">176</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_ba2c6c20e0124d95bcc8d53e23824c45"
      unitRef="U001">1723000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c20241231"
      decimals="0"
      id="Fact_6702def6d03146c2b4bb37faa54a5cd0"
      unitRef="U002">176</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="c20241231"
      decimals="-3"
      id="Fact_054b2693e9fd4ade867614d3344dd388"
      unitRef="U001">1723000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="c20221231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="0"
      id="Fact_3c87f7d102cd49759256d5c94e47fdf1"
      unitRef="U002">1260000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20221231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_1deaaad821414238b346a03bf7e03626"
      unitRef="U001">510000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c20221231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_4db1d1740c2a48f586e5474f1c49c416"
      unitRef="U002">59426005</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20221231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_be795687cb3c4136ba53a15d4573400f"
      unitRef="U001">59000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_ab589d305254411981781407d3297bf4"
      unitRef="U001">275081000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20221231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_c5a85feee317465aacb47a8ceb700d8f"
      unitRef="U001">-309567000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20221231"
      decimals="-3"
      id="Fact_d49412b136364a33a9c727e49a6475da"
      unitRef="U001">-33917000</us-gaap:StockholdersEquity>
    <galt:ConvertiblePreferredStockDividendsShares
      contextRef="c20230101to20231231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_49ad3af2bc8c41279fe2587c9b3c61e4"
      unitRef="U002">25200</galt:ConvertiblePreferredStockDividendsShares>
    <galt:ConvertiblePreferredStockDividends
      contextRef="c20230101to20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_753ada14bb544a218c4fc6864dd13194"
      unitRef="U001">50000</galt:ConvertiblePreferredStockDividends>
    <galt:ConvertiblePreferredStockDividends
      contextRef="c20230101to20231231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_ad9d8c731301437094f15acc4d6e5c61"
      unitRef="U001">-50000</galt:ConvertiblePreferredStockDividends>
    <galt:TemporaryEquityDividendsShares
      contextRef="c20230101to20231231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_b6c8e4382d4a498f82534eb1cb13052d"
      unitRef="U002">35200</galt:TemporaryEquityDividendsShares>
    <galt:TemporaryEquityDividends
      contextRef="c20230101to20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_89088549a1e64265baecebdeaee29680"
      unitRef="U001">-70000</galt:TemporaryEquityDividends>
    <galt:TemporaryEquityDividends
      contextRef="c20230101to20231231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_7fb5df5d4ac3488aaf8cc17ab8eb7f26"
      unitRef="U001">70000</galt:TemporaryEquityDividends>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c20230101to20231231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="0"
      id="Fact_877f640437c7425a9efbd6be7da2afb5"
      unitRef="U002">-25000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c20230101to20231231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_f827682236cb4dc8aba82a9abf7f3e38"
      unitRef="U001">-10000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c20230101to20231231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_4e8436011f7947dabbad6d50263ce8c0"
      unitRef="U002">4257</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c20230101to20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_0bd6f4f8aeb7402c863b546cf549edee"
      unitRef="U001">10000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <galt:StockIssuedDuringPeriodSharesWarrantExercise
      contextRef="c20230101to20231231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_192f9e5309e1472f900922bccf242a56"
      unitRef="U002">2236204</galt:StockIssuedDuringPeriodSharesWarrantExercise>
    <galt:StockIssuedDuringPeriodValueWarrantExercise
      contextRef="c20230101to20231231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_6bace7c72ee84b29af7ef11afa364503"
      unitRef="U001">2000</galt:StockIssuedDuringPeriodValueWarrantExercise>
    <galt:StockIssuedDuringPeriodValueWarrantExercise
      contextRef="c20230101to20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_cfd4ab1fc3be416da6cc1f988216598c"
      unitRef="U001">10031000</galt:StockIssuedDuringPeriodValueWarrantExercise>
    <galt:StockIssuedDuringPeriodValueWarrantExercise
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_18dbae7aed2e429ca8eda5e38bc8883c"
      unitRef="U001">10033000</galt:StockIssuedDuringPeriodValueWarrantExercise>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c20230101to20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_93c178a3da19438381b7af7e15659a2f"
      unitRef="U001">671000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_099b618a1bd841ea9ce2718f23ce0d94"
      unitRef="U001">671000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <galt:WarrantModificationIncreaseDecreaseInEquityAmount
      contextRef="c20230101to20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_69af7fbd6c56407e8cd5a59fa09d8499"
      unitRef="U001">3619000</galt:WarrantModificationIncreaseDecreaseInEquityAmount>
    <galt:WarrantModificationIncreaseDecreaseInEquityAmount
      contextRef="c20230101to20231231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_6b93044f4a0c48ff8cd19f14f3afb5a0"
      unitRef="U001">-3619000</galt:WarrantModificationIncreaseDecreaseInEquityAmount>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="c20230101to20231231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_b08b4ee9eebe416eb52ac8896c08bbae"
      unitRef="U002">126048</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20230101to20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_977262688b8f4253973c1cb301eaae14"
      unitRef="U001">2315000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_b365f87a01d14d2c8cb18a764c7af863"
      unitRef="U001">2315000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="c20230101to20231231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_859aa4d02db34ceeb085bf425ca5793a"
      unitRef="U001">-41066000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_6399920251fb422d8510e48e254bff73"
      unitRef="U001">-41066000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c20231231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="0"
      id="Fact_86e8156ee26a48879993dc0b64dfa2f6"
      unitRef="U002">1235000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20231231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_1d8507c954414b219b8fd07e7f7b7f4c"
      unitRef="U001">500000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c20231231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_19781b40a526446fbc032408e3d86410"
      unitRef="U002">61852914</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20231231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_0904471724734e2082930cd8f1d44871"
      unitRef="U001">61000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_56b7d9d9cdd14e69bf6e8f2f35ef32bf"
      unitRef="U001">291847000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20231231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_8d66303f374148f2a0cdb5939ea401d5"
      unitRef="U001">-354372000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20231231"
      decimals="-3"
      id="Fact_ccc9c93ff99b4c57a5068c330917eebd"
      unitRef="U001">-61964000</us-gaap:StockholdersEquity>
    <galt:ConvertiblePreferredStockDividendsShares
      contextRef="c20240101to20241231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_586eaf6fa6ea4a27a4dabbf192b4f137"
      unitRef="U002">24700</galt:ConvertiblePreferredStockDividendsShares>
    <galt:ConvertiblePreferredStockDividends
      contextRef="c20240101to20241231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_9551a7435ac24758a70ee6e66524bf93"
      unitRef="U001">64000</galt:ConvertiblePreferredStockDividends>
    <galt:ConvertiblePreferredStockDividends
      contextRef="c20240101to20241231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_c0cc495c1ee54383b03c43509276a1ca"
      unitRef="U001">-64000</galt:ConvertiblePreferredStockDividends>
    <galt:TemporaryEquityDividendsShares
      contextRef="c20240101to20241231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_9d17e78d958a4bddaec7ff43781a2bff"
      unitRef="U002">35200</galt:TemporaryEquityDividendsShares>
    <galt:TemporaryEquityDividends
      contextRef="c20240101to20241231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_bca485e916c940aa81821e4c35d0800d"
      unitRef="U001">-89000</galt:TemporaryEquityDividends>
    <galt:TemporaryEquityDividends
      contextRef="c20240101to20241231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_b93dfabd25a64b278210a4fc3a2d5b55"
      unitRef="U001">89000</galt:TemporaryEquityDividends>
    <galt:StockIssuedDuringPeriodSharesWarrantExercise
      contextRef="c20240101to20241231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_b51f6b23474e4ff0878bc976d4dcdf3e"
      unitRef="U002">142370</galt:StockIssuedDuringPeriodSharesWarrantExercise>
    <galt:StockIssuedDuringPeriodValueWarrantExercise
      contextRef="c20240101to20241231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_470cafbfb09b43919adb4278bd500ef5"
      unitRef="U001">1000</galt:StockIssuedDuringPeriodValueWarrantExercise>
    <galt:StockIssuedDuringPeriodValueWarrantExercise
      contextRef="c20240101to20241231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_baf69a505b554a5abb91c81802f22f38"
      unitRef="U001">427000</galt:StockIssuedDuringPeriodValueWarrantExercise>
    <galt:StockIssuedDuringPeriodValueWarrantExercise
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_c7f88344ca51425b996b27b60f7ef6e0"
      unitRef="U001">428000</galt:StockIssuedDuringPeriodValueWarrantExercise>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c20240101to20241231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_3393cd8f1c0b4f749b5f62c9b66ae170"
      unitRef="U002">473370</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20240101to20241231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_366fb6c21c3c42f7ac09d7c997802b4e"
      unitRef="U001">799000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_76d41d6ab41b4f78bde36d810a163d48"
      unitRef="U001">799000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="c20240101to20241231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_ad36457bbb6d44af8bd9aa287dcab527"
      unitRef="U002">378000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c20240101to20241231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_041090d334e04405b928f98c18d48412"
      unitRef="U001">845000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_274005e1208a4e6a8234cd3342ac6dd5"
      unitRef="U001">845000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="c20240101to20241231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_ebaf1d4c03c64d03a0422661aca80e72"
      unitRef="U002">250548</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20240101to20241231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_9ff7a5d6caf442ffb1cc8f9c97cedb77"
      unitRef="U001">2146000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_72fb30f184e14fbba282310673438801"
      unitRef="U001">2146000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="c20240101to20241231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_db4ba997d0aa4f54892ec553b5a7a39d"
      unitRef="U001">-47047000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_f35bc8d3156a4e4a847e3fa13ee66ee1"
      unitRef="U001">-47047000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c20241231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="0"
      id="Fact_94fd06f95bc24fc3b04181f0b802a0d5"
      unitRef="U002">1235000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20241231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_bf96460a203448b3a55abae46fa419a1"
      unitRef="U001">500000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c20241231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_a0a76a1e16284b9a9486fe9024f16dbd"
      unitRef="U002">63157235</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20241231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_69d09af51ae846ff9f1ef4f3d5b85e92"
      unitRef="U001">62000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20241231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_a840f54e14d642048ca195141e6bd53a"
      unitRef="U001">296217000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20241231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_02797e623cbf4ecd87d5b0f8b9fb02b7"
      unitRef="U001">-401572000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20241231"
      decimals="-3"
      id="Fact_ce28eb8bbfe84be28741db7d2e3b500c"
      unitRef="U001">-104793000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_4114b34d5fd145bd9fd4fad2e251c860"
      unitRef="U001">-47047000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_3cebf1671f2a4b96b7bc5ee62610028a"
      unitRef="U001">-41066000</us-gaap:NetIncomeLoss>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_16e1f17e54674154b77472be9df32fa6"
      unitRef="U001">37000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_ea59af9643a044aaab6d533225c92029"
      unitRef="U001">33000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_2cab8b70a6944746a3ed58ebb1b72549"
      unitRef="U001">2447000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_9d54680d04de4f89804adc0aafe60c50"
      unitRef="U001">2261000</us-gaap:ShareBasedCompensation>
    <us-gaap:PaidInKindInterest
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_0d1d6d6034a04a0686c5a94a0199846b"
      unitRef="U001">1100000</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_e0441861310940fdbae77bd43a3e8c40"
      unitRef="U001">697000</us-gaap:PaidInKindInterest>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_71bc96a667004de9acd5bf20197c1f17"
      unitRef="U001">-588000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_48e96c38a32748ce8c849dc385459011"
      unitRef="U001">432000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_33f7059acce44ff3b16af780cda70da9"
      unitRef="U001">82000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_10d1e62a950843c8b05b9aa42d0ea5f3"
      unitRef="U001">90000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_0f6804f36ac7411494eca796fc06b6e5"
      unitRef="U001">4440000</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_5660f13310bf452f936dd53d209f4217"
      unitRef="U001">2097000</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_5d7e6b8c01f04e4bbe5547a15422b318"
      unitRef="U001">-2074000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_a89913ce81124309ac5f91ec32285ad6"
      unitRef="U001">2671000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_cc2dee6c27664a4d9c2b0f46f7a76486"
      unitRef="U001">-41767000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_600ac72197264f7ebda6ccb8f4ac1d82"
      unitRef="U001">-32965000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_6d2ff7ece99a4ff19996082b9b252c9d"
      unitRef="U001">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_12156c678bfa437e8384f2000906f951"
      unitRef="U001">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_d5fa6fafabf84eb3a7bc71224135e1af"
      unitRef="U001">30000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_45c485eee2514c7e987eec45dd4c62d4"
      unitRef="U001">30000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_361c3c30029e4acf9df442b3f441951a"
      unitRef="U001">1227000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_05f53fe537fd4a2aa771ff5cfaac2860"
      unitRef="U001">10033000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_4bf27a7c58c44144a7d114478fcb072a"
      unitRef="U001">31227000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_7731ff9c232a4eaba47e05651a952bc5"
      unitRef="U001">40033000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_9626c2c9170c48a3a6689e3b2e70d36f"
      unitRef="U001">-10540000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_a2e50081d77241a5bb4df251f0648def"
      unitRef="U001">7068000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20231231"
      decimals="-3"
      id="Fact_fe329329184a4fd08ee89a4d735064a5"
      unitRef="U001">25660000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20221231"
      decimals="-3"
      id="Fact_b1f0380f94194989876c9bdbdb97bb75"
      unitRef="U001">18592000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20241231"
      decimals="-3"
      id="Fact_6a1aaeef3516463f9c0ba1dc1d32b032"
      unitRef="U001">15120000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20231231"
      decimals="-3"
      id="Fact_f65b706c6a804afc88b577fbd24c1ced"
      unitRef="U001">25660000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:StockIssued1
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_676c593f2cb64b3b99227a5e855bfa39"
      unitRef="U001">91000</us-gaap:StockIssued1>
    <us-gaap:StockIssued1
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_ec26df895ed34cb7919610c0c07dcac4"
      unitRef="U001">120000</us-gaap:StockIssued1>
    <galt:ReclassificationOfAccruedBonusToAdditionalPaidInCapital
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_485ea77e997a4ba89a5e9b6a0e9c6c1b"
      unitRef="U001">0</galt:ReclassificationOfAccruedBonusToAdditionalPaidInCapital>
    <galt:ReclassificationOfAccruedBonusToAdditionalPaidInCapital
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_ed9cf0a0ee70486d9b95a8b6f06c1d1d"
      unitRef="U001">210000</galt:ReclassificationOfAccruedBonusToAdditionalPaidInCapital>
    <galt:CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_f5fae8713af3428fa88b68459d380088"
      unitRef="U001">845000</galt:CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit>
    <galt:CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_a1fe9c08f3b449eb8f259d23cbfcb396"
      unitRef="U001">671000</galt:CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="c20240101to20241231"
      id="Text_bfab20d001ab4043a7b33c71ade0e2a5">
&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 27.05pt; vertical-align: top; font-weight: bold;"&gt;1.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
              &lt;div style="font-weight: bold;"&gt;Nature of Business, Basis of Presentation, Liquidity, and Going Concern&lt;br/&gt;
              &lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Galectin Therapeutics Inc. and subsidiaries (the &#x201c;Company&#x201d;) is a clinical stage biopharmaceutical company that is applying its leadership in galectin science and drug
        development to create new therapies for fibrotic disease and cancer. These candidates are based on the Company&#x2019;s targeting of galectin proteins which are key mediators of biologic and pathologic function. These compounds also may have application
        for drugs to treat other diseases and chronic health conditions.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company was founded in July 2000, was incorporated in the State of Nevada in January 2001 under the name &#x201c;Pro-Pharmaceuticals, Inc.,&#x201d; and changed its name to
        &#x201c;Galectin Therapeutics Inc.&#x201d; on May 26, 2011.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The Company has operated at a loss since its inception and has had no revenues. The Company anticipates that losses will continue for the foreseeable future. At December 31, 2024, the company had $15,120,000 of unrestricted cash and cash equivalents available to fund future operations. As of December 31, 2024, the Company has available
          borrowings under a line of credit in the amount of $6 million provided by our chairman, Richard Uihlein, (See Notes 10). Additionally,
          in March 2025, we signed a new supplemental line of credit agreement with our chairman for an additional $5 million of available
          borrowings (See Note 16). The Company believes there is sufficient cash, including availability of the two lines of credit, to fund
          currently planned operations through August 2025. To meet its future capital needs, the Company intends to raise additional capital through debt or equity financings, collaborations, partnerships or other strategic transactions. However, there
          can be no assurance that the Company will be able to complete any such transactions on acceptable terms or otherwise. The inability of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on
          the Company&#x2019;s business, results of operations and financial condition.&lt;br/&gt;
        &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company is subject to a number of risks similar to those of clinical stage companies, including dependence on key individuals, uncertainty of product development
        and generation of revenues, dependence on outside sources of capital, risks associated with clinical trials of products, dependence on third-party collaborators for research operations, need for regulatory approval of products, risks associated
        with protection of intellectual property, and competition with larger, better-capitalized companies. Successful completion of the Company&#x2019;s development program and, ultimately, the attainment of profitable operations is dependent upon future
        events, including obtaining adequate financing to fulfill its development activities and achieving a level of revenues adequate to support the Company&#x2019;s cost structure. There are no assurances that the Company will be able to obtain additional
        financing on favorable terms, or at all, or successfully market its products.&lt;/div&gt;
</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="c20241231"
      decimals="-3"
      id="Fact_ef0c0e4e421c428fb33c56bcc58c97bb"
      unitRef="U001">15120000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="c20241231_CreditFacilityAxis_LineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="-6"
      id="Fact_52fed55ceb584ba59e5cd009da127582"
      unitRef="U001">6000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="c20250331_CreditFacilityAxis_SupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_SubsequentEventTypeAxis_SubsequentEventMember"
      decimals="-6"
      id="Fact_dfb8733d4e3640d9a81d2bb8d418cbe9"
      unitRef="U001">5000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <galt:NumberOfLineOfCredit
      contextRef="c20240101to20241231"
      decimals="INF"
      id="Fact_6b50c7cf83d2489b8d0a5c096e42405e"
      unitRef="U004">2</galt:NumberOfLineOfCredit>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="c20240101to20241231"
      id="Text_22755ad67a6841ae90ef10504916f40a">
&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 27.05pt; vertical-align: top; font-weight: bold;"&gt;2.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
            &lt;div style="font-weight: bold;"&gt;Summary of Significant Accounting Policies&lt;/div&gt;
          &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
    &lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (&#x201c;GAAP&#x201d;).&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
    &lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-style: italic;"&gt;Basis of Consolidation.&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; The consolidated
        financial statements include the accounts of the Company and Galectin Therapeutics Security Corp., its wholly-owned subsidiary, which was incorporated in Delaware on December 23, 2003 and Galectin Sciences LLC (see Note 13). All intercompany
        transactions have been eliminated.&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
    &lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-style: italic;"&gt;Use of Estimates.&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; The preparation of financial
        statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and judgments that may affect the reported amounts of assets, liabilities, equity, revenue, expenses and
        related disclosure of contingent assets and liabilities. Management&#x2019;s estimates and judgments include assumptions used in stock option valuations, accrued liabilities, derivative valuations, deferred income taxes and various other assumptions that
        are believed to be reasonable under the circumstances. Actual results may differ from those estimates under different assumptions or conditions.&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
    &lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-style: italic;"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;. The Company has certain
        financial assets and liabilities recorded at fair value. Fair values determined by Level 1 inputs utilize observable data such as quoted prices in active markets. Fair values determined by Level 2 inputs utilize data points other than quoted prices
        in active markets that are observable either directly or indirectly. Fair values determined by Level 3 inputs utilize unobservable data points in which there is little or no market data, which require the reporting entity to develop its own
        assumptions. The estimated value of accounts payable and accrued expenses approximates their carrying value due to their short-term nature. See&lt;/span&gt; Footnote 6 for Fair Value of Derivatives related to Convertible Notes Payable at December 31,
      2024 and 2023, which are level 3 liabilities. &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
    &lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-style: italic;"&gt;Cash and Cash Equivalents.&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; The Company considers
        all highly-liquid investments with original maturities of 90 days or less at the time of acquisition to be cash equivalents. The Company had no
        cash equivalents at December 31, 2024 or 2023.&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
    &lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-style: italic;"&gt;Prepaid Expenses and Other Current Assets.&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;
        Prepaid expenses and other assets consist principally of prepaid insurance, deposits related to the NAVIGATE trial and deferred financing costs (see Note 10).&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
    &lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-style: italic;"&gt;Property and Equipment.&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; Property and equipment,
        including leasehold improvements, are stated at cost, net of accumulated depreciation and amortization, and are depreciated or amortized using the straight-line method over the estimated useful lives of the related assets of generally three years for computers and office equipment, five years
        for furniture and fixtures and the shorter of the useful life or life of the lease for leasehold improvements.&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
    &lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-style: italic;"&gt;Security Deposit.&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; At December 31, 2024 and 2023,
        the Company had a security deposit of $6,000 for leased office space included in Prepaid Expenses and Other Current Assets.&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
    &lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-style: italic;"&gt;Long-Lived Assets.&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; The Company reviews all
        long-lived assets for impairment whenever events or circumstances indicate the carrying amount of such assets may not be recoverable. Recoverability of assets to be held or used is measured by comparison of the carrying value of the asset to the
        future undiscounted net cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment recognized is measured by the amount by which the carrying value of the asset exceeds the discounted future cash
        flows expected to be generated by the asset. There were no impairments of long-lived assets at December 31, 2024 or 2023.&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
    &lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-style: italic;"&gt;Accrued Expenses&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;. As part of the process of
        preparing our consolidated financial statements, we are required to estimate accrued expenses. This process involves identifying services that third parties have performed on our behalf and estimating the level of service performed and the
        associated cost incurred on these services as of each balance sheet date in our consolidated financial statements. Examples of estimated accrued expenses include professional service fees, such as those arising from the services of attorneys and
        accountants and accrued payroll expenses. In connection with these service fees, our estimates are most affected by our understanding of the status and timing of services provided relative to the actual services incurred by the service providers.
        In the event that we do not identify certain costs that have been incurred or we under- or over-estimate the level of services or costs of such services, our reported expenses for a reporting period could be understated or overstated. The date on
        which certain services commence, the level of services performed on or before a given date, and the cost of services are often subject to our judgment. We make these judgments based upon the facts and circumstances known to us in accordance with
        accounting principles generally accepted in the U.S.&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
    &lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-style: italic;"&gt;Warrants.&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; The Company has issued common stock
        warrants in connection with the execution of certain equity and debt financings. The fair value of warrants is determined using the Black-Scholes option-pricing model using assumptions regarding volatility of our common share price, remaining life
        of the warrant, and risk-free interest rates at each period end. There were no warrant liabilities as of December 31, 2024 or 2023.&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
    &lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-style: italic;"&gt;Research and Development Expenses.&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; Research and
        development expenses, including personnel costs, allocated facility costs, lab supplies, outside services, contract laboratory costs related to manufacturing drug product, clinical trials and preclinical studies are charged to research and
        development expense as incurred. The Company accounts for nonrefundable advance payments for goods and services that will be used in future research and development activities as expense when the service has been performed or when the goods have
        been received. Our current NAVIGATE clinical trial is being supported by third-party contract research organizations, or CROs, and other vendors. We accrue expenses for clinical trial activities performed by CROs based upon the estimated amount of
        work completed on each trial. For clinical trial expenses and related expenses associated with the conduct of clinical trials, the significant factors used in estimating accruals include the number of patients enrolled, the number of active
        clinical sites, and the duration for which the patients have been enrolled in the trial. We monitor patient enrollment levels and related activities to the extent possible through internal reviews, review of contractual terms and correspondence
        with CROs. We base our estimates on the best information available at the time. We monitor patient enrollment levels and related activities to the extent possible through discussions with CRO personnel and based our estimates of clinical trial
        costs on the best information available at the time. However, additional information may become available to us which will allow us to make a more accurate estimate in future periods. In that event, we may be required to record adjustments to
        research and development expenses in future periods when the actual level of activity becomes more certain.&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
    &lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-style: italic;"&gt;Income Taxes.&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; The Company accounts for income
        taxes in accordance with the accounting rules that requires an asset and liability approach to accounting for income taxes based upon the future expected values of the related assets and liabilities. Deferred income tax assets and liabilities are
        determined based on the differences between the financial reporting and tax bases of assets and liabilities and for tax loss and credit carry forwards and are measured using the expected tax rates estimated to be in effect when such basis
        differences reverse. Valuation allowances are established, if necessary, to reduce the deferred tax asset to the amount that will, more likely than not, be realized.&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
    &lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-style: italic;"&gt;Concentration of Credit Risk.&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; Financial
        instruments that subject the Company to credit risk consist of cash and cash equivalents. The Company maintains cash and cash equivalents and certificates of deposit with well-capitalized financial institutions. At times, those amounts may exceed
        federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant credit risk beyond the normal credit risk associated with commercial banking relationships. The Company has no other
        significant concentrations of credit risk.&lt;/span&gt;&lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;br/&gt;
      &lt;/span&gt;&lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-style: italic;"&gt;Stock-Based Compensation.&lt;/span&gt; Stock-based compensation cost is measured at the grant date based on
      the fair value of the award and is recognized as expense over the service period, which generally represents the vesting period. For awards that have performance-based vesting conditions the Company recognizes the expense over the estimated period
      that the awards are expected to be earned. The Company generally uses the Black-Scholes option-pricing model to calculate the grant date fair value of stock options. The expense recognized over the service period is required to include an estimate of
      the awards that will be forfeited.&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin: 0px 0px 0px 24.45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; text-align: left;"&gt;Recently Adopted Accounting Pronouncements&lt;/div&gt;

&lt;div style="margin: 0px 0px 0px 24.45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; text-align: left;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin: 0px 0px 0px 24.45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"&gt;In November 2023, the FASB issued ASU 2023-07,&#160;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/span&gt;. This guidance is intended to improve reportable segment disclosure requirements through enhanced disclosures as well as clarify that
        entities with a single reportable segment are subject to new and existing segment reporting requirements. This guidance is effective for annual periods in fiscal years beginning after December 15, 2023, and interim periods within fiscal years
        beginning after December 15, 2024, with early adoption permitted. Entities must apply this guidance on a retrospective basis. Accordingly, the Company adopted this new standard for the fiscal year ended December 31, 2024. See footnote 15 for
        segment disclosures.&lt;/div&gt;

&lt;div style="margin: 0px 0px 0px 24.45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin: 0px 0px 0px 24.45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; text-align: left;"&gt;Recent Accounting Pronouncements - Yet to be Adopted&lt;/div&gt;

&lt;div style="margin: 0px 0px 0px 24.45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; text-align: left;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin: 0px 0px 0px 24.45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"&gt;In December 2023, the FASB issued ASU 2023-09,&#160;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate
        reconciliation and income taxes paid both in the United States and in foreign jurisdictions. This guidance is effective for fiscal years beginning after December 15, 2024 on a prospective basis, with the option to apply the standard
        retrospectively, and early adoption is permitted. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements.&lt;/div&gt;

&lt;div style="margin: 0px 0px 0px 24.45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin: 0px 0px 0px 24.45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"&gt;In November 2024, the FASB issued ASU 2024-03,&#160;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&lt;/span&gt;. The amendments in ASU 2024-03 address investor requests for more
        detailed expense information and require additional disaggregated disclosures in the notes to financial statements for certain categories of expenses that are included on the face of the income statement. This guidance is effective for fiscal years
        beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated
        financial statements.&lt;/div&gt;

&lt;div style="margin: 0px 0px 0px 24.45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin: 0px 0px 0px 24.45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"&gt;In November 2024, the FASB, issued ASUS 2024-04,&#160;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Debt- Debt with Conversions and Other Option.&#160;&lt;/span&gt;ASU 2024-04 is intended to clarify requirements for determining whether certain settlements of convertible debt instruments, including convertible debt instruments with
        cash conversion features or convertible debt instruments that are not currently convertible, should be accounted for as an induced conversion. This ASU is effective for all entities for annual reporting periods beginning after December 15, 2025,
        and interim reporting periods within those annual reporting periods, with early adoption permitted. The Company is currently evaluating the potential impact of this guidance on its disclosures.&lt;/div&gt;
</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="c20240101to20241231"
      id="Text_576bbc0ac16e42daa79f042194dc628e">
&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-style: italic;"&gt;Basis of Consolidation.&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; The consolidated
        financial statements include the accounts of the Company and Galectin Therapeutics Security Corp., its wholly-owned subsidiary, which was incorporated in Delaware on December 23, 2003 and Galectin Sciences LLC (see Note 13). All intercompany
        transactions have been eliminated.&lt;/span&gt;&lt;/div&gt;
</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="c20240101to20241231"
      id="Text_cfb371ba539d4092ae0bcc20029c66a9">
&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-style: italic;"&gt;Use of Estimates.&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; The preparation of financial
        statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and judgments that may affect the reported amounts of assets, liabilities, equity, revenue, expenses and
        related disclosure of contingent assets and liabilities. Management&#x2019;s estimates and judgments include assumptions used in stock option valuations, accrued liabilities, derivative valuations, deferred income taxes and various other assumptions that
        are believed to be reasonable under the circumstances. Actual results may differ from those estimates under different assumptions or conditions.&lt;/span&gt;&lt;/div&gt;
</us-gaap:UseOfEstimates>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="c20240101to20241231"
      id="Text_3aa92e6f871d41cab1ee670d224c8288">
&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-style: italic;"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;. The Company has certain
        financial assets and liabilities recorded at fair value. Fair values determined by Level 1 inputs utilize observable data such as quoted prices in active markets. Fair values determined by Level 2 inputs utilize data points other than quoted prices
        in active markets that are observable either directly or indirectly. Fair values determined by Level 3 inputs utilize unobservable data points in which there is little or no market data, which require the reporting entity to develop its own
        assumptions. The estimated value of accounts payable and accrued expenses approximates their carrying value due to their short-term nature. See&lt;/span&gt; Footnote 6 for Fair Value of Derivatives related to Convertible Notes Payable at December 31,
      2024 and 2023, which are level 3 liabilities. &lt;/div&gt;
</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="c20240101to20241231"
      id="Text_d2f252797760441693f882ab7dac7e3e">
&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-style: italic;"&gt;Cash and Cash Equivalents.&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; The Company considers
        all highly-liquid investments with original maturities of 90 days or less at the time of acquisition to be cash equivalents. The Company had no
        cash equivalents at December 31, 2024 or 2023.&lt;/span&gt;&lt;/div&gt;
</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="c20241231"
      decimals="0"
      id="Fact_c37dd1d510984e23b52d784125c761b0"
      unitRef="U001">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="c20231231"
      decimals="0"
      id="Fact_9290d7cf121341aca9bc9f5b5388e3f7"
      unitRef="U001">0</us-gaap:CashEquivalentsAtCarryingValue>
    <galt:PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock
      contextRef="c20240101to20241231"
      id="Text_f833225790ea4dd19c619b5b7ecb5f7c">
&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-style: italic;"&gt;Prepaid Expenses and Other Current Assets.&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;
        Prepaid expenses and other assets consist principally of prepaid insurance, deposits related to the NAVIGATE trial and deferred financing costs (see Note 10).&lt;/span&gt;&lt;/div&gt;
</galt:PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="c20240101to20241231"
      id="Text_195e6e03ef6741179151f31cfc44129d">
&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-style: italic;"&gt;Property and Equipment.&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; Property and equipment,
        including leasehold improvements, are stated at cost, net of accumulated depreciation and amortization, and are depreciated or amortized using the straight-line method over the estimated useful lives of the related assets of generally three years for computers and office equipment, five years
        for furniture and fixtures and the shorter of the useful life or life of the lease for leasehold improvements.&lt;/span&gt;&lt;/div&gt;
</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="c20241231_PropertyPlantAndEquipmentByTypeAxis_ComputerAndOfficeEquipmentMember"
      id="Fact_4e93b09d587e400e8c3466835704ec43">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="c20241231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember"
      id="Fact_526fdb01eb814eb8ab38e6fb0d161239">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <galt:SecurityDepositPolicyTextBlock
      contextRef="c20240101to20241231"
      id="Text_28429d51bba34e3f93adcc2f7dc95852">
&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-style: italic;"&gt;Security Deposit.&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; At December 31, 2024 and 2023,
        the Company had a security deposit of $6,000 for leased office space included in Prepaid Expenses and Other Current Assets.&lt;/span&gt;&lt;/div&gt;
</galt:SecurityDepositPolicyTextBlock>
    <us-gaap:SecurityDeposit
      contextRef="c20231231"
      decimals="0"
      id="Fact_ddee787e704e4c2dab4d39796316f491"
      unitRef="U001">6000</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit
      contextRef="c20241231"
      decimals="0"
      id="Fact_bea6144633b4466aa7e963b4538d7a39"
      unitRef="U001">6000</us-gaap:SecurityDeposit>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="c20240101to20241231"
      id="Text_4783b54031154a91852e7a053d95ee4c">
&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-style: italic;"&gt;Long-Lived Assets.&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; The Company reviews all
        long-lived assets for impairment whenever events or circumstances indicate the carrying amount of such assets may not be recoverable. Recoverability of assets to be held or used is measured by comparison of the carrying value of the asset to the
        future undiscounted net cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment recognized is measured by the amount by which the carrying value of the asset exceeds the discounted future cash
        flows expected to be generated by the asset. There were no impairments of long-lived assets at December 31, 2024 or 2023.&lt;/span&gt;&lt;/div&gt;
</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="c20240101to20241231"
      decimals="0"
      id="Fact_e091e92fc8bb4622882d646dfeb7e9c7"
      unitRef="U001">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="c20230101to20231231"
      decimals="0"
      id="Fact_9d0e587d39b44e9d9aa9bfa6c40819d5"
      unitRef="U001">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <galt:AccruedExpensePolicyTextBlock
      contextRef="c20240101to20241231"
      id="Text_6dfd834fe4014bc0bf99ea2720f622c1">
&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-style: italic;"&gt;Accrued Expenses&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;. As part of the process of
        preparing our consolidated financial statements, we are required to estimate accrued expenses. This process involves identifying services that third parties have performed on our behalf and estimating the level of service performed and the
        associated cost incurred on these services as of each balance sheet date in our consolidated financial statements. Examples of estimated accrued expenses include professional service fees, such as those arising from the services of attorneys and
        accountants and accrued payroll expenses. In connection with these service fees, our estimates are most affected by our understanding of the status and timing of services provided relative to the actual services incurred by the service providers.
        In the event that we do not identify certain costs that have been incurred or we under- or over-estimate the level of services or costs of such services, our reported expenses for a reporting period could be understated or overstated. The date on
        which certain services commence, the level of services performed on or before a given date, and the cost of services are often subject to our judgment. We make these judgments based upon the facts and circumstances known to us in accordance with
        accounting principles generally accepted in the U.S.&lt;/span&gt;&lt;/div&gt;
</galt:AccruedExpensePolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="c20240101to20241231"
      id="Text_2fb4857d7bc445efa390b93a8c20252f">
&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-style: italic;"&gt;Warrants.&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; The Company has issued common stock
        warrants in connection with the execution of certain equity and debt financings. The fair value of warrants is determined using the Black-Scholes option-pricing model using assumptions regarding volatility of our common share price, remaining life
        of the warrant, and risk-free interest rates at each period end. There were no warrant liabilities as of December 31, 2024 or 2023.&lt;/span&gt;&lt;/div&gt;
</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:DerivativeLiabilities
      contextRef="c20231231"
      decimals="0"
      id="Fact_4b0b15bc84f04e9a9374c583c24b60b8"
      unitRef="U001">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="c20241231"
      decimals="0"
      id="Fact_40c4de5eb08e41888bfb8b9804fbe42b"
      unitRef="U001">0</us-gaap:DerivativeLiabilities>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="c20240101to20241231"
      id="Text_59560cc295c64b9baed774eb1eee90ee">
&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-style: italic;"&gt;Research and Development Expenses.&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; Research and
        development expenses, including personnel costs, allocated facility costs, lab supplies, outside services, contract laboratory costs related to manufacturing drug product, clinical trials and preclinical studies are charged to research and
        development expense as incurred. The Company accounts for nonrefundable advance payments for goods and services that will be used in future research and development activities as expense when the service has been performed or when the goods have
        been received. Our current NAVIGATE clinical trial is being supported by third-party contract research organizations, or CROs, and other vendors. We accrue expenses for clinical trial activities performed by CROs based upon the estimated amount of
        work completed on each trial. For clinical trial expenses and related expenses associated with the conduct of clinical trials, the significant factors used in estimating accruals include the number of patients enrolled, the number of active
        clinical sites, and the duration for which the patients have been enrolled in the trial. We monitor patient enrollment levels and related activities to the extent possible through internal reviews, review of contractual terms and correspondence
        with CROs. We base our estimates on the best information available at the time. We monitor patient enrollment levels and related activities to the extent possible through discussions with CRO personnel and based our estimates of clinical trial
        costs on the best information available at the time. However, additional information may become available to us which will allow us to make a more accurate estimate in future periods. In that event, we may be required to record adjustments to
        research and development expenses in future periods when the actual level of activity becomes more certain.&lt;/span&gt;&lt;/div&gt;
</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="c20240101to20241231"
      id="Text_1bad36be4bf94cfaa50a5da3feef0171">
&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-style: italic;"&gt;Income Taxes.&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; The Company accounts for income
        taxes in accordance with the accounting rules that requires an asset and liability approach to accounting for income taxes based upon the future expected values of the related assets and liabilities. Deferred income tax assets and liabilities are
        determined based on the differences between the financial reporting and tax bases of assets and liabilities and for tax loss and credit carry forwards and are measured using the expected tax rates estimated to be in effect when such basis
        differences reverse. Valuation allowances are established, if necessary, to reduce the deferred tax asset to the amount that will, more likely than not, be realized.&lt;/span&gt;&lt;/div&gt;
</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="c20240101to20241231"
      id="Text_ca88d8c1d6de4a6c849098a0f00aeac1">
&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-style: italic;"&gt;Concentration of Credit Risk.&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; Financial
        instruments that subject the Company to credit risk consist of cash and cash equivalents. The Company maintains cash and cash equivalents and certificates of deposit with well-capitalized financial institutions. At times, those amounts may exceed
        federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant credit risk beyond the normal credit risk associated with commercial banking relationships. The Company has no other
        significant concentrations of credit risk.&lt;/span&gt;&lt;/div&gt;
</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="c20240101to20241231"
      id="Text_5b26e59f6c78407388deb19ff860b827">
&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;br/&gt;
      &lt;/span&gt;&lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-style: italic;"&gt;Stock-Based Compensation.&lt;/span&gt; Stock-based compensation cost is measured at the grant date based on
      the fair value of the award and is recognized as expense over the service period, which generally represents the vesting period. For awards that have performance-based vesting conditions the Company recognizes the expense over the estimated period
      that the awards are expected to be earned. The Company generally uses the Black-Scholes option-pricing model to calculate the grant date fair value of stock options. The expense recognized over the service period is required to include an estimate of
      the awards that will be forfeited.&lt;/div&gt;
</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="c20240101to20241231"
      id="Text_f00615456f664e71bd0ca8f0c58efb6b">
&lt;div&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin: 0px 0px 0px 24.45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; text-align: left;"&gt;Recently Adopted Accounting Pronouncements&lt;/div&gt;

&lt;div style="margin: 0px 0px 0px 24.45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; text-align: left;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin: 0px 0px 0px 24.45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"&gt;In November 2023, the FASB issued ASU 2023-07,&#160;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/span&gt;. This guidance is intended to improve reportable segment disclosure requirements through enhanced disclosures as well as clarify that
        entities with a single reportable segment are subject to new and existing segment reporting requirements. This guidance is effective for annual periods in fiscal years beginning after December 15, 2023, and interim periods within fiscal years
        beginning after December 15, 2024, with early adoption permitted. Entities must apply this guidance on a retrospective basis. Accordingly, the Company adopted this new standard for the fiscal year ended December 31, 2024. See footnote 15 for
        segment disclosures.&lt;/div&gt;

&lt;div style="margin: 0px 0px 0px 24.45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin: 0px 0px 0px 24.45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; text-align: left;"&gt;Recent Accounting Pronouncements - Yet to be Adopted&lt;/div&gt;

&lt;div style="margin: 0px 0px 0px 24.45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; text-align: left;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin: 0px 0px 0px 24.45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"&gt;In December 2023, the FASB issued ASU 2023-09,&#160;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate
        reconciliation and income taxes paid both in the United States and in foreign jurisdictions. This guidance is effective for fiscal years beginning after December 15, 2024 on a prospective basis, with the option to apply the standard
        retrospectively, and early adoption is permitted. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements.&lt;/div&gt;

&lt;div style="margin: 0px 0px 0px 24.45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin: 0px 0px 0px 24.45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"&gt;In November 2024, the FASB issued ASU 2024-03,&#160;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&lt;/span&gt;. The amendments in ASU 2024-03 address investor requests for more
        detailed expense information and require additional disaggregated disclosures in the notes to financial statements for certain categories of expenses that are included on the face of the income statement. This guidance is effective for fiscal years
        beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated
        financial statements.&lt;/div&gt;

&lt;div style="margin: 0px 0px 0px 24.45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin: 0px 0px 0px 24.45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"&gt;In November 2024, the FASB, issued ASUS 2024-04,&#160;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Debt- Debt with Conversions and Other Option.&#160;&lt;/span&gt;ASU 2024-04 is intended to clarify requirements for determining whether certain settlements of convertible debt instruments, including convertible debt instruments with
        cash conversion features or convertible debt instruments that are not currently convertible, should be accounted for as an induced conversion. This ASU is effective for all entities for annual reporting periods beginning after December 15, 2025,
        and interim reporting periods within those annual reporting periods, with early adoption permitted. The Company is currently evaluating the potential impact of this guidance on its disclosures.&lt;/div&gt;
</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="c20240101to20241231"
      id="Text_4d11178decd54050b00dcad6e3799e34">
&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 27.05pt; vertical-align: top; font-weight: bold;"&gt;3.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
              &lt;div style="font-weight: bold;"&gt;Property and Equipment&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Property and equipment consist of the following at December 31:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 27pt;"&gt;
        &lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt; 2024&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;2023&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-indent: -16.2pt; margin-left: 16.2pt;"&gt;Leasehold improvements&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;2&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;2&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                &lt;div style="text-indent: -16.2pt; margin-left: 16.2pt;"&gt;Computer and office equipment&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;13&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;13&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-indent: -16.2pt; margin-left: 16.2pt;"&gt;Furniture and fixtures&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;59&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;59&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                &lt;div style="text-indent: -16.2pt; margin-left: 16.2pt;"&gt;Total&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;74&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;74&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-indent: -16.2pt; margin-left: 16.2pt;"&gt;Less accumulated depreciation and amortization&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;(74&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;(74&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 4px;" valign="bottom"&gt;
                &lt;div style="text-indent: -16.2pt; margin-left: 25.2pt;"&gt;Property and equipment &#x2014; net&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
         &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Depreciation and amortization expense for the years ended December 31, 2024 and 2023 was $0 and $0, respectively.&lt;/div&gt;
</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="c20240101to20241231"
      id="Text_d3264ff0a1a441338b91ce2800081bf7">
&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Property and equipment consist of the following at December 31:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 27pt;"&gt;
        &lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt; 2024&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;2023&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-indent: -16.2pt; margin-left: 16.2pt;"&gt;Leasehold improvements&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;2&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;2&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                &lt;div style="text-indent: -16.2pt; margin-left: 16.2pt;"&gt;Computer and office equipment&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;13&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;13&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-indent: -16.2pt; margin-left: 16.2pt;"&gt;Furniture and fixtures&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;59&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;59&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                &lt;div style="text-indent: -16.2pt; margin-left: 16.2pt;"&gt;Total&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;74&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;74&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-indent: -16.2pt; margin-left: 16.2pt;"&gt;Less accumulated depreciation and amortization&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;(74&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;(74&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 4px;" valign="bottom"&gt;
                &lt;div style="text-indent: -16.2pt; margin-left: 25.2pt;"&gt;Property and equipment &#x2014; net&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
         &lt;/div&gt;
</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20241231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember"
      decimals="-3"
      id="Fact_d20ba1910ae34b82b67412044e849ec1"
      unitRef="U001">2000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20231231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember"
      decimals="-3"
      id="Fact_74fbb1156dd04338a724f72f872035a7"
      unitRef="U001">2000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20241231_PropertyPlantAndEquipmentByTypeAxis_ComputerAndOfficeEquipmentMember"
      decimals="-3"
      id="Fact_aef57c28ddfc4736ab6f50b07d0b0fd7"
      unitRef="U001">13000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20231231_PropertyPlantAndEquipmentByTypeAxis_ComputerAndOfficeEquipmentMember"
      decimals="-3"
      id="Fact_bdf382be1a554dae86e82f7a026fe519"
      unitRef="U001">13000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20241231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember"
      decimals="-3"
      id="Fact_2d21f6bdb2404f418f11d8c282288482"
      unitRef="U001">59000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20231231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember"
      decimals="-3"
      id="Fact_68119940ea94486e898de0a26c8ff8ab"
      unitRef="U001">59000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20241231"
      decimals="-3"
      id="Fact_ee2c7f8adebd49fb98db8215676952d4"
      unitRef="U001">74000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20231231"
      decimals="-3"
      id="Fact_a39af23592d74e339c12009259e71757"
      unitRef="U001">74000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="c20241231"
      decimals="-3"
      id="Fact_afd195cecf5f4c8b944c86e41f1b6fda"
      unitRef="U001">74000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="c20231231"
      decimals="-3"
      id="Fact_7f3c1658dd3e46e2ac7dddd30a02e117"
      unitRef="U001">74000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="c20241231"
      decimals="-3"
      id="Fact_343983fa7c40403885e70e9f88162bf4"
      unitRef="U001">0</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="c20231231"
      decimals="-3"
      id="Fact_b0faded862f44bb4a87584a3c513ec83"
      unitRef="U001">0</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationAndAmortization
      contextRef="c20240101to20241231"
      decimals="0"
      id="Fact_ea5f8495285140608206c59f91f923d7"
      unitRef="U001">0</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="c20230101to20231231"
      decimals="0"
      id="Fact_caa8b27fec16458a989b2b85a2aabe1e"
      unitRef="U001">0</us-gaap:DepreciationAndAmortization>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="c20240101to20241231"
      id="Text_a3471463059d45209ce95f6afbac06bf">
&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 27.05pt; vertical-align: top; font-weight: bold;"&gt;4.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
              &lt;div style="font-weight: bold;"&gt;Accrued Expenses&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Accrued expenses consist of the following at December 31:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 27pt;"&gt;
        &lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;2024&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;2023&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Legal and accounting fees&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;74&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;40&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Accrued compensation&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1,523&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1,129&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Lease liability &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;19&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;46&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Accrued research and development costs and other&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;6,588&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;7,967&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 16.2pt;"&gt;&lt;span style="text-indent: 0pt;"&gt;&lt;span style="-sec-ix-hidden:Fact_a8602fa8d1ea4021ae045ee98e73f8f6"&gt;&lt;span style="-sec-ix-hidden:Fact_5c08786f5dcb4bc5a62f72d8c0d8264d"&gt;Total&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;8,204&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;9,182&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
         &lt;/div&gt;
</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="c20240101to20241231"
      id="Text_8d41e3af9d8b460cba4ca7b9516fc85f">
&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Accrued expenses consist of the following at December 31:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 27pt;"&gt;
        &lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;2024&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;2023&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Legal and accounting fees&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;74&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;40&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Accrued compensation&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1,523&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1,129&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Lease liability &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;19&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;46&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Accrued research and development costs and other&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;6,588&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;7,967&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 16.2pt;"&gt;&lt;span style="text-indent: 0pt;"&gt;&lt;span style="-sec-ix-hidden:Fact_a8602fa8d1ea4021ae045ee98e73f8f6"&gt;&lt;span style="-sec-ix-hidden:Fact_5c08786f5dcb4bc5a62f72d8c0d8264d"&gt;Total&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;8,204&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;9,182&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
         &lt;/div&gt;
</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="c20241231"
      decimals="-3"
      id="Fact_fd74099bb3bb427f8882a7f364e3b335"
      unitRef="U001">74000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_5a0da24b1e934d4ca520827b8e8badd6"
      unitRef="U001">40000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="c20241231"
      decimals="-3"
      id="Fact_3b16079fe16e409da85eac67d670283b"
      unitRef="U001">1523000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_b952b0fe82d94a7cb990f7a88339355a"
      unitRef="U001">1129000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="c20241231"
      decimals="-3"
      id="Fact_0e2bcab54f254f2abe864c9ba8ff20bb"
      unitRef="U001">19000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_a67e474529a44e92bcf5df378b606468"
      unitRef="U001">46000</us-gaap:OperatingLeaseLiabilityCurrent>
    <galt:AccruedResearchAndDevelopmentCostsAndOtherCurrent
      contextRef="c20241231"
      decimals="-3"
      id="Fact_938bd465841046b68ebe233dc6f43985"
      unitRef="U001">6588000</galt:AccruedResearchAndDevelopmentCostsAndOtherCurrent>
    <galt:AccruedResearchAndDevelopmentCostsAndOtherCurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_3ef68296521b4dbdb19d755dea77b8df"
      unitRef="U001">7967000</galt:AccruedResearchAndDevelopmentCostsAndOtherCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="c20241231"
      decimals="-3"
      id="Fact_700b3445211f42718bcd1825d69d7aa0"
      unitRef="U001">8204000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_2ae5f3b6afe54089b5edcce6c7aac88e"
      unitRef="U001">9182000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="c20240101to20241231_LongtermDebtTypeAxis_LoansPayableMember"
      id="Text_30653b6b0e8d44858c5c16baf19a5305">
&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 27pt; vertical-align: top; font-weight: bold;"&gt;5.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
              &lt;div style="font-weight: bold;"&gt;Convertible Notes Payable &#x2013; Related Party&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 22.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;On April 16, 2021, the Company and Richard E. Uihlein entered into a debt financing arrangement whereby Mr. Uihlein loaned $10,000,000 to Company. In consideration for the loan, the Company issued a convertible promissory note (the &#x201c;April 2021 Note&#x201d;) in the principal amount of ten million dollars.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 22.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The April 2021 Note has a maturity date of April 16, 2025,
        is prepayable at the option of the Company in whole or in part at any time and is convertible into the Company&#x2019;s common stock at a conversion price equal to $5.00 per share at the option of the noteholder. The April 2021 Note bears interest at the rate of two percent (2%)
        per annum, compounded annually with an effective interest rate of approximately 3%. For the years ended December 31, 2024 and 2023,
        approximately $212,000 and $207,000,
        respectively, of interest expense was accrued and included with the principal in the financial statements.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 22.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The April 2021 Note also includes a contingent interest component that requires the Company to pay additional interest at a rate of two and one-half percent (2.5%) per quarter (10% per annum) (the
        &#x201c;Additional Interest&#x201d;) beginning on the date of issuance of this Note and ending on the maturity date, provided however, that such payment is only required if and only if the noteholder elects to convert the entire balance of the April 2021 Note
        into the Company&#x2019;s common stock on or prior to maturity. As the contingent event is not based on creditworthiness, such feature is not clearly and closely related to the host instrument and accordingly must be bifurcated and recognized as a
        derivative liability and a debt discount on the April 2021 Note at its inception. The fair value of the contingent interest derivative liability was $420,000
        at note inception (April 16, 2021). The fair value of the contingent interest derivative liability was $47,000 and $431,000 and December 31, 2024 and 2023, respectively, and is recognized as a derivative liability in the consolidated balance sheet. The change in the
        fair value of the derivative liability for the years ended December 31, 2024 and 2023 of ($384,000) and $182,000, respectively, was charged to other expense/(income) for the years ended December 31, 2024 and 2023. The amortization of the original $420,000 debt discount of $105,000 and $105,000 was recorded as additional interest expense for the years ended December 31, 2024 and 2023, respectively.&lt;/div&gt;

&lt;div style="margin-left: 22.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
        &lt;/span&gt;&lt;/div&gt;

&lt;div style="margin-left: 22.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;On May 14, 2024, Mr. Uihlein, as holder of the April 2021 Note irrevocably elected to convert the entire principal amount
          of such note, plus accrued and unpaid interest, into shares of common stock of the Company at a price of $5.00 per share, effective as
          of April 16, 2025, which is the maturity date of the April 2021 Note. The April 2021 Note will remain outstanding and accrue interest
          until maturity and no shares of common stock will be issued as a result of this election until April 16, 2025. As a result, the
          principal, plus accrued interest and related derivative liability are included in noncurrent liabilities at December 31, 2024.&lt;/span&gt; &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 22.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;On September 17, 2021, the Company and Mr. Uihlein entered into a loan agreement in the aggregate of $20,000,000 (the &#x201c;Loan Agreement&#x201d;) to be funded in two closings
        and evidenced by two separate unsecured convertible promissory notes.&#160; The first of the two promissory notes was also executed and delivered on September 17, 2021, (the &#x201c;September 2021 Note&#x201d;) to evidence the first loan in the principal amount of $10,000,000.&#160; The second closing under the Loan Agreement for the remaining $10,000,000 occurred on December 20, 2021.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 22.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The September 2021 Note has a maturity date of September 17, 2025,
        is prepayable at the option of the Company in whole or in part at any time and is convertible into the Company&#x2019;s common stock at a conversion price equal to $8.64 per share at the option of the noteholder. The September 2021 Note bears interest at the rate of two percent (2%)
        per annum, compounded annually with an effective interest rate of approximately 3%. For the years ended December 31, 2024 and 2023,
        approximately $210,000 and $206,000,
        respectively, of interest expense was accrued and included with the principal in the financial statements.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 22.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The September 2021 Note also includes a contingent interest component that requires the Company to pay additional interest at a rate of two and one-half percent (2.5%) per quarter (10% per annum) (the
        &#x201c;Additional Interest&#x201d;) beginning on the date of issuance of this Note and ending on the maturity date, provided however, that such payment is only required if and only if the noteholder elects to convert the entire balance of the September 2021
        Note into the Company&#x2019;s common stock on or prior to maturity. As the contingent event is not based on creditworthiness, such feature is not clearly and closely related to the host instrument and accordingly must be bifurcated and recognized as a
        derivative liability and a debt discount on the September Note at its inception. The fair value of the contingent interest derivative liability was $433,000
        at note inception (September 17, 2021). The fair value of the contingent interest derivative liability was $94,000 and $169,000 and December 31, 2024 and 2023, respectively, and is recognized as a derivative liability in the consolidated balance sheet. The change in the
        fair value of the derivative liability for the years ended December 31, 2024 and 2023 of ($75,000) and $60,000, respectively, was recorded to other expense/(income) for the years ended December 31, 2024 and 2023. The amortization of the original $433,000 debt discount of $108,000 and $108,000 was recorded as additional interest expense for the years ended December 31, 2024 and 2023, respectively.&lt;/div&gt;

&lt;div style="margin-left: 22.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 22.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;On December 20, 2021, the second of the two promissory
        notes under the Loan Agreement was executed and delivered, (the &#x201c;December 2021 Note&#x201d;) to evidence the second loan in the principal amount of $10,000,000.&#160;























































































        The December 2021 Note has a maturity date of December 20, 2025, is prepayable at the option of the Company in whole or in part at any
        time and is convertible into the Company&#x2019;s common stock at a conversion price equal to $5.43 per share at the option of the noteholder.
        The December Note bears interest at the rate of two percent (2%) per annum, compounded annually with an effective interest rate of
        approximately 3%. For the years ended December 31, 2024 and 2023, approximately $209,000 and $204,000, respectively, of interest expense was accrued and
        included with the principal in the financial statements.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 22.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The December 2021 Note also includes a contingent interest component that requires the Company to pay additional interest at a rate of two and one-half percent (2.5%) per quarter (10% per annum) (the
        &#x201c;Additional Interest&#x201d;) beginning on the date of issuance of this Note and ending on the maturity date, provided however, that such payment is only required if and only if the noteholder elects to convert the entire balance of the December 2021 Note
        into the Company&#x2019;s common stock on or prior to maturity. As the contingent event is not based on creditworthiness, such feature is not clearly and closely related to the host instrument and accordingly must be bifurcated and recognized as a
        derivative liability and a debt discount on the December Note at its inception. The fair value of the contingent interest derivative liability was $415,000
        at note inception (December 20, 2021). The fair value of the contingent interest derivative liability was $275,000 and $404,000 at December 31, 2024 and 2023, respectively, and is recognized as a derivative liability in the consolidated balance sheet. The change in the
        fair value of the derivative liability for the years ended December 31, 2024 and 2023 of ($129,000) and $190,000, respectively was recorded to other expense/(income) for the years ended December 31, 2024 and 2023. The amortization of the original $415,000 debt discount of $104,000 and $104,000 was recorded as additional interest expense for the years ended December 31, 2024 and 2023, respectively.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 22.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company&#x2019;s contractual cash obligations related to the outstanding convertible notes payable is a repayment of the repayment of the September 2021 Note of the $10,000,000 plus accrued interest on September 17, 2025 and a repayment of the December 2021 Note of the $10,000,000 plus accrued interest on December 30, 2025, unless converted at the option of the noteholder.&lt;/div&gt;
</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="c20210416_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="0"
      id="Fact_2713fcf124234f9da51a266413ecaf03"
      unitRef="U001">10000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="c20210416to20210416_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="0"
      id="Fact_d2641f5039644251b44b6b5a9803135a"
      unitRef="U001">10000000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="c20240101to20241231_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      id="Fact_4ce33135ab5c444fa78a945711ee65c2">2025-04-16</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c20241231_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="2"
      id="Fact_975609c5e9e3470c8bfe4c4b38be2831"
      unitRef="U003">5</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20241231_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="2"
      id="Fact_499f66d0466944ec9271f8378f4202d6"
      unitRef="U007">0.02</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c20241231_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="2"
      id="Fact_52d8ad51a64643618477246a2e699a1d"
      unitRef="U007">0.03</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:InterestExpenseDebt
      contextRef="c20240101to20241231_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="0"
      id="Fact_11db0d2fd2de45e1a8bd9c138b3180a5"
      unitRef="U001">212000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="c20230101to20231231_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="0"
      id="Fact_e9698cb7514c4dfca3b98d62da3b6857"
      unitRef="U001">207000</us-gaap:InterestExpenseDebt>
    <galt:QuarterlyInterestRate
      contextRef="c20210416_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="3"
      id="Fact_a9a00d44e7944a8198adb35ca1cb9a1c"
      unitRef="U007">0.025</galt:QuarterlyInterestRate>
    <galt:AnnualInterestRate
      contextRef="c20210416_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="2"
      id="Fact_9069c50caa5f47d6a5157af34914fda2"
      unitRef="U007">0.10</galt:AnnualInterestRate>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="c20210416_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="0"
      id="Fact_94e890658938435484d2e437f9120443"
      unitRef="U001">420000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="c20241231_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="0"
      id="Fact_404a67450c554ebcb77a7b60b4bf43c1"
      unitRef="U001">47000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="c20231231_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="0"
      id="Fact_00b2ec7b8cb34ce4b78140aec2202c6d"
      unitRef="U001">431000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="c20240101to20241231_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember"
      decimals="0"
      id="Fact_d5bfe3449aa545e39aa984cc8c838ed3"
      unitRef="U001">384000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="c20230101to20231231_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember"
      decimals="0"
      id="Fact_0552d15706564c5ebfda338497cd2ed4"
      unitRef="U001">-182000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="c20240101to20241231_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember"
      decimals="0"
      id="Fact_5290c79730ba44cdae71a8122da60122"
      unitRef="U001">420000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:InterestExpenseOther
      contextRef="c20240101to20241231_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember"
      decimals="0"
      id="Fact_0b7bd7638b3a465ba3787fe4e929506e"
      unitRef="U001">105000</us-gaap:InterestExpenseOther>
    <us-gaap:InterestExpenseOther
      contextRef="c20230101to20231231_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember"
      decimals="0"
      id="Fact_b512e7f9b7184f43812f49fedc2ce60f"
      unitRef="U001">105000</us-gaap:InterestExpenseOther>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c20240514_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="2"
      id="Fact_2a916b2c399c4072b80d0eb6aecd6066"
      unitRef="U003">5</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="c20240514to20240514_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      id="Fact_99dcb49f39b24322ba1e107efd3b8f15">2025-04-16</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c20240514to20240514_DebtInstrumentAxis_AprilConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="INF"
      id="Fact_8d6040e53d994651b572fa813123df44"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="c20210917_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="0"
      id="Fact_0bea27b5ac724fc9857afe964933abd1"
      unitRef="U001">20000000</us-gaap:DebtInstrumentFaceAmount>
    <galt:NumberOfLoansClosing
      contextRef="c20210917to20210917_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="INF"
      id="Fact_45dae238908247ca809d0e8ec098c9c2"
      unitRef="U005">2</galt:NumberOfLoansClosing>
    <galt:NumberOfPromissoryNotesEvidencedByLoansAgreement
      contextRef="c20210917to20210917_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="INF"
      id="Fact_d4474845663945878b43b01f6460951a"
      unitRef="U006">2</galt:NumberOfPromissoryNotesEvidencedByLoansAgreement>
    <galt:NumberOfPromissoryNotesExecuted
      contextRef="c20210917to20210917_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="INF"
      id="Fact_e77c13f4fac5487c93dc0d4b365f8b39"
      unitRef="U006">2</galt:NumberOfPromissoryNotesExecuted>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="c20210917_DebtInstrumentAxis_FirstClosingMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="0"
      id="Fact_1c5ba7c8514a4095b67127ae2aa6ebc5"
      unitRef="U001">10000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="c20211220_DebtInstrumentAxis_SecondClosingMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="0"
      id="Fact_61c3864063e248b9bc9aa6133acab22d"
      unitRef="U001">10000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="c20240101to20241231_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      id="Fact_cf16a649b11144ceae03f13d7b61be03">2025-09-17</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c20241231_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="2"
      id="Fact_7d647f8fdbe34b69a7919ef06b638d66"
      unitRef="U003">8.64</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20241231_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="2"
      id="Fact_c4c4f6f9e7734c8d9db8f944c64d21cd"
      unitRef="U007">0.02</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c20241231_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="2"
      id="Fact_1aab4d0b75ee4baaa05ddb92a46240ac"
      unitRef="U007">0.03</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:InterestExpenseDebt
      contextRef="c20240101to20241231_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="0"
      id="Fact_82ab2d99d1ea4f8c9d7a01a1e65e7107"
      unitRef="U001">210000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="c20230101to20231231_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="0"
      id="Fact_b2c8bc996e2a42ef9a741c9939f98516"
      unitRef="U001">206000</us-gaap:InterestExpenseDebt>
    <galt:QuarterlyInterestRate
      contextRef="c20210917_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="3"
      id="Fact_01b06df7f31647e384cf453acd3f741d"
      unitRef="U007">0.025</galt:QuarterlyInterestRate>
    <galt:AnnualInterestRate
      contextRef="c20210917_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="2"
      id="Fact_46df9b7b4f5045d78029306178de71ce"
      unitRef="U007">0.10</galt:AnnualInterestRate>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="c20210917_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="0"
      id="Fact_7fdd3ffc8ce04c6cbfbf6ff8445af728"
      unitRef="U001">433000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="c20241231_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="0"
      id="Fact_8ba9cfc1f63e45bab5825a1087d04939"
      unitRef="U001">94000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="c20231231_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="0"
      id="Fact_d843bda2f6ae4cc09f48760e18b0aebf"
      unitRef="U001">169000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="c20240101to20241231_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember"
      decimals="0"
      id="Fact_091315b8c19d41f9a0a3c46327aaecae"
      unitRef="U001">75000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="c20230101to20231231_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember"
      decimals="0"
      id="Fact_3b216d1f547a46a9813492974cc0f8c9"
      unitRef="U001">-60000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="c20240101to20241231_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember"
      decimals="0"
      id="Fact_a0a73beccca4417da21a6312c4e451ff"
      unitRef="U001">433000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:InterestExpenseOther
      contextRef="c20240101to20241231_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember"
      decimals="0"
      id="Fact_6d9e044813a542e09363279674679efd"
      unitRef="U001">108000</us-gaap:InterestExpenseOther>
    <us-gaap:InterestExpenseOther
      contextRef="c20230101to20231231_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember"
      decimals="0"
      id="Fact_c068a148b1f34ee89fd421416326c81a"
      unitRef="U001">108000</us-gaap:InterestExpenseOther>
    <galt:NumberOfPromissoryNotesEvidencedByLoansAgreement
      contextRef="c20211220to20211220_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember"
      decimals="INF"
      id="Fact_b65a953bd97240e49bcf99b447069bf8"
      unitRef="U006">2</galt:NumberOfPromissoryNotesEvidencedByLoansAgreement>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="c20211220to20211220_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember"
      decimals="0"
      id="Fact_55abea4dda984c1998749cbc01e00350"
      unitRef="U001">10000000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="c20211220to20211220_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember"
      id="Fact_ddd323e9960e495a85ca599044de5691">2025-12-20</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c20211220_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember"
      decimals="2"
      id="Fact_69f6ac4e7cf64ef0a66587b369620827"
      unitRef="U003">5.43</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20211220_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember"
      decimals="2"
      id="Fact_c7d8f0469c3f46c5a28ac11c9e869c2c"
      unitRef="U007">0.02</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c20211220_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember"
      decimals="2"
      id="Fact_67439535778c4aecbfe0e88407a22179"
      unitRef="U007">0.03</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:InterestExpenseDebt
      contextRef="c20240101to20241231_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember"
      decimals="0"
      id="Fact_f3c67c2b79b14ed8a5d290d6e944a2d9"
      unitRef="U001">209000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="c20230101to20231231_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember"
      decimals="0"
      id="Fact_fc1598e58e5a4b068f4e5289c8e2d04d"
      unitRef="U001">204000</us-gaap:InterestExpenseDebt>
    <galt:QuarterlyInterestRate
      contextRef="c20211220_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember"
      decimals="3"
      id="Fact_7daeba3064cf4f5fa6a21ca5a0fbd797"
      unitRef="U007">0.025</galt:QuarterlyInterestRate>
    <galt:AnnualInterestRate
      contextRef="c20211220_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember"
      decimals="2"
      id="Fact_6a75ca6e79ce4a88b4d76f920f5eddbb"
      unitRef="U007">0.10</galt:AnnualInterestRate>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="c20211220_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember"
      decimals="0"
      id="Fact_7418275339384953973bbacd6850cab9"
      unitRef="U001">415000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="c20241231_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember"
      decimals="0"
      id="Fact_5d349e641be340b5aadbf6c28f947eb1"
      unitRef="U001">275000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="c20231231_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember"
      decimals="0"
      id="Fact_e65452d95c98400a812f84187fa19a59"
      unitRef="U001">404000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="c20240101to20241231_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember"
      decimals="0"
      id="Fact_385137fbb314408893e958a189fcd2f2"
      unitRef="U001">129000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="c20230101to20231231_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember"
      decimals="0"
      id="Fact_61d7fee3f4164b13a978a95c7d57c38f"
      unitRef="U001">-190000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="c20240101to20241231_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember"
      decimals="0"
      id="Fact_4f77f69517b3443592b348dabe390c48"
      unitRef="U001">415000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:InterestExpenseOther
      contextRef="c20240101to20241231_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember"
      decimals="0"
      id="Fact_6ea03c542dd840698d33869dd64faacb"
      unitRef="U001">104000</us-gaap:InterestExpenseOther>
    <us-gaap:InterestExpenseOther
      contextRef="c20230101to20231231_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember"
      decimals="0"
      id="Fact_27f1dd0ad9c34ac2b98976d419b21ea0"
      unitRef="U001">104000</us-gaap:InterestExpenseOther>
    <us-gaap:RepaymentsOfDebt
      contextRef="c20250917to20250917_DebtInstrumentAxis_SeptemberConvertiblePromissoryNoteMember_StatementScenarioAxis_ScenarioForecastMember"
      decimals="0"
      id="Fact_f6d1f1e1ff0240b3885f310a6abca69f"
      unitRef="U001">10000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="c20251230to20251230_DebtInstrumentAxis_DecemberConvertiblePromissoryNoteMember_StatementScenarioAxis_ScenarioForecastMember"
      decimals="0"
      id="Fact_31bfbcc4c6e544748d33c342d5648514"
      unitRef="U001">10000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="c20240101to20241231"
      id="Text_d4685a0fad0a4c129cfb4ad971b000c4">
&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 27pt; vertical-align: top; font-weight: bold;"&gt;6.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
              &lt;div style="font-weight: bold;"&gt;Fair Value of Financial Instruments&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin: 0px 0px 0px 27pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;There were no level 1 or 2 assets or liabilities at December 31, 2024 or 2023.&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div style="margin: 0px 0px 0px 27pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 27pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Level 3 assets and liabilities measured and recorded at fair value on a recurring basis at December 31, 2024 and 2023 were as follows:&lt;/div&gt;

&lt;div style="margin-left: 27pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 27pt;"&gt;
        &lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-left: 17%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; margin-left: 27pt;"&gt;&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;December 31, 2024&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;December 31, 2023&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 68.7%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Derivative Liability &#x2013; Contingent Interest April Note&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.22%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.22%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.94%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;47,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.22%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.22%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.22%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.94%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;431,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.22%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 68.7%;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Derivative Liability &#x2013; Contingent Interest September Note&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.22%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.22%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.94%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;94,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.22%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.22%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.22%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.94%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;169,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.22%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 68.7%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Derivative Liability &#x2013; Contingent Interest December Note&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.22%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.22%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.94%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;275,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.22%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.22%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.22%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.94%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;404,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.22%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
         &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 27pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The April 2021 Note derivative liability &#x2013; contingent interest was valued using a Monte Carlo Geometric Brownian Stock Path Model. The key assumptions used in the model
        at December 31, 2024 and 2023 are as follows:&lt;/div&gt;

&lt;div style="margin-left: 27pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 27pt;"&gt;
        &lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 70%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;December 31, 2024&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;December 31, 2023&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 70%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Stock Price&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1.29&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1.66&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 70%;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Conversion Price of conversion feature&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;5.00&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;5.00&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 70%;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Term&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; text-indent: 25pt; text-align: right;"&gt;&lt;span style="font-family: 'Times New Roman'; color: rgb(0, 255, 0);"&gt; &lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-indent: 0pt;"&gt;0.29&lt;/span&gt; years&lt;/span&gt;&lt;br/&gt;
                  &lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: right;"&gt;1.29 years&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 70%;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Risk Free Interest Rate&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;4.37&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;%&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;4.79&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;%&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 70%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Credit Adjusted Discount Rate&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;12.43&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;%&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;12.86&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;%&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 70%;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Volatility&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;152&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;%&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;69&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;%&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 70%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Dividend Rate&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;0&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;%&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;0&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;%&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
         &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 27pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The roll forward of the April 2021 Note derivative liability &#x2013; contingent interest is as follows:&lt;/div&gt;

&lt;div style="margin-left: 27pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 27pt;"&gt;
        &lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Balance &#x2013; December 31, &lt;span style="text-indent: 0pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;249,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Fair Value Adjustment&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;182,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Balance &#x2013; December 31, &lt;span style="text-indent: 0pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;431,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 2px;" valign="bottom"&gt;Fair Value Adjustment&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;(384,000&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;Balance &#x2013; December 31, 2024&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;47,000&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

      &lt;/div&gt;

&lt;div style="margin-left: 27pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 27pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The September 2021 Note derivative liability &#x2013; contingent interest was valued using a Monte Carlo Geometric Brownian Stock Path Model. The key assumptions used in the
        model at inception, and at December 31, 2024 and 2023 are as follows:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 27pt;"&gt;
        &lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 70%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="font-weight: bold;"&gt;December 31, 2024&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-weight: bold;"&gt;December 31, 2023&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 70%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Stock Price&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1.29&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1.66&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 70%;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Conversion Price of conversion feature&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;8.64&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;8.64&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 70%;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Term&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;0.72
                years&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;1.72
                years&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 70%;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Risk Free Interest Rate&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;4.16&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;%&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;4.23&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;%&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 70%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Credit Adjusted Discount Rate&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;12.43&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;%&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;12.86&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;%&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 70%;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Volatility&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;111&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;%&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;75&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;%&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 70%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Dividend Rate&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;0&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;%&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;0&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;%&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
         &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 27pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The roll forward of the September 2021 Note derivative liability &#x2013; contingent interest is as follows:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 27pt;"&gt;
        &lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Balance &#x2013; December 31, &lt;span style="text-indent: 0pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;109,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Fair Value Adjustment&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;60,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Balance &#x2013; December 31, &lt;span style="text-indent: 0pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;169,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 2px;" valign="bottom"&gt;Fair Value Adjustment&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;(75,000&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;Balance &#x2013; December 31, 2024&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;94,000&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

      &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 27pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The December 2021 Note derivative liability &#x2013; contingent interest was valued using a Monte Carlo Geometric Brownian Stock Path Model. The key assumptions used in the
        model at inception, and at December 31, 2024 and 2023 are as follows:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 27pt;"&gt;
        &lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 70%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="font-weight: bold;"&gt;December 31, 2024&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-weight: bold;"&gt;December 31, 2023&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 70%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Stock Price&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1.29&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1.66&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 70%;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Conversion Price of conversion feature&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;5.43&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;5.43&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 70%;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Term&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; text-indent: 25pt; text-align: right;"&gt;&lt;span style="font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-indent: 0pt;"&gt;0.97&lt;/span&gt; years&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-indent: 14pt;"&gt;&lt;span style="text-indent: 0pt;"&gt;1.97&lt;/span&gt; years&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 70%;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Risk Free Interest Rate&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;4.16&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;%&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;4.23&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;%&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 70%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Credit Adjusted Discount Rate&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;12.43&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;%&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;12.86&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;%&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 70%;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Volatility&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;102&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;%&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;72&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;%&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 70%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Dividend Rate&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;0&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;%&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;0&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;%&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
         &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 27pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The roll forward of the December 2021 Note derivative liability &#x2013; contingent interest is as follows:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 27pt;"&gt;
          &lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Balance &#x2013; December 31, &lt;span style="text-indent: 0pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;214,000&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Fair Value Adjustment&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;190,000&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Balance &#x2013; December 31, &lt;span style="text-indent: 0pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;404,000&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 2px;" valign="bottom"&gt;Fair Value Adjustment&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;(129,000&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;Balance &#x2013; December 31, 2024&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;275,000&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
        &lt;/div&gt;
</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact_f0f76a611a61480997d5c072d144fb25"
      unitRef="U001">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact_ef06d1c764e94d2c8305902fe179c236"
      unitRef="U001">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact_d95f177c87104dedabf1859521ef9763"
      unitRef="U001">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact_8f0d12c45ed040d78795ae7762682a30"
      unitRef="U001">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact_851b186510764ae28d3dfa53b675b039"
      unitRef="U001">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact_5c9c3ec85ae14451bcdf8626bc94a878"
      unitRef="U001">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact_4386c7aa9d244786ade7c20f5562dc04"
      unitRef="U001">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact_08329a2d9bce4f07a9c6692817c5fcf4"
      unitRef="U001">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="c20240101to20241231"
      id="Text_79e128d45a2c4990bab4a109e52a10b3">
&lt;div style="margin-left: 27pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Level 3 assets and liabilities measured and recorded at fair value on a recurring basis at December 31, 2024 and 2023 were as follows:&lt;/div&gt;

&lt;div style="margin-left: 27pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 27pt;"&gt;
        &lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-left: 17%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; margin-left: 27pt;"&gt;&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;December 31, 2024&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;December 31, 2023&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 68.7%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Derivative Liability &#x2013; Contingent Interest April Note&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.22%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.22%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.94%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;47,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.22%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.22%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.22%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.94%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;431,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.22%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 68.7%;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Derivative Liability &#x2013; Contingent Interest September Note&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.22%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.22%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.94%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;94,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.22%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.22%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.22%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.94%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;169,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.22%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 68.7%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Derivative Liability &#x2013; Contingent Interest December Note&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.22%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.22%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.94%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;275,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.22%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.22%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.22%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.94%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;404,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.22%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
         &lt;/div&gt;
</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact_1896f9b4b5ab4076bca544b7d7022870"
      unitRef="U001">47000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact_0814294ce886446e9090d119fd7befaa"
      unitRef="U001">431000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact_ca51f2581b234435ad9b45dc05d35029"
      unitRef="U001">94000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact_d69554ec004b4f0cafb4917a13e68d57"
      unitRef="U001">169000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact_96a36f0940e748d78009843984146095"
      unitRef="U001">275000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact_2af58f3e8c8e45b7893daa4b42d284be"
      unitRef="U001">404000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="c20240101to20241231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember"
      id="Text_89a76df31fde4a86969b359d4ee886ca">
&lt;div style="margin-left: 27pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The April 2021 Note derivative liability &#x2013; contingent interest was valued using a Monte Carlo Geometric Brownian Stock Path Model. The key assumptions used in the model
        at December 31, 2024 and 2023 are as follows:&lt;/div&gt;

&lt;div style="margin-left: 27pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 27pt;"&gt;
        &lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 70%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;December 31, 2024&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;December 31, 2023&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 70%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Stock Price&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1.29&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1.66&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 70%;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Conversion Price of conversion feature&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;5.00&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;5.00&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 70%;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Term&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; text-indent: 25pt; text-align: right;"&gt;&lt;span style="font-family: 'Times New Roman'; color: rgb(0, 255, 0);"&gt; &lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-indent: 0pt;"&gt;0.29&lt;/span&gt; years&lt;/span&gt;&lt;br/&gt;
                  &lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: right;"&gt;1.29 years&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 70%;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Risk Free Interest Rate&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;4.37&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;%&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;4.79&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;%&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 70%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Credit Adjusted Discount Rate&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;12.43&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;%&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;12.86&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;%&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 70%;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Volatility&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;152&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;%&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;69&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;%&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 70%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Dividend Rate&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;0&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;%&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;0&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;%&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
         &lt;/div&gt;
</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputSharePriceMember"
      decimals="2"
      id="Fact_b5058c32a8f04e3e8abf17bb1ed515c2"
      unitRef="U007">1.29</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputSharePriceMember"
      decimals="2"
      id="Fact_7e5411ee80a0487ab8e5e9fc99d9658d"
      unitRef="U007">1.66</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputConversionPriceMember"
      decimals="2"
      id="Fact_e4500300760f4f95bba0950328aa56b0"
      unitRef="U007">5</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputConversionPriceMember"
      decimals="2"
      id="Fact_825acf07b6c74146b4d2a5fd7c567fa3"
      unitRef="U007">5</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DebtInstrumentTerm
      contextRef="c20240101to20241231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedTermMember"
      id="Fact_f10999370c654da3b05b0d3d10e6355f">P0Y3M14D</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm
      contextRef="c20230101to20231231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedTermMember"
      id="Fact_2b929b50c5ca4e1ca92696a2da1c7c3e">P1Y3M14D</us-gaap:DebtInstrumentTerm>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember"
      decimals="4"
      id="Fact_4d8ab1c8deac454390f0b93df2c899d7"
      unitRef="U007">0.0437</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember"
      decimals="4"
      id="Fact_99e111e12045424e9bce24d384702c4a"
      unitRef="U007">0.0479</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputDiscountRateMember"
      decimals="4"
      id="Fact_a6615a2c3f1644209cd6a504ca2a9a90"
      unitRef="U007">0.1243</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputDiscountRateMember"
      decimals="4"
      id="Fact_aa810dc98df342adb92e31893127302e"
      unitRef="U007">0.1286</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember"
      decimals="2"
      id="Fact_666594034d6146f39588f217fbc67b9b"
      unitRef="U007">1.52</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember"
      decimals="2"
      id="Fact_d39167aebcaf404eae9d2919b7befcba"
      unitRef="U007">0.69</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedDividendRateMember"
      decimals="2"
      id="Fact_9f5d08c29eff4648b019c5096b6a7c87"
      unitRef="U007">0</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedDividendRateMember"
      decimals="2"
      id="Fact_5020ac74888a4e6da19a0a22117f4e8d"
      unitRef="U007">0</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="c20240101to20241231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember"
      id="Text_4a3bfb7e8e0a4e0896b8dc64f4bf4f8b">
&lt;div style="margin-left: 27pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The roll forward of the April 2021 Note derivative liability &#x2013; contingent interest is as follows:&lt;/div&gt;

&lt;div style="margin-left: 27pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 27pt;"&gt;
        &lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Balance &#x2013; December 31, &lt;span style="text-indent: 0pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;249,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Fair Value Adjustment&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;182,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Balance &#x2013; December 31, &lt;span style="text-indent: 0pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;431,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 2px;" valign="bottom"&gt;Fair Value Adjustment&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;(384,000&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;Balance &#x2013; December 31, 2024&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;47,000&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

      &lt;/div&gt;
</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember"
      decimals="0"
      id="Fact_dde33b2e445d47c7811c22b414e9e2a1"
      unitRef="U001">249000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="c20230101to20231231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember"
      decimals="0"
      id="Fact_d9ce2b0549ff47db8a12f731649711c4"
      unitRef="U001">182000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember"
      decimals="0"
      id="Fact_09c1162f2ba044faa607e47d5efae8d8"
      unitRef="U001">431000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="c20240101to20241231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember"
      decimals="0"
      id="Fact_12c6088ee8cf410db530f702106684a0"
      unitRef="U001">-384000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestAprilNoteMember"
      decimals="0"
      id="Fact_794a131ee15a43ecb3925c5cc2c89f98"
      unitRef="U001">47000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="c20240101to20241231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember"
      id="Text_5b5f5494613745f6a0a2150a8423cdf6">
&lt;div style="margin-left: 27pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The September 2021 Note derivative liability &#x2013; contingent interest was valued using a Monte Carlo Geometric Brownian Stock Path Model. The key assumptions used in the
        model at inception, and at December 31, 2024 and 2023 are as follows:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 27pt;"&gt;
        &lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 70%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="font-weight: bold;"&gt;December 31, 2024&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-weight: bold;"&gt;December 31, 2023&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 70%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Stock Price&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1.29&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1.66&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 70%;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Conversion Price of conversion feature&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;8.64&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;8.64&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 70%;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Term&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;0.72
                years&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;1.72
                years&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 70%;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Risk Free Interest Rate&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;4.16&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;%&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;4.23&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;%&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 70%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Credit Adjusted Discount Rate&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;12.43&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;%&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;12.86&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;%&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 70%;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Volatility&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;111&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;%&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;75&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;%&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 70%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Dividend Rate&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;0&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;%&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;0&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;%&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
         &lt;/div&gt;
</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputSharePriceMember"
      decimals="2"
      id="Fact_d1d5e7482ecb45deafd872ac8ff7bba8"
      unitRef="U007">1.29</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputSharePriceMember"
      decimals="2"
      id="Fact_54ffee996f6941459c535e9dbae2761a"
      unitRef="U007">1.66</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputConversionPriceMember"
      decimals="2"
      id="Fact_dd7b1724e534432b9c056dfb7f4a830f"
      unitRef="U007">8.64</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputConversionPriceMember"
      decimals="2"
      id="Fact_3175cfc193ae4e9b9ba8ab369b7bf9c5"
      unitRef="U007">8.64</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DebtInstrumentTerm
      contextRef="c20240101to20241231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedTermMember"
      id="Fact_651bccb5c228416ab4d1e47d9cad801e">P0Y8M19D</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm
      contextRef="c20230101to20231231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedTermMember"
      id="Fact_561cf89cb33b48d09039901d29580e5c">P1Y8M19D</us-gaap:DebtInstrumentTerm>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember"
      decimals="4"
      id="Fact_fd4a286e1b304e12bb815fc6b51b42de"
      unitRef="U007">0.0416</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember"
      decimals="4"
      id="Fact_955bb81e982043028b0b15166fb07688"
      unitRef="U007">0.0423</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputDiscountRateMember"
      decimals="4"
      id="Fact_dae80d81068c425ba92fd8607465b789"
      unitRef="U007">0.1243</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputDiscountRateMember"
      decimals="4"
      id="Fact_14b1d9cd4d7e46e19f150b780f578f71"
      unitRef="U007">0.1286</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember"
      decimals="2"
      id="Fact_c6120f4b53804c9ca9c5d62bd7e61e24"
      unitRef="U007">1.11</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember"
      decimals="2"
      id="Fact_860c6ac12696490a9771474118834e30"
      unitRef="U007">0.75</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedDividendRateMember"
      decimals="2"
      id="Fact_624963a5f6464541a20ecea607d1fb66"
      unitRef="U007">0</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedDividendRateMember"
      decimals="2"
      id="Fact_c7b78da66c2441eba1ee6b45dedbd88b"
      unitRef="U007">0</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="c20240101to20241231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember"
      id="Text_fbea72618b0f4b059c7d91e9f4e15583">
&lt;div style="margin-left: 27pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The roll forward of the September 2021 Note derivative liability &#x2013; contingent interest is as follows:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 27pt;"&gt;
        &lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Balance &#x2013; December 31, &lt;span style="text-indent: 0pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;109,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Fair Value Adjustment&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;60,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Balance &#x2013; December 31, &lt;span style="text-indent: 0pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;169,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 2px;" valign="bottom"&gt;Fair Value Adjustment&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;(75,000&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;Balance &#x2013; December 31, 2024&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;94,000&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

      &lt;/div&gt;
</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember"
      decimals="0"
      id="Fact_1961fdda673348ae9fa10ab2fabe7295"
      unitRef="U001">109000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="c20230101to20231231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember"
      decimals="0"
      id="Fact_7e22ba62158240bab3d97dd4f1f069c0"
      unitRef="U001">60000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember"
      decimals="0"
      id="Fact_9a35f91a2a854c62bc60dad6e215031e"
      unitRef="U001">169000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="c20240101to20241231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember"
      decimals="0"
      id="Fact_d24da70cdeb1463587bb0c9352d5e80a"
      unitRef="U001">-75000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestSeptemberNoteMember"
      decimals="0"
      id="Fact_8c8f0f31aa8744318e7201acd1368dd3"
      unitRef="U001">94000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="c20240101to20241231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember"
      id="Text_6d4a9a81036e4c01b6e0f4aa11080da1">
&lt;div style="margin-left: 27pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The December 2021 Note derivative liability &#x2013; contingent interest was valued using a Monte Carlo Geometric Brownian Stock Path Model. The key assumptions used in the
        model at inception, and at December 31, 2024 and 2023 are as follows:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 27pt;"&gt;
        &lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 70%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="font-weight: bold;"&gt;December 31, 2024&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-weight: bold;"&gt;December 31, 2023&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 70%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Stock Price&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1.29&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1.66&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 70%;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Conversion Price of conversion feature&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;5.43&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;5.43&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 70%;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Term&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; text-indent: 25pt; text-align: right;"&gt;&lt;span style="font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-indent: 0pt;"&gt;0.97&lt;/span&gt; years&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-indent: 14pt;"&gt;&lt;span style="text-indent: 0pt;"&gt;1.97&lt;/span&gt; years&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 70%;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Risk Free Interest Rate&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;4.16&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;%&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;4.23&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;%&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 70%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Credit Adjusted Discount Rate&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;12.43&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;%&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;12.86&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;%&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 70%;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Volatility&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;102&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;%&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;72&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;%&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 70%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Dividend Rate&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;0&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;%&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;0&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;%&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
         &lt;/div&gt;
</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputSharePriceMember"
      decimals="2"
      id="Fact_b193a6757cc9488187040f5ae5a7d142"
      unitRef="U007">1.29</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputSharePriceMember"
      decimals="2"
      id="Fact_a04d29fb9081483fa2126c8a139bd630"
      unitRef="U007">1.66</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputConversionPriceMember"
      decimals="2"
      id="Fact_e9951fb46d2d420fb010d31c1cc96b1d"
      unitRef="U007">5.43</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputConversionPriceMember"
      decimals="2"
      id="Fact_6dbd58e2c4194b5b8986851fe219f6cd"
      unitRef="U007">5.43</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DebtInstrumentTerm
      contextRef="c20240101to20241231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedTermMember"
      id="Fact_c7a8690bc45f4e6d9f287672b4eb5769">P0Y11M19D</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm
      contextRef="c20230101to20231231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedTermMember"
      id="Fact_03f42706943849489b32d86e5d684a3f">P1Y11M19D</us-gaap:DebtInstrumentTerm>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember"
      decimals="4"
      id="Fact_ee7e83d0ac6345c5a928cc5bb119398b"
      unitRef="U007">0.0416</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember"
      decimals="4"
      id="Fact_2d90420fdfa34bcfa73e18bbca165cb3"
      unitRef="U007">0.0423</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputDiscountRateMember"
      decimals="4"
      id="Fact_d3634533083b45a3953abe133a83db34"
      unitRef="U007">0.1243</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputDiscountRateMember"
      decimals="4"
      id="Fact_a112ebe7dd6f461ead70c88a0c6956bf"
      unitRef="U007">0.1286</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember"
      decimals="2"
      id="Fact_b3ac772c819740f4b80c29f44784a006"
      unitRef="U007">1.02</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember"
      decimals="2"
      id="Fact_97af8995a27a4a0f9d3759e69b6ea66c"
      unitRef="U007">0.72</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedDividendRateMember"
      decimals="2"
      id="Fact_1350523f09e04bf089f805d3e57b5a33"
      unitRef="U007">0</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember_MeasurementInputTypeAxis_MeasurementInputExpectedDividendRateMember"
      decimals="2"
      id="Fact_9d4aafdbb44e45c38d73a26275972223"
      unitRef="U007">0</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="c20240101to20241231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember"
      id="Text_a6230b83587249babd93c2994a882880">
&lt;div style="margin-left: 27pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The roll forward of the December 2021 Note derivative liability &#x2013; contingent interest is as follows:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 27pt;"&gt;
          &lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Balance &#x2013; December 31, &lt;span style="text-indent: 0pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;214,000&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Fair Value Adjustment&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;190,000&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Balance &#x2013; December 31, &lt;span style="text-indent: 0pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;404,000&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 2px;" valign="bottom"&gt;Fair Value Adjustment&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;(129,000&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;Balance &#x2013; December 31, 2024&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;275,000&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
        &lt;/div&gt;
</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="c20221231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember"
      decimals="0"
      id="Fact_77eb91b3e1974d3f93db4a052243e5a0"
      unitRef="U001">214000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="c20230101to20231231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember"
      decimals="0"
      id="Fact_0fbead46c73d43dd833d6afd596969f1"
      unitRef="U001">190000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="c20231231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember"
      decimals="0"
      id="Fact_c4ecaea928d24996bd99e69d8f40cca7"
      unitRef="U001">404000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="c20240101to20241231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember"
      decimals="0"
      id="Fact_0104ce9e1ada40c98572f70a73c61535"
      unitRef="U001">-129000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="c20241231_DerivativeInstrumentRiskAxis_ContingentInterestDecemberNoteMember"
      decimals="0"
      id="Fact_6487d94a9e1541768dbe75e4ff68684e"
      unitRef="U001">275000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="c20240101to20241231"
      id="Text_e086e552c31544b38a446bfb96b43ef1">
&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 24.5pt; vertical-align: top; font-weight: bold;"&gt;7.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
              &lt;div style="font-weight: bold;"&gt;Stockholders&#x2019; Equity&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;At December 31, 2024, the Company had 150,000,000
        shares of common stock and 20,000,000 undesignated shares authorized. As of December 31, 2024, 1,742,500 shares have been designated for Series A 12% Convertible Preferred Stock, 900,000 shares have been designated for Series B-1 Convertible Preferred Stock, 2,100,000
        shares have been designated for Series B-2 Convertible Preferred Stock, 1,000 shares have been designated for Series C Super Dividend
        Convertible Preferred Stock, 2,508,000 shares have been designated for Series B-3 Convertible Preferred Stock, 12,748,500 have been designated as common stock and no shares remain undesignated. All issued and outstanding shares of Series B-1, Series B-2 and
        Series B-3 Preferred Stock were converted into Common Stock on January 19, 2019.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;"&gt;2020 At Market Issuance of Common Stock&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;On May 11, 2020, the Company entered into an At Market Issuance Sales Agreement (the &#x201c;2020 At Market Agreement&#x201d;) with a sales agent under which the Company may issue
        and sell shares of its common stock having an aggregate offering price of up to $40.0 million from time to time through the sales agent.
        Sales of the Company&#x2019;s common stock through the sales agent, if any, will be made by any method that is deemed an &#x201c;at the market&#x201d; offering as defined by the U.S. Securities and Exchange Commission. The Company will pay to the sales agent a
        commission rate equal to 3.0% of the gross proceeds from the sale of any shares of common stock sold through the sales agent under the
        2020 At Market Agreement. There were no issuances of common stock under the 2020 At Market Agreement during the year ended December
        31, 2024 or 2023.&lt;br/&gt;
      &lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Series A 12% Convertible Preferred
        Stock &#x2014; February 4, 2008 Private Placement&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;On February 4, 2008, the Company closed a private placement begun in October 2007 of its Series A 12% Convertible Preferred Stock (&#x201c;Series A&#x201d;) and related warrants. In this transaction, the Company sold units of securities at $6.00 per unit, each unit comprised of (i) one share of Series A Preferred,
        (ii) a warrant to purchase one share of common stock for $9.00, and (iii) a warrant to purchase one share of common stock for $12.00. Each share of the Series A is entitled to dividends at the rate of 12% per annum payable at the Company&#x2019;s option in cash or shares of common stock valued at the higher of $6.00 per share or 100% of the value weighted average price of the Company&#x2019;s
        share price for the 20 consecutive trading days prior to the applicable dividend payment date. Dividends are payable semi-annually on
        March 30 and September 30. The dividend paid on the initial dividend payment date is calculated from the date the Company deposited each subscription advance.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The shares of Series A are entitled to vote as a class with the Company&#x2019;s common stock and each share of Series A is convertible at any time to one-sixth of a share
        of common stock, subject to adjustment in the event of a stock dividend, stock split or combination, reclassification or similar event. The Company has the right to require conversion if the closing price of the common stock exceeds $18.00 for 15 consecutive trading days
        and a registration statement covering the resale of the shares of common stock issuable upon conversion of the Series A is then in effect. Each warrant is exercisable solely for cash beginning August 3, 2008 and expired on February 4, 2012. The
        exercise price of each warrant is adjustable in the event of a stock split or stock combination, capital reorganization, merger or similar event.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;In 2023, 25,000 shares of Series A were converted into
        4,257 shares of common stock. Prior to 2021, a total of 507,500 shares of Series A had been converted into 81,152 shares of common
        stock.&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Series C 6% Super Dividend Redeemable
        Convertible Preferred Stock&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;On December 29, 2010, the Company designated and authorized the sale and issuance of up to 1,000 shares of Series C Super Dividend Redeemable Convertible Preferred Stock (&#x201c;Series C&#x201d;) with a par value of $0.01 and a stated value equal to $10,000 (the &#x201c;Stated Value&#x201d;).&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;On December 30, 2010, the Company sold and issued 212
        shares of Series C at a price of $10,000 per share for gross proceeds of $2,120,000. The Company incurred $47,000 of cash transaction costs resulting in
        net cash proceeds of $2,073,000. In addition, the Company issued 500 warrants exercisable at $7.20 to a placement agent which had a de minimis
        value. Additionally, in January 2011, the Company sold and issued 13 shares of Series C at a price of $10,000 per share for gross proceeds of $130,000.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The terms of the Series C are as follows:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-style: italic;"&gt;Conversion Rights&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;. Each holder of Series C may
          convert all, but not less than all, of his Series C shares plus accrued and unpaid dividends into Common Stock at the price of $6.00
          per share of Common Stock (&#x201c;Conversion Price&#x201d;), such that approximately 1,667 shares of Common Stock will be issued per each converted
          share of Series C (accrued and unpaid dividends will be issued as additional shares). At December 31, 2024 and 2023, the 176
          outstanding shares of Series C were convertible into a total of approximately 293,340 shares of Common Stock.&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Subject to the continuing obligation to pay post conversion dividends, the Company may convert all, but not less than all, of the Series C (plus all accrued and
        unpaid dividends) into Common Stock, at the Conversion Price, upon such time that the closing price of the Common Stock is no less than $18.00
        per share for 15 consecutive trading days.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-style: italic;"&gt;Dividends&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;. Holders of Series C shall be
          entitled to receive cumulative non-compounding dividends at the rate per share of Series C equal to the greater of (i) 6% per annum of
          the Stated Value (also defined as the &#x201c;Floor&#x201d;) or (ii) 2.5% of net sales until the total dividends paid is equal to the initial
          investment and 1.25% of net sales thereafter. The maximum amount each Series C shareholder will receive in dividend payments is equal
          to $100,000 (the &#x201c;Maximum Payout&#x201d;). For purposes of this dividend calculation, net sales shall mean gross revenues actually received by
          the Company, from the sale or licensing of the product DAVANAT&lt;sup style="vertical-align: text-top; line-height: 1; font-size: smaller;"&gt;&#xae;&lt;/sup&gt; (GM-CT-01), less chargebacks, returns, expenses attributable to product recalls, duties, customs,
          sales tax, freight, insurance, shipping expenses, allowances and other customary deductions.&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The dividend shall be payable in arrears semiannually on March 31 and September 30, beginning with the first such date after the original issue date; provided,
        however, that all dividends and all other distributions shall cease, and no further dividends or other distributions shall be paid, in respect of each share of Series C from and after such time that the Maximum Payout has been paid in respect of
        such share of Series C. Such dividends shall be payable at the Company&#x2019;s option either in cash or in duly authorized, fully paid and non-assessable shares of Common Stock valued at the higher of (i) $3.00 per share or (ii) the average of the Common Stock trading price for the ten (10)
        consecutive trading days ending on the trading day that is immediately prior to the dividend payment date.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-style: italic;"&gt;Series C Post Conversion Dividend Right&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;. In the
          event that any share of Series C is converted into Common Stock before the Maximum Payout is paid in respect of such converted share of Series C, then the holder shall have the right to continue to receive dividends in respect of such converted
          share of Series C equal to the remaining payout (the &#x201c;Series C Preferred Stock Post Conversion Dividend Right&#x201d;) which shall be equal to the Maximum Payout less the cumulative dividends received through the conversion date. One share of Series C
          Preferred Stock Post Conversion Dividend Right shall be issued for each such converted share of Series C. The holder of each Series C Preferred Stock Post Conversion Dividend Right shall receive the remaining payout on an equal basis and in
          conjunction with the then outstanding shares of Series C and all the other then outstanding Series C Post Conversion Dividend Rights, in the same manner and subject to the same terms and conditions as applicable to the payment of dividends on
          each share of Series C, except that for purposes of calculating the dividend the Floor shall not apply. The Series C Preferred Stock Post Conversion Dividend Right shall have no stated value, liquidation preference or right to any dividends or
          distributions other than the remaining payout. The Series C Preferred Stock Post Conversion Right is subject to redemption in the same manner as outstanding Series C shares.&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;At the date of issuance, the Series C have an embedded dividend right to continue to receive dividend payments after conversion to common stock (the Series C Post
        Conversion Dividend Right) which requires bifurcation. The value of this post conversion dividend right on the date of issuance was determined to be de minimis due to the fact that the payment of a dividend stream other than the 6% dividend and conversion of Series C prior to the Company achieving sales of GM-CT-01 was deemed improbable at that time. Upon a conversion of the
        Series C, the Company will be required to record a liability and the related expense during the period of conversion.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;In July 2011, 5 shares of Series C were converted into 8,334
        shares of common stock and 5 Series C Post Conversion Dividend Rights (Dividend Rights) were issued. In 2013, 24 shares of Series C were
        converted into 40,193 shares of common stock and 24 Dividend Rights were issued. In 2014, 20 shares of Series C were converted into 33,756
        shares of common stock and 20 Dividend Rights were issued. Per the terms of the Series C, these Dividend Rights shall continue to
        participate in dividends, however the Floor shall not apply. At December 31, 2016 and 2015, these Dividend Rights were determined to have a de minimis value, as the payment of a dividend is considered improbable at this time. The Company will
        continue to evaluate and assess the Series C Post Conversion Dividend Right for each reporting period.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-style: italic;"&gt;Liquidation Rights&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;. In the event of any
          liquidation, dissolution or winding up of the Company, either voluntarily or involuntarily, the holders of Series C will receive $10,000
          per share plus accrued and unpaid dividends, payable prior and in preference to any distributions to the holders of Common Stock but after and subordinate to the Series A 12% Convertible Preferred Stock (&#x201c;Series A&#x201d;), Series B-1 and Series B-2, subject to the Maximum Payout.&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-style: italic;"&gt;Redemption&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;. Upon a sale of the Company, the
          Company shall redeem all of the then outstanding shares of Series C and Series C Preferred Stock Post Conversion Rights within thirty (30)
          days after the transaction constituting the sale of the Company is closed and such closing is fully funded. The price to redeem a share of Series C and each redeemed Series C Preferred Stock Post Conversion Redemption Right shall be equal to (i)
          (A) the applicable return on investment (&#x201c;ROI&#x201d;) percentage, multiplied by (B) $10,000, minus (ii) the cumulative dividends received
          through the redemption date. The redemption price shall be payable at the Company&#x2019;s option either in cash or in shares of common stock valued at the higher of (i) $3.00 per share or (ii) the average market price for the &lt;span style="-sec-ix-hidden:Fact_9d42133c6fda4902871913ae7391078b"&gt;ten&lt;/span&gt; consecutive
          trading days ending immediately prior to the date of redemption. The ROI Percentage shall mean the percentage that applies as of the redemption date, as follows:&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;ROI Percentage&lt;/span&gt;&lt;/div&gt;

&lt;div style="margin-left: 27pt;"&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 6%; vertical-align: middle;"&gt;&#160;&lt;/td&gt;

    &lt;td style="width: 94%; vertical-align: middle;"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
                &lt;div&gt;200%&lt;/div&gt;
              &lt;/td&gt;

    &lt;td style="width: 94%; vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
                &lt;div&gt;before the second anniversary of the date of issuance;&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 6%; vertical-align: top;"&gt;
                &lt;div&gt;250%&lt;/div&gt;
              &lt;/td&gt;

    &lt;td style="width: 94%; vertical-align: top;"&gt;
                &lt;div&gt;on or after the second anniversary of the date of issuance, but before the third anniversary of the date of issuance;&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
                &lt;div style="text-indent: -12pt; margin-left: 12pt;"&gt;&lt;span style="text-indent: 0pt;"&gt;300&lt;/span&gt;%&lt;/div&gt;
              &lt;/td&gt;

    &lt;td style="width: 94%; vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
                &lt;div style="text-indent: -12pt; margin-left: 12pt;"&gt;on or after the third anniversary of the date of issuance, but before the fourth anniversary of the date of issuance;&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 6%; vertical-align: bottom;"&gt;
                &lt;div style="text-indent: -12pt; margin-left: 12pt;"&gt;&lt;span style="text-indent: 0pt;"&gt;350&lt;/span&gt;%&lt;/div&gt;
              &lt;/td&gt;

    &lt;td style="width: 94%; vertical-align: top;"&gt;
                &lt;div style="text-indent: -12pt; margin-left: 12pt;"&gt;on or after the fourth anniversary of the date of issuance, but before the fifth anniversary of the date of issuance;&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
                &lt;div style="text-indent: -12pt; margin-left: 12pt;"&gt;&lt;span style="text-indent: 0pt;"&gt;400&lt;/span&gt;%&lt;/div&gt;
              &lt;/td&gt;

    &lt;td style="width: 94%; vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
                &lt;div style="text-indent: -12pt; margin-left: 12pt;"&gt;on or after the fifth anniversary of the date of issuance, but before the sixth anniversary of the date of issuance;&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 6%; vertical-align: bottom;"&gt;
                &lt;div style="text-indent: -12pt; margin-left: 12pt;"&gt;&lt;span style="text-indent: 0pt;"&gt;450&lt;/span&gt;%&lt;/div&gt;
              &lt;/td&gt;

    &lt;td style="width: 94%; vertical-align: top;"&gt;
                &lt;div style="text-indent: -12pt; margin-left: 12pt;"&gt;on or after the sixth anniversary of the date of issuance, but before the seventh anniversary of the date of issuance;&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
                &lt;div style="text-indent: -12pt; margin-left: 12pt;"&gt;&lt;span style="text-indent: 0pt;"&gt;500&lt;/span&gt;%&lt;/div&gt;
              &lt;/td&gt;

    &lt;td style="width: 94%; vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
                &lt;div style="text-indent: -12pt; margin-left: 12pt;"&gt;on or after the seventh anniversary of the date of issuance, but before the eighth anniversary of the date of issuance; and&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 6%; vertical-align: bottom;"&gt;
                &lt;div style="text-indent: -12pt; margin-left: 12pt;"&gt;&lt;span style="text-indent: 0pt;"&gt;550&lt;/span&gt;%&lt;/div&gt;
              &lt;/td&gt;

    &lt;td style="width: 94%; vertical-align: top;"&gt;
                &lt;div style="text-indent: -12pt; margin-left: 12pt;"&gt;on or after the eighth anniversary of the date of issuance, but before the ninth anniversary of the date of issuance.&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
      &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Due to the redemption feature, the Company has presented the Series C outside of permanent equity, in the mezzanine of the consolidated balance sheets at December 31,
        2024 and 2023. At December 31, 2024, the Series C redemption value was $8,018,000.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-style: italic;"&gt;Voting Rights&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;. The Series C shares have no voting rights.&lt;/span&gt;&lt;/div&gt;
</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c20241231"
      decimals="0"
      id="Fact_df254785226a49ada338443f8a746383"
      unitRef="U002">150000000</us-gaap:CommonStockSharesAuthorized>
    <galt:UndesignatedCapitalStockSharesAuthorized
      contextRef="c20241231"
      decimals="0"
      id="Fact_bff5e191f3b74e1bbb7c661f36ebd166"
      unitRef="U002">20000000</galt:UndesignatedCapitalStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c20241231_StatementClassOfStockAxis_SeriesAPreferredStockMember"
      decimals="0"
      id="Fact_685470cd9ce24de384226e69a5d0e1fe"
      unitRef="U002">1742500</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c20241231_StatementClassOfStockAxis_SeriesBOneConvertiblePreferredStockMember"
      decimals="0"
      id="Fact_01a7b4051d6f41149064922a8959faa2"
      unitRef="U002">900000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c20241231_StatementClassOfStockAxis_SeriesBTwoConvertiblePreferredStockMember"
      decimals="0"
      id="Fact_643e7671f7804f3e9e07eeefe33ed2a3"
      unitRef="U002">2100000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c20241231_StatementClassOfStockAxis_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact_f59905fc9d9c45a3bfa57a8ca1ca45d6"
      unitRef="U002">1000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c20241231_StatementClassOfStockAxis_SeriesBThreeConvertiblePreferredStockMember"
      decimals="0"
      id="Fact_6aee83ac89b442e5a47cd6861ab4764a"
      unitRef="U002">2508000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c20241231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_f2e2fc937f294834bf4c4efc82cf5061"
      unitRef="U002">12748500</us-gaap:PreferredStockSharesAuthorized>
    <galt:AggregateOfferingPrice
      contextRef="c20231231_TypeOfArrangementAxis_TwoThousandTwentyMarketAgreementMember"
      decimals="-5"
      id="Fact_acca4a3007244adf89bd9c63188e8dbf"
      unitRef="U001">40000000</galt:AggregateOfferingPrice>
    <galt:CommissionRate
      contextRef="c20231231_TypeOfArrangementAxis_TwoThousandTwentyMarketAgreementMember"
      decimals="3"
      id="Fact_236a85b561bd4e8e961783fdced243e3"
      unitRef="U007">0.03</galt:CommissionRate>
    <us-gaap:CommonStockSharesIssued
      contextRef="c20241231_TypeOfArrangementAxis_TwoThousandTwentyMarketAgreementMember"
      decimals="INF"
      id="Fact_ea699487cda64fd388dd717c0500e46c"
      unitRef="U002">0</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="c20231231_TypeOfArrangementAxis_TwoThousandTwentyMarketAgreementMember"
      decimals="INF"
      id="Fact_66dcb95c168547b58cb56dd92079201d"
      unitRef="U002">0</us-gaap:CommonStockSharesIssued>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="c20080204to20080204_StatementClassOfStockAxis_SeriesAPreferredStockMember"
      decimals="2"
      id="Fact_57f5cea6b93f44098ee283e9aada0b8f"
      unitRef="U007">0.12</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="c20080204to20080204_StatementClassOfStockAxis_SeriesAPreferredStockMember"
      decimals="2"
      id="Fact_640f11e1d132450ab7b83c3997c07407"
      unitRef="U007">0.12</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c20080204_StatementClassOfStockAxis_SeriesAPreferredStockMember"
      decimals="2"
      id="Fact_fa8319fff8a940d191363eb745813294"
      unitRef="U003">6</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="c20080204_StatementClassOfStockAxis_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact_9f8e8fd750de4334af956ba69838289b"
      unitRef="U002">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20080204_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementScenarioAxis_DividendPaymentScenarioOneMember"
      decimals="2"
      id="Fact_84fc14076d884b2d91d9d38b8ca46c25"
      unitRef="U003">9</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20080204_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementScenarioAxis_DividendPaymentScenarioTwoMember"
      decimals="2"
      id="Fact_9baf5742bfa54477898a183e6b077110"
      unitRef="U003">12</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="c20080204to20080204_StatementClassOfStockAxis_SeriesAPreferredStockMember"
      decimals="2"
      id="Fact_24b7bfaf3c3143f69c75d246502a6404"
      unitRef="U007">0.12</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c20080204_StatementClassOfStockAxis_SeriesAPreferredStockMember"
      decimals="2"
      id="Fact_a5bc08538bbc4f65a9c2861f033fd9e3"
      unitRef="U003">6</us-gaap:SharesIssuedPricePerShare>
    <galt:PercentageOfWeightedAverageStockPriceForDividendsPriorToPaymentDate
      contextRef="c20080204to20080204_StatementClassOfStockAxis_SeriesAPreferredStockMember"
      decimals="2"
      id="Fact_a210a11aeffe473c9ef43d63c8373e6f"
      unitRef="U007">1</galt:PercentageOfWeightedAverageStockPriceForDividendsPriorToPaymentDate>
    <galt:NumberOfConsecutiveTradingDays
      contextRef="c20080204to20080204_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementScenarioAxis_DividendPaymentScenarioOneMember"
      id="Fact_818f40e79da9490180fc8eb118e5f5a8">P20D</galt:NumberOfConsecutiveTradingDays>
    <us-gaap:SharePrice
      contextRef="c20080204_RangeAxis_MinimumMember_StatementClassOfStockAxis_SeriesAPreferredStockMember"
      decimals="2"
      id="Fact_a75a68f2092045d188c4fb70aa9887a8"
      unitRef="U003">18</us-gaap:SharePrice>
    <galt:NumberOfConsecutiveTradingDays
      contextRef="c20080204to20080204_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementScenarioAxis_DividendPaymentScenarioTwoMember"
      id="Fact_a7d17af460884037a45016a26f12ca76">P15D</galt:NumberOfConsecutiveTradingDays>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="c20230101to20231231_StatementClassOfStockAxis_SeriesAPreferredStockMember"
      decimals="0"
      id="Fact_296b420cccdc4c64937ae9697d136573"
      unitRef="U002">25000</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="c20230101to20231231_StatementClassOfStockAxis_SeriesAPreferredStockMember"
      decimals="0"
      id="Fact_acfedec74dbc4160893b935c211ffebc"
      unitRef="U002">4257</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="c20200101to20201231_StatementClassOfStockAxis_SeriesAPreferredStockMember"
      decimals="0"
      id="Fact_12bb80f812104d739134c7904db3e5c9"
      unitRef="U002">507500</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="c20200101to20201231_StatementClassOfStockAxis_SeriesAPreferredStockMember"
      decimals="0"
      id="Fact_74f716ead72a465d91b6c0b71afe5811"
      unitRef="U002">81152</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="c20101230to20101230_StatementClassOfStockAxis_SeriesCPreferredStockMember"
      decimals="2"
      id="Fact_3424f5ca515f432faefeca03588626f5"
      unitRef="U007">0.06</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20101229to20101229_RangeAxis_MaximumMember_StatementClassOfStockAxis_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact_302b98ba983e4438961033e524ed7f4c"
      unitRef="U002">1000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c20101229_StatementClassOfStockAxis_SeriesCPreferredStockMember"
      decimals="2"
      id="Fact_608fe797421745229cc08100807957fa"
      unitRef="U003">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="c20101229_RangeAxis_MaximumMember_StatementClassOfStockAxis_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact_9e94c58f51f84647a58fa3b7b1a5bb18"
      unitRef="U003">10000</us-gaap:PreferredStockLiquidationPreference>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20101230to20101230_StatementClassOfStockAxis_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact_dc881ed5354846d6b918b70f38d98499"
      unitRef="U002">212</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c20101230_StatementClassOfStockAxis_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact_fe850a955c814bf8ad471ad0658a1c94"
      unitRef="U003">10000</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="c20101230to20101230_StatementClassOfStockAxis_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact_5e1c2a4ad86d48d9b6c27301b35d89ce"
      unitRef="U001">2120000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="c20101230to20101230_StatementClassOfStockAxis_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact_74d94247be3142ce81f254f5a68bbece"
      unitRef="U001">47000</us-gaap:PaymentsOfStockIssuanceCosts>
    <galt:ProceedsFromIssuanceOfPreferredStockNetOfIssuanceCosts
      contextRef="c20101230to20101230_StatementClassOfStockAxis_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact_be713bc4cccc43e99dbaa04d9c089a41"
      unitRef="U001">2073000</galt:ProceedsFromIssuanceOfPreferredStockNetOfIssuanceCosts>
    <galt:ClassOfWarrantOrRightIssued
      contextRef="c20101230to20101230_StatementClassOfStockAxis_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact_45e58d5086a44ddcb194fffc73b5fab3"
      unitRef="U002">500</galt:ClassOfWarrantOrRightIssued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20101230_StatementClassOfStockAxis_SeriesCPreferredStockMember"
      decimals="2"
      id="Fact_f4da2f90abda431aa006830d2c038f09"
      unitRef="U003">7.2</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20110101to20110131_StatementClassOfStockAxis_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact_86ca22d6c37c4a75b503bf08c92fbcb8"
      unitRef="U002">13</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c20110131_StatementClassOfStockAxis_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact_091d670c07194bf5aa1a50cc7b641683"
      unitRef="U003">10000</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="c20110101to20110131_StatementClassOfStockAxis_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact_e268bd8e43d04556a9c3581a55893886"
      unitRef="U001">130000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <galt:EquityIssuancePerShareAmount
      contextRef="c20101230to20101230_StatementClassOfStockAxis_SeriesCPreferredStockMember"
      decimals="2"
      id="Fact_3a88b4ef92444c2ba490d156b247f031"
      unitRef="U003">6</galt:EquityIssuancePerShareAmount>
    <galt:CommonSharesIssuableUponConversionOfConvertibleStock
      contextRef="c20101230_StatementClassOfStockAxis_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact_761a3dfa1bca4e47a7a15eae7b41e59a"
      unitRef="U002">1667</galt:CommonSharesIssuableUponConversionOfConvertibleStock>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c20241231_StatementClassOfStockAxis_SeriesCPreferredStockMember_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_e38121c16d5749e9b2b3819a2d9f4e19"
      unitRef="U002">176</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c20231231_StatementClassOfStockAxis_SeriesCPreferredStockMember_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_87cdbe2c71e34229a611bc72c62eedd5"
      unitRef="U002">176</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="c20230101to20231231_StatementClassOfStockAxis_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact_60e5481797ac4f5c85a6890bef1c5e74"
      unitRef="U002">293340</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="c20240101to20241231_StatementClassOfStockAxis_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact_254e1d56fb104ca09d06c99be9a33112"
      unitRef="U002">293340</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:SharePrice
      contextRef="c20101230_StatementClassOfStockAxis_SeriesCPreferredStockMember_StatementEquityComponentsAxis_CommonStockMember"
      decimals="2"
      id="Fact_6dafb4f88e4e48f1a163317ed795ad99"
      unitRef="U003">18</us-gaap:SharePrice>
    <galt:NumberOfConsecutiveTradingDays
      contextRef="c20101230to20101230_StatementClassOfStockAxis_SeriesCPreferredStockMember"
      id="Fact_f96faa08361c45db8c0437cafeb364c2">P15D</galt:NumberOfConsecutiveTradingDays>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="c20101230to20101230_StatementClassOfStockAxis_SeriesCPreferredStockMember"
      decimals="2"
      id="Fact_a390204869d44806b9606f1c1571a2a0"
      unitRef="U007">0.06</us-gaap:PreferredStockDividendRatePercentage>
    <galt:DividendAsPercentageOfNetSales
      contextRef="c20101230to20101230_StatementClassOfStockAxis_SeriesCPreferredStockMember_StatementScenarioAxis_DividendPaymentScenarioOneMember"
      decimals="3"
      id="Fact_40b87453f88f4b1e9eceb6516bf985ab"
      unitRef="U007">0.025</galt:DividendAsPercentageOfNetSales>
    <galt:DividendAsPercentageOfNetSales
      contextRef="c20101230to20101230_StatementClassOfStockAxis_SeriesCPreferredStockMember_StatementScenarioAxis_DividendPaymentScenarioTwoMember"
      decimals="4"
      id="Fact_3e80a830351c4fafa8b7b0968588819c"
      unitRef="U007">0.0125</galt:DividendAsPercentageOfNetSales>
    <us-gaap:DividendsPreferredStock
      contextRef="c20101230to20101230_RangeAxis_MaximumMember_StatementClassOfStockAxis_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact_492b12f561964f4eb67c3122b532167b"
      unitRef="U001">100000</us-gaap:DividendsPreferredStock>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="c20101230_StatementClassOfStockAxis_SeriesCPreferredStockMember"
      decimals="2"
      id="Fact_17b43a0ea51c41e98b9183f9a47d077a"
      unitRef="U003">3</us-gaap:PreferredStockRedemptionPricePerShare>
    <galt:NumberOfConsecutiveTradingDays
      contextRef="c20240101to20241231_StatementClassOfStockAxis_SeriesCPreferredStockMember"
      id="Fact_59722c6840f043febe2211d025cca8aa">P10D</galt:NumberOfConsecutiveTradingDays>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="c20101230to20101230_StatementClassOfStockAxis_SeriesCPreferredStockMember"
      decimals="2"
      id="Fact_dd569a345c7946adb6600b5ff47266a6"
      unitRef="U007">0.06</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="c20110731to20110731_StatementClassOfStockAxis_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact_1fa47e23b797493593462dc2f9f2175d"
      unitRef="U002">8334</us-gaap:ConversionOfStockSharesIssued1>
    <galt:PostConversionDividendRightsIssued
      contextRef="c20110731to20110731_StatementClassOfStockAxis_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact_aa77337d441e4524991b4fa91a6f03f4"
      unitRef="U002">5</galt:PostConversionDividendRightsIssued>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="c20131231to20131231_StatementClassOfStockAxis_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact_5e100aee54ab4dfc86f320930815d1e3"
      unitRef="U002">40193</us-gaap:ConversionOfStockSharesIssued1>
    <galt:PostConversionDividendRightsIssued
      contextRef="c20131231to20131231_StatementClassOfStockAxis_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact_6977c303539745afa6f60f7c0ddaf390"
      unitRef="U002">24</galt:PostConversionDividendRightsIssued>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="c20141231to20141231_StatementClassOfStockAxis_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact_321cd5b345414273be07ee8f9be8998d"
      unitRef="U002">33756</us-gaap:ConversionOfStockSharesIssued1>
    <galt:PostConversionDividendRightsIssued
      contextRef="c20141231to20141231_StatementClassOfStockAxis_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact_6955d89a5c9b486da72bf864a591c77d"
      unitRef="U002">20</galt:PostConversionDividendRightsIssued>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="c20101230_StatementClassOfStockAxis_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact_0aba91a0877446368002c778fc3361f8"
      unitRef="U003">10000</us-gaap:PreferredStockLiquidationPreference>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="c20080204to20080204_StatementClassOfStockAxis_SeriesAPreferredStockMember"
      decimals="2"
      id="Fact_d70b322f657c40ef9a471b049040ccf6"
      unitRef="U007">0.12</us-gaap:PreferredStockDividendRatePercentage>
    <galt:ClosingDaysAfterConversionRights
      contextRef="c20240101to20241231_StatementClassOfStockAxis_SeriesCPreferredStockMember"
      id="Fact_e3e5fa04183d4d8fb7938b5b2f629a4b">P30D</galt:ClosingDaysAfterConversionRights>
    <galt:PostConversionRedemptionRightReturnOnInvestmentMultiplierAmount
      contextRef="c20240101to20241231_StatementClassOfStockAxis_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact_b457f5030f124fcc8f0f7c1f4d85d1a5"
      unitRef="U001">10000</galt:PostConversionRedemptionRightReturnOnInvestmentMultiplierAmount>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="c20241231_StatementClassOfStockAxis_SeriesCPreferredStockMember"
      decimals="2"
      id="Fact_55dd51582d9142aabbaf16c2086e807a"
      unitRef="U003">3</us-gaap:PreferredStockRedemptionPricePerShare>
    <galt:ReturnOnInvestmentsPercentagePeriodOne
      contextRef="c20240101to20241231"
      decimals="2"
      id="Fact_26d52204518c48e593f30f5cbe563927"
      unitRef="U007">2</galt:ReturnOnInvestmentsPercentagePeriodOne>
    <galt:ReturnOnInvestmentsPercentagePeriodTwo
      contextRef="c20240101to20241231"
      decimals="2"
      id="Fact_508448f4977f482cbeefd3a2c0cb99cf"
      unitRef="U007">2.50</galt:ReturnOnInvestmentsPercentagePeriodTwo>
    <galt:ReturnOnInvestmentsPercentagePeriodThree
      contextRef="c20240101to20241231"
      decimals="2"
      id="Fact_4331ff0b64c64ad3bd49c2b335e7c612"
      unitRef="U007">3</galt:ReturnOnInvestmentsPercentagePeriodThree>
    <galt:ReturnOnInvestmentsPercentagePeriodFour
      contextRef="c20240101to20241231"
      decimals="2"
      id="Fact_0c1f5d790e234afeba594acbc32fbf70"
      unitRef="U007">3.50</galt:ReturnOnInvestmentsPercentagePeriodFour>
    <galt:ReturnOnInvestmentsPercentagePeriodFive
      contextRef="c20240101to20241231"
      decimals="2"
      id="Fact_d3eec8a6db5d4f6b80cd32d279406be8"
      unitRef="U007">4</galt:ReturnOnInvestmentsPercentagePeriodFive>
    <galt:ReturnOnInvestmentsPercentagePeriodSix
      contextRef="c20240101to20241231"
      decimals="2"
      id="Fact_4e5e8b97ed6d4ce88f41f238c8c7e0cd"
      unitRef="U007">4.50</galt:ReturnOnInvestmentsPercentagePeriodSix>
    <galt:ReturnOnInvestmentsPercentagePeriodSeven
      contextRef="c20240101to20241231"
      decimals="2"
      id="Fact_353a4276a5594c4393a13ec929814074"
      unitRef="U007">5</galt:ReturnOnInvestmentsPercentagePeriodSeven>
    <galt:ReturnOnInvestmentsPercentagePeriodEight
      contextRef="c20240101to20241231"
      decimals="2"
      id="Fact_5fa7246351074f9898097fd8cbb8ccf3"
      unitRef="U007">5.50</galt:ReturnOnInvestmentsPercentagePeriodEight>
    <us-gaap:TemporaryEquityAggregateAmountOfRedemptionRequirement
      contextRef="c20241231_StatementClassOfStockAxis_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact_4080157ea64b48e6862e26ffe3d602fb"
      unitRef="U001">8018000</us-gaap:TemporaryEquityAggregateAmountOfRedemptionRequirement>
    <galt:ConvertiblePreferredStockNumberOfVotingRights
      contextRef="c20240101to20241231_StatementClassOfStockAxis_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact_046ac146462147d8a6046cab129f34c3"
      unitRef="U008">0</galt:ConvertiblePreferredStockNumberOfVotingRights>
    <galt:CommonStockWarrantsDisclosureTextBlock
      contextRef="c20240101to20241231"
      id="Text_7f9a4d7e923e48c892d19edaa82eda5b">
&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 27pt; vertical-align: top; font-weight: bold;"&gt;8.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
              &lt;div style="font-weight: bold;"&gt;Warrants&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Warrant activity is summarized as follows:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 27pt;"&gt;
        &lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: top; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div&gt;&lt;span style="font-weight: bold;"&gt;Warrants&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-weight: bold;"&gt;Weighted average &lt;/div&gt;
                &lt;div style="font-weight: bold;"&gt;exercise price&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Outstanding at December 31, &lt;span style="text-indent: 0pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;11,557,964&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;4.37&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Issued&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;600,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;3.09&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Exercised&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;(2,236,204&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;4.49&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Canceled/Expired&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;(665,267&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;4.94&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Outstanding at December 31, &lt;span style="text-indent: 0pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;9,256,493&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;4.22&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Issued&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;600,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;3.70&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Exercised&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;(142,503&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;3.00&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Canceled/Expired&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;(118,050&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;4.33&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Outstanding at December 31, &lt;span style="text-indent: 0pt;"&gt;2024&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;9,595,940&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;4.21&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
      &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;br/&gt;
      &lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The weighted average expiration of the warrants outstanding as of December 31, 2024 is 2.2 years.&lt;/div&gt;

&lt;div style="margin-left: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;On September 22, 2023, the Company executed an agreement with 10X Fund L.P., and 10X Capital Management LLC (which had been a related party due to having nominated a
        board member) whereby the Company extended the exercise date for a total of 5,732,253 common stock purchase warrants to the earliest of
        (a) September 30, 2026, (b) thirty days after 10X fails to vote all of the shares of common stock in the Company then owned by it in the
        manner recommended by the board of directors of the Company in any vote of the stockholders of the Company&#x37e; or (c) thirty days after the
        shares of common stock of the Company have a closing price of $6.00 or greater for 10 consecutive trading days. Previously, the common stock purchase warrants exercise dates would have expired at various dates from September 22, 2023 through May 10, 2025.&lt;/div&gt;

&lt;div style="margin-left: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Also pursuant to the terms of the agreement, the right of the 10X Fund L.P. to nominate a member of the board of directors was eliminated, and the cashless exercise
        option in certain of the common stock purchase warrants was deleted. Finally, a beneficial ownership limitation provision was added in the Series B Warrants, which would have the effect of decreasing 10X Fund&#x2019;s beneficial ownership to 9.99% and would bar the voluntary exercise of any warrants that would result in 10X Fund&#x2019;s ownership beyond 9.99% without at least 61 days&#x2019; prior notice from 10X Fund.&lt;/div&gt;

&lt;div style="margin-left: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company has accounted for the modified terms of the warrants pursuant to ASC 815, Derivatives and Hedging, whereby the Company has recognized a deemed dividend for
        the change in fair value of the warrants immediately before and immediately after the modification. In September 2023, the Company recognized a non cash deemed dividend of $3,619,000 related to the extension of the 5,732,253 warrants. The following
        assumptions were used to value the extension of the warrants immediately before and immediately after the modification: a) immediately before the modification &#x2014; an expected life range of 0 to 1.63 years, volatility range of 71% to 77%%, risk free interest rate range of 5.37% and zero dividends and&#x37e; b)
        immediately following the modification &#x2014; an expected life of 3 years, volatility of 79%, risk free interest rate range of 4.59% and zero dividends.&lt;/div&gt;

&lt;div style="margin-left: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The following table summarizes information with regard to outstanding warrants issued in connection with equity and debt financings and consultants as of December 31,
        2024.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 27pt;"&gt;
        &lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; font-weight: bold; border-bottom: 2px solid rgb(0, 0, 0); text-align: left;" valign="bottom"&gt;Issued in Connection With&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: right; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Number&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Outstanding&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: right; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Exercise&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Price&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;Exercisable Date&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;Expiration Date&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; text-align: left; width: 25.3333%; text-indent: -9pt; margin-left: 9pt; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="margin-left: 9pt"&gt;&lt;span style="text-indent: 0pt;"&gt;February 12, 2009&lt;/span&gt; Series B-1 Transaction $&lt;span style="text-indent: 0pt;"&gt;3.00&lt;/span&gt; Investor Warrants &#x2013; Class B&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1,200,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;3.00&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;February 12, 2009&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;September 30, 2026&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; text-align: left; width: 25.3333%; text-indent: -9pt; margin-left: 9pt;" valign="bottom"&gt;
                &lt;div style="margin-left: 9pt"&gt;&lt;span style="text-indent: 0pt;"&gt;May 13, 2009&lt;/span&gt; Series B-2 Transaction $&lt;span style="text-indent: 0pt;"&gt;3.00&lt;/span&gt; Investor Warrants &#x2013; Class B&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;525,119&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;3.00&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; white-space: nowrap;" valign="bottom"&gt;May 13, 2009&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; white-space: nowrap;" valign="bottom"&gt;September 30, 2026&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 25.3333%; text-indent: -9pt; margin-left: 9pt; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="margin-left: 9pt"&gt;&lt;span style="text-indent: 0pt;"&gt;June 30, 2009&lt;/span&gt; Series B-2 Transaction $&lt;span style="text-indent: 0pt;"&gt;3.00&lt;/span&gt; Investor Warrants &#x2013; Class B&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;306,547&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;3.00&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;June 30, 2009&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;September 30, 2026&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 25.3333%; text-indent: -9pt; margin-left: 9pt;" valign="bottom"&gt;
                &lt;div style="margin-left: 9pt"&gt;&lt;span style="text-indent: 0pt;"&gt;August 12, 2009&lt;/span&gt; Series B-2 Transaction $&lt;span style="text-indent: 0pt;"&gt;3.00&lt;/span&gt; Investor Warrants &#x2013; Class B&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;183,928&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;3.00&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; white-space: nowrap;" valign="bottom"&gt;August 12, 2009&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; white-space: nowrap;" valign="bottom"&gt;September 30, 2026&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 25.3333%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;&lt;span style="text-indent: 0pt;"&gt;September 30, 2009&lt;/span&gt; Series B-2 Transaction $&lt;span style="text-indent: 0pt;"&gt;3.00&lt;/span&gt; Investor Warrants &#x2013; Class B&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;195,922&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;3.00&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;September 30, 2009&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 25.3333%; text-align: right; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;September 30, 2026&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 25.3333%; text-indent: -9pt; margin-left: 9pt;" valign="bottom"&gt;
                &lt;div style="margin-left: 9pt"&gt;&lt;span style="text-indent: 0pt;"&gt;November 4, 2009&lt;/span&gt; Series B-2 Transaction $&lt;span style="text-indent: 0pt;"&gt;3.00&lt;/span&gt; Investor Warrants &#x2013; Class B&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;85,463&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;3.00&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 25.3333%; text-align: right; white-space: nowrap;" valign="bottom"&gt;November 4, 2009&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 25.3333%; text-align: right; white-space: nowrap;" valign="bottom"&gt;September 30, 2026&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 25.3333%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="margin-left: 9pt; text-indent: -9pt;"&gt;&lt;span style="text-indent: 0pt;"&gt;December 8, 2009&lt;/span&gt; Series B-2 Transaction $&lt;span style="text-indent: 0pt;"&gt;3.00&lt;/span&gt; Investor Warrants &#x2013; Class B&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;110,919&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;3.00&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 25.3333%; text-align: right; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;December 8, 2009&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 25.3333%; text-align: right; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;September 30, 2026&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 25.3333%;" valign="bottom"&gt;
                &lt;div style="margin-left: 9pt; text-indent: -9pt;"&gt;&lt;span style="text-indent: 0pt;"&gt;January 29, 2010&lt;/span&gt; Series B-2 Transaction $&lt;span style="text-indent: 0pt;"&gt;3.00&lt;/span&gt; Investor Warrants &#x2013; Class B&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;198,664&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;3.00&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 25.3333%; text-align: right; white-space: nowrap;" valign="bottom"&gt;January 29, 2010&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 25.3333%; text-align: right; white-space: nowrap;" valign="bottom"&gt;September 30, 2026&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 25.3333%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;&lt;span style="text-indent: 0pt;"&gt;January 29, 2010&lt;/span&gt; Series B-2 Transaction $&lt;span style="text-indent: 0pt;"&gt;3.00&lt;/span&gt; Investor Warrants &#x2013; Class B&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;18,003&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;3.00&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: right;"&gt;January 29, 2010&lt;/div&gt;
              &lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: right;"&gt;January 29, 2025&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 25.3333%;" valign="bottom"&gt;
                &lt;div style="margin-left: 9pt; text-indent: -9pt;"&gt;&lt;span style="text-indent: 0pt;"&gt;March 8, 2010&lt;/span&gt; Series B-2 Transaction $&lt;span style="text-indent: 0pt;"&gt;3.00&lt;/span&gt; Investor Warrants &#x2013; Class B&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;184,132&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;3.00&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 25.3333%; text-align: right; white-space: nowrap;" valign="bottom"&gt;March 8, 2010&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 25.3333%; text-align: right; white-space: nowrap;" valign="bottom"&gt;September 30, 2026&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 25.3333%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;&lt;span style="text-indent: 0pt;"&gt;March 8, 2010&lt;/span&gt; Series B-2 Transaction $&lt;span style="text-indent: 0pt;"&gt;3.00&lt;/span&gt; Investor Warrants &#x2013; Class B&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;39,202&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;3.00&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: right;"&gt;March 8, 2010&lt;/div&gt;
              &lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: right;"&gt;March 8, 2025&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 25.3333%;" valign="bottom"&gt;
                &lt;div style="margin-left: 9pt; text-indent: -9pt;"&gt;&lt;span style="text-indent: 0pt;"&gt;April 30, 2010&lt;/span&gt; Series B-2 Transaction $&lt;span style="text-indent: 0pt;"&gt;3.00&lt;/span&gt; Investor Warrants &#x2013; Class B&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;180,689&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;3.00&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 25.3333%; text-align: right; white-space: nowrap;" valign="bottom"&gt;April 30, 2010&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 25.3333%; text-align: right; white-space: nowrap;" valign="bottom"&gt;September 30, 2026&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 25.3333%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;&lt;span style="text-indent: 0pt;"&gt;April 30, 2010&lt;/span&gt; Series B-2 Transaction $&lt;span style="text-indent: 0pt;"&gt;3.00&lt;/span&gt; Investor Warrants &#x2013; Class B&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;23,503&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;3.00&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: right;"&gt;April 30, 2010&lt;/div&gt;
              &lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: right;"&gt;April 30, 2025&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 25.3333%;" valign="bottom"&gt;
                &lt;div style="margin-left: 9pt; text-indent: -9pt;"&gt;&lt;span style="text-indent: 0pt;"&gt;May 10, 2010&lt;/span&gt; Series B-2 Transaction $&lt;span style="text-indent: 0pt;"&gt;3.00&lt;/span&gt; Investor Warrants &#x2013; Class B&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;112,631&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;3.00&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 25.3333%; text-align: right; white-space: nowrap;" valign="bottom"&gt;May 10, 2010&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 25.3333%; text-align: right; white-space: nowrap;" valign="bottom"&gt;September 30, 2026&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 25.3333%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;&lt;span style="text-indent: 0pt;"&gt;May 10, 2010&lt;/span&gt; Series B-2 Transaction $&lt;span style="text-indent: 0pt;"&gt;3.00&lt;/span&gt; Investor Warrants &#x2013; Class B&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;30,535&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;3.00&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: right;"&gt;May 10, 2010&lt;/div&gt;
              &lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: right;"&gt;May 10, 2025&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 25.3333%;" valign="bottom"&gt;
                &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;&lt;span style="text-indent: 0pt;"&gt;September 22, 2016&lt;/span&gt; Series B-3 Transaction $&lt;span style="text-indent: 0pt;"&gt;3.00&lt;/span&gt; Investor Warrants &#x2013; Class B &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;682,572&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;3.00&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 25.3333%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: right;"&gt;September 22, 2016&lt;/div&gt;
              &lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 25.3333%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: right;"&gt;September 30, 2026&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 25.3333%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;&lt;span style="text-indent: 0pt;"&gt;September 29, 2016&lt;/span&gt; Series B-3 Transaction $&lt;span style="text-indent: 0pt;"&gt;3.00&lt;/span&gt; Investor Warrants &#x2013; Class B &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;843,351&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;3.00&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: right;"&gt;September 29, 2016&lt;/div&gt;
              &lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: right;"&gt;September 30, 2026&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 25.3333%;" valign="bottom"&gt;
                &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;&lt;span style="text-indent: 0pt;"&gt;December 23, 2016&lt;/span&gt; Series B-3 Transaction $&lt;span style="text-indent: 0pt;"&gt;3.00&lt;/span&gt; Investor Warrants &#x2013; Class B &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;922,316&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;3.00&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 25.3333%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: right;"&gt;December 23, 2016&lt;/div&gt;
              &lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 25.3333%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: right;"&gt;September 30, 2026&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 25.3333%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;2018 and 2017 Warrants issued for services&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;290&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;5.00&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: right;"&gt;Various dates in 2017&lt;/div&gt;
                &lt;div style="text-align: right;"&gt;and 2018&lt;/div&gt;
              &lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: right;"&gt;Various dates in &lt;br/&gt;
                &lt;/div&gt;
                &lt;div style="text-align: right;"&gt;2025&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 25.3333%;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;&lt;span style="text-indent: 0pt;"&gt;May 23, 2019&lt;/span&gt; Rights Offering warrants&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;2,622,154&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;7.00&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 25.3333%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: right;"&gt;May 23, 2019&lt;/div&gt;
              &lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 25.3333%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: right;"&gt;May 23, 2026&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: -9pt; margin-left: 9pt; width: 25.3333%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="margin-left: 9pt;"&gt;&lt;span style="text-indent: 0pt;"&gt;July 22, 2022&lt;/span&gt; Warrants issued in connection with related party line of credit&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;330,000&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;5.00&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;July 22, 2022&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;July 31, 2029&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: -9pt; margin-left: 9pt; width: 25.3333%;" valign="bottom"&gt;
                &lt;div style="margin-left: 9pt;"&gt;&lt;span style="text-indent: 0pt;"&gt;December 29, 2023&lt;/span&gt; Warrants issued for draw on related party line of credit&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;200,000&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;3.00&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; white-space: nowrap;" valign="bottom"&gt;December 29, 2023&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; white-space: nowrap;" valign="bottom"&gt;July 31, 2029&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 25.3333%; text-align: left; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-indent: 0pt;"&gt;March 29, 2024&lt;/span&gt; Warrants issued for draw on related party line of credit&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;200,000&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;3.59&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;March 29, 2024&lt;br/&gt;
              &lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;July 31, 2029&lt;br/&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 25.3333%; text-align: left;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;&lt;span style="text-indent: 0pt;"&gt;June 28, 2024&lt;/span&gt; Warrants issued for draw on related&#160; party line of credit&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;200,000&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;3.39&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; white-space: nowrap;" valign="bottom"&gt;&#160;June 29, 2024&lt;br/&gt;
              &lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; white-space: nowrap;" valign="bottom"&gt;&#160;July 31, 2029&lt;br/&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 25.3333%; padding-bottom: 2px; text-align: left; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;&lt;span style="text-indent: 0pt;"&gt;September 30, 2024&lt;/span&gt; Warrants issued for draw on related party line of credit&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;200,000&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;4.13&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;September 30, 2024&lt;br/&gt;
              &lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;July 31, 2029&lt;br/&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 25.3333%; padding-bottom: 4px;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Total Outstanding Warrants&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;9,595,940&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 25.3333%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 25.3333%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
          &lt;/div&gt;
</galt:CommonStockWarrantsDisclosureTextBlock>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="c20240101to20241231"
      id="Text_9e6b387325544389b22e8a1d0a7ec84e">
&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Warrant activity is summarized as follows:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 27pt;"&gt;
        &lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: top; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div&gt;&lt;span style="font-weight: bold;"&gt;Warrants&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-weight: bold;"&gt;Weighted average &lt;/div&gt;
                &lt;div style="font-weight: bold;"&gt;exercise price&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Outstanding at December 31, &lt;span style="text-indent: 0pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;11,557,964&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;4.37&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Issued&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;600,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;3.09&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Exercised&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;(2,236,204&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;4.49&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Canceled/Expired&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;(665,267&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;4.94&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Outstanding at December 31, &lt;span style="text-indent: 0pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;9,256,493&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;4.22&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Issued&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;600,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;3.70&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Exercised&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;(142,503&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;3.00&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Canceled/Expired&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;(118,050&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;4.33&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Outstanding at December 31, &lt;span style="text-indent: 0pt;"&gt;2024&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;9,595,940&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;4.21&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
      &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The following table summarizes information with regard to outstanding warrants issued in connection with equity and debt financings and consultants as of December 31,
        2024.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 27pt;"&gt;
        &lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; font-weight: bold; border-bottom: 2px solid rgb(0, 0, 0); text-align: left;" valign="bottom"&gt;Issued in Connection With&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: right; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Number&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Outstanding&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: right; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Exercise&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Price&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;Exercisable Date&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;Expiration Date&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; text-align: left; width: 25.3333%; text-indent: -9pt; margin-left: 9pt; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="margin-left: 9pt"&gt;&lt;span style="text-indent: 0pt;"&gt;February 12, 2009&lt;/span&gt; Series B-1 Transaction $&lt;span style="text-indent: 0pt;"&gt;3.00&lt;/span&gt; Investor Warrants &#x2013; Class B&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1,200,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;3.00&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;February 12, 2009&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;September 30, 2026&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; text-align: left; width: 25.3333%; text-indent: -9pt; margin-left: 9pt;" valign="bottom"&gt;
                &lt;div style="margin-left: 9pt"&gt;&lt;span style="text-indent: 0pt;"&gt;May 13, 2009&lt;/span&gt; Series B-2 Transaction $&lt;span style="text-indent: 0pt;"&gt;3.00&lt;/span&gt; Investor Warrants &#x2013; Class B&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;525,119&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;3.00&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; white-space: nowrap;" valign="bottom"&gt;May 13, 2009&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; white-space: nowrap;" valign="bottom"&gt;September 30, 2026&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 25.3333%; text-indent: -9pt; margin-left: 9pt; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="margin-left: 9pt"&gt;&lt;span style="text-indent: 0pt;"&gt;June 30, 2009&lt;/span&gt; Series B-2 Transaction $&lt;span style="text-indent: 0pt;"&gt;3.00&lt;/span&gt; Investor Warrants &#x2013; Class B&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;306,547&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;3.00&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;June 30, 2009&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;September 30, 2026&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 25.3333%; text-indent: -9pt; margin-left: 9pt;" valign="bottom"&gt;
                &lt;div style="margin-left: 9pt"&gt;&lt;span style="text-indent: 0pt;"&gt;August 12, 2009&lt;/span&gt; Series B-2 Transaction $&lt;span style="text-indent: 0pt;"&gt;3.00&lt;/span&gt; Investor Warrants &#x2013; Class B&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;183,928&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;3.00&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; white-space: nowrap;" valign="bottom"&gt;August 12, 2009&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; white-space: nowrap;" valign="bottom"&gt;September 30, 2026&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 25.3333%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;&lt;span style="text-indent: 0pt;"&gt;September 30, 2009&lt;/span&gt; Series B-2 Transaction $&lt;span style="text-indent: 0pt;"&gt;3.00&lt;/span&gt; Investor Warrants &#x2013; Class B&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;195,922&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;3.00&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;September 30, 2009&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 25.3333%; text-align: right; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;September 30, 2026&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 25.3333%; text-indent: -9pt; margin-left: 9pt;" valign="bottom"&gt;
                &lt;div style="margin-left: 9pt"&gt;&lt;span style="text-indent: 0pt;"&gt;November 4, 2009&lt;/span&gt; Series B-2 Transaction $&lt;span style="text-indent: 0pt;"&gt;3.00&lt;/span&gt; Investor Warrants &#x2013; Class B&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;85,463&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;3.00&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 25.3333%; text-align: right; white-space: nowrap;" valign="bottom"&gt;November 4, 2009&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 25.3333%; text-align: right; white-space: nowrap;" valign="bottom"&gt;September 30, 2026&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 25.3333%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="margin-left: 9pt; text-indent: -9pt;"&gt;&lt;span style="text-indent: 0pt;"&gt;December 8, 2009&lt;/span&gt; Series B-2 Transaction $&lt;span style="text-indent: 0pt;"&gt;3.00&lt;/span&gt; Investor Warrants &#x2013; Class B&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;110,919&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;3.00&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 25.3333%; text-align: right; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;December 8, 2009&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 25.3333%; text-align: right; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;September 30, 2026&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 25.3333%;" valign="bottom"&gt;
                &lt;div style="margin-left: 9pt; text-indent: -9pt;"&gt;&lt;span style="text-indent: 0pt;"&gt;January 29, 2010&lt;/span&gt; Series B-2 Transaction $&lt;span style="text-indent: 0pt;"&gt;3.00&lt;/span&gt; Investor Warrants &#x2013; Class B&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;198,664&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;3.00&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 25.3333%; text-align: right; white-space: nowrap;" valign="bottom"&gt;January 29, 2010&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 25.3333%; text-align: right; white-space: nowrap;" valign="bottom"&gt;September 30, 2026&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 25.3333%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;&lt;span style="text-indent: 0pt;"&gt;January 29, 2010&lt;/span&gt; Series B-2 Transaction $&lt;span style="text-indent: 0pt;"&gt;3.00&lt;/span&gt; Investor Warrants &#x2013; Class B&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;18,003&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;3.00&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: right;"&gt;January 29, 2010&lt;/div&gt;
              &lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: right;"&gt;January 29, 2025&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 25.3333%;" valign="bottom"&gt;
                &lt;div style="margin-left: 9pt; text-indent: -9pt;"&gt;&lt;span style="text-indent: 0pt;"&gt;March 8, 2010&lt;/span&gt; Series B-2 Transaction $&lt;span style="text-indent: 0pt;"&gt;3.00&lt;/span&gt; Investor Warrants &#x2013; Class B&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;184,132&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;3.00&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 25.3333%; text-align: right; white-space: nowrap;" valign="bottom"&gt;March 8, 2010&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 25.3333%; text-align: right; white-space: nowrap;" valign="bottom"&gt;September 30, 2026&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 25.3333%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;&lt;span style="text-indent: 0pt;"&gt;March 8, 2010&lt;/span&gt; Series B-2 Transaction $&lt;span style="text-indent: 0pt;"&gt;3.00&lt;/span&gt; Investor Warrants &#x2013; Class B&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;39,202&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;3.00&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: right;"&gt;March 8, 2010&lt;/div&gt;
              &lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: right;"&gt;March 8, 2025&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 25.3333%;" valign="bottom"&gt;
                &lt;div style="margin-left: 9pt; text-indent: -9pt;"&gt;&lt;span style="text-indent: 0pt;"&gt;April 30, 2010&lt;/span&gt; Series B-2 Transaction $&lt;span style="text-indent: 0pt;"&gt;3.00&lt;/span&gt; Investor Warrants &#x2013; Class B&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;180,689&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;3.00&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 25.3333%; text-align: right; white-space: nowrap;" valign="bottom"&gt;April 30, 2010&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 25.3333%; text-align: right; white-space: nowrap;" valign="bottom"&gt;September 30, 2026&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 25.3333%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;&lt;span style="text-indent: 0pt;"&gt;April 30, 2010&lt;/span&gt; Series B-2 Transaction $&lt;span style="text-indent: 0pt;"&gt;3.00&lt;/span&gt; Investor Warrants &#x2013; Class B&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;23,503&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;3.00&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: right;"&gt;April 30, 2010&lt;/div&gt;
              &lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: right;"&gt;April 30, 2025&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 25.3333%;" valign="bottom"&gt;
                &lt;div style="margin-left: 9pt; text-indent: -9pt;"&gt;&lt;span style="text-indent: 0pt;"&gt;May 10, 2010&lt;/span&gt; Series B-2 Transaction $&lt;span style="text-indent: 0pt;"&gt;3.00&lt;/span&gt; Investor Warrants &#x2013; Class B&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;112,631&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;3.00&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 25.3333%; text-align: right; white-space: nowrap;" valign="bottom"&gt;May 10, 2010&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 25.3333%; text-align: right; white-space: nowrap;" valign="bottom"&gt;September 30, 2026&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 25.3333%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;&lt;span style="text-indent: 0pt;"&gt;May 10, 2010&lt;/span&gt; Series B-2 Transaction $&lt;span style="text-indent: 0pt;"&gt;3.00&lt;/span&gt; Investor Warrants &#x2013; Class B&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;30,535&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;3.00&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: right;"&gt;May 10, 2010&lt;/div&gt;
              &lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: right;"&gt;May 10, 2025&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 25.3333%;" valign="bottom"&gt;
                &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;&lt;span style="text-indent: 0pt;"&gt;September 22, 2016&lt;/span&gt; Series B-3 Transaction $&lt;span style="text-indent: 0pt;"&gt;3.00&lt;/span&gt; Investor Warrants &#x2013; Class B &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;682,572&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;3.00&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 25.3333%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: right;"&gt;September 22, 2016&lt;/div&gt;
              &lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 25.3333%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: right;"&gt;September 30, 2026&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 25.3333%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;&lt;span style="text-indent: 0pt;"&gt;September 29, 2016&lt;/span&gt; Series B-3 Transaction $&lt;span style="text-indent: 0pt;"&gt;3.00&lt;/span&gt; Investor Warrants &#x2013; Class B &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;843,351&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;3.00&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: right;"&gt;September 29, 2016&lt;/div&gt;
              &lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: right;"&gt;September 30, 2026&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 25.3333%;" valign="bottom"&gt;
                &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;&lt;span style="text-indent: 0pt;"&gt;December 23, 2016&lt;/span&gt; Series B-3 Transaction $&lt;span style="text-indent: 0pt;"&gt;3.00&lt;/span&gt; Investor Warrants &#x2013; Class B &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;922,316&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;3.00&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 25.3333%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: right;"&gt;December 23, 2016&lt;/div&gt;
              &lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 25.3333%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: right;"&gt;September 30, 2026&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 25.3333%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;2018 and 2017 Warrants issued for services&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;290&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;5.00&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: right;"&gt;Various dates in 2017&lt;/div&gt;
                &lt;div style="text-align: right;"&gt;and 2018&lt;/div&gt;
              &lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: right;"&gt;Various dates in &lt;br/&gt;
                &lt;/div&gt;
                &lt;div style="text-align: right;"&gt;2025&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 25.3333%;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;&lt;span style="text-indent: 0pt;"&gt;May 23, 2019&lt;/span&gt; Rights Offering warrants&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;2,622,154&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;7.00&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 25.3333%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: right;"&gt;May 23, 2019&lt;/div&gt;
              &lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 25.3333%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: right;"&gt;May 23, 2026&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: -9pt; margin-left: 9pt; width: 25.3333%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="margin-left: 9pt;"&gt;&lt;span style="text-indent: 0pt;"&gt;July 22, 2022&lt;/span&gt; Warrants issued in connection with related party line of credit&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;330,000&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;5.00&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;July 22, 2022&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;July 31, 2029&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: -9pt; margin-left: 9pt; width: 25.3333%;" valign="bottom"&gt;
                &lt;div style="margin-left: 9pt;"&gt;&lt;span style="text-indent: 0pt;"&gt;December 29, 2023&lt;/span&gt; Warrants issued for draw on related party line of credit&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;200,000&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;3.00&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; white-space: nowrap;" valign="bottom"&gt;December 29, 2023&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; white-space: nowrap;" valign="bottom"&gt;July 31, 2029&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 25.3333%; text-align: left; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-indent: 0pt;"&gt;March 29, 2024&lt;/span&gt; Warrants issued for draw on related party line of credit&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;200,000&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;3.59&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;March 29, 2024&lt;br/&gt;
              &lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;July 31, 2029&lt;br/&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 25.3333%; text-align: left;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;&lt;span style="text-indent: 0pt;"&gt;June 28, 2024&lt;/span&gt; Warrants issued for draw on related&#160; party line of credit&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;200,000&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;3.39&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; white-space: nowrap;" valign="bottom"&gt;&#160;June 29, 2024&lt;br/&gt;
              &lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; white-space: nowrap;" valign="bottom"&gt;&#160;July 31, 2029&lt;br/&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 25.3333%; padding-bottom: 2px; text-align: left; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;&lt;span style="text-indent: 0pt;"&gt;September 30, 2024&lt;/span&gt; Warrants issued for draw on related party line of credit&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;200,000&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;4.13&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;September 30, 2024&lt;br/&gt;
              &lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; text-align: right; width: 25.3333%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;July 31, 2029&lt;br/&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 25.3333%; padding-bottom: 4px;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Total Outstanding Warrants&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;9,595,940&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 25.3333%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 25.3333%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
          &lt;/div&gt;
</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c20221231_FinancialInstrumentAxis_WarrantMember"
      decimals="0"
      id="Fact_be48e1aa8b1749468a808e2c40cdf447"
      unitRef="U002">11557964</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c20221231"
      decimals="2"
      id="Fact_8e1d0fa7d4c04daf8c92c7d97c202d92"
      unitRef="U003">4.37</galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c20230101to20231231_FinancialInstrumentAxis_WarrantMember"
      decimals="0"
      id="Fact_0f3af02305664200a3a7bbc281aeb472"
      unitRef="U002">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice
      contextRef="c20230101to20231231"
      decimals="2"
      id="Fact_23448748e7ad4406b22e1fd55a56020c"
      unitRef="U003">3.09</galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="c20230101to20231231_FinancialInstrumentAxis_WarrantMember"
      decimals="0"
      id="Fact_1ee6e49dc194411789db316feee949e5"
      unitRef="U002">2236204</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c20230101to20231231"
      decimals="2"
      id="Fact_aab36f861f4a4892aa117e819a134af5"
      unitRef="U003">4.49</galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c20230101to20231231_FinancialInstrumentAxis_WarrantMember"
      decimals="0"
      id="Fact_f91455761992423395ba4be963a2649f"
      unitRef="U002">665267</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <galt:ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c20230101to20231231"
      decimals="2"
      id="Fact_4042b18cdf0c4399823eab102d3c7726"
      unitRef="U003">4.94</galt:ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c20231231_FinancialInstrumentAxis_WarrantMember"
      decimals="0"
      id="Fact_de6326986662484b834a233c6bc96c0b"
      unitRef="U002">9256493</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c20231231"
      decimals="2"
      id="Fact_10e3473d10cc4f1195f3dfc67eaac152"
      unitRef="U003">4.22</galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c20240101to20241231_FinancialInstrumentAxis_WarrantMember"
      decimals="0"
      id="Fact_cad509b4e821479db1ce8ce3fe371684"
      unitRef="U002">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice
      contextRef="c20240101to20241231"
      decimals="2"
      id="Fact_865cacdd3db64d5facd39debbf1c1a1f"
      unitRef="U003">3.7</galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="c20240101to20241231_FinancialInstrumentAxis_WarrantMember"
      decimals="0"
      id="Fact_dd528c705c904441af8a3b40b583587a"
      unitRef="U002">142503</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c20240101to20241231"
      decimals="2"
      id="Fact_b83cef91bf074edcb8235f3e7ae863a8"
      unitRef="U003">3</galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c20240101to20241231_FinancialInstrumentAxis_WarrantMember"
      decimals="0"
      id="Fact_15d739cf028c479eb5d0a6b6c793e9bc"
      unitRef="U002">118050</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <galt:ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c20240101to20241231"
      decimals="2"
      id="Fact_e4e117fa49254b3d834daee9683ba92c"
      unitRef="U003">4.33</galt:ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c20241231_FinancialInstrumentAxis_WarrantMember"
      decimals="0"
      id="Fact_3c6932a3d4bb47cabcf05d7d2f28d0b6"
      unitRef="U002">9595940</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c20241231"
      decimals="2"
      id="Fact_40a2c302fd4541169611355ee91ce8cf"
      unitRef="U003">4.21</galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="c20241231"
      id="Fact_9a767e462202443e81bf15d641dcc8c0">P2Y2M12D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c20230922_RelatedPartyTransactionsByRelatedPartyAxis_One0XFundLPAnd10XCapitalManagementLLCMember_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_7f6b0f3bc1bf4fdc8d3e436aed2fd578"
      unitRef="U002">5732253</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <galt:ThresholdPeriodForExtensionOfExerciseDateOfPurchaseWarrantsUnderAgreement
      contextRef="c20240101to20241231_RelatedPartyTransactionsByRelatedPartyAxis_One0XFundLPAnd10XCapitalManagementLLCMember_StatementEquityComponentsAxis_CommonStockMember"
      id="Fact_c8da83c63fba4cb09d7b7e0d77a7a710">P30D</galt:ThresholdPeriodForExtensionOfExerciseDateOfPurchaseWarrantsUnderAgreement>
    <galt:ThresholdPeriodForStockClosingPriceInTenConsecutiveDaysUnderPurchaseWarrantsAgreement
      contextRef="c20240101to20241231_RelatedPartyTransactionsByRelatedPartyAxis_One0XFundLPAnd10XCapitalManagementLLCMember_StatementEquityComponentsAxis_CommonStockMember"
      id="Fact_9cd93f71fe684d3895885d03b7790885">P30D</galt:ThresholdPeriodForStockClosingPriceInTenConsecutiveDaysUnderPurchaseWarrantsAgreement>
    <us-gaap:SharePrice
      contextRef="c20241231_RangeAxis_MinimumMember_RelatedPartyTransactionsByRelatedPartyAxis_One0XFundLPAnd10XCapitalManagementLLCMember_StatementEquityComponentsAxis_CommonStockMember"
      decimals="2"
      id="Fact_dd13348e94cb41a3861e815e9fece375"
      unitRef="U003">6</us-gaap:SharePrice>
    <galt:NumberOfTradingDaysToBeConsideredStockClosingPriceInPurchaseAgreement
      contextRef="c20240101to20241231_RangeAxis_MinimumMember"
      id="Fact_6847d033209a44b3a8f3cb6b03f732bb">P10D</galt:NumberOfTradingDaysToBeConsideredStockClosingPriceInPurchaseAgreement>
    <galt:BeneficialOwnershipPercentage
      contextRef="c20241231_RelatedPartyTransactionsByRelatedPartyAxis_One0XFundLPMember_StatementEquityComponentsAxis_SeriesBWarrantsMember"
      decimals="4"
      id="Fact_aee4532df9ed436c8e5b04f5c86a830c"
      unitRef="U007">0.0999</galt:BeneficialOwnershipPercentage>
    <galt:BeneficialOwnershipPercentage
      contextRef="c20241231_RelatedPartyTransactionsByRelatedPartyAxis_One0XFundLPMember_StatementEquityComponentsAxis_SeriesBWarrantsMember"
      decimals="4"
      id="Fact_1845133d653f418c9698051e7658b0f1"
      unitRef="U007">0.0999</galt:BeneficialOwnershipPercentage>
    <galt:PeriodOfPriorNoticeThatWouldBarVoluntaryExerciseOfAnyWarrants
      contextRef="c20240101to20241231_RelatedPartyTransactionsByRelatedPartyAxis_One0XFundLPMember"
      id="Fact_c78ec0998a134114bcda96e40dae0eaf">P61D</galt:PeriodOfPriorNoticeThatWouldBarVoluntaryExerciseOfAnyWarrants>
    <us-gaap:PreferredStockRedemptionPremium
      contextRef="c20230901to20230930"
      decimals="0"
      id="Fact_8ccc1c1918a5435ea558f66bafb92093"
      unitRef="U001">3619000</us-gaap:PreferredStockRedemptionPremium>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c20230930_RelatedPartyTransactionsByRelatedPartyAxis_One0XFundLPAnd10XCapitalManagementLLCMember_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_5af42fafd8b646dba151fbc789320883"
      unitRef="U002">5732253</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_BeforeModificationMember_FinancialInstrumentAxis_WarrantMember_RangeAxis_MinimumMember"
      id="Fact_d4b7dd462d0149f4a4603b9b5579b8bd">P0Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_BeforeModificationMember_FinancialInstrumentAxis_WarrantMember_RangeAxis_MaximumMember"
      id="Fact_d59ff99e52094f128717de95989f2cb2">P1Y7M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_BeforeModificationMember_FinancialInstrumentAxis_WarrantMember_RangeAxis_MinimumMember"
      decimals="2"
      id="Fact_2490e39dd4a64d8f8e7ca03b56b38f79"
      unitRef="U007">0.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_BeforeModificationMember_FinancialInstrumentAxis_WarrantMember_RangeAxis_MaximumMember"
      decimals="2"
      id="Fact_17dee1cde14c4f649438d58ba1c6673f"
      unitRef="U007">0.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_BeforeModificationMember_FinancialInstrumentAxis_WarrantMember"
      decimals="4"
      id="Fact_0524be557cdd41e0b0c7b15b3e23e668"
      unitRef="U007">0.0537</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_BeforeModificationMember_FinancialInstrumentAxis_WarrantMember"
      decimals="0"
      id="Fact_5076b60aae9f41ca8786f39975257fae"
      unitRef="U007">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_AfterModificationMember_FinancialInstrumentAxis_WarrantMember"
      id="Fact_587b7bac00dd4f789540ca82c380bf3b">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_AfterModificationMember_FinancialInstrumentAxis_WarrantMember"
      decimals="2"
      id="Fact_1dea0029e6f1486f8e10922e799351af"
      unitRef="U007">0.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_AfterModificationMember_FinancialInstrumentAxis_WarrantMember"
      decimals="4"
      id="Fact_a05f4c2f919244eba148f8a99dead20f"
      unitRef="U007">0.0459</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_AfterModificationMember_FinancialInstrumentAxis_WarrantMember"
      decimals="0"
      id="Fact_73726c1615484dd2a79ea4dd382af5df"
      unitRef="U007">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <galt:WarrantIssueDate
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_FebruaryTwelveTwentyZeroNineSeriesBOneTransactionMember"
      id="Fact_1345bf44a71242d1974f0d9f65545565">2009-02-12</galt:WarrantIssueDate>
    <galt:WarrantsIssuedPrice
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_FebruaryTwelveTwentyZeroNineSeriesBOneTransactionMember"
      decimals="2"
      id="Fact_c53425516242433dbb73bc7d861a2c46"
      unitRef="U003">3</galt:WarrantsIssuedPrice>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c20241231_ClassOfWarrantOrRightAxis_FebruaryTwelveTwentyZeroNineSeriesBOneTransactionMember"
      decimals="0"
      id="Fact_3828bbdc4b244bcbbdf6990bfbc71833"
      unitRef="U002">1200000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20241231_ClassOfWarrantOrRightAxis_FebruaryTwelveTwentyZeroNineSeriesBOneTransactionMember"
      decimals="2"
      id="Fact_b59ba3ca7db54a8db7ccb08573476eb1"
      unitRef="U003">3</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_FebruaryTwelveTwentyZeroNineSeriesBOneTransactionMember"
      id="Fact_64d71489e332425fb2298d9d0c4bc0e4">2009-02-12</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_FebruaryTwelveTwentyZeroNineSeriesBOneTransactionMember"
      id="Fact_4bc2f29c22514466b1bcc1d1ac213a69">2026-09-30</galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired>
    <galt:WarrantIssueDate
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_MayThirteenTwentyZeroNineSeriesBTwoTransactionOneMember"
      id="Fact_48c69d40478d42ebb19f96f2a5e207e6">2009-05-13</galt:WarrantIssueDate>
    <galt:WarrantsIssuedPrice
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_MayThirteenTwentyZeroNineSeriesBTwoTransactionOneMember"
      decimals="2"
      id="Fact_7d4a4414282c47bc860ac97f05d41a1b"
      unitRef="U003">3</galt:WarrantsIssuedPrice>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c20241231_ClassOfWarrantOrRightAxis_MayThirteenTwentyZeroNineSeriesBTwoTransactionOneMember"
      decimals="0"
      id="Fact_b324a055c585463a906b72b3ad4eec84"
      unitRef="U002">525119</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20241231_ClassOfWarrantOrRightAxis_MayThirteenTwentyZeroNineSeriesBTwoTransactionOneMember"
      decimals="2"
      id="Fact_2063f28d5d194073be3af592308a757e"
      unitRef="U003">3</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_MayThirteenTwentyZeroNineSeriesBTwoTransactionOneMember"
      id="Fact_57265ad1f3cd4575bd715a7ad5893bda">2009-05-13</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_MayThirteenTwentyZeroNineSeriesBTwoTransactionOneMember"
      id="Fact_22745ee0de194fb382a954ecd45068f2">2026-09-30</galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired>
    <galt:WarrantIssueDate
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_JuneThirtyTwentyZeroNineSeriesBTwoTransactionOneMember"
      id="Fact_68ec3c35863341f6a82af8ccbd8dfd5a">2009-06-30</galt:WarrantIssueDate>
    <galt:WarrantsIssuedPrice
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_JuneThirtyTwentyZeroNineSeriesBTwoTransactionOneMember"
      decimals="2"
      id="Fact_f2fbf9fdebca46269dcb29d8ba163e2d"
      unitRef="U003">3</galt:WarrantsIssuedPrice>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c20241231_ClassOfWarrantOrRightAxis_JuneThirtyTwentyZeroNineSeriesBTwoTransactionOneMember"
      decimals="0"
      id="Fact_059a3f80f7c4445f94987d90a8f7f692"
      unitRef="U002">306547</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20241231_ClassOfWarrantOrRightAxis_JuneThirtyTwentyZeroNineSeriesBTwoTransactionOneMember"
      decimals="2"
      id="Fact_0c2a4e2bf4a040e289737eef42fe9fd3"
      unitRef="U003">3</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_JuneThirtyTwentyZeroNineSeriesBTwoTransactionOneMember"
      id="Fact_ec50a090565e412f8ab09c99d055e75b">2009-06-30</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_JuneThirtyTwentyZeroNineSeriesBTwoTransactionOneMember"
      id="Fact_8841109adcd84c828cfc94160594bbdb">2026-09-30</galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired>
    <galt:WarrantIssueDate
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_AugustTwelveTwentyZeroNineSeriesBTwoTransactionOneMember"
      id="Fact_cbd50dd60d5e475483ff53113d663193">2009-08-12</galt:WarrantIssueDate>
    <galt:WarrantsIssuedPrice
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_AugustTwelveTwentyZeroNineSeriesBTwoTransactionOneMember"
      decimals="2"
      id="Fact_7db17b2c90cb467789fee351dd97a9ad"
      unitRef="U003">3</galt:WarrantsIssuedPrice>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c20241231_ClassOfWarrantOrRightAxis_AugustTwelveTwentyZeroNineSeriesBTwoTransactionOneMember"
      decimals="0"
      id="Fact_a1f5a56301004166b56b48715a4bc06c"
      unitRef="U002">183928</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20241231_ClassOfWarrantOrRightAxis_AugustTwelveTwentyZeroNineSeriesBTwoTransactionOneMember"
      decimals="2"
      id="Fact_55d343aa183c4ee68a69391c526f5af3"
      unitRef="U003">3</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_AugustTwelveTwentyZeroNineSeriesBTwoTransactionOneMember"
      id="Fact_f48693e95a5b46a59a5d5e0110fecd8d">2009-08-12</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_AugustTwelveTwentyZeroNineSeriesBTwoTransactionOneMember"
      id="Fact_9a4cae67ce714dc68412fe16c6a0de18">2026-09-30</galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired>
    <galt:WarrantIssueDate
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_SeptemberThirtyTwentyZeroNineSeriesBTwoTransactionOneMember"
      id="Fact_98f70f1170584fd090c30f3992fcbd30">2009-09-30</galt:WarrantIssueDate>
    <galt:WarrantsIssuedPrice
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_SeptemberThirtyTwentyZeroNineSeriesBTwoTransactionOneMember"
      decimals="2"
      id="Fact_f945db2f84d340c988cf4970258a8e45"
      unitRef="U003">3</galt:WarrantsIssuedPrice>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c20241231_ClassOfWarrantOrRightAxis_SeptemberThirtyTwentyZeroNineSeriesBTwoTransactionOneMember"
      decimals="0"
      id="Fact_0c9314004a834532939b886c23958440"
      unitRef="U002">195922</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20241231_ClassOfWarrantOrRightAxis_SeptemberThirtyTwentyZeroNineSeriesBTwoTransactionOneMember"
      decimals="2"
      id="Fact_ab9ef12bebd747778418ff4cfe973eb6"
      unitRef="U003">3</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_SeptemberThirtyTwentyZeroNineSeriesBTwoTransactionOneMember"
      id="Fact_f08312d0dac94fd09aecc27dfbbbd6eb">2009-09-30</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_SeptemberThirtyTwentyZeroNineSeriesBTwoTransactionOneMember"
      id="Fact_e24a997b5fd84c3cb3710683c0e3403e">2026-09-30</galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired>
    <galt:WarrantIssueDate
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_NovemberFourTwentyZeroNineSeriesBTwoTransactionOneMember"
      id="Fact_e04c3f4ef8ff4c51ace11d8a1941a6e1">2009-11-04</galt:WarrantIssueDate>
    <galt:WarrantsIssuedPrice
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_NovemberFourTwentyZeroNineSeriesBTwoTransactionOneMember"
      decimals="2"
      id="Fact_7d7e267d876f4b30832109e97cf59ea8"
      unitRef="U003">3</galt:WarrantsIssuedPrice>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c20241231_ClassOfWarrantOrRightAxis_NovemberFourTwentyZeroNineSeriesBTwoTransactionOneMember"
      decimals="0"
      id="Fact_7e45701f95834244a59d219aeafb412b"
      unitRef="U002">85463</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20241231_ClassOfWarrantOrRightAxis_NovemberFourTwentyZeroNineSeriesBTwoTransactionOneMember"
      decimals="2"
      id="Fact_71191c9bd350421aa6fa80ddcf3e1d36"
      unitRef="U003">3</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_NovemberFourTwentyZeroNineSeriesBTwoTransactionOneMember"
      id="Fact_596702e694e24ba0aaddada32e3598e6">2009-11-04</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_NovemberFourTwentyZeroNineSeriesBTwoTransactionOneMember"
      id="Fact_a1077d38aef644c683dd62773612c88c">2026-09-30</galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired>
    <galt:WarrantIssueDate
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_DecemberEightTwentyZeroNineSeriesBTwoTransactionOneMember"
      id="Fact_f7ad14ba33fd481192e9e149ed302966">2009-12-08</galt:WarrantIssueDate>
    <galt:WarrantsIssuedPrice
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_DecemberEightTwentyZeroNineSeriesBTwoTransactionOneMember"
      decimals="2"
      id="Fact_60780d6d44a44ae9bb2fb7f1dc6dd592"
      unitRef="U003">3</galt:WarrantsIssuedPrice>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c20241231_ClassOfWarrantOrRightAxis_DecemberEightTwentyZeroNineSeriesBTwoTransactionOneMember"
      decimals="0"
      id="Fact_9bb872e7aa2b4fd287f982d75ecae43b"
      unitRef="U002">110919</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20241231_ClassOfWarrantOrRightAxis_DecemberEightTwentyZeroNineSeriesBTwoTransactionOneMember"
      decimals="2"
      id="Fact_3dba74fbd6574c5d9993a0ac7499e0f5"
      unitRef="U003">3</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_DecemberEightTwentyZeroNineSeriesBTwoTransactionOneMember"
      id="Fact_3310403e448644ba8e7be5e59ea85930">2009-12-08</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_DecemberEightTwentyZeroNineSeriesBTwoTransactionOneMember"
      id="Fact_e85af4eecce44ad3bbc49e75c3222d9b">2026-09-30</galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired>
    <galt:WarrantIssueDate
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionOneMember"
      id="Fact_6c4eb176bf8b4a37b16ddeb2a24cdc9f">2010-01-29</galt:WarrantIssueDate>
    <galt:WarrantsIssuedPrice
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionOneMember"
      decimals="2"
      id="Fact_fd963eab4cb14456a15e8d3ae67f139b"
      unitRef="U003">3</galt:WarrantsIssuedPrice>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c20241231_ClassOfWarrantOrRightAxis_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionOneMember"
      decimals="0"
      id="Fact_aa3b001e9a544ea0ad525716d0f70245"
      unitRef="U002">198664</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20241231_ClassOfWarrantOrRightAxis_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionOneMember"
      decimals="2"
      id="Fact_b4ac31eca4ca4d3f93bf014f3fcc9895"
      unitRef="U003">3</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionOneMember"
      id="Fact_aabbbcb547754be798b764903bc08172">2010-01-29</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionOneMember"
      id="Fact_8b0ab1624b734407822d612c5e4311bc">2026-09-30</galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired>
    <galt:WarrantIssueDate
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionTwoMember"
      id="Fact_ee2614e58d9542a090b61fe5cb08d191">2010-01-29</galt:WarrantIssueDate>
    <galt:WarrantsIssuedPrice
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionTwoMember"
      decimals="2"
      id="Fact_df675e5565cc4823ac8a88d3e7df6c03"
      unitRef="U003">3</galt:WarrantsIssuedPrice>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c20241231_ClassOfWarrantOrRightAxis_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionTwoMember"
      decimals="0"
      id="Fact_a9fa5355936f461d85363abf52b9c869"
      unitRef="U002">18003</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20241231_ClassOfWarrantOrRightAxis_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionTwoMember"
      decimals="2"
      id="Fact_4608507642b9463b9fb9a5b1fc47ba1a"
      unitRef="U003">3</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionTwoMember"
      id="Fact_a1e5295f0323445799f66862bedc19c6">2010-01-29</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_JanuaryTwentyNineTwentyTenSeriesBTwoTransactionTwoMember"
      id="Fact_468b5807a856463e81751d8f3c56fe06">2025-01-29</galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired>
    <galt:WarrantIssueDate
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_MarchEightTwentyTenSeriesBTwoTransactionOneMember"
      id="Fact_2617270096034defb5af37ca398f8e24">2010-03-08</galt:WarrantIssueDate>
    <galt:WarrantsIssuedPrice
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_MarchEightTwentyTenSeriesBTwoTransactionOneMember"
      decimals="2"
      id="Fact_d670c1950ca14d4e960d27e6dd3485ac"
      unitRef="U003">3</galt:WarrantsIssuedPrice>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c20241231_ClassOfWarrantOrRightAxis_MarchEightTwentyTenSeriesBTwoTransactionOneMember"
      decimals="0"
      id="Fact_726027d3bfae41ac90c905a6bc2e4bf5"
      unitRef="U002">184132</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20241231_ClassOfWarrantOrRightAxis_MarchEightTwentyTenSeriesBTwoTransactionOneMember"
      decimals="2"
      id="Fact_5002062f58c64e69aad6809692d0eee3"
      unitRef="U003">3</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_MarchEightTwentyTenSeriesBTwoTransactionOneMember"
      id="Fact_793e8eb1c39d468da21b735f256f2b34">2010-03-08</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_MarchEightTwentyTenSeriesBTwoTransactionOneMember"
      id="Fact_f52f79963ce9492fbf39b16f847baec3">2026-09-30</galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired>
    <galt:WarrantIssueDate
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_MarchEightTwentyTenSeriesBTwoTransactionTwoMember"
      id="Fact_2864a279ace840808def7f2aee4754ec">2010-03-08</galt:WarrantIssueDate>
    <galt:WarrantsIssuedPrice
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_MarchEightTwentyTenSeriesBTwoTransactionTwoMember"
      decimals="2"
      id="Fact_975e0be06ce6448aace6e8424b931183"
      unitRef="U003">3</galt:WarrantsIssuedPrice>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c20241231_ClassOfWarrantOrRightAxis_MarchEightTwentyTenSeriesBTwoTransactionTwoMember"
      decimals="0"
      id="Fact_ff564beaa73042b88838c077285f9f3b"
      unitRef="U002">39202</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20241231_ClassOfWarrantOrRightAxis_MarchEightTwentyTenSeriesBTwoTransactionTwoMember"
      decimals="2"
      id="Fact_c8af4821b14a46d399ef687cc1ca20a2"
      unitRef="U003">3</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_MarchEightTwentyTenSeriesBTwoTransactionTwoMember"
      id="Fact_84f61d6e3dfb470a9f95a1b0f477063d">2010-03-08</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_MarchEightTwentyTenSeriesBTwoTransactionTwoMember"
      id="Fact_2cfd611890e04c2bb60edf93d867e05c">2025-03-08</galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired>
    <galt:WarrantIssueDate
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_AprilThirtyTwentyTenSeriesBTwoTransactionOneMember"
      id="Fact_e3b7f7cc2160462e9b65fefaab09790c">2010-04-30</galt:WarrantIssueDate>
    <galt:WarrantsIssuedPrice
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_AprilThirtyTwentyTenSeriesBTwoTransactionOneMember"
      decimals="2"
      id="Fact_4aeed9664160400d80789815eb8bc94c"
      unitRef="U003">3</galt:WarrantsIssuedPrice>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c20241231_ClassOfWarrantOrRightAxis_AprilThirtyTwentyTenSeriesBTwoTransactionOneMember"
      decimals="0"
      id="Fact_f7dd3cee2d1640c8b9e0ab2371021608"
      unitRef="U002">180689</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20241231_ClassOfWarrantOrRightAxis_AprilThirtyTwentyTenSeriesBTwoTransactionOneMember"
      decimals="2"
      id="Fact_878e248884c44cc0b26b4acf61c41f32"
      unitRef="U003">3</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_AprilThirtyTwentyTenSeriesBTwoTransactionOneMember"
      id="Fact_4edd23c6222544229ff4c4b72d57d1c9">2010-04-30</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_AprilThirtyTwentyTenSeriesBTwoTransactionOneMember"
      id="Fact_664f577e44404813a2cf3cf304595ac8">2026-09-30</galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired>
    <galt:WarrantIssueDate
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_AprilThirtyTwentyTenSeriesBTwoTransactionTwoMember"
      id="Fact_5de23bb05a2b4e1eace29987b68cf3df">2010-04-30</galt:WarrantIssueDate>
    <galt:WarrantsIssuedPrice
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_AprilThirtyTwentyTenSeriesBTwoTransactionTwoMember"
      decimals="2"
      id="Fact_0a379b9f07794d29bc7b6bffb030769a"
      unitRef="U003">3</galt:WarrantsIssuedPrice>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c20241231_ClassOfWarrantOrRightAxis_AprilThirtyTwentyTenSeriesBTwoTransactionTwoMember"
      decimals="0"
      id="Fact_cec6575444754ab3947fa68488133767"
      unitRef="U002">23503</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20241231_ClassOfWarrantOrRightAxis_AprilThirtyTwentyTenSeriesBTwoTransactionTwoMember"
      decimals="2"
      id="Fact_8aa20b9e6fcd4b1e97c7112b3fc9bd31"
      unitRef="U003">3</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_AprilThirtyTwentyTenSeriesBTwoTransactionTwoMember"
      id="Fact_ad30a2637e4044c39633180337ed59f4">2010-04-30</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_AprilThirtyTwentyTenSeriesBTwoTransactionTwoMember"
      id="Fact_520ea5544cb54e70ad60ff6361e55cda">2025-04-30</galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired>
    <galt:WarrantIssueDate
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_MayTenTwentyTenSeriesBTwoTransactionOneMember"
      id="Fact_9b49c6925c6647ebaa8aaf734eefb7fd">2010-05-10</galt:WarrantIssueDate>
    <galt:WarrantsIssuedPrice
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_MayTenTwentyTenSeriesBTwoTransactionOneMember"
      decimals="2"
      id="Fact_7ed9d6c7491c4f4b81bc425dbb5a976a"
      unitRef="U003">3</galt:WarrantsIssuedPrice>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c20241231_ClassOfWarrantOrRightAxis_MayTenTwentyTenSeriesBTwoTransactionOneMember"
      decimals="0"
      id="Fact_7d339babd2ca438d80ea62612756651f"
      unitRef="U002">112631</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20241231_ClassOfWarrantOrRightAxis_MayTenTwentyTenSeriesBTwoTransactionOneMember"
      decimals="2"
      id="Fact_66ea00a6289a438ebd2edc13290dc7ee"
      unitRef="U003">3</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_MayTenTwentyTenSeriesBTwoTransactionOneMember"
      id="Fact_66b77b3f5c2a4da38c2bfdc07b1ff292">2010-05-10</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_MayTenTwentyTenSeriesBTwoTransactionOneMember"
      id="Fact_03f4c1f6d7de45528dc99e5977f6f602">2026-09-30</galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired>
    <galt:WarrantIssueDate
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_MayTenTwentyTenSeriesBTwoTransactionTwoMember"
      id="Fact_d6cdd4e945404756a6b72fcb34dfb3e4">2010-05-10</galt:WarrantIssueDate>
    <galt:WarrantsIssuedPrice
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_MayTenTwentyTenSeriesBTwoTransactionTwoMember"
      decimals="2"
      id="Fact_ce84956ccd484e9a9f992993f8d53459"
      unitRef="U003">3</galt:WarrantsIssuedPrice>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c20241231_ClassOfWarrantOrRightAxis_MayTenTwentyTenSeriesBTwoTransactionTwoMember"
      decimals="0"
      id="Fact_aba5ba053b754a7f913b71db7cff27de"
      unitRef="U002">30535</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20241231_ClassOfWarrantOrRightAxis_MayTenTwentyTenSeriesBTwoTransactionTwoMember"
      decimals="2"
      id="Fact_1b87c58b4560436f8e9f9f69eebe8bc2"
      unitRef="U003">3</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_MayTenTwentyTenSeriesBTwoTransactionTwoMember"
      id="Fact_40d73ffe4aec4238b05a767ca0762fd6">2010-05-10</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_MayTenTwentyTenSeriesBTwoTransactionTwoMember"
      id="Fact_8fbd078f73034cdfb8a41c559e274524">2025-05-10</galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired>
    <galt:WarrantIssueDate
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_SeptemberTwentyTwoTwentySixteenSeriesBThreeTransactionMember"
      id="Fact_bc3dd487c75a4ce897ac414720b6ae0e">2016-09-22</galt:WarrantIssueDate>
    <galt:WarrantsIssuedPrice
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_SeptemberTwentyTwoTwentySixteenSeriesBThreeTransactionMember"
      decimals="2"
      id="Fact_cc9eb9965da042fc8ef9bc1883149c2c"
      unitRef="U003">3</galt:WarrantsIssuedPrice>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c20241231_ClassOfWarrantOrRightAxis_SeptemberTwentyTwoTwentySixteenSeriesBThreeTransactionMember"
      decimals="0"
      id="Fact_5b568945e7734a18a7b4d6a2f565a041"
      unitRef="U002">682572</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20241231_ClassOfWarrantOrRightAxis_SeptemberTwentyTwoTwentySixteenSeriesBThreeTransactionMember"
      decimals="2"
      id="Fact_21665cf314e64457a045ce09a1d479d7"
      unitRef="U003">3</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_SeptemberTwentyTwoTwentySixteenSeriesBThreeTransactionMember"
      id="Fact_a557a6b979d949b2b958deb9f8308c68">2016-09-22</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_SeptemberTwentyTwoTwentySixteenSeriesBThreeTransactionMember"
      id="Fact_c31be64ec7f24099a6b06b9bb77cae74">2026-09-30</galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired>
    <galt:WarrantIssueDate
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_SeptemberTwentyNineTwentySixteenSeriesBThreeTransactionMember"
      id="Fact_ed624306ad1c472991d8cd4a344f089e">2016-09-29</galt:WarrantIssueDate>
    <galt:WarrantsIssuedPrice
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_SeptemberTwentyNineTwentySixteenSeriesBThreeTransactionMember"
      decimals="2"
      id="Fact_34fe274dda3b488e923c4561b0acdc7a"
      unitRef="U003">3</galt:WarrantsIssuedPrice>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c20241231_ClassOfWarrantOrRightAxis_SeptemberTwentyNineTwentySixteenSeriesBThreeTransactionMember"
      decimals="0"
      id="Fact_ec5376642bdf4248b32b5494195eeeda"
      unitRef="U002">843351</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20241231_ClassOfWarrantOrRightAxis_SeptemberTwentyNineTwentySixteenSeriesBThreeTransactionMember"
      decimals="2"
      id="Fact_130303cecdfc4018a48617406e98343f"
      unitRef="U003">3</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_SeptemberTwentyNineTwentySixteenSeriesBThreeTransactionMember"
      id="Fact_172ce59d3faf40278fe565f8f276cb62">2016-09-29</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_SeptemberTwentyNineTwentySixteenSeriesBThreeTransactionMember"
      id="Fact_08097e4df55e45d4ba047d1f7b7120b1">2026-09-30</galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired>
    <galt:WarrantIssueDate
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_DecemberTwentyThreeTwentySixteenSeriesBThreeTransactionMember"
      id="Fact_f44cdafcab3f4ff68c3c33fe1d314a10">2016-12-23</galt:WarrantIssueDate>
    <galt:WarrantsIssuedPrice
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_DecemberTwentyThreeTwentySixteenSeriesBThreeTransactionMember"
      decimals="2"
      id="Fact_db8fa5d9f4a84b659b9efd55289f0e45"
      unitRef="U003">3</galt:WarrantsIssuedPrice>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c20241231_ClassOfWarrantOrRightAxis_DecemberTwentyThreeTwentySixteenSeriesBThreeTransactionMember"
      decimals="0"
      id="Fact_56d0d42abcef441e84038a6e86916f37"
      unitRef="U002">922316</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20241231_ClassOfWarrantOrRightAxis_DecemberTwentyThreeTwentySixteenSeriesBThreeTransactionMember"
      decimals="2"
      id="Fact_81732f8d15d24b3f81b5d1715f24fae3"
      unitRef="U003">3</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_DecemberTwentyThreeTwentySixteenSeriesBThreeTransactionMember"
      id="Fact_97d3c21f414c42b5a2adea9bed8035d1">2016-12-23</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_DecemberTwentyThreeTwentySixteenSeriesBThreeTransactionMember"
      id="Fact_1548d7ca24504140a4e5af63edda5cad">2026-09-30</galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c20241231_ClassOfWarrantOrRightAxis_TwentyEighteenAndTwentySeventeenWarrantsIssuedForServicesMember"
      decimals="0"
      id="Fact_252e3a297d63442a8af29cae4a2ea750"
      unitRef="U002">290</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20241231_ClassOfWarrantOrRightAxis_TwentyEighteenAndTwentySeventeenWarrantsIssuedForServicesMember"
      decimals="2"
      id="Fact_3e32846d056648298913bd649d613bf0"
      unitRef="U003">5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <galt:WarrantIssueDate
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_MayTwentyThreeTwentyNinteenRightsOfferingWarrantsMember"
      id="Fact_7f959e1d245b4149819457d14111b746">2019-05-23</galt:WarrantIssueDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c20241231_ClassOfWarrantOrRightAxis_MayTwentyThreeTwentyNinteenRightsOfferingWarrantsMember"
      decimals="0"
      id="Fact_4e35b034dd3c465ca6f8cedc5fab871c"
      unitRef="U002">2622154</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20241231_ClassOfWarrantOrRightAxis_MayTwentyThreeTwentyNinteenRightsOfferingWarrantsMember"
      decimals="2"
      id="Fact_03525d40fbb249b097c5e4d30ba0c367"
      unitRef="U003">7</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_MayTwentyThreeTwentyNinteenRightsOfferingWarrantsMember"
      id="Fact_d019a58f5052456882816c8130eaea37">2019-05-23</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_MayTwentyThreeTwentyNinteenRightsOfferingWarrantsMember"
      id="Fact_c38f2eec20a04b7895f441785860a46d">2026-05-23</galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired>
    <galt:WarrantIssueDate
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_July222022WarrantsIssuedInConnectionWithRelatedPartyLineOfCreditMember"
      id="Fact_bb6a0e9b78a54fa4a3e5701c8714d60a">2022-07-22</galt:WarrantIssueDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c20241231_ClassOfWarrantOrRightAxis_July222022WarrantsIssuedInConnectionWithRelatedPartyLineOfCreditMember"
      decimals="0"
      id="Fact_6c895356dee9488cb1d0833a52b30749"
      unitRef="U002">330000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20241231_ClassOfWarrantOrRightAxis_July222022WarrantsIssuedInConnectionWithRelatedPartyLineOfCreditMember"
      decimals="2"
      id="Fact_49447cf323db48b4aca1aa66cd06c93b"
      unitRef="U003">5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_July222022WarrantsIssuedInConnectionWithRelatedPartyLineOfCreditMember"
      id="Fact_05035e93438040489d2a1daa4596dfb7">2022-07-22</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_July222022WarrantsIssuedInConnectionWithRelatedPartyLineOfCreditMember"
      id="Fact_24b80677a3f6496aa9cb44e4c38acf91">2029-07-31</galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired>
    <galt:WarrantIssueDate
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_December292023WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember"
      id="Fact_3a81d003c3d04a2e9199de7f98e97769">2023-12-29</galt:WarrantIssueDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c20241231_ClassOfWarrantOrRightAxis_December292023WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember"
      decimals="0"
      id="Fact_81d83403ea1b48c78fc17949b0c840f6"
      unitRef="U002">200000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20241231_ClassOfWarrantOrRightAxis_December292023WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember"
      decimals="2"
      id="Fact_8b00dc4bf2414c268cfada442078c093"
      unitRef="U003">3</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_December292023WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember"
      id="Fact_d1ff867c16eb43cda4eaf99e32073169">2023-12-29</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_December292023WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember"
      id="Fact_ce87301f781448fb9cdcdf923dc64295">2029-07-31</galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired>
    <galt:WarrantIssueDate
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_March292024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember"
      id="Fact_6d2fefee97924eb9a9bb4b1e028f95f3">2024-03-29</galt:WarrantIssueDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c20241231_ClassOfWarrantOrRightAxis_March292024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember"
      decimals="0"
      id="Fact_740f2c9095b946d0b2f1bdd61307dc30"
      unitRef="U002">200000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20241231_ClassOfWarrantOrRightAxis_March292024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember"
      decimals="2"
      id="Fact_ad918febb4d64fd0a33293fdddb138c3"
      unitRef="U003">3.59</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_March292024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember"
      id="Fact_9398d522fe094004b58a7d5ba4dcec51">2024-03-29</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_March292024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember"
      id="Fact_991a79abc6e44ee0b430f889fd3f2772">2029-07-31</galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired>
    <galt:WarrantIssueDate
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_June282024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember"
      id="Fact_f33caca15c1a44ddb560cd917633b063">2024-06-28</galt:WarrantIssueDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c20241231_ClassOfWarrantOrRightAxis_June282024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember"
      decimals="0"
      id="Fact_01b0e30286f54b47a67c971560bf5ad6"
      unitRef="U002">200000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20241231_ClassOfWarrantOrRightAxis_June282024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember"
      decimals="2"
      id="Fact_cec673e718de483ca42c78bc9ce8bd7f"
      unitRef="U003">3.39</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_June282024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember"
      id="Fact_822c69060b7b4af4a12183493fb6e001">2024-06-29</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_June282024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember"
      id="Fact_73b741053afe47daa0611786fb22af91">2029-07-31</galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired>
    <galt:WarrantIssueDate
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_September302024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember"
      id="Fact_c26f8c0696834a1c8bb4c7c37b8a25e7">2024-09-30</galt:WarrantIssueDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c20241231_ClassOfWarrantOrRightAxis_September302024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember"
      decimals="0"
      id="Fact_4d1a187320514a698ae5dd47896d6b8e"
      unitRef="U002">200000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20241231_ClassOfWarrantOrRightAxis_September302024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember"
      decimals="2"
      id="Fact_9cd18ac7a6f44e9a85da041cb31e061a"
      unitRef="U003">4.13</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_September302024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember"
      id="Fact_42997761c9334e8aa227a68716d11321">2024-09-30</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_September302024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember"
      id="Fact_42809897948c45f2982f6bab5928f6fd">2029-07-31</galt:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c20241231"
      decimals="0"
      id="Fact_9e85756ef8114bdab557c729efaffdc6"
      unitRef="U002">9595940</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="c20240101to20241231"
      id="Text_7bc7a5f072db49898e6496e5436a5a7d">
&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 24.5pt; vertical-align: top; font-weight: bold;"&gt;9.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
              &lt;div style="font-weight: bold;"&gt;Stock-Based Compensation&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin: 0px 0px 0px 12.25pt; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;"&gt;Summary of Stock-Based Compensation Plans&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;At December 31, 2024, the Company has a stock-based compensation plan where the Company&#x2019;s common stock has been made available for equity-based incentive grants as
        part of the Company&#x2019;s compensation programs. In December 2019, the Company adopted the 2019 Omnibus Equity Incentive Plan (the &#x201c;2019 Plan&#x201d;) which provided originally for the issuance of up to 4,000,000 shares of the Company&#x2019;s common stock, subsequently increased to 7,000,000
        in December 2021, and increased to 10,000,000 in December 2023 in the form of options, stock appreciation rights, restricted stock and
        other stock-based awards to employees, officers, directors, consultants and other eligible persons. At December 31, 2024, 4,135,213
        shares were available for future grant under the 2019 Plan. Also, the Company previously had the 2009 Incentive Compensation Plan (the &#x201c;2009 Plan&#x201d;) which, after amendments, provided for issuance of up to 6,733,334 shares of the Company&#x2019;s common stock in the form of options, stock appreciation rights, restricted stock and other stock-based awards to employees, officers,
        directors, consultants and other eligible persons. Provisions of the 2009 Plan stipulated that no grants could be made after February 2019; however, grants made prior to that date remain outstanding for their legal term.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin: 0px 0px 0px 12.25pt; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;"&gt;Stock-Based Compensation&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Following is the stock-based compensation expense related to common stock options, restricted common stock, common stock warrants and deferred stock units:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 27pt;"&gt;
        &lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Year Ended&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;December 31, &lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt; 2024&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;2023&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Research and development&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1,222&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;829&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;General and administrative&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1,225&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1,432&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 16.2pt;"&gt;Total stock-based compensation expense&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;2,447&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;2,261&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
         &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The fair value of the options granted is determined using the Black-Scholes option-pricing model. The following weighted average assumptions were used:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 27pt;"&gt;
        &lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt; 2024&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;2023&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Risk-free interest rate&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;3.89&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;%&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;3.84&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;%&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Expected life of the options&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: right;"&gt;5.4 years &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: right;"&gt;5.7 years &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Expected volatility of the underlying stock&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;75.1&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;%&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;85.6&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;%&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Expected dividend rate&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;0&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;%&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;0&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;%&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

      &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;As noted above, the fair value of stock options is determined by using the Black-Scholes option pricing model. For all options granted since January 1, 2006 the
        Company has generally used option terms of between 5 to 10 years, generally with 5 to 6 years representing the estimated life of options granted to employees. The volatility of the common stock is estimated using historical volatility over a period equal to the
        expected life at the date of grant. The risk-free interest rate used in the Black-Scholes option pricing model is determined by reference to historical U.S. Treasury constant maturity rates with terms equal to the expected terms of the awards. An
        expected dividend yield of zero is used in the option valuation model, because the Company does not expect to pay any cash dividends on
        common stock in the foreseeable future. At December 31, 2024, the Company does not anticipate any option awards will be forfeited in the calculation of compensation expense due to the limited number of employees that receive stock option grants and
        the Company&#x2019;s historical employee turnover; however, any forfeitures will be accounted for as incurred.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The following table summarizes the stock option activity in the stock-based compensation plans:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 27pt;"&gt;
        &lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 53%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Number of&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Shares&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Weighted&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Average&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Exercise&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Price&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="text-align: left; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Weighted&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Average&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Remaining&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Contractual&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Life&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;(in years) &lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;" valign="bottom"&gt;&#160;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&#160;&#160;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Aggregate&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Intrinsic Value&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;(in thousands) &lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td style="width: 1%; padding-bottom: 2px;"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 53%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 16.2pt;"&gt;Outstanding, December 31, 2022&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;5,745,561&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;2.90&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 8.95%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 7.95%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 53%;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 25.2pt;"&gt;Granted&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1,025,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1.18&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 8.95%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 7.95%;" valign="bottom"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 53%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 25.2pt;"&gt;Forfeited/Cancelled&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;(436,720&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;2.23&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 8.95%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 7.95%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 53%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 25.2pt;"&gt;Exercised&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.01%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 8.95%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 7.95%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 53%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 16.2pt;"&gt;Outstanding, December 31, 2023&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;6,333,841&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;2.66&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 8.95%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 7.95%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 53%;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 25.2pt;"&gt;Granted&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1,373,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1.86&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 8.95%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 7.95%;" valign="bottom"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 53%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 25.2pt;"&gt;Forfeited/Cancelled&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;(348,750&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;6.35&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 8.95%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 7.95%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 53%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 25.2pt;"&gt;Exercised&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;(503,333&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.01%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1.71&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 8.95%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 7.95%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 53%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 16.2pt;"&gt;Outstanding, December 31, 2024&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;6,854,758&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.01%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;2.39&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 8.95%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: right;"&gt;6.27 &lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;$&lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 7.95%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: right;"&gt;183&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 53%;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Exercisable, December 31, 2024&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;6,138,254&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; white-space: nowrap;" valign="bottom"&gt;2.45&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 8.95%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: right;"&gt;6.00 &lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;$&lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 7.95%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: right;"&gt;176 &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
         &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The aggregate intrinsic value in the table above represents the total pre-tax amount, net of exercise price, which would have been received by option holders if all
        option holders had exercised all options with an exercise price lower than the market price on December 31, 2024, based on the closing price of the Company&#x2019;s common stock of $1.29 on that date.&lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The weighted-average grant-date fair values of options granted during 2024 and 2023 were $1.26 and $0.85, respectively. As of December 31, 2024 and 2023,
        there were unvested options to purchase 716,504 and 1,792,080 shares of common stock, respectively. Total expected unrecognized compensation cost related to such unvested options is $775,000 at December 31, 2024, which is expected to be recognized over a weighted-average period of 1.0
        years.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;During the years ended December 31, 2024 and 2023, 1,966,167
        and 1,119,168 options became vested, respectively. The total grant date fair value of options vested during the years ended December 31,
        2024 and 2023 was $2,772,748 and $1,384,284,
        respectively.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The following table summarizes additional information regarding outstanding and exercisable options under our stock-based compensation plans at December 31, 2024:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 27pt;"&gt;
        &lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 39%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="10" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Options Outstanding&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Options Exercisable&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); width: 39%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-weight: bold;"&gt;Exercise&lt;/div&gt;
                &lt;div style="font-weight: bold;"&gt;Price (Range)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Number of&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Shares&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Weighted&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Average&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Remaining&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Contractual&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Life&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Weighted&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Average&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Exercise&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Price&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Number of&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Shares&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Weighted&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Average&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Exercise&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Price&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 39%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;(in years)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 39%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;$0.89 &#x2013; 1.50&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1,134,206&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;7.13&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1.16&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;934,202&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1.12&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 39%;" valign="bottom"&gt;
                &lt;div&gt;$1.51 &#x2013; 2.50&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;3,691,315&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;6.88&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;2.02&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;3,199,815&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;2.02&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 39%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;$2.51 &#x2013; 5.00&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1,809,237&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;4.88&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;3.48&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1,784,237&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;3.48&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 39%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div&gt;$5.01 &#x2013; 6.71&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;220,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;3.10&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;5.92&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;220,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;5.92&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 39%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;6,854,758&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;6.27&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;2.39&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;6,138,254&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;2.45&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

      &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin: 0px 0px 0px 12.25pt; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;"&gt;Restricted Stock Issuances&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="margin: 0px 0px 0px 24.45pt; text-indent: 0pt;"&gt;&lt;span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;In January 2024, the Company issued 408,000 restricted stock units to its employees valued at $734,000 at the date of grant. These restricted stock units would vest 100% if the Company publicly presents the results of the Interim Analysis of its NAVIGATE clinical trial on or before December 31, 2024. The Company believed it was probable that the
          vesting condition will be met and is amortized the restricted stock unit expense ratably in 2024. The vesting condition was met in December 2024. &lt;/span&gt;&lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;In January 2024, one &lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 0px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;director elected to take a restricted stock grant in lieu of cash retainers for 2024.&lt;/span&gt; A total of 23,256 shares of restricted stock valued at approximately $40,000
        was amortized to expense on a straight-line basis until December 31, 2024 when the stock vested in full.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;In January 2023, one &lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 0px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;director elected to take a restricted stock grant in lieu of cash retainers for 202&lt;/span&gt;3. A total of 36,036 shares of restricted stock valued at approximately $40,000
        was amortized to expense on a straight-line basis until December 31, 2023 when the stock vested in full.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin: 0px 0px 0px 12.25pt; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;"&gt;Deferred Stock Units&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;In September 2020, the Company entered into an employment agreement with its new Chief Executive Officer whereby 20% of his base salary and performance bonuses will be paid in cash, and 80%
        will be paid in the form of deferred stock units (&#x201c;&lt;span style="text-decoration: underline;"&gt;DSUs&lt;/span&gt;&#x201d;) through December 31, 2022 in accordance with the terms and subject to the provisions set forth in the DSU Agreement. DSUs credited to Mr. Lewis as of any date shall be fully vested
        and nonforfeitable at all times.&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt; Pursuant to an amendment to the DSU
          Agreement in July 2022, &lt;/span&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;the
          Company shall issue the shares earned through December 31, 2022 underlying the outstanding whole number of DSUs credited to Mr. Lewis as follows: twenty five percent shall be issued on March 1, 2023, &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;fifty percent shall be issued on March 1, 2024&lt;/span&gt; and&#160;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;twenty five percent &lt;/span&gt;&lt;/span&gt;shall














            be issued on September 1, 2028. &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="margin: 0px 0px 0px 24.45pt; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 0pt;"&gt;&lt;span style="background-color: rgb(255, 255, 255); margin-top: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: left; text-transform: none;"&gt;On &lt;/span&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;March 1, 2024, fifty percent of the
          DSU&#x2019;s were issued to Mr. Lewis in accordance with the DSU Agreement. A total of 367,800 shares were due to be issued&#x37e; however, 153,288 shares were withheld to cover income tax withholding of $300,445 resulting in 214,512 shares actually issued. On March 1, 2023, twenty five percent of the DSU&#x2019;s were issued to Mr. Lewis in accordance with the DSU Agreement. A total of 183,900 shares were due to be issued&#x37e; however, 75,529 shares
          were withheld to cover income tax withholding of $156,345 resulting in 108,371 shares actually issued.&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="margin: 0px 0px 0px 24.45pt; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -27pt;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;br/&gt;
        &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Additionally, a 2023 DSU Agreement was
          executed in July 2022, whereby Mr. Lewis would continue to receive 20% of salary in cash and 80% in DSUs for 2023. The shares under the 2023 DSU Agreement are to be issued fifty percent on March 1, 2025 and fifty percent on January 5, 2026.&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
        &lt;/span&gt;&lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;For the year ended December 31, 2023, approximately $459,000 of his compensation was recorded as stock compensation expense
            representing 275,126 shares of common stock to be issued under the DSU agreement with a weighted average grant date fair value of $1.71 per share. For the year ended December 31, 2022, approximately $418,000 of his compensation was recorded as stock compensation expense representing 268,596
            shares of common stock to be issued under the DSU agreement with a weighted average grant date fair value of $1.56 per share.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
          &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; Also, Mr. Lewis&#x2019; bonus for the year ended December 31, 2022 of $210,000 (which was included in accrued compensation at
            December 31, 2022) was approved in January 2023 and represents 143,836 shares of common stock to be issued under the DSU agreement
            with a grant date fair value of $1.46 per share. The $210,000 was reclassified from accrued compensation to additional paid in capital in January 2023. Mr. Lewis&#x2019; bonus for the year ended December 31, 2021 of $200,000 (which was included in accrued compensation at December 31, 2021) was approved in January 2022, and represents 103,627 shares of common stock to be issued under the DSU agreement with a grant date fair value of $1.93 per share. The $200,000 was reclassified from accrued
            compensation to additional paid in capital in January 2022.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
          &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;There is no unrecognized compensation expense related to the DSUs.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c20191231_PlanNameAxis_EquityIncentivePlan2019Member"
      decimals="0"
      id="Fact_79229601389f4d9c9c3fb221c179ad58"
      unitRef="U002">4000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c20211231_PlanNameAxis_EquityIncentivePlan2019Member"
      decimals="0"
      id="Fact_8bd96a2a20944b628d8e3c6ba28b65bb"
      unitRef="U002">7000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c20231231_PlanNameAxis_EquityIncentivePlan2019Member"
      decimals="0"
      id="Fact_70a2a7958cfd47bb8cc65224e3c23617"
      unitRef="U002">10000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c20241231_PlanNameAxis_EquityIncentivePlan2019Member"
      decimals="0"
      id="Fact_76ca590d44d94d9fa4f0c0104e3a0257"
      unitRef="U002">4135213</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c20241231_PlanNameAxis_IncentiveCompensationPlanTwoThousandNineMemberMember"
      decimals="0"
      id="Fact_0cb81c5c258344aba1135e4d1657c8c1"
      unitRef="U002">6733334</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="c20240101to20241231"
      id="Text_e5cee5aa72524054a1c1da57b9f86b09">
&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Following is the stock-based compensation expense related to common stock options, restricted common stock, common stock warrants and deferred stock units:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 27pt;"&gt;
        &lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Year Ended&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;December 31, &lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt; 2024&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;2023&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Research and development&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1,222&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;829&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;General and administrative&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1,225&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1,432&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 16.2pt;"&gt;Total stock-based compensation expense&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;2,447&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;2,261&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
         &lt;/div&gt;
</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20240101to20241231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Fact_829ffc5b1818412eaa67bead7c8070da"
      unitRef="U001">1222000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20230101to20231231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Fact_08a1860f4f6b48a4b9d1c5f825ead199"
      unitRef="U001">829000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20240101to20241231_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="Fact_b2798822d41a4290af440d9ea1eaae0a"
      unitRef="U001">1225000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20230101to20231231_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="Fact_267dec81156140f09abca524a8c49cb3"
      unitRef="U001">1432000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_aa5e580ff8ac4dfe9ff3d1cd747b7f48"
      unitRef="U001">2447000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_76c2303d94a842dc958d6c36e6e08e83"
      unitRef="U001">2261000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="c20240101to20241231"
      id="Text_2f7c7162c04041e1891796c04ef0ac88">
&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The fair value of the options granted is determined using the Black-Scholes option-pricing model. The following weighted average assumptions were used:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 27pt;"&gt;
        &lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt; 2024&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;2023&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Risk-free interest rate&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;3.89&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;%&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;3.84&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;%&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Expected life of the options&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: right;"&gt;5.4 years &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: right;"&gt;5.7 years &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Expected volatility of the underlying stock&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;75.1&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;%&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;85.6&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;%&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Expected dividend rate&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;0&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;%&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;0&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;%&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

      &lt;/div&gt;
</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20240101to20241231"
      decimals="4"
      id="Fact_9f9bea919ee7485cb31bf95651d1f670"
      unitRef="U007">0.0389</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20230101to20231231"
      decimals="4"
      id="Fact_0fdb8d75699c431c8c5198a42c73dbb0"
      unitRef="U007">0.0384</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20240101to20241231"
      id="Fact_de1687eac25841e892394970b9bcccbf">P5Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20230101to20231231"
      id="Fact_380debffb9504727891b7c0f3028130c">P5Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c20240101to20241231"
      decimals="3"
      id="Fact_983ec67cc3f549b18dbff7d77276682f"
      unitRef="U007">0.751</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c20230101to20231231"
      decimals="3"
      id="Fact_b027e4b53b094874a0cef2a45348aefc"
      unitRef="U007">0.856</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c20240101to20241231"
      decimals="0"
      id="Fact_c885b0a0d7414fb69a64b66c7286dfcf"
      unitRef="U007">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c20230101to20231231"
      decimals="0"
      id="Fact_539d792b86874fc4a44d0e6b8a824cdd"
      unitRef="U007">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfAward
      contextRef="c20240101to20241231_RangeAxis_MinimumMember"
      id="Fact_d742011810944ec088fef185da180bf6">P5Y</galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfAward>
    <galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfAward
      contextRef="c20240101to20241231_RangeAxis_MaximumMember"
      id="Fact_691c5d22f93c4cb4ad86d5d6b6c84fe5">P10Y</galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfAward>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20240101to20241231_RangeAxis_MinimumMember"
      id="Fact_4f8d2c6c72934b5d8e9ac57a246f38f8">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20240101to20241231_RangeAxis_MaximumMember"
      id="Fact_204c0c03f1574f02b312622c1d57cf9d">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c20240101to20241231"
      decimals="0"
      id="Fact_8f9c6e864abc4f3f871d9c8b5e1e7c9f"
      unitRef="U007">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="c20240101to20241231"
      id="Text_2c589c2863d14b8aae26e244e8c6f921">
&lt;div style="margin-left: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The following table summarizes the stock option activity in the stock-based compensation plans:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 27pt;"&gt;
        &lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 53%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Number of&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Shares&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Weighted&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Average&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Exercise&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Price&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="text-align: left; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Weighted&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Average&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Remaining&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Contractual&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Life&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;(in years) &lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;" valign="bottom"&gt;&#160;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&#160;&#160;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Aggregate&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Intrinsic Value&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;(in thousands) &lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td style="width: 1%; padding-bottom: 2px;"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 53%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 16.2pt;"&gt;Outstanding, December 31, 2022&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;5,745,561&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;2.90&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 8.95%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 7.95%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 53%;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 25.2pt;"&gt;Granted&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1,025,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1.18&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 8.95%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 7.95%;" valign="bottom"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 53%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 25.2pt;"&gt;Forfeited/Cancelled&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;(436,720&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;2.23&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 8.95%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 7.95%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 53%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 25.2pt;"&gt;Exercised&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.01%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 8.95%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 7.95%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 53%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 16.2pt;"&gt;Outstanding, December 31, 2023&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;6,333,841&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;2.66&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 8.95%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 7.95%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 53%;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 25.2pt;"&gt;Granted&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1,373,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1.86&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 8.95%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 7.95%;" valign="bottom"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 53%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 25.2pt;"&gt;Forfeited/Cancelled&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;(348,750&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;6.35&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 8.95%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 7.95%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 53%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 25.2pt;"&gt;Exercised&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;(503,333&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.01%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1.71&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 8.95%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 7.95%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 53%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 16.2pt;"&gt;Outstanding, December 31, 2024&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;6,854,758&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.01%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;2.39&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 8.95%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: right;"&gt;6.27 &lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;$&lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 7.95%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: right;"&gt;183&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 53%;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Exercisable, December 31, 2024&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;6,138,254&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.95%; white-space: nowrap;" valign="bottom"&gt;2.45&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 8.95%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: right;"&gt;6.00 &lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;$&lt;/td&gt;

    &lt;td style="vertical-align: bottom; width: 7.95%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: right;"&gt;176 &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
         &lt;/div&gt;
</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c20221231"
      decimals="0"
      id="Fact_17f51877b724487d8e2bae2a680acc8e"
      unitRef="U002">5745561</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c20221231"
      decimals="2"
      id="Fact_a994747107b24a8ba2b5cd76d838bc4a"
      unitRef="U003">2.9</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c20230101to20231231"
      decimals="0"
      id="Fact_aa14a017324a42c9962d371af9c22adf"
      unitRef="U002">1025000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c20230101to20231231"
      decimals="2"
      id="Fact_b232be53802d427e995881de54e57d34"
      unitRef="U003">1.18</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c20230101to20231231"
      decimals="0"
      id="Fact_a831211d2d0b4a5aa471f64ff6063221"
      unitRef="U002">436720</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c20230101to20231231"
      decimals="2"
      id="Fact_bd217fd337b749869b77a9dc835821aa"
      unitRef="U003">2.23</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c20230101to20231231"
      decimals="INF"
      id="Fact_f4d6278a66e74ead82c9b9408d3a02e5"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c20230101to20231231"
      decimals="0"
      id="Fact_5d8e8417fd08420391986d8537195ece"
      unitRef="U003">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c20231231"
      decimals="0"
      id="Fact_3e71c803aace4f17af6475d61e0f9f51"
      unitRef="U002">6333841</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c20231231"
      decimals="2"
      id="Fact_421693bdc3744daf83580a01104549a9"
      unitRef="U003">2.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c20240101to20241231"
      decimals="0"
      id="Fact_557d9c8305774f76a4e166faad392564"
      unitRef="U002">1373000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c20240101to20241231"
      decimals="2"
      id="Fact_c9c4efd1b1524e8ebe088a19226363da"
      unitRef="U003">1.86</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c20240101to20241231"
      decimals="0"
      id="Fact_e1977b5fc736467191443d5e6067ed4c"
      unitRef="U002">348750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c20240101to20241231"
      decimals="2"
      id="Fact_2d1f8ca6d2ab4461abb28393f4c81a5a"
      unitRef="U003">6.35</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c20240101to20241231"
      decimals="0"
      id="Fact_44d8158c34e74348bd1d9cec49c0f905"
      unitRef="U002">503333</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c20240101to20241231"
      decimals="2"
      id="Fact_58c77de0defc4c8892cb05cf02952d90"
      unitRef="U003">1.71</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c20241231"
      decimals="0"
      id="Fact_5497b22fd2994795b89aed33bd8418ca"
      unitRef="U002">6854758</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c20241231"
      decimals="2"
      id="Fact_2b14c77f00334d47af17a67040d93d09"
      unitRef="U003">2.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="c20240101to20241231"
      id="Fact_bb9c758b70f54d049964bd4f95894ca3">P6Y3M7D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="c20241231"
      decimals="-3"
      id="Fact_07a15ad342bc4816a4301b6ccce8d57a"
      unitRef="U001">183000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c20241231"
      decimals="0"
      id="Fact_f19fc6d1ad9e412396c1bca7e0af8b10"
      unitRef="U002">6138254</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c20241231"
      decimals="2"
      id="Fact_a6d7e51ff21c4dfc9b5a4b8871129ca2"
      unitRef="U003">2.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="c20240101to20241231"
      id="Fact_e8d27791f7fa4fe592409ee0f8c341c9">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="c20241231"
      decimals="-3"
      id="Fact_ebbb494781b54b75803ea0680ee957ed"
      unitRef="U001">176000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharePrice
      contextRef="c20241231"
      decimals="2"
      id="Fact_82f8c52d9eaf4fa1ad6482754ae55094"
      unitRef="U003">1.29</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c20240101to20241231"
      decimals="2"
      id="Fact_28ca4ccfda7648369e3994a72bdd9a66"
      unitRef="U003">1.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c20230101to20231231"
      decimals="2"
      id="Fact_a31e41d3fe31487f8ccc17566fe3228f"
      unitRef="U003">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="c20241231"
      decimals="0"
      id="Fact_6319f6c64d3d4315bc8b01f568b47248"
      unitRef="U002">716504</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="c20231231"
      decimals="0"
      id="Fact_876b7057f7e14db3b059aae3c3ac9933"
      unitRef="U002">1792080</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="c20241231"
      decimals="0"
      id="Fact_f4255fd7541f4ab3aa61c4124664c82c"
      unitRef="U001">775000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="c20240101to20241231"
      id="Fact_5aa29eb5145643f2b76ca9fb77717580">P1Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="c20240101to20241231"
      decimals="0"
      id="Fact_7f08c5fcbe8e42f5aa5dc5d7103c9a2a"
      unitRef="U002">1966167</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="c20230101to20231231"
      decimals="0"
      id="Fact_63ec93f4d5424ab2a2dbf89fe78f423e"
      unitRef="U002">1119168</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="c20240101to20241231"
      decimals="0"
      id="Fact_a8ecc398852d4a0c808519c44222c183"
      unitRef="U001">2772748</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="c20230101to20231231"
      decimals="0"
      id="Fact_7d545a6fb16d416f8b6cd82715ce1ad3"
      unitRef="U001">1384284</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock
      contextRef="c20240101to20241231"
      id="Text_9935f85e603949549a8c899d8e1228a5">
&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The following table summarizes additional information regarding outstanding and exercisable options under our stock-based compensation plans at December 31, 2024:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 27pt;"&gt;
        &lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 39%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="10" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Options Outstanding&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Options Exercisable&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); width: 39%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-weight: bold;"&gt;Exercise&lt;/div&gt;
                &lt;div style="font-weight: bold;"&gt;Price (Range)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Number of&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Shares&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Weighted&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Average&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Remaining&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Contractual&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Life&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Weighted&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Average&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Exercise&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Price&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Number of&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Shares&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Weighted&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Average&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Exercise&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Price&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 39%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;(in years)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 39%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;$0.89 &#x2013; 1.50&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1,134,206&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;7.13&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1.16&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;934,202&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1.12&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 39%;" valign="bottom"&gt;
                &lt;div&gt;$1.51 &#x2013; 2.50&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;3,691,315&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;6.88&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;2.02&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;3,199,815&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;2.02&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 39%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;$2.51 &#x2013; 5.00&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1,809,237&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;4.88&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;3.48&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1,784,237&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;3.48&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 39%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div&gt;$5.01 &#x2013; 6.71&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;220,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;3.10&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;5.92&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;220,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;5.92&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 39%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;6,854,758&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;6.27&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;2.39&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;6,138,254&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;2.45&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

      &lt;/div&gt;
</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c20240101to20241231_RangeAxis_MinimumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeOneMember"
      decimals="2"
      id="Fact_db2042862bba4fb194c5791e1b0f73a0"
      unitRef="U003">0.89</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c20240101to20241231_RangeAxis_MaximumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeOneMember"
      decimals="2"
      id="Fact_b278ede36ce749348d4000b81240a5d1"
      unitRef="U003">1.5</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeOneMember"
      decimals="0"
      id="Fact_b43a76e113d94eb4a0c7f007d0db984b"
      unitRef="U002">1134206</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeOneMember"
      id="Fact_64f5d9b7797b44998838841fa3d302ba">P7Y1M17D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeOneMember"
      decimals="2"
      id="Fact_84b2543e46314547925ed82a82f29d4d"
      unitRef="U003">1.16</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeOneMember"
      decimals="0"
      id="Fact_07f9a88b5ad24d26b2227862a241bf6d"
      unitRef="U002">934202</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeOneMember"
      decimals="2"
      id="Fact_0be236027fa04a32baea919bc29e92ff"
      unitRef="U003">1.12</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c20240101to20241231_RangeAxis_MinimumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeTwoMember"
      decimals="2"
      id="Fact_6af57083f3984cabb31dd9e904b874e9"
      unitRef="U003">1.51</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c20240101to20241231_RangeAxis_MaximumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeTwoMember"
      decimals="2"
      id="Fact_7488909fcc5145209db2b1bd1a6e9dd5"
      unitRef="U003">2.5</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeTwoMember"
      decimals="0"
      id="Fact_63ef040b2b01428dada2f2bcafe15cae"
      unitRef="U002">3691315</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeTwoMember"
      id="Fact_ff4638af858347b2a4b05edf6992f969">P6Y10M17D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeTwoMember"
      decimals="2"
      id="Fact_da2bd782fff74f1babe02e12e603b862"
      unitRef="U003">2.02</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeTwoMember"
      decimals="0"
      id="Fact_ea0ebaf467a34ece8e6718f8bf159d96"
      unitRef="U002">3199815</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeTwoMember"
      decimals="2"
      id="Fact_e24dfb86f7824f2fa61cbaea303ebda6"
      unitRef="U003">2.02</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c20240101to20241231_RangeAxis_MinimumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeThreeMember"
      decimals="2"
      id="Fact_69e8929091a54a58aa1dc3595cb21e49"
      unitRef="U003">2.51</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c20240101to20241231_RangeAxis_MaximumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeThreeMember"
      decimals="2"
      id="Fact_1989391763394792955e92e7f9159910"
      unitRef="U003">5</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeThreeMember"
      decimals="0"
      id="Fact_1bd77882dbda40a19cc5d4f3a0aa5051"
      unitRef="U002">1809237</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeThreeMember"
      id="Fact_1ba8d6bb1573440d921d8aa68868a1e2">P4Y10M17D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeThreeMember"
      decimals="2"
      id="Fact_9c2c5aa9d8824b26a4dd60900e5e0e28"
      unitRef="U003">3.48</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeThreeMember"
      decimals="0"
      id="Fact_b093bb1e435546cc985d564464f59cd0"
      unitRef="U002">1784237</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeThreeMember"
      decimals="2"
      id="Fact_07d4c4df9956404f82243d2e09933213"
      unitRef="U003">3.48</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c20240101to20241231_RangeAxis_MinimumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeFourMember"
      decimals="2"
      id="Fact_388aa13c0bf3481e9e59fb8459ee9c27"
      unitRef="U003">5.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c20240101to20241231_RangeAxis_MaximumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeFourMember"
      decimals="2"
      id="Fact_e6adafb6340e4969bb42aa9f27b7bde2"
      unitRef="U003">6.71</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeFourMember"
      decimals="0"
      id="Fact_0b77493d37ea43d4bcd6e9e1681a3b8c"
      unitRef="U002">220000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeFourMember"
      id="Fact_5ab7bc82822f4e2bbab52c163b492952">P3Y1M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeFourMember"
      decimals="2"
      id="Fact_3f4884422dbe44e898d37a51471ca285"
      unitRef="U003">5.92</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeFourMember"
      decimals="0"
      id="Fact_8b6dc5951d6b4f2795b39f217a111ddf"
      unitRef="U002">220000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeFourMember"
      decimals="2"
      id="Fact_ae5e7254411f429d8f4cd3cb2d61edf4"
      unitRef="U003">5.92</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c20241231"
      decimals="0"
      id="Fact_a8fbe935b21a46fbb1870c682ebc9e14"
      unitRef="U002">6854758</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="c20240101to20241231"
      id="Fact_c8f993f54d304af2b95bcc98a7b46eed">P6Y3M7D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="c20241231"
      decimals="2"
      id="Fact_7b0e8c5075704fa2b5b6b13ecf530442"
      unitRef="U003">2.39</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c20241231"
      decimals="0"
      id="Fact_d5bc3f021c0d4dc8aec5ebbb24af2e91"
      unitRef="U002">6138254</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c20241231"
      decimals="2"
      id="Fact_4547acd868c2427aad66b09ca3e66722"
      unitRef="U003">2.45</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c20240101to20240131_AwardTypeAxis_RestrictedStockMember"
      decimals="0"
      id="Fact_1ba9f766171248398171864f0391175a"
      unitRef="U002">408000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c20240101to20240131_AwardTypeAxis_RestrictedStockMember"
      decimals="0"
      id="Fact_25878712710c44f8adcef13a345dbe65"
      unitRef="U001">734000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <galt:VestingPercentageOfRestrictedStockUnits
      contextRef="c20240101to20241231_AwardTypeAxis_RestrictedStockMember"
      decimals="2"
      id="Fact_726a8e12a89e459c871fbc8ba0fb5562"
      unitRef="U007">1</galt:VestingPercentageOfRestrictedStockUnits>
    <galt:NumberOfDirectors
      contextRef="c20231231_AwardTypeAxis_RestrictedStockMember"
      decimals="INF"
      id="Fact_db772f2f617e4e428ba893bb43da3007"
      unitRef="U009">1</galt:NumberOfDirectors>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c20230101to20231231_AwardTypeAxis_RestrictedStockMember"
      decimals="0"
      id="Fact_84b8f31bb2a44a65a245df6546517aa9"
      unitRef="U002">23256</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20230101to20231231_AwardTypeAxis_RestrictedStockMember"
      decimals="0"
      id="Fact_3cccc8d0c46f42c3bd0e3103ec36c3ac"
      unitRef="U001">40000</us-gaap:AllocatedShareBasedCompensationExpense>
    <galt:NumberOfDirectors
      contextRef="c20241231_AwardTypeAxis_RestrictedStockMember"
      decimals="INF"
      id="Fact_40e83dcde60b47ad980e0af5f088df4e"
      unitRef="U009">1</galt:NumberOfDirectors>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c20240101to20241231_AwardTypeAxis_RestrictedStockMember"
      decimals="0"
      id="Fact_e82d9a6a5e354ba99fb32ad954a0baab"
      unitRef="U002">36036</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20240101to20241231_AwardTypeAxis_RestrictedStockMember"
      decimals="0"
      id="Fact_3e172197d217419782168423b22f39ae"
      unitRef="U001">40000</us-gaap:AllocatedShareBasedCompensationExpense>
    <galt:DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent
      contextRef="c20220101to20221231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"
      decimals="2"
      id="Fact_2bde12c4a8b74a39ae23720df188ebc9"
      unitRef="U007">0.20</galt:DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent>
    <galt:DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent
      contextRef="c20220101to20221231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"
      decimals="2"
      id="Fact_e0b064951ecb46048dd3e77ffebef504"
      unitRef="U007">0.80</galt:DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent>
    <galt:DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne
      contextRef="c20221231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"
      decimals="2"
      id="Fact_5c82d541b1f445ce89cf26d7ef243437"
      unitRef="U007">0.25</galt:DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne>
    <galt:DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo
      contextRef="c20221231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"
      decimals="2"
      id="Fact_7b0d17317e8b4f8086a67d9e3968bbe2"
      unitRef="U007">0.50</galt:DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo>
    <galt:DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree
      contextRef="c20221231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"
      decimals="2"
      id="Fact_c6fb62428063432cad201270b1772ce5"
      unitRef="U007">0.25</galt:DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree>
    <galt:DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFour
      contextRef="c20241231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"
      decimals="2"
      id="Fact_4a261d0bbf7349eaa9d192bb30506e88"
      unitRef="U007">0.50</galt:DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFour>
    <us-gaap:CommonStockSharesSubscribedButUnissued
      contextRef="c20241231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact_8e5a1371dc9f4c6685fb2b782153cad7"
      unitRef="U002">367800</us-gaap:CommonStockSharesSubscribedButUnissued>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="c20240101to20241231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact_8627ac6360184ce596234dcafd7afa06"
      unitRef="U002">153288</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="c20240101to20241231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact_ad3723eec8a04f88b2b65a2f405b51fa"
      unitRef="U001">300445</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="c20240101to20241231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact_f28ebeb84848492e918124145953fc24"
      unitRef="U002">214512</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <galt:DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFive
      contextRef="c20231231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"
      decimals="2"
      id="Fact_9391461ffcd24d54a7cc3793470db6c1"
      unitRef="U007">0.25</galt:DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFive>
    <us-gaap:CommonStockSharesSubscribedButUnissued
      contextRef="c20231231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact_788f94492c7540ea998e97e74d73ecb8"
      unitRef="U002">183900</us-gaap:CommonStockSharesSubscribedButUnissued>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="c20230101to20231231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact_9e7c956910374265bff6e2266f53b467"
      unitRef="U002">75529</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="c20230101to20231231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact_be33515774684a59bc618779050fef15"
      unitRef="U001">156345</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="c20230101to20231231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact_c270e2dab81f49538c1e89f5e50616d1"
      unitRef="U002">108371</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <galt:DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent
      contextRef="c20230101to20231231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"
      decimals="2"
      id="Fact_638d03f59a304baa832b363ad8be9cd8"
      unitRef="U007">0.20</galt:DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent>
    <galt:DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent
      contextRef="c20230101to20231231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"
      decimals="2"
      id="Fact_2cb549c8251d4f15b1e1d4347b920f5b"
      unitRef="U007">0.80</galt:DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent>
    <galt:DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSix
      contextRef="c20231231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"
      decimals="2"
      id="Fact_b97cbd8e3bbb48f0b05071f609a2de5d"
      unitRef="U007">0.50</galt:DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSix>
    <galt:DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSeven
      contextRef="c20231231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"
      decimals="2"
      id="Fact_31d21ecb8976450d8116e464cf044ee9"
      unitRef="U007">0.50</galt:DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSeven>
    <us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense
      contextRef="c20230101to20231231_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact_50af2d0d404848c3b38ef8f94df9c288"
      unitRef="U001">459000</us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense>
    <us-gaap:DeferredCompensationArrangementWithIndividualSharesIssued
      contextRef="c20230101to20231231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact_f6b9d1dce0684dd893ce9802785de16c"
      unitRef="U002">275126</us-gaap:DeferredCompensationArrangementWithIndividualSharesIssued>
    <us-gaap:DeferredCompensationArrangementWithIndividualExercisePrice
      contextRef="c20230101to20231231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"
      decimals="2"
      id="Fact_ba8ff613e6aa4298a76739acfe4c34d7"
      unitRef="U003">1.71</us-gaap:DeferredCompensationArrangementWithIndividualExercisePrice>
    <us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense
      contextRef="c20220101to20221231_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact_e15d09f22242412d9c3bc2f98018c1ad"
      unitRef="U001">418000</us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense>
    <us-gaap:DeferredCompensationArrangementWithIndividualSharesIssued
      contextRef="c20220101to20221231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact_7188004f556742b198e60bb2453149db"
      unitRef="U002">268596</us-gaap:DeferredCompensationArrangementWithIndividualSharesIssued>
    <us-gaap:DeferredCompensationArrangementWithIndividualExercisePrice
      contextRef="c20220101to20221231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_DeferredBonusMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"
      decimals="2"
      id="Fact_a9f1d83656f24a3cb15aab32f18c8044"
      unitRef="U003">1.56</us-gaap:DeferredCompensationArrangementWithIndividualExercisePrice>
    <us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense
      contextRef="c20220101to20221231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_BonusSharesMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact_cbd26f87e73c43638b9bda0910f411e1"
      unitRef="U001">210000</us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense>
    <us-gaap:DeferredCompensationArrangementWithIndividualSharesIssued
      contextRef="c20220101to20221231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_BonusSharesMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact_96f9461b58ae42bf8535da19aa0ca5d7"
      unitRef="U002">143836</us-gaap:DeferredCompensationArrangementWithIndividualSharesIssued>
    <us-gaap:DeferredCompensationArrangementWithIndividualExercisePrice
      contextRef="c20220101to20221231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_BonusSharesMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"
      decimals="2"
      id="Fact_2d6d4f8fa0f3404cb60eb60c1289a9cc"
      unitRef="U003">1.46</us-gaap:DeferredCompensationArrangementWithIndividualExercisePrice>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c20230101to20231231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_BonusSharesMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact_6581b4eccb8747739220a7c3d7ed6e4f"
      unitRef="U001">210000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense
      contextRef="c20210101to20211231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_BonusSharesMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact_2ae57f7eb8b3479b8d25feffea683a35"
      unitRef="U001">200000</us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense>
    <us-gaap:DeferredCompensationArrangementWithIndividualSharesIssued
      contextRef="c20210101to20211231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_BonusSharesMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact_d95ccb4bbee24fe4a2849cdc4d41ca38"
      unitRef="U002">103627</us-gaap:DeferredCompensationArrangementWithIndividualSharesIssued>
    <us-gaap:DeferredCompensationArrangementWithIndividualExercisePrice
      contextRef="c20210101to20211231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_BonusSharesMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"
      decimals="2"
      id="Fact_db85a0f85d6b4395a7568850c309073e"
      unitRef="U003">1.93</us-gaap:DeferredCompensationArrangementWithIndividualExercisePrice>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c20220101to20221231_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_BonusSharesMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact_e76a73a6480c4df68fece06282222579"
      unitRef="U001">200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="c20241231_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact_05f33c1c3e884d36a838f6ab5d94868c"
      unitRef="U001">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="c20240101to20241231_LongtermDebtTypeAxis_LineOfCreditMember"
      id="Text_8692324ab2ad4d2786377a23b752b756">
&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 27.05pt; vertical-align: top; font-weight: bold;"&gt;10.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
              &lt;div style="font-weight: bold;"&gt;Convertible Line of Credit &#x2013; Related Party and Supplemental Lines of Credit &#x2013; Related Party&lt;br/&gt;
              &lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt;"&gt;On July 25, 2022, the Company and Richard E. Uihlein (the &#x201c;Lender&#x201d;) entered into a Line of Credit Letter Agreement (the &#x201c;Credit Agreement&#x201d;), pursuant
          to which the Lender shall provide the Company a line of credit of up to $60.0 million (the &#x201c;Line of Credit&#x201d;) to finance the Company&#x2019;s
          working capital needs. The Company may draw upon the Line of Credit through July 31, 2024.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt;"&gt;Each advance made pursuant to the Credit Agreement shall be evidenced by an unsecured, convertible promissory note (individually, a &#x201c;Promissory
          Note,&#x201d; and collectively, the &#x201c;Promissory Notes&#x201d;), and bear interest at the Applicable Federal Rate for short term loans, plus two (2%)
          percent. Principal and interest on the Promissory Notes are due on or before January 31, 2026. Only with the consent of the Lender,
          may the Promissory Notes be prepaid, in whole or in part, at any time without premium or penalty, but with interest on the amount or amounts prepaid.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt;"&gt;At the election of Lender, the principal and accrued interest on Promissory Note(s) may be converted into the number of shares of the Company&#x2019;s
          Common Stock equal to the amount of principal and accrued interest on such Promissory Note divided by the price equal to the closing price of the Common Stock on the date of such Promissory Note, but in no event less than $3.00 per share.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt;"&gt;In connection with the Credit Agreement, the Company agreed to issue the Lender warrants to purchase up to an aggregate of 1,700,000 shares of the Company&#x2019;s common stock, par value $0.001 per share (collectively, the &#x201c;Warrants&#x201d;). Upon execution of the Credit Agreement, the Company issued the Lender a Warrant to purchase up to 500,000 shares of Company&#x2019;s Common Stock at an exercise price of $5.00
          per share, which Warrant is exercisable upon issuance. Further, pursuant to the Credit Agreement, the Company shall issue to the Lender additional Warrants to purchase up to the remaining 1,200,000 shares of the Company&#x2019;s common stock, ratably, upon borrowings under the Credit Agreement, with exercise prices equal to 150% of the closing price of the Company&#x2019;s common Stock on the date of the Promissory Note evidencing such draw, but in no event more than $10.00 per share nor less than $3.00 per share. The Warrants
          expire on July 31, 2029.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt;"&gt;The fair value of the 500,000
          warrants vested at closing on July 25, 2022 was $738,000 at the date of issuance based on the following assumptions: an expected life
          of 7 years, volatility of 92%,
          risk free interest rate of 3.19% and zero
          dividends. The fair value of the vested warrants was recorded in other assets (non-current) as a deferred financing cost and will be amortized on a straight-line basis from July 25, 2022 through January 31, 2026. Amortization for the years ended
          December 31, 2024 and 2023 of $210,000 and $209,000, respectively, was recorded as interest expense.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt;"&gt;On December 19, 2022, the Company executed a $10
          million Promissory Note under the Line of Credit. The interest rate on this draw is 6.46% (Applicable Federal Rate for short term
          loans on date of draw of 4.46% plus 2%).





























































          The effective interest rate is approximately 7.1%. Accrued interest on this draw was approximately $1,399,000 and $688,000 at December 31,
          2024 and 2023, respectively. The principal and accrued interest is convertible at the option of the Lender at $3.00 per share. In
          accordance with the Credit Agreement, the Company issued the Lender a Warrant to purchase up to 200,000 shares of Company&#x2019;s Common
          Stock at an exercise price of $3.00 per share, which Warrant is exercisable upon issuance.&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt;"&gt;The fair value of the 200,000
          warrants vested at closing on December 19, 2022 was $160,780 at the date of issuance based on the following assumptions: an expected
          life of 7 years, volatility of 91%,
          risk free interest rate of 4.06% and zero
          dividends. The proceeds were allocated between the Promissory Note and the warrants issued, and the amount allocated to the warrants was recorded as a debt discount netted against principal to be amortized on a straight-line basis, which is not
          materially different than the effective interest method, from December 19, 2022 through January 31, 2026. Amortization for the years ended December 31, 2024 and 2023 of $52,000 and $51,000, respectively, was recorded as interest
          expense.&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt;"&gt;On March 31, 2023, the Company executed an additional $10
          million Promissory Note under the Line of Credit. The interest rate on this draw is 6.41% (Applicable Federal Rate for short term
          loans on date of draw of 4.41% plus 2%).

















































          The effective interest rate is approximately 7.1%.&#160; Accrued interest on this draw was approximately $1,184,000 and $491,000 at December 31,
          2024 and 2023, respectively. The principal and accrued interest is convertible at the option of the Lender at $3.00 per share. In
          accordance with the Credit Agreement, the Company issued the Lender a Warrant to purchase up to 200,000 shares of Company&#x2019;s Common
          Stock at an exercise price of $3.26 per share, which Warrant is exercisable upon issuance.&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt;"&gt;The fair value of the 200,000
          warrants vested at closing on March 31, 2023 was $296,680 at the date of issuance based on the following assumptions: an expected life
          of 6.33 years, volatility of 88%,
          risk free interest rate of 3.94% and zero
          dividends. The proceeds were allocated between the Promissory Note and the warrants issued, and the amount allocated to the warrants was recorded as a debt discount netted against principal amortized on a straight-line basis, which is not
          materially different than the effective interest method, from March 31, 2023 through January 31, 2026. Amortization for the year ended December 31, 2024 and 2023 of $105,000 and $79,000, respectively, was recorded as interest expense.&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt;"&gt;On June 30, 2023, the Company executed an additional $10
          million Promissory Note under the Line of Credit. The interest rate on this draw is 6.34% (Applicable Federal Rate for short term
          loans on date of draw of 4.34% plus 2%).

















































          The effective interest rate is approximately 7.1%.&#160; Accrued interest on this draw was approximately $995,000 and $321,000 at December 31,
          2024 and 2023, respectively. The principal and accrued interest is convertible at the option of the Lender at $3.00 per share. In
          accordance with the Credit Agreement, the Company issued the Lender a Warrant to purchase up to 200,000 shares of Company&#x2019;s Common
          Stock at an exercise price of $3.00 per share, which Warrant is exercisable upon issuance.&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt;"&gt;The fair value of the 200,000
          warrants vested at closing on June 30, 2023 was $179,920 at the date of issuance based on the following assumptions: an expected life
          of 6.08 years, volatility of 85%,
          risk free interest rate of 3.59% and zero
          dividends. The proceeds were allocated between the Promissory Note and the warrants issued, and the amount allocated to the warrants was recorded as a debt discount netted against principal amortized on a straight-line basis, which is not
          materially different than the effective interest method, from June 30, 2023 through January 31, 2026. Amortization for the year ended December 31, 2024 and 2023 of $69,000 and $35,000, respectively, was recorded as interest expense.&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt;"&gt;On December 29, 2023, the Company executed an additional $10 million Promissory Note under the Line of Credit. The interest rate on this draw is 7.13%
          (Applicable Federal Rate for short term loans on date of draw of 5.13% plus 2%). The effective interest rate is approximately 7.5%.
          Accrued interest on this draw was approximately $737,000 at December 31, 2024. The principal and accrued interest is convertible at the
          option of the Lender at $3.00 per share. In accordance with the Credit Agreement, the Company issued the Lender a Warrant to purchase
          up to 200,000 shares of Company&#x2019;s Common Stock at an exercise price of $3.00 per share, which Warrant is exercisable upon issuance.&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman', Times, serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"&gt; &lt;br/&gt;
          &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="letter-spacing: normal; text-align: left; text-indent: 0px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;The fair value of the 200,000 warrants vested at closing on December 31, 2023 was $193,745 at the date of issuance based on the following assumptions: an expected life of 5.7 years,
            volatility of 79%, risk free interest rate of 4.49% and zero dividends. The proceeds were allocated between the Promissory Note and the warrants
            issued, and the amount allocated to the warrants was recorded as a debt discount netted against principal amortized on a straight-line basis, which is not materially different than the effective interest method, from December 29, 2023 through
            January 31, 2026. Amortization for the year ended December 31, 2024 of $93,000 was recorded as interest expense. On March 29, 2024,
            the Company executed an additional $10 million Promissory Note under the Line of Credit. The interest rate on this draw is 6.62% (Applicable Federal Rate for short term loans on date of draw of 4.62% plus 2%). The effective interest rate is approximately 7.1%. Accrued interest on this draw was $508,000
            at December 31, 2024. The principal and accrued interest is convertible at the option of the Lender at $3.00 per share. In accordance
            with the Credit Agreement, the Company issued the Lender a Warrant to purchase up to 200,000 shares of Company&#x2019;s Common Stock at an
            exercise price of $3.59 per share, which Warrant is exercisable upon issuance.&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="letter-spacing: normal; text-align: left; text-indent: 0px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt; &lt;br/&gt;
          &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="letter-spacing: normal; text-align: left; text-indent: 0px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;The fair value of the 200,000 warrants vested at closing on March 29, 2024, was $277,389 at the date of issuance based on the following assumptions: an expected life of 5.33
            years, volatility of 75%, risk free interest rate of 4.19% and zero dividends. The proceeds were allocated between the
            Promissory Note and the warrants issued, and the amount allocated to the warrants was recorded as a debt discount netted against principal amortized on a straight-line basis, which is not materially different than the effective interest method,
            from March 29, 2024 through January 31, 2026. Amortization for the year ended December 31, 2024 of $114,000 was recorded as interest
            expense.&lt;br/&gt;
            &lt;br/&gt;
            On June 28, 2024, the Company executed an additional $10 million Promissory Note under the Line of Credit. The interest rate on this
            draw is 7.01% (Applicable Federal Rate for short term loans on date of draw of 5.01% plus 2%). The effective interest rate is approximately
            7.4%. Accrued interest on this draw was $336,000
            at December 31, 2024.&#160; The principal and accrued interest is convertible at the option of the Lender at $3.00 per share. In
            accordance with the Credit Agreement, the Company issued the Lender a Warrant to purchase up to 200,000 shares of Company&#x2019;s Common
            Stock at an exercise price of $3.39 per share, which Warrant is exercisable upon issuance.&lt;br/&gt;
            &lt;br/&gt;
            The fair value of the 200,000 warrants vested at closing on June 28, 2024, was $260,000 at the date of issuance based on the following assumptions: an expected life of 5.03 years, volatility of 77%, risk free interest rate of 4.29% and zero dividends. The
            proceeds were allocated between the Promissory Note and the warrants issued, and the amount allocated to the warrants was recorded as a debt discount netted against principal amortized on a straight-line basis, which is not materially different
            than the effective interest method, from June 28, 2024 through January 31, 2026. Amortization for the year ended December 31, 2024 of $82,000
            was recorded as interest expense.&lt;br/&gt;
          &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="letter-spacing: normal; text-align: left; text-indent: 0px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&lt;br/&gt;
            On March 29, 2024, the Company and Richard E. Uihlein (the &#x201c;Lender&#x201d;) entered into a Supplemental Line of Credit Letter Agreement (the &#x201c;Supplemental Credit Agreement&#x201d;), pursuant to which the Lender shall provide the Company a line of credit of
            up to $10.0 million (the &#x201c;Supplemental Line of Credit&#x201d;) to finance the Company&#x2019;s working capital needs. The Company may draw upon the
            Supplemental Line of Credit through March 31, 2025.&lt;br/&gt;
            &lt;br/&gt;
            Each advance made pursuant to the Supplemental Credit Agreement shall be evidenced by an unsecured, convertible promissory note (individually, a &#x201c;Promissory Note,&#x201d; and collectively, the &#x201c;Promissory Notes&#x201d;), and bear interest at the Applicable
            Federal Rate for short term loans, plus two (2%) percent. Principal and interest on the Promissory Notes are due on or before January 31, 2026. Only with the consent of the Lender, may the Promissory Notes be prepaid, in whole or in part, at any time without premium or
            penalty, but with interest on the amount or amounts prepaid.&lt;br/&gt;
            &lt;br/&gt;
            At the election of Lender, the principal and accrued interest on Promissory Note(s) may be converted into the number of shares of the Company&#x2019;s Common Stock equal to the amount of principal and accrued interest on such Promissory Note divided
            by the price equal to the closing price of the Common Stock on the date of such Promissory Note, but in no event less than $3.00 per
            share.&lt;br/&gt;
            &lt;br/&gt;
            In connection with the Supplemental Credit Agreement, the Company agreed to issue the Lender warrants to purchase up to an aggregate of 200,000
            shares of the Company&#x2019;s common stock, par value $0.001 per share (collectively, the &#x201c;Warrants&#x201d;). The Company shall issue to the
            Lender Warrants ratably, upon borrowings under the Supplemental Line of Credit, with exercise prices equal to 150% of the closing
            price of the Company&#x2019;s common Stock on the date of the Promissory Note evidencing such draw, but in no event more than $10.00 per
            share nor less than $3.00 per share. The Warrants expire on July 31, 2029.&lt;br/&gt;
            &lt;br/&gt;
            On September 30, 2024, the Company executed a $10 million Promissory Note under the Supplemental Line of Credit. The interest rate on
            this draw is 6.13% (Applicable Federal Rate for short term loans on date of draw of 5.01% plus 2%). The effective interest rate is approximately
            6.4%. Accrued interest on this draw was $154,000
            at December 31, 2024.&#160; The principal and accrued interest is convertible at the option of the Lender at $3.00 per share. In
            accordance with the Credit Agreement, the Company issued the Lender a Warrant to purchase up to 200,000 shares of Company&#x2019;s Common
            Stock at an exercise price of $4.13 per share, which Warrant is exercisable upon issuance. The fair value of the 200,000 warrants vested at closing on September 30, 2024, was $307,780 at the date of issuance based on the following assumptions: an expected life of 4.83
            years, volatility of 78%, risk free interest rate of 3.58% and zero dividends. The proceeds were allocated between the
            Promissory Note and the warrants issued, and the amount allocated to the warrants was recorded as a debt discount netted against principal amortized on a straight-line basis, which is not materially different than the effective interest method,
            from October 1, 2024 through January 31, 2026. Amortization for the year ended December 31, 2024 of $58,000 was recorded as interest
            expense.&lt;br/&gt;
          &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="letter-spacing: normal; text-align: left; text-indent: 0px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&lt;br/&gt;
            On November 14, 2024, the Company and Richard E. Uihlein (the &#x201c;Lender&#x201d;) entered into an additional Supplemental Line of Credit Letter Agreement (the &#x201c;November 2024 Supplemental Credit Agreement&#x201d;), pursuant to which the Lender shall provide the
            Company a line of credit of up to $6.0 million (the &#x201c;November 2024 Supplemental Line of Credit&#x201d;) to finance the Company&#x2019;s working
            capital needs. The Company may draw upon the November 2024 Supplemental Line of Credit through March 31, 2025.&lt;br/&gt;
            &lt;br/&gt;
            Each advance made pursuant to the November 2024 Supplemental Credit Agreement shall be evidenced by an unsecured, convertible promissory note (individually, a &#x201c;Promissory Note,&#x201d; and collectively, the &#x201c;Promissory Notes&#x201d;), and bear interest at
            the Applicable Federal Rate for short term loans, plus two (2%) percent. Principal and interest on the Promissory Notes are due on or
            before March 31, 2026. Only with the consent of the Lender, may the Promissory Notes be prepaid, in whole or in part, at any time
            without premium or penalty, but with interest on the amount or amounts prepaid.&lt;br/&gt;
            &lt;br/&gt;
            At the election of Lender, the principal and accrued interest on Promissory Note(s) may be converted into the number of shares of the Company&#x2019;s Common Stock equal to the amount of principal and accrued interest on such Promissory Note divided
            by the price equal to the closing price of the Common Stock on the date of such Promissory Note, but in no event less than $3.00 per
            share.&lt;br/&gt;
            &lt;br/&gt;
            In connection with the November 2024 Supplemental Credit Agreement, the Company agreed to issue the Lender warrants to purchase up to an aggregate of 120,000
            shares of the Company&#x2019;s common stock, par value $0.001 per share (collectively, the &#x201c;Warrants&#x201d;). The Company shall issue to the
            Lender Warrants ratably, upon borrowings under the November 2024 Supplemental Line of Credit, with exercise prices equal to 150% of
            the closing price of the Company&#x2019;s common Stock on the date of the Promissory Note evidencing such draw, but in no event more than $10.00
            per share nor less than $3.00 per share. The Warrants expire on July 31, 2029.&lt;br/&gt;
            &lt;br/&gt;
          &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 27pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;The fair value
            of warrants that vest in the future based on borrowings will be computed when those borrowings occur and amortized over the remaining period through March 31, 2026&lt;/span&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;.&lt;/span&gt; &lt;/div&gt;
</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="c20220725_CreditFacilityAxis_LineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="-5"
      id="Fact_cc679c0619224860929208e53cf67b89"
      unitRef="U001">60000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease
      contextRef="c20220725to20220725_CreditFacilityAxis_LineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="2"
      id="Fact_105309e78a754ec0bd05e8cbddbfcdbd"
      unitRef="U007">0.02</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="c20220725to20220725_CreditFacilityAxis_LineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      id="Fact_515a98fb5d9a4cfd9e5bc7e88231ce66">2026-01-31</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:SharePrice
      contextRef="c20220725_CreditFacilityAxis_LineOfCreditMember_RangeAxis_MinimumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="2"
      id="Fact_5674f5a4bd274d8c9be8ee511d03e6c3"
      unitRef="U003">3</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c20220725_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_0433c06a5f134624bf0dba2517c50f51"
      unitRef="U002">1700000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c20220725_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="3"
      id="Fact_c082f17af9f04f639eda3a4150c0681e"
      unitRef="U003">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c20220725_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_0d6e4cdb53494b73b155dc16135bfe0f"
      unitRef="U002">500000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20220725_FinancialInstrumentAxis_WarrantMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="2"
      id="Fact_acbbc5a67f504b45a93b478aee53a5b9"
      unitRef="U003">5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <galt:ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c20220725to20220725_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_9c901907c05d456486c612a5c565e01c"
      unitRef="U002">1200000</galt:ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <galt:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock
      contextRef="c20220725_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="2"
      id="Fact_8d4f93f0ebb747aa913c3881f299f7d8"
      unitRef="U007">1.50</galt:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock>
    <us-gaap:SharePrice
      contextRef="c20220725_CreditFacilityAxis_LineOfCreditMember_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="2"
      id="Fact_ad87526836f24f85a9c929494e641880"
      unitRef="U003">10</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="c20220725_CreditFacilityAxis_LineOfCreditMember_RangeAxis_MinimumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="2"
      id="Fact_15b2d16b684f4b698a9263e058743d4f"
      unitRef="U003">3</us-gaap:SharePrice>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="c20241231_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      id="Fact_cc09fb2bced041af9551a01bc724faec">2029-07-31</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c20220725_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_29c39ff47cde42e2951903663b2cfb24"
      unitRef="U002">500000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <galt:IssuanceOfWarrantsValue
      contextRef="c20220725to20220725_FinancialInstrumentAxis_WarrantMember"
      decimals="0"
      id="Fact_43bb8efbb53f48ebbb90f63ea96715f0"
      unitRef="U001">738000</galt:IssuanceOfWarrantsValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20240101to20241231_FinancialInstrumentAxis_WarrantMember"
      id="Fact_3639be65b72442cab33d950b3cad0939">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c20240101to20241231_FinancialInstrumentAxis_WarrantMember"
      decimals="2"
      id="Fact_c87237d5879a4e3a8ee527b52422f4ac"
      unitRef="U007">0.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20240101to20241231_FinancialInstrumentAxis_WarrantMember"
      decimals="4"
      id="Fact_e91b98af19404d3b8d4105b7c4ae931b"
      unitRef="U007">0.0319</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c20240101to20241231_FinancialInstrumentAxis_WarrantMember"
      decimals="0"
      id="Fact_80d8c78343114658b04fb8497fbba222"
      unitRef="U007">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:InterestExpense
      contextRef="c20240101to20241231_FinancialInstrumentAxis_WarrantMember"
      decimals="0"
      id="Fact_d80b19aa74e54ef9b3dff4a7627a1995"
      unitRef="U001">210000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="c20230101to20231231_FinancialInstrumentAxis_WarrantMember"
      decimals="0"
      id="Fact_f6e78f124544485da04766cbde136660"
      unitRef="U001">209000</us-gaap:InterestExpense>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="c20221219to20221219_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_December2022PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="-6"
      id="Fact_b14e29a4d38848e8b6d6abaf9333c933"
      unitRef="U001">10000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="c20221219to20221219_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_December2022PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="4"
      id="Fact_caf91ed0091f4437b1d616fff494280c"
      unitRef="U007">0.0646</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20221219_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_December2022PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="4"
      id="Fact_18eecdce86d84ea5be10e6e79d18f0ed"
      unitRef="U007">0.0446</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease
      contextRef="c20221219to20221219_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_December2022PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="2"
      id="Fact_37bfa9bc783c4840a4a6035bac478eec"
      unitRef="U007">0.02</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c20221219_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_December2022PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="3"
      id="Fact_235ecaee6b4042dc9fb3665d3aec8f51"
      unitRef="U007">0.071</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <galt:DebtInstrumentAccruedInterest
      contextRef="c20241231_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_December2022PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="0"
      id="Fact_2fb9e997d1a8423a9f79fbd5c0a063e5"
      unitRef="U001">1399000</galt:DebtInstrumentAccruedInterest>
    <galt:DebtInstrumentAccruedInterest
      contextRef="c20231231_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_December2022PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="0"
      id="Fact_1392d10fc9ce449ba93d8d326525b1b5"
      unitRef="U001">688000</galt:DebtInstrumentAccruedInterest>
    <us-gaap:SharePrice
      contextRef="c20241231_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_December2022PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="2"
      id="Fact_9ac9c53006c04474948abdc9608b4d3b"
      unitRef="U003">3</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c20221219_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_56475f877106482092f1e7035815f429"
      unitRef="U002">200000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20221219_FinancialInstrumentAxis_WarrantOneMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="2"
      id="Fact_3a4184e29009404197199281b7c6818a"
      unitRef="U003">3</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c20221219_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_704ab1f3db034807a66583246e0c20eb"
      unitRef="U002">200000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <galt:IssuanceOfWarrantsValue
      contextRef="c20221219to20221219_FinancialInstrumentAxis_WarrantOneMember"
      decimals="0"
      id="Fact_fbdf0517070c45cb851d10160ef1a368"
      unitRef="U001">160780</galt:IssuanceOfWarrantsValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20240101to20241231_FinancialInstrumentAxis_WarrantOneMember"
      id="Fact_9a29b4ed515840339e61175da08639fc">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c20240101to20241231_FinancialInstrumentAxis_WarrantOneMember"
      decimals="2"
      id="Fact_bc319ac9be244c1b8ea73379a20e73e1"
      unitRef="U007">0.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20240101to20241231_FinancialInstrumentAxis_WarrantOneMember"
      decimals="4"
      id="Fact_0ad516faf8ab4a338648f5fa77bd526e"
      unitRef="U007">0.0406</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c20240101to20241231_FinancialInstrumentAxis_WarrantOneMember"
      decimals="0"
      id="Fact_f764f993608240be89b74262f650cf81"
      unitRef="U007">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:InterestExpense
      contextRef="c20240101to20241231_FinancialInstrumentAxis_WarrantOneMember"
      decimals="0"
      id="Fact_471becca59b9466393f87bdf441f939e"
      unitRef="U001">52000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="c20230101to20231231_FinancialInstrumentAxis_WarrantOneMember"
      decimals="0"
      id="Fact_9fa3fa25e4f04e4091e9bd1bdfbc6cd5"
      unitRef="U001">51000</us-gaap:InterestExpense>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="c20240101to20240331_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_March2023PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="-6"
      id="Fact_15c0524cc1cb43dbbbc345914f4730ae"
      unitRef="U001">10000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="c20240101to20240331_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_March2023PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="4"
      id="Fact_0e9cfc0c53884d04b0ff66104b8345d3"
      unitRef="U007">0.0641</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20240331_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_March2023PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="4"
      id="Fact_f8eff09b77f34922beec911833f92947"
      unitRef="U007">0.0441</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease
      contextRef="c20240101to20240331_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_March2023PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="2"
      id="Fact_cf2e33e51cee41459f6b87b711551248"
      unitRef="U007">0.02</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c20240331_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_March2023PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="3"
      id="Fact_6d5a347a2b154075b9dbd8b05e7d190e"
      unitRef="U007">0.071</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <galt:DebtInstrumentAccruedInterest
      contextRef="c20241231_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_March2023PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="0"
      id="Fact_d8015e6a620a4d1ba9aee9de581beb15"
      unitRef="U001">1184000</galt:DebtInstrumentAccruedInterest>
    <galt:DebtInstrumentAccruedInterest
      contextRef="c20231231_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_March2023PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="0"
      id="Fact_f36d54c08fb349a0a6b4306526c683fc"
      unitRef="U001">491000</galt:DebtInstrumentAccruedInterest>
    <us-gaap:SharePrice
      contextRef="c20240331_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_March2023PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="2"
      id="Fact_10a7a1655d0f4189b39d9ffc3e20e3d5"
      unitRef="U003">3</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c20240331_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_f211e39768754cefa6c47447ed2ad21c"
      unitRef="U002">200000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20240331_FinancialInstrumentAxis_WarrantOneMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="INF"
      id="Fact_ffe6c77e69874c94981d6ca7a5fabc18"
      unitRef="U003">3.26</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c20240331_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_1349aa03c8b24f1f834c4c76ae613b56"
      unitRef="U002">200000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <galt:IssuanceOfWarrantsValue
      contextRef="c20240101to20240331_FinancialInstrumentAxis_WarrantTwoMember"
      decimals="0"
      id="Fact_2f83026146bc41949440b89129a6701d"
      unitRef="U001">296680</galt:IssuanceOfWarrantsValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20240101to20240331_FinancialInstrumentAxis_WarrantTwoMember"
      id="Fact_fb85ebb1b82c47509f86890d6d204188">P6Y3M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c20240101to20240331_FinancialInstrumentAxis_WarrantTwoMember"
      decimals="2"
      id="Fact_ac0c7e70fe4045c88ef41173ea5274a1"
      unitRef="U007">0.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20240101to20240331_FinancialInstrumentAxis_WarrantTwoMember"
      decimals="4"
      id="Fact_042c77574b9b4093bde8de332d18896f"
      unitRef="U007">0.0394</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c20240101to20240331_FinancialInstrumentAxis_WarrantTwoMember"
      decimals="0"
      id="Fact_fd1b733b711b4be180d461cc9d749950"
      unitRef="U007">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:InterestExpense
      contextRef="c20240101to20241231_FinancialInstrumentAxis_WarrantTwoMember"
      decimals="0"
      id="Fact_985cd3355f4a439f8f5eeb2306f8d628"
      unitRef="U001">105000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="c20230101to20231231_FinancialInstrumentAxis_WarrantTwoMember"
      decimals="0"
      id="Fact_007455f032e44114b468fe5cb5fb8ef3"
      unitRef="U001">79000</us-gaap:InterestExpense>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="c20240401to20240630_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_June2023PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="-6"
      id="Fact_4cef56d85a854085a9f7b9c8021c156a"
      unitRef="U001">10000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="c20240401to20240630_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_June2023PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="4"
      id="Fact_624e0428d85a47bc8606ed0e52135472"
      unitRef="U007">0.0634</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20240630_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_June2023PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="4"
      id="Fact_9318f1177e7a4a1ea388a11290d55043"
      unitRef="U007">0.0434</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease
      contextRef="c20240401to20240630_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_June2023PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="2"
      id="Fact_57aa1478842b41f0af6d5d7f19ac5b7b"
      unitRef="U007">0.02</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c20240630_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_June2023PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="3"
      id="Fact_843db755d8d74901b9f38aa2a9eea6c8"
      unitRef="U007">0.071</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <galt:DebtInstrumentAccruedInterest
      contextRef="c20241231_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_June2023PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="0"
      id="Fact_a2766e28f06d42d4b44cbd98187db102"
      unitRef="U001">995000</galt:DebtInstrumentAccruedInterest>
    <galt:DebtInstrumentAccruedInterest
      contextRef="c20231231_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_June2023PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="0"
      id="Fact_564d96dd946b4fb7a1325da9b98df16b"
      unitRef="U001">321000</galt:DebtInstrumentAccruedInterest>
    <us-gaap:SharePrice
      contextRef="c20240630_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_June2023PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="2"
      id="Fact_5364a42b75c3445baba469ba16fe12a1"
      unitRef="U003">3</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c20240630_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_177bcd99ce64480caff658a6c68a227c"
      unitRef="U002">200000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20240630_FinancialInstrumentAxis_WarrantOneMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="2"
      id="Fact_2ce41b16367c4f2fb20a7f1db5c6b078"
      unitRef="U003">3</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c20240630_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_ad8d7ad3ff9c4e93ab0ddd9069229fd4"
      unitRef="U002">200000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <galt:IssuanceOfWarrantsValue
      contextRef="c20240401to20240630_FinancialInstrumentAxis_WarrantTwoMember"
      decimals="0"
      id="Fact_ce29850fde7e4294b812b8fba178395a"
      unitRef="U001">179920</galt:IssuanceOfWarrantsValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20240401to20240630_FinancialInstrumentAxis_WarrantTwoMember"
      id="Fact_c7fd4d77cf96462f8d11a69098b7ae4b">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c20240401to20240630_FinancialInstrumentAxis_WarrantTwoMember"
      decimals="2"
      id="Fact_3f15bc1fe1624b77b39a0fbd47ce2a1d"
      unitRef="U007">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20240401to20240630_FinancialInstrumentAxis_WarrantTwoMember"
      decimals="4"
      id="Fact_0bda8c4cbc30420aa11d1c97e4ff8e50"
      unitRef="U007">0.0359</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c20240401to20240630_FinancialInstrumentAxis_WarrantTwoMember"
      decimals="0"
      id="Fact_5aa88eccb1e64a4a984bcc140129b075"
      unitRef="U007">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:InterestExpense
      contextRef="c20240101to20241231_FinancialInstrumentAxis_WarrantThreeMember"
      decimals="0"
      id="Fact_a8cd74c23d3047be8391b16ce9415686"
      unitRef="U001">69000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="c20230101to20231231_FinancialInstrumentAxis_WarrantThreeMember"
      decimals="0"
      id="Fact_9687622b9cc84d488f38a0c7e0b778fd"
      unitRef="U001">35000</us-gaap:InterestExpense>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="c20231229to20231229_CreditFacilityAxis_LineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="-6"
      id="Fact_9357a1c556be49f9878c3a9601b94b96"
      unitRef="U001">10000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="c20231229to20231229_CreditFacilityAxis_LineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="4"
      id="Fact_fdcefb3ea87d42de8b98f94ef4f770ca"
      unitRef="U007">0.0713</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20231229_CreditFacilityAxis_LineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="4"
      id="Fact_f529cff972994f10bc4f5d54fa0ae5aa"
      unitRef="U007">0.0513</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease
      contextRef="c20231229to20231229_CreditFacilityAxis_LineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="2"
      id="Fact_6cdeebd12c9f4b9f8d91652c13a65125"
      unitRef="U007">0.02</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c20231229_CreditFacilityAxis_LineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="3"
      id="Fact_7dae9f0d8bcd4e45ac693d93a701c720"
      unitRef="U007">0.075</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <galt:DebtInstrumentAccruedInterest
      contextRef="c20241231_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_December2023PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="0"
      id="Fact_380ca38cc3084f15be9f05dc8add13c0"
      unitRef="U001">737000</galt:DebtInstrumentAccruedInterest>
    <us-gaap:SharePrice
      contextRef="c20231229_CreditFacilityAxis_LineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="2"
      id="Fact_f5c907ffd3ae4f198b970673cd180a60"
      unitRef="U003">3</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c20231229_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_d4f215a00e5a4731a5d3bf8bd8296356"
      unitRef="U002">200000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20231229_FinancialInstrumentAxis_WarrantOneMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="2"
      id="Fact_b78e97ec22ac4b43abe23bb17b85cc33"
      unitRef="U003">3</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c20231229_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_79084d0a115346ce9a85481a65721f3a"
      unitRef="U002">200000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <galt:IssuanceOfWarrantsValue
      contextRef="c20240101to20241231_FinancialInstrumentAxis_WarrantTwoMember"
      decimals="0"
      id="Fact_2a53c0f389d540f985c1a0f289a9f7dc"
      unitRef="U001">193745</galt:IssuanceOfWarrantsValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20240101to20241231_FinancialInstrumentAxis_WarrantTwoMember"
      id="Fact_dd7fefba05924359a6dabb52a2bf41ba">P5Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c20240101to20241231_FinancialInstrumentAxis_WarrantTwoMember"
      decimals="2"
      id="Fact_03b51062ec8145a09fb81a71b9b86372"
      unitRef="U007">0.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20240101to20241231_FinancialInstrumentAxis_WarrantTwoMember"
      decimals="4"
      id="Fact_9fae9aaa15d24209bcbd56193d2792b0"
      unitRef="U007">0.0449</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c20240101to20241231_FinancialInstrumentAxis_WarrantTwoMember"
      decimals="0"
      id="Fact_7fa18f9d270948aeae04d9ea95630323"
      unitRef="U007">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:InterestExpense
      contextRef="c20240101to20241231_FinancialInstrumentAxis_WarrantFourMember"
      decimals="0"
      id="Fact_8d2f05434bd6496da4e9a60c272b6213"
      unitRef="U001">93000</us-gaap:InterestExpense>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="c20240329to20240329_CreditFacilityAxis_LineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="-6"
      id="Fact_a20f4ca8985a4c7fb2d48432cdacdd57"
      unitRef="U001">10000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="c20240329to20240329_CreditFacilityAxis_LineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="4"
      id="Fact_130f53eeeff049f58ae5f59abd3da1c5"
      unitRef="U007">0.0662</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20240329_CreditFacilityAxis_LineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="4"
      id="Fact_08fd1fd96c09404cb2ac4d118d024c88"
      unitRef="U007">0.0462</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease
      contextRef="c20240329to20240329_CreditFacilityAxis_LineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="2"
      id="Fact_da26bc59051c48cca52a299fae599a10"
      unitRef="U007">0.02</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c20240329_CreditFacilityAxis_LineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="3"
      id="Fact_9db845501e6248baa0e7d795be0553db"
      unitRef="U007">0.071</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <galt:DebtInstrumentAccruedInterest
      contextRef="c20241231_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_March24PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="0"
      id="Fact_b7bf449b11804119ae1b798bf74fd7eb"
      unitRef="U001">508000</galt:DebtInstrumentAccruedInterest>
    <us-gaap:SharePrice
      contextRef="c20240329_CreditFacilityAxis_LineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="2"
      id="Fact_193532f6e5f048ec9129a4b30d363ec1"
      unitRef="U003">3</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c20240329_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_e87613f788be4e1082b445c00da6179a"
      unitRef="U002">200000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20240329_FinancialInstrumentAxis_WarrantOneMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="2"
      id="Fact_2891974e8668402ab58883ead3ea4e7f"
      unitRef="U003">3.59</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c20240329_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_2fc48bc60f0f4c47ba540cabd7268587"
      unitRef="U002">200000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <galt:IssuanceOfWarrantsValue
      contextRef="c20240329to20240329_FinancialInstrumentAxis_WarrantTwoMember"
      decimals="0"
      id="Fact_b628e110ed2f4e1da3da56c72a88544f"
      unitRef="U001">277389</galt:IssuanceOfWarrantsValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20240329to20240329_FinancialInstrumentAxis_WarrantTwoMember"
      id="Fact_756d043a6f6f409697a5aa56cd8ee8e1">P5Y3M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c20240329to20240329_FinancialInstrumentAxis_WarrantTwoMember"
      decimals="2"
      id="Fact_4a6a84888dbe427aaf8e0e5ed2e2105a"
      unitRef="U007">0.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20240329to20240329_FinancialInstrumentAxis_WarrantTwoMember"
      decimals="4"
      id="Fact_9e956f4a94fe4e83ab2319f9b4541fef"
      unitRef="U007">0.0419</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c20240329to20240329_FinancialInstrumentAxis_WarrantTwoMember"
      decimals="0"
      id="Fact_e8724436b55240bb95ade043cb5c9045"
      unitRef="U007">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:InterestExpense
      contextRef="c20240101to20241231_FinancialInstrumentAxis_WarrantFiveMember"
      decimals="0"
      id="Fact_e4a2739536854c339cf623e28976cf59"
      unitRef="U001">114000</us-gaap:InterestExpense>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="c20240628to20240628_CreditFacilityAxis_LineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="-6"
      id="Fact_54f7ec8479224f7daaab976736346c13"
      unitRef="U001">10000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="c20240628to20240628_CreditFacilityAxis_LineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="4"
      id="Fact_3b5d816fe39f406aa2e079eac9b8e91e"
      unitRef="U007">0.0701</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20240628_CreditFacilityAxis_LineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="4"
      id="Fact_815e6e97075f4fb5b5650bd05ab99ed0"
      unitRef="U007">0.0501</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease
      contextRef="c20240628to20240628_CreditFacilityAxis_LineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="2"
      id="Fact_af695518208243228662239cc8f3d646"
      unitRef="U007">0.02</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c20240628_CreditFacilityAxis_LineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="3"
      id="Fact_c765b744e64446e7bc71b88094244aee"
      unitRef="U007">0.074</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <galt:DebtInstrumentAccruedInterest
      contextRef="c20241231_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_June2024PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="0"
      id="Fact_aa5f123e799542f294dcc165f172a8d9"
      unitRef="U001">336000</galt:DebtInstrumentAccruedInterest>
    <us-gaap:SharePrice
      contextRef="c20240628_CreditFacilityAxis_LineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="2"
      id="Fact_7bbc2f9896bc4abd993f4d3534ca0404"
      unitRef="U003">3</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c20240628_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_fa261d98dd364fe7a0ff6dd27af01284"
      unitRef="U002">200000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20240628_FinancialInstrumentAxis_WarrantOneMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="2"
      id="Fact_540a8ce843e44611a4dfb0733b52bca3"
      unitRef="U003">3.39</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c20240628_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_3ad88f9bf22848b1a2dea8d4ffd1c24f"
      unitRef="U002">200000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <galt:IssuanceOfWarrantsValue
      contextRef="c20240628to20240628_FinancialInstrumentAxis_WarrantTwoMember"
      decimals="0"
      id="Fact_f179da1a658d49d49032d5502e54fdde"
      unitRef="U001">260000</galt:IssuanceOfWarrantsValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20240628to20240628_FinancialInstrumentAxis_WarrantTwoMember"
      id="Fact_103592e463894dccacff65dd40192a9d">P5Y10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c20240628to20240628_FinancialInstrumentAxis_WarrantTwoMember"
      decimals="2"
      id="Fact_eec407a2d31041f89f1164a1828452df"
      unitRef="U007">0.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20240628to20240628_FinancialInstrumentAxis_WarrantTwoMember"
      decimals="4"
      id="Fact_bfa969dd15914a1bac1b41b0d9ab2e81"
      unitRef="U007">0.0429</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c20240628to20240628_FinancialInstrumentAxis_WarrantTwoMember"
      decimals="0"
      id="Fact_7ae47251fb0b4c679ebf4c54faa10917"
      unitRef="U007">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:InterestExpense
      contextRef="c20240101to20241231_FinancialInstrumentAxis_WarrantSixMember"
      decimals="0"
      id="Fact_ba1fea2732d04e629f0ef9669e1afd00"
      unitRef="U001">82000</us-gaap:InterestExpense>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="c20240329_CreditFacilityAxis_SupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="-5"
      id="Fact_f5bebd42cebe460080d9a2fcb28f1da2"
      unitRef="U001">10000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease
      contextRef="c20240329to20240329_CreditFacilityAxis_SupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="2"
      id="Fact_259c9047bc634ab19e9c93c82b5f3fd7"
      unitRef="U007">0.02</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="c20240101to20241231_CreditFacilityAxis_SupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      id="Fact_eedf2a4911b042ea87889cb05c3e4ede">2026-01-31</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:SharePrice
      contextRef="c20241231_CreditFacilityAxis_SupplementalLineOfCreditMember_RangeAxis_MinimumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="2"
      id="Fact_e42cd08732184d5cb80cb9e3c9ca98e6"
      unitRef="U003">3</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c20240930_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_0a55fc819c8747fd84f78df0a360ff1f"
      unitRef="U002">200000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c20241231_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember"
      decimals="3"
      id="Fact_e450fc2a6a3146ab9f48820af2db60fb"
      unitRef="U003">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <galt:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock
      contextRef="c20241231_CreditFacilityAxis_SupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="2"
      id="Fact_6e0674f97fcc49eb802d073570d5a854"
      unitRef="U007">1.50</galt:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock>
    <us-gaap:SharePrice
      contextRef="c20241231_CreditFacilityAxis_SupplementalLineOfCreditMember_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="2"
      id="Fact_ede594833f7b477aad6d0e79e4d12b83"
      unitRef="U003">10</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="c20241231_CreditFacilityAxis_SupplementalLineOfCreditMember_RangeAxis_MinimumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="2"
      id="Fact_23b803c794124fd6884b9753780bcbee"
      unitRef="U003">3</us-gaap:SharePrice>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="c20241231_CreditFacilityAxis_SupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      id="Fact_f1c8bc115779412baa4ac4369924b2a6">2029-07-31</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="c20240328to20240930_CreditFacilityAxis_SupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="-6"
      id="Fact_283453b743764cfd90e1f4dfef44512c"
      unitRef="U001">10000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="c20240328to20240930_CreditFacilityAxis_SupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="4"
      id="Fact_c6a0b92767354cbc95041d28579c1cd2"
      unitRef="U007">0.0613</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20240930_CreditFacilityAxis_SupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="4"
      id="Fact_d3c9a7d573ce40c4b26cc558c4dec4f0"
      unitRef="U007">0.0501</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease
      contextRef="c20240328to20240930_CreditFacilityAxis_SupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="2"
      id="Fact_2bbc331360b04168bf701ef79654e605"
      unitRef="U007">0.02</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c20240930_CreditFacilityAxis_SupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="3"
      id="Fact_039d3158147341a788fb5e8f1a57bd92"
      unitRef="U007">0.064</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <galt:DebtInstrumentAccruedInterest
      contextRef="c20241231_CreditFacilityAxis_LineOfCreditMember_LongtermDebtTypeAxis_September2024PromissoryNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="0"
      id="Fact_50bb00cc28c74773981b1e94e59b6863"
      unitRef="U001">154000</galt:DebtInstrumentAccruedInterest>
    <us-gaap:SharePrice
      contextRef="c20241231_CreditFacilityAxis_SupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="2"
      id="Fact_aafca8e464e54c89be5858bfbace1b3d"
      unitRef="U003">3</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c20240930_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_7df0142939a544d49d44a8f7cb7fc6e6"
      unitRef="U002">200000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20240930_CreditFacilityAxis_SupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="2"
      id="Fact_e04f7d3884044241bf63974da5acfc96"
      unitRef="U003">4.13</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c20240930_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_9f7e10d598b141fa967dbffbb4054896"
      unitRef="U002">200000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <galt:IssuanceOfWarrantsValue
      contextRef="c20240328to20240930_CreditFacilityAxis_SupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="0"
      id="Fact_c84704d05d50419589e0ea7b094fb0db"
      unitRef="U001">307780</galt:IssuanceOfWarrantsValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20240328to20240930_FinancialInstrumentAxis_WarrantMember"
      id="Fact_23b0dbe1354b43cc8cc2795574a1326c">P4Y9M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c20240328to20240930_FinancialInstrumentAxis_WarrantMember"
      decimals="2"
      id="Fact_b1fa1b2bd86e4223a72fd80a5a914fe4"
      unitRef="U007">0.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20240328to20240930_FinancialInstrumentAxis_WarrantMember"
      decimals="4"
      id="Fact_3fe314b7ed9e42c4ba2ea76f03be96a2"
      unitRef="U007">0.0358</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c20240328to20240930_FinancialInstrumentAxis_WarrantMember"
      decimals="0"
      id="Fact_e3e44c5ed695464cae89a8ad91e787f1"
      unitRef="U007">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:InterestExpense
      contextRef="c20240101to20241231_FinancialInstrumentAxis_WarrantSevenMember"
      decimals="0"
      id="Fact_9bcd6ad6ba454ec1afc7b8e7f8460b1f"
      unitRef="U001">58000</us-gaap:InterestExpense>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="c20241114_CreditFacilityAxis_AdditionalSupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="-5"
      id="Fact_bf7e4ae665dc47c2a99b70ad28ba9e23"
      unitRef="U001">6000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease
      contextRef="c20241113to20241114_CreditFacilityAxis_AdditionalSupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="2"
      id="Fact_90ecfb0e34bc4528b60dad070f27ef90"
      unitRef="U007">0.02</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="c20241113to20241114_CreditFacilityAxis_AdditionalSupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      id="Fact_418538ee6d074b93b450da7897f9e893">2026-03-31</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:SharePrice
      contextRef="c20241114_CreditFacilityAxis_AdditionalSupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="2"
      id="Fact_047132e3c7644d23aef1a5ff395b79de"
      unitRef="U003">3</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c20241114_CreditFacilityAxis_AdditionalSupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="0"
      id="Fact_60651c293b444296b2c8a3de5301fa28"
      unitRef="U002">120000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c20241114_CreditFacilityAxis_AdditionalSupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="3"
      id="Fact_e83352653ae745c08f525a1403317f69"
      unitRef="U003">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <galt:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock
      contextRef="c20241114_CreditFacilityAxis_AdditionalSupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="2"
      id="Fact_efe631f0c9324fb3aca46e8845d42761"
      unitRef="U007">1.50</galt:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock>
    <us-gaap:SharePrice
      contextRef="c20241114_CreditFacilityAxis_AdditionalSupplementalLineOfCreditMember_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="2"
      id="Fact_c5eeaa72191c4b35a2ff175d00fa6e3b"
      unitRef="U003">10</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="c20241114_CreditFacilityAxis_AdditionalSupplementalLineOfCreditMember_RangeAxis_MinimumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="2"
      id="Fact_ab68cab89a6d43df86f3f79fff7748a8"
      unitRef="U003">3</us-gaap:SharePrice>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="c20241114_CreditFacilityAxis_AdditionalSupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      id="Fact_f13a8ea23728438f982ce0f37762c27b">2029-07-31</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="c20240101to20241231"
      id="Text_0a4dcc0fc2a448d9a1c9226b0d4f33ea">
&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 27.05pt; vertical-align: top; font-weight: bold;"&gt;11.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
              &lt;div style="font-weight: bold;"&gt;Loss Per Share&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Basic net loss per common share is computed by dividing the net loss available to common stockholders by the weighted average number of common shares outstanding
        during the period. For the years ended December 31, 2024 and 2023, as the Company was in a net loss position, the diluted loss per share computations for such periods did not assume the exercise of warrants and stock options or the conversion of
        Convertible Notes, or the conversion of convertible preferred stock as they would have had an anti-dilutive effect on loss per share.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as of December 31, 2024 and 2023
        as the inclusion thereof would have been anti-dilutive:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 27pt;"&gt;
        &lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Year Ended&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;2024&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;(Shares)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;2023&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;(Shares)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Warrants to purchase shares of common stock&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;9,595,940&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;9,256,493&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Options to purchase shares of common stock&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;6,854,758&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;6,333,841&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Shares of common stock issuable upon conversion of convertible notes payable &#x2013; related party&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;7,024,053&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;6,418,913&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: -9pt; margin-left: 9pt; width: 76%;" valign="bottom"&gt;
                &lt;div style="margin-left: 9pt;"&gt;Shares of common stock issuable upon conversion of convertible line of credit &#x2013; related party&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;25,103,873&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;13,833,356&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Shares of common stock issuable upon conversion preferred stock&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;499,174&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;499,174&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                &lt;div style="font-weight: bold;"&gt;49,077,798&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-weight: bold; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-weight: bold; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;36,341,777&lt;/td&gt;

    &lt;td colspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
         &lt;/div&gt;
</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="c20240101to20241231"
      id="Text_eba6844b00424b8993ec13233ebf31fb">
&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as of December 31, 2024 and 2023
        as the inclusion thereof would have been anti-dilutive:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 27pt;"&gt;
        &lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Year Ended&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;2024&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;(Shares)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;2023&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;(Shares)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Warrants to purchase shares of common stock&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;9,595,940&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;9,256,493&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Options to purchase shares of common stock&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;6,854,758&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;6,333,841&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Shares of common stock issuable upon conversion of convertible notes payable &#x2013; related party&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;7,024,053&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;6,418,913&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: -9pt; margin-left: 9pt; width: 76%;" valign="bottom"&gt;
                &lt;div style="margin-left: 9pt;"&gt;Shares of common stock issuable upon conversion of convertible line of credit &#x2013; related party&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;25,103,873&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;13,833,356&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Shares of common stock issuable upon conversion preferred stock&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;499,174&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;499,174&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                &lt;div style="font-weight: bold;"&gt;49,077,798&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-weight: bold; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-weight: bold; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;36,341,777&lt;/td&gt;

    &lt;td colspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
         &lt;/div&gt;
</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20240101to20241231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember"
      decimals="0"
      id="Fact_559a2289b9854e3db5fd0ade080bbae1"
      unitRef="U002">9595940</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20230101to20231231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember"
      decimals="0"
      id="Fact_68cdc9c4fd1443dcb710acf1c5e993fb"
      unitRef="U002">9256493</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20240101to20241231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_c31ab18c70664f64810cc99208e17d39"
      unitRef="U002">6854758</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20230101to20231231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_c1ff56679789410e933e8d8e20085f18"
      unitRef="U002">6333841</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20240101to20241231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertibleNotesPayableMember"
      decimals="0"
      id="Fact_4c35a707e5ce4a0dbef6c550988ed219"
      unitRef="U002">7024053</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20230101to20231231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertibleNotesPayableMember"
      decimals="0"
      id="Fact_39645a82ac344c708a29211ce786489f"
      unitRef="U002">6418913</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20240101to20241231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_LineOfCreditMember"
      decimals="0"
      id="Fact_5787b9113e9c4cd68d3c7d60ef7d7bd1"
      unitRef="U002">25103873</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20230101to20231231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_LineOfCreditMember"
      decimals="0"
      id="Fact_89a0759842e049f490358efbad4670bb"
      unitRef="U002">13833356</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20240101to20241231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertiblePreferredStockMember"
      decimals="0"
      id="Fact_7f2a3a1851374078b3c0e7cff52fc23c"
      unitRef="U002">499174</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20230101to20231231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertiblePreferredStockMember"
      decimals="0"
      id="Fact_49a6b43274454e60b11c6cc12b7d5fa7"
      unitRef="U002">499174</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20240101to20241231"
      decimals="0"
      id="Fact_164b09d545cd482eb697102e12e33171"
      unitRef="U002">49077798</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20230101to20231231"
      decimals="0"
      id="Fact_6df2efca967040b584e7838464f50549"
      unitRef="U002">36341777</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="c20240101to20241231"
      id="Text_4e7485949ee24fa49fbc883acf1a4cb9">
&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 24.5pt; vertical-align: top; font-weight: bold; font-size: 10pt; font-family: 'Times New Roman';"&gt;12.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
              &lt;div style="font-weight: bold; font-size: 10pt; font-family: 'Times New Roman';"&gt;Commitments and Contingencies&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div style="margin: 0px 0px 0px 12.25pt; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;"&gt;Lease Commitments&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company has one operating lease for its office
        space which was amended effective March 1, 2022 for a term of 38 months with no residual value guarantees or material restrictive
        covenants. The amended lease provided for free rent for the first &lt;span style="-sec-ix-hidden:Fact_5e16282e65184d8eabf15666ce8cae25"&gt;six and one-half months&lt;/span&gt; of the lease and continues the security
        deposit of $6,000. In addition to base rental payments included in the contractual obligations table below, the Company is responsible
        for our pro-rata share of the operating expenses for the building. Our lease cost for the years ended December 31, 2024 and 2023 was $44,000
        and $44,000, respectively, and is included in general and administrative expenses. As of December 31, 2024, the right to use lease asset
        consisted of $16,000 and is included in &lt;span style="-sec-ix-hidden:Fact_c96ca38e0f664780917ece0461c411fe"&gt;other assets&lt;/span&gt;. Also, at December 31, 2024, current lease liability of $19,000 is included in &lt;span style="-sec-ix-hidden:Fact_4b297d7d29a9481e88136db097de88dd"&gt;accrued expenses&lt;/span&gt;.&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160; &lt;span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;As of December 31, 2023, the right to use lease asset consisted of $46,000 and is included in &lt;span style="-sec-ix-hidden:Fact_2a011c7177224f80b904fcc70e46eb35"&gt;other assets&lt;/span&gt;.
            Also, at December 31, 2023, current lease liability of $46,000 is included in &lt;span style="-sec-ix-hidden:Fact_3bef161157d441a4b194359a2b8c08a3"&gt;accrued expenses&lt;/span&gt; and the noncurrent lease liability of $20,000 is included
            in &lt;span style="-sec-ix-hidden:Fact_47d32f393cdc43fc8f131674cf3a7b9b"&gt;other long term liabilities&lt;/span&gt;. &lt;/span&gt;The Company renewed its existing office space lease effective in March 2025 for twelve months at substantially the same terms.&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Maturity of operating lease as of December 31, 2024 in thousands:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div style="margin-left: 27pt;"&gt;
        &lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; font-size: 10pt; font-family: 'Times New Roman'; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;2025&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; font-size: 10pt; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;19&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-size: 10pt; font-family: 'Times New Roman';"&gt;Total&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;19&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-size: 10pt; font-family: 'Times New Roman';"&gt;Less imputed interest&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;-&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; padding-bottom: 4px;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-size: 10pt; font-family: 'Times New Roman';"&gt;Present value of lease liability&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;19&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
         &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The discount rate used in calculating the present value of the lease payments was 11%.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&lt;br/&gt;
      &lt;/span&gt;&lt;/div&gt;

&lt;div style="margin: 0px 0px 0px 12.25pt; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;"&gt;Legal Proceedings&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company records accruals for such contingencies to the extent that the Company concludes that their occurrence is probable and the related damages are estimable.
        There are no pending legal proceedings.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div style="margin: 0px 0px 0px 12.25pt; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;"&gt;Clinical Trial and Research Contingencies&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company has entered into agreements with contractors for research and development activities to further its product candidates. The contracts generally may be
        canceled at any time by providing thirty days&#x2019; notice. The Company is involved in a dispute with a contract vendor for clinical trial
        management services provided outside of the United States. The contract in question is a variable contract. The Company has accrued its estimate of the amount owed to the contract vendor. The contract vendor asserts that it is owed approximately $1 million more than the Company&#x2019;s estimate. The Company disagrees with the contract vendor&#x2019;s assertion, and did not accrue that additional amount at December 31, 2024.&lt;/div&gt;
</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <galt:NumberOfOperatingLeases
      contextRef="c20240101to20241231"
      decimals="INF"
      id="Fact_ee1cd955049140f191290f3906215d26"
      unitRef="U010">1</galt:NumberOfOperatingLeases>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="c20241231"
      id="Fact_bc8e5121386c449cb42c96fb0006aeed">P38M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:SecurityDeposit
      contextRef="c20241231"
      decimals="0"
      id="Fact_4feb5d9c5ba14a68ab7a2f38eeab835e"
      unitRef="U001">6000</us-gaap:SecurityDeposit>
    <us-gaap:OperatingLeaseCost
      contextRef="c20240101to20241231_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact_93e890deb7b5498299ad550b493e8984"
      unitRef="U001">44000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="c20230101to20231231_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact_a545e36dd95d498d9bcee651fcd253db"
      unitRef="U001">44000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="c20241231"
      decimals="0"
      id="Fact_a0d815a9f3ab4a57a0d2e4d7e588a6d1"
      unitRef="U001">16000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="c20241231"
      decimals="0"
      id="Fact_ef124626ace84ca9965aea16c95800a1"
      unitRef="U001">19000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="c20231231"
      decimals="0"
      id="Fact_ae28b17e68634613bdfcd4153a910a8d"
      unitRef="U001">46000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="c20231231"
      decimals="0"
      id="Fact_a0ec72fc9e2e4e90970f532543d9e93a"
      unitRef="U001">46000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="c20231231"
      decimals="0"
      id="Fact_a1ed0ae7a4514c2d9deed1609ac1032c"
      unitRef="U001">20000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="c20241231"
      id="Fact_2c2e81c0582f4fe993da5a46ff56f82c">P12M</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="c20240101to20241231"
      id="Text_7b8bcf17c4e34ac1a2f94d50bbe049a5">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Maturity of operating lease as of December 31, 2024 in thousands:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div style="margin-left: 27pt;"&gt;
        &lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; font-size: 10pt; font-family: 'Times New Roman'; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;2025&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; font-size: 10pt; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;19&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-size: 10pt; font-family: 'Times New Roman';"&gt;Total&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;19&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-size: 10pt; font-family: 'Times New Roman';"&gt;Less imputed interest&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;-&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; padding-bottom: 4px;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-size: 10pt; font-family: 'Times New Roman';"&gt;Present value of lease liability&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;19&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
         &lt;/div&gt;
</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="c20241231"
      decimals="-3"
      id="Fact_523f4a94f97544a6a992ed83f8da5fdf"
      unitRef="U001">19000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="c20241231"
      decimals="-3"
      id="Fact_fbee34a0e51d4c9cb06b2926e6404b71"
      unitRef="U001">19000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="c20241231"
      decimals="-3"
      id="Fact_2dbd53b5a092435b83526db1111fdacc"
      unitRef="U001">0</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="c20241231"
      decimals="-3"
      id="Fact_8b696bd79014406cac72ac553ba14099"
      unitRef="U001">19000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="c20241231"
      decimals="2"
      id="Fact_231e960a60b64de3afeefca00f9e7fec"
      unitRef="U007">0.11</us-gaap:LesseeOperatingLeaseDiscountRate>
    <galt:ContractCancelationNoticePeriod
      contextRef="c20240101to20241231"
      id="Fact_a01cb78d6e6b4d5b931a1c828378ef7e">P30D</galt:ContractCancelationNoticePeriod>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="c20241231"
      decimals="-6"
      id="Fact_8acf3564044746efb597b2cf35652234"
      unitRef="U001">1000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:LossContingencyRangeOfPossibleLossPortionNotAccrued
      contextRef="c20241231"
      decimals="-3"
      id="Fact_940c1fa3068842008393e607d27db558"
      unitRef="U001">0</us-gaap:LossContingencyRangeOfPossibleLossPortionNotAccrued>
    <us-gaap:InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock
      contextRef="c20240101to20241231"
      id="Text_47ed3e55fa604b15b7ff1fc7dffcc887">
&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 27.05pt; vertical-align: top; font-weight: bold;"&gt;13.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
              &lt;div style="font-weight: bold;"&gt;Galectin Sciences LLC&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt; In January 2014, we created Galectin Sciences, LLC (the &#x201c;LLC&#x201d; or &#x201c;Investee&#x201d;), a collaborative joint venture co-owned by SBH Sciences, Inc. (&#x201c;SBH&#x201d;), to research and
        develop small organic molecule inhibitors of galectin-3 for oral administration. The LLC was initially capitalized with a $400,000 cash
        investment to fund future research and development activities, which was provided by the Company, and specific in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;) contributed by SBH. The estimated fair value of the IPR&amp;amp;D contributed by SBH, on
        the date of contribution, was $400,000. Initially, the Company and SBH have a 50% equity ownership interest in the LLC, with neither party having control over the LLC. Accordingly, from inception through the fourth quarter of 2014, the Company accounted
        for its investment in the LLC using the equity method of accounting. Under the equity method of accounting, the Company&#x2019;s investment was initially recorded at cost with subsequent adjustments to the carrying value to recognize additional
        investments in or distributions from the Investee, as well as the Company&#x2019;s share of the Investee&#x2019;s earnings, losses and/or changes in capital. The estimated fair value of the IPR&amp;amp;D contributed to the LLC was immediately expensed upon
        contribution as there was no alternative future use available at the point of contribution. The operating agreement provides that if either party does not desire to contribute its equal share of funding required after the initial capitalization,
        then the other party, providing all of the funding, will have its ownership share increased in proportion to the total amount contributed from inception. In the fourth quarter of 2014, after the LLC had expended the $400,000 in cash, SBH decided not to contribute its share of the funding required. As a result, the Company contributed the $73,000 needed for the fourth quarter of 2014 expenses of the LLC and an additional $2,552,000 in total from 2015 through 2021. The Company contributed $350,000
        and $561,000 for the LLC expenses (recorded in research and development expenses) in 2024 and 2023, and SBH has contributed a total of $711,000 since 2014. As of December 31, 2024, the Company&#x2019;s ownership percentage in the LLC was 85.3%. The Company accounts for the interest in the LLC as a consolidated, less than wholly owned subsidiary. Because the LLC&#x2019;s equity is immaterial, the value of the
        non-controlling interest is also deemed to be immaterial. The Company&#x2019;s portion of the LLC&#x2019;s net loss for 2014, prior to the change in accounting discussed previously, was $400,000, which includes the Company&#x2019;s proportionate share of the non-cash charge associated with the contributed IPR&amp;amp;D of $200,000.&lt;/div&gt;
</us-gaap:InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="c20140101to20140131_OwnershipAxis_GalectinSciencesLLCMember"
      decimals="0"
      id="Fact_248b8c53384f49d7b55a1d7e23c0eb99"
      unitRef="U001">400000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure
      contextRef="c20140131_CounterpartyNameAxis_SBHSciencesIncMember_FiniteLivedIntangibleAssetsByMajorClassAxis_InProcessResearchAndDevelopmentMember_OwnershipAxis_GalectinSciencesLLCMember"
      decimals="0"
      id="Fact_34e5c7c950ad4135b33abe1f7702eee0"
      unitRef="U001">400000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="c20140131_CounterpartyNameAxis_SBHSciencesIncMember_OwnershipAxis_GalectinSciencesLLCMember"
      decimals="2"
      id="Fact_47874d14f02f4856a6c335ccc10fbcd4"
      unitRef="U007">0.50</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="c20141001to20141231_OwnershipAxis_GalectinSciencesLLCMember"
      decimals="0"
      id="Fact_c5d89040534e4766b7e2ae9ff930da01"
      unitRef="U001">400000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <galt:CapitalContributionExpense
      contextRef="c20141001to20141231_OwnershipAxis_GalectinSciencesLLCMember"
      decimals="0"
      id="Fact_16ec698acb62492d9ca13f5b5c588544"
      unitRef="U001">73000</galt:CapitalContributionExpense>
    <galt:CapitalContributionExpense
      contextRef="c20150101to20211231_OwnershipAxis_GalectinSciencesLLCMember"
      decimals="0"
      id="Fact_0f23c496f2f845e3accb8d4b4def7ad6"
      unitRef="U001">2552000</galt:CapitalContributionExpense>
    <galt:CapitalContributionExpense
      contextRef="c20240101to20241231_OwnershipAxis_GalectinSciencesLLCMember"
      decimals="0"
      id="Fact_fd0f9893cfeb4d3bafaa78a544258f05"
      unitRef="U001">350000</galt:CapitalContributionExpense>
    <galt:CapitalContributionExpense
      contextRef="c20230101to20231231_OwnershipAxis_GalectinSciencesLLCMember"
      decimals="0"
      id="Fact_37e8d103ecd64fe0a6d625cc6c6f9732"
      unitRef="U001">561000</galt:CapitalContributionExpense>
    <galt:CapitalContributionExpense
      contextRef="c20140101to20231231_CounterpartyNameAxis_SBHSciencesIncMember_OwnershipAxis_GalectinSciencesLLCMember"
      decimals="0"
      id="Fact_fc46d9c3c786410ca756397c72528520"
      unitRef="U001">711000</galt:CapitalContributionExpense>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="c20241231_OwnershipAxis_GalectinSciencesLLCMember"
      decimals="3"
      id="Fact_809981f6607847059facc6954c773dfb"
      unitRef="U007">0.853</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="c20140101to20141231_OwnershipAxis_GalectinSciencesLLCMember"
      decimals="0"
      id="Fact_49145d3d971e4b4fb3b0328c557c4e23"
      unitRef="U001">400000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <galt:NonCashChargeForResearchAndDevelopmentInProcess
      contextRef="c20140101to20141231_OwnershipAxis_GalectinSciencesLLCMember"
      decimals="0"
      id="Fact_f18eb5c55fd747c1b09bd703807d7130"
      unitRef="U001">200000</galt:NonCashChargeForResearchAndDevelopmentInProcess>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="c20240101to20241231"
      id="Text_030e959bff65416bac86157b76c44226">
&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 24.5pt; vertical-align: top; font-weight: bold;"&gt;14.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
              &lt;div style="font-weight: bold;"&gt;Income Taxes&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The components of the net deferred tax assets are as follows at December 31:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 27pt;"&gt;
        &lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt; 2024&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;2023&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Operating loss carryforwards&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;63,057&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;61,427&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Tax credit carryforwards&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;9,010&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;6,476&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Other temporary differences&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;18,276&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;10,533&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;90,343&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;78,436&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Less valuation allowance&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;(90,343&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;(78,436&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 4px;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Net deferred tax asset&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
         &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The primary factors affecting the Company&#x2019;s income tax rates were as follows:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 27pt;"&gt;
        &lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt; 2024&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;2023&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Tax benefit at U.S. statutory rates&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;(21&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;%)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;(21&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;%)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;State tax benefit&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;(2.5&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;%)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;(3.4&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;%)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Permanent differences&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;0.1&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;%&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;0.9&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;%&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Other&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;(4.0&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;%)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;2.3&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;%&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Changes in valuation allowance&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;27.4&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;%&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;21.2&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;%&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-weight: bold;"&gt;0&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-weight: bold;"&gt;%&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-weight: bold;"&gt;0&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-weight: bold;"&gt;%&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
         &lt;/div&gt;

&lt;div style="margin-left: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;As of December 31, 2024, the Company has federal and state net operating loss carryforwards &lt;span style="background-color: rgb(255, 255, 255);"&gt;totaling $131,579,000 and $137,878,000,
          respectively, which will never expire as a result of the 2017 Tax Act. As of December 31, 2023, the Company has federal and state net operating loss carryforwards totaling $120,055,000 and $102,003,000 respectively, which expire through &lt;span style="-sec-ix-hidden:Fact_f036db385a5043f9b416f31ccdd089ed"&gt;2037&lt;/span&gt;. In addition, the Company has federal and state research and development credits of $7,764,000 and $1,245,000,&lt;/span&gt; respectively, which expire through &lt;span style="-sec-ix-hidden:Fact_64f60f3069914649af3fc7ac5db90c6c"&gt;2042&lt;/span&gt;. Ownership changes, as defined by Section 382 of the Internal Revenue Code, may have limited the amount of net operating loss carryforwards that
        can be utilized annually to offset future taxable income. Past and subsequent ownership changes could further affect the limitation in future years. Because of the Company&#x2019;s limited operating history and its recorded losses, management has
        provided, in each of the last two years, a 100% valuation allowance against the Company&#x2019;s net deferred tax assets.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company is subject to taxation in the U.S. and various states. Based on the history of net operating losses all jurisdictions and tax years are open for
        examination until the operating losses are utilized or the statute of limitations expires. As of December 31, 2024 and 2023, the Company does not have any significant uncertain tax positions.&lt;/div&gt;
</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="c20240101to20241231"
      id="Text_1341c291b1814f9ca30842acc2275d31">
&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The components of the net deferred tax assets are as follows at December 31:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 27pt;"&gt;
        &lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt; 2024&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;2023&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Operating loss carryforwards&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;63,057&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;61,427&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Tax credit carryforwards&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;9,010&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;6,476&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Other temporary differences&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;18,276&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;10,533&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;90,343&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;78,436&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Less valuation allowance&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;(90,343&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;(78,436&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 4px;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Net deferred tax asset&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
         &lt;/div&gt;
</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="c20241231"
      decimals="-3"
      id="Fact_4d5210e2ec344051827f6a2c0be968ee"
      unitRef="U001">63057000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="c20231231"
      decimals="-3"
      id="Fact_0aad8e6c10fb4f1c8ce69313c66c8658"
      unitRef="U001">61427000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="c20241231"
      decimals="-3"
      id="Fact_49e57dfaaf8f4df1b61ff46cc7c9ef89"
      unitRef="U001">9010000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="c20231231"
      decimals="-3"
      id="Fact_c0213871460d4a4d84aeb3a2da40b86d"
      unitRef="U001">6476000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="c20241231"
      decimals="-3"
      id="Fact_bb33a838785c410da70795469c73c6d8"
      unitRef="U001">18276000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="c20231231"
      decimals="-3"
      id="Fact_60f0261ac273462cbbb5b282172a347e"
      unitRef="U001">10533000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="c20241231"
      decimals="-3"
      id="Fact_21a18dc1821544fabe6e542a6a8ed938"
      unitRef="U001">90343000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="c20231231"
      decimals="-3"
      id="Fact_6577aa22deba463994da18452a0cae79"
      unitRef="U001">78436000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="c20241231"
      decimals="-3"
      id="Fact_fc81137b4f8a497e8aadd8224fcdd5b1"
      unitRef="U001">90343000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="c20231231"
      decimals="-3"
      id="Fact_4b484d18b30b4be09473c30ecdc0b507"
      unitRef="U001">78436000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="c20241231"
      decimals="-3"
      id="Fact_33f206f9325e4087b6d5210ff408c48c"
      unitRef="U001">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="c20231231"
      decimals="-3"
      id="Fact_3714f07f9c40447bb25a6ca503a2d582"
      unitRef="U001">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="c20240101to20241231"
      id="Text_d4ec01ceef80408fa634ecc673b2c6ba">
&lt;div style="margin-left: 24.45pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The primary factors affecting the Company&#x2019;s income tax rates were as follows:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;div style="margin-left: 27pt;"&gt;
        &lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt; 2024&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;2023&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Tax benefit at U.S. statutory rates&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;(21&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;%)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;(21&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;%)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;State tax benefit&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;(2.5&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;%)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;(3.4&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;%)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Permanent differences&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;0.1&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;%&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;0.9&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;%&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Other&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;(4.0&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;%)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;2.3&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;%&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Changes in valuation allowance&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;27.4&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;%&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;21.2&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;%&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-weight: bold;"&gt;0&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-weight: bold;"&gt;%&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-weight: bold;"&gt;0&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-weight: bold;"&gt;%&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
         &lt;/div&gt;
</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c20240101to20241231"
      decimals="2"
      id="Fact_261744d2345d4d2bbeae2511a9c945f9"
      unitRef="U007">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c20230101to20231231"
      decimals="2"
      id="Fact_bc9277459a74408ca05215eae2c363ee"
      unitRef="U007">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="c20240101to20241231"
      decimals="3"
      id="Fact_f7ecba4f85c444cfbe65d700ccd67c99"
      unitRef="U007">0.025</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="c20230101to20231231"
      decimals="3"
      id="Fact_37adf3f073114dcf98cdd6f8138aa939"
      unitRef="U007">0.034</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="c20240101to20241231"
      decimals="3"
      id="Fact_43262c359abc4bdcb9310335b10d305a"
      unitRef="U007">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="c20230101to20231231"
      decimals="3"
      id="Fact_49affd9376a3440db1928a29430ea1cf"
      unitRef="U007">-0.009</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="c20240101to20241231"
      decimals="3"
      id="Fact_f92e21794dde44c588056db0e87fb56f"
      unitRef="U007">0.04</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="c20230101to20231231"
      decimals="3"
      id="Fact_d6a641daf71540dc9acfbbfc50c2be82"
      unitRef="U007">-0.023</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="c20240101to20241231"
      decimals="3"
      id="Fact_17738fda5dd84fadbc77df34d1385aee"
      unitRef="U007">-0.274</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="c20230101to20231231"
      decimals="3"
      id="Fact_84d502b0c4da453497cfb8d7b16e4b28"
      unitRef="U007">-0.212</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="c20240101to20241231"
      decimals="2"
      id="Fact_5820e575f1754b378990b60c8708a1a3"
      unitRef="U007">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="c20230101to20231231"
      decimals="2"
      id="Fact_09a87882122c472493365c4432778fe6"
      unitRef="U007">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:OperatingLossCarryforwards
      contextRef="c20241231_IncomeTaxAuthorityAxis_DomesticCountryMember_TaxPeriodAxis_ExpiringAsAResultOf2017TaxActMember"
      decimals="0"
      id="Fact_4519ccf32f1d4ee49dd4d4b05b46d773"
      unitRef="U001">131579000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="c20241231_IncomeTaxAuthorityAxis_StateAndLocalJurisdictionMember_TaxPeriodAxis_ExpiringAsAResultOf2017TaxActMember"
      decimals="0"
      id="Fact_e3aa7c410a4349d9b61eccba87b94475"
      unitRef="U001">137878000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="c20241231_IncomeTaxAuthorityAxis_DomesticCountryMember_TaxPeriodAxis_ExpiringThrough2037Member"
      decimals="0"
      id="Fact_9935b6bffd6f49a792755c021f1c44a3"
      unitRef="U001">120055000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="c20241231_IncomeTaxAuthorityAxis_StateAndLocalJurisdictionMember_TaxPeriodAxis_ExpiringThrough2037Member"
      decimals="0"
      id="Fact_d6a1badb81b848359dcbf1e78ecba859"
      unitRef="U001">102003000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="c20240101to20241231_IncomeTaxAuthorityAxis_DomesticCountryMember"
      decimals="0"
      id="Fact_fec4137afe294dd08223f0e0f500b6d7"
      unitRef="U001">7764000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="c20240101to20241231_IncomeTaxAuthorityAxis_StateAndLocalJurisdictionMember"
      decimals="0"
      id="Fact_2761ded680b04045a54b4cdc2e90a8d6"
      unitRef="U001">1245000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <galt:DeferredTaxAssetsValuationAllowancePercentage
      contextRef="c20241231"
      decimals="2"
      id="Fact_dd185aacae904174b2d20d195a818f05"
      unitRef="U007">1</galt:DeferredTaxAssetsValuationAllowancePercentage>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="c20240101to20241231"
      id="Text_28aa5d5b089b4f2ea466162efefda198">
&lt;div&gt;
        &lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;"&gt;


  &lt;tr style="vertical-align: top;"&gt;

    &lt;td style="text-align: right; vertical-align: top; width: 27pt;"&gt;
                &lt;div style="text-align: left; font-weight: bold;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;15.&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td style="text-align: left; vertical-align: top; width: auto;"&gt;
                &lt;div style="text-align: left; font-weight: bold;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman', Times, serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: -36px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"&gt;Segments&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
      &lt;/div&gt;

&lt;div style="margin-top: 0px; margin-bottom: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt; &lt;br/&gt;
        &lt;/span&gt;&lt;/div&gt;

&lt;div style="margin-top: 0px; margin-bottom: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; margin-left: 18pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;Operating segments are identified as components of an entity about which separate discrete financial information is available for evaluation by the CODM, or decision-making group, in making decisions on how to allocate
          resources and assess performance. The Company&#x2019;s CODM, the Chief Executive Officer, views the Company&#x2019;s operations as one operating
          segment, which is focused on creating new therapies for fibrotic disease based on targeting galectin proteins. The Company does not have revenue in the current comparative period, incurs expenses primarily in North America and manages the
          business activities on a consolidated basis.&lt;/span&gt;&lt;/div&gt;

&lt;div style="margin-top: 0px; margin-bottom: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt; &lt;br/&gt;
        &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; margin-left: 9pt;"&gt;The accounting policies of the fibrotic disease therapeutics segment are the same
          as those described in the summary of significant accounting policies.&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
          &lt;/span&gt;&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; margin-left: 9pt;"&gt;The CODM assesses performance for the fibrotic disease therapeutics segment and
          decides how to allocate resources based on net loss that also is reported on the income statement as consolidated net loss. The measure of segment assets is reported on the balance sheet as cash and cash equivalents.&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
          &lt;/span&gt;&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; margin-left: 9pt;"&gt;The Company has not generated any product revenue in the current period and expects
          to continue to incur significant expenses and operating losses for the foreseeable future as the Company advances its product candidates through all stages of development and clinical trials.&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
          &lt;/span&gt;&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; margin-left: 9pt;"&gt;As such, the CODM uses cash forecast models in deciding how to invest into the
          fibrotic disease therapeutics segment. Such cash forecast models are reviewed to assess the entity-wide operating results and performance. Net loss is used to monitor budget versus actual results. Monitoring budgeted versus actual results, net
          cash used in operating activities for the period and cash on hand are used in assessing performance of the segment.&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
          &lt;/span&gt;&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; margin-left: 9pt;"&gt;The table below summarizes the significant expense categories regularly reviewed by
          the CODM for the years ended December 31, 2024 and 2023 (in thousands).&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
          &lt;/span&gt;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="background-color: rgb(255, 255, 255); letter-spacing: normal; word-spacing: 0px; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: left; text-transform: none; width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Year Ended&lt;/div&gt;
                  &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;December 31,&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt; 2024&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;2023&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;
                  &lt;div&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;&lt;span style="text-decoration: underline;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;
                  &lt;div&gt;Operating expenses:&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div&gt;Research and development&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;36,571&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;32,130&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div&gt;General and administrative&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;5,862&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;5,942&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div&gt;Total operating expenses&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;42,433&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;38,072&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div&gt;Total operating loss&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;(42,433&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;(38,072&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div&gt;Other income (expense):&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%;" valign="bottom"&gt;
                  &lt;div&gt;Interest income&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;336&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;230&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div&gt;Interest expense&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;(5,540&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;(2,792&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div&gt;Change in fair value of derivatives&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;590&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;(432&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div&gt;Total other expense&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;(4,614)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;(2,994&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div&gt;Net loss&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;(47,047&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;(41,066&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div&gt;Preferred stock dividends&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;(153&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;(120&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div&gt;Warrant modification&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;(3,619&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div&gt;Net loss applicable to common stockholders&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;(47,200&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;(44,805&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br class="Apple-interchange-newline"/&gt;
          &lt;/span&gt;&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; margin-left: 9pt;"&gt;Other segment items included in segment loss includes interest income and interest
          expense.&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; margin-left: 9pt;"&gt;The Company is a &lt;span style="-sec-ix-hidden:Fact_600409bbedd14e1db752c48e58053e6c"&gt;single&lt;/span&gt; operating segment and therefore the measure of segment net loss is the same as consolidated net loss and does not require reconciliation.&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; margin-left: 9pt;"&gt;For the years ended December 31, 2024 and 2023, the net cash used in operating
          activities was $41.8 million and $33.0
          million, respectively. &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: 400;"&gt;The

















          table below summarizes the significant asset categories regularly reviewed by the CODM for the years ended December 31, 2024 and 2023 (in thousands).&lt;/span&gt;&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
          &lt;/span&gt;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="background-color: rgb(255, 255, 255); letter-spacing: normal; word-spacing: 0px; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: left; text-transform: none; width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt; 2024&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;2023&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;
                  &lt;div&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;Cash and cash equivalents&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;15,120&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;25,660&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c20240101to20241231"
      decimals="INF"
      id="Fact_e8f8f97f051e49deb8b94fa9d84e08ae"
      unitRef="U011">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="c20240101to20241231"
      id="Text_3bdd81287ad742da82a5f28e4be8a1fb">
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; margin-left: 9pt;"&gt;The table below summarizes the significant expense categories regularly reviewed by
          the CODM for the years ended December 31, 2024 and 2023 (in thousands).&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
          &lt;/span&gt;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="background-color: rgb(255, 255, 255); letter-spacing: normal; word-spacing: 0px; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: left; text-transform: none; width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Year Ended&lt;/div&gt;
                  &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;December 31,&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt; 2024&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;2023&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;
                  &lt;div&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;&lt;span style="text-decoration: underline;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;
                  &lt;div&gt;Operating expenses:&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div&gt;Research and development&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;36,571&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;32,130&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div&gt;General and administrative&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;5,862&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;5,942&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div&gt;Total operating expenses&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;42,433&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;38,072&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div&gt;Total operating loss&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;(42,433&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;(38,072&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div&gt;Other income (expense):&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%;" valign="bottom"&gt;
                  &lt;div&gt;Interest income&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;336&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;230&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div&gt;Interest expense&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;(5,540&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;(2,792&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div&gt;Change in fair value of derivatives&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;590&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;(432&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div&gt;Total other expense&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;(4,614)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;(2,994&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div&gt;Net loss&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;(47,047&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;(41,066&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div&gt;Preferred stock dividends&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;(153&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;(120&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div&gt;Warrant modification&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;(3,619&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div&gt;Net loss applicable to common stockholders&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;(47,200&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;(44,805&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br class="Apple-interchange-newline"/&gt;
          &lt;/span&gt;&lt;/div&gt;
&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: 400;"&gt;The

















          table below summarizes the significant asset categories regularly reviewed by the CODM for the years ended December 31, 2024 and 2023 (in thousands).&lt;/span&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
          &lt;/span&gt;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="background-color: rgb(255, 255, 255); letter-spacing: normal; word-spacing: 0px; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: left; text-transform: none; width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt; 2024&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;2023&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;
                  &lt;div&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;Cash and cash equivalents&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;15,120&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;25,660&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20240101to20241231_StatementBusinessSegmentsAxis_BusinessOperatingSegmentMember"
      decimals="-3"
      id="Fact_79a66d5160854c359944e1f3dda95af8"
      unitRef="U001">36571000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20230101to20231231_StatementBusinessSegmentsAxis_BusinessOperatingSegmentMember"
      decimals="-3"
      id="Fact_78887ad17e7e4384a208174f05f3dcdd"
      unitRef="U001">32130000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c20240101to20241231_StatementBusinessSegmentsAxis_BusinessOperatingSegmentMember"
      decimals="-3"
      id="Fact_73d6907b69ee4313861219c6fae53215"
      unitRef="U001">5862000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c20230101to20231231_StatementBusinessSegmentsAxis_BusinessOperatingSegmentMember"
      decimals="-3"
      id="Fact_050dbd6a09f24c17852161a8c7bd3c8f"
      unitRef="U001">5942000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="c20240101to20241231_StatementBusinessSegmentsAxis_BusinessOperatingSegmentMember"
      decimals="-3"
      id="Fact_5cc5f41357924f03b40891875f061d48"
      unitRef="U001">42433000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="c20230101to20231231_StatementBusinessSegmentsAxis_BusinessOperatingSegmentMember"
      decimals="-3"
      id="Fact_a0fcc1b0af8e4d20958b24eebac78358"
      unitRef="U001">38072000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20240101to20241231_StatementBusinessSegmentsAxis_BusinessOperatingSegmentMember"
      decimals="-3"
      id="Fact_c2dd9cbc04f9471e827d12f581f3681c"
      unitRef="U001">-42433000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20230101to20231231_StatementBusinessSegmentsAxis_BusinessOperatingSegmentMember"
      decimals="-3"
      id="Fact_bf618d0777944e1fb5bace232527da60"
      unitRef="U001">-38072000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="c20240101to20241231_StatementBusinessSegmentsAxis_BusinessOperatingSegmentMember"
      decimals="-3"
      id="Fact_17d13a3882484e3fae733321aae375fe"
      unitRef="U001">336000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="c20230101to20231231_StatementBusinessSegmentsAxis_BusinessOperatingSegmentMember"
      decimals="-3"
      id="Fact_cbef480b92ab4da29115eb832b935c3e"
      unitRef="U001">230000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpenseNonoperating
      contextRef="c20240101to20241231_StatementBusinessSegmentsAxis_BusinessOperatingSegmentMember"
      decimals="-3"
      id="Fact_7e1aabd1b88840a6987e1c78d692f2ca"
      unitRef="U001">5540000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="c20230101to20231231_StatementBusinessSegmentsAxis_BusinessOperatingSegmentMember"
      decimals="-3"
      id="Fact_3083c8ff60ef494681024c8baa5895c6"
      unitRef="U001">2792000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="c20240101to20241231_StatementBusinessSegmentsAxis_BusinessOperatingSegmentMember"
      decimals="-3"
      id="Fact_772e753238f946a39c76b5ced5c543ad"
      unitRef="U001">590000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="c20230101to20231231_StatementBusinessSegmentsAxis_BusinessOperatingSegmentMember"
      decimals="-3"
      id="Fact_5d6001597b2f4d3aaa8153f5e58b59e6"
      unitRef="U001">-432000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="c20240101to20241231_StatementBusinessSegmentsAxis_BusinessOperatingSegmentMember"
      decimals="-3"
      id="Fact_06652a52dd744762be01328f7c150dfd"
      unitRef="U001">-4614000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="c20230101to20231231_StatementBusinessSegmentsAxis_BusinessOperatingSegmentMember"
      decimals="-3"
      id="Fact_6c36b9459b684f81bc32c269aaa3b0e9"
      unitRef="U001">-2994000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="c20240101to20241231_StatementBusinessSegmentsAxis_BusinessOperatingSegmentMember"
      decimals="-3"
      id="Fact_dadd542f856a4a18863730365892f7a8"
      unitRef="U001">-47047000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20230101to20231231_StatementBusinessSegmentsAxis_BusinessOperatingSegmentMember"
      decimals="-3"
      id="Fact_716483e9b90d4db6bc92f78a31be169b"
      unitRef="U001">-41066000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="c20240101to20241231_StatementBusinessSegmentsAxis_BusinessOperatingSegmentMember"
      decimals="-3"
      id="Fact_5adf93b4ec3c4e9bb81734b50bd2f8b0"
      unitRef="U001">153000</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="c20230101to20231231_StatementBusinessSegmentsAxis_BusinessOperatingSegmentMember"
      decimals="-3"
      id="Fact_d9afcb2040074ecea6dbff5fb218110a"
      unitRef="U001">120000</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <galt:FairValueAdjustmentOfWarrant
      contextRef="c20240101to20241231_StatementBusinessSegmentsAxis_BusinessOperatingSegmentMember"
      decimals="-3"
      id="Fact_fdd6e128b16844969a9b5f78a8a2775b"
      unitRef="U001">0</galt:FairValueAdjustmentOfWarrant>
    <galt:FairValueAdjustmentOfWarrant
      contextRef="c20230101to20231231_StatementBusinessSegmentsAxis_BusinessOperatingSegmentMember"
      decimals="-3"
      id="Fact_49228b5314014313b02b8770c077f7f4"
      unitRef="U001">3619000</galt:FairValueAdjustmentOfWarrant>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="c20240101to20241231_StatementBusinessSegmentsAxis_BusinessOperatingSegmentMember"
      decimals="-3"
      id="Fact_2de2dc210f7a4c3686a1864c0de340f7"
      unitRef="U001">-47200000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="c20230101to20231231_StatementBusinessSegmentsAxis_BusinessOperatingSegmentMember"
      decimals="-3"
      id="Fact_8448b204313a4204b52c53617e2a381d"
      unitRef="U001">-44805000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="c20240101to20241231"
      decimals="-5"
      id="Fact_25fb5f3ed0d84387a90b3ec18b0d1682"
      unitRef="U001">-41800000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="c20230101to20231231"
      decimals="-5"
      id="Fact_088703719ea741dab3aa13c1dd15b714"
      unitRef="U001">-33000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="c20241231_StatementBusinessSegmentsAxis_BusinessOperatingSegmentMember"
      decimals="-3"
      id="Fact_b3dcda20666c469ebf83cf4738f4ebba"
      unitRef="U001">15120000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="c20231231_StatementBusinessSegmentsAxis_BusinessOperatingSegmentMember"
      decimals="-3"
      id="Fact_3475ea7e773b4957aedea5510b8e84c5"
      unitRef="U001">25660000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="c20240101to20241231"
      id="Text_ff556bf0ded44d3090d6f92b92e30c13">
&lt;div&gt;
        &lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;"&gt;


  &lt;tr style="vertical-align: top;"&gt;

    &lt;td style="text-align: right; vertical-align: top; width: 27pt;"&gt;
                &lt;div style="text-align: left; font-weight: bold;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;16.&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td style="text-align: left; vertical-align: top; width: auto;"&gt;
                &lt;div style="text-align: left; font-weight: bold;"&gt;&lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Subsequent







































                    Event&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
      &lt;/div&gt;

&lt;div&gt;&#160;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="margin: 0px 0px 0px 22.5pt; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 0pt;"&gt;On March 31, 2025, the Company and Richard E. Uihlein (the &#x201c;Lender&#x201d;) entered into a Supplemental Line of Credit Letter
        Agreement (the &#x201c;March 2025 Supplemental Credit Agreement&#x201d;), pursuant to which the Lender shall provide the Company a line of credit of up to $5.0
        million (the &#x201c;Supplemental Line of Credit&#x201d;) to finance the Company&#x2019;s working capital needs. The Company may draw upon the Supplemental Line of Credit through September 30, 2025. In connection with entering into the March 2025 Supplemental Line of
        Credit, the Company agreed to extend the maturity date of the Convertible Promissory Note dated April 16, 2021 from April 16, 2025 to September 30, 2025.&lt;br/&gt;
        &#160;&lt;br/&gt;
        Each advance made pursuant to the March 2025 Supplemental Credit Agreement shall be evidenced by an unsecured, convertible promissory note (individually, a &#x201c;Promissory Note,&#x201d; and collectively, the &#x201c;Promissory Notes&#x201d;), and bear interest at the
        Applicable Federal Rate for short term loans, plus two (2%) percent. Principal and interest on the Promissory Notes are due on or before
        March 31, 2026. Only with the consent of the Lender, may the Promissory Notes be prepaid, in whole or in part, at any time without
        premium or penalty, but with interest on the amount or amounts prepaid.&lt;br/&gt;
        &#160;&lt;br/&gt;
        At the election of Lender, the principal and accrued interest on Promissory Note(s) may be converted into the number of shares of the Company&#x2019;s Common Stock equal to the amount of principal and accrued interest on such Promissory Note divided by
        the price equal to the closing price of the Common Stock on the date of such Promissory Note, but in no event less than $3.00 per share.&lt;br/&gt;
        &#160;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="margin: 0px 0px 0px 22.5pt; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 0pt;"&gt;In connection with the March 2025 Supplemental Credit Agreement, the Company agreed to issue the Lender warrants to purchase
        up to an aggregate of 100,000 shares of the Company&#x2019;s common stock, par value $0.001 per share (collectively, the &#x201c;Warrants&#x201d;).&#160; The Company shall issue to the Lender Warrants ratably, upon borrowings under the March 2025 Supplemental Line of Credit, with exercise
        prices equal to 150% of the closing price of the Company&#x2019;s common Stock on the date of the Promissory Note evidencing such draw, but in
        no event more than $10.00 per share nor less than $3.00 per share. The Warrants expire on July 31, 2029. &lt;/div&gt;
</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="c20250331_CreditFacilityAxis_SupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_SubsequentEventTypeAxis_SubsequentEventMember"
      decimals="-5"
      id="Fact_9ff5590ec19e41b082eb6c32a2819584"
      unitRef="U001">5000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease
      contextRef="c20250331to20250331_CreditFacilityAxis_SupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="2"
      id="Fact_99eb0659c6b244d582c21e49a6c1296c"
      unitRef="U007">0.02</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="c20250331to20250331_CreditFacilityAxis_SupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      id="Fact_d7a54f584b344b389e128cb8a26f506c">2026-03-31</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:SharePrice
      contextRef="c20250331_CreditFacilityAxis_SupplementalLineOfCreditMember_RangeAxis_MinimumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="2"
      id="Fact_753ae85d05ed4c0eb0df30f4d2d90cac"
      unitRef="U003">3</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c20250331_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_a17636b659f14fb382629a8c30cf2b65"
      unitRef="U002">100000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c20250331_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember_StatementEquityComponentsAxis_CommonStockMember"
      decimals="3"
      id="Fact_16e8af0735bc43b3a9b610610da179d0"
      unitRef="U003">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <galt:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock
      contextRef="c20250331_CreditFacilityAxis_SupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="2"
      id="Fact_962e92b51d5342af800b4e0ae2c1845d"
      unitRef="U007">1.50</galt:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock>
    <us-gaap:SharePrice
      contextRef="c20250331_CreditFacilityAxis_SupplementalLineOfCreditMember_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="2"
      id="Fact_f8da07e5a1554ef285c8d23f3fb739da"
      unitRef="U003">10</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="c20250331_CreditFacilityAxis_SupplementalLineOfCreditMember_RangeAxis_MinimumMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      decimals="2"
      id="Fact_0759277438274f3cb9f267a88d183a04"
      unitRef="U003">3</us-gaap:SharePrice>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="c20250331_CreditFacilityAxis_SupplementalLineOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_BoardOfDirectorsChairmanMember"
      id="Fact_63802ca3daa149fdb3fba6c34c346c4c">2029-07-31</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
